<SEC-DOCUMENT>0000950170-22-003366.txt : 20220310
<SEC-HEADER>0000950170-22-003366.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310161421
ACCESSION NUMBER:		0000950170-22-003366
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gritstone bio, Inc.
		CENTRAL INDEX KEY:			0001656634
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38663
		FILM NUMBER:		22729200

	BUSINESS ADDRESS:	
		STREET 1:		5959 HORTON STREET, SUITE 300
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 871-6100

	MAIL ADDRESS:	
		STREET 1:		5959 HORTON STREET, SUITE 300
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gritstone Oncology, Inc.
		DATE OF NAME CHANGE:	20151023
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>grts-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-10T16:11:04.1870+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:grts="http://gritstonebio.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_04b34a3e-8e6a-4d8a-b461-bd6e0ec8bab0" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonFraction id="F_e44b0a47-c709-45b3-a49d-50acaef1364b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_d1078c6b-8904-420f-a972-eb76b8483731" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_b453bd8f-c8eb-4d75-8544-721cf324a7c4" name="grts:PrepaymentsOnFinancingLease" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d9344bdc-5632-4045-a278-82f3c517346c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_a0c12b21-3162-4e9e-8023-973cfc335cb3" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonNumeric id="F_7ed2197d-60a0-4b30-bddb-51e4f0d30759" name="grts:RevenueRecognitionContractEndPeriod" contextRef="C_74c098e4-40eb-413b-bfae-ef00e77cdc53" format="ixt-sec:durwordsen">two years</ix:nonNumeric><ix:nonNumeric id="F_4e8c7678-91f3-47ae-9b2a-8d265e5cbe17" name="dei:CurrentFiscalYearEndDate" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5">--12-31</ix:nonNumeric><ix:nonNumeric id="F_48c2ddc8-6b84-4434-a169-06b7c826acc2" name="dei:EntityCentralIndexKey" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5">0001656634</ix:nonNumeric><ix:nonFraction id="F_d2ca4c51-a192-466d-9b37-5b3c9e4c3d77" name="us-gaap:CommitmentsAndContingencies" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5b7425f1-adce-4088-8983-d4281225892c" name="dei:EntityAddressStateOrProvince" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5">CA</ix:nonNumeric><ix:nonNumeric id="F_87612373-8d49-4891-bde3-56260b7bda50" name="dei:DocumentFiscalPeriodFocus" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5">FY</ix:nonNumeric><ix:nonFraction id="F_dd4ba84a-f9ad-4ac4-b8da-a1e9b6be684e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_10536f93-ecfd-49e9-a7e1-fa1761155af0" unitRef="U_USD" decimals="-3" scale="3" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_e31183f5-6d2a-4c3d-9421-3991b0ed1b06" name="grts:PrepaymentsOnFinancingLease" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e60d516f-467d-487d-9e90-0190ecc9a9a1" name="dei:AmendmentFlag" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_a178817b-a374-434c-9a8a-b04e45420edb" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="grts-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_b922b66e-4124-4802-a0ce-1cecdf096487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f567c768-2291-41ae-b166-d1912a72f707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0ec608c-cdab-41f8-92b0-fabd470a62ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bb37ca5-db5d-4687-89ae-66db04f52143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdb6e5b1-bb05-454c-8661-5dbae465a144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e986ac8-7731-4b24-b71a-e9e6a696434e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb4aa159-88f3-4ae9-872f-ad54eb0054a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2eec9e6d-ddf3-4386-87ac-8ad1c81b0edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8e26511-0489-4f9f-9cb5-3285842a09fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebef1c21-1add-4b82-b86f-c63f3d498c3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f87928d0-309b-467a-826b-88343445bf04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6f878cf-27a6-4a39-8ffb-4b24d54bd0fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79ced502-684c-452e-a1e7-6fcb8df0fce8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa671a96-949e-426a-b9d0-931244a1e019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26228208-a6ee-48f7-a682-d0ebfa815e49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be96c1cb-cdd0-401f-9ffa-ba59e494db4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7de09d33-88c1-42a7-afb7-90f61cda1e04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb979a40-c0d7-43fd-bceb-f181847be79e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31211693-1cda-45e5-a939-9774d55bf2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5b3f31b-7118-424c-be58-60dc31c876aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42b8da6e-7442-4d11-94ba-d9fccabe6043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a5f8053-f39a-415a-be93-1d833d484e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fa0442c-ac78-4809-b069-aed25c97df13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea27018b-ae35-4896-958f-8b3ad75d9f1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cf22661-5fe6-4416-b669-0e1caded7434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa4c4d44-8bce-48ff-a4e4-7256f3516afb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72dfcfb2-eb2b-4d05-8cf1-c1bc2e786747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3984633a-9389-4f12-94bd-7218eb5fa25e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5f6a648-955a-4a5a-bac4-0a73b202d719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee66b39c-2a63-4760-bb71-f8fa3a48775c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80c30ec9-ef76-40b1-9254-a26ab087e7c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9299c473-d0f6-48c7-880f-5c832935a48b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a56f792-e909-4a78-9c9f-369e4b671f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b447ec2-ed8d-4932-a1c9-f1211bf27f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef27cb81-c09f-4cb8-81bf-6b870908b71b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f46bcc8-23a7-4ffa-9d3d-c33aa11216e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbb17c0d-cde0-48c5-b232-0304dab63e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8a47a83-89e6-4e48-884d-6f9289316bbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c539e79-df24-408f-baa2-48c4f8fe8cd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3266dfed-769a-40b0-8646-a9d8b35c1a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64144ed4-7156-4df6-9ed4-71edcffd2730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af382cd1-7c55-4a5b-8f11-f6f806af4f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CepInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d7d9ff9-59ff-40cb-8c0e-59c0bc70d677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa774e87-9154-4d69-beec-62667e7e6728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46f01538-745e-443b-9a6c-602d548493a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b820c59d-b464-4759-bbb7-0c4841c49905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a00145e-06b8-48cf-9669-be9b9d8fc159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e60bfb9-8ab6-4a16-8851-229b4f62c041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85575cb7-32f7-42d3-a21b-cb91af13687d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5581400-90ad-4249-923b-5cba9bd710c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cfda793-d20c-4961-a834-c8650ee91d83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_566f53db-f8e8-41fd-9b20-dcbb06f27fc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda9c57d-6ce6-4fc0-83c9-b59dac2e78ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4425ed7-6aea-4eec-abd2-81111d52a84a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e84c838c-b8b5-42b0-86d2-23e56453e579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9b94c09-f330-4e14-958b-a04cb0904e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff041b65-d516-4554-a158-11af438bd9d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb09cd51-ac40-4ddc-b069-ec80b0a9c3ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10299d1d-13c5-4852-a7f2-89934ae6946e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c07bb700-a02f-45ab-9f15-e2c76e3747cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba034453-4fd5-4226-85c4-36e74505c7b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_576b3dfa-a60b-4b9c-a136-301a277fd0bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1e134b6-2dd5-4505-b2e1-f8a94eb727dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d989933a-3905-49b7-9ee1-1782f59e82ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73464b08-07d2-40b6-ace7-0c62aa972258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef0e97d3-9570-43f8-a443-eefdbce6381d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec9e70d0-23a0-467e-b683-3d2b3eaf2393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8102c196-e4f5-4bf5-824f-1227db0eb3b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be2d704f-9ebb-4151-bfe1-64f9f58a7b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2416b0ec-eb6d-48de-b430-8527dc88fbd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74c098e4-40eb-413b-bfae-ef00e77cdc53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1370d5aa-2b10-4f99-9326-80852218e027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30604600-a913-4a56-bc12-11001d41700a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a11e18b2-bc61-4add-880b-6822c9bfcacf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b31fcc2f-be1c-410a-8c29-d48033722636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4648628a-65c5-480f-b910-360609ce023f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_518a98be-fa4a-4aa6-97cb-3e2f9ad3b79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30aa933-0d6e-4987-a2a1-bbce8c351c9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ea13d69-ee00-43f8-b7f0-e73c7105d779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56fd8f05-2d3d-40b2-a758-c7de82170e4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e162ac57-c6fe-433b-9c8e-4ec41607c846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39f0995b-97b6-4734-859b-932b4f1b1bc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d000fa3-1eaf-460c-a146-fa94750108ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0c12b21-3162-4e9e-8023-973cfc335cb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:CommonStockAndOrPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_451a0b67-f3b2-496e-a299-db96faaae70e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dff844cc-04ee-4272-9f37-98efe57aea15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fad68e3-d917-408c-8c64-eb2b3afa907e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a64849a-720f-4b6d-87cb-b18228eb569e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14f18898-257e-4527-9df2-402224c7a2a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3f22244-1f88-421e-9cc4-3b878d466850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f545e51-7d7d-4b7a-bbdc-f5531a775926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f870e98-f90c-49bb-86f0-83e46e07b98a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab352646-a87b-4f45-b887-2a58f2cb2c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6da601ec-2822-45c8-a4c9-e52839555406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_770c1400-be16-4651-87a2-b63b0c62772f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66671e44-d11b-4168-b422-0fbfe5fa8350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3418f96e-c10b-4a60-a068-01b16dabf6cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03810506-a2c8-49f8-9836-cbebe5541354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82754c58-c826-4434-bf40-87fc89524365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a515cc3e-d845-485c-b8cd-9789fd8a095a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c5d65f-d7ac-4f7f-9b8f-ea4e4e427446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03d9a53a-ccc3-4f13-b052-55cc78345393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a494dd9-b549-41f2-b0e4-223518bdd582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dbc0ba8-cd39-4c20-9b7d-bb253b05b1a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50a00b2f-11c4-485d-982a-768195d22ede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12e26153-82b4-40ab-8b8e-500eff6e7133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-28</xbrli:startDate><xbrli:endDate>2020-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_746d448f-f9d9-418a-89b9-fbac99dc06ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3c26619-b56f-41f8-bdf1-a3ff19582f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7987440-e273-4b4b-a993-e63610db9856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50ba15bc-abe4-40d9-83dd-7f897007ee15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb6c3d89-2dc2-476a-a09b-30ac42c2532e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4028d4f2-0823-4d74-af7d-d47f1f2de8e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c96685cb-4058-4f73-a479-ddc549ba8a42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ea043b7-fa57-4d14-8d34-b78103ca2ed8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd06d670-ff74-493a-bef1-1d7f537c855a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f74a3c85-0277-41dd-9121-429606c196de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca7d4972-2e89-44bd-9c6d-a8139bbbfdaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c627a47-b9a4-42f9-9425-7b48bc442bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25e0aa86-a42f-4054-8323-4060b43924cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3dbdfb2-9a14-4b95-94f9-f7c4fd7b4d2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d171005c-8d0e-451d-ba44-fff86b36b8da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f169b2c6-9283-4498-8fe4-31a18d6b1ec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b424de0c-4fee-48e3-bea3-66f5d512ff60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_382a9f9a-00c6-4098-ba1f-f90f5c3bafd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa002ef1-1e05-4ec8-8b0e-f1fff0822abf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c13a7d1-0de0-4b4a-b307-f31dc3ebf480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbf4938b-d2f9-4fa1-ba69-cec10c693873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d66cd703-3912-46fa-bae2-d9fb061ac072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64253bb9-ade3-45ac-b41f-7d7b2677303d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d3f9f89-ed3a-428d-a261-354556628edc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84b5d7c9-f721-46f5-ac90-4bde76f80644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc289d2c-e7b6-4507-9fb5-87d39ce5490f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad7b7d3a-31f1-4f01-a882-0db818ad07a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74699a7b-9862-48d1-88b1-8c7ce7b44e28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_982f33fb-21c0-4dd6-87c5-65c36e0e5f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21980324-d092-473a-8ef8-6dfaf9956f38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380e370a-6b47-4450-8fb6-5f55120330a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77affe5f-9a99-4ac8-acc3-0fad18eb1e3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f54e27a8-261f-4d2c-b6fd-99f5477f06ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f828de0a-9a64-46e4-8ecc-9355300442d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7622eb6-29c1-4937-a641-db49a22c7d5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60da28f6-7643-4ad1-b263-313f3285ca2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6e42e8c-14e5-4460-9129-ce2242e0271a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1987d89b-7388-4dfe-ba84-c6a897416187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40de9285-a41b-4aba-b67e-ff00d1385e17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36e294a4-e0df-4447-b010-28bd585fdd93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_307b7ee6-24f5-4623-9dd7-769942f70dba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f526cf1-464a-4dda-8e5a-79f43b2772aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2d744ea-ab74-4270-b82e-e2d3674f902d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a29305ba-c997-4325-90de-110968edf965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffaa39a0-354a-45c2-b143-8dff6921739e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0499a53-483b-4201-8223-d8a875e05b6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54016751-a114-4247-b713-e0476cc1ba05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_858b47a6-e592-4ea1-b141-4955b70c5d4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ac0f270-594e-4838-963f-9a5cabbd9055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edaa2ef9-c496-465a-bdc7-7a2547c59678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8adaa80f-a791-410d-a103-9f6d54cf70b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62f90882-9570-4db7-bf40-7696560e7bd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bab2de3-95f2-4e3a-9835-071d68696554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb381328-f186-4340-881a-c3901e4b4c64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a063016e-88e5-4a22-8611-b5879f0bd30e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02b16dbd-b7a0-4b17-815f-637d91f05924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46e79e08-83a1-4420-a9c9-fa98bb9c1247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37e6511c-98ee-405d-9c80-3d0032f397aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b169cdf-cda7-4247-a6bb-d30a8c55839a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10488a3d-db85-443f-947d-6d636d18af49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0bc0c98-2ff1-4535-99bd-4549d5704989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-14</xbrli:startDate><xbrli:endDate>2021-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f772a0a4-efa1-4b33-be2c-131d275bc66b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37521ff6-ee49-47f9-82b9-df82ccbc22a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30cdab96-3f4b-4379-b29a-bcbd8cf5affa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71977700-a9f0-41f2-b868-8e6cb6b931de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_996cd399-bd9d-4157-a800-02de52cbb53e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13ec2a36-3f76-4309-a005-6e83308a21b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26915e15-276f-4d55-92e9-790736763dbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da80cade-f058-4976-8865-56dee50a193b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e130a83e-daf9-47c4-ab36-8190b47e6a2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a314753-a175-4226-8b72-9c3df68982ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90dbde66-ba3c-4738-91d6-2e0290e34f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53c971f9-6a10-4dd2-9fb3-244f2a280440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2caa467-fa23-4f7e-ae1f-5ca204d58c99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f109470-dac2-4731-88ec-db187dd90821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6e24dfd-99c6-486b-bf9c-ed12b545fb8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e326ef4-32be-4c22-a96d-5f69ef9ee281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2196007d-8bbb-41dc-bf26-a59a7a2a5a5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a1a7d8e-2cb5-4480-a9f0-5d9d08ea4e42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ce3523e-57c4-4351-b586-64db47e52605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81d44cfe-4817-47ec-82ff-c16f1b041f0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7d371dd-a94d-4213-a570-7cce5450d104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbee0f17-2c8f-479d-918b-1fd7ddd2f644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b456a1b-1f2c-4ef1-8559-e06dc02c434e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07646176-7861-4b62-81ac-b15ae5bdb75e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9d841a0-65e8-4897-a9d8-b29656c20523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a82f3996-a232-41a2-ba36-db531bddceba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71f8b23d-24fd-4e8b-8f47-dd44d72f6801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82594404-3d52-42ec-86ef-ac5b28a31a88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e021a0aa-375f-4923-9a82-7d2d919305be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41a55fdc-8e37-4a5a-87e7-f6d1171e8e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_931f6700-0cb1-4f20-b677-efdf1bd07c30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_520c653f-3fd9-4afa-a427-6bc66ddc0094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90670968-8bdc-4930-a115-4ce5e59779c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbeb91ff-efca-496e-8f5f-a322f317f314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03449e98-a695-4ee5-a4e7-b5c706a15b67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef3a2d5c-f57f-42c8-acc1-25a55ffcd722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d463622-3449-495d-a283-ead7997ec267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ccb5220-a382-46c0-b2dc-bcad6d8aa290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f018322b-c8aa-48d4-8e6e-49a256954912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62974a0f-14cc-441b-8b01-762333a2a200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df133232-0911-4fa1-b7e9-ad9298b91da0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62787d44-14ba-4275-b041-61b55ece56ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_113f6e9e-2318-4e64-9807-9fb8459e68ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_798c90a9-6bbc-4bcc-a947-9814b7fe2869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e64aab1-349c-4614-83ee-3900dea01a17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba072684-2765-4bcf-b573-e869e31f90c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fc1f7ef-16ae-4f01-b819-fa9c521cd5d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cef8cbb3-30a5-4f27-89df-b90b0bac1878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f0f4dc4-3084-4ed1-9f00-4607611bf19a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f0bfb81-1915-4116-a634-7211fd15e24b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d814b55-408c-482f-b8ae-c5e423b0bacc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7057aae3-6cd0-4063-9952-0286502804a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcafcdf1-b545-44ea-b0b0-4e5a82dc1960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4be9d25f-8253-43d1-96f9-812aa91da2ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51e8d18f-06ae-4779-a286-63d6c005a973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_098479a5-8222-4852-8fef-d20451698abd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c371ea3-28ab-4cab-b5bc-b09e9730fe88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75eb6304-1d47-4d29-95ee-7f072311268b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64dce666-8e1a-4354-b216-dc6c18393077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d99841f-5ce6-4dad-8ba9-7eec24d9d624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8869555a-bdc4-45c5-bdd1-ae2de6f84ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72910c92-ee53-4966-9f0c-433eaf5edd6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8cbe5d8-7e8c-4676-8c42-837291b53456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eeccbfcd-9588-414a-8b16-d9ae566a7a11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0e07771-0a34-485d-8679-411afed4e92f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a58ea4fb-a55d-45cb-81a2-cc200e484f8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a312235c-4cac-4041-b6a1-62babf05fea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7f32053-1fd2-41c7-8b07-52c62c884195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30bd410f-a2b7-4dcd-91e2-e7f9e2231460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e968f552-8dce-4078-8dcd-35f7f02d3616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6bab4a8-6557-40f6-913e-491ef563fcfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f70c7fd-3c98-48c7-9bcd-c95ad6bbd433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a07fc35-5bb5-495e-b5b1-254dbffe7f54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb4a354a-e696-4d8e-b1b8-aeae9a1baedf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b303347-0a5e-49c6-ac04-186377f96bd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1384cd70-847e-4634-a2fe-da83db33a119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fecc12db-2824-4e1a-8f15-21db97eded23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f2d73a7-30b6-410a-8148-9410d7383a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdac7de3-d09c-4ab3-a235-9071478e89a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0c0e728-d84d-443b-9b79-a400660a7213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e526fc2-e10d-4769-a192-466206adab05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60b21bc0-099b-49d6-ab81-649520e924be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e99ad520-a6db-4e84-b622-e394b918c047"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24382739-e4d1-4b7d-9faa-aefc1a06f44a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7df85ae-cc5e-40e1-bb77-a8cc3a896e3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1078c6b-8904-420f-a972-eb76b8483731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85f96acd-07e5-4041-bf06-2c004d61457e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1167d84e-b793-4dcc-9d36-63fe715efdd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78c307af-b902-4ede-acde-cde5afdf5220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8caf9fb-02e0-4bb8-bf86-c54f67dc62ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-02-01</xbrli:startDate><xbrli:endDate>2016-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dc9611e-d586-4a8b-a50f-4a5ff390d4ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a36dfa2d-b3cc-41ba-867f-9bc54ef71a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_566e2de2-e6b3-4e99-b3f7-4d1960d33e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ff103bb-5e1f-4e17-baa5-7a535845418a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5903b0b4-0f34-4cd1-947d-816c01e6afad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f03e706-2fc7-4723-b18d-bade0d235db3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fc2caf3-8c25-4dd7-9e8b-1761b10a0822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22ff4438-130f-423a-bdc3-1d4eb213a8cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16b72b70-3b0a-4109-9890-1c0c21720e60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05bb5bbd-397e-4572-a8c7-c182ee094fb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5672b081-e3ab-444a-bafd-c2358ab76867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9127b8e2-08a8-449b-b838-ac2185db6903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c56ee86-11c9-4117-a515-85c8951a85c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e7aaa1c-e583-4583-8203-409c40fb2c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65526830-3d02-4fa7-a03b-a2007d47fe14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10536f93-ecfd-49e9-a7e1-fa1761155af0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb1328df-a76e-43a9-81e1-d6f6bc50971a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3488b869-cb93-4aac-81c2-cb2237fd526d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7168722-4c89-46f9-8fef-613ec1a338fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b07f71bf-53de-4fff-8190-d439a84be1ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b28b039b-c3f5-4ba2-a4b4-e6a47d32112b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b09e940-512d-4b9b-95b7-0f7a00f1c739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8dfb228-4332-4eda-835f-6dcd119ac01f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5159609-8b4f-4ad9-a130-008c19b07b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b19cfa6-fa43-4b59-b47c-8499f1dcf7a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001656634</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_RenewalTerm"><xbrli:measure>grts:RenewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>grts:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>grts:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15a07b7b-0c08-4be9-9fe5-3f7ff35746a2" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.444%;"></td>
    <td style="width:95.556%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b47e2dc4-4cd9-41c4-bc98-a02c99d5955f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdb52546-5d7f-4201-9ab5-3df99ab6fa4d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d98a568-26f6-4246-8899-ed4af16c71d3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.444%;"></td>
    <td style="width:95.556%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31355fc2-84f4-49d1-a0c1-c5358d2fbe45" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">                      </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1b89d27-9f72-4828-bb71-dca11f0ea717" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-38663</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_863d7ef2-ee57-4833-960a-759fa7c99dac" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:49.5%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23770d6a-1832-41e1-81b5-5731e0580d40" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58b4fcf1-9519-4cf5-ba55-4d5cb56ab61f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">47-4859534</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a6b83f0-79b1-4899-b29f-aeb472059a81" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5959 Horton Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf169f36-ea11-4c47-bd70-865c5718d93a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 300</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19add0b9-5686-4627-8e03-602b68211608" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emeryville</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b7425f1-adce-4088-8983-d4281225892c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CA</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ff9413e-e6bc-4f95-a308-fca816a4c589" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94608</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10997ca1-5850-48e3-bd35-e38cb2ff8189" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">510</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a05df48-c51f-49e8-8f9d-ba60a3e86043" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">871-6100</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.861%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:41.139%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc25c60e-7c66-41b4-9c5a-ab23638ac659" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b909cd16-89db-4c30-a504-0235fabd678b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">GRTS</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cace107-4cfe-427e-9f59-6e446831b699" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities Registered Pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744; </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_932ac89f-86ec-42c7-b652-cf782e6735fa" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744; </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec2a0836-622c-4162-a298-0f23a11f4181" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5b14bd1-38ea-47a1-bf62-7a4c2622e526" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfed1fd9-0fce-42a7-9aba-4d731ec90d6d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.302%;"></td>
    <td style="width:0.603%;"></td>
    <td style="width:55.82%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:20.508%;"></td>
    <td style="width:0.603%;"></td>
    <td style="width:2.106%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1e967a6-88c8-4e1d-8d83-84a6025f982f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27ed4faa-5c3e-4c03-b055-e8affee829f9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4634b6d-3376-46df-a4f9-eeb889bfe6c8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.9231250000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dac10d2c-5940-4c2c-a48c-f0df6b087298" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d985d12-ec71-4e4f-93be-bb806c2383c2" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d41db92-8924-4ea8-b821-2613aada63db" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2021 (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ea9610b-d60a-4c88-b495-8644a3503cbc" contextRef="C_3f46bcc8-23a7-4ffa-9d3d-c33aa11216e1" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">419.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> million, based on the closing price of the registrant&#x2019;s common stock, as reported by the Nasdaq Global Select Market on June 30, 2021 of $9.13 per share. Shares of the registrant&#x2019;s common stock held by each executive officer, director, and holder of 5% or more of the outstanding common stock have been excluded in that such persons may deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 7, 2022 was </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3aebadde-e040-4c00-90e6-dfc30b2ce024" contextRef="C_d0ec608c-cdab-41f8-92b0-fabd470a62ba" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">72,708,342</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_743bd385-8b3e-4ac9-8be5-f2f4c7ac21a5" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 17, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.0%;"></td>
    <td style="width:86.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_related_to_foreign_ju"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K, including &#x201c;Business&#x201d; in Part I Item I and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in Part II Item 7, contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are statements that could be deemed forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;positioned,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our clinical and regulatory development plans for our product candidates;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the potential market size and size of the potential patient populations for our product candidates, in particular those within the CORAL, GRANITE, and SLATE programs and any future product candidates with limited patient populations, if approved for commercial use;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the data to be derived in our ongoing and planned clinical trials including, among other things, our expectations for the size and design of our planned clinical trials, timing of commencement and initiation of our trials and the timing of the availability of data from such trials;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations with regard to our Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> artificial intelligence and vaccine platforms, including our ability to utilize (i) the Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform to predict the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tumor-specific neoantigens </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that will be presented on a patient&#x2019;s tumor cells and identify highly conserved T cell epitopes for durable protection for infectious diseases, such as SARS-CoV-2 and (ii) our vaccine platform to deliver selected antigens to the patient&#x2019;s immune system to drive the destruction of tumors or virally-infected cells;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of commencement of our future nonclinical studies, clinical trials and research and development programs;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations regarding the impact of the COVID-19 pandemic or the end of the COVID-19 pandemic on our operations;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our intentions and ability to establish collaborations and/or partnerships;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing or likelihood of regulatory filings and approvals for our product candidates;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations with respect to the commercialization, marketing and manufacturing of our product candidates;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the implementation of our business model and strategic plans for our business, product candidates and technology platforms, including additional indications for which we may pursue;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the sufficiency of our capital resources and timing of our cash runway, as well as our actual needs for additional financing and our ability to obtain additional capital;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the accuracy of our estimates of our expenses, future revenue and capital requirements;</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our future financial performance; and</span></div></div>
  <div style="margin-left:10.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.5211111111111113%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments and projections relating to our competitors and our industry, including competing therapies and procedures. </span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#x201c;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Item 1A. Risk Factors</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; and elsewhere in this Annual Report on Form 10-K. Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates, including data regarding the estimated patient population and market size for our product candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data are derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph are derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note Regarding Company References</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless the context otherwise requires, the terms &#x201c;Gritstone,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; in this Annual Report on Form 10-K refer to Gritstone bio, Inc. and its subsidiary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview and Strategy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We discover, develop, manufacture, and deliver next generation cancer and infectious disease immunotherapy candidates by leveraging both of our potent and proprietary vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd), with the aim of improving patient outcomes and eliminating disease. The immune system sits at the nexus of many diseases, and we believe that manipulation of the immune system has enormous potential to drive transformational therapeutic and preventative benefits.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our founding, our primary focus has been the generation of antigen-specific T cells, particularly the challenging but critical cytotoxic CD8+ T cell subclass, which we believe can be achieved through utilizing samRNA and ChAd. Recent advances have pointed to T cells as being central to the success of cancer immunotherapy (most visibly with the success of adoptive T cell therapy for liquid tumors) and critical in the elimination of virally infected cells, including SARS-CoV-2. We started work in the field of cancer immunotherapy, leveraging tumor neoantigens in an effort to drive potent CD8+ T cell responses to our vaccines with the goal of tumor cell destruction through CD8+ T cell recognition of tumor cells by virtue of their surface display of neoantigens. More recently, we have expanded the scope of our development efforts to include infectious disease, wherein we believe CD8+ T cells and neutralizing antibodies (nAbs), along with other T cells can be elicited for both therapeutic and protective effect. Our unique chimeric immunogen approach, whereby our vaccines deliver both whole proteins to drive nAb plus protein fragments to drive T cell responses, have the potential to both neutralize incoming pathogens (through nAbs) and then kill infected cells through CD8+ T cell recognition of foreign, pathogen-derived peptides displayed on the surface of infected cells. There are also opportunities to &#x201c;mix and match&#x201d; with our ChAd and samRNA vectors, an approach that has been shown to be attractive (COVID-19 example) as a mechanism for driving potent immune responses.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development strategy is built on harnessing the power of T cells through the optimization of two key platforms (see below), which together along with our manufacturing capabilities drive the discovery and advancement of distinct product candidates in oncology and infectious disease. To date, we have developed four clinical-stage programs across these two therapeutic areas (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 2. Our Clinical-Stage Pipeline and Anticipated Milestones</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our two oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an &#x201c;off-the-shelf&#x201d; shared neoantigen-based immunotherapy. Within our infectious disease pipeline, we have two programs in clinical stage development: CORAL, a second generation COVID-19 vaccine program, which we believe may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that we are collaborating on with Gilead Sciences, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Two Key Platforms</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the following two platforms can build upon each other to further our ability and potential to develop next generation immunotherapies for cancer and infectious disease, and drive advancement of our novel product pipeline:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EDGE&#153; Antigen Discovery and T cell Target Identification Platform</span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our proprietary EDGE&#153; artificial intelligence</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">platform has the ability to provide accurate identification of antigens that can be recognized by the immune system on tumor or virally-infected cells.  In the case of tumor cells, mutations in tumor DNA provide a large set of altered (non-self) candidate protein fragments which can be assessed by EDGE&#153; with selection of high probability antigen targets (neoantigens) for inclusion in our vaccine candidates. In the case of pathogens, with a current focus on viruses, EDGE&#153; is used to analyze the DNA/RNA sequence of the pathogen with the goal of predicting which fragments of which genes will likely function as T cell antigens on the surface of virally-infected cells. Using EDGE&#153; in this way, we design the component of a vaccine candidate which contains the specific target antigens for administration to humans (immunogen), with the aim of generating strong immune responses to those antigens to achieve a desired biological effect. Such immune responses can be preventive (e.g., protecting against viral infections) or therapeutic (e.g., treating cancer by aiming to eliminate tumor cells through recognition of tumor neoantigens).</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unique Delivery Capabilities</span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Having designed suitable immunogens with EDGE&#153;, the next task is to embed the immunogen within a delivery system (vector) to stimulate the human host&#x2019;s immune system and drive generation of T cells and neutralizing antibodies (nAbs) against the immunogen. The generation of CD8+ T cells has historically been challenging, and most vaccine vectors do not drive strong CD8+ T cell responses. This represents a key opportunity for us, and we have developed the following proprietary vectors that are designed to elicit nAb and CD8+ T cell responses: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Immunogens encoded within these vectors are delivered to subjects, and immune responses to the chosen antigens can be measured. We believe these immune responses have the potential to lead to clinical benefit &#x2013; either preventative (through the prevention of pathogen infection and its consequences (e.g., SARS-CoV-2 prophylactic vaccine) or therapeutic (e.g., solid tumor destruction).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The samRNA platform is becoming established as a key asset for Gritstone. The success of first-generation mRNA vaccines for SARS-CoV-2 (Comirnaty and Spikevax) has validated mRNA as a vaccine technology, and we believe the samRNA vector has the potential to offer key benefits over mRNA, including dose sparing and more potent CD8+ T cell induction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Key Technologies and Capabilities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Proprietary Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Platform</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the core of our approach to immunotherapy is our deep understanding of antigens and neoantigens, and specifically which ones will be transcribed, translated, processed and presented on a cell surface. Antigen presentation is complex to predict since these multiple biological steps must be comprehended within any prediction system and, notably, antigenic peptide fragments are displayed on the cell surface by highly variable human leukocyte antigen (HLA) molecules that vary subject-to-subject. We aim to accomplish this by utilizing our proprietary artificial intelligence-based platform, EDGE&#153;.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Developing cancer immunotherapies that include tumor-specific neoantigens is challenging &#x2013; tumors typically have hundreds of mutations, but only a small percentage of those mutations result in tumor-specific neoantigens (TSNA). We believe that our EDGE&#153; platform leads the field in TSNA identification. We believe that previously available technologies cannot predict the presence of TSNA with sufficient accuracy to design a therapy that is likely to be effective. To address this challenge, we trained EDGE&#153;&#x2019;s novel integrated neural network model architecture with millions of datapoints from thousands of tumor and normal tissue samples from patients of various ancestries. As a result, we are able to use sequence data from a patient&#x2019;s routine core needle tumor biopsy in an effort to predict which mutations will generate TSNAs most likely to be presented on the tumor cell surface by the subject&#x2019;s particular HLA. Applying the EDGE&#153; platform to sequence data from human tumors, we have observed a 9-to-10-fold improvement in prediction performance with our EDGE&#153; platform compared to traditional approaches. These data were published in Nature Biotechnology in December 2018, and a US patent covering the concept was issued to us in 2018. Additionally, a large academic study published in Nature Biotechnology supported the potential utility of this class of machine-learning approaches for the prediction of HLA presented peptides and TSNA. We continue to identify novel tumor antigens and improve the performance of EDGE&#153;.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our EDGE&#153; platform is also critical to our development of next-generation vaccine candidates for both the treatment and prevention of infectious diseases. Vaccines against viruses ideally generate both neutralizing antibody responses to whole proteins on the virus surface, and T cell responses to the short fragments of viral proteins which are displayed on the surface of virally infected cells. All viral proteins are foreign to the human immune system, but as noted above, only certain short fragments of proteins (peptides) are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">displayed on the cell surface by HLA and visible to T cells. The specific fragments presented will vary between subjects depending upon the HLA type of the subject (conceptually similar to someone&#x2019;s blood type but more complex). Our EDGE&#153; platform is designed to identify key viral protein fragments that have the potential to drive strong T cell responses.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have filed (and received issuance) of multiple patents around the EDGE&#153; platform, which we believe will protect our intellectual property and enable exclusivity over the coming years. It should be noted that vaccines for infectious disease typically also aim to stimulate nAbs to pathogen surface proteins, which is relatively straightforward since, unlike T cells, nAbs bind to whole proteins which can be readily encoded within vaccines. Combining both nAb targets (whole proteins or protein domains) and T cell targets (peptides) into a single &#x201c;chimeric&#x201d; immunogen is a unique feature of Gritstone&#x2019;s infectious disease vaccines. This approach aims to fully mobilize both effector arms of the protective immune response, nAbs and CD8+ T cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Mix and Match&#x201d; Delivery Systems</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon our founding, we intentionally selected samRNA and ChAd as our vectors of choice due to the benefits provided by using each independently and the belief we could also utilize them in combination to potentially drive potent and broad immune responses. Today, we use these proprietary vectors across our clinical programs both independently and in combination as either a heterologous or homologous prime-boost.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">self-amplifying mRNA (samRNA)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our samRNA vector is based on a synthetic RNA molecule derived from a wild-type Venezuelan Equine Encephalitis Virus (VEEV) replicon with the goal of extending the duration and magnitude of immunogen expression to drive potent and durable immune responses. The samRNA is delivered in a lipid nanoparticle (LNP) formulation. We are deploying this vaccine platform across our clinical stage programs. Like traditional mRNA vaccines, samRNA vaccines use the host cell&#x2019;s transcription system to produce target antigens to stimulate adaptive immunity. Unlike traditional mRNA, samRNA has an inherent ability to replicate by creating copies of the original strand of RNA once it is in the cell.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potential benefits of samRNA may include extended duration and magnitude of antigen expression, strong and durable induction of neutralizing antibody and T cell immunity (CD4+ and CD8+), dose sparing, and a refrigerator stable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Self-amplifying mRNA (samRNA) replicates within transduced cells, potentially driving stronger and more durable immune responses compared to traditional mRNA vaccines</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_0.jpg" alt="img96160895_0.jpg" style="width:720px;height:332px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Chimpanzee Adenovirus 68 (ChAd)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chimpanzee Adenoviral (ChAd) vectors have been utilized in clinical studies in infectious disease and oncology over the last 20 years, and have been demonstrated to be well tolerated and effective at generating rapid and substantial CD4+ and CD8+ T cell responses. Additionally, ChAd vectors can induce B cell immune responses, i.e., elicit nAbs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In-house Manufacturing</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We manufacture our products at our own fully-integrated good manufacturing practice (GMP) biomanufacturing facilities. The ability to control the manufacturing of high-quality tumor-specific immunotherapy products, and scale production, if early data are positive, is critical for efficient clinical development and commercialization. We have invested significant resources in our Cambridge, Massachusetts sequencing lab and our Pleasanton, California biomanufacturing facility to address these needs and position ourselves to control the critical steps in the production of our immunotherapy candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Translation and Optimization of Vaccine Design</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vaccines targeting neoantigens identified from common tumor driver mutations are of increasing interest as evidence of clinical benefit builds, and opportunities to combine such vaccines with immune modulators are growing. Through our work, we gain insights that go from &#x201c;bench to manufacturing to bedside&#x201d; and back, and we have systems and processes in place to translate these insights across functions and systems to optimize vaccine and cassette design. The most notable example of this work is within SLATE, our program focused on developing an &#x201c;off the shelf&#x201d; neoantigen immunotherapy for oncology, where we utilized outcomes from our first candidate (SLATE v1) to develop an optimized a second candidate (SLATE-KRAS), which has since exhibited immunogenic superiority over v1 in human HLA-transgenic mice. This optimized candidate (SLATE-KRAS) is now being evaluated in Phase 2 testing in patients with advanced lung and colorectal cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our team of industry leaders, each possessing specific expertise across our core disciplines of cancer genomics, immunology and vaccinology, clinical development, regulatory, and biomanufacturing, can successfully deliver groundbreaking immunotherapies for cancers and infectious diseases by executing on the following strategic priorities:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leverage our proprietary Gritstone EDGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> platform and maximize its utility across modalities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Using contemporary DNA/RNA sequencing, mass spectrometry and machine-learning approaches, we have developed our proprietary EDGE&#153;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> platform, which is designed to predict the antigenic landscape of a tumor that allows for select targeting with individualized immunotherapy. We have analyzed surface HLA-peptide presentation of over 1,000 human tumor and normal tissue samples from a variety of ethnicities, together with multiple cell lines. We have used this enormous dataset comprising &gt;3 million tumor-presented peptides to advance our detailed understanding of tumor antigens (both neoantigens and other non-mutated shared tumor-specific antigens). We have trained the EDGE&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">model to predict class I HLA-presented neoantigens on human tumors (as used currently in our clinical SLATE and GRANITE programs), and we have extended the model to include class II HLA-presented neoantigens. We have predicted and then validated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">multiple novel shared TSNA, which has enabled development of our SLATE program. We are now using EDGE&#153;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to identify novel classes of tumor antigens across our programs and to predict viral epitopes for inclusion in our SARS-CoV-2 vaccine candidates. These epitopes are derived from viral genes outside of Spike in an effort to broaden the T cell response against the virus and are commonly subsequently validated in samples from convalescent individuals.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Continue to build and optimize our in-house biomanufacturing capabilities to maintain the highest controls on quality and capacity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the speed, quality, reliability and scalability of our manufacturing capabilities will be a core competitive advantage to our clinical development and potential commercial success, and we have invested extensively in building our own manufacturing facilities. We have successfully internalized all biomanufacturing steps to drive down both cost and production time, as well as establish full control over intellectual property and product quality. We have internalized the majority of our quality control testing elements as well, though we outsource where prudent and feasible. We believe that operating our own manufacturing facility provides us with enhanced control of material supply for both clinical trials and the commercial market, will enable the more rapid implementation of process changes, and will allow for better long-term manufacturing cost control. We may elect to outsource certain aspects of product manufacturing (such as lipid nanoparticle encapsulation of our RNA) for convenience; but importantly, we have the capability to manufacture every element of our heterologous prime-boost immunotherapy candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Continue advancing GRANITE through randomized, controlled trials with the goal of evaluating these candidates into community oncology settings and earlier lines of treatment. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1/2 clinical data to date have demonstrated initial positive safety results, induction of substantial neoantigen-specific CD8+ T cell responses and molecular responses for our individualized vaccine program. Building on that success, we now have two studies &#x2013; the Phase 2/3 GRANITE-CRC-1L trial and the Phase 2 GRANITE-CRC-ADJUVANT trial - in process. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are pleased with results observed with GRANITE to date in hard-to-treat, late-line CRC patients, and are optimistic we could see similar or better results from neoantigen immunotherapy in earlier lines of treatment where immune responses have the potential to be stronger and tumor genomic complexity is lower. Through these studies, we are also evaluating the potential of ctDNA as a new biomarker by which cancer progression could be measured. We believe the potential regulatory approval of our individualized vaccine candidate represents a potentially transformative development within cancer care.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Continue advancing and optimizing our SLATE immunotherapy candidate to include other antigen classes to both broaden applicable patient population and drive multiple antigens per patient</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In initial clinical trials, the first format of SLATE (v1), which was focused on KRAS and p53 mutations, demonstrated induction of CD8+ T cells against multiple KRAS driver mutations but that strong responses were observed only in a minority of patients. Specifically, we found that P53 mutations were immunodominant and crowded out the mutant KRAS-specific immune response. Although these initial outcomes were very promising, we believed we could further optimize our immunotherapy to further maximize potential clinical benefit. Consequently, we developed a next-generation SLATE candidate, referred to as SLATE-KRAS, which includes a redesigned cassette and exclusively includes epitopes from mutated KRAS. Our long-term vision is to continue optimizing this immunotherapy candidate to include other antigen classes to both broaden addressable patient population and also drive multiple antigens per patient.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Develop a second-generation vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We have developed an optimized samRNA vaccine candidate that we believe is differentiated from first-generation SARS-CoV-2 vaccines. Differentiating characteristics</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of samRNA include the potential for increased antigen expression relative to non-replicating mRNA and for potent CD8+ T cell responses against numerous T cell targets. SamRNA also holds the potential for dose sparing and refrigerator stability, both of which are not currently provided by first-generation mRNA vaccines. We are currently evaluating five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">distinct SARS-CoV-2 product candidates across four different clinical trials containing Spike plus additional non-Spike T cell epitope (TCE) sequences (and also full-length nucleocapsid) (See: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 2. Our Clinical-Stage Pipeline and Anticipated Milestones</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). These studies include homologous and heterologous prime-boost regimens. We believe this &#x201c;T cell-enhanced samRNA&#x201d; approach could also represent a first step toward developing a pan-coronavirus vaccine.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conduct research and development on additional pathogens/infectious diseases. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research pipeline focuses on the development of a therapeutic HPV vaccine with support from the Bill and Melinda Gates Foundation as well as the development of an influenza (FLU) and pan-coronavirus vaccine utilizing the samRNA vaccine platform and our capability </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in generating chimeric vaccine cassettes to drive broad and potent neutralizing antibodies and CD8+ T cells against these viruses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical-Stage Pipeline</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our dual platform has enabled us to advance potentially differentiated clinical assets across multiple therapeutic areas. The table below summarizes key information about our clinical-stage pipeline.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Clinical-Stage Pipeline and Anticipated Milestones</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:-10.665%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-10.132%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_1.jpg" alt="img96160895_1.jpg" style="width:654px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:-4.022%;padding-left:3.867%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">*       Abbreviations: S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.03pt;font-family:Times New Roman;">WT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2013; Wild type variant Spike (Original); S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.03pt;font-family:Times New Roman;">BETA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2013; South African variant Spike (Beta); S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.03pt;font-family:Times New Roman;">OMICRON </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2013; Omicron variant Spike</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.022%;padding-left:3.867%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">**     CORAL next-generation COVID-19 vaccines includes Spike protein and additional T cell epitopes (TCE) from the SARS-CoV-2 virus; there are 5 different investigational COVID-19 product candidates testing/planned in clinical trials with various antigenic cassettes targeting Wild Type, Beta and Omicron variants of SARS-CoV-2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Oncology Programs</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immuno-oncology (I-O) represents one of the most significant advances in the history of cancer treatment. I-O is an emerging field of cancer therapy that aims to activate the immune system to enhance and/or create anti-cancer immune responses, as well as to overcome the immuno-suppressive mechanisms that cancer cells have developed against the immune system. It is well established that the immune system can, on occasion, successfully eliminate all tumor cells, leading to long-term benefit and even cures in some patients with solid tumors. The primary challenge in immuno-oncology is to extend this useful biology to many more cancer patients, and to do so earlier in the treatment paradigm. Understanding which cells of the immune system are critical, what they recognize on tumor cells, and why they are typically absent or ineffective in cancer patients is core to overcoming this challenge. T cells are the vital foot soldiers in the immune attack upon cancer cells. T cells have evolved to recognize &#x201c;foreign&#x201d; markers (antigens) on cells infected by viruses, and DNA mutations, which are a hallmark of cancer cells, often lead to the generation of equivalent &#x201c;foreign&#x201d; markers (neoantigens), which are different from normal or &#x201c;wild-type&#x201d; proteins. Exploitation of this cancer cell vulnerability using new biological and computational tools lies at the heart of our programs.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The first checkpoint inhibitor (CPI) was approved in 2011 and today, despite only a modest breadth of efficacy across patients, this class of therapies has significantly changed the way cancer is treated. However, because checkpoint inhibitors work through relatively non-specific stimulation of occasional, pre-existing, tumor-specific T cells (typically recognizing neoantigens), they are effective in only a subset of solid tumor patients, with objective responses (substantial tumor shrinkage) observed in 0-20% of all patients with cancer of the lung, breast, prostate, colon/rectum and ovary (the major lethal solid tumor types). Many patients appear not to possess meaningful numbers of T cells that recognize their tumors (so-called &#x201c;cold&#x201d; tumors). We believe the path to broader immuno-oncology efficacy and more meaningful clinical responses resides in the de novo generation of new, potent, tumor-specific CD8+ T cell responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Neoantigen Derived Immunotherapy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Neoantigens are a newly-identified class of targets for cancer immunotherapy and have been validated in cancer patients as potentially the most critical T cell targets. These neoantigens comprise short, tumor-specific, mutated peptide sequences presented on cancer cells, referred to as TSNA or fragments of viral proteins displayed upon the surface of cells infected by virus. Accurate identification of these critical protein fragments a priori is a challenging undertaking. Evidence suggests that when a solid tumor patient responds to anti-PD-(L)1 antibody therapy, they do so because T cells that recognize TSNA are activated. Neoantigens can be classified as either patient-specific, meaning each patient has their own unique neoantigens, or shared, whereby some common driver mutations are presented on the tumor cell surface of multiple patients. We believe that our EDGE&#153; platform leads the field in TSNA identification. A core challenge in TSNA prediction is that T cells recognize short mutant peptides presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, which are platform-like structures that vary profoundly across individuals. Prediction of TSNA, therefore, must be tailored to each individual, comprehending their own tumor mutations and their HLA types.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our therapeutic hypothesis is that treatment with individualized TSNA-containing vectors combined with immune checkpoint inhibitor therapy will generate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">de novo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or augment existing, selective, TSNA-specific T cell response, unleashing the natural power of the immune system on tumor cells, potentially improving efficacy without a substantial increase in off-tumor toxicity. Our individualized immunotherapy candidates are designed to fit easily into a community oncology setting and to be administered in earlier lines of treatment rather than only in refractory or relapsed cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a portfolio of cancer immunotherapy product candidates aimed at the highly targeted activation of tumor-specific T cells in solid tumors. Our two clinical-stage programs (GRANITE, which is &#x201c;individualized&#x201d; and SLATE, which is &#x201c;off-the-shelf&#x201d;) aim to induce a substantial neoantigen-specific CD8+ T cell response using neoantigen-containing immunotherapies. We have designed our individualized immunotherapy candidates such that oncologists will not have to alter their treatment practices, and we believe that this will extend the utility of our product candidates, if approved, into the community setting and not limit their use to scarce centers of excellence. GRANITE patients receive an immunotherapy product candidate made specifically for them, based upon their tumor DNA/RNA sequence. In contrast, SLATE patients are selected to carry both a particular mutation and the matching HLA type. Nevertheless, we have observed cytotoxic T cell responses to multiple administered TSNA and early signs of clinical benefit with both of these oncology product candidates. The immunotherapy regimens consist of administration of the TSNA-containing vectors (vaccines) as a heterologous prime-boost system together with checkpoint inhibitors systemic anti-PD-(L)1 antibody and low-dose subcutaneous anti-CTLA-4 antibody.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Construct and Antigen Delivery System for GRANITE and SLATE</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our individualized immunotherapy candidates consist of (1) a prime vector and (2) a boost vector, both of which contain (3) a neoantigen cassette:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prime Vector. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our prime vector is a chimpanzee adenovirus (ChAd). There is extensive clinical experience with the ChAd vector platform in infectious disease studies over the last 20 years demonstrating that ChAd vectors are well tolerated and consistently generate rapid and substantial CD4+ and CD8+ T cell responses that have been shown, in a Phase 2b randomized controlled trial, to protect humans against infections such as malaria. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Boost Vector.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Our boost vector is a samRNA formulated in a lipid nanoparticle (LNP). A samRNA vector comprises RNA that encodes the selected target antigens, such as TSNA, plus a virus-derived RNA polymerase (RNA copying enzyme). After injection into muscle and uptake into host cells, the RNA is translated into protein, and the RNA polymerase starts to replicate the originally injected source RNA, amplifying the number of copies within the cells dramatically. This leads to production of large amounts of the delivered target antigens. During the RNA replication, RNA structures that are foreign to a normal cell are generated, which drives a strong danger signal to surrounding immune cells, triggering an early immune reaction (innate immune response). The presence of large quantities of antigen in an immune-stimulating environment drives profound antigen-specific T cell responses (adaptive immune responses). This approach is fundamentally distinct from using first-generation mRNA, which does not possess these attractive properties. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Neoantigen Cassette</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Within each of the two vectors used for the prime and boost immunizations, we include a cassette that contains neoantigens. For GRANITE, we have designed the cassette to contain 20 TSNA, based on several considerations, including TSNA prediction performance, breadth of the tumor-specific immune response and potential immune competition and manufacturing factors. For SLATE, the cassette is fixed for all patients, and contains common driver mutations (e.g. KRAS), which are known to be processed and presented by certain HLA molecules such as neoantigens that are shared between some patients. For GRANITE, the cassette is designed and made uniquely for each patient based upon their tumor sequence data and EDGE&#153;-based TSNA predictions. Most SLATE patients&#x2019; tumors will only present a single neoantigen contained within the shared cassette. In contrast, although all of the mutations in a GRANITE cassette are contained within </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient&#x2019;s own tumor and can activate T cell responses post immunizations, it is expected that some of the delivered mutations, while present in the tumor genome, will not be processed and presented as a tumor cell surface neoantigenic HLA-peptide complex. We expect this to be acceptable, since these sequences are not wild-type (found in normal cells) and, therefore, only an irrelevant mutated peptide-specific immune response is expected to be elicited.</span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our therapeutic goal with both SLATE and GRANITE is to drive a large and sustained T cell response against all TSNA presented on a patient&#x2019;s tumor. Cancer patients may have pre-existing memory T cells directed against some of the TSNA delivered within the neoantigen cassette in their individualized immunotherapy. Boosting such pre-activated TSNA-specific T cells requires less antigen-specific stimulation than priming na&#xef;ve T cells that have not yet been activated against their respective neoantigen. Importantly, early clinical data in the field suggest that, for the majority of TSNA within the immunotherapy cassette, priming na&#xef;ve T cells will be required to mount a large and broad immune response. Priming na&#xef;ve T cells is a multi-step process that requires a potent antigen delivery platform able to deliver cassette neoantigens in a highly immunogenic manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human infectious disease vaccine experience has taught us that delivering antigens within an adenoviral vector can prime a substantial T cell response consisting of cytotoxic CD8+ T cells and CD4+ T-helper cells. We believe an adenoviral vector is one of the most potent antigen-delivery platforms to prime na&#xef;ve T cells. Peptide vaccination has not been able to accomplish this goal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that continued strong immune pressure upon the tumor is likely necessary to prevent immune escape by the tumor and drive a durable clinical response. To sustain high numbers of tumor-specific T cells, the same tumor-specific antigen can be given in a different vector from that used to prime, as a boost immunization. This heterologous prime-boost concept has been shown to activate and sustain high antigen-specific T cell responses, as shown in Figure 3 below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Comparison of Heterologous Prime-Boost with Homologous Prime-Boost and Prime Alone</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_2.jpg" alt="img96160895_2.jpg" style="width:676px;height:267px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GRANITE individualized neoantigen-based immunotherapy</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our first oncology product candidate, GRANITE, is an individualized neoantigen-based immunotherapy. The GRANITE process begins with receipt of a routine tumor biopsy from the patient. We utilize our in-house sequencing capabilities on the tumor sample and then apply our proprietary EDGE&#153; platform to derive a set of predicted TSNA likely to be presented on the patient&#x2019;s tumor. Using these TSNA, we design a highly potent individualized immunotherapy candidate containing the relevant neoantigens to be administered by simple intramuscular injection. We have designed each of our tumor-specific immunotherapy candidates such that oncologists will not have to alter their treatment practices, and we believe this approach would extend the utility of our product candidates into the community oncology setting and not limit their use to scarce centers of excellence. We believe that, thanks to its design, our tumor-specific immunotherapy candidate has the potential to expand the efficacy of immunotherapy into broader patient populations. GRANITE was granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of microsatellite stable colorectal cancer (MSS-CRC).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GRANITE GO-004 (NCT03639714)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have completed enrollment (treatment ongoing) for a Phase 1/2 clinical trial for GRANITE in combination with checkpoint inhibitors for patients with MSS-CRC who have progressed on FOLFOX/FOLFIRI therapy and in patients with gastro-esophageal (GEA) cancer who have progressed on chemotherapy. We presented updated interim efficacy, immunogenicity and safety data from this GRANITE Phase 1/2 study during the European Society of Medical Oncology (ESMO) congress in September 2021. As of the August 5, 2021 data cut-off date, GRANITE immunotherapy was generally well tolerated in 26 patients treated in the study with metastatic solid tumors largely focused on MSS-CRC and GEA and showed no dose limiting toxicities, consistent and potent immunogenicity (CD8+ neoantigen-specific T cell induction in all subjects), as well as reduction in circulating tumor ctDNA (molecular response) and tumor lesion size reductions.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the August 5, 2021 data cut-off date, the GRANITE Phase 1/2 study treated 26 patients: 14 in the Phase 1 dose escalation portion and 12 in the Phase 2 portion across three tumor-specific expansion cohorts &#x2013; MSS-CRC, GEA, and non-small cell lung cancer (NSCLC). All patients receive our proprietary heterologous prime-boost consisting of ChAd and samRNA in combination with intravenous nivolumab and subcutaneous ipilimumab.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In MSS-CRC patients, where checkpoint inhibitors have shown minimal activity, GRANITE elicited a 44% molecular response rate in 9 evaluable patients (defined as a 50% or greater reduction in ctDNA from baseline) which is an increasingly well recognized objective efficacy biomarker for novel immunotherapy. Patients who demonstrated molecular response had median overall survival of &gt;17 months (median not reached) whereas those without molecular response exhibited a median overall survival of 7.8 months, consistent with expected outcomes in 3rd line treatment of MSS-CRC.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A confirmed complete RECIST response was observed in a GEA patient (ctDNA negative at baseline). As of the August 5, 2021 data cut-off date, multiple patients remained on treatment for over 6 months with a lack of confirmed disease progression including 2/9 MSS-CRC patients receiving treatment beyond 12 months and one patient at 11+ months, which contrasts sharply with the expected outcome for these patients. As of the August 5, 2021 data cut-off date, 50% of patients (3/6) showed a slow decrease in volume of multiple pulmonary metastasis during the first year of therapy, even though these objective radiological responses did not meet RECIST criteria. These radiological observations were associated with prolonged time on study and decrease in biomarkers such as ctDNA.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical Activity in Previously Treated MSS-CRC Based on Partial and Complete Molecular Responses and Associated Prolonged Progression-Free Survival</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:-10.665%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-10.132%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_3.jpg" alt="img96160895_3.jpg" style="width:516px;height:347px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">SD=stable disease; PD=progressive disease</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">ctDNA assessment based on Gritstone-developed, tumor-informed assay</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">ctDNA assessment not available for the 3 most recently treated patients</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(62,60,63,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Patients G14 and G16 with PD at week 16 and 9 respectively not confirmed on subsequent scans through week 24</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">G8 Case Study: Lung CT Shows Transient Lesion Expansion at Week 8 Then Contraction</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:-10.665%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_4.jpg" alt="img96160895_4.jpg" style="width:528px;height:273px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GRANITE Randomized Controlled Trials: GRANITE-CRC-1L and GRANITE-CRC-ADJUVANT</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the signals of activity observed in the GRANITE Phase 1/2 study, especially in MSS-CRC, we have discussed potential registrational paths with the FDA and are subsequently launching two new studies for patients with MSS-CRC. The first study (GRANITE-CRC-1L, NCT05141721) is a Phase 2/3 study evaluating GRANITE as a maintenance treatment in patients with newly diagnosed, metastatic MSS-CRC who have completed FOLFOX- bevacizumab induction therapy. In support of this study, we entered into a clinical trial collaboration and supply agreement with F. Hoffman-La Roche Ltd to evaluate the safety and tolerability of GRANITE in combination with TECENTRIQ (atezolizumab).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The second study is a separate randomized Phase 2 trial evaluating GRANITE in the adjuvant setting (GRANITE-CRC-ADJUVANT) in patients with stage II/III colon cancer who have minimal residual disease based on the detection of circulating tumor after definitive surgery.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SLATE &#x201c;off-the-shelf&#x201d; neoantigen-based immunotherapy candidate</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our off-the-shelf, TSNA-directed immunotherapy product candidate, SLATE, utilizes the same heterologous prime-boost approach. However, SLATE contains a fixed cassette with TSNA that are shared across a subset of cancer patients rather than a cassette unique to an individual patient, which distinguishes it as a potential off-the-shelf alternative candidate to GRANITE. SLATE is therefore designed to be readily available for rapid initiation of therapy and is less expensive to manufacture than an individualized product such as GRANITE. The key to appropriate utilization of the &#x201c;off-the-shelf&#x201d; product candidate is to accurately identify patients whose tumors contain at least one of the TSNA represented within the SLATE neoantigen cassette. The widespread use of tumor mutation panel sequencing in advanced cancer has enabled the routine identification of such patients, and complementary assessment of a patient&#x2019;s HLA type is a standard clinical test, performed using a simple blood draw, and is designed to be completed within 7-10 days by a clinical immunology laboratory.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patient selection is achieved by screening the patient&#x2019;s tumor for driver mutations using commercially available genomic screens and identifying the patient&#x2019;s HLA type from blood with a standard clinical assay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Prime/Boost Platform is Designed to Enable Multiple Product Options Including Our Off-The-Shelf Immunotherapy Platform, SLATE</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_5.jpg" alt="img96160895_5.jpg" style="width:593px;height:222px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SLATE Phase 1/2 Study (GO-005, NCT03953235)</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine candidate, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The v1 format of SLATE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(focused on KRAS and p53 mutations) was evaluated in this study in collaboration with Bristol-Myers Squibb. In September 2021, we presented updated interim efficacy, immunogenicity, and data, in 26 patients with metastatic solid tumors, largely focused on non-small cell lung cancer (NSCLC), microsatellite-stable colorectal cancer and pancreatic ductal adenocarcinoma (PDA). There were no safety signals of note with the most common adverse events being low grade, self-limiting fever and injection site reactions. SLATE patients developed CD8+ T cells against multiple KRAS driver mutations but strong responses were observed only in a subset of patients. Patients with NSCLC, all of whom had progressed on prior immunotherapies, showed the largest degree of CD8+ T cell development. SLATE v1 exhibited molecular responses (&gt;50% decrease in ctDNA levels in the blood from baseline) observed in 3/5 NSCLC patients who had all progressed on prior anti-PD-(L)1 therapy (often in combination with chemotherapy) who were eligible for analysis (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This initial version of SLATE demonstrated the greatest activity in 6 NSCLC patients with the KRASmut G12C presented by the HLA protein A*02:01. Among these patients, ctDNA responses were observed in 66% of these patients (2/3 eligible for analysis), correlating with clinical benefit, and a RECIST radiologic response (unconfirmed) was observed in one second-line patient who had progressed after 3 months of first line chemo-immunotherapy. One patient who had progressed on prior chemo-immunotherapy after 8 months of treatment was nearing completion of 2 years of therapy with persistent ~20% tumor lesion shrinkage. The patient&#x2019;s ctDNA remained undetectable throughout the study.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Patients with NSCLC, all of whom had progressed on prior IO appeared to have the largest decrease in circulating tumor DNA correlating with longer treatment duration</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_6.jpg" alt="img96160895_6.jpg" style="width:686px;height:238px;" />&#160;</p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the same protocol, a next generation, optimized SLATE cassette (SLATE-KRAS), which exclusively includes epitopes from mutated KRAS and exhibited immunogenic superiority over v1 in human HLA-transgenic mice, is now in Phase 2 for patients with advanced NSCLC and CRC.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Phase 2 portion of the study evaluating SLATE-KRAS has enrolled patients in 3 tumor-specific expansion cohorts (NSCLC post anti-PD-(L)1 and platinum-based chemotherapy, first line maintenance MSS-CRC and third-line MSS-CRC) with the potential to enroll up to 20 patients per cohort based on observed clinical activity. All patients will receive SLATE v2, consisting of a dose of intramuscular adenovirus-based prime with intramuscular self-amplifying mRNA-based boost vaccinations and a single adenovirus-based boost vaccination in combination with anti-PD-1 checkpoint inhibitor Opdivo&#174; (nivolumab) and subcutaneous anti-CTLA-4 antibody Yervoy&#174; (ipilimumab).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Infectious Disease Programs</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In early 2021, we expanded our programs to include infectious diseases with the announcements of a second-generation vaccine program against SARS-CoV-2 (CORAL) and a therapeutic vaccine candidate designed to treat and potentially cure human immunodeficiency virus (HIV) infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CORAL &#x2013; Second Generation COVID-19 Vaccine Program</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our CORAL program is a second-generation SARS-CoV-2 vaccine platform designed to deliver Spike and additional SARS-CoV-2 T cell epitopes, which we believe could offer the potential for more durable protection and broader immunity against SARS-CoV-2 variants. There are five different investigational COVID-19 product candidates being evaluated across four clinical trials with various antigenic cassettes designed to target Wild Type, Beta and Omicron variants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These trials are being evaluated in different populations including elderly adults, immunocompromised individuals, those na&#xef;ve to the virus, and previously vaccinated individuals using different vaccine regimens.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The program is supported by key relationships with the Bill &amp; Melinda Gates Foundation, the National Institute of Allergy and Infectious Disease (NIAID), the Coalition for Epidemic Preparedness Innovations (CEPI), and through a license agreement with the La Jolla Institute for Immunology (LJI). LJI is one of the leading global organizations dedicated to studying the immune system, and through our licensing agreement, we have access to validated SARS-CoV-2 antigens that have been identified through LJI&#x2019;s studies of hundreds of patients recovering from COVID-19. Using such antigens, EDGE&#153; and vaccine platform technologies, we have developed novel vaccine candidates containing Spike (similar to first generation vaccines) but also additional viral antigens that we believe offer potential targets for broad T cell immunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our CORAL vaccine candidates have the potential to improve both T cell and antibody responses to Spike and other viral proteins. By creating a cassette that targets several viral antigens including Spike protein and additional TCE from the SARS-CoV-2 virus, some of which are highly conserved between viral strains (such as SARS and SARS-CoV-2), we believe our vaccine candidates may have pan-coronavirus potential to protect against future coronavirus pandemics. While mutations in the Spike protein</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may reduce protection by antibodies (since the antibody target changes its shape), broad T cell immunity and long-term memory to different viral proteins may provide a second layer of clinical protection.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Early clinical data (described in more detail under the subsection &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CORAL-BOOST (GO-009, NCT05148962)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; have demonstrated that a single 10&#xb5;g boost dose of our samRNA vaccine containing Spike plus additional TCE boosted neutralizing antibody (nAb) and Spike-specific IgG responses against wild-type (WT) Spike and variants of concern (VOCs) Beta and Delta.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">First generation COVID-19 vaccines generate a strong antibody response against SARS-CoV-2. These vaccines elicit nAb that can recognize the surface Spike protein of the virus and neutralize virus prior to cell infection. However, antibody responses have been shown to wane over time necessitating the development of approaches that can offer long-term durability of protection. Additionally, mutations in SARS-CoV-2 continuously arise, particularly in the Spike protein, and may further reduce clinical protection derived from vaccine-induced nAb to Spike. Analysis of blood from convalescent COVID-19 patients shows that recovered patients have both T cell and antibody immune responses. This is expected because T cells play a fundamental role in protective immunity against viruses. If a virus successfully evades nAb and infects a cell, the cell displays pieces of the virus on its surface, which T cells can recognize. Many T cell antigens derive from evolutionarily conserved regions of viral proteins that may thus provide longer, more robust immunity, complementing antibody-based immunity. In sum, mutations in Spike protein may reduce protection by nAb, but broad T cell immunity and long-term memory to conserved viral proteins may provide a durable second layer of clinical protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical data</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have conducted preclinical studies demonstrating that our SARS-CoV-2 vaccine candidate induced significant and sustained levels of neutralizing antibodies and T cells against the Spike protein, plus a broad T cell response against epitopes from multiple viral genes outside of Spike. We published data from one of these studies, a non-human primate challenge study (NHP Challenge Study), in November 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results of the NHP Challenge Study demonstrate immunization with our candidate, a samRNA vaccine, protected rhesus macaques against SARS-CoV-2 infection as either a homologous prime-boost regimen (two doses) or as a single boost following an optimized ChAd vector prime. In the NHP Challenge Study, a samRNA vaccine candidate encoding a prefusion stabilized SARS-CoV-2 spike glycoprotein demonstrated potent cellular and humoral immune responses at low doses in mice and rhesus macaques. The homologous prime-boost vaccination regimen of samRNA at 3, 10 and 30 &#xb5;g induced potent neutralizing antibody titers in rhesus macaques at all dose levels, with the 10&#xb5;g dose generating geometric mean titers (GMT) 48-fold greater than the GMT of a panel of SARS-CoV-2 convalescent human sera, and comparable to that observed with a ChAd and samRNA heterologous prime-boost regimen. Spike-specific T cell responses were observed in all dose groups. samRNA vaccination induced protection against SARS-CoV-2 challenge as both a homologous prime-boost and as a boost following ChAd prime, demonstrating reduction of viral replication in both the upper and lower airways. Observed protection was most effective with a samRNA prime-boost vaccination regimen at 10 and 30 &#xb5;g and with a ChAd/samRNA heterologous prime-boost regimen. The Bill &amp; Melinda Gates Foundation supported the preclinical evaluation of the vaccine candidate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Trials</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our CORAL next-generation COVID-19 vaccine candidates include Spike protein and additional T cell epitopes (TCE) from the SARS-CoV-2 virus. There are five different investigational COVID-19 product candidates being evaluated or are to be evaluated across the following four clinical trials with various antigenic cassettes targeting Wild Type, Beta and Omicron variants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CORAL-BOOST (GO-009, NCT05148962)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.059%;"></td>
    <td style="width:1.975%;"></td>
    <td style="width:43.966%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Candidate</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Construct</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-R910 (samRNA)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">WT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;-TCE5</span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we initiated a Gritstone-sponsored Phase 1 dose escalation boost study evaluating our samRNA SARS CoV-2 vaccine candidate, GRT-R910, which includes construct S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">wt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-TCE5 as a single boost dose in healthy adults &#x2265;60 years of age who have previously been vaccinated with the first-generation AstraZeneca SARS-CoV-2 vaccine. Safety data for the first cohort of participants who received a 10&#xb5;g dose of GRT-R910 showed no grade 3 or 4 events or serious adverse events reported. In this same cohort, robust CD8+ T cell responses to conserved TCEs from SARS-CoV-2 were induced, including Nucleoprotein (N), Membrane (M), and ORF3a, which have been shown to offer T cell targets in convalescent individuals. A boost in pre-existing Spike-specific T cell responses was observed. Furthermore, although this Phase 1 study did not include a head-to-head comparison against other vaccine candidates, potent neutralizing antibodies against Spike (geometric mean titer of 2,370 using standardized pseudovirus neutralizing assay) were observed at levels consistent with published data from first-generation mRNA vaccines in a similar clinical context (CORAL-BOOST study; M</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">unro et al Lancet 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). Initially, a single institution study, this boost study is being amended to investigate the performance of a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">homologous prime and boost dose of GRT-R910 in adults &#x2265; 60 years of age who have previously received an authorized vaccine (either mRNA or adenovirus-based).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CORAL-NIH (NCT04776317)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.059%;"></td>
    <td style="width:1.975%;"></td>
    <td style="width:43.966%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Candidates</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Construct</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-C907 (ChAd)/ -R908 (samRNA)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">WT</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT- C909 (ChAd)/ - R910 (samRNA)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">WT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;-TCE5</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are collaborating with NIAID on a Phase 1 clinical trial which is being conducted through the NIAID-supported IDCRC. The trial was amended to evaluate a CORAL platform candidate as a boost to first- generation SARS-CoV-2 vaccines and is currently evaluating increasing doses of samRNA (in adults 18-60 and &gt;60 years of age) and ChAd (&gt;60 years of age only).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CORAL-IMMUNOCOMPROMISED (GO-011, NCT04776317)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.059%;"></td>
    <td style="width:1.975%;"></td>
    <td style="width:43.966%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Candidates</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Construct</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-C909 (ChAd)/ -R910 (samRNA)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">WT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;-TCE5</span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have initiated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a Gritstone-sponsored Phase 1 trial in the United Kingdom evaluating homologous (ChAd/ChAd) and heterologous (ChAd/samRNA) prime-boost regimens containing S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:6.7pt;font-family:Times New Roman;">wt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-TCE5 in patients being treated with B-cell depleting therapies for hematological malignancies or multiple sclerosis, utilizing GRT-C909 and GRT-R910.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The majority of patients receiving these therapies mount poor immunologic responses to first generation vaccines and are at higher risk for severe infection from SARS-CoV-2. As these patients do not have sufficient B cell function, we believe vaccines like GRT-C909 and GRT-R910 that are designed to induced robust T cell responses may afford greater protection against SARS-CoV-2 than the first-generation vaccines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CORAL-CEPI (GO-012)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:54.059%;"></td>
    <td style="width:1.975%;"></td>
    <td style="width:43.966%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Product Candidates</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Construct</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-R914 (samRNA)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">Beta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-TCE9</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-R912 (samRNA)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">Beta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-N-TCE11</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRT-R918 (samRNA)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:1.0pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">Omicron</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-N-TCE11</span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have initiated a large Phase 1 study in South Africa with up to $25.6 million in funding support from CEPI. The study is intended to evaluate our samRNA platform in multiple populations. Two samRNA vaccines (GRT-R912 and GRT-R914) have been engineered using the Spike protein from the SARS-CoV-2 Beta variant (that contributed to the large second wave of SARS-CoV-2 infections in South Africa) with two different TCE expression cassettes and more recently a samRNA vaccine candidate (GRT-R918) that has been engineered using the Spike protein from the SARS-CoV-2 Omicron variant (contributing to the ongoing fourth wave of SARS-CoV-2 infections in South Africa). GRT-R912 and GRT-R914 are being evaluated as a homologous prime/boost in healthy adults &lt;65 years of age who have neither been previously vaccinated against SARS-CoV-2 or infected with SARS-CoV-2 and as a single boost in healthy adults &lt;65 years of age who previously were infected with SARS-CoV-2. Furthermore, GRT-R912 and GRT-R914 will be evaluated in persons living with HIV, an underserved population with 1st generation vaccines who may be at greater risk of serious infections from SARS-CoV-2. GRT-R918 will be investigated as a homologous prime/boost in healthy adults &#x2265; 18 years of age regardless of vaccination status or prior infection with SARS-CoV-2 to evaluate whether an omicron-variant specific vaccine may be more effective than a beta-variant specific vaccine.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BiSpecific Antibodies</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. Due to internal reprioritization of our resources, we have de-prioritized our BiSAb program and, therefore, will not be spending any internal resources on advancing the BiSAb program at this time. The BiSAb program remains wholly owned by Gritstone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CORAL updates</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 4, 2022, we shared positive Phase 1 clinical data from the first cohort (10 &#x3bc;g dose of samRNA) of our CORAL-BOOST study, which showed both strong neutralizing antibody responses to Spike and robust CD8+ T cell responses. A single 10 &#x3bc;g dose of the CORAL program&#x2019;s samRNA vaccine administered to healthy adults &#x2265; 60 years (n=10) at least 22 weeks after two-dose series of Vaxzevria induced:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">New CD8+ T cell responses across a wide set of non-Spike epitopes, including many validated T cell targets in convalescent individuals, demonstrating the potential for durable protection across variants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proportion of responses to TCE targets assessed by ELISpot:</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36% Nucleoprotein (N);</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22% Membrane (M);</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42% ORF3a;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A boost to pre-existing T cell responses to Spike epitopes (assessed by ELISpot) believed to be additive to antibody-based clinical protection conferred by Spike-dedicated vaccines:</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120 IFNy at peak treatment day vs. 55 at treatment day 1 (Spot-forming units per 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">6 </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cells); assessed by ELISpot; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Broad and potent neutralizing antibodies against SARS-CoV-2 Spike protein. Although the Phase 1 study did not include a head-to-head comparison with any other vaccine, the observed neutralizing antibodies were generally consistent with published data from higher doses of first-generation mRNA vaccines in a similar clinical context (COV-BOOST study; Munro et al., Lancet 2021):</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,370 Geomean ID50 titer values observed at day 29 against Wild Type variant vs. 108 at treatment day 1; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">650 Geomean ID50 titer values observed at day 29 against Beta variant vs. 68 at treatment day 1.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional CORAL updates</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enrollment of the second cohort of the Phase 1 CORAL-BOOST study evaluating 30&#xb5;g samRNA dose has concluded and based on similar efficacy seen at 10 and 30 &#xb5;g and increased reactogenicity at the higher dose, the study is proceeding to additional cohorts utilizing the 10 &#xb5;g dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2022, we initiated both the Phase 1 CORAL-CEPI and the CORAL-IMMUNOCOMPRISED trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GRANITE updates</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 13, 2022, we announced the first patient was enrolled for inclusion in the GRANITE -CRC-1L study, a Phase 2/3 trial evaluating our individualized neoantigen vaccine (GRANITE) for first line (1L) maintenance treatment of metastatic, microsatellite-stable colorectal cancer (MSS-CRC).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 13, 2022, we also announced updated interim data from the Phase 1/2 GRANITE trial evaluating individualized immunotherapy in combination with nivolumab (OPDIVO&#174;) and ipilimumab (YERVOY&#174;) in patients with advanced solid tumors. As of the January 5, 2022 data cutoff date, all 12 MSS-CRC patients treated in such GRANITE trial remained alive, and the correlation between ctDNA and overall survival continued to be observed (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 2022, the first patient was enrolled for inclusion in the GRANITE&#x2013;CRC-ADJUVANT study, a randomized, controlled phase 2 trial of adjuvant GRANITE immunotherapy in MSS-CRC patients with stage II/III disease who are ctDNA+ after definitive surgery.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.0%;"></td>
    <td style="width:88.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;text-indent:24.5pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ctDNA Was Reduction Associated with Prolonged Overall Survival in Phase 1/2 trial assessing GRANITE</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:-10.665%;padding-left:9.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img96160895_7.jpg" alt="img96160895_7.jpg" style="width:686px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">License and Collaborations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV Vaccine in Collaboration with Gilead Sciences, Inc.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, we entered into a collaboration, option and license agreement with Gilead Sciences, Inc. (Gilead) to research and develop a vaccine-based immunotherapy for HIV. Together, we plan to develop an HIV-specific therapeutic vaccine using our proprietary prime-boost vaccine platform, comprised of samRNA and adenoviral vectors, with antigens developed by Gilead. Under the terms of the agreement, Gilead invested $60.0 million, consisting of a $30.0 million upfront cash payment and a $30.0 million equity investment at the closing. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. We are also eligible to receive up to an additional $725.0 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid-single-digit to low double-digit tiered royalties on net sales upon commercialization. Gritstone and Gilead received IND clearance for this program in December 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Strategic Collaboration with 2seventy bio</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, we entered into a research collaboration and license agreement with bluebird bio, Inc. (bluebird), to utilize our EDGE&#153; platform to identify and validate tumor-specific targets and provide TCRs directed to 10 selected targets for use in bluebird&#x2019;s cell therapy platform. In November 2021, bluebird assigned the research collaboration and license agreementto its affiliate, 2seventy bio, Inc. (2seventy), in connection with an internal restructuring and subsequent spin-out of 2seventy (such research collaboration and license agreement, as assigned, 2seventy Agreement). In connection with the 2seventy Agreement, we received a non-refundable up-front cash payment of $20.0 million and an additional $10.0 million in equity investment in our Series C convertible preferred stock. We are also eligible to receive up to an aggregate of $1.2 billion in development, regulatory and commercial milestones associated with 2seventy&#x2019;s resulting cell therapy products, as well as tiered, single-digit royalties on sales of the TCR immunotherapy products that utilize the TCRs discovered by us. The royalty term for each TCR immunotherapy product shall be determined on a product-by-product and country-by-country basis and will commence on the first commercial sale of each product in a country and end on the latest of: (i) expiration or termination of the last to expire valid claim of the last licensed patent that covers the product pursuant to the  2seventy Agreement; (ii) expiration of all periods of regulatory exclusivity for the product in such country (in respect of sales in that country); and (iii) 10 years after the first commercial sale of such product in such country (in respect of sales in that country). 2seventy will be solely responsible for all costs and expenses of its development, manufacturing, and commercial activities for resulting therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The identification, validation, selection and development of the TCRs will be conducted during an estimated 5-year research term and may be extended by an additional year under certain conditions. The collaboration will be governed by a joint steering committee with representatives from Gritstone and 2seventy. We and 2seventy have exchanged non-exclusive licenses to carry out the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">research program, and, on a selected target-by-selected target basis, we have granted 2seventy an exclusive worldwide license to research, develop, and commercialize resulting cell therapy products directed to such targets, including rights to utilize TCRs discovered by us. The collaboration term ends on a country-by-country and product candidate-by-product candidate basis based on completion of all payments owed to us by 2seventy thereon. Either party may terminate the 2seventy Agreement upon written notice to the other party in the event of the other party&#x2019;s uncured material breach, subject to a dispute resolution process. In addition, 2seventy may terminate the 2seventy Agreement for convenience upon prior written notice to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Arbutus Biopharma Corporation and Protiva Biotherapeutics</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 16, 2017, we executed a license agreement with Arbutus Biopharma Corporation (Arbutus) and Protiva Biotherapeutics and subsequently amended certain terms in July 2018 (such amended license agreement, Arbutus License Agreement). Arbutus is a leader in LNP technology with a broad intellectual property estate and a large library of LNPs, including multiple LNPs being used in clinical development by its partners, as well as the chemistry expertise to synthesize novel LNPs with properties optimal for samRNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Arbutus License Agreement, Arbutus granted us a worldwide, exclusive (even as to Arbutus, subject to certain limited exceptions), sublicensable, transferable license, to research, develop, manufacture, and commercialize our novel RNA-based platform for intracellular delivery of samRNA encoding TSNA in combination with one or more of Arbutus&#x2019; proprietary LNPs. The licensed technology includes Arbutus&#x2019; portfolio of proprietary and clinically validated LNP products and associated intellectual property and includes technology transfer of Arbutus&#x2019; manufacturing know-how. Following the execution of the Arbutus License Agreement, we have identified an LNP formulation that we believe will be optimal for use in our GRANITE and SLATE clinical trials. Our goal is to deliver a second-generation samRNA immunotherapy that has the potential to serve as a homologous prime-boost immunotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Arbutus License Agreement, we paid Arbutus an upfront payment of $5.0 million. We also agreed to make (i) aggregate payments of up to $73.5 million upon the achievement of specified development milestones for up to three products, (ii) an aggregate $50.0 million in commercial milestone payments and (iii) royalty payments in the low single-digits on net sales of licensed products for a royalty term lasting until the expiration of the last patent covered under the Arbutus License Agreement. Following acceptance of our first IND in September 2018, we made the first milestone payment of $2.5 million to Arbutus. In August 2019, a milestone was met following the initial patient treatment of SLATE in our GO-005 clinical trial. In connection with such milestone, we recorded $3.0 million as research and development expenses in 2019 and made the milestone payment in October 2019. Further milestone payments are not expected to occur before 2023.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Arbutus License Agreement continues in effect until the last to expire royalty payment or early termination. The Arbutus License Agreement is terminable by us for convenience with 60 days prior written notice, upon payment of a no-cause termination sum. We may also terminate it in the event of material adverse safety data for a product, failure to achieve a primary or secondary efficacy endpoint, or if a regulatory authority takes action that prevents us from commercializing any product. Either party may terminate the Arbutus License Agreement for material breach, and Arbutus may terminate it for abandonment or if we challenge Arbutus patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Genevant Sciences GmbH</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 20, 2020, we entered into an Option and License and Development Agreement with Genevant Sciences GmbH (Genevant, and such agreement, 2020 Genevant Agreement). Pursuant to the 2020 Genevant Agreement, Genevant granted us exclusive license rights under certain intellectual property related to Genevant&#x2019;s lipid nanoparticle technology (LNP Technology) for a single indication (HIV), and we agreed to pay Genevant an initial payment of $2.0 million, up to an aggregate of $71.0 million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The 2020 Genevant Agreement expands our intellectual property rights to the LNP technology originally obtained pursuant to our Arbutus License Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2020 Genevant Agreement, Genevant also granted us certain options to expand the licensed field beyond the single indication. If we exercise any options under the 2020 Genevant Agreement to expand the licensed field, we would be required to pay to Genevant additional option exercise fees, certain development, regulatory and commercial milestones and royalties on net sales of licensed products in respect of the expanded licensed field. We also granted Genevant a nonexclusive license to certain intellectual property developed under the Arbutus License Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 Genevant Agreement continues in effect until the last to expire royalty term or early termination. The 2020 Genevant Agreement is terminable by us for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either us or Genevant may terminate the 2020 Genevant Agreement for material breach, subject to a cure period, and Genevant may terminate it if we challenge a licensed patent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Genevant Sciences GmbH</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 15, 2021, we entered into a Non-Exclusive License and Development Agreement with Genevant (2021 Genevant Agreement). Pursuant to the 2021 Genevant Agreement, we obtained a nonexclusive license to Genevant&#x2019;s LNP Technology to develop and commercialize self-amplifying RNA vaccines against SARS-CoV-2. Further, we (i) agreed to pay Genevant an upfront payment of $1.5 million and (ii) are subject to (x) additional payments up to an aggregate of $166.0 million per product, upon achievement of certain development and commercial milestones and (y) tiered royalties ranging from the mid-single digits to mid-teens on net sales of licensed products for a royalty term lasting until the later of expiration of the last covered patent under the  2021 Genevant Agreement. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of any amounts that we receive from sublicenses to the COVID-19 program subject to certain conditions. The 2021 Genevant Agreement further expands our intellectual property rights to the LNP technology originally obtained pursuant to the Arbutus License Agreement.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2021 Genevant Agreement continues in effect until the last to expire royalty term or early termination. The 2021 Genevant Agreement is terminable by us for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either us or Genevant may terminate the 2021 Genevant Agreement for material breach, subject to a cure period, and Genevant may terminate it if we challenge a licensed patent.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Genevant Agreement contains, among other provisions, representation and warranties, indemnification obligations, confidentiality, audit and inspection, and intellectual property sharing provisions in favor of each party that are customary for an agreement of this nature.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CEPI Funding for CORAL Program</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021, CEPI agreed to provide funding of up to $20.6 million to us to advance our CORAL program, with an initial clinical trial of our second-generation COVID-19 vaccine in South Africa. Under the terms of that agreement (CEPI Funding Agreement), CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study initially planned to evaluate two different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The CEPI Funding Agreement also provides for an agreement on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available for procurement and allocation to the COVAX Facility, which aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of our COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. In December 2021, we and CEPI amended the CEPI Funding Agreement to provide for up to $5 million in additional funding to conduct a Phase 1 clinical trial of the CORAL program&#x2019;s Omicron vaccine candidate in South Africa.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the World Health Organization (WHO), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the our COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, we must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate (the determination of whether to proceed or not with such trial shall be made by us in our sole discretion). In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by us under the CEPI Funding Agreement, (ii) the project undertaken by us under the CEPI Funding Agreement must be terminated, (iii) we become unable to discharge its obligations under the CEPI Funding Agreement, (iv) we fail to meet certain criteria set forth in the CEPI Funding Agreement, or (v) we commit fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement. Certain termination rights for CEPI are subject to cure periods.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional information on all our license and collaboration arrangements, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License Agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; in Note 7 to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing is a vital component of our individualized immunotherapy platform, and we are devoting significant resources to manufacturing and process development in an effort to maintain the potential safety and efficacy of our product candidates, as well as to reduce our per-unit manufacturing costs and time to market. The production of our individualized immunotherapy candidates requires two distinct elements for each patient: tumor biopsy analysis to determine candidate neoantigens, followed by manufacture of vectors containing an individualized cassette encoding the selected neoantigens. SLATE and CORAL contains a fixed cassette with TSNA or SARS-CoV-2 vaccine constructs that is shared across cancer patients/subjects rather than a cassette unique to an individual patient, which is designed to provide an off-the-shelf alternative to our individualized manufactured product candidate, GRANITE. The manufacture of these vectors involves complex processes, including per-patient plasmid production, mammalian cell production of virus and RNA synthesis and lipid encapsulation. SLATE and CORAL manufacturing, as a fixed, &#x201c;off-the-shelf&#x201d; product candidate, are not time-sensitive and while manufacturing scale differs, both are relatively straightforward operationally. GRANITE, on the other hand, is an &#x201c;N of 1&#x201d; product candidate and is manufactured in real-time for each patient, which involves a greater logistical burden.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our goal is to carefully manage our fixed-cost structure, maximize optionality, and drive long-term cost of goods as low as possible. We have used a hybrid approach to manufacturing and release of our individualized immunotherapy candidates whereby certain elements of our product candidates are manufactured and tested on an outsourced basis at CMOs, and other elements of our product candidates are manufactured and released internally at the 42,600 square foot manufacturing facility we established in 2017 in Pleasanton, California, all designed in compliance with cGMP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our manufacturing process begins with receipt of a patient&#x2019;s routine biopsy and blood sample at our Cambridge, Massachusetts facility, where TSNA identification is performed using the EDGE&#153; platform. The TSNA sequences generated by our platform are sent electronically to our Pleasanton, California manufacturing facility to generate the patient-specific TSNA cassette, which is then cloned into each of the ChAd and samRNA vectors and amplified. Following amplification, the ChAd vector containing the cassette is further manufactured into the final drug product and vialed onsite. In parallel at the Pleasanton facility, the samRNA vector is manufactured into RNA, formulated into LNP, and vialed onsite. Currently, the entire manufacturing process, from biopsy receipt at our facilities to the release and shipment of the individualized immunotherapy candidate to the clinical site for patient administration, often takes approximately 16-20 weeks in principle. Our goal is for this production and release timeline (and associated cost) to diminish over time due to process scaling, potential improvements in production and testing technologies, internal process expertise, internalization of potential reductions in regulatory testing requirements based on clinical experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To achieve this, our process development group is focused on several key initiatives. The first is investigating novel approaches to manufacturing our products, including process optimization and quality by design of each intermediate, drug substance and drug product. Additionally, we are systematically characterizing our manufacturing processes, including product intermediates and manufacturing unit operations. This characterization effort is designed to enable us to implement process changes over the entire product lifecycle and to quickly react to evolving process technologies that can lead to reductions in per-unit manufacturing costs and shorter process cycle times. In addition, we plan to establish automated, closed-platform manufacturing processes. Our goal is for these processes to enable us to conduct manufacturing in a lower-classified, lower cost manufacturing environment for multiple steps of our drug product manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our CORAL program, manufacturing of early-stage clinical lots was initiated on our Pleasanton, California manufacturing facility towards the end of 2020 and we have continued to produce next generation, variant-specific clinical lots through 2021 within this facility. Product candidates include both samRNA and adenoviral vectors to deliver SARS-CoV-2 viral antigens. Additional scale-up activities involving CMOs will be needed as the CORAL program progresses leading to large demand for the product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our manufacturing strategy is currently structured to support our U.S., E.U., South African, and Australian development plans. We believe this manufacturing strategy developed for global distribution will enable use in other geographies. Specific supply strategies for other geographies will be developed as part of our clinical and commercial plans for such other geographies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization Plan</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have any approved therapies, and we do not anticipate receiving marketing authorization for our early development candidates in either the United States or other worldwide regions in the near future. An internal expansion of sales, marketing, and commercial distribution capabilities would be developed once we have obtained clinical data that can support licensure following discussions with the FDA or other worldwide health authorities. If and when any of our development candidates are approved for commercialization, we intend to create an infrastructure to support ongoing sales in the United States and, possibly in other regions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries put significant emphasis and resources into the development of novel and proprietary therapies for treatment of cancer and infectious disease. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. We anticipate that we will continue to face increasing competition in our field as new therapies, technologies, and data emerge.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the current standard of care for patients, a number of parties in the field of immunotherapy are pursuing commercial and academic clinical trials. Results from these trials have fueled continued interest in immunotherapy, and our competitors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the neoantigen space, BioNTech AG (which acquired Neon Therapeutics in May 2020) in collaboration with Genentech Inc., Moderna Therapeutics, Inc. in collaboration with Merck &amp; Co. Inc., Advaxis Immunotherapies, Achilles Therapeutics, NousCom AG, Genocea Biosciences Inc., Nykode Therapeutics AS in collaboration with Genentech Inc., PACT Pharma, Inc., Transgene SA, and Geneos Therapeutics, Inc. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the SARS-CoV-2 space, Pfizer, Inc. in collaboration with BioNTech AG, Moderna Therapeutics, Inc., Janssen Pharmaceuticals, Inc., AstraZeneca plc, CureVac AG in collaboration with GlaxoSmithKline plc., Sanofi in collaboration with GlaxoSmithKline plc, Novavax, Inc., Arcturus Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Nykode Therapeutics AS, and VBI Vaccines, Inc.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the Infectious Disease space, Moderna, Pfizer Inc. in collaboration with BioNTech AG, AstraZeneca plc, Johnson &amp; Johnson, Merck, Novavax, Inc., Sanofi, GlaxoSmithKline plc. and CureVac AG.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the samRNA space, GlaxoSmithKline plc, Arcturus Therapeutics, Inc., HDT Bio, Corp. and Imperial College London in collaboration with AstraZeneca plc.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of our programs are likely to be their efficacy, safety, cost and convenience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products and services, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. We rely on a combination of patents and trade secrets, as well as contractual protections, to establish and protect our intellectual property rights. We seek to protect our proprietary position by, among other things, filing patent applications in the United States and internationally. Our patent estate includes patents and patent applications with claims relating to our products, methods, and manufacturing processes, and broader claims for potential future products and developments. As of December 31, 2021, our solely-owned patent portfolio includes, on a worldwide basis, pending patent applications and issued patents relating to our products, methods, and manufacturing processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our solely-owned patent estate includes a portfolio of pending patent applications and issued patents related to our cancer-based platform, including our bispecific antibody platform and TCRs; and a portfolio of pending patent applications related to our infectious disease-based platform. Details regarding these portfolios are provided below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our solely-owned patent portfolio related to our cancer-based platform, including our bispecific antibody platform and TCRs, includes domestic and international patent rights with claims related to antigen identification and related compositions, uses and manufacture. Any patents that have or may issue from these patent rights are expected to expire between 2036 and 2042, absent any patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our solely-owned patent portfolio related to our infectious disease-based platform includes domestic and international patent rights with claims related to infectious disease-based compositions and their related uses and manufacture. Any patents that have or may issue from these patent rights are expected to expire between 2037 and 2042, absent any patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to patents, we have filed for trademark registration with the United States Patent and Trademark Office (USPTO) as well as certain other international trademark agencies, for &#x201c;GRITSTONE,&#x201d; &#x201c;GRANITE,&#x201d; &#x201c;SLATE&#x201d; and our logo. Furthermore, we rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some instances, we submit patent applications directly with the USPTO as provisional patent applications. Provisional applications for patents were designed to provide a lower-cost first patent filing in the United States. Corresponding non-provisional patent applications must be filed not later than twelve (12) months after the provisional application filing date. The corresponding non-provisional application benefits in that the priority date(s) of the patent application is/are the earlier provisional application filing date(s), and the patent term of the finally issued patent is calculated from the later non-provisional application filing date. This system allows us to obtain an early priority date, add material to the patent application(s) during the priority year, obtain a later start to the patent term and to delay prosecution costs, which may be useful in the event that we decide not to pursue examination in an application. We file U.S. non-provisional applications and Patent Cooperation Treaty (PCT) applications that claim the benefit of the priority date of earlier filed provisional applications, when applicable. The PCT system allows a single application to be filed within twelve (12) months of the original priority date of the patent application, and to designate PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the end of the period of two and a half years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first two and a half years of filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For all patent applications, we determine claiming strategy on a case-by-case basis. Advice of counsel and our business model and needs are always considered. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, assuming these are strategically valuable. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum coverage and value are obtained for our processes, and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize that the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws. The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted or further altered even after patent issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates or for our technology platform. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop, manufacture and commercialize specific aspects of our products. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities. The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future technology may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We further own trade secrets relating to our technology, and we maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our trade secrets and know-how by entering into confidentiality agreements with third parties, consultants and employees who have access</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to such trade secrets and know-how. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#x2019;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we enter into employment agreements that require employees to assign to us any inventions, trade secrets or know-how that they develop while employed by us. Although we take steps to protect our proprietary information and trade secrets, including through agreements with our employees and consultants, these agreements may be breached, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a more comprehensive discussion of the risks related to our intellectual property, please see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA regulates biologic products under both the Federal Food, Drug and Cosmetic Act (FDCA) and the Public Health Service Act and their respective implementing regulations. Our product candidates are subject to regulation by the FDA as biological products. Biological products require the submission of a biologics license application (BLA) and licensure, which constitutes approval, by the FDA before being marketed in the United States. None of our product candidates has been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. Failure to comply with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval may result in administrative or judicial sanctions. These sanctions could include the FDA&#x2019;s refusal to approve pending applications, suspension or revocation of approved applications, warning letters, product recalls, product seizures, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#x2019;s good laboratory practice, or GLP, regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an IND which must become effective before clinical trials may begin; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before the trial is commenced;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials in accordance with the IND, protocol, and FDA&#x2019;s good clinical practice (GCP) regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s continued safety, purity and potency, and of selected clinical investigation sites, </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical and Clinical Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, under the National institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (IBC) a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Generally, a separate submission to the IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of BLA approval, human clinical trials are typically conducted in three (3) sequential phases that may overlap or be combined.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1&#x2014;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2&#x2014;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3&#x2014;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and they must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">BLA Submission and Review</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA unless a waiver or exemption applies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once a BLA has been submitted, within sixty (60) days, the FDA first reviews the BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once filed, the FDA&#x2019;s goal is to review standard applications within ten (10) months after the filing date or, if the application qualifies for priority review, six (6) months after the filing date. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The FDA may convene an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites, as well as the sponsor, to assure compliance with GCP.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the product will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use. A REMS program may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#x2019;s risks, or other elements to assure safe use, such as limitations on who may prescribe or dispense the drug, dispensing only under certain circumstances, special monitoring and the use of patient registries. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Product candidates are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for frequent interactions with the review team during product development. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any marketing application for a biologic submitted to the FDA for approval, including a product candidate with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. Sponsors may also obtain a priority review voucher upon approval of a BLA for certain qualifying diseases and conditions that can be applied to a subsequent BLA submission. Generally, priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six (6) months of the sixty (60) day filing date, compared with ten (10) months under standard review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2017, the FDA established the new regenerative medicine advanced therapy (RMAT) designation as part of its implementation of the 21st Century Cures Act, which was signed into law in December 2016. To qualify for RMAT designation, the product candidate must meet the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like fast track and breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process. In addition, even if a product candidate qualifies for one or more of these programs, the FDA may later decide that it no longer meets the conditions for designation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, meaning there is no previously approved &#x201c;same drug&#x201d; for the same orphan condition, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">drug or biologic for the same orphan disease or indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A designated orphan drug may not receive orphan drug exclusivity that covers the full approved indication if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emergency Use Authorization</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Commissioner of the FDA, under delegated authority from the Secretary of Health and Human Services (HHS), may, under certain circumstances in connection with a declared public health emergency, allow for the marketing of a product that does not otherwise comply with FDA regulations by issuing an Emergency Use Authorization (EUA) for such product. Before an EUA may be issued by HHS, the Secretary must declare an emergency based on a determination that public health emergency exists that affects or has the significant potential to affect, national security, and that involves a specified biological, chemical, radiological, or nuclear agent or agents (CBRN), or a specified disease or condition that may be attributable to such CBRN. On February 4, 2020, the HHS Secretary determined that there is such a public health emergency that involves the virus now known as SARS-CoV-2, the virus that causes the COVID-19 infection. Once the determination of the threat or emergency has been made, the Secretary of HHS must then declare that an emergency exists justifying the issuance of EUAs for certain types of products (referred to as EUA declarations). On March 27, 2020, the Secretary of HHS declared, on the basis of his determination of a public health emergency that has the potential to affect national security or the health and security of U.S. citizens living abroad that involves SARS-CoV-2, that circumstances exist justifying authorization of drugs and biologics during the COVID-19 pandemic, subject to the terms of any EUA that is issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once an EUA declaration has been issued, the FDA can issue EUAs for products that fall within the scope of that declaration. To issue an EUA, the FDA Commissioner must conclude that (1) the CBRN that is referred to in the EUA declaration can cause serious or life-threatening diseases or conditions; (2) based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the disease or condition attributable to the CBRN and that the product&#x2019;s known and potential benefits outweigh its known and potential risks; and (3) there is no adequate, approved, and available alternative to the product. Products subject to an EUA must still comply with the conditions of the EUA, including labeling and marketing requirements. Moreover, the authorization to market products under an EUA is limited to the period of time the EUA declaration is in effect, and the FDA can revoke an EUA in certain circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences and significant interruptions in manufacturing, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon BLA sponsors and any third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are for uses of the product approved by the FDA, that are considered consistent with the approved label, and for which the company has appropriate substantiation, as applicable. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses or promotion that is otherwise false or misleading. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biosimilars and Reference Product Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively ACA) signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered to a patient more than once, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four (4) years following the date that the reference product was first licensed by the FDA. In addition, the FDA may not approve a biosimilar product until twelve (12) years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves an original BLA containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the competing product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#x201c;interchangeable&#x201d; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Regulation of Companion Diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may require use of an in vitro diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (PMA).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If use of companion diagnostic is essential to safe and effective use of a biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#x201c;In Vitro Companion Diagnostic Devices.&#x201d; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption (IDE) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of in vitro companion diagnostic devices on issues related to co-development of these products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA generally requires companion diagnostics intended to select the patients who will respond to treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these in vitro companion diagnostics in conjunction with the review of biologics involves coordination of review by the FDA&#x2019;s Center for Drug Evaluation and Research and by the FDA&#x2019;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#x2019;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#x2019;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government Regulation Outside of the United States</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions, including the European Union, governing, among other things, clinical trials, marketing authorizations, post-marketing authorization requirements and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ethical, social and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-clinical studies and clinical trials</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical studies must be conducted in compliance with the principles of good laboratory practice, as set forth in European Union Directive 2004/10/EC. In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials of medicinal products in the European Union must be conducted in accordance with EU and national regulations and the International Conference on Harmonization (ICH) guidelines on GCPs, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products (ATMPs). If the sponsor of the clinical trial is not established within the European Union, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#x2018;no fault&#x2019; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (CTR), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the European Union via a Clinical Trials Information System, which contains a centralized EU portal and database.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and EU-wide regulatory requirements may also apply.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketing Authorization</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to market our future product candidates in the European Union, and in many other foreign jurisdictions, we must obtain separate regulatory approvals. In the European Union, medicinal product candidates can only be commercialized after obtaining a marketing authorization (MA). To obtain regulatory approval of a product candidate (including an investigational biological product)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under EU regulatory systems, we must submit a marketing authorization application (MAA). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAAs:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Centralized MAAs&#x201d; are issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and is valid throughout the European Union. It is compulsory for certain types of product candidates, such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) ATMPs such as gene therapy, somatic cell-therapy or tissue-engineered medicines and (iv) medicinal products containing a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for any other products containing new active substances not authorized in the European Union or for product candidates which constitute a significant therapeutic, scientific, or technical innovation or for which the granting of authorization would be in the interests of public health in the European Union.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Committee for Advanced Therapies (CAT), is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which an MAA is submitted. The CAT&#x2019;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#x2019;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;National MAs&#x201d; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the Mutual Recognition Procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the Reference member state.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the centralized procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days. In exceptional cases, the CHMP might perform an accelerated review of an MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines (PRIME), which provides incentives similar to the breakthrough therapy designation in the United States. In March 2016, the EMA launched a PRIME scheme as a voluntary scheme aimed at enhancing the EMA&#x2019;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment, but this is not guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#x2019;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Moreover, in the European Union, a &#x201c;conditional&#x201d; MA may be granted in cases where all the required safety and efficacy data are not yet available. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#x201c;standard&#x201d; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MA may also be granted &#x201c;under exceptional circumstances&#x201d; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. This MA is close to the conditional MA as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant does not hold the complete data set legally required for the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">grant of an MA. However, unlike the conditional MA, the applicant does not have to provide the missing data and will never have to. Although the MA &#x201c;under exceptional circumstances&#x201d; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the MA is withdrawn in case the risk-benefit ratio is no longer favorable.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MAs have an initial duration of five years. After these five years, the authorization may be renewed for an unlimited period on the basis of a reevaluation of the risk-benefit balance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data and marketing exclusivity</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The European Union also provides opportunities for market exclusivity. Upon receiving MA, reference products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, the data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until 10 years have elapsed from the initial MA of the reference product in the European Union. The overall 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the European Union&#x2019;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the European Union. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Medicinal Products</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the European Union are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition; (2) either (a) such condition affects not more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the European Union to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the European Union or, if such method exists, the product will be of significant benefit to those affected by that condition.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the European Union, an application for designation as an orphan product can be made any time prior to the filing of the application for MA. Orphan drug designation entitles a party to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of an MA, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the regulatory authorities cannot accept another MAA, grant an MA, or accept an application to extend an MA for a similar product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (PIP). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The orphan exclusivity period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan drug destination, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity, or where the prevalence of the condition has increased above the threshold. Granting of an authorization for another similar orphan medicinal product where another product has market exclusivity can happen at any time if: (i) the second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior, (ii) inability of the applicant to supply sufficient quantities of the orphan medicinal product or (iii) where the applicant consents to a second orphan medicinal product application. A company may voluntarily remove a product from the orphan register.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Development</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#x2019;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all member states and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two-year extension of the orphan market exclusivity is granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,128,128,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (PSURs).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> All new MAAs must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The aforementioned EU rules are generally applicable in the European Economic Area (EEA), which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brexit and the Regulatory Framework in the United Kingdom</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United Kingdom left the European Union on January 31, 2020, following which existing EU medicinal product legislation continued to apply in the United Kingdom during the transition period under the terms of the EU-UK Withdrawal Agreement. The transition period, which ended on December 31, 2020, maintained access to the EU single market and to the global trade deals negotiated by the European Union on behalf of its members. The transition period provided time for the United Kingdom and European Union to negotiate a framework for partnership for the future, which was then crystallized in the Trade and Cooperation Agreement (TCA) and became effective on the January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> EU laws which have been transposed into UK law through secondary legislation continue to be applicable as &#x201c;retained EU law&#x201d;. However, new legislation such as the EU CTR will not be applicable. The UK government has passed a new Medicines and Medical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Devices Act 2021, which introduces delegated powers in favor of the Secretary of State or an &#x2018;appropriate authority&#x2019; to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) is the UK&#x2019;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules will apply in Northern Ireland than in England, Wales, and Scotland (Great Britain); broadly, Northern Ireland will continue to follow the EU regulatory regime, but its national competent authority will remain the MHRA. The MHRA has published a guidance on how various aspects of the UK regulatory regime for medicines will operate in Great Britain and in Northern Ireland following the expiry of the Brexit transition period on December 31, 2020. The guidance includes clinical trials, importing, exporting, and pharmacovigilance and is relevant to any business involved in the research, development, or commercialization of medicines in the United Kingdom. The new guidance was given effect via the Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019 (Exit Regulations).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for centrally authorized products were automatically converted or grandfathered into UK MAs, effective in Great Britain (only), free of charge on January 1, 2021, unless the MA holder chooses to opt-out. In order to use the centralized procedure to obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, after Brexit, companies established in the United Kingdom can no longer use the EU centralized procedure and instead an EEA entity must hold any centralized MAs. In order to obtain a UK MA to commercialize products in the UK, an applicant must be established in the United Kingdom and must follow one of the UK national authorization procedures or one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in the United Kingdom. The MHRA may rely on a decision taken by the European Commission on the approval of a new (centralized procedure) MA when determining an application for a Great Britain authorization or use the MHRA&#x2019;s decentralized or mutual recognition procedures which enable MAs approved in EU member states (or Iceland, Liechtenstein, Norway) to be granted in Great Britain.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> There will be no pre-MA orphan designation. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the prevalence of the condition in Great Britain, rather than the European Union, must not be more than five in 10,000). Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in Great Britain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulation of Companion Diagnostics</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, in vitro diagnostic medical devices (IVDs) are regulated by Directive 98/79/EC (the Directive) which regulates the placing on the market, the CE marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufactures and devices as well as the vigilance procedure. In vitro diagnostic medical devices must comply with the requirements provided for in the Directive, and with further requirements implemented at national level (as the case may be).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulation of companion diagnostics will be subject to further requirements once the in-vitro diagnostic medical devices Regulation (No 2017/746) (EU IVDR) will become applicable on May 26, 2022. However, on October 14, 2021, the European Commission proposed a &#x201c;progressive&#x201d; roll-out of the EU IVDR to prevent disruption in the supply of IVDs. The European Parliament and Council voted to adopt the proposed regulation on December 15, 2021 and the regulation entered into force on January 2022. The EU IVDR will fully apply on May 26, 2022 but there will be a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EU IVDR introduces a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue a CE certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or an MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from a national competent authority or the EMA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Healthcare Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business, which may constrain the financial arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and relationships through which we and our partners research, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security and transparency laws regarding drug pricing and payments and other transfer of value to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data Privacy and Security Laws</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder (collectively HIPAA) and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act (CCPA), the California Privacy Rights Act (CPRA) and the EU General Data Protection Regulation, or GDPR, govern the privacy and security of personal data, including health-related data in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. No regulatory authority has granted approval for a individualized cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.   Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through December 31, 2021, and reduced payments to several types of Medicare providers. Recently enacted legislation eliminates the statutory cap on the Medicaid drug rebate, currently set at 100% of a drug&#x2019;s average manufacturer price, beginning January 1, 2024.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things, reduce or limit the prices of drugs and make them more affordable for patients, such as by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries, reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs, bring more transparency to drug pricing rationale and methodologies, enable the government to negotiate prices for drugs covered under Medicare, revise rules associated with the calculation of Medicaid Average Manufacturer Price and Best Price, including removing the current statutory 100% of Average Manufacturer Price per-unit cap on Medicaid rebate liability effective January 1, 2024, which may significantly affect the amount of rebates paid on prescription drugs under Medicaid, and facilitate the importation of certain lower-cost drugs from other countries. More recently, in July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. The executive order required the Secretary of Health and Human Services to develop a comprehensive plan for addressing drug prices. The plan was released on September 9, 2021, and it includes support for legislative and administrative actions that would improve affordability, access, competition, and foster scientific innovation. Congress is currently considering a number of bills relating to drug pricing, including bills that would impose rebate obligations for Medicare (and potentially other utilization) for price increases greater than the rate of inflation, require drug pricing negotiations in Medicare, redesign the Part D benefit to lower patient costs and overall spending, and introduce enhanced transparency measures into drug pricing. In particular, the Build Back Better Act introduces drug pricing reforms that would, among other things, allow the federal government to negotiate prices for some high-cost drugs covered under Medicare Parts B and D, introduce inflationary rebates on certain Medicare Part B and Medicare Part D drugs to support limits on drug price increases in Medicare and private insurance, redesign the structure of the Part D benefit, and require payment of rebates on covered outpatient drugs that are paid for by a state Children&#x2019;s Health Insurance Program. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Interactions with the FDA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EDGE Medical Device Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In two separate FDA interactions, the FDA advised us that our machine-learning software will not be subject to medical device diagnostic regulations. In August 2016, the FDA&#x2019;s Center for Devices and Radiological Health, determined that the TSNA prediction software is a Non-Significant Risk (NSR), device, and that an IDE submission was not required to conduct clinical studies with our product candidate. In April 2017, the FDA&#x2019;s Center for Biologics Evaluation and Research (CBER) confirmed that medical device diagnostic regulations did not apply to our testing and processing of the patient-specific TSNA, and that quality requirements could be met through compliance with biologic cGMPs. Based on these interactions, we believe no additional device-related regulatory submissions (such as an investigational device exemption or pre-market approval application) or device development activities are required, and our TSNA prediction software procedure will be regulated as part of our cGMP manufacturing process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GRANITE Development Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Safety</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a Pre-IND interaction with the FDA&#x2019;s CBER Office of Tissues and Advanced Therapies (OTAT) the FDA advised us that a single toxicological animal study with a representative vector could be able to support preclinical safety for purposes of IND submission. Subsequent to this discussion, we submitted proposed protocols for GLP toxicology and biodistribution studies for OTAT&#x2019;s review in connection with a Pre-IND meeting, and OTAT confirmed that a single GLP toxicology study could support IND submission. In this GLP toxicology study, we administered our ChAd and the samRNA vectors to Indian Rhesus macaques. The heterologous prime-boost immunotherapy approach when administered intramuscularly was well tolerated at the clinical maximal dose of each platform, with some animals presenting flu-like symptoms. Preclinical chemistry findings included a transient increase in select cytokines, which resolved rapidly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our GRANITE Pre-IND meeting with OTAT the FDA previewed Clinical Protocol GO-004 and confirmed that the overall design appeared reasonable, while providing comments on the study populations and dose determination which we incorporated into the Phase1/2 protocol. OTAT also concurred with our dose limiting toxicity assessment criteria, but reserved comment on the starting dose and dose escalation pending the completion of planned preclinical studies. We intend to include these elements in the protocol, which we believe may permit a faster progression and fewer patients to reach the clinical protocol&#x2019;s combination cohort (Phase 1, Part C).</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our Type-C meeting with OTAT, the FDA reviewed the Phase 2/3 clinical study design for the planned study evaluating first-line maintenance in patients with MSS CRC, and discussed approaches for a registrational path. We believe we have aligned with the FDA to conduct a combined, yet regulatorily and statistically distinct Phase 2/3 clinical study. Molecular response is the primary endpoint for the phase 2 component of the trial, an exploratory efficacy endpoint in the FDA&#x2019;s view. We expect that preliminary Phase 2 data, including molecular response, RECIST radiologic response and Progression-Free Survival (utilizing iRECIST/iPFS as well as RECIST/PFS), together with available ctDNA data will be previewed with the FDA in a subsequent meeting. We expect that the MSS-CRC patient population will be defined with local testing to exclude MSI patients, with reference data characterizing the expected negligible contributory effect of PD-(L)1/ipilimumab in combination with GRANITE.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Chemistry, Manufacturing &amp; Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a Type-C Facilities meeting with the FDA&#x2019;s CBER Division of Manufacturing and Product Quality (DMPQ) we obtained FDA feedback on our then-proposed design for the multi-use clinical manufacturing facility in Pleasanton, California. Importantly, the FDA concurred with our plan to build a facility designed to accommodate manufacture of multiple patient-specific lots in parallel within the same manufacturing suite, which we expect will provide a substantial increase in scalability within a smaller allocation of cleanrooms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At our subsequent GRANITE Pre-IND meeting with OTAT, the FDA concurred with our proposed use of select rapid release testing methods in which we proposed replacing standard cell-culture based tests with faster polymerase chain reaction methods. As discussed with the FDA, we submitted qualification of these methods in our IND submission for GRANITE. The FDA also found our proposed stability program to be generally acceptable to support the then-proposed Phase 1 clinical study of GRANITE, where only one representative patient lot per year was placed on product stability during conduct of the clinical program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In support of transitioning the GRANITE manufacturing process from external contract manufacturing organizations to Our Pleasanton manufacturing facility, an IND amendment was submitted to the FDA outlining the Chemistry, Manufacturing, and Controls documentation changes for the ChAd and samRNA product candidates. These revisions included a plasmid backbone change for the samRNA vector and a process improvement for the samRNA drug substance. These updates have been implemented and are currently being utilized in our Pleasanton manufacturing facility.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our Type-C meeting with OTAT, the FDA clarified phase appropriate CMC requirements to support advancement into late clinical development. The FDA detailed qualification efforts for bioinformatics, manufacturing, and testing to be submitted prior to initiation of the Phase 2 and Phase 3 portions of the Phase 2/3 clinical study. These include providing bioinformatics documentation, qualification of critical analytical assays which include a robust potency assay, as well as materials to support manufacturing process improvements being implemented for GRT-C901 and GRT-R902. We expect that a comprehensive review of CMC will occur in a subsequent pre-Phase 3 meeting with the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GRANITE Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA allowed IND for GRANITE to proceed in September 2018. In December 2018, the FDA granted fast track designation to GRANITE for the treatment of colorectal cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SLATE Development Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical Safety</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In pre-IND communications with the FDA, following a justification of comparability of ChAd and samRNA products, we received feedback from the FDA noting that pre-clinical pharmacology, pharmacokinetic, and toxicology studies conducted in support of the GRANITE IND, could be used to support the initiation of the clinical study proposed under the SLATE IND. In follow-up correspondence, the FDA requested additional safety pharmacology information on the general anticipated immunogenicity and auto-reactivity elicited with each of the 20 neoantigens expressed in the SLATE cassette, as well as the impact of order and orientation of the neoantigens within the expression cassette.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical Regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our SLATE Pre-IND communication with OTAT the FDA previewed Clinical Protocol NCT03953235, GO-005 and confirmed that the overall design appeared reasonable, but requested we add language to clarify our proposed dose escalation and stopping rules. The FDA had additional questions on our proposed Next Generation Sequencing method to screen patients for their HLA type and communicated that this novel method may be viewed as a companion diagnostic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulatory Chemistry, Manufacturing &amp; Controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Much of the manufacturing process contained in SLATE was similar to that used in the GRANITE IND, therefore, the FDA&#x2019;s pre-IND feedback focused primarily on the quality of the reagents, drug product characterization and release, and ongoing stability requests. The FDA inquired on the status of certain research-grade reagents and reminded us of the need to progress to GMP grade materials in the manufacture drug product by the time of BLA approval and commercial licensure. In order to retain consistency in the manufactured drug product across SLATE batches, we were asked to amend the specification of certain release assays&#x2019; criteria and continue the development of quantitative potency assays for the ChAd and samRNA products prior to approval, and we were asked to summarize our QC plan to prevent, detect, and correct deficiencies that may compromise product integrity or function, or that may lead to the possible transmission of adventitious infectious agents. Additionally, the FDA provided feedback on the proposed method for qualifying Gritstone&#x2019;s proposed accelerated adventitious agent release assay.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SLATE Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA allowed our IND for SLATE to proceed in June 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CORAL Development Program</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A pre-IND interaction with the FDA was conducted to review the proposed clinical investigation of ChAd vectors encoding the SARS-CoV-2 and CD8+ T-cell epitope spike antigen sequences in normal healthy subjects. The FDA concluded that the overall manufacturing and release testing for the CORAL vaccines candidates, which is similar to the GRANITE/SLATE process, appeared acceptable and requested detail on the transfection process, grade of materials, and release tests be submitted in the IND. We also received feedback that pre-clinical pharmacokinetic, and toxicology studies conducted in support of the GRANITE IND could be used to support the safety information needed to initiate the SARS-CoV-2 clinical study, and that additional animal immune response pharmacodynamic data would be submitted within the IND. The FDA previewed the proposed clinical protocol, confirmed that the overall design appeared reasonable and requested we include language to clarify dose escalation, stopping rules and a sentinel arm. The FDA requested that we exclude those subjects who are being treated with COVID-19 investigational agents or who have a high risk of potential exposure to SARS-CoV-2.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CORAL Regulatory Milestones</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021 the FDA acknowledged our biologics master file which provides CMC and non-clinical sections support of NIH&#x2019;s IND to study CORAL program candidates in previously vaccinated healthy volunteers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2021 the MHRA provided a notice of acceptance for our CTA to initiate a clinical study of certain CORAL program candidates to boost vaccinate healthy volunteers &gt;60 years in the UK. Gritstone will continue to enroll subjects and expand the CORAL-BOOST program in the ongoing trial in the UK. Since study recruitment can be met within the UK, we currently do not plan to expand the CORAL-BOOST clinical trial into the US under our own IND.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021 the MHRA provided a notice of acceptance for our CTA to initiate a clinical study of certain CORAL program candidates in previously vaccinated B-cell deficient subjects in the UK.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">South Africa&#x2019;s SAHPRA provided a notice of acceptance for our CTA to initiate a clinical study to test certain CORAL program candidates in COVID-19 na&#xef;ve, convalescent, and HIV subjects in South Africa.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Information About Segments</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We manage our operations as a single reportable segment for the purposes of assessing performance and making operating decisions. See &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Note 2. Summary of Significant Accounting Policies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; in the notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a mission-driven organization, we value and foster a culture of collaboration, discovery and passion, which is reflected in our hiring and retention strategies. We employ talented individuals who have the skills and expertise to meet the challenges of our mission, and we recognize that our employees are key to our success. Our human capital objectives include hiring goals set to provide us with necessary expertise, integrating new employees, and retaining, incentivizing and developing our existing employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 193 full-time employees, including a total of 53 employees with M.D. or Ph.D. degrees. Within our workforce, 86 employees are engaged in research and development, 68 in manufacturing and quality, and 39 are engaged in business development, finance, legal, human resources, facilities, information technology and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were founded in August 2015 as a Delaware corporation. In May 2021, we changed our name from Gritstone Oncology, Inc. to Gritstone bio, Inc. Our principal executive offices are located at 5959 Horton Street, Suite 300, Emeryville, California 94608, and our telephone number is (510) 871-6100. Our website address is www.gritstonebio.com. The information on, or that can be accessed through, our website is not part of this report and is not incorporated by reference herein. We have included our website address as an inactive textual reference only. We also use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website at www.gritstonebio.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file with the SEC at the SEC&#x2019;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information in or accessible through the SEC and our website or social media sites does not constitute part of this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual references only.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use Gritstone bio, Inc.&#174;, the Gritstone bio logo, and other marks as trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or &#153; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by any other entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="margin-left:20.0%;text-indent:8.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Principal Risks Associated with Our Business</span></p>
  <p style="margin-left:20.0%;text-indent:8.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a biotechnology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control, including the ongoing COVID-19 pandemic and related clinical trial enrollment challenges;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business remains highly dependent on the successful development, regulatory approval and commercialization of our individualized immunotherapy product candidate, GRANITE, our &#x201c;off-the-shelf&#x201d; immunotherapy product candidate, SLATE, and CORAL, our second generation COVID-19 vaccine, all of which are in clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may materially adversely affect our business and operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties in the conduct of all of our preclinical studies and intend to rely on third parties in the conduct of all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements, or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our immunotherapy product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently perform the majority of the manufacturing of our product candidates internally and rely on qualified third parties to supply some components of our product candidates. Our inability to manufacture sufficient quantities of GRANITE, SLATE, CORAL or any future product candidates, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially adversely affect our business;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends on our ability to protect our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price is volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a biotechnology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product development in the biotechnology industry is a highly speculative undertaking and involves a substantial degree of risk. We are a biotechnology company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale, have not yet generated any revenue from product sales and have incurred losses in each year since our inception in August 2015. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have had significant operating losses since our inception (for additional information, see &#x201c;Liquidity&#x201d; in Note 1 to our consolidated financial statements). Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our programs will require substantial additional development time and resources before we (or our collaboration partners) would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. In addition, we incur substantial costs associated with operating as a public company. We also do not yet have a sales organization or commercial infrastructure and, accordingly, if our product candidates are approved, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any commercial product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop our current and any future immunotherapy product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability at some point in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for tumor-specific cancer immunotherapies and infectious disease programs in addition to establishing our in-house manufacturing capabilities. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current and any other future immunotherapy product candidates we may choose to pursue, as well as the continued development of our manufacturing capabilities and other corporate uses. Specifically, in the near term, we expect to incur substantial expenses as we advance GRANITE, SLATE and CORAL through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of GRANITE, SLATE, CORAL or any future immunotherapy product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least twelve (12) months. However, our operating plans and other demands on our capital resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future capital requirements depend on many factors, including:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of developing each of our product candidates, including conducting preclinical studies and clinical trials, either on our own or in collaboration with others;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential delays in our ongoing clinical trials as a result of the COVID-19 pandemic;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and characteristics of any additional product candidates we develop or acquire;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing our tumor-specific immunotherapies we successfully commercialize, including the cost of scaling up our internal manufacturing operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of building a sales force in anticipation of product commercialization;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of commercialization activities, including legal, compliance, marketing, sales and distribution costs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any product liability or other lawsuits related to our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the expenses needed to attract, hire and retain skilled personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with being a public company;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, receipt and amount of sales of any future approved products, if any.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our immunotherapy product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights or jointly own some aspects of our technologies or product candidates that we would otherwise pursue on our own. We may not realize revenue from sales of products or royalties from licensed products in the foreseeable future, and no such revenue will be realized unless and until a product candidate is clinically tested, approved for commercialization and successfully marketed. To date, we have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants, repayment obligations, or other similar restrictions that may affect our business and limit our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of, and level of investment in, research, development and commercialization activities, which may change from time to time;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of receipt of approvals from regulatory authorities in the United States and internationally;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and status of enrollment for our clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of production, the cost of continuing to establish and scale up our internal manufacturing capabilities, and the terms of any agreements we enter into with third-party suppliers;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">coverage and reimbursement policies with respect to our immunotherapy product candidates, if approved, and potential future drugs that compete with our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of demand for our immunotherapy products, if approved, which may vary significantly over time;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which the COVID-19 pandemic, as it continues to evolve, may impact our operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is highly dependent on the successful development, regulatory approval and commercialization of our product candidates, primarily our individualized immunotherapy product candidate, GRANITE, and our &#x201c;off-the-shelf&#x201d; immunotherapy product candidate, SLATE, and CORAL, our second generation COVID-19 vaccine, all of which are in clinical trials.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no products approved for sale, and all three of our clinical programs are in Phase 1 or Phase 2 clinical trials. As such, we face significant clinical risk with our programs and our tumor and viral-specific immunotherapy approach generally. The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of GRANITE, SLATE and CORAL, as well as other product candidates derived from our tumor-specific immunotherapy approach, which may never occur. In the future, we may also become dependent on other product candidates that we may develop or acquire; however, our product candidates based on our immunotherapy approach have only been tested in a small number of humans, and, given our early stage of development, it may be many years, if at all, before we have demonstrated the safety and efficacy, especially of an individualized immunotherapy treatment sufficient to warrant approval for commercialization.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not previously submitted a BLA to the FDA, or similar filing seeking regulatory approval to comparable foreign authorities, for any product candidate, and we cannot be certain that our product candidates will be successful in clinical trials or receive regulatory approval. Further, any product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market a product candidate, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. While the scope of regulatory approval generally is similar in other countries, to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of our product candidates, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical and commercial success of our current and any future product candidates will depend on several factors, including the following:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to raise any additional required capital on acceptable terms, or at all;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely completion of our preclinical studies and clinical trials, which may be significantly slower, or cost more, than we currently anticipate and will depend substantially upon the performance of third-party contractors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to timely execute our ongoing clinical trials and enroll a sufficient number of patients on a timely basis to evaluate the potential of our product candidates in clinical development;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support approval of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to complete an IND, or similar foreign applications, enabling studies, and successfully submit an IND or similar foreign applications for future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to consistently manufacture on a timely basis our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability, and the ability of any third parties with whom we contract, to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMPs or similar foreign requirements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk-benefit profile of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our current or any future product candidates or approved products, if any;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our individualized cancer immunotherapy approach;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully develop a commercial strategy and thereafter commercialize GRANITE, SLATE, CORAL or any future product candidates (including our partnered HIV therapeutic vaccine) in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the convenience of our treatment or dosing regimen;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patient demand for our current or future product candidates, if approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and enforce intellectual property rights in and to our product candidates; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. We may experience delays in enrolling or completing our clinical trials. Additionally, we cannot be certain that studies or trials for our product candidates will begin on time, not require redesign, enroll an adequate number</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of subjects on time or be completed on schedule, if at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in obtaining regulatory authorization to commence a trial;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining IRB, and, where required, IBC approval at each trial site;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recruiting an adequate number of suitable patients to participate in a trial, particularly in light of the unpredictable impact of the COVID-19 pandemic on patient enrollment and clinical site closures;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">having subjects complete a trial or return for post-treatment follow-up;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing subject safety concerns that arise during the course of a trial;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adding a sufficient number of clinical trial sites;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining sufficient quantities of product candidates for use in preclinical studies or clinical trials from third-party suppliers; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">accessing checkpoint inhibitors for use in combination with our product candidates in preclinical studies or clinical trials, including checkpoint inhibitors that have not been approved by the FDA for such use.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite encouraging signs of improvement in the COVID-19 pandemic, the emergence of new variants and/or waning of vaccine efficacy may increase the likelihood that we encounter challenges and delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We are also aware that several CROs based in the U.S. that provide preclinical services are experiencing heavy demand, which may impact their ability to start new studies and lead to delays in the commencement of our preclinical studies. In addition, several U.S.-based academic research organizations have also experienced shutdowns during the initial phase of the COVID-19 pandemic, and this may recur if there is a resurgence of SARS-CoV-2 variants. However, to date neither of these has caused any material impact on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be affected by safety concerns that have a class effect; for example, if a competitor reports negative results with respect to a compound similar to those we are developing, such setbacks could negatively impact our own product development;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon our development programs, including our individualized cancer immunotherapy program;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, or be unable to produce sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive, or if there are safety concerns, we may:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incur unplanned costs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain marketing approval in some countries and not in others;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to additional post-marketing testing requirements, which could be expensive and time consuming; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have the treatment removed from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (DSMB), for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, conducting clinical trials in foreign countries, as we may do for certain of our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our preclinical studies or clinical trials of our product candidates are delayed or terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If our product candidates or our immunotherapy prediction platform generally prove to be ineffective, unsafe or commercially unviable, our entire platform and approach would have little, if any, value, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the FDA&#x2019;s and other regulatory authorities&#x2019; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union recently evolved. The CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate CTA to be submitted in each member state to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#x2019;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials whose CTA was made under the Clinical Trials Directive before January 31, 2022, the Clinical Trials Directive will continue to apply on a transitional basis for three years. Additionally, sponsors may still choose to submit a CTA under either the Clinical Trials Directive or the CTR until January 31, 2023 and, if authorized, those will be governed by the Clinical Trials Directive until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as CROs may impact our developments plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is currently unclear to what extent the United Kingdom will seek to align its regulations with the European Union. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closes on March 14, 2022 and aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The outcome of the consultation will be closely watched and will determine whether the United Kingdom chooses to align with the regulation or diverge from it to maintain regulatory flexibility. A decision by the United Kingdom not to closely align its regulations with the new approach that will be adopted in the European Union may have an effect on the cost of conducting clinical trials in the United Kingdom as opposed to other countries and/or make it harder to seek a marketing authorization in the European Union for our product candidates on the basis of clinical trials conducted in the United Kingdom.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our tumor-specific cancer immunotherapy approach is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regarding our tumor-specific cancer immunotherapies, our foundational science and product development approach are based on our ability to predict the presence of a patient&#x2019;s TSNA and develop a TSNA-directed therapy that will elicit a meaningful T cell response. We believe that this approach may offer an improved therapeutic effect by driving an intense, focused T cell attack selectively upon a patient&#x2019;s tumor. However, this approach to treating cancer is novel and the scientific research that forms the basis of our efforts to predict the presence of TSNA and to develop TSNA-directed cancer immunotherapy candidates is both preliminary and limited. The results of our preclinical animal studies may not translate into humans. For example, our prediction model may fail to accurately predict the presence of TSNA, resulting in little or no tumor-targeted T cell response, or our therapy may fail to elicit a significant or durable enough T cell response to effectively destroy a tumor. As such, we cannot assure you, even if we are able to develop individualized cancer immunotherapy candidates capable of recognizing TSNA and eliciting a T cell response, that such therapy would safely and effectively treat cancers. We may spend substantial funds attempting to develop this approach and never succeed in developing a marketable therapeutic.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No regulatory authority has granted approval for a cancer immunotherapy based on a heterologous prime-boost approach, which may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We may never receive approval to market and commercialize any product candidate. Even if we obtain regulatory approval, the approval may be for targets, disease indications, lines of therapy or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our personalized immunotherapy candidates prove to be ineffective, unsafe or commercially unviable, our entire technology platform and pipeline would have little, if any, value, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The regulatory approval process and clinical trial requirements for novel product candidates can be more expensive and take longer than for other, better known or more extensively studied product candidates, and we cannot predict how long it will take or how much it will cost to complete clinical developments and obtain regulatory approvals for a cell therapy product candidate in the United States or how long it will take to commercialize a product candidate, if and when approved. Regulatory requirements governing cell therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of cell therapies and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions. Additionally, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Additionally, adverse developments in clinical trials conducted by others of cell therapy products or products created using similar technology, or adverse public perception of the field of cell therapies editing, may cause the FDA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing technologies such as ours, either of which could materially harm our business. As we advance our product candidates, we will be required to consult with various regulatory authorities, and we must comply with applicable laws, rules and regulations, which may change from time to time, including during the course of development of our product candidates. If we fail to do so, we may be required to delay or discontinue the clinical development of certain of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Even if we comply with applicable laws, rules, and regulations, and even if we maintain close coordination with the applicable regulatory authorities with oversight over our product candidates, our development programs may fail to succeed. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market would materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the clinical trial process. Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical animal studies, including our non-human primate studies, may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The design of our clinical trials may provide encouraging albeit limited evidence of the efficacy of our individualized immunotherapy product candidate, GRANITE and the off-the-shelf immunotherapy candidate, SLATE, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scientific principles and preclinical data suggest that combination treatment of cancer patients with our TSNA-directed immunotherapy product candidates plus checkpoint inhibitors is likely to be most effective for our target indications. The Phase 1 portion of both of our Phase 1/2 clinical trials, GO-004 (NCT03639714) and GO-005 (NCT03953235), consequently, involved administration of a combination therapy with GRANITE and SLATE, respectively. Notably, all patients in the Phase 1/2 trials received anti-PD-1 monoclonal antibodies (mAb) as background therapy. Some patients in both Phase 1 portions of our trials additionally received anti-CTLA-4 mAb. Checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 mAb are known to be effective treatments in many cancer patients and elicit objective responses in some patients. Any objective responses observed in our trials thus would have been in patients receiving our experimental therapy together with at least one checkpoint inhibitor, and attribution of objective responses to the effects of GRANITE or SLATE alone are not possible at this stage of our development program. Efficacy will be studied carefully in the respective GRANITE and SLATE Phase 2 cohorts, in which we will attempt to compare the relative contributions of our individualized and off-the-shelf immunotherapy candidates and the checkpoint inhibitors to historical data from patients treated with checkpoint inhibitors alone. Of note, patient eligibility for our clinical trials is determined based, in part, upon predicted immunogenicity of the patient&#x2019;s tumor. In particular, we only accept patients predicted to have a neoantigenic burden above a certain threshold. Selection of high-immunogenicity tumors is relevant to interpretation of clinical data, since high immunogenicity (which is related to high tumor mutational burden) may be a positive prognostic factor, which means our selected patients would have a clinical outcome upon standard therapy that is superior to unselected case controls. Conversely, we are also enriching our GRANITE Phase 2 cohorts with patients with intermediate mutational burden, such as MSS-CRC, who do not respond or poorly respond to checkpoint inhibitors. While clinical response in these patients when receiving our individualized vaccines in combination with checkpoint inhibitors would be encouraging, the absence of a randomized controlled cohort will make the interpretation of these results difficult. Overall, interpretation of &#x201c;time-to-event&#x201d; endpoints, such as progression-free survival or overall survival, is challenging without a contemporaneous, randomized control group. As a result, even if our respective Phase 1/2 clinical trials provide early, encouraging results, they may yield limited evidence of the efficacy of GRANITE or SLATE, which may not be fully understood by investors or market participants, potentially leading to negative effects on our stock price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our tumor-specific and infectious disease product candidates are biologics with complex and time-consuming manufacturing processes, and we may encounter difficulties in production, particularly with respect to process development or scaling-out of our manufacturing capabilities. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our immunotherapy product candidates, GRANITE, SLATE and CORAL, are considered to be biologics, and the manufacturing processes are complex, time-consuming, highly-regulated and subject to multiple risks. Our product candidates for SLATE and CORAL are designed using known genetic sequences available from public databases, while the manufacture of our product candidate GRANITE involves extraction of genetic material from patient tumor samples. GRANITE, SLATE and CORAL require genetic manipulations at the gene sequence level, live cell culture operations, specialized formulations and aseptic fill finish operations. As a result of these complexities, the cost to manufacture biologics in general, and our individualized immunotherapy GRANITE in particular, is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and more difficult and time-consuming to reproduce. For example, the entire cGMP manufacturing process, from biopsy receipt and sequencing completion to the release and shipment of GRANITE to the clinical site for patient administration, will initially take</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately 14-18 weeks. In addition, our manufacturing process for GRANITE, SLATE and CORAL are in their early stages of development and will be susceptible to product loss or failure, or product variation that may adversely impact patient outcomes. Our supply chain may not function efficiently due to logistical issues associated with but not limited to the collection of a tumor biopsy from the patient, shipping such material to the manufacturing site, sequencing the biopsy specimen, manufacturing the immunotherapy components, shipping the final immunotherapy back to the patient, and injecting the patient with the immunotherapy. Manufacturing issues or different product characteristics resulting from process development activities or even minor deviations during normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If for any reason we lose a patient&#x2019;s biopsy or an in-process product at any point in the process, the manufacturing process for that patient will need to be restarted, and the resulting delay may adversely affect that patient&#x2019;s outcome. Because GRANITE is manufactured specifically for an individual patient, we will be required to maintain a chain of identity and chain of custody with respect to materials as they move from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity and chain of custody is difficult and complex, and the failure to do so could result in adverse patient outcomes, loss of product or regulatory action, including withdrawal of our products from the market, if licensed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our process development efforts for GRANITE, SLATE and CORAL, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, if microbial, viral or other contaminations are discovered in our supply of our product candidates or in our manufacturing facilities, or those of our CMOs, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any such contaminations or stability failures or other issues relating to the manufacture of our product candidates will not occur in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay or prevent commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To gain approval to market our product candidates, we must provide the FDA and foreign regulatory authorities with clinical data that adequately demonstrate the safety, purity, potency and efficacy of the product candidate for the intended indication applied for in the applicable regulatory filing. Product development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, effective, pure and potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. FDA and foreign regulatory authorities may also conduct pre-license inspections of us and/or our CMOs to ensure the manufacture of a product candidate complies with applicable regulatory requirements, including cGMP or similar foreign requirements. Adverse inspection findings could result in the delay or non-approval of a BLA or other similar regulatory filing and require the implementation of costly corrective actions before potential approval can be granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates for many reasons, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that any of our product candidates are safe, pure, potent and effective for the requested indication;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s disagreement with our trial protocols or the interpretation or reliability of data from preclinical studies or clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate that the clinical and other benefits of any of our product candidates outweigh any safety or other perceived risks;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s requirement for additional preclinical studies or clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s non-approval of the formulation, labeling or specifications of GRANITE, SLATE, CORAL or any of our future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or the applicable foreign regulatory agency&#x2019;s failure to approve our manufacturing processes and facilities or the facilities of third-party manufacturers upon which we rely; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval. For example, the FDA launched Project Optimus as an initiative to reform the dose optimization and dose selection paradigm in oncology product development as FDA&#x2019;s view is that the current paradigm for dose selection results in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating registration/pivotal trials. Through collaboration with industry, academia, and other stakeholders, FDA&#x2019;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, in part due to questions raised by the process underlying the approval of the Alzheimer&#x2019;s disease drug Aduhelm&#174;, government authorities and other stakeholders have been recently scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to the Aduhelm approval, FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. FDA also launched an initiative, known as Project Confirm, to promote the transparency of outcomes related to accelerated approvals for oncology indications. Moreover, spurred by the Aduhelm controversy, the U.S. Department of Health and Human Services Office of Inspector General has initiated an assessment of how the FDA implements the accelerated approval pathway. At this time, it is not clear what, if any, impact these developments may have on the statutory accelerated approval pathway or our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#x2019; approval processes and are commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for any of our product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. Failure to complete such post-marketing requirements in accordance with the timelines and conditions set forth by the FDA or the applicable foreign regulatory agency could significantly increase costs or delay, limit or ultimately restrict the commercialization of the product candidate. The FDA or the applicable foreign regulatory agency also may approve one or more of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of such product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially adversely impact our business and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have chosen to prioritize development of our individualized immunotherapy candidate, GRANITE, our off-the-shelf immunotherapy candidate, SLATE, and our second-generation COVID-19 vaccine program, CORAL. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on other product candidates or indications for which there may be a greater likelihood of success or that may be more profitable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initially developed our GRANITE individualized cancer immunotherapy candidates based on the prediction of a patient&#x2019;s TSNA, to address a variety of cancers, including NSCLC and gastro-esophageal, bladder and colorectal cancers. GRANITE is now being evaluated in the Phase 2 portion of the GO-004 trial (NCT03639714), which started enrolling patients in the third quarter of 2020 with an objective to identify interpretable signals of efficacy when combining our vaccine candidate with immune checkpoint inhibitors with a focus on tumor types that do not respond to immune checkpoint inhibitors (MSS-CRC), respond poorly (gastro-esophageal cancers) or have progressed after first-line therapy with immune checkpoint inhibitors (NSCLC). The clinical trial of SLATE, our off-the-shelf product candidate, is currently evaluating subjects with mutation positive and metastatic and advanced solid tumors, with a focus on NSCLC, who seem to derive the strongest benefit in terms of immune response as compared to patients with colorectal and pancreatic cancers. SLATE is now being evaluated in the Phase 2 portion of the GO-005 trial (NCT03953235), which is now focusing on patients with NSCLC and MSS-CRC. Based on findings in the earlier portion of the SLATE study, we have developed an improved KRAS-focused cassette to treat patients with KRAS-positive tumors, which entered the clinic in the third quarter of 2021. We may resume accrual of patients with pancreatic cancer once this updated version of the SLATE product candidate has shown benefits in terms of immunological and/or clinical response in patients with NSCLC or MSS-CRC. We have strategically determined to initially focus solely on the development of individualized cancer immunotherapy candidates (including our &#x201c;off-the-shelf&#x201d; immunotherapy candidate) rather than pursue other types of immunotherapies based, in part, on the significant resources required to develop and manufacture immunotherapies. As a result, we may initially be foregoing other potentially more profitable therapy indications or those with a greater likelihood of success.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated the CORAL program in 2021, and since have advanced five clinical stage potential product candidates being studied across a variety of populations across four clinical studies and established partnerships and funding agreements to help support the trials. We are committed to seeing the current studies through completion and if successful and regulatory circumstances allow, would seek to execute a pivotal trial. If we are unable to obtain regulatory approval and/or funding for a pivotal trial within our CORAL program, our commercial opportunity and profitability may be limited. We are assessing options to fund a pivotal trial should it occur.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the oncology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain regulatory approval for use of our tumor-specific immunotherapy candidates, GRANITE and SLATE, as a first- and second-line therapy, our commercial opportunity and profitability may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancer therapies for advanced/metastatic cancers are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new systemic therapies initially only for third-line use. When cancer is detected early enough, surgery plus first-line systemic therapy is sometimes adequate to cure the cancer. Whenever first-line therapy (usually chemotherapy, hormone therapy, radiotherapy, surgery or a combination of these) proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor-targeted small molecules or a combination of these. Third-line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies and new technologies such as adoptive cell therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Traditionally, novel oncology therapeutics are developed and approved in late (third) line therapy of cancer patients. Such clinical programs carry risk of failure because patients are often quite frail, with effects of multiple rounds of prior therapy weakening bone marrow, immune systems and general fitness. Immunotherapy, such as checkpoint inhibitors, has generally been shown to be more effective when used in earlier lines of therapy, with the prospect of very durable responses in some patients; and there is a trend towards earlier use of these agents, avoiding in particular cytotoxic chemotherapy agents, which carry substantial toxicity and very little prospect of long-term responses. Our tumor-specific immunotherapy clinical development program also aims to study our products in early stages of cancer treatment (referred to as adjuvant therapy), which carry a higher safety bar, and often a greater expectation of efficacy over</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">control arms. Such studies may thus be relatively large and slow to achieve maturity. There are new tools available to stratify cancer patients for risk of recurrence or progression, such as liquid biopsies that measure the amount of circulating tumor-derived DNA. We will utilize these tools to attempt to expedite clinical trials in early-stage cancer patients by focusing upon patients at above-average risk of disease recurrence or progression, which events are typical endpoints in clinical trials. The development of liquid biopsies is at an early stage, however, and these tools may prove to carry low utility and thus render early-stage cancer trials slow, necessarily large and expensive. The safety of our tumor-specific immunotherapy product candidates in combination with checkpoint inhibitors in early lines of therapy may also prove to be unacceptable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to seek approval of our tumor-specific immunotherapy product candidates as late-line therapy where appropriate, but also as a first-line therapy wherever possible, and potentially as adjuvant therapy. There is no guarantee that our product candidates, even if approved in late-line therapy, would be approved for second-line or first-line or adjuvant therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line or adjuvant therapy.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our SLATE product is designed to be readily available (off-the-shelf), GRANITE will initially take approximately 14-18 weeks post-sequencing to be manufactured and released for human use, and this long timeline demands that either patients are consented and entered into our trials when they start a prior line of therapy, and start our therapy upon disease progression, or we initiate treatment in patients who have entered the maintenance phase of their original line of treatment. For example, we might enroll newly diagnosed patients who are due to receive front-line chemotherapy and then start their therapy with our immunotherapy product candidate as second-line treatment when they progress upon front-line chemotherapy or fail to tolerate it. This carries the risk of time delays or drop-out &#x2013; i.e., patients may not progress after first-line chemotherapy for a long time, or they may decide not to receive an immunotherapy product candidate we have manufactured for them, at our expense. Alternatively, we may treat first-line patients once they have completed their initial treatment and have not progressed (called maintenance therapy)&#x2014;this renders efficacy harder to interpret versus simple treatment studies (any objective response cannot clearly be attributed to our products) and may be complicated by standard of care treatments, which may necessarily be continued alongside our immunotherapy candidates, further confounding interpretation of efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive first-, second- or third-line therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, and may prove to be incorrect. Regulatory authorities also may establish narrower definitions around when a patient is ineligible for other treatments than we have used in our projections, and that would reduce the size of the patient population eligible for our product candidates. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we anticipate that only a fraction of colorectal cancer patients will be predicted to have a high enough probability of TSNA presence to merit their inclusion into our program. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first-line or second-line therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of patients to trial sites;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trial investigators&#x2019; willingness to continue enrolling patients during the COVID-19 pandemic;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new therapies that may be approved for the indications we are investigating; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain patient consents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. While the COVID-19 pandemic appears to be receding in the United States, there is an unquantifiable risk of emergence of variants or current vaccine escape that could impact and delay patient enrollment and generate challenges in monitoring patients once on study. We anticipate facing additional challenges if the COVID-19 pandemic worsens.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the targeting of TSNA may result in unforeseen events, including harming healthy tissues in humans. As a result, it is possible that safety concerns could negatively affect patient enrollment among the patient populations that we intend to treat. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As with most biological products, use of our product candidates could be associated with side effects or adverse events, which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. While we have now completed the Phase 1 portions, and we are in the Phase 2 portions, of our clinical trials of GRANITE and SLATE, we do not yet have a comprehensive understanding of their risks, and it is likely that there will be side effects associated with their use in increasing numbers of patients in Phase 2 and beyond. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. Our other product candidates present similar risks, the severity of which is difficult to predict.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, or comparable foreign regulatory authorities, the IRBs at the institutions in which our studies are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, even if we successfully advance one of our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been several reported cases of severe thrombosis with thrombocytopenia occurring post-vaccination in individuals who received adenovirus-based vaccines for SARS-CoV-2, including those administered under EUA. This syndrome has been termed &#x201c;vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)&#x201d; or &#x201c;vaccine-induced immune thrombotic thrombocytopenia (VITT)&#x201d; but is now termed &#x201c;thrombosis with thrombocytopenia syndrome (TTS)&#x201d; by the Centers for Disease Control and Prevention (CDC) and the FDA. The syndrome appears to be autoimmune in nature and is associated with autoantibodies to a specific platelet-associated antigen. To date, no patients receiving our adenoviral vaccine candidate against SARS-CoV-2, CORAL, have been known to develop TTS, nor have we observed it in our cancer programs where our adenoviral vaccines are used in conjunction with checkpoint inhibitors (e.g., anti-PD1 antibody), which themselves can be associated with autoimmune toxicities; but we cannot be certain that this or similar complications will not arise.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may withdraw their approval of the product;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS), or similar risk management measures, or create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the product may become less competitive; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reputation may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially adversely affect our results of operations and business. In addition, if one or more of our product candidates or our TSNA-directed immunotherapy approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if one of our product candidates obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if one of our product candidates receives FDA or other regulatory approvals, the commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a number of factors, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the safety and efficacy of our product as compared to other available therapies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the time required for manufacture and release of our individualized immunotherapy products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid) and other third-party payors for any of our product candidates that may be approved;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acceptance by physicians, operators of hospitals and clinics and patients of the product as a safe and effective treatment;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">physician and patient willingness to adopt a new therapy over other available therapies for a particular indication;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">proper training and administration of our product candidates by physicians and medical staff;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payers, physicians and patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of side effects;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the FDA or foreign regulatory authorities - approved labeling for our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of physicians, operators of hospitals and clinics and patients to utilize or adopt our products as a solution;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any FDA or foreign regulatory authorities&#x2019; requirement for a REMS or similar risk management measures;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our sales, marketing and distribution efforts;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse publicity about our products or favorable publicity about competitive products; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product liability claims.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently perform the majority of the manufacturing of our product candidates internally and rely on qualified third parties to supply some components of our product candidates. Our inability to manufacture sufficient quantities of GRANITE, SLATE, CORAL or any future product candidates, or the loss of our third-party suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing is a vital component of our immunotherapy approach, and we have invested significantly in our manufacturing facility. To ensure timely and consistent product supply assurance to our patients we previously used a hybrid product supply approach whereby certain elements of our product candidates were manufactured internally at our manufacturing facilities in Pleasanton, California, and other elements were manufactured at qualified third-party contract manufacturing organizations (CMOs). All internal and third-party contract manufacturing is performed under cGMP or similar guidelines. We have internalized a majority of the manufacturing steps to optimize cost and production time, as well as establish full control over intellectual property and product quality. We will need to continue to scale up our manufacturing operations, as we continue to build the infrastructure and improve the capability internally to manufacture all supplies needed for our product candidates or the materials necessary to produce them for use in the conduct of our preclinical studies or clinical trials. We currently lack the internal resources and the capability to manufacture certain elements of our product candidates on a clinical scale. Accordingly, we have made, and will be required to continue to make, significant investments in our manufacturing facility and processing in the future, and our efforts to scale our manufacturing operations may not succeed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our facilities and the facilities used by our CMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing process at our CMOs and are completely dependent on them for compliance with current regulatory requirements. If we or our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on our or their manufacturing facilities for the manufacture of elements of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for the manufacture of our product candidates, or if such facilities are subject to enforcement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, even if one of our vaccine candidates receives regulatory approval, successful commercialization depends on our ability to effectively scale up our in-house manufacturing capabilities and those of our manufacturing partners and contractors. Although we have a dedicated manufacturing facility in Pleasanton, we do not have sufficient manufacturing infrastructure to support a global roll-out of our product candidates on our own. We may not be able to timely and effectively produce our vaccine candidates, if approved, in adequate quantities to address global demand. We have not previously had a commercial launch of any vaccine product and doing so in a pandemic environment with an urgent, critical global need creates additional challenges. We cannot guarantee that any of these new challenges and requirements will be met in a timely manner or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finally, we and our CMOs may experience manufacturing and raw material sourcing difficulties due to resource constraints, as a result of labor disputes or unstable political environments, or due to the impact of the COVID-19 pandemic. If we or our CMOs were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party suppliers for certain materials required for the production of our individualized immunotherapy candidate. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our larger competitors. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements, particularly if the COVID-19 pandemic worsens. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties in the conduct of all of our preclinical studies and intend to rely on third parties in the conduct of all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently do not have the ability to independently conduct preclinical studies that comply with GLP regulatory requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as 10 days&#x2019; prior written notice. Some of these agreements may also be terminated with immediate effect by such third parties under certain other circumstances, including our insolvency. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">due to their failure to adhere to our protocols or to GLPs/GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and the commercial prospects for our product candidates could be harmed, our costs could increase, and our ability to generate revenues could be delayed.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA or foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#x2019;s or foreign regulatory authorities&#x2019; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#x2019;s or foreign regulatory authorities&#x2019; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the COVID-19 pandemic, in March, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July, 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plan to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries in particular are characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of diseases and other conditions for which we may try to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody and immunoregulatory therapeutics fields. We believe that, while our discovery platform, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded biopharmaceutical, biotechnological and therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, if either GRANITE or SLATE is approved, it will compete with a range of therapeutic treatments that are either in development or currently marketed. Indeed, a variety of oncology drugs and therapeutic biologics are on the market or in clinical development. Such marketed therapies range from immune checkpoint inhibitors such as Bristol-Myers Squibb Company&#x2019;s OPDIVO and YERVOY, Merck &amp; Co., Inc.&#x2019;s KEYTRUDA and Genentech, Inc.&#x2019;s TECENTRIQ, and T cell engager immunotherapies such as Amgen, Inc.&#x2019;s BLINCYTO. The most common therapeutic treatments for common solid tumors are chemotherapeutic compounds, radiation therapy, targeted therapies and now immunotherapies. In addition, numerous compounds are in clinical development for cancer treatment. The clinical development pipeline for cancer includes small molecules, antibodies and immunotherapies from a variety of groups, including in the neoantigen space, the bispecific antibody space and engineered cell therapy and T cell receptor ( TCR) space. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we may be unable to produce a successful second-generation COVID-19 CORAL vaccine candidate, and establish a competitive market share for such CORAL vaccine candidate before the COVID-19 outbreak is contained or significantly diminished. A large number of vaccine manufacturers, academic institutions and other organizations have developed COVID-19 vaccines or are developing COVID-19 vaccine candidates. In particular, Moderna and Pfizer/BioNTech received full approval for their COVID-19 vaccines in the U.S. and other countries, Johnson &amp; Johnson received the emergency use authorizations and many other companies, including Novavax, Sinovac Biotech, AstraZeneca, Sinopharm, and Inovio are in various stages of developing and obtaining marketing authorization for COVID-19 vaccine candidates. Furthermore, COVID-19 vaccines approved prior to our CORAL vaccine may develop broad market acceptance that we are challenged to overcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite funding provided to us to date, many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. If any competitors are successful in producing more efficacious products or if any competitors are able to manufacture and distribute competitive products with greater efficiency there may be a diversion of potential governmental and other funding away from us and toward such other parties. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers, and other third-party payors provide coverage, adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability of coverage and adequacy of reimbursement by managed care plans, governmental healthcare programs, such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by third-party payors will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our products, or procedures using our products, could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our product candidates or procedures using our product candidates, or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These third-party payors may deny or revoke the reimbursement status of our product candidates, if approved, or establish prices for our product candidates at levels that are too low to enable us to realize an appropriate return on our investment. If</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products, especially novel products like our immunotherapy product candidates. No regulatory authority has granted approval for a tumor-specific cancer immunotherapy based on a vaccine approach, and there is no model for reimbursement of this type of product. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to support demand for our existing or future services, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage the evolution of our EDGE&#153; platform, our business could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the demand for our individualized and off-the-shelf immunotherapy candidates increases with our clinical trial needs, we will need to continue to increase our workflow capacity for sample intake and general process improvements, expand our internal quality assurance program, and apply our EDGE&#153; platform at a larger scale within expected turnaround times. We will need additional certified laboratory scientists and technicians and other scientific and technical personnel to process higher volumes of tumor biopsies. Portions of our process are not automated and will require additional personnel to scale. We will also need to purchase additional equipment, some of which can take several months or more to procure, set up, and validate, and increase our software and computing capacity to meet increased volume. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities, or process enhancements will be successfully implemented, or that we will have adequate space in our laboratory facilities to accommodate such required expansion.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we progress into clinical development and expand our manufacturing capabilities, we will need to incorporate new equipment, implement new technology systems and laboratory processes, and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service, and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our services and could damage our reputation and the prospects for our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and foreign jurisdictions, if approved, or generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently do not have a marketing or sales organization. In order to commercialize our product candidates, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of them. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our current or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 193 full-time employees. We will need to continue to expand our managerial, regulatory, clinical science, development operations, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize our product candidates or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manage our preclinical studies and clinical trials effectively;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify, recruit, retain, incentivize and integrate additional employees, including sales personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue to improve our operational, financial and management controls, reports systems and procedures.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to attract and retain senior management and key scientific personnel, our business may be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends in part on our continued ability to attract, retain and motivate highly-qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our President and Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our products, initiation or completion of our planned clinical trials or the commercialization of our current or any future product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competition for qualified personnel in the biotechnology and biopharmaceutical fields is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our current or future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend the related litigation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize our current or any future product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of our current or any future product candidates we develop. We currently carry product liability insurance covering our clinical trials in the amount of $10.0 million in the aggregate. Nonetheless, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our strategic collaborations, including those with Gilead and with 2seventy as well as any future arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of such collaborations and adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we announced that we had entered into a collaboration, option and license agreement with Gilead to research and develop a vaccine for HIV. Under the terms of the agreement, Gilead will be responsible for conducting the Phase 1 study and, if it exercises its exclusive option, will develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. In such case, and subject to certain clinical, regulatory and commercial milestones being achieved, we would be eligible to receive up to an additional $725.0 million, as well as certain royalties on net sales upon commercialization. Separately, in August 2018, we entered into a strategic collaboration with 2seventy to utilize our EDGE&#153; platform to identify and validate tumor-specific targets and provide TCRs directed to 10 selected targets for use in 2seventy&#x2019;s cell therapy products. Under that collaboration, we are entitled to receive up to an aggregate of $1.2 billion in development, regulatory and commercial milestones and tiered single digit royalties on sales of 2seventy&#x2019;s cell therapy products utilizing the TCRs we develop directed at the targets we discovered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Apart from these strategic collaborations, in the future we may seek to enter into additional collaboration arrangements for the development or commercialization of certain of our product candidates, depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. To the extent that we decide to enter into collaboration agreements in the future, we may face significant competition in seeking appropriate collaborators. Moreover, all such collaboration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">arrangements are complex and time-consuming to negotiate, document, implement and maintain, as well as challenging to manage. We may not be successful in our efforts with Gilead or 2seventy, and we may never receive any of the payments contemplated in those collaboration arrangements. Further, we may be unable to prudently manage these collaborations or enter into new ones. The terms of any new collaborations or other arrangements that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise perform satisfactorily in carrying out these activities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may own or co-own intellectual property covering products that result from our collaboration with them, and, in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased operating expenses and cash requirements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of our equity securities;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the diversion of our management&#x2019;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We or the third parties upon whom we depend may be adversely affected by risks beyond our control, such as natural disasters, political crises, acts of terrorism, war or other catastrophic events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, our suppliers and third-party service providers are vulnerable to damage from natural disasters, including but not limited to earthquakes, fires or floods, power loss, communications failures, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict and similar events. If any disaster were to occur, our ability to operate our business at any of our facilities could be seriously, or potentially completely, impaired.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters and certain of our other facilities, including our manufacturing facility, are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. For instance, in late February 2022, Russian military forces launched significant military action against Ukraine, and sustained conflict and disruption in the region is likely. The impact to Ukraine, as well as actions taken by other countries, including new and stricter sanctions by the U.S., Canada, the United Kingdom, the European Union and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country&#x2019;s potential response to such sanctions, tensions, and military actions could have a material adverse effect on the global economy and political situation.  As of the date of this Annual Report on Form 10-K, we (i) are not conducting clinical or non-clinical studies in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">either Ukraine, Belarus or Russia, (ii) are not relying upon service providers or vendors from either of these regions to advance our GRANITE, SLATE, or CORAL development programs, (iii) do not source biomanufacturing critical raw materials, equipment, or other supplies directly from either Ukraine, Belarus or Russia, and (iv) are not aware nor have received notification from our supply vendors that the sourcing of any general laboratory or manufacturing materials may be negatively impacted due to such conflict and related sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, including our laboratory information management system and our EDGE&#153; platform. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to attack and damage from computer viruses, and malware (e.g., ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. We have experienced phishing attacks in the past resulting in a security breach of our information technology systems, and we may be a target of phishing attacks or other cyber-attacks in the future. Any significant system failure, accident or security breach could have a material adverse effect on our business, financial condition and results of operations. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is subject to complex and evolving laws and regulations regarding privacy, data protection and other matters relating to information collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are numerous state, federal and foreign laws, regulations, decisions, and directives regarding privacy and the collection, storage, transmission, use, processing, disclosure and protection of different types of personal data and personal information and other personal, customer, or other data, the scope of which is continually evolving and subject to differing interpretations. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the CCPA went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, in November 2020, California voters passed Proposition 24, the CPRA. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. The GDPR has increased our obligations, for example, by imposing higher standards when obtaining consent from individuals to process their personal data, requiring more robust disclosures to individuals, strengthening individual data rights, shortening timelines for data breach notifications, limiting retention periods and secondary use of information, increasing requirements pertaining to health data as well as pseudonymized (i.e., key-coded) data, and imposing additional obligations when we contract third-party processors in connection with the processing of personal data. The GDPR also regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the European Union member states may result in fines of up to the greater of &#x20ac;20 million and 4% of the total worldwide annual turnover of the preceding financial year and other administrative penalties. Compliance with the new data protection rules imposed by GDPR may be onerous and adversely affect our business, financial condition, and results of operations. Further, the GDPR provides that European Union and EEA member states may make their own further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. From January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR (UK GDPR), which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR (i.e., fines up to the greater of &#x20ac;20 million (&#163;17.5 million) or 4% of global turnover). The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains uncertain, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. These uncertainties, as well as any applicable regulatory changes, may lead to additional costs and increase our overall risk exposure.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure, or perceived failure, by us to comply with or make effective modifications to our policies, or to comply with any federal, state or international privacy, data-retention or data-protection-related laws, regulations, orders or industry self-regulatory principles could result in proceedings or actions against us by governmental entities or others, a loss of customer confidence, damage to our brand and reputation and a loss of customers, any of which could have an adverse effect on our business. In addition, various federal, state and foreign legislative or regulatory bodies may enact new or additional laws and regulations concerning privacy, data-retention and data-protection issues, including laws or regulations mandating disclosure to domestic or international law enforcement bodies, which could adversely impact our business or our reputation with customers. For example, some countries have adopted laws mandating that some personal information regarding customers in their country be maintained solely in their country. Having to maintain local data centers and redesign product, service and business operations to limit personal information processing to within individual countries could increase our operating costs significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product and product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our third-party manufacturers&#x2019; facilities pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages; such liability could exceed our resources, and state or federal or other applicable authorities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business may be materially adversely affected by the ongoing COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the COVID-19 pandemic did not materially adversely affect our business operations during the year ended December 31, 2021, economic and health conditions in the United States and across most of the globe have changed considerably since the pandemic began. In particular, supply chain disruptions have become a concern for many businesses in the current environment. The COVID-19 pandemic also caused significant volatility in the U.S. and international markets. The impact of the COVID-19 pandemic may increase the possibility of uncertainty in the global financial markets, high inflation and extended economic downturn. We are subject to inflationary pressures on employee wages, salaries, and the cost of various goods and services that can negatively impact our financial results. We have experienced minor delays in delivery of various products related to our manufacturing processes and in some cases have had to identify new suppliers, which at times resulted in increased costs. While not of the disruptions of our supply chain to date have been material, we cannot exclude the possibility that further supply chain disruptions due to the COVID-19 pandemic could have a material adverse effect on our business, and the extent to which these issues will impact our results remains uncertain.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the risk of such supply chain disruptions, as a result of the COVID-19 pandemic, we may also experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are conducting a number of clinical trials for product candidates in geographies that have been heavily affected by the COVID-19 pandemic. While the availability of first-generation vaccines in the United States (and other countries) have greatly improved the outlook for the pandemic, we believe that the emergence of variants of concern and/or the potential waning of the immune protection offered by existing vaccines has the potential to lead to prolonging the effects of the pandemic, which could in turn have an impact on various aspects of our clinical trials. For example, with respect to clinical trials for our tumor-specific immunotherapy product candidates, investigators may not want to screen or treat cancer patients with our experimental vaccine and potentially expose them to the novel coronavirus during additional clinic visits. Other potential impacts of the COVID-19 pandemic on our various clinical trials include delays or difficulties in any planned clinical site initiation, including difficulties in obtaining IRB or ethics committee approvals, recruiting clinical site investigators and clinical site staff, delays or difficulties in enrolling patients, interruption of planned key clinical trial activities, such as clinical trial site data monitoring due to diversion of resources at clinical sites or limitation on travel imposed by federal or state governments. This may impact the integrity of subject data.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While chimpanzee-based adenoviral (ChAd) vaccines have not yet been approved in the US, there is a risk that patient candidates to our GRANITE or SLATE vaccine candidates may become ineligible due to pre-existing neutralizing antibodies to ChAd vaccines, for example following participation in SARS-CoV-2 clinical trials using such vaccines. This in turn could slow down recruitment to our clinical trials, especially if we were to consider expanding our trials in the EU, and, ultimately, if these ChAd vaccines against SARS-CoV-2 are proven effective and become widely available in the general population, may render our vaccination approach unsuitable for many cancer patients. Similarly, patients who have been previously vaccinated with a mRNA-based vaccine may be reluctant to receive our samRNA vaccines, or may have contraindications such as allergic reaction to their SARS-CoV-2, mRNA-based vaccines.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the COVID-19 pandemic, we have been forced to alter our normal business and operations, for example by encouraging remote work for our employees who, given the nature of their function, can do so effectively. However, many of our employees and contractors perform essential activities that must be completed on-site. While on-site at our facilities, all of our staff are required to wear appropriate personal protective equipment, consistent with public health guidance. The COVID-19 pandemic could disrupt our ability to secure supplies for our facilities and to provide personal protective </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equipment for our employees. The safety, health and well-being of our workforce is of primary concern, and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the novel coronavirus.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our increased reliance on personnel working from home may negatively impact productivity or disrupt, delay or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our employees and contractors conducting research and development activities may not be able to access our laboratories for an extended period of time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and comparable foreign regulatory agencies may experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading prices for our common shares and other biotechnology companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common shares or such sales may be on unfavorable terms.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the outlook is improving, the COVID-19 outbreak continues to evolve. Even as vaccination rates continue to grow in the United States and other countries, it remains unclear when the pandemic will subside, particularly if full global vaccination is not achieved or existing vaccines prove less effective against new variants of the virus. The extent to which the outbreak may impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of COVID-19, the duration of the outbreak, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have applied, and we intend to continue applying, for patents covering aspects of our product candidates, proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent coverage we obtain may not be sufficient to prevent substantial competition. As of December 31, 2021, our solely owned patent portfolio includes pending patent applications and issued patents. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. The patent application process is subject to numerous risks and uncertainties, and there can be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no assurance that we or any of our actual or potential future collaborators will be successful in protecting our product candidates, proprietary technologies and their uses by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patent applications may not result in any patents being issued;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March 16, 2013;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Moreover, the patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties can raise objections against such initial grant. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product or service. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our products are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our products, our competitive position could be harmed, or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any of our pending patent applications or those of our licensors may issue as patents;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others will not or may not be able to make, use, offer to sell, or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we will be able to successfully commercialize our products, if approved, on a substantial scale before the relevant patents that we own or license expire;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors were the first to file patent applications for these inventions;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others will not develop similar or alternative technologies that do not infringe the patents we own or license;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any of the patents we own or license will be found to ultimately be valid and enforceable;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable products or will provide us with any competitive advantages;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a third party may not challenge the patents we own or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may develop or in-license additional proprietary technologies that are patentable;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others will not have an adverse effect on our business;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we will develop additional proprietary technologies or products that are separately patentable; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our commercial activities or products will not infringe upon the patents of others.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent life has expired, we may be open to competition. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we do not have sufficient patent life to protect our product candidates, proprietary technologies and their uses, our business and results of operations will be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information. We have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our products and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs, or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies. The patent protection, prosecution and enforcement for some of our product candidates may be dependent on third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently are reliant upon licenses of certain patent rights and proprietary technology from third parties that is important or necessary to the development of our technology and products, including technology related to our product candidates. For example, we rely on our license agreements with Arbutus and Genevant for certain lipid nanoparticle-based delivery technologies. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to develop and commercialize our technology and products in fields of use and territories for which we are not granted rights pursuant to such licenses.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current licenses, and our future licenses likely will, impose various royalty payments, milestones, and other obligations on us. If we fail to comply with any of these obligations, we may be required to pay damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from developing and commercializing our product candidates and proprietary technologies. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any current or future licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and money and could prevent us from selling our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. We cannot assure you that our operations do not, or will not in the future, infringe existing or future patents.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, inter partes review proceedings and post-grant review proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of and have timely opposed EP Patent 2569633, expiring in May 2031 (absent any patent term adjustments or extensions), directed to certain methods of identifying and using neoantigens. EP Patent 2569633 is currently validated in Great Britain, France, Germany, Netherlands, Italy, Ireland, Spain and Switzerland. Our opposition was filed in our name on November 7, 2016 by Vossius &amp; Partner. Four other parties also filed oppositions to the patent within the required timeframe. The Opposition Division of the European Patent Office (EPO), held opposition hearings on October 15 and 16, 2018, and determined that EP Patent 2569633 does not meet the requirements of the European Patent Convention (EPC) and consequently, revoked the patent. We received notice in April 2019 that EP Patent 2569633 patentees and licensors filed their appeal to the Opposition Division&#x2019;s decision, and we, along with other opposers, filed responses in August 2019. Opponent Christian M&#xfc;ller withdrew his opposition in May 2020, but the appeal proceedings will be continued between the remaining parties. The EPO scheduled the oral proceedings for the appeal for September 27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent applications in the United States and elsewhere are typically published approximately eighteen (18) months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates, and cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">result in costly litigation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">divert the time and attention of our technical personnel and management;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cause development delays;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to pay the attorney&#x2019;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although no third party has asserted a claim of patent infringement against us as of the date of this report, others may hold proprietary rights that could prevent any of our immunotherapy candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market the affected immunotherapy candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Even if such licenses are available, we could incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins, and the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our immunotherapy candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. Also, we may be obligated under our agreements with our collaborators, licensors, suppliers and others to indemnify and hold them harmless for damages arising from intellectual property infringement by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. For example, third parties may petition the USPTO for post-grant review within nine (9) months of our patent&#x2019;s issuance date. Further, after the USPTO period for filing post-grant review has expired, third parties may file a petition for inter partes review on certain grounds. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation, or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have collaborated with U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to various agreements that we depend on to operate our business, including intellectual property rights relating to GRANITE, SLATE and CORAL, in particular, our agreement with Arbutus. Our rights to use currently licensed intellectual property or intellectual property to be licensed in the future are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the sublicensing of patent and other rights;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and duration of our payment obligations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our rights upon termination of such agreement; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and duration of exclusivity obligations of each party to the agreement.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current license agreements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future license agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is common in the biotechnology and biopharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or biopharmaceutical companies including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to defend against</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of FDA marketing approval of GRANITE, SLATE, CORAL or any future immunotherapy candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law in the U.S. or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent rights may be affected by developments or uncertainty in U.S. or ex-U.S. patent statutes, patent case laws in USPTO rules and regulations or in the rules and regulations of ex-U.S. patent offices. There are a number of changes to the U.S. patent laws that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, on September 16, 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#x201c;first to file&#x201d; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. This could have a negative impact on some of our intellectual property and could increase uncertainties surrounding obtaining and enforcement or defense of our issued patents. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending all current and future patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own, and if we license intellectual property we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make individualized cancer immunotherapies that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our pending patent applications will not lead to issued patents;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If one or more of our product candidates is approved, each will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP or similar regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP or similar regulations and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved label. As such, we may not promote our products &#x201c;off-label&#x201d; for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issue warning letters;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impose civil or criminal penalties;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspend or withdraw regulatory approval;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suspend any of our clinical studies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refuse to approve pending applications or supplements to approved applications submitted by us;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impose restrictions on our operations, including closing our contract manufacturers&#x2019; facilities; or</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seize or detain products, or require a product recall.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the CARES Act made a number of changes to the Federal Food, Drug and Cosmetic Act aimed at preventing drug shortages. Similarly, the FDA has issued a number of guidance documents describing the agency&#x2019;s expectations for how drug manufacturers should comply with various FDA requirements during the pandemic, including with respect to conducting clinical trials, distributing drug samples, and reporting post-marketing adverse events. Moreover, as a result of the COVID-19 pandemic, there has been increasing political and regulatory scrutiny of foreign-sourced drugs and foreign drug supply chains, resulting in proposed and enacted legislative and executive actions, including Executive Orders, to incentivize or compel drug manufacturing operations to relocate to the United States. It is not clear how these changes and proposals could impact our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek orphan drug designation for certain future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may pursue orphan drug designation for certain of our future product candidates. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Commission, on the basis of a scientific opinion by the EMA&#x2019;s Committee for Orphan Medicinal Products (COMP), grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, orphan designation is granted only if there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. It is no longer necessary to obtain orphan designation in the UK before an application for marketing authorization is made, and the criteria will be assessed by the MHRA, at the time of assessment of the application for marketing authorization. The criteria in the UK are similar to those in the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for certain clinical trial costs, and application fee waivers. In addition, if an orphan-designated product receives the first FDA approval for the indication for which it has orphan designation (meaning that FDA has not previously approved a drug considered the same drug for same orphan condition), the product is entitled to orphan drug exclusivity. If there is a previously approved same drug for the same orphan condition, to obtain orphan exclusivity, the sponsor of the subsequent drug must demonstrate clinical superiority over the previously approved same drug. If granted, orphan exclusivity means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity to meet the needs of the orphan patient population. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval, subject to the positive outcome of the reassessment of the continued compliance with the orphan designation criteria at the time of approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met at the end of the fifth year since grant of the approval, including where it is shown that the product is sufficiently profitable not to justify</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintenance of market exclusivity. Moreover, upcoming legislative reforms in the European Union may result in a reduction of market exclusivity periods for orphan medicinal products and/or imposition of additional requirements for grant of such exclusivity. In the UK, if the criteria for orphan designation are met at the time of assessment of the marketing authorization, the applicant is entitled to a fee reduction and ten years of market exclusivity. The terms of market exclusivity, and possibility for the period to be reduced, are similar to those in the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain orphan drug designation for a product candidate, we may not be the first to obtain marketing approval for the product candidate for any particular orphan indication due to the uncertainties associated with developing novel biologic products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or foreign regulatory authorities can subsequently approve the same drug with the same active moiety for the same condition if the FDA or foreign regulatory authorities concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received fast track designation for GRANITE for the treatment of colorectal cancer, and we may seek such designation for some or all of our other product candidates. If a drug or biologic, in our case, is intended for the treatment of a serious or life-threatening disease or condition and the biologic demonstrates the potential to address unmet medical needs for this disease or condition, the biologic sponsor may apply for FDA fast track designation. The sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development; and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot guarantee that the FDA would grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Some of our product candidates may require a pediatric development, which may delay our regulatory approvals and ultimately our commercial licensure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The RACE for Children Act enacted in the U.S. in August 2017 and the European Pediatric Regulation implemented in 2007 as well as similar legislation in the UK may require us to develop our products in pediatric cancer patients. Pediatric cancers are rare, mutational burden is usually low in pediatric tumors and our approach may not be suited for children with cancer, or it may be difficult and slow to accrue children with cancers in our clinical trials. We may incur delays in meeting potential regulatory obligations or require additional investments to fulfill our regulatory commitments, and ultimately may be found incompliant if we cannot deliver pediatric data within the agreed timelines. This could lead to delays in regulatory approval and ultimately commercial licensure of our GRANITE or SLATE products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a licensure framework for follow on biologic products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, the expansion of the 340B Drug Discount Program through the ACA has increased the number of purchasers who are eligible for significant discounts on branded drugs. Several drug manufacturers have commenced litigation, which remains ongoing, challenging the legality of contract pharmacy arrangements under the 340B Drug Discount Program, which may affect the way in which manufacturers are required to extend the 340B Drug Discount Program prices to covered entities, including through contract pharmacies. There are also ongoing challenges regarding the implementation of the 340B Drug Discount Program Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that they have been overcharged for covered outpatient drugs by manufacturers. The nature of the current Administrative Dispute Resolution Process, and the outcomes of these court cases, may have a material adverse impact on our revenue should we participate in the 340B Drug Discount Program after receiving approval for our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration will impact our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through fiscal year 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the first six months of the final fiscal year of this sequester. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. For example, Congress is currently considering a number of bills relating to drug pricing, including bills that would impose rebate obligations for Medicare (and potentially other utilization) for price increases greater than the rate of inflation, require drug pricing negotiations in Medicare, redesign the Part D benefit to lower patient costs and overall spending, and introduce enhanced transparency measures into drug pricing. In particular, the Build Back Better Act introduces drug pricing reforms that would, among other things, allow the federal government to negotiate prices for some high-cost drugs covered under Medicare Parts B and D, introduce inflationary rebates on certain Medicare Part B and Medicare Part D drugs to support limits on drug price increases in Medicare and private insurance, redesign the structure of the Part D benefit, and require payment of rebates on covered outpatient drugs that are paid for by a state Children&#x2019;s Health Insurance Program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things, reduce or limit the prices of drugs and make them more affordable for patients, such as by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries, reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs, bring more transparency to drug pricing rationale and methodologies (including, for example, by requiring drug manufacturers to disclose planned drug price increases and the rationales for such increases), implement data collection and reporting under Section 204 of Title II of Division BB of the Consolidated Appropriations Act, 2021, which requires, among other things, health plans and issuers to disclose rebates, fees, and other remuneration provided by drug manufacturers related to certain pharmaceutical products, enable the government to negotiate prices for drugs covered under Medicare, including H.R. 3 which passed the House, revise rules associated with the calculation of Medicaid Average Manufacturer Price and Best Price, including the removal of the current statutory 100% of Average Manufacturer Price per-unit cap on Medicaid rebate liability for single source and innovator multiple source drugs effective as of January 1, 2024 under the American Rescue Plan Act of 2021, which may significantly affect the amount of rebates paid on prescription drugs under Medicaid and the prices that are required to be charged to covered entities under the 340B Drug Discount Program, and facilitate the importation of certain lower-cost drugs from other countries. In July 2021, President Biden issued an Executive Order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition, including directing FDA to support and work with states and Indian Tribes to develop importation plans to import prescription drugs from Canada. The Executive Order required the Secretary of Health and Human Services to develop a comprehensive plan for addressing drug prices. The plan was released on September 9, 2021, and it includes support for legislative and administrative actions that would improve affordability, access and competition, and foster scientific innovation. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union and UK, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Moreover, upcoming legislative and policy changes in the European Union may further impact the price and reimbursement status of our products in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Food, Drug and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by statute), certain non-physician practitioners such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our stock price is volatile, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#x201c;Risk Factors&#x201d; section of this report and others such as:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results from, and any delays in, our clinical trials for GRANITE, SLATE, CORAL or any other future clinical development programs, including public misperception of the results of our trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by academic or other third parties challenging the fundamental premises underlying our approach to treating cancer and infectious disease and/or biopharmaceutical product development;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements of regulatory approval or disapproval of our current or any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure or discontinuation of any of our research and development programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing setbacks or delays of or issues with the supply of the materials for our personalized immunotherapy candidate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements relating to future licensing, collaboration or development agreements, including the early termination or failure of an existing strategic collaboration;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in the commercialization of our current or any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">public misperception regarding the use of our therapies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquisitions and sales of new products, technologies or businesses;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">quarterly variations in our results of operations or those of our current or future competitors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in earnings estimates or recommendations by securities analysts;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by us or our competitors of new products, significant contracts, commercial relationships, acquisitions or capital commitments;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments with respect to intellectual property rights;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our commencement of, or involvement in, litigation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any major changes in our board of directors or management;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">new legislation, particularly in the United States, relating to the sale or pricing of pharmaceuticals;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA or other U.S. or foreign regulatory actions affecting us or our industry;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product liability claims or other litigation or public concern about the safety of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the biopharmaceutical and biotechnology sectors, particularly as a result of the volatility in the market caused by the COVID-19 pandemic; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic conditions in the United States and abroad.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the stock markets in general, and the markets for biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of any particular issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit, and the attention of our management would be diverted from the operation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. For example, we have issued and may continue to issue shares in our &#x201c;at the market offering&#x201d; program or other registered offerings under the 2019 Shelf Registration Statement, and we have issued shares pursuant to the First PIPE Financing and the Second PIPE Financing transactions entered into in December 2020 and September 2021. To the extent that additional capital is raised through the issuance of shares of common stock or other securities convertible into shares of common stock, our stockholders will be diluted. In addition, future issuances of our common stock or other equity securities (or securities convertible into our common stock or other equity securities), or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or other securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of December 31, 2021, we have a total of 69,047,878 shares of common stock outstanding, as well as approximately 17.0 million shares underlying pre-funded warrants and approximately 5.9 million shares of common stock that are subject to outstanding options, restricted stock units or other equity awards. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, until such unused losses expire, if ever. Under Sections 382 and 383 of the Internal Revenue Code of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1986, as amended (IRC), if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Any equity financing transactions, private placements and other transactions that occur within a three-year testing period may trigger additional ownership changes, which could further limit our use of such tax attributes. Any such limitations, whether as a result of prior or future offerings of our common stock or sales of common stock by existing stockholders, could have an adverse effect on our results of operations in our future years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement that a special meeting of stockholders may be called only by our chief executive officer or president or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#x2019; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#x2019;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware and in the U.S. federal district courts for certain disputes between us and our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We incur substantial costs as a result of operating as a public company, and our management devotes substantial time to governance and compliance matters. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct, among other requirements. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#x2019; and officers&#x2019; insurance, on acceptable terms or at all.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we are subject to Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404) and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal controls over financial reporting. We will remain an emerging growth company until the earlier of (1) December 31, 2023, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th or (4) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to provide the reports required by these rules we must conduct reviews and testing of our internal controls. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on third party vendors to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially harm to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#x2019;s conduct was unlawful.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters are currently located at 5959 Horton Street, Emeryville, California, comprising approximately 34,569 square feet of office and laboratory space. The initial lease term for the 5959 Horton lease expires on November 30, 2029 and we have an option to extend the lease term for two consecutive additional terms of 5 years. We also lease an aggregate of 28,600 square feet of space in two Cambridge, Massachusetts facilities, including (i) the lease of approximately 13,900 square feet of office and laboratory space, the term of which expires in April 2025, as the result of our exercise of an option to extend, and (ii) the lease of approximately 14,700 square feet of office and laboratory space, the term of which expires in January 2023, as the result of our agreeing to an extension.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We lease a manufacturing facility in Pleasanton, California, where we occupy approximately 42,600 square feet of space. The current term of our lease expires in November 2024, with an option to extend the term through November 2029. We also lease an additional space in Pleasanton, California, where we occupy approximately 3,223 square feet of general office space. The current term of the lease expires in November 2024.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we have entered into a lease to occupy a newly-built facility in Boston, Massachusetts, comprising approximately 73,495 square feet of office and laboratory space. We expect to take occupancy of this facility in 2023.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional information on all our properties, see &#x201c;Leases&#x201d; in Note 6 to our consolidated financial statements.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing facilities are sufficient for our needs for the immediate future and that, with our new facility in Boston, our facilities will meet the anticipated needs of our business in the medium term. As we continue to grow the business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ety Disclosures.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#x201c;GRTS&#x201d; since September 28, 2018. Prior to that date, there was no public trading market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Common Stock</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 7, 2022, there were 20 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial owners of our common stock represented by these record holders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a &#34;smaller reporting company&#34; as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. [Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. This discussion and analysis, and other parts of this report, contain forward-looking statements, including, but not limited to, statements related to the potential of our therapeutic programs. Such forward-looking statements involve substantial risks and uncertainties that could cause our research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including interim results obtained may differ from those at completion of the studies and clinical trials. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including  our programs&#x2019; early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products,  our ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Our actual results could differ materially from those discussed in these forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see the section titled &#x201c;Risk Factors&#x201d; included elsewhere in this Annual Report on Form 10-K. These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We discover, develop, manufacture, and deliver next generation cancer and infectious disease immunotherapy candidates with the aim of improving patient outcomes and eliminating disease. The immune system sits at the nexus of many diseases, and manipulation of the immune system has enormous potential to drive transformational therapeutic and preventative benefits. Our approach seeks to generate a potent therapeutic or protective immune response by leveraging insights into the immune system&#x2019;s ability to recognize and destroy diseased cells and eliminate virally-infected cells. Our programs are built on two key platforms, the first being our proprietary Gritstone EDGE&#153; artificial intelligence platform, which enables us to identify antigens that can be recognized by the immune system with a high degree of accuracy. The second platform is our potent, flexible, vaccine platform, which we have engineered to deliver selected immunogens to the patient&#x2019;s immune system to drive the destruction of tumors or virally-infected cells. We accomplish this by leveraging our two proprietary vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd), which we have optimized to deliver immunogens selected by EDGE&#153; to the immune system. We utilize these &#x201c;mix and match&#x201d; vectors in a variety of ways, including as a heterologous prime-boost (one vector followed by the other) or homologous prime-boost (use the same vector twice). Our proprietary and synergistic technologies enable us to build robust and distinct pipelines in oncology and infectious disease. Additionally, our in-house manufacturing capabilities enable us to drive down both cost and production time, as well as maintain control over intellectual property and product quality of our products.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below summarizes key information about our clinical-stage pipeline.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.796%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:6.963%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:21.12%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:25.343%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:13.537%;"></td>
    <td style="width:1.241%;"></td>
    <td style="width:14.037%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Program</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Phase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Status</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Indication(s)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Collaborator</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Commercial Rights</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">GRANITE</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1/2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Enrollment Complete; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Early stage &amp; advanced solid tumors</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">GRANITE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2/3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1Q 2022 Initiation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">MSS-CRC* first line maintenance</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">GRANITE</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1Q 2022 Initiation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">MSS-CRC adjuvant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">SLATE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1/2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Complete</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">p53, KRAS Advanced Solid Tumors</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">SLATE</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Enrollment Ongoing; Treatment Ongoing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">KRAS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.221pt;white-space:pre-wrap;font-weight:normal;font-size:6.03pt;font-family:Times New Roman;position:relative;">mut</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CORAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Enrolling</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">COVID-19 na&#xef;ve &amp; booster</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NIAID, IDCRC</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CORAL</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Enrolling</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">COVID-19 booster (60+)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CORAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1Q 2022 Initiation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">COVID-19 immunocompromised</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">NA</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CORAL</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1Q 2022 Initiation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">COVID-19 in South Africa (na&#xef;ve, convalescent, HIV+)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CEPI</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gritstone</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">HIV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4Q 2021 IND Cleared</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">HIV treatment/cure</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gilead Sciences</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Gilead</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">*MSS-CRC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> = </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">microsatellite stable colorectal cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Sources</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have funded our operations to date primarily through private placements of our convertible preferred stock, the sale of our common stock in public offerings and under our &#x201c;at-the-market&#x201d; offering program, private placements of our common stock and pre-funded warrants and with proceeds received from our collaboration arrangements. We also have received targeted funding from charitable foundations. We do not expect to generate revenue from any product candidates that we develop until we obtain regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval for one or more of such product candidates and commercialize our products or enter into additional collaboration agreements with third parties. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our programs will require substantial additional development time and resources before we (or our collaboration partners) would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. In addition, we incur substantial costs associated with operating as a public company. We also do not yet have a sales organization or commercial infrastructure and, accordingly, we will incur significant expenses to develop a sales organization or commercial infrastructure in advance of generating any commercial product sales. As a result, we will need substantial additional capital to support our operating activities.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently anticipate that we will seek to fund our operations through equity or debt financings or other sources, such as additional collaboration agreements we may enter into with third parties. Adequate funding may not be available to us on acceptable terms, or at all, particularly in light of the current COVID-19 pandemic and associated economic uncertainty and potential local and/or global economic recession. If sufficient funds on acceptable terms are not available when needed, we will be required to significantly reduce our operating expenses and delay, reduce the scope of, or eliminate one or more of our development programs. See &#x201c;Liquidity and Capital Resources&#x201d; below and Note 2 to the consolidated financial statements and related notes included elsewhere for additional information.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing is a vital component of our platform approach to immunotherapy, and we have invested significantly in our manufacturing facility, which opened in November 2017. Until December 2019, we used a hybrid approach to manufacture our individualized immunotherapy, wherein certain elements of our product candidates were manufactured on an outsourced basis at qualified third-party contract manufacturing organizations (CMOs) and other elements of our product candidates were manufactured internally. Beginning in March 2020, we internalized the majority of the outsourced elements of the manufacturing process for our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since we commenced operations in August 2015, we have invested a significant portion of our efforts and financial resources in research and development activities and establishing our manufacturing facility. We have had significant operating losses since our inception, and we do not expect positive cash flows from operations in the foreseeable future (for additional information, see &#x201c;Liquidity&#x201d; in Note 1 to our consolidated financial statements). We do not have any products approved for sale. We expect to continue to incur net operating losses for at least the next several years as we advance our product candidates through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following our IPO, in April 2019, we completed an underwritten public offering and sold and issued an aggregate of 6,500,000 shares of common stock at a price to the public of $11.50 per share. We received aggregate net proceeds from the offering of approximately $69.7 million, after deducting underwriting discounts and commissions and offering costs.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, we (i) filed a shelf registration statement on Form S-3 (the 2019 Shelf Registration Statement), with the SEC covering up to $250.0 million of common stock, preferred stock, debt securities, warrants and units, and (ii) entered into a Sales Agreement with Cowen and Company, LLC (Cowen), for an &#x201c;at-the market&#x201d;  $75.0 million in shares of our common stock (ATM Offering Program) . Through December 31, 2021, we have received aggregate proceeds from our ATM Offering Program of $50.0 million, net of commissions and offering costs. During the year ended December 31, 2021, we issued and sold 3,990,869 shares of our common stock through our ATM Offering Program and received net proceeds of approximately $36.6 million. We have $22.9 million available under the 2019 Shelf Registration Statement for the ATM Offering Program as of December 31, 2021.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we entered into private placement transactions, pursuant to which we sold (i) an aggregate of 5,543,351 shares of common stock at a per share purchase price of $3.34, (ii) pre-funded warrants to purchase an aggregate of 27,480,719 shares of common stock, each with an exercise price of $3.34 per share of common stock (of which $3.33 per share was pre-paid by each purchaser), and (iii) an aggregate of 4,043,127 shares of common stock at a per share purchase price of $3.71. The aggregate gross cash proceeds to us for the securities sold in these private placements was $125.0 million, and related costs were $5.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 16, 2021, we entered into a Securities Purchase Agreement, pursuant to which we issued and sold, in an unregistered offering in reliance on an exemption from registration, an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share, at a per share purchase price of $11.00 per share. We received aggregate gross proceeds of $55.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Update</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has placed strains on the providers of healthcare services, including the healthcare institutions where we conduct our clinical trials. These strains have resulted in institutions prohibiting the initiation of new clinical trials, slowing or halting enrollment in existing trials and restricting the on-site monitoring of clinical trials. Our operations have not been materially impacted by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the COVID-19 pandemic. However, we have experienced slowing of patient recruitment and sample collection in our ongoing clinical trials. Additionally, as a result of the COVID-19 pandemic, competition for potential patients in our trials may be further exaggerated as a result of multiple clinical site closures. To date, the COVID-19 pandemic has not materially affected our supply chain or production schedule, but further escalation of the health crisis has the potential to cause delays in our supply chain and manufacturing operations, which could materially adversely impact our business.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not experienced any material disruptions in our supply chain necessary to conduct our ongoing clinical trials. In response to the COVID-19 pandemic, we have implemented heightened health and safety measures designed to comply with applicable federal, state and local guidelines. In particular, we transitioned to a flexible work environment, allowing employees who can work from home effectively to do so. We are further supporting all of our employees by leveraging virtual meeting and messaging technology and by encouraging employees to follow local health authority guidance. As the pandemic continues to evolve, we may need to undertake additional actions that could impact our operations if required by applicable laws or regulations or if we determine such actions to be in the best interests of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Our Operating Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaboration and License, Grant and Contribution Revenue</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. For the years ended December 31, 2021, 2020 and 2019, we recognized $48.2 million, $4.0 million and $4.4 million, respectively, of revenue from the 2seventy Agreement, the Gilead Collaboration Agreement, another small collaboration agreement, and the grant agreement with CEPI. See Note 7 to our consolidated financial statements for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the future, we will continue to recognize revenue from the 2seventy Agreement and the Gilead Collaboration Agreement and may generate revenue from product sales or other collaboration agreements, strategic alliances and licensing arrangements. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of license fees, milestones, reimbursement of costs incurred and other payments and product sales, to the extent that any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have focused significant resources on our research and development activities, including conducting preclinical studies, manufacturing development efforts and related development activities for our product candidates.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development activities account for a significant portion of our operating expenses. Research and development costs are expensed as incurred. These costs include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External research and development expenses, including:</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses incurred under arrangements with third parties, including clinical research organizations, or CROs, preclinical testing organizations, CMOs, academic and non-profit institutions and consultants;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fees related to our license agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Internal research and development expenses, including:</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Headcount-related expenses, including salaries, payroll taxes, benefits, non-cash stock-based compensation and travel, for employees contributing to research and development activities, including the costs associated with the development of our EDGE&#153; platform; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses, which include direct and allocated expenses for laboratories, facilities and other costs.</span></div></div>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, we reimbursed Arbutus for materials and personnel costs totaling $0.4 million and recorded $3.0 million as research and development expenses in connection with the milestone under the Arbutus License Agreement. In 2020, we recorded the upfront payment of $2.0 million under the 2020 Genevant License Agreement as research and development expenses.  In 2021, we recorded the $1.5 million upfront and $1.0 million milestone payments under the 2021 Genevant License Agreement as research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase substantially in the future as we continue to advance our product candidates into and through clinical studies and pursue regulatory approval. Conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming, and such clinical studies generally become larger and more costly to conduct as they advance into later stages. The successful development of our product candidates is highly uncertain. The actual probability of success for our product candidates may be affected by a variety of risks and uncertainties associated with drug development, including those set forth in the section entitled &#x201c;Risk Factors&#x201d; included in Part II, Section 1A and elsewhere in this report.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses by program and category (in thousands):</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.164%;"></td>
    <td style="width:1.354%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.255%;"></td>
    <td style="width:0.603%;"></td>
    <td style="width:1.354%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.255%;"></td>
    <td style="width:0.603%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GRANITE program external expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,962</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,875</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SLATE program external expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,706</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,747</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CORAL program external expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,879</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,067</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other program external research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,362</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,721</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel-related expenses </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,138</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,764</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other unallocated research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,443</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,469</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,490</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,643</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);margin-right:84.0%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Personnel-related expenses include stock-based compensation expense of $6.6 million and $4.5 million for the years ended December 31, 2021 and 2020, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not track internal related expenses on a program-by-program basis, because our research and development employees and infrastructure resources are utilized across our development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our general and administrative expenses consist primarily of salaries and related costs, including payroll taxes, benefits, non-cash stock-based compensation and travel. Other general and administrative expenses include legal costs of pursuing patent protection of our intellectual property, and professional service fees for auditing, tax and general legal services. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities and prepare for potential commercialization of our current and future product candidates, increase our headcount and support our operations as a public company, including increased expenses related to legal, accounting, regulatory and tax-related services associated with maintaining compliance with requirements of the Nasdaq Global Select Market and the SEC, directors and officers liability insurance premiums and investor relations activities. Allocated expenses consist of rent expenses related to our office and research and development facilities, depreciation and other allocated costs not otherwise included in research and development expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net, consists primarily of interest income and investment income earned on our cash, cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the significant components of our results of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.546%;"></td>
    <td style="width:1.159%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.992%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.159%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:11.001%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.159%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.973%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,717</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,462</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,255</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,497</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">575</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">922</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,214</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,037</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,177</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,490</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,643</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,847</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,933</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,411</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,522</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123,423</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,054</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,369</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(75,209</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(106,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,808</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">703</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(576</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(75,082</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(105,314</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,232</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License, Grant and Contribution Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration and licenses revenues were $46.7 million and $3.5 million for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2021, we recorded $38.6 million in license revenue and $5.1 million in collaboration revenue related to the Gilead Collaboration Agreement, and $3.0 million in collaboration revenue related to the 2seventy Agreement. Contribution revenue was $1.5 million and $0.6 million for the years ended December 31, 2021 and 2020, respectively. During the year ended December 31, 2021, we recognized $1.5 million of grant revenue from the CEPI Funding Agreement. See Note 7 to our consolidated financial statements for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses were $97.5 million for the year ended December 31, 2021 compared to $88.6 million for the year ended December 31, 2020. The increase of $8.8 million for the year ended December 31, 2021 was primarily due to increases in personnel-related expenses and clinical trial expenses. Personnel-related costs increased by $4.9 million, as a direct result of our increased research and development headcount. Outside services and consultants increased by $6.3 million, as a result of clinical trials and preclinical testing, including additional temporary personnel to carry out the research and development activities. Milestone and license payments increased by $0.7 million reflecting payments to Genevant Sciences GmbH. These increases were partially offset by a decrease of $3.1 million in laboratory supplies and consumables.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses were $25.9 million for the year ended December 31, 2021 compared to $21.4 million for the year ended December 31, 2020. The increase of $4.5 million was primarily attributable to a $1.5 million increase in personnel-related costs as we expanded our headcount, a $1.6 million increase in outside services for legal, finance, recruiting and other professional services to support our ongoing operations and operate as a public company and $1.0 million in professional services expenses due to costs incurred in the Gilead Collaboration Agreement. Facility-related expenses increased by $0.4 million to accommodate our increased general and administrative personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net was $0.1 million for the year ended December 31, 2021 compared to $0.7 million for the year ended December 31, 2020. The income for both years represents interest and investment income from cash, cash equivalents and marketable securities. The decrease of $0.6 million was due to a lower average cash, cash equivalents and marketable securities balance in 2021 than in 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2020 and 2019</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the significant components of our results of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.342%;"></td>
    <td style="width:1.261%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.964%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.261%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.954%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.261%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.945%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,462</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,365</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(903</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">575</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">575</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,037</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,365</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(328</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88,643</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82,896</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,747</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,411</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,409</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,002</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,054</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102,305</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,749</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(106,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(97,940</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,077</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">703</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,507</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,804</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(105,314</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(94,433</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10,881</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License and Contribution Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue was $3.5 million and $4.4 million for the years ended December 31, 2020 and 2019, respectively. The $0.9 million decrease was due to less required FTEs to complete the required research work under the 2seventy Agreement during 2020. Contribution revenue is related to $0.6 million cash proceeds received from a philanthropic institution, which was restricted and was to be spent in accordance with the contribution agreement. All of the contribution grant was spent in accordance with the contribution agreement and therefore recognized as revenue as of December 31, 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses were $88.6 million for the year ended December 31, 2020 compared to $82.9 million for the year ended December 31, 2019. The increase of $5.7 million for the year ended December 31, 2020 was primarily due to increases in personnel-related expenses and expenses related to in-house laboratory supplies and consumables and facilities expenses. Personnel-related costs increased by $5.4 million, as a direct result of our increased research and development headcount. Outside services and consultants decreased by $4.3 million for clinical trials, preclinical testing and contract manufacturing expansion. In-house expenses for laboratory supplies and consumables increased by $0.8 million and reflect our increased research and development personnel and manufacturing expansion. Facility-related expenses increased by $4.8 million to accommodate our manufacturing expansion and increased research and development personnel. Milestone and license payments decreased by $1.0 million, reflecting a $3.0 million payment made in 2019 under the Arbutus License Agreement upon the achievement of certain milestones and a $2.0 million in-licensing payment made in 2020 under our new agreement with Genevant Sciences GmbH.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses were $21.4 million for the year ended December 31, 2020 compared to $19.4 million for the year ended December 31, 2019. The increase of $2.0 million was primarily attributable to a $1.4 million increase in personnel-related costs as we expanded our headcount, and a $0.3 million increase in outside services for legal, finance, recruiting and other professional services to support our ongoing operations and operate as a public company. Facility-related expenses increased by $0.2 million to accommodate our increased general and administrative personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net was $0.7 million for the year ended December 31, 2020 compared to million $3.5 million for the year ended December 31, 2019. The income for both years represents interest and investment income from cash, cash equivalents and marketable securities. The decrease of $2.8 million was due to a lower average cash, cash equivalents and marketable securities balance in 2020 than in 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From our inception through December 31, 2021, we have funded our operations primarily through sales of our convertible preferred stock, sales of our common stock in public offerings and under our ATM Offering Program, the private placement of our common stock and pre-funded warrants, and our collaborations, including with the receipt of proceeds from the 2seventy Agreement and the Gilead Collaboration Agreement. As of December 31, 2021, we had cash, cash equivalents, and marketable securities of $206.3 million and an accumulated deficit of $401.4 million, compared to cash, cash equivalents, and marketable securities of $171.1 million and an accumulated deficit of $326.3 million as of December 31, 2020. We expect that, as of December 31, 2021 our cash will enable us to fund our current and planned operating expenses and capital expenditures for at least the next 12 months from the date of the filing of this report.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, we filed the 2019 Shelf Registration Statement, covering the offering of up to $250.0 million of common stock, preferred stock, debt securities, warrants and units, including the sale and issuance of up to $75.0 million in shares of our common stock to be issued, from time to time, in our ATM Offering Program. Through December 31, 2021, we have received aggregate proceeds from our ATM Offering Program of $50.0 million, net of commissions and offering costs. We have $22.9 million available under the 2019 Shelf Registration Statement for our ATM Offering Program as of December 31, 2021.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, we completed a private placement of securities (the First PIPE Financing, pursuant to which we sold (i) an aggregate of 5,543,351 shares of common stock at a per share purchase price of $3.34, (ii) pre-funded warrants to purchase an aggregate of 27,480,719 shares of common stock at a price per warrant share of $3.34 per share of common stock (of which $3.33 per share was pre-paid by each purchaser), and (iii) an aggregate of 4,043,127 shares of common stock at a per share purchase price of $3.71. The aggregate gross cash proceeds to us for the securities sold in the First PIPE Financing was $125.0 million, and related costs were $5.7 million.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we completed a second private placement of securities (the Second PIPE Financing), pursuant to which we sold an aggregate of 5,000,000 shares of common stock at a per share purchase price of $11.00. The aggregate gross cash proceeds to us for the securities sold in the Second PIPE Financing was $55.0 million, and related costs were $2.3 million.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we received a non-refundable upfront payment of $30.0 million under the Gilead Collaboration Agreement and $30.0 million under the Gilead Stock Purchase Agreement.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, we received an upfront payment of $11.3 million under the CEPI Funding Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not expect positive cash flows from operations in the foreseeable future. Historically, we have incurred operating losses as a result of ongoing efforts to develop our cancer immunotherapy candidates, including conducting ongoing research and development, clinical and preclinical studies and providing general and administrative support for these operations. We do not have any products approved for sale, and we do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our current and future product candidates and/or enter into additional significant collaboration or grant agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur net operating losses for at least the next several years and we expect the losses to increase as we advance our CORAL, GRANITE, and SLATE programs, as well as any future product candidates, through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization, continue our research and development efforts and invest in our manufacturing facility. We are subject to all the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover, we incur substantial costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until we can generate a sufficient amount of revenue from the commercialization of immunotherapy product candidates or from additional significant collaboration or license agreements with third parties, if ever, we expect to finance our future cash needs through private and public equity offerings, including our ATM Offering Program, debt financings, and potential future collaboration, license and development agreements. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our current or future product candidates. If we raise additional funds by issuing equity or convertible debt securities, it could result in dilution to our existing stockholders and increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur indebtedness, we could become subject to covenants that would restrict our operations and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term, but we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $401.4 million through December 31, 2021. We expect to incur substantial additional losses in the future as we conduct and expand our research and development activities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our projected operations through at least the next twelve (12) months from the date of this Annual Report on Form 10-K. We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our operating capital requirements. Our future capital requirements depend on many factors, including:</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of developing our product candidates, and of conducting preclinical studies and clinical trials, including our clinical trials for GRANITE, SLATE and CORAL;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential delays in our ongoing clinical trials as a result of the COVID-19 pandemic;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of, and the costs involved in, obtaining regulatory approvals for our oncology and infectious disease immunotherapy product candidates; in particular, any costs incurred in connection with any future regulatory requirements that may be imposed by the FDA or foreign regulatory bodies;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and characteristics of any additional product candidates we develop or acquire;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing our product candidates we successfully commercialize, including the cost of scaling up our internal manufacturing operations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of building a sales force in anticipation of product commercialization;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of commercialization activities, including building a commercial infrastructure, marketing, sales and distribution costs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any product liability or other lawsuits related to our products;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs to attract, hire and retain skilled personnel;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with being a public company;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, receipt and amount of sales of any future approved products, if any.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.55%;"></td>
    <td style="width:1.234%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.722%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:1.234%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.712%;"></td>
    <td style="width:0.983%;"></td>
    <td style="width:1.234%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.749%;"></td>
    <td style="width:0.983%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(50,678</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(89,102</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(85,011</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(118,553</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,949</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,841</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,760</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,801</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,395</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(60,471</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,648</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,225</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Used in Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash used in operating activities was $50.7 million, which consisted of a net loss of $75.1 million, adjusted by non-cash charges of $25.8 million and cash used due to changes in our operating assets and liabilities of $1.4 million. The non-cash charges consisted primarily of depreciation expense of $6.3 million, stock-based compensation of $10.6 million, and non-cash operating lease expense of $8.1 million. The change in our operating assets and liabilities was primarily due to decreases of $7.9 million in lease liability, $0.9 million in accrued and other non-current liabilities, $3.4 million in prepaid expenses and other assets, $0.6 million in deposits and long-term assets and $0.4 million in accounts payable, offset by increases of $8.6 million in deferred revenue , $2.6 million in accrued research and development expenses, and $0.6 million in accrued compensation.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash used in operating activities was $89.1 million, which consisted of a net loss of $105.3 million, adjusted by non-cash charges of $21.1 million and cash used due to changes in our operating assets and liabilities of $4.9 million. The non-cash charges consisted primarily of depreciation and amortization expense of $6.6 million, stock-based compensation of $7.1 million, and non-cash operating lease expense of $7.5 million. The change in our operating assets and liabilities was primarily due to decreases of $3.8 million in lease liability, $2.8 million in deferred revenue, $0.7 million in accrued research and development expenses, and $0.9 million in prepaid expenses and other assets, offset by increases of $0.8 million in accounts payable, $1.7 million in accrued compensation and $0.7 million in accrued and other non-current liabilities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2019, cash used in operating activities was $85.0 million, which consisted of a net loss of $94.4 million, adjusted by non-cash charges of $15.1 million and cash used due to changes in our operating assets and liabilities of $5.7 million. The non-cash charges consisted primarily of depreciation and amortization expense of $4.7 million, stock-based compensation of $5.3 million, and non-cash operating lease expense of $6.4 million. The change in our operating assets and liabilities was primarily due to a decrease of $4.3 million as a result of the deferred revenue recorded in connection with the 2seventy Agreement, a decrease of $3.3 million due to pre-payments made per our lease agreements, and a decrease of $0.3 million in deposits and other long-term assets, offset by increases of $1.5 million in accrued research and development expenses and $0.7 million in accrued compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Provided by (Used in) Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash used in investing activities was $118.6 million, which consisted of $199.9 million of purchases of marketable securities, $5.5 million of capital expenditures to purchase property and equipment, and $0.2 million of prepayment of financing lease, offset by $82.2 million in proceeds from the maturity of marketable securities and $4.8 million in proceeds from the sale of marketable securities.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash provided by investing activities was $65.9 million, which consisted of $72.9 million in proceeds from the maturity of marketable securities and $5.4 million in proceeds from the sale of marketable securities, offset by $8.8 million of purchases of marketable securities and $3.5 million of capital expenditures to purchase property and equipment.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2019, cash provided by investing activities was $15.8 million, which consisted of $113.0 million in proceeds from the maturity of marketable securities, offset by $81.0 million of purchases of marketable securities and $16.2 million of capital expenditures to purchase property and equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Provided by Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, cash provided by financing activities was $108.8 million, which primarily consisted of proceeds from the issuance of common stock of $55.0 million from the second PIPE financing, $36.6 million from &#x201c;at the market offering&#x201d;, net of issuance costs, $21.2 million under the Gilead Stock Purchase Agreement, $3.4 million from the exercise of stock options, warrants and other, and $0.9 million from the purchase of shares under our employee stock purchase plan, offset by $8.4 million of payments of financing costs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, cash provided by financing activities was $135.8 million, which primarily consisted of $125.0 million in proceeds from sale of common stock and pre-funded warrants to purchase shares of our common stock in a series of private placement transactions, $9.8 million in proceeds from the issuance of common stock related to our &#x201c;at the market offering,&#x201d; $0.9 million in proceeds from the issuance of common stock from the purchase of shares under our employee stock purchase plan, and $0.2 million in proceeds from the exercise of stock options, offset by $0.1 million of payments of financing costs.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2019, cash provided by financing activities was $74.4 million, which primarily consisted of $70.3 million in proceeds from the issuance of common stock in a public offering, $4.0 million in proceeds from the issuance of common stock related to our &#x201c;at the market offering,&#x201d; $0.4 million in proceeds from the issuance of common stock from the purchase of shares under our employee stock purchase plan, and $0.5 million of proceeds from the exercise of stock options, offset by $0.8 million of payments of financing costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not entered into any off-balance sheet arrangements, as defined under SEC rules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We lease office, laboratory and storage space in facilities at several locations in California and Massachusetts. The terms of our lease agreements have expiration dates between 2023 to 2033. </span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total future minimum lease payments under the agreements are $112.0 million, of which $9.6 million of the payments are due in the next year. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 6 to our consolidated financial statements.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to license agreements pursuant to which we have in-licensed various intellectual property rights. The license agreements obligate us to make certain milestone payments related to achievement of specified events, as well as royalties in the low-single digits based on sales of licensed products. In August 2019, following the initial patient treatment of SLATE, we recorded $3.0 million as research and development expense in connection with the milestone. In October 2020, we made a milestone payment of $2.0 million pursuant to an option and license development agreement with Genevant. During the years ended December 31, 2021 and 2020, no royalties were due from the sales of licensed products. See Note 7 to our consolidated financial statements for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2017, we entered into a contract research and development agreement with a third party CRO to provide research, analysis and antibody samples to further the development of our antibody drug candidates. During the years ended December 31, 2021, 2020 and 2019, we recognized an immaterial amount of research and development expense under the agreement. We are also obligated to pay the CRO certain milestone payments of up to $36.4 million on achievement of specified events. None of these events had occurred as of December 31, 2021. We are unable to estimate the timing or likelihood of achieving the milestones. See Note 7 to our consolidated financial statements for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, we entered into a contract research and testing agreement with a third party CRO to provide antibody discovery related services. During the year ended December 31, 2021, no research and development expense was recorded under the agreement. During the year ended December 31, 2020, we recognized an immaterial amount of research and development expense under the agreement. During the year ended December 31, 2019, we recognized a total of $1.0 million of research and development expense under the agreement. We are also obligated to pay the CRO certain milestone payments of up to $34.8 million on achievement of specified events. None of these events had occurred as of December 31, 2021. We are unable to estimate the timing or likelihood of achieving the milestones. See Note 7 to our consolidated financial statements for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into contracts in the normal course of business with CROs for clinical trials and CMOs for clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes, which generally provide for termination within 30 days of notice, and therefore are cancelable contracts and not included in the table above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Use of Estimates</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This discussion and analysis of financial condition and results of operation is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to preclinical study trial accruals, fair value of assets and liabilities, and the fair value of common stock and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are more fully described in the notes to our financial statements, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements and understanding and evaluating our reported financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We perform research and development under collaboration, license, grant, and clinical development agreements. Our revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, we analyze a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, our revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (ASC 606) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (ASC 958-605), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaboration agreements, we analyze each agreement to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customer guidance. For elements of collaboration arrangements that are accounted for pursuant to the revenue from contracts with customer guidance, an appropriate recognition method is determined and applied consistently, generally by analogy to the revenue from contracts with customers guidance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The terms of the collaboration and license agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration, and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our consolidated balance sheets. If we expect to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, we assess the goods or services promised in a contract with a customer and identify those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consider the terms of the contract and our customary business practices to determine the transaction price. The transaction price is the amount of consideration to which we expect to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using objective evidence if it is available. If objective evidence is not available, we use our best estimate of the selling price for the deliverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, we satisfy a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service, is considered to be as the services are received and used. We recognize revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation using an appropriate input or output method based on the nature of the good or service promised to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success, and estimating the progress towards satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. We concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We record research and development expenses to operations as incurred. Research and development expenses represent costs incurred by us for the discovery and development of our product candidates and the development of our technology and include: internal research and development expense, including employee-related expenses (such as salaries, benefits, travel and non-cash stock-based compensation expense); external research and development expenses incurred under arrangements with third parties, such as CROs, preclinical testing organizations, contract manufacturing organizations (CMOs), academic and non-profit institutions and consultants; license fees; other expenses, which include direct and allocated expenses for laboratory, facilities and other costs; and costs incurred related to our collaboration agreements. Costs to develop our technologies are recorded as research and development expense unless the criteria to be capitalized as internal-use software costs is met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing financial statements, we are required to estimate and accrue expenses. We record the estimated expenses of research and development activities conducted by third-party service providers based upon the estimated amount of services provided within research and development expense in the consolidated statements of operations and comprehensive loss. These services include the conduct of clinical and preclinical studies, contract manufacturing activities and consulting services. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are realized or consumed. If the costs have been prepaid, this expense reduces the prepaid expenses in the consolidated balance sheets, and if not yet invoiced, the costs are included in accrued liabilities in the consolidated balance sheets. These costs are a significant component of our research and development expenses. We record amortization of prepaid expenses or accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these third parties. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks. We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from external CROs, CMOs, and other third-party service providers. To date, we have not experienced material differences between our accrued expenses and actual expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We determine whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. Leases with a term greater than one year are recognized on the consolidated balance sheets as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. We derived our incremental borrowing rate by assessing rates in recent market transactions, as adjusted for security interests and our credit quality. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the right-of-use asset is impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">JOBS Act</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012. As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have nonetheless irrevocably elected not to avail ourselves of this exemption and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest of (1) December 31, 2023, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Refer to &#x201c;Note 2. Summary of Significant Accounting Policies&#x201d; to our audited financial statements for a discussion of recent accounting pronouncements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ive Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Sensitivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risk related to changes in interest rates. We had cash, cash equivalents and marketable securities of $206.3 million as of December 31, 2021, which consisted primarily of money market funds and marketable securities, largely composed of investment grade, short-term and long-term fixed income securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, according to our board-approved investment charter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investments are subject to interest rate risk and could fall in value if market interest rates increase. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">s and Supplementary Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Index to Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:92.324%;"></td>
    <td style="width:1.278%;"></td>
    <td style="width:6.398%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Pages</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_941a46e1-cd3f-49f4-99d1-eaef8ada7ccb" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">REPORT OF INDEPENDENT REGIS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and the Board of Directors of</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Gritstone bio, Inc. (&#x201c;the Company&#x201d;) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_384b6919-a2c3-4661-8fe9-5c4f63a94b88" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2016.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43cf5528-e701-41b8-8703-d2af67fb803b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share amounts and par value)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.736%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.644%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.644%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4919ea89-cfe5-484b-856c-161b3f728bdd" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb8f0bc5-db4c-4415-8caf-178bfe3b3677" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,056</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94455e73-6ddc-41ad-965c-ef7df0998125" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfacf0f9-2341-458c-b87a-e47c8502366a" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3362d1ba-4042-41c0-9ad3-4f01628ab043" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5ae0211-cfbe-4c83-8f27-99afd615d8ba" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bca2dfee-3ac8-4cf8-8676-a8ad112faec5" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c13396c0-95a9-468a-b552-08d6e0f1a4f2" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e2615a3-cf44-4dda-8790-7e4e10bef986" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,590</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_520d74ed-e6d2-4ff2-b206-23b8382425a3" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,390</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b875dd3d-c784-437b-9ed0-effda53453ca" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0dbd6b10-8b9d-49a6-8696-092f56deb724" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">992</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_adace193-7425-49cb-89de-fd17f74bc11b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3dbfbad-8ba7-4055-937f-3c2887abf9dc" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f3c9be2-1e70-4d59-a6ba-1d4c500d7e5d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,920</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db1a25a0-58be-4e92-9876-9bccfd270fac" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c43f62a-1be4-4e94-87c5-af3711109fd0" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d950f511-d976-4532-ad91-031d3261b04c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ec6cdf6-4c0c-41f3-96b8-d0a7f74b92a0" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_589c1070-e0f3-4a23-937d-810a1adade0f" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49074eda-e103-4546-b7d5-07cf4949aecf" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34dfa367-2fbf-49a6-ab0f-252ba758e179" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0febc8c5-cf85-4a10-b0dc-ef69879bba3e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86cb19bd-1986-4024-9451-c62b33373ccc" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_958edf0c-0ea2-450b-a9a6-17b34cc14564" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b02c67fa-52fe-4f5b-92dc-f4dc7b81507b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cccd1efe-f5e2-4114-8949-0f3f78417e10" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06a49180-abe9-4fba-a080-df7cc1306c9d" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a1c2328-d909-40b7-86e3-ecfa7c552491" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2d0611a-fa05-4257-bf8b-3c0544effa65" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,053</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b92c0b3-41ad-4ac6-b806-3db42b5e6911" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10db373e-633d-4a73-ad89-9b2c46a41e6d" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98b867ad-4f20-4163-a120-fdb403e067b2" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bab3ba8d-22bb-4907-bfc7-6351fe69768c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1fe5725-63fe-446c-bb4b-f0936dbf8a62" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_069077f0-de53-4423-9dc6-af4b2da5fde1" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0651c443-bc89-441c-8fda-c81c86513418" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e371f23e-2d05-46df-ba6e-19dc73d249ed" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0678d17-0a81-4336-bd52-01ea1ac4980f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6d350ed-417c-42b9-aef5-effffbb9b64d" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e217c89c-fcc3-4b75-bb05-d8504342500d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4067ac0-4b82-4204-9d68-c2147cc66a47" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57c9a391-9914-4ce2-b295-6687a3d60dff" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,020</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce15f0c1-6d30-44fa-ac3c-d0ccc572dc14" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a178817b-a374-434c-9a8a-b04e45420edb;"><span style="-sec-ix-hidden:F_d2ca4c51-a192-466d-9b37-5b3c9e4c3d77;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies (Notes 6 and 7)</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8daad606-f897-4754-b292-5966a931b80c" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_3fb1d5a2-6b08-428c-941e-41afbd86ea3b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a32dcc2-c775-41c4-af01-694f361ef376" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e36a2aea-caaf-4041-8bcf-f61d9838f356" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2201eef8-6808-4993-a9f4-bc977cdabe62" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7ac896c1-266a-4567-aa2c-eba367cc498e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_57a25dbf-e0d6-4f3f-ba50-1eab5e269ccd" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7cd6ec6b-16ff-4b86-bfa6-2b275c54d1e1" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares<br />&#160;&#160;&#160;issued and outstanding at December 31, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4542f11a-4002-4c7d-8750-119e72f158c8" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f80dae77-884b-4a32-8e4e-2749955e36f4" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97543f53-f074-4eef-8718-c6df40b714f6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_6072a0f3-c7e1-497a-85c1-8704174b58cd" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_353e4d28-03d7-4c3e-90df-415f5d7d8444" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2cd8f846-0b9d-404c-8728-ffbf004ac183" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized at <br />&#160;&#160;&#160;December 31, 2021 and 2020; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7e4bbc5-dc83-4764-a158-fe8be3bab33d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_e5f402e2-6ded-44f8-96b9-41fda6f1f48a" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4b54c8b-4506-43d5-b9ed-afe04886f15a" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3e9fff68-23f6-4f56-bcbb-73009df8d78c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,552,693</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued<br />&#160;&#160;&#160;and outstanding at December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d52ec19f-9b67-453d-b2f7-2f4c50636171" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b78efe6e-200f-42c8-84c0-827478870bf9" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3992cd88-7cb5-4647-b5ac-e1d3759d922e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_580a295a-0bcf-4f63-a727-922b66575e97" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">493,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated other comprehensive gain</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1ebc7d2-e121-417f-9362-04acb12aaa6e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d47037d-d25d-44db-8270-d59405107116" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52cfab50-42eb-4884-a37e-18cc43d1bd19" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">401,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a0bb822-59b1-4a5c-8a84-e4bcc223e98b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a1dab38-b05a-48be-9f31-062a1bbd0c94" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f1e76b1-e7d7-4fb3-8e1b-1a25cfc06a8b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6db6d999-5d08-4cba-906e-e8ee4281b27e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_831e3706-5634-4924-88e3-57c6f94e3c46" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations_comprehensive_loss"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.874%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.953%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.953%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.953%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration and license revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0760fbe-4c1b-4f94-bca3-329b53153aa5" contextRef="C_a82f3996-a232-41a2-ba36-db531bddceba" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e98242f-4e1b-489a-ab08-a2d76d7f29a5" contextRef="C_ba034453-4fd5-4226-85c4-36e74505c7b0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f68d3e4-db1b-4e5e-ba25-5c645f4539d1" contextRef="C_73464b08-07d2-40b6-ace7-0c62aa972258" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5ac9e19-347d-40a0-83b7-fd3a67ae0f0a" contextRef="C_3f870e98-f90c-49bb-86f0-83e46e07b98a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_302245ca-782c-46ac-978d-324672541421" contextRef="C_e84c838c-b8b5-42b0-86d2-23e56453e579" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e88e17-9511-4640-90c7-c16ae0826278" contextRef="C_380e370a-6b47-4450-8fb6-5f55120330a2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenues</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_914d5fa4-7ebf-4356-a331-3eabcc99743e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e46c4bad-bc77-451a-b1c3-2727dda810d9" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29b3a8fb-9a3f-4cb6-9653-8e8cd8d6a8cf" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a893a075-e87d-4f0c-9fc8-040bb4a39279" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccfe0500-756c-4c95-97aa-a8d9bac73670" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca562485-d176-4979-a3f8-fabaf196e716" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20ceda47-4442-4401-8269-03f519812314" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12588d4e-ceab-4b32-9ec5-c3e25169d74d" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29bc375b-6ff1-4a6d-aa33-787dea738af5" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34e39092-d636-446e-8910-3407b6fa3da4" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,423</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_345b2833-cc0d-4f6b-b56a-25ffd7c871c8" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5e0d8dd-222a-40a3-abc6-03bb4fed694a" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,305</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98ea0853-271b-421b-94fc-3ec072e26033" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2704283e-5f3e-4b35-8528-0de008dc1354" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3509a452-71e2-4530-820a-7845b522939d" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">97,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_504b5691-8bef-49a2-b2e5-5b7a844ee239" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53e48645-a005-49cb-8a5a-944b1606a8d1" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">703</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00be176f-5f2f-4c1e-9bfe-6a4b5c0ce7da" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_802c072f-70b8-4266-b222-9e963bf51719" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86d01d0e-d596-4536-bd6f-aea24e089f9d" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c53d0774-6be3-48c0-8d4a-d8af5f4cbec4" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive gain (loss):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f17a9f5-0cf4-446e-afd8-bf9df8974877" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2d20d31-c34d-4188-90f5-80498c144c0e" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_607d59b5-6ab6-4a1c-9c25-6c05d6c56993" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_653cc11f-d4eb-45ff-ba23-20103b8465f2" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c33ce5f-bb22-42cf-b61b-d1a2126d2ade" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ea4b356-e0a2-4531-98f7-7ae5ee0ec249" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,324</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9b0325e-d019-42f6-b345-0750de9c0e47" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3a9074d-6cab-4b16-b995-af32668e1aa4" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.79</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e9f4471-ae75-4656-b798-26a5b5b0a2a1" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.81</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average number of shares used in computing net loss per share,<br />&#160;&#160;&#160;basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f866516d-ce73-4a25-8f72-e582b610fd6c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,885,186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a524f526-c9e3-42a5-9660-f50fb87ffa27" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,792,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1575eae5-0fce-4833-ab10-b3aa97706218" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">33,554,823</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_stockholders_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">kholders&#x2019; Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.416%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:7.885%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:7.458%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:7.468%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:8.302%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:7.338%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:7.338%;"></td>
    <td style="width:0.64%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Total<br />Stockholders</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Gain (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2018</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5387b168-04c5-4d59-9863-22bfed4b25f3" contextRef="C_0cfda793-d20c-4961-a834-c8650ee91d83" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">28,823,130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0940fce6-2e1f-49ab-9ca9-1ce9d6ec35bd" contextRef="C_0cfda793-d20c-4961-a834-c8650ee91d83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39922742-9418-4fb5-8acd-7ad7cc0bd3da" contextRef="C_b8cbe5d8-7e8c-4676-8c42-837291b53456" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">275,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd28cf3-9985-4775-85f7-5a9d52314c6c" contextRef="C_bdb6e5b1-bb05-454c-8661-5dbae465a144" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">85</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37e5e15b-686d-413b-9741-39d72e5ff9a9" contextRef="C_5a1a7d8e-2cb5-4480-a9f0-5d9d08ea4e42" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">126,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34bf55bb-1d75-4524-9bd1-3da0cc5bbc67" contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_04b34a3e-8e6a-4d8a-b461-bd6e0ec8bab0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cumulative effect of adoption of Topic 842</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab649b90-b188-47b2-a3bb-728697508a2d" contextRef="C_5e526fc2-e10d-4769-a192-466206adab05" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7051f31-b91e-4220-b495-eaaa5b6b0363" contextRef="C_36e294a4-e0df-4447-b010-28bd585fdd93" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock upon public offering<br />&#160;&#160;&#160;at $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f266ec85-2107-4907-8f00-9edb53eae1d2" contextRef="C_9b169cdf-cda7-4247-a6bb-d30a8c55839a" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;per share for cash, net of issuance<br />&#160;&#160;&#160;costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa4de390-9ab1-4b0a-82aa-4693c362c140" contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43dc1e81-112d-4c88-9508-a8759974d30f" contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,500,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9097872c-8e38-41cd-afee-3b95ab23284c" contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd357e28-85e1-40f2-8ca0-4cbf71972090" contextRef="C_81d44cfe-4817-47ec-82ff-c16f1b041f0a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5236e243-ce06-4b0d-be96-4eab0471b1e5" contextRef="C_0e326ef4-32be-4c22-a96d-5f69ef9ee281" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under at the market<br />&#160;&#160;&#160;(&#x201c;ATM&#x201d;) equity offering program, net of <br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8664caa-e0c8-4cb0-bc72-4cd0fedc0268" contextRef="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d263b41-be05-43f3-8170-17a5d994c0ba" contextRef="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">490,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce9765ce-dde4-46bd-b02a-7edae9dc2ffc" contextRef="C_4028d4f2-0823-4d74-af7d-d47f1f2de8e1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bc3e6f5-7188-48db-8ba3-5224188c8074" contextRef="C_3266dfed-769a-40b0-8646-a9d8b35c1a67" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under employee <br />&#160;&#160;&#160;stock purchase plan (&#x201c;ESPP&#x201d;)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e663a53-d1d6-415a-b9c1-327e0ff11905" contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48864bf1-5269-4c62-9faf-938e95c9606d" contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_621544d5-f135-40b3-87e7-68cf1cabe42c" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unrealized gain on marketable securities,<br />&#160;&#160;&#160;net of tax</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d36c2656-2d17-447e-85d2-cb2e987e664f" contextRef="C_b07f71bf-53de-4fff-8190-d439a84be1ad" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd764693-73bb-4a9e-ad81-63bfd9c93050" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Lapse of repurchase rights related to common<br />&#160;&#160;&#160;stock issued pursuant to early exercises</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2130b178-bbce-4ce3-8f32-2e65466dd866" contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">182,195</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebcc7424-a77d-48fe-9fab-439153f28647" contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32ad1690-34f0-4b78-83de-1c45d979d10b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89c8f6fc-ad5b-4000-848c-89a6f51d8975" contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">281,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_293b472b-6a32-4827-af94-f84b7f9c3d09" contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0add331a-329c-4675-a483-8f0fbbaa30e9" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d8f1c6c-e728-412b-9000-2a4d8fdaa421" contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61c6682f-ebc0-42ff-9eb1-e1a6209a2170" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69085040-4d87-40a9-84bc-1196ed06f1e1" contextRef="C_7d3f9f89-ed3a-428d-a261-354556628edc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb1e06b8-67a5-4fd5-8198-6eaf28111248" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7dd50e6-5b32-4578-b0e2-e9deaa8056a1" contextRef="C_113f6e9e-2318-4e64-9807-9fb8459e68ef" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,332,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67d1c0c7-acd9-4530-808b-461d167b8eff" contextRef="C_113f6e9e-2318-4e64-9807-9fb8459e68ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4f4522-71b2-4b37-8034-4f4141d8c031" contextRef="C_566e2de2-e6b3-4e99-b3f7-4d1960d33e69" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">355,291</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbb71c61-ec0f-4782-8858-20d070f8c259" contextRef="C_ef3a2d5c-f57f-42c8-acc1-25a55ffcd722" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_982336ac-4c8b-4019-a979-a6de2f093ebe" contextRef="C_eb09cd51-ac40-4ddc-b069-ec80b0a9c3ed" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">220,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c851946-c374-459b-b58f-1420b3426d33" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under private<br />&#160;&#160;&#160;investment in public equity  (&#x201c;PIPE&#x201d;) <br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fce4ab6-dd52-4e10-92e1-942566d37744" contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95447887-e4b4-4e4b-af3b-57e7104e7f75" contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,586,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_961f572a-edaa-440e-9c43-8ee46fdf43a3" contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_746b8071-a918-41be-9361-9b168a9440c9" contextRef="C_982f33fb-21c0-4dd6-87c5-65c36e0e5f27" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6c3c131-af0e-4eda-a939-a9b8cfcd6baf" contextRef="C_aa774e87-9154-4d69-beec-62667e7e6728" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of pre-funded warrants, net of issuance<br />&#160;&#160;&#160;costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d881f32-f1a4-45fc-a230-370e0411112f" contextRef="C_f3f22244-1f88-421e-9cc4-3b878d466850" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_572c2780-fa3f-4436-9119-08e97aee93c3" contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99e7cf7f-cb30-4bc1-a004-4bc86b91e7dc" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under ATM <br />&#160;&#160;&#160;equity offering program, net of <br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26d59512-3655-41e4-aae3-024ff53e5b2f" contextRef="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff951cab-ee03-4306-8fb9-72cbea26af9a" contextRef="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,160,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a01e46ae-977d-4c9a-9add-8d8f683d9c2e" contextRef="C_03d9a53a-ccc3-4f13-b052-55cc78345393" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_984f9088-7239-4546-b744-8f07c36eb55e" contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e994a56a-cced-4a1b-a023-ef0058b331d8" contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">243,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40c8c1c9-188d-4462-a7f9-5329ad3cd683" contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f830d2f-e9b7-4717-89ad-f4312411c207" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e029c1de-ef0b-4f7b-9b66-b061ddecfbf4" contextRef="C_7057aae3-6cd0-4063-9952-0286502804a7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68d61846-5ac3-4293-ba89-71bca9fcd7d8" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Lapse of repurchase rights related to common<br />&#160;&#160;&#160;stock issued pursuant to early exercises</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89e85674-58c3-4595-8bc9-f0a86e8e4822" contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9caad56e-2aed-474e-9f10-3800c66bc477" contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4067f623-2a36-453e-95a1-c78b0cfc846f" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_111a3ac3-7ada-4bb8-aba6-daf1f62a058d" contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">197,544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8a0fc68-c034-47de-88b0-0048f009430d" contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_460dc568-2f48-496e-b0e0-b083c231ac99" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f54573c4-58a2-4159-9f6c-87e81ff99c36" contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74c334ec-45b7-4e49-92c3-12b995ffc67e" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72fe0825-e6c6-4aa2-894a-4d74773e07f6" contextRef="C_fbf4938b-d2f9-4fa1-ba69-cec10c693873" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ba6d0cc-76cc-4f26-addf-9ef0f14ce198" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c5b405c-85dc-4e39-b6c3-417188372a58" contextRef="C_50ba15bc-abe4-40d9-83dd-7f897007ee15" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,552,693</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6ba8c62-550f-4db5-9a25-d1165cf602ae" contextRef="C_50ba15bc-abe4-40d9-83dd-7f897007ee15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb56181f-84d7-457c-b97d-f9364ce2c45f" contextRef="C_37521ff6-ee49-47f9-82b9-df82ccbc22a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">493,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6889201f-43df-41e8-9022-293d91becb05" contextRef="C_098479a5-8222-4852-8fef-d20451698abd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">326,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34d355bd-1165-4602-8486-51e5ef1f593e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166,739</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Offering costs related to the sale of<br />&#160;&#160;&#160;&#160;common stock and pre-funded warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c93d90d-72bb-42aa-b5da-e181e0f99769" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a813272e-e125-4956-9dc3-4235c5838efc" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under Sales<br />&#160;&#160;&#160;Purchase Agreement, net of issuance<br />&#160;&#160;&#160;costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6900f258-0520-4252-9a9c-f89a4b832d2f" contextRef="C_6f2d73a7-30b6-410a-8148-9410d7383a67" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b391472-33a7-44f1-aea4-615ba1bf68d6" contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271" name="grts:StockIssuedDuringPeriodSharesPurchaseAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff179ec8-6a4d-43ff-9773-8ab5417018b4" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="grts:StockIssuedDuringPeriodValuePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f020aa24-1bbf-4ee2-a908-9e1d9f2e92a0" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:StockIssuedDuringPeriodValuePurchaseAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,830</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under the<br />&#160;&#160;&#160;ATM equity offering program, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05b2f547-3402-4b34-9475-7e9a082d24c6" contextRef="C_82754c58-c826-4434-bf40-87fc89524365" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10bbc2f9-1c28-4f6c-bcdf-77644ea23dc5" contextRef="C_82754c58-c826-4434-bf40-87fc89524365" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,990,869</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc080f72-1964-4cba-b856-148269708c66" contextRef="C_798c90a9-6bbc-4bcc-a947-9814b7fe2869" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8be0499d-5899-4d53-906b-934b0f30a0ce" contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,595</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under PIPE<br />&#160;&#160;&#160;financing, net of issuance costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1365a49-8169-40bd-84c3-8a179095d641" contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8981e2bf-4401-4e39-8d60-91351db90127" contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb3dc401-7808-448c-b98f-61668bc8dcca" contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3584d053-2114-4ab1-add6-cd2f9a266dc9" contextRef="C_78c307af-b902-4ede-acde-cde5afdf5220" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dd6bd17-a57f-4e8b-a006-72d1b0a0ae15" contextRef="C_a58ea4fb-a55d-45cb-81a2-cc200e484f8e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under the ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e078f509-c3ab-4094-8d65-7bad871378aa" contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">183,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b4b562a-a27c-4714-9425-f9d1be219c3f" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee6247b8-4667-4693-903b-5f707b29615f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_113fbc75-a7bf-4c56-87e6-f43cf0020d65" contextRef="C_03810506-a2c8-49f8-9836-cbebe5541354" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bd454b7-2a4a-48d1-a822-566b8a795e9d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise<br />&#160;&#160;&#160;of warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d584da9-6749-41d8-9ec9-215e005e9d21" contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271" name="grts:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7984f5a7-1858-4842-a5b4-c2528145c6ee" contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271" name="grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd496d25-dfd7-451c-8f0b-4218bf789508" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1959de15-7190-488a-9a13-c67348061928" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise of<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba2c9f57-6799-48d6-9441-0ef43fae41c6" contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">692,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e5e0967-0aa6-4342-83b9-4173198a5906" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bd0fc3f-392f-4e46-b61b-c6a02d9a5bb1" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57791856-56fd-44d1-a690-3929ad9deea7" contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d878cd4-0fd1-448e-9bc5-8d71e1ced4a7" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22cc9c41-144f-452b-90f0-18df602a2a63" contextRef="C_ee66b39c-2a63-4760-bb71-f8fa3a48775c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d694121-3570-453c-80ca-ae59802a283c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_981acf8f-00a2-4a89-b9fa-e6bb0c57c053" contextRef="C_62974a0f-14cc-441b-8b01-762333a2a200" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3cbde87-55bc-47ac-900f-4d4a4bb14c56" contextRef="C_62974a0f-14cc-441b-8b01-762333a2a200" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c15299b-910c-405a-bdbd-6e426047b6c4" contextRef="C_da80cade-f058-4976-8865-56dee50a193b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">617,523</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00c37dbe-e230-4e1b-b9bf-006f9708cda4" contextRef="C_0ccb5220-a382-46c0-b2dc-bcad6d8aa290" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74250735-c2a9-4fae-a622-890f70497a13" contextRef="C_382a9f9a-00c6-4098-ba1f-f90f5c3bafd2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">401,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41e5820a-089f-4343-8b1c-a685829ccc63" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">f Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.542%;"></td>
    <td style="width:1.16%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.993%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.16%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.993%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.16%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:10.983%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63e7a424-c61d-47f1-9333-8581c056910b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_426fa4f8-161f-41da-b643-9e5b0949b781" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00f81d5e-b7e2-48bc-8e8f-e01800b5bae4" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_494a95f1-11aa-4060-8ed9-48963c9cd764" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06f29724-0698-4868-87f6-41dbe0675366" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ed724c4-6106-4550-9632-5aaa076b7205" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net amortization of premiums and discounts on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f13adb19-bc40-4343-93de-fee718575fc0" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21cb7737-8bbe-4596-9295-70e1a8401323" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_639c9804-4916-4045-9896-26cddf83fbb5" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,349</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01e1bf0d-b981-4f7d-93e9-2120fd4cf527" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_709a6b9a-0b44-4880-b324-1c47685e7f78" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27857a33-78b1-4ed1-a7e7-705797efddb8" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash operating lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4379d5e-df99-4d0b-a0b9-eb4d44be6b37" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:OperatingLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb9c0726-d944-4ae7-ab22-4cdafd606baa" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:OperatingLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fccb2cd2-dd1a-4d0e-a411-29999187d6ed" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:OperatingLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7892bdaa-0228-42b5-8b6f-93655d910fe9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,426</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b4d7a70-00b6-4c04-9eaf-799b8ef54618" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59eeb014-1346-4be8-9c98-5119f4b16fb2" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1112471-df87-4fff-8992-48c8be3ef202" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e81904a-6f99-4c75-84b4-37bd31bf370d" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f86d9115-e6e6-4c63-91c0-bdb5fb7a8a03" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e91c3798-7d17-48bd-aec2-9fbffa6ca5a7" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cfbc368-2975-4140-aaa9-6eaa6acb06b4" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e2e7ca8-0530-47cc-80c0-18f56ce2cfc0" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_368a7ac9-e7b2-42ea-9b59-197668bbbbde" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ad457ee-c7ca-4fc7-b302-e1ba86d819cb" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db3cc6bb-0991-4739-8a81-3ac506a0c359" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f2c6a84-4edc-4f05-afb7-5ae1ea49ff05" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07b34832-1e9c-49a3-ab6b-1f3f9e1bba35" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91e969fb-f173-43c6-a3cb-99108524bbaf" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other non-current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2f135fb-656b-4305-ac9b-a5a9d122b51e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d461fad-a52e-4b1a-98e9-e6728378f989" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76f30a48-eefe-4fa3-9e39-73d216c5df62" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e6c67c0-583d-4738-a50f-fbe1e091dc41" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d0d46e2-81d9-4b67-b2d5-64e1154819e5" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_525db09c-93ec-487b-867b-b4a569c6a266" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,526</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3da04110-d8f3-402b-9e1c-85c608251f37" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3e1e278-653e-4724-bd61-67730767f421" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98256b73-7ca8-44bb-aa91-235b8cb5954e" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:IncreaseDecreaseInLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62cfd20a-842f-4d9a-ab97-644f47f4a568" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40480660-c252-43ba-8cc6-69ab9b01ad4c" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c206e0c4-6a9d-4368-b057-7af19f8784fd" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85ed81ac-033d-460f-b24b-43c228f2f095" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e18f24b-5169-45d5-9c13-6082b21f8dfc" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70994a19-c5e1-49fb-a1ee-609e76a3872c" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">85,011</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e1944dd-c9dc-453d-8060-f1aa890a0088" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">199,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b15d0e3-0b34-4c56-91b7-19efd4264949" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de0d999a-77b7-4336-8e0e-85a6099afef4" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03bfb6c5-19f7-4653-a875-115340dc17c9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cf056ce-047d-4ea4-8029-1b1f1ef0132c" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84b89f7f-1479-46b7-9b53-c5dae110a04b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:ProceedsFromMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4ebbed4-a3cb-4681-8afe-0c95abe909a1" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bed8f8ad-4d4d-4fb3-b1c4-9ed105f738d2" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64dda2be-df32-47f9-a184-471cd998e55f" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec44781a-f165-4a81-b1f1-2640c747cc3d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd8f54d9-38ad-4aab-97c3-7d8948cafbd1" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,515</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc6ddac7-3288-4777-82b8-8e33b965ec39" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,173</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments on financing lease</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e553882-46db-4faa-b8b9-3098a4df1b63" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:PrepaymentsOnFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b453bd8f-c8eb-4d75-8544-721cf324a7c4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e31183f5-6d2a-4c3d-9421-3991b0ed1b06;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b030de8-1d04-4f6c-80ea-0d4fada8960b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">118,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d18cba8e-4cfd-49cd-86fd-f8015ec64e9b" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,949</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b77dc382-a915-448f-b9c8-b8c3f514af4b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock from public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_803e0ab4-626f-49be-be49-ccc0f499b9c4" contextRef="C_8102c196-e4f5-4bf5-824f-1227db0eb3b5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d9344bdc-5632-4045-a278-82f3c517346c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fcae761-2375-4af2-9996-7aed70e597be" contextRef="C_e021a0aa-375f-4923-9a82-7d2d919305be" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock from PIPE financing</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8682ca74-f68a-487c-ba39-b9e1cb2d3f44" contextRef="C_60da28f6-7643-4ad1-b263-313f3285ca2c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_dd4ba84a-f9ad-4ac4-b8da-a1e9b6be684e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e44b0a47-c709-45b3-a49d-50acaef1364b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock upon exercise of stock <br />&#160;&#160;&#160;options, warrants and other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85c795f8-c4a4-4d6d-9790-ebf7cbff3786" contextRef="C_90dbde66-ba3c-4738-91d6-2e0290e34f20" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,408</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ecca34ee-34e1-483a-a18f-5e5006025b75" contextRef="C_f169b2c6-9283-4498-8fe4-31a18d6b1ec0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_688f8dd1-b52b-4eae-87dd-a1cadcd79272" contextRef="C_b820c59d-b464-4759-bbb7-0c4841c49905" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock from ATM equity offering<br />&#160;&#160;&#160;&#160;program</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68769eac-9d5e-48e8-800a-bdd94e5c42ea" contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb3bd005-ca6c-4960-b051-5c1a399f2980" contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,770</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3942cb92-cf96-46e1-a686-f99c038d66af" contextRef="C_3266dfed-769a-40b0-8646-a9d8b35c1a67" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock under the ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0e8fbcb-e406-4bc0-8dae-fa7d0109cb68" contextRef="C_f0499a53-483b-4201-8223-d8a875e05b6e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63111eba-da3a-4077-aa19-97eeed5574b4" contextRef="C_1167d84e-b793-4dcc-9d36-63fe715efdd4" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc1085f2-8fca-4ccb-a592-dbdb94fa925f" contextRef="C_eeccbfcd-9588-414a-8b16-d9ae566a7a11" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock and pre-funded warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e49b27fe-abf1-48fe-b853-c50f4cacb036" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bca8cc51-ba5e-4c83-afa5-73c39f60bff8" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,026</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cacbc01-091a-4bf3-9c52-641234ccca33" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments of financing costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71ea3ab5-e782-4589-a817-ac377fca0e14" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf323b1e-9e3a-4fc3-8636-882dadc8ab9a" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c350ae53-3e0e-4cc4-b31a-d14a998738a8" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">807</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments of financing lease</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28af280e-5045-4bc1-bb50-1d2e8f73e9cf" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e87e2693-ce78-4b69-b3bb-dc14492b4887" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48593b10-c2c3-48ad-a9e1-4fca848d998b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:PaymentsOfFinancingLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e5d07e9-a6c0-4625-a613-a705b0c82bc4" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_493a139e-0b93-46b2-8882-bf44341cbf0e" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59f50c11-9c15-491c-9b4c-86145dad5576" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb3c1914-bea4-4951-b728-d529b3ae5863" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5638dc77-f388-4359-a6c0-b17f8950ff2d" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fd5fc73-bd76-42c5-b374-ed71c303814a" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b43ff9a-fa7c-4816-89a6-2e4e7abee950" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89aa865c-d021-436c-a1ef-5477f4b527d3" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7de7f630-870e-4f10-9b95-3b38860507f8" contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cbafdb1-eb3d-4d79-8fba-2b31145e1c4f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d6cb2df-64f3-47ec-9398-959bfc63eb73" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e92bbe2e-d217-4851-9ac3-9603b8c5cdf3" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosures of non-cash investing and financing<br />&#160;&#160;&#160;information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment purchases accrued but not yet paid</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d954ae9-dfbb-4df1-8cf5-1d910d54ad4c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d514678-f523-494a-b780-a8ac52f74608" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f56ed3d3-933d-4cae-bf1c-be2e8a690f59" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing costs included in accrued liabilities and accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93775392-77fa-43c7-b1b9-8b49fbd7bce6" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e18aea8-1da2-4900-834c-ba7e73266324" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9acf90c5-e099-4638-8295-cf85c3532576" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remeasurement of operating lease right-of-use asset for lease modification</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73a8a197-b8d3-4f5c-a6f8-c95ec14772ab" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a907018b-8e5f-4ec0-bb30-6d5e1f0a4e7f" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b10f0c5-ee9b-44c0-879a-64629c30942f" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,878</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f069f76-6724-4797-a29c-9d9e327bb6c3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.	Organizat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc. (&#x201c;Gritstone&#x201d; or &#x201c;the Company&#x201d;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58769f1e-d1a7-4d46-a346-1b9a5253de5e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">drug</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f09b07ce-a105-4175-9585-40464ff6fb94" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">75.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c0947cf-a714-4b47-a7f2-156a6c89a510" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">105.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02de9f6d-6ed3-48d6-b25a-19da807c1939" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">94.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. The Company used net cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64d878cc-9018-46da-8f9d-d34f2166333d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">50.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dd56983-38be-4775-b348-4f6a5074e879" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">89.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6f100fd-8b81-49c7-9ed6-72319905dade" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">85.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through its operating activities for the years ended December 31, 2021, 2020 and 2019, respectively. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39d68d80-9247-4914-888e-868b49e0b7ef" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">401.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba25524a-9a2d-4677-b873-5ac7dce05da9" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">326.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#x201c;at the market offering&#x201d; (the &#x201c;ATM Offering Program&#x201d;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3925d072-286b-45d1-a198-98e6dfdc3643" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ec534b0-6446-4b47-9e5a-d42110931895" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.	Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9611c4d-e222-47a3-bed8-cef066ca3de8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Securities and Exchange Commission (the &#x201c;SEC&#x201d;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for reporting. </span><span style="background-color:rgba(255,255,255,1);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83703696-3831-4c2b-97ed-e3fa5219f986" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fb2c44e-8fb4-4f62-bd25-48252904879e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e713cced-451c-44c4-bdf5-9c89be64a152" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the CEPI Funding Agreement and Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d55347ed-db3c-4909-a436-918f1041323a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.52%;"></td>
          <td style="width:1.549%;"></td>
          <td style="width:1.206%;"></td>
          <td style="width:13.883%;"></td>
          <td style="width:0.603%;"></td>
          <td style="width:1.549%;"></td>
          <td style="width:1.206%;"></td>
          <td style="width:13.883%;"></td>
          <td style="width:0.603%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78808c24-306f-4e38-a39c-47c60c682e0a" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,287</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e8e491d-db1b-4ed4-835d-c1c631b2c05b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,056</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10429401-3cfe-4b50-af88-c651387eec15" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,285</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a33dc3fa-6e06-4279-9ace-5267257b95bb" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,005</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75426924-fb88-44e5-a170-0b9efbf17863" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">992</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdf31028-fe2d-42c5-8dbd-7ef582a8558b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,577</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fd90a38-54da-4f98-a3c4-ebfee6fc0ef4" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">171,048</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22ea0ae4-3841-4bb3-acb6-083201fa552f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_214edb7b-c714-47d2-baaf-fa1813fc3ff7" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9abf25b0-4995-40fa-a138-c2a366d174a2" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7c6c6dbe-d56b-456b-9759-62633cde9bf0" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7052ed54-425a-44ec-a640-ef1844b7eb26" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9c54a1d-a0ab-40d9-866d-cd2796bc6952" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:OtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared the global novel coronavirus disease (&#x201c;COVID-19&#x201d;) outbreak a pandemic. To date, the Company&#x2019;s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_824de26e-e141-4830-99ff-c628b45f7da3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a036fed-ea15-4cc7-9027-d00acf212427" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.318%;"></td>
          <td style="width:1.583%;"></td>
          <td style="width:31.099%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e019c21-59b3-4f0d-b795-f16371aa9db2" contextRef="C_1c539e79-df24-408f-baa2-48c4f8fe8cd7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87e7a328-33ca-4f0b-a085-d88d314a892b" contextRef="C_fb979a40-c0d7-43fd-bceb-f181847be79e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_511ebfd7-e208-4dc7-b722-0700d4edf9ed" contextRef="C_ca7d4972-2e89-44bd-9c6d-a8139bbbfdaf" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b35530e-99b1-4c28-9f11-b6f6cacc2df7" contextRef="C_6f545e51-7d7d-4b7a-bbdc-f5531a775926" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a43be87d-1aca-4b8c-82c5-aa9768e3458e" contextRef="C_30604600-a913-4a56-bc12-11001d41700a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f54f374-b383-4596-8002-42f470e4d2d0" contextRef="C_10488a3d-db85-443f-947d-6d636d18af49" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b54986d-fc26-49ea-b62f-514b6841c00c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5166e3ef-be5f-4893-9b03-84a85f326a69" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_df80392f-5189-4b02-8182-88cbad7eb793" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ba33ea2d-cbd4-472f-8606-4654b7b1dd7e" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2021, 2020 or 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46fd5189-a34e-4d94-84dc-b9c9da01c5df" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_302a42a4-a9ca-4dc5-981f-351a28851ae9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation of the expected term for its stock options. Volatility is based on an average of the historical volatilities of the common stock of entities with characteristics similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a134409-0750-42c3-8389-bc3866781774" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbb24cb3-a42c-46a6-ba6d-1e4b424e51d6" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2021 and 2020. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14b9a10a-c39c-4f04-8e1d-67b4c0f68749" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e27b55bf-82ea-49ee-9224-7eef2247a897" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2021, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed338364-3585-43e2-a5ac-b24c67594828" contextRef="C_9e986ac8-7731-4b24-b71a-e9e6a696434e" name="grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4000937c-9bbc-480d-9611-6ac69d9371c8" contextRef="C_9e986ac8-7731-4b24-b71a-e9e6a696434e" name="grts:UseOfBusinessIncentiveTaxCreditsPeriodCap" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a89a8f68-ebc4-48c0-859e-b85e0cec12e1" contextRef="C_1370d5aa-2b10-4f99-9326-80852218e027" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_386fd6a2-36b8-4055-9e95-c646e6b3f890" contextRef="C_edaa2ef9-c496-465a-bdc7-7a2547c59678" name="grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_092ddcb1-bd81-4e0d-921c-e0765b4910d3" contextRef="C_1370d5aa-2b10-4f99-9326-80852218e027" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90bc7efd-5d0c-424a-bdd6-6a6023c1a955" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f169ef8-9f56-4031-a11f-ff6f5d239781" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dc79ccb-afea-4db5-833b-67ae4af44f28" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">does not expect the adoption of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2020-06 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to have a material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated financial statements and related disclosures.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_917f20f3-4c91-48a4-9a26-f15ec6b52d18" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7bbb760a-226f-466c-a7e4-e18951ba071e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.558%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.916%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.916%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.73%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.916%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29efcbf9-e374-4f5d-8aa2-ef6fa3189a16" contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15fca577-5527-4bf6-bd59-2aa9a56e517b" contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4a64e98-b31f-4660-9d70-e331775fb16a" contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc57109f-d302-450c-8dc2-c96c8d729d57" contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c9266ff-704a-4eb6-988d-010d7df21c91" contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72a2c2a9-6d5e-46d6-881f-ce022d44f0ec" contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69b7aec5-b406-428a-96a2-90912e85188b" contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c76bddf1-e52a-4d1b-9289-5cd27a2aab68" contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b33a9f61-9e4a-4f4e-9d96-7fe669b0f044" contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dd53450-f0da-45bf-8241-3935d293d2be" contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_726101c0-737b-4e34-a21e-8170bf35ae5b" contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d091c951-d35d-42c0-8f63-6e177d3fdc0e" contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d5c5899-a198-437f-a747-ff0a94ec41eb" contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf191a58-c484-4f2f-a313-4dbfa935f1fb" contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73f52849-7212-4fa4-888f-2b2b249018e5" contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f955c5e-8930-42f8-888a-31007aa051f9" contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a6bfb7d-e83c-417f-adcd-67ebabe6304d" contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bec3a81-3e66-468a-bc6c-68f3db6744c6" contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f1a3a1b-869c-4f0d-8350-cb5e953cdf4c" contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6796f1a9-1a40-41ef-afc3-11827dc9982e" contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae80b14a-06c5-4d94-965a-3fbe11b4acd8" contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_837a53fa-f17e-48ea-8608-b1d2ea5308f4" contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eeb79507-cca4-4dff-8937-a3887981fdf2" contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c77bb63c-1499-4083-aa82-fa5095ba4e5c" contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a6d9df5-e02d-44ab-b555-a88077d316dc" contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f0c28ee-f55d-4747-8c7b-74a807c8ab65" contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfd6414e-ebea-4277-9996-470efe37abb2" contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c94a06b5-786c-4a27-b127-d581c78915a6" contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60f9a9bf-3f0a-432e-bee6-d6a296d7c57d" contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51fe5650-e409-4f0f-8bd9-570b11ad3d4c" contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_191cd8a9-57b5-477b-af9d-0866a70d7a09" contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8a9149b-283c-4077-b226-369afeb869b7" contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_084d2d16-a97d-4b1d-90fb-744b91177ed2" contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cf8a7ab-0697-418b-aa3a-9aacededf80f" contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_725fc54d-bca9-48a3-a84f-919ddb771f4a" contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a747d19c-e85d-4739-ad63-cff912809f6c" contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c0c8cc7-68fe-4666-8c55-6faf3269c30d" contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,565</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b425db86-9fe3-4a48-98f0-2508908b6af0" contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0fe3689-2fea-4894-b9c1-625685144822" contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8699abc7-c421-4b59-a284-20b9e0e480f6" contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8630183-9127-43a1-9cf5-443cf058fcc3" contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1eb9b11b-854a-4f9a-85cc-429bef10b6b5" contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ba9eead-4b04-47bd-85f1-7985b0b08afc" contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1c1390b-39e3-4bf3-a85e-3aa7d04c7424" contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee89c8ab-8839-43f7-89eb-25177f3fce0c" contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,637</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e580c4a-076d-40f1-b1d2-b1cc1c93a4a5" contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bac58785-2b75-49c9-94d4-501b8bb5edfa" contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83a503a6-27e4-4d6e-a85e-eec046d094be" contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a09da88-0d59-44f3-96f1-31ea5e993caa" contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_184f82c4-7941-4259-b321-dd42150f9894" contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59f0a891-634c-4b8c-b2d7-e8dc8db04b50" contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2382506-f6be-4c7d-87f6-26d1f8ae95dc" contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_930c7809-f74b-4675-83bf-e718af06948d" contextRef="C_26915e15-276f-4d55-92e9-790736763dbc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,628</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_814f5fbe-813a-4871-a8a5-0f6a7048fa38" contextRef="C_26915e15-276f-4d55-92e9-790736763dbc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5562cb9-dc62-477f-b45b-067f5f9fe2b9" contextRef="C_26915e15-276f-4d55-92e9-790736763dbc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50e20f0b-3906-4364-9ad0-d70c5eceaa7b" contextRef="C_26915e15-276f-4d55-92e9-790736763dbc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3185d122-aaee-4cf6-afdb-1c6c8e2538b5" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46d27bc2-dc9c-407c-b5c1-b47e75fb7952" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b977cc60-ff7a-4a89-a32e-c8efdc1309da" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e547c826-1b98-48a5-bafb-367b2e27d29b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.581%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.917%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.917%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.917%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.907%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a26a37d-575a-493f-8c49-fe7b35e89724" contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67a69e62-0885-4bc6-bb51-8218a1df6605" contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87f48773-04ab-4934-8134-6ca9d86b8a2e" contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b125a623-9873-410d-aeb0-4e151336d904" contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68e1c8a2-c40b-4541-985a-641dbddc84c3" contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8404440-e062-4009-ba75-f978521e18b8" contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0" name="grts:CashAndCashEquivalentsUnrealizedGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b63d7400-e78d-41e8-a7ce-5a050b05b4a7" contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0" name="grts:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9da11a3b-889e-41dd-a851-21a7d5aa4eb4" contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_963ca075-88fd-4833-8dd5-18e6c5e43176" contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42c152e9-1f0b-4035-8442-324ceaa9a5ff" contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac7227ee-b83f-438e-8837-00b494288591" contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d8dd88f-cd09-416b-9114-7394938b25c9" contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a16a410-2bbd-4c08-a559-22839aa55c06" contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9457789c-11bb-4c9f-bab2-2110b51305a1" contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9d1cd14-ae41-4394-9373-7ef8881a3690" contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4caf180-2a0c-4f72-8dfa-8f89b815d71a" contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6be8db6f-0aa3-4fc0-98ac-7e3091bceba8" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df5fbe12-74c2-41b5-a1b5-2ed2ae49c312" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f979a07-cd18-4485-aed4-9e76eb3b3c3e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08e48c61-d278-434d-9a16-f8a9c0f99d4e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53b33938-00b2-4318-8d46-b1547a437184" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52ac1bb0-5982-4c48-aaa3-515b65422341" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">171.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash, cash equivalents and marketable securities, which includes $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ff68530-8295-4942-b4aa-e031b98be7ac" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">93.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fe7c4e4-37ea-493e-8549-ef0ffa5f48f3" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">170.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c48ee3f-2757-4531-826e-33d345f9d66b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">113.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74e958fb-feb4-4c4f-8be4-cb94245196e8" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in marketable securities, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All marketable securities held as of December 31, 2021, had contractual effective maturities of less than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84a3ec27-1c4e-4215-a87b-f32b66528fa3" contextRef="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841" name="grts:MarketableSecuritiesContractualMaturitiesPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ceb05eeb-03c8-41f1-b509-d219632dba19" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:MarketableSecuritiesRealizedGainLossDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no material realized gains or losses</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on marketable securities for the periods presented. As of December 31, 2021, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccc24f76-7720-414f-9ffa-87d1c1065937" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Security" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t hold any individual securities in an unrealized loss position </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for 12 months or greater</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2808735-87de-4922-9daf-03e5a69d391e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aa3b0327-4846-4780-82c1-756c4df3f761" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4f9b303a-52be-43a2-8fe1-1e3e70889146" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Thus, the Company has not recorded an allowance for credit losses as of December 31, 2021. The Company will continue to assess the current and expected future economic and market conditions surrounding the COVID-19 pandemic, as further development arises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 4 for further information regarding the fair value of the Company&#x2019;s financial instruments.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00072498-8758-40ad-95ee-843d9556d20a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.	Fair Value Measurements</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56028780-095a-4a8d-a6b6-238544da9577" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.622%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.927%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.908%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.908%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.141%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.871%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b32dc7cc-27b6-40f5-a2f0-96186e1dbae8" contextRef="C_72910c92-ee53-4966-9f0c-433eaf5edd6d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e3db09d-2d44-46b2-a516-ca9a03e5a9d7" contextRef="C_c6e24dfd-99c6-486b-bf9c-ed12b545fb8f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a5732ba-9457-41bd-a62b-9d882e6a08cf" contextRef="C_dbeb91ff-efca-496e-8f5f-a322f317f314" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37b4c9e5-281b-4dd6-80e1-892d1c6ef04a" contextRef="C_f772a0a4-efa1-4b33-be2c-131d275bc66b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7f6e8aa-5d64-4bb4-b148-38f7456a39e3" contextRef="C_53c971f9-6a10-4dd2-9fb3-244f2a280440" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_afaec218-13fb-4f78-ab9d-b3feeabd40c1" contextRef="C_bd06d670-ff74-493a-bef1-1d7f537c855a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a041268-e373-429c-a428-69d5925d9a45" contextRef="C_770c1400-be16-4651-87a2-b63b0c62772f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27b1b642-2993-4307-b857-59d7e16c866e" contextRef="C_a9b94c09-f330-4e14-958b-a04cb0904e83" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d9cfac2-249a-4d64-b782-63f1d56ca1cb" contextRef="C_4d000fa3-1eaf-460c-a146-fa94750108ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dad5e36e-e6a3-41eb-8429-7469bdf036ec" contextRef="C_c8dfb228-4332-4eda-835f-6dcd119ac01f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce4f40bf-f207-4f53-8725-5a98a58a8630" contextRef="C_b28b039b-c3f5-4ba2-a4b4-e6a47d32112b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_733cd379-fcc1-4209-b388-1b8c78167641" contextRef="C_b922b66e-4124-4802-a0ce-1cecdf096487" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c77ee547-45a2-4242-81c4-4e09a4235695" contextRef="C_931f6700-0cb1-4f20-b677-efdf1bd07c30" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e549772-8e52-456c-9ff0-c5a1ad27c92c" contextRef="C_21980324-d092-473a-8ef8-6dfaf9956f38" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86b70c58-91b2-406b-9fbb-eb097ab1f2b1" contextRef="C_f5f6a648-955a-4a5a-bac4-0a73b202d719" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5579ba24-e9ab-4c84-829b-c8e02ee14117" contextRef="C_e2caa467-fa23-4f7e-ae1f-5ca204d58c99" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea26fbd3-e2d3-4554-bd99-7cba6ad48c23" contextRef="C_05bb5bbd-397e-4572-a8c7-c182ee094fb2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85231f9e-23e1-4d1f-ae2b-1ee64c2180f7" contextRef="C_9c371ea3-28ab-4cab-b5bc-b09e9730fe88" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1d5207c-24a2-4352-996f-b95b6b06804d" contextRef="C_f567c768-2291-41ae-b166-d1912a72f707" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,594</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7233c77c-2d5f-4be9-a895-90b614cff32c" contextRef="C_2bb37ca5-db5d-4687-89ae-66db04f52143" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4566a25b-4114-493e-b94e-e0bad1cfd9dc" contextRef="C_e130a83e-daf9-47c4-ab36-8190b47e6a2f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_317bb7a0-445b-4f85-a97f-12f219efb627" contextRef="C_ec9e70d0-23a0-467e-b683-3d2b3eaf2393" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54c24eea-3279-431b-8fdd-fda76090c0ea" contextRef="C_22ff4438-130f-423a-bdc3-1d4eb213a8cb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75a67aa7-f73b-43fc-8b11-489aede4d673" contextRef="C_858b47a6-e592-4ea1-b141-4955b70c5d4c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a92e9e57-451e-46bb-bb68-398fef2d9edc" contextRef="C_518a98be-fa4a-4aa6-97cb-3e2f9ad3b79b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c86b8409-f345-455c-ad13-677d948200bd" contextRef="C_d8e26511-0489-4f9f-9cb5-3285842a09fa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e4e048f-4dca-4728-b53d-7b109a1ceafe" contextRef="C_3984633a-9389-4f12-94bd-7218eb5fa25e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,953</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_352e9241-e037-4261-a904-32cd59fcc8e9" contextRef="C_a8a47a83-89e6-4e48-884d-6f9289316bbc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31c53df0-895d-4f1d-ad8f-f93d19c52795" contextRef="C_6f03e706-2fc7-4723-b18d-bade0d235db3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bda83d97-26a9-4f91-9af2-7947d72457cd" contextRef="C_7de09d33-88c1-42a7-afb7-90f61cda1e04" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be3439af-6662-4d62-ba4d-106f8bd1c239" contextRef="C_25e0aa86-a42f-4054-8323-4060b43924cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d08787d-d70f-4ac0-b1d9-93afc7933a2e" contextRef="C_576b3dfa-a60b-4b9c-a136-301a277fd0bc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2f96800-29f1-48af-a5b0-dc8ab9ad15db" contextRef="C_71f8b23d-24fd-4e8b-8f47-dd44d72f6801" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_368aff1c-225a-46f7-8798-6f4679835150" contextRef="C_24382739-e4d1-4b7d-9faa-aefc1a06f44a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d80610c1-fbd0-4142-844f-1cf2e650c611" contextRef="C_9299c473-d0f6-48c7-880f-5c832935a48b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4691bb3a-6f93-406b-9d58-da5b11c2b0ba" contextRef="C_f54e27a8-261f-4d2c-b6fd-99f5477f06ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_261bd368-eb22-4efa-a2e2-a2ea2167cefc" contextRef="C_13ec2a36-3f76-4309-a005-6e83308a21b5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1359504a-ba42-4f61-a45b-5cbcff1afc80" contextRef="C_62787d44-14ba-4275-b041-61b55ece56ea" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a4aab90-7e85-474d-86cb-88e0804c0646" contextRef="C_e3c26619-b56f-41f8-bdf1-a3ff19582f5f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b75eb3bb-c1e3-442a-ae73-61aa4e4fd833" contextRef="C_6da601ec-2822-45c8-a4c9-e52839555406" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4559440c-a7bb-4acc-9fa6-79a185643628" contextRef="C_c9d841a0-65e8-4897-a9d8-b29656c20523" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d54716e3-2860-4379-ab8f-d409c8e29c54" contextRef="C_64dce666-8e1a-4354-b216-dc6c18393077" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c722fd57-23cd-437d-8c37-afcb8692ecf1" contextRef="C_9c13a7d1-0de0-4b4a-b307-f31dc3ebf480" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3a4bda4-7d02-4925-af6e-8173d0b89723" contextRef="C_2196007d-8bbb-41dc-bf26-a59a7a2a5a5b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3d68ea2-52b5-4dee-9d24-4601cd228214" contextRef="C_7c56ee86-11c9-4117-a515-85c8951a85c4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1556d927-bc26-47db-ac5a-82a742c03abe" contextRef="C_b424de0c-4fee-48e3-bea3-66f5d512ff60" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6afb1820-0cbc-4739-bd45-c35ba6991f17" contextRef="C_51e8d18f-06ae-4779-a286-63d6c005a973" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_340d6ffa-fb61-4585-91bc-78ea058e6edc" contextRef="C_1f0f4dc4-3084-4ed1-9f00-4607611bf19a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0794c2a9-fae8-471a-a111-c7173ae3a9a9" contextRef="C_2eec9e6d-ddf3-4386-87ac-8ad1c81b0edd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8bb830e-4d3c-41d2-9d92-30b5974a2f1d" contextRef="C_9ea13d69-ee00-43f8-b7f0-e73c7105d779" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aee9b7ad-5cc6-421a-989c-3582ccfc8429" contextRef="C_ba072684-2765-4bcf-b573-e869e31f90c1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a27a2f0b-ccdf-4564-97d9-6ffa53dc7246" contextRef="C_bc289d2c-e7b6-4507-9fb5-87d39ce5490f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd8a6219-9ed2-4b7f-97b8-10fec0582d8a" contextRef="C_64253bb9-ade3-45ac-b41f-7d7b2677303d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f7a6dfe-70ea-4d98-bfde-775e7e2bb25d" contextRef="C_54016751-a114-4247-b713-e0476cc1ba05" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4f7b3a3-d164-4133-ad85-91841a6c3e29" contextRef="C_e30aa933-0d6e-4987-a2a1-bbce8c351c9a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f757a640-1638-4283-be7c-ad2fae8c23c4" contextRef="C_1b456a1b-1f2c-4ef1-8559-e06dc02c434e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b26bb04e-712a-4220-8d73-c1a2fa5d7271" contextRef="C_ef27cb81-c09f-4cb8-81bf-6b870908b71b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0424a092-2866-4af3-8ade-1b519e97e847" contextRef="C_4ea043b7-fa57-4d14-8d34-b78103ca2ed8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d3d66a7-d152-4d30-acf4-22b37e8d6abb" contextRef="C_5dc9611e-d586-4a8b-a50f-4a5ff390d4ee" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,739</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d321ec46-c027-4c87-ac1e-fa951f20e9c4" contextRef="C_6b19cfa6-fa43-4b59-b47c-8499f1dcf7a3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.531%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.556%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.556%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.519%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.28%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.519%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2e111e1-a579-4930-8787-2582e23180f8" contextRef="C_1fc1f7ef-16ae-4f01-b819-fa9c521cd5d2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d190868-9dca-4923-b8fa-a959b1214d5f" contextRef="C_9f0bfb81-1915-4116-a634-7211fd15e24b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54e3dec4-4321-4309-804d-12b82101a3e2" contextRef="C_451a0b67-f3b2-496e-a299-db96faaae70e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f12335a7-a997-4228-8618-550ff6a5130a" contextRef="C_74699a7b-9862-48d1-88b1-8c7ce7b44e28" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d761303d-1e52-496d-8a48-0ed438bd1573" contextRef="C_56fd8f05-2d3d-40b2-a758-c7de82170e4b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bd3b378-f1d3-4c7c-9b0d-2d1fa1f7de37" contextRef="C_ebef1c21-1add-4b82-b86f-c63f3d498c3e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c31b069-148f-4557-9a37-03d329f7b836" contextRef="C_c4425ed7-6aea-4eec-abd2-81111d52a84a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d212e5f-a1aa-4389-8788-7e253060921e" contextRef="C_9a00145e-06b8-48cf-9669-be9b9d8fc159" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,002</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4394d02-c81c-490e-a468-4db9370a8376" contextRef="C_cef8cbb3-30a5-4f27-89df-b90b0bac1878" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abfb81d9-6668-4ce5-af65-d6fa74b8130b" contextRef="C_14f18898-257e-4527-9df2-402224c7a2a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, U.S. treasuries and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edbe3664-b473-48ed-8a99-2ef8966c174c" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bf057781-e7f5-4aed-a395-a0fa8973083b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3c1f2571-121d-43a1-bc96-f517489d6d0d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a73c6044-21d3-435d-a72e-b403447e0d9b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f7aae10-7be0-4255-8f8e-6aac39d39e3b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Property and Equipment, Net</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c511821-bf23-4d0a-9c3a-f4beb5d07523" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.662%;"></td>
        <td style="width:1.512%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.459%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.512%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.477%;"></td>
        <td style="width:0.983%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eecfe247-9187-48d1-95a3-b88bc1945a3a" contextRef="C_d5159609-8b4f-4ad9-a130-008c19b07b91" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3c2494f-27b8-473d-be00-8fdf1eb5c09f" contextRef="C_bb1328df-a76e-43a9-81e1-d6f6bc50971a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4357b61-1b42-462b-a051-6d30782c0c7b" contextRef="C_5f70c7fd-3c98-48c7-9bcd-c95ad6bbd433" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,113</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a187995-7139-4060-a168-6e6d48be63ae" contextRef="C_aa002ef1-1e05-4ec8-8b0e-f1fff0822abf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,054</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98ff7733-3ce9-4879-b570-90e52ac5e4fb" contextRef="C_37e6511c-98ee-405d-9c80-3d0032f397aa" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce65c2b3-7b8e-46bd-a855-1807fd326ddb" contextRef="C_aa4c4d44-8bce-48ff-a4e4-7256f3516afb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fbee63e-4d00-47cd-9457-ee2a0a748f86" contextRef="C_ef0e97d3-9570-43f8-a443-eefdbce6381d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dae90d97-2374-4c53-8378-ee6f4e5acd3b" contextRef="C_66671e44-d11b-4168-b422-0fbfe5fa8350" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6eb82b9c-9d95-4927-9b55-e1a5b1af3445" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,907</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_262eeac7-75f5-461d-a168-3b9fe9e1e232" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,964</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d24d515e-6ac9-4b11-8f35-3bcdf7062198" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_157d9f85-f7a1-44a8-955d-f1b749163d53" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b65a44d3-52b3-40cc-a628-97760bc462b0" contextRef="C_be2d704f-9ebb-4151-bfe1-64f9f58a7b29" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd03d2dd-4753-4bde-a6ab-70eac683fe4d" contextRef="C_6dbc0ba8-cd39-4c20-9b7d-bb253b05b1a0" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe7bd6ca-6758-494d-a767-ac643da42220" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28e8f705-4a7a-4dd4-bc90-aeeecabde4f9" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac174f59-0253-4d15-a290-e514900368c9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d16d7a60-4554-4c4e-aedf-f861cc41d5af" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3626f30f-e026-4d4e-afc3-492b1ee47083" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cf448a6-b9c6-4268-8ffe-ab46f66461c5" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office, laboratory and storage space in facilities at several locations:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emeryville Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaef8b8f-8cb5-4823-b823-f53aebb5ddad" contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#x201c;Emeryville Lease&#x201d;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3783a7b3-f19f-476f-9ba3-0f5dc9d39513" contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_2c0732b6-355a-4ec0-99ea-3669f24abb98" contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is recorded as a deposit on the Company&#x2019;s consolidated balance sheets as of December 31, 2021 and 2020. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc65a991-4a62-4de1-8060-c79bdb9ff644" contextRef="C_72dfcfb2-eb2b-4d05-8cf1-c1bc2e786747" name="grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" unitRef="U_RenewalTerm" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b07f94e1-fa38-4125-a19c-d310e9a701b8" contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5808c1f5-569e-448e-a478-38aa7ca31820" contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_edb4d5a3-f2e5-4f96-a694-35e0b4cbc623" contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36c906d1-8cdb-4913-ba0d-ff3a80a8ddb2" contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2021. The Company recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1527544-1ec7-4b68-b079-7395c919c202" contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46e4909d-2641-45de-9db2-a4b8515e0068" contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pleasanton Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9e64cb9-6fe5-4eee-9397-93b8d9085dd6" contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">42,620</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#x201c;Pleasanton Lease&#x201d;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70cfa89c-b7c0-41d9-b5a8-449ec7a6ad03" contextRef="C_a312235c-4cac-4041-b6a1-62babf05fea6" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 30, 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has the option to extend the lease term for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09163d2e-aae0-47f6-ab7c-d8d336ec9889" contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3544f9b-2629-4de7-b52e-65c7dfd4909d" contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform all of its obligations. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97fd0653-134a-4284-a867-4a79fec66e88" contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17" name="grts:AmountOfIrrevocableLettersOfCreditWithdrawn" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_265993b0-bd2a-481b-9da6-b449ca07092d" contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of  December 31, 2021 and 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in May 2019, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82b683e2-36fc-4d83-93ca-c49086178c6a" contextRef="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04ce09b4-fa93-42d0-99dc-c5e94c4021cc" contextRef="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a962322c-99cd-475b-a012-588d787e3707" contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf7a3d2a-cf84-4271-b31c-574ec2189b4d" contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2021, and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0a253e3-a5d3-4f0f-b0b9-8fc1778e3e1c" contextRef="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7bcc9ed-3d29-47ae-a33d-1d9191356e2a" contextRef="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cambridge Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s facility located at 40 Erie Street and 200 Sidney Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42e6521c-bb06-47a7-b8fc-d1da7b199da6" contextRef="C_4648628a-65c5-480f-b910-360609ce023f" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease (the &#x201c;40 Erie Lease&#x201d;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13364c37-6aa0-4f7c-b481-87882c867d2d" contextRef="C_4648628a-65c5-480f-b910-360609ce023f" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9767731-9a26-4b3f-a3da-f73167afa961" contextRef="C_d8caf9fb-02e0-4bb8-bf86-c54f67dc62ef" name="grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and provides for monthly base rent amounts, subject to annual increases over the term of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c854b374-d8c1-4855-896e-54b442779e32" contextRef="C_10299d1d-13c5-4852-a7f2-89934ae6946e" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease (the &#x201c;21 Erie Lease&#x201d;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended three times, as a result of which the lease term extends through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66afc85f-fe2f-40cb-976f-7179f2964e6d" contextRef="C_30c5d65f-d7ac-4f7f-9b8f-ea4e4e427446" name="grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e4ecc0b-f73c-447e-be8d-e6f473c3eaac" contextRef="C_3bab2de3-95f2-4e3a-9835-071d68696554" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#x201c;Cambridge Storage Lease&#x201d;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c47b7060-a606-4054-9102-f08858f134f2" contextRef="C_0d99841f-5ce6-4dad-8ba9-7eec24d9d624" name="us-gaap:OperationsCommencedDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company also paid an immaterial cash security deposit.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain advanced payments, which in each case included amounts for the applicable last month&#x2019;s rent and security deposit. The portion of the advanced payment related to last month&#x2019;s rent has been classified as part of the operating lease ROU Assets. Security deposits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52d30fe0-20a7-4961-ba9e-1c570b2a8e46" contextRef="C_b6bab4a8-6557-40f6-913e-491ef563fcfa" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dce47442-3b4b-45d9-8e4c-01460acd0d69" contextRef="C_f87928d0-309b-467a-826b-88343445bf04" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, are recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheets as of December 31, 2021 and 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Boston Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f4808d9-58e2-4d21-a95a-4002e6f88704" contextRef="C_ad7b7d3a-31f1-4f01-a882-0db818ad07a9" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#x201c;Boston Lease&#x201d;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a57b26da-6386-4663-88b8-ebdfa8eb4577" contextRef="C_d7987440-e273-4b4b-a993-e63610db9856" name="grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" unitRef="U_RenewalTerm" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91719c7d-954a-48ef-abf7-b9ae55469f2e" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ec01a0e-5ead-4880-ac89-4d7411819daa" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for costs relating to the design, permitting and construction of improvements. The Company&#x2019;s obligation to pay rent is anticipated to commence in January 2023, subject to free rent periods of three and six months with respect to certain premises. The commencement date of the Boston Lease is expected to be in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c76d34d-89d8-4468-9c02-5617f93765ca" contextRef="C_d7987440-e273-4b4b-a993-e63610db9856" name="grts:OperationsExpectedCommencedDate" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, given the Company&#x2019;s early access rights to the leased space, and the term will expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6f9c6e3-8a96-4614-921f-0e44574cf451" contextRef="C_d7987440-e273-4b4b-a993-e63610db9856" name="grts:LeaseExpirationTerm" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a464789a-a460-4c86-8203-921006348883" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is collateralized by a restricted cash deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd603aa1-85ac-4240-bc38-8f7cee07057a" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and which may be reduced in the fifth and seventh years of the Boston Lease. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5267d77-0c9e-4cad-ba81-d640924d3689" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="grts:AmountOfIrrevocableLettersOfCreditWithdrawn" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the irrevocable letter of credit amount had been drawn.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not recognized a right-of-use asset or lease liability as of December 31, 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the period ended December 31, 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2d999df-377c-43f4-b35c-4fe30b262a9a" contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78b36ed4-cb32-4a2e-8ca1-6b685ba7f012" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.807%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.596%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.596%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.596%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cad9f37-9c1d-42cb-a3ad-bb75c9439d1f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56e3a04c-bcf8-491a-ac9b-652356be14f7" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7efe0ad-e56c-4395-82d1-5d681c99c517" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,382</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa0300d8-960d-4b2e-a02f-b6700a1a106e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb064be5-c3fa-444e-96d1-7814dac619c1" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a9996fc-a17f-4683-82aa-78ba2002a468" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4322aa3-fd11-4874-893f-5df8aa0db9b8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab2d69c3-ac30-4e92-875a-d25d0a7c4bac" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba4facae-b446-41cd-92a0-472c87a96baa" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6fd0669-8341-4476-8c4e-7307eff3f16a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental information related to leases was as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.498%;"></td>
        <td style="width:1.318%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:10.318%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.318%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:10.318%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.318%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:10.337%;"></td>
        <td style="width:1.995%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cc9ed4e-7695-43c7-a0f6-ef1f1f7e1ecd" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b1f2534-97bd-4b43-ab5d-07e488a453b1" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ceb89d88-898f-4474-84bd-552ee229dcf6" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c41747c-0637-4cad-bf54-8462fd0c60bf" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,562</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cc7a8ec-aae6-4d68-a4e9-fb4414e9b7e2" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88b49b08-40e1-4e21-8302-5613a820a3c7" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cc6e194-cac6-4585-b5d5-8bdbe4a29929" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.30</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd5ee5b2-7ff7-46f7-817a-2e506394e62c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ed80b0a-662f-45ce-bc3e-53c49efcb5f4" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.20</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb354804-9bdb-4f08-a215-7f5399a87d08" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df33eedf-23f2-4d59-9d73-27a668d37d72" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_765f28ef-de63-4938-a2a4-db45d49e0969" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ba5f264-e1e3-43d7-80ae-64eee0a2f9b8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.787%;"></td>
        <td style="width:2.078%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:16.132%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lease Financing<br />Obligation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19eebe28-afcc-4908-9be7-d3c1fa13b07f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,642</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48a7d1db-930e-42b9-a6fb-415852a540ff" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,501</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f91ad23-9bb8-4e5d-a165-a34089d79d7c" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57b00481-21e3-4b5d-a718-4f5cd6e3ea2b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,504</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35a19fce-d58e-442c-865f-f122c0323fb2" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0342e386-3afd-4888-9162-8d6dc3e18cc0" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a63be045-c3bf-4be0-9d2f-a26dd2881df6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,048</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0027f46-9898-4912-a977-828ec52244bb" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,515</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ce95655-0353-47fb-97bb-491454e8603e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:OperatingLeasePaymentUnderTheBostonLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dbcda3a-bbbc-4e7c-9deb-c77fd8bb3f19" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa5acb11-a014-4cb6-a29b-c612b200f031" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,483</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_500f1e45-7ab8-4137-b594-40281aa43a5d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,936</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreements with CROs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2017, the Company entered into a contract research and development agreement with a third-party contract research organization (&#x201c;CRO&#x201d;) to provide research, analysis and antibody samples to further the Company&#x2019;s development of its antibody drug candidates. The Company is also obligated to pay the CRO certain milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_605c874e-0e36-4ec4-ad4c-efdbf2cb983e" contextRef="C_a515cc3e-d845-485c-b8cd-9789fd8a095a" name="grts:MaximumMilestonePaymentObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None of these events had occurred as of December 31, 2021. During the year ended December 31, 2021, the Company had immaterial research and development expense under the agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c13f3adc-6706-4b78-aace-b63e17224a44" contextRef="C_c07bb700-a02f-45ab-9f15-e2c76e3747cf" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During the year ended December 31, 2019, the Company recognized an immaterial amount of research and development expense under the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, the Company entered into a contract research and testing agreement with a third-party CRO to provide antibody discovery related services. The Company is also obligated to pay the CRO certain milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe44e997-8097-4901-801e-1bf8bd6eba75" contextRef="C_ffaa39a0-354a-45c2-b143-8dff6921739e" name="grts:MaximumMilestonePaymentObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of these events had occurred as of December 31, 2021. During the year ended December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89c45632-b06e-4db5-8fdd-83d2b0662f1f" contextRef="C_aa671a96-949e-426a-b9d0-931244a1e019" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During the year ended December 31, 2020, the Company recognized an immaterial amount of research and development expense under the agreement. The Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c440ba41-0dd4-431d-9e19-910582f84525" contextRef="C_cb381328-f186-4340-881a-c3901e4b4c64" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development expense under the agreement during the year ended December 31, 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees and Indemnifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#x2019;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#x2019;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b69f87c2-bbda-4751-a898-df40578b3285" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.	Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2seventy bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#x201c;bluebird&#x201d;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#x201c;2seventy Agreement&#x201d;), to its affiliate, 2seventy bio, Inc. (&#x201c;2seventy&#x201d;), in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (&#x201c;TCR&#x201d;) directed to those targets. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f593e008-176c-43e9-b77f-102d1f3b25df" contextRef="C_dcafcdf1-b545-44ea-b0b0-4e5a82dc1960" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and 2seventy also concurrently acquired </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c05d3c4-f55c-4ec1-b108-892f32ea774b" contextRef="C_1384cd70-847e-4634-a2fe-da83db33a119" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">768,115</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s Series C convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b3d3541-0a69-4dbc-9424-65d1cc4656ba" contextRef="C_40de9285-a41b-4aba-b67e-ff00d1385e17" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc875cac-d98a-4987-8167-c8d369c194e8" contextRef="C_1384cd70-847e-4634-a2fe-da83db33a119" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#x2019;s common stock at the same price as all other investors in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). In October 2018, 2seventy purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2256c1d2-202f-4a9d-8a22-463f6ef6a346" contextRef="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">666,667</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock at the price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a973790e-7eed-4706-851f-fc17a44a206e" contextRef="C_85575cb7-32f7-42d3-a21b-cb91af13687d" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">15.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99b9564d-7f9c-41bf-a9f7-bd0b2d635192" contextRef="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a89d860e-4e41-4e55-b07b-f095b927a7f8" contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b" name="grts:MaximumPotentialMilestoneReceivable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">into a First Amendment to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Agreement, which extended the timeline for the Company and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy may terminate the 2seventy Agreement by giving a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed0daaf8-47b1-4fa9-a863-60c53d92d9eb" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="grts:CollaborationAgreementEarlyTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fa05142-cc6e-4cfd-a04b-d7e6b3f7819b" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aca8622-90c0-4ccc-b704-cc62ea133cb1" contextRef="C_4fc2caf3-8c25-4dd7-9e8b-1761b10a0822" name="grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the remainder of the agreement term.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted to 2seventy a license to its intellectual property and provided research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following three material promises under the 2seventy Agreement: 1) transfer of a license to intellectual property and related technology know-how (&#x201c;License and Know-How&#x201d;); 2) the obligation to perform target selection and TCR generation services (&#x201c;Research and Development Services&#x201d;); and 3) participation on the Joint Steering Committee (the &#x201c;JSC&#x201d;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#x2019;s specifications and is not an obligation to provide goods or services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32b2d1a6-21f1-410e-91cf-a4ac3d68e7e4" contextRef="C_307b7ee6-24f5-4623-9dd7-769942f70dba" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02b1c807-9e7d-4282-8042-e26c5f327af4" contextRef="C_307b7ee6-24f5-4623-9dd7-769942f70dba" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million received from 2seventy for the purchase of the Company&#x2019;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $10.0 million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7260804e-29d9-4937-ac46-0a32a82e7393" contextRef="C_e99ad520-a6db-4e84-b622-e394b918c047" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">768,115</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series C convertible preferred stock at fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b08f2f33-d0e5-4673-868f-126a97ce44c9" contextRef="C_e99ad520-a6db-4e84-b622-e394b918c047" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">13.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and recorded in stockholders&#x2019; equity.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#x2019;s development efforts. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ab088f0-c779-4167-9f19-fe4e8978dba5" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="grts:RevenueRecognitionContractStartMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5bf8e29c-ea9f-4a22-a6fa-821065fe5f37" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="grts:RevenueRecognitionContractEndMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020 and 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a57e380-f5b3-4646-9d9d-6968835ec809" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4fa9a79-dc9e-4eb4-a7ca-9a4ce545340c" contextRef="C_a36dfa2d-b3cc-41ba-867f-9bc54ef71a20" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_932e96a5-3863-4d75-bdb6-7d760ffd2c15" contextRef="C_8869555a-bdc4-45c5-bdd1-ae2de6f84ba3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in collaboration revenue under the 2seventy Agreement.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce3009a4-3e45-4266-8d50-f9375146c45c" contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a1b90e2-3174-4aa8-af72-8505d0ab3a00" contextRef="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021 and 2020, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through mid-2023.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9c33ed0-0dfd-4173-9f10-68808e9b53bc" contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.694%;"></td>
        <td style="width:1.753%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:15.796%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.753%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d24b4a40-9fb8-4d74-b872-57258d01fdaa" contextRef="C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cb7b7ee-f3ca-465f-8a83-63943f2d8836" contextRef="C_79ced502-684c-452e-a1e7-6fcb8df0fce8" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5aa68b47-40e8-4201-b96a-7d236e8b5fdd" contextRef="C_79ced502-684c-452e-a1e7-6fcb8df0fce8" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,970</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcb63bdd-62c8-4861-8fa3-23d9b9cb939a" contextRef="C_4be9d25f-8253-43d1-96f9-812aa91da2ec" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d62df3-1067-43a3-b955-e09083e38df8" contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b" name="grts:ReceivablesGross" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad3552c3-23af-45b4-8141-e35c22d9e28a" contextRef="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed" name="grts:ReceivablesGross" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> receivables or net contract assets recorded as of December 31, 2021 or 2020 associated with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gilead Sciences, Inc.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Gilead Collaboration Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) to research and develop a vaccine-based immunotherapy as part of Gilead&#x2019;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#x2019;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#x201c;research and development activities&#x201d;). Concurrently with execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#x201c;Gilead Supply Agreement&#x201d;) under which the Company will supply research product and GMP product (&#x201c;Product Supply&#x201d;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#x201c;product supply activities&#x201d;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#x201c;Gilead Stock Purchase Agreement&#x201d;) under which Gilead acquired, in a private placement transaction, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb9b9f20-6323-49c0-981f-b2f27ffc706e" contextRef="C_7b303347-0a5e-49c6-ac04-186377f96bd4" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. The common shares were issued to Gilead with certain registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (&#x201c;the Gilead Arrangement&#x201d;).</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e35531b4-4a99-42aa-8bcf-1621b44bd12d" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c194d2dd-6b6f-4535-9c06-87b9e86fce46" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">25.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d535b527-0a63-413d-99be-182a52c66bbc" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s common stock at fair value on closing was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87450d7a-7862-44f6-b1cd-8c382baa1ce8" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="grts:CommonStockFairValueClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#x201c;Option&#x201d;), the Company will receive a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd776dca-3963-4920-8367-f1c6cdb09084" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="grts:NonRefundableOptionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million non-refundable option fee and will be eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_343b55fe-494c-40de-9575-b9f275c26e88" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="grts:MaximumAggregateContingentMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">685.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None of these events had occurred as of December 31, 2021 and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may terminate the Gilead Collaboration Agreement for convenience by giving a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a677fb8-c05a-4393-8785-e7bb39066f1d" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:CollaborationAgreementEarlyTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ffb3304-0175-48b4-bf84-935c6f31fb64" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bbbcd0e-f553-4e9d-ae39-f6614f849f8d" contextRef="C_d0e07771-0a34-485d-8679-411afed4e92f" name="grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the remainder of the agreement term.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Furthermore, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26edfe48-8f36-4932-939d-f19654fa1612" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:CollaborationAgreementTerminationTerm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Supply of Product, as defined below, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option Term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following performance obligations under the Gilead Collaboration Agreement: 1) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercial license subject to restrictions on its use during the Option Term and an exclusive option to release such restrictions; 2) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and 3) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e62ba6-d93c-4655-826f-ddb6d2cdd91c" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59300fa9-a0d2-4dbb-a239-9bccb73a6b99" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million received for the sale of the Company&#x2019;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee2ba6fe-8481-4854-a340-91e466f43124" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6f784d6-76b6-46e1-b409-6fa46251676f" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,169,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shares of the Company&#x2019;s common stock at fair value on closing of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04aec871-81a9-40b8-a1d8-4fd5daedf5f7" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="grts:CommonStockFairValueClosingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and recorded in stockholders&#x2019; equity. The remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e29651ec-f811-4ff4-999b-0940498d401d" contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222" name="grts:CommonStockPurchasePriceInExcessOfFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2021 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the variable consideration for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_030d18ee-ef33-4a4c-bad3-1f1b1852449b" contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e" name="grts:NonRefundableOptionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27faf330-2f34-4785-8c09-dd200873659c" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:RevenueRecognitionContractStartMonthYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and ends upon (i) the completion of the Option term, which is expected to end </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7ed2197d-60a0-4b30-bddb-51e4f0d30759;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf520b27-36ae-4ba7-8b7b-56512235877a" contextRef="C_566f53db-f8e8-41fd-9b20-dcbb06f27fc9" name="grts:RevenueRecognitionContractEndPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d0adce6-9e85-4cb1-80cf-8b418eb02e0a" contextRef="C_ab352646-a87b-4f45-b887-2a58f2cb2c1b" name="grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">38.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_721623aa-e790-49f7-b312-a0a05be51be9" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. A contract asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_631ba071-68bd-47ca-b882-bf6fe78242e6" contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement and is being recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through December 2022. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd30fd83-c4b1-4a6d-9490-b2856c08388d" contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contract asset as of December 31, 2020, and there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26d65c72-5ab8-4c52-a5e7-bae4184cbc3d" contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1ab81764-e16b-4f2a-97c8-706d07741c56" contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> deferred revenue as of December 31, 2021 and 2020 associated with the Gilead Collaboration Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9b9b92c-9d52-47a8-9ada-8d27487983c0" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the contract asset and deferred revenue balance during the year ended December 31, 2021 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.679%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.173%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.173%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contract Asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3fa5b02f-71f6-4f0d-a703-e3773b490b29" contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63587b1f-843b-43f5-885e-d108c5247f1f" contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c488f85-eb50-466c-abb8-d9f42475ead4" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:ContractWithCustomerAssetAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32ee75d5-c0ea-4d3a-82fc-06f43624e0f7" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b69dc24e-4fc8-420d-aa5a-02e42ad26b7c" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:ContractWithCustomerAssetDeduction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,670</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5892e83-0d91-430d-9115-4bc8ecfbcde1" contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c046944c-16d5-469b-999f-a4786f91b3f9" contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a" name="us-gaap:ContractWithCustomerAssetNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_baabb814-4d4e-4330-a294-f629bd2302b9" contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There was $0.7 million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 and there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d43940ba-05c3-4798-af71-2a5b6915c4cb" contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126" name="grts:ReceivablesGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> receivables or net contract assets recorded as of December 31, 2020 associated with the Gilead Collaboration Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company deferred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72568fa1-76d5-4e3a-be9d-2cda551969a5" contextRef="C_ea27018b-ae35-4896-958f-8b3ad75d9f1b" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2021, deferred contract acquisition costs were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f7b52d6-25c8-41b1-bf81-a878fbdafa3c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:DeferredContractAcquisitionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Deferred contract acquisition costs amortized during the year ended December 31, 2021 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3558b080-d6b6-4b06-ac2f-7c8f6e480a9c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:DeferredContractAcquisitionCostsAmortized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Arbutus Biopharma Corporation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2021 and 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97ce0310-d5e5-4d19-b55b-b27b6aad9a0b" contextRef="C_4b447ec2-ed8d-4932-a1c9-f1211bf27f20" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_75cfb9a6-63a1-4e6b-9d87-345642ba8a1d" contextRef="C_80c30ec9-ef76-40b1-9254-a26ab087e7c8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During 2019, the Company reimbursed Arbutus for materials and personnel costs totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73af8bc5-5d4b-4676-b7ba-b7d20f97bb37" contextRef="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b" name="grts:ReimbursementsExpenseMaterialsAndPersonnelCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company is obligated to pay Arbutus certain milestone payments up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e735f7b8-bbab-4184-b20d-5627b2fd384c" contextRef="C_a063016e-88e5-4a22-8611-b5879f0bd30e" name="grts:MaximumMilestoneConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">123.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c9ea952-6185-4a59-ac72-8caf5bdbd217" contextRef="C_5903b0b4-0f34-4cd1-947d-816c01e6afad" name="grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#x2019;s GO-005 clinical trial. In 2019, the Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7135272-c31c-4dab-903f-143a1059ad2e" contextRef="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b" name="grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Profit Hospital Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immaterial upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. None of the other milestone events had occurred as of December 31, 2021 and no royalties were due from the sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Genevant Sciences GmbH</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2020 Genevant License Agreement, Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#x2019;s lipid nanoparticle, or LNP, technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9bb8265-87c0-4050-b9ad-4da3475b8a9d" contextRef="C_5b09e940-512d-4b9b-95b7-0f7a00f1c739" name="grts:AgreedUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8984ee0-0c4d-4227-882a-5bc0e6606187" contextRef="C_bdac7de3-d09c-4ab3-a235-9071478e89a2" name="grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">71.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e248adb2-9b0d-4cac-8636-b1716cea8d10" contextRef="C_42b8da6e-7442-4d11-94ba-d9fccabe6043" name="grts:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was included in research and development expense for the year ended December 31, 2020. The 2020 Genevant License Agreement expands Gritstone&#x2019;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#x2019;s license agreement with Arbutus. Genevant is a spin-off of Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#x2019; LNP technology for indications in the oncology space. The remainder of Arbutus&#x2019; IP portfolio was transferred to Genevant in the spin-off.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9924f9ed-847a-42bb-bd36-a67b618fd301" contextRef="C_be96c1cb-cdd0-401f-9ffa-ba59e494db4a" name="grts:PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for each indication and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc741d10-2040-43c3-9927-7012130ef57d" contextRef="C_fbb17c0d-cde0-48c5-b232-0304dab63e18" name="grts:AmountToExtendOptionTerm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#x2019;s LNP technology to develop and commercialize self-amplifying RNA (&#x201c;samRNA&#x201d;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_620006c9-61dc-442f-a6ce-4c5d911448cb" contextRef="C_746d448f-f9d9-418a-89b9-fbac99dc06ec" name="grts:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ddda71f-f75f-432b-b42b-baf3b027198b" contextRef="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5" name="grts:MaximumAggregateContingentMilestonePaymentToBeMade" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">166.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e169256-24a6-41bb-86d6-c552a8088b78" contextRef="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5" name="grts:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported IDCRC. Both the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2baa1818-d570-484b-a18f-e9062f221fc1" contextRef="C_46f01538-745e-443b-9a6c-602d548493a0" name="grts:UpFrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10bccd06-cbfc-490c-bffd-fab6256f85bc" contextRef="C_fbee0f17-2c8f-479d-918b-1fd7ddd2f644" name="grts:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone payments were recorded as research and development expense during the year ended December 31, 2021. None of the other milestone events had occurred as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coalition for Epidemic Preparedness Innovations</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_428d49f7-640b-4df0-aaad-0d01a1087222" contextRef="C_a0bc0c98-2ff1-4535-99bd-4549d5704989" name="grts:InitialFundingDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company to advance the Company&#x2019;s CORAL program, which is developing a second-generation COVID-19 vaccine, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study will evaluate two different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding will also support pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (WHO), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate (the determination of whether to proceed or not with such trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shall be made by the Company in its sole discretion). In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50b2d9d8-174f-468e-a769-2f673aa986d7" contextRef="C_9e7aaa1c-e583-4583-8203-409c40fb2c09" name="grts:AdditionalFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa7266e6-afb3-46ea-af95-a28f4d6119f4" contextRef="C_9e7aaa1c-e583-4583-8203-409c40fb2c09" name="grts:AgreementTotalFunding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to the Company to conduct a Phase I clinical trial of the Company's Omicron vaccine candidate in South Africa.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cadadd1d-db13-4a2d-9c98-ff6cbb13d77c" contextRef="C_d0c0e728-d84d-443b-9b79-a400660a7213" name="grts:FirstTrancheOfFundingsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was received in September 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. In the year 2021, the Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6b4b574-c73d-443c-b9c9-588937e02196" contextRef="C_1d814b55-408c-482f-b8ae-c5e423b0bacc" name="grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the CEPI Funding Agreement. As of December 31, 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54102434-b8e9-4d25-babb-e6fb55def1c7" contextRef="C_f1e134b6-2dd5-4505-b2e1-f8a94eb727dd" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through the end of the year 2022. As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f06431b0-ad9d-4b24-b848-3f92b0b32ce6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:RestrictedCashEquivalentsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as short-term restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94c2e2b9-587a-4253-9c60-38c42a77163a" contextRef="C_af382cd1-7c55-4a5b-8f11-f6f806af4f5e" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.095%;"></td>
        <td style="width:1.79%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:16.112%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f3a861f-a3e3-4862-85ba-1ffcff614949" contextRef="C_2d463622-3449-495d-a283-ead7997ec267" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_001b6369-f1ed-452b-b096-3b2d29a41e76" contextRef="C_a29305ba-c997-4325-90de-110968edf965" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe3ece48-001f-4af2-bc4d-baa2ea96fe3c" contextRef="C_a29305ba-c997-4325-90de-110968edf965" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,903</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f1fb017-d14e-4872-8d0e-973ac9c20919" contextRef="C_60b21bc0-099b-49d6-ab81-649520e924be" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the Company entered into a Grant Agreement with the Gates Foundation, under which the Company will develop an optimal immunogen in the context of a therapeutic Human papillomavirus (HPV) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de9c02f7-e0fa-4d0a-8f9d-0f20158ddb23" contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605" name="grts:ProceedsFromNonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in December 2021, and future funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03a6d040-f705-43bb-980b-0fffbc0bea1a" contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605" name="grts:FutureFundingExpected" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is expected to be received by the Company in February 2023, for a total grant amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1fd0640-f152-48ce-8de6-3133351d9aad" contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605" name="grts:FundingDevelopmentCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. For the year ended 2021, the Company did not recognize any grant revenue under the Grant Agreement. As of December 31, 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5999691-5e8b-4029-bc51-fde713b2d3a8" contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and long term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05ebbada-ce42-4f64-a8dd-9f99a3bac175" contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through early 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a646893-be5b-4916-a18a-4661df30ab64" contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.239%;"></td>
        <td style="width:1.874%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:17.078%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73bd2323-2d40-420e-854b-97d1516fd5b9" contextRef="C_77affe5f-9a99-4ac8-acc3-0fad18eb1e3a" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aecdcc3a-6928-4869-8eb0-25a28a9462d8" contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7" name="grts:ContractWithCustomerLiabilityAddition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e7e2cd7-08fc-416f-8d03-595f4017619f" contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7" name="grts:ContractWithCustomerLiabilityDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f61aa094-4000-4254-bec1-7c7602fd4829" contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5173466-4071-474b-82d9-4858deeb501a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.	Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prepaid Expenses and Other Assets</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_edf5947d-d625-435e-9a61-e10cf118e81b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"></td>
        <td style="width:1.549%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.867%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.549%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.867%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37a4911b-f07e-490d-b84e-c871cf2d7771" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:PrepaidExpenseForResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_118fb646-2fcb-43e1-9ff7-43aee186d48f" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:PrepaidExpenseForResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5274cd7a-1443-4f37-891f-4e00e1d858a6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:NetContractAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_096d32d7-de93-491a-ace7-d6c47d718586" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:NetContractAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46a9b041-8ea9-4680-8e94-6b22466ab2aa" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f206a7a9-aa27-4e39-baf1-2fa1d1c58041" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f983f2b-8992-4ae3-b312-e888ac1b5da9" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f202109-34fb-40db-a48b-d04ba316150e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65b3f819-a8b6-4fed-aad1-26c1fe202c04" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:InterestAndOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a413947-3254-481b-8b20-8e7e498fdaca" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:InterestAndOtherReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_101ead73-4adc-40c2-a0ab-7b38edb1d838" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e3e437e-b3b0-48b4-b53c-6d6eb343fb39" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7cc66ce-d147-4e94-a531-89947a49e5b9" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3fbb375-629d-4323-a5e5-4a281a196b1e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,332</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deposits and Other Long-Term Assets</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07ab4581-605c-47dd-9ae7-cd485b470209" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"></td>
        <td style="width:1.549%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.867%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.549%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.867%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b26af62-288e-4b68-ae3d-66f3f2abcb5f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2470b0c-94d4-4f29-9e72-91f7b6450dfc" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97ae0b72-d60b-4e23-87bc-971b22084637" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db410430-f0e1-4c0a-b6be-5c8db86f87b1" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a4b1c23-1c2e-41e7-8306-f9f6eda7aaa0" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,352</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94bcbe0d-b0fd-417b-9e7e-be9cb6acf96c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,736</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0a7b3fb-3a87-45a7-bd12-2d691782ef33" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.	Stockholders&#x2019; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s amended and restated certificate of incorporation provides for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19dfb8eb-ba38-42aa-b7b0-2b3c808d88f6" contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_050dbfc4-8b47-4ff3-89bf-9698e4d491c8" contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock authorized for issuance, each with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12432789-0f71-4f4e-85bf-ffc690eedf62" contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bbffb5e-a7c8-441a-92d3-668fef3a92cf" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b90db34a-f2cd-4ed1-945f-6f8f0513b4c2" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c5800379-c542-4551-b5ac-1f238666fc3b" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e368f842-01b1-44c2-8081-f3806e1a9253" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were issued and outstanding.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_818b2ac3-8367-453c-9f39-ae061de350ab" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_39517eae-fc13-4757-98d0-76dc476262f6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,047,878</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00b2f812-cea4-460e-8f96-e4ccd206c252" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dfdb63c2-0b36-4d90-afd2-aedcb99ad002" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,552,693</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issued and outstanding, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24623f57-d9ab-4d22-b4fc-69e69532675b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of the Company&#x2019;s common stock are entitled to one vote per share.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company filed a Registration Statement on Form S-3 (the &#x201c;2019 Shelf Registration Statement&#x201d;) with the SEC, covering the offering of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_daa15484-697b-42c3-a604-df094802dcca" contextRef="C_30bd410f-a2b7-4dcd-91e2-e7f9e2231460" name="grts:MaximumSecuritiesCoveredUnderRegistrationAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee31e706-e608-40fc-a35d-d52064dd3d12" contextRef="C_02b16dbd-b7a0-4b17-815f-637d91f05924" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#x2019;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company also entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) to sell shares of the Company&#x2019;s common stock, from time to time, with aggregate gross sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e0a5250-f5ad-4f24-904b-873c0be38140" contextRef="C_02b16dbd-b7a0-4b17-815f-637d91f05924" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through the ATM Offering Program, under which Cowen will act as its sales agent. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5938a332-b94c-4a91-b5d3-b47ec27ffaa6" contextRef="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b" name="grts:PercentageOfProceedsPayableAsCompensationToUnderwriter" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. In addition, the Company has agreed to reimburse a portion of the expenses of Cowen in connection with the offering, up to a maximum of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5e0c560-a162-4931-a4dd-275c7923ce98" contextRef="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b" name="grts:MaximumOfferingExpensesAgreedToBeReimbursed" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de0fcba3-bb65-44d1-b981-6cfa4e76acc6" contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,160,193</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock through its ATM Offering Program and received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbe999c0-a03b-4ffa-b6d4-573fa8069487" contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of commissions and other offering costs. During the year ended December 31, 2021, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bdc6fd6-19d4-4003-b43a-171c52d68b28" contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,990,869</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock through its ATM Offering Program and received aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ab9e0dd-f5f3-432c-b8d0-7a9ab04f5026" contextRef="C_82754c58-c826-4434-bf40-87fc89524365" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of commissions and other costs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into two private placement financing transactions (collectively, the &#x201c;First PIPE Financing&#x201d;), as follows: (1) pursuant to a securities purchase agreement entered into on December 22, 2020 to sell </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6dad563-4374-4de9-a984-e57d4c3c00dc" contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,543,351</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_955be8b7-2f5e-4e93-b80d-0dc773fb4bf4" contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccf2b306-de58-440c-be45-78994f9e2b5a" contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7" name="grts:WarrantsToPurchaseSharesOfCommonStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,480,719</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70623ef6-f692-4693-9638-533a67b4878b" contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share (of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d645cd4-0510-4b8d-a488-f9d796360426" contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf" name="grts:SaleOfStockPricePerSharePrepaidByPurchaser" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share was prepaid by each purchaser), and (2) pursuant to a securities purchase agreement entered into on December 28, 2020, to sell an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ff9949d-1a37-45b4-ac39-653e1b110365" contextRef="C_12e26153-82b4-40ab-8b8e-500eff6e7133" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,043,127</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19673b8b-7a02-47a1-8647-4c3d1d84d529" contextRef="C_30cdab96-3f4b-4379-b29a-bcbd8cf5affa" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.71</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f2ec29d-8328-4547-8514-55255f29ce00" contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7" name="grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">119.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting placement agent commissions and offering expenses payable by the Company. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a9d39c9-c815-49ca-a1ee-4956aa59804d" contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The underwriter placement and legal fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e14e038-83f8-4d43-bd88-851f416041b8" contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7" name="grts:PlacementAgentCommissionsAndLegalFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to these two PIPE financing transactions were included in accounts payable and accrued liabilities on the consolidated balance sheet as of December 31, 2020 and were paid during the year ended December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e702d22e-f607-46a2-aa41-191c0fa96683" contextRef="C_84b5d7c9-f721-46f5-ac90-4bde76f80644" name="grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfa95f01-ee88-435f-8195-a761256c5dc8" contextRef="C_d989933a-3905-49b7-9ee1-1782f59e82ee" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">87.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eecaed77-0f1e-4e60-b2b4-3ac05307b4e4" contextRef="C_fecc12db-2824-4e1a-8f15-21db97eded23" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aeda6ee-9ff7-4fd4-a183-e3d71b57553d" contextRef="C_46e79e08-83a1-4420-a9c9-fa98bb9c1247" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#x201c;Second PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44dfeb25-7099-4de9-a0b1-14640b9c7ba4" contextRef="C_fecc12db-2824-4e1a-8f15-21db97eded23" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab4bfe73-52d3-4e8e-876a-2c99583905f3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.577%;"></td>
        <td style="width:1.438%;"></td>
        <td style="width:27.892%;"></td>
        <td style="width:1.438%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.503%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.438%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:12.541%;"></td>
        <td style="width:1.002%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Issue Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43781400-75ad-4e1c-b4ea-57f5370e29da" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ClassOfWarrantOrRightIssueDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 28, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9aff6e65-4d41-4ed5-83fb-2c640106551c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ClassOfWarrantOrRightsExpiration"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6d8885d-9b74-436e-b3bc-36128a042f28" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8df9d2f4-1f3b-4fc5-bc9f-2b1e32125af2" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,016,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6adc26d4-59af-472f-b472-47bf146f7fb8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_396f5a4e-d292-447b-b29a-6e03cc413e50" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:WarrantsCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,872</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants cancelled due to net exercise of the warrants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0af6396-d516-4304-97b5-ca3b925c1b80" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:WarrantsOutstanding" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised during the year ended December 31, 2020. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1c915d8-f68b-4d9d-b4da-c50fad82aaf8" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants issued or outstanding in previous years.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_c9329c9c-21ad-4616-88cf-35ee9056bdad" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.	Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Award Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2015, the Company&#x2019;s board of directors approved the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;). In connection with the Company&#x2019;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#x201c;2018 Plan&#x201d;), discussed below, the 2015 Plan terminated, and no further awards will be granted under the 2015 Plan. The </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4b8c058-c0f3-4cc6-b762-d8acfe9e6e4d" contextRef="C_9127b8e2-08a8-449b-b838-ac2185db6903" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">92,815</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company&#x2019;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6af5b5cd-81de-442a-8a86-a26b50b9a460" contextRef="C_9127b8e2-08a8-449b-b838-ac2185db6903" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,690,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7ddc978-6b5d-4d75-a831-7bf110fde550" contextRef="C_6cf22661-5fe6-4416-b669-0e1caded7434" name="grts:IncreaseInSharesAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of the Company&#x2019;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8073ee0-122b-41db-bcef-01e42b48de71" contextRef="C_6cf22661-5fe6-4416-b669-0e1caded7434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeeaa554-c817-4cc7-af19-d79b528dd69b" contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42ca96e3-d3cf-4d4c-9f6f-e454d408fa96" contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0" name="grts:MinimumPercentageOfOutstandingSharesHeldByIndividual" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% or more of the outstanding shares, the price of each share shall be at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f390026-7aaf-47b4-b14c-9f7f9ae8a5f8" contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0" name="grts:MinimumPercentageFairMarketValueOfSharePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair market value, as determined by the board of directors. Options granted have a term of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9160bef4-fef0-4a7b-b6d2-e81da90b7e8a" contextRef="C_5672b081-e3ab-444a-bafd-c2358ab76867" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9beed182-b935-425b-8cca-73b26bd98bc6" contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year period with a straight-line vesting.</span></ix:nonNumeric></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Material Features of the 2021 Employment Inducement Incentive Award Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#x201c;employment inducement awards&#x201d; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c691c01-f0e3-4a40-9bfc-3e1eb367bfa4" contextRef="C_2416b0ec-eb6d-48de-b430-8527dc88fbd4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">790,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company&#x2019;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#x201c;2018 ESPP&#x201d;). The 2018 ESPP also became effective in September 2018. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e685cca0-6f2f-4ed5-897f-1df112815a49" contextRef="C_e162ac57-c6fe-433b-9c8e-4ec41607c846" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">282,334</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c1c18b7-9349-4a64-9235-367f354aadf1" contextRef="C_f74a3c85-0277-41dd-9121-429606c196de" name="grts:IncreaseInSharesAvailableForIssuancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#x2019;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab6274e0-df40-4acd-9eea-1976e3d3b633" contextRef="C_f74a3c85-0277-41dd-9121-429606c196de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_521ddee5-b564-4dfc-8a97-24a1e14a7cb7" contextRef="C_f74a3c85-0277-41dd-9121-429606c196de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of an employee&#x2019;s eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcb0cd37-e379-4283-82cf-63ed5d6d54e9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.695%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:0.788%;"></td>
        <td style="width:14.164%;"></td>
        <td style="width:2.004%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:0.788%;"></td>
        <td style="width:14.164%;"></td>
        <td style="width:2.004%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bffc119-38e9-46bc-879c-8d338d856658" contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8998969-7b05-4805-9020-6bf17fb8a27f" contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06d4358f-cefc-402a-800e-4f7bec188a79" contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.57</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3dd89bb-cb0d-4fdc-9eb5-8b028bd47eab" contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.48</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e831b0-68cc-468f-81f9-c42f05833ef7" contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9f5dd6b-46e5-49fb-91d2-61e9d922faf6" contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e02c6484-9293-485d-adf4-40781d173e63" contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">88.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3215ce3b-5a8a-40c0-92dc-ed01a668d670" contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation of Stock Options</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8afbaf57-f9cf-45ab-a846-775537fcb313" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.337%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:0.789%;"></td>
        <td style="width:10.521%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:0.789%;"></td>
        <td style="width:10.521%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.243%;"></td>
        <td style="width:0.789%;"></td>
        <td style="width:10.54%;"></td>
        <td style="width:1.995%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31f41dc7-ac1e-4c9c-9a91-443e9ed7893c" contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10e15154-248a-4524-9f72-64769d27d8c3" contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_673afaf7-f96b-4374-a6af-1c5937aa3da1" contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25527f4d-6123-4c2e-830e-1ebb23dfe826" contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8fca22b-e304-415e-8dfd-263273423bbf" contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d5dfd54-6783-4183-a05c-72dde17d7a9a" contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe9eb200-1fdb-479d-9a5c-3ee7681fe19a" contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6cd14b1-6ccc-494e-88d2-11a2d019132f" contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fa49575-5718-42b7-86ba-f5c1678ca95b" contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea1691eb-1804-475b-acc8-7595e7a45372" contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3faca945-3442-485d-a02a-d89a4782a5fd" contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">73.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6194a9f3-fe2b-4da3-97e8-656d1abe3c07" contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">83.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_852c9d67-3831-47a6-b11e-67ace495829b" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">8.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a53d1fd0-105b-4fed-8688-f94da0e5be74" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">5.39</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eed0e631-8931-4895-9fb5-611daecc5b0b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">8.08</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share during the years ended December 31, 2021, 2020, and 2019, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_721e1e2d-1f17-4743-bb33-677837b01aa8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the 2015 Plan, 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.395%;"></td>
        <td style="width:1.001%;"></td>
        <td style="width:1.085%;"></td>
        <td style="width:8.15%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:1.103%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:7.928%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:1.103%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:7.918%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:1.103%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:7.928%;"></td>
        <td style="width:0.964%;"></td>
        <td style="width:1.103%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:8.02%;"></td>
        <td style="width:0.964%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Shares<br />Available<br />for<br />Issuance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number<br />of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate    <br />Intrinsic<br />Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cfbc967-a133-4dc9-a407-24475d840591" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,108,412</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bef3a1e-c2ed-494e-a879-ae3edca2fe70" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,166,441</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ce6327e-99ba-4da1-afcb-cf9bcef110f6" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c3c3393-9382-4571-acb2-83693e9d12fe" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.15</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef014482-0aaa-465b-98ec-2f9ead0d63ab" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,092</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d4f5e5c-082f-4d1f-96d7-b80e4787d2e1" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,692,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c5bd6ee-29c0-43db-b3c1-42cd21ef3a80" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,195,124</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a03cd5c6-4d60-461c-94cc-909ce1ccdb4f" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,314,524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_231e2951-db78-46be-b643-1f5a14014d66" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc4e1b9a-1ae6-4734-b468-7cfaeb4cb01c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d93f1278-5363-4201-9167-cfc5f9a9834d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">692,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63524d08-e89f-4f39-9db8-ffbf29d0b3e8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_836b6599-28b8-4d95-a089-37d5a501d437" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">853,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cd94ee5-df65-4e77-89e8-a51d2ba6d495" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">681,592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81770593-4af2-4437-a4e2-f2f1a0be6b91" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0f3356a-850f-4d9d-883c-08b3a885859e" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,459,187</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e8fa677-d34c-48d8-8b38-eba53f18b04c" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,107,335</ix:nonFraction></span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49fb9142-0f79-489d-bb94-86407a8cc69d" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25582304-21a1-4eed-990a-cf148172dd51" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_553f8ca6-a2cf-46f5-a898-29a0cdc75e63" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable &#x2013; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f0f54a6-fb57-4028-b104-a499b48af402" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,253,957</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccd738bc-acb5-4d03-9380-4818bc11bb8f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03cdbda5-e613-4bbf-9967-87c8c7e720a9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.21</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5539d764-d138-4bd2-b819-0220d0bec4f5" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,901</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest &#x2013; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac9665b1-518f-4623-9b8e-450b174ae1c6" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,741,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44b17488-16cc-4a7b-8830-62ae96ec62e8" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4aad737-19c1-4ccb-9296-bab4d6f7a22d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.06</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92f54f72-f3b2-4d6b-b1dd-b9d57d34cd95" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,267</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020, and 2019, the total intrinsic value of stock option awards exercised was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e124b35e-c1fb-4251-9050-349ea44d9ca4" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4c54176-4e84-442e-a63b-4a6ad33db553" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35488d9b-4bdd-47a5-bc33-230feb54a008" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e2738de-a6b4-480b-941e-5755dce2055e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0d0dcd0-e6ea-4b2a-ab01-7d53a845edc0" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a983e9ad-35f9-4025-9680-392086e84c40" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t significant for 2020 or 2019. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd13ba90-3d62-4714-a293-bd3d763407c9" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59a5bec2-acf9-43e5-939e-628c1012aee5" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The total fair value of shares vested during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cece48c5-cc26-495f-acbe-2a84cfab20a8" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense and awards granted to non-employees was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec923fde-b49d-4880-b88a-ba9baf850967" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021, and immaterial for the years ended December 31, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02fce04d-f342-4157-bbe6-cf753f1bdfc4" contextRef="C_f018322b-c8aa-48d4-8e6e-49a256954912" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cc41592-b6b3-48ed-ab50-f6d4c110cd6f" contextRef="C_41a55fdc-8e37-4a5a-87e7-f6d1171e8e83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93b6a417-d385-44f3-a58f-6c6cbd59fd08" contextRef="C_f018322b-c8aa-48d4-8e6e-49a256954912" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year period</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47ef9cfc-f343-4c21-80c1-f22a5670b751" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true" continuedAt="F_47ef9cfc-f343-4c21-80c1-f22a5670b751_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_47ef9cfc-f343-4c21-80c1-f22a5670b751_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.262%;"></td>
        <td style="width:1.707%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:13.831%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.707%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.284%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f041832d-096b-47c7-ae6e-b7e3d25eb23a" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c5133e9-d936-4366-bbe3-ea4c62823d8e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5841095-2a90-4c7a-b5f2-d99c290a38c0" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">880,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6c932e7-79d4-48ab-8f03-8e2ed48262b3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4228ba4a-1303-41bb-9f74-1f7a460f5e33" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0de1288-35a4-492a-9261-d85341a42d49" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8eb637ec-f361-4050-8d77-5d29d9099726" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">171,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_710e54a8-8313-4a3e-a682-52f7ab5f3670" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00da3968-c6c2-4fb8-9cf3-de52785f9e5f" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">708,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64d40034-642e-4e1e-a9b0-fcee44cbba36" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84981b17-6005-4edf-8721-fd098149f079" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.75%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.741%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.456%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.741%;"></td>
        <td style="width:0.974%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a891f401-93a9-4f0d-838d-82dcca5a0b6e" contextRef="C_4a494dd9-b549-41f2-b0e4-223518bdd582" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a23db2d2-f573-47a8-b7eb-9a02d9a50f1c" contextRef="C_f7168722-4c89-46f9-8fef-613ec1a338fd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b07e28bb-f5c7-44ec-8717-036f929f5ba4" contextRef="C_b6f878cf-27a6-4a39-8ffb-4b24d54bd0fe" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_082919b7-ee8a-4450-b35b-4f13b52b2efc" contextRef="C_e968f552-8dce-4078-8dcd-35f7f02d3616" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,926</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_377c77f7-da29-427c-bbdc-2a66c4c9381f" contextRef="C_c7df85ae-cc5e-40e1-bb77-a8cc3a896e3e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e05993b8-f404-4073-93d4-9988df692300" contextRef="C_39f0995b-97b6-4734-859b-932b4f1b1bc9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,862</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da1a9746-e13d-471c-970e-d524dc438594" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,552</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_254f9491-e3f6-4627-9fdd-143c871b22af" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83c77d8f-1c5d-472b-97d3-41357ba8ee63" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_d2f9d850-516a-421b-aa8c-c933a58b256a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.	Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate for the years ended December 31, 2021, 2020 and 2019 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b733b325-95fd-4ecf-af67-f9b2b6cefd1d" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_b733b325-95fd-4ecf-af67-f9b2b6cefd1d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_b733b325-95fd-4ecf-af67-f9b2b6cefd1d_1"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.489%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:10.421%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:10.421%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:10.421%;"></td>
        <td style="width:1.995%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33ac89e0-abea-4032-94db-98ad0eb66ded" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_671d01fc-6dca-4870-a30d-c83667117918" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db7e94fa-b53a-432d-ab53-704585ca0922" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dae31a66-bb13-4dfd-a0ae-2ca1137966ed" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">10.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f8e3ac0-5c8a-439a-b3f1-bc2484a8d679" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f763f380-ba2d-4b03-bcb1-ec1244c78d98" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfe5cb4e-5fde-4611-870d-bb8775811b26" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40fe5b96-b0b2-4632-8419-38dde4bf7a0b" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8689457-17b0-4327-a0d1-9da993726716" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_047ac083-e569-47d3-ba3f-4f5618746f43" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0312b523-558e-49e9-bd3c-7c3f07adb267" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ff22a50-da6d-4b75-a9e3-c7ba20b9c7e5" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11d3087c-b94d-4c6c-aa3d-3e6953594458" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e63b94c9-ede0-440c-afda-fd0257d68c7f" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_606ca62a-3272-4ef2-8b52-024f10bdc221" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e44d29f-0856-41d9-8fb7-068d3999219e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ac650d9-c6f1-4bf8-bb1d-329045a5b03f" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dda6820-ae47-4ba0-8a11-abb0e150eb35" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b80152f-2d47-4aaf-b475-364fe7ab52a1" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60ed3a0e-1dfa-41f8-967c-4766157a8b5d" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80c2648f-d0b8-4bbb-9e93-dc4840ef94e8" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="grts:NonTaxableStockPremium" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a87e3db-5740-4608-8d05-81e20d4d35d5" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">33.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9243942f-aa9e-40f1-ada3-6a34f5f4a336" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">40.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8124c2a-b4f2-4494-b173-aeed5760c2ba" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">26.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42dec986-869b-49b7-b1ea-196d7af4bb96" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d32f2241-77cf-4931-96d6-c6da344542c9" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2edd4b2-2a50-4184-ae2d-727a789e10e2" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2021 and 2020. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards. The increase in valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_132760a8-7899-417a-907a-9fdd9f601ff6" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67ac42bb-a606-4311-98ea-c38209c10d62" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and 2020, respectively, was primarily attributable to the Company&#x2019;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#x2019;s state apportionment factors.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_52af464b-373a-4c93-8cf9-9e9f55df4dd9" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.736%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.644%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.644%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76281e2c-7a96-4181-939c-668f19aa4238" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96d80c9f-7ce1-4709-b0a1-b54afaf3b6f8" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_205d7ac2-d9ef-4160-b89b-8e965d7c72ab" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77859751-8807-4b78-87d7-406ae8d88856" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,247</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01d5a7ae-7485-420e-a4f6-5c71763fcb6b" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0467362-603a-4e83-a2bb-a63c0a297dbc" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2634cc0d-8ee3-4f6e-9942-5d766046b9c0" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2616fb4e-bf31-4766-b040-e323911dc48c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,354</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38d6620d-8db7-4625-abe3-391f44cc3e79" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78a718a9-db19-4504-99ba-3a9dd8e19a31" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DeferredTaxAssetsAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd1821cc-b6dc-4709-8141-0cbc5803b6dd" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,537</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1120f845-0d3d-4879-ac4e-466b518a1265" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,414</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca0ea7ef-6736-47d5-8904-84aa89b4e66a" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,884</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42e1d997-9665-432b-b4d7-48f845d2a02f" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_728bdaa9-3a4e-4a71-8567-c37d99bd3fee" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9ce6687-dde4-44fe-9e9c-75dc49815e29" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">101,781</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58145a50-71b1-40f8-8ddd-2b0414e503cf" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aae96821-7423-4b3c-9468-b0f3c3dee759" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56cd86fc-a804-4830-bbca-daa91b5e2901" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DeferredTaxLiabilitiesOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a38f49d-c92e-413d-9768-885691f2e335" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DeferredTaxLiabilitiesOtherDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_943aca95-2148-4236-8dba-8fc3959263f3" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ebe6071-4a2d-406b-8ab2-20ce0bc3af3c" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,231</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd286e30-2ea6-4b7f-82df-be6a15459c4c" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e857438e-e78c-42f6-93ba-38431919865e" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 and 2020, the Company&#x2019;s federal and state income tax net operating loss carryforwards were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e34c1958-92d2-4f26-b9f6-c0653b5c294f" contextRef="C_d171005c-8d0e-451d-ba44-fff86b36b8da" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">353.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1e4c4bf-5838-46b0-b9c7-e5e5a5bb7d58" contextRef="C_82594404-3d52-42ec-86ef-ac5b28a31a88" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">347.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82c78f5a-3fd5-404a-8e47-9539cac9f241" contextRef="C_6f109470-dac2-4731-88ec-db187dd90821" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the state tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8415a3a0-50cb-4e7c-a7ca-8211c8a1b471" contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca" name="grts:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7b42a7e-3553-4133-a596-5a810da77a8f" contextRef="C_9a5f8053-f39a-415a-be93-1d833d484e98" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">303.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00823679-5cb4-4f30-9dbe-db8220b1d02e" contextRef="C_5fad68e3-d917-408c-8c64-eb2b3afa907e" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96df5882-0834-49a8-922b-76307b912ec3" contextRef="C_3418f96e-c10b-4a60-a068-01b16dabf6cb" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f916553-8775-4df6-9fba-48a4470c93f2" contextRef="C_5e60bfb9-8ab6-4a16-8851-229b4f62c041" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e6615ac-aa76-48f3-9312-333b89861465" contextRef="C_6c627a47-b9a4-42f9-9425-7b48bc442bfb" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebed4312-4f29-48b2-97d2-968d8feff98f" contextRef="C_bb4a354a-e696-4d8e-b1b8-aeae9a1baedf" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d04ad0b6-1304-4978-8444-175bd600506c" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss and tax credit carryforwards as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.406%;"></td>
        <td style="width:1.457%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.886%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.457%;"></td>
        <td style="width:20.985%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddbb1605-3430-4226-b6fb-09ffca14209b" contextRef="C_b3dbdfb2-9a14-4b95-94f9-f7c4fd7b4d2d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303,229</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fcf59c4-a05e-4774-bb25-4b8865560f33" contextRef="C_cb4aa159-88f3-4ae9-872f-ad54eb0054a3" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Do not expire</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cc2ea70-c9c9-4e53-99b6-ea9df62a8a87" contextRef="C_d6e42e8c-14e5-4460-9129-ce2242e0271a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7ad56b2-2c8e-455c-97d8-90d75b461b32" contextRef="C_3488b869-cb93-4aac-81c2-cb2237fd526d" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2037</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b66e724-0824-4e04-ad4a-a5bbc2df91ef" contextRef="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">347,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28408495-9bb4-4638-ba1b-ead0b9009dd6" contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_606ff7b8-6985-4ec8-8e28-07b434c2fd01" contextRef="C_d171005c-8d0e-451d-ba44-fff86b36b8da" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,990</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_993aa968-e5c3-495c-887e-dd74c040a3a1" contextRef="C_6f109470-dac2-4731-88ec-db187dd90821" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_790b7dab-c6f0-4e02-85d0-67a11f651a86" contextRef="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4032ea3b-9d53-4b78-adac-ca4009d931a2" contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CA: credits do not expire<br />MA: 2035 - 2040</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea7d9397-ee60-4afb-9e73-df2b0f152076" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:OwnershipInterestChangeOverPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period in excess of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e0d0c2b-de06-4f51-a6ac-50cf3acbce27" contextRef="C_7a07fc35-5bb5-495e-b5b1-254dbffe7f54" name="grts:CumulativeChangesInOwnershipInterestOfShareholders" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership changes may further affect the limitation in future years. In connection with the Company&#x2019;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2021 under IRC Sections 382 and 383 to determine if the Company&#x2019;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">137</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4aafbe4f-f680-4fe9-96de-185a9ae44736" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.772%;"></td>
        <td style="width:1.15%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.722%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.15%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.722%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.15%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.786%;"></td>
        <td style="width:0.983%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning of year&#x2014;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1ddb6b4-f428-4b8e-9d80-999b69478945" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52ac9323-3370-48c5-a68d-86488492ac4c" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5fe8cdf-9df1-4472-be34-029b83dfc182" contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6393ece7-9498-4542-aa88-f6b4d7587040" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d6b973-3b3c-450b-a3bb-97f1ab6fa904" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a3bf560-6f3b-491a-ad4f-437a54242981" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">711</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c940118-4850-44ec-b463-a22a9c48d0ec" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,456</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24feb3ce-c82b-4922-9db2-869e87714ebf" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efba100b-93a2-4a2b-8d21-585d3c2df652" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">End of year&#x2014;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7712069-873d-4f33-afbf-08bf2835a505" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,481</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa9280ca-d192-4c39-b594-a9b91e06e168" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53ae9a61-81f5-4ad3-8e62-0d0112cf9f4c" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If recognized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66e0db84-9d75-44aa-8644-2c59d4f56004" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e3d2904e-a719-457c-a67a-2ac080b4b3ed" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the unrecognized tax benefits as of December 31, 2021, 2020, and 2019 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021, 2020, and 2019, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12cf3f4f-76b0-41c7-b2a9-d3b02ccdc906" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_178eff4f-8396-44b0-ad0f-5c58f6d251de" contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_190902c7-8584-4491-ad33-bdfbf7a3f9ad" contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_8b3b2ab9-3043-499d-b186-d0d72157039e" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12.	Net Loss Per Common Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abb8dfd4-8add-452b-9654-372ba629536a" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.785%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.298%;"></td>
        <td style="width:8.431%;"></td>
        <td style="width:0.965%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.111%;"></td>
        <td style="width:0.881%;"></td>
        <td style="width:1.104%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.13%;"></td>
        <td style="width:0.881%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3959d3d1-4a8d-4b89-ba48-d2d30f517245" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">75,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2be09a2b-7745-401a-9399-39541a5bfe3e" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87936e14-01c1-476c-98fc-d22797342f9b" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">94,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f054804-e5c0-4675-9adb-ad075c1d9ddb" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,885,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8463dbd-9bef-4d7d-ab74-1cdde6ae3813" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,792,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5df47a63-82a4-475a-8e16-679692b5c931" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">33,554,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd1d052a-ef6e-4adb-bd8b-6d1b13afeb48" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_732fbcde-5b17-4d6b-a6b3-1244779357f4" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4abe2599-7a4c-45cb-a954-fb94253d77bf" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">2.81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0fc873e1-f978-4640-8160-e7232f38ad8b" contextRef="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,480,719</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9a86ca1-c230-4688-94b5-219f6bca0561" contextRef="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be" name="grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.01</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share (see Note 9). During the year ended December 31, 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68ab0731-7462-4d09-91cd-88ce8ad466c3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,459,576</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_075b172e-d4de-4316-bcad-fdf9265778e0" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="grts:WarrantsCancelled" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,872</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants cancelled due to net exercise of the warrants. As of December 31, 2021, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb9d1761-6829-4d15-866b-a100c847494a" contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,016,271</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8a9fc4e-7215-40b3-82af-9d8fb17fa000" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_c8a9fc4e-7215-40b3-82af-9d8fb17fa000_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_c8a9fc4e-7215-40b3-82af-9d8fb17fa000_1"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.707%;"></td>
        <td style="width:1.169%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:11.723%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.169%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:11.723%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.169%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:11.723%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09323325-6524-4c3f-8e05-c81fd281e06e" contextRef="C_d66cd703-3912-46fa-bae2-d9fb061ac072" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,170,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19d2b6bd-f38b-44e1-bb31-bf2ee243f5b2" contextRef="C_8ac0f270-594e-4838-963f-9a5cabbd9055" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,213,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b0dfbc9-e570-4cd1-90c5-da40ba204656" contextRef="C_50a00b2f-11c4-485d-982a-768195d22ede" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,179,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Early exercised common stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f3af81b-af29-439e-b59c-73da9e72f18e" contextRef="C_3d7d9ff9-59ff-40cb-8c0e-59c0bc70d677" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d206f59b-847f-4ed1-bc8c-ddb5da1b9bd2" contextRef="C_a11e18b2-bc61-4add-880b-6822c9bfcacf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17292e71-5df7-4d01-9e43-f60ace8703d9" contextRef="C_3f526cf1-464a-4dda-8e5a-79f43b2772aa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e86c9698-88ff-4308-9b74-1755e56ffbdf" contextRef="C_fda9c57d-6ce6-4fc0-83c9-b59dac2e78ac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">708,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95f3be5f-b540-4820-84a4-c0563abe5f93" contextRef="C_03449e98-a695-4ee5-a4e7-b5c706a15b67" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a256bbf-242e-4b8c-8018-c3ddf783ed65" contextRef="C_cb6c3d89-2dc2-476a-a09b-30ac42c2532e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7b647e4-fc6a-460f-ab41-f56e3474cac3" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,879,131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c73639e2-a8ce-423f-b1a7-17eb81542360" contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,213,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2febe539-70fd-4fa8-aee8-19b33e70a24d" contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,209,915</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">138</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a41940b-32d5-4d9f-acb0-722c088761ec" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13.	Defined Contribution Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f407c74f-79aa-4397-9a4f-1d1afc6f707f" contextRef="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the first </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0560d27d-ca33-4b36-b1c0-ac03c6bd7350" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of each employee&#x2019;s contribution. During the year ended December 31, 2021, expenses recognized for the 401(k) Plan was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f499c081-9dd8-480d-944e-f7233fe64074" contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, while the amount was immaterial for the years ended December 31, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements With Acco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">untants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, management, with the participation of our principal executive, financial and accounting officers, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including the principal executive, financial and accounting officers, to allow timely decisions regarding required disclosures.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2021, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the year ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:6.107%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and our Principal Financial Officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#x201c;Internal Control-Integrated Framework&#x201d; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2021.</span></p>
  <p style="text-indent:6.107%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9c_disclosure_related_to_foreign_ju"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Dis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">closure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers, employees and consultants. The Code of Business Conduct and Ethics is available on the Corporate Governance page of our website at www.gritstonebio.com. If we ever were to amend or waive any provision of our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer, controller or any person performing similar functions, we intend to satisfy our disclosure obligations with respect to any such waiver or amendment by posting such information on our internet website set forth above rather than filing a Form 8-K.</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All other information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with our 2022 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;), which is expected to be filed not later than 120 days after December 31, 2021, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information required by this item will be contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits and Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The following documents are filed as part of this report:</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	Financial Statements</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	Financial Statement Schedules</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></p>
  <p style="margin-left:4.533%;text-indent:-2.432%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.	Exhibits</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.329%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:52.203%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:8.116%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:9.285%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:6.985%;"></td>
    <td style="width:3.404%;"></td>
    <td style="width:7.254%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Incorporated by Reference</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Herewith</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.1pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.1pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000119312521152379/d403517dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certificate of Amendment to Amendment and Restated Certificate of Incorporation.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">05/06/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reference is made to exhibits </span><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(46,116,181,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">3.1</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;through </span><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290860/d623029dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(46,116,181,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">3.2</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Common Stock Certificate.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Common Stock.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1(a)&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex101a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License Agreement, dated as of October 16, 2017, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva Biotherapeutics Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1(b)&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex101b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment Number One to License Agreement, dated as of July 20, 2018, by and among Gritstone Oncology, Inc., Arbutus Biopharma Corporation and its subsidiary Protiva Biotherapeutics Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1(c)&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000156459020050916/grts-ex101_91.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to Research Collaboration and License Agreement, by and between Gritstone Oncology, Inc. and bluebird bio, Inc., effective August 19, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11/05/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000156459021041578/grts-ex101_164.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to Research Collaboration and License Agreement by and between Gritstone Oncology, Inc. and bluebird bio, Inc., effective February 18, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/05/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3&#165;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Collaboration, Option and License Agreement by and between Gilead Sciences, Inc. and Gritstone Oncology, Inc., dated as of January 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4(a)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290941/d612395dex992a.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(A)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4(b)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4(c)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Restricted Stock Award Grant Notice under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.329%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:52.203%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:8.116%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:9.285%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:6.985%;"></td>
    <td style="width:3.404%;"></td>
    <td style="width:7.254%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4(d)#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex107d.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Restricted Stock Unit Award Grant Notice under the 2018 Incentive Award Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone Oncology, Inc. and Andrew Allen, M.D., Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone Oncology, Inc. and Matthew Hawryluk, Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone Oncology, Inc. and Karin Jooss, Ph.D., effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone Oncology, Inc. and Erin Jones, effective as of September 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000156459020022416/grts-ex101_143.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone Oncology, Inc. and Rahsaan Thompson, effective as of March 2, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">05/07/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex10_10.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Agreement by and between Gritstone bio, Inc., and Vassiliki Economides, effective as of June 23, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Non-Employee Director Compensation Program.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518290941/d612395dex993.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2018 Employee Stock Purchase Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10/02/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex104.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease, dated as of February 11, 2016, by and between Gritstone Oncology, Inc. and BMR-Sidney Research Campus LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518255669/d565416dex105.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office Building Net Lease, dated as of March 24, 2017, by and between Gritstone Oncology, Inc. and Hacienda Portfolio Venture, LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/23/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312519028323/d702385dex101.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and Emery Station West, LLC, effective as of January 28, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">02/05/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000156459019042681/grts-ex102_207.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of September 6, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11/20/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001656634/000156459019042681/grts-ex103_206.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of July 11, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11/20/19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000156459020036449/grts-ex101_78.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to Office/Laboratory Lease, by and between Gritstone Oncology, Inc. and MIL 21E, LLC, effective as of May 20, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">08/05/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office/Laboratory Lease, by and between Gritstone bio, Inc. and RREF II Kenmore Lessor III LLC and RREF II Kenmore Lessor IV LLC, effective as of September 23, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Lease, by and between Gritstone bio, Inc. and MIL 21E, LLC, effective as of September 21, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000095017021001926/grts-20210921ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to Office/Laboratory Lease, by and between Gritstone bio, Inc. and MIL 21E, LLC, effective as of September 21, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/29/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312518274609/d565416dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312520326728/d51703dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Securities Purchase Agreement, dated December 22, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12/28/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312520329870/d101143dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Securities Purchase Agreement, dated December 28, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12/30/20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1656634/000119312521276245/d221390dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Securities Purchase Agreement, dated September 16, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">09/17/21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.329%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:52.203%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:8.116%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:9.285%;"></td>
    <td style="width:1.141%;"></td>
    <td style="width:6.985%;"></td>
    <td style="width:3.404%;"></td>
    <td style="width:7.254%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="grts-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification by the Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 36 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cover page from the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 has been formatted in Inline XBRL.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#134;	Confidential treatment has been granted for certain information contained in this exhibit. Such information has been omitted and filed separately with the SEC.</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#165;	Portions of the exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. A copy of any omitted portions will be furnished to the SEC upon request.</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">#	Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*	The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Gritstone bio, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 10-K Summary</span></p>
  <p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TURES</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.873%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:3.042%;"></td>
    <td style="width:46.461%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GRITSTONE BIO, INC.</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;/s/ Andrew Allen</span></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Allen, M.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Andrew Allen, Vassiliki Economides, and Rahsaan Thompson his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or their, his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.997%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:44.996%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:17.841%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Allen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Allen, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Vassiliki Economides</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vassiliki Economides</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ James Cho</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Accounting Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">James Cho</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Elaine Jones</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chairperson of our Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Elaine Jones, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Clare Fisher</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clare Fisher</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Steve Krognes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Steve Krognes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Naiyer A. Rizvi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Naiyer A. Rizvi, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Richard Heyman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Richard Heyman, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Shefali Agarwal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shefali Agarwal, M.D., M.P.H.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>grts-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF THE REGISTRANT&#x2019;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	As of March 10, 2022, Gritstone bio, Inc. had one class of common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The following summary describes our common stock and the material provisions of our amended and restated certificate of incorporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">certificate of incorporation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), our amended and restated bylaws (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">bylaws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), and of the Delaware General Corporation Law (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DGCL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our certificate of incorporation and bylaws, filed as Exhibits 3.1 and 3.2, respectively, to our Annual Report on Form 10-K filed with the Securities Exchange Commission, of which this Exhibit 4.3 is a part.  We encourage you to read those documents and the DGCL carefully.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The certificate of incorporation authorizes 300,000,000 shares of common stock, $0.0001 par value per share.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting Rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66-2/3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Subject to preferences that may be applicable to any then outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of convertible preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights and Preferences</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred stock that we may designate in the future.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fully Paid and Nonassessable</font></p>
  <p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All outstanding shares of common stock are fully paid and non-assessable.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Undesignated Preferred Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Under our certificate of incorporation, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock, $0.0001 par value per share, in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. As of March 10, 2022, no shares of convertible preferred stock were outstanding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware Law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware Anti-Takeover Statute</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	We are subject to Section 203 of the DGCL, which prohibits persons deemed &#x201c;interested stockholders&#x201d; from engaging in a &#x201c;business combination&#x201d; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#x201c;interested stockholder&#x201d; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#x2019;s voting stock. Generally, a &#x201c;business combination&#x201d; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Undesignated Preferred Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Special Stockholder Meetings</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated bylaws provide that a special meeting of stockholders may be called by our board of directors, or by our President or Chief Executive Officer.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Elimination of Stockholder Action by Written Consent</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation and our amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Classified Board; Election and Removal of Directors; Filling Vacancies</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Choice of Forum</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation and our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. The exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. In addition, our amended and restated certificate of incorporation provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The enforceability of similar federal court choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable or unenforceable. If a court were to find either of the choice of forum provisions contained in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The choice of forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with the company or its directors, officers or other employees, which may discourage such lawsuits against the company and its directors, officers and other employees and result in increased costs for investors to bring a claim.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amendment of the Certificate of Incorporation and Bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66-2/3% of the voting power of the then outstanding voting stock. The provisions of the DGCL, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Limitations of Liability and Indemnification Matters</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:91.014%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any breach of the director&#x2019;s duty of loyalty to us or our stockholders;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:91.014%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:91.014%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.979%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:91.014%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any transaction from which the director derived an improper personal benefit.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors&#x2019; and officers&#x2019; liability insurance.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder&#x2019;s investment may be adversely affected to the extent that we pay the costs of settlement and damages.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Listing</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Our common stock is listed on the Nasdaq Global Select Market under the symbol &#x201c;GRTS.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transfer Agent and Registrar</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#x2019;s address is 6201 15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Avenue, Brooklyn, New York 11219.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>grts-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 10.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="origsetcursorloc"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">COLLABORATION, Option AND LICENSE AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">by and between</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">gilead sciences, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone oncology, inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">TABLE OF CONTENTS</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.967%;"></td>
    <td style="width:86.925%;"></td>
    <td style="width:3.108%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article I DEFINITIONS AND INTERPRETATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article II COLLABORATION AND OPTION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">25</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Research and Development Activities</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">25</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead Composition</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Materials Transfer</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Option</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article III LICENSES; EXCLUSIVITY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Licenses to Gilead</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">License to Gritstone</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">33</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Subcontracting</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">No Other Rights; Retained Rights</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exclusivity</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Change of Control</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article IV GOVERNANCE</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Joint Steering Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dispute Resolution</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Alliance Managers</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Ad-Hoc Committees</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Costs of Governance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article V TECHNOLOGY TRANSFERS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclosure of Know-How</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Consultation and Assistance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VI DEVELOPMENT AND REGULATORY MATTERS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Development</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Development Reports</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Regulatory</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Development Diligence</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Pharmacovigilance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Compliance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Regulatory Notices</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VII MANUFACTURING</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Supply Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Manufacturing</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Manufacturing Know-How and Assistance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Manufacturing Technology Transfer</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Future Manufacturing Improvements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone Operational Documentation</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">7.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Transfer Limitation</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VIII COMMERCIALIZATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Commercialization</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">8.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Commercialization Diligence</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article IX FINANCIAL PROVISIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Upfront Payment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Equity Investment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Fee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Milestone Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Royalty Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Royalty Reductions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">i</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.967%;"></td>
    <td style="width:86.925%;"></td>
    <td style="width:3.108%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Third Party Obligations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">50</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.8.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Cumulative Effect of Reductions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">53</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.9.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">No Projections</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.10.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Non-Refundable and Non-Creditable Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article X REPORTS AND PAYMENT TERMS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Reports; Payment Terms</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Currency</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Blocked Currency</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Taxes; Withholding</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Records and Audit Rights</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XI INTELLECTUAL PROPERTY RIGHTS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Inventorship</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Ownership</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Prosecution and Maintenance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Enforcement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Defense</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">61</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Recovery.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Trademarks</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.8.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Product Listings</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.9.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Patent Term Extensions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XII CONFIDENTIALITY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">63</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Nondisclosure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">63</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exceptions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Authorized Disclosure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Terms of this Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Securities Filings; Disclosure under Applicable Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Publicity</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Publications</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XIII TERM AND TERMINATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Term</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Termination for Material Breach</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Termination for Insolvency</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">68</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Termination by Gilead for Convenience</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">68</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">68</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Rights in Bankruptcy</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">69</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XIV EFFECT OF TERMINATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Termination by Gilead for Convenience or by Gritstone for Material Breach or Insolvency of Gilead or Expiration Without Option Exercise</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Termination by Gilead for Material Breach by or Insolvency of Gritstone</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Alternative to Termination.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Surviving Provisions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XV REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Representations and Warranties by Each Party</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Representations and Warranties by Gritstone as of the Effective Date</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Representations and Warranties by Gritstone as of the Disclosure Letter Date</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">79</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Covenants.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">80</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Additional Covenants of Gritstone</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">81</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Limitation on Scope of Representations, Warranties and Covenants</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclaimer</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">ii</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:9.967%;"></td>
    <td style="width:86.925%;"></td>
    <td style="width:3.108%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XVI INDEMNIFICATION; LIABILITY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Indemnification by Gritstone</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Indemnification by Gilead</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">84</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Indemnification Procedure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">84</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Mitigation of Loss</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">85</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Limitation of Liability</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">85</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Insurance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XVII GENERAL PROVISIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Assignment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Extension to Affiliates</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Severability</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Governing Law and Waiver of Jury Trial</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dispute Resolution; Rules of Arbitration</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">88</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Force Majeure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">89</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Waivers and Amendments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.8.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Relationship of the Parties</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.9.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Notices</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.10.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Further Assurances</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.11.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Compliance with Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.12.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Parties in Interest; No Third Party Beneficiary Rights</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.13.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">English Language</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.14.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Expenses</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.15.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Interpretation</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.16.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Entire Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">92</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.17.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Counterparts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">92</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:11.9pt;word-break:break-word;vertical-align:top;"><p style="margin-left:11.9pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.18.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Cumulative Remedies</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">92</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">iii</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">LIST OF SCHEDULES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedules</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.996%;"></td>
    <td style="width:81.004%;"></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.29</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">ChAdV and SAM Platform Technology</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.66</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">EDGE&#153; Machine-Learning Platform Technology</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.71</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Excluded Technology</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.122</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Existing In-License Agreements</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.153</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 2.1.2(a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Plan</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 2.1.2(b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone R&amp;D Budget</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 3.1.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Future In-License Agreement [**]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 3.5.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Selected Provisions of Gritstone-[**] Arrangement</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 5.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 6.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Form of Development Report</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 7.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 9.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Stock Purchase Agreement</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 11.10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]-Related Provisions of Third Party Agreements</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 12.6.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Press Release</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclosure Schedule</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Licensed Patents</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclosure Schedule as of the Bringdown Letter Date</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.002in;word-break:break-word;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Licensed Patents as of the Bringdown Letter Date</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">iv</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">COLLABORATION, option AND LICENSE AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This COLLABORATION, OPTION AND LICENSE AGREEMENT (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) is made as of January 29, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), by and between Gilead Sciences, Inc., a Delaware corporation having an office at 333 Lakeside Drive, Foster City, CA 94404 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and Gritstone Oncology, Inc., a Delaware corporation having an office at 5959 Horton Street, Suite 300, Emeryville, California 94608 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Gilead and Gritstone are each referred to individually as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and together as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead is a pharmaceutical company with expertise in the development and commercialization of pharmaceutical and biological products;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone is a biotechnology company focused on discovering and developing therapeutics using its platform technology;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead and Gritstone wish to collaborate with respect to certain development and manufacturing process development activities with respect to a potential vaccine product using or incorporating the Licensed Technology for the Field of Use (each, as defined below); and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead wishes to obtain, and Gritstone wishes to grant, an exclusive option to a license under the Licensed Technology (as defined below) and, following the exercise by Gilead of such option, Gilead will have the right to perform further development, manufacturing, commercialization or Exploitation of products incorporating a Vaccine (each, as defined below), in each case in the Field of Use, subject to the terms and conditions set forth herein.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">NOW</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article I<br>DEFINITIONS AND INTERPRETATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized will have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.1.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ACA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Patient Protection and Affordable Care Act.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.2.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Accounting Standards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means U.S. generally accepted accounting principles, consistently applied.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.3.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Acquired Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 1.33</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.4.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Acquiring Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means, collectively, the Person referenced as the acquirer of the Acquired Person or the Acquired Person&#x2019;s securities or assets in the definition of Change of Control and such Person&#x2019;s Affiliates, other than the Acquired Person in the definition of Change of Control and such Acquired Person&#x2019;s Affiliates, determined immediately prior to the closing of such Change of Control.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.5.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Action</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation by or before, or otherwise involving, any Governmental Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.6.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Person, any entity or person that controls, is controlled by, or is under common control with that Person, but solely during the period in which such entity or person controls, is controlled by, or is under common control with that Person.  For the purpose of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 1.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> only, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">controlled</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, (a) direct or indirect, ownership of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation or more than fifty percent (50%) of the equity interest in the case of any other type of legal entity; (b) status as a general partner in any partnership; or (c) any other arrangement whereby the entity or person appoints or has the right to appoint (other than through the ownership of voting securities) a majority of the members of the board of directors or equivalent governing body of a corporation or other entity or has the ability to cause the direction of the management or policies of a corporation or other entity; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in the case of this clause (c), no person or entity will be deemed to be an Affiliate of such Person solely by virtue of such person&#x2019;s or entity&#x2019;s direct or indirect ownership of any securities of such Person.  The Parties acknowledge that in the case of entities organized under the laws of certain countries where the maximum percentage ownership permitted by Applicable Law for a foreign investor is less than fifty percent (50%), such lower percentage will be substituted in clause (a) of the preceding sentence;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that such foreign investor has the power to direct the management and policies of such entity.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.7.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.8.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.9.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Alliance Manager</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.10.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antitrust Filing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.11.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antitrust Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Applicable Law that is designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization, lessening of competition or restraint of trade, including the HSR Act.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.12.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Applicable Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all applicable laws, statutes, rules, regulations, treaties (including tax treaties), orders, judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city or other political subdivision, including, to the extent applicable, GCP, GLP and GMP, as well as all applicable data protection and privacy laws, rules and regulations, in each case that may be in effect from time to time during the Term, including, to the extent applicable, the United States Department of Health and Human Services privacy rules under the Health Insurance Portability and Accountability Act and the Health Information Technology for Economic and Clinical Health Act and the EU General Data Protection Regulation (Regulation (EU) 2016/679).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.13.	&#x201c;[**]&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.14.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Audited Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.15.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Auditing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.16.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Auditor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.17.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Biosimilar Application</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(f)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.18.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Biosimilar Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Product that has Regulatory Approval in the country or jurisdiction in question, a biological medicine or biological product for human use which: (a) is highly similar to such Product; (b) has no clinically meaningful differences from such Product as determined by Applicable Laws or any applicable Regulatory Authority; and (c) is approved for use (i) in the U.S., as biosimilar (as defined in the ACA) to such Product pursuant to an abbreviated regulatory approval process established under the ACA in 42 U.S.C. &#167; 262(k) as such regulations may be amended from time to time, or a successor regulatory classification, (ii) in the EU, as a similar biological medicinal product pursuant to Directive 2001/83/EC or Regulation (EC) No 726/2004 (as applicable) as such regulations may be amended from time to time, or a successor regulatory classification, or (iii) in any other country or jurisdiction, pursuant to an equivalent regime in such country or jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.19.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">BLA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Biologics License Application filed with the FDA in the United States with respect to a Product, as defined in 42 U.S.C. &#167; 262(a) and Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et seq.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.20.	&#x201c;[**]&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.21.	&#x201c;[**]&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.22.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Breaching Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.23.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Brief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.24.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Business Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a day other than: (a) Saturday or Sunday; (b) any other day on which commercial banks located in San Francisco, California are obligated by Applicable Laws or executive order to close; (c) the Sunday through Saturday containing July 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (d) December 26 through December 31.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.25.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Calendar Quarter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means each successive period of three (3) calendar months commencing on January 1, April 1, July 1, and October 1, except that the first Calendar Quarter of the Term will commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1, or October 1 after the Effective Date, and the last Calendar Quarter will end on the last day of the Term.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.26.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Calendar Year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term will commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term will commence on January 1 of the year in which the Term ends and end on the last day of the Term.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.27.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cassette</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">HIV Antigen</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sequences that may additionally include [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.28.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ChAdV</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a chimpanzee adenovirus vector.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.29.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ChAdV and SAM Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.30.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Challenge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.31.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Challenge Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.32.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Challenging Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref25"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.33.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Person (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Acquired Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), the occurrence of any of the following events from and after the Effective Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> any Person or group of Persons becomes the beneficial owner (directly or indirectly) of more than fifty percent (50%) of the voting shares of such Acquired Person; </font><font id="docxtextref26"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> such Acquired Person consolidates with or merges into or with another Person pursuant to a transaction in which more than fifty percent (50%) of the voting shares of the acquiring or resulting entity outstanding immediately after such consolidation or merger is not held by the holders of the outstanding voting shares of such Acquired Person immediately preceding such consolidation or merger; or </font><font id="docxtextref27"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> such Acquired Person sells or transfers to a Person other than an Affiliate of such Acquired Person all or substantially all of such Acquired Person&#x2019;s assets.  Notwithstanding the foregoing, the following will not constitute a Change of Control: (i) a sale of capital stock to underwriters in an underwritten public offering of a Party&#x2019;s capital stock solely for the purpose of financing, (ii) the acquisition of securities of the Acquired Person by any Person or group of Persons that acquires the Acquired Person&#x2019;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Acquired Person through the issuance of equity securities, (iii) a transaction solely to change the domicile of a Party; or (iv) a transaction or series of related transactions involving solely the Acquired Person and one or more Affiliates of the Acquired Person.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.34.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.35.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Clinical Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any human clinical trial of a pharmaceutical or biological product.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.36.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CMC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means chemistry, manufacturing, and controls portion of a Regulatory Filing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.37.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CMO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Third Party contract manufacturer.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.38.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.39.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, collectively, all Collaboration Know-How and Collaboration Patents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.40.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Collaboration Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any and all Know-How that is conceived, discovered or otherwise made by or on behalf of either Party or their respective Affiliates in the course of performing activities under this Agreement during the Term, whether solely or jointly with the other Party or any Third Party(ies); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for clarity, that Collaboration Know-How excludes (a) Know-How that is [**] and (b) Know-How that is [**], except that this clause (b) shall not exclude Know-How that is (i) [**] or (ii) [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.41.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any Patent Right of a Party or any of its Affiliates that claims any Collaboration Know-How.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.42.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Combination Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Product, in any dosage strength, formulation, or method of administration, that includes: (a) a Vaccine; and (b) one (1) or more [**] (each in clause (b), an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Other Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), whether in fixed dose combination, co-formulated, co-packaged, or otherwise sold together for one (1) price; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, however,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that in the case of any Product that includes [**], an &#x201c;Other Product&#x201d; is deemed to exclude [**].  For clarity, Combination Products include [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.43.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Commercialize</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all activities directed to the commercialization of a product, including marketing; detailing; promotion; distributing; order processing; handling returns and recalls; booking sales; administering and commercially selling such product; importing, exporting and transporting such product for commercial sale; and seeking Pricing Approval of a product (if applicable),</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref34"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">whether before or after Regulatory Approval has been obtained, as well all regulatory compliance with respect to the foregoing.  For clarity, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Commercialization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; does not include: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Manufacturing; or </font><font id="docxtextref35"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> any Clinical Trials and other trials commenced after Regulatory Approval.  When used as a verb, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Commercialize</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means to engage in Commercialization.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.44.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Commercially Reasonable Efforts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a particular activity, Product and Party, that [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.45.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Competing Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.46.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Competing Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.47.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Compulsory License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Product in a country or territory, a license, or rights granted to a Third Party by a governmental agency within such country or territory to sell or offer for sale such Product in such country or territory under any Patent Right or Know-How owned or controlled by either Party or its Affiliates, without direct or indirect authorization from such Party or its Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.48.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Compulsory Licensee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Third Party granted a Compulsory License.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.49.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Confidential Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Party, all confidential and proprietary information, including chemical or biological materials, chemical structures, nucleic acid or amino acid sequences, Commercialization plans, correspondence, customer lists, data, Development plans, formulae, improvements, Inventions, Know-How, processes, Regulatory Materials, reports, strategies, techniques or other confidential or proprietary business, scientific or technical information, in each case, that are disclosed by or on behalf of such Party to the other Party in connection with this Agreement, whether prior to, on or after the Effective Date, regardless of whether any of the foregoing are marked &#x201c;confidential&#x201d; or &#x201c;proprietary&#x201d; or communicated to the other Party by or on behalf of the disclosing Party in oral, written, visual, graphic or electronic form.  Without limitation to the foregoing, (a) Gritstone Collaboration IP shall be deemed Confidential Information of Gritstone, and Gritstone shall be deemed the disclosing Party and Gilead shall be deemed the receiving Party with respect thereto; (b) Gilead Collaboration IP shall be deemed the Confidential Information of Gilead, and Gilead shall be deemed the disclosing Party and Gritstone shall be deemed the receiving Party with respect thereto; and (c) Joint Collaboration IP shall be deemed Confidential Information of both Parties, and both Parties shall be deemed the disclosing Party and the receiving Party with respect thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.50.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Controlled</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means with respect to (a) any Patent Rights, Know-How, other intellectual property right, Regulatory Materials or Confidential Information, the ability of a Party or its Affiliates, as applicable (whether through ownership or license (other than a license granted in this Agreement)) to grant to the other Party or its Affiliates the licenses or sublicenses as provided herein and to otherwise disclose such Know-How, intellectual property right, Regulatory Materials or Confidential Information to the other Party as provided herein, and (b) any right of reference, the ability of a Party or its Affiliates to grant such right of reference as provided herein in each case ((a) and (b)), to the extent not in violation of the terms of any then-existing agreement with any Third Party at the time such Party or its Affiliates, as applicable, (x) in the case of clause (a), would be required hereunder to grant the other Party or its Affiliates such license or sublicenses as provided herein or to otherwise disclose such Know-How, intellectual property right, Regulatory Materials or Confidential Information to the other Party or its Affiliates or (y) in the case of clause (b), would be required to grant the other Party or its Affiliates such right of reference.  Notwithstanding the foregoing, a Party and its Affiliates will be deemed not to &#x201c;Control&#x201d; any intellectual property rights or rights of reference that are owned or in-licensed by a Third Party (or any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Affiliates of such Third Party in existence prior to the Change of Control, other than such Party or its Affiliates) that becomes an Affiliate of such Party (or that merges or consolidates with such Party) after the Effective Date as a result of a Change of Control of such Party unless (a) prior to the consummation of such Change of Control, such Party or any of its Affiliates also Controlled such Patent Right, Know-How, other intellectual property right, Regulatory Materials or right of reference; or (b) after the consummation of such Change of Control, such Party or any of its Affiliates uses, develops or invents any such Patent Right, Know-How, other intellectual property right, Regulatory Materials or right of reference in the performance of its obligations or exercise of its rights under this Agreement (for clarity, other than in the case of Gritstone or any of its Affiliates or sublicensees pursuant to the license granted in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), in each of which cases ((a) and (b)), such Patent Right, Know-How, other intellectual property right, Regulatory Materials or right of reference will be deemed to be &#x201c;Controlled&#x201d; by such Party for purposes of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.51.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cover</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with reference to a Valid Claim and a product, that the making, using, offering to sell, selling, importing or exporting of such product would infringe such Valid Claim in the country in which such activity occurs without a license thereto (or ownership thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.52.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cure Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.53.	&#x201c;[**]&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.54.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means: (a) any breach, violation or default; (b) the existence of circumstances or the occurrence of an event that with the passage of time or the giving of notice or both would constitute a breach, violation or default; or (c) the existence of circumstances or the occurrence of an event that, with or without the passage of time or the giving of notice or both, would give rise to a right of termination, renegotiation, acceleration or material change of terms.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.55.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Develop</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means clinical drug development activities and other development activities with respect to a product, including Clinical Trials, test method development and stability testing; toxicology; formulation; qualification; validation; statistical analysis and report writing; the preparation and submission of INDs and MAAs; regulatory affairs with respect to the foregoing and all other activities necessary or useful or otherwise requested or required by a Regulatory Authority or as a condition or in support of obtaining or maintaining a Regulatory Approval.  For clarity, &#x201c;Development&#x201d; does not include Research or Manufacturing.  When used as a verb, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Develop</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means to engage in Development.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.56.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.57.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.58.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.59.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosure Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.60.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosure Letter Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.61.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.62.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Divestment Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.63.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">DOJ</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.64.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Dollars</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">$</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the legal tender of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.65.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Drug Master File</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.66.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EDGE&#153; Machine-Learning Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.67.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.68.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EMA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the European Medicines Agency, or any successor agency or authority thereto with comparable responsibilities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.69.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Encumbrance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, assignment to a Third Party, power of sale, right of pre-emption, or security interest of any kind.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.70.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">European Union</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EU</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all of the European Union member states as of the Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.71.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Excluded Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.72.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing CDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Mutual Confidential Disclosure Agreement between the Parties, dated May 5, 2017.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.73.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing In-License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 1.122</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.74.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exploit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means to make, have made, import, export, distribute, use, have used, sell, have sold, or offer for sale, including to Research, Develop, Manufacture, perform or have performed medical affairs, Commercialize, register, modify, enhance, improve, or otherwise exploit.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exploitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exploiting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will be construed accordingly.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.75.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the United States Food and Drug Administration, or any successor agency or authority thereto with comparable responsibilities.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.76.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FDA Debarment List</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the list of firms or persons debarred pursuant to Sections 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FDCA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) (21 U.S.C. &#167; 335(a)).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.77.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FDCA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 1.76</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.78.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Field of Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all uses in the field of HIV, including treatment, cure, diagnosis, or prevention thereof and, for clarity, acquired immunodeficiency syndrome; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, with respect to any Licensed Technology for which Gilead receives a sublicense under (a) the [**], the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Field of Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will be limited to [**], (b) [**], (c) [**]; (d) [**] or (e) [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref50"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.79.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">First Commercial Sale</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, on a Product-by-Product and country-by-country basis, the first sale of such Product in such country for use or consumption by the general public (following receipt of all Regulatory Approvals that are required in order to sell such Product in such country) and for which any of Gilead or its Affiliates or Sublicensees has invoiced sales of Products in the Territory; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that the following will not constitute a First Commercial Sale: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> any sale to an Affiliate or Sublicensee, unless such Affiliate or Sublicensee is the last Person in the distribution chain of the Product; </font><font id="docxtextref51"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> any use of such Product in Clinical Trials or non-clinical development activities with respect to such Product by or on behalf of a Party; or </font><font id="docxtextref52"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> [**].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.80.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.81.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foundational Licensed Patent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.82.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FPFD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the administration of the first dose of a Product to the first patient (or healthy volunteer, as relevant) while such patient or healthy volunteer is participating in a Clinical Trial.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.83.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FTC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.84.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FTE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**] hours per year.  Any person who devotes less than [**] hours per year on the activities under the R&amp;D Plan will be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by [**].  Overtime, and work on weekends, holidays, and the like will not be counted with any multiplier (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">e.g.,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution.  For the avoidance of doubt, no individual shall count as more than one (1) FTE for any year.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.85.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Core In-License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Gritstone In-License Agreement other than an Existing In-License Agreement pursuant to which Gritstone in-licenses, or otherwise acquires, Control of Patent Rights, Know-How or other intellectual property rights [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.86.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Gritstone Product-Related Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means an agreement, other than a Future Core In-License Agreement, entered into by Gritstone or any of its Affiliates and one or more Third Party(ies) after the Effective Date that (a) [**], or (b) [**], in each case (a) and (b), [**];</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.87.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Future Gritstone Product-Related </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means a Future Gritstone Product-Related Agreement, excluding any Future Gritstone Product-Related [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.88.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Gritstone Product-Related </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]&#x201d; means (i) a Future Gritstone Product-Related Agreement described in clause (a) of the definition of Future Gritstone Product-Related Agreement or (ii) [**], including, for clarity, [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.89.	&#x201c;[**]&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means any issued Patent Rights that (a) are Controlled by Gritstone or any of its Affiliates [**], and (b) would be [**] (for clarity, other than [**], excluding [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.90.	&#x201c;[**]&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means any [**] that is Controlled by Gritstone or any of its Affiliates [**].</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.91.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Gritstone Product-Related Agreement Sublicense</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.92.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Other In-License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Gritstone In-License Agreement other than an Existing In-License Agreement, a Future Core In-License Agreement or a Future Gritstone Product-Related Agreement Sublicense.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.93.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">GCP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the then-current standards, practices and procedures concerning Clinical Trials promulgated or endorsed by a Regulatory Authority of competent jurisdiction, as such regulations may be amended from time to time, including: (a) for the United States, as set forth in 21 C.F.R. Parts 11, 50, 54, 56, and 312, and guidance for industry, including &#x201c;Guidance for Industry E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1),&#x201d; including related regulatory requirements imposed by the FDA; (b) for the European Union, as set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005/28/EC of 8 April 2005; (c) as set forth in ICH</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Guideline for Good Clinical Practice E6(R2); and (d) analogous Applicable Laws of an applicable Regulatory Authority of competent jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.94.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Generic Version</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Product, a product (including a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">biogeneric</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">follow-on biologic</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">follow-on biological medicine or product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">follow-on protein product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">similar biological medicine or product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">biosimilar product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) that: (a) within the U.S., is &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">biosimilar</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">interchangeable</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; with respect to such Product as evaluated by the FDA or otherwise determined by Applicable Law; or (b) in the ROW, is determined by the applicable Regulatory Authority or by Applicable Law to be &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">similar</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">interchangeable</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">bioequivalent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">biosimilar</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; to such Product.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> For clarity, with respect to a Product, a Biosimilar Product will constitute a Generic Version of such Product.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.95.	&#x201c;[**]&#x201d; means [**], or any successor or permitted assignee under [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.96.	&#x201c;[**]&#x201d; means that certain [**] between [**] and as may be further amended from time to time in accordance with its terms and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.5.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.97.	&#x201c;[**]&#x201d; means that certain [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.98.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.99.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Background IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Patent Rights, Know-How and other intellectual property rights: (a) in existence and owned or otherwise controlled by Gilead or its Affiliates as of the Effective Date; or (b) invented, conceived, discovered or otherwise made outside of this Agreement and owned or otherwise controlled by Gilead or its Affiliates after the Effective Date, but during the Term.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.100.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, collectively, the Gilead Collaboration Know-How and the Gilead Collaboration Patents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.101.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Collaboration Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Collaboration Know-How other than (a) Gritstone Collaboration Know-How; or (b) Joint Collaboration Know-How.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.102.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Collaboration Patents other than (a) Gritstone Collaboration Patents; or (b) Joint Collaboration Patents.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.103.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Composition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any HIV Antigen [**] provided by or on behalf of Gilead under the Agreement, and any nucleic acid encoding such HIV Antigen [**], including [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.104.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.105.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Licensed Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Know-How Controlled by Gilead or any of its Affiliates as of the Effective Date or during the Term, other than Joint Collaboration Know-How, that is (a) [**] for Gritstone to conduct any Gritstone R&amp;D Activities or any of its activities under the Supply Agreement, in each case in accordance with this Agreement or the Supply Agreement, as applicable; and (b) either (i) [**] by Gilead to Gritstone [**] for use in such activities, (ii) relate to Gilead Compositions or Gilead Materials transferred by Gilead to Gritstone under this Agreement, or (iii) constituting Gilead Collaboration Know-How [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.106.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Licensed Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Patent Right Controlled by Gilead or any of its Affiliates as of the Effective Date or during the Term, other than Joint Collaboration Patents, that (a) claims any Gilead Licensed Know-How; or (b) is otherwise [**] for Gritstone to conduct any Gritstone R&amp;D</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Activities or any of its activities under the Supply Agreement, in each case in accordance with this Agreement or the Supply Agreement, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.107.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all Gilead Licensed Know-How, Gilead Licensed Patents and any Materials Controlled by Gilead or any of its Affiliates as of the Effective Date or during the Term that are provided to Gritstone for use in the performance of the Gritstone R&amp;D Activities or Gritstone&#x2019;s activities under the Supply Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.108.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.109.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead R&amp;D Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.110.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">GLP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and analogous Applicable Laws of an applicable Regulatory Authority and all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.111.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">GMP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the then-current standards, practices and procedures concerning Good Manufacturing Practice promulgated or endorsed by a Regulatory Authority of competent jurisdiction, including: (a) section 501(a)(2)(B) of the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351(a)(2)(B)); (b) relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including Parts 11, 210, 211, 600, and 610); (c) EU Commission Directive 2003/94/EC; (d) the European Community Guide to Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, in Volume 4 of the European Commission&#x2019;s Rules Governing Medicinal Products in the European Union; (e) ICH Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; (f) analogous Applicable Laws of an applicable Regulatory Authority at the time of Manufacture; and (g) all additional Regulatory Authority documents, regulations, policies, guidances, or guidelines, that replace, amend, modify, supplant, or complement any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.112.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">GMP Supply Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Supply Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.113.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Good Faith Efforts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a stated goal of a Party, that such Party will use good faith efforts to achieve such goal; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref61"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.114.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Governmental Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> federal, state, local, municipal, foreign or other government; </font><font id="docxtextref62"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> governmental or quasi-governmental authority of any nature (including any agency, board, body, branch, bureau, commission, council, department, entity, governmental division, instrumentality, office, officer, official, organization, representative, subdivision, unit and any court or other tribunal); </font><font id="docxtextref63"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> multinational governmental organization or body; or </font><font id="docxtextref64"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature (including any arbiter).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.115.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.116.	&#x201c;[**]&#x201d; means that certain [**] by and between Gritstone, on the one hand, and [**], on the other hand, dated as of [**] and as may be further amended from time to time in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.5.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.117.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Background IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Patent Rights, Know-How and other intellectual property rights: (a) in existence and owned or otherwise Controlled by Gritstone or its Affiliates</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">as of the Effective Date; or (b) invented, conceived, discovered or otherwise made outside of this Agreement and owned or otherwise Controlled by Gritstone or its Affiliates after the Effective Date, but during the Term, in each case ((a) and (b)) that is necessary or reasonably useful to Exploit the Product in the Field of Use in the Territory.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.118.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Background Patent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Patent Right within the Gritstone Background IP.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.119.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means collectively, the Gritstone Collaboration Know-How and Gritstone Collaboration Patents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.120.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Collaboration Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any Know-How within the Collaboration Know-How that:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.120.1.	  is conceived, discovered or otherwise made [**]; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.120.2.	  is conceived, discovered or otherwise made [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.121.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any Collaboration Patents that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.121.1.	  are invented [**]; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.121.2.	  are invented [**];</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.121.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">  provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that [**], all Patent Rights within [**] will be considered Gritstone Collaboration Patents for purposes of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.122.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone In-License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any contract or agreement with a Third Party (a) (i) pursuant to which Gritstone in-licenses, or otherwise acquires, Control of Patent Rights, Know-How or other intellectual property rights that constitute Licensed Technology for purposes of this Agreement that is set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.122</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as of the Effective Date or (ii) that becomes an Existing In-License Agreements pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(h)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as of the date such agreement becomes an Existing In-License Agreement (each, ((i) and (ii)), an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing In-License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); or (b) that becomes a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as of the date such agreement becomes a Gritstone In-License Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.123.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.124.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.125.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Operational Documentation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means documents and information specifically related to the internal practices, policies, operating procedures, equipment and systems used by or on behalf of Gritstone or any of its Affiliates in carrying out its operations and activities, including all such documents and information maintained to comply with Applicable Law, which are (a) generally applicable to Gritstone&#x2019;s operations, facilities or equipment (e.g., with respect to calibration and environmental monitoring); and (b) [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.126.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Other Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; mean an Other Agent that is owned or exclusively licensed by Gritstone.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.127.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Platform Technologies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the ChAdV and SAM Platform Technology and the LNP Platform Technology.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.128.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Product Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.1(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.129.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Product-Related Agreement Selected Improvement IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.130.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone R&amp;D Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.131.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone R&amp;D Budget</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.132.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Reimbursable Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.133.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means human immunodeficiency virus.</font></p>
  <p style="text-indent:7.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.134.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HIV Antigen</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any [**], intended to stimulate an HIV specific immune response in humans.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref65"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.135.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">HSR Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> U.S.C. &#167; 18a).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.136.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ICC Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.137.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">IND</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means an investigational new drug application (including any amendment or supplement thereto) submitted to the FDA pursuant to U.S. 21 C.F.R. Part 312, including any amendments thereto.  References herein to IND will include, to the extent applicable, any comparable filing(s) outside the U.S. for the investigation of any product in any other country or group of countries (such as a clinical trial application in the EU).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.138.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnification Claim Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.139.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnified Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.140.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnifying Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.141.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Gilead Indemnitee or a Gritstone Indemnitee, as the context requires.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.142.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.143.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Infringement Action</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.144.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Initial Outside Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.145.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Initiating Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(e)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.146.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Invention</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any invention or discovery that is created, conceived or reduced to practice.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.147.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Joint Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, collectively, the Joint Collaboration Know-How and Joint Collaboration Patents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.148.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Joint Collaboration Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Know-How within the Collaboration Know-How that (a) relates to [**]; (b) is not related to [**]; and (c) is conceived, discovered or otherwise made [**] jointly by or on behalf of Gritstone or any of its Affiliates, on the one hand, and by or on behalf of Gilead or any of its Affiliates, on the other hand.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.149.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Joint Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Collaboration Patents that (a) relate to any [**]; (b) are not related to any [**]; and (c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">claim Joint Collaboration Know-How.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.150.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Joint Steering Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">JSC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.151.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">JSC Co-Chair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.152.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means algorithms, data, Inventions, methods (including methods of use or administration or dosing), practices, results, software, techniques, technology and trade secrets, including analytical and quality control data, analytical methods (including applicable reference standards), assays, batch records, chemical structures and formulation information, compositions of matter, formulae, manufacturing data and information, pharmacological, toxicological and clinical test data and results, processes, reports, research data, research tools, sequences, standard operating procedures and information of a scientific or technical nature, in each case, whether patentable or not, and, in each case, tangible manifestations thereof, excluding any Regulatory Materials and Gritstone Operational Documentation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.153.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Knowledge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to Gritstone, [**]; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that with respect to the &#x201c;Knowledge&#x201d; of [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.154.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Gritstone Background Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Licensed Know-How within the Gritstone Background IP, excluding, for clarity, any Collaboration Know-How.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.155.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Gritstone Background Patent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Licensed Patent within the Gritstone Background IP, excluding, for clarity, any Collaboration Patent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.156.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Gritstone Background Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Licensed Gritstone Background Know-How and Licensed Gritstone Background Patents.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.157.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Know-How Controlled by Gritstone or any of its Affiliates [**] (including Gritstone Collaboration Know-How, but excluding Joint Collaboration Know-How) which is [**] to Exploit any Product in the Field of Use in the Territory, but excluding any Know-How within the Excluded Technology.  For clarity, Licensed Know-How excludes any Licensed Patents.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.158.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Patent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Patent Right Controlled by Gritstone or any of its Affiliates [**] (including Gritstone Collaboration Patents, but excluding Joint Collaboration Patents) which is [**] to Exploit any Product in the Field of Use in the Territory, but excluding any Patent Rights within the Excluded Technology.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.159.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Licensed Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, collectively, all Licensed Patents and Licensed Know-How.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.160.	&#x201c;[**]&#x201d; means that certain [**] between Gritstone and [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.161.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">LNP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means lipid nanoparticle technology.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.162.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">LNP Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.163.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Losses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.164.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">MAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a BLA, a marketing authorization application submitted to the EMA or to the competent Regulatory Authority of a member state of the EU or any equivalent filing in a country or regulatory jurisdiction other than the U.S. or EU with the applicable Regulatory Authority, and all amendments and supplements thereto, to obtain marketing approval for a pharmaceutical or biological product, in a country or in a group of countries.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.165.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Major European Market</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means each of France, Germany, Italy, Spain and the United Kingdom.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.166.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Manufacture</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all activities related to the manufacturing of a product or any component or ingredient thereof, including the production, manufacture, having manufactured, processing, filling, finishing, packaging, labeling, shipping and holding of product or any intermediate thereof, including process development, process qualification and validation, scale-up, commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.  For clarity, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Manufacture</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; does not include Research, Development, or Commercialization.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.167.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Manufacturing Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.168.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Material Breach</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a breach of this Agreement which is material to the rights and obligations of the Parties and the transactions contemplated by this Agreement, taken as a whole.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.169.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Material Manufacturing Improvement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a [**] that is Controlled by Gritstone or any of its Affiliates with respect to the Manufacturing process for a [**], including [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.170.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Material Platform Improvement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a [**] that is Controlled by Gritstone or any of its Affiliates with respect to the Gritstone Platform Technology, including [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.171.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.172.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.173.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Milestones</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the Development Milestone Events and Sales Milestone Events.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.174.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Net Receipts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.175.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Net Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**]:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">With respect to [**], the following will apply:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.176.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">New License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.1.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.177.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Breaching Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.178.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Challenging Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.179.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Prosecuting Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.180.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Notice of Possible Option Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.181.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.182.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.183.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.184.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.185.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.186.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.187.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Other Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means an active agent, other than an HIV Antigen, including [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.188.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Other Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 1.42</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.189.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Outside Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.190.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Owned Licensed Gritstone Background Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Licensed Gritstone Background Technology owned by Gritstone.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.191.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Owned Licensed Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any and all Licensed Technology owned by Gritstone.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.192.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.193.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Patent Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all rights, title, and interests in and to: (a) all national, regional, and international patents and patent applications filed in any country of the world, including provisional patent applications and all supplementary protection certificates; (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority to any of the foregoing, including any continuation, continuation-in-part, divisional, provisional, converted provisional and continued prosecution application, or any substitute application; (c) any patent issued with respect to or in the future issued from any such patent applications, including utility models, petty patents, design patents, and certificates of invention; and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations, and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.194.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Patent Term Extensions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any patent term extension, supplementary protection certificate or similar extension.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.195.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Payee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Party receiving a payment under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.196.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Payor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Party owing or making a payment under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.197.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Per Product Annual Net Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.198.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, Governmental Authority or any other entity not specifically listed herein.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.199.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Pharmacovigilance Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.200.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phase 1 Clinical Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Clinical Trial that provides for the first introduction into humans of a pharmaceutical or biological product conducted in normal volunteers or patients to get information on product safety, tolerability, immunogenicity, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. &#167; 312.21(a) (or the foreign equivalent thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.201.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phase 1b Clinical Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Phase 1 Clinical Trial in the target patient population that is designed to establish safety and immunogenicity, which may also be designed to establish an initial indication of efficacy.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.202.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Phase 3 Clinical Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Clinical Trial of a pharmaceutical or biologic product on a sufficient number of patients, which trial the FDA permits to be conducted under an open IND and is designed to: (a) establish that the pharmaceutical or biologic product is safe and efficacious for its intended use; (b) define warnings, precautions and adverse reactions that are associated with the pharmaceutical or biologic product in the dosage range to be prescribed; and (c) together with other results, support an MAA to a Regulatory Authority for the pharmaceutical or biologic product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(c) and its successor regulation or equivalents in other jurisdictions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.203.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Pivotal Clinical Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any (a) Phase 3 Clinical Trial; or (b) other Clinical Trial of a pharmaceutical or biologic product on a sufficient number of patients, the results of which, together with prior data and information concerning such product, are intended to be or otherwise are sufficient, without any additional Clinical Trial to meet the evidentiary standard for demonstrating the safety, purity, efficacy, and potency of such product established by a Regulatory Authority in any particular jurisdiction and that is intended to support, or otherwise supports, the filing of an MAA to a Regulatory Authority in such jurisdiction (including any bridging study).  Notwithstanding any provision to the contrary set forth in this Agreement,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">treatment of patients as part of an expanded access program, compassionate sales or use program (including named patient program or single patient program), or an indigent program, in each case, will not be included in determining whether or not a Clinical Trial is a Pivotal Clinical Trial or whether a patient has been dosed thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.204.	&#x201c;[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**] Agreement between the Parties, [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.205.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Pricing Approval</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any approval, agreement, determination or decision establishing prices that can be charged to consumers for a pharmaceutical or biological product or that will be reimbursed by Governmental Authorities for a pharmaceutical or biological product, in each case, in a country where Governmental Authorities approve or determine pricing for pharmaceutical or biological products for reimbursement or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.206.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any product that contains, incorporates or otherwise includes a Vaccine, in any form, dosage strength or formulation for any method of administration [**] and does not include any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i) [**]; or (ii) [**].  All Products that [**], will be considered the same Product for purposes of this Agreement.  For clarity, a Product may constitute a Combination Product.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.207.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product Mark</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.208.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product-Specific Third Party IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.209.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecuting Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.210.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecution and Maintenance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecute and Maintain</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Patent Right, the preparation, filing, prosecution and maintenance of such Patent Right, as well as re-examinations, reissues, and appeals with respect to such Patent Right, together with the initiation or defense of interferences, oppositions, inter partes review, derivations, re-examinations, post-grant proceedings and other similar proceedings (or other defense proceedings with respect to such Patent Right, but excluding the defense of challenges to such Patent Right as a counterclaim in an infringement proceeding) with respect to the particular Patent Right, and any appeals therefrom.  For clarification, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecution and Maintenance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecute and Maintain</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will not include any other enforcement actions taken with respect to a Patent Right.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.211.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Publication</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.212.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Publishing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.213.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Qualifying Use of Gritstone Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.214.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the plan set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 2.1.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as may be updated from time to time pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.215.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all activities conducted solely or jointly by the Parties during the Option Term pursuant to the R&amp;D Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.216.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Team Review Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.217.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Receiving Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.218.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Regulatory Approval</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all approvals, licenses and authorizations of the applicable Regulatory Authority necessary for the marketing and sale of a pharmaceutical or biological product for a particular indication in a country or region (including separate Pricing Approvals, as applicable), and, as applicable, including the approvals by the applicable Regulatory Authority of any expansion or modification of the label for such indication.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.219.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Regulatory Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any national or supranational Governmental Authority, including the FDA, the EMA or any health regulatory authority in any country or region that is a counterpart to the foregoing agencies, in each case, that holds responsibility for development and commercialization of, and the granting of Regulatory Approval for, a pharmaceutical or biological product in such country or region.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.220.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Regulatory Exclusivity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the ability to exclude Third Parties from obtaining Regulatory Approval or Commercializing a Product in a country, either through data exclusivity rights (including as described in 42 U.S.C. &#167; 351(k)), orphan-drug exclusivity, pediatric exclusivity (including as</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">described in 42 U.S.C. &#167; 351(m)) or such other rights conferred by Applicable Laws or a Regulatory Authority in such country or jurisdiction, in each case, other than through Patent Rights.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.221.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Regulatory Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any submission to a Regulatory Authority of any appropriate regulatory application, including any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto.  For the avoidance of doubt, Regulatory Filings will include any IND or MAA.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.222.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Regulatory Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means Regulatory Filings, submissions, notifications, communications, correspondence, registrations, marketing approvals or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to develop, manufacture, market, sell or otherwise commercialize a Product in a particular country or jurisdiction, including INDs, BLAs, and other applications for marketing approval.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.223.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Research</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means activities related to the characterization, design, discovery, generation, identification, non-clinical or pre-clinical studies, pre-clinical development, analytical and process development, optimization, production, or profiling of vaccine candidates or products.  For clarity, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Research</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; does not include Development or Manufacturing.  When used as a verb, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Research</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means to engage in Research.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.224.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Response</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.225.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Reviewing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.226.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ROW</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all countries and territories of the world in the Territory other than the U.S.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.227.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.228.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalty Floor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.8.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.229.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalty Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.230.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sales Milestone Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.231.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sales Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.232.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SAM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a self-amplifying mRNA system.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.233.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Securities Regulator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3.1(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.234.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any [**] that relates to (i) [**] or (ii) [**].</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.235.	 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Patent Right within the Selected Collaboration IP.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.236.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.237.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Licensed Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1.2(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.238.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selling Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means Gilead, its Affiliates, or its Sublicensees, in each case, expressly excluding distributors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.239.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Senior Officers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to Gilead, its Chief Medical Officer or his or her designee, and, with respect to Gritstone, its Chief Executive Officer or his or her designee.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.240.	&#x201c;[**]&#x201d; means a [**] agreement between such Third Party and a Party, any of its Affiliates, or any of its or their respective licensees or sublicensees, which agreement was entered into in connection with [**] regarding such Third Party&#x2019;s ability to Exploit [**] in one or more countries [**] owned or controlled by such Party or its Affiliates; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that no such Third Party shall be deemed a [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.241.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Stock Purchase Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.242.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Subcontractor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a Third Party contractor engaged by a Party to perform certain obligations or exercise certain rights of such Party under this Agreement (for clarity, not including the performance of any obligations or exercise of any rights of Gritstone, its Affiliates or its or their sublicensees under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) on a fee-for-service basis (including contract research organizations, Third Parties acting as distributors, or CMOs), which Third Party is not otherwise granted licenses or other rights to Exploit Products.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.243.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sublicensees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Third Party to whom a Party, any of its Affiliates or any of its Sublicensees grants a sublicense of its rights hereunder to Exploit Products, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that [**], Sublicensees shall not include Subcontractors.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.244.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.245.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Supply Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.246.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.247.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.248.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Terminated Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means, with respect to: (a) the termination of this Agreement with respect to a Product, the Product subject to such termination; (b) the termination of this Agreement with respect to a country in the Territory, all Products in the country in the Territory subject to such termination; and (c) the termination of this Agreement in its entirety, all Products in all countries in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.249.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Territory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means all countries and territories of the world.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.250.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any Person other than a Party or an Affiliate of a Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.251.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Acquisition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.252.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Agreement-Governed Intellectual Property Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.253.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.254.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any amount paid or required to be paid by Gritstone pursuant to any Gritstone In-License Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.255.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transfer Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.256.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transferrable Manufacturing Improvement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.257.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transferrable Platform Improvement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means [**].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.258.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transition Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.259.	&#x201c;[**]&#x201d; means that certain [**], as may be amended from time to time in accordance with its terms and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.5.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.260.	&#x201c;[**]&#x201d; means that certain [**] between Gritstone [**], and as may be further amended from time to time in accordance with its terms.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.261.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">United States</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">U.S.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means the United States of America, its territories, and its possessions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.262.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vaccine</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means any vaccine developed under this Agreement, which vaccine (i) was developed from or otherwise uses the Gritstone Platform Technologies; and (ii) incorporates a ChAdV vector or a SAM vector, with or without LNP, that expresses one or more HIV Antigens; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such vaccine will not include any (1) [**] or (2) [**].</font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> For clarity, [**].</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">1.263.	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Valid Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means a claim in: (a) an issued and unexpired patent which has not been revoked or held unenforceable or invalid by a decision of a court, patent office, or other governmental agency of competent jurisdiction from which no appeal can be or has been taken within the time allowed for appeal, and which has not been disclaimed, donated to the public or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer, or otherwise; or (b) an [**].</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article II<br>Collaboration and Option</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.1.	Research and Development Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Each Party&#x2019;s Responsibilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will be responsible for conducting all activities assigned to it under the R&amp;D Plan, including conducting a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Clinical Trial of a Vaccine and, at Gilead&#x2019;s sole discretion, (a) one or more </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (such activities, collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead R&amp;D Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Gritstone will be responsible for performing all activities assigned to it under the R&amp;D Plan, including conducting any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">activities provided in such plan (such activities, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone R&amp;D Activities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Gritstone will perform, or have performed, all Gritstone R&amp;D Activities in accordance with the R&amp;D Plan and this Agreement.  Gritstone will not perform any activities with respect to a Product other than in accordance with the R&amp;D Plan or the Supply Agreement.  If the Gritstone R&amp;D Activities have not been completed prior to Gilead&#x2019;s delivery of an Option Exercise Notice pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, at Gilead&#x2019;s request, Gritstone will continue performing all remaining Gritstone R&amp;D Activities in accordance with the R&amp;D Plan and this Agreement and the license granted to Gritstone under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will survive until completion of the remaining Gritstone R&amp;D Activities or until Gilead otherwise requests that Gritstone stop performing such remaining Gritstone R&amp;D Activities.  Gilead will reimburse Gritstone for the Gritstone Reimbursable Costs incurred by Gritstone in performing or having performed </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in accordance with the Gritstone R&amp;D Budget.  Gritstone shall promptly inform Gilead upon Gritstone determining that it is likely to overspend or underspend by more than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> for such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">shall be deemed Gritstone Reimbursable Costs and reimbursed by Gilead </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Plan and Gritstone R&amp;D Budget</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The initial draft of the R&amp;D Plan agreed to by the Parties is attached hereto on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 2.1.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From time to time during the Option Term, and on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the JSC will review the then-current R&amp;D Plan for potential amendments.  Each Party&#x2019;s JSC</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">representatives will consider in good faith all such amendments proposed by the other Party&#x2019;s JSC representatives.  Any proposed amendments to the R&amp;D Plan will become effective only upon approval by the JSC, and subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The R&amp;D Plan will be consistent with the terms of this Agreement and will form a part of this Agreement.  In the event of an inconsistency between the R&amp;D Plan and this Agreement, the terms of this Agreement will prevail.  The R&amp;D Plan will be deemed the Confidential Information of each Party.  In addition, attached as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 2.1.2(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is a written budget for the Gritstone R&amp;D Activities, which budget includes </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (collectively, clause (a) and (b), the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone R&amp;D Budget</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Records</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will prepare and maintain complete and accurate written records of all activities performed as well as results and data obtained pursuant to the R&amp;D Plan, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.  In addition to the reporting obligations set forth herein, upon reasonable request of Gilead, Gritstone will grant Gilead and its Affiliates reasonable access to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that is generated in the course of performance of the R&amp;D Program in a format (e.g., remote web-access secured by end-user identity and authentication solutions or by other means providing a comparable, sufficient level of data security) reasonably acceptable to both Parties.  Gilead and its Affiliates will also have the right, at reasonable intervals and upon reasonable notice to Gritstone, to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All such records in their disclosed form will be deemed the Confidential Information of each Party (without affecting the ownership of or confidentiality and non-use obligations related to the information therein).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.1.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Reporting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will keep the other Party reasonably informed on the status, progress and results of its activities under the R&amp;D Plan through the regularly-scheduled JSC meetings described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  At least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">before each regularly-scheduled JSC meeting, each Party will submit to the JSC a written summary (in the form of a slide deck or as otherwise reasonably determined by such Party) of the status, progress and results of its activities under the R&amp;D Plan since its prior report.  The JSC will review and discuss the status, progress and results of the R&amp;D Program.  In addition, Gritstone will provide Gilead with a final written report within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following the completion of its activities under the R&amp;D Plan, which report will summarize the activities undertaken and all accomplishments achieved under the R&amp;D Plan.  All such summaries and reports in their disclosed form will be deemed the Confidential Information of each Party (without affecting the ownership of or confidentiality and non-use obligations related to the information therein).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.2.	Gilead Composition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Provision of Gilead Compositions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will provide Gritstone with Gilead Compositions consisting of HIV Antigens or otherwise as Gilead believes to be reasonably necessary for Gritstone to conduct its activities under the R&amp;D Plan or the Supply Agreement, in each case as set forth in the R&amp;D Plan.  All such Gilead Compositions will remain at all times the property of Gilead.  No such Gilead Compositions, or any derivatives, analogs, modifications or components thereof, may be transferred, delivered or disclosed to any Third Party other than a Third Party identified for such purpose in the R&amp;D Plan without the prior written approval of Gilead.  Gritstone and its Affiliates may only use, and will only permit the use by any permitted Third Party of, such Gilead Compositions provided to Gritstone as contemplated under the R&amp;D Plan or the Supply Agreement and for no other purpose.  Gritstone will not, and Gritstone will cause its Affiliates and permitted Third Party transferees to not, distribute or release any such Gilead Compositions to any Person other than Gritstone&#x2019;s or Gritstone Affiliate&#x2019;s or permitted Third Party&#x2019;s laboratory personnel under the direct supervision of Gritstone or a Gritstone Affiliate.  Gilead will have no obligation to provide to Gritstone additional Gilead Compositions beyond those consisting of HIV Antigens described in the R&amp;D Plan or the Supply Agreement.  Gritstone will not use, and will ensure that its Affiliates and permitted Third Party transferees (each as applicable) do not use, any such Gilead</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Compositions in connection with any Research, Development, Manufacturing or other activities that are subject to consulting or licensing obligations to any Third Party.  Gritstone will use, and will ensure that its Affiliates and permitted Third Party transferees (each as applicable) use, such Gilead Compositions in compliance with all Applicable Law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.2.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">No Warranties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  GRITSTONE UNDERSTANDS THAT ALL GILEAD COMPOSITIONS ARE SUPPLIED ON AN &#x201c;AS IS&#x201d; AND &#x201c;WHERE IS&#x201d; BASIS.  GRITSTONE ACKNOWLEDGES THAT GILEAD COMPOSITIONS ARE EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN HAZARDOUS CHARACTERISTICS, THAT GRITSTONE IS AWARE OF THE RISKS OF WORKING WITH EXPERIMENTAL MATERIAL AND THAT GRITSTONE WILL STRICTLY ADHERE TO PROPER LABORATORY PROCEDURES FOR HANDLING MATERIAL WITH UNKNOWN HAZARDS AND ANY OTHER INSTRUCTIONS PROVIDED BY GILEAD WITH RESPECT TO SUCH GILEAD COMPOSITIONS.  THE GILEAD COMPOSITIONS WILL NOT BE USED IN HUMANS BY OR ON BEHALF OF GRITSTONE OR ITS AFFILIATES.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.3.	Materials Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In addition to any Gilead Compositions transferred pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, during the Option Term, Gilead or Gritstone may also transfer to Gritstone or Gilead, as applicable, or its respective designee, certain biological or chemical materials (including assays) within such Party&#x2019;s or any of its Affiliates&#x2019; Control (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, as applicable, and together, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) that are designated for transfer in the R&amp;D Plan, which Materials will be used by the receiving Party solely to conduct the R&amp;D Plan; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that any transfer of such Materials by a Party to the other Party will be documented in a material transfer agreement executed by the Parties that sets forth the type, name and amount of Materials transferred, the recipient(s) and the date of the transfer.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> The receiving Party and any of its Affiliates or Subcontractors will have the right to use the Materials solely for conducting the R&amp;D Plan or as otherwise specified in the applicable material transfer agreement or for such other purposes as may be agreed to by the Parties in writing and for no other purposes.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.4.	Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Option Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone hereby grants to Gilead the exclusive option, exercisable at Gilead&#x2019;s sole discretion, to obtain the license set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (such exclusive option, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead may exercise the Option by delivering written notice of such exercise to Gritstone at any time after the Effective Date and before the earlier of (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after the earlier of (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (subject to extension under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, such notice, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and the date of delivery of such notice, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that the Option Term will be extended beyond </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> if (x) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (y) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In order to rely on the immediately foregoing proviso to extend the Option Term, Gilead must (1) provide Gritstone with written notice that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in a timely manner, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (2) promptly follow-up with written notice to Gritstone specifying </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gilead does not provide an Option Exercise Notice prior to the expiration of the Option Term, then Gilead&#x2019;s right to exercise the Option will terminate and Gritstone will have no further obligations to Gilead with respect to such Option and this Agreement will terminate.  Unless and until the Option Effective Date occurs, Gilead shall not, and shall cause its Affiliates and its or their Sublicensees not to, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disclosure Schedule Update(s)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In connection with Gilead&#x2019;s consideration of whether to exercise the Option, Gilead will have the right to provide Gritstone written notice requesting a Disclosure Letter (such notice provided pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Notice of Possible Option Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for clarity, that Gilead shall have the right to deliver an Option Exercise Notice without first delivering a Notice of Possible Option Exercise.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following Gritstone&#x2019;s receipt of the Notice of Possible Option Exercise, Gritstone will deliver to Gilead a written document,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">signed by a duly authorized officer of Gritstone (such letter, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosure Letter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), setting forth a schedule of exceptions to the representations and warranties in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as of the Disclosure Letter Date and a completed </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From the delivery of the Disclosure Letter until Gilead&#x2019;s exercise of the Option (and, as applicable, from the Option Exercise Date until the Option Effective Date), Gritstone shall have a right, but not an obligation, to further update the Disclosure Letter to reflect any further changes, supplements or amendments of which Gritstone becomes aware or as a result of an event, condition, fact or circumstance occurring during such period; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that if Gritstone or its Affiliates receives any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after the Disclosure Letter Date but before Gilead&#x2019;s exercise of the Option, Gritstone shall notify Gilead in writing no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The date on which Gritstone delivers any Disclosure Letter pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or any update to such Disclosure Letter pursuant to the immediately preceding sentence, shall be a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosure Letter Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; with respect to such Disclosure Letter or update thereto, as applicable.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">2.4.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Antitrust Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="ftc"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gilead determines that any filings, notices, applications or other submissions under Antitrust Law are necessary in connection with Gilead&#x2019;s exercise of the Option (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Antitrust Filing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then Gilead and Gritstone will submit such Antitrust Filings within a time that Gilead determines, in its sole discretion, is prudent, and in any event, no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after the Option Exercise Date; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that Gilead shall notify Gritstone in the Option Exercise Notice of any and all such Antitrust Filings that will or may be required.  In connection with any such Antitrust Filing, the Parties will furnish promptly to the United States Federal Trade Commission (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FTC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), the Antitrust Division of the United States Department of Justice (the &#x201c;</font><font id="doj"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">DOJ</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and any other applicable Governmental Authority any additional information requested within their authority under the HSR Act or other Antitrust Law, use commercially reasonable efforts to obtain antitrust clearance for the transactions contemplated hereunder as soon as practicable and otherwise cooperate with each other in any such governmental antitrust clearance process.  Gilead will bear all fees in connection with any filings under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and each Party will bear its respective attorneys&#x2019; fees and other expenses in connection therewith.  Notwithstanding the foregoing, nothing in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or otherwise in this Agreement will require either Party or its Affiliates to, in connection with obtaining antitrust clearance for the transaction contemplated hereunder, (i) propose, negotiate, effect or agree to, the sale, divestiture, license or other disposition of any assets or businesses of such Party or any of its Affiliates or otherwise take any action that limits its freedom of action with respect to, or its ability to retain, any of the businesses, product lines or assets of such Party or any of its Affiliates, or (ii) litigate or otherwise formally oppose any determination (whether judicial or administrative in nature) by a Governmental Authority seeking to impose any of the restrictions referenced in clause (ii) above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Effectiveness</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Following the Option Exercise Notice, Gilead may not exercise the license set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> unless and until: (i) the applicable waiting period provided by the HSR Act has expired or terminated and all other required antitrust clearances have been obtained (solely to the extent applicable to any Antitrust Filings) or (ii) the Option Exercise Date occurs, where Gilead determines no Antitrust Filings are required, in each case ((i) and (ii)), the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.&#x201d;  In addition, following the Option Exercise Notice, the Option Term will continue until the earlier of the Option Effective Date or the Outside Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="initial_outside_date"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Outside Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. If (i) Gilead determines any Antitrust Filings are necessary or advisable in connection with Gilead&#x2019;s exercise of the Option and (ii) the Option Effective Date does not occur on or before </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after the Option Exercise Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Initial Outside Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then Gilead may, in its sole discretion, provide written notice to Gritstone on or prior to the applicable Initial Outside Date to extend such Initial Outside Date by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the Initial Outside Date, as it may be extended, if applicable, the &#x201c;</font><font id="outside_date"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Outside Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that the Parties may mutually agree to extend the Outside Date if such extension is necessary for Gilead to litigate, defend against, or otherwise contest any challenge, claim,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">23</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">lawsuit or other cause of action in connection with the Gilead&#x2019;s exercise of the Option pursuant to or under any Antitrust Law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Further Assurances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the foregoing obligations in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, each Party will promptly notify the other of the receipt and content of any inquiries or requests for additional information made by any Governmental Authority in connection with Gilead&#x2019;s exercise of the Option and keep the other apprised on a prompt basis of the status of any such inquiry or request.  To the extent permitted under Applicable Law and subject to a joint defense agreement between the Parties and their respective counsel, each Party will promptly inform the other Party of any oral communication with, and provide copies of written communications with, any Governmental Authority regarding Gilead&#x2019;s exercise of the Option, and permit the other Party or its counsel to review in advance, and in good faith consider the views of the other Party or its counsel concerning, any submission, filing or communication (and documents submitted therewith) intended to be given to the applicable Governmental Authority(ies).  Except as prohibited by Applicable Law, no Party will independently participate in any meeting or conference call with any Governmental Authority in respect of any such filings, investigation or other such inquiry without giving the other Party prior notice of the meeting and, to the extent permitted by such Governmental Authority, the opportunity to attend and participate.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article III<br>LICENSES; EXCLUSIVITY</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.1.	Licenses to Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Collaboration License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to the terms and conditions of this Agreement, Gritstone hereby grants to Gilead and its Affiliates, during the Option Term, an exclusive (even as to Gritstone, except to the extent necessary or reasonably useful for Gritstone to perform (or have performed) the Gritstone R&amp;D Activities under the R&amp;D Plan in accordance with this Agreement), royalty-free, worldwide license, with the right to sublicense through multiple tiers (subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), under the Licensed Technology and Gritstone&#x2019;s right, title and interest in the Joint Collaboration IP, solely for the purpose of performing (or having performed) Gilead R&amp;D Activities in the Field of Use and for use in Regulatory Filings to enable such activities for Products in the Field of Use in the Territory; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that while such license permits Gilead to conduct Gilead R&amp;D Activities with respect to a Product that contains, incorporates or otherwise includes one or more Other Agents in addition to the Vaccine, Gritstone does not grant to Gilead and its Affiliates hereunder any license or other rights under Licensed Technology to Exploit any Other Agent.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Development and Commercial License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to the terms and conditions of this Agreement, Gritstone hereby grants to Gilead and its Affiliates an exclusive (even as to Gritstone), worldwide, royalty-bearing license, with the right to sublicense through multiple tiers (subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), under the Licensed Technology and Gritstone&#x2019;s right, title and interest in the Joint Collaboration IP, solely (subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) to Exploit all Products in the Field of Use in the Territory; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, however, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that, while such license permits Gilead to Exploit a Product that contains, incorporates or otherwise includes one or more Other Agents in addition to the Vaccine, Gritstone does not grant to Gilead and its Affiliates hereunder any license or other rights under Licensed Technology to Exploit any Other Agent.  Gilead covenants to Gritstone that Gilead and its Affiliates and its and their Sublicensees will not exercise the rights granted to it pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> unless and until the Option Effective Date occurs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sublicensing by Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead and its Affiliates may grant sublicenses under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to any Affiliate or Third Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that any sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">any Third Party will require Gritstone&#x2019;s prior written consent.</font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Any sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be consistent with the terms of this Agreement and will include confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of this Agreement.  Gilead will deliver to Gritstone notice of, and, upon Gritstone&#x2019;s written request, a copy of, any executed sublicense agreement granted by Gilead to a Third Party under any of the rights and licenses granted to it under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (which may be redacted to protect confidential information that is not necessary to confirm the scope of the sublicensed rights and compliance with this Agreement) no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following the execution thereof;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided, however,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that unless required pursuant to a Gritstone In-License Agreement under which a sublicense is granted by Gilead, Gilead shall not have such obligation to deliver notice and a copy of a sublicense agreement entered into with a Subcontractor solely for the purposes of the subcontracted activities.  In no event will Gilead or its Affiliates have a license under, or grant any Third Party a sublicense under, the Licensed Technology or Gritstone&#x2019;s interest in any Joint Collaboration IP for a purpose or activity outside the scope of the license grants set forth under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Gritstone In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Limitations on Sublicense Scope</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  With respect to any Licensed Know-How or Licensed Patents with respect to which Gilead receives a sublicense under any Gritstone In-License Agreement, the sublicenses granted under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> are subject to (i) any limitations under the applicable Gritstone In-License Agreements with respect to such sublicensed rights, including with respect to the scope of licensed products, the permitted field of use, the licensed territory and the scope of exclusivity (if any) (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for clarity, that in no event shall the sublicense granted by Gritstone to Gilead be greater in scope than provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), and (ii) terms governing prosecution, enforcement and defense of Licensed Know-How or Licensed Patents governed by the applicable agreements, including as further provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Existing In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone has provided to Gilead a true and complete copy of each Existing In-License Agreement as of the Effective Date.  Gilead shall cause its Affiliates, and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with all provisions of such Existing In-License Agreements to the extent applicable.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Future Core In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Upon adoption by Gilead of a potential Future Core In-License Agreement as a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to such Gritstone In-License Agreement.  Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(f)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone shall have the right to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead shall, and shall cause its Affiliates and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (including with respect to sublicensees and the Exploitation of any Product in the Field of Use) and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to applicable terms </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> governed by the applicable agreements, in each case, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Future Other In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Upon adoption by Gilead of a potential Future Other In-License Agreement as a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall, and shall cause its Affiliates and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to the extent applicable (including with respect to sublicensees and the Exploitation of any Product in the Field of Use) and either:  (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, with respect to such agreement or (ii) included in the copy of the such agreement provided to Gilead for review </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable based on Gritstone&#x2019;s election thereunder, or were consented to by Gilead in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Future Gritstone Product-Related Agreement Sublicense</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Upon adoption by Gilead of a potential Future Gritstone Product-Related Agreement Sublicense as a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall, and shall cause its Affiliates and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the extent applicable (including with respect to sublicensees and the Exploitation of any Product in the Field of Use) and either: (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, with respect to such agreement or (ii) included in the copy of the such agreement provided to Gilead for review </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(iii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable based on Gritstone&#x2019;s election thereunder, or were consented to by Gilead in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. If any question of interpretation arises with respect to any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, at the request of either Party, the Parties shall confer in good faith as requested by either Party from time to time and discuss approaches </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In the event that Gritstone requests any amendment to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall consider such requested amendment in good faith.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(g)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Compliance by Gilead Sublicensees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If a Sublicensee (of Gilead or its Affiliates) fails to comply with a Gritstone In-License Agreement in accordance with the requirements in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and either Gilead becomes aware or Gritstone provides notice of such failure to Gilead, then Gilead shall, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of becoming aware of such failure, either (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and, in the event of either (i) or (ii), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> this Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(except to the extent required to comply or maintain Gritstone&#x2019;s rights under such Gritstone In-License Agreement); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that Gilead shall remain responsible for the consequences of such breach.  In the event that Gritstone provides notice to Gilead of an alleged failure to comply under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, if the Parties in good faith disagree as to whether there has been a failure to comply, then: (1) Gilead may contest the allegation by referring such matter, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following its receipt of notice, for resolution in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (2) the relevant </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to such alleged failure to comply will be tolled from the date on which the disputing Party notifies the other Party of such Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement (provided that such tolling is consistent with the applicable Gritstone In-License Agreement and Gritstone&#x2019;s ability to comply with and maintain Gritstone&#x2019;s rights under such Gritstone In-License Agreement); and (3) if it is ultimately determined that such failure to comply occurred, then Gilead will have the right to cure such failure to comply, after such determination, within the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> cure period in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, which will commence as of the date of such determination (to the extent such a cure is consistent with the applicable Gritstone In-License Agreement and Gritstone&#x2019;s ability to comply with and maintain Gritstone&#x2019;s rights under such Gritstone In-License Agreement).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(h)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or any other terms or conditions of this Agreement to the contrary, if Gilead requests a sublicense under Section 2.1(a) of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then (i) Gritstone will grant such sublicense to Gilead, (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">will be considered an Existing In-License Agreement as of the effective date of such sublicense, and (iii) in addition to being subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, such sublicense shall also subject to all the obligations and requirements of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as they pertain to any Product for which a sublicense is granted thereunder, including Sections </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and without limitation to the foregoing, Gilead hereby explicitly agrees to the requirements set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as required pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.1.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or any other terms or conditions of this Agreement to the contrary and subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the sublicense granted by Gritstone under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is, as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in each</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">26</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">case ((a) and (b)), in the Field of Use during the term of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For purposes of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">have the meanings given in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> has the meaning given </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> has the meaning given </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.2.	License to Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Collaboration License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to the terms and conditions of this Agreement, Gilead hereby grants to Gritstone, during the Option Term, a non-exclusive, royalty-free, worldwide license, with the right to sublicense through multiple tiers (subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) under the Gilead Licensed Technology solely for the purpose of performing (or having performed) the Gritstone R&amp;D Activities or Gritstone&#x2019;s activities under the Supply Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.2.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Grantback License</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Subject to the terms and conditions of this Agreement, Gilead hereby grants to Gritstone a non-exclusive, royalty-free, worldwide license, with the right to sublicense through multiple tiers (subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) under the Selected Collaboration IP </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that Gilead does not </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, further, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that such license does not include any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided, further, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In no event will Gritstone or its Affiliates have a license under, or grant any Third Party a sublicense under, the Selected Collaboration IP for a purpose or activity outside the scope of the license grant set forth under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.2.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sublicensing by Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone may not grant any sublicense of the rights granted to it under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> without the prior written consent of Gilead.  Any sublicense granted by Gritstone of the rights granted to it under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be consistent with the terms of this Agreement and will include confidentiality, non-disclosure and non-use provisions at least as restrictive or protective of the Parties as those set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of this Agreement.  Further, (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such sublicense shall be sufficient to satisfy the requirements of this clause (b) if </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will deliver to Gilead notice of, and, upon Gilead&#x2019;s written request, a copy of, any executed sublicense agreement granted by Gritstone of the rights granted to it under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (redacted as necessary to protect confidential information that is not necessary to confirm compliance with this Agreement) no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> following the execution thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.3.	Subcontracting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party may subcontract the performance of tasks and other obligations hereunder to its Affiliates or Third Parties (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), which subcontract may include a sublicense of rights necessary for the performance of the subcontract as reasonably required, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any such Third Party will not be deemed to be a Sublicensee solely as a result of such sublicense to the extent granted to enable the performance by the subcontractor of the subcontracted activities.  Notwithstanding any other term or condition of this Agreement, in the event that the R&amp;D Plan provides for Gritstone to conduct or have conducted any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and Gritstone engages </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to perform such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">: (a) such performance may, at Gritstone&#x2019;s election, be conducted under the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (b) the terms of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall be deemed to meet all requirements for subcontracts under this Agreement and (c) Gritstone shall be deemed in compliance with all its applicable obligations under this Agreement with respect to the engagement of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to perform such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.4.	No Other Rights; Retained Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party expressly reserves and retains all Patent Rights, Know-How or other intellectual property rights not expressly granted herein, and no right or license under any Patent Rights, Know-How or other intellectual property rights of either Party is granted or will be granted by implication.  Without limiting the immediately preceding sentence and for clarity, Gritstone will retain the right to use one or more HIV or SIV polypeptides in connection with Research outside the Field of Use.  Except as otherwise expressly provided in this Agreement, neither Party will receive any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">27</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">rights under this Agreement to own, use, or access the Patent Rights, Know-How, or other intellectual property rights of the other Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.5.	Exclusivity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exclusivity Obligation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exception for Third Party Acquisition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, except in the case of a Change of Control (which is governed by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.3)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, if Gritstone or its Affiliates acquires a Third Party (whether such acquisition occurs by way of a purchase of assets, merger, consolidation, change of control or otherwise) (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Acquisition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) that is, prior to such acquisition, researching, developing, manufacturing or commercializing a product where such activities, if conducted by Gritstone or its Affiliates at such time, would constitute a breach of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Competing Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then Gritstone will not be in breach of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as a result of such Third Party Acquisition; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gritstone provides written notice to Gilead no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following the closing of such Third Party Acquisition that such Third Party Acquisition occurred and whether it elects to either: (x) include such Competing Product as a Product within the scope of this Agreement (subject to Gilead&#x2019;s prior written approval), in which case such Competing Product in the Field of Use will be deemed a Product and be subject to the terms and conditions of this Agreement; (y) divest its rights in and to such Competing Product in the Field of Use, in which case, Gritstone and the Acquired Person will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Divestment Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) in which event the continued Exploitation of such Competing Product during the Divestment Period while the divestment is being pursued shall not constitute a breach of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gritstone and the Acquired Person </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (z) cease all research, development, manufacturing and commercialization activities with respect to such Competing Product in the Field of Use, in which case, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">except in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  No Licensed Technology, Joint Collaboration IP or Gritstone&#x2019;s Confidential Information shall be used in connection with any subsequent performance of any such activities with respect to any such Competing Products in the Field of Use following the consummation of such Third Party Acquisition.  In the event that, following notice to Gilead that Gritstone (or its Affiliate) intends to pursue divestment of the applicable Competing Product pursuant to clause (y) of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, such divestment is not completed during the Divestment Period, Gritstone shall notify Gilead whether it would like to elect to include such Competing Product as a Product pursuant to clause (x) above (subject to Gilead&#x2019;s consent) or cease all research, development, manufacturing and commercialization activities with respect to such Competing Product in the Field of Use pursuant to clause (z) above (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that in such case such activities shall be required to cease within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> except in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">).  In the event that, following notice to Gilead that Gritstone (or its Affiliate) would like to include such Competing Product as a Product under this Agreement but Gilead does not approve of such inclusion, Gritstone shall notify Gilead whether it elects to divest its rights to such Competing Product pursuant to clause (y) above or cease all research, development, manufacturing and commercialization activities with respect to such Competing Product in the Field of Use pursuant to clause (z) above (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that in such case such activities shall be required to cease </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> except in the case of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  As used herein, &#x201c;divest&#x201d; means, with respect to a Competing Product, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Exception for Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the foregoing, in the event of a Change of Control of Gritstone, from and after the date of such Change of Control, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.5.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Certain Third Party Arrangements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead acknowledges that (a) prior to the Effective Date, Gritstone entered into (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (iii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, pursuant to which, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (b) following the Effective Date, Gritstone may </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> pursuant to which Gritstone may </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> similar terms to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">28</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">those contained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to be subject to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone shall provide Gilead with notice of, and, upon Gilead&#x2019;s written request, a redacted copy of, any such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> The Parties agree that this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is not intended and shall not be construed to restrict the agreements described in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and Gritstone&#x2019;s continued performance of such obligations will not be considered a breach of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone represents, warrants and covenants </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) would or will require Gritstone or its Affiliates to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.6.	Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.6.1.	If Gritstone undergoes a Change of Control during the Term, then Gilead shall have the right, in its sole and absolute discretion, by written notice delivered to Gritstone (or its successor) at any time following the written notice contemplated in clause (a) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, to modify the Parties rights and obligations under this Agreement in any or all of the following ways, effective as of the date Gilead delivers such notice to Gritstone: (a) Gilead will have the right to conduct any activities allocated to Gritstone under the R&amp;D Plan (and will have final decision-making authority at the JSC with respect to any such assumed activities or the costs thereof), (b) Gilead will have the right terminate the Supply Agreement and assume responsibility for supply of Vaccine, and (c) Gilead will have the right to immediately dissolve the JSC with any decisions formerly to be made by the JSC under this Agreement to be made (i) mutually by the Parties (subject to the final decision-making authority principles as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable) or (ii) with respect to any activities Gilead elects to conduct as described in clause (a), by Gilead.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">3.6.2.	Gritstone covenants that, following such Change of Control, there shall be no material change in the level or nature of efforts or resources expended by Gritstone and its Affiliates in the performance of Gritstone&#x2019;s obligations under this Agreement, which material change would reasonably be expected to adversely impact (a) Gritstone&#x2019;s ability to perform its obligations under this Agreement or (b) the Exploitation of any Product under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article IV<br>GOVERNANCE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.1.	Joint Steering Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Formation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Promptly after the Effective Date, the Parties will establish a joint steering committee (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Joint Steering Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">JSC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) to coordinate, oversee and, as applicable, approve the Parties&#x2019; activities under this Agreement during the Option Term until dissolution of the JSC pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The JSC will dissolve upon the earlier of (a) Gilead&#x2019;s exercise of the Option, (b) termination of this Agreement or (c) dissolution by Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in the event Gritstone undergoes a Change of Control;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that if Gilead exercises the Option prior to completion of the R&amp;D Plan, Gilead may elect for the JSC to remain intact until completion of all activities under the R&amp;D Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The JSC will consist of three (3) representatives from each of the Parties (or such other equal number of representatives as the JSC may determine), each with the requisite experience and seniority to enable such person to make decisions on behalf of such Party with respect to the issues falling within the jurisdiction of the JSC.  From time to time, each Party may substitute one (1) or more of its representatives on the JSC upon written notice to the other Party.  Gilead will designate one (1) of its JSC representatives as one (1) of the co-chairpersons of the JSC, and Gritstone will designate one (1) of its representatives as the other co-chairperson of the JSC (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">JSC Co-Chair</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  The JSC Co-Chairs, in consultation with the Alliance Managers, will have the following roles and responsibilities: (a) to call meetings, send notice of each such meeting and designate the time, date and place of each such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">29</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">meeting; (b) to convene or poll the representatives by other permitted means; and (c) to approve (including via email) the final minutes of any meeting of the JSC.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Meetings and Minutes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Unless otherwise agreed by the Parties, until dissolution of the JSC pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the JSC will meet quarterly to address matters within its jurisdiction.  Meetings of the JSC may be held in person or by audio or video teleconference; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that unless otherwise agreed by the Parties, the location of any such in-person meetings will alternate between locations designated by Gilead and locations designated by Gritstone.  The JSC Co-Chairs will be responsible for scheduling meetings and setting agendas based on the input of each Party.  The JSC Co-Chairs will prepare and circulate for review and approval of the Parties minutes of each meeting promptly after the meeting.  The Parties will agree on the minutes of each meeting promptly, but in no event later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Business Days after receipt of such meeting minutes.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Procedural Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The JSC will have the right to adopt such standing rules as will be necessary for its work to the extent that such rules are not inconsistent with this Agreement.  A quorum will exist whenever there is present at a meeting at least two (2) representatives appointed by each Party.  The JSC will take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having a single vote irrespective of the number of representatives of such Party in attendance, or by a written resolution signed by at least two (2) representatives appointed by each Party.  Employees or consultants of either Party that are not representatives of the Parties on the JSC may attend JSC meetings with prior notice and with respect to any consultants, prior consent, of the other Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that such attendees: (a) will not vote; (b) will not be counted when determining whether a quorum exists at any such meeting; and (c) will be bound by obligations of confidentiality and non-disclosure equivalent to those set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.1.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Specific Responsibilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Until dissolution of the JSC pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the JSC&#x2019;s responsibilities are as follows: (a) coordinating and serving as a forum for discussing the Parties&#x2019; activities under the R&amp;D Plan; (b) reviewing and approving any amendments to the R&amp;D Plan proposed by either Party; (c) reviewing and approving any amendments to the Gritstone R&amp;D Budget proposed by either Party; (d) resolving disputes that arise in connection with the performance of the R&amp;D Plan; (e) coordinating and serving as a forum for discussing the Parties&#x2019; activities under the Supply Agreement; (f) resolve matters presented by any ad hoc committee that are within the scope of responsibilities delegated to such ad hoc committee by the JSC; and (g) fulfilling such other responsibilities as may be allocated to the JSC under this Agreement, the Supply Agreement or by mutual written agreement of the Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.2.	Dispute Resolution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">JSC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If after reasonable discussion and good faith consideration of each Party&#x2019;s view on a particular matter before the JSC and within the scope of its authority, the representatives of the Parties on the JSC cannot reach consensus as to such matter in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after such matter was brought to the JSC for resolution, then either Party may refer such disagreement to the Senior Officers for resolution.  If the Senior Officers cannot resolve such matter within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after such matter has been referred to them in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the foregoing but subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, without </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, no decision of the JSC </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> may be adopted, in each case, (a) to the extent pertaining to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (b) with respect to or that may result in a material change </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; or (c) with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that may (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">4.2.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Limitations on Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will retain the rights, powers and discretion granted to it under this Agreement, and no such rights, powers or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights, powers or discretion is expressly provided for in this</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">30</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Agreement or the Parties expressly so agree in writing.  The JSC will not have the power to amend, modify or waive compliance with this Agreement or the Supply Agreement, which may only be amended, modified or waived as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or the Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.3.	Alliance Managers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Promptly following the Effective Date, each Party will appoint (and notify the other Party of the identity thereof in writing) one (1) senior representative having a general understanding of therapeutic vaccine Research and Development to act as its alliance manager under this Agreement (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Alliance Manager</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  The Alliance Managers will serve as the contact points between the Parties and will be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties, including: (a) facilitating periodic communications between the Parties in connection with the Parties&#x2019; reporting requirements; (b) providing single-point communication for seeking consensus both internally within the respective Party&#x2019;s organization and together regarding key global strategy and planning issues, as appropriate, including facilitating review of external corporate communications; (c) raising cross-Party or cross-functional disputes in a timely manner; and (d) consulting with the JSC Co-Chairs, in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 4.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Alliance Manager may be a member of the JSC and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">vice versa</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that such Alliance Manager has the requisite experience and seniority to enable such person to make decisions on behalf of such Party with respect to the issues falling within the jurisdiction of the JSC.  From time to time, each Party may substitute its Alliance Manager at any time upon written notice to the other Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.4.	Ad-Hoc Committees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  By mutual agreement, the JSC may establish and disband ad-hoc committees having such responsibilities as may be expressly delegated by the JSC;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that the JSC may not grant any responsibilities to an ad-hoc committee that are beyond the scope of the responsibilities of the JSC as set forth herein.  Each such committee will consist of the number of representatives that is mutually agreed upon by the Parties.  Each Party shall be free to change its representatives on any such committee by notice to the other Party or to send substitute representatives to any meeting of any such committee (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that any non-employee representatives must receive prior approval of the JSC to attend committee meetings).  Each Party&#x2019;s representatives and any substitutes for such representatives on any such committee shall be bound by obligations of confidentiality and non-disclosure equivalent to those set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  No such committee shall have the authority to bind the Parties hereunder.  Each such committee shall make recommendations to, and any unresolved disputes shall be referred for resolution to, the JSC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">4.5.	Costs of Governance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties agree that the costs incurred by each Party in connection with its participation at any meetings under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article IV</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be borne solely by such Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article V<br>TECHNOLOGY TRANSFERS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5.1.	Disclosure of Know-How</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.1.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Initial Know-How Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will provide to Gilead copies of the Licensed Know-How (other than Licensed Know-How relating to the Manufacture of Products, any transfer of which will be performed under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or pursuant to the Supply Agreement as provided therein) that (a) exists as of the Effective Date, (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (c) is either (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (ii) otherwise reasonably requested by Gilead, in each case no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in a format reasonably acceptable to both Parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">31</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.1.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Periodic Know-How Transfers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	At Gilead&#x2019;s request, the Parties shall meet and confer in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, through research or development colleagues that each Party may designate from time to time, regarding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (any such meeting, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">R&amp;D Team Review Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Gritstone shall use </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Such meetings shall occur </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and thereafter on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or as otherwise mutually agreed until </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	As Gilead may reasonably request </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following each R&amp;D Team Review Meeting, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will provide to Gilead copies of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and that is (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; or (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and, in each case ((a) and (b)), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, with respect to any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that is Controlled by Gritstone or its Affiliates </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone&#x2019;s obligations to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">shall be subject to the applicable </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable.  Gritstone shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in a format reasonably acceptable to both Parties, with respect to such Selected Licensed Data.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Licensed Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; means </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	As Gilead may reasonably request </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> following any such R&amp;D Team Review Meeting, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will provide to Gilead copies of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, with respect to any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that is Controlled by Gritstone or its Affiliates </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone&#x2019;s obligations to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall be subject to the applicable </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable with respect to such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in a format reasonably acceptable to both Parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the foregoing, to the extent reasonably requested by Gilead for Gilead&#x2019;s conduct of Gilead R&amp;D Activities or Gilead&#x2019;s Exploitation of any Vaccine component of a Product pursuant to this Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone shall consider in good faith any other reasonable requests from Gilead for Gritstone to transfer Licensed Know-How not otherwise covered by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (other than Licensed Know-How relating to the Manufacture of Products, which shall be addressed under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or under the Supply Agreement).  For clarity, safety data exchanges will occur pursuant to the Pharmacovigilance Agreement entered into pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5.1.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Limitations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the foregoing or any term or condition of this Agreement, unless Gritstone otherwise agrees in writing, Gritstone shall not have an obligation to provide or license to Gilead under this Agreement (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and this Agreement shall be deemed to exclude such data (under clauses (a) and (b)) from the Licensed Technology licensed to Gilead in this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall not modify Gritstone&#x2019;s obligations pursuant to the last sentence of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or under the Pharmacovigilance Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5.2.	Consultation and Assistance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In addition to providing copies of the relevant Licensed Know-How in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will make its personnel reasonably available to Gilead, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, so as to enable Gilead to practice the Licensed Technology in connection with its performance of the Gilead R&amp;D Activities and the Exploitation of the Products (and any components thereof).  To the extent reasonably requested by Gilead after Gilead&#x2019;s exercise of the Option, Gritstone will provide technical assistance and support to enable Gilead to utilize Licensed Know-How with respect to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for use Exploiting the Products (and any components thereof), including by coordinating with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to request that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> provide reasonable ongoing technical support in connection with the foregoing </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (it being understood that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is not obligated to provide such support pursuant to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">).  If Gilead requests assistance pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VI<br>DEVELOPMENT AND REGULATORY MATTERS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.1.	Development</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From and after the Option Effective Date, Gilead will be solely responsible for conducting all Development activities with respect to Products in the Field of Use in the Territory, at Gilead&#x2019;s sole expense.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.2.	Development Reports</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From and after the Option Effective Date, Gilead will provide to Gritstone within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after the end of each </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">a written report, substantially in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, which </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> during the prior </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to Products in the Field of Use in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each report will be the Confidential Information of Gilead.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.3.	Regulatory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">General Responsibility</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From and after the Effective Date, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as between the Parties, Gilead will have the sole right (and will solely control, at its discretion), itself or with or through its Affiliates, Sublicensees or other Third Parties, to: (a) prepare and submit to applicable Regulatory Authorities all Regulatory Materials, including INDs, for Products; (b) obtain and maintain all Regulatory Approvals for Products; and (c) conduct communications with the Regulatory Authorities for the Products.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Gritstone Responsibility</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  As between the Parties, during the Option Term, Gritstone will be responsible for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, except that Gilead shall remain responsible for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (subject to the foregoing proviso) in a timely manner to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (c) timely prepare </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (d) provide timely support </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the foregoing, Gritstone will assist Gilead as may be reasonably requested by Gilead in connection with Gilead&#x2019;s preparation, submission to Regulatory Authorities and maintenance of Regulatory Materials for respective Products, including Gilead&#x2019;s preparation for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the foregoing or any term or condition of this Agreement, including </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in no event will Gilead have </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Ownership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All Regulatory Materials generated under this Agreement with respect to any Product, including in the course of the R&amp;D Program, will be owned by and held in the name of Gilead or its designee.  Nothing contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is intended or shall be construed to convey to Gilead any ownership of any Licensed Know-How contained in any such Regulatory Materials or any Gritstone Operational Documentation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Communication with Regulatory Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For clarity and without limiting </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will have the exclusive right to correspond or communicate with Regulatory Authorities regarding the Products and other regulatory matters in the Field of Use under this Agreement.  Unless required by Applicable Law, Gritstone, its Affiliates and its Subcontractors will not correspond or communicate with Regulatory Authorities regarding any Product without first, in each case, obtaining Gilead&#x2019;s prior written consent, either during or after the Option Term; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that, upon Gilead&#x2019;s request, Gritstone or its Affiliates will attend any meeting with a Regulatory Authority regarding any Product.  If Gritstone, its Affiliates or its Subcontractors receive any correspondence or other communication from a Regulatory Authority regarding a Product, Gritstone will provide Gilead with access to or copies of all such material written or electronic correspondence promptly (and in any event, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) after its receipt.  If any correspondence, communication or meeting with a Regulatory Authority regarding the Products or other regulatory matters in the Field of Use under this Agreement concerns a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gritstone has any correspondence, communication or meeting with a Regulatory Authority </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">33</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">6.3.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Right of Reference; Access to Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead and its designees will have, and Gritstone (on behalf of itself and its Affiliates) hereby grants to Gilead and its designees, a right of reference (without any further action required on the part of Gritstone or its Affiliates, except as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, whose authorization to file this consent with any Regulatory Authority is hereby granted) to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and its designees to exercise its rights and perform its obligations under this Agreement with respect to the applicable Products in the Field of Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In the interim, Gilead and its designees will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and Gritstone will ensure that Gilead and its designees </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in a format reasonably acceptable to both Parties.  During the Term, with respect to other products or programs of Gritstone or its Affiliates, upon Gilead&#x2019;s reasonable request for rights of reference with respect to Regulatory Materials Controlled by Gritstone and its Affiliates with respect to other products and programs, as may be reasonably useful to Gilead with respect to the Vaccine component of any Product, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.4.	Development Diligence</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Beginning as of the Option Effective Date and subject to the terms and conditions of this Agreement, Gilead will itself, or with or through its Affiliates, Sublicensees or other Third Parties, use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in the Field of Use; and (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For clarity, subject to compliance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the other applicable terms and conditions of this Agreement, the Development of Products will be in Gilead&#x2019;s sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.5.	Pharmacovigilance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Prior to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Parties will agree upon and implement a procedure for the mutual exchange of adverse event reports and safety information associated with the Products.  Details of the operating procedure respecting such adverse event reports and safety information exchange will be the subject of a mutually-agreed written pharmacovigilance agreement between the Parties which will be entered into within the same period (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Pharmacovigilance Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.6.	Compliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party agrees that in performing its obligations under this Agreement, it: (a) will comply with all Applicable Law, including applicable current international regulatory standards, such as GMP, GLP, GCP, and other rules, regulations, and requirements; and (b) will not employ or use any person that has been debarred under Sections 306(a) or 306(b) of the FDCA.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.7.	Regulatory Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In the event that: (a) based on the results of an audit or inspection by a Regulatory Authority of any facility of a Party (including its CRO or CMO, subject to the terms of such Party&#x2019;s contract with such CRO or CMO) involved in the Research, Development or Manufacture of a Product, a Regulatory Authority notifies such Party in writing of a finding; or (b) a Regulatory Authority takes, or gives notice in writing of its intent to take, any regulatory action with respect to any activity of a Party, in each case ((a) or (b)), which finding or action would reasonably be expected to have a material adverse effect on, with respect to Gritstone, its activities under any R&amp;D Plan or Manufacture of a Product or, with respect to Gilead, any activities under any R&amp;D Plan or the Research, Development, Manufacture or Commercialization of a Product, such Party will promptly notify the other Party thereof and provide a copy of such notice or summary of such action taken, as applicable.  Such notice, finding, action, and all information related thereto will constitute the Confidential Information of the disclosing Party.  Notwithstanding the foregoing, this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will terminate and be of no further force or effect, on a Product-by-Product basis, following First Commercial Sale of such Product.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VII<br>MANUFACTURING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.1.	Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Concurrent with the Effective Date,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the Parties will execute a supply agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) (and a corresponding quality agreement with customary terms and conditions) pursuant to which Gritstone will Manufacture and supply (a) Research Supply Product (as</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">34</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">defined in the Supply Agreement) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (b) GMP Supply Product containing </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to the extent necessary for approximately </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.2.	Manufacturing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the terms of the Supply Agreement and the Parties&#x2019; rights and responsibilities in connection with the R&amp;D Program as provided in the R&amp;D Plan, Gilead and its Affiliates or its Sublicensees will be solely responsible, at Gilead&#x2019;s expense, for the Manufacture of the Products being Developed or Commercialized under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.3.	Manufacturing Know-How and Assistance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In addition to its obligations under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and without limiting its obligations under the Supply Agreement, during the Term, Gritstone will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> provide assistance to Gilead or its designee, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, to enable Gilead or its designee, in an efficient and timely manner, to prepare for Manufacturing of the Product, it being understood that any Manufacturing technology transfer and support for obtaining Regulatory Approvals for Manufacturing shall be carried out pursuant to, and governed by, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limitation to any amounts due to Gritstone pursuant to the terms of the Supply Agreement, if Gilead requests assistance pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.4.	Manufacturing Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the other provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article VII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or Gritstone&#x2019;s obligations under the Supply Agreement, as soon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following the Option Effective Date or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of Gritstone (and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to complete no later than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> after the Option Effective Date or such written notice), Gritstone will transfer or cause to be transferred (from Gritstone, its Affiliates, or its CMOs) to Gilead and its designees copies (in writing and in an electronic format) of Licensed Know-How Controlled by Gritstone or its Affiliates with respect to the Manufacturing process for the Product supplied by Gritstone to Gilead pursuant to the Supply Agreement, as such Licensed Know-How is further described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in order to enable Gilead and its designees to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (such transfer, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Manufacturing Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Such transfers will include </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as such Licensed Know-How is further described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Promptly upon Gilead&#x2019;s initiation of the Manufacturing Technology Transfer, the Parties will meet and confer regarding the Licensed Know-How used by or on behalf of Gritstone to Manufacture Product for Gilead pursuant to the Supply Agreement and the Parties will update </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the extent reasonably requested by Gilead based on such discussions.  In addition, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (such period, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transition Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), Gritstone will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to Gilead and its designees </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in order to ensure an orderly transition of the Manufacturing technology and operations to Gilead and its designees and to assist Gilead and its designees pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in the Manufacture of the Products.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.5.	Future Manufacturing Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  At the request of either Party, the Parties shall meet and confer </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> during the period following the Manufacturing Technology Transfer and prior to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">regarding any Transferrable Manufacturing Improvements.  With respect to Transferrable Manufacturing Improvements </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will transfer or cause to be transferred (from its Affiliates or its CMOs) to Gilead and its designees copies (in writing and in an electronic format) of such Licensed Know-How detailing identified Transferrable Manufacturing Improvements, as is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to enable Gilead and its designees to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, with respect to any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that is Controlled by Gritstone or its Affiliates </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone&#x2019;s obligations </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">shall be subject to the applicable </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable, with respect to such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Operational Documentation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  To the extent reasonably requested by Gilead during the term of the Supply Agreement, Gritstone will permit Gilead pursuant to the audit provisions of the Supply Agreement to review, during regular business hours, the Gritstone Operational Documentation at Gritstone&#x2019;s facilities to the extent such documents or information is reasonably useful for Gilead to conduct Research, Development or Manufacturing activities under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">35</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transfer Limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding any term or condition of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article VII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (including </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) or this Agreement to the contrary, in no event shall Gritstone have any obligation to transfer, cause to be transferred or provide any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, unless Gilead has either (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in a form reasonably satisfactory to Gritstone </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article VIII<br>COMMERCIALIZATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">8.1.	Commercialization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  From and after the Option Effective Date, Gilead will be solely responsible for Commercializing Products in the Field of Use in the Territory, at Gilead&#x2019;s sole expense.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">8.2.	Commercialization Diligence</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Following Regulatory Approval of a Product in the Field of Use in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will itself, or with or through its Affiliates, Sublicensees or other Third Parties, use </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to Commercialize such Product in the Field of Use in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gilead&#x2019;s sublicense under the Genevant Agreement is in effect, following Regulatory Approval of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (for clarity, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) in the Field of Use in (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For clarity, subject to compliance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 8.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the other applicable terms and conditions of this Agreement, the Commercialization of the Products will be in Gilead&#x2019;s sole discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article IX<br>FINANCIAL PROVISIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.1.	Upfront Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In consideration of the licenses and rights granted to Gilead and its Affiliates hereunder, within [**] days following the Effective Date, Gilead will pay Gritstone a non-refundable, non-creditable, one-time upfront payment of Thirty Million Dollars ($30,000,000).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.2.	Equity Investment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Concurrently with the execution of this Agreement, the Parties will execute the Stock Purchase Agreement in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 9.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Stock Purchase Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), pursuant to which Gilead will purchase the Shares (as such term is defined in the Stock Purchase Agreement) on the terms set forth in the Stock Purchase Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.3.	Option Exercise Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In the event that Gilead exercises (in its sole discretion) the Option pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will pay Gritstone </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after receipt of an invoice from Gritstone for such payment (such payment, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Option Exercise Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  For clarity, Gritstone will not issue an invoice for the Option Exercise Fee until on or after the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">      </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.4.	Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Development Milestones</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In further consideration of the licenses and rights granted to Gilead and its Affiliates hereunder, Gilead will make one-time milestone payments to Gritstone set forth in Table 9.4.1 below upon the first achievement by Gilead or its Affiliates or Sublicensees of each of the development milestone events set forth in Table 9.4.1 below for the first Product to achieve such milestone event (the development milestone events set forth in Table 9.4.1, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and the development milestone payments set forth in Table 9.4.1, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  For the avoidance of doubt, each Development Milestone Payment hereunder will be payable only once upon the first achievement of the applicable Development Milestone Event.  If Gilead or its Affiliates or sublicensees achieve all Development Milestone Events, then the maximum amount payable by Gilead under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All payments to be made pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be made as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article X</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">36</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:76.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.482%;"></td>
    <td style="width:37.518%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Table 9.4.1 - Development Milestone Event</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Payment</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Commercial Milestones</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will make one-time milestone payments to Gritstone set forth in Table 9.4.2 below upon the achievement by Gilead or its Affiliates or sublicensees of each of the sales-based milestones events set forth in Table 9.4.2 below with respect </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (for each Product, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Per Product Annual Net Sales</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; and the sales-based milestone events set forth in Table 9.4.2, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sales Milestone Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,&#x201d; and the sales-based milestone payments set forth in Table 9.4.2, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sales Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; and together with the Development Milestone Payments, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  For purposes of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each of the Sales Milestone Payments set forth below will be payable only once upon the first achievement of the applicable Sales Milestone Event.  If Gilead or its Affiliates or sublicensees achieve all Sales Milestone Events, then the maximum amount payable by Gilead under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All payments to be made pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be made as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article X</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:67.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.395%;"></td>
    <td style="width:33.605%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Table 9.4.2 - Sales Milestone Event</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Sales Milestone Payment</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.5.	Royalty Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref290"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.5.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Royalty Rates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In further consideration of the licenses and rights granted to Gilead and its Affiliates hereunder, subject to the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, on a Product-by-Product basis, Gilead will pay to Gritstone royalties in the amount of the marginal royalty rates set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Table </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.5.1 below based on the Per Product Annual Net Sales for such Product (such payments, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  For purposes of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For clarity, the royalty tiers will be calculated </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All payments made pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be made as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article X</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.96%;"></td>
    <td style="width:28.04%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Table 9.5.1 - Pre Product Annual Net Sales</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(156,194,229,1);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalty Rate</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**], and less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**], and less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**], and less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**], and less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**], and less than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Portion of Per Product Annual Net Sales that is equal to or greater than [**]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref294"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.5.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Royalty Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On a Product-by-Product and country-by-country basis, Gilead&#x2019;s obligation to pay Royalties for a Product in a country will begin upon the First Commercial Sale of such Product in such country and will expire upon the last to occur of (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> [**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalty Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Upon expiration of the Royalty Term for a given Product in a given country </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> no further Royalties will be payable in respect of sales of such Product in such country, and </font><font id="docxtextref295"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the licenses granted to Gilead under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the Exploitation of such Product in such country will automatically become fully paid-up, perpetual, irrevocable and royalty free.  For clarity, only a single Royalty will be payable as a result of one or more Valid Claims in a Licensed Patent Covering the sale of such Product during the applicable Royalty Term.  On a Product-by-Product and country-by-country basis, from and after the expiration of the Royalty Term for a Product in a country, Net Sales of such Product in such country shall be excluded for purposes of calculating the Net Sales thresholds set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the Net Sales thresholds and ceilings set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.6.	Royalty Reductions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref217"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.6.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">No Valid Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On a Product-by-Product and country-by-country basis, if the sale of such Product is no longer Covered by a Valid Claim within the Licensed Patents in such country, then the royalties payable with respect to such Product during the Royalty Term pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">9.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in such country will be reduced by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> during such period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.6.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Loss of Market Exclusivity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On a Product-by-Product and country-by-country basis, if </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then, thereafter, the royalties payable with respect to annual Net Sales of such Product during the Royalty Term pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as may be adjusted by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in such country will be reduced to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of the royalties otherwise payable pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as may be adjusted by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.7.	Third Party Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.7.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Product-Specific Third Party IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> a license agreement or otherwise acquire rights to Patent Rights, Know-How or other intellectual property (including by way of settlement of litigation) that is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to Exploit a Product in the Field of Use in the Territory and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (any such intellectual property, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product-Specific Third Party IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">subject to the remainder of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For clarity, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">38</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.7.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Other Third Party IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Notice; Negotiation of Future In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i)	If Gritstone reasonably determines that any Patent Rights, Know-How or other intellectual property rights owned or otherwise controlled by a Third Party are necessary in order for Gilead to practice any Qualifying Use of Gritstone Platform Technology to Exploit a Product in the Field of Use in the Territory, then Gritstone will notify Gilead of any such intellectual property.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii)	If Gritstone reasonably determines, or Gilead notifies Gritstone, that any Patent Rights, Know-How, or other intellectual property rights owned or otherwise controlled by a Third Party are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to Exploit the Gritstone Platform Technologies in the Field of Use in the Territory and such intellectual property is not Product-Specific Third Party IP, then </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to the terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(a)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the foregoing, if Gritstone is negotiating a proposed Future Core In-License Agreement that is, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Disclosure of Future In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i)	Except for Future Gritstone Product-Related Agreements, which are subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in the event that Gritstone enters into an agreement with a Third Party after the Effective Date pursuant to which Gritstone in-licenses, or otherwise acquires, Control of Patent Rights, Know-How or other intellectual property rights that are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in order to Exploit the Gritstone Platform Technologies in the Field of Use in the Territory (excluding any such intellectual property rights that would constitute Excluded Technology), then Gritstone will promptly provide Gilead with notice of such license or other agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii)	In the event that Gritstone enters into any Future Gritstone Product-Related Agreement and pursuant to such agreement Gritstone in-licenses, or otherwise acquires, Control in the Field of Use of (1) any (A) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (B) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (3) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (in each case, ((1), (2) and (3)), &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Product-Related Agreement Selected Improvement IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), then Gritstone will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (x) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (y) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (or, if later, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">).  For clarity, Gritstone&#x2019;s obligation to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">will not arise in relation to a Future Gritstone Product-Related Agreement unless and until there are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iii)	If Gritstone provides Gilead with notice of a potential Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then Gritstone will provide Gilead with a copy of the applicable license or other agreement with the Third Party (redacted as necessary to protect agreement terms and confidential information that are not necessary to confirm the scope of the sublicensed rights and compliance with this Agreement), together with a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> under any such potential </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> applicable to sublicensees, and (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (including with respect to sublicensees under the Licensed Technology Controlled by Gritstone pursuant to such agreement) and (b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable to the Licensed Technology that would be subject to such sublicense agreement.  If Gritstone provides Gilead with notice of a potential Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then Gilead may </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (x) (I) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (II) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (y) a copy of the applicable proposed Gritstone In-License Agreement (redacted as necessary to protect agreement terms and confidential information that are not necessary to confirm the scope of the sublicensed rights and compliance with this Agreement).  For clarity, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Acceptance or Non-Acceptance of Future In-License Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">39</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i)	Within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days following receipt of such notice pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will decide, in its sole discretion, whether or not to accept the applicable Patent Rights, Know-How or other intellectual property as Licensed Technology licensed under this Agreement and will provide Gritstone written notice of such decision.  If Gilead decides to accept a sublicense under such intellectual property, then (x) such Patent Rights, Know-How or other intellectual property will constitute Licensed Technology sublicensed to Gilead under this Agreement pursuant to the license grants in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (y) such agreement will thereafter be included within the definition of Gritstone In-License Agreements, and (z) subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall, and shall cause its Affiliates and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with all applicable terms (including with respect to sublicensees and the Exploitation of any Product in the Field of Use) pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">11.10.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to such Gritstone In-License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(ii)	Within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days following receipt of such notice pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(b)(ii)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will decide, in its sole discretion, whether or not to accept a sublicense under the applicable Gritstone Product-Related Agreement Selected Improvement IP that would be Licensed Technology for purposes of this Agreement if such agreement had been in effect as of the Effective Date.  If Gilead decides to accept a sublicense under such intellectual property, then (x) such Gritstone Product-Related Agreement Selected Improvement IP will constitute Licensed Technology sublicensed to Gilead under this Agreement pursuant to the license grants in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (y) such agreement will thereafter be included within the definition of Gritstone In-License Agreements solely with respect to the applicable Gritstone Product-Related Agreement Selected Improvement IP and the terms and conditions applicable thereto (any such Gritstone In-License Agreement, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future Gritstone Product-Related Agreement Sublicense</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and (z) subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall and shall cause its Affiliates and, subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, its and their Sublicensees to, comply with all applicable terms (including with respect to sublicensees and the Exploitation of any Product in the Field of Use) pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">11.10.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to such Future Gritstone Product-Related Agreement Sublicense.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(iii)	If Gilead does not accept any Third Party agreement as a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or (ii), as applicable (including by failing to respond within such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-day period), then (1) Gilead and its Affiliates will have no obligations with respect to such Third Party agreement and (2) Gritstone will have no obligation to grant any sublicense or other rights to Gilead under such Third Party agreement.  Notwithstanding any other term or condition of this Agreement, the definitions of Licensed Know-How, Licensed Patents and Licensed Technology, Licensed Technology under this Agreement shall be deemed to exclude Patent Rights, Know-How or other intellectual property licensed to Gritstone or any of its Affiliates pursuant to a license or other agreement entered into by Gritstone or its Affiliates after the Effective Date unless and until such agreement becomes a Gritstone In-License Agreement pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Responsibility for Payments under Gritstone In-License Agreements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Gritstone will be solely responsible for, and will satisfy, all financial obligations, including royalties, due from Gritstone to any Third Party under the Existing In-License Agreements </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (i) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">With respect to any Gritstone In-License Agreement that becomes a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">will be responsible for all payment obligations under such agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, except as follows.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties shall coordinate in good faith to agree upon timing and mechanics for payments and any required notice of milestone achievement under each Gritstone In-License Agreement that are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under this Agreement with the goal of ensuring that such payments are made and notices </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in sufficient time </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to make corresponding payments and notices to the Third Party in a timely manner under the Gritstone In-License Agreement.  All such payments that are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in accordance with the terms of the applicable Gritstone In-License Agreement.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Qualifying Use of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">40</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Platform Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">means any aspect of the Gritstone Platform Technology that both (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (1)  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or (2) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.7.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Offset for Third Party Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gilead, any of its Affiliates or any of its Sublicensees obtains a right or license under any Patent Rights, Know-How or other intellectual property right of a Third Party after the Effective Date that is </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for the Development, Manufacturing, Commercialization or other Exploitation of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in the Field of Use in the Territory by or on behalf of Gilead, its Affiliates or its Sublicensees, including any rights or licenses obtained pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then Gilead may deduct from the Royalties that would otherwise have been due in a particular </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">an amount equal to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of the amount of any payments (including payments for obtaining such right or license, royalties, milestones, amounts paid in settlement and any other amounts) paid or accrued by Gilead or any of its Affiliates or Sublicensees to such Third Party for such right or license or the exercise thereof during </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the foregoing, to the extent any amounts paid to such Third Party for such right or license are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead may not deduct such amounts from the Royalties.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.8.	Cumulative Effect of Reductions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.8.1.	On a country-by-country and Product-by-Product basis, in no event will Royalties payable to Gritstone in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in any country in any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for any Product be reduced, pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 9.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">9.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">9.7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">14.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, to less than the amount provided pursuant to clause (a) or clause (b) (as applicable, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Royalty Floor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	 in the event that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	in the event that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">9.8.2.	In the event that Gilead would, but for the restriction set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, have the right to reduce the Royalties due to Gritstone for Products pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in a country in a given </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.6.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">9.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">9.7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, alone or together to an amount lower than the Royalty Floor, then such unused reduction may be carried forward and used as a credit in one or more future </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for Products in the same country, and such unused reduction will be </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Royalties due in such country are not reduced by more than the Royalty Floor for each such Product in each such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.9.	No Projections</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each of Gritstone and Gilead hereby acknowledges and agrees that nothing in this Agreement will be construed as representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise been discussed by the Parties are merely intended to define the Milestone Payments and royalty obligations to Gritstone in the event such Milestones or Net Sales levels are achieved.  NEITHER GRITSTONE NOR GILEAD MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP, OBTAIN REGULATORY APPROVAL FOR, OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR NET SALES LEVEL OF SUCH PRODUCT WILL BE ACHIEVED.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.10.	Non-Refundable and Non-Creditable Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding the non-refundable or non-creditable nature of any payments hereunder, but subject to the limitations set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, nothing in this Agreement will limit either Party&#x2019;s rights to assert or obtain damages for breach of this Agreement, including damages calculated based on the payments made under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">41</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article X<br>REPORTS AND PAYMENT TERMS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.1.	Reports; Payment Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.1.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Development Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will furnish to Gritstone a written notice of the achievement by Gilead, its Affiliates or its Sublicensees of a Development Milestone Event within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Business Days after such Development Milestone Event has been achieved.  After the receipt of any such notice, Gritstone will submit an invoice to Gilead with respect to the corresponding Development Milestone Payment.  Gilead will pay such Development Milestone Payment within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after receipt of such invoice.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.1.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Royalties and Sales Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  During the period from the First Commercial Sale of any Product until the end of the last-to-expire Royalty Term, Gilead will, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> following the end of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">each </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for which Royalties are due: (a) furnish to Gritstone a written report, showing the (i) aggregate Net Sales of each Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sold in each country during the relevant </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in Dollars and amounts of such Net Sales </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (ii) Royalties and any Sales Milestone Events that have accrued hereunder in respect of Net Sales </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and (iii) the exchange rates used in determining the amounts payable in Dollars; and (b) pay such Royalties and Sales Milestone Payments with respect to such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">as set forth in such written report.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Gritstone Reimbursable Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead shall reimburse Gritstone for Gritstone Reimbursable Costs incurred in accordance with this Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  After each </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">during the Term, Gritstone will invoice Gilead for any Gritstone Reimbursable Costs incurred during </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for which reimbursement is due to Gritstone under this Agreement and Gilead shall reimburse Gritstone for undisputed Gritstone Reimbursable Costs within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days of receipt of Gritstone&#x2019;s invoice therefor.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Reimbursable Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; shall mean </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.1.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Payment Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On or before the Effective Date, Gritstone will provide its current IRS Tax Form W-9 to Gilead.  All payments under this Agreement will be made by deposit of Dollars in the requisite amount to the following bank account of Gritstone or such other account as Gritstone may from time to time designate by notice to Gilead.  Any payment which falls due on a date which is not a Business Day may be made on the next succeeding Business Day.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">   </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.2.	Currency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All payments under this Agreement will be payable in Dollars.  With respect to sales of a Product and other amounts received or to be paid to a Third Party in a currency other than Dollars, such amounts and amounts payable will be converted to Dollars using the exchange rate mechanism generally applied by Gilead in preparing its audited financial statements for the applicable </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such mechanism is in compliance with Accounting Standards and Gilead&#x2019;s normal practices used to prepare its audited financial statements.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.3.	Blocked Currency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If at any time legal restrictions in the Territory prevent the prompt remittance of any payments with respect to sales therein, Gilead will have the right and option to make such payments by depositing the amount thereof in local currency to Gritstone&#x2019;s account in a bank or depository designated by Gritstone in the Territory.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">42</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.4.	Taxes; Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Payee will be liable for all income and other taxes (including interest) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) imposed upon any payments made by the Payor to Payee under this Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Agreement Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  The amounts set forth herein are exclusive of all applicable sales or use, goods and services, value added, consumption or other similar fees or taxes (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Transfer Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) arising on the Agreement Payments, and the Payor will be responsible for and pay any such Transfer Taxes imposed on it with respect to the Agreement Payments due to the Payee hereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Applicable Law requires the withholding of Taxes in respect of any Agreement Payment, the Payor is authorized to deduct the amount thereof from such Agreement Payment and shall remit such withheld amount to the relevant Governmental Authority in a timely manner.  Notwithstanding the foregoing, except if as a result of Gritstone assigning this Agreement or changing its domicile, additional taxes become due that would not have otherwise been due hereunder with respect to the upfront payment pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the Option Exercise Fee pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall pay to Gritstone the upfront payment pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the Option Exercise Fee pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> free and clear of any withholding, and without any deduction, on account of any Taxes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> For the avoidance of doubt, the Payor&#x2019;s remittance of Taxes withheld in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, together with payment to the Payee of the remaining Agreement Payments, will constitute the Payor&#x2019;s full satisfaction of Agreement Payments under this Agreement.  The Payor will promptly (as available) submit to the Payee appropriate proof of payment of the withheld Taxes as well as the official receipts within a reasonable period of time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.4.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Tax Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate such withholding of Taxes, Transfer Taxes, or similar obligations in respect of payments made under this Agreement, as permitted under Applicable Law, including under any applicable provision of any present or future income tax treaty.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">10.5.	Records and Audit Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.5.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Records</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will keep, and will cause its Affiliates and as applicable sublicensees, to keep complete, true and accurate books and records in accordance with its Accounting Standard in relation to this Agreement and Net Sales, Royalties, Development Milestone Payments, Sales Milestone Payments and any other payments and reimbursements required hereunder, as applicable.  Each Party will keep such books and records for at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">years following the Calendar Year to which they pertain or for such longer period of time as required under any Applicable Law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref224"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.5.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Audit Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to the other terms of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, during the Term, at the request of a Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Auditing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), which will not be made more frequently than one (1) time per </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, upon at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days&#x2019; prior written notice from the Auditing Party, the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Audited Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) will permit an independent, nationally-recognized certified public accountant selected by the Auditing Party and reasonably acceptable to the Audited Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Auditor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) to inspect, during regular business hours, the relevant records required to be maintained by the Audited Party under </font><font id="docxtextref220"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">10.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such audit right will not apply to records beyond </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">years from the end of the Calendar Year to which they pertain and that records for a particular period may only be audited once.  Prior to its inspection, the Auditor will enter into a confidentiality agreement with both Parties having obligations of confidentiality and non-use no less restrictive than those set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and limiting the disclosure and use of such information by such Auditor to authorized representatives of the Parties and the purposes germane to </font><font id="docxtextref221"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">10.5.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">43</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref226"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.5.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In the event such audit leads to the discovery of a discrepancy to the Auditing Party&#x2019;s detriment, the Audited Party will, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days after receipt of such report from the Auditor, pay any undisputed amount of the discrepancy.  The Auditing Party will pay the full cost of the audit unless the underpayment of amounts due to or overpayment of amounts payable by the Auditing Party is greater than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of the amount due for the entire period being examined, in which case the Audited Party will pay the reasonable cost charged by the Auditor for such review.  Any undisputed overpayments by the Audited Party revealed by an examination will be paid by the Au</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">diting Party within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days of the Auditing Party&#x2019;s receipt of the applicable report.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">10.5.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disputes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Any disagreement regarding the results of any audit conducted under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be subject to the dispute resolution provisions for Selected Disputes set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XI<br>INTELLECTUAL PROPERTY RIGHTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.1.	Inventorship</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as otherwise expressly provided herein, determination of inventorship of any Inventions (whether patentable or not) created, conceived or reduced to practice by or on behalf of a Party or any of its Affiliates, whether solely or jointly with any Third Party (or with the other Party or any of its Affiliates), in the course of activities performed under this Agreement, will be determined by application of U.S. patent law pertaining to inventorship.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.2.	Ownership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Background Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  As between the Parties, and subject to the licenses granted under this Agreement, each Party retains all rights, title and interests in and to all Patent Rights, Know-How and other intellectual property rights that such Party owns or otherwise Controls as of the Effective Date or that it develops or otherwise acquires after the Effective Date outside the performance of the activities under this Agreement.  Without limiting the generality of the foregoing, as between the Parties, and subject to the licenses granted under this Agreement, Gilead retains all of its rights, title and interests in and to the Gilead Background IP, and Gritstone retains all of its rights, title and interest in and to the Gritstone Background IP.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.2.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Gritstone Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  As between the Parties, Gritstone will own and retain all right, title and interest in and to all Gritstone Collaboration IP.  Gilead will promptly disclose to Gritstone in writing the creation, conception or reduction to practice of any Invention within Gritstone Collaboration IP by or on behalf of Gilead or any of its Affiliates.  Gilead, for itself and on behalf of any of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign) to Gritstone all its right, title and interest in and to any Gritstone Collaboration IP.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Gilead Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  As between the Parties, Gilead will own and retain all right, title and interest in and to all Gilead Collaboration IP.  Gritstone will promptly disclose to Gilead in writing the creation, conception or reduction to practice of any Invention within Gilead Collaboration IP by or on behalf of Gritstone or any of its Affiliates.  Gritstone, for itself and on behalf of any of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign) to Gilead all its right, title and interest in and to any Gilead Collaboration IP.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">44</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Joint Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Joint Collaboration IP will be owned jointly by Gilead and Gritstone on the basis of an equal, undivided interest and will be deemed to be Controlled by each Party.  Each Party, for itself and on behalf of any of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign) to the other Party a joint, equal and undivided right, title and interest in and to any Joint Collaboration IP.  Subject to the licenses granted under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the exclusivity obligations under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, each Party will have the right to use such Joint Collaboration IP, or license such Joint Collaboration IP to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Collaboration IP to its Affiliates or a Third Party, in each case, without a duty to seek consent or account to the other Party, so long as such use, sale, license or transfer is consistent with this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will reasonably cooperate, and will cause its Affiliates to reasonably cooperate, with the other Party to effectuate and perfect the ownership rights set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, including by promptly executing and recording affidavits, assignments, agreements and other documents, as applicable, consistent with such ownership.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Third Party Arrangements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  In addition, each Party will ensure that its arrangements with any of its Affiliates, employees, Subcontractors and successors-in-interest include provisions that allow such Party to comply with its obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  with respect to any Collaboration IP developed, conceived or reduced to practice from the activities of any of such Party&#x2019;s Affiliates, employees, and successors-in-interest with respect to any Licensed Technology and with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, without limiting </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (i) each sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall provide, and Gilead shall ensure, that each sublicensee thereunder (through multiple tiers) shall comply with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (to the extent applicable) and (ii) Gilead will </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to ensure that each sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> provides a present grant of rights or present assignment such that Gritstone receives a present grantback license pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to any Patent Rights or Know-How conceived, discovered, otherwise made or invented by or on behalf of such sublicensee that (x) would be </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and (y) that would be </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.3.	Prosecution and Maintenance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.3.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Right to File and Prosecute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Solely Owned Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as otherwise expressly provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as between the Parties, each Party will have the sole right (but not the obligation) to Prosecute and Maintain any Patent Rights that it owns, at its sole cost and expense.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Joint Collaboration Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the first right (but not the obligation) to Prosecute and Maintain the Joint Collaboration Patents, at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> sole cost and expense.  If, during the Term, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in any country decides not to file a Joint Collaboration Patent, or intends to allow such Patent Right to lapse or become abandoned, then it will promptly provide written notice to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of such decision (and, in any event, no less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in advance of any applicable deadline).  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> may, upon written notice to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, assume the Prosecution and Maintenance of such Patent Right.  In such event </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be responsible for </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">of the costs and expenses incurred thereafter for the Prosecution and Maintenance of such Patent Right.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Licensed Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have (i) the first right (but not the obligation) to Prosecute and Maintain </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (such Licensed Patents, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Product Patents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and (ii) the sole right (but not the obligation) to Prosecute and Maintain all other Licensed Patents, each at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sole cost</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">45</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and expense.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> If, during the Term, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in any country decides not to file a Gritstone Product Patent, or intends to allow such Gritstone Product Patent to lapse or become abandoned, then it will promptly provide written notice to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of such decision (and, in any event, no less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in advance of any applicable deadline).  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">may, upon written notice to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, assume the Prosecution and Maintenance of such Gritstone Product Patent at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sole cost and expense.  In such event </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be responsible </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> of the costs and expenses incurred thereafter for the Prosecution and Maintenance of such Gritstone Product Patent.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.3.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Review and Comment Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Party having the right to Prosecute and Maintain a </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Prosecuting Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) will keep the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Prosecuting Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) informed as to material developments with respect to the Prosecution and Maintenance of such Patent Right, including by providing copies of all substantive office actions or any other substantive documents to or from any patent office, including notice of all interferences, reissues, reexaminations, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">inter partes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> reviews, post grant proceedings, oppositions or requests for patent term extensions.  The Prosecuting Party will also provide the Non-Prosecuting Party with a reasonable opportunity to comment substantively on the Prosecution and Maintenance of such Patent Right prior to taking material actions (including the filing of initial applications), and will in good faith consider and, solely in the case of Gritstone Product Patents, incorporate, any reasonable comments timely made by and actions timely recommended by the Non-Prosecuting Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.3.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Cooperation and Coordination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will (a) upon reasonable request by a Party, obtain and deliver to the other Party any necessary documents for the other Party to exercise its rights to Prosecute and Maintain all Patent Rights pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (b) render all signatures that will be necessary in connection with all such patent filings consistent with this Article XI; and (c) assist the other Party in all other reasonable ways that are necessary for the issuance of those Patent Rights for which such other Party is responsible, as well as for the preparation, prosecution, defense and maintenance of such Patent Rights.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.4.	Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Notification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  During the Term, the Parties will promptly inform each other in writing if either Party becomes aware of any suspected, threatened or actual: (a) infringement by any Third Party of any Licensed Patents or Collaboration Patents; or (b) unauthorized use or misappropriation of any of the Licensed Know-How or Collaboration Know-How (such infringement or unauthorized use or misappropriation, in each case of (a) and (b), an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) that arises as a result of the making, using, offering to sell, selling or importing of a vaccine product that would be competitive with a Product in the Field of Use in the Territory (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Competing Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Each Party will provide any available evidence of such Infringement with such notification.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Infringement Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Solely Owned IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as otherwise expressly provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as between the Parties, each Party will have the sole right (but not the obligation) to initiate an infringement, misappropriation or other appropriate suit (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Infringement Action</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) with respect to any infringement or misappropriation of any Patent Rights or Know-How that such Party solely Controls, by counsel of its own choice, in such Party&#x2019;s own name and under such Party&#x2019;s sole direction and control and at such Party&#x2019;s sole cost and expense.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Joint Collaboration IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the first right (but not the obligation) to initiate an Infringement Action with respect to any Infringement of any Joint Collaboration IP at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sole</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">46</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">cost and expense.  If </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> fails to initiate an Infringement Action against any such Infringement with respect to any Joint Collaboration IP within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after written notice of such Infringement is first provided by a Party under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the right to initiate and control an Infringement Action with respect to such Infringement by counsel of its own choice, at its own discretion and at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> cost and expense and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the right, at its own expense, to be represented in any such action by counsel of its own choice; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that if </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Licensed Technology</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the first right (but not the obligation) to initiate an Infringement Action with respect to any Competing Infringement of any Licensed Technology at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> sole cost and expense.  If </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> fails to initiate an Infringement Action against any Competing Infringement with respect to any Licensed Technology within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after written notice of such Competing Infringement is first provided by a Party under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the right to initiate and control an Infringement Action with respect to such Competing Infringement by counsel of its own choice, at its own discretion and at </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> cost and expense and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will have the right, at its own expense, to be represented in any such action by counsel of its own choice; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that if </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Gritstone Background IP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will have the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> right (but not the obligation) to initiate an Infringement Action with respect to any Competing Infringement of any Licensed Gritstone Background Technology at Gritstone&#x2019;s sole cost and expense.  Gritstone will keep Gilead informed of the status and progress of such enforcement efforts and will reasonably consult with Gilead, including using reasonable efforts to take Gilead&#x2019;s comments into good faith consideration with respect to the infringement or claim construction of any claim in any Patent Rights contained in the Licensed Gritstone Background Technology.  If </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  Notwithstanding the foregoing </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall have no right </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and, for clarity, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Procedures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If the Party having the right to initiate an Infringement Action under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Initiating Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) desires to initiate such Infringement Action but may not do so due to Applicable Law or regulation (even as the assignee or exclusive licensee of such infringed Patent Right), then such Initiating Party may require that the other Party join as a named party in such action or itself initiate such Infringement Action, at the Initiating Party&#x2019;s sole cost and expense.  The Initiating Party will take the lead in the control and conduct of any such Infringement Action under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and will keep the other Party reasonably informed of any such Infringement Action, and the other Party will reasonably assist the Initiating Party in any such Infringement Action under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> at the Initiating Party&#x2019;s expense.  In no event may the Initiating Party settle any such Infringement Action in a manner that would limit the rights of the other Party or impose any obligation on the other Party, in each case, without the other Party&#x2019;s prior written consent, which consent will not be unreasonably withheld, delayed or conditioned.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(f)	Notwithstanding the foregoing, if either Party receives a copy of an application submitted to the FDA for a Biosimilar Product (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Biosimilar Application</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) referencing a Product, whether or not such copy is provided in accordance with the BPCI Act, or otherwise becomes aware that such a Biosimilar Application has been submitted to or approved by a Regulatory Authority (such as through receipt of a notice of commercial marketing described in Section 351(l)(8)(A) of the PHSA or in an instance described in Section 351(1)(9)(C) of the PHSA), then (i) such Party shall promptly provide the other Party with written notice and (ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">47</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.5.	Defense</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.5.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Notification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will promptly notify the other Party of any actual or potential claim alleging that the Research, Development, Manufacture, Commercialization or Exploitation of any Product infringes, misappropriates or otherwise violates any Patent Rights, Know-How or other intellectual property rights of any Third Party (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Infringement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  In any such instance, the Parties will as soon as practicable thereafter discuss in good faith the best response to such notice of Third Party Infringement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.5.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Right to Defend</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead will have the sole right (but not the obligation) to defend, and take other actions (including to settle) with respect to, any such claim of Third Party Infringement, at Gilead&#x2019;s sole discretion, cost and expense, and Gritstone will have the right to be represented in any such action by counsel of its own choice at Gritstone&#x2019;s sole cost and expense; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that in no event will Gilead settle or otherwise compromise any Third Party Infringement by admitting that any Patent Right included within the Licensed Technology is invalid or unenforceable without first obtaining the prior written consent of Gritstone, which consent will not be unreasonably withheld, conditioned or delayed.  In the event that Gilead enters into any settlement with respect to any actual or potential claim of Third Party Infringement which includes the acceptance of any license to Patent Rights, Know-How or other intellectual property rights owned or otherwise Controlled by any Third Party and necessary or reasonably useful for the Exploitation of any Product, such settlement will further be subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the extent applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.6.	Recovery</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.6.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Enforcement Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Any recovery received as a result of any action under clauses (b) through (d) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be allocated in the following order: (a) to pay to any applicable Third Party any applicable portion of such recovery owed to such Third Party pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (b) to reimburse the Party taking legal action for the costs and expenses (including attorneys&#x2019; and professional fees) incurred in connection with such action, to the extent not previously reimbursed; (c) to reimburse the non-enforcing Party, where it joins a legal action as provide under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (d) the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.6.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Defense Actions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Any recovery received as a result of any action under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be allocated in the following order: (a) to pay to any applicable Third Party any applicable portion of such recovery owed to such Third Party pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (b) to reimburse Gilead for the costs and expenses (including attorneys&#x2019; and professional fees) that Gilead incurred in connection with such action, to the extent not previously reimbursed; (c) to reimburse Gritstone, where it joins a legal action as provided under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for the costs and expenses (including attorneys&#x2019; and professional fees) that Gritstone incurred in connection with such action, to the extent not previously reimbursed; and (d) the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.7.	Trademarks</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will have the right, but not the obligation, to brand the Products using trademarks, trade dress and trade names owned or Controlled by Gilead that it determines appropriate in its sole discretion for the Products, which may vary within the Territory (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Product Mark</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  Gilead will own all rights, title and interests in and to the Product Marks, and all goodwill in the Product Marks will inure to the benefit of Gilead.  Gilead will register and maintain the Product Marks to the extent it determines reasonably necessary.  Except as otherwise agreed in writing by both Parties, Gilead does not grant to Gritstone, by implication, estoppel or otherwise, any license to any Product Mark.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.8.	Product Listings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  With respect to filings in the FDA&#x2019;s Orange Book or Purple Book or other similar filings or listings as may be applicable to a biologic or drug (and foreign equivalents) for</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">48</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">issued patents for a Product, upon request by Gilead, Gritstone will provide reasonable cooperation to Gilead in filing and maintaining any such listing and filings.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.9.	Patent Term Extensions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will cooperate, at Gilead&#x2019;s reasonable expense, with Gilead upon Gilead&#x2019;s reasonable request in obtaining patent term extension or supplemental protection certificates and the like with respect to any Licensed Patent that is not a Gritstone Background Patent, in each country and region where it is possible to do so.  Gilead will make the election in accordance with the preceding sentence, and Gritstone agrees to abide by such election.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.10.	Third Party Agreement-Governed Intellectual Property Rights.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.10.1.	  Notwithstanding any term or condition of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the contrary, Gritstone will own all right, title and interest in and to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  For purposes of this Agreement, any such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">will be deemed to be Gritstone Collaboration IP with respect to which Gritstone grants to Gilead in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 3.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> a sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">11.10.2.	  Notwithstanding the foregoing or any term or condition of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XI</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the contrary:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	Gilead acknowledges that Third Party counterparties to the Existing In-License Agreements and the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">have, and the Third Party counterparties to future Gritstone In-License Agreements may have, certain rights with respect to the prosecution, maintenance, enforcement and defense of certain of Patents Rights (x) owned or controlled by the Third Party counterparties (including (I) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (II) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or (y) otherwise governed by the applicable agreement, that in each case ((x) and (y)) constitute Licensed Gritstone Background IP or Collaboration IP hereunder (such Patent Rights, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Party Agreement-Governed Intellectual Property Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	The Parties agree that the rights and obligations of the Parties with respect to the prosecution, maintenance, enforcement and defense of any Third Party Agreement-Governed Intellectual Property Rights under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XI</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be subject to the prosecution, maintenance, enforcement and defense rights of such Third Party counterparties (i) pursuant to the applicable Existing In-License Agreement as applicable (including with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (ii) pursuant to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or applicable Future Core In-License Agreement, as applicable, solely to the extent such obligations are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), (iii) pursuant to the applicable Future Other In-License Agreement, solely to the extent the terms and conditions were provided to Gilead for review prior to the Effective Date or prior to such agreement becoming a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or were consented to by Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.5.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and (iv) pursuant to the applicable Future Gritstone Product-Related Agreement, solely to the extent such obligations are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or included in the copy of the such agreement provided to Gilead for review prior to such agreement becoming a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable based on Gritstone&#x2019;s election thereunder, or were consented to by Gilead in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XII<br>CONFIDENTIALITY</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref261"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.1.	Nondisclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party agrees that a Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Receiving Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) which receives the Confidential Information of the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) pursuant to this Agreement will:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> maintain in confidence such Confidential Information using not less than the efforts that such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of efforts; </font><font id="docxtextref262"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> not disclose such Confidential Information to any Third Party without first obtaining the prior written consent of the Disclosing Party, except for disclosures</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">49</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref263"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">expressly permitted pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> not use such Confidential Information for any purpose except those permitted under this Agreement, including, in the case of each Party, the performance of obligations and the exercise of the rights and licenses granted to such Party hereunder.  The obligations of confidentiality, non-disclosure and non-use under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be in full force and effect from the Effective Date until </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">years following the Term.  Except as otherwise requested in writing by the Disclosing Party, the Receiving Party will destroy the Confidential Information of the Disclosing Party disclosed or transferred to it by the Disclosing Party pursuant t</font><font id="docxtextref265"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">o this Agreement, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after the expiration or termination of this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that a Party may retain: </font><font id="docxtextref264"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Confidential Information of the Disclosing Party to exercise rights and licenses which expressly survive such termination or expiration pursuant to this Agreement; (ii) one (1) copy of all other Confidential Information in archives solely for the purpose of establishing the contents thereof or in accordance with Applicable Law and (iii) any backup media copies made in the ordinary course of business.  In addition, Gritstone will keep confidential, and will cause its Affiliates and its and their employees, consultants, licensees, sublicensees, professional advisors and Affiliates to keep confidential, the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> on confidentiality and non-disclosure terms at least as protective as the confidentiality provisions of this Agreement without regard to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.2.	Exceptions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will not apply with respect to any portion of the Confidential Information of the Disclosing Party to the extent that such Confidential Information:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	was known to, or otherwise in the possession of, the Receiving Party or any of its Affiliates, as evidenced by written records, prior to disclosure by the Disclosing Party;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party or any of its Affiliates;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	is subsequently disclosed to the Receiving Party or any of its Affiliates on a confidential basis by a Third Party that is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party or any of its Affiliates, solely for use and disclosure within the scope agreed between the Receiving Party or any of its Affiliates and such Third Party;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	is or becomes publicly available or enters the public domain, either before or after it is disclosed to the Receiving Party, through no breach by the Receiving Party or any of its Affiliates of its obligations hereunder; or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	is independently developed by or on behalf the Receiving Party or any of its Affiliates, as evidenced by written records, without reference to or reliance upon the Disclosing Party&#x2019;s Confidential Information.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Any combination of features or disclosures will not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">50</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.3.	Authorized Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.3.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party in the following instances:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.5,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to comply with Applicable Law (including the rules and regulations of the U.S. Securities and Exchange Commission or any national securities exchange in any jurisdiction in the Territory) (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Securities Regulator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) or with judicial process (including prosecution or defense of litigation) if, in the reasonable opinion of the Receiving Party&#x2019;s counsel, such disclosure is necessary for such compliance or for such judicial process (including prosecution or defense of litigation);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	disclosure to a Governmental Authority in order to obtain Patent Rights, to obtain or maintain approval to conduct Clinical Trials or to market the Products or make other Regulatory Filings, in each case under this Agreement and in accordance with this Agreement or, in the case of Gritstone with respect to any Confidential Information of Gilead that constitutes Selected Collaboration IP licensed to Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in connection with the exercise of a sublicense thereunder in accordance with this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that reasonable steps are taken to ensure confidential treatment of such Confidential Information to the extent available;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	disclosure to (i) any of its officers, employees, consultants, agents or Affiliates as necessary or useful to perform on behalf of such Party or exercise rights and licenses granted to such Party under this Agreement, (ii) in the case of Gilead, any actual or potential collaborators, licensees or Sublicensees to the extent reasonably necessary to conduct negotiations or in connection with the Exploitation of Products, (iii) in the case of Gritstone (1) to any actual or potential licensors of any Licensed Technology under any actual or potential Gritstone In-License Agreements to the extent reasonably necessary to conduct negotiations of any potential Gritstone In-License Agreement or to comply with any actual Gritstone In-License Agreement, as applicable or (2) without limitation to clause (1), with respect to the terms of this Agreement or any Confidential Information of Gilead that constitutes Selected Collaboration IP licensed to Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, licensees or sublicensees to the extent reasonably necessary to conduct negotiations or in connection with the grant or exercise of a sublicense thereunder, and (iv) in the case of either Party, such Party&#x2019;s actual or potential Subcontractors, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that prior to any such disclosure ((i)-(iv)), each such disclosee is bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (subject to a commercially reasonably period of confidentiality appropriate to the circumstances) to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that, in each of the above situations in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3.1(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> ((i)-(iv)), the Receiving Party will remain responsible for any failure by any Person who receives Confidential Information from such Receiving Party pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3.1(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to treat such Confidential Information as required under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	disclosure to its advisors (including attorneys, financial advisors and accountants) in connection with activities under this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that prior to any such disclosure, each such disclosee is bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (subject to a commercially reasonably period of confidentiality appropriate to the circumstances) (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that in the case of legal advisors, no written agreement will be required), to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that, in each of the above situations in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3.1(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Receiving Party will remain responsible for any failure by any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">51</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Person who receives Confidential Information from such Receiving Party pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3.1(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to treat such Confidential Information as required under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(e)	in the case of each Party with respect to any Confidential Information of the other Party that constitutes </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as reasonably necessary or useful in the exercise of such Party&#x2019;s rights pursuant to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.3.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Terms of Disclosure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If and whenever any Confidential Information is disclosed in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, such disclosure will not cause any such information to cease to be Confidential Information, except to the extent that such disclosure results in a public disclosure of such information other than by breach of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.4.	Terms of this Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties agree that this Agreement and the terms hereof will be deemed to be Confidential Information of both Gritstone and Gilead, and each Party agrees not to disclose this Agreement or any terms hereof without obtaining the prior written consent of the other Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.5.	Securities Filings; Disclosure under Applicable Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party acknowledges and agrees that the other Party may submit this Agreement to, or file this Agreement with, the Securities Regulators or to other Persons as may be required by Applicable Law, and if a Party submits this Agreement to, or files this Agreement with, any Securities Regulator or other Person, as may be required by Applicable Law, such Party agrees to consult with the other Party with respect to the preparation and submission of a confidential treatment request for this Agreement.  Notwithstanding the foregoing, if a Party is required by any Securities Regulator or other Person to make a disclosure of the terms of this Agreement in a filing or other submission as required by such Securities Regulator or such other Person, in each case under Applicable Law, and such Party has: (a) provided copies of the disclosure to the other Party reasonably in advance under the circumstances of such filing or other disclosure; (b) promptly notified the other Party in writing of such requirement and any respective timing constraints; and (c) given the other Party reasonable time under the circumstances from the date of provision of copies of such disclosure to comment upon and request confidential treatment for such disclosure, then such Party will have the right to make such disclosure at the time and in the manner reasonably determined by its counsel to be required by such Securities Regulator or such other Person.  Notwithstanding the foregoing, if a Party seeks to make a disclosure as required by a Securities Regulator or other Person as may be required by Applicable Law as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the other Party provides comments in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Party seeking to make such disclosure or its counsel, as the case may be, will consider in good faith such comments.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.6.	Publicity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.6.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Use of Names</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as otherwise expressly set forth herein, neither Party (or any of its respective Affiliates) will use the name, trademark, trade name or logo of the other Party or any of its Affiliates, or its or their respective employees, in any publicity, promotion, news release or other public disclosure relating to this Agreement or its subject matter, without first obtaining the prior written consent of the other Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such consent will not be required to the extent use thereof may be required by Applicable Law, including the rules of any securities exchange or market on which a Party&#x2019;s or its Affiliate&#x2019;s securities are listed or traded.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">12.6.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Press Releases</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On or promptly after the Effective Date, the Parties will issue a public announcement of the execution of this Agreement in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 12.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.   Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, neither Party will, and each Party will cause</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">52</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">its Affiliates not to, issue any other press release or other public statement disclosing this Agreement, the activities hereunder or the transactions contemplated hereby, without first obtaining the other Party&#x2019;s prior written consent; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that (a) after the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead may issue press releases or other public statements going forward, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, upon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Business Days&#x2019; prior written notice to Gritstone (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that such right of issuance without consent shall not apply to any press release or other public statement that contains the Confidential Information of Gritstone); and (b) each Party will be authorized to make any disclosure, without first obtaining the other Party&#x2019;s prior written consent, that is required by Applicable Law, the rules of any Securities Regulator or by judicial process, subject to and in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 12.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">12.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.7.	Publications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  During </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, a Party (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Publishing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) will, prior to publishing, publicly presenting or otherwise publicly disclosing any paper, publication, oral presentation, abstract, poster, manuscript or other presentation relating to the Exploitation of any Product or the use of the Licensed Technology in the Field of Use under this Agreement (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Publication</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) provide the other Party (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Reviewing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) an opportunity to review such Publication to determine whether such Publication contains the Confidential Information of the Reviewing Party.  The Publishing Party will deliver to the Reviewing Party a copy of any such proposed Publication or an outline of the proposed oral disclosure at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days prior to submission for publication or presentation for review by the Reviewing Party.  The Reviewing Party will have the right, in its sole discretion, to: (a) require the removal of its Confidential Information from any such Publication by the Publishing Party; or (b) request a reasonable delay in publication or presentation in order to protect patentable information.  If the Reviewing Party requests such a delay, the Publishing Party will delay submission or presentation for a period of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after its provision of the copy of the proposed Publication to enable patent applications protecting the Reviewing Party&#x2019;s rights in such information.  Following </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (x) any proposed Publication (whether written, electronic, oral or otherwise) by Gritstone or any of its Affiliates related to activities under this Agreement or the Products will require, in each case, the prior written consent of Gilead (such consent to be given or withheld in Gilead&#x2019;s sole discretion) and (y) Gilead or any of its Affiliates will have the sole right, without any required consents from Gritstone, to publish or have published information about Clinical Trials related to the Products, including the results of such Clinical Trials, or other activities under this Agreement.  This </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will not affect the rights or obligations of the Parties pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XIII<br>TERM AND TERMINATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.1.	Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The term of this Agreement will commence upon the Effective Date and, unless earlier terminated as permitted by this Agreement, will expire in its entirety upon the date of expiration of the last Royalty Term for the last Product; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that (a) if the Option is not exercised by Gilead by the last day of the Option Term, this Agreement will expire on the last day of the Option Term and (b) if Gilead exercises the Option but the Option Effective Date does not occur on or before the Outside Date, this Agreement will expire on the Outside Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.2.	Termination for Material Breach</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Material Breach</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If a Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Non-Breaching Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) reasonably believes that there has been a Material Breach by the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Breaching Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the Non-Breaching Party may give written notice to the Breaching Party specifying the breach in reasonable detail.  The Breaching Party will have </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following receipt of the Non-Breaching Party&#x2019;s written notice to either cure such breach or, if cure cannot be reasonably effected within such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period, then such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period will be extended for an additional </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">so long as the Breaching Party continues to use Commercially Reasonable</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">53</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Efforts to cure such Material Breach during such extension period (such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period, as may be extended in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Cure Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).  In the event such breach is not cured within the Cure Period, the Non-Breaching Party will have the right thereafter to terminate this Agreement immediately, in its entirety or in part, with the consequences as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable, by giving written notice to the Breaching Party to such effect.  Notwithstanding the foregoing, in the event that any Material Breach </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref316"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.2.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Disagreement as to Material Breach</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, if the Parties in good faith disagree as to whether there has been a Material Breach, then: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the Party that disputes whether there has been a Material Breach may contest the allegation by referr</font><font id="docxtextref321"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">ing such matter, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> following its receipt of notice of the alleged Material Breach, for resolution in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font id="docxtextref317"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the relevant Cure Period with respect to such alleged Material Breach will be tolled from the date on which the Party that disputes in good faith whether there has been a Material Breach notifies the other Party of such Dispute and through the resolution of such Dispute in accordance with the applicable provisions of this Agreement; </font><font id="docxtextref318"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> during the pendency of such Dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder; and </font><font id="docxtextref319"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> if it is ultimately determined that the breaching Party committed such Material Breach, then the breaching Party will have the right to cure such Material Breach, after such determination, within the Cure Period (as may be extended in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) which will commence as of the date of such determination.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.3.	Termination for Insolvency</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Either Party may terminate this Agreement at any time during the Term upon the other Party&#x2019;s filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that in the case of any involuntary bankruptcy proceeding, such right to terminate will only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after the filing thereof.  In addition, Gilead may terminate this Agreement in the event that Gritstone rejects this Agreement under Section 365 of the United States Bankruptcy Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.4.	Termination by Gilead for Convenience</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.4.1.	At any time during the Term, Gilead will have the right to terminate this Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for convenience upon ninety (90) days&#x2019; prior written notice to Gritstone; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in the event Gilead terminates this Agreement in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone will have the right to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> upon written notice to Gilead.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.4.2.	At any time during the Term, Gilead will have the right to terminate </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> upon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> prior written notice to Gritstone, and upon such termination (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and (b) Gilead&#x2019;s obligations pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall terminate.  On the effective date of termination of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gilead shall promptly return to Gritstone or destroy all Confidential Information with respect to any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.4.3.	At any time during the Term, Gilead will have the right to terminate Gilead&#x2019;s sublicense under any Existing In-License Agreement (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) in its entirety upon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> prior written notice to Gritstone, and upon such termination any Patent Rights or Know-How licensed by Gritstone under such Existing In-License Agreement shall be deemed excluded from the Licensed Technology and the scope of the licenses granted by Gritstone to Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  On the effective date of termination of such sublicense, Gilead shall promptly return to Gritstone or destroy all Confidential Information provided by Gritstone to Gilead and identified as Confidential Information of the applicable counterparty to such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">54</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Existing In-License Agreement or any other applicable Third Party in connection with such Existing In-License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">          </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">13.6.	Rights in Bankruptcy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.6.1.	The Parties agree that this Agreement constitutes an executory contract under Section 365 of the Code for the license of &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">intellectual property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; as defined under Section 101 of the Code and constitutes a license of &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">intellectual property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; for purposes of any similar Applicable Laws in any other country in the Territory.  The Parties further agree that Gilead, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights, and elections under the Code, including under Section 365(n) of the Code, and any similar Applicable Laws in any other country in the Territory.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">13.6.2.	All rights, powers, and remedies of Gilead provided for in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> are in addition to and not in substitution for any and all other rights, powers, and remedies now or hereafter existing at law or in equity (including under the Code and any similar Applicable Laws in any other country in the Territory).  Gilead, in addition to the rights, power, and remedies expressly provided herein, will be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity, including under the Code.  The Parties agree that they intend the following Gilead rights to extend to the maximum extent permitted by law, including for purposes of the Code, and the Gritstone In-License Agreements: (i) the right of access to any Licensed Technology (including all embodiments thereof), or receive the name and contact information of any Third Party with whom Gritstone contracts to perform an obligation of Gritstone under this Agreement for purposes of entering into negotiations for such Third Party to perform such obligation directly on behalf of Gilead which is necessary for the Exploitation of Products in the Field of Use in the Territory; (ii) the right to contract directly with any Third Party described in paragraph (i) to complete the contracted work; and (iii) the right to cure any breach of or default under any such agreement with a Third Party and, subject to Section 365(n) of the Code, set off or recoup the costs thereof against amounts payable to Gritstone under this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XIV<br>EFFECT OF TERMINATION</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14.1.	Termination by Gilead for Convenience or by Gritstone for Material Breach or Insolvency of Gilead or Expiration Without Option Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Upon termination of this Agreement by Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, termination of this Agreement by Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">13.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, expiration of this Agreement on the last day of the Option Term because Gilead has not exercised the Option or because Gilead has exercised the Option but the Option Effective Date has not occurred on or before the Outside Date, the following will apply as of the effective date of such termination or expiration, but, in the case of partial termination of this Agreement, solely with respect to the applicable Terminated Products (except that, for clarity, the limitation as to Terminated Products will not be applicable to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">):</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref343"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.1.	the licenses (and sublicenses) granted by Gritstone to Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the Terminated Product will terminate and Gilead will not have any rights to use or exercise any rights under the Licensed Technology with respect to such Terminated Product;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">55</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.2.	the license granted by Gilead to Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the Terminated Product will terminate and Gritstone will not have any rights to use or exercise any rights under the Gilead Licensed Technology with respect to such Terminated Product;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.4.	Gilead will be released from its Development and Commercialization obligations under this Agreement with respect to the Terminated Product, including with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 8.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; for clarity, it being understood that Gilead&#x2019;s obligations under such Sections survive as to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.5.	Gilead, its Affiliates or its Sublicensees will cease all Commercialization of Products in a prompt manner and in accordance with Applicable Laws; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gilead, its Affiliates or its Sublicensees will be entitled (and the applicable licenses to Gilead will survive solely to the extent and for so long as is necessary to permit), during the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period following the effective date of a termination, to sell any commercial inventory of Terminated Products which remains on hand as of the effective date of the termination; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gilead pays to Gritstone the Royalties and, if applicable, Sales Milestone Payments applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.1.6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14.2.	Termination by Gilead for Material Breach by or Insolvency of Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Upon termination of this Agreement by Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">13.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> the following will apply as of the effective date of such termination:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.1.	subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the licenses (and sublicenses) granted by Gritstone to Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will terminate and Gilead will not have any rights to use or exercise any rights under the Licensed Technology and Gilead, its Affiliates or its Sublicensees will cease all Commercialization of Products in a prompt manner and in accordance with Applicable Laws; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gilead, its Affiliates or its Sublicensees will be entitled (and the applicable licenses to Gilead will survive solely to the extent and for so long as is necessary to permit), during the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period following the effective date of a termination, to sell any commercial inventory of Terminated Products for which Regulatory Approval has been obtained which remains on hand as of the effective date of the termination; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gilead pays to Gritstone the Royalties and, if applicable, Sales Milestone Payments applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.2.	the license granted by Gilead to Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will terminate and Gritstone will not have any rights to use or exercise any rights under the Gilead Licensed Technology;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.3.	solely in the case of termination of this Agreement in its entirety, the license granted by Gilead to Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will terminate and Gritstone will not have any rights to use or exercise any rights under the Selected Collaboration IP;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.4.	Gilead will be released from its Development and Commercialization obligations under this Agreement, including with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 8.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">56</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.2.7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14.3.	Alternative to Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If Gilead has the right to terminate this Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">13.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following the expiration of the relevant cure period or insolvency event, if any, Gilead may, by written notice to Gritstone, and as its sole and exclusive remedy and in lieu of exercising its right under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to any applicable breach, elect </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in which case, effective as of the date Gilead delivers notice of such election to Gritstone, the licenses granted by Gritstone to Gilead pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the Product that would have become a Terminated Product had Gilead exercised its termination right </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that (a) with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and, solely with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and (b) solely if there </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">14.4.	Surviving Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Accrued Rights; Remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The expiration or termination of this Agreement for any reason will be without prejudice to any rights that will have accrued to the benefit of any Party prior to such expiration or termination, and any and all damages or remedies (whether at law or in equity) arising from any breach hereunder, each of which will survive expiration or termination of this Agreement.  Such expiration or termination will not relieve any Party from obligations which are expressly indicated to survive expiration or termination of this Agreement.  Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">14.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Without limiting the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.4.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the following provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and any other obligations and rights which are expressly intended to survive, will survive expiration or termination of this Agreement: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.1 (Each Party&#x2019;s Responsibilities)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse, pursuant to Section 10.1.3, Gritstone any unreimbursed Gritstone Reimbursable Costs incurred during the Term under the Gritstone R&amp;D Budget, including any permitted overages as set forth under Section 2.1.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.1.3 (Records)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (for a period of at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">after termination or expiration or such longer period as may be required by Applicable Law for particular records); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.2.1 (Gilead Composition)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (excluding the first sentence but, for clarity, without limiting Gritstone&#x2019;s obligation to destroy the Confidential Information of Gilead under Section 12.1 unless otherwise requested by Gilead); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.2.2 (No Warranties)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (for clarity, without limiting Gritstone&#x2019;s obligation to destroy the Confidential Information of Gilead under Section 12.1 unless otherwise requested by Gilead); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 2.3 (Material Transfer)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (last sentence only but, for clarity, without limiting the Receiving Party&#x2019;s obligation to destroy the Confidential Information of the Disclosing Party under Section 12.1 unless otherwise agreed or requested by the Disclosing Party); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(b) (Existing In-License Agreements)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (second sentence solely with respect to any applicable provisions to the extent surviving pursuant to the terms and conditions of the applicable Gritstone In-License Agreement or this Section 14.4.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(c) (Future Core In-License Agreements)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (last sentence solely with respect to any applicable provisions to the extent surviving pursuant to the terms and conditions of the applicable Gritstone In-License Agreement or this Section 14.4.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(d) (Future Other In-License Agreements)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(e) (Future Gritstone Product-Related Agreement Sublicense)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (in each case, solely with respect to any applicable provisions to the extent surviving pursuant to the terms and conditions of the applicable Gritstone In-License Agreement or this Section 14.4.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(f) (Cooperation)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(g) (Compliance by Gilead Sublicensees)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s responsibility for consequences of a Sublicensee&#x2019;s failure to comply (i) during the Term, with the applicable Gritstone In-License Agreement or (ii) after the effective date of termination or expiration, any applicable provisions surviving pursuant to the terms and conditions of the applicable Gritstone In-License Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">57</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or this Section 14.4.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.1.4(h) (Sublicense under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (in the event the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> is an Existing In-License Agreement, solely with respect to any applicable provisions surviving pursuant to the terms and conditions of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">or this Section 14.4.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2 (Grantback License)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely to the extent provided in Section 14.1.3 unless terminated under Section 14.3); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.3 (Sublicensing by Gritstone)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (to the extent the license under Section 3.2.2 survives, the second sentence (with respect to consistency with surviving provisions of this Agreement) and last sentences); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 5.2 (Consultation and Assistance)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to any unreimbursed expense incurred by Gritstone during the Term that would have been reimbursed but for termination or expiration); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.2 (Gritstone Responsibility)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse Gritstone for any unreimbursed Gritstone Reimbursable Costs incurred during the Term in carrying out activities pursuant to Section 6.3.2); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.3 (Ownership)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.3.4 (Communication with Regulatory Authorities)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">: (with respect to any applicable correspondence or other communications by a Regulatory Authority to Gilead, its Affiliates or its Sublicensees or Subcontractors as it relates to activities under this Agreement, and (solely during any sell off period or as it relates to activities under this Agreement) any applicable correspondence or other communications by a Regulatory Authority to Gritstone, its Affiliates or Sublicensees); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.6 (Compliance)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely to the extent a Party has obligations under this Agreement that survive termination of this Agreement including if Gilead continues to sell any commercial inventory of Terminated Products pursuant to Sections 14.1.5 and 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.3 (Manufacturing Know-How and Assistance)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse Gritstone for any unreimbursed Gritstone Reimbursable Costs incurred during the Term by Gritstone pursuant to Section 7.3); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.4 (Manufacturing Technology Transfer)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse Gritstone for any unreimbursed Gritstone Reimbursable Costs incurred during the Term by Gritstone pursuant to Section 7.4); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 7.5 (Future Manufacturing Improvements)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse Gritstone for any unreimbursed Gritstone Reimbursable Costs incurred during the Term   by Gritstone pursuant to Section 7.5); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.1 (Development Milestones)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to any unpaid Development Milestone Payment achieved prior to the effective date of termination or expiration); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.4.2 (Commercial Milestones)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to applicable Net Sales prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.5 (Royalty Payments)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to applicable Net Sales during the applicable Royalty Term prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.6 (Royalty Reductions)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Net Sales prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(d) (Responsibility for Payments under Gritstone In-License Agreements)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (entire provision except for last sentence, solely with respect to any amounts accrued and not paid prior to the effective date of termination or expiration); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.3 (Offset for Third Party Payments)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.8 (Cumulative Effect of Reductions)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (subject to Section 14.3 (Alternative to Termination); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.10 (Non-Refundable and Non-Creditable Payments)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.1.1 (Development Milestone Payments)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to any unpaid and owed Development Milestone Payment achieved prior to the effective date of termination or expiration); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.1.2 (Royalties and Sales Milestone Payments)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to applicable Net Sales prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.1.3 (Gritstone Reimbursable Costs)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Gilead&#x2019;s obligation to reimburse Gritstone for any unreimbursed Gritstone Reimbursable Costs incurred during the Term); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.1.4 (Payment Method), Section 10.2 (Currency), Section 10.3 (Blocked Currency)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.4 (Taxes, Withholding)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (in each case, solely with respect to any amounts accrued and not paid prior to the effective date of termination or expiration or accrued after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 10.5 (Records and Audit Rights)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely for the term set forth therein, but for clarity, including with respect to any sales or amounts accrued prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.1 (Inventorship)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.2 (Ownership)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (except for Section 11.2.2(e), which shall only survive with respect to (a) obligations under Section 11.10 (to the extent applicable and surviving) or (b) with respect to activities during the Term or any Patent Rights or Know-How conceived, discovered or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">58</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">otherwise made or invented during the Term pursuant to the last sentence.  For clarity, no Collaboration IP shall be developed, conceived or reduced to practice following the Term); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.1(b) (Joint Collaboration Patents)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.2 (Review and Comment Rights)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Joint Collaboration Patents); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.3.3 (Cooperation and Coordination)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Joint Collaboration Patents); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.1 (Notifications)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Joint Collaboration Patents); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(b) (Infringement Actions &#x2013; Joint Collaboration IP)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.4.2(e) (Procedures)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Joint Collaboration IP); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.5 (Defense)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to Research, Development, Manufacture, Commercialization or Exploitation of any Product prior to the effective date of termination or expiration or after such date pursuant to Section 14.1.5 or 14.2.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.6 (Recovery)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (solely with respect to any surviving rights and obligations under the Sections cited therein (including Section 11.10 with respect to recoveries allocable under a Gritstone In-License Agreement) and recoveries under any applicable actions initiated prior to the effective date of termination or expiration); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 11.10 (Third Party Agreement-Governed Intellectual Property Rights)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (in the case of Section 11.10.2, solely to the extent necessary to comply with applicable terms of any Gritstone In-License Agreement that survive termination or expiration of this Agreement); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 12.1-12.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (including with respect to all Confidential Information under this Agreement and, with respect to Section 12.1, for the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">period, as applicable, cited under Section 12.1); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 12.6  (Publicity)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 13.6 (Rights in Bankruptcy)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 14.1-14.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (as applicable); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.3 (Alternative to Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) (solely with respect to the royalty reduction in the event that royalties are otherwise payable after the Term for Net Sales during the Term); this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 14.4 (Surviving Provisions)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article 16 (Indemnification; Liability)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (with respect to Section 16.6 (Insurance), solely for the duration set forth under Section 16.6.3) and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article 17 (General Provisions)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">If this Agreement is terminated with respect to a given Product or a given country, but not in its entirety, then following such termination the foregoing provisions of this Agreement shall remain in effect with respect to the Terminated Product(s), as applicable (to the extent they would survive and apply in the event the Agreement expires or is terminated in its entirety or as otherwise necessary for the Parties to exercise their rights with respect thereto) and all provisions not surviving in accordance with the foregoing shall terminate with respect to the Terminated Product(s), as applicable, upon the effective date of termination thereof.  Notwithstanding the foregoing, for clarity, in no event shall </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XV<br>REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.1.	Representations and Warranties by Each Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party represents and warrants to the other Party, as of the Effective Date, that:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.1.	such Party is duly organized, validly existing and in good standing under the Applicable Law of the jurisdiction of its formation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.2.	such Party has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref272"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.3.	this Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms, except to the extent that enforcement of the rights and remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> created hereby is subject to: (a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors; or (b) laws governing specific performance, injunctive relief and other equitable remedies;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">59</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.4.	the execution, delivery and performance of this Agreement by such Party does not breach or conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which such Party is a party or by which such Party is bound, nor violate any Applicable Law of any Governmental Authority having jurisdiction over such Party;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref273"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.5.	no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any Applicable Law currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> under this Agreement, except</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or Commercialize any Product(s); and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref274"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.1.6.	such Party has obtained all necessary authorizations, consents and approvals of any Third Party that is required to be obtained by it for, or in connection with, the transactions contemplated by this Agreement, or for the performance by it of its obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> under this Agreement, except</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as may be required to conduct Clinical Trials or to seek or obtain Regulatory Approvals or applicable Regulatory Materials, or to Manufacture or Commercialize any Product(s).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.2.	Representations and Warranties by Gritstone as of the Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone represents and warrants to Gilead except as set forth in the disclosure schedule set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as of the Effective Date, that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> sets forth a complete and accurate list of all (a) Patent Rights within the Owned Licensed Gritstone Background Technology and, (b) to the Knowledge of Gritstone, published and issued Licensed Gritstone Background Patents exclusively licensed (including exclusivity with respect to a field or country) to Gritstone pursuant to any Existing In-License Agreement, including under the relevant Existing In-License Agreement set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All issued Patent Rights constituting Owned Licensed Gritstone Background Technology (and all applications in such Patent Rights constituting Owned Licensed Gritstone Background Technology, when issued) are or will be, as applicable, in full force and effect and, to the Knowledge of Gritstone, valid and enforceable.  To the Knowledge of Gritstone, all published and issued Licensed Gritstone Background Patents exclusively licensed (including exclusivity with respect to a field or country) to Gritstone pursuant to an Existing In-License Agreement are or will be, as applicable, in full force and effect and valid and enforceable. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All application, registration, maintenance and renewal fees due as of the Effective Date with respect to all Patent Rights within the Owned Licensed Gritstone Background Technology have been paid (or are in process) and all necessary documents and certificates have been filed with the relevant patent registries for the purpose of maintaining such Licensed Patents (or are in process);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.2.	no claim has been issued or served, or written threat of a claim or litigation made by any Person, against Gritstone or its Affiliates that alleges that any Licensed Gritstone Background Patent is invalid or unenforceable;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.3.	Gritstone has the right and authority to grant the option, rights and licenses granted to Gilead (or purported to be granted to Gilead) hereunder with respect to Owned Licensed Technology free from Encumbrances, and has the right and authority to grant the sublicenses granted to Gilead with respect to Licensed Technology licensed to Gritstone pursuant to any Existing In-License Agreement, and neither Gritstone nor its Affiliates have granted any option, right, license or right of first refusal to any Third Party under any of the Licensed Technology in the Field of Use, in each case that would conflict with or limit the scope of any of the options, rights or licenses granted to Gilead hereunder;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">60</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.4.	all Affiliates of Gritstone have exclusively licensed or assigned all of their rights, title and interests in and to the Licensed Gritstone Background Technology to Gritstone.  Neither Gritstone nor any of its Affiliates has granted any mortgage, pledge, claim, security interest, lien or other charge of any kind on the Licensed Technology, and the Owned Licensed Technology is free and clear of any mortgage, pledge, claim, security interest, lien or charge of any kind (provided, for clarity, that no representation or warranty is made under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the grant of any option, license or right of first refusal);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.5.	Gritstone and its Affiliates have obtained from all individuals who participated in any respect in the invention or authorship of any Owned Licensed Gritstone Background Technology effective assignments of all ownership rights of such individuals in such Licensed Technology, either pursuant to written agreement or by operation of law, except with respect to any Know-How within Owned Licensed Gritstone Background Technology (a) that is not material for the Exploitation of Products in the Field of Use or (b) that is co-owned by Gritstone or any of its Affiliates and a Third Party, including any such Licensed Technology jointly created or conceived by or on behalf of Gritstone or any of its Affiliates, on the one hand, and such Third Party, on the other hand, in which case Gritstone has obtained from all individuals who are employees, officers or consultants of Gritstone and participated in the invention or authorship of such Licensed Technology effective assignments of all ownership rights of such individuals in such Know-How; and no Person who claims to be an inventor of an Invention claimed in a Patent Right within the Owned Licensed Gritstone Background Technology is not identified as an inventor of such Invention in the filed patent documents for such Licensed Patent;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref276"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.6.	all of Gritstone&#x2019;s and its Affiliates&#x2019; employees, officers and consultants: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> have executed agreements or have existing obligations under Applicable Law thereby assigning to Gritstone or its Affiliates all Inventions made during the course of and as the result of their association with Gritstone or its Affiliates, as applicable, which terms are applicable to Inventions that may be made by such employees, officers and consultants during the course of Gritstone&#x2019;s performance under this Agreement; (b) to the Knowledge of Gritstone, are not subject to any agreement with any other Third Party that requires such officer or employee or consultant to assign any interest in any Licensed Technology to such Third Party; and (c) have executed agreements or have existing obligations under Applicable Law obligating the individual to maintain as confidential Gritstone&#x2019;s Confidential Information as well as confidential information of other parties (including of Gilead and its Affiliates) that such individual may receive in its performance under this Agreement, to the extent required to support Gritstone&#x2019;s obligations under this Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.7.	neither Gritstone nor its Affiliates have received any written notice of any claim that any Patent Right or Know-How (including any trade secret right) owned or controlled by a Third Party would be infringed, misappropriated or otherwise violated by Exploitation of the Products in the Field of Use;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.8.	to the Knowledge of Gritstone, the use of Gritstone Platform Technology in the Exploitation of the Products in the Field of Use, as anticipated to be utilized by Gritstone in conducting the R&amp;D Plan or the Manufacture of Product under the Supply Agreement, and any anticipated Qualifying Use of Gritstone Platform Technology in the Exploitation of Products in the Field of Use by Gilead and its Affiliates, will not infringe, misappropriate or otherwise violate any intellectual property or proprietary right of any Third Party, except in the absence of a license or sublicense granted under the Existing In-License Agreements; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that, for clarity, Gritstone makes no representation or warranty with respect to the Exploitation of any HIV Antigen or Other Agent (including any Gilead Composition);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">61</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.9.	there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, or legal, administrative or other proceedings, or governmental investigations pending or, to the Knowledge of Gritstone, threatened against Gritstone or its Affiliates which would reasonably be expected to adversely affect or restrict the ability of Gritstone to consummate or perform the transactions contemplated under this Agreement, or which would reasonably be expected to adversely affect the Owned Licensed Technology (or Gritstone&#x2019;s Control thereof) or, to the Knowledge of Gritstone, any other Licensed Technology or Gritstone&#x2019;s Control thereof;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.10.	 neither Gritstone nor any of its Affiliates has made a claim against a Third Party alleging that a Third Party is infringing or has infringed, is misappropriating or has misappropriated, or is violating or has violated, any Licensed Gritstone Background Technology, and, to the Knowledge of Gritstone, no Licensed Gritstone Background Technology is being infringed, misappropriated or violated by any Third Party, nor has Gritstone or any of its Affiliates received any written notice regarding any such alleged infringement, misappropriation or violation;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.11.	 the Excluded Technology in existence as of the Effective Date is not necessary for the Exploitation of the Products as contemplated herein;</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref278"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.12.	neither Gritstone nor any of its Affiliates has employed or otherwise used in any capacity with respect to the Product or any Licensed Gritstone Background Technology, the services of any Person suspended, proposed for debarment or debarred under United States law, including under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">21</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> U.S.C. &#167; 335a, or any foreign equivalent thereof, with respect to the performance of activities hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref279"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.13.	 except as set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.122</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, neither Gritstone nor its Affiliates have entered into any agreement under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">which Gritstone or its Affiliates: (a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> has obtained a license or sublicense of rights from a Third Party to any Licensed Gritstone Background Technology in the Field of Use, other than under any (i) non-material licenses granted to the Gritstone or its Affiliates under (x) agreements with vendors or contractors working on Gritstone&#x2019;s or any of its Affiliate&#x2019;s behalf, or (y) clinical trial agreements or sponsored research agreements with clinical trial sites and other educational or non-profit medical institutions relating to products and programs outside the Field of Use, or (ii) non-disclosure agreements; or (b) has granted a license, sublicense, option or right to a Third Party that remains in effect to Exploit any Product;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.14.	 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 1.122</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> sets forth a complete and accurate list of the Existing In-License Agreements in effect as of the Effective Date in the Field of Use.</font><font style="background-color:rgba(0,0,0,0);color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone has provided Gilead true, correct and complete (subject to redactions thereto) copies of each such Existing In-License Agreement.  Each such Existing In-License Agreement is in full force and effect, and there has been no Default of or under (or notice of Default of or under) any such Existing In-License Agreement as a result of any action or omission or alleged act or omission of Gritstone or its Affiliates or, to the Knowledge of Gritstone, the actions or omissions of any Third Party.  Gritstone has not waived any of its rights under any such Existing In-License Agreement to which it is party;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.15.	 other than the Existing In-License Agreements, Gritstone (or its Affiliates, as applicable) has not entered into any agreement specifically relating to the Research or Development or other Exploitation of any Product contemplated hereunder in the Field of Use;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.16.	 the Existing In-License Agreements are not redacted in a manner that would affect Gilead&#x2019;s understanding of its rights or obligations under this Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">62</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.17.	 Gritstone (or its Affiliates, as applicable) has the right and authority to use and license (as Licensed Know-How under this Agreement) any Know-How conceived, reduced to practice or otherwise created </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as contemplated herein;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.18.	 the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (as defined in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">) in the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">does not include the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> under this Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.19.	 a Product is not </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.20.	 no Patent Rights that are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">have been filed as of the Effective Date pursuant to the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.21.	Gritstone has disclosed to Gilead (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (b) summaries of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, (c) summaries of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and (d) all </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, and in each case ((a)-(d)) excluding CMC or Manufacturing data with respect to any products that utilize the Gritstone Platform Technology;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.22.	 Gritstone has not obtained, or filed, any INDs, MAAs or other Regulatory Approvals or any other form of regulatory application for approval of Clinical Trials, marketing or other purpose, in each case for any Product, and, to the Knowledge of Gritstone, no other Person has obtained, or filed for, any such INDs, MAAs or other Regulatory Approvals; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref282"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.2.23.	 no funding, facilities or personnel of any Governmental Authority were used to develop or create any Owned Licensed Gritstone Background Technology, and neither Gritstone nor any of its Affiliates has entered into a government funding relationship, or any public or private education or research institution relationship, that, in each case, would result in rights to the Products residing in the U.S. Government, the National Institutes of Health, the National Institute for Drug Abuse or other agency, and the options and licenses granted hereunder are not subject to overriding obligations to the U.S. Government as set forth in Public Law </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">96</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-</font><font id="docxtextref281"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">517</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (</font><font id="docxtextref284"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">35</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> U.S.C. &#167;&#167; </font><font id="docxtextref283"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">200</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-</font><font id="docxtextref285"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">204</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), or any similar obligations under the laws of any other country in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.3.	Representations and Warranties by Gritstone as of the Disclosure Letter Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone represents and warrants to Gilead except as set forth in the disclosure schedule set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as of the Disclosure Letter Date, that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">sets forth a complete and accurate list of all (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and, (b) to the Knowledge of Gritstone, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, including under the relevant </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All issued Patent Rights constituting Owned Licensed Technology (and all applications in such Patent Rights constituting Owned Licensed Technology, when issued) are or will be, as applicable, in full force and effect and, to the Knowledge of Gritstone, valid and enforceable. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All application, registration, maintenance and renewal fees due as of the Effective Date with respect to all Patent Rights within the Owned Licensed Technology have been paid (or are in process) and all necessary documents and certificates have been filed with the relevant patent registries for the purpose of maintaining such Licensed Patents (or are in process);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.2.	no claim has been issued or served, or written threat of a claim or litigation made by any Person, against Gritstone or its Affiliates that alleges that any Licensed Patent is invalid or unenforceable;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.3.	Gritstone has the right and authority to grant the option, rights and licenses granted to Gilead (or purported to be granted to Gilead) hereunder with respect to Owned Licensed Technology free from Encumbrances, and has the right and authority to grant the sublicenses granted to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">63</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead with respect to Licensed Technology licensed to Gritstone pursuant to any Gritstone In-License Agreement, and neither Gritstone nor its Affiliates have granted any option, right, license or right of first refusal to any Third Party under any of the Licensed Technology in the Field of Use, in each case that would conflict with or limit the scope of any of the options, rights or licenses granted to Gilead hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.4.	neither Gritstone nor any of its Affiliates has granted any mortgage, pledge, claim, security interest, lien or other charge of any kind on the Licensed Technology, and the Owned Licensed Technology is free and clear of any mortgage, pledge, claim, security interest, lien or charge of any kind (provided, for clarity, that no representation or warranty is made under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> with respect to the grant of any option, license or right of first refusal);</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.5.	Gritstone and its Affiliates have obtained from all individuals who participated in any respect in the invention or authorship of any Owned Licensed Technology effective assignments of all ownership rights of such individuals in such Licensed Technology, either pursuant to written agreement or by operation of law, except with respect to any Know-How within Owned Licensed Technology (a) that is not material for the Exploitation of Products in the Field of Use or (b) that is co-owned by Gritstone or any of its Affiliates and a Third Party, including any such Licensed Technology jointly created or conceived by or on behalf of Gritstone or any of its Affiliates, on the one hand, and such Third Party, on the other hand, in which case Gritstone has obtained from all individuals who are employees, officers or consultants of Gritstone and participated in the invention or authorship of such Licensed Technology effective assignments of all ownership rights of such individuals in such Know-How; and no Person who claims to be an inventor of an Invention claimed in a Patent Right within the Owned Licensed Technology is not identified as an inventor of such Invention in the filed patent documents for such Licensed Patent;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.6.	neither Gritstone nor its Affiliates have received any written notice of any claim that any Patent Right or Know-How (including any trade secret right) owned or controlled by a Third Party would be infringed, misappropriated or otherwise violated by Exploitation of the Products in the Field of Use;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.7.	to the Knowledge of Gritstone, the use of Gritstone Platform Technology in the Exploitation of the Products in the Field of Use, as anticipated to be utilized by Gritstone in conducting the R&amp;D Plan or the Manufacture of Product under the Supply Agreement, and any anticipated Qualifying Use of Gritstone Platform Technology in the Exploitation of Products in the Field of Use by Gilead and its Affiliates, will not infringe, misappropriate or otherwise violate any intellectual property or proprietary right of any Third Party, except in the absence of a license or sublicense granted under the (a) Gritstone In-License Agreements or (b) any license agreement with respect to which Gilead decides not to accept such agreement as a Gritstone In-License Agreement pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 9.7.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">that, for clarity, Gritstone makes no representation or warranty with respect to the Exploitation of any HIV Antigen or Other Agent (including any Gilead Composition).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.8.	there are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, or legal, administrative or other proceedings, or governmental investigations pending or, to the Knowledge of Gritstone, threatened against Gritstone or its Affiliates which would reasonably be expected to adversely affect the Owned Licensed Technology (or Gritstone&#x2019;s Control thereof) or, to the Knowledge of Gritstone, any other Licensed Technology or Gritstone&#x2019;s Control thereof;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.9.	 neither Gritstone nor any of its Affiliates has made a claim against a Third Party alleging that a Third Party is infringing or has infringed, is misappropriating or has misappropriated, or is violating or has violated, any Licensed Technology, and, to the Knowledge of Gritstone, no Licensed Technology is being infringed, misappropriated or violated by any Third Party, in each case in the Field of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">64</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Use, nor has Gritstone or any of its Affiliates received any written notice regarding any such alleged infringement, misappropriation or violation;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.10.	the Excluded Technology described in clause (a) of the definition thereof in existence as of the Disclosure Letter Date is not necessary for the Exploitation of the Products as contemplated herein; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.3.11.	neither Gritstone nor any of its Affiliates has employed or otherwise used in any capacity with respect to the Product, the services of any Person suspended, proposed for debarment or debarred under United States law, including under 21 U.S.C. &#167; 335a, or any foreign equivalent thereof, with respect to the performance of activities hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.4.	Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party hereby covenants to the other Party that such Party and its Affiliates will perform such Party&#x2019;s activities pursuant to this Agreement in compliance (and will ensure compliance by any of its Subcontractors) with all Applicable Law, including, to the extent applicable, GCP, GLP and GMP.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.5.	Additional Covenants of Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone hereby covenants to Gilead that:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.1.	neither Gritstone nor its Affiliates will grant any option, right or license to any Third Party relating to any of the intellectual property rights it Controls (including the Licensed Technology) with respect to any Product, which conflict with the option, rights or licenses granted to Gilead in the Field of Use hereunder; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, following the Effective Date as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, Gritstone may </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> provided, further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gritstone shall provide Gilead with notice of, and, upon Gilead&#x2019;s written request, a redacted copy of, any such </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.2.	subject to Gritstone&#x2019;s retained rights as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.4,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> except as otherwise expressly agreed to by Gilead in writing, neither Gritstone nor its Affiliates will use or otherwise Exploit (and neither will grant any Third Party the right to use or otherwise Exploit) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.3.	except as otherwise expressly permitted under this Agreement, Gritstone will not, and will cause its Affiliates not to assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (through a lien, charge, security interest, mortgage or similar encumbrance) or dispose of, any Licensed Technology or any Product, except to the extent that such assignment, transfer, conveyance, encumbrance or disposition would not conflict with, be inconsistent with or adversely affect in any respect any of the option, rights or licenses granted to Gilead hereunder;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.4.	Gritstone will not </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> under, any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in a manner that results in the counterparty thereto </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in the Field of Use in a manner that would diminish the scope or exclusivity of the licenses granted to Gilead under any Licensed Technology; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, however, that Gritstone shall not be in violation of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 15.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in the case of any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that results from any action or inaction of Gilead or any of its Affiliates or its or their sublicensees or subcontractors;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.5.	all activities (including Research, Development and Manufacturing activities) conducted by or on behalf of Gritstone or its Affiliates hereunder with respect to any Product will be conducted in accordance with all Applicable Law (including, to the extent applicable, GCP, GLP and GMP), and in sufficient detail and in a good scientific manner appropriate for scientific, regulatory and intellectual property protection purposes, and all such activities will be segregated from other activities not performed under this Agreement and all records kept in connection with such activities will be complete</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">65</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">and accurate, and fully and accurately reflect all work done, data and developments made, and results achieved in the performance of the R&amp;D Program and Supply Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.6.	if Gritstone receives notice of an alleged </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, then Gritstone will promptly, but in no event less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> Business Days thereafter, provide written notice thereof to Gilead;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.7.	Gritstone will not (a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in each case in a manner that would adversely affect Gilead&#x2019;s rights or Gritstone&#x2019;s ability to perform its obligations under this Agreement or (b) modify or amend any </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in a manner that would impose additional obligations on Gilead </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in each case ((a) and (b)), without first obtaining Gilead&#x2019;s prior written consent;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.8.	Gritstone will notify Gilead in the event that Gritstone modifies, amends, terminates or assigns </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, in each case in a manner that would adversely affect Gilead&#x2019;s </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.9.	all of Gritstone&#x2019;s employees, officers and consultants who will perform activities under this Agreement with respect to any Product have executed or will execute agreements or have existing obligations under Applicable Laws requiring assignment to Gritstone of all Inventions made during the course of and as the result of their association with Gritstone, free from any Encumbrances, and obligating the individual to maintain as confidential Gritstone&#x2019;s Confidential Information as well as the confidential information of other parties (including Confidential Information of Gilead and its Affiliates) which such individual may receive (it being understood that such confidentiality obligations may be general in nature and need not be specific to Confidential Information under this Agreement), in each case above, to the extent required to support Gritstone&#x2019;s obligations under this Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.10.	without limitation of Gritstone&#x2019;s other obligations under this Agreement (including </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 6.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">), if, at any time after execution of this Agreement, Gritstone becomes aware that it or any employee, agent, or Subcontractor of Gritstone who participated, or is participating, in the performance of any activities with respect to the Product or any Licensed Technology is on, or is being added to, the FDA Debarment List, it will provide written notice of this to Gilead within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Business Days of its becoming aware of this fact;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.11.	 Gritstone will maintain sufficient security systems and intellectual property protection practices within its organization equivalent to international industry standards to avoid any unauthorized disclosure of intellectual property rights, including Know-How and Gilead Confidential Information, to any Third Party; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">15.5.12.	 Gritstone will not modify or amend the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in a manner that </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, which would include, for example, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, without first obtaining Gilead&#x2019;s prior written consent.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.6.	Limitation on Scope of Representations, Warranties and Covenants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding anything contained in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XV</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to the contrary, the Parties agree that for purposes of the representations, warranties and covenants contained herein, Gritstone makes no representation, warranty or covenant with respect to any HIV Antigen or Other Agent (including any Gilead Composition) contained, incorporated or otherwise included in any Product or any Know-How, Patent Rights or other intellectual property rights with respect to any HIV Antigen or Other Agent, and references to &#x201c;Product&#x201d; under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XV</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> shall be deemed to include only the Vaccine contained, incorporated or otherwise included in such Product, excluding any HIV Antigen or Other Agent.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.7.	Disclaimer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">66</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED (AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY PROVIDED IN THIS AGREEMENT), INCLUDING WITH RESPECT TO ANY PATENT RIGHTS, KNOW-HOW OR MATERIALS, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE AND NON-INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY RIGHT.  WITHOUT LIMITING THE FOREGOING, THE PARTIES AGREE THAT THE DEVELOPMENT MILESTONE EVENTS, SALES MILESTONE EVENTS AND NET SALES LEVELS SET FORTH IN THIS AGREEMENT OR THAT HAVE OTHERWISE BEEN DISCUSSED BY THE PARTIES ARE MERELY INTENDED TO DEFINE THE MILESTONE PAYMENTS AND ROYALTY OBLIGATIONS IF SUCH DEVELOPMENT MILESTONE EVENTS, SALES MILESTONE EVENTS OR NET SALES LEVELS ARE ACHIEVED.  NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP, MANUFACTURE OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT (LOSS) OF PRODUCT WILL BE ACHIEVED.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XVI<br>INDEMNIFICATION; LIABILITY</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.1.	Indemnification by Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will indemnify, defend and hold Gilead, its Affiliates, and its and their respective officers, directors, employees, agents, successors and assigns (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) harmless from and against any and all liability, damage, loss, cost or expense of any nature (including reasonable attorney&#x2019;s fees and litigation expenses) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Losses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) incurred by or imposed upon the Gilead Indemnitees or any of them in connection with any claim, suit, action, demand, proceeding, cause of action or judgment resulting from a Third Party claim (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Claims</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), in each case, to the extent arising or resulting from:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.1.	Gritstone&#x2019;s, or any of its Affiliates&#x2019;, (sub)contractors&#x2019; or (sub)licensee&#x2019;s activities in connection with the R&amp;D Program, except to the extent arising from use of any Gilead Composition, HIV Antigen or Other Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.2.	the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">under this Agreement or the Supply Agreement </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.3.	Gritstone&#x2019;s, or any of its Affiliates&#x2019;, (sub)contractors&#x2019; or (sub)licensee&#x2019;s use of the license granted pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.4.	the negligence or willful misconduct of Gritstone or any of its Affiliates or its (sub) licensees (other than Gilead or its Affiliate or sublicensee), or any directors, officers, employees, (sub)contractors or agents thereof, in connection with Gritstone&#x2019;s performance of its obligations under this Agreement; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.1.5.	the breach of any of the obligations, covenants, representations or warranties made by Gritstone to Gilead under this Agreement;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gritstone will not be obliged to so indemnify, defend and hold harmless the Gilead Indemnitees for any Claims to the extent Gilead has an obligation to indemnify Gritstone Indemnitees pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or the Supply Agreement or to the extent that such Claims arise from the breach, negligence or willful misconduct of Gilead or any Gilead Indemnitee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">67</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.2.	Indemnification by Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead will indemnify, defend and hold Gritstone, its Affiliates, and its and their respective officers, directors, employees, agents, successors and assigns (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gritstone Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) harmless from and against any and all Losses incurred by or imposed upon the Gritstone Indemnitees or any of them in connection with any Claims, in each case, to the extent arising or resulting from:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.2.1.	Gilead&#x2019;s, or any of its Affiliates&#x2019;, Sublicensees&#x2019; or (sub)contractors&#x2019; activities in connection with the R&amp;D Program or the Exploitation of Products in the Territory;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.2.2.	Gritstone&#x2019;s, or any of its Affiliates&#x2019; or (sub)contractors&#x2019; use of any Gilead Composition in accordance with this Agreement or the Supply Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.2.3.	the negligence or willful misconduct of Gilead or any of its Affiliates or its Sublicensees, or any directors, officers, employees, (sub)contractors or agents thereof, in connection with Gilead&#x2019;s performance of its obligations under this Agreement; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.2.4.	the breach of any of the obligations, covenants, representations or warranties made by Gilead to Gritstone under this Agreement;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that Gilead will not be obliged to so indemnify, defend and hold harmless the Gritstone Indemnitees for any Claims to the extent Gritstone has an obligation to indemnify Gilead Indemnitees pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or the Supply Agreement or to the extent that such Claims arise from the breach, negligence, or willful misconduct of Gritstone or any Gritstone Indemnitee.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.3.	Indemnification Procedure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.3.1.	A Gilead Indemnitee or Gritstone Indemnitee seeking indemnification under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnified Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) will notify the other Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnifying Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) in writing reasonably promptly after the assertion against the Indemnified Party of any Claim in respect of which the Indemnified Party intends to base a claim for indemnification hereunder (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Indemnification Claim Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that the failure or delay to so notify the Indemnifying Party will not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is adversely affected thereby.  The Indemnification Claim Notice will contain a description of the Claim and the nature and amount of the Claim (to the extent that the nature and amount of such Claim is known at such time).  Upon the request of the Indemnifying Party, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all correspondence, communications and official documents (including court documents) received or sent in respect of such Claim.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.3.2.	Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 16.3.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">16.3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Indemnifying Party will have the right, upon written notice given to the Indemnified Party within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days after receipt of the Indemnification Claim Notice, to assume the defense and handling of such Claim, at the Indemnifying Party&#x2019;s sole expense, in which case the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> below will govern; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that any such Claim is only for monetary damages.  The assumption of the defense of a Claim by the Indemnifying Party will not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any Indemnitee in respect of the Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party&#x2019;s claim for indemnification.  In the event that it is ultimately decided that the Indemnifying Party is not obligated to indemnify or hold an Indemnitee harmless from and against the Claim, the Indemnified Party will reimburse the Indemnifying Party for any and all reasonable costs and expenses (including reasonable attorneys&#x2019; fees and costs of suit) and any losses incurred by the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">68</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Indemnifying Party in its defense of the Claim.  If the Indemnifying Party does not give written notice to the Indemnified Party, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> days after receipt of the Indemnification Claim Notice, of the Indemnifying Party&#x2019;s election to assume the defense and handling of such Claim, the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will govern.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.3.3.	Upon assumption of the defense of a Claim by the Indemnifying Party: (a) the Indemnifying Party will have the right to and will assume sole control and responsibility for dealing with the Claim; (b) the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such Claim any law firm or counsel reasonably selected by the Indemnifying Party; (c) the Indemnifying Party will keep the Indemnified Party informed of the status of such Claim; and (d) the Indemnifying Party will have the right to settle the Claim on any terms the Indemnifying Party chooses; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that it will not, without the prior written consent of the Indemnified Party (such consent not to be unreasonably withheld, conditioned or delayed), agree to a settlement of any Claim which could lead to liability or create any financial or other obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party.  The Indemnified Party will cooperate with the Indemnifying Party and will be entitled to participate in, but not control, the defense of such Claim with its own counsel and at its own expense.  In particular, the Indemnified Party will furnish such records, information, and testimony, provide witnesses, and attend such conferences, discovery proceedings, hearings, trials, and appeals as may be reasonably requested in connection therewith.  Such cooperation will include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.3.4.	If the Indemnifying Party does not give written notice to the Indemnified Party as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> or fails to conduct the defense and handling of any Claim in good faith after having assumed such Claim, the Indemnified Party may, at the Indemnifying Party&#x2019;s expense, select counsel reasonably acceptable to the Indemnifying Party in connection with conducting the defense and handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate.  In such event, the Indemnified Party will keep the Indemnifying Party timely apprised of the status of such Claim and will not settle such Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned, or delayed.  If the Indemnified Party defends or handles such Claim, the Indemnifying Party will cooperate with the Indemnified Party, at the Indemnified Party&#x2019;s request but at no expense to the Indemnified Party, and will be entitled to participate in the defense and handling of such Claim with its own counsel and at its own expense.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.4.	Mitigation of Loss</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Nothing in this Agreement will or will be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.5.	Limitation of Liability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  NEITHER GRITSTONE NOR GILEAD, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES UNDER OR IN CONNECTION WITH THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES, OR LOST PROFITS OR LOST REVENUES (WHETHER CONSEQUENTIAL OR DIRECT), WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY, CONTRIBUTION OR OTHERWISE, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">69</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">DAMAGE.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SECTION 16.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> IS INTENDED TO OR WILL LIMIT OR RESTRICT: (A) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; (B) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; OR (C) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">16.6.	Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.6.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Insurance Maintained by Gilead</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  During the Term, Gilead will have and maintain, at its own expense, insurance (with a Third Party or through a program of self-insurance) against liability and other risks associated with its activities and obligations under this Agreement, in such amounts and on such terms as are customary for the activities to be conducted by Gilead under this Agreement.  Gilead will furnish to Gritstone evidence of such insurance upon request.  It is understood that such insurance shall not be construed to create a limit of either Party&#x2019;s liability with respect to its indemnification obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XVI</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.6.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Insurance Maintained by Gritstone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  During the Term, Gritstone will have and maintain in full force and effect, at its own expense, insurance coverage to include:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)	Commercial general liability insurance with limits of liability not less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">per occurrence and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">in the aggregate.  General liability limit requirements may be satisfied by a combination of primary and umbrella or excess liability insurance coverage;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)	Workers&#x2019; compensation insurance in compliance with Applicable Law (including the local law requirements of the state or jurisdiction in which the work is to be performed).  Employer&#x2019;s liability insurance in amounts not less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">for each of: (i) bodily injury by accident (each accident); (ii) bodily injury by disease (policy limit); and (iii) bodily injury by disease (each employee).  Where permitted by Applicable Law, such policies will contain a waiver of the insurer&#x2019;s subrogation rights against Gilead;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)	Automobile liability insurance for bodily injury, property damage and automobile contractual liability covering all owned, hired and non-owned automobiles with a combined single limit of liability for each accident of not less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(d)	during the term of the Supply Agreement, Supply Products and Completed Operations Liability Insurance with a per occurrence limit of not less than </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">16.6.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Additional Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gritstone will name Gilead as an additional insured on the insurance policies maintained pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 16.6.2(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">16.6.2(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable, either by endorsement or blanket additional insured endorsement, and Gritstone will provide evidence of insurance maintained pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> on request of Gilead.  Gritstone will provide Gilead a notice of insurance policy cancellation in accordance with the provisions of the applicable insurance policy maintained pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Insurance policies maintained by Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> should be occurrence type.  If policies maintained by Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> are claims made, then insurance will be maintained by Gritstone for at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following completion of Gritstone&#x2019;s activities under the R&amp;D Plan (or in the case of clause (d) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, for at least </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">following expiration or termination of the Supply Agreement).  All insurance maintained by Gritstone pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 16.6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be underwritten by companies with an AM best rating of at least A-VII.  In addition, such insurance will not be construed to create a limit of either Party&#x2019;s liability with respect to its indemnification obligations under this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XVI</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">70</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Article XVII<br>GENERAL PROVISIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref363"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.1.	Assignment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that (and notwithstanding anything elsewhere in this Agreement to the contrary) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in whole: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> to an Affiliate of such Party; </font><font id="docxtextref364"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> in connection with the transfer or sale of all or substantially all of its assets or business related to the subject matter of this Agreement; or </font><font id="docxtextref365"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> pursuant to a merger or consolidation (or similar transaction) of the assigning Party.  Any attempted assignment not in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be void.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.2.	Extension to Affiliates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will have the right to extend the rights, immunities, and obligations granted in this Agreement to one (1) or more of its Affiliates.  All applicable terms and provisions of this Agreement will apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to the assigning Party.  The assigning Party will remain primarily liable for any acts or omissions of its Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;" id="docxtextref354"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.3.	Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  If one or more of the terms or provisions of this Agreement is held by a court of competent jurisdiction to be void, invalid or unenforceable in any situation in any jurisdiction, such holding will not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the void, invalid or unenforceable term or provision in any other situation or in any other jurisdiction, and the term or provision will be considered severed from this Agreement solely for such situation and solely in such jurisdiction, unless the void, invalid or unenforceable term or provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the void, invalid or unenforceable term or provision.  If the final judgment of such court declares that any term or provision hereof is void, invalid or unenfo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">rceable, the Parties agree to: (a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> reduce the scope, duration, area or applicability of the term or provision or to delete specific words or phrases to the minimum extent necessary to cause such term or provision as so reduced or amended to be enforceable; and </font><font id="docxtextref355"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> make a good faith effort to replace any void, invalid or unenforceable term or provision with a valid and enforceable term or provision such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.4.	Governing Law and Waiver of Jury Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.4.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  This Agreement and any dispute arising from the performance or breach hereof will be governed by and interpreted in accordance with the laws of the State of New York, without giving effect to the application of any conflict of laws principles that would require application of the laws of another jurisdiction.  The provisions of the United Nations Convention on Contracts for the International Sale of Goods will not apply to this Agreement or any subject matter hereof.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.4.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Waiver of Jury Trial</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT, OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE.  THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY, AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT WILL</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">71</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">INSTEAD BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.5.	Dispute Resolution; Rules of Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.1.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;"> Initial Dispute Resolution Process</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Except as otherwise set forth in this Agreement, in the event of an unresolved matter, dispute, or issue which relates to the breach or alleged breach or interpretation of this Agreement (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) or which this Agreement expressly provides will be resolved in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Selected Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), the Parties will refer the Dispute or Selected Dispute to the Alliance Managers for discussion and resolution.  If the Alliance Managers are unable to resolve such Dispute or Selected Dispute within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days of the Dispute or Selected Dispute being referred to them by either Party in writing, either Party may require that the Parties forward the matter to the Senior Officers (or designees with similar authority to resolve such dispute), who will attempt in good faith to resolve such Dispute or Selected Dispute.  If the Senior Officers cannot resolve such Dispute or Selected Dispute within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days of the matter being referred to them in writing, then the Dispute or Selected Dispute will be resolved as provided in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 17.5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">17.5.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, as applicable.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.2.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Dispute Escalation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Any unresolved Dispute between the Parties arising out of or in connection with this Agreement will be resolved through litigation in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  This Agreement and any Dispute arising from the performance or breach hereof will be governed by and interpreted in accordance with the laws of the State of New York, without giving effect to any choice of law rules, without giving effect to the application of any conflict of laws principles that would require application of the laws of another jurisdiction.  The provisions of the United Nations Convention on Contracts for the International Sale of Goods will not apply to this Agreement or any subject matter hereof.  Each Party irrevocably submits to the exclusive jurisdiction of (a) the courts of the State of New York located in New York, NY; and (b) the United States District Court for the Southern District of New York, for the purposes of any Dispute arising out of this Agreement.  Each Party agrees to commence any Action either in the United States District Court for the Southern District of New York or if such Action may not be brought in such court for jurisdictional reasons, in the courts of the State of New York located in New York, NY.  Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party&#x2019;s respective address set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> will be effective service of process for any Action in New York with respect to any matters to which it has submitted to jurisdiction in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party irrevocably and unconditionally waives any objection to the laying of venue of any Action arising out of this Agreement in (i) the courts of the State of New York located in New York, NY and (ii) the United States District Court for the Southern District of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action brought in any such court has been brought in an inconvenient forum.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.3.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Any unresolved Selected Dispute between the Parties arising out of or in connection with this Agreement will be resolved by final and binding arbitration.  Whenever a Party decides to institute arbitration proceedings, it will give written notice to that effect to the other Party.  Arbitration will be held in New York, New York, according to the Rules of Arbitration of the International Chamber of Commerce (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">ICC Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) in effect at the Effective Date, except as they may be modified herein or by mutual agreement of the Parties.  All arbitration proceedings will be conducted by three (3) arbitrators unless otherwise mutually agreed by the Parties.  The claimant and the respondent will each nominate an arbitrator in accordance with the ICC Rules, and the third arbitrator, who will be the president of the arbitral tribunal, will be appointed by the two (2) Party-appointed arbitrators in consultation with the Parties.  The arbitrators will: (i) be disinterested, neutral, and independent from both Parties and all of their respective Affiliates; and (ii) have the requisite experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology industries, will have appropriate experience with</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">72</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">respect to the subject matter(s) to be arbitrated, and will have some experience in mediating or arbitrating issues relating to such agreements.  In the case of any Selected Dispute, the arbitrators shall in addition include an individual with experience and expertise in the worldwide development and commercialization of pharmaceuticals and the business, legal and scientific considerations related thereto.  The arbitrators will have the authority to engage additional experts as necessary in order to facilitate resolution of the Dispute or Selected Dispute, as applicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.4.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Selected Dispute Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding anything contained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after the arbitrators are nominated or appointed, each Party will provide the arbitrators a proposal and written memorandum in support of its position regarding the Selected Dispute, including its specific proposal to resolve the Selected Dispute, as well as any documentary evidence it wishes to provide in support thereof (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Brief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and the arbitrators will provide each Party&#x2019;s Brief to the other Party after it receives a Brief from each Party.  Within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days after a Party submits its Brief, the other Party will have the right to respond thereto.  The response and any material in support thereof (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Response</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) will be provided to the arbitrators and the other Party.  The arbitrators will have the right to meet with the Parties as necessary to inform the arbitrators&#x2019; determination and to perform independent research and analysis.  Within </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">days of the receipt by the arbitrators of both Parties&#x2019; Responses (or expiration of the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-day period if any Party fails to submit a Response), the arbitrators will deliver their decision regarding the Selected Dispute in writing; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that the arbitrators will select one (1) of the resolutions proposed by the Parties which corresponds with, or comes closer to, the determination of the arbitrators.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.5.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Confidentiality; Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The Parties undertake to maintain confidentiality in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> as to the existence of the arbitration proceedings and as to all submissions, correspondence, evidence, and findings relating to the arbitration proceedings.  No arbitrator (nor any arbitral tribunal) will have the power to award punitive damages under this Agreement, and such award is expressly prohibited.  Decisions of the arbitrator(s) will be final and binding on the Parties.  Judgment on the award so rendered may be entered in any court of competent jurisdiction.  The costs of the arbitration will be shared by the Parties during the course of such arbitration, as assessed by the International Chamber of Commerce, and will be borne as determined by the arbitrator(s).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">17.5.6.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Preliminary Injunctive Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Notwithstanding anything to the contrary, either Party may at any time seek to obtain preliminary injunctive relief or other applicable provisional relief from a court of competent jurisdiction with respect to an issue arising under this Agreement if the rights of such Party would be prejudiced absent such relief.  A request by a Party to a court of competent jurisdiction for interim measures necessary to preserve the Party&#x2019;s rights, including attachments or injunctions, will not be deemed incompatible with, or a waiver of, the agreement to mediate or arbitrate contained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, or the availability of interim measures of protection under the ICC Rules.  Notwithstanding anything to the contrary in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, any disputes regarding the scope, validity, enforceability, or inventorship of any Patent Rights will be submitted for final resolution by a court of competent jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.6.	Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Neither Party will be held liable to the other Party nor be deemed to have breached this Agreement for failure or delay performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from a cause beyond the reasonable control of such Party, including acts of God, embargoes, war, acts of war (whether war be declared or not), terrorism, insurrections, riots, civil commotions, strikes, lockouts, or other labor disturbances (other than strikes, lockouts, or labor disturbances involving a Party&#x2019;s own employees), government actions, fire, earthquakes, floods, epidemics, pandemics, or quarantines  (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and for so long as such failure or delay continues to be caused by or result from such Force Majeure event.  The Parties agree the effects of the COVID-19 pandemic that is ongoing as of the Effective Date may be invoked as a Force Majeure (to the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">73</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">extent causing the applicable failure or delay) for the purposes of this Agreement, even though the pandemic is ongoing.  The affected Party will notify the other Party in writing of any Force Majeure circumstances that may affect its performance under this Agreement as soon as reasonably practical, will provide a good faith estimate of the period for which its failure or delay in performance under the Agreement is expected to continue based on currently available information, to the extent reasonably practicable, and will undertake reasonable efforts necessary to mitigate and overcome such Force Majeure circumstances and resume normal performance of its obligations hereunder as soon as reasonably practicable under the circumstances.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.7.	Waivers and Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party.  No waiver will be effective unless it has been given in writing and signed by the Party giving such waiver.  No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.8.	Relationship of the Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Nothing contained in this Agreement will be deemed to constitute a partnership, joint venture, agency, employee-employer relationship, or legal entity of any type between Gritstone and Gilead, or to constitute one as the agent of the other.  Each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes.  Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give any Party the power or authority to act for, bind, or commit the other.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.9.	Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All notices, requests, claims, demands, waivers and other communications under this Agreement will be in writing and will be sent by internationally-recognized courier or express delivery service with tracking capabilities or personal delivery to the following addresses, or to such other addresses as will be designated from time to time by a Party in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Section 17.9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">If to Gilead, addressed to:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead Sciences, Inc.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">333 Lakeside Drive</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Foster City, CA 94404</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Attention: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">Alliance Management</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">With copies (which will not constitute, nor be required for effective, notice) to:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead Sciences, Inc.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">333 Lakeside Drive</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Foster City, CA 94404</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Attention: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.5pt;font-family:Times New Roman;">General Counsel</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">If to Gritstone, addressed to:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone Oncology, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5959 Horton St., Suite 300</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Emeryville, CA 94608</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Attention: Chief Scientific Officer</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">With copies (which will not constitute, nor be required for effective, notice) to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">74</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone Oncology, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">5959 Horton St., Suite 300</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Emeryville, CA 94608</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Attention: Rahsaan Thompson, General Counsel</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All notices, requests, claims, demands, waivers and other communications under this Agreement will be deemed to have been duly given: (a) when delivered by hand, if personally delivered; or (b) upon receipt when delivered by a courier or express delivery service (such date of receipt being evidenced by the courier&#x2019;s or express delivery service&#x2019;s records).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.10.	Further Assurances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Gilead and Gritstone hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge, and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.11.	Compliance with Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will perform its obligations under this Agreement in accordance with all Applicable Laws. No Party will, or will be required to, undertake any activity under or in connection with this Agreement which violates, or which it reasonably believes in good faith may violate, any Applicable Law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.12.	Parties in Interest; No Third Party Beneficiary Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  All of the terms and provisions of this Agreement will be binding upon, and will inure to the benefit of and be enforceable by, the Parties hereto and their respective successors, heirs, administrators and permitted assigns.  The provisions of this Agreement are for the sole benefit of the Parties and their permitted successors and assigns, and they will not be construed as conferring any rights to any Third Party (including any third party beneficiary rights), except for the indemnification rights of the Gilead Indemnitees pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 16.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">16.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the indemnification rights of the Gritstone Indemnitees pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Sections 16.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">16.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.13.	English Language</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  This Agreement is written and executed in the English language.  Any translation into any other language will not be an official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version will prevail.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.14.	Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Each Party will pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution, and delivery of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.15.	Interpretation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  Headings used herein are for convenience only and will not in any way affect the construction of or be taken into consideration in interpreting this Agreement.  The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic, or otherwise.  Accordingly, the terms of this Agreement will be interpreted and construed in accordance with the definitions for such terms provided herein or, if no such definitions are provided, with their usual and customary meanings, and each of the Parties hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Applicable Laws to the effect that ambiguous or conflicting terms or provisions contained in this Agreement will be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement.  Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Exhibit, or Schedule will be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Exhibit, or Schedule, of or to, as the case may be, this Agreement.  Except where the context</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">75</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">otherwise requires: (a) any definition of or reference to any agreement, instrument, or other document refers to such agreement, instrument, other document as from time to time amended, supplemented, or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein); (b) any reference to any Applicable Laws refers to such Applicable Laws as from time to time enacted, repealed or amended; (c) the words &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">herein</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">hereof</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">hereunder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (d) the words &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">include</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">includes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">including</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will be deemed to be followed by the phrase &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">but not limited to</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">without limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;, or words of similar import; (e) the word &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">or</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; is used in the inclusive sense (and/or), unless explicitly indicated otherwise by the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">either/or</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;; (f) the word &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">will</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; will have the same meaning and effect as the word &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">shall</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;; (g) the singular will include the plural, the plural the singular, the use of any gender will be applicable to all genders; (h) a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d; includes its permitted assignees or the respective successors in title to substantially the whole of its undertaking; and (i) the Exhibits and Schedules to this Agreement form part of the operative provision of this Agreement, and references to this Agreement will, unless the context otherwise requires, include references to the Exhibits and Schedules.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.16.	Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  This Agreement, together with its Exhibits and Schedules, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, that this Agreement does not supersede (a) the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[**] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Agreement, which shall remain in effect; or (b) the Existing CDA with respect to any subject matter or disclosures other than with respect to Confidential Information governed by this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> that, as of the Effective Date, the Existing CDA will be deemed not to apply to Confidential Information governed by this Agreement, which shall be governed by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Article XII</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> and the other terms and conditions of this Agreement.  In the event of any conflict between a substantive provision of this Agreement and any Exhibit or Schedule hereto, the substantive provisions of this Agreement will prevail.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.17.	Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.  This Agreement may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one (1) and the same instrument.  Counterparts and any other document required to be executed and delivered hereunder may be delivered via electronic mail (including .pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com)) or other transmission method and any counterpart or such document so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">17.18.	Cumulative Remedies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">No remedy referred to in this Agreement is intended to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Signature Page Follows</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">76</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:53.184%;"></td>
    <td style="width:46.816%;"></td>
   </tr>
   <tr style="height:8.65pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.100in;vertical-align:top;padding-bottom:0.010in;padding-right:0.100in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GILEAD SCIENCES, INC.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.100in;vertical-align:top;padding-bottom:0.010in;padding-right:0.100in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">GRITSTONE ONCOLOGY, INC.</font></p></td>
   </tr>
   <tr style="height:38.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.100in;vertical-align:top;padding-bottom:0.010in;padding-right:0.100in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Tahoma;">&#xfeff;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Dickinson</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Andrew Dickinson</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title: Executive Vice President and Chief Financial Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.100in;vertical-align:top;padding-bottom:0.010in;padding-right:0.100in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Tahoma;">&#xfeff;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Allen</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name: Andrew Allen</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title: CEO &amp; President</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Signature Page to Collaboration, Option and License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1.29</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CHADV AND SAM PLATFORM TECHNOLOGY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.66-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1.66</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.66-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1.71</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Excluded Technology</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.71-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1.122</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EXISTING IN-LICENSE AGREEMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.122-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 1.153</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1.153-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULES 2.1.2(A) AND (B)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">R&amp;D PLAN AND GRITSTONE R&amp;D BUDGET</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2.1.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 3.1.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Future IN-LICENSE AGREEMENT [**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Not applicable as of the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.1.4-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 3.5.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SELECTED PROVISIONS OF [**] AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3.5.4-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 5.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">5.1-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 6.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">FORM OF DEVELOPMENT REPORT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">6.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 7.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">7.4-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 9.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Stock purchase agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">9.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 11.10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[**]-RELATED PROVISIONS OF THIRD PARTY AGREEMENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">11.10-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 12.6.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">PRESS RELEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><img src="img62856508_0.jpg" alt="img62856508_0.jpg" style="width:167px;height:55px;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">						</font><img src="img62856508_1.jpg" alt="img62856508_1.jpg" style="width:190px;height:46px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Gilead Contacts:  	Gritstone Contacts:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Jacquie Ross, Investors 	Alexandra Santos, Investors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(650) 425-8408								       (510) 871-6161</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Mark Snyder, Media	 Dan Budwick, Media	</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">(650) 446-6957	 (973) 271-6085	</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">                           </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">Confidential Draft &#x2013; Not for Distribution</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">GILEAD  SCIENCES  AND  GRITSTONE  ANNOUNCE  COLLABORATION  UTILIZING  GRITSTONE&#x2019;S  VACCINE  PLATFORM  TECHNOLOGY  FOR  HIV  CURE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Foster City, Calif. and Emeryville, Calif., February 1, 2021 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x2013; Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead&#x2019;s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone&#x2019;s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,&#x201d; said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. &#x201c;Curing HIV remains the ultimate aspiration for Gilead&#x2019;s HIV research and development efforts. Gritstone&#x2019;s vaccine technology has the potential to educate the immune system to specifically recognize and destroy HIV-infected cells by leveraging SAM and adenoviral vectors. This, along with our other partnerships and internal programs, reflects Gilead&#x2019;s commitment to continuing innovation to discover a cure for HIV and bring about an end to the HIV epidemic.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;We are excited to be partnering with Gilead, a company that has decades long experience improving care for people living with HIV, to advance a novel immunotherapy using our proprietary platform for the treatment of HIV infection,&#x201d; said Andrew Allen, MD, PhD, Co-Founder, President and Chief Executive Officer of Gritstone. &#x201c;It is well-established that CD8+ T cells are critical for the elimination of virally infected cells, and we have built a highly differentiated vaccine platform that has been shown to generate large numbers of antigen-specific T cells, including CD8+ T cells, even in advanced and immunocompromised cancer patients. On the heels of our recent COVID-19 program initiation in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.6.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">partnership with the NIH, this program adds to our growing infectious disease pipeline supported by collaborations with leading biopharma and renowned institutions.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,&#x201d; said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-more-</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201c;Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. The resulting strong, durable and broad anti-SIV CD8+ T cell responses and T cell memory data captured the attention of Gilead&#x2019;s virology team. We jointly performed further experiments that generated additional compelling data, which was also complemented by our exciting clinical data with neoantigens in cancer patients. We are delighted to now advance our partnership and product candidates for the treatment of patients with HIV infection.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Terms of the Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Under the terms of the agreement, Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment at a premium. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. Gritstone is also eligible to receive up to an additional $725 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid single-digit to low double-digit tiered royalties on net sales upon commercialization.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Locust Walk served as transaction advisor to Gritstone.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">About Gritstone Oncology</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars&#x2014;first, a proprietary machine learning-based platform, Gritstone EDGE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:7.37pt;font-family:Times New Roman;">TM</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient&#x2019;s immune system to specifically attack and destroy disease-causing cells. The company&#x2019;s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an &#x201c;off the shelf&#x201d; shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine with support from departments within the National Institutes of Health (NIH) and the Bill &amp; Melinda Gates Foundation and a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstoneoncology.com.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">About Gilead Sciences</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company&#x2019;s website at </font><font><font style="background-color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">www.gilead.com</font></font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.6.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Gritstone Forward-Looking Statements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone&#x2019;s therapeutic programs; the advancements in the Company&#x2019;s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">-more-</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone&#x2019;s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone&#x2019;s programs&#x2019; early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone&#x2019;s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone&#x2019;s most recent Quarterly Report on Form 10-Q filed on November 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Gilead Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to meet potential milestones in the estimated timelines or at all and the risk that the parties may not realize the expected benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"># # #</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">12.6.2-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.5pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">SCHEDULE 15.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">DISCLOSURE SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.2-1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.2.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">LICENSED PATENTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.2.1-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">DISCLOSURE SCHEDULE AS OF THE BRINGDOWN LETTER DATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">[Intentionally Blank as of the Effective Date]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.3-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Certain identified information has been omitted from this Exhibit 10.3 because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks [**] denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Schedule 15.3.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">LICENSED PATENTS AS OF THE BRINGDOWN LETTER DATE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;font-style:italic;">[Intentionally Blank as of the Effective Date]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">15.3.1-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>grts-ex10_10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<html>
 <head>
  <title>EX-10.10</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GRITSTONE ONCOLOGY, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Employment Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), entered into as of June 14, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), is between Gritstone bio, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and Vassiliki Economides (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and, together with the Company, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Company desires to engage Executive to perform services as an employee of the Company under the terms hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Executive desires to provide services to the Company on the terms herein provided.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Employment.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall employ Executive upon the terms and conditions provided herein effective as of the Effective Date.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Position and Duties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Effective on the Effective Date, Executive: (i) shall serve as the Company&#x2019;s Executive Vice President and Chief Financial Officer, with responsibilities, duties, and authority usual and customary for such position, subject to direction by the Chief Executive Officer of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">CEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); (ii) shall report directly to the CEO; and (iii) agrees promptly and faithfully to comply with all present and future policies, requirements, rules and regulations, and reasonable directions and requests, of the Company in connection with the Company&#x2019;s business. At the Company&#x2019;s request, Executive shall serve the Company and/or its subsidiaries and affiliates in such other capacities in addition to the foregoing as the Company shall designate, provided that such additional capacities are consistent with Executive&#x2019;s position as the Company&#x2019;s Executive Vice President and Chief Financial Officer.  In the event that Executive serves in any one or more of such additional capacities, Executive&#x2019;s compensation shall not automatically be increased on account of such additional service.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Performance of Executive&#x2019;s Duties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During Executive&#x2019;s employment with the Company, and except for periods of illness, vacation, disability, or reasonable leaves of absence or as discussed in Section 1(e), Executive shall devote Executive&#x2019;s full time and attention to the business and affairs of the Company pursuant to the general direction of the CEO.  The rights of Executive under this Agreement shall not be affected by any change in the title, duties, or capacity of Executive during Executive&#x2019;s employment with the Company.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Principal Office</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Executive will work principally at the Company&#x2019;s facility located in Emeryville, California.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exclusivity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except with the prior written approval of the CEO (which the CEO may grant or withhold in his or her sole and absolute discretion), Executive shall devote substantially all of Executive&#x2019;s working time, attention, and energies to the business of the Company, except during any paid vacation or other excused absence periods.  Nothing in this section prevents Executive from engaging in additional activities in connection with personal investments and community affairs. Executive may also serve as a member of the board of directors or board of advisors of another organization provided (i) such organization is not a competitor of the Company; (ii) Executive receives prior written approval from the Company&#x2019;s CEO; and (iii)  such activities do not individually or in the aggregate interfere with the performance of Executive&#x2019;s duties under this Agreement, violate the Company&#x2019;s standards of conduct then in effect, or raise a conflict under the Company&#x2019;s conflict of interest policies.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The period of Executive&#x2019;s employment under this Agreement shall commence on the Effective Date and shall continue until Executive&#x2019;s employment with the Company is terminated pursuant to Section 5.  The phrase &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; as used in this Agreement shall refer to the entire period of employment of Executive by the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Compensation and Related Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annual Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During the Term, Executive shall receive a base salary at the rate of $400,000 per year (as may be increased from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Annual Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), subject to withholdings and deductions, which shall be paid to Executive in accordance with the customary payroll practices and procedures of the Company.  Such Annual Base Salary shall be reviewed by the CEO, and, as applicable, the Board of Directors of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and/or the Compensation Committee of the Board, not less than annually.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;" id="ole_link1"><font id="ole_link2"></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive shall be eligible to receive a discretionary annual bonus based on Executive&#x2019;s achievement of performance objectives as mutually agreed between Executive and the CEO, such bonus to be targeted at 40% of Executive&#x2019;s Annual Base Salary (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Any Annual Bonus approved by the Board, the Compensation Committee of the Board and/or the CEO shall be paid at the same time annual bonuses are paid to other executives of the Company generally, subject to Executive&#x2019;s continuous employment through the date of approval.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Benefits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive shall be entitled to participate in such employee and executive benefit plans and programs as the Company may from time to time offer to provide to its executives, subject to the terms and conditions of such plans.  Notwithstanding the foregoing, nothing herein is intended, or shall be construed, to require the Company to institute or continue any, or any particular, plan or benefit.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Business Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall reimburse Executive for all reasonable, documented, out-of-pocket travel and other business expenses incurred by Executive </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in the performance of Executive&#x2019;s duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as are in effect from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Vacation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive will be entitled to paid vacation in accordance with the Company&#x2019;s vacation policy.										</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sign-On Bonus.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> On the first payroll date following the Effective Date, the Company shall pay Executive a one-time sign on bonus of $40,000, less applicable withholdings and deductions (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Sign on Bonus&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">). Notwithstanding the foregoing, Executive acknowledges and agrees that the Sign on Bonus will only be fully earned on the first anniversary of the Effective Date if Executive remains continuously employed with the Company through the first anniversary of the Effective Date. In the event Executive&#x2019;s employment with the Company terminates for any reason other than due to a Covered Termination (as defined below) prior to the first anniversary of the Effective Date, Executive hereby agrees to repay the Company the full amount of the Sign On Bonus.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Equity Awards.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In connection with entering into this Agreement, following the Effective Date, the Company will recommend to the Board or the Compensation Committee of the Board that it grant Executive an option to purchase 215,000 shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) at a per-share purchase price equal to the closing sales price of the Company&#x2019;s common stock as quoted on the Nasdaq Global Market on the date of grant, or if the date of grant is not a trading day, on the most recent trading day before the date of grant, provided that Executive is employed by the Company on the date of grant. Subject to Executive&#x2019;s continued employment with the Company through the applicable vesting date, 25% of the shares underlying the Stock Option will vest on the first anniversary of the Effective Date and 1/48th of the total number of shares initially underlying the Stock Option will vest on each monthly anniversary thereafter. The Stock Option will otherwise be subject to the terms and conditions of the Company&#x2019;s 2018 Incentive Award Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and a stock option agreement to be entered into between Executive and the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">        </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">At-Will Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company and Executive acknowledge that Executive&#x2019;s employment will be at-will, as defined under applicable law.  This means that it is not for any specified period of time and can be terminated by Executive or by the Company at any time, with or without advance notice, and for any or no particular reason or cause.  It also means that Executive&#x2019;s job duties, title, and responsibility and reporting level, work schedule, compensation, and benefits, as well as the Company&#x2019;s personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of the Company (subject to any ramification such changes may have under Section 6 of this Agreement).  This &#x201c;at-will&#x201d; nature of Executive&#x2019;s employment shall remain unchanged during Executive&#x2019;s tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly-authorized officer of the Company.  If Executive&#x2019;s employment terminates for any lawful reason, Executive shall not be entitled to any payments, benefits, damages, award, or compensation other than as provided in this Agreement.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During the Term, any termination of Executive&#x2019;s employment by the Company or by Executive (other than by reason of death) shall be communicated by written notice (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) from one Party hereto to the other Party hereto (i) indicating the specific termination provision in this Agreement relied upon, if any, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#x2019;s employment under the provision so indicated, and (iii) specifying the Date of Termination (as defined below).  The failure by the Company to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing of Cause (as defined below) shall not waive any right of the Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing their rights hereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Date of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Date of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean the date of the termination of Executive&#x2019;s employment with the Company specified in a Notice of Termination.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Deemed Resignation.  Upon termination of Executive&#x2019;s employment for any reason, Executive shall be deemed to have resigned from all offices and board memberships, if any, then held with the Company or any of its affiliates, and, at the Company&#x2019;s request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Consequences of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Payments of Accrued Obligations upon all Terminations of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Upon a termination of Executive&#x2019;s employment for any reason, Executive (or Executive&#x2019;s estate or legal representative, as applicable) shall be entitled to receive, within 30 days after Executive&#x2019;s Date of Termination (or such earlier date as may be required by applicable law): (i) any portion of Executive&#x2019;s Annual Base Salary earned through Executive&#x2019;s Date of Termination not theretofore paid, (ii) any expenses owed to Executive under Section 3, (iii) any accrued but unused paid time-off owed to Executive, (iv) any Annual Bonus approved by the Board, Compensation Committee of the Board and/or the CEO on or prior to the Date of Termination but unpaid as of the Date of Termination, and (v) any amount arising from Executive&#x2019;s participation in, or benefits under, any employee benefit plans, programs, or arrangements under Section 3, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs, or arrangements.  Except as otherwise set forth in Sections 6(b) and (c), the payments and benefits described in this Section 6(a) shall be the only payments and benefits payable in the event of Executive&#x2019;s termination of employment for any reason.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Severance Payments upon Covered Termination Outside a Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If, during the Term, Executive experiences a Covered Termination outside a Change in Control Period (each as defined below), then in addition to the payments and benefits described in Section 6(a), the Company shall, subject to Executive&#x2019;s delivery to the Company of a waiver and release of claims agreement in a form approved by the Company (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that becomes effective and irrevocable in accordance with Section 11(d), provide Executive with the following:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company shall pay to Executive an amount equal to the sum of (i) Executive&#x2019;s Annual Base Salary multiplied by 0.75 and (ii) Executive&#x2019;s target Annual Bonus.  Such amount will be subject to applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release becomes effective and irrevocable in accordance with Section 11(d). </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the period commencing on the Date of Termination and ending on the nine-month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan (in any case, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Non-CIC COBRA Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), subject to Executive&#x2019;s valid election to continue healthcare coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and the regulations thereunder, the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for coverage under its group health plan (if any) at the same levels in effect on the Date of Termination; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A&#x2011;1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive&#x2019;s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the Non-CIC COBRA Period (or remaining portion thereof).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Severance Payments upon Covered Termination During a Change in  Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If, during the Term, Executive experiences a Covered Termination during a Change in Control Period, then, in addition to the payments and benefits described in Section 6(a), the Company shall, subject to Executive&#x2019;s delivery to the Company of a Release that becomes effective and irrevocable in accordance with Section 11(d), provide Executive with the following:</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company shall pay to Executive an amount equal to the sum of (i) Executive&#x2019;s Annual Base Salary and (ii) Executive&#x2019;s target Annual Bonus.  Such amount will be subject to applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release becomes effective and irrevocable in accordance with Section 11(d). </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the period commencing on the Date of Termination and ending on the 12-month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan (in any case, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">CIC COBRA Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), subject to Executive&#x2019;s valid election to continue healthcare coverage under Section 4980B of the Code and the regulations thereunder, the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for coverage under its group health plan (if any) at </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the same levels in effect on the Date of Termination; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided, however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive&#x2019;s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the CIC COBRA Period (or remaining portion thereof).</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cause any unvested equity awards, including any stock options, restricted stock awards and any such awards subject to performance-based vesting, held by Executive as of the Date of Termination, to become fully vested and, if applicable, exercisable, and cause all restrictions and rights of repurchase on such awards to lapse with respect to all of the shares of the Company&#x2019;s Common Stock subject thereto. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Other Severance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The provisions of this Section 6 shall supersede in their entirety any severance payment provisions in any severance plan, policy, program, or other arrangement maintained by the Company except as otherwise approved by the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Requirement to Mitigate; Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other employment or in any other manner. Notwithstanding anything to the contrary in this Agreement, the termination of Executive&#x2019;s employment shall not impair the rights or obligations of any Party. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definition of Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean any one of the following: (i) Executive&#x2019;s material violation of any applicable material law or regulation respecting the business of the Company; (ii) Executive&#x2019;s conviction of, or plea of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">nolo contendere </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to, a felony or other crime involving moral turpitude; (iii) any act of dishonesty, fraud, or misrepresentation in relation to Executive&#x2019;s duties to the Company which act is materially and demonstrably injurious to the Company; (iv) Executive&#x2019;s willful and repeated failure to perform in any material respect Executive&#x2019;s duties hereunder after 15 days&#x2019; notice and an opportunity to cure such failure and a reasonable opportunity to present to the Board Executive&#x2019;s position regarding any dispute relating to the existence of such failure (other than on account of disability); (v) Executive&#x2019;s failure to attempt in good faith to implement a clear and reasonable directive from the CEO or to comply with any of the Company&#x2019;s policies and procedures which failure is either material or occurs after written notice from the CEO; (vi) any act of gross misconduct which is materially and demonstrably injurious to the Company; or (vii) Executive&#x2019;s breach of fiduciary duty owed to the Company. Notwithstanding any other aspects of this provision Section 6(f), the Company will not have Cause unless (1) the Company first provides Executive with written notice of the condition giving rise to Cause within 30 days of its initial occurrence, and (2) Executive fails to cure such condition within 30 days after receiving such written notice (the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Executive Cure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Period&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">).</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definition of Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For purposes of this Agreement, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean (i) the acquisition by any person or group of affiliated or associated persons of more than 50% of the outstanding capital stock of the Company or voting securities representing more than 50% of the total voting power of outstanding securities of the Company; (ii) the consummation of a sale of all or substantially all of the assets of the Company to a third party; (iii) the consummation of any merger involving the Company in which, immediately after giving effect to such merger, less than a majority of the total voting power of outstanding stock of the surviving or resulting entity is then &#x201c;beneficially owned&#x201d; (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended) in the aggregate by the stockholders of the Company, as applicable, immediately prior to such merger.  For the avoidance of doubt and notwithstanding anything herein to the contrary, in no event shall a transaction constitute a &#x201c;Change in Control&#x201d; if: (w) its sole purpose is to change the state of the Company&#x2019;s incorporation; (x) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction; (y) it is effected primarily for the purpose of financing the Company with cash (as determined by the Board without regard to whether such transaction is effectuated by a merger, equity financing, or otherwise); or (z) it constitutes, or includes sales of shares in connection with, the initial public offering of the Company&#x2019;s capital stock. Notwithstanding the foregoing, a &#x201c;Change in Control&#x201d; must also constitute a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation &#167;1.409A-3(i)(5).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definition of Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. For purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Change in  Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean the period of time commencing three months prior to a Change in Control and ending 12 months after such Change in Control.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definition of Covered Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. For purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Covered Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean the termination of Executive&#x2019;s employment by the Company without Cause or by Executive for Good Reason, and shall not include a termination due to Executive&#x2019;s death or disability.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definition of Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Good Reason</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean any one of the following: (i) the material reduction of Executive&#x2019;s base salary or target annual performance bonus, (ii) the assignment to Executive of any duties materially and negatively inconsistent in any respect of Executive&#x2019;s position (including status, offices, titles and reporting requirements), authority, duties or responsibilities, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities (including without limitation a requirement to report to any person or entity other than the CEO); or (iii) the Company&#x2019;s material breach of this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that, in each case, Executive will not be deemed to have Good Reason unless (1) Executive first provides the Company with written notice of the condition giving rise to Good Reason within 30 days of its initial occurrence, (2) the Company or the successor company fails to cure such condition within 30 days after receiving such written notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cure Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and (3) Executive&#x2019;s resignation based on such Good Reason is effective within 30 days after the expiration of the Cure Period.</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assignment and Successors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise).  This Agreement shall be binding upon and inure to the benefit of the Company, Executive, and their respective successors, assigns, personnel, and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable.  None of Executive&#x2019;s rights or obligations may be assigned or transferred by Executive, other than Executive&#x2019;s rights to payments hereunder, which may be transferred only by will, operation of law, or as otherwise provided herein.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Miscellaneous Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Confidentiality Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  As a condition of Executive&#x2019;s employment with the Company, Executive  must sign and comply with the Company&#x2019;s Proprietary Information and Inventions Assignment Agreement, a copy of which is attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Confidentiality Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The Confidentiality Agreement shall survive the termination of this Agreement and Executive&#x2019;s employment with the Company for the applicable period(s) set forth therein.  Notwithstanding the foregoing, in the event of any conflict between the terms of the Confidentiality Agreement and the terms of this Agreement, the terms of this Agreement shall prevail.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Non-Solicitation of Employees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For a period of one year following Executive&#x2019;s Date of Termination, Executive shall not, either directly or indirectly (i) solicit for employment by any individual, corporation, firm, or other business, any employees, consultants, independent contractors, or other service providers of the Company or any of its affiliates, or (ii) solicit any employee or consultant of the Company or any of its affiliates to leave the employment or consulting of or cease providing services to the Company or any of its affiliates; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the foregoing clauses (i) and (ii) shall not apply to a general advertisement or solicitation (or any hiring pursuant to such advertisement or solicitation) that is not specifically targeted to such employees or consultants.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall be governed, construed, interpreted, and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of California, without giving effect to any principles of conflicts of law, whether of the State of California or any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Validity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.  Signatures delivered by facsimile shall be deemed effective for all purposes.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The terms of this Agreement, together with the Confidentiality Agreement, are intended by the Parties to be the final expression of their agreement with respect to the employment of Executive by the Company and supersede all prior understandings and agreements, whether written or oral, regarding Executive&#x2019;s service to the Company.    The Parties further intend that this Agreement, together with the Confidentiality Agreement, shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement or the Confidentiality Agreement.  Notwithstanding the foregoing, in the event of any conflict between the terms of the Confidentiality Agreement and the terms of this Agreement, the terms of this Agreement shall prevail.    </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Amendments; Waivers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may not be modified, amended, or terminated except by an instrument in writing signed by Executive and a duly authorized representative of the Company.  By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company, as applicable, may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure.  No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Dispute Resolution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all controversies, claims and disputes arising out of or relating to this Agreement, including without limitation any alleged violation of its terms, shall be resolved be resolved solely and exclusively by final and binding arbitration held in Alameda County, California through JAMS in conformity with California law and the then-existing JAMS employment arbitration rules, which can be found at </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">https://www.jamsadr.com/rules-employment-arbitration/</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The arbitrator shall: (a) provide adequate discovery for the resolution of the dispute; and (b) issue a written arbitration decision, to include the arbitrator&#x2019;s essential findings and conclusions and a statement of the award. The arbitrator shall award the prevailing Party attorneys&#x2019; fees and expert fees, if any. Notwithstanding the foregoing, it is acknowledged that it will be impossible to measure in money the damages that would be suffered if the Parties fail to comply with any of the obligations imposed on them under Section 8(a), and that in the event of any such failure, an aggrieved person will be irreparably damaged and will not have an adequate remedy at law.  Any such person shall, therefore, be entitled to injunctive relief, including specific performance, to enforce such obligations, and if any action shall be brought in equity to enforce any of the provisions of Section 8(a), none of the Parties shall raise the defense that there is an adequate remedy at law.  Executive and the Company understand that by agreement to arbitrate any claim pursuant to this Section 8(h), they will not have the right to have any claim decided by a jury or a court, but shall instead have any claim decided through arbitration. Executive and the Company waive any constitutional or other right to bring claims covered by this Agreement other than in their individual capacities. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as may be prohibited by applicable law, the foregoing waiver includes the ability to assert claims as a plaintiff or class member in any purported class or representative proceeding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from this Agreement.  Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid, and enforceable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local, or foreign withholding or other taxes or charges which the Company is required to withhold.  The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Whistleblower Protections and Trade Secrets</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits Executive from reporting possible violations of federal law or regulation to any United States governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. &#167; 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#x2019;s attorney, and may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Prior Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive represents and warrants that Executive&#x2019;s acceptance of employment with the Company has not breached, and the performance of Executive&#x2019;s duties hereunder will not breach, any duty owed by Executive to any prior employer or other person.  Executive further represents and warrants to the Company that (a) the performance of Executive&#x2019;s obligations hereunder will not violate any agreement between Executive and any other person, firm, organization, or other entity; (b) Executive is not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would be violated by Executive entering </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">into this Agreement and/or providing services to the Company pursuant to the terms of this Agreement; and (c) Executive&#x2019;s performance of Executive&#x2019;s duties under this Agreement will not require Executive to, and Executive shall not, rely on in the performance of Executive&#x2019;s duties or disclose to the Company or any other person or entity or induce the Company in any way to use or rely on any trade secret or other confidential or proprietary information or material belonging to any previous employer of Executive.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Golden Parachute Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Best Pay</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Any provision of this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive from the Company pursuant to this Agreement or otherwise (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Payment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Excise Tax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then such Payment will be equal to the Reduced Amount (as defined below).  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Reduced Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; will be either (A) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (B) the entire Payment, whichever amount after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive&#x2019; s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (A) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Pro Rata Reduction Method</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A (as defined below) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:  (1) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (2) as a second priority, Payments that are contingent on future events (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">e.g</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (3) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Accounting Firm</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The accounting firm engaged by the Company for general tax purposes as of the day prior to the Change in Control will perform the calculations set forth in Section 10(a).  If the firm so engaged by the Company is serving as the accountant or auditor for the acquiring company, the Company will appoint a nationally recognized accounting firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder.  The accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">documentation, to the Company within 30 days before the consummation of a Change in Control (if requested at that time by the Company) or such other time as requested by the Company.  If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it will furnish the Company with documentation reasonably acceptable to the Company that no Excise Tax will be imposed with respect to such Payment.  Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Company and Executive.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">General</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date, (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  If Executive notifies the Company that Executive has received advice of tax counsel of a national reputation with expertise in Section 409A that any provision of this Agreement would cause Executive to incur any additional tax or interest under Section 409A (with specificity as to the reason therefor) or the Company independently makes such determination, the Company and Executive shall take commercially reasonable efforts to reform such provision to try to comply with or be exempt from Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Section 409A, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that any such modifications shall not increase the cost or liability to the Company.  To the extent that any provision hereof is modified in order to comply with or be exempt from Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding any provision to the contrary in this Agreement:  (i) no amount that constitutes &#x201c;deferred compensation&#x201d; under Section 409A shall be payable pursuant to Section 6 unless the termination of Executive&#x2019;s employment constitutes a &#x201c;separation from service&#x201d; within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Separation from Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); (ii) for purposes of Section 409A, Executive&#x2019;s right to receive installment payments shall be treated as a right to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits constitutes &#x201c;deferred compensation&#x201d; under Section 409A, such reimbursement or benefit shall be provided no later than December 31</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the year following the year in which the expense was incurred.  The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year.  The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Specified Employee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the Company at the time of Executive&#x2019;s Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service with the Company or (ii) the date of Executive&#x2019;s death.  Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as otherwise provided herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Release</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding anything to the contrary in this Agreement, to the extent that any payments due under this Agreement as a result of Executive&#x2019;s termination of employment are subject to Executive&#x2019;s execution and delivery of a Release, (i) the Company shall deliver the Release to Executive within ten business days following Executive&#x2019;s Date of Termination, and the Company&#x2019;s failure to deliver a Release prior to the expiration of such ten business day period shall constitute a waiver of any requirement to execute a Release, (ii) if Executive fails to execute the Release on or prior to the Release Expiration Date (as defined below) or timely revokes Executive&#x2019;s acceptance of the Release thereafter, Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (iii) in any case where Executive&#x2019;s Date of Termination and the Release Expiration Date fall in two separate taxable years, any payments required to be made to Executive that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of Section 409A shall be made in the later taxable year.  For purposes of this Section 11(d), &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Release Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean the date that is 21 days following the date upon which the Company timely delivers the Release to Executive, or, in the event that Executive&#x2019;s termination of employment is &#x201c;in connection with an exit incentive or other employment termination program&#x201d; (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is 45</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">days following such delivery date.  To the extent that any payments of nonqualified deferred compensation (within the meaning of Section 409A) due under this Agreement as a result of Executive&#x2019;s termination of employment are delayed pursuant to this Section 11(d), such amounts shall be paid in a lump sum on the first payroll date following the date that Executive executes and does not revoke the Release (and the applicable revocation period has expired) or, in the case of any payments subject to Section 11(d)(iii), on the first payroll period to occur in the subsequent taxable year, if later.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Employee Acknowledgement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#x2019;s own judgment.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Signature Page Follows</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Parties have executed this Agreement as of the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">			</font>&#160;</p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GRITSTONE ONCOLOGY, INC.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Andrew Allen</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name: Andrew Allen</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title: President and Chief Executive Officer</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EXECUTIVE</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:30.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> /s/ Vassiliki Economides</font></p>
  <p style="margin-left:6.667%;text-indent:35.714%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name: Vassiliki Economides</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Address:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Proprietary Information and Inventions Assignment Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;">Omitted pursuant to Regulation S-K, Item 601(a)(5)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">|||</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>grts-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10.11</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED GRITSTONE BIO, INC. (F/K/A GRITSTONE ONCOLOGY, INC.)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Amended and Restated Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc. (the &#x201c;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;)) Non-Employee Director Compensation Program (this &#x201c;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Program</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) has been adopted under the Company&#x2019;s 2018 Incentive Award Plan (the &#x201c;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) and shall be effective upon March 8, 2021 (the &#x201c;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effective Date</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Compensation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the Effective Date, annual retainers will be paid in the following amounts to Non-Employee Directors:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:83.315%;"></td>
    <td style="width:5.687%;"></td>
    <td style="width:1.587%;"></td>
    <td style="width:8.641%;"></td>
    <td style="width:0.77%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-Executive Chair:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit Committee Chair:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation Committee Chair:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nominating and Corporate Governance Committee Chair:</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit Committee Member (non-Chair):</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,500</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation Committee Member (non-Chair):</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nominating and Corporate Governance Committee Member (non-Chair):</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All annual retainers will be paid in cash quarterly in arrears promptly following the end of the applicable calendar quarter, but in no event more than 30 days after the end of such quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described above, for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Compensation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.998%;"></td>
    <td style="width:3.002%;"></td>
    <td style="width:75.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial Stock Option Grant:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each Non-Employee Director who is initially elected or appointed to serve on the Board after the closing of the Company&#x2019;s initial public offering of its common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IPO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase 38,000 shares of Common Stock.</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Initial Option will be automatically granted on the date on which such Non-Employee Director commences service on the Board, and will vest as to 1/36</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:normal;font-size:5.695pt;font-family:Times New Roman;position:relative;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of the shares subject thereto on each monthly anniversary of the applicable date of grant such that the shares subject to the Initial Option are fully vested on the third anniversary of the grant, subject to the Non-Employee Director continuing in service on the Board through each vesting date.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.306%;"></td>
    <td style="width:1.06%;"></td>
    <td style="width:72.634%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Annual Stock Option Grant:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each Non-Employee Director who is serving on the Board as of the date of each annual shareholder meeting of the Company (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Annual Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;) shall be granted an Option under the Plan or any other applicable Company equity incentive plan then-maintained by the Company to purchase 19,000 shares of Common Stock, provided that the number of shares subject to the Annual Option will be prorated for any partial year of service as a Non-Employee Director.</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Annual Option will be automatically granted on the date of the applicable Annual Meeting, and will vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The per share exercise price of each Option granted to a Non-Employee Director shall equal the Fair Market Value of a share of common stock on the date the Option is granted.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of each Option granted to a Non-Employee Director shall be ten years from the date the Option is granted.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No portion of an Initial Option or Annual Option which is unvested or unexercisable at the time of a Non-Employee Director&#x2019;s termination of service on the Board shall become vested and exercisable thereafter.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Option, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Annual Options as described above.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Control</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon a Change in Control of the Company, all outstanding equity awards granted under the Plan and any other equity incentive plan maintained by the Company that are held by a Non-Employee Director shall become fully vested and/or exercisable, irrespective of any other provisions of the Non-Employee Director&#x2019;s Award Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reimbursements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company shall reimburse each Non-Employee Director for all reasonable, documented, out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as in effect from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Miscellaneous</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The other provisions of the Plan shall apply to the Options granted automatically pursuant to this Program, except to the extent such other provisions are inconsistent with this Program. All applicable terms of the Plan apply to this Program as if fully set forth herein, and all grants of Options hereby are subject in all respects to the terms of the Plan. The grant of any Option under this Program shall be made solely by and subject to the terms set forth in a written agreement in a form to be approved by the Board and duly executed by an executive officer of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effectiveness</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Program shall become effective upon the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>grts-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statements (Form S-3 Nos. 333-234211, 333-252564 and 333-260292) and related Prospectuses of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.),</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statements (Form S-8 Nos. 333-230581, 333-237095, 333-254177 and 333-255847) pertaining to the 2018 Incentive Award Plan, the 2018 Employee Stock Purchase Plan, and the 2021 Employment Inducement Incentive Plan, in each case, of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.), and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Registration Statement (Form S-8 No. 333-227665) pertaining to the 2015 Equity Incentive Plan, the 2018 Incentive Award Plan and the 2018 Employee Stock Purchase Plan, in each case, of Gritstone bio, Inc. (f/k/a Gritstone Oncology, Inc.)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of our report dated March 10, 2022, with respect to the consolidated financial statements of Gritstone bio, Inc. included in this Annual Report (Form 10-K) of Gritstone bio, Inc. for the year ended December 31, 2021.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 10, 2022</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>grts-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER PURSUANT TO <br>EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), <br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Andrew Allen, M.D., Ph.D., certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Gritstone bio, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:45.925%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:3.056%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:3.056%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:44.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Allen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Allen, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>grts-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO <br>EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), <br>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Vassiliki Economides, certify that:</font></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Gritstone bio, Inc.;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.541%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:3.445%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:3.158%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:44.523%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid rgba(0,0,0,1);margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.011111111111111112in;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>grts-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Gritstone bio, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of Andrew Allen, M.D., Ph.D., President and Chief Executive Officer (Principal Executive Officer) of the Company, and Vassiliki Economides, Chief Financial Officer (Principal Financial Officer) of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:3.467%;text-indent:-3.591%;padding-left:3.467%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.768%;"></td>
    <td style="width:0.176%;"></td>
    <td style="width:1.262%;"></td>
    <td style="width:48.794%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.250pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Allen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Allen, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 10, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.250pt solid;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vassiliki Economides</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img62856508_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62856508_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W *<# 2(  A$! Q$!_\0
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MWS0!T_VJ RQQB9"\F[8H;EMOWL?2I:Y"'0=3M[=HH%\L@7N")OO&3'EGV/\
M+%07UC=Z98C[1-)]C-U$[Q/=E3(/+PPW]OGYP3@XH [*>>*V@>:>18XD&6=C
M@ 5'9W]IJ$1EL[B.= <$HV<'T-<]8VUWJ'@":W4.UQ/%*(O.<DD%FVY)YQC'
M--O/#UW"D<D+3WQEDWWD7G"%I"$"I@C  7'3^= '5U%-<P6[(LTJ(7SM#'&<
M#)_3FN8BTG6DU*PDED>4):B*>0W! #;6!*@?Q<CD@@XSQ3-.T?6(K.UBG!_=
MRS%P\Y8LK0[1NY/\1[8]<"@#IWOK6.R%X\\:VQ4,)2WRX/0Y]\BK%<-#X>U?
M^RI[58##FTBB,<EUYBRRJRDN/[HP".WTXK2M-*U>/Q3)=S2N;<RNWF>;PT9'
MRQ[?8^PZ=: .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img62856508_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62856508_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N +X# 2(  A$! Q$!_\0
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MUME!>YC@5[F2)?W*2="@;//.<8R"!P36W7E;P6]RFQ!+J:0D;M/TB%UMT8'
M9I""6+*&^;!)_O  5Z98S7,]G'+=VOV6=L[H?,#[>3CYAP>,'\:X,31C#6/]
M?UZ6\STL)7E4O&>ZZ_UI^-_)%BBN%\3>.M0M_$)\,^%])_M+65C\R9I3MB@'
MRMSR,Y4]=R@%E&2217*ZE\0?B/I&JV.FW^@:7#=7S*ENI1F60EMN PE*YR1G
M)XR,\$5RV.QR1[)17EVL>/\ Q;X:US3H-7T&V>UO(%\J.V^::6?REW(N'; $
MSA?NDXZ;N\=G\0?&3^)ET:]\/6=M<7UE-<Z? S$2 A':(2$M@Y*%2"$.3GY<
M8IV#F1T_@?QY:^-_[1^SV4UK]CD4#S'#;XVW;6XZ-\IRO('')[=6)HFG> 2(
M9D57:,,-RJ20"1V!*M@^Q]*X3P5XTUS7X/$-MJ&E6W]JZ2VU8+>38LK_ #CR
M\L6 .Z,C=DCYNG'/G^G:CXZ7XI:M<VVC6+^('M56ZM6<>6D>(L$?O!S@1_Q'
MJ>/0L*^A[]17$:_XRU;P_H.BQSZ9;2>)=480QV:3'RUD(QNW8Q@,T8*[A][A
MB!NK(A\7^/\ 3-7TI/$?A_3K?3[Z]CLB\,@WAI,@8Q*_3KR.<$9&<TAW/2WF
MBB>)))$1I6V1JS %VP6P/4X4G'H#Z4^O%/'M[XJG\?Z&)=$L56WNY3HZ37 Q
M<,NS#.1(N#D(RJ=O)"_-W[ZP\1ZQI/A&^UGQM8PV,MM(<16@W[T(4+C#M\Q=
MB.2!TS@<T!<ZVBO*_P#A,_B1J-C_ &MI/A*T73)(O-A65C)*R@=0/,5FSC(P
MG((QG@G9TGQW?>+/!=[J/AS3H3K=O*L?V&>967EA\V<I\I0L03MY4CG')8+H
M[NBO)-)^)/C+Q+I<(T'PQ#<7B;C=7+Y2W!!/R)EQSM,9Y?/+?+CFND\'^-=3
MU77KSPWK^E)8ZQ9P^?(8) T;*2O;)VG#I_$V>>F,46!21V]%>?:WXXUZY\0W
MFA^#=%AU&XL-OVJYFE'E*2#E!\RC(.!RV<JXV\9J"P^*#Z5>R:7XZT_^QKZ.
M,2++$K212@DXP%W$<=P6!*MD@C%.P71@:P38126444UFDDI,ELNI)/&N.,%$
M&0V=O+'/'?%6?"[V\^JZ?IUNS3"XDWW:RIM5@JD[<%F5U')&5!SC!&<B&^T^
M-!%;/'86UT9%#06;S33@[MI7&YD+=3MW \#IG%6]&D\J]LI9H#%<V!WRK$JJ
MS1@E3N"*NW&!DRR 8))!!Q7OS=Z5E_7YW^\^8@K5E?R_X*Z6^X]9HJ.WGCNK
M>*XA;=%*@=&P1E2,@\TZ21(HVDD=41 69F. H'4DU\_;H?3W5KCJ\XU_7-,U
MG5-L D>6VS'&WV9;@,=^TF-3*$;.1_ 3W[#"^)O'$MR%@T6=H+5E<->-&P\Q
M@N2B<9!Y'/!R1RHY/.VD$QN7MM+L!/=3N)0KVRN(XB?E!616V\,K;MY&".M>
MIAL+*"YYZ/\ K<\?&8R-1^SAJNOZ6.BMK*;6KF+399-:;" W0>1+6&% ?D_<
MJ& /R\*<$X!Z'(]"MX(K6VBMX5VQ1($1<YPH& .:SM!T2+0[)HE,<D\CL\TR
MQ"/>220-HX  . !Q^=:M<>(J\[M'9'?A:'LX\TOB?]6_KJ>+W^J/X/\ C??W
M%O93:L=1MU!M[65I9H@VQFX()W 1LP3(&TKR!P-%HM?^(7CC2;R?1+C1=*T2
M;[0LE[&RR3'>K  $ 9/EJ,#(7YB6.5!R%TBY\9_%CQ-+I6OS:*]MMA9HV(FD
MV!8VPJL,INCR3GNG'/%WQ#:^*OAOI(U=/&TVHA[B.,VM[ SB3[QP"S.5X!S@
MKD#KD ' W_(U/B;_ ,CMX!_[")_]&P5Z488FG2<QH9D5D60J-RJ2"0#V!*KG
MZ#TKQKQ*\_B+Q?HDMWJVHZ7*LEO]FC.D"2&PNI(XY/):4LI9\JAP5(&X9P <
M:=O\2+>X\&RQ#7[Q=3ALC>2:D=/A+*!<>6(S"KE0YRJ@'C#!B10-/5ECX9?\
MCMX__P"PB/\ T;/2:)_R<%XD_P"P<O\ Z#;UA>'KI_"-[<Z_-J>M7;7DTTFI
MZ8-#$<^44N9)"7(C4>>C9!P=X'KC3EM[?4_&7B#Q/X?\37.E-;V$$MY-)IR3
MHT+Q"0,@)W8V1J2"N<@^N "Z'0^/_#UGXI?3[*#6;:P\06K-<60:7$C#!. H
M8$ LBG> 2-AQWKG[O6_%7A&:Q/CJVTS6-*>ZC*7Z*NZUE)X8*$!)55=N$SS]
M[M7//;K>+8:E'K?B6+Q+HSK:-%-IC27<Y<R31D(9#QL,N=S$%4Y & VA9K9>
M)M5T>?7O%>HZVD_V>:TTU;!(5D8RR*2\8+*53RY?,;;]TC#$$ @7-KXF_P#(
M[_#_ /[")_\ 1D%+\<_^1)L_^PBG_HJ6NC\9>#6\4SZ5=V^IOI][IDQE@E$(
ME7)*GE21R"BD<XZ@@YX@M_!-Y=Z=K-EXF\0W.LQ:DL2X$?D" IDAD4,5!SM/
M  )7D')H&UN=C7F7PR_Y';Q__P!A$?\ HV>K-CX \5:;I;:;:?$"Y2U*E IL
M%9D7:%PC%RR  # 4C';%;6C^#6\.>#GT70]4>TO'82O?O")29,KN;RR=H!5=
MH'88ZGDH-3F_@7_R)-[_ -A%_P#T5%1HA_XR#\2=?^0<G_H-O6UX%\#WW@OS
MH/[>^V:?+N?[+]C6/$IVC?NW$_=7&.G.:S(/ASXBMO$-SKT7C?;J=S&(II_[
M*C^90%&-I;:/N+T';W-,+.R..\-Z?XSNO%_B\>'-8L;29+]OMCRQ865O,EVE
M0R28&0_&>XY-6=>^%GCOQ->QWFK:QI%Q<)&(E?<R84$D#"Q =6/YUVNM_#C[
M5XD&OZ!K,NA7S\W!@BWK,V0<E=P')'S Y#<$C.29M-\'>(K?5YK^_P#'>HW'
MF1[/+AMXXU!^7!"-O0<+V4'GKUR"L0>+[%K.Z-RN5@NF$2V]C (Y9V;.X/+@
MYSD'&#N_N\%JY6&8I'+&9(O)ADWDJHE@AR"?E4Y$LARR MGA2<D#<GK]Y;)>
MV5Q:2,RI/&T;%>H##!Q[\UY_J_AJ;2)81:RIY,DL5I898[HI'QOE8X^]E2,C
M)&01C8HKT\+74H\DM_Z_K^K'DXW#2A+VD=OZ_K^KD-GX@N--6>XAN$6&25BL
M+SLZ;E_>2*LC%LG "[@!N:<D$A5KG?$.HZU<7;VVJW;S>4S*H4;(V*LR%@
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M\8M:9X%TS2CH/D7%XW]B?:/LWF.IW^=G?OPHSC/&,?C73T4!9!1110,****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img96160895_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ($!& # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRWE1X 5!EG8]%'O6I7+^/M,TO6/#3V&J:I;Z<'<-!//(J*)!G'4C/&>*:WU
MY;_A;]U'$MY<^#]1BTQB,7>\D$'TR@4_]]5Z-IFI6NKZ9;ZA92>9;W"!T;&.
M/<>O:O)KF'XC>&-*>*[AL=<T:%/G255E7RP.X.&( 'OBHO$T]MJ_@+0_%^B6
M,=A)I5SAH(4"K%E\G& !C>%/3^(UHXI["/::*\E\47D7CKQEX6T:V.^R,2W]
MP!V5ANP??:,?\#JEXFTF76_C4NF17DMFD]JJRRPG#>6$)('UQC\?PJ5#N,]G
MK TSQ;9ZOXGU'1+6*4R6"_OI6X&[=C:!W^M>;:%HG_"-?%:;PQ:WUR^FW=HX
M=789(:,GG QD$=<52\$>#-.F^).IVK37031;D2VY#+ERDG&_Y>1QVQ3Y%W$>
MF>&_&7_"0>(M;TG[!]G_ ++F:+S?.W^;AV7.-HQ]W/4]:ZFO#-"\,?\ "5>/
M?%]C/?W5K8B\E:9+=@&E/FOM!)!X')QBK'@_5K[PK8^-[&.X>>/2=PMM_(5P
MSH& Z ' )'M0X+H![76!XN\667A#25O;N.25I'\N**,<NV">3V''6O#;73;C
M5='.L"V\77.NREGCNK>UWVY(8X^<'<?J.AR,<5H^/K.ZO?!^@>(-72[AUEE^
MPSQ3IL^5"Y#%2 =QSG/3FFJ:OJPN>P^)]?O]"CM&L-"N=5,\FQU@W?NA_>.%
M;C\JWZ\5^(GARS\*^'- TRQDGDA%^[[IV!;) ST 'Z5H^+ENO%_Q.@\)2WTU
MKID,(DE6(X,AV[B?0GD 9Z<TN5-#/6:*X7PCX%U#PCKUT]MK#2Z+(N$M906?
M/8GH 0<\CJ.U:GQ#_P"2?ZU_U[_U%397L@.FHKYX'A/=\*(_%DFIW9NH& MH
M0_[N-/.\O [@Y);(-3Z]H=T_@.P\;76LWT^K2R)@E\*BG( 7N#P.<_A5>S7<
M5SU/QQXV;P:E@4TPW[7CL@43;"",?[)SG-<Y<?%?5K"/S]2\#:E:6H(#32.X
M S_O1@?K65\3KFYN=$\%W0Q)=R 2#=P&<K&>?J:H^*?%7C2]9?#&O6FF:0M]
MA3*RL%*Y_O[G&,CDCI[548JR ]&UKQW:Z=X*@\3V5L;RWG9 D;2>61DD')P>
M000:MZ!XMMO$'A-M<MXMICC<RV^_)1U&2I./ISCH:XOQWH:^&_@Y:Z2LOFFW
MFC#/C&YBS,Q'MDFN9T^6X^'M^L4S.VC:]IP96/17:/\ FK'!_P!E@:2BFM /
M6O!?BK_A,-";4OL7V3$S1>7YOF= #G.!Z^E<QK_Q<M]#\2SZ4-*:X@MY5BEN
MA<;=I/WOEVGISWYP:J_"_4XM&^%FH:E-]RVGFD(]2$7 _$X'XUP6F7WA^X\$
M^(1JVHJNN7\WG1!H9&.Y/F'S!2!N+,.O?FFH*[ ^CD=9(U=&#(P!4CH13JXO
MX6Z[_;7@FU21]UQ9?Z-)D\X7[I_[Y(_(UVE9-6=AA1112 **** "BBB@ HHH
MH **** "BBB@ HHHH *^2H_$.MF-2=8U#H/^7I_\:^M:^.(_]4G^Z*VHK<3-
M3_A(=;_Z#&H?^!+_ .-'_"0ZW_T&-0_\"7_QK-KWFQ^'^G7WPL@M%L+9=6FL
MQ.MPT2B42-\X!;&<?P_2M)-1W \8_P"$AUO_ *#&H?\ @2_^-'_"0ZW_ -!C
M4/\ P)?_ !KM_ &E6=OX2\4:YJ>GVUR;6,QPI=0AMLBJ21\PX.605EZ!\+?$
M7B#38[^$6MK;RC,9NG92Z_W@ I./K1>/4#G/^$AUO_H,:A_X$O\ XT?\)#K?
M_08U#_P)?_&M5_ >KP>*X?#MT]M;7<XW0R2NWE2#!/# $]B.1UJS:?#7Q!>>
M)+S1$2!);10TL[LPAP1E2#MR<]N.Q]*=X@8/_"0ZW_T&-0_\"7_QH_X2'6_^
M@QJ'_@2_^->A> _AQI]YJUU/JNH:;J-K:90P6MPQ(<-]YA@';PWUQZ=> \2V
MT-IXCOX[>>RFA,I=&LGW1!6^8*IP!P#CCCBA.+=@&?\ "0ZW_P!!C4/_  )?
M_&C_ (2'6_\ H,:A_P"!+_XUT_P]\&V>O"]U?6I#'HU@,R$-MWL!DC(Y  Y.
M.>1BM^+QSX";4DL?^$-M4T]B$-V\,>]><9*XSCOG=GVI-J]D@/.?^$AUO_H,
M:A_X$O\ XT?\)#K?_08U#_P)?_&M_P 4>&+)O&,>G^$IXM0ANUW11V\PD\MN
M=REL]!C.3V/M5^\^#OBBTL)+H&RG*+N,$,K&0_3*@$_C3O$#D?\ A(=;_P"@
MQJ'_ ($O_C1_PD.M_P#08U#_ ,"7_P :T_#7@;5O%5A>WFGM;B.UX(E9@TC8
M)VKA3D].N.HK1UCX6>(M$T275;G[(\4*AY8HI"SH.Y(VXX[X)HO&]@.;_P"$
MAUO_ *#&H?\ @2_^-'_"0ZW_ -!C4/\ P)?_ !K>\.?#3Q!XFL!?6RV]O;/_
M *N2Y<KO]P "<>]9^L^#-8T'7+72;V./SKIE6"1&)CDR0.#C/4\\9HO&]@*/
M_"0ZW_T&-0_\"7_QH_X2'6_^@QJ'_@2_^-=7=_"3Q!8I=S7%SIR6UK#YTDYE
M?81R2!\F<@#TQR.:BMOA7KLT5K]HN]+L;BZ!,-K=W)65\<\*%.3CMV[TKQ Y
MG_A(=;_Z#&H?^!+_ .-'_"0ZW_T&-0_\"7_QKI?#?P_GO/&;Z+K$]M:FUD4S
M0-/MDG4@M^ZX^;@9/H#70:MX2LQ\4-,L-(M=*GM(UR;(7!^41C<?/.UB"Q..
M0V0.:'*-[ >=?\)#K?\ T&-0_P# E_\ &C_A(=;_ .@QJ'_@2_\ C75ZKX8U
M+Q;XZU&ST;2M/M([0K#*+5@((2!@Y;:N26#?PY_+-5O$'PO\0^'=,?4)_LMS
M;Q\R&U=F*#U(*CCZ9IWB!SO_  D.M_\ 08U#_P "7_QH_P"$AUO_ *#&H?\
M@2_^-;&@?#[6_$FAS:KI_P!G,4<IB6*1F5Y&&/N\8Q\W4D=#Z5/XC^&NN^&-
M)_M.\:TEMU8*_D2,Q3/ )RHXS@<9ZT7C>P&!_P )#K?_ $&-0_\  E_\:/\
MA(=;_P"@QJ'_ ($O_C6<JL[JB*69C@ #))KT3_A2_B?[0(O/T[;LW&3S7V@^
MGW,Y^@H?*MP.,_X2'6_^@QJ'_@2_^-'_  D.M_\ 08U#_P "7_QKJ;+X1>*+
MRZNX62UMQ;OL\R:0A9#C.4P"2,$<X'IU!H\$>$Y3\3$TC5K6*066^2YB<!T8
M!>..A!+*?QI7B!RW_"0ZW_T&-0_\"7_QH_X2'6_^@QJ'_@2_^->H7OBSPY#X
MHN-%L?A[I]^89S!OBACW,0<$A?+]<]_QJ#Q=X,TN/XE^'[/3K:*&*_97N+50
M-H56RQQV!4$8Z<&ES+J@/-O^$AUO_H,:A_X$O_C1_P )#K?_ $&-0_\  E_\
M:]0^+W@^QM-*M=9TFQM[:.%_)N4MXE12"?E8@8'!X_$>E8GC/3=/T/X<>&;5
M;&"/4KL">6?R5\TC;DJ6QGK(O&>WM34D[: <5_PD.M_]!C4/_ E_\:H2S2W$
MSS32/)*YRSNQ8D^Y->J?##PMIJ:;)XA\06\$MM<2I:VD5Q&'5BSA=V#G^(@#
MTPU<I\2M+BTCQU?P6]O';VSA)(8XT"J%*#. .!\P:FI+FL@.3KL_ 7CVZ\(W
MODS;YM*F;,T.>4/]]/?VZ'\B.,HIM)JS$?7MC?6NI64-Y9S)-;S+N21#P1_G
MMVJQ7S;X"\>W7A&]\F;?-I4S?OH<\H?[Z>_MW_(CZ*L;ZUU*RAO+.9)K>9=R
M2(>"/\]NU<TX.+*+%%%%0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 45ROB;QF-#U>QT:RTV34M5O%WQVZRK$-O/)8].A_(U'X>\<?VK
MK\^@:GI4NE:K$N_R7E$BN.O# #/!SZ>]/E=K@==17G6I_%58=5NK/1M O-7C
MLR1<3PDA4P<$C"MQ[G%0>+?$UCXL^#NJ:C8[U :))(G^]&XECR#^8.:?(^H'
MIE%>(>+-;N+/X2^'M-MXKV/[1#"TERB$0E=K?NR^?O$@''H*]!^'5CIEKX;6
M73M*O=.\W;YRWBL&E<*/G )/RG/&,#VIN-E<#KJ*Y[Q9XMM_"MM:EK:2[N[R
M7RK:VC(!D;COV'(_,5E:7X_FF\4Q>'=;T*72KZ9-\(^T+,K<$C) &.A]>1BI
MY7:X';45YO>?%9[?7]1T:W\.75Y=6LK11+;RES+M."2 F5'YU%;_ !AAO-/)
MM/#]]<:HK-OL8B6VJ.K%@N<<_P!VGR2 ]-HKB--^(]KJ?@K4/$$%BXEL.);1
MI>_&,/CH<]<=CQ6"/C-))8K>P>%;R6V3 N9A*?+B;/3=LP>,=<4<D@/5:*\J
M^)VLVGB#X76>IV+EH)[N,@,,%2 X(/N#D4GC62P1_ 0O+:YFD)'DM#<+&$/[
MGE@4;=VZ$=#Z\-0 ]6HKPSQQJRZQ\3K2QU#3-6GTVVS$U@D;!YR"V7C4,-P.
M!ALC(%=]X/\ %,%SK%WX5727TTZ;$/)22<NSQ\=00"#@J>IZ^U#@TK@=K17'
MV?C(:WXAUW1(-/S:Z=$XENQ/]YNFT+MX.=W.?X?PKF/ FO6.@?"_5]7T_3[@
MQ6UZ28+BZ5V=BL0^^(UP,$<;3TZ\\+D8'J]%>62?&5A9Q7T?A>]>R^59KGS"
M(T<]5#;,-CIR173ZSX_TK2/"EIKQ62:.\4&W@& [$C)!],=S_.CDD!UE%>67
M7QDDL+!);SPO=VUU(P,4,TI19(R#EU<IS@@#&._7BO3X)?/MXI<;=Z!L9SC(
MS2<6MP)**\YU#XJM9>)-0T2'P]<WES;N4A%O)N:9AZJ%RHQGIFH;7XP17EDZ
MV_AZ^FU='*FPB)<A0.6+!<@#H?EI\D@/3**X;3?&=MXR\#Z[<16SVL]O:RI+
M"S;L9C8@@X&1U[#I7FO@[PGX,UCP^+O7/$'V&\\QE,/VR&/Y1T.UE)IJ'<#Z
M#HKR#X374\'BO6]'L[^6]T2!"T4K'Y=P<!2/3(W=.N*X_P *>)9O"GC:YOI
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M>#4IVDA6)F+*"[-\P*@#AAT)JMH?@*XM=9\5S:I);2V.M/)L2%VWJK.QYRH
M.&'3/-=[11S,#RBV^'OC?2X'TG2O%44&CERRD;EE4$YXPN1] P!K>\8> [G7
M_"-CI-MJ3O=6;AQ/>NS&8X(.YN3GG/?TKN:*.=WN!YGK?@;Q5K^@:7;:CJEC
M<:A:W3322LS*I0@  83KP>PK2\8>!K[5=<MO$'A_4EL-7A786DSL<<C.0#@X
M)'0@BNZHHYV!P?A3P9KMCXBFU[Q%K?VN\=-@BMV(C/&,L,*#@=!C'>ND\5:5
M/KGA?4-,MGC2>YBV(TI(4'(ZX!/Z5L44G)MW X'_ (0?4_\ A4?_  B?GVGV
M_P#YZ;V\K_7^9UVYZ>W6FZIX&U.]^&-CX9CGM!>P%"SL[>6<$DX.W/?TKT"B
MGS,#@/$_@;4]:TWPQ;VT]HCZ4%\\R.P#8"#Y<*<_=/7%;/CGPE%XOT!K3*1W
MD1\RVF;HK=P<<[2.OX'M7344<S \[U#P;XEU;X<1>'KV[T][^"5-D_FN5:->
MFX[,[ATZ=JU?$'@H:_X%M=%E>);ZU@C$,W.U9%4#KC.T\CI[XXKKZ*.9@>5I
M\.O$4/PX?PU#=Z>L\U[Y\S^;)L,>!A?N9SN /3M78:7X'\/6.E6EK-HFF3S0
MPJDDLEJC,[ <L21DY.37244.38'">#?!>I>$_$VK31SVK:->$F*%7;S$(;*Y
M&W' )'7TKNZ**3=]6 4444@"BBB@ HHHH **** "BBB@ HHHH **** "OCB/
M_5)_NBOL>OCB/_5)_NBMJ/43+^D6#:KK-EIZYS<SI%E1R-S 9_"O;-4\7C2?
MC#9:;YNVP^RI9RQ]D=SN4_7E!]":\0TW4KO2-0AO[&417,)W1N4#;3C'0@CO
M2ZEJ=YJ^I3:A?3&6ZF(9Y-H7)  '   X K64;O4#VWXF16'A_P 'R64,?EQ:
MMJ8EN O!P3O=A^*+5_QRAGFTN"+PC<:Y:;08)+:_DA6)NV0@P!@##$^O3OXA
MKGBG6O$BVZZO>FY%N&$68T7;G&?N@9Z#K5W3?'_BG2;!+&RU>5+=!M1&C1]H
M] 6!('M4>S=D!U_B.3Q%XQ\;Z1IL>C2:/J%BOF!GG$VQ=P(D+8 P"OODUV_Q
M,U'4;7P/<SZ/-&?WHAO)HOO(OW6QCH<X!] 37BEAXX\1Z9+=S6NILLUXVZ>9
MHD>1R!@99E)P!T&<#M4-EXLUS3],O--M[\BTO"S7$;QI)O+##'+ G)'I3Y'I
MY >@^!LZ'\)/$>LX\N6XWQQR8Y.%"*?P=VKGM$U/X<6VC6T6L:'J=UJ"J?.F
M1R%8Y)X E' &!T'2L31?&OB+P[:-:Z7J300,Q?RS&C@$]<;@<=.U8<LKSS/+
M*Q>1V+,QZDGDFGRZNX'K_AB#_A(/A%KVEZ(@CNS=,RVX;G:65@N2><J"N3Z5
M'X#TVY@CM](U'X=).?./GZC?1JNU2>H#QG.!T //MFO,-)UO4M"N_M6EWDMM
M-C!*'AAZ$'@CZUMW?Q)\7WL#0RZW,$88/E1I&?S50:3@^@'JWAW^R(_BSKEM
M8V5K:O:V4<,*01K&K<AI#@#KDJ,]>*SK'4]4T?4-3U>V^'-_%<<BZFDU61A(
M.N0&!# 8X*@XKQJTU&]L-02_M;J6*[1MXF5CNSWR>^>_K6SJGCWQ/K-DUG?:
MO+);MPR(B1[AZ':!D>QI>S8'H5CJ,OAGX,7.K6^;>]U2Y=X^>5+OMR/HBDC\
MZK6<TNB_ >\NI)'-QJLSX\TDD[VV'\U5C^.:\YOO$VKZEHUII%W=^986F/)B
M\I%VX! Y !/!/4T7WB;6-2T:TTB[N_,L+3;Y,(B1=N 0.0 3P3U-/D8'MWBU
M89= T2"T\+3Z]IKQKY2VEY)"L?"["0@Y&.A/ QVS60)]0U_XA^&--U+P_)I@
MTE)+@++=?:"Z@+M.['.&1>223FO--)\=>)M#LA9Z?JTD5N/NQLB2!?IN!P/8
M5#:>,-?LM:FUB'4I/[0F0QO/(BR$J2#C# @#@=*2@T!UOB.:?QO\6QH_VZ2*
MTBN#;Q;2<1[ 2Y4?WB5;GZ5V%AI>A-\08-+_ +/UC4K_ $Q5=]1OKIF6+ WJ
M1D\_,>!@#.3VKP]=0NUU+^T4N'2\\TS><IPV\G.>/>ND/Q.\8M)'(=:?,><8
MAC Z8Y&W!_&FX/9 >E>'#_:_QG\1:ED&"PA^S#C[K#"_^R/^=9/PRECO/$_B
MGQ9<%A"@=@S= KL7/Y!!^=><6'B[7=+U6[U.RU!H;N[8O.XC0B0DY)*D;>I/
M;O5F?Q[XFN(+^&74RT>H#%R/)C^<;0F/N\#: .,?K1R,#TCPW-J%]\(]9NM$
M#/K-U=2R3"(_.&9EW;>^=G3].:C\*6-_X7^&?B*[\0++%'<QL(;2Y.#DH1T/
M(+,P&#Z=*\LT3Q)J_AR:272;Z2V:0 .  RMCIE6!!_*I=;\5ZYXC$:ZMJ,EP
MD9RJ85%!]=J@#/O1R/Y >DZI?W'A'X*:1;6<KQ76H $R*<,JOF1L?@0OXU7U
M]VT7X%:38NQ>3471SD]%9C+_ $45YWK/B;5]?AM(=3N_/CM%*P*(D0(#@'[H
M&?NCKZ4:QXFUC7X+6'4[SSXK0%84$:($! '\(&>@ZT*# N> ]/&I^.='MCG:
M+@2MCT3Y_P#V6O3KF]NM?^.=M8K(_P!BTE2VP,<9"9+8]=S!?H*\?T;6]0\/
MWXOM,G$%R%*!_+5\ ]>&!%6=/\5ZUI6L76K6=[Y=_=;O.F,2,6W-N/!! R1V
MIRBV[@>K:/=S^)?C=>S--*UGI"2)$F?E4@",\>Y+'\/:I?!5U'/X@\:>+KC9
MY$;M%')_TS3)/_CJQUY+I7BS7-$N+RXT^^,,UX<SOY2,7.2?X@<<D]*99>*-
M8T_1+G1K2\\JPN2QFB$2'?N !^8C=T [TG!@>R^ _B->^+Y;W3+J.UM=1$)D
MMI(D8H>W*DGH2#UY&>F*PO 0U75/B7JNJ>('\RYTN%XW8C C;.T!1V&W?^?O
M7E>EZI>:-J,.H:?,8;J$DQR!0V,@@\$$=":U3XV\0^;J4HU +)J:!+ME@C!D
M 4J.B\<$],4.GO8#T_X?:U#XUT;7_#^IG_722SH."0DK$G'NKG.?]H5E^.]/
MF\7?%&Q\.VC$0VL")*0.(E/S.W_?)4?7 KS/1]:U'0-06^TNY-O<A2N\*&X/
M4$$$&M&T\;>(;'5KS5+>_"7UY@3S&"-BP'897@=.F.@]*.1IW0'K?B/5/ ?F
MV&D7>O7-D-%F4QV]K$S*'3 &X^6V2.1P>YSS7*?&VU4:]IFH(<I<VA08[[6S
MG\G%>8R2/+(\DCL\CDLS,<EB>I)]:U=8\3ZQK]M:6^IW8N([0%8 8D4H" #R
M ">@Z^E"A9I@9%%%26]O-=W$=O;Q/+-(P1$09+$] !6@@M[>:[N([>WB>6:1
M@B(@R6)Z "OI'X=>$[KPGH+0WMT\ES<,)'@#9CA..B^_J>^!Z9-+X>?#R'PM
M;K?WZI+J\B\GJ+<'^%??U/X#C)/>USU)WT0T%%%%9#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /+?B99^'-1\0:=:ZO)?:;>/'M@U)44
MV^W).UR6SP?IC=Z5E^"M0UK3/B##H%MKXU[2S&S2R))YB1C:2""2=I!QP#@Y
MQ7K]W8VFH0&&]M8+F(]4FC#K^1J.QTO3],1DL+"UM%;[PMX5C!^N!5J>E@/
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MPTXRFQL;:U,QW2&")4WGU.!R>31S[V \(^'1OT^*5C::EN%S9PRVQ#=5"(P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIQ4H[,****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI^HH Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZG:W-W:;+2\:UG5@ZR*
M,@X[$=Q32N[,4FTKI7+E%<[]E\62_(^HZ? O]^*$LWY-Q7.SIK-E(QU/6[W[
M9(Q%K9VK O)Z,P' %;PH*3MS+\3EJ8IPM>#_  _S_P"'/1**PO"^I7M[9SV^
MI*!?6DGERD8^;C(/'&?\*W:QG!PDXLZ*<U.*D@HHHJ2PHHHH **** "BBB@
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MV"<QB7(SG+*2 3G)].3Q2Z/X GTOQ%=ZS)KDMY/>6K07'G0#+%L?,"&X VC
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M9&^\P!.,^_.*@UOQ-XP.BV>@ZQI^F6%E?PK%%=2*Q4K@8)8,P!Z=LCVKMO\
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MB[,]",E)7B] HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U348]*TV:^FBEDBA
M&YUB4%L>N"1TZUS_ (.\2V>K_:+.VAN=Z2SSL[J H5Y691G/7#?H:ZJ2-)HG
MBD4/&ZE64C((/45C>&?#<'ANRG@B;>TLS.7/7;GY1^ _4FNB$J?L9*7Q:6.:
MI&LZ\7%^[9W-NBBBN<Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDDFOZ_KJ4? VQ;._CM6D>PCN2MNTG4C S_GWKJZY3PM.=)AM]%O'B%VP++!
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M17W=/S]#SZM"=%KV<GJ[+7K_ %OO^IW%%%%<1ZH4444 %%%% !1110 4444
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M85I\\W+O_7F=-"G[.FH=OG^B_(FHHHK,U"BBB@ HHHH **** "BBB@ HHHH
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M/2MZBBLYSYG=FD(*"LO/\=0HHHJ2PHHHH *H:/-)/92/*Y=A=7" GT69U _
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M3[)]D0+Y>)8=^<1IURGKT/3O]'T %%%% !1110 4444 %%%% !1110 4444
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M_AM_9.JV-_Y.JCS/LEPDNS,L&,[2<9P>OH:]PH **** "BBB@ HHHH ****
M"BBB@ KG-<OI]0O1X?TURLT@S=SK_P L(_3_ 'C5O7M7?3X8[:S42ZE='9;Q
M>_=C["I=#TA=(LBC2&:ZE;S+B=NLCGJ?IZ5M!*"YW\O\SGJ-U)>SCMU_R]7^
M1R+?"73RQ(\0:XH)Z VV!_Y!KK?#NA6_AK0X=*M9IYXHGD?S)RI=B[L[$[0!
MU8] *U**B52<_B;9I"E3A\$4@HHHJ#0**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH X_P 4\^-_!H[_ &BX/_D.NPKCO$_/CSP8/^FMT?\
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MKE]>\$6>N>*])UJ7:/LF?.0C_6@<I^39SZBNKH **** "BBB@ HHHH ****
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M5/X7M3;V,UY=Z?'97&?++;2"T:C@\_4UE^/YKB.* M,+>R169Y-FXLQXQGL
M.??/M5"W@N;G188(K_486LPNQ\M''.=V2@SC.03U]NU8XK$2HQC'D;O=JVVW
M5W_#T./#T8U<;.I=>ZDO/O>UO/=>93@\-3ZEXR@N+W396L9F>5RV"FUE8@EQ
MGN>F<\]L4W5M*N;!)19ZA!J.EPX#G>KSP+_"C-_=XZ4^XM#;11ZS#(EE?Q9@
M-O++E65^ <@'ONX''3I5*PM[F]?4%A@G1'E2*YNFA98' .>/8>N..O&:\O"X
MFM1A[-TKJ6KNU>[[6M:W]7/7J8:,ES<VNVVGFG?1^A?\+ZM=)Y5_- MW:AO)
MFEMQF:V R%#<Y:/'/_Z@*FLM ^U_$%M3UG4S=):S'^RXHHRT:H1C!8# QTQW
M(SFLSP-9Z7-XC>4BXMM0D0J+7+*I08W,3WSZ>U>F6$*PW%RBQ&)%("(%P@7&
M<KV^ON*]O#8F/(Y4TUS*SO:Z^?\ E8\^6&G2FH2VZ;_U^+]67Z***DW D 9)
MP!54W$TJAK:$%&'#R-M'U P3_*IIX_.@DBW%=ZE<CMD4V&5BWE21E' SUR&'
MJ*:V);UL<+JD8N/$SQV6G27DL2);RM)&=H0\$@@]B<^QS6UXJL=^@1:786P)
M/^KACP-J*IZ ]<9' KD3/=+XJ\ZZN95NXV:8VT$39 )VX& 0<;AUZUHW-G.+
MP/)+>7=O<A2\=Q,0;4GKP3GH0< >O'2N#,L1/6@J<F[+M;?IO_6Z.;*J$9*5
M927O2;]/+R].Y5TKPK';^&OM5Q<?V1J0GD*33MY8D0\;74X^4@=.?7OBLBYD
MU'3M4CM[Y[:WN9R(W? \DQGH !QL/&<YQUZT_4X3IEM+I,=Q]NT^)ALCA5I)
MF\PY"@ <<$9YJ+Q!9/\ 9XCJ=M,(Y (0KH=]N@4$,1_%U]>,8K.CC9QBJ52F
M^6.ETU?_ "MY?E<]&K@E/X7>_EUZ6ZI^:_'8Z34Y]6O/"<]A:'^Q]6@<!@?N
M21$_-Y)],=,>F.^:Z#P5HVGZ%X=CL].DDE0.S2221&,LY.3\I P/2JNA6-C'
MX4M9-.::XA0;8)GRTBKG#%1U'.3@=JZM0%4 = ,"O7]LO9>RA\-[]OO_ .'.
M*G3E&7O[H6FR2+%&TCG"J,DTZHKF(S0E%.&R&'U!!_I62-GMH0R-<7"F-80D
M3C!=WPP!] !_,BN)B@BU3Q/<>3I37%K-/Y=S)/&0 HZ$<XQQ@>W&*[>2XE-K
M<&*!OM$:$K&Q'S'''/N:\STJ>:'6II&N[F>X1/+DBM86#9?)R  0/NGZ4JU9
MT*,JG*VO+5_F<&(IQKUZ5._6^NE[=-K==F=+XZLY]1M8;2TMVE:)3(RQ@$J,
M@#Y>IZ'H*QX/"XL?#FGRP74.FZLT6V2WNW'EW)+$A70XYR1CCCI[U)-I6ZZE
MLKVYN;JRF+?Z7+/EH 1RN"<G!SVP./>L*\$Z-;Z9-NU&.VF%M$EFC/(2G.2<
M< $=,FO(AB:U*O*JJ>^FMK6_7\;GM?5XSC9RVUT$AEU"#6O[.E^S+=RD^;#=
M &.5QRJD=,9Z'UP!Q6YXC%_K_A^RM8+B72\2^3J=O*I:5H\<E1U9<^G4'VQ7
M.>(+&)[R-=<$L?GL7EN50[H,'&"/4@#G/.<UZ9:6ENNG:=+;+(\<@0+,27D\
MKJH)ZXQ@'Z_6O5P>*CS*:BXR71V:^7^3NUW//K86=/WEL^RMK\M/NLGV1:\.
M6%EI?A^RLM/+FUAC"H74JQ]R"!@_A6I116DFY-MFJ5E8****0PHHHH ****
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MUP_^ J4>WG_S[?\ Y+_\D'LH?SK\?\C7HK(_LW5>^MO_ . RT?V9J??6Y?\
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M*** "J;:7:/N$D9D0G(C=BRJ>O / JY133:V%**DK-#8XTAB2*-%2- %55&
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M,5YDL'!8JI/4JI.U?P Q705,FGL,****D HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \\M[/QC92Z>(=%L9$L&F$;->X,@?/)&.*ZCPS;:A;V-R^IV\=
MO<W%U).8XY-ZJ&QW_"JVO:OK.DZK"]GI,VHV+PD2".1$\M]W!RW7CC%:ND7U
MUJ%B)[O3I;"7<1Y,K!FQZY'% %^BBB@#&\3>*-*\(Z-+JFK7 BA0?*@(WRMV
M5 2,D_\ Z\"JMSXWT>R\%0>*KIIH=/GA26-&3,K%_NH%!/S'/KCWQS6'\5/#
M&DZEX6U;6[VU$][8Z9.ML7Y6,D9W ?WN!@]NU<7XG^7X._#N9^+>*\L&F8_=
M5=AY/M26J^:_%M#>GW/\$F>C:!XYMO%D&I6NE6MU8ZQ:1@FSU: PLI8?(S $
M_*?;G\Q63X+U/Q3%XSU'0?$6KP:B([1+@.;,6K+(6PRQ# ,L8_YZ8QDCGM69
M<6,&O_'/6++?OLY/#@M[LQ-RI=^!D=&P014R?#;Q)I5I/>Z;XM-WKT%HECI4
MUW;I'%:P"12P8 /O8J"-Q'?\12W4O+_-?Y?TM5+JO3]'_G_6V?\ %_\ Y*'\
M,?\ L*G_ -&V]>P5\@:7XV\1>,?B'X/_ +?U#[9]EU6#R?W,<>W=+'N^XHSG
M:O7TKZ_I %%%% !1110 5!>20Q6-Q)<7 MX$C9I)RX01J!RVX\# YSVI;BZM
M[5-]Q-'$OJ[8S7)^,=;@O/!.OPVL,\L3:=<*\_ED1H/+;))[XZXK&I6IQ?+)
MZ]NOW;FD*4Y>]%:'-ZGXS@B,\NES:W?6*1G;>HX,6\'!/4,R 9Y53G'!QS7<
M:##8:5HZ7;7\4[7@%Q)>%QB<L,@@]Q@\5YG8:SIAT*.\2>*&VBC 96.#%@8*
MD=B,8Q7;?#_1+/\ X0_3;R:V5WN%:XB#G<%BD=GC '081EKS\#B*TE.G"%M>
MM_N^7;0[L;AZ2<*DIWTZ6^_Y]]3=.OI,2NGVL]XW]Y5VI^+&D\C6KS_77,-E
M&?X81O?\ST_"M< *    .@%+7;["<OXDV_):+_/\3D]K&/P1^_7_ ('X&7#H
M%C&_FRH]S+WDN&WG_"M+RT\OR]B[,8VXXQ]*=16M.E"G\"L9SJ3G\3N<[!X%
M\-6U\MW%I:!T?>D9D=HD;U6(ML4CMA>./2NBHHJTDMB6V]PHHHIB"BBB@ HJ
M"]NDL;"XO)0QC@B:5@HY(49./?BO/?\ A=GAO_GQU;_OU'_\<H ])HK!\*^+
M;#Q?93W6GPW,4<,GEL+A54DX!XP3ZUKWEW#86-Q>7#;8+>-I9&QG"J,D_D*
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M%K&B?$/PI_:VE7UAYVJVWE_:[=XM^)4SC<!G&1T]17V?7R!I>C_V5\0_!_\
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MCNQ&FF0[2%XP3R0,\Y]:Y%0DU>Z^\]V>9TH-IQEII\+.QKC_ !7XN;39&L+
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MHH **** *=ZUO9))J+PAI$3:6 ^8C/2HX9[7599$>#)MG5AO /)&013=?_Y
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M>W0UVX3X96W/FL]_C474^"^OX'H=O]EMU:VM_+C$0&Y%XV_6G3?9YP;>;RY
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M3VJ6]\37]S$5:41H>N#7J&H:#I6JMNO;"&9^F\KAO^^AS56U\(>'[.021:7
M6'(,F9,?]]$UU_6J;U<=3P/[$Q4?<C6]WYGG_AKPW<Z]<I,Z/'IZG+S'CS/9
M/7Z]J]91%C1410JJ  !T I0     !T I:YJM:55W9[. P%/!PY8:M[ON%%%%
M9'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45ROCGQ]I'
M@323<W\@DNY%/V:S5L/,P_ [5]6/3W/%5[[X@VNF_#VP\57-E(7OHXO(LHG#
M,\L@RJ!B![\XZ \=J5]+A;H=E17%^'/&U_KUYJFB7FB'1/$-I )DMKF831NK
M#Y6W*!D XR!Z]<YQ1^'<^M?\)-XPL=:U>74IK2YMU5R-L:;H]Q")G"CGMUQD
M\U5M?E?\; W;^O*YYEXE^(^C_$#XA^ /[)MKZ'[#JJ>9]K1%SOEAQC:S?W#U
MQVKZ/KQ_XO\ _)0_AC_V%3_Z-MZ]@I %%%<EXC\?V/AO61I<VF:E=S_9TN"U
MJ(MJJS.H!WR*<YC;H/2G&+D[15V3*48J\G9%G6_^)KXAT[1AS#$?MEU]%X4'
MZFNDK@/!?B>UU7Q9J=N]K=)?72-<I*X3RQ#&44("&+;AY@SP![UW]:UTXM4^
MQCAVIIU%U_+9!1116)T!1110 4444 %%%% !1110 4444 %%%% !6=:Z!HUC
M>->6FDV%O=-]Z>*V1'/U8#-:-% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5R?C/Q')I<265HVVYE7<SCJB^WN:ZRO*O'*R#Q/.7/RLB%/IM']
M<UT86"G4U/(SO$5*&%;IZ-NUR+2?#=WK"_:II?*A8_?899_H/ZUN_P#"$6&S
M'VFXW?WOE_EBM:V9VTBR:S*A2D8^[GY> ?RITUQ>J[+%:!AE@&+>W!_&MY5I
MMZ.QYU'+\+3IKGCS/OJ]SA=4T:\T"XCG24M'N_=S)P0?0^AKT#PIK_\ ;>GD
M3$?:H<"3'\0[-5+64\[PU<_:5 <0[B/1AR/UKD_!]W-:ZW^Z8#S(V5LQLX]>
MB\]JJ2]M2;>Z,:4O[/QL8TW[D^AZQ17G%]>.VNN7\120'S!F,)*H7VP:?9W)
M;Q-$O_"1R2@W0'EXDP_S?=].>GI7/]6=KW_!GJ_VQ'GY>7K;XH_YGHA&017(
MW]G/IETCF9@H/[BZ/5#_ '']1[UUU,FACN(6BE0.C#!!KF/3KT?:+S11TW54
MO(G68"&XA'[U#V]Q[5BZGJAU%@B!_LF[:B+PUPW]%_SUZ;,/V#2(Q;M*0P0M
MEQEB@/KCH/2I+;3K1+DWT0W-(HV9Z(N/X1VH,90J5(J',O/^OZOZ$>CV$UG"
MSW$F99,9C7[D8'0 5I444'5""A'E04444%!7FWB?Q9<7MT]CI\C);J=A9/O2
MG_"N_P!3:1-*O&B_U@@<K]=IQ7E?A5(W\0P>: <!F4'^\!Q77A81LYO6Q\_G
M5>IS4\-3=N?=EJR\&WUR@DN94MP>=K#<WXCM4MUX)NHHR]M=),P_@9=I/TKK
MY+F2*2?=#NCC564KG+9[?ABHH]0:6Y2);655+%2[#&,=ZT]O5O<YO[,P2CRM
M._?6_P#D<?H'B.[T&]^S7.\VV[;)$W5/<>A_G7J<<B2QK)&P9' 96'0@UYEX
MWMXX[^WG4 /*A#^^.A_7]*UM$UJY'A+R8IK6.:(,B22W"J1SD?*1Z'%*M352
M*J1W8\MQ<L)5J86J[J.J_P CN:*X"WU/7FLKMSK-@Q0+AC(AV\^W _&MWPI=
MZA=1W1O[Z"ZVE=GE,K;>N<[?P_6N>=!Q3=UH>M0S.%:I&FH-7[V\_/R-;4K)
M[VUV13-%*IW(P/&??U%<Y97LVE7$@,155.;BV'\/^VGM_GI77U4N]-M[R6&6
M0,LD395T."1Z'VK$Z:U%R:G!V9'=ZM;6UBERK>;YO^J5>KGTKGHHKO5=0;Y_
M](Z2RC[L"_W5_P!K_/J:WS-I]]$EK'(!O#"/8N"N.#MXXQ5JSLX;&V6"!=J+
M^9/J:"9TW6DKOW5V)(8A#"D09F"*%!8Y)^M/HHH.M*V@4444 %%%% !1110
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M\'1>(/$&FW>H37I72I88P%@EWQ?,^(ER-QC/1NAX]>[_ .$>^.?_ $.>A_\
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M^AST/_ORO_R/1_PCWQS_ .AST/\ [\K_ /(]>P44 >/_ /"/?'/_ *'/0_\
MORO_ ,CT?\(]\<_^AST/_ORO_P CU[!10!X__P (]\<_^AST/_ORO_R/1_PC
MWQS_ .AST/\ [\K_ /(]>P57OK^STRT>[O[N"TMDQNFGD$:+DX&6/ YH \$L
MM4^,-]X\U'P?%XLTT:A86XN)9&MX_**D1G"GR,Y_>+U Z'\>C_X1[XY_]#GH
M?_?E?_D>NHA\*6>@_$36/B!>:Y!%:WUFMNT4RB-(@!$ QE+8.?+]!][VY["R
MOK34K5+JQNH+JW?[DT$@=&^A'!H \G_X1[XY_P#0YZ'_ -^5_P#D>C_A'OCG
M_P!#GH?_ 'Y7_P"1Z]@HH \?_P"$>^.?_0YZ'_WY7_Y'H_X1[XY_]#GH?_?E
M?_D>O8** /'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>A_\ ?E?_ )'K
MV"JUYJ-EIXA-[>6]L)I!%%YTJIYCGHJY/)/H.: /!/#>J?&'Q1K.NZ79>+--
MCGT6X^SW#36\85VW.N4Q 21F,]0.U=)_PCWQS_Z'/0_^_*__ "/71:%X?TKX
M=:]XCUG5?$EE$GB"\\]$NBMN(R&D;:&9_G_UGH.GO79Z=JNG:Q;&YTR_M;V
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M<E;;<2B+M 9SG[OKWKO00P!!!!Y!'>@#R#_A'OCG_P!#GH?_ 'Y7_P"1Z/\
MA'OCG_T.>A_]^5_^1Z]@HH \?_X1[XY_]#GH?_?E?_D>C_A'OCG_ -#GH?\
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M9-GH@M+F";S]WE;^-F,[OQK6H.;"TY4X6E_6B"BBB@Z0HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&",C-7;FT70-0NUL]$O[J.+0TM](B6V>10?WAE5GP=K-^[SN()P,9/%>C44
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MNKV_9%:5"K>3$JQ*!G^$E"P]=V?2NDHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img96160895_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (4!18# 2(  A$! Q$!_\0
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MHH ])_X658_\^%Q_WT*/^%E6/_/A<?\ ?0KS:B@#TG_A95C_ ,^%Q_WT*/\
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M (658_\ /A<?]]"C_A95C_SX7'_?0KS:B@#TG_A95C_SX7'_ 'T*/^%E6/\
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M%>;44 >D_P#"RK'_ )\+C_OH4?\ "RK'_GPN/^^A7FU% 'I/_"RK'_GPN/\
MOH4?\+*L?^?"X_[Z%>;44 >E'XD62XS83\C(^84G_"RK'_GPN/\ OH5YS)T3
M_=IE 'I/_"RK'_GPN/\ OH4?\+*L?^?"X_[Z%>;44 >D_P#"RK'_ )\+C_OH
M4?\ "RK'_GPN/^^A7FU% 'I/_"RK'_GPN/\ OH4?\+*L?^?"X_[Z%>;44 >D
M_P#"RK'_ )\+C_OH4?\ "RK'_GPN/^^A7FU% 'I/_"RK'_GPN/\ OH4?\+*L
M?^?"X_[Z%>;44 >D_P#"RK'_ )\+C_OH4?\ "RK'_GPN/^^A7$CP_J&Z)"MN
MKRJK(C7<2LP;I\I;/-9SH\<C1R*RNI(96&"".Q% 'H__  LJQ_Y\+C_OH4?\
M+*L?^?"X_P"^A7FU% 'I/_"RK'_GPN/^^A1_PLJQ_P"?"X_[Z%>;44 >D_\
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M\0+%=Z1=11,[V46R17X#DELX(]FZ_I0!4FT:5(O-M[JUNXQ*(7:%SA&/3=N
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M+G]X<YRWKSSS0!U\UI!+I6M1R)://:(,_9K(1I"X?&T2'#L<#G(_$UB^+?\
MD9KOZ1_^@+5&75=1F4K+J%U(I4H0\S$;3C(Z].!^55III;B4RS2/)(W5W8DG
MMU- '47D<TGQ)80!MZW:L2.RC!)/MC-/8Z;:V7VZ)0PN+V4%Q9)<  'Y4PS
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M5_\ M24V-W"^^2>[=3+/(^XE5Y YYZX.<]A5"@ HHHH **** "BBB@ HHHH
M**** 'K_ *E_J*93U_U+_44R@ HHK4TC17U>&]:.8));QAE0KGS"3@+G/% &
M716GIFC2:C9WUUYHCCM(B_*YWL 3M'X \]N/6@:1NTZZN]\R>1#%)LEAV[][
M8X.?N^A[^@H S**L26%Y#;)<RVDZ0/C;*T9"MGI@XP:<VFWZ112-97(CF(6)
MC$V')Z!3CG/;% %6BM.]T&_M-4?3UMY9YD4/B*-CD8&2.,D9XS56/3KZ662*
M.SN'DC.'18F)4],$8XH K458^PW?VS[)]EG^T_\ /'RSOZ9^[UZ<T?8+S[9]
MC^R3_:O^>/EG?TS]WKTYH KT5)/!-;3-#<1212K]Y)%*L._(-1T %/?[D?\
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M20HZ ;5+9'()R>>?3WH IT444 >A_#/_ %6H_P"]'_[-11\,_P#5:C_O1_\
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ME"EY&]P+2U@>19/]<ZL=VT]6&,#/MZ4UKM)%MX8Y+"XB;3K=)[>>X\O>5;.
M^0%8>A/3L: ,2WT*_N+:^F^SRJ;,#?&8VW$D@8QCL#D^PJ!])U*.,R/I]TJ
M%BS0L!@<DYQ707#6;0ZO;6]XK2SVL#!9KI7"LK@M&LAP&VC&.>W&:?/?03^*
M=1'VN$QSV!MXI&D&P,8EXW= ,Y_&@#E1;7#"$B"4B9ML1"'YSG&%]3DCI6A9
M^'M1N[Q[5K6>&1(6F(DB8' SC QW(P/>MRVFMK&QTRUDO+<7/DW<:R1S!A!(
M^-A+*3CZCIGV-5-(5K&Y2&[U&U*O;7"11"Y5EC9E[L#L7)'K]: .:961BK*5
M93@@C!!I*5U*.RG&5.#@@C\QUI* "BBB@ HHHH **** "BBB@ I\?W9/]W^H
MIE/C^[)_N_U% #**** "BBB@ HHHH Z#1KB"+1ITDFC1S>V[!68 D G)^@JV
M^H6[7?B22>9)HY+B-D7>#YJK,.%]?E_2N4HH [!I%67Q%=MJ=L\%Y Q@47"E
MI,L"HVYR"HXP0/:C6+BWU ZI:VEU;B:2>&7<TRHDT:Q@;0Q."0QS@G^5<?10
M!U,4,<EG,MS?VU_<BX"E)K[9"HVJ/,ZJSD %?E/YU8UBYMKE_$@ANK=_--L\
M9\U0'"C+;<GDCTZUQU% '9ZU-#J0U"WL[VU$G]H>?EIU19$V  AB<'!![]ZB
MUC4K:>QUE8;J-VDEME)#<S%5PS =2,CK^-<C10!U.M75L+2>>*>&6>ZAMH6*
M2!F 5 7)_%4'Y^E7]7;[)KVI7=Q>0FW>Q,*Q><"Y+( $V9W#YOFSC'?-</4]
MW=SWUT]S<OOE?&YL 9P,#@>PH ZDW5M_;)U?[7!_9IL_+^S^:-^/+V>5Y?7[
MW/3;WS5D,;:]T&_FO88[2"P3?&TP#8VG("9R=W X'\JX:I[F[GN_*\]]_E1K
M$G &%'0<4 =5IDEO+J7A^^-Y:QPVT BF\R=59&!?^$G.#N'(J&RDLYM.TN&6
M["%+2X#1)<+%O)D)$;,?NAAZ]:Y2B@#N8KFS@N- 4S6,/DBY61(;C<D19?E!
M8L>N>N<9S5:SNK>&PLK1KN".X-E=6X?S01'(TAQEAT!&>??TKCZ* .STN[@T
MZ'3[:>\@^TPI=/N6966(,A"KN!QDD$X![^]8=Q-$_A2RB\U&FCNI?DW995(7
MMV!(K(HH **** "BBB@ HHHH E>1U5 KL!M[&F^=)_ST;\Z)?X/]VF"@!_G2
M_P#/1OSH\Z7_ )Z-^=2V$23ZC:Q2#<CS(K#.,@D UU']C1MJ]U;7&A"TT]#*
M!>?OEV*,[6W,Q4]NW.: .2\Z7_GHWYT>=+_ST;\ZU!X>N"MF%N+8S7B"2* ,
MV\J>Y^7  P>I[&J]UI;6]J;J*YM[J!9/*=X"WR-C(!# 'G!P1QQ0!3\Z7_GH
MWYT>=+_ST;\ZLV>G/=02W#SPV]O$0K2S%L%CT4!023P3P.@K7MM#0V2(%MI[
MHZDENLGFL8G0H2.5/0\'U^E '/\ G2_\]&_.CSI?^>C?G6NGAV:1+>1[NS@^
MTS-%"CL^2P;;CA3@9[G\::NA7DL5I$L,"RRSRQ9WG<"F-V[G: .>1[T 97G2
M_P#/1OSH\Z7_ )Z-^=7QI <H8]1L7B;.Z7S&41X&?F#*&Y[8!SVJ_I>@QG5-
M.^T2P7=G=^;M,3.,E%.0<A2.<4 8/G2_\]&_.CSI?^>C?G3** )EED\ISO;M
MWIGG2_\ /1OSH7_5/^%,H ?YTO\ ST;\Z/.E_P">C?G3*[&?1@FLQ6L/AT26
M+>5NN#Y_1E4L=V_:,9/; Q0!R/G2_P#/1OSH\Z7_ )Z-^=='<:!9R6%H]K=V
M\1DNYH!+,['S@& 3&T$=,\X YK)CTEB95N;NUM&CE,)69R26'7A0W ]3QSUH
M I>=+_ST;\Z/.E_YZ-^=:K>';F&2=;NYM;58I_L^^5F*L^,\;5.!C!R<=:@B
MTAVA>::[M;>$2F%9)&+!V'7;L#9 XYZ<CF@"CYTO_/1OSH\Z7_GHWYU)>6<U
MA=R6MPH66,X(!R/4$'Z5JZEI^G6_A^UN;.5YY7G>.29E*AL*#A5]!GJ>3S0!
MC>=+_P ]&_.CSI?^>C?G3** )I99 PP[?='?VIGG2_\ /1OSHE^\O^ZO\J90
M _SI?^>C?G1YTO\ ST;\Z95S28([G6;&WF7=%+<1HZYQD%@".* *WG2_\]&_
M.CSI?^>C?G73OI2&6_2[T7^S[6*.1DO/WJ[2#\OWV(;)P, 9.>*KWWA^-UM#
M9S6Z2R6"7!MV=M\AV;F(X(]>,CITH P/.E_YZ-^='G2_\]&_.M*TT.2],,<=
M[9BYF0NEN68L1@G!(4J"0.A([4S^QG6WBDEO+2&26$SQPR.P9DYQSC;DX. 3
MF@"AYTO_ #T;\Z/.E_YZ-^=:4.@W$RVX^T6R7%RF^"W=F#R#MVVC/;)&:IV1
MM8KL-?1R21("3&AP78#A2>PSC)'.,XH A\Z7_GHWYT>=+_ST;\ZU-1M;<Z-9
M:@ELMI+,[IY*,S+(HQAQN)(Y)'7G':LB@!_G2_\ /1OSH\Z7_GHWYTRB@":2
M60,,.WW1W]J9YTO_ #T;\Z)?O#_='\J90 _SI?\ GHWYT>=+_P ]&_.NNGT8
M)K,5K#X=$EBWE;K@^?T95+'=OVC&3VP,54N- LY+"T>UN[>(R7<T EF=CYP#
M )C:".F>< <T <YYTO\ ST;\Z/.E_P">C?G5Z+1W9W2XO+6TD68P[)G8L6'!
MX4'C/&3Q[U,?#UQ$\XNKFUM5BN/LV^5FVL^,X&U3@8YR<#F@#+\Z7_GHWYT>
M=+_ST;\ZO1:0[1&6>[M;:+S3$CRN2)&'7;M!R!QSTY'-5KFTDLKUK6[!C>-@
M'VX; ]1S@\>] $7G2_\ /1OSH\Z7_GHWYUNW5I8S:'=7\5@]G$DJ):2L[$W
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M]<ZO\^T]6&.,^@]*X^B@#LDO[0VZ0![62XETJ*)?.E*IE6):-F5@5)&."0.
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MJU]D'_/3_P =H^R#_GI_X[1]5K?RL/[3PG_/Q%6BK7V0?\]/_':/L@_YZ?\
MCM'U6M_*P_M/"?\ /Q%6BK7V0?\ /3_QVC[(/^>G_CM'U6M_*P_M/"?\_$5:
M*M?9!_ST_P#':/L@_P">G_CM'U6M_*P_M/"?\_$5:*M?9!_ST_\ ':/L@_YZ
M?^.T?5:W\K#^T\)_S\1 _P#JH_Q_G3*Z'3?"MUJ]KYMO/$JHQ4[\@YZ]JN?\
M*_U+_GYMOS;_  K"47%V9V0G&<5*+NF<E176_P#"O]2_Y^;;\V_PH_X5_J7_
M #\VWYM_A2*.2HKK?^%?ZE_S\VWYM_A1_P *_P!2_P"?FV_-O\* .2HKK?\
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M^I?\_-M^;?X4?\*_U+_GYMOS;_"@#DJ*ZW_A7^I?\_-M^;?X4?\ "O\ 4O\
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M$,RD8Y_V36BNOV/F7<D;7=I+-=R3-+!&OF21LP(0ON!3IVR/K5K_ (5QJO\
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M4 <]K5]%J6JR74*NJ,D:@. #\J*IZ>XJ8:G"+'2(-LFZSGDDD.!@AF4C'/\
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M  KC5?\ GYM/^^F_PH XZBNQ_P"%<:K_ ,_-I_WTW^%'_"N-5_Y^;3_OIO\
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M )][/_OAO_BJ/[/K!_;N#[O[CT6BO.O^$]U7_GWL_P#OAO\ XJC_ (3W5?\
MGWL_^^&_^*H_L^L']NX/N_N/1:*\Z_X3W5?^?>S_ .^&_P#BJ/\ A/=5_P"?
M>S_[X;_XJC^SZP?V[@^[^X[VT_U3_P#75_\ T(U8KS>/QSJ<2D+!:<L6Y1NI
M.?[U/_X3W5?^?>S_ .^&_P#BJ/[/K!_;N#[O[CT6BO.O^$]U7_GWL_\ OAO_
M (JC_A/=5_Y][/\ [X;_ .*H_L^L']NX/N_N/1:*\Z_X3W5?^?>S_P"^&_\
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M(]N.",Y[_P"<BII-4T^) SWMN 8S*/WJ\H.2PYY'!YJ2BW156+4[&9+=X[R
MBY&8?W@S)]/6G1WUI,[)'=0.R+O8+("0OJ?:@"Q14<$\-S"LT$J2Q-]UXV#
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M/4>**04M=1YP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSC=N &[.<8'(ZFH/[5UTVFER)<7$TVJN[K'!'"## /G!7?@%RNT98XY^Z3U
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MP?M*D7324;=9/?TU.#U6R@L+TP6]Y'=IM!\V/&,^G!-4JOZP6?4Y)&T\V <
MK;E=NT8QQP.N#VJA7I4[N*N?/UU%5)**LK^?ZZ_>%%%%69'=^"?^05-_UV_H
M*Z:N9\$_\@J;_KM_05TU?-8K^-+U/T++O]TI^B"BBBL#M"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JK=_Z
M^R_Z[G_T!ZM53OBPELBJ[CYYXSC^!Z +E%0>;/\ \^__ (^*/-G_ .??_P ?
M% $]%0>;/_S[_P#CXH\V?_GW_P#'Q0!/14'FS_\ /O\ ^/BCS9_^??\ \?%
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M_"(:[_SX_P#D9/\ XJO21-<?\^O_ )$%+YMQ_P ^O_D05?\ :57LOQ_S,/\
M5["_S2^]?Y'FO_"(:[_SX_\ D9/_ (JC_A$-=_Y\?_(R?_%5Z5YMQ_SZ_P#D
M04>;<?\ /K_Y$%']I5>R_'_,/]7L+_-+[U_D>:_\(AKO_/C_ .1D_P#BJ/\
MA$-=_P"?'_R,G_Q5>E>;<?\ /K_Y$%'FW'_/K_Y$%']I5>R_'_,/]7L+_-+[
MU_D>:_\ "(:[_P ^/_D9/_BJ/^$0UW_GQ_\ (R?_ !5>E>;<?\^O_D04>;<?
M\^O_ )$%']I5>R_'_,/]7L+_ #2^]?Y'FO\ PB&N_P#/C_Y&3_XJC_A$-=_Y
M\?\ R,G_ ,57I7FW'_/K_P"1!1YMQ_SZ_P#D04?VE5[+\?\ ,/\ 5["_S2^]
M?Y'FO_"(:[_SX_\ D9/_ (JC_A$-=_Y\?_(R?_%5Z5YMQ_SZ_P#D04>;<?\
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M5>AVLLXC?%MG]Z_\8_O&I_-N/^?7_P B"C^TJO9?C_F'^KV%_FE]Z_R/-?\
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MBB@ HHHH **** "BH);R"&Z@MI)-LT^[R@0<-M&2,],XYQU(!]#4] !1110
M4444 4E/[^3_ 'C5^$\5YEXUP?$*@_\ /$?^A-6/&JXZ5Z%+ >T@I<V_E_P3
MQJ^;2I5)04+V\_\ @'MXI:\5"+Z4NQ?2MO[+_O\ X?\ !,/[<E_S[_\ )O\
M[4]IHKQ;8OI1L7TH_LO^_P#A_P $/[<E_P ^_P#R;_[4]IHKQ;8OI1L7TH_L
MO^_^'_!#^W)?\^__ ";_ .U/::*\6V+Z4;%]*/[+_O\ X?\ !#^W)?\ /O\
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M.*W=8O(7AU=8;B-O-N(2 K@[U"G./4 XJQJLT5]*R6=];QR1WBS,S3* 08U
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M3%/!, 'C8<X."0<@@@@D$&KU8/A9+06=Q+#J=KJ5W/,9KN>WD5E\P@#:,$X
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M:?3/^7NY_P!\?^@K3Z .%UJXF\+>-I/$$UA<76FW=HL$DENFYX74YY'H0/\
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MDX P._K59=7:ZTZ6SU*6XE&?,ADSO97Z8.3R",_2A?"NNX_X\/\ R,G^-/\
M^$4UW_GP_P#(R?XULGAU]I?>CF<L4]'"5O\ "^UNWD2?\)!Y6J0R01)]CA"Q
MHKPH9/+ P1NQGGGOWJ&358X%L_L'F*;665U,@'*L1@'!]!@T[_A%-=_Y\/\
MR,G^-'_"*:[_ ,^'_D9/\::>'7VE]Z_KJ#>*=_<E_P" ORVT\D2W6LVDUQ.\
M,$D<<EC]G5,#Y6R#Z]./_K5G"[C_ +%-GAO,-P)<XXQMQ^=7/^$4UW_GP_\
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MQ +FSM+.XCM&GEFG7RR\B! J9!( #').!4TNH6,-K.EA',AGDC<I(!MC"Y.
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M ZPHHHH **** "BBB@ HHHH KV?^JD_ZZO\ ^A&K%5[/_52?]=7_ /0C5B@
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MN:NT44#*Z_\ (0E_ZY)_-J*%_P"0A+_UR3^;44 5_P#E[N?]\?\ H*T^F?\
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M3_\ $U-10!#NNO\ GC#_ -_3_P#$TQIKE713!%ER0/WI],_W:LU#+_Q\6_\
MO'^1H -UU_SQA_[^G_XFC==?\\8?^_I_^)J:B@"'==?\\8?^_I_^)HW77_/&
M'_OZ?_B:FHH AW77_/&'_OZ?_B:-UU_SQA_[^G_XFIJ* (=UU_SQA_[^G_XF
MC==?\\8?^_I_^)J:B@"'==?\\8?^_I_^)HW77_/&'_OZ?_B:FHH AW77_/&'
M_OZ?_B:-UU_SQA_[^G_XFIJ* (=UU_SQA_[^G_XFC==?\\8?^_I_^)J:B@"'
M==?\\8?^_I_^)HW77_/&'_OZ?_B:FHH AW77_/&'_OZ?_B:JW3W'GV>8HO\
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M)J:B@"'==?\ /&'_ +^G_P")HW77_/&'_OZ?_B:FHH AW77_ #QA_P"_I_\
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M6** *^^[_P">$/\ W^/_ ,31ON_^>$/_ '^/_P 35BB@"OON_P#GA#_W^/\
M\31ON_\ GA#_ -_C_P#$U8HH K[[O_GA#_W^/_Q-&^[_ .>$/_?X_P#Q-6**
M *^^[_YX0_\ ?X__ !-&^[_YX0_]_C_\35BB@"A:O=>6^((3^]?K*?[Q_P!F
MI]]W_P \(?\ O\?_ (FBT_U3_P#75_\ T(U8H K[[O\ YX0_]_C_ /$T;[O_
M )X0_P#?X_\ Q-6** *^^[_YX0_]_C_\31ON_P#GA#_W^/\ \35BB@"OON_^
M>$/_ '^/_P 31ON_^>$/_?X__$U8HH K[[O_ )X0_P#?X_\ Q-&^[_YX0_\
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M -_C_P#$U8HH K[[O_GA#_W^/_Q-&^[_ .>$/_?X_P#Q-6** *^^[_YX0_\
M?X__ !-&^[_YX0_]_C_\35BB@"OON_\ GA#_ -_C_P#$T;[O_GA#_P!_C_\
M$U8HH K[[O\ YX0_]_C_ /$T;[O_ )X0_P#?X_\ Q-6** *^^[_YX0_]_C_\
M34$#W7GW.((<^8,_O3_=7_9J_5>#_CXNO^N@_P#0%H -]W_SPA_[_'_XFC?=
M_P#/"'_O\?\ XFK%% %??=_\\(?^_P ?_B:-]W_SPA_[_'_XFK%% %??=_\
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MN^F0P#[&VQ+B60E6P@9F"@<[<X S@D'D4 ;]%4-#N9;S0--NIWWS36L4DC8
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M' Z#>BL3CJ<4:E/+!J^HC7%UR*W.6M+VP>7[/#"%!RRQ'[P;<274]/2M2_\
M!>D3V*QZ=96>G7<3I)!=PVR[XV5@0>,$],'GO5I]-U>&XN38ZRBP3L7"7=L9
MVB8]0C!UPOH"#CZ<4 7M+E,VE6DIO$O2T2DW,:!1+Q]X $XSZ5;JIIFGP:5I
MMO86^XQ0($4N<D^Y]SUXXJW0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!SFHW5O!J+++/%&QYP[@'&35RSU*Q&,WMO\ ]_5_QKCO&?\
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MQ_D:XSPQ?3:=XIO- OV%WJA'FSW[3*/-C55$0"=0V"<CMC=EMU=G+_Q\6_\
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M_'_]:NR "@   #@ 5]!E.$J1?MI.R?3N>)F>*A)>RBKM=>PM%%%>Z>,%%%%
M%>S_ -5)_P!=7_\ 0C5BJ]G_ *J3_KJ__H1JQ0 4444 %%%% !1110 4444
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MK6^GS(C")E&UR4Y5"3_".F/>@#L&570HZAE88((R"*J66D:;IK.UAI]I:LX
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M;_OMO\:/LD/HW_?;?XT 3T5!]DA]&_[[;_&C[)#Z-_WVW^- $]%0?9(?1O\
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M5?[%!Z/_ -_&_P :/L4'H_\ W\;_ !KH,2Q15?[%!Z/_ -_&_P :/L4'H_\
MW\;_ !H L457^Q0>C_\ ?QO\:/L4'H__ '\;_&@ L_\ 52?]=7_]"-6*H6EG
M"8WR'_UKC[[?WC[U/]B@]'_[^-_C0!8HJO\ 8H/1_P#OXW^-'V*#T?\ [^-_
MC0!8HJO]B@]'_P"_C?XT?8H/1_\ OXW^- %BBJ_V*#T?_OXW^-'V*#T?_OXW
M^- %BBJ_V*#T?_OXW^-'V*#T?_OXW^- !)_Q^P?[K_TJQ5"2SA^V0##X*O\
MQM[>]3_8H/1_^_C?XT 6**K_ &*#T?\ [^-_C1]B@]'_ ._C?XT 6**K_8H/
M1_\ OXW^-'V*#T?_ +^-_C0!8HJO]B@]'_[^-_C1]B@]'_[^-_C0!8HJO]B@
M]'_[^-_C1]B@]'_[^-_C0!8HJO\ 8H/1_P#OXW^-'V*#T?\ [^-_C0!8HJO]
MB@]'_P"_C?XT?8H/1_\ OXW^- %BJ\'_ !\77_70?^@+1]B@]'_[^-_C4$%G
M"9[D8?B0?QM_=7WH OT57^Q0>C_]_&_QH^Q0>C_]_&_QH L457^Q0>C_ /?Q
MO\:/L4'H_P#W\;_&@"Q15?[%!Z/_ -_&_P :/L4'H_\ W\;_ !H L457^Q0>
MC_\ ?QO\:/L4'H__ '\;_&@"Q15?[%!Z/_W\;_&C[%!Z/_W\;_&@ 7_D(2_]
M<D_FU%,@B2*_F" X,2'EB>[>M% $7_+W<_[X_P#05I],_P"7NY_WQ_Z"M/H
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M?^N0_P#0FK.MNU?.XS%5H59*,K(]["8:E.G%RB=='XNO\?ZFV_[Y;_XJI/\
MA+]0_P">-M_WRW_Q5<XG2I*X'C\3_.SL^I8?^1'0?\)?J'_/&V_[Y;_XJC_A
M+]0_YXVW_?+?_%5S]%+Z_B?YV/ZEA_Y$=!_PE^H?\\;;_OEO_BJ/^$OU#_GC
M;?\ ?+?_ !5<_11]?Q/\[#ZEA_Y$=!_PE^H?\\;;_OEO_BJ/^$OU#_GC;?\
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MK3_^$OU#_GC;?]\M_P#%5S]%'U_$_P [#ZEA_P"1'0?\)?J'_/&V_P"^6_\
MBJ/^$OU#_GC;?]\M_P#%5S]%'U_$_P [#ZEA_P"1'0?\)?J'_/&V_P"^6_\
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MQJT:6HR#(3M#AAP22=N3@#I0!U=%<_K=S>2:]I&DV=]+:?:%FFGDA6-G"(H
M^^K 99E[=C54ZS>Z->ZI97,W]HBVMX;F&:=HX"H<LI$K@*@ *9R%S@]"<9 .
MJHKA[GQC>WVG2Q:4EB;[[=!9K-#>>= ?,&[<K[.2!D$%>.3SC!OW'C VFMQ:
M?/;V2E[E+8QB_5KD%L8?R0OW,D<E@<<X[4 =31110 57@_X^+K_KH/\ T!:L
M57@_X^+K_KH/_0%H L45F:WJ#V%CF+_6R':OM6=!HEW-$LTE[,)&Y.)"*TC3
M3CS-V,I56I<L5<Z2BL2%KRPN(XI)VF1F"[7.3SZ'_/\ C)<:\D%[]F2RN9@)
MO(,J; HDV;]O+ _=[XQ4RC8J,^8UZ*YN7Q,YMFO8K*\5!9RW$<$J(OG!0C!L
M[N.&Z?7N*M3>(/+>6)=.N7FBA\V1 8_D.TL ?F[XQD9&2!FI*N;5%8:>)$\B
M&26QN5_=1RW!&PB .< M\W/3/&<#DXH'BBV59))[2[@B596#R!<.8VVLHPQY
MR1C. :!W-RBJ6F:E%J<$DD:/&T4ACD1RI*L #U4D'@@\'O5V@"NO_(0E_P"N
M2?S:BA?^0A+_ -<D_FU% %?_ )>[G_?'_H*T^F?\O=S_ +X_]!6GT %%%% !
M65XB_P"0/)_O+_.M6LKQ%_R!Y/\ >7^=8XC^#/T?Y&M#^+'U7YG&T445\0?7
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 =5X6_X\I_^NG]!6[6
M%X6_X\I_^NG]!6[7V>"_W>'HCY3%_P >?J%%%%=1S!1110 4444 %%%% !11
M10 5#+_Q\6_^\?Y&IJAE_P"/BW_WC_(T 34444 %-D021LA+ ,",J<$?0]J=
M10!@PZ#>->:?)J&IK=1:>S/!BWV2LVTJ#(^X[OE)S@+DX)Z8JM!X;U6'P\VB
M?VQ;"U,!@$B63+*%/4Y,I&<$]JZ>B@#%@\,V-AJUI?:7!;V(BC>*:.& +YZL
M!@$C'((!R<]_6FR>'?,T/6--^U8_M&29_,\O_5^9VQGG'U&:W** ,J#3[^2,
MVVJW&G7EFR;&A6Q9=WIG=(P(]L57E\*Z=+>2OY,*6CV)LA;1Q! BERY*D=.2
M.@Z@&MVB@##LM!FCO([C4+Y;XK9M9L'@QYBE@<MR03@8/'/7CI5>/PE&YL8=
M0N$O["Q$H@MYX V=Q&S>6)#;%RH.!USVYZ2B@#GK?PY<:<6&EZBMK$MP\T%O
MY!,**X&Y&0,-PW988*X)[BM#1]+.EPW/F3B:>ZN&N)G6/8NX@#Y5R<#"CJ2>
MISS6C10 4444 %5;O_7V7_7<_P#H#U:JK=_Z^R_Z[G_T!Z +5<DGA&4>&HK5
M988=5MKF6[MKJ/HLC2,RYXR05(5ACIZX%=;10!@Z?I-X=8O;_4DM"MW9PP20
MQ,77<N_=]Y1E3N'ZUG'POJ36"Z')<Q/HJ7:.C&9Q-]G'S>3P.S!0#N^[Z8%=
M?10!S<OAA[?6[#4M,N9T:,/#<FYNY96:)A_#O+<A@#CH>]1W^DZWJ^D_V3J*
MZ=(A*AK]9&$GRG.\1;,*Y [/@$YZ<5U%% !1110 5S%[I>NZCH]QHU\--NX)
MU,9O9&8/M/1O)";=XZC# 9 /'2NGHH YF71=5LKO46TMK26*_C17:[D96B=4
M$>[Y5.\8 ./EY'7FJ$_@NY6VN+:UGA,1T^UM(VD)!)BD+$M@'&1Z=Z[6B@#D
M-4\.ZQ)I^M:9I[6)MM3=I1+/(ZO$SXW+M"D,#C@Y&,]#CGK(E*0HAZJH!Q3Z
M* ,;3=&EMK#5+6X="+RZN)5*$G"2$XSG'/-9MAH>LI=Z!]K^P+;Z2C1DQ2NS
M3 Q% V"H"]N,GJ>>.>KHH Y;3/#=Y96OAB*26 MI6_S]K'#;HF0;>.>6'7%,
M3PYJ-I??VC;/:R7,=_<3I%([*CQ2X!!8*2K#:#T(KK** .43PU?/<P7LTMN+
ME]5%_<(C,41!$T:HIQEB 5Y(&>>G2C5O#E[J&IO<16^GP3^8#%J<$LD5Q&F%
M!#*HQ(< CEP,$<<<]710 4444 %%%% !1110 4444 %%%% 'FWC3_D8%_P"N
M0_\ 0FK.MNU=#XETBXU#6O-B>)5"!?G)!SN/M[U%:^%;YO\ EK;_ /?3?X5\
M[C,+6G5DXQNCWL)B:4*<5*123I4E;B>$;_'^NMO^^F_^)I__  B&H?\ /:V_
M[Z;_ .)K@> Q/\C.SZ[A_P"=&!170?\ "(:A_P ]K;_OIO\ XFC_ (1#4/\
MGM;?]]-_\32^H8G^1C^NX?\ G1S]%=!_PB&H?\]K;_OIO_B:/^$0U#_GM;?]
M]-_\31]0Q/\ (P^NX?\ G1S]%=!_PB&H?\]K;_OIO_B:/^$0U#_GM;?]]-_\
M31]0Q/\ (P^NX?\ G1S]%=!_PB&H?\]K;_OIO_B:/^$0U#_GM;?]]-_\31]0
MQ/\ (P^NX?\ G1S]%=!_PB&H?\]K;_OIO_B:/^$0U#_GM;?]]-_\31]0Q/\
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M.,[L9*6W@^XMVL(?[4C^PV5Z;Q(EM=KRDEC^\??\Q&[J .G(/&.KHH ****
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M"'S)_P#GW_\ 'Q1YD_\ S[_^/BIJ* (?,G_Y]_\ Q\4>9/\ \^__ (^*FHH
MA\R?_GW_ /'Q1YD__/O_ ./BIJ* .;O9)OM[?N/_ !\>IJ_923\?Z/\ ^/BL
M;6];T[3-5,-Y<>7(R[@-C'C)'8>QI]IXQT!0,W__ )!D_P#B:I0D]D!UD<MQ
MC_CV'_?P5)YMQ_S[#_OX*PX_&WAT#_D(?^09/_B:?_PF_AW_ *"/_D"3_P")
MI^SGV V?-N/^?8?]_!1YMQ_S[#_OX*Q_^$X\._\ 01_\@2?_ !-'_"<>'?\
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MT_U3_P#75_\ T(U8JO:?ZI_^NK_^A&K% !1110 4444 %%%% !1110 4444
M%%%% %>S_P!5)_UU?_T(U8JO9_ZJ3_KJ_P#Z$:L4 %%%% !1110 4444 %%%
M% %>3_C]@_W7_I5BJ\G_ !^P?[K_ -*L4 0->6ZWR61E'VEXS*(QR=@(!)]!
MD@<U1F\2:5!-)&]RV(G\N6587:*)N.'D **1D9R1C/-9]KIT2>(]<GLD*7 M
MDB\UG+,TC;F.2<G@>6 .@ P.*QH/$VE:1X5L]&9'.H/;&W:T(&_SR,%74G(W
M,2<XP>N>1D ZV_UW3M-D6.YG8.T9EQ'$\FV,=7;:#M7W.!^5)>Z_IFGE!<7/
MWX_-S'&T@6/^^Q4':O\ M' Z^E<M/?VEM'#X<%_I]G>1V45OJ%_/*BL%"XV)
MGEV.2>>%SGDG%1EHK&V\0:3 0VK73K9VELQ^=H?*5(V]U +,6Z#!S0!UMSK^
MF6ET;::Y(<!"Y6-V2/><+O< JF>VXBDE\0:9!?FRDN2)@ZQL1$Y1';[JLX&U
M2>P)!Y'K7,S76F:G=R^'(;VQM;='CMKR5I$2>[D4!?+1<Y/15+'Z+G&1*=3T
MOQ#JLFEP7=C:V*76Z=1*@FO9E8'"KG(7*C+=6Q@8'- '4ZAJ5KID"373NJNX
MC0)$TC,QZ *H)/Y4RQU>RU&66&"2031 %XIH7B< ]#M< X]\8K%\27UG#XBT
M""]NX;>%));IFFD"+E4VKR3CJ_Z5GZY?)<W-SJMJHFL$M%LOM D9(G,DJ[F\
MQ>=B!>2/4C(YP =E=74%C:2W5S((X(4+NYZ #K4JL&4,,X(SR,&O*95L)9-2
M@$FF'3Y)[& R6EN(;<YD9G< LPSM&W=GGIVJSJCVLUY(ENFGVUXNI164$(C+
MW42+(JJZMN'DICH N.1SEJ /3J*** "J\'_'Q=?]=!_Z M6*KP?\?%U_UT'_
M * M $.JZ@-.LC+@%R=J ]S61"NNW$8G%T4W<A0@P/TJ;Q2#]GMG_@63YN/I
M_A6M'<PI9I(74(%]:W7NP32O<YI>_4:;LD4+:^O89DBO0CACM#J,$'Z58N-<
MTZUNQ:S7&)B=NT1LW.-V,@8SCG'7'-0VCG4[LW.,6\9^7C[[?_6_G7.S7,D7
MBN[4_O$^U!H[42E6#>2%\TKL)*]>=V.^,CF*F_F:4V[;Z&V_BG3O+DN8;E)K
M6*"29RBN7.W8?E&,$88<Y[CWJS-XATR$?/.VXQF4*(GS@*6QTX.%)P>>*RET
MR[O-.M;:-K3,6FRV<K+*3AV50"/EY'R>W7VJ:32]3NM0\]X[>U$D968Q7+N'
M&PJ%*%0"02"&X.!BHL:)W+\?B'3)$M6-P4-RJLBNC @$X&[CY<G@9QD]*6+Q
M#I4[2A+U/W2,[D@@ *<-R1C@]1U%90T;5'MV@D2T5;F"*"=A*S&,1DC*_*-V
M0>G&#ZTVZ\/ZC=V4=NWV9"/M)9EE;@R2!TQA0>V#TQVS2#4Z*SO;?4(/.MI-
MZ;BIRI4@CJ"#R#]:L5GZ19M9VLGF0+#++(9' N7GR< 9+N >@'Y5H4#*Z_\
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MBB@ JK=_Z^R_Z[G_ - >K55;O_7V7_7<_P#H#T 6JI76C:7>W*W-WIMG<3J
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ME?4KZ2U%J][<M;@ ")I6* #H,9Q7LB:#H^/^058_^ Z?X5)_8.C_ /0)L?\
MP&3_  J_K$>P6/$&FE>..-Y':./.Q2Q(7/)P.U2S7UW<0K%-=3RQ+C:CR%@,
M @8!],G\Z]J_L'1_^@38_P#@,G^%']@Z/_T";'_P&3_"G]9CV"QXI#>W=LJK
M!=31*K[U"2%0&QC(QWQQFGW.I7]Z@2ZO;F= <A9968 ^O)KVC^P='_Z!-C_X
M#)_A1_8.C_\ 0)L?_ 9/\*7UB/8+'B]MJ5_91F.UO;F!"<E8I64$^N :B:ZN
M'NOM+3RFXW!O-+G?N'0YZYKVW^P='_Z!-C_X#)_A1_8.C_\ 0)L?_ 9/\*/K
M$>P6/%;J^N[TJ;NZGN"O"F60OCZ9IR:E?1VIM4O;E;<@@Q+*P0@]1C.*]H_L
M'1_^@38_^ R?X4?V#H__ $";'_P&3_"CZQ'L%CQ6UOKNR+&TNI[<M][RI"F?
MKBF-<3O<?:&FD:?=N\PL2V?7/7->V_V#H_\ T";'_P !D_PH_L'1_P#H$V/_
M (#)_A1]9CV"QX>[M([.[%G8DLS'))]33:]KDT/2!=P*-*L<$-D?9TYZ>U3_
M -@Z/_T";'_P&3_"G]978+'AM%>Y?V#H_P#T";'_ ,!D_P */[!T?_H$V/\
MX#)_A1]9785CPVI+>WENKA(((VDED.U44<DU[=_8.C_] FQ_\!D_PJ6WTO3K
M27S;:PM89,8WQPJIQ]0*'B5V'8QO"OA6+0K?SI@LE_(/G?L@_NK_ (]ZZ2BB
MN24G)W8PHHHI %%%% %>T_U3_P#75_\ T(U8JO:?ZI_^NK_^A&K% !1110 4
M444 %%%% !1110 4444 %%%% %>S_P!5)_UU?_T(U8JO9_ZJ3_KJ_P#Z$:L4
M %%%% !1110 4444 %%%% %>3_C]@_W7_I5BJ\G_ !^P?[K_ -*L4 %,FABN
M(7AGC26)P5='4,K ]B#U%/HH **** "BBB@ HHHH **** "BBB@ JO!_Q\77
M_70?^@+5BJ\'_'Q=?]=!_P"@+0 MY:1WML\$OW6[CL:RH/#I7"7-V\L"](P-
MH/U-;E%7&I**LF1*G&3NT-1%C0(BA548  P *4@$$$9!Z@TM%06,2*.+/EQJ
MF>NT8I]%% !1110 4444 5U_Y"$O_7)/YM10O_(0E_ZY)_-J* *__+W<_P"^
M/_05I],_Y>[G_?'_ *"M/H **** "L'QE_R+%U]5_F*WJP?&7_(L77U7^8JH
M?$@/*****],@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T7P'!
M%+HLQDC5B)B!D>PKJ?L=M_SQ3\JYKX?_ /($F_Z[G^0KK*\VK\;+(/L=M_SQ
M3\J/L=M_SQ3\JYV+9JAU34-0N-1\FVNWMH8+*69-BH0I.V$AG).3SG QC'.<
MN;4(I9-#AFU/5+NV#744KP17$,SLFW:'2/#DKT)P!G)P,U ';?8[;_GBGY4?
M8[;_ )XI^5<QH,<6L2ZB+>YU&31-Z>0\EW.DOG $2 ,6$FT?+P3C=G%.\,&T
ML]!35M0U&X4^9-&\MYJ$AC $K*O#OM!P ,XS0!TOV.V_YXI^5'V.V_YXI^58
M+7,?B#Q ;.*^<Z;#:)<!K.X*>>[NZY\Q"#M78> 1R3G.!46J66H6%K#"E]?W
M.F?;09Q!O>ZBA*\('4[V&_;DCYPIZG!- '1_8[;_ )XI^5'V.V_YXI^5<19:
ME-J.MKH:W%_'IZW;X:222.X9%A1PA<X<?,Q/)#8 ![TY)KYYTMKJ?4YM)L[V
MXMY)+4RM.Q 4Q!S'^\*@,PR.I"[J .U^QVW_ #Q3\J/L=M_SQ3\JQ_#6J-/H
M5Q/=R2".TN)XO,GX<1QL0"_^T .?ISS7.>'=9G3Q$!J=[-#YP81I<22M]M\R
M3]U)'&1B-0!C QUY H [O[';?\\4_*H9;2W$\ \E,%CGCV-7:AE_X^+?_>/\
MC0 GV.V_YXI^5'V.V_YXI^53T4 0?8[;_GBGY4?8[;_GBGY5/10!!]CMO^>*
M?E1]CMO^>*?E4]% $'V.V_YXI^5'V.V_YXI^53UR^OK?1ZH]S/::I>:6EN/+
MCTNY,3I)D[BRJZ,^1MQ@G&#QSF@#H?L=M_SQ3\J/L=M_SQ3\JQ=)URPM]&8S
MZL]Y]F0O)/);NC[-[* RXR6!7:>,DC..:M7/B?2K698GEN'9@A'DVDLH^<94
M912,D=NM &A]CMO^>*?E1]CMO^>*?E4J.)(U=0P# $;E*G\0>1]#3J (/L=M
M_P \4_*C[';?\\4_*IZ* (/L=M_SQ3\J/L=M_P \4_*IZ* (/L=M_P \4_*J
MUU:P">S A09F(/'7Y&K0JK=_Z^R_Z[G_ - >@!_V.V_YXI^5'V.V_P">*?E4
M]% $'V.V_P">*?E1]CMO^>*?E4]% $'V.V_YXI^5'V.V_P">*?E4]% $'V.V
M_P">*?E1]CMO^>*?E4]% $'V.V_YXI^5'V.V_P">*?E4]% $'V.V_P">*?E1
M]CMO^>*?E4]% $'V.V_YXI^5'V.V_P">*?E4]% $'V.V_P">*?E1]CMO^>*?
ME4]% $'V.V_YXI^5'V.V_P">*?E4]% $'V.V_P">*?E1]CMO^>*?E4]% $'V
M.V_YXI^5'V.V_P">*?E4]% $'V.V_P">*?E1]CMO^>*?E4]% $'V.V_YXI^5
M'V.V_P">*?E4]% $'V.V_P">*?E1]CMO^>*?E4]% $'V.V_YXI^5'V.V_P">
M*?E4]% &!<VEN;ULPI^7O5^TLK; _<)^5<;XN\37NBZZ+>VBMW1H@Y,BDG.Y
MAV(]*SX/B%JR@8M[+_OA_P#XJM8T925T*YZHEC:X_P!1'^5/^PVO_/"/\J\T
M7XCZP!_Q[6/_ 'P__P 53O\ A9.L?\^UC_W[?_XJJ^KS"YZ3]AM?^>$?Y4?8
M;7_GA'^5>;?\+)UC_GVL?^_;_P#Q5'_"R=8_Y]K'_OV__P 51]7F%STG[#:_
M\\(_RH^PVO\ SPC_ "KS;_A9.L?\^UC_ -^W_P#BJ/\ A9.L?\^UC_W[?_XJ
MCZO,+GI/V&U_YX1_E1]AM?\ GA'^5>;?\+)UC_GVL?\ OV__ ,51_P +)UC_
M )]K'_OV_P#\51]7F%STG[#:_P#/"/\ *C[#:_\ /"/\J\V_X63K'_/M8_\
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MI]*],MYX[FWCGA</%(H9&'0@]#0XM*XKJ]BK:V=L8WS A_>N.G^T:G^PVO\
MSPC_ "HM/]4__75__0C5BD,K_8;7_GA'^5'V&U_YX1_E5BB@"O\ 8;7_ )X1
M_E1]AM?^>$?Y58HH K_8;7_GA'^5'V&U_P">$?Y58HH K_8;7_GA'^5'V&U_
MYX1_E5BB@"O]AM?^>$?Y4?8;7_GA'^56** *_P!AM?\ GA'^5'V&U_YX1_E5
MBB@"A:6=L8WS A_>N.G^T:G^PVO_ #PC_*BS_P!5)_UU?_T(U8H K_8;7_GA
M'^5'V&U_YX1_E5BB@"O]AM?^>$?Y4?8;7_GA'^56** *_P!AM?\ GA'^5'V&
MU_YX1_E5BB@"O]AM?^>$?Y4?8;7_ )X1_E5BB@"A)9VPO(!Y"8*OV^E3_8;7
M_GA'^5$G_'[!_NO_ $JQ0!7^PVO_ #PC_*C[#:_\\(_RJQ10!7^PVO\ SPC_
M "H^PVO_ #PC_*K%% %?[#:_\\(_RH^PVO\ SPC_ "JQ10!7^PVO_/"/\J/L
M-K_SPC_*K%% %?[#:_\ /"/\J/L-K_SPC_*K%% %?[#:_P#/"/\ *C[#:_\
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M+OAG7>24.5) (/7'!JSX?T1M+EO+F2"TMGN2JK;68_=0HN< '"Y)+,Q.!RU
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MVG^J?_KJ_P#Z$:L5!84444 %%%% !1110 4444 %%%% !1110!7L_P#52?\
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M)^'_ /R!)O\ KN?Y"NLKC_ 9F&BS>6B,/..=SD=A[&NJW77_ #QA_P"_I_\
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M\2[8XD"(/0 8%-W77_/&'_OZ?_B:-UU_SQA_[^G_ .)H FJ&7_CXM_\ >/\
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M *!W_D:/_P"*IW_"#^(O^@=_Y'C_ /BJ]75[O'^H@_[_ !_^)IV^[_YX0?\
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M1ON_^>$'_?X__$T?69A8\F_X0?Q%_P! [_R/'_\ %4?\(/XB_P"@=_Y'C_\
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M"O!HUI;W8N5\QG5G9 \A*H6^\0.@SFM"J^^[_P">$'_?X_\ Q-&^[_YX0?\
M?X__ !- !:?ZI_\ KJ__ *$:L50M6NO+?$,)_>OUE/\ >/\ LU/ON_\ GA!_
MW^/_ ,30!8HJOON_^>$'_?X__$T;[O\ YX0?]_C_ /$T 6**K[[O_GA!_P!_
MC_\ $T;[O_GA!_W^/_Q- %BBJ^^[_P">$'_?X_\ Q-&^[_YX0?\ ?X__ !-
M%BBJ^^[_ .>$'_?X_P#Q-&^[_P">$'_?X_\ Q- %BBJ^^[_YX0?]_C_\31ON
M_P#GA!_W^/\ \30!8HJOON_^>$'_ '^/_P 31ON_^>$'_?X__$T %G_JI/\
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M'_?X_P#Q-&^[_P">$'_?X_\ Q- %BBJ^^[_YX0?]_C_\31ON_P#GA!_W^/\
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M2KQDC)   ()+$ ?7BH)?%%O;VUZ]Q8WT-Q9P^?):,BF1H_[ZD,48#OAN,<T
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M_ A_\:/[>UC_ *"U]_X$O_C5?5GW"Y[E17AO]O:Q_P!!:^_\"7_QH_M[6/\
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MX([&KE<S5M&,**** "BBB@ HHHH **** *]I_JG_ .NK_P#H1JQ5>T_U3_\
M75__ $(U8H **** "BBB@ HHHH **** "BBB@ HHHH KV?\ JI/^NK_^A&K%
M5[/_ %4G_75__0C5B@ HHHH **** "BBB@ HHHH KR?\?L'^Z_\ 2K%5Y/\
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MTNZ6.S2\9HF'V9W"B;(Y4D@@9''/%<E;PSK=VR>'9M<MQ(NR:WU".4P01A&
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M?ZI_^NK_ /H1JQ0 4444 %%%% !1110 4444 %%%% !1110!7L_]5)_UU?\
M]"-6*KV?^JD_ZZO_ .A&K% !1110 4444 %%%% !1110!7D_X_8/]U_Z5,[^
M7&SD,=H)PHR3]!4,G_'[!_NO_2K% 'GFF:3J,,*6SV]S$NI6227SA&RO[R62
M1<XX<B0+CKS[5'#I&I-X><"SN$D73]SQA"K,9Y_,F0#N0B 8Z\@>U>CT4 <C
M!;S7_BJ6_P!,M38I;V"6\4]Y9.JOER2%0E#P% YQC/3!!,FL:CJ!N%TB07<4
M1B!NK^TT^9]V?X(@H?:<=6).,\<].JHH XSR9='N-7M]/TZY+75O!%IX2%_+
M"A"H#/C";6+,=V#SW)IC;R(?#4T5_#I-I#';S2164S&]PH!4,JD+'_>.<GD#
M Y/;44 <A?7!U?5'TFZMKZUTB&18O+2QF/VLCU=5VK$#COSCJ!UN^*&;[3HJ
MFWN9+=+T3S/! \NP(K%<A 3RQ7\JZ*B@#C];-[JN[4+*PD>"RMI%1+FW96G:
M3"L/+;#$*F[C W$@#-8M]:7MP=3*)JMU;_V?%:I)-9>4S*\H#A$6-3A5!.,9
M_#%>E44 >>^(DO[R+688K>^BDN-D,,-K896>':/GDD9#TW,-H*D8Z9.:]!50
MBA5& !@4M% !5>#_ (^+K_KH/_0%JQ5>#_CXNO\ KH/_ $!: ,?Q3_J+7.-O
MF<_Y_.MJ!HTM48$! O6HM1L4U"S:!C@]5/H:RH-&U!T$%S=*MNO_ #SY9A_2
MMERR@DW:QSOFC4;2O<M1,NHZANC \B%LEO5NP_K7.W$RCQ-=M-%NM4OAY;*D
M;,TQ@"A22X8+S_=_'&:[2""*VA6&% D:] *C:PLWN3<M:P&X*[3-Y8WXQC&[
MKTK.4DWIL:QBTM=SE1HTQTJUMK?2UC<Z5-;RX,8 E*H #@\YV=1GM4\UA=W>
MHF2+2Y8$FCVR"?RF0#RV4$8)97!.,#(()KI8+6&V#"%-N[KR34U)^127<XX:
M7>RVYC.DNKSV\$*.S1_Z,T;').&Z<[AMSD^E1W&AWLUB(H-.,$L@O-[ QC[\
MH=0>3G<!CH?>NUHI!8R]"M?LMI*QBN8GFF,C+<^6&S@#I'\H''\ZU***!E=?
M^0A+_P!<D_FU%"_\A"7_ *Y)_-J* *__ "]W/^^/_05KSY8-?T&2\D\+WNC7
MND7-T[A+F7_42$_,H8,!U[9_"O0?^7NY_P!\?^@K7ATOB/38/"CZ1)*PO$U<
MW#+L.-@DSG- 'H_A;3Y[;6]2NM8U"VN->N4C,L$'W8(A]T 'U_I^)3Q[-9)9
MV,$VC)JUY<3^5:6[MM&XCDD_2L[PKK5EK_Q#U>_T^1GMVLHE!92IR#SP:V?&
MMIH]WI]LNJZH=,DCF\RUNEDV,C@=C0!Y[J'V&.ZOY;#PAIDVGZ3L2_9W;<7/
MW@A#8X.1T/2O0_$S0OX+9K==L)CC,8]%XQ^E<H;'P8-$ATB/Q8J6QG,]X1.-
M]V3CACZ<#U_/FNN\5^5_PB$OD;?)VILV]-N1C'X54/B0'EE%%%>F03074ULL
MRPOM$T9BDX!RN0<<^X%0T44 6;R]DOGB:54!BA2%=H/W5&!GWXJ6WU-HK/[)
M-;074"N71)@WR,1@X*D'GC(SC@51HI66P&N?$5T\DWFPV\MO+&L1MF0B-54Y
M4+@@C&3CGN:2'7Y[=V,%M:1(7A<(D9 'EDE>^3DGDDDGUK)HHY4,O6NJ36FJ
MG44CB:4LY*,#M.X$'H0>Y[U9LM3M$U*SD;3K6V2.XC=I8S*2H# G@N1T]JR*
M*'%,#=D\22P:@TMC;VL48N3<'8K?OF&=I;)SCD\# Y/%5X->N8(K:,0V[""-
MH<LK'S(V))1AG&,GM@^]95%+D0'16'B! +E;B&WC@6Q>&"V56*%F921U+9.#
MSG\15,>(+D$IY%L;0Q"'[)M;R@H.?7=G))W9SD]:R:*.1 :7]KJ=ZOI>GM$P
M4+'Y3+LQZ,K!CGOECFJM]>S:C>RW<Y4R2')VC '8 ?A5>BFDD(****8'I'@!
ME&B39('[X]3["NKWI_>7\ZY+P%%')HLQ>-&(F/WAGL*ZK[-!_P \(_\ O@5Y
MM7XV6/WI_>7\Z-Z?WE_.F?9H/^>$?_? H^S0?\\(_P#O@5 #]Z?WE_.C>G]Y
M?SIGV:#_ )X1_P#? H^S0?\ /"/_ +X% #]Z?WE_.C>G]Y?SIGV:#_GA'_WP
M*/LT'_/"/_O@4 /WI_>7\Z-Z?WE_.F?9H/\ GA'_ -\"C[-!_P \(_\ O@4
M/WI_>7\Z-Z?WE_.F?9H/^>$?_? H^S0?\\(_^^!0 _>G]Y?SJ&5U^T6_S#[Q
M[^QI_P!F@_YX1_\ ? J&6W@%Q /)CY8_PCT- %G>G]Y?SHWI_>7\Z9]F@_YX
M1_\ ? H^S0?\\(_^^!0 _>G]Y?SHWI_>7\Z9]F@_YX1_]\"C[-!_SPC_ .^!
M0 _>G]Y?SHWI_>7\Z9]F@_YX1_\ ? H^S0?\\(_^^!0 _>G]Y?SHWI_>7\Z9
M]F@_YX1_]\"C[-!_SPC_ .^!0 _>G]Y?SHWI_>7\Z9]F@_YX1_\ ? H^S0?\
M\(_^^!0 _>G]Y?SHWI_>7\Z9]F@_YX1_]\"C[-!_SPC_ .^!0 _>G]Y?SHWI
M_>7\Z9]F@_YX1_\ ? H^S0?\\(_^^!0 _>G]Y?SHWI_>7\Z9]F@_YX1_]\"C
M[-!_SPC_ .^!0 _>G]Y?SJK=NOGV7S#_ %Y[_P"P]3_9H/\ GA'_ -\"JMW;
MPB>RQ#&,S$'Y1S\CT 7=Z?WE_.C>G]Y?SIGV:#_GA'_WP*/LT'_/"/\ [X%
M#]Z?WE_.C>G]Y?SIGV:#_GA'_P!\"C[-!_SPC_[X% #]Z?WE_.C>G]Y?SIGV
M:#_GA'_WP*/LT'_/"/\ [X% #]Z?WE_.C>G]Y?SIGV:#_GA'_P!\"C[-!_SP
MC_[X% #]Z?WE_.C>G]Y?SIGV:#_GA'_WP*/LT'_/"/\ [X% #]Z?WE_.C>G]
MY?SIGV:#_GA'_P!\"C[-!_SPC_[X% #]Z?WE_.C>G]Y?SIGV:#_GA'_WP*/L
MT'_/"/\ [X% #]Z?WE_.C>G]Y?SIGV:#_GA'_P!\"C[-!_SPC_[X% #]Z?WE
M_.C>G]Y?SIGV:#_GA'_WP*/LT'_/"/\ [X% #]Z?WE_.C>G]Y?SIGV:#_GA'
M_P!\"C[-!_SPC_[X% #]Z?WE_.C>G]Y?SIGV:#_GA'_WP*/LT'_/"/\ [X%
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M>8G]]?SJ/[+;_P#/O%_WP*/LMO\ \^\7_? H D\Q/[Z_G1YB?WU_.H_LMO\
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M?]\"C[+;_P#/O%_WP* &1D-J$N"#^Z3I]6HI(8TCOYA&BH#$G"C'=J* (?\
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MVFSV%WJ6AM!.NUPH<''UV5O>)(&M?!'V=R"\4<2,5Z9&!Q50^) >84445Z9
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M^3:&89R&=C@ ]@O<FNH\.XGLY]1ZF_N'G!]4^['_ ..*I_&@#8J&7_CXM_\
M>/\ (U-4,O\ Q\6_^\?Y&@":BBB@ HHHH XO4]*>ZU34;L:78>((9'2+:;A5
MGL\* R)N!48SO^\IRWT-7M+\2VQLK.*"#4[N$10!KN7RRR[SM7?\P8MD8.U3
MSZUIW?A_3KRZEN9$GCEF4+*UO=2P^8 ,#<$8!CCC)R<<5EWW@Z"ZU,7$7V"&
M +"JK]B!EA$9R/*<,-F?]TXH T+?7);L2O!HVH/$C.JR;H )"C%2 #)GJ#U
MJ$>*8%T6359["]MX%8*BN(V>4YP=H5STP>N. 33-(\-G2M2DNA_9C!WE<R)8
M;+@[V+8,N\YQG'W><4I\,1S06-M<W4KV]H9'"1,\+-(Q.&W*P( #,,=]WX4
M:$U_92S"QEBGF6=,<6DDD+*P[N%*8(]36!I6@:,GB[6 NDV $ MFA MD_=MA
MCE>.#D#IZ5T>F61TW3H;+S3*D(*1L1R$!.T'DY(7 SWQGC-2165O#>7%W''B
M>X"B5LGYMH(7CH.IZ4 <KI&D:;JWA:/5=41?M\T;3S7YP)H'!).U^J;,8 '
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MK?"WB^+70;>Y"0WPY"KPKC_9SW]JF5&<5=A<Z>BBBLAA1110 4444 %%%&:
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MR+%U]5_F*J'Q(#RBBBBO3("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGN?;IWJH=5O+B>![R\N;A(I X$DI?'/.,FG9] &:G;)9:K>6L98I#.\:ENI
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M,KCC.'/'WAN;VYZ=*;'X3TZ/3GLMT[1M;16P8N-R",EE8''WMS;CVR!Q@8H
MS)-2U&S\56<6MZC8V]I#:/.[Q,T,;.Q"!&#,<X^8@]_08JYKLUI-!#?OJUP;
M-HRMO;Z?,RO<RM]TJR'+'T'3J3P.-&PT6.QU"XOWN[J[NIXTB:2X*\*I) 4*
MH ^]V';/7),-WX>%SK/]JIJ=[;W B\I1&(F5%[[0\;8SW]: ,2!M0U"*YAUB
M\N(/[+L(_M'V6=HR\[(69BR$?=&..A)/M45U+>7&BV5W<:E=MJ]Y91BQLK1S
M%^_*[B[ '##)&XL-J@'UKH+OPW;7L\TDMS=".Y5%NH%90EQLZ;OER..#M*Y
MP::/#@CU>XU*#5+V&:?:'55A*A5Z(-T9(7V!]^M &5KZWD4F(]2N)-9G2,6-
MI;2,B1LOWG90<,A.22XQC '/73\4RS"QL[2"62)[V]A@,D3E75<[FP001\JM
M3X?#OV?5;G4(=5ODDN9 \J[86# =$R8RP4#C /Z\U8U31TU.>SG^UW-M-:.S
MQ/#L/)7:<AU8=">W>@#(O9AX;UBW$%W*UO/;3/-%>WCNBE "K[W+%.6VGMR.
M,@5G7'BO4UL=2C#PM.E@+B&46,UN%<MMV[9#EP<\,, 8Y!Z5T,GANUN;:ZCO
M+BYN9[A!&US(RB10#E0NU0JX// Y(YS5>;PC;7+7<EQJ%_-/<I$CS,T>X"-]
MZX 0*.<<8P?3.30!EZCX@U#0;*6'[9:W4FGVZ>;MM9YFE;'\;J<1$C'+%B>O
M KM%)*@L-I(Y&<XK N_"5M>+<Q/?WR6]U*)IH$9 KR *-Q.S/.T<9Q[5T% !
M5>#_ (^+K_KH/_0%JQ5>#_CXNO\ KH/_ $!: *FMZ@]A8YB_ULAVK[5G0:)=
MS1+-)>S"1N3B0BI_%$;&T@F49$<G/'^?2K2ZQ:QV"S%Q]WI71&Z@N3=G+)1E
M4:F]$5X6O+"XCBDG:9&8+M<Y//H?\_XR7&O)!>_9DLKF8";R#*FP*)-F_;RP
M/W>^,5)I\<]S-]NN5*9_U49Z@>IK"FTW4D\37=[%:L?,E!$CI&T:Q>6%)4[M
MP?@]O;I6<]7YFM/17Z%R7Q,YMFO8K*\5!9RW$<$J(OG!0C!L[N.&Z?7N*M3>
M(/+>6)=.N7FBA\V1 8_D.TL ?F[XQD9&2!FJ\&CB\M(+=[FX6."R>S.^)5+J
MX W?4;14[>'WN+N*>\OC.8U(&(51N4*D!AR%P<[?6H:MN6G?5")XD3R(9);&
MY7]U'+<$;"( YP"WS<],\9P.3B@>*+95DDGM+N")5E8/(%PYC;:RC#'G)&,X
M!IJ^''\M8WU&1D>-(KA1&H\U4)VC_9X.#CJ/2B7PRMQ;I!->R,B^?G$:C/F-
MNS^!QC]:0]31TS4HM3@DDC1XVBD,<B.5)5@ >JD@\$'@]ZNU4TZS:QM?)>1)
M&W$EDB6,?D*MT#*Z_P#(0E_ZY)_-J*%_Y"$O_7)/YM10!7_Y>[G_ 'Q_Z"M/
MIG_+W<_[X_\ 05I] !1110 5@^,O^18NOJO\Q6]6#XR_Y%BZ^J_S%5#XD!Y1
M1117ID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >D_#_\ Y DW
M_7<_R%=97)_#_P#Y DW_ %W/\A765YM7XV6%81\,1+#):VVIZA:V,A.;2%TV
M 'JJDH74'GA6&,\8K=HJ ,ZPT6STV>:2V#A988H/+9LJJ1@A0,\]#SDFH;?P
M]:VVC7FDQS7'V.Y$BK&67]PK@@JG' &3@'.*UZ* (X(5M[>.%"2L:A 3UP!B
MJ<6C6D<.H0NIFBOY6EG27!!W*%(''3"BM"B@#$3PXT5G!;0ZWJT0AB,(=94+
M,AZ Y0C(Z!@ WO5F?0[*718](1&@M(_+"+$>5",& R<]U&?QK2HH Q;GP[Y^
MM2:K'JM_;W#QB(",0LJ*.R[XV(R>3@\_@*V$4I&JL[.0 "S8RWN<8'Y4ZB@
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MY)_-J* *_P#R]W/^^/\ T%:?3/\ E[N?]\?^@K3Z "BBB@ K$\6()/#TZ$D
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M_P#?L_XT;;K_ )Z0_P#?L_XU-12.DAVW7_/2'_OV?\:-MU_STA_[]G_&IJ*
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M/^_9_P#BJ-MY_P ]8/\ OV?_ (JK%% %?;>?\]8/^_9_^*HVWG_/6#_OV?\
MXJK%% %?;>?\]8/^_9_^*HVWG_/6#_OV?_BJL44 5]MY_P ]8/\ OV?_ (JC
M;>?\]8/^_9_^*JQ10!0M5N_+?$L/^M?K&?[Q_P!JI]MY_P ]8/\ OV?_ (JB
MT_U3_P#75_\ T(U8H K[;S_GK!_W[/\ \51MO/\ GK!_W[/_ ,55BB@"OMO/
M^>L'_?L__%4;;S_GK!_W[/\ \55BB@"OMO/^>L'_ '[/_P 51MO/^>L'_?L_
M_%58HH K[;S_ )ZP?]^S_P#%4;;S_GK!_P!^S_\ %58HH K[;S_GK!_W[/\
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MUP<GMD O;;S_ )ZP?]^S_P#%4;;S_GK!_P!^S_\ %58HH K[;S_GK!_W[/\
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MOF.6P/;-15)Y$W_/)_\ OFCR)O\ GD__ 'S0)T:S=W%_<R.BI/(F_P">3_\
M?-'D3?\ /)_^^:!>PJ_RO[B.BI/(F_YY/_WS1Y$W_/)_^^: ]A5_E?W$=%2>
M1-_SR?\ [YH\B;_GD_\ WS0'L*O\K^X[#P=_R#9_^NO]!71US7A21+?3YEF8
M1DRY 8X["M_[7;_\]X_^^A5'V^!36&@GV1-14/VNW_Y[Q_\ ?0H^UV__ #WC
M_P"^A0=9-14/VNW_ .>\?_?0H^UV_P#SWC_[Z% $U%0_:[?_ )[Q_P#?0H^U
MV_\ SWC_ .^A0!-14/VNW_Y[Q_\ ?0H^UV__ #WC_P"^A0!-14/VNW_Y[Q_]
M]"C[7;_\]X_^^A0!-14/VNW_ .>\?_?0H^UV_P#SWC_[Z% $U%0_:[?_ )[Q
M_P#?0H^UV_\ SWC_ .^A0!-14/VNW_Y[Q_\ ?0H^UV__ #WC_P"^A0!-14/V
MNW_Y[Q_]]"C[7;_\]X_^^A0!-14/VNW_ .>\?_?0H^UV_P#SWC_[Z% $U%0_
M:[?_ )[Q_P#?0H^UV_\ SWC_ .^A0!-14/VNW_Y[Q_\ ?0H^UV__ #WC_P"^
MA0!-14/VNW_Y[Q_]]"C[7;_\]X_^^A0!-14/VNW_ .>\?_?0H^UV_P#SWC_[
MZ% $U%0_:[?_ )[Q_P#?0H^UV_\ SWC_ .^A0!-14/VNW_Y[Q_\ ?0H^UV__
M #WC_P"^A0!-14/VNW_Y[Q_]]"C[7;_\]X_^^A0!-14/VNW_ .>\?_?0H^UV
M_P#SWC_[Z% $U%0_:[?_ )[Q_P#?0H^UV_\ SWC_ .^A0!-14/VNW_Y[Q_\
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M:?\ /S#_ -]BC[=:?\_,/_?8H L457^W6G_/S#_WV*/MUI_S\P_]]B@ M/\
M5/\ ]=7_ /0C5BJ%K>VJQOFXB'[USRX_O&I_MUI_S\P_]]B@"Q15?[=:?\_,
M/_?8H^W6G_/S#_WV* +%%5_MUI_S\P_]]BC[=:?\_,/_ 'V* +%%5_MUI_S\
MP_\ ?8H^W6G_ #\P_P#?8H L457^W6G_ #\P_P#?8H^W6G_/S#_WV* +%%5_
MMUI_S\P_]]BC[=:?\_,/_?8H L457^W6G_/S#_WV*/MUI_S\P_\ ?8H +/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img96160895_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &K!#@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M TE*:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "EI*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH #24II* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]#\/Z!I>CZEJ]U87<D\U]/YMPC2AQ&W/  Z=3UI220&_1114 %%%% !1110
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M^E7YG,<$CCJJDC/TKDO"_CO3=3T33'U34["#5+M,FW$@7G<0!@GC.!UJE?=
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MSR"62(R.=S#H<YS700Q)!#'#$NV.-0JKZ # %/HH;; ****0!1110 4M)2T
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MWK >)ZCX6U66XU-)O "OJ5P66&ZM+@BV4G_EIL+$9[]NO2O1['P'877@32]
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MG:'[3;"\FMTF>V24%DW*"1CKWH;DT!SL/PG\)0Z@+H64K*K[UMVF8Q _[O\
M2M;Q'X+T3Q2(3J5LWFPC$4T+E'4>F1VI^B:_)JNL:[920I&FFW*PHX8DN"N[
M)]*U+74K&^=TM+VWN&3[ZQ2JY7ZX/%#<K@8^E>!_#^CZ1=:9;V"O;W8Q<><2
M[2C_ &B:S;#X6^&-/O8+E(;F80/OAAGN&>.-O4*>*[.L#6/$+:5XBT;3C'%Y
M%_YQDF=]OEA%W9]/SH3D!%=>!M$N_%,7B-XYUU"-E?*2E58KP"5[\ 5<T?PS
MINA7VI7EBDBS:C+YUP7<L"W/0=NIJ:[U17T6[O=*FM+N2*-FCS.HC+ 9 9QP
M![U(NI0V^FVUUJ5Q:VK21J6+3*$#$9(#'@BB[ O45@>)O$J:+X7U#5K(P7<E
MHJ-Y8DX^9@!G'3@YK4MM3LKJ3R8KNWDN%&7B2569?J <BE9[@6Z***0!1110
M 4444 %%%% !1110 4444 %%%% !1110!QGQ35#X OF95.V2$@D?=_>K^54;
MBQTW4_BOIX>"VN;5-&9XEVJ\>?,(R!T[FN[NK2WOK62VNH8YH)!M>.1=RL/<
M56L]$TO3Y(I+.PMX'AB,,;(@!5"=Q4'TSS5*5D!P$UT)O%'B :7;:'8I;%(K
MR[U1F=F"KQL3("J!QZ&N>T>WM]0\+^$+:=4GMWUZ12NW"LN6.,=@?2O6KSPS
MH>H7ZWUYI-G/=+C][)$"3CIGU_&I8]"TF+R_+TZV3RYS<IMC VRGJX]#[U7.
MK <=J-K96?Q+D"QBW@ET"8S_ &=,$@/C.!U('2N8@==%TK1)G.C:[H:W,7V1
MXU,-Y&Q;Y3@=2,\CVYKV!K&T:_6^:WB-VL9B$Q4;@A.=N?3-4+?PKH%IJ/V^
MWT>RBN]VX2K" 0?4>A^E)3 \O\2>?_9_C40G$1UBW^T$@D"/:,[L<XSC-:AM
MYO\ A)O#,D^JZ DJS_Z,FEVSAY(\?,I() 3'KQ7I*:;8QFZ*6D(-V=UQ\@_>
MG&/F]>/6JFF^&M$TBX:XT[2K2VF88+Q1 ''IGL*?/H!P&@Z1I\WP]\5W$MG#
M)-)/>DR.@+?*#MY]NM%LUN-1^&TUX80K6$H9YL8)\E=H)/OTKTF+2[""SFM(
MK.%+:<L98E0!7+?>R.^>]077A_1[VSM[.YTVUEM[;'D1O&"L>.!M]*7.!I5Q
M6B?\E7\4?]>UK_Z#7:U7CL+2&^FO8[:)+J<*LLP4!G Z GOBI3L!#K7V@Z%J
M'V3/VG[-)Y6WKOVG&/QKSW2F\'Q_"_2VU".*11Y>Y(/^/@W&[G&/FW;OT]J]
M0K)3PQH4>J?VDFDV:WN[=YPB&[=Z_7WIIV \VTV/4)=?\5&2YT&*;[8WGIJL
M+-)Y./DP<CY-O^>E.T&,0S^ 8TO!>0K<7OE2B-D!3;P &YP.0*](U+PUHFL3
MK/J.EVES,HP'EC!./3/I5HZ98M+:R&S@WVF1;G8/W61@[?3CCBJYP.8^&7_(
MK3?]?]Q_Z&:J66F65_\ %GQ!)=VL,YBM+8)YJ!@N1R1GOP*[6SL;73X3#9V\
M<$18N4C4*-Q.2?J:([&UBO9KR.WC6YF55EE"C<X'0$]\5/-JV!Y%I,5],?$_
MGW>@1/\ ;9OMJZG"S2[.QSD?)CIBI;.R1[+PJ++7[7^UH;2;[(;ZV;R+B$N>
M/FY5@, =R!7I6H>&-#U:Z6ZO])M+F<8'F21 D@>I[_C4VHZ'I6K6L=M?Z?;W
M$,?^K22,$)VX]/PJN<#R34KRUF\#Z]:7&G6EG);ZK!]M>QD+03%F&67T.!R!
M74:W_91\5^#ET+[-]I$Y_P"/7'%ML^;./X?3-;/B3PG'>>%ET?1K:TM4%Q%+
MY878F%<%N@ZD"MC3O#VCZ1/+/IVF6MK++]]XHPI/M]/:CF0'G_A?^PO^$&UK
M^V_LOV[S[G^T//QYF_)QUYZ8Q[]*I^&K/[?K?@E=5A$SQZ1+(JS+GHV$)!_V
M2*](O/"^A:A?"^O-(LY[H$'S7B!)QTSZ_C5XV%HU[%>&VB-S$ACCEVC<JGJ
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MQ\4/#,*V%LL2V<Y$8C 7Y0-N1WQGBN;UR(V^G>/X;5#':KJ%JTR0C&(R%,F
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MK=TMDO\ XB:7,WB>/6+N"WE)-G9HJ+&PZ2.K>N,#_&L>!A_PJ71SD8_MM/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  TE*:2@ HHHH **** "BBB@".6"&?9YT4<
MFQ@Z[U!VL.A&>AHG@AN86BGB26)OO)(H8'Z@U)10!#:V=K8P^5:6\-O'G.R)
M HS]!4<>FV,-VUW%96Z7+?>F6)0Y^IQFK5% $(L[9;IKH6\(N6&TS!!O(],]
M<5';Z986L[SV]E;0S/\ >DCB56;ZD"K5% $<<$,)<Q1(AD;<Y50-Q]3ZFB6"
M*= DT22*"& =01D=#S4E% %>VL+.S9VM;2" R'+F*,+N/OCK2FQM#:M:FU@-
MNV<Q>6-AYSTZ=:GHH KPV%E;A1!:01!5*+LC"X4\D# Z>U.^QVOV7[+]FA^S
MXQY6P;,?3I4U% $$EG:RS1326T+RQ?ZMVC!9/H>U1II>GQW9NTL;9;D\F81*
M'/\ P+&:MT4 (RJZ,CJ&5A@@C((JM'IEA#<+<16-LDZKM$BQ*& Z8SC.*M44
M 5[NPL[]56\M(+A5.5$T8< ^V:D\B+R/(\I/)V[?+VC;CTQZ5)10!7M+"SL%
M9;.T@MU8Y80QA 3[XI@TO3UO#>"QMA=$Y,PB7?\ ]]8S5NB@"%[.VDN4N7MH
M6GC&$E9 64>QZBI'1)49)%5T88*L,@BG44 5[33[.P5EL[2"W#'+"&,)D^^*
M46-H(%@%K!Y2MO6/RQM#9SD#US4]% %>ZL;2^0)>6L%P@.0LT8< _C4B011P
M"%(D6(#:(U4!0/3%244 5K73[*QW_8[.WM]YRWDQA-WUP.:?!9VUJ9#;VT,)
MD.YS&@7<?4XZU-10 4444 %%%% !1110 4M)2T %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  :2E-)0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM;Q66=(<LK=5R20#] 0*J5^74#H:***S **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M&DI324 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4M)2T
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M2Q8D;&-Q!*Y_'&?QK6>PC>HHHK$84444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 !I*4TE &%IOBS3-3TW4;Z,RQ1Z=))'<K,NUD*#)XS5W1
M=8M]=TBVU*V26."Y7=&LR[6(SUQ7E7C6SO\ 3O%VH:-I\;?9_%8A!8=(W#XD
M/XC.?K67XKMGM/$^J6EU*+7[/%!'I#,)BZ(  #"(^"<CG-:\B8'O!(&,D#-4
M4UFQDUN31TFW7T4(GDC /RJ3@9/3GTKRKQ VGCQ->?\ ":M?-&-.@.G&$.I:
M3;\Y0#@/N]:1;:&U\>W<MK#=1:G<:*LNF_:BQE:X,9!W=M^ <YXS[TN0#V0$
M$D C(ZT9'J*\3\-&S_MCPM_837YUPR'^W!)YGW<?/YF[CKT_QKI?A=HEH8K[
M6Y5E:_\ MMS KO(V%CW= O2DX6 ZKQ+XPTGPH;,:F\BF[D*((UW8QC+'T R*
MW00P!!!!Y!%>/Z]::KXU\7:V^GZ9;WUE9V[:9&;B;RQ'(>6=>.2#_2NU^'6K
MRZIX2@ANPPOK!C9W"MUW)P#^(Q^M#C97 ZRBBBH **K#4+8WQLP_[X#.,<?3
M-6:;36XDT]C)O/$5E8^(;'1;@2K<WR,T#[?D;;U7/K1;>(;*[\1WFAPB5KFS
MB629]O[M=W09SU]JY_XF6<HT*UURT4F[T:Y2[3'4ID!Q^6#^%<#>P:A+X.CU
MZ:-DBUO5_M-_G?M6#D1J^WYMG7./45:BFKC/=,C&<\50U;6K#1+$7E_/Y<)=
M8U(!8LS'   KQU3=IX&N_L]S--H7]KQ^<+190L=M_P M%C+?,4SBFZ_;>&KC
MPK>S:%!J+:;;:E Q>4N8%#</Y0/.,=<^U"AJ![ED#&2.>E!('4@5XMK3:(VL
MZB=;:[_L\:?%_P (\8_,V;=G\&/X\X^][YJQ!H]QKWB#PC8>)!<L[:/(URA=
MD+$,=NXCOC!/N*.0#UN]O(-/L9[RY?9!!&TCMZ*!DUG>&_$NG^*M*_M#36D\
MH.8V61=K*P]1^(KF?B;/<RZ18>&-,CWW>JRB,)NP/*3ELGL.@S]:S/"+ZCX;
M\?W.FZEIT&GP:S$)K>"WE\R-9(Q@@''<9X^E)1]VX'J-%%%0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4M)2T %8=]XF@T_Q5IVASV\
MBG4(W:&XR-FY>J'OG'\ZW*XOXE:;<SZ#;:MI\32:AI%REW"J*2S '#* .3D?
MRIQLW9@:UIXIM;OQ'JNDK&R)IB(T]T[ 1AFYV_7%;"W=L]M]I2XB:#&?-#@K
MCUSTKQF^T#5Y/A]!J4MK*T^HZM_:&I0B%G81DG:&3@LHX.WWJ :1=MX8NIK>
MTO;C1CK$,]Q:)9&!9(5!WF./<3MSC(XZ5?(NX'K6L>*=*T31_P"U)[E9;8N(
MT,#!][$X './\*T)-0LH4B>6[MT67_5EI0 _TYYKQ[6].TW4?!FKW&B>%[VT
MM4OX)4WQ,/-'1VCBZH,<' YS4NJVVFKKEW=ZIX?OKS2+K3(H]&2.T9A!A<%-
M@_U;9QUQ1R(#UZ>^M+4XN+J&(XW8DD"\=,\TV^OH-.TZXOKAP(((FE=O]D#-
M>3:3X5N;[Q#X4L_$MA)<K#HTGFB92RJP<[%9NF0".,]JZCXF+?W^D67AS2X'
M:75)Q$[A&\N.)>3N(' Z#\Z7*KV V?"'BZS\8Z5)>VD4D!BE,<D,I&Y3@$'C
ML0:Z&O,/#UGKOACXB;=2M;;[+K, 4G3HW,,<D8 4G(^4D<?C7I]*22>@!111
M4@%%%% !6=H'_(OV'_7!?Y5HUG:!_P B_8?]<%_E3Z :-%%%(#G?&EW]GT!H
M@?FG<1CZ=3_*O-JZSQY=^9J5O:@\0Q[B/=O_ *PKDZ]S!0Y:*\]3Y/-*O/B6
MNV@4445UGGA73>"=0^RZLUJ[8CN5P/\ >'3^M<S3HY'BE22-BKH0RL.Q%15I
MJI!Q?4UH571J1J+H>TT5E:#K46LV"R A9T&)8_0^OT-:M?.SBX2<9;GVE.I&
MI%3B]&%%%%26%%%% !1110 4444 %97B74Y-%\,ZEJ42AI;:W>1 >FX#C/XU
MJU#=VL-[:36MS&)()D,<B'HRD8(H0'G>C>%]9N=+TC7X_%U\FI7'ESSB=]\#
MJW)C$? '7 J36/BI'IFM7T$=A#)8Z?,L%S(]T$F9CU,<>/F [\U8@^&2J;2T
MN?$&H7.BV<PE@TYPH4$'*@N.2!Z58O?AU'/K-Y>VFKW%E!?3+/=01Q(Q9AUV
MN1E,]\5I>+>H'*:]K&H+8_$"2#4+E1!<6GV=EE(\M6 SM],UN7_Q(N+'Q(^C
M1:?;-]G,2-]JO!#)/N ):,,-I SW-:>H?#Z"_@\0Q'4)8QK,D,C8C!\GR\8
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M*<]C:27"7#VL#3I]R1HP67Z'J*GHI 1K!"L[3K$@E< -(%&Y@.@)H%O +@W
MAC\\KM,FT;B/3/7%244 1?9H/M'VCR8_/V[?,VC=CTSUQ4M%% !112$@ D]!
M0!&+B(SF$./, SBI:YP7!%Y]H_V\_A71 A@".AYJYPY3.G/FN+1114&@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* #'.:,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF3R6_GVWS922/VX';\.*YI=)^(MMHA\-0OICZ?L, NO,7/EGC'7/0_W<UO\
MAWP9J6G>)[&\N;J.6PTRP%M;;3DR,1\YQV&2WZ5M+EL([ZBBBL1A6;JO^OTS
M_K\'_H#UI5FZK_K],_Z_!_Z ]- :5%%%( HHHH **** "JNH2>59.<\M\H_&
MK59.L29:.(=OF-7!7D14=HLS*W-,F\VT"D_,AVGZ=JPZNZ9-Y=UL/208_'M6
M]17B<U*5I&Y1117*=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  :2E-)0 4444 9H_Y&=_^O-?_0S6
ME6:/^1G?_KS7_P!#-:5-@%%%%( HHHH *PO$TVVUAA!^^^X_0?\ ZZW:Y+Q#
M-YFI[,\1H%_$\UM0C>9AB96IOS,FM30;G[/J2H3A91L/U[?Y]ZRZ569&#*<,
MIR#[UW2CS)H\V$N62D>A45#:3BZM(IUZ.H/XU-7EM6T/83NKHS==_P"02_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_0UT-<M6U8WZ2QK'(P60<<_Q5C5C?5&]&=M&7Z***P.D**** "BBB@ HHHH
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M_J][<3&Y/^CPRGB*)>!@>YS^&*?X#O\ ;-<6#'AQYJ#W'!_I7<*JHH50 HX
M Z5X.)C[.;@?8X&M[:A&779_(X[Q]=X@M+,'EF,C#V' _G7#5N>+;O[7XAG
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M:6W^^/\ T8:SQ&\/\2-L%M5_PO\ 0X^O9K;_ (]8?]Q?Y5XS7LUM_P >L/\
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M#%:MM*9[=)2,%AG%1*#CN7&HI;$M%%%26!I*4TE !1110!FC_D9W_P"O-?\
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M[!]SH-Z?WU_[Z%&]/[Z_]]"N?_X4EX=_Y_\ 5/\ OZG_ ,11_P *2\._\_\
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MCZQ /J;[DN1ZC\Z,CU'YU%_PI7P__P!!'5O^_P O_P 31_PI7P__ -!'5O\
MO\O_ ,31]8@'U-]R7(]1^=&1ZC\ZB_X4KX?_ .@CJW_?Y?\ XFC_ (4KX?\
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M_P#Q-'_"IM-_Z#FN?^!*_P#Q-']H4^P?V+4_F1R=%=9_PJ;3?^@YKG_@2O\
M\31_PJ;3?^@YKG_@2O\ \31_:%/L']BU/YD<G176?\*FTW_H.:Y_X$K_ /$T
M#X4:<O37=<'_ &\K_P#$T?VA3[,7]BU/YD<G177?\*JT_P#Z#VN_^!*__$T?
M\*JT_P#Z#VN_^!*__$T?VA3[,/[%J_S(Y&BNN_X55I__ $'M=_\  E?_ (FC
M_A56G_\ 0>UW_P "5_\ B:/[0I]F']BU?YD<C177?\*JT_\ Z#VN_P#@2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 !I*4TE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %+24M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 &DI:* $HI:* $HI:* $HI:* $
MHI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $
MHI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $I:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img96160895_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '/ K # 2(  A$! Q$!_\0
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MH Z.BJC:G8II1U-KJ,6/E>=Y^?EV8SFET_4+;5;"&^LW9[>9=T;M&R;AZX8
MT 6J*** "BJ::K8237<,=U$\EFH:X53GR@<_>QT/!XZUSB_%'P8S!1K(R>.;
M:8#_ - H Z^BJ3:OIZZ0^K?:XVL$B,QG0[EV 9)&.O3H.:;I&MZ=KVGB_P!,
MN1/;%BN_:5Y'4$, 10!?HK.T77=-\0V;W>EW/VB!)#$7V,OS  D?,!GJ.>E5
M9/%VA1>(%T)]04:DS!1"(W/)&0-P&T''O0!MT444 %%4]4U2ST73IM0U";R;
M6'&^3:6QD@#@ GJ14UG=P7]E!>6SEX)XUDC8J5W*1D'!Y'% $U%%% !1110
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M4U]X.^(FNVS6&L>)K V,A'F+"G)P<]!&N?IFMC6? #M9Z&^A726]_HP"P/<
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MU6>XNI8C(+='))(49R<ENW;WXTK_ .&5PO@NT\/Z9=P;C=BYO9YRRF0X(^4
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MMI)M2GWQ^2S'8FYC@Y ]1Z]*W]=M+J_T"_L[)HTN;B!XHVE)"J6&,G )[^E
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M38D66%7822LJX], 8 &<YP353Q)\)-'NM(:/P_9PV=_O4B2:XE*[>XY+?RH
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MRJ[>6 RA>3MS_>[=Z ,/PSXC\;Z[I+:I+?P6^F6D[2W5R\2;WB4 M'&H7!P
M>3CD]>*MV>L^-?$/AV_\3VFJVVG6<(D>WL_LJOYJIUR[<CH1D=QVKL/#WAA=
M,\#Q>'KPH^Z"2*X:(\-OSNP2/]KN*Y6'P-XNM=!D\,0:SIHT5V8><8W^T"-B
M2R@?=P<GOWZT 5M:^(.JW'@'1-0TMEMM5U"Y\E@J*P^7(; 8$<G;],T^YUKQ
MOI_CBQT$:I97D]];^8T?V8+';9W9.1\S8VD\GGTYK5NO $W]J>%H[*6!=)T0
M[V21CYCON#$X P<D ]1U-7[3PM?#XE7OB6ZEMVM6MA#;1HS%U.%!)R !T;H>
M] &?X*US7;KQ=KNBZGJ":A!88"SB!8B&SC&%[=>N>E6/BO?_ &+P!>(#AKEX
MX%_%MQ_135CP1X6OO#TVLW6HRV\MSJ-UYQ:!F88R3R2!SEC3/'_A*_\ &%OI
MUG;7,$%M%.9+@R$[L8P-H P3@MU(H Y2XO/%?P_T[PZUQJ%O-8R%+>33UM@O
ME\#(W_>8XSSP,]L5T'C'Q%=66L1V<'BK2]&MU3,I,1N+C<?]C& .G?/>FCP=
MXAUO7-.N_%.HV,UGIQWPPV:L/-<8PSY''09QD=AC-5Y? NOVOBG5]2TN[TKR
MM1);S;J%GF@)R?D&,=^N?3CB@"MX;\<:[>>#/$%^XCU&XTYMMO,L.WS@>Y48
MZ#YNW!JMX6\4:[K=W8M!XPTZXGD.;C3;JT$)7N51@,N??-;&@>#?$?A_P?\
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M5NM/6Q,(@!(X5RHW?7/7U%=39?#9O^%;MX;O;B);MIFN/.ARR+)GY>H!(V@
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M+10 R**.&)(HD6.-%"HB# 4#@ #L*?110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56&HV37\MB
M+J$W<48EDA#C>B'HQ'4#BK->766@Q:-\0_%BV45[LN=$65I1NEDDE9Y,[=QY
M;IA<CH!0!W-OXL\.WD5S);:[ITT=LF^=DN4(B7U8YX'UJ1_$FAQZ0FK/K%BN
MG.<+=&X41L?0-G&:\!@M9ET"\LM)BN]1\/VB6,UU+/I@@F4K,#)"0%!D 4;B
M/FQCJ>M:D4<=NUIKUU83'PJ?$M[<+&;1F41/#MC?R\9"EPV..] 'O<,T=Q"D
MT,B21.H9'0Y# ]"".HI]<)\/M+UB'X9Z#;-=2:?<)$S,LD =@A8E%(;IA2*V
MX&U6R\16=G=:F+N"X@F<@VZH59"F,$?[QH Z"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKC-=\77^F:S<6
M<$-LT<>W!=6)Y4'LP]:SO^$]U3_GWL_^^&_^*KKC@:LHJ2ZGE5,YPM.;A)NZ
M=MNQZ)17G?\ PGNJ?\^]G_WPW_Q5'_">ZI_S[V?_ 'PW_P 55?4*Q']NX3N_
MN/1**\[_ .$]U3_GWL_^^&_^*H_X3W5/^?>S_P"^&_\ BJ/J%8/[=PG=_<>B
M45P>G^-=2N]2M;:2"T"2S)&Q5&R 2!Q\U=Y6%:A.BTI';A,;2Q2<J70****Q
M.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *QKW_D;](_Z];K^<5;-8U[_P C?I'_ %ZW7\XJ -FD9U12SL%4
M=R<"EK(\3_\ (OW/_ ?_ $(5,G9-EPCS24>YH_:K?_GO%_WV*/M5O_SWB_[[
M%>48HQ7+]:?8]'^SE_,>K_:K?_GO%_WV*/M5O_S\1?\ ?8KRC I".#1]:?8/
M[.7\QZ\#D9'2BH;7_CS@_P"N:_RJ:NQ'F-684444""BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \M\7_P#(T7G_  #_ - 6L2MOQ?\ \C1>?\ _
M] 6L2OI:'\*/HOR/SO&_[S4_Q/\ ,****U.8**** +VC?\AW3_\ KYC_ /0A
M7K]>0:-_R'=/_P"OF/\ ]"%>OUX^9?'$^KX=_A3]3E)M<UO4O$.HZ7HBZ;"-
M/V"5[[>S2,R[OE52,*,XR:9=^)=8M/!^I7]QIT=MJ=E*(=LBN89?F4!T/!*D
M-Z]JSM>N?"UQK5S%XIL?[-NX6"VMZ'=3/'CAED0#D<C:<XK,N)[EOAWXA9[J
M[N=*2XC^P7%X#YCQ;TSR>2H.<$]:\T^B.BU'5?%F@63ZEJ$6D7MC!AKA+1)(
MY53NR[F(..N.*ZV&:.X@CFB8-'(H=&'<$9!KB?$/C+2-7T"^TO1;D:CJ%]"U
MM%! C,<N-I).,  $G)]*Z_3;0V&E6=F6#&W@2(L.^U0,_I0!D1>./#DTJQIJ
M0YD\HL89 BOG;M9BN%.1W(['H:NZGXATO1YD@O;DK,Z[UBCB>5]O3=M0$@>_
M2O.[/6-+?X;W^A(AEU6YDN8H[41G?-(TK[67U XYZ#;[5<N(1I'BZ[?6=:OM
M*2>RMA#=0%/+E**5=2SHV#NY XSF@#MKCQ-HUMIEMJ4E^GV.Z?RX945F#MAC
M@8!.?E;\1CKQ5^RO(-0M([JW+F*3.TO&R'@XY5@".G<5Y[%;64>E^''L_P"T
M'MY_$0G5K]55W)20[@% PI(R.!UKTF@#C-#U7Q7K^G/?6\^BPQB>6)8Y+65C
M\C%>2)/;TJ&X\::B/!DVI0VUJFHP7XL95;<\.\2!"RX()'.1S63X;\,/K'@Z
MZDM=4U&TNWNK@((KR18LB1N"@(&#T..:@U:_LKGX5_9UMAILME>PP7ENA(,,
M@D&XYZ\]0>?J: .UMH_&(NH3=7.A&WWCS1%;S!RN>=I+XSCIFFW.M:E?:[=:
M1H<5J&LE4W5U=AF16895%52"QQR>1BL'3=2\(Q:E;-!XRU*XE\P!(9M1E=')
MX *G@U<AO(/"GB[6GU5S;V6IM'<6]VP/E[@NUD8]%/&1GJ* -:QU/64FO[35
M;&,2V\/G17=NK>1,,'CGE6!'(R>*R%\97\GA;0;M+>T_M+6'$:&0LD$9Y))Y
M)Z#@9R<U?M=?EURXU,V4*OHL-J0EV5(,TQSD)GJH'?'7O7.Z9=V,'PW\.PZQ
MI7VW2)HRMS-@M]F(SM8J 3@G(R,8_&@#I[&_\1VVM06.L6=K/!<HQ2[L$D"1
M,HSMD#9QD=#GKQ63?:KXTL=:TK3&ET!GU%I51Q;S838F\Y^?O5#1)=.C\5:=
M%X/U"\N;!M_V^ R/);Q)M^4@O]UMV, ']*W/$'_(^>#_ /KI=_\ H@T ;]@;
M^.P#:J]L]RN2YM48)CM@$DYQ7,:!XU_M6[UBYNYK:UTJQ>1%WV\J/A6 #L[?
M+SS\F-P.*[.O+C!++X=UF9(7FAM?%4ES<Q(NXO"DH+#'?CG\* .\TSQ)I.KW
M#6]G=%IU3?Y4D3Q,5_O . 2/<<4FE^)=)UF<PZ?<M.P4L2(9 N!C/S%<9Y'&
M<U@-JEEXC\:Z!/H\GVJ.R6>2YN(P=L:M'M5"?4L0=OM5_P"'RJO@?3]H R92
M<>OFO0 _Q#X>-[<C5K76KG2;V&(1^<C@Q%020'0\$9)]*PO#WCJ]N/$::!>I
M::FYR/[0TQBT8X)^<8P.G8XJ7QEH]U?Z_;W"^%9=<MX[=0 VJ+!$K[FS^[/4
MX(YZ=!VJ]H=_K\-Q;V+>!XM*L"<-)%J$++&,==B@9["@#:UV^OK&Q0Z=9&ZN
MYIDA12#L3<>7<CD*!R:S]/UC58/$BZ)K LI))K8W,,UFK(,*P#*RL21U&#FI
MO%OB:#PKHIO95$DLCB*",MM#.>F3V P237.>';BPU%K^2T\1V]YXHO8"#.BD
MI HZ*BG^%2?J3R: -6X\72'QSIVA6=NCVDCRQ7-RV>)$C+[$YZCY=W7KCK70
MZCJ-KI5D]Y>R^5;H5#/M+8R0!T!/4BO.YM(UO1_$?A"Q2YTLF-[D0,MM)R?*
M)=I,R$L3SSD<G//2N_US3EU?0K[3G (N('C&>Q(X/X'!H 5]7L(]9CTAK@"_
MDA,Z0[3DH#C.<8Z@]ZKR>)M'BL&OGO5%N)VMPVQLM(I(*J,98Y!Z ]*\OCU.
MZ&EKXY:%OM=G/%9%2,DJ("C_ )RO^E;>JZ.^B6G@XW%U>6EI9)*EW=VP!:&6
M10=YRK  MO!..-U '=6&O:9J5K/<VUVICM\^?YBF-HL#/S*P!7CGD5!I_BK1
M=4NTM;2\W32*6C5XG02 =2A8 -^&:X:\T^WU?1O$\NB7NK:K<R6L<3W,VSRI
M@K;ML955W,!D=#U JU9/HNJ:MHJ0Z[KFI7$4PF2WVQ8MBJG/FXC4J.=I&><]
M* .ATKQ9#+I0NM5DCADDOI;2&.&-F,A5RJ@*,DG YQ^E7+[Q9HFFW<EK=7NR
M2+'FE8G98L]-[*"J_B17GVAQR:#=IXIN)//T_P"WW5G.KH/]#1I3B13_ +V=
MQ]&QVJ]KUW8V.I:VUCK4VFW4I)FTZ\MEF@OR4'**<DAAA>#^&.H!T?B]9X-.
M?5K2XU O$J.KP7&V&W16W-(Z CS!MZ@A^ , <FNH1UD170Y5AD'U%846@V.L
M:?9W6IZ<8;B6VB%Q;1RO&G SY;HI <*20 P/?UK?H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K&O?^1OTC_KUNOYQ5LUC7O_ "-^D?\ 7K=?
MSBH V:R/$_\ R+]S_P !_P#0A6O61XG_ .1?N?\ @/\ Z$*BI\#-:/\ $CZH
M\YHHHKS#Z *#T-%!Z&@#UBU_X\X?^N:_RJ6HK7_CSA_ZYK_*I:]5;'S<MPHH
MHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XS7?"-_J>LW%Y!
M-;+')MP'9@>% [*?2L[_ (0+5/\ GXL_^^V_^)KT2BNN.-JQBHKH>54R;"U)
MN<D[MWW[GG?_  @6J?\ /Q9_]]M_\31_P@6J?\_%G_WVW_Q->B457U^L1_86
M$[/[SSO_ (0+5/\ GXL_^^V_^)H_X0+5/^?BS_[[;_XFO1**/K]8/["PG9_>
M<'I_@K4K34K6YDGM"D4R2,%=LD @\?+7>445A6KSK-.1VX3!TL*G&EU"BBBL
M3K"BBB@#,T#2/[#T>/3_ #_/V22OYFS;G?(SXQD]-V/PK3HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "J&JZWIFAVXGU.]AM8SG;YC<MCK@=3^%7ZQ/$/A>P\2"V
M>Y>XAN;4LUO<6\I1XRV,X['H.H[4 <QJ7Q#U"X^RQZ!HDWEWEPMM!?:@ICB9
MV!QA>K#@G/'2NM\/V>KV=A(-:U%+Z\DE,A:./8D:X "*.X&"<^]<=K6@^,X3
MI[)=V^NVMA>)>(D@$%PQ0$;<_=/#'GKTKLM!UAM:L9)Y-/N["6*0Q2072;6#
M  Y'JOS#!H U**** "BBB@ KSG2KOQ/)\0_$>FZCJT"'^RUFM%A0F&UW.X5B
MK'YF  )/&>G2O1JR;KPUI5Y>7UW-;L9[ZT^QW#K*REX>?EX/'WCR.: /*+.]
M\6SZ)XD&@:WJ&KVVV"WM+^ZD2/S+KS )FA8X C R!R>>F:+36]6OO[,\,#6=
M<L[R;5[BVU">>>.2>(QP[PB2*NW:3@],]:[VU^%WA"SL+FQATR3[+<H$DB>Z
ME< !MP*Y8[2",Y&#4[_#KPN^AKI!TT_9EG-R&$\@E\TC!<R;MQ)''7I0!4\$
M>(]4U/X>Z-J=S93ZC>3(RRM"8U)VL5WG<RCG&>*NK?7-WXQTL3Z7<V86UN<&
M9XVW<Q=-C']:WM/T^TTK3X+"Q@6"UMT$<4:]%4=JS[W_ )&_2/\ KUNOYQ4
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M 4444 %%%% !1110!YUXG_Y&*Z_X!_Z M9%=UJGA7^TM1EN_MOE^9CY?*SC
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M1D9 RQR<G Z"NDHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLW<#T%&!Z"L+_A+]*_O3?]^Z/^$OTK^]-_W[H]K#N'U>K_*S>HIJ.)(U=>C
M$4ZM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Y6;XB>'8KJ:!)KF=HF*.T%K(ZAAU&0,&MG1M;M->LWNK(3"-)#&?.B:,Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<U_E4M16O_'G#_US7^52UZJV/FY;A17+ZKXIGT[4IK5+:-U3&&+$$Y -4O\
MA-KG_GSA_P"^S6;KP3LSHCA*LDFD=K17%?\ ";7/_/G%_P!]FC_A-KG_ )\X
MO^^S2]O#N5]2K=CM:*P= UZ76)YHY($C$:A@5).>:WJTC)25T<]2G*G+EEN%
M%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!Y<VD>(M'O=+BTNXT>]L=
M,EE>S::XV.JR*R[7'?&[J/2NS\*::^FZ;/\ :;V&[OKJX>ZNI(3\GF-@87V
M  ^E</X2T#P//H+2:O%8IJ7F2"\BN)O+:!@Q&T+D;0.Q_6J>AV6EZ;+IU_H^
MZ.:37C:6DBN<W5ID;R1T8#+?-CL* /8J*** "BBB@ HHHH **** "L:]_P"1
MOTC_ *];K^<5;-8U[_R-^D?]>MU_.*@#9K(\3_\ (OW/_ ?_ $(5KUD>)_\
MD7[G_@/_ *$*BI\#-:/\2/JCSFBBBO,/H H/0T4'H: /6+7_ (\X?^N:_P J
MEJ*U_P"/.'_KFO\ *I:]5;'S<MSSCQ-_R,-U]5_]!%9-:WB;_D8+KZK_ .@B
MLFO-J?$SZ"C_  X^B"BBBI-#J?!/_'Y=_P#7-?YUVE<7X)_X_+O_ *YK_.NT
MKOH? CQ<;_&84445L<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI_Y%ZX^J?^A"O.ZPQ'QG;@/X3]?\@HHHK [0KUBV_P"/6'_<7^5>3UZQ;?\
M'K#_ +B_RKIPV[/.S':/S):J2ZI802M%+=PHZ]59P"*MUYMXB_Y#]W_O#^0K
M:K-P5T<>&HJM)Q;.[_MG3/\ G^@_[[%']LZ9_P _UO\ ]]BO,**P^LR['=_9
M\.[/3_[9TS_G^M_^^Q4UO?6MV6%O<1RE?O;&SBO*JZSP1_KKW_=3^M73KN4D
MK&-?!QITW)/8[&BBH+N\M["W,]U*(X@0"Q]ZZDFW9'G2DHJ[=D3T5C_\)3HG
M_00C_P"^6_PH_P"$IT3_ *"$?_?+?X5I[&K_ "O[C#ZWA_\ GXOO1L45C_\
M"4Z)_P!!"/\ [Y;_  H_X2G1/^@A'_WRW^%'L:O\K^X/K>'_ .?B^]&Q12 @
M@$=#2UD= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=7T>QUW3
MGL=0A$L#\XS@J1T8$="*O5&T\*3QP/+&LT@)2,L S 8S@=\9&?K0!Q__  KJ
M%_W-QXCU^XL?^?62].TCT)QR/:NLL;&UTRQALK*%8;:%=L<:] *Q]6UO4HM8
M72='TZ&ZNA +F5IY_*1$+%0!@$DDJ?ICWJWH.KR:O:SFXM?LUW:SM;7$0?>H
M< 'Y6[@A@?TH U:*** "BBB@ HHHH **** "L:]_Y&_2/^O6Z_G%6S6->_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45[4/NCZ5Y.:?9^?Z'TW#O\ R\^7ZBUY-XB_Y&*__P"NIKUFO)O$7_(Q7_\
MUU-9Y9_$?H;\0_P(>OZ,S*2EI*]H^2%KM_A]]S4/K'_[-7$5V_P^^YJ'U3_V
M:N/'?P)?+\SU,F_WV'S_ "9VM<WXX_Y%[_MLG]:Z2N;\<?\ (O?]MD_K7C87
M^-'U/J\Q_P!TJ>C/-Z**2OI3X *?%_KD_P!X?SIM.B_UT?\ O#^=)[#6Z/:A
MT%% Z"BOE#]+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BD)"@DD #DDUPFN_$ZRT76YK/[*D]I#:FX:Z%Q@.=KMY<8VD,WR=-PZ^U '
M>45Y\OQ.>.54N] N8O+>:*[:.3S%A= " &"X;=E>N.6'6NGN?$UEIVB6NHZ@
MX4SE8Q%;9N"TIZHFP$L1@]!V- &U17!S?$H7&K+IFBZ/->7+W*VZ&Y=K9&S
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M^-OWMW&WTYSVJO\ :O$/V7=_9=CY_P!FW[/MAV^=NQLSL^[MYW8Z\8[ULT4
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MHII;:&26(YC=T!9/H>U $%\VIK%'_9\-I))_&+B5D ^F%.:Q9K7Q/-J]I?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img96160895_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (X!$P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S1]KN?^?B7_ +[-2#3;PW9M1 WG 9*^@]<],476G7=FJM/"55C@,"&!/U%
M$?VNY_Y^)?\ OLT?:[G_ )^)?^^S5B31]0BM_/>V<1@9)R,@>XZU/_9D/]GZ
M?< RL]Q+L=01TR1QGO\ 6E<"A]KN?^?B7_OLT?:[G_GXE_[[-6Y=)G>\N(K2
M"5EAQE79=PR/8X/X5!=Z;>6*JUQ 4#< Y!'Z4P(_M=S_ ,_$O_?9H^UW/_/Q
M+_WV:L2:/J$5L;A[5Q&!DG(R![CK5&@";[7<_P#/Q+_WV:/M=S_S\2_]]FH:
M* )OM=S_ ,_$O_?9H^UW/_/Q+_WV:AHH F^UW/\ S\2_]]FC[7<_\_$O_?9J
M&B@";[7<_P#/Q+_WV:/M=S_S\2_]]FH:* )OM=S_ ,_$O_?9H^UW/_/Q+_WV
M:AHH F^UW/\ S\2_]]FC[7<_\_$O_?9J&B@";[7<_P#/Q+_WV:/M=S_S\2_]
M]FH:* )OM=S_ ,_$O_?9H^UW/_/Q+_WV:AHH F^UW/\ S\2_]]FC[7<_\_$O
M_?9J&B@";[7<_P#/Q+_WV:/M=S_S\2_]]FH:* )OM=S_ ,_$O_?9H^UW/_/Q
M+_WV:AHH F^UW/\ S\2_]]FC[7<_\_$O_?9J2UL);R"XEC9 (%WL&)R1STX]
MJE@TBYN-.DO4*"),G!)R0.N.* *WVNY_Y^)?^^S1]KN?^?B7_OLU(UA*NG+?
M,R")GV*,G<3^7L:JT 3?:[G_ )^)?^^S1]KN?^?B7_OLU#5J.PEDTZ6^#)Y4
M;!2"3G/'M[T 1_:[G_GXE_[[-'VNY_Y^)?\ OLU#5^STF>]@,XDABB#;=\K[
M03Z"@"M]KN?^?B7_ +[-'VNY_P"?B7_OLTMW:365RT$P =?0Y!'J*@H F^UW
M/_/Q+_WV:/M=S_S\2_\ ?9J&B@";[7<_\_$O_?9H^UW/_/Q+_P!]FH:* )OM
M=S_S\2_]]FC[7<_\_$O_ 'V:AHH F^UW/_/Q+_WV:/M=S_S\2_\ ?9J&B@";
M[7<_\_$O_?9H^UW/_/Q+_P!]FH:* )OM=S_S\2_]]FC[7<_\_$O_ 'V:AHH
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MS4-% $WVNY_Y^)?^^S1]KN?^?B7_ +[-0T4 3?:[G_GXE_[[-'VNY_Y^)?\
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MW.M'3Q-P%W>;L[8STSZ\=:5="=M9>P\[ 1=YDV]L>F?4XZT 9WVNY_Y^)?\
MOLT?:[G_ )^)?^^S0MK/+O:&&65%.-RH2/TID<4DS[(HW=_[JC)H ?\ :[G_
M )^)?^^S1]KN?^?B7_OLU+:6$EQJ,=G)NA9R0=R<CC/2FS6,T<UPJ1R2) Y5
MI%0XX/?TH 9]KN?^?B7_ +[-'VNY_P"?B7_OLU#6G=:-)9Z9#=ROAY& \K;T
MR">OX4 4OM=S_P _$O\ WV:/M=S_ ,_$O_?9K6_X1T;A ;U!>%-XAV'_ -"S
M6&1@D'J* )OM=S_S\2_]]FC[7<_\_$O_ 'V:AHH F^UW/_/Q+_WV:/M=S_S\
M2_\ ?9J&B@";[7<_\_$O_?9H^UW/_/Q+_P!]FH:* )OM=S_S\2_]]FC[7<_\
M_$O_ 'V:AHH F^UW/_/Q+_WV:Z7PI-)*MUYDCO@KC<Q..M<I74>$?NW?U7^M
M '34AI:0TA"T444 <=XL_P"0I%_UP'_H35A5N^+/^0I%_P!<!_Z$U85,8444
M4 %%%% !1110 4444 %%%% !6UX7_P"0O_VS;^E8M*&*G*D@^U F=?8'67F9
M-353:,A#E]HP,>U5;.Q1].,ENDEXIF8+$9RBH 3AB/7I^=<V9'(P78CW-(&8
M @$@'KS0,[&Z:X&O_P"CI%*'M1NC=L;QD]*J7=K;6L=E<R0M9LMPN83)O7&<
MDBN9W,2#N.1TYZ4,S,<L2?J: .UG,L%U<W*6*,ACYF:Y(5UQTQR*S4_Y!6B?
M]?(_]"-<YN8KMW''IFC<V -QP.G/2DT!UNYDN]?92581 @CJ/E-58I%7P[I[
MS'*+=J6)],FN=WMS\QYZ\]:3<=NW)QZ9IK01VTS2P7EQ=1V*,ACR9WN2%=?3
M'(%<12[FV[=QQZ9I*0PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% &OX;E":J(F *S(R'/Y_TK:A=;"XL-*;H\+"3T)/_P!<
M'\ZY&&5X)DFC.'1@P^HJ>;4+F>^6\=QYRD$$#@8Z<4 =&UO''>:3I4F'5%:1
MU/0G!(_7-,U"YM9[*\BGN1,R$^6!;,OE,/X<_A6!/J5U<7BW;R8F7&UE&,8J
M6YUJ^NX##)* C?>"J!N^M(#I7:UL)+>T\]%@,?,'V<N9??(^E5M,CLGTZ]1W
MQ9_:N"W'&5P#G\!6+#KNH00+"DPVJ,*2H) ^M5A?W M);7>#'*^]\C))X[_A
M3$6_$$ERVJ21S\*G$2CH%[8JY:&&W\.+)>Q&X@>?Y(U."IY!.?P/^361=7T]
MZ(O/(8QKM#8Y(]SWJ2SU6[L8S'#(-A.=K*",^M RWXEC==5WL^X/&&48QM'3
M'Z5CU-<W,UW.TT[EW;O4-) %%%%, HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "ND\.HEY8S6CC_5S)*#^/_P!;]:YNI8+F
M>U<M!*T;$8)4XR* .KM)UU6XO8&8$)<)(F>Z@@'^7ZT6TT<\VKS#S?-#A/W&
M"^T<#;GZ&N4@N9[9R\$K1L1@E3C(HAN)K>3S(97C?IE3BD!U7F13:AI:RP7(
M=2VU[D*"PQQG!ZYQ27TX^QZ@DD&H2*<\RJNQ#V*^W2N6FNIYY1)+,[N.C%N1
M]*?-?W=Q'Y<US*Z?W6;B@#L8W3[):0HP2[EM,0N1TP!_G\*XB0.LKK)G>"0V
M>N:E-[<EHF,[YB&(SG[OTJ*21YI&DD8L['))[T ;NF7$UQI6JF61GVPJ!D]!
MANE3V,S#PPI@MDN)8Y2"C)NQD]<?0USL=Q-#')''(RI(,. ?O#WIUO=W%J28
M)GC+==IQFGU T?$,$4%]&8HUB,D09T7H#613Y)9)I#)*[.[=68Y)IE !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =C+,O]
MDMJNX>:]J(LCLQ//ZG]*'E0Z0^K9/FO:B+(['./YG]*Y,W,YMA;F5O)!R$SQ
MFE^U3_9OLWG/Y.<[,\4,#K(76&PTSREO"-@.+8+M)[[L_C3;9H"-5ECBN(I3
M(-R1 >:!@=!TZ[JY>&_N[>/RX;F5$_NJV!3(KJ>"4RQ3.DAZL&Y/UH$=295E
MU72LPW*.-V'G"@L-O?'>HM<*S:9+]B8B.*=A<(!C+9ZG\?\ /%<ZU[=-<+<-
M/(95^ZY;D4BW=POF[9G'G?ZSG[WU_.@9;T6*VDU -=2QI'&-X$C !CV'^?2M
MO5(WN=!5I;JV9O.+EU?*GKPOJ?;VKDZE-Q,UNMN9&,*G(3/ - '9_O%U&.T%
MNS1F#:;S^,?\"KB9%"RNH;< 2 ?6IQJ%X(/)%U+Y>,;=QQCTJM0 4444 %%%
M% !1110 4444 %=1X1^[=_5?ZUR]=1X1^[=_5?ZT =-2&EI#2$+1110!C:MH
M1U2Z6<7'E[4"8V9[D^OO5#_A$#_S^C_OU_\ 7KHIKNWMW"33QHQ&0&;'%1_V
ME8C_ )>X?^^Q0!@_\(@?^?T?]^O_ *]'_"('_G]'_?K_ .O6]_:-E_S]0_\
M?8I/[4L!_P OD/\ WV* ,+_A$#_S^C_OU_\ 7H_X1 _\_H_[]?\ UZW/[6T_
M_G]@_P"^Q3AJ-D1D746/]\4 8/\ PB!_Y_1_WZ_^O1_PB!_Y_1_WZ_\ KUOI
MJ%F_W+J)OHPI6O[1,;KF(9Z984 <_P#\(@?^?T?]^O\ Z]'_  B!_P"?T?\
M?K_Z];;:QIJ];ZW'UD%-_MK2\X_M"VS_ -=!0!C?\(@?^?T?]^O_ *]'_"('
M_G]'_?K_ .O6T=9TQ5W-?VP7U,@J,>(=&8X75+0GVE% &3_PB!_Y_1_WZ_\
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M]'_?K_Z]'_"('_G]'_?K_P"O6^]_;1IO:3"YQG:>OY5 =<TY20;C!'_3-O\
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MM[C_ %,\<G^ZP-2-(B EF  &3DT <S_PB!_Y_1_WZ_\ KT?\(@?^?T?]^O\
MZ];O]J6 ZWD/_?8I/[5T_P#Y_(/^^Q0!A_\ "('_ )_1_P!^O_KT?\(@?^?T
M?]^O_KUN_P!IV'_/W#_WV*#J=B.MW#_WV* ,+_A$#_S^C_OU_P#7H_X1 _\
M/Z/^_7_UZW?[5L/^?R#_ +[%']J6'_/Y!_WV* ,+_A$#_P _H_[]?_7H_P"$
M0/\ S^C_ +]?_7K=_M.Q_P"?N'_OL4?VG89Q]LA_[[% &%_PB!_Y_1_WZ_\
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MZ/\ A$#_ ,_H_P"_7_UZW_[1LO\ GZB_[[%']HV7_/U%_P!]"@# _P"$0/\
MS^C_ +]?_7H_X1 _\_H_[]?_ %ZWCJ5D.MU%_P!]"D_M.Q_Y^X?^^Q0!A?\
M"('_ )_1_P!^O_KT?\(@?^?T?]^O_KUN'5M/'6]@_P"^Q2?VOIV<?;K?_OX*
M ,3_ (1 _P#/Z/\ OU_]>C_A$#_S^C_OU_\ 7K;_ +7T[_G^@_[^"C^U]._Y
M_8/^^Q0!B?\ "('_ )_1_P!^O_KT?\(@?^?T?]^O_KUMG6-.'6^MQ_P,4?VO
MIW_/];_]_!0!B?\ "('_ )_1_P!^O_KUJZ/I!TH3 S^;YF/X<8QGW]ZF_M?3
MO^?V#_OL59AGBN(Q)#(LB'@,IR* )*0TM(: %HHHH Y3Q-($U&,'_GB.WN:Q
M9Y"BJR8.?2MCQ3$9-3C.X >2/K]XUC"!$QP7/O0!"#<2C Z>YQ4BVIZO(?PJ
M8+C@#\NU-=TB^\<'T'-  $BB&<]/:I+:WGU&416Z';W8]!4NFZ7<:K-N;,=N
M.K>OTK9U+6-+\*V.9,!@.%SRU $\=E9:-8M-.0 HRS-W/M7G>M^+(GN796]@
M%& !7-^)/'M[K4Q (2('Y4!Z5Q\EQ-(Q+.W/;- '3W7B-VD)$AQ6?-KTKKA)
M,8[CK6&0Q/ )S0?]6#GJ>@H MR7UQ*"6D9A]<TQ;NX4Y$IX_2JZ$[L8[<U)(
MAC4)D$MSF@#K= \4_P!GVTK3,SR$87/:K47C,K,KGYL-FN+MK2:ZF\J*-F;T
MK8MO#&H-(N82 QQF@#NM9UE-2T0E,@D9'UKG=%T^:\G#G(0=3BNG7PZEOI\<
M4C=@"!76^'=!BBMU;R]J>M &#%;B.,9&,#TJO+<$2[1SCM7>7]GI8CVW15<C
MCYL$_2N:N-&M0[&R#A#SE^IH YZ]U)+%=S$$GL*C'B^TBTQF9_G]*A\1Z-<3
M6;+&A\U1D#UKS%Q(LK(Q((.".G- ';ZCXS673&C@)\S=QCCBN-N+ZXN)"TDA
MR?0U"1A<YY[BDCB>1B$4DX)(%  LL@Y$C<]3FDW-GJ:6.8I[KC&"*<GE@.7R
M7(P,&@"(GD^WXT$$#GC\*50!DC/%.*D0K(P.&.!0 D<CHP*.5([YKL- ^(6K
MZ*%C,IFA'\+\UQQ*A%&TY!ZTJ DY':@#W_1OB#H^O1""Z"Q2G^%CQ4FKZ68E
M^UV<QE@[C.=O_P!:OG]&9<NK8*]ZZSP[X\OM)(AN"9;<\,"<\4 =ZET5P'&?
M>IEGC8?>Q]:HVUS;:I#]HM7!5N=OI2,A0X/'XT 7S.@YW?D:ZWPPXDTDL.GF
MM_2N#Z'D5W'A/_D#'_KJW\A0!<UY@NC3D]/E_P#0A7&/*%( Y8] *[#Q$ADT
M*X4=3L_]#%<?#$(QCJW<T -\DORYQD]!0+>('@$_C4QP <_I49F1!RP!H 41
M(.0@J3C/':JK7:@G:"3ZU9T^SN=4F\M/E0?>;L* !=\THBA&]VZ>U=#8:1#8
M1_:KYT,V,Y;[J_2JNHZII'@ZQWRNIF(]?F)KR#Q-\0M1UN5DB<QVXZ!>* /2
M/$GQ'T[25:*S83W'3<>@KR75_&6IZI.SM,RAO0US\DCN^YR23ZF@@+L8$$]P
M>U $YU"[8_ZYR?7-21ZG=J-JR-^=5-I(R".O04WIQC![4 :D6NW\1SYK8KH=
M'\92QW47V@ KD FN+Y*^A%*C>WS9ZYH ]QT_7K2[,@$BA@<@>HK%USQ2NGLT
M: '/(->91WEQ$VY)"&'<&G7E[)>*K2DY]: -J;Q9=LY*]*W_  WK,VHW2PN,
MYKSQ%,DHCC!9F. !SFO3_"VA-IELD\B_OVZ\]!0!T+1L@+(QR.PJY9:U=VY"
MB0E?[K52N+@1KD#WYKD[SQ%]EG:,'G- 'IT=]!J$4L<IVMMR"/6L=G(/S+SZ
MUS&E>)8UC>61]H P*AU/Q>B6R/&1OR: .TCN(YP$E !Z U5NGBMW.)05]:\S
MG\8SNQ/(/M5>3Q#+<*09",]R: /3?M5J_P#RU3/UIX2.0 HZL/8UXW)JER[Y
M60C%36^OZC;$-',: /;H=&>[M_,MY<]B/2J=Q87EJVV52N>ASP?QKBM ^),]
ME.OV@=>&/8BO6=*UW3/$EHIADC;</FB8\B@#E!'.O*Y'XTOGS*1N4G%;>IZ5
M+9$RQ R0>W5:S@V[&>_- $2W*-UX^M2B0'@&F/#&_P##@^QJ+R73.PY'H10!
M:BB1KF/*C.\']:[RO.[9Y8[F(.,C>/YUZ)0!Q7C $ZO#_P!<!_Z$U8D=NTA!
MZ#U-=/XE13J4;$ GR0/U-8KN%'49]* &+%'$,]3ZFFO= MB,9-*(G9"I)"M4
MJ0I']T#/K0!#LEEY8[1[5(L:1C@?B:M+;32QF1(SM ZXK UO7[31X"97WS$?
M+&#UH OW=[%:0F6>58XQW8XKAM6\?W D=-*_<CIYQ^]^%<UJ^M7>L3F2XD(3
M^&,=!6:.A]!0!8NKVYO)#)<W$DSGG+L34';I4@ :54 /( YIJE02KDXZ8% "
M#&.>*7G(4<^F*>[1A-D><9SENM1$ !>>3UH =C Y!!/2I8)Y[=BT<SH>G!--
MA!EN$5SP.3GL*$99)3G/<C% &NOBC4_LGV7[0VWIG-9DMY<SO\\[G\:@QN8X
M&*<TI(8';@^U "B>96XD;\Z[KP--<78N1,2T48 W-ZUQ-E:3ZA=16L"EY'.
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M@9;&1R*ZW0 !I,8'3<W\ZXE8&1]W)7K@]J[7P^Q;24)!'S-U^M &I2&EI#0
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M2"<@5!JVK6NCVQDE==Y'RIZU)K6IQ:/;222,-R\*O?->2:GJ5QJ=TT\[DY/
M/:@!^K:K-JMT97X3/"BJ3H0%9L $<8-('& ".E..P+@,?IB@ \IO*5E.1SD^
ME!=65<J=X[U(EPPMGMARC$-R*8J^8P2, ,QQS0 QL!L#YO?M0AVMNP,U)=6K
MVMRT3[2R]U.138P&X.?2@!FW!R>E2F,+ K Y+'\A2K:S$X4!@!GAA5C3[=KM
M[B%AC9&9,>F* *8X())V^U:.AWB:?KMM<296,/AB>PK,!)QGG%*22?FR>PH
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MU2;6-2>XD)()^12>@JD&*D;>/:@"2*)BY1E.6! (Z9I@4*^V0%>QH#OMP&(
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MS'[.KPX^93P:\F\6(?\ A(KD]-V#^E>HW,TDLC.PQGKBO*O$<GF:_<GT8 4
M4($1R%9@&SP/6D>,JS*X*D'D4PE21QCCJ.YJ=948 3[F/J#0!$(R48 $XY)'
MI2,0P &./UK>TO4[72!,\-J;@RIY;";& #W%9<Z6P19('8[R00?X30!2 _\
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ML=UY% $,GED%D4CVII$>5W?*.,$'DCOQ6_I'AV36=&N;S[=%$(<[8V(!8XK
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M#\:]O^*L;/8M@\"$9_[Z->';L>AH 4X))P<^E"C!!-.9C(PR>GI3<'W_ #H
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MM4G [5%D Y/2@#?LO!D>I$/::C&T?<8^8#Z5T\\MIX#\-R+:$->3G"L>I/\
M@*XG0]1ET_5(98R=K,%9?4'BO2=8\-VFI/;R7*,'4[@,\'VH M:3<RWFE6=[
M+P\L88UJM,"GS8 '>LNZNH[.U78@$<2[54=A7(W/B*:>4@,5'L: .E\1R0W>
MD30(RE\<5Y-;0RW-VEJ@ D=PB@\9).*VK^[ED<DR-SSUK'+.LWG!R&_O9P:
M-HVEOX?\1VPN +B .K*S#JI_B]..1^%=%JEEIOB36"9'%F%@1QL*D?,P49/3
MJ:XL+(EM&[NZJK9B4-T/J*D235?+DU!6N1'G:TO./IF@#I9? 4<$:ROJD;*W
MW5 Y)R .?JP'XUD:KHGV6Q61/+*(1DJQW<^O'T_.LM+R\CCVK<3*H;(&\\'(
M/]!^5:(EE^R1"<RR&3N[D*?\: $T_1;N:(3[2(^QVY)^@[UL7/AZ^T2%Y87C
ME# -(K1@XP<@X-;'ARY>2R'F>0D<1&UF.<'//'TJ36KS3X89G.YI4!CC9I=V
M00!D^OX^IH X2ZU 2NYA5D:1-LKG^/D$G\Q4?]IW:6GV9) (CV"C(YSC/7&>
M:KN5+'L#4D_V'8HA,Y8CG=C% $QUJ_\ F'G_ 'E*M\HY! !_E4%W>W%Z0TTI
M?;G!P!U.3^M5A@@X.,4XA0H);YCVH Z?X>2M'XRL%4X#R '\Z^CJ^<OAW'O\
M:6+?W9 ?UKZ-H ^>_BJ/^+@7?3_5Q'G_ '!7&1_(02H/H&'%=K\5EQX\NS_>
MBB_]!%<46+$ ]N@]* !2 A8<,IXI5;YB6'7K30/KGM2[E&,!LXYS0 $J =I'
M-+TBV[><YYJS874-I<+/):1W&W)"2$[:AGE>>=[A@JF0DX'0?2@"73K^?2K^
M.\M\+,@.TGIS4<T\U[<33SR[I7.26[U#][C&3]:5XV0C<,$@''I0 S)).:Z*
M#Q7J4>@C2$DB6+IN=?X/2L*)(V;:[$9_B]*VK#3=%FT:_NKK4B+F-?W,2KC)
M_K0!H:!K>A6=M??:+*0S/'MCV@$=.Q[<US2V\]W*WEPL['YB!S@5"#\N ,5;
MTW4[C3+GSX&&XJ48$<$$4 5701MARK8ZA34MC<FSOX;I!GRG#BJY)))P!DYX
MX%'(SB@#1\06;7-V^H6PWPSG?P.A/45B)!+)($1&9SP !6I:7]Q8NNT[XS]Z
M-N5(KT#2;C39-*_M&WLU,JG# #)!]* *_A:Q'A30Y[_4L+)<LJB//(&>!]:[
M".,$EEY/6O,-9N=5\5:J(;6%_(A(PJ]%[9->EQR?8HE#N&VQJKECW Y- $\B
M/M+$G&.3Z5P7CQC]FM$Y W$_7BNFO/%&GKF/[0,#KCFN0\77UMJ-I;R6K[_*
M<AE[\T <@7)QP.*4,<D[CN[4]80[8+*BD9Y/2NFT32_#]UH5Y=7]^$NTRJ*3
MC&!QQWS0!CV]Y>2V[0O<.8D4O@MTP.U0),LB3M.GFRNH".6RP/J?PJ#+,>![
M#'>I;:QN[Z4Q6L#22#JJ]J (AW7:-Q&,FG;&4$9/([=#5[4]$OM)VB]B\MF&
M0,@U28,AP3VZ]Z &A2Q)YX'4"GNL.V/[.LC.5R^1GGVKK/!TI>#[+'*H=[E7
M>,M("4"Y. O#<9X8$>U4;1GT#Q%>0.T<0:/8LDC21?*=K _+\P) !Q[T <_%
M'O$A9MN!G)&::S;N<=L&NDL=1L[?3[Z W899&F(WEMSADPG'1CNZ[NG5>:BL
M)-!.E6B7$2&YP!,QWY!,CY/''";/\YH [[X730ZAHMU#,/,EM"-JG^[7J%HL
M2VZB%=J'D#TKR#P#K.D6?B006BI&;D-'QO\ FP4*YS]7_+Z5[%#&(DVKTR30
M!)2&EI#0 M%%% '#^/X1<0RQ[<DV^?U-?/[ *2I'0XS7TKXCTV6[D,J(658M
MI'XG_&OG?6+5K35;B(C&'- %)$0]6QSUITH5'*KT'ZT@0OR,9^M!0#.YP"!P
M* !4:3[JDL.N!22QR*0'C9 >1D=:L6]_-:QE(2JENK8YQ4+R/*VZ1RQ'3)H
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MVL,;: ,Y89'*A$9]W3 H97C;8^01V]*D-[<$@K)L"] HP!379&^;;ECWSWH
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MPR8;N-IH X&>1Y&QU X%36=NRRH]QL$;'A6Y+5"1YO*'!QR#2(A8AY"/D]Z
M$NKAKBY9G  4X51T JQ%J]]'9O9BX86KG)B XS4(A0S;IY0%8_P\FH9Q&LK!
M"2@/'% $UG<16]VDDMNLT:G<4)QDU+>SW%[/)<@,L6>!_"H]!19:>UQ"9G/E
MH#\I_O4M[?+(A@4-A6^\>X%=$*4?9N<W;MYG+4KR]JJ=-7[^2(X;N54\L.^Q
MCTSUJ&65MQ#,3]320RHDZ2.N44]#WIUY.MY.91 D1/4)T-<YU$)Y[XI"NW!(
MZ],U>U*W%NMJ5 P\08FF64Y >W>-)$<$ L/NGVH KJ$+X.0IZXJ)AAB%SUI2
MHZ ]Z,G&#B@#OOA38/=>(O. XBPQ/I@U[S7!_##0_P"R/#$=U(F)[Q@YSU"]
MJ[R@#P;XMPLOC%I<<-$G/K\M<%Y;*JN<%0>1FO7/BM8?:9'N50EX-N2/0@5Y
M(JC).2,#.,=: "5DDD)"! >B^E-/RY5E'/'O0V=QR,&I94C7A)"SX'; H B4
M,?E7OP*N0:1J$R2F.SE81\N0.!5'!QSD?2NMM;HZ#X4(AN&>]U#GRPW^K3IG
MZT <U#875U)(D$3.T2%W"C[H'6HQ@J"3DGBI(9)(B[)*ZLPP6!()]14L&EWM
MS!+<10,T* EG],4 )9?8T,ANHWD=E/E(IV\CUJS>VFG0Z?9S079FN95+31@8
M$?H*SEPNW+C!]>U-Z,01SWH V-$\.W.MP7<ENZ@P)G!YR?2LAE9&*,I#CA@?
M6MWPSK]UHCW*6L8>6X 5 3P"*R=1N[F_N7FN&!E)YP,4 5NJ_CQ3XHS*Y7<J
MD#C)Z^U-5%WJKOM'J>U/GB>%PK8SC((]* %1"!M)7_:%>G^$O#T^EZ4;B2=6
M-R5<1CHHQ7ET,,ES.D,*;I'8  =S7O.@:?+::5;K=$O(B !?H.M &>EM':;C
M#$L8DY8JO4UY[XLU>XFU:6QCD*Q1\<'&3BO9SLD_=N@8'MCI7E/CGPM<VNJF
M^LXGEMYL,VT9*]J .,4@*23SZ4\ $'JN>AQQ02%&TQ@X/.!S4;$J>1CF@"/!
M)!9>,\XIHPISW/M4F[YS@9R<\ULZ1K-GI\I>ZTF"X+(0">"/>@#+A$:W<)N2
M5BWC?CT[UJ:Q-!IFLNN@W+K#M'SJ>23VS65<O"\F^)R00258<J?0>U/6WEB2
M">XA;R9"=G;>!UH LNU[>KY\\QF9ASO;I^-7+7PV;BVFDDO4AECB\U8E7>7'
M3&1T/.?7CWJR=2MKBU1SI=M;"$8#KG/_ -<UE3:M))'L@+(K<L/7!XKH5**I
M<\W9]%W.1UY2K*G35TMWV\B.8'3G>*VGW;UVNR=QZ5!=WMQ>"+SV#>4FQ>V%
MJ,(67=G ^O2F$ GM7.=8Z%@DFXJ& [&FG+/E0!Z>U6+J6">91;VXA4( ?FSD
M]S4"HS'&[ /<T :?AN5H_$-F^3NW\8ZYKZ4TJZ-YI\<I&#R#^'%?.GA*S%UX
MAA;!"1#>>?2OH3P__P @B/\ WF_G0!J4AI:0T +1110!&TBAF3(+!=Q'M_D5
MXQ\6/#?V2[CU>V3$$WROM_A:O3M2O?L6NQ-D[#" X]MS5/K>EV^O:%/9N T<
MJ?*?0]C0!\NC'7J133\P'(_&K^JZ7/I.H2VDZD,C8!(ZBJ63_%0 A0J 2.#T
M-201M*VU>6P>.M-<[]I.,@8JS83"VO(I"#QD8]<C% $$<K0N'4J&%.>XDE9G
M=R2WK3'!#L,#.3U%/DB5 H#;FVY.#TH <KQ"T.Y29&?KZ"FPF+[0HFR(0<DJ
M.U-5!(552 S<<TC*H8H""R]3ZT 6+V_>]DY^6-!A$[ 5 CO$X9&V,.X-.4QK
M"S/G?T4=J:DBF(QNI(ZAAU% %CS8;H9N6V/G D'?ZU5= C8)!]"#29.T#' I
M0I/.,>^: 'PPO/.D$?S.YP!7M6AZ:+#0[>  !@OS''>N!\$Z0DUVU_-\Z1?=
M'O7H\,KQJS #'O0!V!C18E=B%B5!SVK!O=7,DA6W0I$/PS5>6Z>6S52>.W-4
MP>.N: -:QU?;F&Z!,;=P?NUK.;.2TD N%(9",9YKDSCVITDS")=JMSW% &7K
M6FP:I;2VLF"W53[UY%=VTMG>2V\JD,C$'/'%>TL$<;LD$=37 ^/-/874>H11
MDHPVN?<4 <=@D@ ;O2K5S</.$A"!%4<(IXJJ&8<Y_*A6*@[>I[BJ4Y13BNI$
MJ<924FM5L2"8K%M4X96R"#0MPXN!,V&;.3N[U$%^8 G&>M/G0+*P!R,\5)8L
MIS*S)P,YQZ4-M,"%22V3N%,4_*<#(-."%ER. .M #><8YQ3D7>2H^\>F:;MX
MR<4Y1@*P/2@ (<':1@BB-&>4*JEG8X %.R6;&=Q8].M=UX4\-&$+?7:#S.J*
M?X?>@#<\&:+_ &/ LK@?:Y<9]1[5ZO:!Q;+O/S5QUB(;*/[;<X)'^JC]372:
M#<275@\TK99I6_#IQ0!:U)5:Q=6^Z2H/_?0KCO%GAQVTJ9XAN3:2P':NLUIM
MFDS-G&"O_H0HL9TO]/&X Y&QQ0!\MR1>7<.AX*G%1L=W!YQQQ79?$/PR^AZT
MTL:DVTWS*<5QG?!Z4 (!WR12XY]13GY7*] <?6I+:(SW$<73<PY]J &Q*C.
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M=[#N(SC.XU#96JR2+N " 85<XKJK+28E E=>.H44 9^L7;M:10+E5 &[WK$
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M22(.=C_>7M0!&0<=,"G*A()*M@<Y'2I(;=I59AQM''O]*:C.RN-S8( .3Z4
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M]C7,6=Q-:2@JV4)Y3'!J[?ZH;BU$-O'Y1)!9L=Q0 SQ%X0TGQ!\D\8AN?X7
MZUY;XB^'FI:*V^&&2XA_OHN<?E7L-GKT#0@7@VS+QD+UK5@N[>X&(I0WL: /
MEJ2%X6(9&![A@12$.1SCCI7T_=:58W7^OL+>7W*#-9__  C.@E_^01"#Z[:
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MC"PB4YC1Q]X^IKUC1O 7A_1"'@LQ+*/^6DQWG]>E:^IVD-W8O&^X*@R E '
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MG_?(I]% #/)B_P">2?\ ?(H\F+_GDG_?(I]% #/)B_YYI_WR*/)B_P">:?\
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M$<UKM\5+-S#*[O;*ZG$13)/O7BUO!)<W"QHI;/)"^G>EFE^T2EF('8#/0=J
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MJ#;&A)]A0(I9,;VP.P% &M_;E^HYNP?JB_X4QO$-ZO6Z_)%_PJNFEN%WNFU
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MG;&NS<XX7_T$5C<T :O_  DNKD\7>/\ MFO^%'_"2:O_ ,_?_D-/\*RU4G@
MD^E6XK4#F0_AZ4 78]?UF0X%U^/EK_A5@:[J2#Y[LD^GEK_A6:6=L+$,*.]
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M:[J'_/R?^^%_PKRL?$.[*,K64.=N%.>E4'\;:N6RC(@] * /8QKNH'_EX_\
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MCDLQH N:OK][K$I,TA6$?=B3( K.2(NP"C)].],R <$?G3Y&42[HLXXQN[4
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M+?>J:VMI+ER(P3CJQZ5G>([ZW\/6ZR7DGS.,K&O4T 275W%:0-++(J(HY8\
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M&4;U]J /+0_R%< Y/7'-:$ES#)IEM;JBF9"<OZBLUXGAE:*561T."".<U*)
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M<Y&$3S6']X]A_*@"#Q#XCT[PKI0E=5WL/W%N.K'U->"ZWK=WK^I27MXY9V/
M'11Z4NN:Y=^(=5FOKN1F9R=JYX1>P%9NTG.#T[T /P$=&)^4@$Y%/"FWG#@_
MNSG#=014)8E<'D#H3VJ>&YE0>4BAT_N'G- $+(5.<':>A]:FD6-K%)$4AU8J
M_/!]#4FRWN $4M#+T"N<K] >U:%MHEZL<B7$2Q1RKP689![&@##'TS2LA R0
M<&I;FRGLW*S(5/;T-6+&REU16@A :6,;E7/44 6--MVO+2]L(_G?"RQX]15H
MZ/8VJ;=0U 1RD98*NXCVQ6E#'_PC7A[[1+@ZC=?(!_<%<K*7DF_>$LY/)/4T
M 27BV"$K:2328Z,ZX!JL,;> 0WKFII(XXHP"^9.XQT_&M/0] N-7N  I%NIS
M(_\ 0>] '1^"_"ZWJC4+Q-T>?W:-W]Z]+CA2)0JJH&. *K:?#';64442[4"@
M >@JWG(Z\4 !12N",U4N+4%2R?E5O(^E*O!H Q)(=Z_S%>:>,=&%E>"ZA&(I
M?O = :]5N4$4O' -8>OZ<-1TJ>(*"VW*_6@#Q_J:M75LT$4$@YCE3<#GOWJN
MV8]Z,.<X^F*F^TL]FEL?X&ROL.] $) QD'(J63;@%7Z#IFKFBZ:-5OS;;PI,
M;,OU JEY+&0QX 920Q[4 1*2#D<&CGOTJ4K&L&0<R%OR%,+J\841C>3]X']*
M +FEZM?:/=I<V$[12#T/7ZUZUX<^)>G:TJ6.NQ+!.>!-_ Q_I7CLZ^0XB'#*
MN&^M, 'E,>^<4 ?0]]I;6Z^?;GSK<\@J<X%9+(K?,/E]Z\_\(^/KW19$L[N4
MRV1X&XYV?_6KT&:2"XQ-#_JI1N !X_"@""X7?'_M"N^TK_D$6?\ UP3^0K@]
MFP$%LKVS7>Z9_P @JT_ZXI_(4 6J0TM(: %HHHH X+Q$"=?NO0;/_016=?7<
M6G:?)<RGY8EW8]3V%=9J.EF74YKN0@1G&!W) %>;?%"YAL8X]+0YE?;(WL/2
M@#SN]O9=1OI;N8Y:0YYYP*B1"QV@9!XR*8N"""VVE"<<NN,]<T ( 58@CD=J
MFGN'NF&X(I  &!CBIFB3RE+W"$G[K*,_@:>;&VC4-+J$:L1G:BDT 4 I&>].
M! /'.1@@U+*+?.%G+>^W%1)M649P5!R1G&: &$X(XYS2'@]OI6I=7UC.H6/3
MQ'@8W;\DFJ4Z1XCVC&5R,?7O0!7.1CU[5N:99:?J-C<-/=&WNT^90PP'K(P5
MPS#.!P"*;*YD8,S?D.E #HIA'<+NQM5_TS7T#X=@AOX8V@;"%0S$=,>E?/BQ
M>=.L2'(9@H.*]TT".XT&UM=K;MJ!9 >XH V[J%K2Z.9$V XP*=VX((K%O96N
M[V5U8B.1]YRQ/-21SO;LJEMRGWQ0!JGZ]*#WS^M01W"N.&&?2I=W.?ZT *PW
M*1^E8=W#B8Y..?PK=[8Y]*S[V+(S0!Y=XRT<B=M00A1G##IS7(%>./TKTWQD
MF_1_N\+(#]:\Y"LQPHY_.@!MD";ZW5<[C(H'J>:]!\2V/VJ>W,LRP"./!,GZ
MUPEH[6FHVUS_ !PR!QGVK=\5:XVN3PRKM0*O SR3WH S;N>SMU:&RR_9IF')
M^E9[7$HA$2NR)Z*<9J$L2<G@T?>[X- #U15!DR" ,8/7-1?05(K%5P>1WSTI
M%#,6(ZXYQZ4 -SDFE6,L.G0<FE1"6&?RJ6X:X+*948Q@C&!@8H :\+Q-&K1N
MI<!E!!R0>F*G.G7?VEX%M9C(J[BNTYQZU<GU1K^2&26)8C P*E2=NP'(4COC
MMSWJ3_A($CU3[9!:%/EY4E#N;=N!;Y<<'TP<8Y!&2 >F?"GQ$+W2Y='NW!:
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M37DW*HPHQW ZTP$YX% 'L?A36DUM;>4?+,DBB1??->JU\V^!]7_LSQ+:J?\
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M7"YBBWLW10PW'\*]8U2#PK'I8MYDM54KB/9C?FO/1IUO!KJWB:K$L8?=CG>
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ME?0&N<ZY=#TVG_QT5XOXFL#IVN7" 8CD/F)GT- &*>FW:"??K4L(^;*!6?\
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M-O;K=S[/,*-CICC% $&GRS0ZA"UON$FX 8[U[;:32I;1)/&WF[1T[USW@;P
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MOT],U[QXQ^'MMX@1[RQ5;?4 ,LO\,GU]_>O&-3TJ\T>Z>VNX&BD4_P 7?Z4
M9[IY;G.<CUIH//&,U*YWMN8Y/?/>E278IPBY]2.: $$;>6Q*\#J:C/'0$ ^M
M/+L%().&//-,P2.G% "YSC&015S4/WKQ7$9R)4&[ _B'!J&0B<DQH%8#D8Z^
M]0 N %S@9S0!(,B)@#C/7)I4629DC1&=V.U5'))K1TG1=0UZ>.VLH6=NA8C@
M?6O8/"_@73O",(U'49!<WV/E./E0^BCU]Z '>!/"2^%]$>[OBJ7MRH,A/_+-
M>R_6NFA9Y!<S>64CD*F,,,%CCDXJK<7CRR++*NXCF.+^%?=O4U)!'+?S1S.7
MW(>2#@"@#/U]I%NH86!$0C!4=B>]99*@<FNYNK&"]@\J9 PQP>X^E8>G>'6B
MOG:ZD$L2?<4#&?K0!-HOFG2CYN[8)/E^G>KH(2Z99!M5WW(_56XZ5:FMEFB\
MLX"=@.*P;F6XLYC$8F,!XV$<'Z>AH X[XE^$F> ZE:1EBF2<=AZ5Y,I95))_
M,=*^F;2[CGC%M<XDCD!"EAU_V3[UYCXY^&LL#R:EHL9DA/S20#JON/44 >9R
M2%HT5N2 :>]R#!'%&OE$#YRI^^:B<,C%6!5@>01@BFD KD_GF@"U93+ 9MT:
MR;XRNUN<>]5E4NP4*6/8 9I8R%<,6(%2V]Q-97'FPMAL$ XS0 PJ\1&Y<9[,
M*?YT+IM:$*W9E-*]PUPK/.#)*.C&HNHQT]C0 WC) 89I88VDD"(I9V.  .M6
M-/TV[U.Z6VLK=YI6. $&?SKV7P=\/+;0=E[J6VXU$\I&.52@"#P!X %G&FI:
MFF9F&4C(Q@5V.OZBEI:BUB \QQC _A%2ZCJD>FQ\D/=./E0=!7*N\D\S2RON
MD8_,: '6,>+N GKO7^=>@5P=KC[7#_UT7^==Y0!S=_)&NM3Q39\F955CZ''!
MK'NK5[2<Q..1T/J/6KVNG_B;2CV7^0J*&>.YC%M=G@<)(>J'_"@"E!<O8W*3
MJ3\IZ>U=5>P66O:,T4P\RVN%P<=5/K7.75C-;,5="4/(8<@BI-*OVTV4Q2#=
M:R'D>GO0!X]XJ\,W?AK56MYPS0,<PRXX9?\ &L,8#?N\Y%?2>L:1I^MZ<;*]
M17MW&8I1U0^QKP_Q1X0O_#%V1*OF6C']W.O0^Q]#0!S<C;F)/WCUH7:OWE)'
MM2X&>.!^=-(RWZT /:X)3RU&U.X'?ZU/<G,%MTW!-I /3FH(TW,'( C![TC%
MF9CAN3TH 0O@# ' IHY]*FPB+L(PQ')]*TM'\,:OKK;=.M'E3.#*PPH_$T 9
M*HSNL:J6D8X4#J3[5[UX'\-)X9T M.0M[.!)<,Q_U8ZA:I>#?A[:^'Y1?ZE)
M'<7Z#(Q_JX?\376;XKBX028\K=E4/\1_O-_04 7+=XY;<SI$<'<5!'7WKBFG
M:YD:9SDN<G-=_LYR&X]*XSQ'9KI]PLUORLI)9/[I]J &Z9*\>I0"+DLP!'J*
MZ:X\M+MO+_U_EY4>M4/#VG)]E6[D_P!>^=O^P/\ &M6>SC-N,,1(G*2=P: /
M.?B5HOVG3WNHUW, )5('<###^M>1KM/&[:!SR:^EY;:'4;&:*;C?PX/(1O7Z
M&O ?%?AV?P[K$D$L9\ER6B;L10!G"54L6B0 F1OF;'.!V%));"WMXS*V&D&]
M .?EJM_",8P._O0.@+$8[4 3FW=]/DN@5VJX4KGGZU5P3]*E5\HXW=.0!5JV
MLDDMO.DN(TRQ 3/)H I+#*PPJLW? %(5V-AL@CJ#4C!XI,#<C#OWI)9GD?=(
MVY^['J:  ^5YNU263UQ5S2M.EU*]2"('D_,<=!5:TM);ZZ2"!"TC'  %>W^#
M_ \>EV:S7*@2L,G(YH HV6G1Z=IZ1HNU%'IU-.C3>2Y[UH:S+')>?9X/]6AQ
MQ591M2@!0 !@5W.G_P#(.MO^N2_RKD+:VW9EFRL0ZGU]A796C*UE RKM4QJ0
M/08H FI#2TAH 6BBB@#D-;/_ !-Y\?[/_H(JE%/)!*)(FP1[]?K6UJ>EWMSJ
M,LL48,;;<'<!G@53_L+4/^>*_P#?8_QH 84M[\$QA(+CO&3\K?3TJE-"\3&.
M6,H?0UH?V%J!_P"60_[[%68K'547RY8$GB_NR.#^1[4 <XUN1RIROUI@D9#A
M_P R*Z^/0K>89D@D@;^Z) PK,O\ PS=%_P#1@LB^I(!'YT <7J_A:PU;,BCR
M9_[Z=#]17&7_ (1U.QR47SX_5.M>NKX<U:,#$2-_P,?XU(/#^I,,-;J/^!K0
M!X))!-$=LD3H1V(IA))'7 KWB;PG=SC$EI&WU9:KIX$8-DV,(_X$* /$DADD
M^5(V8^PS6SIWA'6-295BM9 #W(KVFQ\)0VP+-9H6[ $5JB"^@39;6D4?N"*
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MT =U17"?V[?$<7$E5I?%4T!_>Z@$_P!Y@* /1**\ND\?1H2#JC$C^Z.*JO\
M$:,'G49!0!ZW17D\?Q#CEQMU20'WXK9M_$ZRVSS+K 9%Y)R* ._HKR>7XIP6
MS$+<2S8.?NBFM\9XEZ:<S?5L4 >M45Y5;?&6W>7;-82*#TV\TD_Q-MGGQ]NE
MC /*A.E 'JU%>37OQ+M8X#)!J,SOG C ZUC/\6K\-\BRX]VH ]RHKPE_BQJF
MTA-^2."6JF?BIXA/2?% 'T%17@,7Q4UU3^\D+#V-:=K\499<"XN+F$^HPPH
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M\:L:3<2W-U(L]Y.2H.Q3,RAC0!UU%9T<EXJX,./3Y]W\S36GOMX!MR5[X)%
M&G17':I=W-K?&*.[F&5#%?-)V'TZU435+DGYKRX'_ VH [RBN'&HW?474Y'_
M %T-*-1NB?\ CZG_ ._AH [>BN'-_==[N?\ [^G_ !I!>W1Z7MS_ -_6_P :
M .YHKAS=W6/^/VY_"5O\:BDGOSS'J%S_ -_6_P : .]HKSA[[5(S\UY=?]_F
M_P ::-5U '_C]N?^_K?XT >DT5YX-8NV'S75R,^DC?XT@U"\8Y74KGZ&5O\
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M1:G=1I=R*B3,  1P,FJW]MZIG'VV7\Q0!Z+17G1UW4^U[(??(_PI/[=U,_\
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MSMY+R8P18,A&5![FEE#PJ(&&&4Y;/KZ5'%)(LZRA]K Y!'6AB[LS.V6SR30
MUXV0*2#AAD'UJ2*VW1^=*=D>< GJ?I6Q!>PKX>CBDMTFDCE/+#H#65=W)N9
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M0?>F;_"@!MQ:Z;H=@U[JMP,*,XSP3Z =Z\<\4>,9=6N)8;$>1;,W.."PK/\
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M.5()!%/D=[B1I)7=G;DLW.30 P9!X-;3:=-J.C'5[<+N@8),F?;@@5CML+Y
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M&F?\@RW_ -P5PMM?2G2A'O)1U!&3FNYTHYTJV/\ TS% '&ZHH.J7+8_Y:/\
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M/!P?4&K*QW-RNYXNG_+0_+^?K0!"EI+(A=0"/3<,U;T[29[NX&^)D@7F21^
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M$5[3;3">VCE P'4'%>*^!(MFDR2;?ORGGZ5[)IG_ "#+;_KFO\J +=(:6D-
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ME "QRNC8A+(,8X-6-0O&O;A9Y#F4HJN=N,X&*K.RHSA6R.F[IF@9"YQU[^M
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M#MX7(Q@5+?78NM1N+J.'R%ED+JBG@9IS6;R1V\B(2LN1^(ZTTFW9";45=E8
MDXP3UP!6MH]W=^=%8VL:S23-M57C#;<\9''%,FECM[22!-IDQABHQ]:Z3X:V
M,D^HW5Y$FY[9%()'3)_^M6M:DJ32O=]?+R.?#5Y5DY.-ET\_,]@TS24TK2HX
MXX4\\@%B%'RGVI_V*1P6(8L>YXJG_;,YC" C<!RV.35BVU)I#NED"CISQ6)T
MD,\*S0-;2$J.J,>-I]/I65;S!&,$HVE3C'K70[HIWY"D]O0UD:M9^6RW )WO
M\N,<GWH )9DB0.[@#'<UYQXM\1Q7\ILX')A0_.P/!([?2L[Q5KVHOJ\UFT^V
M&$!553C/UK#@8W0:%+=C(W._/ _.@"O@+\Q.!U/O4<L[R+M+$KNSCU/K2 \'
MTI&V@C)^M  "-N*:S*,8X/0BI'0?>C<'Z\4^T=(69Y(RQ'*@#C-5"*E))NQ%
M23C%R2N^Q9C"6=JLLZ#SB24!Z_C5%S)*?/<,P=L G^5+/<2W!._UXXJ/N&.<
M>F:TJU$UR0TBOZNS&A1<6ZE363_#R7E^9;BM1<VTCPR(9D;/D_Q$>WK4=H(S
M*T5QD*XP&/53V-1I(@96'RLN<%3UJ9YS+"?,2-WSC/>L3I("9$4Q,P**2>M>
MA^!-$:S,>HR<3R$"+/&T>M<QX:T!]5O%DD4K;QG+$C[Q]*])"!"L42X X'L*
M .@UC5%N46")PRK@NRC[Q_PKHM-&-,MAG/[L?RKA43Y ,9_E7=:;QIMM_P!<
MQ_*@"U2&EI#0 M%%% ',ZW$LMS<21@>9#M#CU! P?Z5BD9%:^H7)M=?FEP&7
MY59?4;1FJ5W:B$B2([K>3E6]/8^] &;*A5A(HY[BL;7_  ];Z[:[TPEV@^20
M]_8UT#H6&,D&JH#1.>,KWH \;N[&>QN7MKF,QRJ>0148P(V]>]>KZYH-MKEM
ME@$G4?)(!R/8^U>9:EIEUI<[07*%3V;LU %$#)]/PJ56 R54<=S3%'X_6G2#
MYRHYP>H% #6<N26)+'G-+MSDYX]ZD\M$3+,"W]T#I1(RD)MP-JXZ=30!'QG#
M<5=MHS>69A# /&P9<_W3UJ&V1))"CXRPP/K5F>06D8@@'+???U]JVI4TUSS^
M%?CY'-7JR35.G\3_  7=_P!:B2RK"IMH,A<?/)_>-41TVXSSP<TY3M!&[J.Q
MKTCP!\/I+R>+5M61H[<'=# _!D/J1Z5-2HZCN_\ AC2C1C2C9;]7W9O_  Z\
M-/I6B27DJ%;J\7"@]D]:[;36:1W&S,2*%5R/O'OBJNJ7 )^R0D#H)".,#^Z*
MNIJ5G#;+EP@ P%Q69J<EJ,$MEJ,L<HX9BR-V8&H48RR"-!N=N H[FM_5]2L[
M^S\A%#E^A88*FL;3[6XTVY6Z"%]N<4 =5;V<D>FQVH8K*HW;^P;KBF $F2&6
M,>:PRZ?PR#U'O56#Q)OE42Q!$/4YS5Z\(D5)T.4'*NO5: /.O'?@E[F'[7:C
M+H/D;'4?W3[UY'+&\+O'(I60'#!NHKZACN%N!M)4N>,'[K_AV-<;XI^']CKS
M/+9@6]\HR4/>@#Q&,^7&QX);Y<5&Q(.,?E6UJWAG5=$D*7EI(JYX8+\IK)8;
MR..0.U $EG)]GG2XR04.5/O2RSR7-Q(]PREVR<X[TQQN(7/RKQ05&#AMWIQ0
M!$#\P_E3@,-[5/;V-U=N$M[>61F/ 52<UZ#X9^%=]>.ESK!^RVXY\H'YV']*
M .:\*>$K[Q1?K'$#':H?WLQ'"^P]37N]CI]EI.FI9VP$5G;C+L?XB/6I+:"P
MTC3%@MHUM;.,8R!C/^-<YJ>IR:D?*C#16B=%SRWN: ':A?2:S>".($0J<1H.
MI]\5:72%MH!-?.(XP.(UZM[5'I=Y::=9O/@-<GY57'055N;U[F0RS2[CT'H/
MI0!:ANVN-4M@%$<2S*$C7H!D5V-<%83I_:EH@Y/FI_Z$*[V@#%\2<V47_73^
MAKF#E3\I(*G*D=C73^)/^/*(_P#33^AKFF&X8H AU2W@UNRE$H42NNV5<=_[
MU>,:EIL^E7\EM,.A^4^H[&O99-Z2!T].:R=;T:WUVR*,%69?]6^.A]/I0!Y1
M&C*V[8&XJ2.!&&^:540<8')/M3KRRN-/NGM[B,I(I[]Z@VY( 7- #Y?*,A\A
M&11_>;FK%O RQ^;)<*B'HIY8_054;Y'P,Y]Z5%,D@!&YOY4 2,OG3;8HR.<!
M1U-6QI4T49DNL11A<C)Y_*JD=W);LWD.5)&-W>E9Y&M7>1F8LXY)S0!>ANHK
M/3?]#NS]HN"T<T>W&%^M-MX=+:W(DGE2X X!7Y<UF+@ CG\*>J//*J(,D\"F
MDV[(3:2NR:*T,LNV.6,^W-6[M[>WMC%$$WY ; _&HY76P@,4)W3-]]QV]A4.
MF6$NJ7T=M&IY.7)["NIR5"+@M9/?R\O\SA498F:JO2"V7?S?EV/1_AEHH-NV
MJ31DJ[[0<<8'_P!>O3,@DF1E4]02<5FZ1"NC^'[6"),($)88ZGL*SKT7<4<;
MSHZASQN[5R'>;LVH6J8#S$G'1!FGPS0SC,<RD?[1P:Y@$'J:4'#@ ]3VH Z6
M6S%S#)&V"P&4QV->,?$FVDM]9MPZE?W94^@.:]?L!-9K.KJ?/&"N[^Z?2N-^
M(VD-?6\CJNYT42Q^O3D4 >0I(Z']T6!/<4^5 K_ZW>V 3]:B7J,=1VJ:W\H+
M*TJE\+\H!QS0!$6.*4$CC-.2,X+E3Y?3=CH:DAA>YF6& ,[-P!TH @SD]*4M
MG&1GTH:-D8JP*D'!!ZBA4<GY2,_6@!.V2*6GM;RHNYXW"^N.*0>6(SRP?/ Q
MQ0 TD#^'-+NXP1^5/5@8R,?,3U-=)X8\//J-PMS<*1;H>!C[U &KX/T'RT&H
M7"_.W^K4]AZUUK#S)0O\"\GWI6Q&HC0;>, #L*?&F!@=^IH FM8_](B8DX#C
M^=>@UP=N!]HCR?XA_.N\H X[70?[8F]/E_\ 016MIEV;K3UXS/!P1ZBLK7 #
MJ\^>^WK_ +HJO97K6-TDH^[T<>HH XCXH>%_L-ZNM6D>+6Y/[T+_  O_ /7K
MS@A0>M?3UY96FJ:?+9S+YEI=*<'K@FOGSQ-X>N?#>KS6<HRH.8I".&7L: ,9
MD. P^Z:C.>AXQ[U("54L6RQXP*(8WGDV>Q)R>PH 6"XE@?,4C(WJ*?+-+<R%
MY7+OZGTJN"0>E./+ +G\: %.<^U31*(0DTD>]0P.W/49J1;98XO-N&*@_=4=
M6I+IBZ02XVH5*XH T/$FKVFKW,,UG8BU1$"D#'/Y5G0 S0R18RP&]<_J*@ !
M3L"#P/6GVZ2/,BQ YSFFDV[(4I**N]AUI +B<(=X]=HJ6_AB@>..!?F(R6SG
M.>E232I:QFWA;,A_UDG]*U?!.AG6->CDF&;:!@SY[GL*Z:G)3A[.UY=7V\CB
MI>TK5%6O:'1=_-_H>A^ M*>PT^&*0;9G4R-GWKK#"0W--A>-M7M5B'*Y1L#C
M':I]9O1IZ)%"!Y\F3D_PBN4[AHAF/&PX';O431,6X5N/6L,3S[]_G/OSG.XU
MT>D79U"%XY0#-'CYO44 8&K6)E:50IRR'/%>&W*O;W,L3@AT8J17THCQ->W<
M#\2-\O3^'%>)^/=%:PU4W2H DAPW&,-0!RD9V.'RRD="#4H6+[*[N?WF0$7^
M9J##'T)I]NL37,2RABA.&V]: (U ! ;/YTTC/)/Z5+<^2MRZVVXQ@X4O@&GO
M<;]/CMV1<HY(8#D@]J *^ <\\]A3BF%Y/)Z#VI\,JQM\UNCCWXJ64P3)YR1.
MISAE!R!0!5]#WIY XS@9&<TC#/S <#TJ1Y1,0\@S@ <=* (VCVX.\'=SQ6CH
M6CW&M:O#96R;B[<GT%4[>)[B98((R[N<*!U)KW?P/X33PUIR/,@;4K@9<_\
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MK6UHGA;6===8[*T<Q$\RNNU%_$U[=IW@'PWIA#)I\<CCHTYW_P ZVY;JRLD
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MR9#QYL8P#]13Y]!E5//M9EEQ\RD#!_ UC"16P<<$=:M6FI2V3_N-Q4]5/(H
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M<DR2C(A2(_[!.#5S2-"O]=NUBLX&8'JP&<5ZGIWPJT:SF5M0NI+QP?\ 5HN
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M^7S>.QD7'\ZD>+7G !W*!V5E%='10!R;Z7JTO^L1V^L@_P :C.BZB>/L^?\
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M+/;SQRP-ADZ^]=58ZY;W2^5/MCDQR">#6K]G@_YXQ_\ ?(I/LT&<^3'G_<%
M&1J'A30]6!-Q8Q,3_$G!_2N:O/A+HDRG[-)+"W;G(KT!551A5 ^@I: /*O\
MA3D(;/\ :!Q_NU9M?A'I\3@W%T\B^@%>F48H YS3O"FB:/'\EL@(_B>DO_$4
M5JA2T4.PX&!P*Z)HT?[R*WU&:9]F@_YX1_\ ? H \\EN+B\E\V=BWH*=$C[L
ME>IXQ7H/V:#_ )XQ_P#?(I1!".D2#_@(H XV*RD"^;<?N8^N3U/T%$UZ1&8;
M93'#W/=OK79M%&_WHU/U%)]GA_YXQ_\ ?(H X:W8_:(N/XQ7>U'Y$(.?*CS_
M +HJ2@#F=6T^[GU.62.!F0XP1]!5)-+U&)PZ6\BL.A':NSHH PX)+UL+>:>)
M1TW;1FI;O1+>[BW1*8)#[?S%:]% '(VT&MZ7.PAMVEBSR@/RGWK0GTQ=3@+M
M;/!(1RCXK>HH \PU3X;Q7C,RVK(Y_BCP,US5S\)]5#$VY9AV# 5[I10!X"/A
M;XA)P80!]:N0?"?4SCSF=1Z*!7N5% 'DEK\,X[=P\EK-.P_OXQ6\FA7\48BA
MLO+0= H %=[10!Q^G:=?VDK[K63YUVYXXK3N[>^CM#%$A8OUV=A6[10!QHTJ
M^V_\>TGTIO\ 9-^"&%M)D=#WKM** .7+ZZD)B6&1@>AXR*I?V1?M\SV\A8G)
M)KM:* .,_LJ^'2UD'Y5KV]O-);J;FWE$J>WWJW** .:N1JTERLT-JR;?X1W^
MM5IK.]N]PET]P6Z]"*ZZB@#S2[\ PWKEI--P3W7BLZ3X5QMRD4J^V:]<HH \
MEA^$Z9S)YGTS6]IOPUTNU<-) #CUYKO** *EI8V^GV_EV\(50.BCDUFZA<:I
M< Q6MK)$G=SC)^GI6[10!PKZ+?\ 7[+*S$Y)/>M*P\/.T6^ZW1D'[@ZFNHHH
M Y>X@O\ :8+6Q>*'USRWU-4QI5__ ,^KUVE% '$/I>H@9%I(?88KK-,22/3;
M=)4*.$ 93V-6Z* //]2L;U]3NV6TN&5IG((B)!&X\U6&G:AWLIR!_P!,6KTF
MB@#S@:??@8^QW/3_ )Y,*5+&_5MPLK@-_P!<F_PKT:B@#A$M;QL'['<#/4&,
MTOV"Z_Y];C/H(CS7=44 <0+.]_Y]IQ_P \4_[-J !&VZ(/4;&YKM** .)-G>
M'GR+G\$:D-C>X_U$Q]RAKMZ* .!ETRZQQ;7#'VB-)!8W2J%-I<C!ZF)O\*[^
MB@#B!9W@&/L\W_?MO\*C>SO "PL9LYZA#G_&N[HH X465W@9MY_QB8U>TB*X
MMM0226WN C @GRCQ^E=910!R&I6MU)J4SQ6\K(6X;RSS5)[.ZQDV4^?]F)J[
MRB@#A19W)7_CSN/QB(_I2FRNB/\ CUN/PB-=S10!Q-BNIVA/E172#/0JQ'Y8
MQ6JNI:FHQ+8-+](R*Z&B@# %SO/[S2)Q_NJ:F2ZA5>=/O2?0Q$XK9HH P)M0
MO0NRUL)(U]3&21^E9,T.H3ONE@N'/NA_PKM:* .&^QW9X-I,![1GFD6WOX',
MT5M<+(1U6-J[JB@#@#!J!!S93LQ[F)O\*B:UU#&/L5Q]?):O1** /-SI]^3_
M ,>=QG_KDW^%=YI2NFE6JNI5Q$H((P0<5<HH *0TM(: %HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img96160895_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $X T,# 2(  A$! Q$!_\0
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M76O:>;B\NHKN-KR\MM1N!'$QV1ME73 '. %R* /6BRA@I8 GH">M#,%4LQ
MZDFO*UGNKS6=.U>\?51:)J-XB%8W4JA4>6-N,@'IFJEU>:YJW]M6974%AN+6
M=Q;,KDQR(_"AB,<CL.,4 >N"XA-Q]G$J>=LW[,\[>F<>E25Y?/-J<(FN-%>_
MESHRE))HF+JPE 8#</O!<D"G6]QJ]Y=P6EK>:N-*DU%(X[F1665HS"Q<$D9"
MA@O)[F@#TZBL+PC<7MQX?0Z@96GCEDBW2J59E5R%)S[8YK=H **** "BBB@
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M:]TK1[<O/JD%I<ZA<F]EA1FFX+^6>!G:2!DT >KU!)>VL,CQRW$2.D?FLK,
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MC()HHY XB:+*G!&XC=QFK\LVI6JSQRS:C!IS:O<"::WB;S2OEJ8^@R5+<9H
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MUH M455\Y_6CSG]: +5%5?.?UH\Y_6@"U157SG]:/.?UH M455\Y_6CSG]:
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M@+?/E1N!R,?A3&AC30A.#AVFV,Q<XQNK-8^\>91Z-[]OEYHT>"M+E<NW3O\
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M #^C_OT*MT4 5/(O/^?T?]^A1Y%Y_P _H_[]"K=% %3R+S_G]'_?H4>1>?\
M/Z/^_0JW10!4\B\_Y_1_WZ%'D7G_ #^C_OT*MT4 5/(O/^?T?]^A1Y%Y_P _
MH_[]"K=% %3R+S_G]'_?H4>1>?\ /Z/^_0JW10!4\B\_Y_1_WZ%20Q7"/F6X
M\Q<=-@%3T4 %68/]7^-5JLP?ZO\ &@"2BBB@ ILG^K;Z4ZFR?ZMOI0!4J.=_
M+MI9"NX*A;![X%25!>_\>%Q_UR;^5-;@<#_PF\'_ $!+?_OK_P"M1_PF\'_0
M$M_^^O\ ZU<?W-%>C[*)C[.'9?<=A_PF\'_0$M_^^O\ ZU'_  F\'_0$M_\
MOK_ZU<?1]*/91#V<.R^X[#_A-X/^@);_ /?7_P!:C_A-X/\ H"6__?7_ -:J
MVI^%%L/#L-^LS-< (UQ'_<5NAJOKV@6NDV%I<0WHG>889..#C.>#QVJ$J;V_
M4?LH?RK[C1_X3>#_ * EO_WU_P#6H_X3>#_H"6__ 'U_]:HK3PG;3Z7 TEW(
MNH7,#W$487Y-J]C4<7AS3KG1YY[;47DNK>#SI<+^[!_N9]:5J?\ 5P]E#^5?
M<6?^$W@_Z EO_P!]?_6H_P"$W@_Z EO_ -]?_6JAIOADM-.VJ2&"W@MA<N8B
M&)4]/ZU<@\'0R>(/LC7RK:%%D1B0)) PX 'K0U37],/90_E7W#_^$W@_Z EO
M_P!]?_6H_P"$W@_Z EO_ -]?_6KE;J(07DT*DE8W*@GV-0U?LHB]G#LON.P_
MX3>#_H"6_P#WU_\ 6H_X3>#_ * EO_WU_P#6KCZ*?LHA[.'9?<>S:+>#4-'M
M[I85A$@)\M>@YJ_6+X2_Y%>R_P!T_P S6U7GS5I,U6B+,'^K_&I*C@_U?XU)
M4C"BBB@ HHHH *KS_?'TJQ5>?[X^E $5<_XXD,7@S4R.\6W\R!_6N@K \;1&
M7P9JBCM"6_(Y_I6E+XX^IE7_ (4O1G@-%%%?0'R@4444 %%%% '=_#*X2WO-
M1+$9,:[1GJ<FNZED>5RSGGT]*\,1WC</&[(PZ%3@UNV'C'5K'"M*+B,?PRC/
MZUC*E>7,CHA7M%09ZG17*V'CO3[C"W<;VS^OWEKI+:[MKV/?;3QS+_L-G]*S
M::W-5)/8FHHHI#"MO1VS:,N/NO\ SK$K;T<#[&S#NY!_"N?%? =F"_B_(LVW
M!G7L)#^N#_6BZNH[2-'DSAW6,8]2<"BUY$K?WI&_3C^E5=:L&U*R2W49'G(S
M_-CY0>>:X%:^IZPDFMVZAC'%-,OFB%6C48=_1?7&*DBU6"1+DNDL+6P#2I*N
M" <X/Z&LU]&N?*BL,!K*&Y62)P^&$?.5_#/6F/HEVOVBQB(^R7$J.UPSYD"#
MJISU]OK5VB(TO[:M3IL-ZJR,LS!$C"_.6_NX]:LV=XEY&[+')&R-L=)%P5-8
MSZ3>PBXA"17EK)*LVV4[23_$ 1]T]#FK^CVMS:PS"?*HSYBB:3>8UP.-W?FI
M:C;09I4445 !1110 4444 %%%% 'B_Q1E+^+A&3Q';IC\<UQ5=I\4(ROC N>
MCVZ8_#-<77O8?^%'T/E\7_'EZA1116QSA1110 5[Q8W@CT2P1.7^RQ?0?(*\
M'KT;P5KGVRT_LZ=OW\ _=D_Q)Z?A6-:',D^QT8>IR-I=3K22Q)8DD]2:2BBL
MC8**** "I+<9NX/^NBG]:CJ2W.+J#_KHH_6IE\++A\2.@NN$C/I*A_6I^]07
M7*1CUE0?K4]>3T/?.1A66&^:ZO!YFG)?2@( ?W;%N)&]1GCVZU$;>86HFE2$
M6?VYS)(D1\Y!OX.<]*Z"/7+62+4'*LHL6*R@]\9Y'Y&K-KJ%O<V:7&Y8U9 [
M*YY4'IFM>9KH(YUI[G^TCKOD'[-YWE;PW/D_=^[]?FI+ PQ:C:I$$F)N&)1X
MRD\)).2Q'##Z]JWX]8L)(7D-Q&B+(T1WG&2.M(NJVDEVT$15Y%9%8@C^+H??
M_P"O2YGV OT56&H61$A%W"1%]\[Q\OUJ6"XAN8_,@E21,XW(<\UG9C)*FM^K
M5#4UOU:D!/1110 V3_5M]*J5;D_U;?2JE !117(:]<31ZO(J3.J[5X#8KEQ>
M*6&I\[5]3IPN'>(GR)V.OHKS[[7<_P#/Q+_WT:/M=S_S\2_]]&O-_MN/\GXG
M?_9$OY_P/0:*\^^UW/\ S\2_]]&C[7<_\_$O_?1H_MN/\GXA_9$OY_P/0:*\
M^%U=$X$\I/H&-'VNY_Y^)?\ OHT?VW'^3\0_LB7\_P"!Z#17GWVJYSCSY<^F
MXT"ZNCTGF/T8T?VW'^1_>']D2_G_  /0:*\^^UW/_/Q+_P!]&C[7<_\ /Q+_
M -]&C^VX_P GXA_9$OY_P/0:*\^^UW/_ #\2_P#?1H^UW/\ S\2_]]&C^VX_
MR?B']D2_G_ ]!HKS[[7<_P#/Q+_WT:V_#,\TMY.LDKN/+SACGN*VP^:QKU53
M4;7,:^6RHTW4<KV.FJS!_J_QJM5F#_5_C7K'FDE%%% !39/]6WTIU-D_U;?2
M@"I4%[_QX7'_ %R;^53U'.$:WE60D(4(8CTQS0@/#NYHKM?[%\)?\_EY^?\
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MQZQJD16W0[H(6'^L/]XCT_G6=6K&G'FD:T:,JT^6)TOP[\-'1M(-[<IMO+L
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M']L:A_S]R_G1_;-'^5_@'^IU'O\ BR3_ (0^^_Y[0_K1_P (???\]H?UJ/\
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M!6W'0'J__P!:K-%%<IV!1110 4444 %%%% !1110 5-;]6J&IK?JU $]%%%
M#9/]6WTJI5N3_5M]*J4 %>5>-?\ D:+C_<3^5>JU@:GX2T_5;Y[RX:82, #M
M; XK6C-0E=B9Y317I?\ P@.D_P!^X_[[H_X0'2?[]Q_WW73]8@*QYI17I?\
MP@.D_P!^X_[[H_X0'2?[]Q_WW1]8@%CFM)U?3VT>+3]0EEMY+:?SH)XTW\^A
M%+XAUVRU'5;"6V,ACMP!)(R!2YR"3@?2ND_X0'2?[]Q_WW1_P@.D_P!^X_[[
MJ/:4[W'9F/;:OH#^*[_5KMW8,P-L#%G!V@;B/;%,.M:5<#4M/O+RYEMKQEE%
MUY>&5QVV^G K;_X0'2?[]Q_WW1_P@.D_W[C_ +[I>TI^869Q&M/I!>"+2(G"
M1IB2:3@RMZX[5EUZ7_P@.D_W[C_ONC_A =)_OW'_ 'W6BKP2L*QYI17I?_"
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M@"2BF2310H'EEC13P"S  T^@ HHHH **** "BBB@ HHHH KWM[#86YFF)V9
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M^>TG_?NC_A+M(_Y[2?\ ?NCV%3LR/J6 ?_,0OO1QO]G7O_/I/_WP:/[.O?\
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M!=\;>*;WP_':0Z7;)=7LY9S&P)Q$@RS<5T6FWT.IZ7:W\# Q7$2R*?J*Y-O
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M/_D8?X4?:+S_ )\?_(P_PJWD>H_.C(]1^= %3[1>?\^/_D8?X4?:+S_GQ_\
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M</(V,L8CS^E1?8KO_GUG_P"_3?X5UO\ PE?_ $Y_^/\ _P!:C_A*_P#IS_\
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M4]>:SV@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV?\ SUF_,?X5N44?V?AOY$'UW$?SLP_^$7L_^>LWYC_"C_A%[/\ YZS?F/\
M"MRBC^S\-_(@^NXC^=F'_P (O9_\]9OS'^%'_"+V?_/6;\Q_A6Y11_9^&_D0
M?7<1_.R&TMDM+9($)*IT+=:FHHKKC%12BMD<TFY.[+,'^K_&I*C@_P!7^-24
MQ!1110 4444 %5Y_OCZ58JO/]\?2@"*BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH AGB9MLD>!*G3/0CN#3)(XM0MBIR#^J-5FH)(6#^="0).X/1
MQZ'_ !IIV$TFK,Y^>"2VE\N48/8CH?I4==$P@OHFBD3YAU1OO*?7_P"O65<Z
M9/ 2T>98_;[P_P :[Z6(4M):,\JOA)0UAJBE12 @Y]1U'<4M=)QA1110 444
MJJTC[$4N_P#=49-#=AI-Z(2K=C8M=L'88A'4_P![V%6;72"2'NCQ_P \P?YF
MM!YL'R;=07'!_NI]?\*Y*N(Z0._#X1WYJGW!*^P+!  )".!V0>IJ2*-8HPBY
MP.YZD^M)#"(@>2SMRS'J34E<1Z1@>-=,N]8\(:AI]C&)+F95"*6"YPP/4_2J
M+>"=/L=&OSI]JS:E<6;0!Y92YR5Z D\<UM:_J,FE:4UU%LW>8B9=2P&Y@,X'
M)Z]JRD\7"UM9)=0@8J)66.6-#&)5"J2P5R&ZMC'?%(##MM$\1ZC9Z%IM_I<5
ME::6RRO(+@.TQ0<  =,FJ<_@/Q#?Z=?:A-?"'4Y[HWBV852-ZD[/G[<?AS79
M-XML4:3?!<K&I94D*#$C* 2%Y]"*?-XGM[5W6YL[R'RH?.EWJO[L9('?G)&!
MB@#4LWN)+&![N(17+1J98P<A6QR,_6IZYZ7QEIL5JDY24J79&&5RI&,XY^;[
MPZ?TID/BM6ED$ULZX=HXHT&6D(8 8.>^: .DHK(U#4[I+6R:TB$4UU<+#MN5
M^YG.<@'VJ&U\0[7NK:_C"W5KO+F$?(RJH;(STX/2@#=HKG[CQ0JVCW%I87$R
M"18Q(0 C$LJD9SU&[\<4V7Q;;F[:TMXF\]9 IWE2"/,"-T)P<GH: .BHK!UK
MQ)'I.LV5D3#LD(,Y=P&56.U2H[G=U]JAG\7VT%[AX)5LA%*PF8#]XRNJ +SZ
MMWQVH Z2BN?'B^Q;84@N77:6D95!$8#!>3GGEATJ0^*;(8Q#<DR'_1_D'^D?
M,%^7GU(ZXX- &Y16'/XIL[6ZAMYX+B*27 *OM!4DD#(SGJ.O3D4MOXEBNA'Y
M5C>9=!(?D!V(3@,>>A_E0!MT5SUOXNLW1#-%,J84/.$ C#-&) .N>AITGBRU
MC #6=X)B-QA*+N";2^X\XQ@&@#?HKGI/&%C%:F=[>X3! V/M5L%0P/)YR#T'
M-;T$R7%O'/&28Y$#J3Z$9% #Z*** "IK?JU0U-;]6H GHHHH ;)_JV^E5*MR
M?ZMOI57!]#0 E%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?0T
M )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "59@_U?XU7
MP?0U8A_U?XT 24444 %-D_U;?2G4V3_5M]* *E%+@^AHP?0T )12X/H:,'T-
M "44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?
M0T )12X/H:,'T- "44N#Z&C!]#0!8@_U?XU)4</^K_&I* "BBB@ HHHH *KS
M_?'TJQ5><'>..U $5%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AH
MP?0T )12X/H:,'T- "44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "44N#Z
M&C!]#0!%+"DN"<AU^ZRG!%1[YX?]8OFI_?0<_B/\/RJS@^AHP?0T[@4WCLKW
M[P1F'X,/ZBJ[Z+'DF.61?13R!_6M"2".7[\8;T)'(J/[(%_U<DR#V;/\ZN-2
M4=F9SI0G\2,W^Q)O^?J/_OV?\:5=$DW?-<H1[1D?UK1\B<=+A_\ @2@TOV>4
M_>N)?^ C%7[>IW,OJE'L5(]&MTYD>209S\QP!^6*L+);6X\J%1D?P1+FG?8T
M)R_F2'_:)Y_"IDC$:[40*/0#%9RFY;NYM"G"'PJQ!MGG^^?)C_NJ?F/U/;\/
MSJ9(TB0(BA5'84_!]#1@^AJ"Q**7!]#1@^AH KW5I#>Q+%.I9%=7 !(Y4Y'Z
MU6U/1;+5V5KM)"51H_DD9,JV,J<'D' K1P?0T8/H: ,MO#^FM"D30,40N0#(
MW!8 $]?0"A- TY8YT:.23[1'Y<K22L[.,D\DG.<D\UJ8/H:,'T- &))X5TJ9
M LB3MPP9OM#[G#8R&.>?NKU]*D_X1O3,R'RY07.<^<V5.0<KS\IR!TK7P?0T
M8/H: ,V;1+.:QAM&\]8X9/,1DG97#<G.X'.>34$GAC2Y;=82DP +EG6=P[[A
MAMS9RV1CKZ5LX/H:,'T- &0_AK37#@QS!6'W5F8!3D'*C/!RHY'I3(_"^E13
MB98I2ZDE=TS$+E@YP,\?, :VL'T-&#Z&@"A/I%C<F[,T D-VH24L220!@ >G
MX54'A;2@6S%*P*LH5IG(0,P8[1G@[E!R.];6#Z&C!]#0!E)X>TY(W3RI&WIL
M<M*Q+#<&Y.>N0.:;_P (WIFYSY<N6^[^^;]U\P;Y.?D^8 \8Z5KX/H:,'T-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img96160895_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9!)L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ.JZSI
MFA6BW6JW]O96[.(Q)/($4L02!D]^#^57@01D=#0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8?\ 8FI_]#1K'_@0W^-']B:G_P!#1K'_ ($-_C6Y11_:.*_G_(/J&'_E,/\
ML34_^AHUC_P(;_&C^Q-3_P"AHUC_ ,"&_P :W**/[1Q7\_Y!]0P_\IA_V)J?
M_0T:Q_X$-_C1_8FI_P#0T:Q_X$-_C6Y11_:.*_G_ "#ZAA_Y3#_L34_^AHUC
M_P "&_QH_L34_P#H:-8_\"&_QK<HH_M'%?S_ )!]0P_\IA_V)J?_ $-&L?\
M@0W^-']B:G_T-&L?^!#?XUN44?VCBOY_R#ZAA_Y3#_L34_\ H:-8_P# AO\
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M!!P0>U75Q6.I6]HVK^A%/#X.K\"3,+^Q-3_Z&C6/_ AO\:/[$U/_ *&C6/\
MP(;_ !K<HK'^T<5_/^1K]0P_\IA_V)J?_0T:Q_X$-_C1_8FI_P#0T:Q_X$-_
MC6Y4UK;O=W4=O&5#R-M!;I3688N3LI_D)X+#)7<3G?[$U/\ Z&C6/_ AO\:/
M[$U/_H:-8_\  AO\:ZPZ3(E]-:2W5K$\0!+22;5.1GCCWK/JIX[&0^*7Y=!1
MPF%E\,?S,/\ L34_^AHUC_P(;_&C^Q-3_P"AHUC_ ,"&_P :W**C^T<5_/\
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MBBBO2. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_L&W'_HMJ^5Z]S)LIAF'/SR:Y;;>=_\ (Y,5B'1M97N?2'_"U_!7_08;_P
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M0/\ H%ZQ_P!^X?\ XY4RG&'Q.QO1PM>O?V,'*V]DW^1UO_"&^%_^A;T?_P
M8O\ XFC_ (0WPO\ ]"WH_P#X Q?_ !-<E_PNG0/^@7K'_?N'_P".4?\ "Z=
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M;4*E:$535]3T\LK0I3DYNQIT5SW_  E]O_T#-3_[\#_XJC_A+[?_ *!FI_\
M?@?_ !5>']0Q/\C/8^NX?^='0T5SW_"7V_\ T#-3_P"_ _\ BJ/^$OM_^@9J
M?_?@?_%4?4,3_(P^NX?^='0T5SW_  E]O_T#-3_[\#_XJC_A+[?_ *!FI_\
M?@?_ !5'U#$_R,/KN'_G1T-%<]_PE]O_ - S4_\ OP/_ (JC_A+[?_H&:G_W
MX'_Q5'U#$_R,/KN'_G1T-%<]_P )?;_] S4_^_ _^*H_X2^W_P"@9J?_ 'X'
M_P 51]0Q/\C#Z[A_YT=#17/?\)?;_P#0,U/_ +\#_P"*H_X2^W_Z!FI_]^!_
M\51]0Q/\C#Z[A_YT=#17/?\ "7V__0,U/_OP/_BJ/^$OM_\ H&:G_P!^!_\
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M4_\ OP/_ (JHC2QJ5N32UMNFY<IX1N_/K>^_R._N]=@EU^VU"*.3RXDVLK
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M<'^=:^A^)/%L6IV^F^)_#7EB=MB7]@_F0@XS\XR2H]_TH [:BBN+^('Q"M_
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MK2^M+^W^T6=U!<09QYD,@=?S'%>97-A<VMKX,CN;J"V^U27%S<37,/FQ?:9
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MNFW$5N]O');1LL+DDH-HP,GD_7O0!I4444 %9<O^N?\ WC6I67+_ *Y_]XT
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MQ;MVKZ3B_P!4G^Z*\H_:'_Y)W:?]A.+_ - DKU>+_5)_NB@!U%%% 'RI?_\
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M-_:LUK$\=J8-I^5@0%+9Q@+[YZ<=5\3?^107_K_M/_1Z5V-% !1110 4444
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M^#'^NI^5<2?\C.K\O_24%%%%=)X84444 %%%% !1110 4444 %%%% !1110
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M5'_SS3_OD4>5'_SS3_OD5S6A>++F^\03^']8TAM+U6.V%VD:W GCEAW;=RN
M.0< @@=>]:7B7Q%9^%M!N-6OA(\46%6.)=SR.QPJJ.Y)(% &GY4?_/-/^^11
MY4?_ #S3_OD5R5IXSU&#4]/M/$GAU]'34I/)M)A=K.IEP2(Y, ;&(!QU!(QF
MHY?&NJWNI:G;>&_#+:I#IDYMKBXEO4MP9@ 61 0=Q&1UP/>@#L?*C_YYI_WR
M*/*C_P">:?\ ?(K+\,^(;7Q1H<.J6B2Q*Y9)(9AAXI%)5D8>H(K7H 9Y4?\
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M\&/]=3\JXD_Y&=7Y?^DH****Z3PPHHHH **** "BBB@ HHHH **** "BBB@
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ME2ZCV#"NGT?1[#0=*@TS3+9+>S@7;'&O;U)/4D]230!>HHHH **** "BBB@
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M/RKB3_D9U?E_Z2@HHHKI/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<^W?],__ !ZC[=_TS_\ 'JIT4 7/MW_3/_QZC[=_TS_\>JG10!<^W?\ 3/\
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M<^W?],__ !ZC[=_TS_\ 'JIT4 7HKKS) FS&>^:LUG6O_'RGX_RK1H ****
M"BBB@ HHHH **** ,CQ44'A+6#)<-;I]CEW3*"2@V'GCTKP+PUK'PIAT"UAU
MO1+I]21=L\@WL)&_O##C@^F!7T1J][#INC7M].F^&W@>5T_O!021^E>2:=IO
MQ&\3:7'XCL]1TFRBG4RVNG_9D*E.P)*'K[D_A0!WWP_N?#MUX867PO;/;Z;Y
MS@1N"#OXR>23Z5K>(KJRLO#FH7>I6ZW-G! \DL+*&#@#.,'BLOP!X@_X27PE
M;Z@]K':SAVBGBC&%$BG!(]CUJCXXTWQKJ<RP>';K38].EMS'<Q7B!MY)(/\
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M)@DA^S I,_3<<C/)Y/!KT?X::;J>D^ M.L]75DND#$1,?FC0L2JGW /3MTH
MZVBBB@ HHHH **** "BBL#QIJ^JZ%X5O-2T731J%Y  P@)/W<_,<#DX&3@4
M;]<;XQ^'.F^+=1T_5!/+I^JV4J,MY;<.R YVG^A[?I6AX,\9Z7XWT--2TU\,
M,+/;L?G@?^Z?Z'O714  & !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FRQ2&5R
M$8C<>U:5% &7Y4G_ #S?_ODT>5)_SS?_ +Y-:E% &7Y4G_/-_P#ODT>5)_SS
M?_ODUJ44 9?E2?\ /-_^^31Y4G_/-_\ ODUJ44 9?E2?\\W_ .^31Y4G_/-_
M^^36I10!E^5)_P \W_[Y-'E2?\\W_P"^36I10!E^5)_SS?\ [Y-'E2?\\W_[
MY-:E% &7Y4G_ #S?_ODT>5)_SS?_ +Y-:E% &7Y4G_/-_P#ODT>5)_SS?_OD
MUJ44 9?E2?\ /-_^^31Y4G_/-_\ ODUJ44 9?E2?\\W_ .^31Y4G_/-_^^36
MI10!E^5)_P \W_[Y-'E2?\\W_P"^36I10!E^5)_SS?\ [Y-'E2?\\W_[Y-:E
M% &7Y4G_ #S?_ODT>5)_SS?_ +Y-:E% &7Y4G_/-_P#ODT>5)_SS?_ODUJ44
M 9?E2?\ /-_^^31Y4G_/-_\ ODUJ44 9?E2?\\W_ .^31Y4G_/-_^^36I10!
ME^5)_P \W_[Y-'E2?\\W_P"^36I10!E^5)_SS?\ [Y-'E2?\\W_[Y-:E% &7
MY4G_ #S?_ODT>5)_SS?_ +Y-:E% &7Y4G_/-_P#ODT>5)_SS?_ODUJ44 9?E
M2?\ /-_^^31Y4G_/-_\ ODUJ44 9?E2?\\W_ .^31Y4G_/-_^^36I10!E^5)
M_P \W_[Y-'E2?\\W_P"^36I10!E^5)_SS?\ [Y-'E2?\\W_[Y-:E% &7Y4G_
M #S?_ODT>5)_SS?_ +Y-:E% &7Y4G_/-_P#ODT>5)_SS?_ODUJ44 9?E2?\
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M?KU;[;:?\_4/_?P5Z>'G*=-2EN?"9SAJ6%QLZ-'X5;\DR>BH/MMI_P _4/\
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MH T:*SOM4W]_]!1]JF_O_H* -&BL[[5-_?\ T%'VJ;^_^@H T:*SOM4W]_\
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M^Z267+K%##$,O-(QPJ*/4FN<N?'.MZ-"M[XA\(3:?I>Y5DNHKZ.X,()P"Z*
M0.1G&:U?&<&B7^F6NF:W=RVOVV[CBLYHLAUN.J%6 (4\'D\5@:H_C;P9ILVJ
MOK%GKVFVJ^9/#<VX@G$8Z[74X) ]1S0!V>L:YIV@Z8^H:C=)#;J."3DN>P4=
M6)[ 50T3Q5;:MX+B\33Q_8[5H9)W5FW;$4MDYP,\+FKHL]-UH:;JLUHDSQ)Y
MUJTJY,6\ Y /0XQSU%>;V"NW[-3A 2?[.E/'H'8G],T =%#X^O4AL=2U+PY-
M8Z%?2(D5ZUTKN@?B-I(P/D5LCG)QGFNXK@?B+)#)\'+PQ89);:W$(49W$NFW
M'Z5W<0<1()"#(%&XCN>] #Z*** "BBB@ HHHH KWU[;:;83WMY*L5M!&9))&
MZ*H&2:Y6'Q;X@U"U6_TSP=/-I[C?&T]ZD,TJ=F6,@]>HRPS47Q;CDD^&^I;$
M=T1H7F5.IC$JEOTY_"NM&H6$=I;3_:K>.WN-H@<N%63(RH7UR.0!0!EZ;XPT
MG4O#=QK@E>"VM0_VN.==LENR?>1U[,/3OVK''CN_MX[*_P!3\-3V6C7DJ11W
M37*M(F\X1I(@/E!R.Y(STKAO$GFW.E?%:YTXYLVGLT4IR"Z;?/\ _KUT/B.#
M4_"GA:#Q7;^(=3O+R!H'GMY)0UO<J[JK(L0&$^]QMYP._6@#L?%?BS3?".CR
MW]_*I<*?)MPWSS,!T4?S/0=33-2\3?V?X%?Q-]C\S;9K=?9_,QG< =N['OUQ
M5;QQI5A)X8U_5'M(FODT>YA2=ERR)Y;G ].IZ5D^)/\ DA<W_8'B_P#0%H [
MBSN/M=C;W.W9YT:R;<YQD9QFLKPCXB_X2G0(]4^R_9=\LD?E>9OQL<KG.!UQ
MGI7/Z7X;\7/I-FT?CV>-&@0J@TNW.T;1@9(YI?A &7X>6RLVYA<W +8QD^:W
M- '=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <#J
MWC;Q7H>EW&I:CX+MH+2W7=([:TG'L!Y?))X [DUJ-X@\42Z/IM[9^$5FFNHC
M)/;R:BL1MS_",E/F)'/08Z50UX'Q'\1-*\/,-VGZ;%_:EXO:1\[84/T.6QWQ
M73>(]83P_P"'-0U:10PM(&D"G^)@/E'XG _&@#G_  ]XRU?6/%=UH=[X<CLC
M:0B2XGCU!9Q$6^ZAP@^8]<9Z5O>(M>MO#>BS:G<QRRJA5$BB&7D=B%51]216
M=X#T:32/"UNUV2VI7Q-Y?2-]YYI/F.?ID+^%=#<W,-G;2W-S*D4$2EY)';"J
MHZDF@#E4\8ZG9:GI]MXA\.MID&H3"WM[B.\6=1*V=J. !M)QQC(S3KCQ?J<^
MIZA:Z%X<DU.'3I/*N9VNE@S( "4C!!W$ CK@<]:S;7[5\0M;L-5:*2U\,Z;.
M+FS$B[9+Z9<[9,?PQCJ.Y_ET&N6EQXDTV:UT7Q&=/>-WAFEM525E<#E&[J1D
M$@8/3D4 7= URT\2:%::O8EC;7*;E#C#*02"#[@@C\*TJX_X97:S>#(;06D-
ML=.GELF6 DQLR-@NI/.#G//?-=A0 4444 %%%% !1110 4444 %%%% !1110
M 4444 36O_'RGX_RK1K.M?\ CY3\?Y5HT %%%% !1110 4444 %%%% &7XE2
MZD\+ZJECN^U-:2B';UW;3C'O7SU9>'_!UII?A_5=:BO$TZ_LYX;F8;\QW:-U
M 'K\P QCCZU]&ZKJ$>DZ1>:C*K/':PO,RKU(4$X'Y5Y/!KGQ'\5Z3'=6_A'0
MY-+N?WD45T%8,,\-AF_7 H Z;X-NK_#FT*6P@42RJK!<>: V Y]ST/TKK/$.
MHOI'AS4=12W^T/:V[RB+^^5!./I53PB=;.@1KK]C:65XCE5@M,>6J#[N,$@5
M/XGGN[;PKJL]@%-W':R-#OQC=M..O% 'FFE3_%C6=-MM5LWT&*"ZC$L0*#(4
M\CL?YUZ3X877DT2,>)'MWU+<V\V_W-N?E_2O&/"GA""\\.6EU%\3I=/,R;Y+
M6*81B)SU7'F#D'V%>P^#]/\ [+\/16O]N/K6UW/VQWWELGIG)Z=.M &]1110
M 4444 %%%% !1110!Y-^T/\ \D[M/^PG%_Z!)7J\7^J3_=%>4?M#_P#).[3_
M +"<7_H$E>KQ?ZI/]T4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\(_:%_P"/[0/^N4W\TKW>O"/VA?\ C^T#_KE-_-*][AK_
M )&=/Y_^DLRK? SQ6BBBOU,X@HHHH *Z+P#_ ,E T#_K_B_]"%<[71> ?^2@
M:!_U_P 7_H0KFQG^[U/\+_(J.Z/K^BBBOQ<] *^-O%G_ ".6N?\ 80N/_1C5
M]DU\;>+/^1RUS_L(7'_HQJ^RX-_C5?1?F<^(V1CT445]^<H4444 %>Q_L^?\
MAS6?^O9/_0J\<KV/]GS_ )#FL_\ 7LG_ *%7C<0?\BVKZ+\T:4OC1[]1117Y
M.=QR_P 1_P#DG6O?]>C5\C5]<_$?_DG6O?\ 7HU?(U?H?!_^ZU/\7Z(Y<1\2
M"BBBOKCG"BBB@ KZT^&/_)-M"_Z]_P#V8U\EU]:?#'_DFVA?]>__ +,:^2XP
M_P!TA_B_1F^'^)G6T445^=G6%%%% !1110 4444 %9<O^N?_ 'C6I55[/<[-
MYF,G/2@"E15S[#_TT_\ ':/L/_33_P =H P];T33_$.ER:=J=N)K=R#C)!5A
MT8$<@CUKFU^&NGR%(]0UK7M3LD8,+*]OB\)P<C<H + <<$FO0/L/_33_ ,=H
M^P_]-/\ QV@"F    , =!63HOAVQT/PW!H,/F3V44;18N"&9U8DD-@ 'J>U=
M%]A_Z:?^.T?8?^FG_CM '"6?PZTJTGM-U]JES964@EM=/N+G?;PL/ND+C)V]
MMQ.*Z^KGV'_II_X[1]A_Z:?^.T 4Z*N?8?\ II_X[1]A_P"FG_CM %.BKGV'
M_II_X[1]A_Z:?^.T 4Z*N?8?^FG_ ([1]A_Z:?\ CM %"6*.>%XI45XW4JZ,
M,A@>""/2N-N?ACI-Q9OIZ:CJ\&E.<G3H[D& <YP RDJ,]@17H/V'_II_X[1]
MA_Z:?^.T <AH/@^TT'3+S1XYC<Z-/GR[2>,$QAL[U+]7!SWY'J:J6GP[TNVF
MM/,O]5N[*R<26NGW5SOMXF'W2!C)V]MQ.*[K[#_TT_\ ':/L/_33_P =H R-
M4T^+5M(O=-N&=8;N!X)&C(#!74J2,@C.#Z52OO#EG?\ A1O#DLDXLVMEMBZL
M/,V@  YQC/'I72?8?^FG_CM'V'_II_X[0!G6T"6MK#;H24B144MU( QS6?X=
M\/VGAG1TTRRDFDA61Y TS MEV+'H .I]*Z'[#_TT_P#':/L/_33_ ,=H IT5
M<^P_]-/_ !VC[#_TT_\ ': *=%7/L/\ TT_\=H^P_P#33_QV@"G15S[#_P!-
M/_':/L/_ $T_\=H IT5<^P_]-/\ QVC[#_TT_P#': *=%7/L/_33_P =H^P_
M]-/_ !V@"G15S[#_ --/_':/L/\ TT_\=H IT5<^P_\ 33_QVC[#_P!-/_':
M *=%7/L/_33_ ,=H^P_]-/\ QV@"G15S[#_TT_\ ':/L/_33_P =H IT5<^P
M_P#33_QVC[#_ --/_': .>L] M;+Q#J6MI),]UJ"11R*[#8BQ@@!0!D9SDY)
MY]*/$>@6OB?0[C2+V29+:<H9#"P#$*P;&2#P2HS70_8?^FG_ ([1]A_Z:?\
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MRF_FE>[UX1^T+_Q_:!_URF_FE>]PU_R,Z?S_ /2695O@9XK1117ZF<04444
M%=%X!_Y*!H'_ %_Q?^A"N=KHO /_ "4#0/\ K_B_]"%<V,_W>I_A?Y%1W1]?
MT445^+GH!7QMXL_Y'+7/^PA<?^C&K[)KXV\6?\CEKG_80N/_ $8U?9<&_P :
MKZ+\SGQ&R,>BBBOOSE"BBB@ KV/]GS_D.:S_ ->R?^A5XY7L?[/G_(<UG_KV
M3_T*O&X@_P"1;5]%^:-*7QH]^HHHK\G.XY?XC_\ ).M>_P"O1J^1J^N?B/\
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M +Z% #Z*9YL?_/1/^^A1YL?_ #T3_OH4 /HIHD1C@.I/H#3J "BBB@ HHHH
M**** "BBB@#SOXD>)-1T?4-,LXM7_L/3KE)&FU+[(;C#C&V/';/)S61X4T:W
M\>6M_>:A.\MU9W CLO$%E";.:==H).!UP>.0:]9=$D7:ZJR^C#(I5544*H
MZ "@#(\.V.LZ=9RVVL:HFI,LG[BX$7EN8\# <#@MG/(K8HHH **** "BBB@
MHHHH **** "BBB@#R;]H?_DG=I_V$XO_ $"2O5XO]4G^Z*\H_:'_ .2=VG_8
M3B_] DKU>+_5)_NB@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7C/QR\/ZQK=YHK:7IEW>K%'*)#!$7VY*XSCIT->S45VY?C98
M+$1Q$5=J_P"*L3./,K'Q_P#\('XM_P"A;U7_ ,!7_P */^$#\6_]"WJO_@*_
M^%?8%%?1_P"N.(_Y]K\3'ZNNY\?_ /"!^+?^A;U7_P !7_PH_P"$#\6_]"WJ
MO_@*_P#A7V!11_KCB/\ GVOQ#ZNNY\?_ /"!^+?^A;U7_P !7_PK=\%>#/$U
MGXWT2YN= U&&"*\B>21[9@JJ&&23C@5]1T5%7BW$5*<H.FM4UUZC5!)WN%%%
M%?)&X5\;>+/^1RUS_L(7'_HQJ^R:^0?%6E:C)XOUITL+IE:_G(80L01YC>U?
M8\'R4:U6[Z+\SGQ&R.<HJ[_8^I_] Z[_ ._#?X4?V/J?_0.N_P#OPW^%?>^T
MAW1S6*5%7?['U/\ Z!UW_P!^&_PH_L?4_P#H'7?_ 'X;_"CVD.Z"Q2KV/]GS
M_D.:S_U[)_Z%7E/]CZG_ - Z[_[\-_A7KOP#LKNUUK6#<6LT(:W0 R1E<_-[
MUXV?SB\MJI/HOS1=)>^CW>BBBORH[CE_B/\ \DZU[_KT:OD:OKGXC_\ ).M>
M_P"O1J^1J_0^#_\ =:G^+]$<N(^)!1117UQSA1110 5]:?#'_DFVA?\ 7O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ+H_]IBQEM())7%OYIYEB!PLF,#&[KBII_#FAW5Y]LN-%TZ:ZSGSY+5&?/\
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M"\&_]#3H_P#X&Q_XT?\ "PO!O_0TZ/\ ^!L?^- '245S?_"PO!O_ $-.C_\
M@;'_ (T?\+"\&_\ 0TZ/_P"!L?\ C0!TE%<W_P +"\&_]#3H_P#X&Q_XT?\
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M_P *OG_Z&_6_^_Q_QH_X5?/_ -#?K?\ W^/^->A44 >>_P#"KY_^AOUO_O\
M'_&C_A5\_P#T-^M_]_C_ (UZ%10!Y[_PJ^?_ *&_6_\ O\?\:/\ A5\__0WZ
MW_W^/^->A44 >>_\*OG_ .AOUO\ [_'_ !H_X5?/_P!#?K?_ '^/^->A44 >
M>_\ "KY_^AOUO_O\?\:/^%7S_P#0WZW_ -_C_C7H5% 'GO\ PJ^?_H;];_[_
M !_QH_X5?/\ ]#?K?_?X_P"->A44 >>_\*OG_P"AOUO_ +_'_&C_ (5?/_T-
M^M_]_C_C7H5% 'GO_"KY_P#H;];_ ._Q_P :/^%7S_\ 0WZW_P!_C_C7H5%
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MAOUO_O\ '_&C_A5\_P#T-^M_]_C_ (UZ%10!Y[_PJ^?_ *&_6_\ O\?\:/\
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MA<A_[_2__%5W-% '#?\ "G? '_0N0_\ ?Z7_ .*H_P"%.^ /^A<A_P"_TO\
M\57<T4 <-_PIWP!_T+D/_?Z7_P"*H_X4[X _Z%R'_O\ 2_\ Q5=S10!PW_"G
M? '_ $+D/_?Z7_XJO./@QX!\+^)O#&HW6LZ1'=SQ:C)"CM(ZX0(A X8=R:^@
M*X?X7^"[[P/H-]87]S;SR7%Z]RK0%L!2JC!R!S\IH 3_ (4[X _Z%R'_ +_2
M_P#Q5'_"G? '_0N0_P#?Z7_XJNYHH X;_A3O@#_H7(?^_P!+_P#%4?\ "G?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V21(8G
MEE=4C12S,QP% ZDFO.[CXX^ [>^-M_:DL@#;3-';NT?YXY'N!76^+-'E\0>$
M]4TB"?R)KNV>))#T!(XS[=C[5X/INK:CX"\.R>'/%OPY%QIX#I)?01#+@YY+
MX*L>>#D8P* /H.VUK3+O1AK%O?0/IQC,OVD/\FP=23VQWKE='^+O@S7-;72;
M/5#]H=MD1EB9$E;T5B.I[9QFO.-8N?#]I^SOJ/\ PB%W>O8SW2)(ETX,D+,R
M[D.!P.!]<^]1_$C1-/TGX+^$K^QM88+NW:V99D0*Y+1EFR>IRP!H ]F\4>,=
M#\'6276M7JVZR$B- I9Y".NU1S^/2H_"GC?0?&EK+/HMYYQA($L3J4=,],J>
MQ]>E>)^.-<)^-FDS7NDSZP+:PB-MI\2[C+*R%AQ@_P 39/!^[7:?##6?#FI^
M+=8V>&I?#_B<INN[9Y&(=,C)"G '.,C:.N: /6:*** "BBB@#-UWQ!I7AK3'
MU'6+R.UM5(7>^223T  Y)]A7):1\9_!&LZC'8PZF\,TK!8S<0M&K$]!N/ _'
M%4OC-X.U?Q5HVG7&C1)=7&G7!F-G(1B8$#UX)&.G<$UY[K/BW0-8MK71_'_@
M:\T#RY!MN[*+R]AQV!4';Z@;J /</%/C'0_!MBEWK5X(%D.V)%4L\A[[5'\^
ME)X5\::%XSLY+C1;T3>40)8V4J\9/3*GU]>E>6ZQ%::Q\?/"6GR,+W3;?3%E
M@\TAQ)\KL&/8YVJ<^U6M!ABT?]I;6+*QC2&VNK#S)(HQA=VU&S@>^3^- 'I/
MBKQCHO@S3X[S6;DQ)*_EQHB[G<^RCL.];D<BRQ)(OW74,,^AKYW^-/@EM+TR
M3Q)J&K76H7]UJ(CA60XCMX3O8(H_ <_I7T'8_P#(/MO^N2_R% $]%%% !111
M0!R'BGXF>%?!]V+/5=0(NR Q@AC,CJ#T)QP/QJYX5\=^'?&<<AT6_$TD0S)"
MZE)$'J5/;W'%>4^(M#\2^"OB7JOBJU\,Q>)-.O\ +<IO>'ID# )4C&,X(Q5_
MX?:SX+U_XCR:C;:=?:%XD,3*]BY5891M^;  'S=\''3/K0!Z?XH\6:1X.TK^
MT=9N#%"7"(JKN=V/8#OZU>?5K&'1O[7GN%@L1")VEE^4*A&<G\*\,^-G@EK7
M1]0\4:AJUU>W4EZD=I QQ%:PL3\H'<\#GC^M;GQ@NI;?X':;'&Q59_LL;X[K
MLW8_-10!UWA_XL>#_$NL#2M/U)OM3DB)9HFC$I_V2>_MUKMJ\#^*^E6/A_PO
MX'O],M8;:YM;B)$DB0*Q&P-R1UY7/X^]>]J<J#ZB@!:*** "D)"J22 !R2>U
M+5'6K!]5T*_T])C"]U;R0K(/X"RD9_6@#BK_ .-W@6POVM&U228H=K200,Z
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MYDT0S)!(A211ZX/4>XKIJ\4\ 6D?B;XOZMXRT:R^QZ!%";:*01[!<R8 ) _
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&UAN[NSA\B:SD8#>H! (R1GAB.N>!1X!\*^);OQ_J/CKQ3:1:?<W$/D06<;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4J:!\>O%6FZBRQ3WK2F N<;\R!P!GU4Y_"O4?&WC[1_ EI:W&J>:YN9?+2*
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M>;'-$H)&1@CGL>/R%:.H^'!J?@N7PY<WLK"6T%J]SM&\\8W8Z9XH Y'X$?\
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MBBB@ HHHH **** "BBB@ HHHH **** (F)9@5!( P#_6I ,  =J6B@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img96160895_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96160895_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2+"C0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH-G%93Q17]I$H6-925=%'0!AV^H-,9:\=_# >&-,.JZ==RW%HCA94F WQ@G
M.1@$9P.@ZTWX/:]-8>*?[*9_]%OU;Y2>!(H)!'U (]^*[2R^+/A;6X#9ZQ:2
M6Z28#I<1":(]^<9[^HKK]+TCPRXAU'2=-TD_Q17%M;QY'T912$;5%<?\4_\
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M=>)]#N!J,XFO[67#MM5=R-RIPH [,.G:@#N:*S?$&K)H7A^^U.3&+>(LH/\
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M:\D^#>A?;_$LVJRIF&P3Y,]Y'R!^0W'\J]NU.S&HZ3>6)( N8'AR>VY2/ZT
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M%@.X8Y)/TKYXUN\BU#7]1O8%*Q7%U+*@(Z*S$C]#3&?4VC?\@/3_ /KVC_\
M017RA=?\?D__ %T;^=?5^C?\@/3_ /KVC_\ 017RA=?\?D__ %T;^=(1]>44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\:X,34B\0J<E:*9Z&%I26&=2$KRDCQW2]&\1>/+FXF%UYOED>9+<RD*I.<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;;P""0#T [=:\<G^"WB.2>207NE89B1F63N?]RO=J* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /)OBEXJE:Y.@6<FV) &NBI^\QY"_0<$__6KE?"?B6R\,W#W4FCB]
MNSQ'*T^P1CV&T\^]>G:C\,-&U/4KF^N+O4?-N)&D8+(F 2<X'R=*J_\ "HM
M_P"?S4_^_L?_ ,17M4L5A(T52=_,\.KA<7.NZJMY&7_PN7_J _\ DY_]A75^
M(?%8TGP=%JZHJW-U$GD1$YP[KG\0!D_A[UD?\*BT#_G\U/\ [^Q__$5MZUX*
MT[7=/T^QN;B\2&Q39'Y3J"W &6RIYPO;'4US5)8+GCR*RZ[G33CC5"7.[NVF
MQX3%?++JPO=3C>]#2>9,ADV&0^[8./RKT.'XOQ6\*0P^'5CB0;51;O  ] -E
M;'_"HM _Y_-3_P"_L?\ \11_PJ+0/^?S4_\ O['_ /$5V5<5@JMN=-V]3CHX
M3'4;\C2OZ?Y&OX-\8?\ "6QWC_8?LGV<H,>=YF[=G_9&.E=16#X:\)V'A5+E
M+&:YD%P5+^>RG&,XQ@#UK>KQZ[INH_9?">S0514U[7XNH5X'X^T]]%\;W,D.
M8Q,PNHF'&">21_P(&O?*YWQ+X,TSQ3+;RWLEQ') I56@906!QP<@]/ZFM\#B
M%0J7ELS#'X:5>E:.Z9Y_\(M.\[6KW4&7*V\(C4^C.?\ !3^=<[XTLWT?QGJ4
M<1\L2.TB[>!MD&2/_'B*]J\-^&+'PO9RVUBTSB63>SS,"W3&. ./\35+Q%X$
MTKQ-?I>WDMU%*D8C_<,H! )/.5//-=<,?!8F51_"U8XYY?-X6--?$G<X[X0:
M7NGU#57'"*+>,X[GYF_DOYUH?%G1);O3[75H$+_9<I, ,D(>0WT!_G7:Z!H5
MIX<TM=/LC(T08N6E(+,3ZX 'H.G:M)E5T9'4,K#!!&017-/&/ZS[:.WZ'5#!
M+ZK["6_ZGD'P]\=6.B6#Z7JK-%"',D4RJ6 SU4@<^_XT>(_BC?/JP&@3;+)$
M"DRP@^8W<\C('05UE_\ "_PY>SM*B7-IN.2MO( OX!@<?A5G1_AYX?T:Y6XC
M@EN9D.4>Y<-M/J  !^E=$J^#<W5<6V^G0YHX?&J"HJ2277J7+&WU#7/!A@UD
M1QW=[;L'")M"!@=N1GJ!@UXKI%]=>#?%B37%NWFVKM'-$>"5(P<?AR#]*^B:
MP]>\):/XCVM?VW[Y1@31G:X'IGN/KFL,+BXTW*,U[LNQT8K!RJ*,J;]Z/?J<
MQK_Q1TQ=%?\ L6>1[^083="0(O4G<,'\,TGP]\3>(_$5_-]N:%[&%/GD\K:2
MYZ $<>IJS%\)O#L<H=I;^50?N/*N#^2@_K796&GVFF6:6EE;I! GW40?K[GW
MIU:N%C2<*4;M]7T%2I8J553JRLET74\D^+__ ",=E_UZ#_T-JVO WAO3]7^'
MEQ#+"HEO&=6FQE@5/RD?0\X^M=)XD\#Z9XHO8KJ]GNXY(X_+ A=0,9)[J?6M
M/0=#MO#VE)I]H\SPHS,&E(+9)SV JIXN/U:-.#]Y$PP<OK4JDU[K/#-#U*[\
M&>+0TZLIAD,-S&/XDSS]>Q'T%>O>,=8U2P\-)JFA&*5 0\C%-_[LCAAS]/\
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M&YE*]& ZD8X/IBO/M"\3>*-%#Z=H]W<Q[R?]'6(2')]%(.#]*^H:* /G/5_
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ME60*?0D$U:H **** "BBB@ HHHH **** "BBF3316\32S2)%&O+.[!0/J30
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M_A1>>'K0ZMX>U&XF>W^=HS\LJ@=65EZX],5[910!P7PR\;2^*-.EL[]@=2M
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MSX?^"K3QS-JM[JL]U&L<BE3;LJEG;<6SE3[?G7;_ /"D_#?_ #_:M_W]C_\
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M_P"^:]3T#5H]=T&RU.+ 6XB#D#^%NC#\""/PH T:*\I^./\ R"-)_P"N[_\
MH(KT/P[_ ,BQI/\ UYP_^@"@#3HKR[XW_P#(NZ;_ -?9_P#0#79^';J&Q\ :
M3=W#A(8=+ADD8]E$0)- &]17AML?$7Q:UJZQ>O8Z+ WW!]U >@P"-[XY)/3V
MX%:.H?#[6O!-JVL^&M:FE-L/,FMV7&]1UX!PW'8CZ<T >PT5XK\%YC<^)=:G
M8 &2$.0.V7S7M5 "$A5+,0 !DD]J\+0:A\6O&EQ"]W)!HUKEE5>B)G P.F]N
MN3[^F*]SDC66-XW&4<%6'J#67HOAC1O#SW#Z58K;&XV^;M=CNVYQU)Q]X]*
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M_P#B*/L?Q/\ ^@CI?_?*_P#Q%'LO[R#ZP_Y']W_!/0J*\]^Q_$__ *".E_\
M?*__ !%'V/XG_P#01TO_ +Y7_P"(H]E_>0?6'_(_N_X)Z%17GOV/XG_]!'2_
M^^5_^(H^Q_$__H(Z7_WRO_Q%'LO[R#ZP_P"1_=_P3T*BO/?L?Q/_ .@CI?\
MWRO_ ,11]C^)_P#T$=+_ .^5_P#B*/9?WD'UA_R/[O\ @GH5%>>_8_B?_P!!
M'2_^^5_^(H^Q_$__ *".E_\ ?*__ !%'LO[R#ZP_Y']W_!/0J*\]^Q_$_P#Z
M".E_]\K_ /$4?8_B?_T$=+_[Y7_XBCV7]Y!]8?\ (_N_X)Z%17GOV/XG_P#0
M1TO_ +Y7_P"(H^Q_$_\ Z".E_P#?*_\ Q%'LO[R#ZP_Y']W_  3T*BO/?L?Q
M/_Z".E_]\K_\11]C^)__ $$=+_[Y7_XBCV7]Y!]8?\C^[_@GH5%>>_8_B?\
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M]Y!]8?\ (_N_X)Z%17GOV/XG_P#01TO_ +Y7_P"(H^Q_$_\ Z".E_P#?*_\
MQ%'LO[R#ZP_Y']W_  3T*BO/?L?Q/_Z".E_]\K_\11]C^)__ $$=+_[Y7_XB
MCV7]Y!]8?\C^[_@GH5%>>_8_B?\ ]!'2_P#OE?\ XBC['\3_ /H(Z7_WRO\
M\11[+^\@^L/^1_=_P3T*BO/?L?Q/_P"@CI?_ 'RO_P 11]C^)_\ T$=+_P"^
M5_\ B*/8_P!Y!]8?\C^[_@GH5%>>_8_B?_T$=+_[Y7_XBC['\3_^@CI?_?*_
M_$4>Q_O(/K#_ )']W_!/0J*\]^Q_$_\ Z".E_P#?*_\ Q%'V/XG_ /01TO\
M[Y7_ .(H]C_>0?6'_(_N_P"">A45Y[]C^)__ $$=+_[Y7_XBC['\3_\ H(Z7
M_P!\K_\ $4>Q_O(/K#_D?W?\$]"HKSW['\3_ /H(Z7_WRO\ \11]C^)__01T
MO_OE?_B*/8_WD'UA_P C^[_@GH5%>>_8_B?_ -!'2_\ OE?_ (BC['\3_P#H
M(Z7_ -\K_P#$4>Q_O(/K#_D?W?\ !/0J*\]^Q_$__H(Z7_WRO_Q%'V/XG_\
M01TO_OE?_B*/8_WD'UA_R/[O^">A45Y[]C^)_P#T$=+_ .^5_P#B*/L?Q/\
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M89;/Q]8:A>PM/I[1Q%5[,JL2Z?KG_@5 &RGQ2\3ZK\VB^$9)(S]UBLDH_$J
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MB4K:-*+A0!P8GR'4?3Y@/H* .I^./_((TG_KN_\ Z"*]#\._\BQI/_7G#_Z
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MX,/:U?Y/Q1Z%17GO_"M=0_Z''5/_ ![_ .+H_P"%:ZA_T..J?^/?_%T<E/\
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MCDI_S?@P]K5_D_%'H5%>>_\ "M=0_P"AQU3_ ,>_^+H_X5KJ'_0XZI_X]_\
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M?_%T<E/^;\&'M:O\GXH]"HKSW_A6NH?]#CJG_CW_ ,71_P *UU#_ *''5/\
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M*_#'_DJNO_\ 7*X_]'I7;?"W29M)\#VPN$*2W+M<E2.0&P%S^ !_&N)^&/\
MR577_P#KE<?^CTH ['XM_P#)/KO_ *ZQ?^ABK'PL_P"2;Z3_ -MO_1SU7^+?
M_)/KO_KK%_Z&*L?"S_DF^D_]MO\ T<] '85D^*D,GA#6D7JUA.!_W[:M:HYX
M4N+>2"0921"C?0C!H \L^!Q']DZN,C(G0X_X":]7KQ'X::@OA#QEJGA[59!
M9F$:LYPOF(3M^FX,<'Z5[#JNJV>BZ=-?W\RQ01#))/)/H/4GL* /(-%'F_M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;&W@DD\QD\QWRV ,_,3V _*M.B@ HHHH RM8\-:+KX7^U-.@N6485V&' ]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRZL%;^%D\S ] 0RG'US5[0OA%H^F7:WFHW,NJ3J<@2J%CSZE<DG\3BO0Z*
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M>B@#R2[^"<EY>3W4OB4F2:1I&)LLDDG)_P"6E0_\**_ZF/\ \D?_ +97L-%
M'DEK\$/LUY#/_P )#N\J17V_8L9P<X_UE>MT5A>,#K#>&[J#0K1KB^G'E*1(
MB>6#U;+$=NGN10!YSI$7_":_&2ZU5?GT_3'!1NQV?*F/JP+?@:]CKF_!'A6/
MPGX>CL\J]U(?,N9!_$_H/8=!^?>NDH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
M"=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F
M!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[
M8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_
M '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?
M_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y_P )WX7_ .@[8?\ ?X4?\)WX
M7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\ "=^%_P#H.V'_ '^%%F!T=%<Y
M_P )WX7_ .@[8?\ ?X4?\)WX7_Z#MA_W^%%F!T=%<Y_PG?A?_H.V'_?X4?\
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MHVG_ #]0_P#?P4?VC:?\_4/_ '\% %JBJO\ :-I_S]0_]_!1_:-I_P _4/\
MW\% %JBJO]HVG_/U#_W\%']HVG_/U#_W\% %JBJO]HVG_/U#_P!_!1_:-I_S
M]0_]_!0!:HJK_:-I_P _4/\ W\%']HVG_/U#_P!_!0!:HJK_ &C:?\_4/_?P
M4?VC:?\ /U#_ -_!0!:HJK_:-I_S]0_]_!1_:-I_S]0_]_!0!:HJK_:-I_S]
M0_\ ?P4?VC:?\_4/_?P4 6J*J_VC:?\ /U#_ -_!1_:-I_S]0_\ ?P4 6J*J
M_P!HVG_/U#_W\%']HVG_ #]0_P#?P4 6J*J_VC:?\_4/_?P4?VC:?\_4/_?P
M4 6J*J_VC:?\_4/_ '\%']HVG_/U#_W\% %JBJO]HVG_ #]0_P#?P4?VC:?\
M_4/_ '\% %JBJO\ :-I_S]0_]_!1_:-I_P _4/\ W\% %JBJO]HVG_/U#_W\
M%']HVG_/U#_W\% %JBJO]HVG_/U#_P!_!1_:-I_S]0_]_!0!:HJK_:-I_P _
M4/\ W\%']HVG_/U#_P!_!0!:HJK_ &C:?\_4/_?P4?VC:?\ /U#_ -_!0!:H
MJK_:-I_S]0_]_!1_:-I_S]0_]_!0!:HJK_:-I_S]0_\ ?P4?VC:?\_4/_?P4
M 6J*J_VC:?\ /U#_ -_!1_:-I_S]0_\ ?P4 6J*J_P!HVG_/U#_W\%']HVG_
M #]0_P#?P4 6J*J_VC:?\_4/_?P4?VC:?\_4/_?P4 6J*J_VC:?\_4/_ '\%
M']HVG_/U#_W\% %JBJO]HVG_ #]0_P#?P4?VC:?\_4/_ '\% %JBJO\ :-I_
MS]0_]_!1_:-I_P _4/\ W\% %JBJO]HVG_/U#_W\%']HVG_/U#_W\% %JBJO
M]HVG_/U#_P!_!1_:-I_S]0_]_!0!:HJK_:-I_P _4/\ W\%']HVG_/U#_P!_
M!0!:HJK_ &C:?\_4/_?P4?VC:?\ /U#_ -_!0!:HJK_:-I_S]0_]_!1_:-I_
MS]0_]_!0!:HJK_:-I_S]0_\ ?P4?VC:?\_4/_?P4 6J*J_VC:?\ /U#_ -_!
M1_:-I_S]0_\ ?P4 6J*J_P!HVG_/U#_W\%']HVG_ #]0_P#?P4 6J*J_VC:?
M\_4/_?P4?VC:?\_4/_?P4 6J*J_VC:?\_4/_ '\%']HVG_/U#_W\% %JBJO]
MHVG_ #]0_P#?P4?VC:?\_4/_ '\% %JBJO\ :-I_S]0_]_!1_:-I_P _4/\
MW\% %JBJO]HVG_/U#_W\%']HVG_/U#_W\% %JBJO]HVG_/U#_P!_!1_:-I_S
M]0_]_!0!:HJK_:-I_P _4/\ W\%']HVG_/U#_P!_!0!:HJK_ &C:?\_4/_?P
M4?VC:?\ /U#_ -_!0!:HJK_:-I_S]0_]_!1_:-I_S]0_]_!0!:HJK_:-I_S]
M0_\ ?P4?VC:?\_4/_?P4 6J*J_VC:?\ /U#_ -_!1_:-I_S]0_\ ?P4 6J*J
M_P!HVG_/U#_W\%']HVG_ #]0_P#?P4 6J*J_VC:?\_4/_?P4?VC:?\_4/_?P
M4 6J*J_VC:?\_4/_ '\%']HVG_/U#_W\% %JBJO]HVG_ #]0_P#?P4?VC:?\
M_4/_ '\% %JBJO\ :-I_S]0_]_!1_:-I_P _4/\ W\% %JBJO]HVG_/U#_W\
M%']HVG_/U#_W\% %JBJO]HVG_/U#_P!_!1_:-I_S]0_]_!0!:HJK_:-I_P _
M4/\ W\%']HVG_/U#_P!_!0!:HJK_ &C:?\_4/_?P4?VC:?\ /U#_ -_!0!:H
MJK_:-I_S]0_]_!1_:-I_S]0_]_!0!:HJK_:-I_S]0_\ ?P4?VC:?\_4/_?P4
M 6J*J_VC:?\ /U#_ -_!1_:-I_S]0_\ ?P4 6J*J_P!HVG_/U#_W\%']HVG_
M #]0_P#?P4 6J*J_VC:?\_4/_?P4?VC:?\_4/_?P4 6J*J_VC:?\_4/_ '\%
M']HVG_/U#_W\% %JBJO]HVG_ #]0_P#?P4?VC:?\_4/_ '\% %JBJO\ :-I_
MS]0_]_!1_:-I_P _4/\ W\% %JBJO]HVG_/U#_W\%']HVG_/U#_W\% %JBJO
M]HVG_/U#_P!_!1_:-I_S]0_]_!0!:HJK_:-I_P _4/\ W\%']HVG_/U#_P!_
M!0!:HJK_ &C:?\_4/_?P4?VC:?\ /U#_ -_!0!:HJK_:-I_S]0_]_!1_:-I_
MS]0_]_!0!:HJK_:-I_S]0_\ ?P4?VC:?\_4/_?P4 6J*K+?6KL%6XB9CP '!
M)J<,#0 ZBC-% !7!?$B**XNO"D$T:212:U CHZAE92<$$'J"*[VN$^(7_(2\
M(_\ 8<@_G51W Z+_ (1'PU_T+VD_^ 4?_P 31_PB/AK_ *%[2?\ P"C_ /B:
MV:*5V!C?\(CX:_Z%[2?_  "C_P#B:/\ A$?#7_0O:3_X!1__ !-;-%%V!C?\
M(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-;-%%V!C?\ "(^&O^A>
MTG_P"C_^)H_X1'PU_P!"]I/_ (!1_P#Q-;-%%V!C?\(CX:_Z%[2?_ */_P")
MH_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG_P  H_\ XFC_ (1'PU_T
M+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P# */\ ^)H_X1'PU_T+VD_^ 4?_
M ,36S11=@8W_  B/AK_H7M)_\ H__B:/^$1\-?\ 0O:3_P" 4?\ \36S11=@
M8W_"(^&O^A>TG_P"C_\ B:/^$1\-?]"]I/\ X!1__$ULT478&-_PB/AK_H7M
M)_\  */_ .)H_P"$1\-?]"]I/_@%'_\ $ULT478&-_PB/AK_ *%[2?\ P"C_
M /B:/^$1\-?]"]I/_@%'_P#$ULT478&-_P (CX:_Z%[2?_ */_XFC_A$?#7_
M $+VD_\ @%'_ /$ULT478&-_PB/AK_H7M)_\ H__ (FC_A$?#7_0O:3_ . 4
M?_Q-;-%%V!C?\(CX:_Z%[2?_  "C_P#B:/\ A$?#7_0O:3_X!1__ !-;-%%V
M!C?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-;-%%V!C?\ "(^&
MO^A>TG_P"C_^)H_X1'PU_P!"]I/_ (!1_P#Q-;-%%V!C?\(CX:_Z%[2?_ */
M_P")H_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG_P  H_\ XFC_ (1'
MPU_T+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P# */\ ^)H_X1'PU_T+VD_^
M 4?_ ,36S11=@8W_  B/AK_H7M)_\ H__B:/^$1\-?\ 0O:3_P" 4?\ \36S
M11=@8W_"(^&O^A>TG_P"C_\ B:/^$1\-?]"]I/\ X!1__$ULT478&-_PB/AK
M_H7M)_\  */_ .)H_P"$1\-?]"]I/_@%'_\ $ULT478&-_PB/AK_ *%[2?\
MP"C_ /B:/^$1\-?]"]I/_@%'_P#$ULT478&-_P (CX:_Z%[2?_ */_XFC_A$
M?#7_ $+VD_\ @%'_ /$ULT478&-_PB/AK_H7M)_\ H__ (FC_A$?#7_0O:3_
M . 4?_Q-;-%%V!C?\(CX:_Z%[2?_  "C_P#B:/\ A$?#7_0O:3_X!1__ !-;
M-%%V!C?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q-;-%%V!C?\
M"(^&O^A>TG_P"C_^)H_X1'PU_P!"]I/_ (!1_P#Q-;-%%V!C?\(CX:_Z%[2?
M_ */_P")H_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG_P  H_\ XFC_
M (1'PU_T+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P# */\ ^)H_X1'PU_T+
MVD_^ 4?_ ,36S11=@8W_  B/AK_H7M)_\ H__B:/^$1\-?\ 0O:3_P" 4?\
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M%[2?_ */_P")H_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG_P  H_\
MXFC_ (1'PU_T+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P# */\ ^)H_X1'P
MU_T+VD_^ 4?_ ,36S11=@8W_  B/AK_H7M)_\ H__B:/^$1\-?\ 0O:3_P"
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MX:_Z%[2?_ */_P")H_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG_P
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M:3_X!1__ !-;-%%V!C?\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\
MQ-;-%%V!C?\ "(^&O^A>TG_P"C_^)H_X1'PU_P!"]I/_ (!1_P#Q-;-%%V!C
M?\(CX:_Z%[2?_ */_P")H_X1'PU_T+VD_P#@%'_\36S11=@8W_"(^&O^A>TG
M_P  H_\ XFC_ (1'PU_T+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P# */\
M^)H_X1'PU_T+VD_^ 4?_ ,36S11=@8W_  B/AK_H7M)_\ H__B:/^$1\-?\
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MA>TG_P  H_\ XFC_ (1'PU_T+VD_^ 4?_P 36S11=@8W_"(^&O\ H7M)_P#
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M X[_ (57X+_Z W_DU-_\71_PJOP7_P! ;_R:F_\ BZ[&BCFEW X[_A5?@O\
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M] ;_ ,FIO_BZ[&BCFEW X[_A5?@O_H#?^34W_P 71_PJOP7_ - ;_P FIO\
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M[_A5?@O_ * W_DU-_P#%T?\ "J_!?_0&_P#)J;_XNNQHHYI=P.._X57X+_Z
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MPJOP7_T!O_)J;_XNNQHHYI=P.._X57X+_P"@-_Y-3?\ Q='_  JOP7_T!O\
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M6;;XM^$[J-GBO'VJ,G*?_7I3\(?!!.3HL>?]\_XU+%\*?!L"E8]'C4'J-QH
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M_KK%_P"ABJA\2 [NBBBI **** "BBB@ HHHH **** "BBB@ JCK.GC5=&N[
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MWH,]10!KT5R.L?$31-%OFM+F8"1>OS"K7A_QMI/B.<PV4H9QSC.: .DHHHH
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MDU*RDP'CW J>G%8_QBTNWOO!%W-)&IEA0LK8Y%<C\/;\W7P@OH68EHQCD^U
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M3[L!7GU_\07;X=#7-/C,MTZE0%&<-BO.-'\&^//'UFVJWVJ"R24Y56!7/Y4
M?1"2QR?<=6^AS3R0!DU\RQ:AXJ^&/BZUT^\OA<V\LBJ3R<@_6O1?BQX[O-!\
M,V;Z>=DMZ@(8CI0!ZC]H@SCSH\^FX4\$,,@@CVKYXL/AGXNUC3!K,7B*,S.G
MF",,W/?%=5\+M?\ %,5_<Z/XBA<QP'"2E,  >] 'KK,JC+$ >I-,6>%CA94)
M] PKP7Q=XVUWQ;XO;PSX>G6*$'#OCIV/-5M6\ ^-O!>GOK=KK:7#PX+)DG-
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M_P"/^S^O]*].^$/_ "(MK]!_*@#O:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KC/BG_P B'>?5:[.N,^*?_(AWGU6@!GPF_P"2=Z=_P+^==M7$
M_"?_ ))WIW_ OYUVU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P^F>$[.V^(VJZZM
M[$]Q<;=T"M\R8'<5W%<EIMKHZ>.M3G@O)7U%]OG0D?*O'&* .MHHHH ****
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M_#V^N]8_MS5+?;9J"4W_ 'B_7I7T*VD:>\PE:R@+COY8JVD:1+MC147T48%
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MOX:?\B79?]<U_E0!U]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXKG(/"OC'XE:W#<ZZKV]HC!FC=2O%>T:QHJZ7X"ETRQA+^7%M55')XH \]^
M7,%]Z%F_G67\6?"5SX8U^'Q9HJLB[MT^SCDFMWX&:;J%A#>B^LIK;+-CS%QG
MFO5]8TNWUG2YK*Y0.DBD8/K0!\S^)O%MOXM\0^'[I#^_6=0Z_2O4_BMXB&B_
M#N.UCDVW5PB[,>E>/S_#_5]"^(MM!%87$UJMP&$BH2H&?6NJ\?:?KGB_Q=I.
MFKIUREI; *TA7Y>#0!A^!X/'&@V+7.D:=O6?.7+8)S5?QQ:^--6BCU'6-/\
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MQ5'Q/X9\1> _&+:]H$#W%M*?FBC7)ZY-+KOQ.\7Z]IATVPT*[@FEPK.8L8H
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M(8$AC)[UZY10!X O[.5XB[5\3X'H(R!_.K5E^SK%'.KWVMM<H#DIM(S7NM%
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M&.O2J\U^)O\ R,WA+_?N?_08ZJ.X&KI/\-=9;?<%<GI/\-=9;?<%2!9HHHH
M**** "N$^+G_ "(%W_UUB_\ 0Q7=UPGQ<_Y$"[_ZZQ?^ABJA\2 [NBBBI **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \/^(GQ>U#PKXQN-)MX"T<2*<[L=17GWB;XR:CXE\/W.DS0%8YQ@G=7TCJG
M@O0M8OFO+VPAEG88+L@)KA/BAX(T#2_A[JEY::?#%/&F5=4 (H \_P#V?KME
M\5-:XX:-FS^%?3=?-O[/D*'6I92HW@,,_A7TE0 4444 %%%% !1110 4444
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M^0EX1_[#<'\Z[NN$^(7_ "$O"/\ V&X/YU4=P.[HHHJ0"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(/X58$U8H **BGN8;6/S)Y4C3IN8X%.BECFC$D3JZ'HRG(- #Z*** "BBB@
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MB@ HHHH **** "BBB@ KA?C#_P DPUC_ *YC^==UD>M<+\8/^28:Q_US'\Z
M/*_V>_\ D*3?1OY5]'5\X_L]_P#(4F^C?RKZ.H **** "BBB@ HHHH ****
M"BBB@#A?C!_R3'5O]U?YU;^&G_(EV7_7-?Y54^,'_),=6_W5_G5OX:?\B79?
M]<U_E0!U]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!ROB"QBN-7MI'U:.U*LI$3=6KJAT%<CXC?P\-:MAJ5WY5UN7RUQG)[
M5UPZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"O&F^!>@V$D<\^J1HJ,#\QZU[%I%O#::1:V]NX>&.,*C#H10!=HHHH ****
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M<^U>QUQ.F>%]-M_B)JFM1WT<EY/MWP#JF!WH [:BBB@ HHHH **** "BBB@
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MLZ]8:#:_:+^7RX\XSBM.LK6_#]CK]MY%\K,GH#B@# _X6CX7_P"?W_QTTO\
MPM'PQ_S^_P#CIJ/_ (55X9_YX2_]]4O_  JOPU_SPD_[ZH ?_P +1\,?\_O_
M (Z:\+^.?B+3O$.OV$NG2F5(X,,<8YS7N/\ PJOPU_SPD_[ZH_X55X8_BM6;
MZG- '*?#/Q_H&E> K"TN[HI.F0R[:Z[_ (6CX8_Y_?\ QTTS_A57AD=+>0#T
M#4?\*K\-?\\)/^^J '_\+1\+_P#/[_XZ:=%\3?#,TJQI>99C@?*:B_X55X9_
MYX2_]]4Z+X7>&XI5D6&3<IR/FH [&*5)XED0Y5AD&GU'!"EO"L29VJ,#-24
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M<MNR<\8KVSP3_P B3H__ %[+7EO[1W_(*T;_ *^#_*O4O!/_ ").C_\ 7LM
M%OQ#I-MK6BW-G<Q+(KH0-PZ'UKPGX13/H/Q+U#P^DA$+.QV=C@5] ZC<+:Z=
M<3L<+&A8DU\[?#53JGQKN]3B!:)&D&X=.10!1\;:(GB'XV3Z;(<"5445J>!]
M;NOAUXZN?#FHNPLI)2(RW3%&J'_C(I#[I_.NS^,O@7^VM-&L6*$7MMS\G4T
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MV4;. >E=UH_QU-GH4-HVBRF[B78J!&P37!^(&\2W/B^P\4Z[82)'-,NP("V
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M&.O2J\U^)O\ R,WA+_?N?_08ZJ.X&KI/\-=9;?<%<GI/\-=9;?<%2!9HHHH
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MF&L?]<Q_.NYR!U(KAOC 0?AAK'(_U8_G0!Y7^SW_ ,A2;Z-_*OHZOG']GO\
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MW_YXQ_\ ?(H^RV__ #QC_P"^10!Y)_PN'7O^A'O_ /OH4?\ "X=>_P"A'O\
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MYBV[[SRL"3(_O=Z .KHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2_8Y!B3=%@?G7US<:3874IEGM8Y'/5F'-<)\6M(T^W^&FK216L:.L8(8#D4
M>4_L_2S#Q<T0_P!28V)^N*^G:^</V>U7^UIFQ\V&Y_"OH^@ HHHH **** "B
MBB@ HHHH **** .0^)VFW.K> -3LK2-I)Y%&U5&2>:\RT#Q!XYT/2(;!-(N2
ML:@#]U7OE% 'BW_";^._^@/<_P#?JC_A-_'?_0'N?^_5>TT4 >+?\)OX[_Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!_*O,OVB1B^L_K_2O3?A#_R(MK]!_*@#O:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
MR?ZIOH:=39/]6WT- 'CWP:_Y#?B7_K_D_G7L=>.?!K_D-^)?^O\ D_G7L= !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W8ZAK<GB[4+2;3(X
M],CV^5=!OF?UXKI*\TT?Q;JUS\7=:T&:5386^SRDV\C(YYH ]+HHHH ****
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M(=V'ED<"%N&8GO0!].T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.QZ?+<><XRQ.,8SVKKZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD+-!=!0X).3Q7U'X>MI;/P_8V\^?-CB"MGKF@#2HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *FJ221:3>20DB58'*$=C@XKY,N/'_Q%2YD4:MJ&
M QQA>.OTKZ^(!&",@U7^P69_Y=(/^_8H ^)/$.O>(-:D1M=NKB=U^Z9ABOIC
MX(2S2>!QYK$[7 7/IBO//VA88HKZS$4,<?/\"@9XKU#X0@#P+:X ' Z?2@#O
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "FR?ZIOH:=39/\ 5O\ 0T >/?!G_D-^)?\
MK_D_G7L=>.?!G_D-^)?^O^3^=>QT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ=SK'ANUOKP*)Y%RVT8% &W1110 4444 %%%% !1110 4444 %%%% !1110
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MNQZC(KFJT9TG::/0PV+HXF/-2=PHHHK(Z0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \_P#BY_R -(_["\/_ *!)4FE=5J/XN?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ<O9:->W48R\4+NH]P,T <F?@_X')).B19)R?F--;X.^!F&/[$C'N&->)?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU]<Z'IW]D:'9Z?NW?9XPF:X;P)\4/#'B2[%C:0BRO"N2I3:K>P->DT %%%%
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M,J@30MW7(/H<'J#7H_AG7(]7L=I5([B$ /&O QV('I5+QEHGVZS^W0+_ *1
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MO%<+XEMI@X21'[KGFOL;1M235]*@O8QA9%SB@"_1110 4444 %%%% !1110
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MW9%'\+#K_C^-+'X=0?M([,K),>ZL70J?%';T_P" :-%%%><>^%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G_P 7/^0!I'_87A_]
M DJ32NJU'\7/^0!I'_87A_\ 0)*DTKJM4]D!U</^J%%$/^J%%2!HUPGQ"_Y"
M7A'_ +#<'\Z[NN$^(7_(2\(_]AN#^=5'<#NZ***D HHHH 1B%4D] ,U\:^))
M]2\=?$2> DO*UP;=#Z*&(%?9,B"2-D/1@17QY8:@?"7Q2EGNDQ&MXQ;/]TL3
MF@#U#QA;S_#GX1_V,EX6O9ROS#@@="*\Y^%_PY_X3R\NVN+AH(+< EL9W$U;
M^,7CNV\8ZO:1Z:6^S0(5/.=QS7JOPHBL?!WPXBU;594M6G!+>9P2 >* /$?$
MOAR?X=^/;>U6Y+&-UF20#'&>*^MO#M\VI>'K&]=MS31!B?6OE'XC>)8?'/CV
M.XLT/E_+ F/XN:^I_"%H]CX1TNUD4J\4 4@]10!M4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !103@9/2H?M=O_ ,]D_.@#YZ_:)_X_[/Z_TKT[
MX0_\B+:_0?RKR_\ :&ECDO[/8X;!YP?:O4/A"<^!;7GL/Y4 =[1110 4444
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MSZ8KS_\ :)_X_K/@=?3VKT[X0_\ (BVOT'\J .]HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *1P61@.I%+10!X-;?#SXB:)K>IW.CRV:075PTHS/@X)K0_L#XN_\_%E_
MX$5[310!XM_8'Q<_Y^++_P "*/[ ^+O_ #\67_@17M-% 'BW]@?%S_GXLO\
MP(H_L#XN_P#/Q9?^!%>TT4 >+?V!\7?^?FR_\"*/[ ^+G_/Q9?\ @17M-% '
MBW]@?%W_ )^++_P(H_L#XN_\_%E_X$5[310!XM_8'Q=_Y^++_P "*/[ ^+G_
M #\67_@17M-% 'BW]@?%S_GYLO\ P(J#PMKWC"P^)%KH/B"6-@Q(81ON'2O<
M*\6NO^2_VO\ OG^5 'M-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFE>,M!UNX:#3[])I%."HK>H Q?#_ (5TCPQ9BVTNU6)!W/)_.MJBB@ HHHH
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M7_"O?B3_ -#?:_\ ?LT?\*]^)/\ T-]K_P!^S7LM% 'C7_"O?B3_ -#?:_\
M?LT?\*]^)/\ T-]K_P!^S7LM% 'C7_"O?B3_ -#?:_\ ?LT?\*]^)/\ T-]K
M_P!^S7LM% 'SYJB>./!VOV4.H:_%>13$'"+CO7OULQ>UA8]2@)_*O(?BW_R,
MVE?1?YUZ[:?\>4'_ %S7^5 $U%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ B.5=RY]*\3@_9WL4FCE759G56#<8P:]ITJQ73-*MK)6++"@0$]Z +E%%%
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M;6N+64=N4/Y5Z!X2\3OJP:SO"/M2+N5QQYB_3U%:GB'1QK6E/;J(Q."&B=^
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M$T-PCJ68?,":^P+JVAO+=X)T#QN,$&O+=<^!WAA[.]N+.WE6X,;.B[R?FZT
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M^+?_ ",VE?1?YUZ[:?\ 'E!_US7^5>1?%O\ Y&;2OHO\Z]=M/^/*#_KFO\J
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MQY:_V1Y0F*+N$.-H;/MWKZ(\'"4>#]*$_P#K?(7=]: -RBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH J:I')-I-Y%",RO"ZH!W)!Q7RA<?#'XB/<
MR,-*N\%B1B3_ .O7UU10!\/>(_#6O^'Y$37+66!F^[YC9S7TM\$(9HO P\U2
M-S@K],5Y_P#M$G_3K/Z_TKT[X0_\B+:_0?RH [VBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJGJ&J66E0>=>W"1+V!/+?0
M=30!<KQ:Z_Y+_:_[Y_E79W7Q)L8W(MK*>8#^)V"9_G7!?;4F^(]OXGE4QPHV
M7A7YF'&.#QF@#W.BL[2]<T[6(RUE<J[#[T9X9?J#6C0 4444 %%%% !1110
M4444 %%%% !7C.M_\A_4?^OJ7_T(U[-7C.M_\A_4?^OJ7_T(TT-&IXLLS!_9
M<^.);.-2?5E !_0BMEM7_P"+; [CYI'V3]>G_?%2>+K3SO".GW !W0"/)]%9
M<']<5PWVN7[!]CR?*\WS<9_BQC^5 &[X4M/,BU>Z*Y$-DZ@^A8'^@-96B?\
M(?T[_KZB_P#0A78^%K,Q^"]0FQAKA9<$]P%('ZYKCM$_Y#^G?]?47_H0H ]
M\=DCPX<'K,F?UKD?!(!\46Y/4*Y'_?)KN?%MH;SPW=*H)>,"50/8\_IFO-=#
MOQIFM6MVV=B/A\?W3P?T-" ]EHIJ.LD:NC!D8 JP/!%.I"/./B$/^)U;'O\
M9Q_Z$U:7PZ)^QWPSQYB_R-<YXNU)-2U^5XFW11*(D8=\=3^9-=;X$M6MM!DN
M61MT\A8#U4# Q^.:?0?0/%?A5M5?[;98%V!AT8X$@'3GL:\\NK*ZLI/+NK>2
M%O1U(S7=/\1+82833Y2N<9>0# ^@!KL"(;J 95)8G (R,@B@#QVRUO4M/(^S
M7DJ*#G86ROY'BN[\->+UU646=ZJQW1'R,O"R>WL:FUKPGI5Q9SS10K;3(C.'
MCX7@9Y'3%>;64KP7T$L9(=)%9<>H-&X'MU%%%(04444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% &3XAUR'0=--PXWRL=L4?\ >;_
M5X]?ZA=:G=O=7<IDE;N>@'H!V%;WCO46O?$<D 8F*U41J/?JQ_/C\*YB@ HH
MHH EM[B:TN$GMY&CE0Y5U."#7K7A/Q(NO6127"WD('F =&'9A7D%:_AG46TS
MQ#:3AB$9Q')[JW!_Q_"@#VFBBB@ HHHH **** "BBB@ HHHH *\9UO\ Y#^H
M_P#7U+_Z$:]FJD^CZ9+(TDFG6CNQ+,S0*22>I)Q0!3O[/[5X0DMCRWV0$8]5
M4$?J*\CKW0 *H50  , #M5+^Q-)_Z!EE_P" Z?X4[CN5;:T^Q>$1;X(*6AW
M_P!XJ2?U)KS'1/\ D/Z=_P!?47_H0KV5E5U*LH96&"",@BJ::/ID4BR1Z=:(
MZD,K+ H((Z$'% BX0&4JP!!&"#WKR[Q-X8GTFY>XMXV>Q<Y!49\OV/M[UZE0
M0""",@]J0'D6E^)]3TB,103!X1TCE&Y1].XJ;4?%^K:E"T+RI#$W#+"NW/XD
MD_K7H-QX8T6Z<O+I\6X]=F4_]!(ID/A30X'#)I\9(.?G9G'Y$FG<=SSS0?#U
MUK=RNU62U4_O)B./H/4UZQ;P16MO'!"@2.-0JJ.P%.1$C0(BJJ@8"J, 4ZD(
M\L\5Z!-I>H27$49-G,VY6 X0G^$^GM4&E^*]4TJ!8(I$EA7[L<JY ^A&#^M>
MLNBR(4=0RD8((R#6/-X4T.=R[Z?&"3D[&9!^0(IW'<\_U/Q9JNJP-!+(D4+?
M>2)< _B<G]:G\):#+J6I17,D9%G VYF(X<CHH]?>NYA\*:' X9-/C)'/SLSC
M\B36NB)&@1%55 P%48 HN%QU%%%(04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:_$W_D9O"7^_<_\
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MJP37$B81%/)- '$_L]_\A2;Z-_*OHZOF[]GN:,:S+$6'F$,0/PKZ1H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BB@D 9)P!0 R66.")I976.-!EF8X 'N:X_4_B)8VSM'80-=,./,)V)^
M'<US'BWQ/+K-XUM;N5L(FPH!_P!81_$?Z5S- %SQ+J+^)]0M[RY18F@QM6/H
M>>^:[C2OB);;(H+^T:$* OFQG</J1U_G7G=% 'O5K=V][;K/;3)+$W1D.14U
M>,>'?$-QH-\'4L]LY_?0YX(]1[U['!/'<P1SPN'CD4,K#N#0!)1110 4444
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MC 'Z_I7IU#$PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ KS7XF_\ (S>$O]^Y_P#08Z]*KS7XF_\
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M2Y'@#1Q"-W]G@M*0.Q%<O\$?'=AX86]L+]MJ7#APV< 8% $7[0Q'_"=0#O\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_XN?\
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M)P#@U[GX\^+<?A37+:PLS%/&ZJ6*X.W-;FL>#]'^)NC:9?ZEYH!B#+Y38ZT
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MHHH *X3XN?\ (@7?_76+_P!#%=W7"?%S_D0+O_KK%_Z&*J'Q(#NZ***D I"
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M20PLV5A*9VBO?** /&O!WP&LM$U)+W5KI+XIADC"XVMV->R !5  P ,"EHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#N>\QO&<DU]5>'5G3P]8K<DF81#?GKF@#3HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BF2RK#"\KG"(I9C["N1;XH>%$<JVH<@X/RT >2_M$_\
M?]G]?Z5Z=\(?^1%M?H/Y5XW\;O$VE>(;RU;3;CS0AYX]J]@^#LR2^!K?8<[<
M _7% 'H-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:60$=5 YK<\<^'!XJ\+7&DEPGFD'<3C&*XCP-\+$\)2:DTEY$WVNV:#[^>M
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MY $'_7TO_H+UB_#W_D,W/_7N?_0EHZ!T(?'EV\^O"W/W+>, #W/)/\ORKH?
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M HHHH **** "BBB@ HHHH \_^+G_ " -(_["\/\ Z!)4FE=5J/XN?\@#2/\
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M/Z_TKT[X0_\ (BVOT'\J .]HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O.O%OPHL?%6LG4I;@Q2D]5R#^E>BT4 >/_
M /"A['_H)3?]]M1_PH>Q_P"@E-_WVW^->P44 >/?\*'L?^@E-_WVU+_PH>Q_
MZ"4W_?;5[!10!X__ ,*'L<_\A*;_ +[;_&L7X>:4WAWXMZOHJ7$DL-OLV[F)
MZBO>J\8T#_DX#Q#]8_Y4 >ST444 %%%% !1110 4444 %%%% !1110 4444
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MU/X*GN;CPI9RW>?/9?FS7F<?Q5\"M(BC3;;). =M>MZ'?6VHZ1!=6:!('&5
MZ4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >-^/?@M>
M>,/%<^L0ZK% DJJOELI)&*\_\6? Z]\+>&KO6)-7AG2V7<8PI!-?4E<+\8?^
M28:Q_P!<Q_.@#R#]GVR+>)WN]PPJ,NW\*^F:^<?V>_\ D*3?1OY5]'4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/%%Y;/I=RDRH>2OTKV7X.3QS^!H-ASLPI^N* /0J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ
MC0/^3@/$/U3^5>SUXQH'_)P'B'ZI_*@#V>BBB@ HHHH **** "BBB@ HHHH
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MU^Z/I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %>,:!_R<!XA^L?\ *O9Z\8T#_DX#Q#]4_E0![/1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO\#3ZA%J-EJ;73Q/N2%I%)X]17M:(L:!$4*H&  , 4 .HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Q?XF?\C]I?_72/^=>SK]T?2O&/B9_R/VE_]=(_
MYU[.OW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_2O3OA#_ ,B+:_0?RKP;XK>.['QI<P26:X$9Y_*O<O@S=+<^!H=O_+,A3^5
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M"7A'_L-P?SKNZX3XA?\ (2\(_P#8;@_G51W [NBBBI **** "D.<''7M2T4
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MHH **** "BBB@ HHHH *\8T#_DX#Q#]4_E7L]>,:!_R<!XA^J?RH ]GHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\U^)O\ R,WA+_?N?_08Z]*KS7XF_P#(S>$O]^Y_]!CJH[@:
MND_PUUEM]P5R>D_PUUEM]P5(%FBBB@ HHHH *X3XN?\ (@7?_76+_P!#%=W7
M"?%S_D0+O_KK%_Z&*J'Q(#NZ***D#B?BQ87FI> +RVL YN&92H3.:^9_^$(\
M6_\ /&\_-J^SJ3 ]!0!\7-\/O$LC[FLIV8]RI)J0> O%@7:+6["^@#8KWSX@
M?&&P\)7#Z?:1"ZO1PP4C]W]:\M/Q[\0FY#CB/^Y@4 <I!\/_ !+'=Q.+*=3O
M!W!3D5]7^"K:XM/"MG#=%S,J_-OZUPG@+XTV'B2Y6PU*(6MP>%=B,,?2O6QT
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^\4?"'P]X
MKUR75KXSBXD #;'P.*X+Q_\ !OPYX:\%W^K637!N(%RNY\BO?JX7XP_\DPUC
M_KF/YT >1_L^6D;>(9+HY\Q591^5?2U?./[/?_(4F^C?RKZ.H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Q?XF?\ (_:7_P!=(_YU[.OW1]*\8^)G_(_:7_UT
MC_G7LZ_='TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_L_K_2O3OA#_ ,B+:_0?RKY_^)OQ#M/'=Q!);6,ML(STD8'/'M7O'P7NUNO
MT6U2OED(<]^* /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KQC0/^3@/$/UC_ )5[/7@!\3:;
MX8^.NOW.IS+%$Q0!FX[4 >_T5Y__ ,+D\'_]!*+_ +ZH_P"%R>#_ /H)1?\
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M?SKG_&_QBC\)>)Y](,)<Q*"2%SUK@/&7QIC\3>%KS2%@93<+C.W% %O]GO\
MY"DWT;^5?1U?,W[/MX%\3/:=V1F_2OIF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /%_B9_R/VE_]=(_YU[.OW1]*\1^+=V-.\7Z?>20R/%&T;-L&>E=1_P +
MG\/ #%M>]/\ GG0!Z/17G'_"Z/#W_/M>_P#?NC_A='A[_GVO?^_= 'H]%><?
M\+H\/?\ /M>_]^Z/^%T>'O\ GVO?^_= 'H]%><?\+H\/?\^U[_W[H_X71X>_
MY]KW_OW0!Z/17G'_  NCP]_S[7O_ '[H_P"%T>'O^?:]_P"_= 'H]%><?\+H
M\/?\^U[_ -^Z/^%T>'O^?:]_[]T >CT5YQ_PNCP]_P ^U[_W[H_X71X>_P"?
M:]_[]T >CT5YQ_PNCP]_S[7O_?NC_A='A[_GVO?^_= 'H]%><?\ "Z/#W_/M
M>_\ ?NC_ (71X>_Y]KW_ +]T >CT5YQ_PNCP]_S[7O\ W[H_X71X>_Y]KW_O
MW0!Z/17G'_"Z/#W_ #[7O_?NC_A='A[_ )]KW_OW0!Z/17G'_"Z/#W_/M>_]
M^Z/^%T>'O^?:]_[]T >CT5YQ_P +H\/?\^U[_P!^Z/\ A='A[_GVO?\ OW0!
MZ/17G'_"Z/#W_/M>_P#?NC_A='A[_GVO?^_= 'H]%><?\+H\/?\ /M>_]^Z/
M^%T>'O\ GVO?^_= 'H]%><?\+H\/?\^U[_W[H_X71X>_Y]KW_OW0!TWC/5YM
M$\.SWMNNZ1 <#\*\[^$?Q&U7Q?K-[:WT:JD2!E(.>],\:?%+1M:\-SV=M;79
ME<'&4QVKF?V?+&[BU_4)Y;>5(VC #,I /- 'T=1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Y_P#%S_D :1_V%X?_ $"2I-*ZK4?Q<_Y &D?]A>'_ - DJ32NJU3V
M0'5P_P"J%%$/^J%%2!HUPGQ"_P"0EX1_[#<'\Z[NN$^(7_(2\(_]AN#^=5'<
M#NZ***D HHHH *\2^*OQ?N- U$Z/HOEO*%!DE/;V%>VGI7QK'IZZ_P#%62TN
M3NA>_*N#W7=TH T;'XS>++"<3-.95)SMD)P17T/\._'=OXWT43@!+N,?OHQT
M%<S\1/AMX<B\#SFQT^*WG@ V2KU KBOV<I6BUO5X0?E:-0?S- 'T;1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $5S MU:RV[YV2H4./0C%
M>62? #PO+*TAN+O+')Y%>L44 ?)GQ9\!Z7X*N;>/3I97$AY\SMQ7M_P9MDMO
M T.PD[R&.?7%><?M$_\ '_9_7^E>G?"'_D1;7Z#^5 '>T444 %%%% !1110
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MW!4@6:*** "BBB@ KA/BY_R(%W_UUB_]#%=W7"?%S_D0+O\ ZZQ?^ABJA\2
M[NBBBI *9-,EO \TC!412S$]@*?67XCMY;KPYJ,$)(D>!POUQ0!YWXG\->#?
MB5*'L-3M5U(GEE;))^E<4?V;]1^T[?[9@\H]]AR*XKP!>Q^$_'T*ZQ(;<1R@
M28Y%?5%MXKT6[B62&^C9&&0<T <AX&^$6F>$;D7DK)=78& ^./RKTFLT:]IA
M( NX^?>K\<B31AXV#*>A% #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH XGQ#\+O#GB76)-3U"UWW$@ 9LXSBN"^(OPH\,^'_ VHZG8VNR
MYA3*-NZ5[G7"_&'_ ))AK'_7,?SH \E_9\M8VU^2X(_>*K '\*^E*^<?V>_^
M0I-]&_E7T=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN(LB]'S#G<U?5W@F"XM_"=E%=%C,J_-NZUO>7'_<7\J< !TH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7XP_\DPUC_KF/YURGCWXQ
M2^$_%D^D):O((E4[ACO7G_BSXTS>)O#5WI#6KH+A<%B10!K_ +/?_(4F^C?R
MKZ.KYE_9]O-OBA[3'WD9L_A7TU0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FOQ-_Y&;PE_OW/_H,=
M>E5YK\3?^1F\)?[]S_Z#'51W U=)_AKK+;[@KD])_AKK+;[@J0+-%%% !111
M0 5PGQ<_Y$"[_P"NL7_H8KNZX3XN?\B!=_\ 76+_ -#%5#XD!W=%%%2!Q7Q6
MU&?2_ %]<VTACD!"[AZ&OFKX=^"6\>^(I+62=H8U!E=\9SS7T/\ &S_DF-__
M +Z5X[\$/$>F>']7N9=0E\M7C(!H /B?\)HO"%E#?V%P\\;DB12N-N*[;]G3
M4)9=%U*UE<LJ2KLR>@Q3?BOXYT'6O"[VUI.7E(.*YCX'^*M+\.Q7RZC*4,C@
MK^5 'TQ17&#XH^&6<*+LY)P.*ZNRO8=0M$N;=MT;\@T 6**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH Y36_AYX?U_4WU"_L8Y;AP 68<UP
M?Q*^''AS1? .I7]E8Q1W$295@.E>SUPOQA_Y)AK'_7,?SH \F_9\MXSKDLY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \_P#BY_R -(_["\/_ *!)4FE=5J/XN?\
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M7=UPGQ<_Y$"[_P"NL7_H8JH?$@.[HHHJ0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .>U7P7HNL7S7EY:1R3,,%F4
M$UP?Q/\  ^AZ7\/=4O+6SCCFC3*L% (KUVN%^,/_ "3#6/\ KF/YT >3_L^0
MH=:EE(&\*PS^%?25?./[/?\ R%)OHW\J^CJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=T445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[4 345Y=?_'/PS:W9A@E$Z X+@XQ78^&/&>C>++8RZ9=I*R_?0=10!T%%%%
M#9(TEC:.10R,"K*>A!KG&^'WA%F+-X?L23R3Y==+10!\Q_'70=)T2\M5TRP@
MM Q^81+C/%>N?!Z*.+P+;[$"[@"<=SBO-/VB?^/^S^O]*].^$/\ R(MK]!_*
M@#O:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-?B;_R,WA+_?N?
M_08Z]*KS7XF_\C-X2_W[G_T&.JCN!JZ3_#766WW!7)Z3_#766WW!4@6:***
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M45\I_P#"Y_&'_/%O_'O\*/\ A<_C#_G@W_CW^% 'U917RG_PN?QA_P \6_\
M'O\ "C_A<_C#_G@W_CW^% 'U917RG_PN?QA_SP;_ ,>_PH_X7/XP_P">#?\
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M/?X4?\+G\8?\\6_\>_PH ^K**^4_^%S^,/\ GB__ (]_A1_PN?QA_P \7_\
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M>-,C[0ZQGMF,B@#ZVR#W%+D>M?)MK\8/''D_N,2)_>$1-3?\+?\ 'W_//_R
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M ?5F1ZT9'K7RG_PM_P ??\\__(!H_P"%O^/O^>?_ ) - 'U9D>M&1ZU\I_\
M"W_'W_//_P @&C_A;_C[_GG_ .0#0!]69'K1D>M?*?\ PM_Q]_SS_P#(!H_X
M6_X^_P">?_D T ?5F1ZT9'K7RG_PM_Q]_P \_P#R :/^%O\ C[_GG_Y - 'U
M9D>M&1ZU\I_\+?\ 'W_//_R :/\ A;_C[_GG_P"0#0!]69'K1D>M?*?_  M_
MQ]_SS_\ (!H_X6_X^_YY_P#D T ?5F1ZTFY?4?G7RFWQ?\>;#N3 QR?)-4+?
MXO\ C#S?W4RNWH$)H ^O,CUHR/6OE/\ X6_X^_YY_P#D T?\+?\ 'W_//_R
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M (6_X^_YY_\ D T ?5F1ZT9'K7RG_P +?\??\\__ " :/^%O^/O^>?\ Y -
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M,'CKRE\M0R8X(A)S0!]89'K1D>M?*?\ PM_Q]_SS_P#(!H_X6_X^_P">?_D
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MK=HH PO^$.T'_H'Q?E1_PAV@_P#0/B_*MVB@#"_X0[0?^@?%^5'_  AV@_\
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M(=H/_0/B_*C_ (0_0?\ H'Q?E6[10!A?\(=H/_0/B_*C_A#M!_Z!\7Y5NT4
M87_"':#_ - ^+\J\.^/>CV&F?9?L=NL18C.WZ5]'5\__ +17_+G]1_*@#I?A
M#X<TF_\ !<,US9I)(0,L17??\(=H/_0/B_*N5^"O_(BP?0?RKT>@#"_X0[0?
M^@?%^5'_  AV@_\ 0/B_*MVB@#"_X0[0?^@?%^5'_"'Z#_T#XORK=HH PO\
MA#M!_P"@?%^5'_"':#_T#XORK=HH PO^$/T'_H'Q?E1_PAV@_P#0/B_*MVB@
M#"_X0[0?^@?%^5'_  AV@_\ 0/B_*MVB@#"_X0[0?^@?%^5'_"':#_T#XORK
M=HH PO\ A#]!_P"@?%^5'_"':#_T#XORK=HH PO^$.T'_H'Q?E1_PA^@_P#0
M/B_*MVB@#"_X0[0?^@?%^5'_  AV@_\ 0/B_*MVB@#"_X0[0?^@?%^5'_"':
M#_T#XORK=HH PO\ A#M!_P"@?%^5'_"'Z#_T#XORK=HH PO^$.T'_H'Q?E1_
MPAV@_P#0/B_*MVB@#"_X0_0?^@?%^5'_  AV@_\ 0/B_*MVB@#E]5\):''I-
MTRV$8(C)!Q7S-X1LK:?XHM;2QAH?-8;?QKZSUC_D#7?_ %R-?*G@O_DK;_\
M79_YT ?3G_"'Z"0/^)?%T]*/^$.T'_H'Q?E6XOW1]*6@#"_X0[0?^@?%^5'_
M  AV@_\ 0/B_*MVB@#"_X0[0?^@?%^5'_"':#_T#XORK=HH PO\ A#M!_P"@
M?%^5'_"':#_T#XORK=HH PO^$.T'_H'Q?E1_PAV@_P#0/B_*MVB@#"_X0_0?
M^@?%^5'_  AV@_\ 0/B_*MVB@#"_X0[0?^@?%^5'_"'Z#_T#XORK=HH PO\
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MZ^T328-$TB"PMQB.)<8]Z +=S;17<#0SH'C;JI[UE?\ "*:+_P ^,?Y5M44
M8O\ PBFB_P#/C'^5<9\5_#VEV?PWU:>"T1)$0%6 Z5Z;7"_&'_DF&L?]<Q_.
M@#Q_X#Z58ZAJLINX!(0#C/TKZ _X131?^?&/\J\+_9[_ .0I-]&_E7T=0!B_
M\(IHO_/C'^5'_"*:+_SXQ_E6U10!B_\ "*:+_P ^,?Y4?\(IHO\ SXQ_E6U1
M0!B_\(IHO_/C'^5'_"*:+_SXQ_E6U10!B_\ "*:+_P ^,?Y4?\(IHO\ SXQ_
ME6U10!B_\(IHO_/C'^5'_"*:+_SXQ_E6U10!B_\ "*:+_P ^,?Y4?\(IHO\
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M ,^,?Y4?\(IHO_/C'^5;5% &+_PBFB_\^,?Y4?\ "*:+_P ^,?Y5M44 8O\
MPBFB_P#/C'^5'_"*:+_SXQ_E6U10!B_\(IHO_/C'^5'_  BFB_\ /C'^5;5%
M 'C/QPT/3;#P9%);6J1OYN,J/:N?_9]TFQU&WU0W=NLI4#&[M78?'S_D1XO^
MNW]*YS]F_P#X]]6_X#_.@#U__A%-%_Y\8_RH_P"$4T7_ )\8_P JVJ* ,7_A
M%-%_Y\8_RH_X131?^?&/\JVJ* ,7_A%-%_Y\8_RH_P"$4T7_ )\8_P JVJ*
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MH45(&C7"?$+_ )"7A'_L-P?SKNZX3XA?\A+PC_V&X/YU4=P.[HHHJ0"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#YW_:%AFEO[/RXI'&>JJ2.E>F?"-'3P-:AT9#@<,,'I79W.GVEX0;B!),
M?WAFI88(K>,1Q($4=@* )**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "LWQ "= O0 2?*/ K2I&4.I5AD'J*
M/D_X<6\Z_%!V:WE \UN2A'\5?6-4XM*L8)O.CMHUD_O!1FKE !1110 4444
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M0 FE@C3+<$8.P<'Z5<I  !@=*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M,$5T=QI]K=',\*.?<5-'&D,82-0JC@ 4 /HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FR?ZMOI3J* /DF\LKP_&2YD%I.4-V3NV'&/7-?5U@"+
M"W!&#Y8_E3#IEF9S,;=/,)SNQS5L  8'2@ HHHH **** "BBB@#S_P"+G_(
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M*** "BBB@ HHHH **** "BBB@ HHHH ***Y7QYXVM/!&B&^G DE8[8X_[S4
M=517RO=_&[Q9J-P\UM;F*/.=D6X@?I79?#_XX3ZEJT&D:W;I&96"),"22?>@
M#W:BJ6I:G;Z7I<^H3N!#%&7SGK@5\XZY\=M>U*_D32+7R[=6^0IG<P]Q0!]-
MT5X/\/?C;<ZCK4.CZY J&9@D<N3G=[U[N"& (.0>XH 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1V5$9V.%49)]!0
MM%?.WQ'^,VH6_B%[#0I0MO;G!E4_?KV/P%JUSK7A:VO;MBTKCDGZ4 =-17F7
MQ1^*2^"5BLK.))[Z9=P!/"BO)(?C?XKMK@74L!>(G(5\A3^.* /JBBN5\!>-
M+;QMH"W\("2J=DD?HW>NJH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ&GKY*J$E3'8D9KZF\*W#7?A32IV;<SVR%C[XKYE^.[ _$NY4=1"F?RKZ/\
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M_$W_ )&;PE_OW/\ Z#'51W U=)_AKK+;[@KD])_AKK+;[@J0+-%%% !1110
M5PGQ<_Y$"[_ZZQ?^ABN[KA/BY_R(%W_UUB_]#%5#XD!W=%%%2 4444 %%%%
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MR(5CS]!BL7PSX \.^$G>32;+RY'&&=SN/ZUT] !1110 4444 %%%% !1110
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M998R%45]3^#/#47A3PW;Z7%@[/F8CU- &_1110 4444 %%%% !1110 4444
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ME&@!?#$?]L?$=/+7<)9BPQ7V3:IY=I"G]U%'Z5XA\&?AE=Z3=IKVJ1^5.O\
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MFN(0^^-H5)VUDMH/C/QAJ5O#>65T2/E$DD9"J* /2/V>+%B;B]VG:"R[L5]
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MTKKOAC\+-4U36X]4UBW>WBB?S LJD%FSG- 'T'X1M&LO#%E R[2J=*VZ0
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M'_L-P?SKNZX3XA?\A+PC_P!AN#^=5'<#NZ***D HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KS7XF_P#(S>$O]^Y_]!CKTJO-
M?B;_ ,C-X2_W[G_T&.JCN!JZ3_#766WW!7)Z3_#766WW!4@6:*** "BBB@ K
MA/BY_P B!=_]=8O_ $,5W=<)\7/^1 N_^NL7_H8JH?$@.[HHHJ0"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D90R
ME6 (/4&EHH :D:1KM10H] *=110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4SRHS)YFQ=_KCFGT4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 (0""",@TB1I&,(H4>PIU% !1110 4444 %%%%
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M+P_^@25)I75:I[(#JX?]4**(?]4**D#1KA/B%_R$O"/_ &&X/YUW=<)\0O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^,M+%W8L58<-&QY!JKXX\?Z9X)L!+=$R3/D)&G)!]Z .NHKYKF_:"UIKG=!
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M6HH!! (.0:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_C1\.=9\3ZE8W>A68G8*PG^<+@]NM3?!7X>ZSX1OKZ\UFU$,DT81!N![^U
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M_P#0Q50^) =W1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)>F121U7=FOJO0?B#H6H^'8K\WBHJ1C>#U&!0!\N^.M$?PEXUN[>S!BACES
M1Z5ZYXPN=0\3?!&":WW2M%Y:R(HY..IKR;XBZZOB;QM>S69,EN9<0X')%>[6
M&LV/P^^'MJNKP;DN(E;85R#D4 >"^"?%5CX6U!I[[2_MJD8V9QBN\FU/X?\
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M!7'_ !V_Y'Z?_=7^5>Z_"50OP]TP^L0H XOXSZ+9:!\.EL["(1P^>GRBN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU#7)([B2,YVJ<@FO;J* &HBQHJ( %48 ':G444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!Y_\7/^0!I'_87A_P#0)*DTKJM1_%S_ ) &
MD?\ 87A_] DJ32NJU3V0'5P_ZH440_ZH45(&C7GWQ-NH;&7PQ>7+[+>WUB&6
M5\$[57DG Y/ ->@U6N84FCVR(KKUPPR*:=G<#E_^%J>"_P#H,_\ DK-_\11_
MPM3P7_T&?_)6;_XBK%]I5NV<6\7_ 'P*QI=%B)_U$?\ WR*?N@:/_"U/!?\
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MG@O_ *#/_DK-_P#$5E?V)%_SP3_OD4?V)%_SP3_OD4>Z!J_\+4\%_P#09_\
M)6;_ .(H_P"%J>"_^@S_ .2LW_Q%97]B1?\ /!/^^11_8D7_ #P3_OD4>Z!J
M_P#"U/!?_09_\E9O_B*/^%J>"_\ H,_^2LW_ ,165_8D7_/!/^^11_8D7_/!
M/^^11[H&K_PM3P7_ -!G_P E9O\ XBC_ (6IX+_Z#/\ Y*S?_$5E?V)%_P \
M$_[Y%']B1?\ /!/^^11[H&K_ ,+4\%_]!G_R5F_^(H_X6IX+_P"@S_Y*S?\
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M7_/!/^^11_8D7_/!/^^11[H&K_PM3P7_ -!G_P E9O\ XBC_ (6IX+_Z#/\
MY*S?_$5E?V)%_P \$_[Y%']B1?\ /!/^^11[H&K_ ,+4\%_]!G_R5F_^(H_X
M6IX+_P"@S_Y*S?\ Q%97]B1?\\$_[Y%']B1?\\$_[Y%'N@:O_"U/!?\ T&?_
M "5F_P#B*/\ A:G@O_H,_P#DK-_\165_8D7_ #P3_OD4?V)%_P \$_[Y%'N@
M:O\ PM3P7_T&?_)6;_XBC_A:G@O_ *#/_DK-_P#$5E?V)%_SP3_OD4?V)%_S
MP3_OD4>Z!J_\+4\%_P#09_\ )6;_ .(H_P"%J>"_^@S_ .2LW_Q%97]B1?\
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M97]B1?\ /!/^^11_8D7_ #P3_OD4>Z!J_P#"U/!?_09_\E9O_B*/^%J>"_\
MH,_^2LW_ ,165_8D7_/!/^^11_8D7_/!/^^11[H&K_PM3P7_ -!G_P E9O\
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M3P7_ -!G_P E9O\ XBC_ (6IX+_Z#/\ Y*S?_$5E?V)%_P \$_[Y%']B1?\
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M_H,_^2LW_P 15R^TNW;.+>+_ +X%8DVBQ%C^XC_[X%/W0+__  M3P7_T&?\
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MS?\ Q%9/]AQ?\\$_[Y%']AQ?\\$_[Y%'N@:W_"U/!?\ T&?_ "5F_P#B*/\
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M(H_X6IX+_P"@S_Y*S?\ Q%9/]AQ?\\$_[Y%']AQ?\\$_[Y%'N@:W_"U/!?\
MT&?_ "5F_P#B*/\ A:G@O_H,_P#DK-_\163_ &'%_P \$_[Y%']AQ?\ /!/^
M^11[H&M_PM3P7_T&?_)6;_XBC_A:G@O_ *#/_DK-_P#$5D_V'%_SP3_OD4?V
M'%_SP3_OD4>Z!K?\+4\%_P#09_\ )6;_ .(H_P"%J>"_^@S_ .2LW_Q%9/\
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MG@O_ *#/_DK-_P#$5D_V'%_SP3_OD4?V'%_SP3_OD4>Z!K?\+4\%_P#09_\
M)6;_ .(H_P"%J>"_^@S_ .2LW_Q%9/\ 8<7_ #P3_OD4?V'%_P \$_[Y%'N@
M:W_"U/!?_09_\E9O_B*/^%J>"_\ H,_^2LW_ ,163_8<7_/!/^^11_8<7_/!
M/^^11[H&M_PM3P7_ -!G_P E9O\ XBC_ (6IX+_Z#/\ Y*S?_$5D_P!AQ?\
M/!/^^11_8<7_ #P3_OD4>Z!K?\+4\%_]!G_R5F_^(H_X6IX+_P"@S_Y*S?\
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M7_/!/^^11_8<7_/!/^^11[H&M_PM3P7_ -!G_P E9O\ XBC_ (6IX+_Z#/\
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M!?\ T&?_ "5F_P#B*/\ A:G@O_H,_P#DK-_\163_ &'%_P \$_[Y%']AQ?\
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M &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?\
M8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_8E]*/
ML2^E:&!1@4 9_P!B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI
M6A@48% &?]B7TH^Q+Z5H8%&!0!G_ &)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%
M&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?\ 8E]*/L2^E:&!1@4
M9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_P!B
M7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?]B7TH^Q
M+Z5H8%&!0!G_ &)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:
M&!1@4 9_V)?2C[$OI6A@48% &?\ 8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48
M% &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_P!B7TH^Q+Z5H8%&!0!G
M_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_ &)?
M2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$O
MI6A@48% &?\ 8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8
M%&!0!G_8E]*/L2^E:&!1@4 9_P!B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4
M 9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_ &)?2C[$OI6A@48% &?]
MB7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?\ 8E]*
M/L2^E:&!1@4 9_V)?2C[$OI6A@48% &?]B7TH^Q+Z5H8%&!0!G_8E]*/L2^E
M:&!1@4 9_P!B7TH^Q+Z5H8%&!0!G_8E]*/L2^E:&!1@4 9_V)?2C[$OI6A@4
M8% &?]B7TH^Q+Z5H8%&!0!G_ &)?2E%FH/2K^!1@4 5XX O:IU&*=BB@ HHH
MH **** "D(S2T4 5Y(0W:H#9J>U7\48H SOL2^E'V%?2M'%&* ,[["OI1]A7
MTK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#
M.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?8
M5]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H
M SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'
MV%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&
M* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI
M1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q
M1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PK
MZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T
M<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL
M*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2
MM'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[
M["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7
MTK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#
M.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?8
M5]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H
M SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'
MV%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&
M* ,[["OI1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI
M1]A7TK1Q1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q
M1B@#.^PKZ4?85]*T<48H SOL*^E'V%?2M'%&* ,[["OI1]A7TK1Q1B@#.^PK
MZ4?85]*T<48H SOL*^E'V%?2M'%&* ,\62CM4R6X7M5K%&* &!<"BGT4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:[CP;N0^3:IC.9#T..X'7\*P?A?K?B#7$U637+TSBWE6&-?*1 K#)?[JC/\
M#7-Z_JY\0^(]4UQ3NTCPW"PMB?NR7)X4^_SX/T4>M==\)[$V?@*UE8?/=RR3
MMGJ<G:#^2B@#+U+QEXDU[Q)=Z)X.MH EFQ6>\F (# D'&> ,Y X).,]*AO'^
M*GA^%KZ>[L-6@B&^2**-<[1UX"(3^&:SFDU?X5^)=2N_[.>]T'4)=YD3JG)(
M!/8C<1@\&O0/#_CG0/$NU+&]5;@_\NTWR2?@._X$T 2>$/%%OXMT%-1AC\J0
M,8YHB<['';/<8((^M<OKOC/7]1\43^&_"-I$T]L/](NIAD(>^,\ #ISG)Z"N
MST7P]I7AZ"6'2K06T<K;W4.S9/\ P(FO-=436/AQXTU+7[>P-_H^I.7F*]8R
M3N.3SM().">"#Z] "[<1_%?283>-?:?J2(-S6\<:YP.HQL4G\#FNK\%>+H?%
M^C-="'R+F%_+N(<YVMCJ/8_XBF^'O'_A[Q(4BM;P0W3?\NUQ\CD^@[-^!-:F
MD^'M*T*2ZDTVT%NUV^^8AV;><D]R<=3TH TZJ:EJ5II&G37]],L-M"NYW/\
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M(,"5>.PXS@@Y'!%=W7D-KJD.L?'R*:Q=7@@B>%Y%Y#[8F!.>_P Q S[5Z]0
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M1ZM?HB/<RR-'&@P$0-M ]3T/)]:FTNU\11^(=1GU*_MY=*?BSMHE&Z/GJQV
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MO0!Z!"KI"BR/O<* SXQN/<\4^O._%?BC6-1\2IX1\*NL=YMW75V>D(QG /;
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M?0;O0+"6&^UJ[U:>23?YUPS?*,8"@%FQW[]ZUKJ?[+:37'E22^4C/Y<2EG;
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M+:WEGD.$C0NQ]@,FN.^&>MZOXAT*ZU+5KD2[[ID@41JNQ0!_= SR<<^E:'Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9&ED@1/GD8K@'E?EZ+G#=J (-1_XG'QTT^WSF+2[7S& _O8+ _FZ?E3_ (L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#GA72?"UHT&F6Y5GQYDSG<\F/4_T&!0!B_$72XC\-+VUA3"6D<;1#KM",O\
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M&"W6!BRX$F!@DCWY./>N'G^$WV>ZFDT'Q)?Z3!,?G@CRP(],AEX^N: .=NO
MW@BW\4V_AV.ZUZZOYOO?9WA98?\ ?)48P!D\'BM753%;_'C1UNP%@%JJ6^[H
M#M<+_P"/9 ]ZZ[PGX&TSPFLDL!DN+Z88ENIOO$9S@>@S^?<TGC'P/8>,(83-
M*]M=P9$5Q&,D ]B.XH U/$6N6WAW0[K4[I@%B0[%)YD?^%1[DUPWP5LBGA[4
M-1?_ %EW=;<^H4?XLU/;X2F[M)$U7Q)?:C<",I;R3ABD'N%+DG\P*[+PMH">
M&/#MMI*3>?Y.XM+LV[R6)SC)QUQU[4 ;%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!%<6MO=H$N8(ID5@P61 P!'0\]ZEHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>grts-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T16:11:15.1974+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="grts-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1" xlink:href="grts-20211231.xsd#DisclosureOrganization1" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="grts-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="grts-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="grts-20211231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:href="grts-20211231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:href="grts-20211231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="grts-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:href="grts-20211231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:href="grts-20211231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" xlink:href="grts-20211231.xsd#DisclosureOrganizationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:href="grts-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:href="grts-20211231.xsd#DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="grts-20211231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_ContributionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_25"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeaseCost1" xlink:label="grts_OperatingLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PipeFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_StockOptionsWarrantsAndOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grts_OperatingLeaseCost1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_PaymentsOfFinancingLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_PrepaymentsOnFinancingLease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_EsppEmployeeStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_OtherRisksAndUncertaintiesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborativeAndLicenseAgreementsAbstract" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CollaborativeAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CepInnovationsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="grts_CashCashEquivalentsAndMarketableSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="grts_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember_3"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_ContractResearchOrganizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_EmeryvilleCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_PleasantonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="grts_CommitmentsAndContingenciesDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_BostonLeaseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_TenantImprovements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_PaymentOfLeaseBaseRent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperationsExpectedCommencedDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDeposit" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AnnualBaseRent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LeaseExpirationTerm" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MaximumMilestonePaymentObligation" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WeightedAverageDiscountRateAbstract" xlink:label="grts_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_WeightedAverageRemainingLeaseTermYearsAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="grts_WeightedAverageDiscountRateAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GenevantSciencesGmbHMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_SeventyMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumPotentialMilestoneReceivable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractStartMonthYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndMonthYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReceivablesGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockFairValueClosingPricePerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_NonRefundableOptionFee" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePayment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementTerminationTerm" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndPeriod" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpFrontPayment" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureFundingExpected" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumMilestoneConsiderationPayable" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreedUpfrontPayment" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmountToExtendOptionTerm" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePayments" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_InitialFundingDevelopmentCosts" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FundingDevelopmentCosts" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCosts" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCostsAmortized" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FirstTrancheOfFundingsReceived" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AdditionalFunding" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreementTotalFunding" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_3"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetAddition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityAddition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityDeductions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetDeduction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_NetContractAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_CollaborationReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="grts_InterestAndOtherReceivablesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PlacementAgentCommissionsAndLegalFees" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsCancelled" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsOutstanding" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightIssueDate" xlink:label="grts_ClassOfWarrantOrRightIssueDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightsExpiration" xlink:label="grts_ClassOfWarrantOrRightsExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="grts_ClassOfWarrantOrRightIssueDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="grts_ClassOfWarrantOrRightsExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="grts_EmployeeOrDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonTaxableStockPremium" xlink:label="grts_NonTaxableStockPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_NonTaxableStockPremium" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="grts_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesTable" xlink:to="grts_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OwnershipInterestChangeOverPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="grts_DeferredTaxAssetsAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PostDecember312017Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PreJanuary12018Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsCancelled" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>grts-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T16:11:15.4049+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:href="grts-20211231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="grts-20211231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="grts-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:href="grts-20211231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="grts_ContributionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="grts_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeaseCost1" xlink:label="grts_OperatingLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PipeFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_StockOptionsWarrantsAndOtherMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="grts_OperatingLeaseCost1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="grts_PaymentsOfFinancingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_EsppEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="grts_PrepaymentsOnFinancingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="grts_IncreaseDecreaseInLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CepInnovationsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_ShortTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="grts_LongTermMarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="grts_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_EmeryvilleCaliforniaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_ContractResearchOrganizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_CambridgeMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_PleasantonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="grts_BostonLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperationsCommencedDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_PaymentOfLeaseBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_OperationsExpectedCommencedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_RestrictedCashDeposit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_AnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_LeaseExpirationTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_MaximumMilestonePaymentObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GenevantSciencesGmbHMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumPotentialMilestoneReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractStartMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndMonthYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReceivablesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockFairValueClosingPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_NonRefundableOptionFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CollaborationAgreementTerminationTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_RevenueRecognitionContractEndPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_UpFrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FutureFundingExpected" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumMilestoneConsiderationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreedUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AmountToExtendOptionTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_InitialFundingDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FundingDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_DeferredContractAcquisitionCostsAmortized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_FirstTrancheOfFundingsReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AdditionalFunding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="grts_AgreementTotalFunding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BluebirdBioIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_GileadSciencesIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_BlueBirdBioTo2SeventyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetAddition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityAddition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="grts_GatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="grts_ContractWithCustomerLiabilityDeductions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_CEPIFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="grts_ContractWithCustomerAssetDeduction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_FundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="grts_GrantAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="grts_CommonStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_PrivateInvestmentInPublicEquityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_PlacementAgentCommissionsAndLegalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsCancelled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="grts_WarrantsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="grts_EmployeeOrDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="grts_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_OwnershipInterestChangeOverPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="grts_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PostDecember312017Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="grts_PreJanuary12018Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="grts_WarrantsCancelled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>grts-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T16:11:15.6104+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" xlink:href="grts-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="grts-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" xlink:href="grts-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="grts-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:href="grts-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:href="grts-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:href="grts-20211231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:href="grts-20211231.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="grts_DepositsAndOtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="grts_PaymentsOfFinancingLease" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_OperatingLeaseCost1" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="grts_PrepaymentsOnFinancingLease" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="grts_IncreaseDecreaseInLeaseLiability" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="14" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeaseCost1" xlink:label="grts_OperatingLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_NetContractAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_CollaborationReceivable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="grts_InterestAndOtherReceivablesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="us-gaap_SecurityDeposit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsLeaseLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="grts_DeferredTaxAssetsAmortization" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>grts-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T16:11:14.6819+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightWarrantsExercised" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborativeAndLicenseAgreementsAbstract" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ComputerEquipmentAndSoftwareMember" xlink:label="grts_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BluebirdBioIncMember" xlink:label="grts_BluebirdBioIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingAgreementMember" xlink:label="grts_FundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GatesFoundationMember" xlink:label="grts_GatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PreJanuary12018Member" xlink:label="grts_PreJanuary12018Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractResearchOrganizationMember" xlink:label="grts_ContractResearchOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FundingDevelopmentCosts" xlink:label="grts_FundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightIssueDate" xlink:label="grts_ClassOfWarrantOrRightIssueDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsAmortization" xlink:label="grts_DeferredTaxAssetsAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndOrPreFundedWarrantsMember" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CEPIFundingAgreementMember" xlink:label="grts_CEPIFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightsExpiration" xlink:label="grts_ClassOfWarrantOrRightsExpiration"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PostDecember312017Member" xlink:label="grts_PostDecember312017Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsCancelled" xlink:label="grts_WarrantsCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WeightedAverageDiscountRateAbstract" xlink:label="grts_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GenevantSciencesGmbHMember" xlink:label="grts_GenevantSciencesGmbHMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureTable" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA" xlink:label="stpr_MA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenStockIncentivePlanMember" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesCConvertiblePreferredStockMember" xlink:label="grts_SeriesCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AtTheMarketEquityOfferingProgramMember" xlink:label="grts_AtTheMarketEquityOfferingProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetDeduction" xlink:label="grts_ContractWithCustomerAssetDeduction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePayments" xlink:label="grts_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LaboratoryEquipmentMember" xlink:label="grts_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCosts" xlink:label="grts_DeferredContractAcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromSaleOfMarketableSecurities" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PublicOfferingMember" xlink:label="grts_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerAssetAddition" xlink:label="grts_ContractWithCustomerAssetAddition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockAndWarrantsMember" xlink:label="grts_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrivateInvestmentInPublicEquityMember" xlink:label="grts_PrivateInvestmentInPublicEquityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PlacementAgentCommissionsAndLegalFees" xlink:label="grts_PlacementAgentCommissionsAndLegalFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLossCarryforwardsExpirationYear" xlink:label="grts_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeriesABAndCConvertiblePreferredStockMember" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesTable" xlink:label="grts_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedStockSubjectToFutureVestingMember" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LeaseExpirationTerm" xlink:label="grts_LeaseExpirationTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GileadSciencesIncMember" xlink:label="grts_GileadSciencesIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperationsExpectedCommencedDate" xlink:label="grts_OperationsExpectedCommencedDate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ResearchCollaborationAndLicenseAgreementMember" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CepInnovationsMember" xlink:label="grts_CepInnovationsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NetContractAsset" xlink:label="grts_NetContractAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UpFrontPayment" xlink:label="grts_UpFrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SummaryOfSignificantAccountingPoliciesTable" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmeryvilleCaliforniaMember" xlink:label="grts_EmeryvilleCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShortTermMarketableSecuritiesMember" xlink:label="grts_ShortTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndMonthYear" xlink:label="grts_RevenueRecognitionContractEndMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreedUpfrontPayment" xlink:label="grts_AgreedUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SeventyMember" xlink:label="grts_SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BostonLeaseMember" xlink:label="grts_BostonLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureFundingExpected" xlink:label="grts_FutureFundingExpected"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationReceivable" xlink:label="grts_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InterestAndOtherReceivablesCurrent" xlink:label="grts_InterestAndOtherReceivablesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AnnualBaseRent" xlink:label="grts_AnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CambridgeMassachusettsMember" xlink:label="grts_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonTaxableStockPremium" xlink:label="grts_NonTaxableStockPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestoneConsiderationPayable" xlink:label="grts_MaximumMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsToPurchaseSharesOfCommonStock" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedGains" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredContractAcquisitionCostsAmortized" xlink:label="grts_DeferredContractAcquisitionCostsAmortized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EsppEmployeeStockPurchasePlanMember" xlink:label="grts_EsppEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PipeFinancingMember" xlink:label="grts_PipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityDeductions" xlink:label="grts_ContractWithCustomerLiabilityDeductions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentOfLeaseBaseRent" xlink:label="grts_PaymentOfLeaseBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesRealizedGainLossDescription" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdditionalFunding" xlink:label="grts_AdditionalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LongTermMarketableSecuritiesMember" xlink:label="grts_LongTermMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractStartMonthYear" xlink:label="grts_RevenueRecognitionContractStartMonthYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashCashEquivalentsAndMarketableSecurities" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContributionMember" xlink:label="grts_ContributionMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RevenueRecognitionContractEndPeriod" xlink:label="grts_RevenueRecognitionContractEndPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaymentsOnFinancingLease" xlink:label="grts_PrepaymentsOnFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumMilestonePaymentObligation" xlink:label="grts_MaximumMilestonePaymentObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:label="us-gaap_OperationsCommencedDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementMember" xlink:label="grts_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OwnershipInterestChangeOverPeriod" xlink:label="grts_OwnershipInterestChangeOverPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_RestrictedCashDeposit" xlink:label="grts_RestrictedCashDeposit"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumAggregateContingentMilestonePayment" xlink:label="grts_MaximumAggregateContingentMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_GrantAgreementMember" xlink:label="grts_GrantAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FollowOnPublicOfferingMember" xlink:label="grts_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPotentialMilestoneReceivable" xlink:label="grts_MaximumPotentialMilestoneReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_WarrantsOutstanding" xlink:label="grts_WarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_BlueBirdBioTo2SeventyMember" xlink:label="grts_BlueBirdBioTo2SeventyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AgreementTotalFunding" xlink:label="grts_AgreementTotalFunding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CommonStockFairValueClosingPricePerShare" xlink:label="grts_CommonStockFairValueClosingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountToExtendOptionTerm" xlink:label="grts_AmountToExtendOptionTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ContractWithCustomerLiabilityAddition" xlink:label="grts_ContractWithCustomerLiabilityAddition"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ReceivablesGross" xlink:label="grts_ReceivablesGross"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CashAndCashEquivalentsUnrealizedLosses" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DepositsAndOtherAssetsNoncurrent" xlink:label="grts_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromNonRefundableUpfrontPayment" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PaymentsOfFinancingLease" xlink:label="grts_PaymentsOfFinancingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationOptionAndLicenseAgreementMember" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PrepaidExpenseForResearchAndDevelopment" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_PleasantonMember" xlink:label="grts_PleasantonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EmployeeOrDirectorMember" xlink:label="grts_EmployeeOrDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeasePaymentUnderTheBostonLease" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_OperatingLeaseCost1" xlink:label="grts_OperatingLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncreaseDecreaseInLeaseLiability" xlink:label="grts_IncreaseDecreaseInLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_StockOptionsWarrantsAndOtherMember" xlink:label="grts_StockOptionsWarrantsAndOtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_CollaborationAgreementTerminationTerm" xlink:label="grts_CollaborationAgreementTerminationTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_IncomeTaxesLineItems" xlink:label="grts_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_ProceedsFromMaturityOfMarketableSecurities" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_FirstTrancheOfFundingsReceived" xlink:label="grts_FirstTrancheOfFundingsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_InitialFundingDevelopmentCosts" xlink:label="grts_InitialFundingDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_NonRefundableOptionFee" xlink:label="grts_NonRefundableOptionFee"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="grts-20211231.xsd#grts_DeferredTaxAssetsLeaseLiability" xlink:label="grts_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 1 to Level 2 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates Of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificates of Deposit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New right-of-use assets obtained in exchange for lease obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New right-of-use assets obtained in exchange for lease obligations (in thousands):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arbutus Biopharma Corporation And Protiva Biotherapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative and license agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborativeAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative And License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment and Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option and License and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option And License And Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option and license and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bluebird Bio Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bluebird Bio Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BluebirdBioIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bluebird Bio Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled/Forfeited | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued and other liabilities non-current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued And Other Liabilities Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; 69,047,878 and 47,552,693 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share, prepaid by purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share, Prepaid by Purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Stock, Price Per Share, Prepaid by Purchaser</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision Of Prior Period Accounting Standards Update Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gates Foundation Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement early termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Early Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement early termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average common shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, estimated useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre January 1, 2018.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre January12018 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PreJanuary12018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre January12018</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Research Organization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research Organization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractResearchOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Research Organization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for consulting services, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, issue date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issue Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightIssueDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issue Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of need for additional capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Need For Additional Capital Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Need for Additional Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and Rights outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasuries [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock purchase price in excess of fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Purchase Price In Excess Of Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Price In Excess Of Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Notes 6 and 7)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Potentially Anti-Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock-based compensation expense and awards granted to non-employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Years 2020 and 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Years Two Thousand and Twenty Two Thousand and Twenty One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable years two thousand and twenty two thousand and twenty one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan ("ESPP"), shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and/or pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Or Pre Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndOrPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Pre-funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C E P I Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CEPI funding agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CEPIFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C E P I Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reclassified common stock and additional paid in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightsExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Exclusive license and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Exclusive License And Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Exclusive License and Development Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases accrued but not yet paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post December 31, 2017.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post December312017 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PostDecember312017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post December312017</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short term deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants cancelled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases additional number of renewal terms.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Additional Number Of Renewal Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases number of renewal terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Canceled/Forfeited | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genevant Sciences GmbH.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genevant Sciences Gmb H [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genevant Sciences GmbH [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GenevantSciencesGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Genevant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right nominal exercise price of warrants or rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Nominal Exercise Price Of Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant nominal exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Class of warrant nominal exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum securities covered under registration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Securities Covered Under Registration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remeasurement of operating lease right-of-use assets for lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of operating lease right-of-use asset for lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposit assets and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of net operating loss and tax credit carryforwards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Net Operating Loss And Tax Credit Carryforwards Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Operating Loss and Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities accumulated gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate contingent milestone payments to be made by company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Contingent Milestone Payment To Be Made</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate contingent milestone payment to be made.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Award Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities that were not included in the diluted per share calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity offering program member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ATM Equity Offering Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Sales Purchase Agreement, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Deduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset deduction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets, Level 2 to Level 1 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for issuance cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for warrant exercises, Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs related to the sale of common stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases for tax positions taken during current period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended And Restated Certificate Of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Certificate Of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated Certificate of Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent income tax rate differential.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restatement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred contract acquisition costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Contract Acquisition Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred contract acquisition costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Sale of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncurrent portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deposit and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deposit And Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Addition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerAssetAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer asset addition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Land</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net rentable area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Investment In Public Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrivateInvestmentInPublicEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Investment in Public Equity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, unvested Beginning balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, unvested ending balance | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of New Accounting Pronouncements Not Yet Adopted 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities accumulated gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent commissions and legal fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Commissions And Legal Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PlacementAgentCommissionsAndLegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent commissions and legal fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lapse of repurchase rights related to common stock issued pursuant to early exercises.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lapse of repurchase rights related to common stock issued pursuant to early exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A, B, and C convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A B And C Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeriesABAndCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A B And C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Minimum Annual Payments Under Lease Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation by shared based payment award, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position Number Of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individual securities in an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Subject to Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Subject to Future Vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents operating lease notice period to terminate for the additional temporary space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Notice Period To Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary space lease termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LeaseExpirationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gilead Sciences, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Sciences Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GileadSciencesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of stock option awards exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage fair market value of share price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Fair Market Value Of Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage fair market value of share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operations expected commenced date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operations commenced date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperationsExpectedCommencedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operations expected commenced date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ResearchCollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CEPI [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cep Innovations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CepInnovationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net contract asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Contract Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NetContractAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net contract asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UpFrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense For Research And Development Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emeryville California.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emeryville California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmeryvilleCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emeryville California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShortTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized Including New Contracts In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability revenue recognized including new contracts in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract end year-month.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract End Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract end month year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early termination reduction of future milestone and royalty payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Termination Reduction Of Future Milestone And Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination reduction of future milestone and royalty payments, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale debt securities amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreed upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreed Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreedUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2 Seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2 Seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BostonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BostonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Funding Expected</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Funding Expected</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureFundingExpected_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of funding expected in future.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Receivables Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InterestAndOtherReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other receivables current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for issuance granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number of Shares, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-taxable stock premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Taxable Stock Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonTaxableStockPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-taxable stock premium.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Quarterly Financial Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">End of year&#8212;unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning of year&#8212;unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Amounts representing lease payments under Boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase in shares available for issuance percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Shares Available For Issuance Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum consideration to be paid in the future based on milestones per the License Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Consideration Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone consideration payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Net Deferred Tax Assets/Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsToPurchaseSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer's matching contribution percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents, unrealized gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceed from issuance of stock and pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock And Pre Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating lease right of uset assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Lease Right Of Uset Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to shares of common stock at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Price Allocated To Shares Of Common Stock At Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price allocated to shares of common stock at fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other than Temporary Impairment Losses, Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities recognition of other-than-temporary impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred contract acquisition costs, amortized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Contract Acquisition Costs Amortized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredContractAcquisitionCostsAmortized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred contract acquisition costs amortized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EsppEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private investment in public equity financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term (years).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term Years [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (years):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability deductions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the first twelve months of prepaid operating lease base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Lease Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentOfLeaseBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent paid for the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leasing term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash deposit used as collateral for letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Deposit Used as Collateral for Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash deposit used as collateral for letter of credit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on marketable securities, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Realized Gain Loss Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesRealizedGainLossDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities realized gain loss, description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdditionalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LongTermMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract start year-month.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract Start Month Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractStartMonthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract start month year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases term of contract month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative changes in ownership interest of shareholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Changes In Ownership Interest Of Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership interest of shareholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for consulting services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred incremental costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, other depreciation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contribution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContributionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contribution [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition contract end period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Contract End Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RevenueRecognitionContractEndPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition contract end period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements expense materials and personnel costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements Expense Materials And Personnel Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements expense materials and personnel costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contribution of employee's eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to Right-Of-Use Assets and Lease Liability .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Right Of Use Assets And Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to right-of-use assets and lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepayments on financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments on financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments on Financing Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaymentsOnFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments on financing lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state tax apportionment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount of taxable income where use of net operating losses is suspended</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Amount Of Taxable Income Where Use Of Net Operating Losses Suspended</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum amount of taxable income where use of net operating losses is suspended.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum amount to be paid upon achievement of certain milestones as defined under the research and development agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumMilestonePaymentObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Operating Activities Lessee [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of realization of tax benefit upon ultimate settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of realization of tax benefit upon ultimate settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option granted expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Storage space commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Use of business incentive tax credits period cap.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Business Incentive Tax Credits Period Cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of business incentive tax credits period cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">cash received upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award options cash received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents operating lease term for the additional temporary space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Period For Additional Temporary Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease period or additional temporary space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership interest change over period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Interest Change Over Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OwnershipInterestChangeOverPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in ownership over period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_RestrictedCashDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted cash deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate contingent milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Contingent Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumAggregateContingentMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate contingent milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer matching contribution, percent of employees' gross pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_GrantAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain/(Loss) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable consideration relating to future milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Potential Milestone Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPotentialMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum development, regulatory, and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_WarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate payment in specified development regulatory and commercial milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Payment In Specified Development Regulatory And Commercial Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate payment in specified development regulatory and commercial milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment included in research and development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Included In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment included in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding and ESPP shares issuable and outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding And E S P P Shares Issuable And Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Bluebird bio to 2seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Blue Bird Bio to 2seventy [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_BlueBirdBioTo2SeventyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Blue Bird Bio to 2seventy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Use of net operating losses suspension period for medium and large business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Net Operating Losses Suspension Period For Medium And Large Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of net operating losses suspension period for medium and large business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cash security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease security deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and available for sale securities debt securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares common stock warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock called by warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost related to non-vested employee and consultant options expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement total funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Total Funding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AgreementTotalFunding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement total funding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Number of Shares, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock fair value closing price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Fair Value Closing Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CommonStockFairValueClosingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock fair value closing price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value granted employee stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit Outstanding Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of credit outstanding, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount to extend option term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount To Extend Option Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountToExtendOptionTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount to extend the option term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability addition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Addition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ContractWithCustomerLiabilityAddition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivables Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ReceivablesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents unrealized losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of irrevocable letters of credit withdrawn.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Irrevocable Letters Of Credit Withdrawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Withdrawal from irrevocable letters of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent Deposits And Other Assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits And Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deposits and other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for options to license for each indication.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Options To License Payments For Options To License For Each Indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for options to license for each indication</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from non refundable upfront payment included in transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromNonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from non refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation Calculated Using Straight Line Method Over Estimated Useful Lives Of Assets Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Lives of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost related to non-vested employee and consultant options unrecognized weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PaymentsOfFinancingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of financing lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of proceeds payable as compensation to underwriter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Proceeds Payable As Compensation To Underwriter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of gross proceeds as underwriter compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license revenues [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Assets Noncurrent [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deposits and Other Long-Term Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of individual securities in an unrealized loss position for 12 months or greater</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for grants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future Milestone And Royalty Payments, Reduction Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration, option and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Option And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationOptionAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration, Option and License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of future minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense For Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PrepaidExpenseForResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, unvested ending balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, unvested beginning balance | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Tax Status [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Tax Status [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxable Year 2021 and 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxable Year Two Zero Two One And Two Zero Two Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Taxable Year Two Zero Two One And Two Zero Two Zero [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit Awards under 2018 Equity Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs included in accrued liabilities and accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of outstanding shares held by individual.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Outstanding Shares Held By Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of outstanding shares held by individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leasing renewal option to extend lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue, non- current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_PleasantonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pleasanton [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities contractual maturities period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Contractual Maturities Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities contractual maturities period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Liabilities, Level 2 to Level 1 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum offering expenses agreed to be reimbursed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Offering Expenses Agreed To Be Reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum offering expense agreed to be reimbursed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CEPI [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coalition For Epidemic Preparedness Innovation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coalition for Epidemic Preparedness Innovation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coalition for Epidemic Preparedness Innovation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee or Director.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Or Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EmployeeOrDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee or Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory federal income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Amounts representing lease payments under the Boston Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease payment under the boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeasePaymentUnderTheBostonLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease payment under the boston lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease for tax positions taken during prior periods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock ownership to exercise warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Common Stock Ownership To Exercise Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock ownership to exercise warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value common stock warrants exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_OperatingLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Cost 1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised common stock subject to future vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Common Stock Subject To Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Common Stock Subject To Future Vesting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncreaseDecreaseInLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan (&#8220;ESPP&#8221;)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_StockOptionsWarrantsAndOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options, Warrants and Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_CollaborationAgreementTerminationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business incentive tax credits to offset against taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from maturity of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_ProceedsFromMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First tranche of funding received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Tranche of Fundings Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_FirstTrancheOfFundingsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche of Fundings Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets, Level 1 to Level 2 Transfers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InitialFundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial funding development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_InitialFundingDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial funding development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable option fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Option Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_NonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable option fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one employment inducement incentive award plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="grts_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightWarrantsExercised" xlink:to="grts_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" xlink:to="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborativeAndLicenseAgreementsAbstract" xlink:to="grts_CollaborativeAndLicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ComputerEquipmentAndSoftwareMember" xlink:to="grts_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OptionAndLicenseAndDevelopmentAgreementMember" xlink:to="grts_OptionAndLicenseAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BluebirdBioIncMember" xlink:to="grts_BluebirdBioIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" xlink:to="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SaleOfStockPricePerSharePrepaidByPurchaser" xlink:to="grts_SaleOfStockPricePerSharePrepaidByPurchaser_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FundingAgreementMember" xlink:to="grts_FundingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GatesFoundationMember" xlink:to="grts_GatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementEarlyTerminationNoticePeriod" xlink:to="grts_CollaborationAgreementEarlyTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PreJanuary12018Member" xlink:to="grts_PreJanuary12018Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractResearchOrganizationMember" xlink:to="grts_ContractResearchOrganizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="us-gaap_ContractWithCustomerAssetNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="grts_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FundingDevelopmentCosts" xlink:to="grts_FundingDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightIssueDate" xlink:to="grts_ClassOfWarrantOrRightIssueDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" xlink:to="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockPurchasePriceInExcessOfFairValue1" xlink:to="grts_CommonStockPurchasePriceInExcessOfFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" xlink:to="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsAmortization" xlink:to="grts_DeferredTaxAssetsAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" xlink:to="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockAndOrPreFundedWarrantsMember" xlink:to="grts_CommonStockAndOrPreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CEPIFundingAgreementMember" xlink:to="grts_CEPIFundingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightsExpiration" xlink:to="grts_ClassOfWarrantOrRightsExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" xlink:to="grts_NonExclusiveLicenseAndDevelopmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PostDecember312017Member" xlink:to="grts_PostDecember312017Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsCancelled" xlink:to="grts_WarrantsCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WeightedAverageDiscountRateAbstract" xlink:to="grts_WeightedAverageDiscountRateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" xlink:to="grts_StockIssuedDuringPeriodSharesPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GenevantSciencesGmbHMember" xlink:to="grts_GenevantSciencesGmbHMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" xlink:to="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" xlink:to="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" xlink:to="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommitmentsAndContingenciesDisclosureTable" xlink:to="grts_CommitmentsAndContingenciesDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" xlink:to="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" xlink:to="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumAggregateContingentMilestonePaymentToBeMade" xlink:to="grts_MaximumAggregateContingentMilestonePaymentToBeMade_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandEighteenStockIncentivePlanMember" xlink:to="grts_TwoThousandEighteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeriesCConvertiblePreferredStockMember" xlink:to="grts_SeriesCConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AtTheMarketEquityOfferingProgramMember" xlink:to="grts_AtTheMarketEquityOfferingProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodValuePurchaseAgreement" xlink:to="grts_StockIssuedDuringPeriodValuePurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerAssetDeduction" xlink:to="grts_ContractWithCustomerAssetDeduction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IssuanceOfCommonStockForWarrantExercisesShare" xlink:to="grts_IssuanceOfCommonStockForWarrantExercisesShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MilestonePayments" xlink:to="grts_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" xlink:to="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmendedAndRestatedCertificateOfIncorporationMember" xlink:to="grts_AmendedAndRestatedCertificateOfIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" xlink:to="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LaboratoryEquipmentMember" xlink:to="grts_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredContractAcquisitionCosts" xlink:to="grts_DeferredContractAcquisitionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromSaleOfMarketableSecurities" xlink:to="grts_ProceedsFromSaleOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PublicOfferingMember" xlink:to="grts_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" xlink:to="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerAssetAddition" xlink:to="grts_ContractWithCustomerAssetAddition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockAndWarrantsMember" xlink:to="grts_CommonStockAndWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrivateInvestmentInPublicEquityMember" xlink:to="grts_PrivateInvestmentInPublicEquityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" xlink:to="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="grts_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PlacementAgentCommissionsAndLegalFees" xlink:to="grts_PlacementAgentCommissionsAndLegalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" xlink:to="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="grts_CashAndCashEquivalentsAndMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLossCarryforwardsExpirationYear" xlink:to="grts_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeriesABAndCConvertiblePreferredStockMember" xlink:to="grts_SeriesABAndCConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncomeTaxesTable" xlink:to="grts_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedStockSubjectToFutureVestingMember" xlink:to="grts_RestrictedStockSubjectToFutureVestingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LessorOperatingLeaseNoticePeriodToTerminate" xlink:to="grts_LessorOperatingLeaseNoticePeriodToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LeaseExpirationTerm" xlink:to="grts_LeaseExpirationTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GileadSciencesIncMember" xlink:to="grts_GileadSciencesIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumPercentageFairMarketValueOfSharePrice" xlink:to="grts_MinimumPercentageFairMarketValueOfSharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperationsExpectedCommencedDate" xlink:to="grts_OperationsExpectedCommencedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ResearchCollaborationAndLicenseAgreementMember" xlink:to="grts_ResearchCollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CepInnovationsMember" xlink:to="grts_CepInnovationsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NetContractAsset" xlink:to="grts_NetContractAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UpFrontPayment" xlink:to="grts_UpFrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" xlink:to="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SummaryOfSignificantAccountingPoliciesTable" xlink:to="grts_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EmeryvilleCaliforniaMember" xlink:to="grts_EmeryvilleCaliforniaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShortTermMarketableSecuritiesMember" xlink:to="grts_ShortTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" xlink:to="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractEndMonthYear" xlink:to="grts_RevenueRecognitionContractEndMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" xlink:to="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AgreedUpfrontPayment" xlink:to="grts_AgreedUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SeventyMember" xlink:to="grts_SeventyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BostonLeaseMember" xlink:to="grts_BostonLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FutureFundingExpected" xlink:to="grts_FutureFundingExpected_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationReceivable" xlink:to="grts_CollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_InterestAndOtherReceivablesCurrent" xlink:to="grts_InterestAndOtherReceivablesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AnnualBaseRent" xlink:to="grts_AnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CambridgeMassachusettsMember" xlink:to="grts_CambridgeMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonTaxableStockPremium" xlink:to="grts_NonTaxableStockPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseInSharesAvailableForIssuancePercentage" xlink:to="grts_IncreaseInSharesAvailableForIssuancePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumMilestoneConsiderationPayable" xlink:to="grts_MaximumMilestoneConsiderationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsToPurchaseSharesOfCommonStock" xlink:to="grts_WarrantsToPurchaseSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsUnrealizedGains" xlink:to="grts_CashAndCashEquivalentsUnrealizedGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" xlink:to="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" xlink:to="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" xlink:to="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredContractAcquisitionCostsAmortized" xlink:to="grts_DeferredContractAcquisitionCostsAmortized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EsppEmployeeStockPurchasePlanMember" xlink:to="grts_EsppEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PipeFinancingMember" xlink:to="grts_PipeFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WeightedAverageRemainingLeaseTermYearsAbstract" xlink:to="grts_WeightedAverageRemainingLeaseTermYearsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityDeductions" xlink:to="grts_ContractWithCustomerLiabilityDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentOfLeaseBaseRent" xlink:to="grts_PaymentOfLeaseBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" xlink:to="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MarketableSecuritiesRealizedGainLossDescription" xlink:to="grts_MarketableSecuritiesRealizedGainLossDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdditionalFunding" xlink:to="grts_AdditionalFunding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LongTermMarketableSecuritiesMember" xlink:to="grts_LongTermMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractStartMonthYear" xlink:to="grts_RevenueRecognitionContractStartMonthYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" xlink:to="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CumulativeChangesInOwnershipInterestOfShareholders" xlink:to="grts_CumulativeChangesInOwnershipInterestOfShareholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashCashEquivalentsAndMarketableSecurities" xlink:to="grts_CashCashEquivalentsAndMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxLiabilitiesOtherDepreciation" xlink:to="grts_DeferredTaxLiabilitiesOtherDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContributionMember" xlink:to="grts_ContributionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RevenueRecognitionContractEndPeriod" xlink:to="grts_RevenueRecognitionContractEndPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" xlink:to="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" xlink:to="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaymentsOnFinancingLease" xlink:to="grts_PrepaymentsOnFinancingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesTable" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" xlink:to="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumMilestonePaymentObligation" xlink:to="grts_MaximumMilestonePaymentObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" xlink:to="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" xlink:to="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" xlink:to="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLeasePeriodForAdditionalTemporarySpace" xlink:to="grts_OperatingLeasePeriodForAdditionalTemporarySpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementMember" xlink:to="grts_CollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OwnershipInterestChangeOverPeriod" xlink:to="grts_OwnershipInterestChangeOverPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_RestrictedCashDeposit" xlink:to="grts_RestrictedCashDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumAggregateContingentMilestonePayment" xlink:to="grts_MaximumAggregateContingentMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_GrantAgreementMember" xlink:to="grts_GrantAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FollowOnPublicOfferingMember" xlink:to="grts_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumPotentialMilestoneReceivable" xlink:to="grts_MaximumPotentialMilestoneReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_WarrantsOutstanding" xlink:to="grts_WarrantsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" xlink:to="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" xlink:to="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" xlink:to="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_BlueBirdBioTo2SeventyMember" xlink:to="grts_BlueBirdBioTo2SeventyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" xlink:to="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" xlink:to="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AgreementTotalFunding" xlink:to="grts_AgreementTotalFunding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CommonStockFairValueClosingPricePerShare" xlink:to="grts_CommonStockFairValueClosingPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="grts_CashEquivalentsAndMarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmountToExtendOptionTerm" xlink:to="grts_AmountToExtendOptionTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ContractWithCustomerLiabilityAddition" xlink:to="grts_ContractWithCustomerLiabilityAddition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="grts_OtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ReceivablesGross" xlink:to="grts_ReceivablesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CashAndCashEquivalentsUnrealizedLosses" xlink:to="grts_CashAndCashEquivalentsUnrealizedLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" xlink:to="grts_AmountOfIrrevocableLettersOfCreditWithdrawn_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DepositsAndOtherAssetsNoncurrent" xlink:to="grts_DepositsAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" xlink:to="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromNonRefundableUpfrontPayment" xlink:to="grts_ProceedsFromNonRefundableUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PaymentsOfFinancingLease" xlink:to="grts_PaymentsOfFinancingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" xlink:to="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" xlink:to="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" xlink:to="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationOptionAndLicenseAgreementMember" xlink:to="grts_CollaborationOptionAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PrepaidExpenseForResearchAndDevelopment" xlink:to="grts_PrepaidExpenseForResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTaxStatusExtensibleList" xlink:to="us-gaap_DefinedContributionPlanTaxStatusExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" xlink:to="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" xlink:to="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_PleasantonMember" xlink:to="grts_PleasantonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MarketableSecuritiesContractualMaturitiesPeriod" xlink:to="grts_MarketableSecuritiesContractualMaturitiesPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumOfferingExpensesAgreedToBeReimbursed" xlink:to="grts_MaximumOfferingExpensesAgreedToBeReimbursed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CoalitionForEpidemicPreparednessInnovationMember" xlink:to="grts_CoalitionForEpidemicPreparednessInnovationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EmployeeOrDirectorMember" xlink:to="grts_EmployeeOrDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="grts_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLeasePaymentUnderTheBostonLease" xlink:to="grts_OperatingLeasePaymentUnderTheBostonLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" xlink:to="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_OperatingLeaseCost1" xlink:to="grts_OperatingLeaseCost1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" xlink:to="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncreaseDecreaseInLeaseLiability" xlink:to="grts_IncreaseDecreaseInLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_StockOptionsWarrantsAndOtherMember" xlink:to="grts_StockOptionsWarrantsAndOtherMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_CollaborationAgreementTerminationTerm" xlink:to="grts_CollaborationAgreementTerminationTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_IncomeTaxesLineItems" xlink:to="grts_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_ProceedsFromMaturityOfMarketableSecurities" xlink:to="grts_ProceedsFromMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_FirstTrancheOfFundingsReceived" xlink:to="grts_FirstTrancheOfFundingsReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_InitialFundingDevelopmentCosts" xlink:to="grts_InitialFundingDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_NonRefundableOptionFee" xlink:to="grts_NonRefundableOptionFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" xlink:to="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="grts_DeferredTaxAssetsLeaseLiability" xlink:to="grts_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>grts-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-10T16:11:11.3245+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://gritstonebio.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:grts="http://gritstonebio.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="grts-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3">
        <link:definition>100030 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4">
        <link:definition>100050 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1" id="DisclosureOrganization1">
        <link:definition>100090 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities" id="Role_DisclosureCashEquivalentsAndMarketableSecurities">
        <link:definition>100110 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100150 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100160 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100170 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100180 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare" id="Role_DisclosureNetLossPerCommonShare">
        <link:definition>100200 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100210 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100220 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" id="Role_DisclosureSelectedQuarterlyFinancialDataUnaudited">
        <link:definition>100230 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100260 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100280 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100290 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables" id="Role_DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>100300 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100310 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100320 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100330 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables" id="Role_DisclosureNetLossPerCommonShareTables">
        <link:definition>100350 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>100360 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail" id="DisclosureOrganizationAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail">
        <link:definition>100410 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100420 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail">
        <link:definition>100450 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail">
        <link:definition>100480 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail">
        <link:definition>100520 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100530 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail" id="Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail">
        <link:definition>100540 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail" id="DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail">
        <link:definition>100560 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail" id="Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail" id="Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
        <link:definition>100620 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail">
        <link:definition>100630 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100640 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail" id="Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail">
        <link:definition>100650 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail" id="Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail">
        <link:definition>100660 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail">
        <link:definition>100670 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail" id="Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail">
        <link:definition>100680 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail" id="Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail">
        <link:definition>100690 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail" id="Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail">
        <link:definition>100700 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetail">
        <link:definition>100710 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborativeAndLicenseAgreementsAbstract" name="CollaborativeAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" name="DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_WeightedAverageRemainingLeaseTermYearsAbstract" name="WeightedAverageRemainingLeaseTermYearsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdditionalFunding" name="AdditionalFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" name="AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AdjustmentToRightOfUseAssetsAndLeaseLiability" name="AdjustmentToRightOfUseAssetsAndLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" name="AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AgreedUpfrontPayment" name="AgreedUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AgreementTotalFunding" name="AgreementTotalFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_AmountOfIrrevocableLettersOfCreditWithdrawn" name="AmountOfIrrevocableLettersOfCreditWithdrawn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_AmountToExtendOptionTerm" name="AmountToExtendOptionTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_AnnualBaseRent" name="AnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashAndCashEquivalentsAndMarketableSecurities" name="CashAndCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashAndCashEquivalentsUnrealizedGains" name="CashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CashAndCashEquivalentsUnrealizedLosses" name="CashAndCashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" name="CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ClassOfWarrantOrRightIssueDate" name="ClassOfWarrantOrRightIssueDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightsExpiration" name="ClassOfWarrantOrRightsExpiration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ClassOfWarrantOrRightWarrantsExercised" name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationAgreementEarlyTerminationNoticePeriod" name="CollaborationAgreementEarlyTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationAgreementTerminationTerm" name="CollaborationAgreementTerminationTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_CommonStockFairValueClosingPricePerShare" name="CommonStockFairValueClosingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_CommonStockPurchasePriceInExcessOfFairValue1" name="CommonStockPurchasePriceInExcessOfFairValue1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerAssetAddition" name="ContractWithCustomerAssetAddition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ContractWithCustomerAssetDeduction" name="ContractWithCustomerAssetDeduction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityAddition" name="ContractWithCustomerLiabilityAddition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityDeductions" name="ContractWithCustomerLiabilityDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" name="ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_CumulativeChangesInOwnershipInterestOfShareholders" name="CumulativeChangesInOwnershipInterestOfShareholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DeferredContractAcquisitionCosts" name="DeferredContractAcquisitionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredContractAcquisitionCostsAmortized" name="DeferredContractAcquisitionCostsAmortized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DeferredTaxLiabilitiesOtherDepreciation" name="DeferredTaxLiabilitiesOtherDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" name="EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" name="EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_FirstTrancheOfFundingsReceived" name="FirstTrancheOfFundingsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FundingDevelopmentCosts" name="FundingDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FutureFundingExpected" name="FutureFundingExpected" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage" name="FutureMilestoneAndRoyaltyPaymentsReductionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" name="IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" name="IncreaseDecreaseInDepositAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_IncreaseInSharesAvailableForIssuancePercentage" name="IncreaseInSharesAvailableForIssuancePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_InitialFundingDevelopmentCosts" name="InitialFundingDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_InterestAndOtherReceivablesCurrent" name="InterestAndOtherReceivablesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_IssuanceOfCommonStockForWarrantExercisesShare" name="IssuanceOfCommonStockForWarrantExercisesShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" name="LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" name="LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LeaseExpirationTerm" name="LeaseExpirationTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" name="LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" name="LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_LessorOperatingLeaseNoticePeriodToTerminate" name="LessorOperatingLeaseNoticePeriodToTerminate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MarketableSecuritiesContractualMaturitiesPeriod" name="MarketableSecuritiesContractualMaturitiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MarketableSecuritiesRealizedGainLossDescription" name="MarketableSecuritiesRealizedGainLossDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MaximumAggregateContingentMilestonePayment" name="MaximumAggregateContingentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumAggregateContingentMilestonePaymentToBeMade" name="MaximumAggregateContingentMilestonePaymentToBeMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumMilestoneConsiderationPayable" name="MaximumMilestoneConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumMilestonePaymentObligation" name="MaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MaximumOfferingExpensesAgreedToBeReimbursed" name="MaximumOfferingExpensesAgreedToBeReimbursed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" name="MaximumPercentageOfCommonStockOwnershipToExerciseWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MaximumPotentialMilestoneReceivable" name="MaximumPotentialMilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MaximumSecuritiesCoveredUnderRegistrationAgreement" name="MaximumSecuritiesCoveredUnderRegistrationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense" name="MilestonePaymentIncludedInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" name="MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_MinimumPercentageFairMarketValueOfSharePrice" name="MinimumPercentageFairMarketValueOfSharePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_MinimumPercentageOfOutstandingSharesHeldByIndividual" name="MinimumPercentageOfOutstandingSharesHeldByIndividual" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_NetContractAsset" name="NetContractAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_NonRefundableOptionFee" name="NonRefundableOptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_NonTaxableStockPremium" name="NonTaxableStockPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperatingLeaseCost1" name="OperatingLeaseCost1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_OperatingLeasePaymentUnderTheBostonLease" name="OperatingLeasePaymentUnderTheBostonLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_OperatingLeasePeriodForAdditionalTemporarySpace" name="OperatingLeasePeriodForAdditionalTemporarySpace" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OperationsExpectedCommencedDate" name="OperationsExpectedCommencedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_OwnershipInterestChangeOverPeriod" name="OwnershipInterestChangeOverPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PaymentOfLeaseBaseRent" name="PaymentOfLeaseBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" name="PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PaymentsOfFinancingLease" name="PaymentsOfFinancingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_PercentageOfProceedsPayableAsCompensationToUnderwriter" name="PercentageOfProceedsPayableAsCompensationToUnderwriter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" name="PercentageOfRealizationOfTaxBenefitUponUltimateSettlement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_PlacementAgentCommissionsAndLegalFees" name="PlacementAgentCommissionsAndLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaidExpenseForResearchAndDevelopment" name="PrepaidExpenseForResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent" name="PrepaidExpenseForResearchAndDevelopmentNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_PrepaymentsOnFinancingLease" name="PrepaymentsOnFinancingLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromMaturityOfMarketableSecurities" name="ProceedsFromMaturityOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromNonRefundableUpfrontPayment" name="ProceedsFromNonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ProceedsFromSaleOfMarketableSecurities" name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ReceivablesGross" name="ReceivablesGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_ReimbursementsExpenseMaterialsAndPersonnelCosts" name="ReimbursementsExpenseMaterialsAndPersonnelCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" name="RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RestrictedCashDeposit" name="RestrictedCashDeposit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit" name="RestrictedCashDepositUsedAsCollateralForLetterOfCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_RevenueRecognitionContractEndMonthYear" name="RevenueRecognitionContractEndMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RevenueRecognitionContractEndPeriod" name="RevenueRecognitionContractEndPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RevenueRecognitionContractStartMonthYear" name="RevenueRecognitionContractStartMonthYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_SaleOfStockPricePerSharePrepaidByPurchaser" name="SaleOfStockPricePerSharePrepaidByPurchaser" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" name="StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_StockIssuedDuringPeriodSharesPurchaseAgreement" name="StockIssuedDuringPeriodSharesPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_StockIssuedDuringPeriodValuePurchaseAgreement" name="StockIssuedDuringPeriodValuePurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" name="TransactionPriceAllocatedToSharesOfCommonStockAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_UpFrontPayment" name="UpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="grts_UseOfBusinessIncentiveTaxCreditsPeriodCap" name="UseOfBusinessIncentiveTaxCreditsPeriodCap" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" name="UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_WarrantsCancelled" name="WarrantsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_WarrantsOutstanding" name="WarrantsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="grts_WarrantsToPurchaseSharesOfCommonStock" name="WarrantsToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesLineItems" name="CashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AmendedAndRestatedCertificateOfIncorporationMember" name="AmendedAndRestatedCertificateOfIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" name="ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BluebirdBioIncMember" name="BluebirdBioIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BlueBirdBioTo2SeventyMember" name="BlueBirdBioTo2SeventyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_BostonLeaseMember" name="BostonLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CEPIFundingAgreementMember" name="CEPIFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CepInnovationsMember" name="CepInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CoalitionForEpidemicPreparednessInnovationMember" name="CoalitionForEpidemicPreparednessInnovationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockAndOrPreFundedWarrantsMember" name="CommonStockAndOrPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ContractResearchOrganizationMember" name="ContractResearchOrganizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ContributionMember" name="ContributionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EarlyExercisedCommonStockSubjectToFutureVestingMember" name="EarlyExercisedCommonStockSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EmeryvilleCaliforniaMember" name="EmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EmployeeOrDirectorMember" name="EmployeeOrDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_EsppEmployeeStockPurchasePlanMember" name="EsppEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_FundingAgreementMember" name="FundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GatesFoundationMember" name="GatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GenevantSciencesGmbHMember" name="GenevantSciencesGmbHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GileadSciencesIncMember" name="GileadSciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_GrantAgreementMember" name="GrantAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_LongTermMarketableSecuritiesMember" name="LongTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_NonExclusiveLicenseAndDevelopmentAgreementMember" name="NonExclusiveLicenseAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OptionAndLicenseAndDevelopmentAgreementMember" name="OptionAndLicenseAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" name="OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PipeFinancingMember" name="PipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PleasantonMember" name="PleasantonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PostDecember312017Member" name="PostDecember312017Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PreJanuary12018Member" name="PreJanuary12018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PrivateInvestmentInPublicEquityMember" name="PrivateInvestmentInPublicEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ResearchCollaborationAndLicenseAgreementMember" name="ResearchCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_RestrictedStockSubjectToFutureVestingMember" name="RestrictedStockSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeriesABAndCConvertiblePreferredStockMember" name="SeriesABAndCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SeventyMember" name="SeventyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ShortTermMarketableSecuritiesMember" name="ShortTermMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_StockOptionsWarrantsAndOtherMember" name="StockOptionsWarrantsAndOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" name="TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" name="TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" name="TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_OtherRisksAndUncertaintiesPolicyTextBlock" name="OtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_CashEquivalentsAndMarketableSecuritiesTable" name="CashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1" name="DescriptionOfNewAccountingPronouncementsNotYetAdopted1" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" name="DisclosureOfNeedForAdditionalCapitalPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" name="ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" name="ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741289448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gritstone bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001656634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRTS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,708,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4859534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5959 Horton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-6100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 17, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742308568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,287<span></span>
</td>
<td class="nump">$ 170,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">108,346<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">11,285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">4,332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">220,590<span></span>
</td>
<td class="nump">175,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">6,005<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,622<span></span>
</td>
<td class="nump">22,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">22,920<span></span>
</td>
<td class="nump">21,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other long-term assets</a></td>
<td class="nump">2,352<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">278,106<span></span>
</td>
<td class="nump">221,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,230<span></span>
</td>
<td class="nump">9,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,925<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">3,706<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">7,483<span></span>
</td>
<td class="nump">5,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">17,201<span></span>
</td>
<td class="nump">3,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">39,956<span></span>
</td>
<td class="nump">26,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">18,936<span></span>
</td>
<td class="nump">19,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">8,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">62,020<span></span>
</td>
<td class="nump">54,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; 69,047,878 and 47,552,693 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">617,523<span></span>
</td>
<td class="nump">493,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(401,384)<span></span>
</td>
<td class="num">(326,302)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">216,086<span></span>
</td>
<td class="nump">166,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 278,106<span></span>
</td>
<td class="nump">$ 221,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncurrent Deposits And Other Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741375704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">69,047,878<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">69,047,878<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742577512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 48,214<span></span>
</td>
<td class="nump">$ 4,037<span></span>
</td>
<td class="nump">$ 4,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">97,490<span></span>
</td>
<td class="nump">88,643<span></span>
</td>
<td class="nump">82,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,933<span></span>
</td>
<td class="nump">21,411<span></span>
</td>
<td class="nump">19,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">123,423<span></span>
</td>
<td class="nump">110,054<span></span>
</td>
<td class="nump">102,305<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(75,209)<span></span>
</td>
<td class="num">(106,017)<span></span>
</td>
<td class="num">(97,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,082)<span></span>
</td>
<td class="num">(105,314)<span></span>
</td>
<td class="num">(94,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (75,155)<span></span>
</td>
<td class="num">$ (105,338)<span></span>
</td>
<td class="num">$ (94,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
<td class="nump">33,554,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Collaboration and license revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 46,717<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="nump">$ 4,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,497<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736575672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Equity Offering Program [Member]</div></th>
<th class="th"><div>Follow-on Public Offering [Member]</div></th>
<th class="th"><div>Private Investment in Public Equity [Member]</div></th>
<th class="th"><div>Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>ATM Equity Offering Program [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Follow-on Public Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Private Investment in Public Equity [Member]</div>
</th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>ATM Equity Offering Program [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>Follow-on Public Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>Private Investment in Public Equity [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain/(Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 149,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (153)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (126,402)<span></span>
</td>
<td class="num">$ (153)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,823,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update201602 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,763<span></span>
</td>
<td class="nump">$ 69,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,763<span></span>
</td>
<td class="nump">$ 69,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,880<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (&#8220;ESPP&#8221;)</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan ("ESPP"), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(94,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">134,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="num">(220,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,332,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,160,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,586,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">87,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (&#8220;ESPP&#8221;)</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan ("ESPP"), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares', window );">Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(105,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">166,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants', window );">Offering costs related to the sale of common stock and pre-funded warrants</a></td>
<td class="num">(451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan (&#8220;ESPP&#8221;)</a></td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan ("ESPP"), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">692,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodSharesPurchaseAgreement', window );">Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodValuePurchaseAgreement', window );">Issuance of common stock under Sales Purchase Agreement, net of issuance costs</a></td>
<td class="nump">$ 20,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(75,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 216,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (401,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lapse of repurchase rights related to common stock issued pursuant to early exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodSharesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodSharesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockIssuedDuringPeriodValuePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockIssuedDuringPeriodValuePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742569320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Follow-on Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="nump">$ 2,348<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741030088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,082)<span></span>
</td>
<td class="num">$ (105,314)<span></span>
</td>
<td class="num">$ (94,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,347<span></span>
</td>
<td class="nump">6,644<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">817<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,552<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="nump">5,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OperatingLeaseCost1', window );">Non-cash operating lease expense</a></td>
<td class="nump">8,052<span></span>
</td>
<td class="nump">7,511<span></span>
</td>
<td class="nump">6,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,426)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent', window );">Deposits and other long-term assets</a></td>
<td class="num">(614)<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(419)<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">593<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent', window );">Accrued and other non-current liabilities</a></td>
<td class="num">(859)<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">2,653<span></span>
</td>
<td class="num">(725)<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(7,925)<span></span>
</td>
<td class="num">(3,801)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">8,633<span></span>
</td>
<td class="num">(2,821)<span></span>
</td>
<td class="num">(4,297)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,678)<span></span>
</td>
<td class="num">(89,102)<span></span>
</td>
<td class="num">(85,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(199,905)<span></span>
</td>
<td class="num">(8,809)<span></span>
</td>
<td class="num">(80,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">82,253<span></span>
</td>
<td class="nump">72,872<span></span>
</td>
<td class="nump">112,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromSaleOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,463)<span></span>
</td>
<td class="num">(3,515)<span></span>
</td>
<td class="num">(16,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PrepaymentsOnFinancingLease', window );">Prepayments on financing lease</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(118,553)<span></span>
</td>
<td class="nump">65,949<span></span>
</td>
<td class="nump">15,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">125,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of deferred financing costs</a></td>
<td class="num">(8,394)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PaymentsOfFinancingLease', window );">Payments of financing lease</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">108,760<span></span>
</td>
<td class="nump">135,801<span></span>
</td>
<td class="nump">74,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(60,471)<span></span>
</td>
<td class="nump">112,648<span></span>
</td>
<td class="nump">5,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">171,048<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
<td class="nump">53,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">110,577<span></span>
</td>
<td class="nump">171,048<span></span>
</td>
<td class="nump">58,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases accrued but not yet paid</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred financing costs included in accrued liabilities and accounts payable</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification', window );">Remeasurement of operating lease right-of-use asset for lease modification</a></td>
<td class="nump">6,452<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="nump">1,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">21,169<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember', window );">Stock Options, Warrants and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">3,408<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">36,719<span></span>
</td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">4,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember', window );">ESPP Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued and other liabilities non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deposit and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperatingLeaseCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Cost 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperatingLeaseCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PaymentsOfFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of financing lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PaymentsOfFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaymentsOnFinancingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments on financing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaymentsOnFinancingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of operating lease right-of-use assets for lease modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_StockOptionsWarrantsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_EsppEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744749800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><p id="notes_to_financial_statements" style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.	Organizat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gritstone bio, Inc. (&#8220;Gritstone&#8221; or &#8220;the Company&#8221;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">drug</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively. The Company used net cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million through its operating activities for the years ended December 31, 2021, 2020 and 2019, respectively. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">401.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021 and 2020, respectively. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#8220;at the market offering&#8221; (the &#8220;ATM Offering Program&#8221;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740614856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.	Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Securities and Exchange Commission (the &#8220;SEC&#8221;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for reporting. </span><span style="background-color:rgba(255,255,255,1);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#8217;s restricted cash includes payments received under the CEPI Funding Agreement and Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.52%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170,056</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,285</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">992</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,577</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,048</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared the global novel coronavirus disease (&#8220;COVID-19&#8221;) outbreak a pandemic. To date, the Company&#8217;s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.318%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.099%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2021, 2020 or 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#8217;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#8211; Revenue Recognition (&#8220;ASC 958-605&#8221;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#8217;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#8220;the Black-Scholes model&#8221;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation of the expected term for its stock options. Volatility is based on an average of the historical volatilities of the common stock of entities with characteristics similar to the Company&#8217;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#8217;s technologies are recorded as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#8217;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#8217;s consolidated balance sheets at December 31, 2021 and 2020. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes and measures uncertain tax positions using a two&#8212;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#8217;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2021, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2020, the Families First Coronavirus Response Act (the &#8220;FFCR Act&#8221;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 29, 2020, Assembly Bill 85 (&#8220;A.B. 85&#8221;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#8217;s consolidated financial statements as of December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#8217;s marketable securities.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2020-06&#8221;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">does not expect the adoption of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2020-06 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to have a material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2020-10&#8221;). The standard contains improvements to the FASB Accounting Standards Codification (the &#8220;Codification&#8221;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated financial statements and related disclosures.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740568984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.	Cash Equivalents and Marketable Securities</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.558%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.73%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,976</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,277</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,991</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,348</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.581%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.907%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, the Company had a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash, cash equivalents and marketable securities, which includes $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash and cash equivalents and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in marketable securities, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All marketable securities held as of December 31, 2021, had contractual effective maturities of less than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There have been </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no material realized gains or losses</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on marketable securities for the periods presented. As of December 31, 2021, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t hold any individual securities in an unrealized loss position </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for 12 months or greater</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Thus, the Company has not recorded an allowance for credit losses as of December 31, 2021. The Company will continue to assess the current and expected future economic and market conditions surrounding the COVID-19 pandemic, as further development arises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 4 for further information regarding the fair value of the Company&#8217;s financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740700600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.	Fair Value Measurements</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.622%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.927%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.908%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.908%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.871%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,739</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.531%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.556%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.556%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.519%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.519%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, U.S. treasuries and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744730168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Property and Equipment, Net</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.662%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.459%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.477%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,113</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,054</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,276</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,925</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,622</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740687928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office, laboratory and storage space in facilities at several locations:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emeryville Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#8220;Emeryville Lease&#8221;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is recorded as a deposit on the Company&#8217;s consolidated balance sheets as of December 31, 2021 and 2020. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2021. The Company recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Pleasanton Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,620</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#8220;Pleasanton Lease&#8221;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 30, 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has the option to extend the lease term for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform all of its obligations. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of  December 31, 2021 and 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in May 2019, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2021, and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million ROU Asset and a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million lease liability on the consolidated balance sheet as of December 31, 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cambridge Leases</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s facility located at 40 Erie Street and 200 Sidney Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease (the &#8220;40 Erie Lease&#8221;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and provides for monthly base rent amounts, subject to annual increases over the term of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> non-cancelable operating lease (the &#8220;21 Erie Lease&#8221;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended three times, as a result of which the lease term extends through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#8220;Cambridge Storage Lease&#8221;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company also paid an immaterial cash security deposit.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain advanced payments, which in each case included amounts for the applicable last month&#8217;s rent and security deposit. The portion of the advanced payment related to last month&#8217;s rent has been classified as part of the operating lease ROU Assets. Security deposits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, are recorded in deposits and other long-term assets on the Company&#8217;s consolidated balance sheets as of December 31, 2021 and 2020.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Boston Lease</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating lease (the &#8220;Boston Lease&#8221;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for costs relating to the design, permitting and construction of improvements. The Company&#8217;s obligation to pay rent is anticipated to commence in January 2023, subject to free rent periods of three and six months with respect to certain premises. The commencement date of the Boston Lease is expected to be in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, given the Company&#8217;s early access rights to the leased space, and the term will expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is collateralized by a restricted cash deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and which may be reduced in the fifth and seventh years of the Boston Lease. As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the irrevocable letter of credit amount had been drawn.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not recognized a right-of-use asset or lease liability as of December 31, 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the period ended December 31, 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.807%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,382</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,518</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,653</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental information related to leases was as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.498%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.318%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.318%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.337%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,925</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,495</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,562</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,174</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,331</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.30</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.10</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.20</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, minimum annual payments under the Company&#8217;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.787%;"/>
        <td style="width:2.078%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.132%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lease Financing<br/>Obligation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,642</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,627</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,504</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,048</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,515</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,114</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,483</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,936</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreements with CROs</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2017, the Company entered into a contract research and development agreement with a third-party contract research organization (&#8220;CRO&#8221;) to provide research, analysis and antibody samples to further the Company&#8217;s development of its antibody drug candidates. The Company is also obligated to pay the CRO certain milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None of these events had occurred as of December 31, 2021. During the year ended December 31, 2021, the Company had immaterial research and development expense under the agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During the year ended December 31, 2019, the Company recognized an immaterial amount of research and development expense under the agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, the Company entered into a contract research and testing agreement with a third-party CRO to provide antibody discovery related services. The Company is also obligated to pay the CRO certain milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of these events had occurred as of December 31, 2021. During the year ended December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During the year ended December 31, 2020, the Company recognized an immaterial amount of research and development expense under the agreement. The Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in research and development expense under the agreement during the year ended December 31, 2019.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees and Indemnifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#8217;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#8217;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740683992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.	Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2seventy bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#8220;bluebird&#8221;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#8220;2seventy Agreement&#8221;), to its affiliate, 2seventy bio, Inc. (&#8220;2seventy&#8221;), in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (&#8220;TCR&#8221;) directed to those targets. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and 2seventy also concurrently acquired </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">768,115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s Series C convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#8217;s common stock at the same price as all other investors in connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;). In October 2018, 2seventy purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">666,667</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock at the price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">into a First Amendment to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Agreement, which extended the timeline for the Company and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy may terminate the 2seventy Agreement by giving a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, all of 2seventy&#8217;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the remainder of the agreement term.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted to 2seventy a license to its intellectual property and provided research and development services, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following three material promises under the 2seventy Agreement: 1) transfer of a license to intellectual property and related technology know-how (&#8220;License and Know-How&#8221;); 2) the obligation to perform target selection and TCR generation services (&#8220;Research and Development Services&#8221;); and 3) participation on the Joint Steering Committee (the &#8220;JSC&#8221;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#8217;s specifications and is not an obligation to provide goods or services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million received from 2seventy for the purchase of the Company&#8217;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $10.0 million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">768,115</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series C convertible preferred stock at fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and recorded in stockholders&#8217; equity.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#8217;s development efforts. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020 and 2019, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in collaboration revenue under the 2seventy Agreement.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021 and 2020, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through mid-2023.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.694%;"/>
        <td style="width:1.753%;"/>
        <td style="width:1.206%;"/>
        <td style="width:15.796%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.753%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,970</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,725</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> receivables or net contract assets recorded as of December 31, 2021 or 2020 associated with the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2seventy Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gilead Sciences, Inc.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#8220;Gilead Collaboration Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;) to research and develop a vaccine-based immunotherapy as part of Gilead&#8217;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#8217;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#8220;research and development activities&#8221;). Concurrently with execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#8220;Gilead Supply Agreement&#8221;) under which the Company will supply research product and GMP product (&#8220;Product Supply&#8221;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#8220;product supply activities&#8221;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#8220;Gilead Stock Purchase Agreement&#8221;) under which Gilead acquired, in a private placement transaction, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,169,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. The common shares were issued to Gilead with certain registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (&#8220;the Gilead Arrangement&#8221;).</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s common stock at fair value on closing was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#8220;Option&#8221;), the Company will receive a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million non-refundable option fee and will be eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">685.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None of these events had occurred as of December 31, 2021 and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may terminate the Gilead Collaboration Agreement for convenience by giving a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#8217;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#8217;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the remainder of the agreement term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Furthermore, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Supply of Product, as defined below, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option Term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following performance obligations under the Gilead Collaboration Agreement: 1) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercial license subject to restrictions on its use during the Option Term and an exclusive option to release such restrictions; 2) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and 3) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million received for the sale of the Company&#8217;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the transaction price was allocated to the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,169,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shares of the Company&#8217;s common stock at fair value on closing of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and recorded in stockholders&#8217; equity. The remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2021 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the variable consideration for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#8217;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and ends upon (i) the completion of the Option term, which is expected to end </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7ed2197d-60a0-4b30-bddb-51e4f0d30759;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue as a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. A contract asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement and is being recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through December 2022. There was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contract asset as of December 31, 2020, and there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> deferred revenue as of December 31, 2021 and 2020 associated with the Gilead Collaboration Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the contract asset and deferred revenue balance during the year ended December 31, 2021 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.679%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.173%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.173%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contract Asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,055</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There was $0.7 million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 and there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> receivables or net contract assets recorded as of December 31, 2020 associated with the Gilead Collaboration Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company deferred $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2021, deferred contract acquisition costs were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Deferred contract acquisition costs amortized during the year ended December 31, 2021 were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Arbutus Biopharma Corporation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2021 and 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research and development expense under the agreement. During 2019, the Company reimbursed Arbutus for materials and personnel costs totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company is obligated to pay Arbutus certain milestone payments up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#8217;s GO-005 clinical trial. In 2019, the Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Profit Hospital Cancer Center</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immaterial upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. None of the other milestone events had occurred as of December 31, 2021 and no royalties were due from the sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Genevant Sciences GmbH</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2020 Genevant License Agreement, Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#8217;s lipid nanoparticle, or LNP, technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was included in research and development expense for the year ended December 31, 2020. The 2020 Genevant License Agreement expands Gritstone&#8217;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#8217;s license agreement with Arbutus. Genevant is a spin-off of Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#8217; LNP technology for indications in the oncology space. The remainder of Arbutus&#8217; IP portfolio was transferred to Genevant in the spin-off.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for each indication and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#8217;s LNP technology to develop and commercialize self-amplifying RNA (&#8220;samRNA&#8221;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">166.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported IDCRC. Both the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million milestone payments were recorded as research and development expense during the year ended December 31, 2021. None of the other milestone events had occurred as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coalition for Epidemic Preparedness Innovations</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company to advance the Company&#8217;s CORAL program, which is developing a second-generation COVID-19 vaccine, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program&#8217;s samRNA vaccine in na&#239;ve, convalescent, and HIV+ patients. The study will evaluate two different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding will also support pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#8217;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (WHO), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#8217;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate (the determination of whether to proceed or not with such trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shall be made by the Company in its sole discretion). In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to the Company to conduct a Phase I clinical trial of the Company's Omicron vaccine candidate in South Africa.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was received in September 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. In the year 2021, the Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the CEPI Funding Agreement. As of December 31, 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through the end of the year 2022. As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as short-term restricted cash on the consolidated balance sheet.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.095%;"/>
        <td style="width:1.79%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.112%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,282</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021, the Company entered into a Grant Agreement with the Gates Foundation, under which the Company will develop an optimal immunogen in the context of a therapeutic Human papillomavirus (HPV) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in December 2021, and future funding of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is expected to be received by the Company in February 2023, for a total grant amount of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. For the year ended 2021, the Company did not recognize any grant revenue under the Grant Agreement. As of December 31, 2021, short term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and long term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through early 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.239%;"/>
        <td style="width:1.874%;"/>
        <td style="width:1.206%;"/>
        <td style="width:17.078%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744763224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.	Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prepaid Expenses and Other Assets</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,769</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,480</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,332</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deposits and Other Long-Term Assets</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,047</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,352</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,736</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740670344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.	Stockholders&#8217; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s amended and restated certificate of incorporation provides for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock authorized for issuance, each with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were issued and outstanding.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,047,878</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,552,693</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issued and outstanding, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of the Company&#8217;s common stock are entitled to one vote per share.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sale of Common Stock and Pre-Funded Warrants</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company filed a Registration Statement on Form S-3 (the &#8220;2019 Shelf Registration Statement&#8221;) with the SEC, covering the offering of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#8217;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2019, the Company also entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) to sell shares of the Company&#8217;s common stock, from time to time, with aggregate gross sales proceeds of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through the ATM Offering Program, under which Cowen will act as its sales agent. Cowen is entitled to compensation for its services equal to up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. In addition, the Company has agreed to reimburse a portion of the expenses of Cowen in connection with the offering, up to a maximum of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,160,193</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock through its ATM Offering Program and received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of commissions and other offering costs. During the year ended December 31, 2021, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,990,869</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock through its ATM Offering Program and received aggregate proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of commissions and other costs.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company entered into two private placement financing transactions (collectively, the &#8220;First PIPE Financing&#8221;), as follows: (1) pursuant to a securities purchase agreement entered into on December 22, 2020 to sell </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,543,351</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and pre-funded warrants (the &#8220;Warrants&#8221;) to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,480,719</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share (of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share was prepaid by each purchaser), and (2) pursuant to a securities purchase agreement entered into on December 28, 2020, to sell an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,043,127</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.71</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting placement agent commissions and offering expenses payable by the Company. The Warrants are exercisable upon issuance at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The underwriter placement and legal fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to these two PIPE financing transactions were included in accounts payable and accrued liabilities on the consolidated balance sheet as of December 31, 2020 and were paid during the year ended December 31, 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The outstanding Warrants generally may not be exercised if the holder&#8217;s aggregate beneficial ownership would be more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total issued and outstanding shares of the Company&#8217;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#8220;Warrant Shares&#8221;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#8220;cashless&#8221; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, the Company completed a PIPE financing transaction, in which it sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#8220;Second PIPE Financing&#8221;). The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock Warrants</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the following warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.577%;"/>
        <td style="width:1.438%;"/>
        <td style="width:27.892%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.503%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.438%;"/>
        <td style="width:0.983%;"/>
        <td style="width:12.541%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Issue Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 28, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,016,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,459,576</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,872</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants cancelled due to net exercise of the warrants. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised during the year ended December 31, 2020. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants issued or outstanding in previous years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740703928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.	Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Award Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2015, the Company&#8217;s board of directors approved the 2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;). In connection with the Company&#8217;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#8220;2018 Plan&#8221;), discussed below, the 2015 Plan terminated, and no further awards will be granted under the 2015 Plan. The </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,815</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company&#8217;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,690,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the total number of shares of the Company&#8217;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#8217;s board of directors. The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% or more of the outstanding shares, the price of each share shall be at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair market value, as determined by the board of directors. Options granted have a term of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year period with a straight-line vesting.</span></span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Material Features of the 2021 Employment Inducement Incentive Award Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;2021 Plan&#8221;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#8220;employment inducement awards&#8221; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">790,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company&#8217;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#8220;2018 ESPP&#8221;). The 2018 ESPP also became effective in September 2018. A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">282,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#8217;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of an employee&#8217;s eligible compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.695%;"/>
        <td style="width:1.197%;"/>
        <td style="width:0.788%;"/>
        <td style="width:14.164%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.197%;"/>
        <td style="width:0.788%;"/>
        <td style="width:14.164%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.57</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.48</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation of Stock Options</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.337%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.521%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.521%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.54%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management&#8217;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.08</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share during the years ended December 31, 2021, 2020, and 2019, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the 2015 Plan, 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.395%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.085%;"/>
        <td style="width:8.15%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:0.964%;"/>
        <td style="width:7.928%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.205%;"/>
        <td style="width:7.918%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:0.964%;"/>
        <td style="width:7.928%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.02%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Shares<br/>Available<br/>for<br/>Issuance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number<br/>of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,108,412</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,166,441</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.15</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,092</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,692,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,195,124</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,314,524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">692,038</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.86</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">853,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">681,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,459,187</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,107,335</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable &#8211; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,253,957</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.21</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,901</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest &#8211; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,741,858</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.74</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.06</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,267</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020, and 2019, the total intrinsic value of stock option awards exercised was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in 2021 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t significant for 2020 or 2019. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years. The total fair value of shares vested during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense and awards granted to non-employees was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021, and immaterial for the years ended December 31, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years and generally vest over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.262%;"/>
        <td style="width:1.707%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.831%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.707%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.284%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">880,600</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,800</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.75%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.741%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.741%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,926</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,657</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740541512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.	Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate for the years ended December 31, 2021, 2020 and 2019 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate of the Company&#8217;s provision for income taxes differs from the federal statutory rate as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.489%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#8217;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2021 and 2020. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards. The increase in valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and 2020, respectively, was primarily attributable to the Company&#8217;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#8217;s state apportionment factors.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.736%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.644%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.644%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,575</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,247</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,327</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,155</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,884</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,877</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,994</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021 and 2020, the Company&#8217;s federal and state income tax net operating loss carryforwards were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">353.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">347.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the state tax loss carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss and tax credit carryforwards as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.406%;"/>
        <td style="width:1.457%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.886%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.457%;"/>
        <td style="width:20.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Do not expire</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2037</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">347,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CA: credits do not expire<br/>MA: 2035 - 2040</span></span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period in excess of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership changes may further affect the limitation in future years. In connection with the Company&#8217;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2021 under IRC Sections 382 and 383 to determine if the Company&#8217;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.772%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.722%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.722%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.786%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,610</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">End of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,481</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If recognized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the unrecognized tax benefits as of December 31, 2021, 2020, and 2019 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, 2021, 2020, and 2019, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize accrued interest and penalties related to unrecognized tax benefits.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740543160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12.	Net Loss Per Common Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.785%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.298%;"/>
        <td style="width:8.431%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.111%;"/>
        <td style="width:0.881%;"/>
        <td style="width:1.104%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.13%;"/>
        <td style="width:0.881%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,433</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,885,186</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,792,365</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,554,823</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company issued and sold Warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,480,719</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock at a nominal exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share (see Note 9). During the year ended December 31, 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,459,576</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants exercised and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,872</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants cancelled due to net exercise of the warrants. As of December 31, 2021, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,016,271</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.707%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,170,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,179,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Early exercised common stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,874</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,879,131</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,213,738</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,209,915</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744730168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13.	Defined Contribution Plan</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the first </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of each employee&#8217;s contribution. During the year ended December 31, 2021, expenses recognized for the 401(k) Plan was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, while the amount was immaterial for the years ended December 31, 2020 and 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742346024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Securities and Exchange Commission (the &#8220;SEC&#8221;) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for reporting. </span><span style="background-color:rgba(255,255,255,1);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></p><p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:</span></p><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.</span></div></div><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</span></div></div><div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 inputs are unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div></div><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#8217;s restricted cash includes payments received under the CEPI Funding Agreement and Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.52%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170,056</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,285</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">992</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,577</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,048</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Securities</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#8217;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OtherRisksAndUncertaintiesPolicyTextBlock', window );">Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the World Health Organization declared the global novel coronavirus disease (&#8220;COVID-19&#8221;) outbreak a pandemic. To date, the Company&#8217;s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.318%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.099%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Long-Lived Assets</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2021, 2020 or 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#8217;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#8217;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#8211; Revenue Recognition (&#8220;ASC 958-605&#8221;), which applies to business entities that receive contributions within the scope of ASC 958-605.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#8217;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#8220;the Black-Scholes model&#8221;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation of the expected term for its stock options. Volatility is based on an average of the historical volatilities of the common stock of entities with characteristics similar to the Company&#8217;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#8217;s technologies are recorded as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#8217;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#8217;s consolidated balance sheets at December 31, 2021 and 2020. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes lease expense on a straight-line basis over the expected lease term.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes and measures uncertain tax positions using a two&#8212;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#8217;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2021, the Company had not accrued interest or penalties related to uncertain tax positions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 18, 2020, the Families First Coronavirus Response Act (the &#8220;FFCR Act&#8221;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 29, 2020, Assembly Bill 85 (&#8220;A.B. 85&#8221;) was signed into California law. A.B. 85 provides for a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> suspension of the use of net operating losses for medium and large businesses and a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cap on the use of business incentive tax credits to offset no more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for taxable years 2020 and 2021.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#8217;s consolidated financial statements as of December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Loss</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#8217;s marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt - Debt with Conversion and Other Options </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Subtopic 470-20) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2020-06&#8221;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">does not expect the adoption of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASU 2020-06 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to have a material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, the FASB issued ASU No. 2020-10, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Codification Improvements </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(&#8220;ASU 2020-10&#8221;). The standard contains improvements to the FASB Accounting Standards Codification (the &#8220;Codification&#8221;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated financial statements and related disclosures.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740713896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:65.52%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
          <td style="width:1.549%;"/>
          <td style="width:1.206%;"/>
          <td style="width:13.883%;"/>
          <td style="width:0.603%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93,287</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170,056</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,285</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,005</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">992</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,577</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,048</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.318%;"/>
          <td style="width:1.583%;"/>
          <td style="width:31.099%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Useful Life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of useful life or lease term</span></span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744726408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.558%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.73%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.916%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,976</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,277</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,565</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,637</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,991</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,628</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,348</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.581%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.917%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.907%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740651320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.622%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.927%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.908%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.908%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.141%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.871%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,031</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,281</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certificates of deposit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,594</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,974</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,953</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. government debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Asset backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,557</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,346</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;U.S. treasuries</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total long-term marketable securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,986</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,631</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">194,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,536</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,739</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.531%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.556%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.556%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.519%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.28%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.519%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,801</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;US treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total short-term marketable securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,002</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,803</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744754008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.662%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.459%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.512%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.477%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment and software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,113</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,054</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,726</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41,907</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,964</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,276</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,925</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction-in-progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,991</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,622</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,105</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741264328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Costs</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.807%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.596%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,382</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,973</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,518</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,653</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Information Related to Leases</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental information related to leases was as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.498%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.318%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.318%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.197%;"/>
        <td style="width:10.337%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of lease liabilities (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,925</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,495</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">New right-of-use assets obtained in exchange for lease obligations (in thousands):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,562</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,174</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,331</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term (years):</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.30</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.10</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.20</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum Annual Payments Under Lease Agreements</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, minimum annual payments under the Company&#8217;s lease agreements are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.787%;"/>
        <td style="width:2.078%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.132%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lease Financing<br/>Obligation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,642</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,627</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,504</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum payments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,048</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,515</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Amounts representing lease payments under Boston lease</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,114</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of future minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Current portion of lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,483</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncurrent portion of lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,936</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744534888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.694%;"/>
        <td style="width:1.753%;"/>
        <td style="width:1.206%;"/>
        <td style="width:15.796%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.753%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,970</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,725</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the Grant Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.239%;"/>
        <td style="width:1.874%;"/>
        <td style="width:1.206%;"/>
        <td style="width:17.078%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,225</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember', window );">Gilead [Member] | Collaboration, Option and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the contract asset and deferred revenue balance during the year ended December 31, 2021 for the Gilead Collaboration Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.679%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.173%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.173%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contract Asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,055</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,670</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_CepInnovationsMember', window );">CEPI [Member] | Funding Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue Balance</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in the deferred revenue balance during the year ended December 31, 2021 for the CEPI Funding Agreement are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.095%;"/>
        <td style="width:1.79%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.112%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deferred Revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,282</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deductions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,379</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CepInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CepInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742357064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,584</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,769</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,480</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest and other receivables</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">292</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">866</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,332</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Deposits and Other Long-Term Assets</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other long-term assets consist of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.551%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.549%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.867%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease security deposits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid research and development-related expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,047</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">518</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deposits and other long-term assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,352</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,736</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740539960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the following warrants to purchase shares of the Company&#8217;s common stock were issued and outstanding:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:38.577%;"/>
        <td style="width:1.438%;"/>
        <td style="width:27.892%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.503%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.438%;"/>
        <td style="width:0.983%;"/>
        <td style="width:12.541%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Issue Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Warrants Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 28, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,016,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742538200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.695%;"/>
        <td style="width:1.197%;"/>
        <td style="width:0.788%;"/>
        <td style="width:14.164%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.197%;"/>
        <td style="width:0.788%;"/>
        <td style="width:14.164%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.57</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.48</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.337%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.521%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.521%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.243%;"/>
        <td style="width:0.789%;"/>
        <td style="width:10.54%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the 2015 Plan, 2018 Plan and 2021 Plan activity is as follows:</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.395%;"/>
        <td style="width:1.001%;"/>
        <td style="width:1.085%;"/>
        <td style="width:8.15%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:0.964%;"/>
        <td style="width:7.928%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.205%;"/>
        <td style="width:7.918%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:0.964%;"/>
        <td style="width:7.928%;"/>
        <td style="width:0.964%;"/>
        <td style="width:1.103%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.02%;"/>
        <td style="width:0.964%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Shares<br/>Available<br/>for<br/>Issuance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number<br/>of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate    <br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,108,412</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,166,441</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.15</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,092</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,692,507</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,195,124</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,314,524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">692,038</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.86</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">853,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">681,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,459,187</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,107,335</span></p></td>
        <td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.82</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.13</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable &#8211; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,253,957</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.21</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,901</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest &#8211; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,741,858</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.74</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.06</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,267</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:</span><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.262%;"/>
        <td style="width:1.707%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.831%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.707%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.284%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">880,600</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Canceled/Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">171,800</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding, unvested as December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation for all awards granted to employees, consultants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 ESPP, before taxes, is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.859%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.75%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.741%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.456%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.741%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,437</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,926</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,657</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,862</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,552</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,110</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113743602760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate of the Company&#8217;s provision for income taxes differs from the federal statutory rate as follows:</span><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.489%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.16%;"/>
        <td style="width:0.594%;"/>
        <td style="width:10.421%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Statutory federal income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent differences</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in state tax apportionment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-taxable stock premium</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Tax Assets/Liabilities</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the net deferred tax assets/liabilities are as follows (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.736%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.644%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.644%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97,575</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74,278</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,247</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,327</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,354</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,633</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,155</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,537</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,414</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,884</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,775</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,781</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,877</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,994</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">763</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,665</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,231</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock', window );">Schedule of Net Operating Loss and Tax Credit Carryforwards</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss and tax credit carryforwards as of December 31, 2021 are as follows (in thousands):</span></p><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.406%;"/>
        <td style="width:1.457%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.886%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.457%;"/>
        <td style="width:20.985%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Expiration Years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (post December 31, 2017)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Do not expire</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating losses, federal (pre January 1, 2018)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,587</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2037</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">347,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,990</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2035 - 2040</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits, state</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CA: credits do not expire<br/>MA: 2035 - 2040</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.772%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.722%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.722%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.15%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.786%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,610</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease for tax positions taken during prior periods</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increases for tax positions taken during current period</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,456</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">End of year&#8212;unrecognized tax benefits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,481</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of net operating loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113743824328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):</span></p><p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.785%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.298%;"/>
        <td style="width:8.431%;"/>
        <td style="width:0.965%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.111%;"/>
        <td style="width:0.881%;"/>
        <td style="width:1.104%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.13%;"/>
        <td style="width:0.881%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,082</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94,433</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,885,186</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,792,365</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,554,823</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Potentially Anti-Dilutive Securities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.707%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.169%;"/>
        <td style="width:0.603%;"/>
        <td style="width:11.723%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding and ESPP shares issuable and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,170,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,213,738</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,179,041</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Early exercised common stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,874</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">708,800</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,879,131</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,213,738</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,209,915</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113744526792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">$ 75,082<span></span>
</td>
<td class="nump">$ 105,314<span></span>
</td>
<td class="nump">$ 94,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">50,678<span></span>
</td>
<td class="nump">89,102<span></span>
</td>
<td class="nump">$ 85,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">401,384<span></span>
</td>
<td class="nump">$ 326,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 206,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741431448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Marketable securities recognition of other-than-temporary impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement', window );">Percentage of realization of tax benefit upon ultimate settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness', window );">Use of net operating losses suspension period for medium and large business</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_UseOfBusinessIncentiveTaxCreditsPeriodCap', window );">Use of business incentive tax credits period cap</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember', window );">Taxable Years 2020 and 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended', window );">Minimum amount of taxable income where use of net operating losses is suspended</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember', window );">Taxable Years 2020 and 2021 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of taxable income where use of net operating losses is suspended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization of tax benefit upon ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UseOfBusinessIncentiveTaxCreditsPeriodCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Use of business incentive tax credits period cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UseOfBusinessIncentiveTaxCreditsPeriodCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Use of net operating losses suspension period for medium and large business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740939144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 93,287<span></span>
</td>
<td class="nump">$ 170,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">11,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">6,005<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 110,577<span></span>
</td>
<td class="nump">$ 171,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113739728120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, and equipment, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, and equipment, estimated useful lives</a></td>
<td class="text">Shorter of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736342856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">$ 93,287<span></span>
</td>
<td class="nump">$ 170,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">194,348<span></span>
</td>
<td class="nump">37,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">194,275<span></span>
</td>
<td class="nump">37,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">81,312<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">81,312<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">79,281<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">79,281<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value, Total</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedGains', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsUnrealizedLosses', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">108,408<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">108,346<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,277<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,269<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">44,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">44,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">26,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | U.S. Government Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember', window );">Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents, unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale debt securities accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale debt securities accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale debt securities amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741379928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 206,300<span></span>
</td>
<td class="nump">$ 171,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">93,287<span></span>
</td>
<td class="nump">170,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 113,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of individual securities in an unrealized loss position for 12 months or greater | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Marketable securities recognition of other-than-temporary impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MarketableSecuritiesRealizedGainLossDescription', window );">Realized gains or losses on marketable securities, description</a></td>
<td class="text">no material realized gains or losses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash equivalents and marketable securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MarketableSecuritiesContractualMaturitiesPeriod', window );">Marketable securities contractual maturities period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MarketableSecuritiesContractualMaturitiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities contractual maturities period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MarketableSecuritiesContractualMaturitiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MarketableSecuritiesRealizedGainLossDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities realized gain loss, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MarketableSecuritiesRealizedGainLossDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736668616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">$ 194,275<span></span>
</td>
<td class="nump">$ 37,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">81,312<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">79,281<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">108,346<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">12,269<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">44,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">26,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">16,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">94,536<span></span>
</td>
<td class="nump">37,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">79,281<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">79,281<span></span>
</td>
<td class="nump">36,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">12,269<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">12,269<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">99,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">2,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">96,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">44,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">26,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">16,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | U.S. government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Short-Term Marketable Securities [Member] | Asset Backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member] | U.S. Treasuries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member] | Long-term Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_ShortTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=grts_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742285256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair Value, Assets, Level 1 to Level 2 Transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair Value, Liabilities, Level 1 to Level 2 Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair Value, Assets, Level 2 to Level 1 Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair Value, Liabilities, Level 2 to Level 1 Transfers</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742516072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 41,907<span></span>
</td>
<td class="nump">$ 38,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(22,276)<span></span>
</td>
<td class="num">(16,925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">21,622<span></span>
</td>
<td class="nump">22,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,679<span></span>
</td>
<td class="nump">22,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,128<span></span>
</td>
<td class="nump">13,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 1,991<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=grts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113746607224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 6,347<span></span>
</td>
<td class="nump">$ 6,644<span></span>
</td>
<td class="nump">$ 4,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113738326584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>RenewalTerm</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>RenewalTerm</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,305,000<span></span>
</td>
<td class="nump">$ 1,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,920,000<span></span>
</td>
<td class="nump">21,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,490,000<span></span>
</td>
<td class="nump">88,643,000<span></span>
</td>
<td class="nump">$ 82,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_ContractResearchOrganizationMember', window );">Contract Research Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumMilestonePaymentObligation', window );">Maximum milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember', window );">Emeryville California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms', window );">Operating leases number of renewal terms | RenewalTerm</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_PleasantonMember', window );">Pleasanton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">64 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Net rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn', window );">Withdrawal from irrevocable letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember', window );">Cambridge Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">67 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Operating lease cash security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear', window );">Operating lease termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Storage space commenced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=grts_BostonLeaseMember', window );">Boston Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leasing term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating leasing renewal option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms', window );">Operating leases number of renewal terms | RenewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn', window );">Withdrawal from irrevocable letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OperationsExpectedCommencedDate', window );">Operations expected commenced date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit', window );">Restricted cash deposit used as collateral for letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_LeaseExpirationTerm', window );">Lease expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AmountOfIrrevocableLettersOfCreditWithdrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of irrevocable letters of credit withdrawn.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AmountOfIrrevocableLettersOfCreditWithdrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LeaseExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LeaseExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases additional number of renewal terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases term of contract month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount to be paid upon achievement of certain milestones as defined under the research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperationsExpectedCommencedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operations commenced date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperationsExpectedCommencedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash deposit used as collateral for letter of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_ContractResearchOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_ContractResearchOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_EmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_PleasantonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_PleasantonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=grts_BostonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=grts_BostonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736515496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 7,973<span></span>
</td>
<td class="nump">$ 7,511<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 7,973<span></span>
</td>
<td class="nump">$ 7,518<span></span>
</td>
<td class="nump">$ 6,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741028248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="nump">$ 5,389<span></span>
</td>
<td class="nump">$ 2,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>New right-of-use assets obtained in exchange for lease obligations (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 6,562<span></span>
</td>
<td class="nump">$ 3,174<span></span>
</td>
<td class="nump">$ 12,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WeightedAverageRemainingLeaseTermYearsAbstract', window );"><strong>Weighted average remaining lease term (years):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 months 3 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New right-of-use assets obtained in exchange for lease obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WeightedAverageRemainingLeaseTermYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term (years).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WeightedAverageRemainingLeaseTermYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742554120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">9,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">12,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">10,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">10,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">59,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">112,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest expense</a></td>
<td class="num">(6,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OperatingLeasePaymentUnderTheBostonLease', window );">Less: Amounts representing lease payments under the Boston Lease</a></td>
<td class="num">(79,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">26,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of lease liability</a></td>
<td class="num">(7,483)<span></span>
</td>
<td class="num">$ (5,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion of lease liability</a></td>
<td class="nump">$ 18,936<span></span>
</td>
<td class="nump">$ 19,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperatingLeasePaymentUnderTheBostonLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease payment under the boston lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperatingLeasePaymentUnderTheBostonLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113729128648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,201,000<span></span>
</td>
<td class="nump">$ 3,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,128,000<span></span>
</td>
<td class="nump">$ 8,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,490,000<span></span>
</td>
<td class="nump">$ 88,643,000<span></span>
</td>
<td class="nump">$ 82,896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredContractAcquisitionCosts', window );">Deferred contract acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredContractAcquisitionCostsAmortized', window );">Deferred contract acquisition costs, amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,285,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Short-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,005,000<span></span>
</td>
<td class="nump">992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember', window );">Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage', window );">Future Milestone And Royalty Payments, Reduction Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember', window );">Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage', window );">Future Milestone And Royalty Payments, Reduction Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird Bio Inc [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds From Issuance Of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumPotentialMilestoneReceivable', window );">Maximum development, regulatory, and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod', window );">Collaboration agreement early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments', window );">Early termination reduction of future milestone and royalty payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, all of 2seventy&#8217;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RevenueRecognitionContractStartMonthYear', window );">Revenue recognition contract start month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndMonthYear', window );">Revenue recognition contract end month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ReceivablesGross', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumMilestoneConsiderationPayable', window );">Maximum milestone consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense', window );">Milestone payment included in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ReimbursementsExpenseMaterialsAndPersonnelCosts', window );">Reimbursements expense materials and personnel costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | 2 Seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds From Issuance Of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | 2 Seventy [Member] | Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod', window );">Collaboration agreement early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments', window );">Early termination reduction of future milestone and royalty payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#8217;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#8217;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RevenueRecognitionContractStartMonthYear', window );">Revenue recognition contract start month year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ReceivablesGross', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommonStockFairValueClosingPricePerShare', window );">Common stock fair value closing price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_NonRefundableOptionFee', window );">Non-refundable option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumAggregateContingentMilestonePayment', window );">Maximum aggregate contingent milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CollaborationAgreementTerminationTerm', window );">Collaboration agreement termination term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue', window );">Transaction price allocated to shares of common stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CommonStockPurchasePriceInExcessOfFairValue1', window );">Common stock purchase price in excess of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,385,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Deferred incremental costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Maximum [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndPeriod', window );">Revenue recognition contract end period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Minimum [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_RevenueRecognitionContractEndPeriod', window );">Revenue recognition contract end period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Collaboration and license revenues [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AgreedUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AmountToExtendOptionTerm', window );">Amount to extend the option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember', window );">Option and License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone', window );">Aggregate payment in specified development regulatory and commercial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication', window );">Payments for options to license for each indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember', window );">Non-Exclusive License and Development Agreement [Member] | Genevant Sciences GmbH [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumAggregateContingentMilestonePaymentToBeMade', window );">Maximum aggregate contingent milestone payments to be made by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember', window );">C E P I Funding Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AdditionalFunding', window );">Additional funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_AgreementTotalFunding', window );">Agreement total funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember', window );">C E P I Funding Agreement [Member] | Coalition for Epidemic Preparedness Innovation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod', window );">Collaboration and license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_InitialFundingDevelopmentCosts', window );">Initial funding development costs</a></td>
<td class="nump">$ 20,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_FirstTrancheOfFundingsReceived', window );">First tranche of funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromNonRefundableUpfrontPayment', window );">Proceeds from non refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,225,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non- current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_FutureFundingExpected', window );">Future Funding Expected</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_FundingDevelopmentCosts', window );">Funding development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AdditionalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AdditionalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment in specified development regulatory and commercial milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AgreedUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AgreedUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AgreementTotalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement total funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AgreementTotalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_AmountToExtendOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to extend option term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_AmountToExtendOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationAgreementEarlyTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement early termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationAgreementEarlyTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationAgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationAgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommonStockFairValueClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock fair value closing price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommonStockFairValueClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CommonStockPurchasePriceInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchase Price In Excess Of Fair Value1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CommonStockPurchasePriceInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability revenue recognized including new contracts in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredContractAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred contract acquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredContractAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredContractAcquisitionCostsAmortized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred contract acquisition costs amortized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredContractAcquisitionCostsAmortized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early termination reduction of future milestone and royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FirstTrancheOfFundingsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First Tranche of Fundings Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FirstTrancheOfFundingsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FundingDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FundingDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FutureFundingExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funding expected in future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FutureFundingExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Milestone And Royalty Payments, Reduction Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_InitialFundingDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial funding development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_InitialFundingDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumAggregateContingentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate contingent milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumAggregateContingentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumAggregateContingentMilestonePaymentToBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate contingent milestone payment to be made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumAggregateContingentMilestonePaymentToBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumMilestoneConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration to be paid in the future based on milestones per the License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumMilestoneConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumPotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable consideration relating to future milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumPotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NonRefundableOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable option fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NonRefundableOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for options to license for each indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromNonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from non refundable upfront payment included in transaction price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromNonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ReceivablesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ReceivablesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ReimbursementsExpenseMaterialsAndPersonnelCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursements expense materials and personnel costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ReimbursementsExpenseMaterialsAndPersonnelCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractEndMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract end year-month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractEndMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractEndPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract end period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractEndPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_RevenueRecognitionContractStartMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition contract start year-month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_RevenueRecognitionContractStartMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price allocated to shares of common stock at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BluebirdBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BluebirdBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_OptionAndLicenseAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GenevantSciencesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GenevantSciencesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_NonExclusiveLicenseAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736268024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember', window );">Research Collaboration and License Agreement [Member] | Bluebird bio to 2seventy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 11,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">8,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Gilead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerAssetAddition', window );">Additions</a></td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerAssetDeduction', window );">Deductions</a></td>
<td class="num">(3,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Balance at December 31, 2021</a></td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember', window );">C E P I Funding Agreement [Member] | CEPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember', window );">Funding Agreement [Member] | CEPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">11,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">9,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember', window );">Grant Agreement [Member] | Gates Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityAddition', window );">Additions</a></td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ContractWithCustomerLiabilityDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 2,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerAssetAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset addition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerAssetAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerAssetDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer asset deduction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerAssetDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability addition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_BlueBirdBioTo2SeventyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_CEPIFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=grts_CoalitionForEpidemicPreparednessInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_FundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=grts_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=grts_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=grts_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742692536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PrepaidExpenseForResearchAndDevelopment', window );">Prepaid research and development-related expenses</a></td>
<td class="nump">$ 2,672<span></span>
</td>
<td class="nump">$ 2,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_NetContractAsset', window );">Net contract asset</a></td>
<td class="nump">1,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CollaborationReceivable', window );">Collaboration receivable</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_InterestAndOtherReceivablesCurrent', window );">Interest and other receivables</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 7,672<span></span>
</td>
<td class="nump">$ 4,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_InterestAndOtherReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other receivables current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_InterestAndOtherReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NetContractAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net contract asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NetContractAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaidExpenseForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaidExpenseForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113743280280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract', window );"><strong>Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Lease security deposits</a></td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent', window );">Prepaid research and development-related expenses</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DepositsAndOtherAssetsNoncurrent', window );">Total deposits and other long-term assets</a></td>
<td class="nump">$ 2,352<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposit assets and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncurrent Deposits And Other Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113735836584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,047,878<span></span>
</td>
<td class="nump">47,552,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of the Company&#8217;s common stock are entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumSecuritiesCoveredUnderRegistrationAgreement', window );">Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PercentageOfProceedsPayableAsCompensationToUnderwriter', window );">Percentage of gross proceeds as underwriter compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumOfferingExpensesAgreedToBeReimbursed', window );">Maximum offering expense agreed to be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,704,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WarrantsCancelled', window );">Warrants cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember', window );">Amended and Restated Certificate of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period Shares New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="nump">1,160,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,719,000<span></span>
</td>
<td class="nump">$ 9,770,000<span></span>
</td>
<td class="nump">$ 4,064,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember', window );">ATM Equity Offering Program [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Equity Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period Shares New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,990,869<span></span>
</td>
<td class="nump">1,160,963<span></span>
</td>
<td class="nump">490,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period Shares New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">9,586,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member] | Private Investment in Public Equity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period Shares New Issues</a></td>
<td class="nump">4,043,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants', window );">Proceed from issuance of stock and pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,543,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_SaleOfStockPricePerSharePrepaidByPurchaser', window );">Offering price per share, prepaid by purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WarrantsToPurchaseSharesOfCommonStock', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,480,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_PlacementAgentCommissionsAndLegalFees', window );">Placement agent commissions and legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant', window );">Maximum percentage of common stock ownership to exercise warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumOfferingExpensesAgreedToBeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum offering expenses agreed to be reimbursed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumOfferingExpensesAgreedToBeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock ownership to exercise warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MaximumSecuritiesCoveredUnderRegistrationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum securities covered under registration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MaximumSecuritiesCoveredUnderRegistrationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PercentageOfProceedsPayableAsCompensationToUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds payable as compensation to underwriter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PercentageOfProceedsPayableAsCompensationToUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_PlacementAgentCommissionsAndLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement agent commissions and legal fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_PlacementAgentCommissionsAndLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SaleOfStockPricePerSharePrepaidByPurchaser">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Price Per Share, Prepaid by Purchaser</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SaleOfStockPricePerSharePrepaidByPurchaser</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AmendedAndRestatedCertificateOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=grts_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740554056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightIssueDate', window );">Issue Date</a></td>
<td class="text">Dec. 28,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightsExpiration', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding | shares</a></td>
<td class="nump">17,016,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, issue date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113737473704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="nump">3,459,187<span></span>
</td>
<td class="nump">3,108,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value granted employee stock options granted</a></td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="nump">$ 5.39<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees', window );">Stock-based compensation expense and awards granted to non-employees</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock option awards exercised</a></td>
<td class="nump">5,800,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived', window );">cash received upon exercise of stock options</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total cost related to non-vested employee and consultant options expected to be recognized</a></td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total cost related to non-vested employee and consultant options unrecognized weighted average period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit Awards under 2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation by shared based payment award, description</a></td>
<td class="text">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to 10 years and generally vest over a 2-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Restricted Stock Unit Awards under 2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option granted expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Award Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,690,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseInSharesAvailableForIssuancePercentage', window );">Increase in shares available for issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MinimumPercentageOfOutstandingSharesHeldByIndividual', window );">Minimum percentage of outstanding shares held by individual</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_MinimumPercentageFairMarketValueOfSharePrice', window );">Minimum percentage fair market value of share price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation by shared based payment award, description</a></td>
<td class="text">If an individual owns stock representing 10% or more of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the board of directors. Options granted have a term of up to 10 years and generally vest over a 4-year period with a straight-line vesting.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Award Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option granted expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncreaseInSharesAvailableForIssuancePercentage', window );">Increase in shares available for issuance</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contribution of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember', window );">2021 Employment Inducement Incentive Award Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncreaseInSharesAvailableForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in shares available for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncreaseInSharesAvailableForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumPercentageFairMarketValueOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage fair market value of share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumPercentageFairMarketValueOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_MinimumPercentageOfOutstandingSharesHeldByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of outstanding shares held by individual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_MinimumPercentageOfOutstandingSharesHeldByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options cash received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense and awards granted to non-employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736552184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail) - 2018 Employee Stock Purchase Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 months 25 days<span></span>
</td>
<td class="text">5 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=grts_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741345016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail) - Employee or Director [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=grts_EmployeeOrDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=grts_EmployeeOrDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736148424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Options Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Number of Shares Available for Issuance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of options beginning balance</a></td>
<td class="nump">3,108,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Authorized</a></td>
<td class="nump">2,692,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted', window );">Granted</a></td>
<td class="num">(3,195,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled', window );">Cancelled</a></td>
<td class="nump">853,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of options ending balance</a></td>
<td class="nump">3,459,187<span></span>
</td>
<td class="nump">3,108,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">4,166,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">2,314,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(692,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(681,592)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">5,107,335<span></span>
</td>
<td class="nump">4,166,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options Outstanding, Number of Shares, Vested and exercisable</a></td>
<td class="nump">2,253,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options Outstanding, Number of Shares, Vested and expected to vest</a></td>
<td class="nump">4,741,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="nump">$ 8.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">9.82<span></span>
</td>
<td class="nump">$ 8.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">8.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 9.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted-Average Remaining Contractual Term (in years)</a></td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)</a></td>
<td class="text">7 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)</a></td>
<td class="text">8 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 17,153<span></span>
</td>
<td class="nump">$ 2,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">9,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 16,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for grants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for issuance cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for issuance granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742524664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, unvested Beginning balance | shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued | shares</a></td>
<td class="nump">880,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled/Forfeited | shares | shares</a></td>
<td class="nump">171,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, unvested ending balance | shares | shares</a></td>
<td class="nump">708,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, unvested beginning balance | $ / shares | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued | $ / shares | $ / shares</a></td>
<td class="nump">5.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled/Forfeited | $ / shares | $ / shares</a></td>
<td class="nump">5.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, unvested ending balance | $ / shares | $ / shares</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113736622584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 10,552<span></span>
</td>
<td class="nump">$ 7,110<span></span>
</td>
<td class="nump">$ 5,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">6,626<span></span>
</td>
<td class="nump">4,453<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 3,926<span></span>
</td>
<td class="nump">$ 2,657<span></span>
</td>
<td class="nump">$ 1,862<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741379960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in state tax apportionment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_NonTaxableStockPremium', window );">Non-taxable stock premium</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.70%)<span></span>
</td>
<td class="num">(40.30%)<span></span>
</td>
<td class="num">(26.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent income tax rate differential.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_NonTaxableStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-taxable stock premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_NonTaxableStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113737498888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="nump">$ 42,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OwnershipInterestChangeOverPeriod', window );">Changes in ownership over period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_CumulativeChangesInOwnershipInterestOfShareholders', window );">Cumulative changes in ownership interest of shareholders</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development | Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 353,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 10,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 347,184<span></span>
</td>
<td class="nump">$ 347,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 7,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">CA: credits do not expireMA: 2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_CumulativeChangesInOwnershipInterestOfShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative changes in ownership interest of shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_CumulativeChangesInOwnershipInterestOfShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_OwnershipInterestChangeOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership interest change over period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_OwnershipInterestChangeOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113729121288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 97,575<span></span>
</td>
<td class="nump">$ 74,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development tax credits</a></td>
<td class="nump">12,271<span></span>
</td>
<td class="nump">9,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredTaxAssetsLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">7,684<span></span>
</td>
<td class="nump">7,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Accruals and other</a></td>
<td class="nump">3,184<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="nump">10,633<span></span>
</td>
<td class="nump">11,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">3,414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">133,884<span></span>
</td>
<td class="nump">108,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(127,007)<span></span>
</td>
<td class="num">(101,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">6,877<span></span>
</td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredTaxLiabilitiesOtherDepreciation', window );">Other depreciation</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(6,665)<span></span>
</td>
<td class="num">(6,231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of uset assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_DeferredTaxLiabilitiesOtherDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, other depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_DeferredTaxLiabilitiesOtherDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113741434696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 353,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 10,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Post December312017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 303,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">Do not expire<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Pre January12018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 50,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 347,184<span></span>
</td>
<td class="nump">$ 347,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Business incentive tax credits to offset against taxes</a></td>
<td class="nump">$ 7,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating losses, Expiration year</a></td>
<td class="text">2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credits, Expiration year</a></td>
<td class="text">CA: credits do not expireMA: 2035 - 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=grts_PostDecember312017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=grts_PostDecember312017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=grts_PreJanuary12018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=grts_PreJanuary12018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113742576056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year&#8212;unrecognized tax benefits</a></td>
<td class="nump">$ 4,025<span></span>
</td>
<td class="nump">$ 2,610<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease for tax positions taken during prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for tax positions taken during current period</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="nump">1,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year&#8212;unrecognized tax benefits</a></td>
<td class="nump">$ 5,481<span></span>
</td>
<td class="nump">$ 4,025<span></span>
</td>
<td class="nump">$ 2,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113743545144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,082)<span></span>
</td>
<td class="num">$ (105,314)<span></span>
</td>
<td class="num">$ (94,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">78,885,186<span></span>
</td>
<td class="nump">37,792,365<span></span>
</td>
<td class="nump">33,554,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (2.81)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113740939688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">10,459,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_WarrantsCancelled', window );">Warrants Cancelled</a></td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">17,016,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember', window );">Common Stock and Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,480,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights', window );">Class of warrant nominal exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right nominal exercise price of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_grts_WarrantsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">grts_WarrantsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>grts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=grts_CommonStockAndOrPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113739700472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">5,879,131<span></span>
</td>
<td class="nump">4,213,738<span></span>
</td>
<td class="nump">3,209,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember', window );">Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">5,170,331<span></span>
</td>
<td class="nump">4,213,738<span></span>
</td>
<td class="nump">3,179,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_EarlyExercisedCommonStockSubjectToFutureVestingMember', window );">Early Exercised Common Stock Subject To Future Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember', window );">Restricted Stock Subject to Future Vesting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities that were not included in the diluted per share calculations</a></td>
<td class="nump">708,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_EarlyExercisedCommonStockSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_EarlyExercisedCommonStockSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=grts_RestrictedStockSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113743280280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan cost</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer's matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>grts-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:grts="http://gritstonebio.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="grts-20211231.xsd" xlink:type="simple"/>
    <context id="C_b922b66e-4124-4802-a0ce-1cecdf096487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f567c768-2291-41ae-b166-d1912a72f707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d0ec608c-cdab-41f8-92b0-fabd470a62ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_2bb37ca5-db5d-4687-89ae-66db04f52143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bdb6e5b1-bb05-454c-8661-5dbae465a144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_9e986ac8-7731-4b24-b71a-e9e6a696434e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="C_cb4aa159-88f3-4ae9-872f-ad54eb0054a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2eec9e6d-ddf3-4386-87ac-8ad1c81b0edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d8e26511-0489-4f9f-9cb5-3285842a09fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ebef1c21-1add-4b82-b86f-c63f3d498c3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f87928d0-309b-467a-826b-88343445bf04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b6f878cf-27a6-4a39-8ffb-4b24d54bd0fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_79ced502-684c-452e-a1e7-6fcb8df0fce8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa671a96-949e-426a-b9d0-931244a1e019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_26228208-a6ee-48f7-a682-d0ebfa815e49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be96c1cb-cdd0-401f-9ffa-ba59e494db4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7de09d33-88c1-42a7-afb7-90f61cda1e04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fb979a40-c0d7-43fd-bceb-f181847be79e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_31211693-1cda-45e5-a939-9774d55bf2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b5b3f31b-7118-424c-be58-60dc31c876aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_42b8da6e-7442-4d11-94ba-d9fccabe6043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_9a5f8053-f39a-415a-be93-1d833d484e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_3fa0442c-ac78-4809-b069-aed25c97df13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ea27018b-ae35-4896-958f-8b3ad75d9f1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6cf22661-5fe6-4416-b669-0e1caded7434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aa4c4d44-8bce-48ff-a4e4-7256f3516afb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_72dfcfb2-eb2b-4d05-8cf1-c1bc2e786747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_3984633a-9389-4f12-94bd-7218eb5fa25e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f5f6a648-955a-4a5a-bac4-0a73b202d719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ee66b39c-2a63-4760-bb71-f8fa3a48775c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80c30ec9-ef76-40b1-9254-a26ab087e7c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9299c473-d0f6-48c7-880f-5c832935a48b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1a56f792-e909-4a78-9c9f-369e4b671f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4b447ec2-ed8d-4932-a1c9-f1211bf27f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ef27cb81-c09f-4cb8-81bf-6b870908b71b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3f46bcc8-23a7-4ffa-9d3d-c33aa11216e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_fbb17c0d-cde0-48c5-b232-0304dab63e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a8a47a83-89e6-4e48-884d-6f9289316bbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1c539e79-df24-408f-baa2-48c4f8fe8cd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3266dfed-769a-40b0-8646-a9d8b35c1a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_64144ed4-7156-4df6-9ed4-71edcffd2730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_af382cd1-7c55-4a5b-8f11-f6f806af4f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CepInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3d7d9ff9-59ff-40cb-8c0e-59c0bc70d677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aa774e87-9154-4d69-beec-62667e7e6728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_46f01538-745e-443b-9a6c-602d548493a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b820c59d-b464-4759-bbb7-0c4841c49905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_9a00145e-06b8-48cf-9669-be9b9d8fc159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5e60bfb9-8ab6-4a16-8851-229b4f62c041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_85575cb7-32f7-42d3-a21b-cb91af13687d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_f5581400-90ad-4249-923b-5cba9bd710c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0cfda793-d20c-4961-a834-c8650ee91d83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_566f53db-f8e8-41fd-9b20-dcbb06f27fc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fda9c57d-6ce6-4fc0-83c9-b59dac2e78ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c4425ed7-6aea-4eec-abd2-81111d52a84a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e84c838c-b8b5-42b0-86d2-23e56453e579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a9b94c09-f330-4e14-958b-a04cb0904e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ff041b65-d516-4554-a158-11af438bd9d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eb09cd51-ac40-4ddc-b069-ec80b0a9c3ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_10299d1d-13c5-4852-a7f2-89934ae6946e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_c07bb700-a02f-45ab-9f15-e2c76e3747cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ba034453-4fd5-4226-85c4-36e74505c7b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_576b3dfa-a60b-4b9c-a136-301a277fd0bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f1e134b6-2dd5-4505-b2e1-f8a94eb727dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d989933a-3905-49b7-9ee1-1782f59e82ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_73464b08-07d2-40b6-ace7-0c62aa972258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ef0e97d3-9570-43f8-a443-eefdbce6381d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ec9e70d0-23a0-467e-b683-3d2b3eaf2393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8102c196-e4f5-4bf5-824f-1227db0eb3b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be2d704f-9ebb-4151-bfe1-64f9f58a7b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2416b0ec-eb6d-48de-b430-8527dc88fbd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_74c098e4-40eb-413b-bfae-ef00e77cdc53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1370d5aa-2b10-4f99-9326-80852218e027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_30604600-a913-4a56-bc12-11001d41700a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a11e18b2-bc61-4add-880b-6822c9bfcacf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b31fcc2f-be1c-410a-8c29-d48033722636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4648628a-65c5-480f-b910-360609ce023f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-28</instant>
        </period>
    </context>
    <context id="C_518a98be-fa4a-4aa6-97cb-3e2f9ad3b79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e30aa933-0d6e-4987-a2a1-bbce8c351c9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9ea13d69-ee00-43f8-b7f0-e73c7105d779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_56fd8f05-2d3d-40b2-a758-c7de82170e4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e162ac57-c6fe-433b-9c8e-4ec41607c846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_39f0995b-97b6-4734-859b-932b4f1b1bc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_4d000fa3-1eaf-460c-a146-fa94750108ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a0c12b21-3162-4e9e-8023-973cfc335cb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:CommonStockAndOrPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_451a0b67-f3b2-496e-a299-db96faaae70e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dff844cc-04ee-4272-9f37-98efe57aea15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5fad68e3-d917-408c-8c64-eb2b3afa907e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7a64849a-720f-4b6d-87cb-b18228eb569e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_14f18898-257e-4527-9df2-402224c7a2a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f3f22244-1f88-421e-9cc4-3b878d466850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6f545e51-7d7d-4b7a-bbdc-f5531a775926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f870e98-f90c-49bb-86f0-83e46e07b98a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ab352646-a87b-4f45-b887-2a58f2cb2c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6da601ec-2822-45c8-a4c9-e52839555406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_770c1400-be16-4651-87a2-b63b0c62772f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66671e44-d11b-4168-b422-0fbfe5fa8350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3418f96e-c10b-4a60-a068-01b16dabf6cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_03810506-a2c8-49f8-9836-cbebe5541354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_82754c58-c826-4434-bf40-87fc89524365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a515cc3e-d845-485c-b8cd-9789fd8a095a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_30c5d65f-d7ac-4f7f-9b8f-ea4e4e427446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_03d9a53a-ccc3-4f13-b052-55cc78345393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_817472bf-f8f1-43c2-a0d3-5d601d69a222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_4a494dd9-b549-41f2-b0e4-223518bdd582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6dbc0ba8-cd39-4c20-9b7d-bb253b05b1a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_50a00b2f-11c4-485d-982a-768195d22ede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_12e26153-82b4-40ab-8b8e-500eff6e7133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-28</startDate>
            <endDate>2020-12-28</endDate>
        </period>
    </context>
    <context id="C_746d448f-f9d9-418a-89b9-fbac99dc06ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_e3c26619-b56f-41f8-bdf1-a3ff19582f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d7987440-e273-4b4b-a993-e63610db9856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_50ba15bc-abe4-40d9-83dd-7f897007ee15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cb6c3d89-2dc2-476a-a09b-30ac42c2532e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_4028d4f2-0823-4d74-af7d-d47f1f2de8e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_c96685cb-4058-4f73-a479-ddc549ba8a42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4ea043b7-fa57-4d14-8d34-b78103ca2ed8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bd06d670-ff74-493a-bef1-1d7f537c855a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f74a3c85-0277-41dd-9121-429606c196de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ca7d4972-2e89-44bd-9c6d-a8139bbbfdaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6c627a47-b9a4-42f9-9425-7b48bc442bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_25e0aa86-a42f-4054-8323-4060b43924cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b3dbdfb2-9a14-4b95-94f9-f7c4fd7b4d2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PostDecember312017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d171005c-8d0e-451d-ba44-fff86b36b8da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_f169b2c6-9283-4498-8fe4-31a18d6b1ec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b424de0c-4fee-48e3-bea3-66f5d512ff60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_382a9f9a-00c6-4098-ba1f-f90f5c3bafd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aa002ef1-1e05-4ec8-8b0e-f1fff0822abf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9c13a7d1-0de0-4b4a-b307-f31dc3ebf480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fbf4938b-d2f9-4fa1-ba69-cec10c693873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d66cd703-3912-46fa-bae2-d9fb061ac072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_64253bb9-ade3-45ac-b41f-7d7b2677303d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d3f9f89-ed3a-428d-a261-354556628edc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_84b5d7c9-f721-46f5-ac90-4bde76f80644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bc289d2c-e7b6-4507-9fb5-87d39ce5490f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ad7b7d3a-31f1-4f01-a882-0db818ad07a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_74699a7b-9862-48d1-88b1-8c7ce7b44e28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_982f33fb-21c0-4dd6-87c5-65c36e0e5f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_21980324-d092-473a-8ef8-6dfaf9956f38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="C_380e370a-6b47-4450-8fb6-5f55120330a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_77affe5f-9a99-4ac8-acc3-0fad18eb1e3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f54e27a8-261f-4d2c-b6fd-99f5477f06ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f828de0a-9a64-46e4-8ecc-9355300442d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b7622eb6-29c1-4937-a641-db49a22c7d5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_60da28f6-7643-4ad1-b263-313f3285ca2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d6e42e8c-14e5-4460-9129-ce2242e0271a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1987d89b-7388-4dfe-ba84-c6a897416187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_40de9285-a41b-4aba-b67e-ff00d1385e17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_36e294a4-e0df-4447-b010-28bd585fdd93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_307b7ee6-24f5-4623-9dd7-769942f70dba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_3f526cf1-464a-4dda-8e5a-79f43b2772aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:EarlyExercisedCommonStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f2d744ea-ab74-4270-b82e-e2d3674f902d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a29305ba-c997-4325-90de-110968edf965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ffaa39a0-354a-45c2-b143-8dff6921739e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_f0499a53-483b-4201-8223-d8a875e05b6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_54016751-a114-4247-b713-e0476cc1ba05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_858b47a6-e592-4ea1-b141-4955b70c5d4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8ac0f270-594e-4838-963f-9a5cabbd9055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_edaa2ef9-c496-465a-bdc7-7a2547c59678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">grts:TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8adaa80f-a791-410d-a103-9f6d54cf70b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_62f90882-9570-4db7-bf40-7696560e7bd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AmendedAndRestatedCertificateOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3bab2de3-95f2-4e3a-9835-071d68696554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_cb381328-f186-4340-881a-c3901e4b4c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:ContractResearchOrganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a063016e-88e5-4a22-8611-b5879f0bd30e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02b16dbd-b7a0-4b17-815f-637d91f05924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_46e79e08-83a1-4420-a9c9-fa98bb9c1247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_37e6511c-98ee-405d-9c80-3d0032f397aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9b169cdf-cda7-4247-a6bb-d30a8c55839a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_10488a3d-db85-443f-947d-6d636d18af49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a0bc0c98-2ff1-4535-99bd-4549d5704989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-14</endDate>
        </period>
    </context>
    <context id="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_f772a0a4-efa1-4b33-be2c-131d275bc66b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_37521ff6-ee49-47f9-82b9-df82ccbc22a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_30cdab96-3f4b-4379-b29a-bcbd8cf5affa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-28</instant>
        </period>
    </context>
    <context id="C_71977700-a9f0-41f2-b868-8e6cb6b931de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_996cd399-bd9d-4157-a800-02de52cbb53e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_13ec2a36-3f76-4309-a005-6e83308a21b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_26915e15-276f-4d55-92e9-790736763dbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_da80cade-f058-4976-8865-56dee50a193b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e130a83e-daf9-47c4-ab36-8190b47e6a2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3a314753-a175-4226-8b72-9c3df68982ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_90dbde66-ba3c-4738-91d6-2e0290e34f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:StockOptionsWarrantsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_53c971f9-6a10-4dd2-9fb3-244f2a280440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e2caa467-fa23-4f7e-ae1f-5ca204d58c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f109470-dac2-4731-88ec-db187dd90821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c6e24dfd-99c6-486b-bf9c-ed12b545fb8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0e326ef4-32be-4c22-a96d-5f69ef9ee281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_2196007d-8bbb-41dc-bf26-a59a7a2a5a5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5a1a7d8e-2cb5-4480-a9f0-5d9d08ea4e42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_9ce3523e-57c4-4351-b586-64db47e52605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_81d44cfe-4817-47ec-82ff-c16f1b041f0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_d7d371dd-a94d-4213-a570-7cce5450d104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fbee0f17-2c8f-479d-918b-1fd7ddd2f644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1b456a1b-1f2c-4ef1-8559-e06dc02c434e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_07646176-7861-4b62-81ac-b15ae5bdb75e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c9d841a0-65e8-4897-a9d8-b29656c20523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_a82f3996-a232-41a2-ba36-db531bddceba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_71f8b23d-24fd-4e8b-8f47-dd44d72f6801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_82594404-3d52-42ec-86ef-ac5b28a31a88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e021a0aa-375f-4923-9a82-7d2d919305be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_41a55fdc-8e37-4a5a-87e7-f6d1171e8e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_931f6700-0cb1-4f20-b677-efdf1bd07c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_520c653f-3fd9-4afa-a427-6bc66ddc0094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_90670968-8bdc-4930-a115-4ce5e59779c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:GrantAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dbeb91ff-efca-496e-8f5f-a322f317f314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_03449e98-a695-4ee5-a4e7-b5c706a15b67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">grts:RestrictedStockSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ef3a2d5c-f57f-42c8-acc1-25a55ffcd722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_2d463622-3449-495d-a283-ead7997ec267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0ccb5220-a382-46c0-b2dc-bcad6d8aa290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f018322b-c8aa-48d4-8e6e-49a256954912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_62974a0f-14cc-441b-8b01-762333a2a200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_df133232-0911-4fa1-b7e9-ad9298b91da0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_62787d44-14ba-4275-b041-61b55ece56ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_113f6e9e-2318-4e64-9807-9fb8459e68ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_798c90a9-6bbc-4bcc-a947-9814b7fe2869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4e64aab1-349c-4614-83ee-3900dea01a17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ba072684-2765-4bcf-b573-e869e31f90c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">grts:EmployeeOrDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1fc1f7ef-16ae-4f01-b819-fa9c521cd5d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cef8cbb3-30a5-4f27-89df-b90b0bac1878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_525c3994-76ab-46e8-a2ba-480c5eb3a271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1f0f4dc4-3084-4ed1-9f00-4607611bf19a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f0bfb81-1915-4116-a634-7211fd15e24b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1d814b55-408c-482f-b8ae-c5e423b0bacc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7057aae3-6cd0-4063-9952-0286502804a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dcafcdf1-b545-44ea-b0b0-4e5a82dc1960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4be9d25f-8253-43d1-96f9-812aa91da2ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_51e8d18f-06ae-4779-a286-63d6c005a973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_098479a5-8222-4852-8fef-d20451698abd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9c371ea3-28ab-4cab-b5bc-b09e9730fe88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75eb6304-1d47-4d29-95ee-7f072311268b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_64dce666-8e1a-4354-b216-dc6c18393077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d99841f-5ce6-4dad-8ba9-7eec24d9d624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_8869555a-bdc4-45c5-bdd1-ae2de6f84ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_72910c92-ee53-4966-9f0c-433eaf5edd6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b8cbe5d8-7e8c-4676-8c42-837291b53456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_eeccbfcd-9588-414a-8b16-d9ae566a7a11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_d0e07771-0a34-485d-8679-411afed4e92f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a58ea4fb-a55d-45cb-81a2-cc200e484f8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a312235c-4cac-4041-b6a1-62babf05fea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:NonExclusiveLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_c7f32053-1fd2-41c7-8b07-52c62c884195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_30bd410f-a2b7-4dcd-91e2-e7f9e2231460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_e968f552-8dce-4078-8dcd-35f7f02d3616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b6bab4a8-6557-40f6-913e-491ef563fcfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">grts:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5f70c7fd-3c98-48c7-9bcd-c95ad6bbd433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7a07fc35-5bb5-495e-b5b1-254dbffe7f54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bb4a354a-e696-4d8e-b1b8-aeae9a1baedf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7b303347-0a5e-49c6-ac04-186377f96bd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_1384cd70-847e-4634-a2fe-da83db33a119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BluebirdBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_fecc12db-2824-4e1a-8f15-21db97eded23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_6f2d73a7-30b6-410a-8148-9410d7383a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bdac7de3-d09c-4ab3-a235-9071478e89a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_d0c0e728-d84d-443b-9b79-a400660a7213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_5e526fc2-e10d-4769-a192-466206adab05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:PleasantonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_60b21bc0-099b-49d6-ab81-649520e924be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:CoalitionForEpidemicPreparednessInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:FundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e99ad520-a6db-4e84-b622-e394b918c047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_24382739-e4d1-4b7d-9faa-aefc1a06f44a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c7df85ae-cc5e-40e1-bb77-a8cc3a896e3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d1078c6b-8904-420f-a972-eb76b8483731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_85f96acd-07e5-4041-bf06-2c004d61457e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1167d84e-b793-4dcc-9d36-63fe715efdd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:EsppEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_78c307af-b902-4ede-acde-cde5afdf5220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8caf9fb-02e0-4bb8-bf86-c54f67dc62ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-29</endDate>
        </period>
    </context>
    <context id="C_5dc9611e-d586-4a8b-a50f-4a5ff390d4ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a36dfa2d-b3cc-41ba-867f-9bc54ef71a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_566e2de2-e6b3-4e99-b3f7-4d1960d33e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_9ff103bb-5e1f-4e17-baa5-7a535845418a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5903b0b4-0f34-4cd1-947d-816c01e6afad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_6f03e706-2fc7-4723-b18d-bade0d235db3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4fc2caf3-8c25-4dd7-9e8b-1761b10a0822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:BlueBirdBioTo2SeventyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_22ff4438-130f-423a-bdc3-1d4eb213a8cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1a206a0-0c5d-488d-8f91-92aaeff32126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">grts:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_16b72b70-3b0a-4109-9890-1c0c21720e60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05bb5bbd-397e-4572-a8c7-c182ee094fb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:ShortTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5672b081-e3ab-444a-bafd-c2358ab76867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9127b8e2-08a8-449b-b838-ac2185db6903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">grts:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_7c56ee86-11c9-4117-a515-85c8951a85c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">grts:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9e7aaa1c-e583-4583-8203-409c40fb2c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:CEPIFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_65526830-3d02-4fa7-a03b-a2007d47fe14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10536f93-ecfd-49e9-a7e1-fa1761155af0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:PipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bb1328df-a76e-43a9-81e1-d6f6bc50971a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">grts:EmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3488b869-cb93-4aac-81c2-cb2237fd526d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">grts:PreJanuary12018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f7168722-4c89-46f9-8fef-613ec1a338fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b07f71bf-53de-4fff-8190-d439a84be1ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_b28b039b-c3f5-4ba2-a4b4-e6a47d32112b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b09e940-512d-4b9b-95b7-0f7a00f1c739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">grts:OptionAndLicenseAndDevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">grts:GenevantSciencesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_c8dfb228-4332-4eda-835f-6dcd119ac01f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d5159609-8b4f-4ad9-a130-008c19b07b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">grts:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">grts:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6b19cfa6-fa43-4b59-b47c-8499f1dcf7a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001656634</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_RenewalTerm">
        <measure>grts:RenewalTerm</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>grts:Segment</measure>
    </unit>
    <unit id="U_Security">
        <measure>grts:Security</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      id="F_04b34a3e-8e6a-4d8a-b461-bd6e0ec8bab0">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_d1078c6b-8904-420f-a972-eb76b8483731"
      decimals="-3"
      id="F_e44b0a47-c709-45b3-a49d-50acaef1364b"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      id="F_b453bd8f-c8eb-4d75-8544-721cf324a7c4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a0c12b21-3162-4e9e-8023-973cfc335cb3"
      decimals="-3"
      id="F_d9344bdc-5632-4045-a278-82f3c517346c"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:RevenueRecognitionContractEndPeriod
      contextRef="C_74c098e4-40eb-413b-bfae-ef00e77cdc53"
      id="F_7ed2197d-60a0-4b30-bddb-51e4f0d30759">P2Y</grts:RevenueRecognitionContractEndPeriod>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_4e8c7678-91f3-47ae-9b2a-8d265e5cbe17">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_48c2ddc8-6b84-4434-a169-06b7c826acc2">0001656634</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      id="F_d2ca4c51-a192-466d-9b37-5b3c9e4c3d77"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_5b7425f1-adce-4088-8983-d4281225892c">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_87612373-8d49-4891-bde3-56260b7bda50">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_10536f93-ecfd-49e9-a7e1-fa1761155af0"
      decimals="-3"
      id="F_dd4ba84a-f9ad-4ac4-b8da-a1e9b6be684e"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      id="F_e31183f5-6d2a-4c3d-9421-3991b0ed1b06"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_e60d516f-467d-487d-9e90-0190ecc9a9a1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      id="F_a178817b-a374-434c-9a8a-b04e45420edb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_15a07b7b-0c08-4be9-9fe5-3f7ff35746a2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_b47e2dc4-4cd9-41c4-bc98-a02c99d5955f">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_bdb52546-5d7f-4201-9ab5-3df99ab6fa4d">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_0d98a568-26f6-4246-8899-ed4af16c71d3">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_31355fc2-84f4-49d1-a0c1-c5358d2fbe45">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_e1b89d27-9f72-4828-bb71-dca11f0ea717">001-38663</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_863d7ef2-ee57-4833-960a-759fa7c99dac">Gritstone bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_23770d6a-1832-41e1-81b5-5731e0580d40">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_58b4fcf1-9519-4cf5-ba55-4d5cb56ab61f">47-4859534</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_7a6b83f0-79b1-4899-b29f-aeb472059a81">5959 Horton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_cf169f36-ea11-4c47-bd70-865c5718d93a">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_19add0b9-5686-4627-8e03-602b68211608">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_2ff9413e-e6bc-4f95-a308-fca816a4c589">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_10997ca1-5850-48e3-bd35-e38cb2ff8189">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_0a05df48-c51f-49e8-8f9d-ba60a3e86043">871-6100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_bc25c60e-7c66-41b4-9c5a-ab23638ac659">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_b909cd16-89db-4c30-a504-0235fabd678b">GRTS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_7cace107-4cfe-427e-9f59-6e446831b699">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_932ac89f-86ec-42c7-b652-cf782e6735fa">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_ec2a0836-622c-4162-a298-0f23a11f4181">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_c5b14bd1-38ea-47a1-bf62-7a4c2622e526">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_dfed1fd9-0fce-42a7-9aba-4d731ec90d6d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_b1e967a6-88c8-4e1d-8d83-84a6025f982f">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_27ed4faa-5c3e-4c03-b055-e8affee829f9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_f4634b6d-3376-46df-a4f9-eeb889bfe6c8">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_dac10d2c-5940-4c2c-a48c-f0df6b087298">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_5d985d12-ec71-4e4f-93be-bb806c2383c2">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_5d41db92-8924-4ea8-b821-2613aada63db">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_3f46bcc8-23a7-4ffa-9d3d-c33aa11216e1"
      decimals="-5"
      id="F_8ea9610b-d60a-4c88-b495-8644a3503cbc"
      unitRef="U_USD">419000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_d0ec608c-cdab-41f8-92b0-fabd470a62ba"
      decimals="0"
      id="F_3aebadde-e040-4c00-90e6-dfc30b2ce024"
      unitRef="U_shares">72708342</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_743bd385-8b3e-4ac9-8be5-f2f4c7ac21a5">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement relating to the Annual Meeting of Shareholders, scheduled to be held on June 17, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the fiscal year to which this report relates.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_941a46e1-cd3f-49f4-99d1-eaef8ada7ccb">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_384b6919-a2c3-4661-8fe9-5c4f63a94b88">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_43cf5528-e701-41b8-8703-d2af67fb803b">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_4919ea89-cfe5-484b-856c-161b3f728bdd"
      unitRef="U_USD">93287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_bb8f0bc5-db4c-4415-8caf-178bfe3b3677"
      unitRef="U_USD">170056000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_94455e73-6ddc-41ad-965c-ef7df0998125"
      unitRef="U_USD">108346000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_dfacf0f9-2341-458c-b87a-e47c8502366a"
      unitRef="U_USD">1002000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_3362d1ba-4042-41c0-9ad3-4f01628ab043"
      unitRef="U_USD">11285000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_c5ae0211-cfbe-4c83-8f27-99afd615d8ba"
      unitRef="U_USD">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_bca2dfee-3ac8-4cf8-8676-a8ad112faec5"
      unitRef="U_USD">7672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_c13396c0-95a9-468a-b552-08d6e0f1a4f2"
      unitRef="U_USD">4332000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_7e2615a3-cf44-4dda-8790-7e4e10bef986"
      unitRef="U_USD">220590000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_520d74ed-e6d2-4ff2-b206-23b8382425a3"
      unitRef="U_USD">175390000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_b875dd3d-c784-437b-9ed0-effda53453ca"
      unitRef="U_USD">6005000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_0dbd6b10-8b9d-49a6-8696-092f56deb724"
      unitRef="U_USD">992000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_adace193-7425-49cb-89de-fd17f74bc11b"
      unitRef="U_USD">21622000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_d3dbfbad-8ba7-4055-937f-3c2887abf9dc"
      unitRef="U_USD">22105000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_3f3c9be2-1e70-4d59-a6ba-1d4c500d7e5d"
      unitRef="U_USD">22920000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_db1a25a0-58be-4e92-9876-9bccfd270fac"
      unitRef="U_USD">21344000</us-gaap:OperatingLeaseRightOfUseAsset>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_9c43f62a-1be4-4e94-87c5-af3711109fd0"
      unitRef="U_USD">2352000</grts:DepositsAndOtherAssetsNoncurrent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_d950f511-d976-4532-ad91-031d3261b04c"
      unitRef="U_USD">1736000</grts:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_7ec6cdf6-4c0c-41f3-96b8-d0a7f74b92a0"
      unitRef="U_USD">4617000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_589c1070-e0f3-4a23-937d-810a1adade0f"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Assets
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_49074eda-e103-4546-b7d5-07cf4949aecf"
      unitRef="U_USD">278106000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_34dfa367-2fbf-49a6-ab0f-252ba758e179"
      unitRef="U_USD">221567000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_0febc8c5-cf85-4a10-b0dc-ef69879bba3e"
      unitRef="U_USD">4230000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_86cb19bd-1986-4024-9451-c62b33373ccc"
      unitRef="U_USD">9578000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_958edf0c-0ea2-450b-a9a6-17b34cc14564"
      unitRef="U_USD">6925000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_b02c67fa-52fe-4f5b-92dc-f4dc7b81507b"
      unitRef="U_USD">6331000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_cccd1efe-f5e2-4114-8949-0f3f78417e10"
      unitRef="U_USD">411000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_06a49180-abe9-4fba-a080-df7cc1306c9d"
      unitRef="U_USD">677000</us-gaap:AccruedLiabilitiesCurrent>
    <grts:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_5a1c2328-d909-40b7-86e3-ecfa7c552491"
      unitRef="U_USD">3706000</grts:AccruedResearchAndDevelopmentExpenseCurrent>
    <grts:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f2d0611a-fa05-4257-bf8b-3c0544effa65"
      unitRef="U_USD">1053000</grts:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_6b92c0b3-41ad-4ac6-b806-3db42b5e6911"
      unitRef="U_USD">7483000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_10db373e-633d-4a73-ad89-9b2c46a41e6d"
      unitRef="U_USD">5874000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_98b867ad-4f20-4163-a120-fdb403e067b2"
      unitRef="U_USD">17201000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_bab3ba8d-22bb-4907-bfc7-6351fe69768c"
      unitRef="U_USD">3475000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_c1fe5725-63fe-446c-bb4b-f0936dbf8a62"
      unitRef="U_USD">39956000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_069077f0-de53-4423-9dc6-af4b2da5fde1"
      unitRef="U_USD">26988000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_0651c443-bc89-441c-8fda-c81c86513418"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_e371f23e-2d05-46df-ba6e-19dc73d249ed"
      unitRef="U_USD">395000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_a0678d17-0a81-4336-bd52-01ea1ac4980f"
      unitRef="U_USD">18936000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_b6d350ed-417c-42b9-aef5-effffbb9b64d"
      unitRef="U_USD">19225000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_e217c89c-fcc3-4b75-bb05-d8504342500d"
      unitRef="U_USD">3128000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_d4067ac0-4b82-4204-9d68-c2147cc66a47"
      unitRef="U_USD">8220000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_57c9a391-9914-4ce2-b295-6687a3d60dff"
      unitRef="U_USD">62020000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_ce15f0c1-6d30-44fa-ac3c-d0ccc572dc14"
      unitRef="U_USD">54828000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_8daad606-f897-4754-b292-5966a931b80c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_3fb1d5a2-6b08-428c-941e-41afbd86ea3b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_9a32dcc2-c775-41c4-af01-694f361ef376"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_e36a2aea-caaf-4041-8bcf-f61d9838f356"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_2201eef8-6808-4993-a9f4-bc977cdabe62"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_7ac896c1-266a-4567-aa2c-eba367cc498e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_57a25dbf-e0d6-4f3f-ba50-1eab5e269ccd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_7cd6ec6b-16ff-4b86-bfa6-2b275c54d1e1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_4542f11a-4002-4c7d-8750-119e72f158c8"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f80dae77-884b-4a32-8e4e-2749955e36f4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_97543f53-f074-4eef-8718-c6df40b714f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_6072a0f3-c7e1-497a-85c1-8704174b58cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_353e4d28-03d7-4c3e-90df-415f5d7d8444"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_2cd8f846-0b9d-404c-8728-ffbf004ac183"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_c7e4bbc5-dc83-4764-a158-fe8be3bab33d"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_e5f402e2-6ded-44f8-96b9-41fda6f1f48a"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_c4b54c8b-4506-43d5-b9ed-afe04886f15a"
      unitRef="U_shares">47552693</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_3e9fff68-23f6-4f56-bcbb-73009df8d78c"
      unitRef="U_shares">47552693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_d52ec19f-9b67-453d-b2f7-2f4c50636171"
      unitRef="U_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_b78efe6e-200f-42c8-84c0-827478870bf9"
      unitRef="U_USD">18000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_3992cd88-7cb5-4647-b5ac-e1d3759d922e"
      unitRef="U_USD">617523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_580a295a-0bcf-4f63-a727-922b66575e97"
      unitRef="U_USD">493023000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_d1ebc7d2-e121-417f-9362-04acb12aaa6e"
      unitRef="U_USD">-73000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_6d47037d-d25d-44db-8270-d59405107116"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_52cfab50-42eb-4884-a37e-18cc43d1bd19"
      unitRef="U_USD">-401384000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_8a0bb822-59b1-4a5c-8a84-e4bcc223e98b"
      unitRef="U_USD">-326302000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_8a1dab38-b05a-48be-9f31-062a1bbd0c94"
      unitRef="U_USD">216086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_5f1e76b1-e7d7-4fb3-8e1b-1a25cfc06a8b"
      unitRef="U_USD">166739000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_6db6d999-5d08-4cba-906e-e8ee4281b27e"
      unitRef="U_USD">278106000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_831e3706-5634-4924-88e3-57c6f94e3c46"
      unitRef="U_USD">221567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a82f3996-a232-41a2-ba36-db531bddceba"
      decimals="-3"
      id="F_a0760fbe-4c1b-4f94-bca3-329b53153aa5"
      unitRef="U_USD">46717000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ba034453-4fd5-4226-85c4-36e74505c7b0"
      decimals="-3"
      id="F_0e98242f-4e1b-489a-ab08-a2d76d7f29a5"
      unitRef="U_USD">3462000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_73464b08-07d2-40b6-ace7-0c62aa972258"
      decimals="-3"
      id="F_2f68d3e4-db1b-4e5e-ba25-5c645f4539d1"
      unitRef="U_USD">4365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3f870e98-f90c-49bb-86f0-83e46e07b98a"
      decimals="-3"
      id="F_b5ac9e19-347d-40a0-83b7-fd3a67ae0f0a"
      unitRef="U_USD">1497000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e84c838c-b8b5-42b0-86d2-23e56453e579"
      decimals="-3"
      id="F_302245ca-782c-46ac-978d-324672541421"
      unitRef="U_USD">575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_380e370a-6b47-4450-8fb6-5f55120330a2"
      decimals="-3"
      id="F_02e88e17-9511-4640-90c7-c16ae0826278"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_914d5fa4-7ebf-4356-a331-3eabcc99743e"
      unitRef="U_USD">48214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_e46c4bad-bc77-451a-b1c3-2727dda810d9"
      unitRef="U_USD">4037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_29b3a8fb-9a3f-4cb6-9653-8e8cd8d6a8cf"
      unitRef="U_USD">4365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_a893a075-e87d-4f0c-9fc8-040bb4a39279"
      unitRef="U_USD">97490000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_ccfe0500-756c-4c95-97aa-a8d9bac73670"
      unitRef="U_USD">88643000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_ca562485-d176-4979-a3f8-fabaf196e716"
      unitRef="U_USD">82896000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_20ceda47-4442-4401-8269-03f519812314"
      unitRef="U_USD">25933000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_12588d4e-ceab-4b32-9ec5-c3e25169d74d"
      unitRef="U_USD">21411000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_29bc375b-6ff1-4a6d-aa33-787dea738af5"
      unitRef="U_USD">19409000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_34e39092-d636-446e-8910-3407b6fa3da4"
      unitRef="U_USD">123423000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_345b2833-cc0d-4f6b-b56a-25ffd7c871c8"
      unitRef="U_USD">110054000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_d5e0d8dd-222a-40a3-abc6-03bb4fed694a"
      unitRef="U_USD">102305000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_98ea0853-271b-421b-94fc-3ec072e26033"
      unitRef="U_USD">-75209000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_2704283e-5f3e-4b35-8528-0de008dc1354"
      unitRef="U_USD">-106017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_3509a452-71e2-4530-820a-7845b522939d"
      unitRef="U_USD">-97940000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_504b5691-8bef-49a2-b2e5-5b7a844ee239"
      unitRef="U_USD">127000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_53e48645-a005-49cb-8a5a-944b1606a8d1"
      unitRef="U_USD">703000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_00be176f-5f2f-4c1e-9bfe-6a4b5c0ce7da"
      unitRef="U_USD">3507000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_802c072f-70b8-4266-b222-9e963bf51719"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_86d01d0e-d596-4536-bd6f-aea24e089f9d"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_c53d0774-6be3-48c0-8d4a-d8af5f4cbec4"
      unitRef="U_USD">-94433000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_8f17a9f5-0cf4-446e-afd8-bf9df8974877"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_c2d20d31-c34d-4188-90f5-80498c144c0e"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_607d59b5-6ab6-4a1c-9c25-6c05d6c56993"
      unitRef="U_USD">109000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_653cc11f-d4eb-45ff-ba23-20103b8465f2"
      unitRef="U_USD">-75155000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_3c33ce5f-bb22-42cf-b61b-d1a2126d2ade"
      unitRef="U_USD">-105338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_9ea4b356-e0a2-4531-98f7-7ae5ee0ec249"
      unitRef="U_USD">-94324000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_d9b0325e-d019-42f6-b345-0750de9c0e47"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="2"
      id="F_b3a9074d-6cab-4b16-b995-af32668e1aa4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="2"
      id="F_7e9f4471-ae75-4656-b798-26a5b5b0a2a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_f866516d-ce73-4a25-8f72-e582b610fd6c"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="INF"
      id="F_a524f526-c9e3-42a5-9660-f50fb87ffa27"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="INF"
      id="F_1575eae5-0fce-4833-ab10-b3aa97706218"
      unitRef="U_shares">33554823</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="C_0cfda793-d20c-4961-a834-c8650ee91d83"
      decimals="0"
      id="F_5387b168-04c5-4d59-9863-22bfed4b25f3"
      unitRef="U_shares">28823130</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0cfda793-d20c-4961-a834-c8650ee91d83"
      decimals="-3"
      id="F_0940fce6-2e1f-49ab-9ca9-1ce9d6ec35bd"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b8cbe5d8-7e8c-4676-8c42-837291b53456"
      decimals="-3"
      id="F_39922742-9418-4fb5-8acd-7ad7cc0bd3da"
      unitRef="U_USD">275593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bdb6e5b1-bb05-454c-8661-5dbae465a144"
      decimals="-3"
      id="F_dcd28cf3-9985-4775-85f7-5a9d52314c6c"
      unitRef="U_USD">-85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5a1a7d8e-2cb5-4480-a9f0-5d9d08ea4e42"
      decimals="-3"
      id="F_37e5e15b-686d-413b-9741-39d72e5ff9a9"
      unitRef="U_USD">-126402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa"
      decimals="-3"
      id="F_34bf55bb-1d75-4524-9bd1-3da0cc5bbc67"
      unitRef="U_USD">149122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e526fc2-e10d-4769-a192-466206adab05"
      decimals="-3"
      id="F_ab649b90-b188-47b2-a3bb-728697508a2d"
      unitRef="U_USD">-153000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_36e294a4-e0df-4447-b010-28bd585fdd93"
      decimals="-3"
      id="F_e7051f31-b91e-4220-b495-eaaa5b6b0363"
      unitRef="U_USD">-153000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9b169cdf-cda7-4247-a6bb-d30a8c55839a"
      decimals="2"
      id="F_f266ec85-2107-4907-8f00-9edb53eae1d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e"
      decimals="-3"
      id="F_fa4de390-9ab1-4b0a-82aa-4693c362c140"
      unitRef="U_USD">556000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e"
      decimals="INF"
      id="F_43dc1e81-112d-4c88-9508-a8759974d30f"
      unitRef="U_shares">6500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1d97c903-d09e-4edd-9c57-1ecf9de2831e"
      decimals="-3"
      id="F_9097872c-8e38-41cd-afee-3b95ab23284c"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_81d44cfe-4817-47ec-82ff-c16f1b041f0a"
      decimals="-3"
      id="F_dd357e28-85e1-40f2-8ca0-4cbf71972090"
      unitRef="U_USD">69708000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0e326ef4-32be-4c22-a96d-5f69ef9ee281"
      decimals="-3"
      id="F_5236e243-ce06-4b0d-be96-4eab0471b1e5"
      unitRef="U_USD">69709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b"
      decimals="-3"
      id="F_e8664caa-e0c8-4cb0-bc72-4cd0fedc0268"
      unitRef="U_USD">301000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_51a65cb8-cc40-44b0-9428-fefeb6e07f2b"
      decimals="INF"
      id="F_9d263b41-be05-43f3-8170-17a5d994c0ba"
      unitRef="U_shares">490880</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4028d4f2-0823-4d74-af7d-d47f1f2de8e1"
      decimals="-3"
      id="F_ce9765ce-dde4-46bd-b02a-7edae9dc2ffc"
      unitRef="U_USD">3763000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3266dfed-769a-40b0-8646-a9d8b35c1a67"
      decimals="-3"
      id="F_4bc3e6f5-7188-48db-8ba3-5224188c8074"
      unitRef="U_USD">3763000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f"
      decimals="INF"
      id="F_3e663a53-d1d6-415a-b9c1-327e0ff11905"
      unitRef="U_shares">55727</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e"
      decimals="-3"
      id="F_48864bf1-5269-4c62-9faf-938e95c9606d"
      unitRef="U_USD">413000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_621544d5-f135-40b3-87e7-68cf1cabe42c"
      unitRef="U_USD">413000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_b07f71bf-53de-4fff-8190-d439a84be1ad"
      decimals="-3"
      id="F_d36c2656-2d17-447e-85d2-cb2e987e664f"
      unitRef="U_USD">109000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_dd764693-73bb-4a9e-ad81-63bfd9c93050"
      unitRef="U_USD">109000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f"
      decimals="INF"
      id="F_2130b178-bbce-4ce3-8f32-2e65466dd866"
      unitRef="U_shares">182195</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e"
      decimals="-3"
      id="F_ebcc7424-a77d-48fe-9fab-439153f28647"
      unitRef="U_USD">63000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_32ad1690-34f0-4b78-83de-1c45d979d10b"
      unitRef="U_USD">63000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c9c4a8a3-0732-4317-b302-b0287a68bd5f"
      decimals="INF"
      id="F_89c8f6fc-ad5b-4000-848c-89a6f51d8975"
      unitRef="U_shares">281024</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e"
      decimals="-3"
      id="F_293b472b-6a32-4827-af94-f84b7f9c3d09"
      unitRef="U_USD">452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_0add331a-329c-4675-a483-8f0fbbaa30e9"
      unitRef="U_USD">452000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7a64849a-720f-4b6d-87cb-b18228eb569e"
      decimals="-3"
      id="F_3d8f1c6c-e728-412b-9000-2a4d8fdaa421"
      unitRef="U_USD">5299000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_61c6682f-ebc0-42ff-9eb1-e1a6209a2170"
      unitRef="U_USD">5299000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_7d3f9f89-ed3a-428d-a261-354556628edc"
      decimals="-3"
      id="F_69085040-4d87-40a9-84bc-1196ed06f1e1"
      unitRef="U_USD">-94433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_fb1e06b8-67a5-4fd5-8198-6eaf28111248"
      unitRef="U_USD">-94433000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_113f6e9e-2318-4e64-9807-9fb8459e68ef"
      decimals="INF"
      id="F_f7dd50e6-5b32-4578-b0e2-e9deaa8056a1"
      unitRef="U_shares">36332956</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_113f6e9e-2318-4e64-9807-9fb8459e68ef"
      decimals="-3"
      id="F_67d1c0c7-acd9-4530-808b-461d167b8eff"
      unitRef="U_USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_566e2de2-e6b3-4e99-b3f7-4d1960d33e69"
      decimals="-3"
      id="F_7c4f4522-71b2-4b37-8034-4f4141d8c031"
      unitRef="U_USD">355291000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ef3a2d5c-f57f-42c8-acc1-25a55ffcd722"
      decimals="-3"
      id="F_bbb71c61-ec0f-4782-8858-20d070f8c259"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb09cd51-ac40-4ddc-b069-ec80b0a9c3ed"
      decimals="-3"
      id="F_982336ac-4c8b-4019-a979-a6de2f093ebe"
      unitRef="U_USD">-220988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_7c851946-c374-459b-b58f-1420b3426d33"
      unitRef="U_USD">134344000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae"
      decimals="-3"
      id="F_9fce4ab6-dd52-4e10-92e1-942566d37744"
      unitRef="U_USD">1394000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae"
      decimals="INF"
      id="F_95447887-e4b4-4e4b-af3b-57e7104e7f75"
      unitRef="U_shares">9586478</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3a314753-a175-4226-8b72-9c3df68982ae"
      decimals="-3"
      id="F_961f572a-edaa-440e-9c43-8ee46fdf43a3"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_982f33fb-21c0-4dd6-87c5-65c36e0e5f27"
      decimals="-3"
      id="F_746b8071-a918-41be-9361-9b168a9440c9"
      unitRef="U_USD">32121000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_aa774e87-9154-4d69-beec-62667e7e6728"
      decimals="-3"
      id="F_d6c3c131-af0e-4eda-a939-a9b8cfcd6baf"
      unitRef="U_USD">32122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_f3f22244-1f88-421e-9cc4-3b878d466850"
      decimals="-3"
      id="F_9d881f32-f1a4-45fc-a230-370e0411112f"
      unitRef="U_USD">3806000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"
      decimals="-3"
      id="F_572c2780-fa3f-4436-9119-08e97aee93c3"
      unitRef="U_USD">87704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_99e7cf7f-cb30-4bc1-a004-4bc86b91e7dc"
      unitRef="U_USD">87704000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb"
      decimals="-3"
      id="F_26d59512-3655-41e4-aae3-024ff53e5b2f"
      unitRef="U_USD">104000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9f2e91b8-4ca7-482c-a597-8645a617bbeb"
      decimals="INF"
      id="F_ff951cab-ee03-4306-8fb9-72cbea26af9a"
      unitRef="U_shares">1160963</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_03d9a53a-ccc3-4f13-b052-55cc78345393"
      decimals="-3"
      id="F_a01e46ae-977d-4c9a-9add-8d8f683d9c2e"
      unitRef="U_USD">9670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636"
      decimals="-3"
      id="F_984f9088-7239-4546-b744-8f07c36eb55e"
      unitRef="U_USD">9670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b"
      decimals="INF"
      id="F_e994a56a-cced-4a1b-a023-ef0058b331d8"
      unitRef="U_shares">243878</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"
      decimals="-3"
      id="F_40c8c1c9-188d-4462-a7f9-5329ad3cd683"
      unitRef="U_USD">910000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_3f830d2f-e9b7-4717-89ad-f4312411c207"
      unitRef="U_USD">910000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_7057aae3-6cd0-4063-9952-0286502804a7"
      decimals="-3"
      id="F_e029c1de-ef0b-4f7b-9b66-b061ddecfbf4"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_68d61846-5ac3-4293-ba89-71bca9fcd7d8"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares
      contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b"
      decimals="INF"
      id="F_89e85674-58c3-4595-8bc9-f0a86e8e4822"
      unitRef="U_shares">30874</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"
      decimals="-3"
      id="F_9caad56e-2aed-474e-9f10-3800c66bc477"
      unitRef="U_USD">11000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_4067f623-2a36-453e-95a1-c78b0cfc846f"
      unitRef="U_USD">11000</grts:LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9c1c4689-d4b4-4f31-875b-e6dcf91ea02b"
      decimals="INF"
      id="F_111a3ac3-7ada-4bb8-aba6-daf1f62a058d"
      unitRef="U_shares">197544</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"
      decimals="-3"
      id="F_d8a0fc68-c034-47de-88b0-0048f009430d"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_460dc568-2f48-496e-b0e0-b083c231ac99"
      unitRef="U_USD">206000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5d1dea6f-6fbc-44d3-9c44-793e93d9dfb1"
      decimals="-3"
      id="F_f54573c4-58a2-4159-9f6c-87e81ff99c36"
      unitRef="U_USD">7110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_74c334ec-45b7-4e49-92c3-12b995ffc67e"
      unitRef="U_USD">7110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_fbf4938b-d2f9-4fa1-ba69-cec10c693873"
      decimals="-3"
      id="F_72fe0825-e6c6-4aa2-894a-4d74773e07f6"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_6ba6d0cc-76cc-4f26-addf-9ef0f14ce198"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_50ba15bc-abe4-40d9-83dd-7f897007ee15"
      decimals="INF"
      id="F_9c5b405c-85dc-4e39-b6c3-417188372a58"
      unitRef="U_shares">47552693</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_50ba15bc-abe4-40d9-83dd-7f897007ee15"
      decimals="-3"
      id="F_f6ba8c62-550f-4db5-9a25-d1165cf602ae"
      unitRef="U_USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_37521ff6-ee49-47f9-82b9-df82ccbc22a6"
      decimals="-3"
      id="F_eb56181f-84d7-457c-b97d-f9364ce2c45f"
      unitRef="U_USD">493023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_098479a5-8222-4852-8fef-d20451698abd"
      decimals="-3"
      id="F_6889201f-43df-41e8-9022-293d91becb05"
      unitRef="U_USD">-326302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_34d355bd-1165-4602-8486-51e5ef1f593e"
      unitRef="U_USD">166739000</us-gaap:StockholdersEquity>
    <grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_1c93d90d-72bb-42aa-b5da-e181e0f99769"
      unitRef="U_USD">-451000</grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants>
    <grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_a813272e-e125-4956-9dc3-4235c5838efc"
      unitRef="U_USD">-451000</grts:AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_6f2d73a7-30b6-410a-8148-9410d7383a67"
      decimals="-3"
      id="F_6900f258-0520-4252-9a9c-f89a4b832d2f"
      unitRef="U_USD">339000</us-gaap:PaymentsOfStockIssuanceCosts>
    <grts:StockIssuedDuringPeriodSharesPurchaseAgreement
      contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"
      decimals="INF"
      id="F_8b391472-33a7-44f1-aea4-615ba1bf68d6"
      unitRef="U_shares">1169591</grts:StockIssuedDuringPeriodSharesPurchaseAgreement>
    <grts:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_ff179ec8-6a4d-43ff-9773-8ab5417018b4"
      unitRef="U_USD">20830000</grts:StockIssuedDuringPeriodValuePurchaseAgreement>
    <grts:StockIssuedDuringPeriodValuePurchaseAgreement
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_f020aa24-1bbf-4ee2-a908-9e1d9f2e92a0"
      unitRef="U_USD">20830000</grts:StockIssuedDuringPeriodValuePurchaseAgreement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_82754c58-c826-4434-bf40-87fc89524365"
      decimals="-3"
      id="F_05b2f547-3402-4b34-9475-7e9a082d24c6"
      unitRef="U_USD">124000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_82754c58-c826-4434-bf40-87fc89524365"
      decimals="INF"
      id="F_10bbc2f9-1c28-4f6c-bcdf-77644ea23dc5"
      unitRef="U_shares">3990869</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_798c90a9-6bbc-4bcc-a947-9814b7fe2869"
      decimals="-3"
      id="F_dc080f72-1964-4cba-b856-148269708c66"
      unitRef="U_USD">36595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49"
      decimals="-3"
      id="F_8be0499d-5899-4d53-906b-934b0f30a0ce"
      unitRef="U_USD">36595000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3"
      decimals="-3"
      id="F_e1365a49-8169-40bd-84c3-8a179095d641"
      unitRef="U_USD">2348000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3"
      decimals="INF"
      id="F_8981e2bf-4401-4e39-8d60-91351db90127"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8adaa80f-a791-410d-a103-9f6d54cf70b3"
      decimals="-3"
      id="F_fb3dc401-7808-448c-b98f-61668bc8dcca"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_78c307af-b902-4ede-acde-cde5afdf5220"
      decimals="-3"
      id="F_3584d053-2114-4ab1-add6-cd2f9a266dc9"
      unitRef="U_USD">52652000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a58ea4fb-a55d-45cb-81a2-cc200e484f8e"
      decimals="-3"
      id="F_6dd6bd17-a57f-4e8b-a006-72d1b0a0ae15"
      unitRef="U_USD">52653000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"
      decimals="INF"
      id="F_e078f509-c3ab-4094-8d65-7bad871378aa"
      unitRef="U_shares">183111</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_6b4b562a-a27c-4714-9425-f9d1be219c3f"
      unitRef="U_USD">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_ee6247b8-4667-4693-903b-5f707b29615f"
      unitRef="U_USD">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_03810506-a2c8-49f8-9836-cbebe5541354"
      decimals="-3"
      id="F_113fbc75-a7bf-4c56-87e6-f43cf0020d65"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_9bd454b7-2a4a-48d1-a822-566b8a795e9d"
      unitRef="U_USD">-73000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <grts:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"
      decimals="INF"
      id="F_9d584da9-6749-41d8-9ec9-215e005e9d21"
      unitRef="U_shares">10459576</grts:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"
      decimals="-3"
      id="F_7984f5a7-1858-4842-a5b4-c2528145c6ee"
      unitRef="U_USD">1000</grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_fd496d25-dfd7-451c-8f0b-4218bf789508"
      unitRef="U_USD">48000</grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_1959de15-7190-488a-9a13-c67348061928"
      unitRef="U_USD">49000</grts:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_525c3994-76ab-46e8-a2ba-480c5eb3a271"
      decimals="INF"
      id="F_ba2c9f57-6799-48d6-9441-0ef43fae41c6"
      unitRef="U_shares">692038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_9e5e0967-0aa6-4342-83b9-4173198a5906"
      unitRef="U_USD">3360000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_6bd0fc3f-392f-4e46-b61b-c6a02d9a5bb1"
      unitRef="U_USD">3360000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_65526830-3d02-4fa7-a03b-a2007d47fe14"
      decimals="-3"
      id="F_57791856-56fd-44d1-a690-3929ad9deea7"
      unitRef="U_USD">10552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_0d878cd4-0fd1-448e-9bc5-8d71e1ced4a7"
      unitRef="U_USD">10552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_ee66b39c-2a63-4760-bb71-f8fa3a48775c"
      decimals="-3"
      id="F_22cc9c41-144f-452b-90f0-18df602a2a63"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_1d694121-3570-453c-80ca-ae59802a283c"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_62974a0f-14cc-441b-8b01-762333a2a200"
      decimals="INF"
      id="F_981acf8f-00a2-4a89-b9fa-e6bb0c57c053"
      unitRef="U_shares">69047878</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_62974a0f-14cc-441b-8b01-762333a2a200"
      decimals="-3"
      id="F_b3cbde87-55bc-47ac-900f-4d4a4bb14c56"
      unitRef="U_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_da80cade-f058-4976-8865-56dee50a193b"
      decimals="-3"
      id="F_8c15299b-910c-405a-bdbd-6e426047b6c4"
      unitRef="U_USD">617523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0ccb5220-a382-46c0-b2dc-bcad6d8aa290"
      decimals="-3"
      id="F_00c37dbe-e230-4e1b-b9bf-006f9708cda4"
      unitRef="U_USD">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_382a9f9a-00c6-4098-ba1f-f90f5c3bafd2"
      decimals="-3"
      id="F_74250735-c2a9-4fae-a622-890f70497a13"
      unitRef="U_USD">-401384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_41e5820a-089f-4343-8b1c-a685829ccc63"
      unitRef="U_USD">216086000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_63e7a424-c61d-47f1-9333-8581c056910b"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_426fa4f8-161f-41da-b643-9e5b0949b781"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_00f81d5e-b7e2-48bc-8e8f-e01800b5bae4"
      unitRef="U_USD">-94433000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_494a95f1-11aa-4060-8ed9-48963c9cd764"
      unitRef="U_USD">6347000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_06f29724-0698-4868-87f6-41dbe0675366"
      unitRef="U_USD">6644000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_5ed724c4-6106-4550-9632-5aaa076b7205"
      unitRef="U_USD">4745000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_f13adb19-bc40-4343-93de-fee718575fc0"
      unitRef="U_USD">-817000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_21cb7737-8bbe-4596-9295-70e1a8401323"
      unitRef="U_USD">122000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_639c9804-4916-4045-9896-26cddf83fbb5"
      unitRef="U_USD">1349000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_01e1bf0d-b981-4f7d-93e9-2120fd4cf527"
      unitRef="U_USD">10552000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_709a6b9a-0b44-4880-b324-1c47685e7f78"
      unitRef="U_USD">7110000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_27857a33-78b1-4ed1-a7e7-705797efddb8"
      unitRef="U_USD">5299000</us-gaap:ShareBasedCompensation>
    <grts:OperatingLeaseCost1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_c4379d5e-df99-4d0b-a0b9-eb4d44be6b37"
      unitRef="U_USD">8052000</grts:OperatingLeaseCost1>
    <grts:OperatingLeaseCost1
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_bb9c0726-d944-4ae7-ab22-4cdafd606baa"
      unitRef="U_USD">7511000</grts:OperatingLeaseCost1>
    <grts:OperatingLeaseCost1
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_fccb2cd2-dd1a-4d0e-a411-29999187d6ed"
      unitRef="U_USD">6382000</grts:OperatingLeaseCost1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_7892bdaa-0228-42b5-8b6f-93655d910fe9"
      unitRef="U_USD">3426000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_9b4d7a70-00b6-4c04-9eaf-799b8ef54618"
      unitRef="U_USD">852000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_59eeb014-1346-4be8-9c98-5119f4b16fb2"
      unitRef="U_USD">-37000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_b1112471-df87-4fff-8992-48c8be3ef202"
      unitRef="U_USD">0</grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_1e81904a-6f99-4c75-84b4-37bd31bf370d"
      unitRef="U_USD">0</grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_f86d9115-e6e6-4c63-91c0-bdb5fb7a8a03"
      unitRef="U_USD">3328000</grts:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_e91c3798-7d17-48bd-aec2-9fbffa6ca5a7"
      unitRef="U_USD">614000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_5cfbc368-2975-4140-aaa9-6eaa6acb06b4"
      unitRef="U_USD">-49000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_3e2e7ca8-0530-47cc-80c0-18f56ce2cfc0"
      unitRef="U_USD">351000</grts:IncreaseDecreaseInDepositAndOtherAssetsNoncurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_368a7ac9-e7b2-42ea-9b59-197668bbbbde"
      unitRef="U_USD">-419000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_0ad457ee-c7ca-4fc7-b302-e1ba86d819cb"
      unitRef="U_USD">826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_db3cc6bb-0991-4739-8a81-3ac506a0c359"
      unitRef="U_USD">45000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_4f2c6a84-4edc-4f05-afb7-5ae1ea49ff05"
      unitRef="U_USD">593000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_07b34832-1e9c-49a3-ab6b-1f3f9e1bba35"
      unitRef="U_USD">1731000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_91e969fb-f173-43c6-a3cb-99108524bbaf"
      unitRef="U_USD">650000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_e2f135fb-656b-4305-ac9b-a5a9d122b51e"
      unitRef="U_USD">-859000</grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent>
    <grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_6d461fad-a52e-4b1a-98e9-e6728378f989"
      unitRef="U_USD">662000</grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent>
    <grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_76f30a48-eefe-4fa3-9e39-73d216c5df62"
      unitRef="U_USD">9000</grts:IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_2e6c67c0-583d-4738-a50f-fbe1e091dc41"
      unitRef="U_USD">2653000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_6d0d46e2-81d9-4b67-b2d5-64e1154819e5"
      unitRef="U_USD">-725000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_525db09c-93ec-487b-867b-b4a569c6a266"
      unitRef="U_USD">1526000</grts:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_3da04110-d8f3-402b-9e1c-85c608251f37"
      unitRef="U_USD">-7925000</grts:IncreaseDecreaseInLeaseLiability>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_d3e1e278-653e-4724-bd61-67730767f421"
      unitRef="U_USD">-3801000</grts:IncreaseDecreaseInLeaseLiability>
    <grts:IncreaseDecreaseInLeaseLiability
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_98256b73-7ca8-44bb-aa91-235b8cb5954e"
      unitRef="U_USD">54000</grts:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_62cfd20a-842f-4d9a-ab97-644f47f4a568"
      unitRef="U_USD">8633000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_40480660-c252-43ba-8cc6-69ab9b01ad4c"
      unitRef="U_USD">-2821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_c206e0c4-6a9d-4368-b057-7af19f8784fd"
      unitRef="U_USD">-4297000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_85ed81ac-033d-460f-b24b-43c228f2f095"
      unitRef="U_USD">-50678000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_2e18f24b-5169-45d5-9c13-6082b21f8dfc"
      unitRef="U_USD">-89102000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_70994a19-c5e1-49fb-a1ee-609e76a3872c"
      unitRef="U_USD">-85011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_0e1944dd-c9dc-453d-8060-f1aa890a0088"
      unitRef="U_USD">199905000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_9b15d0e3-0b34-4c56-91b7-19efd4264949"
      unitRef="U_USD">8809000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_de0d999a-77b7-4336-8e0e-85a6099afef4"
      unitRef="U_USD">80979000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_03bfb6c5-19f7-4653-a875-115340dc17c9"
      unitRef="U_USD">82253000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_6cf056ce-047d-4ea4-8029-1b1f1ef0132c"
      unitRef="U_USD">72872000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromMaturityOfMarketableSecurities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_84b89f7f-1479-46b7-9b53-c5dae110a04b"
      unitRef="U_USD">112993000</grts:ProceedsFromMaturityOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_c4ebbed4-a3cb-4681-8afe-0c95abe909a1"
      unitRef="U_USD">4800000</grts:ProceedsFromSaleOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_bed8f8ad-4d4d-4fb3-b1c4-9ed105f738d2"
      unitRef="U_USD">5401000</grts:ProceedsFromSaleOfMarketableSecurities>
    <grts:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_64dda2be-df32-47f9-a184-471cd998e55f"
      unitRef="U_USD">0</grts:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_ec44781a-f165-4a81-b1f1-2640c747cc3d"
      unitRef="U_USD">5463000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_fd8f54d9-38ad-4aab-97c3-7d8948cafbd1"
      unitRef="U_USD">3515000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_bc6ddac7-3288-4777-82b8-8e33b965ec39"
      unitRef="U_USD">16173000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <grts:PrepaymentsOnFinancingLease
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_4e553882-46db-4faa-b8b9-3098a4df1b63"
      unitRef="U_USD">238000</grts:PrepaymentsOnFinancingLease>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_6b030de8-1d04-4f6c-80ea-0d4fada8960b"
      unitRef="U_USD">-118553000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_d18cba8e-4cfd-49cd-86fd-f8015ec64e9b"
      unitRef="U_USD">65949000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_b77dc382-a915-448f-b9c8-b8c3f514af4b"
      unitRef="U_USD">15841000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8102c196-e4f5-4bf5-824f-1227db0eb3b5"
      decimals="-3"
      id="F_803e0ab4-626f-49be-be49-ccc0f499b9c4"
      unitRef="U_USD">21169000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e021a0aa-375f-4923-9a82-7d2d919305be"
      decimals="-3"
      id="F_0fcae761-2375-4af2-9996-7aed70e597be"
      unitRef="U_USD">70265000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_60da28f6-7643-4ad1-b263-313f3285ca2c"
      decimals="-3"
      id="F_8682ca74-f68a-487c-ba39-b9e1cb2d3f44"
      unitRef="U_USD">55000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_90dbde66-ba3c-4738-91d6-2e0290e34f20"
      decimals="-3"
      id="F_85c795f8-c4a4-4d6d-9790-ebf7cbff3786"
      unitRef="U_USD">3408000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f169b2c6-9283-4498-8fe4-31a18d6b1ec0"
      decimals="-3"
      id="F_ecca34ee-34e1-483a-a18f-5e5006025b75"
      unitRef="U_USD">198000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b820c59d-b464-4759-bbb7-0c4841c49905"
      decimals="-3"
      id="F_688f8dd1-b52b-4eae-87dd-a1cadcd79272"
      unitRef="U_USD">460000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49"
      decimals="-3"
      id="F_68769eac-9d5e-48e8-800a-bdd94e5c42ea"
      unitRef="U_USD">36719000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636"
      decimals="-3"
      id="F_cb3bd005-ca6c-4960-b051-5c1a399f2980"
      unitRef="U_USD">9770000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3266dfed-769a-40b0-8646-a9d8b35c1a67"
      decimals="-3"
      id="F_3942cb92-cf96-46e1-a686-f99c038d66af"
      unitRef="U_USD">4064000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f0499a53-483b-4201-8223-d8a875e05b6e"
      decimals="-3"
      id="F_f0e8fbcb-e406-4bc0-8dae-fa7d0109cb68"
      unitRef="U_USD">914000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1167d84e-b793-4dcc-9d36-63fe715efdd4"
      decimals="-3"
      id="F_63111eba-da3a-4077-aa19-97eeed5574b4"
      unitRef="U_USD">911000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_eeccbfcd-9588-414a-8b16-d9ae566a7a11"
      decimals="-3"
      id="F_dc1085f2-8fca-4ccb-a592-dbdb94fa925f"
      unitRef="U_USD">413000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_e49b27fe-abf1-48fe-b853-c50f4cacb036"
      unitRef="U_USD">0</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_bca8cc51-ba5e-4c83-afa5-73c39f60bff8"
      unitRef="U_USD">125026000</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_5cacbc01-091a-4bf3-9c52-641234ccca33"
      unitRef="U_USD">0</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_71ea3ab5-e782-4589-a817-ac377fca0e14"
      unitRef="U_USD">8394000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_bf323b1e-9e3a-4fc3-8636-882dadc8ab9a"
      unitRef="U_USD">104000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_c350ae53-3e0e-4cc4-b31a-d14a998738a8"
      unitRef="U_USD">807000</us-gaap:PaymentsOfFinancingCosts>
    <grts:PaymentsOfFinancingLease
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_28af280e-5045-4bc1-bb50-1d2e8f73e9cf"
      unitRef="U_USD">56000</grts:PaymentsOfFinancingLease>
    <grts:PaymentsOfFinancingLease
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_e87e2693-ce78-4b69-b3bb-dc14492b4887"
      unitRef="U_USD">0</grts:PaymentsOfFinancingLease>
    <grts:PaymentsOfFinancingLease
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_48593b10-c2c3-48ad-a9e1-4fca848d998b"
      unitRef="U_USD">0</grts:PaymentsOfFinancingLease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_3e5d07e9-a6c0-4625-a613-a705b0c82bc4"
      unitRef="U_USD">108760000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_493a139e-0b93-46b2-8882-bf44341cbf0e"
      unitRef="U_USD">135801000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_59f50c11-9c15-491c-9b4c-86145dad5576"
      unitRef="U_USD">74395000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_eb3c1914-bea4-4951-b728-d529b3ae5863"
      unitRef="U_USD">-60471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_5638dc77-f388-4359-a6c0-b17f8950ff2d"
      unitRef="U_USD">112648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_6fd5fc73-bd76-42c5-b374-ed71c303814a"
      unitRef="U_USD">5225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_6b43ff9a-fa7c-4816-89a6-2e4e7abee950"
      unitRef="U_USD">171048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_89aa865c-d021-436c-a1ef-5477f4b527d3"
      unitRef="U_USD">58400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa"
      decimals="-3"
      id="F_7de7f630-870e-4f10-9b95-3b38860507f8"
      unitRef="U_USD">53175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_7cbafdb1-eb3d-4d79-8fba-2b31145e1c4f"
      unitRef="U_USD">110577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_8d6cb2df-64f3-47ec-9398-959bfc63eb73"
      unitRef="U_USD">171048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_e92bbe2e-d217-4851-9ac3-9603b8c5cdf3"
      unitRef="U_USD">58400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_7d954ae9-dfbb-4df1-8cf5-1d910d54ad4c"
      unitRef="U_USD">738000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_0d514678-f523-494a-b780-a8ac52f74608"
      unitRef="U_USD">316000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_f56ed3d3-933d-4cae-bf1c-be2e8a690f59"
      unitRef="U_USD">1232000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_93775392-77fa-43c7-b1b9-8b49fbd7bce6"
      unitRef="U_USD">69000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_0e18aea8-1da2-4900-834c-ba7e73266324"
      unitRef="U_USD">5200000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_9acf90c5-e099-4638-8295-cf85c3532576"
      unitRef="U_USD">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_73a8a197-b8d3-4f5c-a6f8-c95ec14772ab"
      unitRef="U_USD">6452000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_a907018b-8e5f-4ec0-bb30-6d5e1f0a4e7f"
      unitRef="U_USD">3174000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_8b10f0c5-ee9b-44c0-879a-64629c30942f"
      unitRef="U_USD">1878000</grts:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_9f069f76-6724-4797-a29c-9d9e327bb6c3">&lt;p id="notes_to_financial_statements" style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1.	Organizat&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;ion&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gritstone bio, Inc. (&#x201c;Gritstone&#x201d; or &#x201c;the Company&#x201d;) is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. The Company was incorporated in the state of Delaware in August 2015, and is based in Emeryville, California and Cambridge, Massachusetts, with a manufacturing facility in Pleasanton, California. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; segment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;drug&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had net losses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively. The Company used net cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million through its operating activities for the years ended December 31, 2021, 2020 and 2019, respectively. The Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;401.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021 and 2020, respectively. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through private placements of its convertible preferred stock, the sale of common stock in public offerings, under an &#x201c;at the market offering&#x201d; (the &#x201c;ATM Offering Program&#x201d;), the private placement of common stock and pre-funded warrants, and through proceeds received from its collaboration arrangements. As of December 31, 2021, the Company had cash, cash equivalents and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;206.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_58769f1e-d1a7-4d46-a346-1b9a5253de5e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_f09b07ce-a105-4175-9585-40464ff6fb94"
      unitRef="U_USD">-75100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-5"
      id="F_2c0947cf-a714-4b47-a7f2-156a6c89a510"
      unitRef="U_USD">-105300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-5"
      id="F_02de9f6d-6ed3-48d6-b25a-19da807c1939"
      unitRef="U_USD">-94400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_64d878cc-9018-46da-8f9d-d34f2166333d"
      unitRef="U_USD">-50700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-5"
      id="F_6dd56983-38be-4775-b348-4f6a5074e879"
      unitRef="U_USD">-89100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-5"
      id="F_b6f100fd-8b81-49c7-9ed6-72319905dade"
      unitRef="U_USD">-85000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_39d68d80-9247-4914-888e-868b49e0b7ef"
      unitRef="U_USD">-401400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-5"
      id="F_ba25524a-9a2d-4677-b873-5ac7dce05da9"
      unitRef="U_USD">-326300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <grts:CashCashEquivalentsAndMarketableSecurities
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_3925d072-286b-45d1-a198-98e6dfdc3643"
      unitRef="U_USD">206300000</grts:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_1ec534b0-6446-4b47-9e5a-d42110931895">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2.	Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for reporting. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the CEPI Funding Agreement and Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.52%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;results &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease (&#x201c;COVID-19&#x201d;) outbreak a pandemic. To date, the Company&#x2019;s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.318%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.099%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2021, 2020 or 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation of the expected term for its stock options. Volatility is based on an average of the historical volatilities of the common stock of entities with characteristics similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2021 and 2020. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes lease expense on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2021, the Company had not accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; suspension of the use of net operating losses for medium and large businesses and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; cap on the use of business incentive tax credits to offset no more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for taxable years 2020 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt - Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;does not expect the adoption of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU 2020-06 &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2020, the FASB issued ASU No. 2020-10, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Codification Improvements &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_c9611c4d-e222-47a3-bed8-cef066ca3de8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for reporting. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements are comprised of the consolidation of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_83703696-3831-4c2b-97ed-e3fa5219f986">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_3fb2c44e-8fb4-4f62-bd25-48252904879e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. GAAP establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.84%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value is established as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, an established three-tier fair value hierarchy distinguishes between the following:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 inputs are quoted prices in active markets that are accessible at the market date for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:2.269%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.3216788941072948%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 inputs are unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the assets or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts reflected on the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued compensation and accrued liabilities approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_e713cced-451c-44c4-bdf5-9c89be64a152">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents, which consist primarily of highly liquid investments with original maturities of three (3) months or less when purchased, are stated at fair value. These assets include investments in money market funds that invest in U.S. Treasury obligations and certificates of deposit, which are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has issued letters of credit under certain lease agreements that have been collateralized by cash deposits for an equal amount and are recorded within deposits and other long-term assets on the consolidated balance sheets based on the term of the underlying lease. Additionally, the Company&#x2019;s restricted cash includes payments received under the CEPI Funding Agreement and Gates Foundation Grant Agreement (see Note 7). The Company will utilize the CEPI and Gates Foundation funds as it incurs expenses for services performed under the agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.52%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_d55347ed-db3c-4909-a436-918f1041323a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table provides a reconciliation of cash, cash equivalents and short term and long term restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:65.52%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
          &lt;td style="width:1.549%;"/&gt;
          &lt;td style="width:1.206%;"/&gt;
          &lt;td style="width:13.883%;"/&gt;
          &lt;td style="width:0.603%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_78808c24-306f-4e38-a39c-47c60c682e0a"
      unitRef="U_USD">93287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_4e8e491d-db1b-4ed4-835d-c1c631b2c05b"
      unitRef="U_USD">170056000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_10429401-3cfe-4b50-af88-c651387eec15"
      unitRef="U_USD">11285000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_a33dc3fa-6e06-4279-9ace-5267257b95bb"
      unitRef="U_USD">6005000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_75426924-fb88-44e5-a170-0b9efbf17863"
      unitRef="U_USD">992000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_fdf31028-fe2d-42c5-8dbd-7ef582a8558b"
      unitRef="U_USD">110577000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_5fd90a38-54da-4f98-a3c4-ebfee6fc0ef4"
      unitRef="U_USD">171048000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_22ea0ae4-3841-4bb3-acb6-083201fa552f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company invests its excess cash in investment grade short-term and long-term fixed income securities. Such investments in marketable securities are considered available for sale, and reported at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss). Marketable securities with maturities of greater than three (3) months from the date of purchase but less than one year from the consolidated balance sheet date are classified as short-term, while marketable securities with maturities in one year or beyond one year from the consolidated balance sheet date are classified as long term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in interest income, net. The cost of securities sold is determined using specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other than temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;results &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and the Company&#x2019;s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Additionally, the Company has determined that it has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_214edb7b-c714-47d2-baaf-fa1813fc3ff7"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_9abf25b0-4995-40fa-a138-c2a366d174a2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_7c6c6dbe-d56b-456b-9759-62633cde9bf0"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_7052ed54-425a-44ec-a640-ef1844b7eb26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents and marketable securities. Cash, cash equivalents and marketable securities are invested through banks and other financial institutions in the United States. Such deposits may be in excess of federally insured limits. The Company maintains cash equivalents and marketable securities with various high-credit-quality and capitalized financial institutions. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the consolidated balance sheets. As of December 31, 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <grts:OtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_e9c54a1d-a0ab-40d9-866d-cd2796bc6952">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to a number of risks similar to those of other clinical-stage biotechnology companies, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease (&#x201c;COVID-19&#x201d;) outbreak a pandemic. To date, the Company&#x2019;s business has not been materially impacted by the COVID-19 pandemic. However, the Company has experienced slowing of patient recruitment and sample collection in its ongoing clinical trials and cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.&lt;/span&gt;&lt;/p&gt;</grts:OtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_824de26e-e141-4830-99ff-c628b45f7da3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.318%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.099%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_3a036fed-ea15-4cc7-9027-d00acf212427">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.318%;"/&gt;
          &lt;td style="width:1.583%;"/&gt;
          &lt;td style="width:31.099%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1c539e79-df24-408f-baa2-48c4f8fe8cd7"
      id="F_2e019c21-59b3-4f0d-b795-f16371aa9db2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_fb979a40-c0d7-43fd-bceb-f181847be79e"
      id="F_87e7a328-33ca-4f0b-a085-d88d314a892b">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ca7d4972-2e89-44bd-9c6d-a8139bbbfdaf"
      id="F_511ebfd7-e208-4dc7-b722-0700d4edf9ed">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_6f545e51-7d7d-4b7a-bbdc-f5531a775926"
      id="F_2b35530e-99b1-4c28-9f11-b6f6cacc2df7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_30604600-a913-4a56-bc12-11001d41700a"
      id="F_a43be87d-1aca-4b8c-82c5-aa9768e3458e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_10488a3d-db85-443f-947d-6d636d18af49"
      id="F_1f54f374-b383-4596-8002-42f470e4d2d0">Shorter of useful life or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_3b54986d-fc26-49ea-b62f-514b6841c00c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates long-lived assets, including property and equipment and ROU assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; indicators of impairment of long-lived assets and no impairment losses have been recorded as of and for the year ended December 31, 2021, 2020 or 2019&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_5166e3ef-be5f-4893-9b03-84a85f326a69"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_df80392f-5189-4b02-8182-88cbad7eb793"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_ba33ea2d-cbd4-472f-8606-4654b7b1dd7e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_46fd5189-a34e-4d94-84dc-b9c9da01c5df">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company performs research and development under collaboration, license, grant, and clinical development agreements. The Company&#x2019;s revenue primarily consists of collaboration agreements and grant funding agreements. At contract inception, the Company analyzes a revenue arrangement to determine the appropriate accounting under U.S. GAAP. Currently, the Company&#x2019;s revenue arrangements represent customer contracts within the scope of ASC Topic 606, Revenue from Contracts with Customers (Topic 606) (&#x201c;ASC 606&#x201d;) or grant funding agreements subject to the contribution guidance in ASC Topic 958-605, Not-for-Profit Entities &#x2013; Revenue Recognition (&#x201c;ASC 958-605&#x201d;), which applies to business entities that receive contributions within the scope of ASC 958-605.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaboration agreements, the Company analyzes to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements that are considered to be in the scope of the collaboration guidance and that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of the collaboration guidance and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of the revenue with contracts with customers guidance. Elements of collaboration arrangements that are reflective of a vendor-customer relationship are accounted for pursuant to the revenue from contracts with customers guidance. The terms of the licensing and collaboration agreements entered into typically include payment of one or more of the following: non-refundable, up-front fees; development, regulatory, and commercial milestone payments; payments for manufacturing supply services; and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. The core principle of the accounting for revenue from contracts with customers guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve (12) months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in the Company&#x2019;s consolidated balance sheets. If the Company expects to have an unconditional right to receive consideration in the next twelve (12) months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not separately identifiable from other promises in the contract (either because it is not capable of being separated or because it is not separable in the context of the contract), or if the performance obligation does not provide the customer with a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations, based on the relative standalone selling prices. The relative selling price for each performance obligation is estimated using objective evidence if it is available. If objective evidence is not available, the Company uses its best estimate of the selling price for the performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the relevant performance obligation, using an appropriate input or output method based on the nature of the good or service promised to the customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes, such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations (which may include forecasted revenue, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success) and estimating the progress towards satisfaction of performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For grant funding agreements, grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred. The Company concluded that payments received under these grants represent nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606 as the organization providing the grant does not meet the definition of a customer. Grant revenue relates primarily to the CEPI Funding Agreement (see Note 7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_302a42a4-a9ca-4dc5-981f-351a28851ae9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and recognizes compensation expense for all stock-based awards made to employees, directors, and non-employees based on the grant date estimated fair value of each award. Such expense is recognized on a straight-line basis over the requisite service period which is generally the vesting period for the entire award. Expense is adjusted for estimated forfeitures. Forfeitures of awards are estimated based on historical forfeiture experience and the experience of other companies in the same industry. The estimate of forfeitures will be adjusted over the service period to the extent that actual forfeitures differ, or are expected to differ, from prior estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates the fair value of stock option grants and ESPP purchase rights using the Black-Scholes option-pricing model (&#x201c;the Black-Scholes model&#x201d;). The Black-Scholes model requires management to make assumptions and judgments about the variables used in the calculation, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate, and expected dividends the Company may pay. Management uses the simplified calculation of the expected term for its stock options. Volatility is based on an average of the historical volatilities of the common stock of entities with characteristics similar to the Company&#x2019;s. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_2a134409-0750-42c3-8389-bc3866781774">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All research and development costs, including work performed by third parties, are expensed as incurred. Research and development costs consist of salaries and other personnel-related expenses, including associated non-cash stock-based compensation, consulting fees, laboratory supplies, and facility costs, as well as external research and development expenses incurred under arrangements with third parties, fees paid to other entities that conduct certain research and development activities on behalf of the Company, and costs incurred related to our collaboration agreements. Costs to develop the Company&#x2019;s technologies are recorded as&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;research and development expense unless certain costs which meet the criteria to be capitalized as internal-use software costs is met. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or services are realized or consumed. Such payments are evaluated for current or long-term classification based on when they will be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Clinical and pre-clinical costs are a component of research and development expense. The Company accrues and expenses clinical and pre-clinical trial activities performed by third parties based upon actual work completed in accordance with agreements established with its service providers. The Company determines the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of services and the agreed-upon fee to be paid for such services.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_bbb24cb3-a42c-46a6-ba6d-1e4b424e51d6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The majority of the Company&#x2019;s leases are classified as operating leases. Leases with a term greater than one year are included in operating lease ROU Assets, lease liabilities, current portion, and lease liabilities, net of current portion in the Company&#x2019;s consolidated balance sheets at December 31, 2021 and 2020. The Company has elected not to recognize on the consolidated balance sheets leases with terms of one year or less. Lease liabilities and their corresponding ROU Assets are recorded based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the appropriate incremental borrowing rate, which is the rate that would be incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU Assets may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU Asset is impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers a lease term to be the non-cancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes lease expense on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has elected not to separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU Asset have been recorded on the consolidated balance sheets and amortized as lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_14b9a10a-c39c-4f04-8e1d-67b4c0f68749">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes and measures uncertain tax positions using a two&#x2014;step approach set forth in authoritative guidance. The first step is to evaluate the tax position taken or expected to be taken by determining whether the weight of available evidence indicates that it is more likely than not that the tax position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% likely to be realized upon ultimate settlement. Significant judgment is required to evaluate uncertain tax positions. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate. It is the Company&#x2019;s policy to recognize interest and penalties related to income tax matters in income tax expense. Through December 31, 2021, the Company had not accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 18, 2020, the Families First Coronavirus Response Act (the &#x201c;FFCR Act&#x201d;), and on March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) were each enacted in response to the COVID-19 pandemic. The FFCR Act and the CARES Act contain numerous income tax provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 29, 2020, Assembly Bill 85 (&#x201c;A.B. 85&#x201d;) was signed into California law. A.B. 85 provides for a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; suspension of the use of net operating losses for medium and large businesses and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; cap on the use of business incentive tax credits to offset no more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of tax per year. A.B. 85 suspends the use of net operating losses for taxable years 2020 and 2021 for certain taxpayers with taxable income of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million or more. The carryover period for any net operating losses that are suspended under this provision will be extended. A.B. 85 also requires that business incentive tax credits, including carryovers, may not reduce the applicable tax by more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for taxable years 2020 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The FFCR Act, CARES Act and A.B. 85 did not have a material impact on the Company&#x2019;s consolidated financial statements as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_e27b55bf-82ea-49ee-9224-7eef2247a897"
      unitRef="U_pure">0.50</grts:PercentageOfRealizationOfTaxBenefitUponUltimateSettlement>
    <grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness
      contextRef="C_9e986ac8-7731-4b24-b71a-e9e6a696434e"
      id="F_ed338364-3585-43e2-a5ac-b24c67594828">P3Y</grts:UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness>
    <grts:UseOfBusinessIncentiveTaxCreditsPeriodCap
      contextRef="C_9e986ac8-7731-4b24-b71a-e9e6a696434e"
      id="F_4000937c-9bbc-480d-9611-6ac69d9371c8">P3Y</grts:UseOfBusinessIncentiveTaxCreditsPeriodCap>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1370d5aa-2b10-4f99-9326-80852218e027"
      decimals="-5"
      id="F_a89a8f68-ebc4-48c0-859e-b85e0cec12e1"
      unitRef="U_USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended
      contextRef="C_edaa2ef9-c496-465a-bdc7-7a2547c59678"
      decimals="-5"
      id="F_386fd6a2-36b8-4055-9e95-c646e6b3f890"
      unitRef="U_USD">1000000.0</grts:MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1370d5aa-2b10-4f99-9326-80852218e027"
      decimals="-5"
      id="F_092ddcb1-bd81-4e0d-921c-e0765b4910d3"
      unitRef="U_USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_90bc7efd-5d0c-424a-bdd6-6a6023c1a955">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are excluded from net loss, primarily unrealized gains and losses on the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_1f169ef8-9f56-4031-a11f-ff6f5d239781">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_9dc79ccb-afea-4db5-833b-67ae4af44f28">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt - Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2020-06&#x201d;). The standard eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the standard modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU 2020-06 are effective for the Company as defined by the SEC for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020. The Company &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;does not expect the adoption of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASU 2020-06 &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2020, the FASB issued ASU No. 2020-10, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Codification Improvements &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&#x201c;ASU 2020-10&#x201d;). The standard contains improvements to the FASB Accounting Standards Codification (the &#x201c;Codification&#x201d;) by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The standard also improves various topics in the Codification so that entities can apply guidance more consistently on codifications that are varied in nature where the original guidance may have been unclear. The amendments in ASU 2020-10 are effective for the Company for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2020-10 to have a material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_917f20f3-4c91-48a4-9a26-f15ec6b52d18">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3.	Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.558%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.73%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.581%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.907%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;US treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, the Company had a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;206.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash, cash equivalents and marketable securities, which includes $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash and cash equivalents and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;113.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in marketable securities, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All marketable securities held as of December 31, 2021, had contractual effective maturities of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. There have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no material realized gains or losses&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on marketable securities for the periods presented. As of December 31, 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t hold any individual securities in an unrealized loss position &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for 12 months or greater&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by us, thus there has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; recognition of any other-than-temporary impairment in the year ended December 31, 2021, 2020 or 2019. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. Thus, the Company has not recorded an allowance for credit losses as of December 31, 2021. The Company will continue to assess the current and expected future economic and market conditions surrounding the COVID-19 pandemic, as further development arises.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 4 for further information regarding the fair value of the Company&#x2019;s financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_7bbb760a-226f-466c-a7e4-e18951ba071e">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amortized cost, unrealized gains and losses and fair values of cash equivalents and marketable securities were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.558%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.73%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.916%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.581%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.917%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.907%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;US treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f"
      decimals="-3"
      id="F_29efcbf9-e374-4f5d-8aa2-ef6fa3189a16"
      unitRef="U_USD">79281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f"
      decimals="-3"
      id="F_15fca577-5527-4bf6-bd59-2aa9a56e517b"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f"
      decimals="-3"
      id="F_e4a64e98-b31f-4660-9d70-e331775fb16a"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_59a9f10c-bbed-4dc7-9d45-29b34760c35f"
      decimals="-3"
      id="F_dc57109f-d302-450c-8dc2-c96c8d729d57"
      unitRef="U_USD">79281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0"
      decimals="-3"
      id="F_6c9266ff-704a-4eb6-988d-010d7df21c91"
      unitRef="U_USD">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0"
      decimals="-3"
      id="F_72a2c2a9-6d5e-46d6-881f-ce022d44f0ec"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0"
      decimals="-3"
      id="F_69b7aec5-b406-428a-96a2-90912e85188b"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_31211693-1cda-45e5-a939-9774d55bf2e0"
      decimals="-3"
      id="F_c76bddf1-e52a-4d1b-9289-5cd27a2aab68"
      unitRef="U_USD">1000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de"
      decimals="-3"
      id="F_b33a9f61-9e4a-4f4e-9d96-7fe669b0f044"
      unitRef="U_USD">1031000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de"
      decimals="-3"
      id="F_6dd53450-f0da-45bf-8241-3935d293d2be"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de"
      decimals="-3"
      id="F_726101c0-737b-4e34-a21e-8170bf35ae5b"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_71977700-a9f0-41f2-b868-8e6cb6b931de"
      decimals="-3"
      id="F_d091c951-d35d-42c0-8f63-6e177d3fdc0e"
      unitRef="U_USD">1031000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b"
      decimals="-3"
      id="F_6d5c5899-a198-437f-a747-ff0a94ec41eb"
      unitRef="U_USD">81312000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b"
      decimals="-3"
      id="F_bf191a58-c484-4f2f-a313-4dbfa935f1fb"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b"
      decimals="-3"
      id="F_73f52849-7212-4fa4-888f-2b2b249018e5"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_75eb6304-1d47-4d29-95ee-7f072311268b"
      decimals="-3"
      id="F_7f955c5e-8930-42f8-888a-31007aa051f9"
      unitRef="U_USD">81312000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07"
      decimals="-3"
      id="F_8a6bfb7d-e83c-417f-adcd-67ebabe6304d"
      unitRef="U_USD">5600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07"
      decimals="-3"
      id="F_2bec3a81-3e66-468a-bc6c-68f3db6744c6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07"
      decimals="-3"
      id="F_1f1a3a1b-869c-4f0d-8350-cb5e953cdf4c"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_8ff26993-aa3b-4b52-8260-dc56b9be1c07"
      decimals="-3"
      id="F_6796f1a9-1a40-41ef-afc3-11827dc9982e"
      unitRef="U_USD">5594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8"
      decimals="-3"
      id="F_ae80b14a-06c5-4d94-965a-3fbe11b4acd8"
      unitRef="U_USD">44990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8"
      decimals="-3"
      id="F_837a53fa-f17e-48ea-8608-b1d2ea5308f4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8"
      decimals="-3"
      id="F_eeb79507-cca4-4dff-8937-a3887981fdf2"
      unitRef="U_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9e3e5bb6-2b82-4fb0-b7ab-b1e63cf92ec8"
      decimals="-3"
      id="F_c77bb63c-1499-4083-aa82-fa5095ba4e5c"
      unitRef="U_USD">44974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d"
      decimals="-3"
      id="F_5a6d9df5-e02d-44ab-b555-a88077d316dc"
      unitRef="U_USD">26976000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d"
      decimals="-3"
      id="F_4f0c28ee-f55d-4747-8c7b-74a807c8ab65"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d"
      decimals="-3"
      id="F_bfd6414e-ebea-4277-9996-470efe37abb2"
      unitRef="U_USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f2d744ea-ab74-4270-b82e-e2d3674f902d"
      decimals="-3"
      id="F_c94a06b5-786c-4a27-b127-d581c78915a6"
      unitRef="U_USD">26953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a"
      decimals="-3"
      id="F_60f9a9bf-3f0a-432e-bee6-d6a296d7c57d"
      unitRef="U_USD">12277000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a"
      decimals="-3"
      id="F_51fe5650-e409-4f0f-8bd9-570b11ad3d4c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a"
      decimals="-3"
      id="F_191cd8a9-57b5-477b-af9d-0866a70d7a09"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fb2a1ff8-84a4-484d-a9f9-bd5ca9b82b8a"
      decimals="-3"
      id="F_a8a9149b-283c-4077-b226-369afeb869b7"
      unitRef="U_USD">12269000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187"
      decimals="-3"
      id="F_084d2d16-a97d-4b1d-90fb-744b91177ed2"
      unitRef="U_USD">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187"
      decimals="-3"
      id="F_1cf8a7ab-0697-418b-aa3a-9aacededf80f"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187"
      decimals="-3"
      id="F_725fc54d-bca9-48a3-a84f-919ddb771f4a"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1987d89b-7388-4dfe-ba84-c6a897416187"
      decimals="-3"
      id="F_a747d19c-e85d-4739-ad63-cff912809f6c"
      unitRef="U_USD">1999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15"
      decimals="-3"
      id="F_6c0c8cc7-68fe-4666-8c55-6faf3269c30d"
      unitRef="U_USD">16565000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15"
      decimals="-3"
      id="F_b425db86-9fe3-4a48-98f0-2508908b6af0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15"
      decimals="-3"
      id="F_d0fe3689-2fea-4894-b9c1-625685144822"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_dff844cc-04ee-4272-9f37-98efe57aea15"
      decimals="-3"
      id="F_8699abc7-c421-4b59-a284-20b9e0e480f6"
      unitRef="U_USD">16557000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60"
      decimals="-3"
      id="F_a8630183-9127-43a1-9cf5-443cf058fcc3"
      unitRef="U_USD">108408000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60"
      decimals="-3"
      id="F_1eb9b11b-854a-4f9a-85cc-429bef10b6b5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60"
      decimals="-3"
      id="F_0ba9eead-4b04-47bd-85f1-7985b0b08afc"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_16b72b70-3b0a-4109-9890-1c0c21720e60"
      decimals="-3"
      id="F_f1c1390b-39e3-4bf3-a85e-3aa7d04c7424"
      unitRef="U_USD">108346000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4"
      decimals="-3"
      id="F_ee89c8ab-8839-43f7-89eb-25177f3fce0c"
      unitRef="U_USD">1637000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4"
      decimals="-3"
      id="F_0e580c4a-076d-40f1-b1d2-b1cc1c93a4a5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4"
      decimals="-3"
      id="F_bac58785-2b75-49c9-94d4-501b8bb5edfa"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ff041b65-d516-4554-a158-11af438bd9d4"
      decimals="-3"
      id="F_83a503a6-27e4-4d6e-a85e-eec046d094be"
      unitRef="U_USD">1631000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a"
      decimals="-3"
      id="F_9a09da88-0d59-44f3-96f1-31ea5e993caa"
      unitRef="U_USD">2991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a"
      decimals="-3"
      id="F_184f82c4-7941-4259-b321-dd42150f9894"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a"
      decimals="-3"
      id="F_59f0a891-634c-4b8c-b2d7-e8dc8db04b50"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b7622eb6-29c1-4937-a641-db49a22c7d5a"
      decimals="-3"
      id="F_a2382506-f6be-4c7d-87f6-26d1f8ae95dc"
      unitRef="U_USD">2986000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_26915e15-276f-4d55-92e9-790736763dbc"
      decimals="-3"
      id="F_930c7809-f74b-4675-83bf-e718af06948d"
      unitRef="U_USD">4628000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_26915e15-276f-4d55-92e9-790736763dbc"
      decimals="-3"
      id="F_814f5fbe-813a-4871-a8a5-0f6a7048fa38"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_26915e15-276f-4d55-92e9-790736763dbc"
      decimals="-3"
      id="F_c5562cb9-dc62-477f-b45b-067f5f9fe2b9"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_26915e15-276f-4d55-92e9-790736763dbc"
      decimals="-3"
      id="F_50e20f0b-3906-4364-9ad0-d70c5eceaa7b"
      unitRef="U_USD">4617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_3185d122-aaee-4cf6-afdb-1c6c8e2538b5"
      unitRef="U_USD">194348000</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_46d27bc2-dc9c-407c-b5c1-b47e75fb7952"
      unitRef="U_USD">0</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_b977cc60-ff7a-4a89-a32e-c8efdc1309da"
      unitRef="U_USD">73000</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_e547c826-1b98-48a5-bafb-367b2e27d29b"
      unitRef="U_USD">194275000</grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13"
      decimals="-3"
      id="F_6a26a37d-575a-493f-8c49-fe7b35e89724"
      unitRef="U_USD">36801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13"
      decimals="-3"
      id="F_67a69e62-0885-4bc6-bb51-8218a1df6605"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13"
      decimals="-3"
      id="F_87f48773-04ab-4934-8134-6ca9d86b8a2e"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3fa0442c-ac78-4809-b069-aed25c97df13"
      decimals="-3"
      id="F_b125a623-9873-410d-aeb0-4e151336d904"
      unitRef="U_USD">36801000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0"
      decimals="-3"
      id="F_68e1c8a2-c40b-4541-985a-641dbddc84c3"
      unitRef="U_USD">36801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <grts:CashAndCashEquivalentsUnrealizedGains
      contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0"
      decimals="-3"
      id="F_d8404440-e062-4009-ba75-f978521e18b8"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedGains>
    <grts:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0"
      decimals="-3"
      id="F_b63d7400-e78d-41e8-a7ce-5a050b05b4a7"
      unitRef="U_USD">0</grts:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_df133232-0911-4fa1-b7e9-ad9298b91da0"
      decimals="-3"
      id="F_9da11a3b-889e-41dd-a851-21a7d5aa4eb4"
      unitRef="U_USD">36801000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42"
      decimals="-3"
      id="F_963ca075-88fd-4833-8dd5-18e6c5e43176"
      unitRef="U_USD">1002000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42"
      decimals="-3"
      id="F_42c152e9-1f0b-4035-8442-324ceaa9a5ff"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42"
      decimals="-3"
      id="F_ac7227ee-b83f-438e-8837-00b494288591"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c96685cb-4058-4f73-a479-ddc549ba8a42"
      decimals="-3"
      id="F_2d8dd88f-cd09-416b-9114-7394938b25c9"
      unitRef="U_USD">1002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc"
      decimals="-3"
      id="F_8a16a410-2bbd-4c08-a559-22839aa55c06"
      unitRef="U_USD">1002000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc"
      decimals="-3"
      id="F_9457789c-11bb-4c9f-bab2-2110b51305a1"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc"
      decimals="-3"
      id="F_f9d1cd14-ae41-4394-9373-7ef8881a3690"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5cc64b5a-ea88-4d07-bf3e-50e80e47c5dc"
      decimals="-3"
      id="F_b4caf180-2a0c-4f72-8dfa-8f89b815d71a"
      unitRef="U_USD">1002000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_6be8db6f-0aa3-4fc0-98ac-7e3091bceba8"
      unitRef="U_USD">37803000</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_df5fbe12-74c2-41b5-a1b5-2ed2ae49c312"
      unitRef="U_USD">0</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_1f979a07-cd18-4485-aed4-9e76eb3b3c3e"
      unitRef="U_USD">0</grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_08e48c61-d278-434d-9a16-f8a9c0f99d4e"
      unitRef="U_USD">37803000</grts:CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities>
    <grts:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_53b33938-00b2-4318-8d46-b1547a437184"
      unitRef="U_USD">206300000</grts:CashAndCashEquivalentsAndMarketableSecurities>
    <grts:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-5"
      id="F_52ac1bb0-5982-4c48-aaa3-515b65422341"
      unitRef="U_USD">171100000</grts:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_1ff68530-8295-4942-b4aa-e031b98be7ac"
      unitRef="U_USD">93300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-5"
      id="F_0fe7c4e4-37ea-493e-8549-ef0ffa5f48f3"
      unitRef="U_USD">170100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_0c48ee3f-2757-4531-826e-33d345f9d66b"
      unitRef="U_USD">113000000.0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-5"
      id="F_74e958fb-feb4-4c4f-8be4-cb94245196e8"
      unitRef="U_USD">1000000.0</us-gaap:MarketableSecurities>
    <grts:MarketableSecuritiesContractualMaturitiesPeriod
      contextRef="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841"
      id="F_84a3ec27-1c4e-4215-a87b-f32b66528fa3">P2Y</grts:MarketableSecuritiesContractualMaturitiesPeriod>
    <grts:MarketableSecuritiesRealizedGainLossDescription
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_ceb05eeb-03c8-41f1-b509-d219632dba19">no material realized gains or losses</grts:MarketableSecuritiesRealizedGainLossDescription>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="0"
      id="F_ccc24f76-7720-414f-9ffa-87d1c1065937"
      unitRef="U_Security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_c2808735-87de-4922-9daf-03e5a69d391e"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_aa3b0327-4846-4780-82c1-756c4df3f761"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_4f9b303a-52be-43a2-8fe1-1e3e70889146"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_00072498-8758-40ad-95ee-843d9556d20a">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4.	Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.622%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.927%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.908%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.908%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.871%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.531%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.556%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.556%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.519%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.519%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;US treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Commercial paper, corporate debt securities, certificates of deposits, asset backed securities, U.S. treasuries and U.S. government debt securities are valued taking into consideration valuations obtained from third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between Level 1 and Level 2 during the periods presented. See Note 3 for further information regarding the amortized cost of our financial instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_56028780-095a-4a8d-a6b6-238544da9577">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.622%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.927%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.908%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.908%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.141%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.871%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;44,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,953&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. government debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;U.S. treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;194,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;99,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.531%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.556%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.556%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.519%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.28%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.519%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;US treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_72910c92-ee53-4966-9f0c-433eaf5edd6d"
      decimals="-3"
      id="F_b32dc7cc-27b6-40f5-a2f0-96186e1dbae8"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c6e24dfd-99c6-486b-bf9c-ed12b545fb8f"
      decimals="-3"
      id="F_8e3db09d-2d44-46b2-a516-ca9a03e5a9d7"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dbeb91ff-efca-496e-8f5f-a322f317f314"
      decimals="-3"
      id="F_7a5732ba-9457-41bd-a62b-9d882e6a08cf"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f772a0a4-efa1-4b33-be2c-131d275bc66b"
      decimals="-3"
      id="F_37b4c9e5-281b-4dd6-80e1-892d1c6ef04a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_53c971f9-6a10-4dd2-9fb3-244f2a280440"
      decimals="-3"
      id="F_b7f6e8aa-5d64-4bb4-b148-38f7456a39e3"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bd06d670-ff74-493a-bef1-1d7f537c855a"
      decimals="-3"
      id="F_afaec218-13fb-4f78-ab9d-b3feeabd40c1"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_770c1400-be16-4651-87a2-b63b0c62772f"
      decimals="-3"
      id="F_0a041268-e373-429c-a428-69d5925d9a45"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a9b94c09-f330-4e14-958b-a04cb0904e83"
      decimals="-3"
      id="F_27b1b642-2993-4307-b857-59d7e16c866e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4d000fa3-1eaf-460c-a146-fa94750108ca"
      decimals="-3"
      id="F_2d9cfac2-249a-4d64-b782-63f1d56ca1cb"
      unitRef="U_USD">1031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c8dfb228-4332-4eda-835f-6dcd119ac01f"
      decimals="-3"
      id="F_dad5e36e-e6a3-41eb-8429-7469bdf036ec"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b28b039b-c3f5-4ba2-a4b4-e6a47d32112b"
      decimals="-3"
      id="F_ce4f40bf-f207-4f53-8725-5a98a58a8630"
      unitRef="U_USD">1031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b922b66e-4124-4802-a0ce-1cecdf096487"
      decimals="-3"
      id="F_733cd379-fcc1-4209-b388-1b8c78167641"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_931f6700-0cb1-4f20-b677-efdf1bd07c30"
      decimals="-3"
      id="F_c77ee547-45a2-4242-81c4-4e09a4235695"
      unitRef="U_USD">81312000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_21980324-d092-473a-8ef8-6dfaf9956f38"
      decimals="-3"
      id="F_6e549772-8e52-456c-9ff0-c5a1ad27c92c"
      unitRef="U_USD">79281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f5f6a648-955a-4a5a-bac4-0a73b202d719"
      decimals="-3"
      id="F_86b70c58-91b2-406b-9fbb-eb097ab1f2b1"
      unitRef="U_USD">2031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e2caa467-fa23-4f7e-ae1f-5ca204d58c99"
      decimals="-3"
      id="F_5579ba24-e9ab-4c84-829b-c8e02ee14117"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_05bb5bbd-397e-4572-a8c7-c182ee094fb2"
      decimals="-3"
      id="F_ea26fbd3-e2d3-4554-bd99-7cba6ad48c23"
      unitRef="U_USD">5594000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c371ea3-28ab-4cab-b5bc-b09e9730fe88"
      decimals="-3"
      id="F_85231f9e-23e1-4d1f-ae2b-1ee64c2180f7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f567c768-2291-41ae-b166-d1912a72f707"
      decimals="-3"
      id="F_b1d5207c-24a2-4352-996f-b95b6b06804d"
      unitRef="U_USD">5594000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2bb37ca5-db5d-4687-89ae-66db04f52143"
      decimals="-3"
      id="F_7233c77c-2d5f-4be9-a895-90b614cff32c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e130a83e-daf9-47c4-ab36-8190b47e6a2f"
      decimals="-3"
      id="F_4566a25b-4114-493e-b94e-e0bad1cfd9dc"
      unitRef="U_USD">44974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ec9e70d0-23a0-467e-b683-3d2b3eaf2393"
      decimals="-3"
      id="F_317bb7a0-445b-4f85-a97f-12f219efb627"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_22ff4438-130f-423a-bdc3-1d4eb213a8cb"
      decimals="-3"
      id="F_54c24eea-3279-431b-8fdd-fda76090c0ea"
      unitRef="U_USD">44974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_858b47a6-e592-4ea1-b141-4955b70c5d4c"
      decimals="-3"
      id="F_75a67aa7-f73b-43fc-8b11-489aede4d673"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_518a98be-fa4a-4aa6-97cb-3e2f9ad3b79b"
      decimals="-3"
      id="F_a92e9e57-451e-46bb-bb68-398fef2d9edc"
      unitRef="U_USD">26953000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d8e26511-0489-4f9f-9cb5-3285842a09fa"
      decimals="-3"
      id="F_c86b8409-f345-455c-ad13-677d948200bd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3984633a-9389-4f12-94bd-7218eb5fa25e"
      decimals="-3"
      id="F_0e4e048f-4dca-4728-b53d-7b109a1ceafe"
      unitRef="U_USD">26953000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8a47a83-89e6-4e48-884d-6f9289316bbc"
      decimals="-3"
      id="F_352e9241-e037-4261-a904-32cd59fcc8e9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6f03e706-2fc7-4723-b18d-bade0d235db3"
      decimals="-3"
      id="F_31c53df0-895d-4f1d-ad8f-f93d19c52795"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7de09d33-88c1-42a7-afb7-90f61cda1e04"
      decimals="-3"
      id="F_bda83d97-26a9-4f91-9af2-7947d72457cd"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_25e0aa86-a42f-4054-8323-4060b43924cf"
      decimals="-3"
      id="F_be3439af-6662-4d62-ba4d-106f8bd1c239"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_576b3dfa-a60b-4b9c-a136-301a277fd0bc"
      decimals="-3"
      id="F_2d08787d-d70f-4ac0-b1d9-93afc7933a2e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_71f8b23d-24fd-4e8b-8f47-dd44d72f6801"
      decimals="-3"
      id="F_f2f96800-29f1-48af-a5b0-dc8ab9ad15db"
      unitRef="U_USD">1999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_24382739-e4d1-4b7d-9faa-aefc1a06f44a"
      decimals="-3"
      id="F_368aff1c-225a-46f7-8798-6f4679835150"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9299c473-d0f6-48c7-880f-5c832935a48b"
      decimals="-3"
      id="F_d80610c1-fbd0-4142-844f-1cf2e650c611"
      unitRef="U_USD">1999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f54e27a8-261f-4d2c-b6fd-99f5477f06ff"
      decimals="-3"
      id="F_4691bb3a-6f93-406b-9d58-da5b11c2b0ba"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13ec2a36-3f76-4309-a005-6e83308a21b5"
      decimals="-3"
      id="F_261bd368-eb22-4efa-a2e2-a2ea2167cefc"
      unitRef="U_USD">16557000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62787d44-14ba-4275-b041-61b55ece56ea"
      decimals="-3"
      id="F_1359504a-ba42-4f61-a45b-5cbcff1afc80"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e3c26619-b56f-41f8-bdf1-a3ff19582f5f"
      decimals="-3"
      id="F_2a4aab90-7e85-474d-86cb-88e0804c0646"
      unitRef="U_USD">16557000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6da601ec-2822-45c8-a4c9-e52839555406"
      decimals="-3"
      id="F_b75eb3bb-c1e3-442a-ae73-61aa4e4fd833"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c9d841a0-65e8-4897-a9d8-b29656c20523"
      decimals="-3"
      id="F_4559440c-a7bb-4acc-9fa6-79a185643628"
      unitRef="U_USD">108346000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_64dce666-8e1a-4354-b216-dc6c18393077"
      decimals="-3"
      id="F_d54716e3-2860-4379-ab8f-d409c8e29c54"
      unitRef="U_USD">12269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c13a7d1-0de0-4b4a-b307-f31dc3ebf480"
      decimals="-3"
      id="F_c722fd57-23cd-437d-8c37-afcb8692ecf1"
      unitRef="U_USD">96077000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2196007d-8bbb-41dc-bf26-a59a7a2a5a5b"
      decimals="-3"
      id="F_a3a4bda4-7d02-4925-af6e-8173d0b89723"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c56ee86-11c9-4117-a515-85c8951a85c4"
      decimals="-3"
      id="F_e3d68ea2-52b5-4dee-9d24-4601cd228214"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b424de0c-4fee-48e3-bea3-66f5d512ff60"
      decimals="-3"
      id="F_1556d927-bc26-47db-ac5a-82a742c03abe"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_51e8d18f-06ae-4779-a286-63d6c005a973"
      decimals="-3"
      id="F_6afb1820-0cbc-4739-bd45-c35ba6991f17"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1f0f4dc4-3084-4ed1-9f00-4607611bf19a"
      decimals="-3"
      id="F_340d6ffa-fb61-4585-91bc-78ea058e6edc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2eec9e6d-ddf3-4386-87ac-8ad1c81b0edd"
      decimals="-3"
      id="F_0794c2a9-fae8-471a-a111-c7173ae3a9a9"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9ea13d69-ee00-43f8-b7f0-e73c7105d779"
      decimals="-3"
      id="F_d8bb830e-4d3c-41d2-9d92-30b5974a2f1d"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ba072684-2765-4bcf-b573-e869e31f90c1"
      decimals="-3"
      id="F_aee9b7ad-5cc6-421a-989c-3582ccfc8429"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bc289d2c-e7b6-4507-9fb5-87d39ce5490f"
      decimals="-3"
      id="F_a27a2f0b-ccdf-4564-97d9-6ffa53dc7246"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_64253bb9-ade3-45ac-b41f-7d7b2677303d"
      decimals="-3"
      id="F_dd8a6219-9ed2-4b7f-97b8-10fec0582d8a"
      unitRef="U_USD">4617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_54016751-a114-4247-b713-e0476cc1ba05"
      decimals="-3"
      id="F_4f7a6dfe-70ea-4d98-bfde-775e7e2bb25d"
      unitRef="U_USD">2986000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e30aa933-0d6e-4987-a2a1-bbce8c351c9a"
      decimals="-3"
      id="F_d4f7b3a3-d164-4133-ad85-91841a6c3e29"
      unitRef="U_USD">1631000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1b456a1b-1f2c-4ef1-8559-e06dc02c434e"
      decimals="-3"
      id="F_f757a640-1638-4283-be7c-ad2fae8c23c4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ef27cb81-c09f-4cb8-81bf-6b870908b71b"
      decimals="-3"
      id="F_b26bb04e-712a-4220-8d73-c1a2fa5d7271"
      unitRef="U_USD">194275000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4ea043b7-fa57-4d14-8d34-b78103ca2ed8"
      decimals="-3"
      id="F_0424a092-2866-4af3-8ade-1b519e97e847"
      unitRef="U_USD">94536000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5dc9611e-d586-4a8b-a50f-4a5ff390d4ee"
      decimals="-3"
      id="F_6d3d66a7-d152-4d30-acf4-22b37e8d6abb"
      unitRef="U_USD">99739000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6b19cfa6-fa43-4b59-b47c-8499f1dcf7a3"
      decimals="-3"
      id="F_d321ec46-c027-4c87-ac1e-fa951f20e9c4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1fc1f7ef-16ae-4f01-b819-fa9c521cd5d2"
      decimals="-3"
      id="F_a2e111e1-a579-4930-8787-2582e23180f8"
      unitRef="U_USD">36801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9f0bfb81-1915-4116-a634-7211fd15e24b"
      decimals="-3"
      id="F_6d190868-9dca-4923-b8fa-a959b1214d5f"
      unitRef="U_USD">36801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_451a0b67-f3b2-496e-a299-db96faaae70e"
      decimals="-3"
      id="F_54e3dec4-4321-4309-804d-12b82101a3e2"
      unitRef="U_USD">36801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_74699a7b-9862-48d1-88b1-8c7ce7b44e28"
      decimals="-3"
      id="F_f12335a7-a997-4228-8618-550ff6a5130a"
      unitRef="U_USD">36801000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56fd8f05-2d3d-40b2-a758-c7de82170e4b"
      decimals="-3"
      id="F_d761303d-1e52-496d-8a48-0ed438bd1573"
      unitRef="U_USD">1002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ebef1c21-1add-4b82-b86f-c63f3d498c3e"
      decimals="-3"
      id="F_6bd3b378-f1d3-4c7c-9b0d-2d1fa1f7de37"
      unitRef="U_USD">1002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c4425ed7-6aea-4eec-abd2-81111d52a84a"
      decimals="-3"
      id="F_6c31b069-148f-4557-9a37-03d329f7b836"
      unitRef="U_USD">1002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9a00145e-06b8-48cf-9669-be9b9d8fc159"
      decimals="-3"
      id="F_1d212e5f-a1aa-4389-8788-7e253060921e"
      unitRef="U_USD">1002000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cef8cbb3-30a5-4f27-89df-b90b0bac1878"
      decimals="-3"
      id="F_b4394d02-c81c-490e-a468-4db9370a8376"
      unitRef="U_USD">37803000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_14f18898-257e-4527-9df2-402224c7a2a0"
      decimals="-3"
      id="F_abfb81d9-6668-4ce5-af65-d6fa74b8130b"
      unitRef="U_USD">37803000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_edbe3664-b473-48ed-8a99-2ef8966c174c"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_bf057781-e7f5-4aed-a395-a0fa8973083b"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_3c1f2571-121d-43a1-bc96-f517489d6d0d"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_a73c6044-21d3-435d-a72e-b403447e0d9b"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_0f7aae10-7be0-4255-8f8e-6aac39d39e3b">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5.	Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.662%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.459%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_1c511821-bf23-4d0a-9c3a-f4beb5d07523">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment and related accumulated depreciation and amortization are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.662%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.459%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.512%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41,907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction-in-progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d5159609-8b4f-4ad9-a130-008c19b07b91"
      decimals="-3"
      id="F_eecfe247-9187-48d1-95a3-b88bc1945a3a"
      unitRef="U_USD">987000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bb1328df-a76e-43a9-81e1-d6f6bc50971a"
      decimals="-3"
      id="F_a3c2494f-27b8-473d-be00-8fdf1eb5c09f"
      unitRef="U_USD">971000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5f70c7fd-3c98-48c7-9bcd-c95ad6bbd433"
      decimals="-3"
      id="F_c4357b61-1b42-462b-a051-6d30782c0c7b"
      unitRef="U_USD">2113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aa002ef1-1e05-4ec8-8b0e-f1fff0822abf"
      decimals="-3"
      id="F_2a187995-7139-4060-a168-6e6d48be63ae"
      unitRef="U_USD">2054000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_37e6511c-98ee-405d-9c80-3d0032f397aa"
      decimals="-3"
      id="F_98ff7733-3ce9-4879-b570-90e52ac5e4fb"
      unitRef="U_USD">24679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_aa4c4d44-8bce-48ff-a4e4-7256f3516afb"
      decimals="-3"
      id="F_ce65c2b3-7b8e-46bd-a855-1807fd326ddb"
      unitRef="U_USD">22213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ef0e97d3-9570-43f8-a443-eefdbce6381d"
      decimals="-3"
      id="F_6fbee63e-4d00-47cd-9457-ee2a0a748f86"
      unitRef="U_USD">14128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_66671e44-d11b-4168-b422-0fbfe5fa8350"
      decimals="-3"
      id="F_dae90d97-2374-4c53-8378-ee6f4e5acd3b"
      unitRef="U_USD">13726000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_6eb82b9c-9d95-4927-9b55-e1a5b1af3445"
      unitRef="U_USD">41907000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_262eeac7-75f5-461d-a168-3b9fe9e1e232"
      unitRef="U_USD">38964000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_d24d515e-6ac9-4b11-8f35-3bcdf7062198"
      unitRef="U_USD">22276000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_157d9f85-f7a1-44a8-955d-f1b749163d53"
      unitRef="U_USD">16925000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_be2d704f-9ebb-4151-bfe1-64f9f58a7b29"
      decimals="-3"
      id="F_b65a44d3-52b3-40cc-a628-97760bc462b0"
      unitRef="U_USD">1991000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6dbc0ba8-cd39-4c20-9b7d-bb253b05b1a0"
      decimals="-3"
      id="F_fd03d2dd-4753-4bde-a6ab-70eac683fe4d"
      unitRef="U_USD">66000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_fe7bd6ca-6758-494d-a767-ac643da42220"
      unitRef="U_USD">21622000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_28e8f705-4a7a-4dd4-bc90-aeeecabde4f9"
      unitRef="U_USD">22105000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_ac174f59-0253-4d15-a290-e514900368c9"
      unitRef="U_USD">6300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-5"
      id="F_d16d7a60-4554-4c4e-aedf-f861cc41d5af"
      unitRef="U_USD">6600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-5"
      id="F_3626f30f-e026-4d4e-afc3-492b1ee47083"
      unitRef="U_USD">4700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_4cf448a6-b9c6-4268-8ffe-ab46f66461c5">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6.	Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases office, laboratory and storage space in facilities at several locations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Emeryville Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s principal executive offices in Emeryville, California, consisting of office and laboratory space, are leased pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating lease (the &#x201c;Emeryville Lease&#x201d;), which the Company entered into in January 2019, with the obligation to pay rent commencing in November 2019. In conjunction with signing the Emeryville Lease, the Company paid a cash security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is recorded as a deposit on the Company&#x2019;s consolidated balance sheets as of December 31, 2021 and 2020. The Emeryville Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend this lease for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; periods at the then market rental rate. The lessor provided the Company a tenant improvement allowance for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to complete the laboratory and office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2021. The Company recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Pleasanton Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,620&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of office, cleanroom, and laboratory support manufacturing space in Pleasanton, California pursuant to a non-cancelable operating lease (the &#x201c;Pleasanton Lease&#x201d;), which the Company entered into in March 2017, with the obligation to pay rent commencing in December 2017. The Pleasanton Lease includes a free rent period, escalating rent payments and a term that expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has the option to extend the lease term for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; at the then market rental rate. The Company obtained an irrevocable letter of credit in March 2017 in the initial amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a security deposit to the Pleasanton Lease, which may be drawn down by the landlord in the event the Company fails to fully and faithfully perform all of its obligations. The letter of credit may be reduced based on certain levels of cash and cash equivalents the Company holds. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the irrevocable letter of credit amount had been drawn. The Pleasanton Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Pleasanton Lease, the Company received a tenant improvement allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from the landlord for the costs associated with the design, development and construction of tenant improvements. The unamortized tenant improvement balance is recognized as a component of operating lease ROU Assets on the consolidated balance sheets as of  December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, in May 2019, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; non-cancelable operating lease for additional office space in Pleasanton, California, with an obligation to pay rent commencing in August 2019. The lessor provided the Company a tenant improvement allowance for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to complete the office renovation. The Company has determined the tenant improvements to be lessee owned and therefore has recorded a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2021, and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million ROU Asset and a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million lease liability on the consolidated balance sheet as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Cambridge Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases laboratory, office and storage space in several facilities in Cambridge, Massachusetts, pursuant to three separate agreements:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s facility located at 40 Erie Street and 200 Sidney Street in Cambridge, Massachusetts is leased pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; non-cancelable operating lease (the &#x201c;40 Erie Lease&#x201d;), which the Company entered into in February 2016, with an obligation to pay rent commencing in October 2016. The lessor provided the Company a tenant improvement allowance for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to complete the laboratory and office renovation. In September 2021, the Company executed an amendment to the 40 Erie Lease, which extends its term through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and provides for monthly base rent amounts, subject to annual increases over the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s facility located at 21 Erie Street in Cambridge, Massachusetts is leased pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; non-cancelable operating lease (the &#x201c;21 Erie Lease&#x201d;), which the Company entered into in September 2018. The 21 Erie Lease has since been amended three times, as a result of which the lease term extends through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2021, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating lease (the &#x201c;Cambridge Storage Lease&#x201d;) for additional office and laboratory storage space in Cambridge, Massachusetts, which commenced on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company also paid an immaterial cash security deposit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In conjunction with the 40 Erie Lease, the 21 Erie Lease and the Cambridge Storage Lease, each as amended (if applicable), the Company has paid certain advanced payments, which in each case included amounts for the applicable last month&#x2019;s rent and security deposit. The portion of the advanced payment related to last month&#x2019;s rent has been classified as part of the operating lease ROU Assets. Security deposits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, are recorded in deposits and other long-term assets on the Company&#x2019;s consolidated balance sheets as of December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Boston Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company plans to occupy a newly-built facility in Boston, Massachusetts, with office and laboratory space, in 2023 pursuant to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating lease (the &#x201c;Boston Lease&#x201d;), which the Company entered into in September 2021. The Boston Lease includes a free rent period, an escalation clause for increased rent and a renewal provision allowing the Company to extend the Boston Lease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; periods at the then market rental rate. The landlord provided the Company with a tenant improvement allowance of up to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for costs relating to the design, permitting and construction of improvements. The Company&#x2019;s obligation to pay rent is anticipated to commence in January 2023, subject to free rent periods of three and six months with respect to certain premises. The commencement date of the Boston Lease is expected to be in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, given the Company&#x2019;s early access rights to the leased space, and the term will expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Boston Lease further provides that the Company is obligated to pay to the landlord its proportionate share of certain basic operating costs, including taxes and operating expenses. In connection with the Boston Lease and as a security deposit thereunder, the Company has provided the landlord an irrevocable letter of credit in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is collateralized by a restricted cash deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and which may be reduced in the fifth and seventh years of the Boston Lease. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the irrevocable letter of credit amount had been drawn.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has not recognized a right-of-use asset or lease liability as of December 31, 2021 for the Boston Lease as the Company did not control the underlying assets at any time in the period ended December 31, 2021. Under the Boston Lease, the Company is obligated to make minimum lease payments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years from 2023 to 2033, which includes rent abatement during the free rent periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.807%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.498%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.318%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.318%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.337%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;New right-of-use assets obtained in exchange for lease obligations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.787%;"/&gt;
        &lt;td style="width:2.078%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.132%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Lease Financing&lt;br/&gt;Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;112,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Amounts representing interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Amounts representing lease payments under Boston lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Noncurrent portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Agreements with CROs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2017, the Company entered into a contract research and development agreement with a third-party contract research organization (&#x201c;CRO&#x201d;) to provide research, analysis and antibody samples to further the Company&#x2019;s development of its antibody drug candidates. The Company is also obligated to pay the CRO certain milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million on achievement of specified events. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None of these events had occurred as of December 31, 2021. During the year ended December 31, 2021, the Company had immaterial research and development expense under the agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2020, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; research and development expense under the agreement. During the year ended December 31, 2019, the Company recognized an immaterial amount of research and development expense under the agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2019, the Company entered into a contract research and testing agreement with a third-party CRO to provide antibody discovery related services. The Company is also obligated to pay the CRO certain milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million on achievement of specified events. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of these events had occurred as of December 31, 2021. During the year ended December 31,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; research and development expense under the agreement. During the year ended December 31, 2020, the Company recognized an immaterial amount of research and development expense under the agreement. The Company recognized a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in research and development expense under the agreement during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws, and pursuant to indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, with respect to which the officer or director is or was serving at the Company&#x2019;s request in such capacity. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance limits the Company&#x2019;s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094"
      id="F_aaef8b8f-8cb5-4823-b823-f53aebb5ddad">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482"
      decimals="-5"
      id="F_3783a7b3-f19f-476f-9ba3-0f5dc9d39513"
      unitRef="U_USD">600000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05"
      decimals="-5"
      id="F_2c0732b6-355a-4ec0-99ea-3669f24abb98"
      unitRef="U_USD">600000</us-gaap:SecurityDeposit>
    <grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms
      contextRef="C_72dfcfb2-eb2b-4d05-8cf1-c1bc2e786747"
      decimals="INF"
      id="F_bc65a991-4a62-4de1-8060-c79bdb9ff644"
      unitRef="U_RenewalTerm">2</grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094"
      id="F_b07f94e1-fa38-4125-a19c-d310e9a701b8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="C_520c653f-3fd9-4afa-a427-6bc66ddc0094"
      decimals="-5"
      id="F_5808c1f5-569e-448e-a478-38aa7ca31820"
      unitRef="U_USD">4000000.0</us-gaap:TenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482"
      decimals="-5"
      id="F_edb4d5a3-f2e5-4f96-a694-35e0b4cbc623"
      unitRef="U_USD">8700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7e7e2d25-c1fe-4fde-a67f-0b236c035482"
      decimals="-5"
      id="F_36c906d1-8cdb-4913-ba0d-ff3a80a8ddb2"
      unitRef="U_USD">13900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05"
      decimals="-5"
      id="F_e1527544-1ec7-4b68-b079-7395c919c202"
      unitRef="U_USD">9300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_1a56f792-e909-4a78-9c9f-369e4b671f05"
      decimals="-5"
      id="F_46e4909d-2641-45de-9db2-a4b8515e0068"
      unitRef="U_USD">14800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AreaOfLand
      contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e"
      decimals="0"
      id="F_a9e64cb9-6fe5-4eee-9397-93b8d9085dd6"
      unitRef="U_sqft">42620</us-gaap:AreaOfLand>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_a312235c-4cac-4041-b6a1-62babf05fea6"
      id="F_70cfa89c-b7c0-41d9-b5a8-449ec7a6ad03">2024-11-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e"
      id="F_09163d2e-aae0-47f6-ab7c-d8d336ec9889">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e"
      decimals="-5"
      id="F_d3544f9b-2629-4de7-b52e-65c7dfd4909d"
      unitRef="U_USD">1000000.0</us-gaap:LettersOfCreditOutstandingAmount>
    <grts:AmountOfIrrevocableLettersOfCreditWithdrawn
      contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17"
      decimals="INF"
      id="F_97fd0653-134a-4284-a867-4a79fec66e88"
      unitRef="U_USD">0</grts:AmountOfIrrevocableLettersOfCreditWithdrawn>
    <us-gaap:TenantImprovements
      contextRef="C_825cc7f3-5492-4dfa-b2aa-3fd9dbce041e"
      decimals="-5"
      id="F_265993b0-bd2a-481b-9da6-b449ca07092d"
      unitRef="U_USD">1200000</us-gaap:TenantImprovements>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635"
      id="F_82b683e2-36fc-4d83-93ca-c49086178c6a">P64M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:TenantImprovements
      contextRef="C_0235bf11-1f2e-49ff-a0cc-bf4fc2c6b635"
      decimals="-5"
      id="F_04ce09b4-fa93-42d0-99dc-c5e94c4021cc"
      unitRef="U_USD">100000</us-gaap:TenantImprovements>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17"
      decimals="-5"
      id="F_a962322c-99cd-475b-a012-588d787e3707"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_4e64aab1-349c-4614-83ee-3900dea01a17"
      decimals="-5"
      id="F_bf7a3d2a-cf84-4271-b31c-574ec2189b4d"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2"
      decimals="-5"
      id="F_b0a253e3-a5d3-4f0f-b0b9-8fc1778e3e1c"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_48dca5b8-6308-44a5-b9cf-dfb683c455e2"
      decimals="-5"
      id="F_a7bcc9ed-3d29-47ae-a33d-1d9191356e2a"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_4648628a-65c5-480f-b910-360609ce023f"
      id="F_42e6521c-bb06-47a7-b8fc-d1da7b199da6">P67M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:TenantImprovements
      contextRef="C_4648628a-65c5-480f-b910-360609ce023f"
      decimals="-5"
      id="F_13364c37-6aa0-4f7c-b481-87882c867d2d"
      unitRef="U_USD">2100000</us-gaap:TenantImprovements>
    <grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear
      contextRef="C_d8caf9fb-02e0-4bb8-bf86-c54f67dc62ef"
      id="F_c9767731-9a26-4b3f-a3da-f73167afa961">2025-04</grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_10299d1d-13c5-4852-a7f2-89934ae6946e"
      id="F_c854b374-d8c1-4855-896e-54b442779e32">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear
      contextRef="C_30c5d65f-d7ac-4f7f-9b8f-ea4e4e427446"
      id="F_66afc85f-fe2f-40cb-976f-7179f2964e6d">2023-01</grts:LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3bab2de3-95f2-4e3a-9835-071d68696554"
      id="F_5e4ecc0b-f73c-447e-be8d-e6f473c3eaac">P17M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperationsCommencedDate1
      contextRef="C_0d99841f-5ce6-4dad-8ba9-7eec24d9d624"
      id="F_c47b7060-a606-4054-9102-f08858f134f2">2021-04-01</us-gaap:OperationsCommencedDate1>
    <us-gaap:SecurityDeposit
      contextRef="C_b6bab4a8-6557-40f6-913e-491ef563fcfa"
      decimals="-5"
      id="F_52d30fe0-20a7-4961-ba9e-1c570b2a8e46"
      unitRef="U_USD">700000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_f87928d0-309b-467a-826b-88343445bf04"
      decimals="-5"
      id="F_dce47442-3b4b-45d9-8e4c-01460acd0d69"
      unitRef="U_USD">600000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_ad7b7d3a-31f1-4f01-a882-0db818ad07a9"
      id="F_2f4808d9-58e2-4d21-a95a-4002e6f88704">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms
      contextRef="C_d7987440-e273-4b4b-a993-e63610db9856"
      decimals="INF"
      id="F_a57b26da-6386-4663-88b8-ebdfa8eb4577"
      unitRef="U_RenewalTerm">2</grts:LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      id="F_91719c7d-954a-48ef-abf7-b9ae55469f2e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      decimals="-5"
      id="F_5ec01a0e-5ead-4880-ac89-4d7411819daa"
      unitRef="U_USD">19100000</us-gaap:TenantImprovements>
    <grts:OperationsExpectedCommencedDate
      contextRef="C_d7987440-e273-4b4b-a993-e63610db9856"
      id="F_5c76d34d-89d8-4468-9c02-5617f93765ca">2022-11</grts:OperationsExpectedCommencedDate>
    <grts:LeaseExpirationTerm
      contextRef="C_d7987440-e273-4b4b-a993-e63610db9856"
      id="F_d6f9c6e3-8a96-4614-921f-0e44574cf451">2033-01</grts:LeaseExpirationTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      decimals="-5"
      id="F_a464789a-a460-4c86-8203-921006348883"
      unitRef="U_USD">4600000</us-gaap:LettersOfCreditOutstandingAmount>
    <grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      decimals="-5"
      id="F_cd603aa1-85ac-4240-bc38-8f7cee07057a"
      unitRef="U_USD">4700000</grts:RestrictedCashDepositUsedAsCollateralForLetterOfCredit>
    <grts:AmountOfIrrevocableLettersOfCreditWithdrawn
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      decimals="INF"
      id="F_d5267d77-0c9e-4cad-ba81-d640924d3689"
      unitRef="U_USD">0</grts:AmountOfIrrevocableLettersOfCreditWithdrawn>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_c43bee37-d145-46c9-8b72-ab6093ffa3d9"
      decimals="-5"
      id="F_f2d999df-377c-43f4-b35c-4fe30b262a9a"
      unitRef="U_USD">79100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_78b36ed4-cb32-4a2e-8ca1-6b685ba7f012">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of lease costs, which were included in our consolidated statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.807%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.596%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_4cad9f37-9c1d-42cb-a3ad-bb75c9439d1f"
      unitRef="U_USD">7973000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_56e3a04c-bcf8-491a-ac9b-652356be14f7"
      unitRef="U_USD">7511000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_b7efe0ad-e56c-4395-82d1-5d681c99c517"
      unitRef="U_USD">6382000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_aa0300d8-960d-4b2e-a02f-b6700a1a106e"
      unitRef="U_USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_eb064be5-c3fa-444e-96d1-7814dac619c1"
      unitRef="U_USD">7000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_7a9996fc-a17f-4683-82aa-78ba2002a468"
      unitRef="U_USD">271000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_a4322aa3-fd11-4874-893f-5df8aa0db9b8"
      unitRef="U_USD">7973000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_ab2d69c3-ac30-4e92-875a-d25d0a7c4bac"
      unitRef="U_USD">7518000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_ba4facae-b446-41cd-92a0-472c87a96baa"
      unitRef="U_USD">6653000</us-gaap:LeaseCost>
    <grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_a6fd0669-8341-4476-8c4e-7307eff3f16a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.498%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.318%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.318%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:10.337%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;New right-of-use assets obtained in exchange for lease obligations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_6cc9ed4e-7695-43c7-a0f6-ef1f1f7e1ecd"
      unitRef="U_USD">7925000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_7b1f2534-97bd-4b43-ab5d-07e488a453b1"
      unitRef="U_USD">5389000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_ceb89d88-898f-4474-84bd-552ee229dcf6"
      unitRef="U_USD">2495000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_3c41747c-0637-4cad-bf54-8462fd0c60bf"
      unitRef="U_USD">6562000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_0cc7a8ec-aae6-4d68-a4e9-fb4414e9b7e2"
      unitRef="U_USD">3174000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_88b49b08-40e1-4e21-8302-5613a820a3c7"
      unitRef="U_USD">12331000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      id="F_8cc6e194-cac6-4585-b5d5-8bdbe4a29929">P5Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      id="F_cd5ee5b2-7ff7-46f7-817a-2e506394e62c">P6M3D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      id="F_3ed80b0a-662f-45ce-bc3e-53c49efcb5f4">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="3"
      id="F_cb354804-9bdb-4f08-a215-7f5399a87d08"
      unitRef="U_pure">0.074</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="3"
      id="F_df33eedf-23f2-4d59-9d73-27a668d37d72"
      unitRef="U_pure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="3"
      id="F_765f28ef-de63-4938-a2a4-db45d49e0969"
      unitRef="U_pure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_8ba5f264-e1e3-43d7-80ae-64eee0a2f9b8">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, minimum annual payments under the Company&#x2019;s lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.787%;"/&gt;
        &lt;td style="width:2.078%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.132%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Lease Financing&lt;br/&gt;Obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;112,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Amounts representing interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Amounts representing lease payments under Boston lease&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Current portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Noncurrent portion of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_19eebe28-afcc-4908-9be7-d3c1fa13b07f"
      unitRef="U_USD">9642000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_48a7d1db-930e-42b9-a6fb-415852a540ff"
      unitRef="U_USD">9501000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_7f91ad23-9bb8-4e5d-a165-a34089d79d7c"
      unitRef="U_USD">12627000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_57b00481-21e3-4b5d-a718-4f5cd6e3ea2b"
      unitRef="U_USD">10504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_35a19fce-d58e-442c-865f-f122c0323fb2"
      unitRef="U_USD">10217000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_0342e386-3afd-4888-9162-8d6dc3e18cc0"
      unitRef="U_USD">59557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_a63be045-c3bf-4be0-9d2f-a26dd2881df6"
      unitRef="U_USD">112048000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_a0027f46-9898-4912-a977-828ec52244bb"
      unitRef="U_USD">6515000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <grts:OperatingLeasePaymentUnderTheBostonLease
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_4ce95655-0353-47fb-97bb-491454e8603e"
      unitRef="U_USD">79114000</grts:OperatingLeasePaymentUnderTheBostonLease>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_8dbcda3a-bbbc-4e7c-9deb-c77fd8bb3f19"
      unitRef="U_USD">26419000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_fa5acb11-a014-4cb6-a29b-c612b200f031"
      unitRef="U_USD">7483000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_500f1e45-7ab8-4137-b594-40281aa43a5d"
      unitRef="U_USD">18936000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <grts:MaximumMilestonePaymentObligation
      contextRef="C_a515cc3e-d845-485c-b8cd-9789fd8a095a"
      decimals="-5"
      id="F_605c874e-0e36-4ec4-ad4c-efdbf2cb983e"
      unitRef="U_USD">36400000</grts:MaximumMilestonePaymentObligation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c07bb700-a02f-45ab-9f15-e2c76e3747cf"
      decimals="-3"
      id="F_c13f3adc-6706-4b78-aace-b63e17224a44"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <grts:MaximumMilestonePaymentObligation
      contextRef="C_ffaa39a0-354a-45c2-b143-8dff6921739e"
      decimals="-5"
      id="F_fe44e997-8097-4901-801e-1bf8bd6eba75"
      unitRef="U_USD">34800000</grts:MaximumMilestonePaymentObligation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_aa671a96-949e-426a-b9d0-931244a1e019"
      decimals="-3"
      id="F_89c45632-b06e-4db5-8fdd-83d2b0662f1f"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cb381328-f186-4340-881a-c3901e4b4c64"
      decimals="-5"
      id="F_c440ba41-0dd4-431d-9e19-910582f84525"
      unitRef="U_USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_b69f87c2-bbda-4751-a898-df40578b3285">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7.	Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2seventy bio, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the Company entered into a Research Collaboration and License Agreement with bluebird bio, Inc. (&#x201c;bluebird&#x201d;). In November 2021, bluebird assigned the Research Collaboration and License Agreement (the &#x201c;2seventy Agreement&#x201d;), to its affiliate, 2seventy bio, Inc. (&#x201c;2seventy&#x201d;), in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of the 2seventy Agreement, the Company provides to 2seventy tumor-specific targets across several tumor types and, in certain cases, T cell receptors (&#x201c;TCR&#x201d;) directed to those targets. The Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and 2seventy also concurrently acquired &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;768,115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s Series C convertible preferred stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. Per the 2seventy Agreement, 2seventy was also provided an option to acquire shares of the Company&#x2019;s common stock at the same price as all other investors in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;). In October 2018, 2seventy purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;666,667&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock at the price to the public of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Under the terms of the 2seventy Agreement, the Company is eligible to earn development, regulatory, and sales-based milestones in an amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; billion, and single-digit royalties on sales of products that utilize the technology subject to the 2seventy Agreement. None of these events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2019, the Company entered &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;into a First Amendment to the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2seventy&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Agreement, which extended the timeline for the Company and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2seventy &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;to execute a Patient Selection Services Agreement from within one year to within two years after the Effective Date of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2seventy&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Agreement. In August 2020, the Company entered into a Second Amendment, which extended the timeline of the Patient Selection Services Agreement to within three years and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;also extended the Tissue Analysis Period from February 28, 2021 to June 30, 2021. In April 2021, the Company entered into a Third Amendment, which removed the Patient Selection Services Agreement in its entirety and extended the Tissue Analysis Period from June 30, 2021 to December 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;amendments were entered into for administrative purposes, and the Company determined the amendments were not a modification of contract under the contract with customers guidance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2seventy may terminate the 2seventy Agreement by giving a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the last payment owed by the Company on a licensed product. The 2seventy Agreement may be terminated for cause by either party based on uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to 2seventy under the licensed intellectual property will remain in effect in accordance with their respective terms. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% for the remainder of the agreement term.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that 2seventy is a customer, and the contract is not subject to guidance on collaborative arrangements. This is because the Company granted to 2seventy a license to its intellectual property and provided research and development services, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company identified the following three material promises under the 2seventy Agreement: 1) transfer of a license to intellectual property and related technology know-how (&#x201c;License and Know-How&#x201d;); 2) the obligation to perform target selection and TCR generation services (&#x201c;Research and Development Services&#x201d;); and 3) participation on the Joint Steering Committee (the &#x201c;JSC&#x201d;). The Company provided to 2seventy standard indemnification and protection of licensed intellectual property, which is part of assurance that the license meets the contract&#x2019;s specifications and is not an obligation to provide goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered that the License and Know-How has standalone functionality, was considered to be functional intellectual property, and is capable of being distinct. However, the Company determined that the License and Know-How is not distinct from the Research and Development Services or participation on the JSC within the context of the 2seventy Agreement, because 2seventy is dependent on the Company to execute the Research and Development Services and participate on the JSC in order for 2seventy to benefit from the License and Know-How. As such, the License and Know-How is combined with the Research and Development Services and participation on the JSC into a single performance obligation, and the transaction price under this arrangement will be allocated to this single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has also determined that all other goods or services that are contingent upon 2seventy reaching various milestones are not considered performance obligations at the inception of the arrangement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price at the inception of the 2seventy Agreement consisted of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million received from 2seventy for the purchase of the Company&#x2019;s Series C convertible preferred stock. The sale of the Series C convertible preferred stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $10.0 million of the transaction price was allocated to the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;768,115&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series C convertible preferred stock at fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and recorded in stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The variable consideration related to the remaining development, regulatory, and sales-based milestones payments has not been included in the initial transaction price and continues to be fully constrained as of December 31, 2021. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestones is outside the control of the Company and contingent upon initiation of clinical trials for early-stage targets and 2seventy&#x2019;s development efforts. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the License and Know-How granted to 2seventy. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For revenue recognition purposes, the Company determined that the duration of the 2seventy Agreement began on the effective date in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and ends upon completion of the Research and Development Services, which is also when the participation on the JSC is no longer an obligation. The contract duration is defined as the period in which parties to the contract have present enforceable rights and obligations. The Company also analyzed the impact of 2seventy terminating the agreement prior to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to 2seventy for doing so.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue is recognized when, or as, the Company satisfies its performance obligation by transferring the promised services to 2seventy. Revenue is being recognized over time using a cost-based input method, based on internal labor cost effort to perform the research services, since the internal labor cost incurred over time is thought to best reflect the transfer of services to 2seventy. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021, 2020 and 2019, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in collaboration revenue under the 2seventy Agreement.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded on the consolidated balance sheets in both current and long-term liabilities as of December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue relates to the performance obligations identified under the 2seventy Agreement and will be recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through mid-2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.694%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:15.796%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; receivables or net contract assets recorded as of December 31, 2021 or 2020 associated with the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2seventy Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Gilead Sciences, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2021, the Company entered into a Collaboration, Option and License Agreement (the &#x201c;Gilead Collaboration Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;) to research and develop a vaccine-based immunotherapy as part of Gilead&#x2019;s efforts to find a curative treatment for HIV infection. Under the terms of the Gilead Collaboration Agreement, the Company granted to Gilead an exclusive, worldwide license to develop and commercialize a HIV-specific therapeutic vaccine utilizing the Company&#x2019;s technology. Gilead is responsible for conducting all development and commercialization activities beginning with a Phase 1 study, and the Company is responsible for contributing to preclinical research studies and participation in a joint steering committee (collectively, &#x201c;research and development activities&#x201d;). Concurrently with execution of the Gilead Collaboration Agreement, the Company and Gilead entered into a Supply Agreement (the &#x201c;Gilead Supply Agreement&#x201d;) under which the Company will supply research product and GMP product (&#x201c;Product Supply&#x201d;) that may be required under the Gilead Collaboration Agreement until Gilead completes its first GMP product batch, and the Company will participate in a joint manufacturing team (collectively, &#x201c;product supply activities&#x201d;). In addition, the Company also concurrently entered into a Stock Purchase Agreement (the &#x201c;Gilead Stock Purchase Agreement&#x201d;) under which Gilead acquired, in a private placement transaction, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,169,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. The common shares were issued to Gilead with certain registration rights and certain standstill and market stand-off provisions. The Company determined that these concurrent contracts represent a combined arrangement (&#x201c;the Gilead Arrangement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Gilead Collaboration Agreement, the Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Under the Gilead Collaboration Agreement and the Gilead Supply Agreement, the Company will receive additional reimbursement payments for expenses incurred in the research and development activities and product supply activities. Under the Gilead Stock Purchase Agreement, the common shares were sold at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s common stock at fair value on closing was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If Gilead decides to move forward with development beyond the initial Phase 1 study (the &#x201c;Option&#x201d;), the Company will receive a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million non-refundable option fee and will be eligible to receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;685.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million if certain clinical, regulatory and commercial milestones are achieved, as well as tiered royalties ranging from the mid-single digits to low double-digits on net sales of a therapeutic product utilizing its technology. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None of these events had occurred as of December 31, 2021 and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gilead &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;may terminate the Gilead Collaboration Agreement for convenience by giving a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-day prior written notice to the Company at any time after the effective date of the agreement. Unless terminated early, the agreement has a term that ends upon the expiration of the royalty term, or, if the Option is not exercised, by the end of the Option term. The Gilead Collaboration Agreement may be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or patent challenge. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses will terminate. The licenses granted by the Company to Gilead under the licensed intellectual property will remain in effect in accordance with their respective terms. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% for the remainder of the agreement term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Furthermore, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that Gilead is a customer and therefore revenue recognition should be accounted for in accordance with ASC 606, because the Company granted to Gilead licenses to its intellectual property and will provide research and development services and Supply of Product, as defined below, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration. The Option, if exercised by Gilead, will be considered a modification that increases the scope of the arrangement beyond the Option Term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company identified the following performance obligations under the Gilead Collaboration Agreement: 1) licenses including an exclusive (in the HIV field), royalty-free, worldwide collaboration license and transfer of know-how and an exclusive (in the HIV field) worldwide, royalty-bearing development and commercial license subject to restrictions on its use during the Option Term and an exclusive option to release such restrictions; 2) preclinical research and development activities, manufacturing-related activities, and participation on a Joint Steering Committee; and 3) product supply, including research and GMP product, until Gilead completes its first GMP batch, and participation on a Joint Manufacturing Team.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered that the licenses and know-how have standalone functionality, are considered to be functional intellectual property and are capable of being distinct. The Company also determined that the research and development activities and product supply by Gritstone could be provided by resources otherwise available to Gilead and thus are capable of being distinct.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has also determined that the pricing for optional goods and services and release of license restrictions upon exercise of the Option do not constitute material rights and are not a potential performance obligation. The Company evaluated whether there is an interdependence between the promises and determined that the licenses are a combined solution and the predominant performance obligation, while the other promises are separately identifiable in the context of the contract; however, the research and development activities are dependent on the research product supply, which is accounted for as a combined performance obligation. As a result, the Company identified three performance obligations in the Gilead Arrangement: (i) exclusive licenses and know-how, (ii) research and development activities and product supply, and (iii) GMP product supply.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price at the inception of the Gilead Collaboration Agreement consisted of the upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million received for the sale of the Company&#x2019;s common stock. The sale of the common stock was not considered to be a performance obligation, as it was a separate financing component of the transaction. Accordingly, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the transaction price was allocated to the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,169,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;shares of the Company&#x2019;s common stock at fair value on closing of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and recorded in stockholders&#x2019; equity. The remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the common stock purchase price in excess of the fair value of the shares received is added to the transaction price for the Gilead Collaboration Agreement. In addition, the initial transaction price includes estimated variable consideration for budgeted reimbursement of research and development costs and product supply. The variable consideration related to reimbursable costs and product supply has been constrained as of December 31, 2021 based on the current research and development plan forecast. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determined that the variable consideration for the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million option exercise fee and for the development, regulatory, and sales-based milestones payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were not included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the exclusive licenses and know-how granted to Gilead.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price is allocated to the performance obligation based upon relative standalone selling prices, which were determined for the exclusive licenses and know-how using an adjusted market approach and for the research and development activities and product supply using a cost plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and ends upon (i) the completion of the Option term, which is expected to end &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7ed2197d-60a0-4b30-bddb-51e4f0d30759;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; after the effective date, if the Option is not exercised or (ii) the expiration of the royalty-term on a product-by-product and country-by-country basis. The Company also analyzed the impact of Gilead terminating the agreement prior to the end of the Option term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Gilead for doing so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue for the exclusive licenses and know-how was recognized on the effective date of the Gilead Collaboration Agreement at the point in time that the licenses are effective. The research and development activities and product combined performance obligation and the GMP product supply performance obligation are recognized over time when, or as, the Company transfers the promised goods&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and services to Gilead. Research and development service and product supply revenues will be recognized over time using a cost-based input method, based on internal and external labor cost effort to perform the services, costs to acquire research materials, and costs of product supply, since the costs incurred over time are thought to best reflect the transfer of goods and services to Gilead. In applying a cost-based input method of revenue recognition, we use actual costs incurred relative to estimated total costs to fulfill each performance obligation. A cost-based input method of revenue recognition requires us to make estimates of costs to complete the performance obligation. The cumulative effect of any revisions to estimated costs to complete the performance obligation and associated variable consideration will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the year ended December 31, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as license revenue, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as collaboration revenue as a&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;result of satisfying its performance obligations by transferring the promised goods and services estimated by the costs incurred for the Gilead Collaboration Agreement. A contract asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 for supply costs that were incurred during the year ended December 31, 2021, but not billable until future periods when the asset is released. The contract asset relates to the performance obligations yet to be satisfied under the Gilead Collaboration Agreement and is being recognized over the period the performance obligations are expected to be satisfied, which is currently estimated to be through December 2022. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; contract asset as of December 31, 2020, and there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; deferred revenue as of December 31, 2021 and 2020 associated with the Gilead Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the contract asset and deferred revenue balance during the year ended December 31, 2021 for the Gilead Collaboration Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.679%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contract Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There was $0.7 million of receivables recorded on the consolidated balance sheet as a current asset in the prepaid expenses and other current assets balance as of December 31, 2021 and there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; receivables or net contract assets recorded as of December 31, 2020 associated with the Gilead Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company deferred $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in incremental costs to acquire the Gilead Collaboration Agreement in the first quarter of 2021 allocated to performance obligations recognized over time, which will be recognized over time in each period proportionate to revenue recognition. As of December 31, 2021, deferred contract acquisition costs were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Deferred contract acquisition costs amortized during the year ended December 31, 2021 were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Arbutus Biopharma Corporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2017, the Company entered into an Exclusive License Agreement with Arbutus and its wholly-owned subsidiary, Protiva Biotherapeutics Inc. Certain terms of the agreement were modified by amendment in July 2018. Under the license agreement, the Company has an exclusive license to utilize certain Arbutus intellectual property, including patents and know-how relating to immunotherapy. During the years ended December 31, 2021 and 2020, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; research and development expense under the agreement. During 2019, the Company reimbursed Arbutus for materials and personnel costs totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company is obligated to pay Arbutus certain milestone payments up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;123.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million on achievement of specified events, and royalties on sales of its licensed products. Following the acceptance of our investigational new drug application for GRANITE by the FDA, the Company made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million development milestone payment to Arbutus in September 2018 that was recorded as research and development expense. In August 2019, a milestone was met following the initial patient treatment of SLATE in the Company&#x2019;s GO-005 clinical trial. In 2019, the Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as research and development expense in connection with the milestone. None of the other events had occurred as of December 31, 2021, and no royalties were due from the sale of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Non-Profit Hospital Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2016, the Company entered into an Exclusive License Agreement with a non-profit hospital cancer center. Under the license agreement, the Company has an exclusive license to utilize certain patents and know-how relating to immunotherapy for an&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;immaterial upfront payment, cash milestone payments on achievement of specified events, and a low single digit royalty on sales of licensed products. The achievement of the milestones and payment of royalties is dependent upon obtaining regulatory approval. None of the other milestone events had occurred as of December 31, 2021 and no royalties were due from the sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Genevant Sciences GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the 2020 Genevant License Agreement, Genevant granted the Company exclusive license rights under certain intellectual property related to Genevant&#x2019;s lipid nanoparticle, or LNP, technology for a single therapeutic indication, and the Company agreed to pay Genevant an initial payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in specified development, regulatory, and commercial milestones, and low to mid-single digit royalties on net sales of licensed products. The upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was included in research and development expense for the year ended December 31, 2020. The 2020 Genevant License Agreement expands Gritstone&#x2019;s intellectual property rights to such LNP technology originally obtained pursuant to the Company&#x2019;s license agreement with Arbutus. Genevant is a spin-off of Arbutus. Prior to the 2020 Genevant License Agreement, the Company licensed Arbutus&#x2019; LNP technology for indications in the oncology space. The remainder of Arbutus&#x2019; IP portfolio was transferred to Genevant in the spin-off.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the 2020 Genevant License Agreement, Genevant also granted the Company certain options to license the LNP technology for additional therapeutic indications of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for each indication and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to extend the option term. The 2020 Genevant License Agreement continues in effect until the last to expire royalty term or early termination. It is terminable by the Company for convenience with 90 days prior written notice or immediately if based on certain product safety or efficacy or regulatory criteria. Either party may terminate the agreement for material breach, subject to a cure period, and Genevant may terminate the agreement if the Company challenges a licensed patent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the 2021 Genevant License Agreement, the Company obtained a nonexclusive license to Genevant&#x2019;s LNP technology to develop and commercialize self-amplifying RNA (&#x201c;samRNA&#x201d;) vaccines against SARS-CoV-2, the virus that causes COVID-19. Under the 2021 Genevant License Agreement, the Company made a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment to Genevant, and Genevant is eligible to receive from the Company up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;166.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in contingent milestone payments per product, plus certain tiered royalties, upon achievement of development and commercial milestones. In certain scenarios, in lieu of milestones and royalties, Genevant will be entitled to a percentage of amounts that the Company receives from sublicenses under the 2021 Genevant License Agreement, subject to certain conditions. In March 2021, a milestone in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was met following the initial patient treatment in the Phase 1 clinical trial conducted through the NIAID-supported IDCRC. Both the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million milestone payments were recorded as research and development expense during the year ended December 31, 2021. None of the other milestone events had occurred as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Coalition for Epidemic Preparedness Innovations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On August 14, 2021, the Company entered into the CEPI Funding Agreement with CEPI, under which CEPI agreed to provide funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to the Company to advance the Company&#x2019;s CORAL program, which is developing a second-generation COVID-19 vaccine, with an initial clinical trial in South Africa. Under the terms of the agreement, CEPI will fund a multi-arm Phase 1 study evaluating the CORAL program&#x2019;s samRNA vaccine in na&#xef;ve, convalescent, and HIV+ patients. The study will evaluate two different samRNA vaccine constructs that each target both the spike protein and other SARS-CoV-2 targets and are designed to drive both robust B and T cell immune responses. The funding will also support pre-clinical studies, scale-up and formulation development to enable manufacturing of large quantities of stable vaccine product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the terms of the CEPI Funding Agreement, among other things, the Company and CEPI agreed on the importance of global equitable access to the vaccine produced pursuant to the CEPI Funding Agreement. The vaccine, if approved, is expected to be made available to the COVAX Facility for procurement and allocation. The COVAX Facility aims to deliver equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The scope and continuation of the CEPI Funding Agreement may be amended depending on ongoing developments of the COVID-19 outbreak and the success of the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement relative to other third-party COVID-19 vaccine candidates or treatments. If the World Health Organization (WHO), CEPI or a regulatory authority having jurisdiction over a clinical trial performed under the CEPI Funding Agreement determines that a third-party product candidate has substantially greater potential than the Company&#x2019;s COVID-19 vaccine candidate developed under the CEPI Funding Agreement and should be prioritized instead for a particular trial, the Company must consider in good faith any written request of CEPI not to proceed with a clinical trial of such COVID-19 vaccine candidate (the determination of whether to proceed or not with such trial&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;shall be made by the Company in its sole discretion). In addition, CEPI has the right to unilaterally terminate the CEPI Funding Agreement upon prior written notice if CEPI determines that (i) there are material safety, regulatory, scientific misconduct or ethical issues with the project undertaken by the Company under the CEPI Funding Agreement, (ii) the project undertaken by the Company under the CEPI Funding Agreement should be terminated, (iii) the Company becomes unable to discharge its obligations under the CEPI Funding Agreement, (iv) the Company fails to meet certain criteria set forth in the CEPI Funding Agreement, or (v) the Company commits fraud or a financial irregularity, as such terms are defined in the CEPI Funding Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company and CEPI entered into an amendment to the CEPI Funding Agreement, under which CEPI agreed to provide additional funding up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, for a total of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, to the Company to conduct a Phase I clinical trial of the Company's Omicron vaccine candidate in South Africa.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;CEPI advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the CEPI Funding Agreement. The first tranche of funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was received in September 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the CEPI Funding Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. In the year 2021, the Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the CEPI Funding Agreement. As of December 31, 2021, short term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through the end of the year 2022. As of December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded as short-term restricted cash on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 for the CEPI Funding Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.095%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.112%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Gates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021, the Company entered into a Grant Agreement with the Gates Foundation, under which the Company will develop an optimal immunogen in the context of a therapeutic Human papillomavirus (HPV) vaccine. In consideration for the work to be performed, the Gates Foundation provided the Company with an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in December 2021, and future funding of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million is expected to be received by the Company in February 2023, for a total grant amount of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future performance are deferred and recognized as grant revenue when the research and development activities are performed. Cash payments received under the Grant Agreement are restricted as to their use until expenditures contemplated in the funding agreement are incurred. For the year ended 2021, the Company did not recognize any grant revenue under the Grant Agreement. As of December 31, 2021, short term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and long term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million were recorded on the consolidated balance sheet. Deferred revenue will be recognized over the period in which the funding agreement activities related to the first tranche of funding are expected to take place, which is currently estimated to be through early 2023.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 for the Grant Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.239%;"/&gt;
        &lt;td style="width:1.874%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:17.078%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_dcafcdf1-b545-44ea-b0b0-4e5a82dc1960"
      decimals="-5"
      id="F_f593e008-176c-43e9-b77f-102d1f3b25df"
      unitRef="U_USD">20000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1384cd70-847e-4634-a2fe-da83db33a119"
      decimals="INF"
      id="F_9c05d3c4-f55c-4ec1-b108-892f32ea774b"
      unitRef="U_shares">768115</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_40de9285-a41b-4aba-b67e-ff00d1385e17"
      decimals="-5"
      id="F_2b3d3541-0a69-4dbc-9424-65d1cc4656ba"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_1384cd70-847e-4634-a2fe-da83db33a119"
      decimals="2"
      id="F_fc875cac-d98a-4987-8167-c8d369c194e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.04</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7"
      decimals="INF"
      id="F_2256c1d2-202f-4a9d-8a22-463f6ef6a346"
      unitRef="U_shares">666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_85575cb7-32f7-42d3-a21b-cb91af13687d"
      decimals="2"
      id="F_a973790e-7eed-4706-851f-fc17a44a206e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8e5e468d-b07b-48ab-9a68-77eb950ebbe7"
      decimals="-5"
      id="F_99b9564d-7f9c-41bf-a9f7-bd0b2d635192"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:MaximumPotentialMilestoneReceivable
      contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b"
      decimals="-8"
      id="F_a89d860e-4e41-4e55-b07b-f095b927a7f8"
      unitRef="U_USD">1200000000</grts:MaximumPotentialMilestoneReceivable>
    <grts:CollaborationAgreementEarlyTerminationNoticePeriod
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      id="F_ed0daaf8-47b1-4fa9-a863-60c53d92d9eb">P120D</grts:CollaborationAgreementEarlyTerminationNoticePeriod>
    <grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      id="F_5fa05142-cc6e-4cfd-a04b-d7e6b3f7819b">Additionally, all of 2seventy&#x2019;s payment obligations that have not yet accrued related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments>
    <grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage
      contextRef="C_4fc2caf3-8c25-4dd7-9e8b-1761b10a0822"
      decimals="2"
      id="F_8aca8622-90c0-4ccc-b704-cc62ea133cb1"
      unitRef="U_pure">0.50</grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_307b7ee6-24f5-4623-9dd7-769942f70dba"
      decimals="-5"
      id="F_32b2d1a6-21f1-410e-91cf-a4ac3d68e7e4"
      unitRef="U_USD">20000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_307b7ee6-24f5-4623-9dd7-769942f70dba"
      decimals="-5"
      id="F_02b1c807-9e7d-4282-8042-e26c5f327af4"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e99ad520-a6db-4e84-b622-e394b918c047"
      decimals="INF"
      id="F_7260804e-29d9-4937-ac46-0a32a82e7393"
      unitRef="U_shares">768115</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e99ad520-a6db-4e84-b622-e394b918c047"
      decimals="2"
      id="F_b08f2f33-d0e5-4673-868f-126a97ce44c9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.04</us-gaap:SaleOfStockPricePerShare>
    <grts:RevenueRecognitionContractStartMonthYear
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      id="F_0ab088f0-c779-4167-9f19-fe4e8978dba5">2018-08</grts:RevenueRecognitionContractStartMonthYear>
    <grts:RevenueRecognitionContractEndMonthYear
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      id="F_5bf8e29c-ea9f-4a22-a6fa-821065fe5f37">2023-08</grts:RevenueRecognitionContractEndMonthYear>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      decimals="-5"
      id="F_2a57e380-f5b3-4646-9d9d-6968835ec809"
      unitRef="U_USD">3000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_a36dfa2d-b3cc-41ba-867f-9bc54ef71a20"
      decimals="-5"
      id="F_d4fa9a79-dc9e-4eb4-a7ca-9a4ce545340c"
      unitRef="U_USD">2800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_8869555a-bdc4-45c5-bdd1-ae2de6f84ba3"
      decimals="-5"
      id="F_932e96a5-3863-4d75-bdb6-7d760ffd2c15"
      unitRef="U_USD">4300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b"
      decimals="-5"
      id="F_ce3009a4-3e45-4266-8d50-f9375146c45c"
      unitRef="U_USD">8700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed"
      decimals="-5"
      id="F_0a1b90e2-3174-4aa8-af72-8505d0ab3a00"
      unitRef="U_USD">11700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_64144ed4-7156-4df6-9ed4-71edcffd2730"
      id="F_f9c33ed0-0dfd-4173-9f10-68808e9b53bc">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.694%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:15.796%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.753%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db"
      decimals="-3"
      id="F_d24b4a40-9fb8-4d74-b872-57258d01fdaa"
      unitRef="U_USD">11695000</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_79ced502-684c-452e-a1e7-6fcb8df0fce8"
      decimals="-3"
      id="F_2cb7b7ee-f3ca-465f-8a83-63943f2d8836"
      unitRef="U_USD">0</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_79ced502-684c-452e-a1e7-6fcb8df0fce8"
      decimals="-3"
      id="F_5aa68b47-40e8-4201-b96a-7d236e8b5fdd"
      unitRef="U_USD">-2970000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4be9d25f-8253-43d1-96f9-812aa91da2ec"
      decimals="-3"
      id="F_bcb63bdd-62c8-4861-8fa3-23d9b9cb939a"
      unitRef="U_USD">8725000</us-gaap:ContractWithCustomerLiability>
    <grts:ReceivablesGross
      contextRef="C_ed705e9f-0546-480a-9f48-a5ee2b641d9b"
      decimals="INF"
      id="F_07d62df3-1067-43a3-b955-e09083e38df8"
      unitRef="U_USD">0</grts:ReceivablesGross>
    <grts:ReceivablesGross
      contextRef="C_5ad2b3b8-01af-4264-b0a3-bb08be59a2ed"
      decimals="INF"
      id="F_ad3552c3-23af-45b4-8141-e35c22d9e28a"
      unitRef="U_USD">0</grts:ReceivablesGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7b303347-0a5e-49c6-ac04-186377f96bd4"
      decimals="INF"
      id="F_eb9b9f20-6323-49c0-981f-b2f27ffc706e"
      unitRef="U_shares">1169591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_e35531b4-4a99-42aa-8bcf-1621b44bd12d"
      unitRef="U_USD">30000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="2"
      id="F_c194d2dd-6b6f-4535-9c06-87b9e86fce46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_d535b527-0a63-413d-99be-182a52c66bbc"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <grts:CommonStockFairValueClosingPricePerShare
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="2"
      id="F_87450d7a-7862-44f6-b1cd-8c382baa1ce8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.10</grts:CommonStockFairValueClosingPricePerShare>
    <grts:NonRefundableOptionFee
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="-5"
      id="F_fd776dca-3963-4920-8367-f1c6cdb09084"
      unitRef="U_USD">40000000.0</grts:NonRefundableOptionFee>
    <grts:MaximumAggregateContingentMilestonePayment
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="-5"
      id="F_343b55fe-494c-40de-9575-b9f275c26e88"
      unitRef="U_USD">685000000.0</grts:MaximumAggregateContingentMilestonePayment>
    <grts:CollaborationAgreementEarlyTerminationNoticePeriod
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      id="F_4a677fb8-c05a-4393-8785-e7bb39066f1d">P90D</grts:CollaborationAgreementEarlyTerminationNoticePeriod>
    <grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      id="F_9ffb3304-0175-48b4-bf84-935c6f31fb64">Additionally, if terminated early by Gilead for convenience or by the Company for material breach or insolvency, all of Gilead&#x2019;s payment obligations for reimbursable costs or for future milestone and royalty payments remain. If terminated early by Gilead for material breach or insolvency, all of Gilead&#x2019;s unaccrued payment obligations related to future milestone and royalty payments will be reduced by 50% for the remainder of the agreement term.</grts:EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments>
    <grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage
      contextRef="C_d0e07771-0a34-485d-8679-411afed4e92f"
      decimals="2"
      id="F_8bbbcd0e-f553-4e9d-ae39-f6614f849f8d"
      unitRef="U_pure">0.50</grts:FutureMilestoneAndRoyaltyPaymentsReductionPercentage>
    <grts:CollaborationAgreementTerminationTerm
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      id="F_26edfe48-8f36-4932-939d-f19654fa1612">Gilead may terminate the Gilead Supply Agreement without cause by giving six months prior written notice and any active orders with 60-day notice without terminating the agreement, and either party may terminate based on an uncured material breach, insolvency of the other party, or in the event that the Gilead Collaboration Agreement is terminated. Upon termination, the Company will deliver all supply products that have been produced and destroy, reimburse or deliver materials that Gilead has reimbursed, and Gilead must pay for any manufacturing costs that the Company has actually incurred or committed to pay, including any cancellation costs owed to subcontractors.</grts:CollaborationAgreementTerminationTerm>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_02e62ba6-d93c-4655-826f-ddb6d2cdd91c"
      unitRef="U_USD">30000000.0</grts:ProceedsFromNonRefundableUpfrontPayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_59300fa9-a0d2-4dbb-a239-9bccb73a6b99"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_ee2ba6fe-8481-4854-a340-91e466f43124"
      unitRef="U_USD">21200000</grts:TransactionPriceAllocatedToSharesOfCommonStockAtFairValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="INF"
      id="F_f6f784d6-76b6-46e1-b409-6fa46251676f"
      unitRef="U_shares">1169591</us-gaap:CommonStockSharesIssued>
    <grts:CommonStockFairValueClosingPricePerShare
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="2"
      id="F_04aec871-81a9-40b8-a1d8-4fd5daedf5f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.10</grts:CommonStockFairValueClosingPricePerShare>
    <grts:CommonStockPurchasePriceInExcessOfFairValue1
      contextRef="C_817472bf-f8f1-43c2-a0d3-5d601d69a222"
      decimals="-5"
      id="F_e29651ec-f811-4ff4-999b-0940498d401d"
      unitRef="U_USD">8800000</grts:CommonStockPurchasePriceInExcessOfFairValue1>
    <grts:NonRefundableOptionFee
      contextRef="C_996cd399-bd9d-4157-a800-02de52cbb53e"
      decimals="-5"
      id="F_030d18ee-ef33-4a4c-bad3-1f1b1852449b"
      unitRef="U_USD">40000000.0</grts:NonRefundableOptionFee>
    <grts:RevenueRecognitionContractStartMonthYear
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      id="F_27faf330-2f34-4785-8c09-dd200873659c">2021-01</grts:RevenueRecognitionContractStartMonthYear>
    <grts:RevenueRecognitionContractEndPeriod
      contextRef="C_566f53db-f8e8-41fd-9b20-dcbb06f27fc9"
      id="F_cf520b27-36ae-4ba7-8b7b-56512235877a">P4Y</grts:RevenueRecognitionContractEndPeriod>
    <grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod
      contextRef="C_ab352646-a87b-4f45-b887-2a58f2cb2c1b"
      decimals="-5"
      id="F_6d0adce6-9e85-4cb1-80cf-8b418eb02e0a"
      unitRef="U_USD">38600000</grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod>
    <grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      decimals="-5"
      id="F_721623aa-e790-49f7-b312-a0a05be51be9"
      unitRef="U_USD">5100000</grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a"
      decimals="-5"
      id="F_631ba071-68bd-47ca-b882-bf6fe78242e6"
      unitRef="U_USD">1400000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"
      decimals="-3"
      id="F_fd30fd83-c4b1-4a6d-9490-b2856c08388d"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a"
      decimals="-3"
      id="F_26d65c72-5ab8-4c52-a5e7-bae4184cbc3d"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"
      decimals="-3"
      id="F_1ab81764-e16b-4f2a-97c8-706d07741c56"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      id="F_a9b9b92c-9d52-47a8-9ada-8d27487983c0">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the contract asset and deferred revenue balance during the year ended December 31, 2021 for the Gilead Collaboration Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.679%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contract Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"
      decimals="-3"
      id="F_3fa5b02f-71f6-4f0d-a703-e3773b490b29"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"
      decimals="-3"
      id="F_63587b1f-843b-43f5-885e-d108c5247f1f"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerAssetAddition
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      decimals="-3"
      id="F_5c488f85-eb50-466c-abb8-d9f42475ead4"
      unitRef="U_USD">5055000</grts:ContractWithCustomerAssetAddition>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      decimals="-3"
      id="F_32ee75d5-c0ea-4d3a-82fc-06f43624e0f7"
      unitRef="U_USD">220000</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerAssetDeduction
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      decimals="-3"
      id="F_b69dc24e-4fc8-420d-aa5a-02e42ad26b7c"
      unitRef="U_USD">3670000</grts:ContractWithCustomerAssetDeduction>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_d3fd5a39-9946-4c81-bb8a-5779b8a9f865"
      decimals="-3"
      id="F_f5892e83-0d91-430d-9115-4bc8ecfbcde1"
      unitRef="U_USD">220000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a"
      decimals="-3"
      id="F_c046944c-16d5-469b-999f-a4786f91b3f9"
      unitRef="U_USD">1385000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_9ff103bb-5e1f-4e17-baa5-7a535845418a"
      decimals="-3"
      id="F_baabb814-4d4e-4330-a294-f629bd2302b9"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <grts:ReceivablesGross
      contextRef="C_c1a206a0-0c5d-488d-8f91-92aaeff32126"
      decimals="-3"
      id="F_d43940ba-05c3-4798-af71-2a5b6915c4cb"
      unitRef="U_USD">0</grts:ReceivablesGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_ea27018b-ae35-4896-958f-8b3ad75d9f1b"
      decimals="-5"
      id="F_72568fa1-76d5-4e3a-be9d-2cda551969a5"
      unitRef="U_USD">100000</us-gaap:CapitalizedContractCostGross>
    <grts:DeferredContractAcquisitionCosts
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_9f7b52d6-25c8-41b1-bf81-a878fbdafa3c"
      unitRef="U_USD">0</grts:DeferredContractAcquisitionCosts>
    <grts:DeferredContractAcquisitionCostsAmortized
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_3558b080-d6b6-4b06-ac2f-7c8f6e480a9c"
      unitRef="U_USD">100000</grts:DeferredContractAcquisitionCostsAmortized>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4b447ec2-ed8d-4932-a1c9-f1211bf27f20"
      decimals="-3"
      id="F_97ce0310-d5e5-4d19-b55b-b27b6aad9a0b"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_80c30ec9-ef76-40b1-9254-a26ab087e7c8"
      decimals="-3"
      id="F_75cfb9a6-63a1-4e6b-9d87-345642ba8a1d"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <grts:ReimbursementsExpenseMaterialsAndPersonnelCosts
      contextRef="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b"
      decimals="-5"
      id="F_73af8bc5-5d4b-4676-b7ba-b7d20f97bb37"
      unitRef="U_USD">400000</grts:ReimbursementsExpenseMaterialsAndPersonnelCosts>
    <grts:MaximumMilestoneConsiderationPayable
      contextRef="C_a063016e-88e5-4a22-8611-b5879f0bd30e"
      decimals="-5"
      id="F_e735f7b8-bbab-4184-b20d-5627b2fd384c"
      unitRef="U_USD">123500000</grts:MaximumMilestoneConsiderationPayable>
    <grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense
      contextRef="C_5903b0b4-0f34-4cd1-947d-816c01e6afad"
      decimals="-5"
      id="F_9c9ea952-6185-4a59-ac72-8caf5bdbd217"
      unitRef="U_USD">2500000</grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense>
    <grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense
      contextRef="C_2b950f0f-7472-4e9c-adc0-587c6d2cfd6b"
      decimals="-5"
      id="F_c7135272-c31c-4dab-903f-143a1059ad2e"
      unitRef="U_USD">3000000.0</grts:MilestonePaymentIncludedInResearchAndDevelopmentExpense>
    <grts:AgreedUpfrontPayment
      contextRef="C_5b09e940-512d-4b9b-95b7-0f7a00f1c739"
      decimals="-5"
      id="F_d9bb8265-87c0-4050-b9ad-4da3475b8a9d"
      unitRef="U_USD">2000000.0</grts:AgreedUpfrontPayment>
    <grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone
      contextRef="C_bdac7de3-d09c-4ab3-a235-9071478e89a2"
      decimals="-5"
      id="F_e8984ee0-0c4d-4227-882a-5bc0e6606187"
      unitRef="U_USD">71000000.0</grts:AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone>
    <grts:UpFrontPayment
      contextRef="C_42b8da6e-7442-4d11-94ba-d9fccabe6043"
      decimals="-5"
      id="F_e248adb2-9b0d-4cac-8636-b1716cea8d10"
      unitRef="U_USD">2000000.0</grts:UpFrontPayment>
    <grts:PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication
      contextRef="C_be96c1cb-cdd0-401f-9ffa-ba59e494db4a"
      decimals="-5"
      id="F_9924f9ed-847a-42bb-bd36-a67b618fd301"
      unitRef="U_USD">1500000</grts:PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication>
    <grts:AmountToExtendOptionTerm
      contextRef="C_fbb17c0d-cde0-48c5-b232-0304dab63e18"
      decimals="-5"
      id="F_dc741d10-2040-43c3-9927-7012130ef57d"
      unitRef="U_USD">1000000.0</grts:AmountToExtendOptionTerm>
    <grts:UpFrontPayment
      contextRef="C_746d448f-f9d9-418a-89b9-fbac99dc06ec"
      decimals="-5"
      id="F_620006c9-61dc-442f-a6ce-4c5d911448cb"
      unitRef="U_USD">1500000</grts:UpFrontPayment>
    <grts:MaximumAggregateContingentMilestonePaymentToBeMade
      contextRef="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5"
      decimals="-5"
      id="F_9ddda71f-f75f-432b-b42b-baf3b027198b"
      unitRef="U_USD">166000000.0</grts:MaximumAggregateContingentMilestonePaymentToBeMade>
    <grts:MilestonePayments
      contextRef="C_2e446cab-9db3-406f-bdfa-8e466af2e3e5"
      decimals="-5"
      id="F_6e169256-24a6-41bb-86d6-c552a8088b78"
      unitRef="U_USD">1000000.0</grts:MilestonePayments>
    <grts:UpFrontPayment
      contextRef="C_46f01538-745e-443b-9a6c-602d548493a0"
      decimals="-5"
      id="F_2baa1818-d570-484b-a18f-e9062f221fc1"
      unitRef="U_USD">1500000</grts:UpFrontPayment>
    <grts:MilestonePayments
      contextRef="C_fbee0f17-2c8f-479d-918b-1fd7ddd2f644"
      decimals="-5"
      id="F_10bccd06-cbfc-490c-bffd-fab6256f85bc"
      unitRef="U_USD">1000000.0</grts:MilestonePayments>
    <grts:InitialFundingDevelopmentCosts
      contextRef="C_a0bc0c98-2ff1-4535-99bd-4549d5704989"
      decimals="-5"
      id="F_428d49f7-640b-4df0-aaad-0d01a1087222"
      unitRef="U_USD">20600000</grts:InitialFundingDevelopmentCosts>
    <grts:AdditionalFunding
      contextRef="C_9e7aaa1c-e583-4583-8203-409c40fb2c09"
      decimals="-5"
      id="F_50b2d9d8-174f-468e-a769-2f673aa986d7"
      unitRef="U_USD">5000000.0</grts:AdditionalFunding>
    <grts:AgreementTotalFunding
      contextRef="C_9e7aaa1c-e583-4583-8203-409c40fb2c09"
      decimals="-5"
      id="F_aa7266e6-afb3-46ea-af95-a28f4d6119f4"
      unitRef="U_USD">25600000</grts:AgreementTotalFunding>
    <grts:FirstTrancheOfFundingsReceived
      contextRef="C_d0c0e728-d84d-443b-9b79-a400660a7213"
      decimals="-5"
      id="F_cadadd1d-db13-4a2d-9c98-ff6cbb13d77c"
      unitRef="U_USD">11300000</grts:FirstTrancheOfFundingsReceived>
    <grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod
      contextRef="C_1d814b55-408c-482f-b8ae-c5e423b0bacc"
      decimals="-5"
      id="F_a6b4b574-c73d-443c-b9c9-588937e02196"
      unitRef="U_USD">1500000</grts:ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_f1e134b6-2dd5-4505-b2e1-f8a94eb727dd"
      decimals="-5"
      id="F_54102434-b8e9-4d25-babb-e6fb55def1c7"
      unitRef="U_USD">9400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_f06431b0-ad9d-4b24-b848-3f92b0b32ce6"
      unitRef="U_USD">9400000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_af382cd1-7c55-4a5b-8f11-f6f806af4f5e"
      id="F_94c2e2b9-587a-4253-9c60-38c42a77163a">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 for the CEPI Funding Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.095%;"/&gt;
        &lt;td style="width:1.79%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.112%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2d463622-3449-495d-a283-ead7997ec267"
      decimals="-3"
      id="F_3f3a861f-a3e3-4862-85ba-1ffcff614949"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_a29305ba-c997-4325-90de-110968edf965"
      decimals="-3"
      id="F_001b6369-f1ed-452b-b096-3b2d29a41e76"
      unitRef="U_USD">11282000</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_a29305ba-c997-4325-90de-110968edf965"
      decimals="-3"
      id="F_fe3ece48-001f-4af2-bc4d-baa2ea96fe3c"
      unitRef="U_USD">-1903000</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_60b21bc0-099b-49d6-ab81-649520e924be"
      decimals="-3"
      id="F_3f1fb017-d14e-4872-8d0e-973ac9c20919"
      unitRef="U_USD">9379000</us-gaap:ContractWithCustomerLiability>
    <grts:ProceedsFromNonRefundableUpfrontPayment
      contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605"
      decimals="-5"
      id="F_de9c02f7-e0fa-4d0a-8f9d-0f20158ddb23"
      unitRef="U_USD">2200000</grts:ProceedsFromNonRefundableUpfrontPayment>
    <grts:FutureFundingExpected
      contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605"
      decimals="-5"
      id="F_03a6d040-f705-43bb-980b-0fffbc0bea1a"
      unitRef="U_USD">1000000.0</grts:FutureFundingExpected>
    <grts:FundingDevelopmentCosts
      contextRef="C_9ce3523e-57c4-4351-b586-64db47e52605"
      decimals="-5"
      id="F_d1fd0640-f152-48ce-8de6-3133351d9aad"
      unitRef="U_USD">3200000</grts:FundingDevelopmentCosts>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e"
      decimals="-5"
      id="F_f5999691-5e8b-4029-bc51-fde713b2d3a8"
      unitRef="U_USD">1900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e"
      decimals="-5"
      id="F_05ebbada-ce42-4f64-a8dd-9f99a3bac175"
      unitRef="U_USD">300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7"
      id="F_5a646893-be5b-4916-a18a-4661df30ab64">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in the deferred revenue balance during the year ended December 31, 2021 for the Grant Agreement are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.239%;"/&gt;
        &lt;td style="width:1.874%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:17.078%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_77affe5f-9a99-4ac8-acc3-0fad18eb1e3a"
      decimals="-3"
      id="F_73bd2323-2d40-420e-854b-97d1516fd5b9"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiability>
    <grts:ContractWithCustomerLiabilityAddition
      contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7"
      decimals="-3"
      id="F_aecdcc3a-6928-4869-8eb0-25a28a9462d8"
      unitRef="U_USD">2225000</grts:ContractWithCustomerLiabilityAddition>
    <grts:ContractWithCustomerLiabilityDeductions
      contextRef="C_90670968-8bdc-4930-a115-4ce5e59779c7"
      decimals="-3"
      id="F_3e7e2cd7-08fc-416f-8d03-595f4017619f"
      unitRef="U_USD">0</grts:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_07646176-7861-4b62-81ac-b15ae5bdb75e"
      decimals="-3"
      id="F_f61aa094-4000-4254-bec1-7c7602fd4829"
      unitRef="U_USD">2225000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_d5173466-4071-474b-82d9-4858deeb501a">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8.	Balance Sheet Components&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Prepaid Expenses and Other Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.551%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Collaboration receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest and other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deposits and Other Long-Term Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deposits and other long-term assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.551%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deposits and other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_edf5947d-d625-435e-9a61-e10cf118e81b">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.551%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Collaboration receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest and other receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <grts:PrepaidExpenseForResearchAndDevelopment
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_37a4911b-f07e-490d-b84e-c871cf2d7771"
      unitRef="U_USD">2672000</grts:PrepaidExpenseForResearchAndDevelopment>
    <grts:PrepaidExpenseForResearchAndDevelopment
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_118fb646-2fcb-43e1-9ff7-43aee186d48f"
      unitRef="U_USD">2584000</grts:PrepaidExpenseForResearchAndDevelopment>
    <grts:NetContractAsset
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_5274cd7a-1443-4f37-891f-4e00e1d858a6"
      unitRef="U_USD">1385000</grts:NetContractAsset>
    <grts:NetContractAsset
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_096d32d7-de93-491a-ace7-d6c47d718586"
      unitRef="U_USD">0</grts:NetContractAsset>
    <grts:CollaborationReceivable
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_46a9b041-8ea9-4680-8e94-6b22466ab2aa"
      unitRef="U_USD">688000</grts:CollaborationReceivable>
    <grts:CollaborationReceivable
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f206a7a9-aa27-4e39-baf1-2fa1d1c58041"
      unitRef="U_USD">0</grts:CollaborationReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_3f983f2b-8992-4ae3-b312-e888ac1b5da9"
      unitRef="U_USD">1769000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_2f202109-34fb-40db-a48b-d04ba316150e"
      unitRef="U_USD">1480000</us-gaap:PrepaidInsurance>
    <grts:InterestAndOtherReceivablesCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_65b3f819-a8b6-4fed-aad1-26c1fe202c04"
      unitRef="U_USD">292000</grts:InterestAndOtherReceivablesCurrent>
    <grts:InterestAndOtherReceivablesCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_8a413947-3254-481b-8b20-8e7e498fdaca"
      unitRef="U_USD">0</grts:InterestAndOtherReceivablesCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_101ead73-4adc-40c2-a0ab-7b38edb1d838"
      unitRef="U_USD">866000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_5e3e437e-b3b0-48b4-b53c-6d6eb343fb39"
      unitRef="U_USD">268000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_b7cc66ce-d147-4e94-a531-89947a49e5b9"
      unitRef="U_USD">7672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_d3fbb375-629d-4323-a5e5-4a281a196b1e"
      unitRef="U_USD">4332000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_07ab4581-605c-47dd-9ae7-cd485b470209">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deposits and other long-term assets consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.551%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.549%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.867%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease security deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid research and development-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deposits and other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:SecurityDeposit
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_8b26af62-288e-4b68-ae3d-66f3f2abcb5f"
      unitRef="U_USD">1305000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f2470b0c-94d4-4f29-9e72-91f7b6450dfc"
      unitRef="U_USD">1218000</us-gaap:SecurityDeposit>
    <grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_97ae0b72-d60b-4e23-87bc-971b22084637"
      unitRef="U_USD">1047000</grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent>
    <grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_db410430-f0e1-4c0a-b6be-5c8db86f87b1"
      unitRef="U_USD">518000</grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_1a4b1c23-1c2e-41e7-8306-f9f6eda7aaa0"
      unitRef="U_USD">2352000</grts:DepositsAndOtherAssetsNoncurrent>
    <grts:DepositsAndOtherAssetsNoncurrent
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_94bcbe0d-b0fd-417b-9e7e-be9cb6acf96c"
      unitRef="U_USD">1736000</grts:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_d0a7b3fb-3a87-45a7-bd12-2d691782ef33">&lt;p style="text-indent:-6.188%;padding-left:5.84%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.	Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s amended and restated certificate of incorporation provides for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock authorized for issuance, each with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,047,878&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,552,693&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock issued and outstanding, respectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Sale of Common Stock and Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2019, the Company filed a Registration Statement on Form S-3 (the &#x201c;2019 Shelf Registration Statement&#x201d;) with the SEC, covering the offering of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of common stock, preferred stock, debt securities, warrants and units. The 2019 Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company&#x2019;s common stock, from time to time, through the ATM Offering Program under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The SEC declared the 2019 Shelf Registration Statement effective on November 8, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2019, the Company also entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;) to sell shares of the Company&#x2019;s common stock, from time to time, with aggregate gross sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, through the ATM Offering Program, under which Cowen will act as its sales agent. Cowen is entitled to compensation for its services equal to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the gross proceeds of any shares of common stock sold through Cowen under the Sales Agreement. In addition, the Company has agreed to reimburse a portion of the expenses of Cowen in connection with the offering, up to a maximum of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the year ended December 31, 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,160,193&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock through its ATM Offering Program and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, net of commissions and other offering costs. During the year ended December 31, 2021, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,990,869&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock through its ATM Offering Program and received aggregate proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, net of commissions and other costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company entered into two private placement financing transactions (collectively, the &#x201c;First PIPE Financing&#x201d;), as follows: (1) pursuant to a securities purchase agreement entered into on December 22, 2020 to sell &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,543,351&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and pre-funded warrants (the &#x201c;Warrants&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,480,719&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share (of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share was prepaid by each purchaser), and (2) pursuant to a securities purchase agreement entered into on December 28, 2020, to sell an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,043,127&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.71&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In connection with the First PIPE Financing, the Company received aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;119.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting placement agent commissions and offering expenses payable by the Company. The Warrants are exercisable upon issuance at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The underwriter placement and legal fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to these two PIPE financing transactions were included in accounts payable and accrued liabilities on the consolidated balance sheet as of December 31, 2020 and were paid during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The outstanding Warrants generally may not be exercised if the holder&#x2019;s aggregate beneficial ownership would be more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the total issued and outstanding shares of the Company&#x2019;s common stock following such exercise. The exercise price and number of shares of common stock issuable upon the exercise of the Warrants (the &#x201c;Warrant Shares&#x201d;) are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrant agreements. Under certain circumstances, the Warrants may be exercisable on a &#x201c;cashless&#x201d; basis. In connection with the issuance and sale of the common stock and Warrants, the Company granted the purchasers certain registration rights with respect to the Warrants and the Warrant Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in-capital and were recorded at the issuance date using a relative fair value allocation method. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such Warrants do not provide any guarantee of value or return. The Company valued the Warrants at issuance, concluding their sales price approximated their fair value, and allocated net proceeds from the sale proportionately to the common stock and Warrants, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, net of issuance costs, was allocated to the Warrants and recorded as a component of additional paid-in-capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2021, the Company completed a PIPE financing transaction, in which it sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share pursuant to a securities purchase agreement entered into on September 16, 2021 (the &#x201c;Second PIPE Financing&#x201d;). The Company received aggregate net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting placement agent commissions and offering expenses payable by the Company. In connection with the issuance and sale of the common stock, the Company agreed to file a registration statement with the SEC registering the resale of the shares of common stock issued in the Second PIPE Financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.577%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:27.892%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.503%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:12.541%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,016,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.4%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2021, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,459,576&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,872&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants cancelled due to net exercise of the warrants. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants exercised during the year ended December 31, 2020. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants issued or outstanding in previous years.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2"
      decimals="INF"
      id="F_19dfb8eb-ba38-42aa-b7b0-2b3c808d88f6"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2"
      decimals="INF"
      id="F_050dbfc4-8b47-4ff3-89bf-9698e4d491c8"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_62f90882-9570-4db7-bf40-7696560e7bd2"
      decimals="4"
      id="F_12432789-0f71-4f4e-85bf-ffc690eedf62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_5bbffb5e-a7c8-441a-92d3-668fef3a92cf"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_b90db34a-f2cd-4ed1-945f-6f8f0513b4c2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_c5800379-c542-4551-b5ac-1f238666fc3b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_e368f842-01b1-44c2-8081-f3806e1a9253"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_818b2ac3-8367-453c-9f39-ae061de350ab"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_39517eae-fc13-4757-98d0-76dc476262f6"
      unitRef="U_shares">69047878</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_00b2f812-cea4-460e-8f96-e4ccd206c252"
      unitRef="U_shares">47552693</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_dfdb63c2-0b36-4d90-afd2-aedcb99ad002"
      unitRef="U_shares">47552693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_24623f57-d9ab-4d22-b4fc-69e69532675b">Holders of the Company&#x2019;s common stock are entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <grts:MaximumSecuritiesCoveredUnderRegistrationAgreement
      contextRef="C_30bd410f-a2b7-4dcd-91e2-e7f9e2231460"
      decimals="-5"
      id="F_daa15484-697b-42c3-a604-df094802dcca"
      unitRef="U_USD">250000000.0</grts:MaximumSecuritiesCoveredUnderRegistrationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_02b16dbd-b7a0-4b17-815f-637d91f05924"
      decimals="-5"
      id="F_ee31e706-e608-40fc-a35d-d52064dd3d12"
      unitRef="U_USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_02b16dbd-b7a0-4b17-815f-637d91f05924"
      decimals="-5"
      id="F_2e0a5250-f5ad-4f24-904b-873c0be38140"
      unitRef="U_USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <grts:PercentageOfProceedsPayableAsCompensationToUnderwriter
      contextRef="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b"
      decimals="3"
      id="F_5938a332-b94c-4a91-b5d3-b47ec27ffaa6"
      unitRef="U_pure">0.030</grts:PercentageOfProceedsPayableAsCompensationToUnderwriter>
    <grts:MaximumOfferingExpensesAgreedToBeReimbursed
      contextRef="C_922bc37d-8987-47f0-b82b-bdc9fd78ad9b"
      decimals="0"
      id="F_b5e0c560-a162-4931-a4dd-275c7923ce98"
      unitRef="U_USD">50000</grts:MaximumOfferingExpensesAgreedToBeReimbursed>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636"
      decimals="INF"
      id="F_de0fcba3-bb65-44d1-b981-6cfa4e76acc6"
      unitRef="U_shares">1160193</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b31fcc2f-be1c-410a-8c29-d48033722636"
      decimals="-5"
      id="F_bbe999c0-a03b-4ffa-b6d4-573fa8069487"
      unitRef="U_USD">9800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_26228208-a6ee-48f7-a682-d0ebfa815e49"
      decimals="INF"
      id="F_9bdc6fd6-19d4-4003-b43a-171c52d68b28"
      unitRef="U_shares">3990869</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_82754c58-c826-4434-bf40-87fc89524365"
      decimals="-5"
      id="F_2ab9e0dd-f5f3-432c-b8d0-7a9ab04f5026"
      unitRef="U_USD">36600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7"
      decimals="INF"
      id="F_b6dad563-4374-4de9-a984-e57d4c3c00dc"
      unitRef="U_shares">5543351</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf"
      decimals="2"
      id="F_955be8b7-2f5e-4e93-b80d-0dc773fb4bf4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:SharesIssuedPricePerShare>
    <grts:WarrantsToPurchaseSharesOfCommonStock
      contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7"
      decimals="0"
      id="F_ccf2b306-de58-440c-be45-78994f9e2b5a"
      unitRef="U_shares">27480719</grts:WarrantsToPurchaseSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf"
      decimals="2"
      id="F_70623ef6-f692-4693-9638-533a67b4878b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:SaleOfStockPricePerShare>
    <grts:SaleOfStockPricePerSharePrepaidByPurchaser
      contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf"
      decimals="2"
      id="F_9d645cd4-0510-4b8d-a488-f9d796360426"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.33</grts:SaleOfStockPricePerSharePrepaidByPurchaser>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_12e26153-82b4-40ab-8b8e-500eff6e7133"
      decimals="0"
      id="F_9ff9949d-1a37-45b4-ac39-653e1b110365"
      unitRef="U_shares">4043127</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_30cdab96-3f4b-4379-b29a-bcbd8cf5affa"
      decimals="2"
      id="F_19673b8b-7a02-47a1-8647-4c3d1d84d529"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.71</us-gaap:SharesIssuedPricePerShare>
    <grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
      contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7"
      decimals="-5"
      id="F_2f2ec29d-8328-4547-8514-55255f29ce00"
      unitRef="U_USD">119800000</grts:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_492c8d7f-2c9c-44e2-b7b7-5307ab252fcf"
      decimals="2"
      id="F_0a9d39c9-c815-49ca-a1ee-4956aa59804d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <grts:PlacementAgentCommissionsAndLegalFees
      contextRef="C_f2b9ad44-987f-43a7-8f2c-203942f63ba7"
      decimals="-5"
      id="F_4e14e038-83f8-4d43-bd88-851f416041b8"
      unitRef="U_USD">5700000</grts:PlacementAgentCommissionsAndLegalFees>
    <grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant
      contextRef="C_84b5d7c9-f721-46f5-ac90-4bde76f80644"
      decimals="4"
      id="F_e702d22e-f607-46a2-aa41-191c0fa96683"
      unitRef="U_pure">0.0999</grts:MaximumPercentageOfCommonStockOwnershipToExerciseWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_d989933a-3905-49b7-9ee1-1782f59e82ee"
      decimals="-5"
      id="F_dfa95f01-ee88-435f-8195-a761256c5dc8"
      unitRef="U_USD">87700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fecc12db-2824-4e1a-8f15-21db97eded23"
      decimals="INF"
      id="F_eecaed77-0f1e-4e60-b2b4-3ac05307b4e4"
      unitRef="U_shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_46e79e08-83a1-4420-a9c9-fa98bb9c1247"
      decimals="2"
      id="F_8aeda6ee-9ff7-4fd4-a183-e3d71b57553d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_fecc12db-2824-4e1a-8f15-21db97eded23"
      decimals="-5"
      id="F_44dfeb25-7099-4de9-a0b1-14640b9c7ba4"
      unitRef="U_USD">52700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_ab4bfe73-52d3-4e8e-876a-2c99583905f3">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the following warrants to purchase shares of the Company&#x2019;s common stock were issued and outstanding:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:38.577%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:27.892%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.503%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:12.541%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Issue Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,016,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <grts:ClassOfWarrantOrRightIssueDate
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_43781400-75ad-4e1c-b4ea-57f5370e29da">2020-12-28</grts:ClassOfWarrantOrRightIssueDate>
    <grts:ClassOfWarrantOrRightsExpiration
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_9aff6e65-4d41-4ed5-83fb-2c640106551c">None</grts:ClassOfWarrantOrRightsExpiration>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="2"
      id="F_e6d8885d-9b74-436e-b3bc-36128a042f28"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_8df9d2f4-1f3b-4fc5-bc9f-2b1e32125af2"
      unitRef="U_shares">17016271</us-gaap:ClassOfWarrantOrRightOutstanding>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_6adc26d4-59af-472f-b472-47bf146f7fb8"
      unitRef="U_shares">10459576</grts:ClassOfWarrantOrRightWarrantsExercised>
    <grts:WarrantsCancelled
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_396f5a4e-d292-447b-b29a-6e03cc413e50"
      unitRef="U_shares">4872</grts:WarrantsCancelled>
    <grts:WarrantsOutstanding
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="INF"
      id="F_b0af6396-d516-4304-97b5-ca3b925c1b80"
      unitRef="U_USD">0</grts:WarrantsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_e1c915d8-f68b-4d9d-b4da-c50fad82aaf8"
      unitRef="U_USD">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_c9329c9c-21ad-4616-88cf-35ee9056bdad">&lt;p style="text-indent:-6.007%;padding-left:5.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10.	Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Award Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2015, the Company&#x2019;s board of directors approved the 2015 Equity Incentive Plan (&#x201c;2015 Plan&#x201d;). In connection with the Company&#x2019;s IPO and the effectiveness of the 2018 Award Incentive Plan (&#x201c;2018 Plan&#x201d;), discussed below, the 2015 Plan terminated, and no further awards will be granted under the 2015 Plan. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;92,815&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock that were then unissued and available for future issuance under the 2015 Plan became available under the 2018 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2018, the Company&#x2019;s board of directors approved the 2018 Plan. Under the 2018 Plan, a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,690,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were initially reserved for issuance under the 2018 Plan, plus the number of shares remaining available for future awards under the 2015 Plan, as of the effective date of the 2018 Plan. The number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the total number of shares of the Company&#x2019;s outstanding stock on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued upon the exercise of stock options under the 2018 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s board of directors has the authority to determine to whom options will be granted, the number of shares, the term, and the exercise price. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If an individual owns stock representing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% or more of the outstanding shares, the price of each share shall be at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the fair market value, as determined by the board of directors. Options granted have a term of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years and generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-year period with a straight-line vesting.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Material Features of the 2021 Employment Inducement Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), pursuant to Nasdaq Listing Rule 5635(c)(4). The principal purpose of the 2021 Plan is to promote the success and enhance the value of the Company by inducing new employees to commence employment with us, and by aligning the individual interests of new employees with the interests of our stockholders. Awards granted under the 2021 Plan are intended to constitute &#x201c;employment inducement awards&#x201d; under Nasdaq Listing Rule 5635(c)(4), and, therefore, the 2021 Plan is intended to be exempt from the Nasdaq Listing Rules regarding shareholder approval of stock option and stock purchase plans. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;790,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of non-qualified stock options, restricted stock units, restricted stock awards, stock appreciation rights, and other stock-based and cash-based awards. The 2021 Plan does not provide for the grant of incentive stock options. Awards under the 2021 Plan may be granted to eligible employees who are either new employees or who are commencing employment with us or one of our subsidiaries following a bona fide period of non-employment with us, and for whom such awards are granted as a material inducement to commencing employment with us or one of our subsidiaries. Awards under the 2021 Plan may not be granted to our consultants or non-employee directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Plan is administered by our board of directors and, to the extent our board of directors delegates its authority to it, our compensation committee. In the event of a change in control in which the successor corporation refuses to assume or substitute any outstanding award under the 2021 Plan, the vesting of such award will accelerate in full. Our board of directors may terminate, amend, or modify the 2021 Plan at any time, provided that no termination or amendment may materially impair any rights under any outstanding award under the 2021 Plan without the consent of the holder.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2018, the Company&#x2019;s Board of Directors approved the 2018 Employee Stock Purchase Plan (&#x201c;2018 ESPP&#x201d;). The 2018 ESPP also became effective in September 2018. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;282,334&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were initially reserved for issuance under the 2018 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2018 ESPP will increase automatically each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares of common stock outstanding on December 31 of the preceding calendar year or (2) such lesser number of shares determined by the Company&#x2019;s Board of Directors. The maximum number of shares that may be issued under the 2018 ESPP is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The offering periods are scheduled to start on the first trading day on or after June 1 or December 1 of each year. Contributions under the 2018 ESPP are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of an employee&#x2019;s eligible compensation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.695%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:0.788%;"/&gt;
        &lt;td style="width:14.164%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:0.788%;"/&gt;
        &lt;td style="width:14.164%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.57&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.48&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Valuation of Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.337%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.521%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.521%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.54%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;83.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management&#x2019;s calculations are based on a grant date valuation approach. Using the Black-Scholes model, the weighted-average grant-date fair value of employee stock options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.39&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.08&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share during the years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the 2015 Plan, 2018 Plan and 2021 Plan activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.395%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.085%;"/&gt;
        &lt;td style="width:8.15%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:7.928%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:7.918%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:7.928%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.02%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for&lt;br/&gt;Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,108,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,166,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,692,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,195,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,314,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;692,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;853,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;681,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,459,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,107,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable &#x2013; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,253,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.21&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest &#x2013; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,741,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021, 2020, and 2019, the total intrinsic value of stock option awards exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, determined at the date of option exercise, and the total cash received upon exercise of stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in 2021 and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t significant for 2020 or 2019. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying stock option awards and the estimated fair value of the common stock on the date of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of total cost related to non-vested employee and consultant options is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years. The total fair value of shares vested during the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense and awards granted to non-employees was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2021, and immaterial for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years and generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-year period&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.262%;"/&gt;
        &lt;td style="width:1.707%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.831%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.707%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.284%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding, unvested as December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;880,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding, unvested as December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation for all awards granted to employees, consultants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;our&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018 ESPP, before taxes, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.859%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.75%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.741%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.741%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9127b8e2-08a8-449b-b838-ac2185db6903"
      decimals="INF"
      id="F_c4b8c058-c0f3-4cc6-b762-d8acfe9e6e4d"
      unitRef="U_shares">92815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9127b8e2-08a8-449b-b838-ac2185db6903"
      decimals="INF"
      id="F_6af5b5cd-81de-442a-8a86-a26b50b9a460"
      unitRef="U_shares">2690000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <grts:IncreaseInSharesAvailableForIssuancePercentage
      contextRef="C_6cf22661-5fe6-4416-b669-0e1caded7434"
      decimals="2"
      id="F_f7ddc978-6b5d-4d75-a831-7bf110fde550"
      unitRef="U_pure">0.04</grts:IncreaseInSharesAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_6cf22661-5fe6-4416-b669-0e1caded7434"
      decimals="INF"
      id="F_f8073ee0-122b-41db-bcef-01e42b48de71"
      unitRef="U_shares">45000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0"
      id="F_aeeaa554-c817-4cc7-af19-d79b528dd69b">If an individual owns stock representing 10% or more of the outstanding shares, the price of each share shall be at least 110% of the fair market value, as determined by the board of directors. Options granted have a term of up to 10 years and generally vest over a 4-year period with a straight-line vesting.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <grts:MinimumPercentageOfOutstandingSharesHeldByIndividual
      contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0"
      decimals="2"
      id="F_42ca96e3-d3cf-4d4c-9f6f-e454d408fa96"
      unitRef="U_pure">0.10</grts:MinimumPercentageOfOutstandingSharesHeldByIndividual>
    <grts:MinimumPercentageFairMarketValueOfSharePrice
      contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0"
      decimals="2"
      id="F_7f390026-7aaf-47b4-b14c-9f7f9ae8a5f8"
      unitRef="U_pure">1.10</grts:MinimumPercentageFairMarketValueOfSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_5672b081-e3ab-444a-bafd-c2358ab76867"
      id="F_9160bef4-fef0-4a7b-b6d2-e81da90b7e8a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f828de0a-9a64-46e4-8ecc-9355300442d0"
      id="F_9beed182-b935-425b-8cca-73b26bd98bc6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2416b0ec-eb6d-48de-b430-8527dc88fbd4"
      decimals="INF"
      id="F_4c691c01-f0e3-4a40-9bfc-3e1eb367bfa4"
      unitRef="U_shares">790400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e162ac57-c6fe-433b-9c8e-4ec41607c846"
      decimals="INF"
      id="F_e685cca0-6f2f-4ed5-897f-1df112815a49"
      unitRef="U_shares">282334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <grts:IncreaseInSharesAvailableForIssuancePercentage
      contextRef="C_f74a3c85-0277-41dd-9121-429606c196de"
      decimals="2"
      id="F_8c1c18b7-9349-4a64-9235-367f354aadf1"
      unitRef="U_pure">0.01</grts:IncreaseInSharesAvailableForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_f74a3c85-0277-41dd-9121-429606c196de"
      decimals="0"
      id="F_ab6274e0-df40-4acd-9eea-1976e3d3b633"
      unitRef="U_shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_f74a3c85-0277-41dd-9121-429606c196de"
      decimals="2"
      id="F_521ddee5-b564-4dfc-8a97-24a1e14a7cb7"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_fcb0cd37-e379-4283-82cf-63ed5d6d54e9">&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of stock purchase rights granted under the 2018 ESPP were calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.695%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:0.788%;"/&gt;
        &lt;td style="width:14.164%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:0.788%;"/&gt;
        &lt;td style="width:14.164%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.57&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.48&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9"
      decimals="2"
      id="F_5bffc119-38e9-46bc-879c-8d338d856658"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e"
      decimals="2"
      id="F_c8998969-7b05-4805-9020-6bf17fb8a27f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9"
      id="F_06d4358f-cefc-402a-800e-4f7bec188a79">P0Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e"
      id="F_f3dd89bb-cb0d-4fdc-9eb5-8b028bd47eab">P0Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9"
      decimals="3"
      id="F_02e831b0-68cc-468f-81f9-c42f05833ef7"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e"
      decimals="3"
      id="F_e9f5dd6b-46e5-49fb-91d2-61e9d922faf6"
      unitRef="U_pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_71278cac-f4bb-4914-9100-9aa2c97ad1c9"
      decimals="3"
      id="F_e02c6484-9293-485d-adf4-40781d173e63"
      unitRef="U_pure">0.880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_85f96acd-07e5-4041-bf06-2c004d61457e"
      decimals="3"
      id="F_3215ce3b-5a8a-40c0-92dc-ed01a668d670"
      unitRef="U_pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_8afbaf57-f9cf-45ab-a846-775537fcb313">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option granted to an employee or a director was estimated as of the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.337%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.521%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.521%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.243%;"/&gt;
        &lt;td style="width:0.789%;"/&gt;
        &lt;td style="width:10.54%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;83.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f"
      decimals="2"
      id="F_31f41dc7-ac1e-4c9c-9a91-443e9ed7893c"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90"
      decimals="2"
      id="F_10e15154-248a-4524-9f72-64769d27d8c3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3"
      decimals="2"
      id="F_673afaf7-f96b-4374-a6af-1c5937aa3da1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f"
      id="F_25527f4d-6123-4c2e-830e-1ebb23dfe826">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90"
      id="F_b8fca22b-e304-415e-8dfd-263273423bbf">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3"
      id="F_2d5dfd54-6783-4183-a05c-72dde17d7a9a">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f"
      decimals="3"
      id="F_fe9eb200-1fdb-479d-9a5c-3ee7681fe19a"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90"
      decimals="3"
      id="F_c6cd14b1-6ccc-494e-88d2-11a2d019132f"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3"
      decimals="3"
      id="F_5fa49575-5718-42b7-86ba-f5c1678ca95b"
      unitRef="U_pure">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f"
      decimals="3"
      id="F_ea1691eb-1804-475b-acc8-7595e7a45372"
      unitRef="U_pure">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5f17bf1a-ca28-4906-bc49-a4c6fd28dc90"
      decimals="3"
      id="F_3faca945-3442-485d-a02a-d89a4782a5fd"
      unitRef="U_pure">0.730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_9e106ee9-c84f-47c8-a116-e14cc2cd21b3"
      decimals="3"
      id="F_6194a9f3-fe2b-4da3-97e8-656d1abe3c07"
      unitRef="U_pure">0.830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_852c9d67-3831-47a6-b11e-67ace495829b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="INF"
      id="F_a53d1fd0-105b-4fed-8688-f94da0e5be74"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="INF"
      id="F_eed0e631-8931-4895-9fb5-611daecc5b0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_721e1e2d-1f17-4743-bb33-677837b01aa8">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of the 2015 Plan, 2018 Plan and 2021 Plan activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.395%;"/&gt;
        &lt;td style="width:1.001%;"/&gt;
        &lt;td style="width:1.085%;"/&gt;
        &lt;td style="width:8.15%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:7.928%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:7.918%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:7.928%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
        &lt;td style="width:1.103%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.02%;"/&gt;
        &lt;td style="width:0.964%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for&lt;br/&gt;Issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate    &lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,108,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,166,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.15&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,692,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,195,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,314,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;692,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;853,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;681,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,459,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,107,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.500pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.13&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable &#x2013; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,253,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.21&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest &#x2013; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,741,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_1cfbc967-a133-4dc9-a407-24475d840591"
      unitRef="U_shares">3108412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_5bef3a1e-c2ed-494e-a879-ae3edca2fe70"
      unitRef="U_shares">4166441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="2"
      id="F_8ce6327e-99ba-4da1-afcb-cf9bcef110f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      id="F_3c3c3393-9382-4571-acb2-83693e9d12fe">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_ef014482-0aaa-465b-98ec-2f9ead0d63ab"
      unitRef="U_USD">2092000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_6d4f5e5c-082f-4d1f-96d7-b80e4787d2e1"
      unitRef="U_shares">2692507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_4c5bd6ee-29c0-43db-b3c1-42cd21ef3a80"
      unitRef="U_shares">3195124</grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_a03cd5c6-4d60-461c-94cc-909ce1ccdb4f"
      unitRef="U_shares">2314524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_231e2951-db78-46be-b643-1f5a14014d66"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="0"
      id="F_fc4e1b9a-1ae6-4734-b468-7cfaeb4cb01c"
      unitRef="U_shares">0</grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_d93f1278-5363-4201-9167-cfc5f9a9834d"
      unitRef="U_shares">692038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_63524d08-e89f-4f39-9db8-ffbf29d0b3e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_836b6599-28b8-4d95-a089-37d5a501d437"
      unitRef="U_shares">853392</grts:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_3cd94ee5-df65-4e77-89e8-a51d2ba6d495"
      unitRef="U_shares">681592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_81770593-4af2-4437-a4e2-f2f1a0be6b91"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_e0f3356a-850f-4d9d-883c-08b3a885859e"
      unitRef="U_shares">3459187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_4e8fa677-d34c-48d8-8b38-eba53f18b04c"
      unitRef="U_shares">5107335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="2"
      id="F_49fb9142-0f79-489d-bb94-86407a8cc69d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_25582304-21a1-4eed-990a-cf148172dd51">P8Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_553f8ca6-a2cf-46f5-a898-29a0cdc75e63"
      unitRef="U_USD">17153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_1f0f54a6-fb57-4028-b104-a499b48af402"
      unitRef="U_shares">2253957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="2"
      id="F_ccd738bc-acb5-4d03-9380-4818bc11bb8f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_03cdbda5-e613-4bbf-9967-87c8c7e720a9">P7Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_5539d764-d138-4bd2-b819-0220d0bec4f5"
      unitRef="U_USD">9901000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_ac9665b1-518f-4623-9b8e-450b174ae1c6"
      unitRef="U_shares">4741858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="2"
      id="F_44b17488-16cc-4a7b-8830-62ae96ec62e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_e4aad737-19c1-4ccb-9296-bab4d6f7a22d">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_92f54f72-f3b2-4d6b-b1dd-b9d57d34cd95"
      unitRef="U_USD">16267000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_e124b35e-c1fb-4251-9050-349ea44d9ca4"
      unitRef="U_USD">5800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-5"
      id="F_b4c54176-4e84-442e-a63b-4a6ad33db553"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-5"
      id="F_35488d9b-4bdd-47a5-bc33-230feb54a008"
      unitRef="U_USD">3000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_6e2738de-a6b4-480b-941e-5755dce2055e"
      unitRef="U_USD">3400000</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="0"
      id="F_a0d0dcd0-e6ea-4b2a-ab01-7d53a845edc0"
      unitRef="U_USD">0</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="0"
      id="F_a983e9ad-35f9-4025-9680-392086e84c40"
      unitRef="U_USD">0</grts:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-5"
      id="F_fd13ba90-3d62-4714-a293-bd3d763407c9"
      unitRef="U_USD">18200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_59a5bec2-acf9-43e5-939e-628c1012aee5">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_cece48c5-cc26-495f-acbe-2a84cfab20a8"
      unitRef="U_USD">7500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_ec923fde-b49d-4880-b88a-ba9baf850967"
      unitRef="U_USD">700000</grts:StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_f018322b-c8aa-48d4-8e6e-49a256954912"
      id="F_02fce04d-f342-4157-bbe6-cf753f1bdfc4">We have granted restricted stock unit awards under the 2018 Equity Plan. Our restricted stock unit awards have a term of up to 10 years and generally vest over a 2-year period</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_41a55fdc-8e37-4a5a-87e7-f6d1171e8e83"
      id="F_9cc41592-b6b3-48ed-ab50-f6d4c110cd6f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f018322b-c8aa-48d4-8e6e-49a256954912"
      id="F_93b6a417-d385-44f3-a58f-6c6cbd59fd08">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_47ef9cfc-f343-4c21-80c1-f22a5670b751">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:&lt;/span&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.262%;"/&gt;
        &lt;td style="width:1.707%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.831%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.707%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.284%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding, unvested as December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;880,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;171,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding, unvested as December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="INF"
      id="F_f041832d-096b-47c7-ae6e-b7e3d25eb23a"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="0"
      id="F_1c5133e9-d936-4366-bbe3-ea4c62823d8e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_a5841095-2a90-4c7a-b5f2-d99c290a38c0"
      unitRef="U_shares">880600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_d6c932e7-79d4-48ab-8f03-8e2ed48262b3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_4228ba4a-1303-41bb-9f74-1f7a460f5e33"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="0"
      id="F_d0de1288-35a4-492a-9261-d85341a42d49"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_8eb637ec-f361-4050-8d77-5d29d9099726"
      unitRef="U_shares">171800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_710e54a8-8313-4a3e-a682-52f7ab5f3670"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_00da3968-c6c2-4fb8-9cf3-de52785f9e5f"
      unitRef="U_shares">708800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="2"
      id="F_64d40034-642e-4e1e-a9b0-fcee44cbba36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_84981b17-6005-4edf-8721-fd098149f079">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation for all awards granted to employees, consultants&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;our&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018 ESPP, before taxes, is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.859%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.75%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.741%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.456%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.741%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,552&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4a494dd9-b549-41f2-b0e4-223518bdd582"
      decimals="-3"
      id="F_a891f401-93a9-4f0d-838d-82dcca5a0b6e"
      unitRef="U_USD">6626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f7168722-4c89-46f9-8fef-613ec1a338fd"
      decimals="-3"
      id="F_a23db2d2-f573-47a8-b7eb-9a02d9a50f1c"
      unitRef="U_USD">4453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b6f878cf-27a6-4a39-8ffb-4b24d54bd0fe"
      decimals="-3"
      id="F_b07e28bb-f5c7-44ec-8717-036f929f5ba4"
      unitRef="U_USD">3437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e968f552-8dce-4078-8dcd-35f7f02d3616"
      decimals="-3"
      id="F_082919b7-ee8a-4450-b35b-4f13b52b2efc"
      unitRef="U_USD">3926000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c7df85ae-cc5e-40e1-bb77-a8cc3a896e3e"
      decimals="-3"
      id="F_377c77f7-da29-427c-bbdc-2a66c4c9381f"
      unitRef="U_USD">2657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_39f0995b-97b6-4734-859b-932b4f1b1bc9"
      decimals="-3"
      id="F_e05993b8-f404-4073-93d4-9988df692300"
      unitRef="U_USD">1862000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_da1a9746-e13d-471c-970e-d524dc438594"
      unitRef="U_USD">10552000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_254f9491-e3f6-4627-9fdd-143c871b22af"
      unitRef="U_USD">7110000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_83c77d8f-1c5d-472b-97d3-41357ba8ee63"
      unitRef="U_USD">5299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_d2f9d850-516a-421b-aa8c-c933a58b256a">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11.	Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective tax rate for the years ended December 31, 2021, 2020 and 2019 is different from the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.489%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-taxable stock premium&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. Due to the Company&#x2019;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December 31, 2021 and 2020. The deferred tax assets were primarily comprised of federal and state tax net operating losses and tax credit carryforwards. The increase in valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2021 and 2020, respectively, was primarily attributable to the Company&#x2019;s current year taxable loss and increase in the effective state tax rate due to changes in the Company&#x2019;s state apportionment factors.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the net deferred tax assets/liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.736%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.644%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.644%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;97,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;127,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;101,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021 and 2020, the Company&#x2019;s federal and state income tax net operating loss carryforwards were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;353.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;347.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, which may be subject to limitations as described below. If not utilized, the federal tax loss carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the state tax loss carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Under the Tax Act, federal net operating losses generated after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. The federal net operating losses generated after December 31, 2017 of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million are carried forward indefinitely. In addition, the Company has certain federal, California and Massachusetts research and development income tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. If not utilized, the federal research and development income tax credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The California research and development income tax credit carryforwards do not expire and can be carried forward indefinitely. The Massachusetts research and development income tax credit carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss and tax credit carryforwards as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.406%;"/&gt;
        &lt;td style="width:1.457%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.886%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.457%;"/&gt;
        &lt;td style="width:20.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses, federal (post December 31, 2017)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Do not expire&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses, federal (pre January 1, 2018)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2037&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;347,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits, federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;CA: credits do not expire&lt;br/&gt;MA: 2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, as defined under IRC Sections 382 and 383. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. Subsequent ownership changes may further affect the limitation in future years. In connection with the Company&#x2019;s IPO, which closed in October 2018, the Company did experience an ownership change pursuant to Section 382. There was no reduction in federal or California net operating loss carryforwards or research and development income tax credits as a result of this ownership change. The Company is in the process of completing an analysis through December 31, 2021 under IRC Sections 382 and 383 to determine if the Company&#x2019;s net operating loss carryforwards and research and development credits are limited due to a change in ownership and may have an ownership change pursuant to Section 382.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.772%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.722%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.722%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.786%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Decrease for tax positions taken during prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases for tax positions taken during current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;End of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If recognized, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the unrecognized tax benefits as of December 31, 2021, 2020, and 2019 would impact the annual effective tax rate, primarily due to corresponding adjustments to the valuation allowance. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next twelve (12) months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the years ended December 31, 2021, 2020, and 2019, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recognize accrued interest and penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States and various state tax jurisdictions in which the Company files tax returns.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_b733b325-95fd-4ecf-af67-f9b2b6cefd1d">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective tax rate of the Company&#x2019;s provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.489%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.16%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:10.421%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in state tax apportionment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-taxable stock premium&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_33ac89e0-abea-4032-94db-98ad0eb66ded"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_671d01fc-6dca-4870-a30d-c83667117918"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_db7e94fa-b53a-432d-ab53-704585ca0922"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_dae31a66-bb13-4dfd-a0ae-2ca1137966ed"
      unitRef="U_pure">0.102</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_6f8e3ac0-5c8a-439a-b3f1-bc2484a8d679"
      unitRef="U_pure">0.079</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_f763f380-ba2d-4b03-bcb1-ec1244c78d98"
      unitRef="U_pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_dfe5cb4e-5fde-4611-870d-bb8775811b26"
      unitRef="U_pure">-0.001</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_40fe5b96-b0b2-4632-8419-38dde4bf7a0b"
      unitRef="U_pure">-0.006</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_a8689457-17b0-4327-a0d1-9da993726716"
      unitRef="U_pure">-0.008</grts:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_047ac083-e569-47d3-ba3f-4f5618746f43"
      unitRef="U_pure">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_0312b523-558e-49e9-bd3c-7c3f07adb267"
      unitRef="U_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_8ff22a50-da6d-4b75-a9e3-c7ba20b9c7e5"
      unitRef="U_pure">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_11d3087c-b94d-4c6c-aa3d-3e6953594458"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_e63b94c9-ede0-440c-afda-fd0257d68c7f"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_606ca62a-3272-4ef2-8b52-024f10bdc221"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_5e44d29f-0856-41d9-8fb7-068d3999219e"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_5ac650d9-c6f1-4bf8-bb1d-329045a5b03f"
      unitRef="U_pure">0.094</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="2"
      id="F_1dda6820-ae47-4ba0-8a11-abb0e150eb35"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <grts:NonTaxableStockPremium
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_4b80152f-2d47-4aaf-b475-364fe7ab52a1"
      unitRef="U_pure">0.025</grts:NonTaxableStockPremium>
    <grts:NonTaxableStockPremium
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="2"
      id="F_60ed3a0e-1dfa-41f8-967c-4766157a8b5d"
      unitRef="U_pure">0</grts:NonTaxableStockPremium>
    <grts:NonTaxableStockPremium
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="2"
      id="F_80c2648f-d0b8-4bbb-9e93-dc4840ef94e8"
      unitRef="U_pure">0</grts:NonTaxableStockPremium>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="3"
      id="F_3a87e3db-5740-4608-8d05-81e20d4d35d5"
      unitRef="U_pure">-0.337</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="3"
      id="F_9243942f-aa9e-40f1-ada3-6a34f5f4a336"
      unitRef="U_pure">-0.403</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="3"
      id="F_c8124c2a-b4f2-4494-b173-aeed5760c2ba"
      unitRef="U_pure">-0.263</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_42dec986-869b-49b7-b1ea-196d7af4bb96"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="2"
      id="F_d32f2241-77cf-4931-96d6-c6da344542c9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="2"
      id="F_e2edd4b2-2a50-4184-ae2d-727a789e10e2"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_132760a8-7899-417a-907a-9fdd9f601ff6"
      unitRef="U_USD">25200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-5"
      id="F_67ac42bb-a606-4311-98ea-c38209c10d62"
      unitRef="U_USD">42400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_52af464b-373a-4c93-8cf9-9e9f55df4dd9">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the net deferred tax assets/liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.736%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.644%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.644%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;97,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;127,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;101,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_76281e2c-7a96-4181-939c-668f19aa4238"
      unitRef="U_USD">97575000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_96d80c9f-7ce1-4709-b0a1-b54afaf3b6f8"
      unitRef="U_USD">74278000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_205d7ac2-d9ef-4160-b89b-8e965d7c72ab"
      unitRef="U_USD">12271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_77859751-8807-4b78-87d7-406ae8d88856"
      unitRef="U_USD">9247000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <grts:DeferredTaxAssetsLeaseLiability
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_01d5a7ae-7485-420e-a4f6-5c71763fcb6b"
      unitRef="U_USD">7684000</grts:DeferredTaxAssetsLeaseLiability>
    <grts:DeferredTaxAssetsLeaseLiability
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f0467362-603a-4e83-a2bb-a63c0a297dbc"
      unitRef="U_USD">7327000</grts:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_2634cc0d-8ee3-4f6e-9942-5d766046b9c0"
      unitRef="U_USD">3184000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_2616fb4e-bf31-4766-b040-e323911dc48c"
      unitRef="U_USD">3354000</us-gaap:DeferredTaxAssetsOther>
    <grts:DeferredTaxAssetsAmortization
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_38d6620d-8db7-4625-abe3-391f44cc3e79"
      unitRef="U_USD">10633000</grts:DeferredTaxAssetsAmortization>
    <grts:DeferredTaxAssetsAmortization
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_78a718a9-db19-4504-99ba-3a9dd8e19a31"
      unitRef="U_USD">11155000</grts:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_fd1821cc-b6dc-4709-8141-0cbc5803b6dd"
      unitRef="U_USD">2537000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_1120f845-0d3d-4879-ac4e-466b518a1265"
      unitRef="U_USD">3414000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_ca0ea7ef-6736-47d5-8904-84aa89b4e66a"
      unitRef="U_USD">133884000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_42e1d997-9665-432b-b4d7-48f845d2a02f"
      unitRef="U_USD">108775000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_728bdaa9-3a4e-4a71-8567-c37d99bd3fee"
      unitRef="U_USD">127007000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_d9ce6687-dde4-44fe-9e9c-75dc49815e29"
      unitRef="U_USD">101781000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_58145a50-71b1-40f8-8ddd-2b0414e503cf"
      unitRef="U_USD">6877000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_aae96821-7423-4b3c-9468-b0f3c3dee759"
      unitRef="U_USD">6994000</us-gaap:DeferredTaxAssetsNet>
    <grts:DeferredTaxLiabilitiesOtherDepreciation
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_56cd86fc-a804-4830-bbca-daa91b5e2901"
      unitRef="U_USD">212000</grts:DeferredTaxLiabilitiesOtherDepreciation>
    <grts:DeferredTaxLiabilitiesOtherDepreciation
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_5a38f49d-c92e-413d-9768-885691f2e335"
      unitRef="U_USD">763000</grts:DeferredTaxLiabilitiesOtherDepreciation>
    <grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_943aca95-2148-4236-8dba-8fc3959263f3"
      unitRef="U_USD">6665000</grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets>
    <grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_4ebe6071-4a2d-406b-8ab2-20ce0bc3af3c"
      unitRef="U_USD">6231000</grts:DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_bd286e30-2ea6-4b7f-82df-be6a15459c4c"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_e857438e-e78c-42f6-93ba-38431919865e"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d171005c-8d0e-451d-ba44-fff86b36b8da"
      decimals="-5"
      id="F_e34c1958-92d2-4f26-b9f6-c0653b5c294f"
      unitRef="U_USD">353800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_82594404-3d52-42ec-86ef-ac5b28a31a88"
      decimals="-5"
      id="F_e1e4c4bf-5838-46b0-b9c7-e5e5a5bb7d58"
      unitRef="U_USD">347200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_6f109470-dac2-4731-88ec-db187dd90821"
      id="F_82c78f5a-3fd5-404a-8e47-9539cac9f241">2035</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <grts:OperatingLossCarryforwardsExpirationYear
      contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca"
      id="F_8415a3a0-50cb-4e7c-a7ca-8211c8a1b471">2035</grts:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9a5f8053-f39a-415a-be93-1d833d484e98"
      decimals="-5"
      id="F_b7b42a7e-3553-4133-a596-5a810da77a8f"
      unitRef="U_USD">303200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5fad68e3-d917-408c-8c64-eb2b3afa907e"
      decimals="-5"
      id="F_00823679-5cb4-4f30-9dbe-db8220b1d02e"
      unitRef="U_USD">11000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3418f96e-c10b-4a60-a068-01b16dabf6cb"
      decimals="-5"
      id="F_96df5882-0834-49a8-922b-76307b912ec3"
      unitRef="U_USD">6600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5e60bfb9-8ab6-4a16-8851-229b4f62c041"
      decimals="-5"
      id="F_0f916553-8775-4df6-9fba-48a4470c93f2"
      unitRef="U_USD">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_6c627a47-b9a4-42f9-9425-7b48bc442bfb"
      id="F_5e6615ac-aa76-48f3-9312-333b89861465">2035</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_bb4a354a-e696-4d8e-b1b8-aeae9a1baedf"
      id="F_ebed4312-4f29-48b2-97d2-968d8feff98f">2035</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_d04ad0b6-1304-4978-8444-175bd600506c">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss and tax credit carryforwards as of December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.406%;"/&gt;
        &lt;td style="width:1.457%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.886%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.457%;"/&gt;
        &lt;td style="width:20.985%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Expiration Years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses, federal (post December 31, 2017)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Do not expire&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating losses, federal (pre January 1, 2018)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2037&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;347,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits, federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax credits, state&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;CA: credits do not expire&lt;br/&gt;MA: 2035 - 2040&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b3dbdfb2-9a14-4b95-94f9-f7c4fd7b4d2d"
      decimals="-3"
      id="F_ddbb1605-3430-4226-b6fb-09ffca14209b"
      unitRef="U_USD">303229000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_cb4aa159-88f3-4ae9-872f-ad54eb0054a3"
      id="F_3fcf59c4-a05e-4774-bb25-4b8865560f33">Do not expire</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d6e42e8c-14e5-4460-9129-ce2242e0271a"
      decimals="-3"
      id="F_2cc2ea70-c9c9-4e53-99b6-ea9df62a8a87"
      unitRef="U_USD">50587000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_3488b869-cb93-4aac-81c2-cb2237fd526d"
      id="F_e7ad56b2-2c8e-455c-97d8-90d75b461b32">2035 - 2037</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b"
      decimals="-3"
      id="F_7b66e724-0824-4e04-ad4a-a5bbc2df91ef"
      unitRef="U_USD">347184000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca"
      id="F_28408495-9bb4-4638-ba1b-ead0b9009dd6">2035 - 2040</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d171005c-8d0e-451d-ba44-fff86b36b8da"
      decimals="-3"
      id="F_606ff7b8-6985-4ec8-8e28-07b434c2fd01"
      unitRef="U_USD">10990000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_6f109470-dac2-4731-88ec-db187dd90821"
      id="F_993aa968-e5c3-495c-887e-dd74c040a3a1">2035 - 2040</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b32b1b8f-3230-41ce-a9f9-321e7c479c6b"
      decimals="-3"
      id="F_790b7dab-c6f0-4e02-85d0-67a11f651a86"
      unitRef="U_USD">7806000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_60bc16bb-733c-46e5-8ee6-cfbead44d8ca"
      id="F_4032ea3b-9d53-4b78-adac-ca4009d931a2">CA: credits do not expireMA: 2035 - 2040</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <grts:OwnershipInterestChangeOverPeriod
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_ea7d9397-ee60-4afb-9e73-df2b0f152076">P3Y</grts:OwnershipInterestChangeOverPeriod>
    <grts:CumulativeChangesInOwnershipInterestOfShareholders
      contextRef="C_7a07fc35-5bb5-495e-b5b1-254dbffe7f54"
      decimals="2"
      id="F_4e0d0c2b-de06-4f51-a6ac-50cf3acbce27"
      unitRef="U_pure">0.50</grts:CumulativeChangesInOwnershipInterestOfShareholders>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_4aafbe4f-f680-4fe9-96de-185a9ae44736">&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.772%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.722%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.722%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.15%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.786%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Decrease for tax positions taken during prior periods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Increases for tax positions taken during current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;End of year&#x2014;unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_f1ddb6b4-f428-4b8e-9d80-999b69478945"
      unitRef="U_USD">4025000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_52ac9323-3370-48c5-a68d-86488492ac4c"
      unitRef="U_USD">2610000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b5b3f31b-7118-424c-be58-60dc31c876aa"
      decimals="-3"
      id="F_a5fe8cdf-9df1-4472-be34-029b83dfc182"
      unitRef="U_USD">2077000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_6393ece7-9498-4542-aa88-f6b4d7587040"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_36d6b973-3b3c-450b-a3bb-97f1ab6fa904"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_6a3bf560-6f3b-491a-ad4f-437a54242981"
      unitRef="U_USD">711000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_4c940118-4850-44ec-b463-a22a9c48d0ec"
      unitRef="U_USD">1456000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_24feb3ce-c82b-4922-9db2-869e87714ebf"
      unitRef="U_USD">1415000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_efba100b-93a2-4a2b-8d21-585d3c2df652"
      unitRef="U_USD">1244000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_e7712069-873d-4f33-afbf-08bf2835a505"
      unitRef="U_USD">5481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_fa9280ca-d192-4c39-b594-a9b91e06e168"
      unitRef="U_USD">4025000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_53ae9a61-81f5-4ad3-8e62-0d0112cf9f4c"
      unitRef="U_USD">2610000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_66e0db84-9d75-44aa-8644-2c59d4f56004"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_e3d2904e-a719-457c-a67a-2ac080b4b3ed"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="-3"
      id="F_12cf3f4f-76b0-41c7-b2a9-d3b02ccdc906"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_7042b1ea-e9df-44d9-b8d5-859ef3010de3"
      decimals="-3"
      id="F_178eff4f-8396-44b0-ad0f-5c58f6d251de"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_c7f32053-1fd2-41c7-8b07-52c62c884195"
      decimals="-3"
      id="F_190902c7-8584-4491-ad33-bdfbf7a3f9ad"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_8b3b2ab9-3043-499d-b186-d0d72157039e">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12.	Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.785%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.298%;"/&gt;
        &lt;td style="width:8.431%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.111%;"/&gt;
        &lt;td style="width:0.881%;"/&gt;
        &lt;td style="width:1.104%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.13%;"/&gt;
        &lt;td style="width:0.881%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78,885,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,792,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,554,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company issued and sold Warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,480,719&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock at a nominal exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.01&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share (see Note 9). During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,459,576&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants exercised and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,872&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants cancelled due to net exercise of the warrants. As of December 31, 2021, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,016,271&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants outstanding. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The shares of common stock into which the Warrants may be exercised are considered outstanding for the purposes of computing earnings per share, because the shares may be issued for little or no consideration, they are fully vested and they are immediately exercisable upon their issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During a period of net loss, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential common shares outstanding would have been anti-dilutive. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.707%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding and ESPP shares issuable and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,170,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,179,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Early exercised common stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,879,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,209,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_abb8dfd4-8add-452b-9654-372ba629536a">&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except for share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.785%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.298%;"/&gt;
        &lt;td style="width:8.431%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.111%;"/&gt;
        &lt;td style="width:0.881%;"/&gt;
        &lt;td style="width:1.104%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.13%;"/&gt;
        &lt;td style="width:0.881%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78,885,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37,792,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,554,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-3"
      id="F_3959d3d1-4a8d-4b89-ba48-d2d30f517245"
      unitRef="U_USD">-75082000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="-3"
      id="F_2be09a2b-7745-401a-9399-39541a5bfe3e"
      unitRef="U_USD">-105314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="-3"
      id="F_87936e14-01c1-476c-98fc-d22797342f9b"
      unitRef="U_USD">-94433000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_9f054804-e5c0-4675-9adb-ad075c1d9ddb"
      unitRef="U_shares">78885186</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="INF"
      id="F_b8463dbd-9bef-4d7d-ab74-1cdde6ae3813"
      unitRef="U_shares">37792365</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="INF"
      id="F_5df47a63-82a4-475a-8e16-679692b5c931"
      unitRef="U_shares">33554823</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_cd1d052a-ef6e-4adb-bd8b-6d1b13afeb48"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="2"
      id="F_732fbcde-5b17-4d6b-a6b3-1244779357f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="2"
      id="F_4abe2599-7a4c-45cb-a954-fb94253d77bf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be"
      decimals="INF"
      id="F_0fc873e1-f978-4640-8160-e7232f38ad8b"
      unitRef="U_shares">27480719</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights
      contextRef="C_fc5b8ba8-c6a4-48e5-882f-42a0934367be"
      decimals="2"
      id="F_e9a86ca1-c230-4688-94b5-219f6bca0561"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</grts:ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights>
    <grts:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_68ab0731-7462-4d09-91cd-88ce8ad466c3"
      unitRef="U_shares">10459576</grts:ClassOfWarrantOrRightWarrantsExercised>
    <grts:WarrantsCancelled
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_075b172e-d4de-4316-bcad-fdf9265778e0"
      unitRef="U_shares">4872</grts:WarrantsCancelled>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_d7d371dd-a94d-4213-a570-7cce5450d104"
      decimals="INF"
      id="F_cb9d1761-6829-4d15-866b-a100c847494a"
      unitRef="U_shares">17016271</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_c8a9fc4e-7215-40b3-82af-9d8fb17fa000">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;p style="text-indent:5.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.707%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.169%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:11.723%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding and ESPP shares issuable and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,170,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,179,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Early exercised common stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;708,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,879,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,213,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,209,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d66cd703-3912-46fa-bae2-d9fb061ac072"
      decimals="INF"
      id="F_09323325-6524-4c3f-8e05-c81fd281e06e"
      unitRef="U_shares">5170331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8ac0f270-594e-4838-963f-9a5cabbd9055"
      decimals="INF"
      id="F_19d2b6bd-f38b-44e1-bb31-bf2ee243f5b2"
      unitRef="U_shares">4213738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_50a00b2f-11c4-485d-982a-768195d22ede"
      decimals="INF"
      id="F_0b0dfbc9-e570-4cd1-90c5-da40ba204656"
      unitRef="U_shares">3179041</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3d7d9ff9-59ff-40cb-8c0e-59c0bc70d677"
      decimals="0"
      id="F_3f3af81b-af29-439e-b59c-73da9e72f18e"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a11e18b2-bc61-4add-880b-6822c9bfcacf"
      decimals="0"
      id="F_d206f59b-847f-4ed1-bc8c-ddb5da1b9bd2"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3f526cf1-464a-4dda-8e5a-79f43b2772aa"
      decimals="INF"
      id="F_17292e71-5df7-4d01-9e43-f60ace8703d9"
      unitRef="U_shares">30874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fda9c57d-6ce6-4fc0-83c9-b59dac2e78ac"
      decimals="INF"
      id="F_e86c9698-88ff-4308-9b74-1755e56ffbdf"
      unitRef="U_shares">708800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_03449e98-a695-4ee5-a4e7-b5c706a15b67"
      decimals="0"
      id="F_95f3be5f-b540-4820-84a4-c0563abe5f93"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cb6c3d89-2dc2-476a-a09b-30ac42c2532e"
      decimals="0"
      id="F_0a256bbf-242e-4b8c-8018-c3ddf783ed65"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="INF"
      id="F_f7b647e4-fc6a-460f-ab41-f56e3474cac3"
      unitRef="U_shares">5879131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_161f2b5e-48b4-46a0-afcb-bca51d0e4fc8"
      decimals="INF"
      id="F_c73639e2-a8ce-423f-b1a7-17eb81542360"
      unitRef="U_shares">4213738</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1f7b818c-8340-4df6-96d6-c2cabc21fd1d"
      decimals="INF"
      id="F_2febe539-70fd-4fa8-aee8-19b33e70a24d"
      unitRef="U_shares">3209915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      id="F_5a41940b-32d5-4d9f-acb0-722c088761ec">&lt;p style="text-indent:-6.082%;padding-left:5.733%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13.	Defined Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.733%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company began sponsoring a 401(k) Plan in 2017, which provides that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a pretax basis. The Company matches up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the first &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of each employee&#x2019;s contribution. During the year ended December 31, 2021, expenses recognized for the 401(k) Plan was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, while the amount was immaterial for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_e7c7b8fa-f6e4-4279-8f6c-57e64fcd0841"
      decimals="2"
      id="F_f407c74f-79aa-4397-9a4f-1d1afc6f707f"
      unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="2"
      id="F_0560d27d-ca33-4b36-b1c0-ac03c6bd7350"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_f5581400-90ad-4249-923b-5cba9bd710c5"
      decimals="-5"
      id="F_f499c081-9dd8-480d-944e-f7233fe64074"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanCostRecognized>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF)>G3$I#SV[]W2JI](791! %;FA.JWM=CUY.<CHC^TQF_]IL1EHIYS,Y#L7
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M]/=KKA&ZOS$_"?0_ :W^!5!+ P04    " #&@6I4O]*1!,$"  !+"0  &
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MP?74ISMU<,31&^!NTD_ZKX"/ [M)'(>]0=3,&^#_IP2^GOA"VU:6+;@;(D^
M^WLGG7W-^$+DDG*%&"R,%'<2XR'+D[N<:+%RA]]<:'.4NF%NWG9 V@!S?2&$
MWDWL>5J_/XW_ 5!+ P04    " #&@6I47%- 6[@$  ##$   &    'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)U8VV[C-A#]%<+8AUU@-R)U5^ 8V-CM=H&F
M#9)-]Z'H RW1MA!)=$G*3OOU'5**+$NTFO8ENOC,:,[AD#.3^9&+9[EC3*&7
MLJCDS6RGU/[:<62Z8R655WS/*OAEPT5)%3R*K2/W@M',&)6%XV(<.B7-J]EB
M;M[=B\6<UZK(*W8OD*S+DHJ_;EG!CS<S,GM]\9!O=TJ_<!;S/=VR1Z:>]O<"
MGIS.2Y:7K)(YKY!@FYO99W*](HDV,(C?<G:4O7NDJ:PY?]8/7[.;&=81L8*E
M2KN@<#FP)2L*[0GB^+-U.NN^J0W[]Z_>?S3D@<R:2K;DQ?<\4[N;63Q#&=O0
MNE /_/@3:PD%VE_*"VG^HF.+Q3.4UE+QLC6&",J\:J[TI16B9T#""P9N:^ .
M#?P+!EYKX+W5P&\-?*-,0\7HL***+N:"'Y'0:/"F;XR8QAKHYY5>]T<EX-<<
M[-1BR2O)BSRCBF7H4<$%%E5)Q#?HUST35"^.1+3*T)*7D%D[O>0'AG[F4J)/
MZ.EQA=Z_^X#>H;Q"WW:\E@"5<T=!:/H#3MJ&<=N$X5X(@[CHCE=J)]$/5<:R
M<P<.<.J(N:_$;MU)CRN67B&/?$0N=HDEH.7;S;'%?/5F<Y),L/&Z9?*,/_^"
MOP=V8%7-;,(VAJ$QU+O\L/!CE_ASY]!G:T%A+SH'K2P@+PPZT%GD?A>Y;ZR\
M"Y&W651M$7N!PTHR>3VA1]!Y#?Y%#\FH2'<F,S,0I^![G;@V@1I/08]5$OD)
M'@@T1L5QZ'L#A2PH-TY"NT1A1R:<)/.%5:!18;C0##9Y+I76[&!=[W 4@ALD
MWB#0I05%?$(&=,8HDO@XL=.).CK1))UO7 $9/EIW&YEH'(#K^>Z0C05&, X&
M2;ZRP+#KX0L9''=\XDD^YJC;"%Z^<H(3T<8E'GW]4Q2X/34;+A88P2$FP\UH
MP241K(Z=3-*122;)?*T4$TPJ.*]37K*/J&+639-8%F80X7*,B?!PPXPQ7H C
M.P>"3T4+3[+X!1JB I;%6FBP;1UP[ ZBM^$(#KSAT;FR 1/?[VVY<Q:]TDNF
MCT:U8P*E9W5U"ZT:>J^Y?9@Z)XE[^H@[*=53!>U@D?\-Y;WG&T'+!7W>,U-T
M73 D65J+7.7V3=I^X5S1X1:U@=R1E&,0N73<D%-M)-/%\;PSN9@7X^H&>4&"
M8$C$@M-YX<5#,A9@XGL]TN=\3A63^&_*;@3'#9([*F";0F^;ITVURXM:#5ND
MEF+C-^Y'A*^2$4,+S+V*DB$_*RPF%^B=2C>9KMW?32_.LD_T ,?IEJ&J+M?
M%%I.0U:B6D*V0J[JK5&;&E+];TG&%3N*XS@@<3A498STHBAQ^QU0*XP%Z04!
MM%V7CH13)T"F6P$87PJZYDV5,=R*/-75$V8LTP%*]/L=TW+],74ZG$HUF:[5
M$WUE:WG6#8;1L$PM+3#/#]VA9!9G%UM+<JK,9+HT?Q&T4O]-FE.A)-.5<DJ:
M9,2&^,E(F3$JB$:Y- 8-*[S3F^Y*)K9F2I:P.>I*-?-0][:;Q#^;^7/P_E9/
MZ&9J/+EIQOL[*K8YS'D%VX!+?!5!;HMF8FX>%-^;&7+-%4RDYG;':,:$!L#O
M&\[5ZX/^0/=_B\4_4$L#!!0    ( ,:!:E0O'O(B  D  $,Q   8    >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&ULO5O9<MLX%OT5E*9K)JF*(F+AUFV[*G8<
MQ5NLQ,G,0]<\T"1D<4*1:I"RG?[Z 2A*%+%)IIWD(1*E<R_N!MP#0#YX*-CW
M<D9I!1[G65X>#F95M?A]-"KC&9U'Y=MB07/^S;1@\ZCBC^QN5"X8C9)::)Z-
MD.-XHWF4YH.C@_JS"3LZ*)95EN9TPD"YG,\C]N.89L7#X0 .UA]\2>]FE?A@
M='2PB.[H#:V^+2:,/XTV6I)T3O,R+7+ Z/1P\ [^_IGX0J!&_#NE#^76>R!<
MN2V*[^+A+#D<.,(BFM&X$BHB_G)/3VB6"4W<CK\:I8/-F$)P^_U:^X?:>>[,
M;532DR+[3YI4L\-!,  )G4;+K/I2/'RDC4.NT!<765G_#QX:K#, \;*LBGDC
MS"V8I_GJ-7IL K$E0+!! #4"2!+ OD$ -P)8%G - J01(+)))@&W$7 E =\D
MX#4"GB2 D$' ;P1\2< -# )!(Q#( IY!(&P$0DG ,PE 9YTY1PZL4623;#G;
MOLEQN$XWE//M&RMJG7 H9]Q<A.N40SGGKJD,X3KI4,XZ"DTBZ[1#.>]FP]:)
MAW7F1ZMY54_*]U$5'1VPX@$P@>?ZQ)MZ9M?R?"ZFN5B$;BK&OTVY7'5T4N1E
MD:5)5-$$W%3\A:\P50F**7\JXN^S(DLH*_\%3O]:IM4/, 3?;MZ#5[^]!K^!
M- =?9\6RC/*D/!A5W!JA<Q0W(Q^O1D:&D;\6591IQ$[L8N^^7JUMN9Y.*4OS
M.S!AQ1V+YN#/*SJ_I>R_&JWO[5H_%!E?CH=\59PL;[,T;G5;=)[:=4Y8>L_C
M"<[R>UI6(JPB8HW^Q@6+]@]V[5_H?5IW IXI/E+!P(0;7"1OP+LX+I9Y)8SG
M"<V3B"4E^+80*>9?)O];-L98QA[;QSXIYG,^<ET@-C4?>ZCIF=^S'D/U2OIY
MCX&>60D7.V9$DJ2BH4<9F$1I,CS+P4FT2/GLLBF]?+;2GIFZ>O; O?+VZ=G#
M/C.+USL,B./E?)G5Z_!U-:,,\%+BO'(F"-\]!6-.*$>O+HNR?&T;9;+_*._I
M-(U3ZSKPN;^VG[4^C7B#VW0YM.ERJ#:4& P]CK(HCRF(*FYG_!9@^ 8@!P:Z
MKK72Y-6:!(6_/X(DA @=C.ZW5V<5-H0N[H+&&EU>%W*A0I#ONJ&DZ5HS7.!V
M,1.=2<@CCF3ZYQVF=R*,-Q'&^T3X#2AG$:/E/I$>KS2ZVZX' <(0.WI;R,86
M8K7%4F#@S]/'2LRHVXR"R[2L=%5_W%L]]]1ST#Z5ZVY\<:V#G97ELBY=/HU*
MT53>@)QO3?E3NOXF+LI*Q[].7"7/V/>DPGJO@KS0=\(NZDQ%P2[B<I_!KO2#
M!?IT>YL0>2\2HG5MZHB*IY0B"9T@<*0PJ##/=<0_O0?^Q@-_;P_B%8&H'0'+
MG)-O0.>+K/A!:?/A8LGB&=]W@P6?<N#5/_\1(.3\<7HSF=1OX1^O=37M*Z$G
M4$K/A:]& 1K6A6#C6O#S7!L(IP:O+8D;!XK)KNLC7V]TN#$ZM!K]+6<TRM*_
M>5M[E=4=]XYW7\!MGT?L.ZTBL7J4-%XRSAEHN:FW*GK4A3Y4;(3R!+NV8SI>
M0*?=VSE6/RZC15E'GM%-9)DXE2GY)ZNV717=M(@IPS_F<)&W2GQ/(Y;] /21
MLC@MM5DX;NSH3 RYN.R8KH=;NU?XZSVTU5MC3R=1 8*A:_"D92C03E',$V7!
MWZYMVZQQH%@(NJK/!E+GL8OD=-A!72]:%@#M-*"G%]:(ZV@"=! QV-JR!&CO
MX_4>;2A.,!-AZX+3@DA8HPTI4=<9%(9R3'>@NH:V% #:.< GOKJ(94AKF*L,
M.0P)P=+LF^S&=8UKFR^T=U\#M0ZUQJK]$V*""9%H<X/KT U?CK6J"[L\VA(O
MN=;@$)&#HV*&O*>&@8&9P+:Q0WMGWT&+=5$:0[4-8P]C%+J>P9RV&</]N_%3
MV62C>CLIH>=+#.E4@\)(V3V=:V RH81J:U?'^V08#QHBU3( :*< +T J3Z"F
MJ?/] 90W=Q\-P%#NH><:8.@&'O$-A8I:JH#L5&';WP6CPZG@9PEXB!CC3;+<
MOTZ.D=KG ]]WI#EWL1/6=:1E!,C."'X%ET8J"0BA(SMH!W7=VSK(Z$L37H9/
M(Y46(((#8X&US #9F<$+<VJDLH*AO*Y?[P!U/6EY [+SAE_&JI%*)R"4J\R*
MZ7K8$@YD)QR_G%4CE9U@)_!-J6K)"=K_:."9I!II>(2C'.;905TO6A*!^AX/
M]";52.48,/1=8HIXRS"0G6$\A50CM</[4%U'=Z"ZAK8-'MD;O(U4([7-#J'C
M8B@3QSV W=/4MA]C>S_6TVKDZ,S%:BN%GN=C:7LR;G =TA5(T=;H(B%VD+R?
MT."&&'G8,6PA<=O L;V!VRFS-@)CK/9:XO/=@!>:CK7;AHOW;[A/I<Q8/6G'
MGAM*Y_:G&A@W7;Y,.-? 9,Z\WX"?# .:4K=U![#_[K\O:<9JS\9AZ 2>5,T?
M]P6>:X"K0UO#&H);)H#M3&!S[UA[M=T;JQDG,U&F+ME1GNCXM79:JZU]2%R9
M .Q"=5UK*0#>_][A9]%HK';]4%YB+W: NNZUQ #W)08O0Z.QYJ0CP-!$S7#+
M!;"="[PPC<8J#QCZ\MWC#E#7DY8IX+XW T_F9EAS"( ]F4A@E4AT4%T_6B*!
M]S\I>!EV=HQ56N&%R,&!W-!WXKKWIRW[(/N?!FBFQPU?V4HP6<^*=W>,UC\;
M>_IR/R8:[@*]T T-,X6T/((\ZR#@B3YHKXFA>G?O!%BN.Z*2DRZLZV#+3(B=
MF9QNE5;'05M3(9IC?YDGDIU$XT*GQE1U+7T@=OJPTR%K(:E='CJ$<Q_?L/\B
M6S\G>+F+ J+9CSNN<ONR$]8UM6W;I/]5 =%< ?BN$TBV37;CNL:U39?TN2H0
M9[4:8]4K  0]SN[D6M7@E FH8CSHN_*>YEJ#4YKA1 <B#L2!@9.0MK63Y]P5
M:,,T)FIK]D*'^.J!W6CK-\+BSPNN(G:7YB7(Z)2+.F_%3]/9ZA?[JX>J6-0_
M&[XMJJJ8UV]G-.)+IP#P[Z=%4:T?Q"^1-W\W<?1_4$L#!!0    ( ,:!:E0;
M;5];(@,  (X)   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK59=;]HP
M%/TK5C1IJ[0VGU"8 *F%3>M#-53:]6':@TDNQ&IB4]N!5MJ/W[437 H4H:HO
MB3_N.3[W7MO7O960#RH'T.2I++CJ>[G6BV^^K](<2JK.Q (XSLR$+*G&KIS[
M:B&!9A94%GX4!&V_I(Q[@YX=&\M!3U2Z8!S&DJBJ+*E\OH1"K/I>Z*T';M@\
MUV; '_06= X3T'>+L<2>[U@R5@)73' B8=;W+L)OH] "K,5O!BNUT2;&E:D0
M#Z9SE?6]P"B" E)M*"C^EC"$HC!,J..Q(?7<F@:XV5ZS_[#.HS-3JF HBGN6
MZ;SO=3R2P8Q6A;X1JY_0.-0R?*DHE/V256,;>"2ME!9E T8%)>/UGSXU@=@
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M@@4%B@"A72D 0/:FV@LYIF*R#.K/,L#UO3ZY"D9B;G: @R2.;#^$<#1T<VD
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MD.,+."\MWA7]@@T,OT;._@%02P,$%     @ QH%J5.Q9T[)O*   ^X   !@
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M>BG-UL73V7Y3H$V,?@>:_ )WJ@15/+XPLYRIV)_M/7<IZK=NH3A<+OU=VR)
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M+)6V$'!%!9AL(;DAIFN8;O9N(V@/"@M57"1X$I +R7<*#_MG^1P\_(EKN (
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M7YSN'/%KF4^SL]DD.STYG>T8[\SO^XS&.QL9[W6S%)7ZC;=]I2NC2U7P7Y=
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MUKICINYJ' X6.3T%)1-QM@$ZE_*X@#G;K-$;4;;(GT@6'!G?!;8I0*& G*^
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M*K+ M6C0FR2K .-WZ*^@@8 7&C2T<PC!@9'M2G3TCL8XM7K?='6;;QQ-H@>
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MLB*;Y]!EWXF*B[_["KM7:<7I=7T@K,O.G*+!MB!>O/KA57Z>C.3?H !BN](
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MMY1[*45NJ],A2S+)9I/9Q=/)^=/9/>" +J#G3_@U,GD$U(F5&V-;;(:E 4W
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M+Z1,0HH8=NN&8M0L FF7<"A+BQ+[++MX<AZ-KQ8!NVYM=EQLZ/D/_9(<%NR
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M&1>LIQ+_^M?3LZ=?XFU?:/_1^\]]K^^KZY__W8F5]?]Y-EI10/?>@1U2^$N
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MIB\'VNP $AK N""18Z3GH4.[D5?P+)/6ZZ'SB)Q[VQ/O6LARV6@C,"B5MKV
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MEHN"-Z7]J+9_%UZ?.=++5&GHDVW=VB0Y8UECK*K\9I"@DK7[YO?>#H,-R_#
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MN!-8$/ 0%<(E(59-3QR<VT"+0/J\PB3%C'%\NB=3]K9O6X\[!^0M57"0%R
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M&N'1\ &2;S1E6K?A"X8_!9?_ %!+ P04    " #&@6I41I'U&_ "  !=!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM5=MNVS ,_17"NV #@OB2
M9.VZ)$"2;M@>"@3M+@_#'F2;L;7*DB?)=;*O'R4G;CHL>=I++-'D.8<TR4Q;
MI>]-B6AA6PEI9D%I;7T5AB8KL6)FJ&J4]&:C=,4L7741FEHCRWU0)<(DBMZ$
M%>,RF$^];:WG4]58P26N-9BFJIC>+5&H=A;$P<%PRXO2.D,XG]:LP#NT7^JU
MIEO8H^2\0FFXDJ!Q,PL6\=5R[/R]PU>.K3DZ@\LD5>K>73[ELR!R@E!@9AT"
MH\<#KE (!T0R?NTQ@Y[2!1Z?#^@??.Z42\H,KI3XQG-;SH++ '+<L$;86]5^
MQ'T^$X>7*6'\+[2=[R0*(&N,5=4^F!147'9/MMW7X2C@\E1 L@](O.Z.R*N\
M9I;-IUJUH)TWH;F#3]5'DS@NW4>YLYK><HJS\VO<D"6'E9)6\[3QI5H+)J>A
M)7CG%&9[J&4'E9R BA.X(932P'N98_X4("1=O;CD(&Z9G$6\QFP(HW@ 293$
M9_!&?;(CCS<Z@;=2%36S83[)A<SA%BW72#UFX9J;3"C3:(3OB]183?WRXPSG
MN.<<>\[Q_RCP62@WGU>F9AG. AI @_H!@WD\&L))#OA<(KBLF=Q!B@593*VD
M49K+ AB,H_C5_>O.E4LJ<WPQ@+;D60FU5@\\1P.V9!90\(*G @&K6J@=DCVC
M&#]<8!5D!V9T-TNL1] #&OGTY\$3M:5= 8)7W/HO80;@QI,8T;*MFS%NAD^4
MT_#1,C+0U YA$L$+4!O/LN':6!AW!F2D^R#PY;/+)+YX9QZE$165JO&IN]@=
M,@WH6I4*F&&5HNZ;;0"X=:U"I!HS54C^F]QH!_Z=&[3,P'.(AF.:3B&(PQ>0
M*N4<6:4:ZBWGPVGI6=2<B1[&"3 G%$3 J#_I@[P=PK^Z,#P:^0IUX1>;2Y;X
MNNGOK?WN7'0KX]&]6[PW3!=<&A"XH=!H>#$)0'?+K+M85?L%DBI+Z\@?2]K_
MJ)T#O=\H90\71]#_H\S_ %!+ P04    " #&@6I4B'U&"J$I  #EB0  &0
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M4'0 _^=2FMV"%/3-]^(_4$L#!!0    ( ,:!:E3K-C*3S@,  " /   9
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MW"?F5*^9- ZP<*;)Z=B]=;IIT9N)555HBU?*NB8[#$MWK4'M#[C]0BF[FWB
M]J(T^P502P,$%     @ QH%J5!(S>I-2!P  MS(  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&ULO9O;;MLX$(9?A3!ZT0)Q+)'B0442H$VVNP5:(&B2
M[D6Q%XK-Q$)U<"4Z:1?[\$O)CD<V18:I#-\DMCPDAQS.)_XC^^2QK+[7<RD5
M^IEG17TZFBNU>#N9U-.YS)/ZN%S(0G]R5U9YHO3;ZGY2+RJ9S-I&>3;!0< F
M>9(6H[.3]MIE=792+E66%O*R0O4RSY/JUWN9E8^GHW#T=.%+>C]7S87)V<DB
MN9=74MTL+BO];K+I99;FLJC3LD"5O#L=O0O?GL=M@];B:RH?Z\YKU$SEMBR_
M-V\^SDY'0>.1S.14-5TD^M^#/)=9UO2D_?BQ[G2T&;-IV'W]U/N'=O)Z,K=)
M+<_+[.]TIN:G(S%",WF7+#/UI7S\2ZXG1)O^IF56MW_1X]HV&*'ILE9EOFZL
M/<C38O4_^;E>B$Z#,+(TP.L&V+<!63<@[417GK73NDA4<G92E8^H:JQU;\V+
M=FW:UGHV:=&$\4I5^M-4MU-GYTD]1W_\6*8/228+5:.DF*'/2?5=JN0VD^A*
M3I=5JE)9HS&ZTIMHMM17RSOT+B\KE?XK9^B\K-41NBGT+LK:"W_JW;/JZ%-9
MUW+U\D.25NAKDBW;UCO#.D9]?:&OI=D;/?S-U05Z_>H->H72 EW/RV6MF]4G
M$Z77H9G-9+J>\_O5G+%ESA=R>HQ(>(1P@,.>YN?^S8/MYA.]^IL0X$T(<-L?
M<85 [H0@A\6H83&^?=)MT4<E\_H?Q\AD,S)I1XY<(S>C[>Z"(Y0H?;&J?J7%
M_2IJ1^BZ5$G6M]JK05@[2(.-A[.88,%/)@_=136M0AX$E&W,MJ80;:80.:>P
MO0W[O%NUI]UQXXA$8L<]TXQP$9!^[^C&.^KT;C<I^ORCQL#!CFLNBRVWV,8M
MYNO6*D/[_&+&J&-.=CPS;2R>\8UGW.D94*+/)=X72LSICE>FF2.48N.9>#Y7
MNJ#\]EGFM[)RY6&\Z3L^, '" /@?'((!ZU&ZBRY"$N*=T/28$2:"L#\V8><N
M%@Y.M'47KDQSFFR[!G0/\?!D6_?A],UELNT;\#]TWP#<Z;9N_&Q,33-73('L
MH1OMUHQ#_Z'/92%_K4\,Z,-2'P-\\C$$;H?TT!D)< [==-Y71IIPYC$6X6[T
M3#-7] #DH9OD7AEIDMK8]2Z3;=> Y*$;Y7X9*9[WS66R[1O<"<)X2$;&?C$U
MS1PQQ7"OP![W"DM&GI=Y+JMIFF3H,EG(RB<?,? =AP?.1]PYGKL!OJ=\Q":_
MPR"P;!@,",=NA/OD&38);1L7Z(S==/9*(FR>JFT# YJQ^TSMSA!L'I8=JPQ,
MQAY,MN[\:E%6B9+H0MZJKG;U20$ *N:'3@$@)O8X_.XA!4Q@A@&Q80F8B=W,
M]$H!$XF634$ A\2-0Z\4(.:)US8PT)"X3[ON%"#F(=:^R@0P2-P8O)IKI3V^
MEE5NJ=1X[';2J4R00Q=% &UD:$V!]!05 A$%NT6%7KL 6T(!""3#RPKD^;J"
MTV3;-0 EV4-I@?34%MBNK.@QLGD'#"5#R@NDI[X0"!*Q7<_Z[*Q1!<@2-V2]
M$TS?<VZ.KX[1M5[J6G_HF7O 4W+H<D0$3(W<3/6HYYE #3'FN^7&/C-KD")
M;S2\T! ]7VAPFFR[!H".]E!HB,Q3Z-@HA7I7&B+@>32DTA"9!U0=4Q;O.M93
M0[;'M%-"=O/^)8GW.S(G K!'ARX[1$#NR$UNC\PSB1Q%<6S;&T#E:'BI(/*N
M T0 W&@/=8#(/+..0]M#"T!L-$3F1^9A52\TCRP/(P"NU W7EVWT :J& D_I
MH84]!6!2-S"?W_'4)*&F$K>$GP(-Z7#13KU%.P72T3V(=FH>6L?8]B"L\R1L
MB&RGYE%4+S2UC0I0HVZHO6C'2[T;[M*IWO-U\XSZ0B[*.E5>^QU81P^MXBGP
MCKIYY['?3=A19JN>4* ='2[0J;= 9\ [M@>!SLR#XMB2X RPQH8H=&:>_BB-
M+7AGP#.V)X7^)"#^+!]D5>3-%S!^ _(,<,<.+>89((\-%?/,Y!VVE@P9 (\-
M%^G,_]%^Y]G^/A[N]RAP2X6( =O8$'7-^I[>Q[%E4( :VY]J?J>70Z'WR?2[
M7IP7;G: '3NT>N8 /#Y4/?,>6<PHH_UAX  \/EP7<V_1RX%Y? ^BESM%[_;(
M #4^1-'R'D7+*.6640%GW(VS3V5Q/U:#BK <$,8/+4<Y8(P/E:.\1XXR;(MK
MYQM(P]4H]U:C'$#&]Z!&>9\:M8"; [+X$#7*>]0H"RT[60"KA)M5OCOY]ZJ=
M L@E#JU !=!+#%6@HD>!QK$EX@+@)88+4.$M0 7@2^Q!@(H> 6JY00E@F1BB
M/T6/_HR%108(@)AP0^P%>WQ0O44 W<2A]:?H?(-RJ/X4/0^(&;&A!O@FANM/
MX:T_8T!<O ?]&?OKSQB@%@_1G^O&;'N9=Z$RZ?RJH/E)A]["]\T7^S-YIYL%
MQ\WAH5K]2F+U1I6+]H<&MZ529=Z^G,MD)JO&0']^5Y;JZ4WSVX7-;U7._@=0
M2P,$%     @ QH%J5+HX]Q"/ P  5 L  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&ULO59-;]LX$/TKA-!#"S31AS]3V ;BN(L-T"R"9+M[*/9 2V.+
MB$BJ)&4G17_\#BE95FQ9=7OHQ1:EF3?OS9##F6RE>M(I@"'//!-ZZJ7&Y!]\
M7\<I<*HO90X"OZRDXM3@4JU]G2N@B7/BF1\%P=#GE EO-G'O[M5L(@N3,0'W
MBNB"<ZI>YI#)[=0+O=V+![9.C7WASR8Y7<,CF,_YO<*57Z,DC(/03 JB8#7U
MKL,/BS"R#L[B'P9;W7@F5LI2RB>[N$VF7F 900:QL1 4_S9P UEFD9#'UPK4
MJV-:Q^;S#OT/)Q[%+*F&&YG]RQ*33KVQ1Q)8T2(S#W+[)U2"!A8OEIEVOV1;
MV08>B0MM)*^<D0%GHORGSU4B&@Z]T0F'J'*(#ARB\(1#KW+HG>O0KQSZ+C.E
M%)>'!35T-E%R2Y2U1C3[X)+IO%$^$[;NCT;A5X9^9G9#=4H^?BW8AF8@C"94
M).2.JB<P=)D!>82X4,PPT.2"7"<)L]6B&;D5Y9ZSM7N[0&.6O2-O"!/D[U06
M&E'TQ#=(T(;QXXK,O"03G2 31N1."I-J\E$DD+P&\%%9+2_:R9M'G8@+B"])
M+WQ/HB */S\NR-LW[RI)+RW\;LY'"RJT%I3%V2CA52O**ZF]NI(]!]OKJB0<
M5)+O*ZGWE?SR"7W)K0&N_^N(W*\C]UWD?E=D&RT^FT+;WBB##%T0VZXVLR@8
M]H)@XF^:)3HV"T=AV#![I6%0:QC\FH8VIB74H$'AJA>-1P=$CZW"41 ,ANU$
MAS7182?1NW/3.3S.4XC9/$SG\)AE<"J9HYKCJ)/C7P5?@B)RA?T@81N6%-@Q
M&OL/NP05I!!X467L&R0DDUJ37&K770AV%H*M@)>M !=K-#0(^)UTG-WYZ$C)
M"1GC6L;XYU.-EUTLUZ)DB@JE24%=F)2*"SQ/N51X>Q+&<\H47H^FC>CXJ#*'
M1?FAQ:++XI78JUKL5:?8AUTMUC@LN*S;HJ!>E-EZA-_C]:ICQ7*;B3:9W?&$
M1%@L*L.MH4[$[NA-8;"_X((?5/&9\8*3+W=@=V57PPL;MV;XFYMM&.UC1[^P
M+6,\+0JG*'O4,+&[USEF6":M5W%WE(B\ %6M)? ;XP8'M79CFV50"%->S?7;
M>C2\=@/1P?NY'1G=&+.'*>=-U+BV6R&#%4(&ER,\UJH<X<J%D;D;:I;2X(CD
M'E,<>T%9 _R^DM+L%C9 /4C/_@=02P,$%     @ QH%J5"G2/J,V"@  XF@
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M/6G'=BV%7>V).0LO$ O)/X)P@5B$]9T@0+*.T!-VM"G\P'T;(+%'D%XP$Q*
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M>8"D%Q*_T:)U3VLNM'FH;ED;[05I'<SY0@B]WM@ @YKG?P!02P,$%     @
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MG9W9E33<Q5&J[[H",.BIYD(OH\J8YBJ.];:"FNI+V8"P=_92U=38K3K$NE%
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MP.^KHJBZ+^)(P,VIGR?_ U!+ P04    " #&@6I4_-H[SQ4$  !Y$@  &0
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M4VO#+=*W-M&-_C<1>A: N92H;"UD*$3L&'IU"[5&$S%L(G8XV5OH'$Y]K]\
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M6*PZ,1%40K5?_M3E84\0#XX(DDZ0?%20=H+4!]J2^;!FW/+Q4..6:6=-WMS
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MWNXJKI@KL6.4^@&^2X$]/,8=CW$O3'L? 7>H4F[N8J5XBO *;UE]CUL#>N%
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M$%:[7I2[DF=VQ03=BE0M<_0^C5BTK6  )M1VD(T=%\2I\8J%?>3C(T0\@CL
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M?#_H9DS?,J;OYK 731I[=.,]9.-;>O0/._9\YZ11:=UZ[.<:-'S+?KZ;M3:
M0J$?3LX*DUFZ75?Y_6N.6,P77'NQR42=*-U;X>$^-UI^]-U,I=]M5"5H\OPF
MC8J059>;_EDF_\$%:9NU/WT=!1G8+AZX'YJ]^%3ROMJ@F6'CJ1>T$FS0>#V8
M,+DP+W)S2(TB5>4;MOIN_;+XW+PBW;E_@=]=E:]\K9KR#?0ME0L.)!ZS.:CT
M^F, )<N7NN47)3+S$G(FE!*)N5PR&C&I%\#O<R'4YHO>H'ZU?O8?4$L#!!0
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M#\D9'^*$(BSMSL!-R9&_) C)U-;9Y-G99=++F&$^A#3^#9(HB3L"NKX<'G7
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MRN8O>+B#? ;\U/)%S5S11W2WU837>G=W*\5PRY(H\J(=<_=!01#Z.^;N@_S
M;QTVM]UDU#Z9T1<H@&-JO!VDZJ@E0G*LJ]+_V-MI9NM\1'M=YZ4N..]N<"VY
M_=/YG3V'#Z"\*&SM6'P Y;8C;\=C>ZORY< 7Y@8A4,*6A:SJ0C/:W%(&IC;O
MC _U[<54U!>9ZNISA_F"% )1F"M)YZJEMAVO;A-51[+2U-<9DZI:FV:F;F#
M-4!]GS,F-QT]07.GZ_\#4$L#!!0    ( ,:!:E1HD-=UQ ,  &P.   9
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MBB%D?4BM!UH<[#GO06@\-=K;/1[L01H#?+\50C\/S-&Q_:NP^@]02P,$%
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MA,NP,:^+A%K53#5MH5OM'K GT[=/UF?PL#7OT%^:YE5\QF)#F40%60.E,XC
M<-&\-,U$\<KTWC>NH).;80Z/,Q$Z /;7G*O]1'^@>^ZG?P!02P,$%     @
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MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M-OXC;O$"4$L! A0#%     @ QH%J5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #&@6I4/+"4JNX
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ QH%J5+_2D03! @
M2PD  !@              ("!"18  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( ,:!:E1<4T!;N 0  ,,0   8              " @0 9
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #&@6I4+Q[R
M(@ )  !#,0  &               @('N'0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ QH%J5!MM7ULB P  C@D  !@
M ("!)"<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,:!
M:E0:=AWQ+@D  $HJ   8              " @7PJ  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #&@6I4 ,G4L:,%  "9#   &
M        @('@,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( ,:!:E14%=S);@\  #8T   9              "
M@?9Q  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ QH%J
M5(4NX-UO(P  888  !D              ("!FX$  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #&@6I4$K/]?SH#  ""!P  &0
M        @(%!I0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( ,:!:E08M,U?5 H  -,>   9              " @;*H  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ QH%J5-R,4WED#0  \R8
M !D              ("!/;,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #&@6I4]/_G@*@+  ##(0  &0              @('8P
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,:!:E2.IKD*
M- 4  " ,   9              " @;?,  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ QH%J5$:1]1OP @  708  !D
M ("!(M(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #&
M@6I4B'U&"J$I  #EB0  &0              @(%)U0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,:!:E1R0#K,P ,  &L(   9
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M970R-BYX;6Q02P$"% ,4    " #&@6I4ZS8RD\X#   @#P  &0
M    @(&"$P$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M ,:!:E0Z[KSM60,  /\'   9              " @8<7 0!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ QH%J5,()5].= @  EP4  !D
M             ("!%QL! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #&@6I4 #_3L#L&   B$   &0              @('K'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,:!:E1T9+[DYP4
M  P/   9              " @5TD 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ QH%J5)E(-9W> P  H@@  !D              ("!
M>RH! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #&@6I4
MO"2B\R<#  "/"   &0              @(&0+@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,:!:E0(XM&>GP,  /<+   9
M      " @>XQ 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ QH%J5":)^1R2 @  IP8  !D              ("!Q#4! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #&@6I4AX1N&$\#   T#0
M&0              @(&-. $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( ,:!:E02,WJ34@<  +<R   9              " @1,\ 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ QH%J5+HX]Q"/
M P  5 L  !D              ("!G$,! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #&@6I4*=(^HS8*  #B:   &0
M@(%B1P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,:!
M:E1#*ZG>*P(  +\%   9              " @<]1 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ QH%J5&;<.K*0 P  U0T  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( ,:!:E0@>63G4@,  &H*   9
M  " @<YH 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MQH%J5*48W3BK#@   50  !D              ("!5VP! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #&@6I4_-H[SQ4$  !Y$@  &0
M            @($Y>P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( ,:!:E2,YIDV_P(  *$(   9              " @85_ 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ QH%J5%R2=!B: @
M,P8  !D              ("!NX(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #&@6I4UAF>:,0'  #1)0  &0              @(&,
MA0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,:!:E3U
MC-FQG@(  %X&   9              " @8>- 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ QH%J5+BC/DD*!P  9A\  !D
M     ("!7) ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,:!:E1IV2%X#0,  -\)   9              "
M@>.F 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ QH%J
M5&B0UW7$ P  ; X  !D              ("!)ZH! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " #&@6I4K9WKF_\$  !F%@  &0
M        @($BK@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( ,:!:E3X[?#YL0,  #8,   9              " @5BS 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ QH%J5$'C3H?) P  3P\
M !D              ("!0+<! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " #&@6I4&TW#E0<#  "6"   &0              @(% NP$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,:!:E2!F$JF
MYP(  /H'   9              " @7Z^ 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ QH%J5#WWW6;F @  X@<  !D
M ("!G,$! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #&
M@6I41NU\DWD#  #:#   &0              @(&YQ $ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( ,:!:E3+WZX0C0(  +H&   9
M          " @6G( 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#
M%     @ QH%J5"_J6H(> P  ,!(   T              ( !+<L! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " #&@6I4EXJ[',     3 @  "P
M    @ %VS@$ 7W)E;',O+G)E;'-02P$"% ,4    " #&@6I4B\"9;P<%  #1
M+   #P              @ %?SP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ QH%J5,A<P5(@ @  T"<  !H              ( !D]0! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ QH%J5.(A,D+Q 0  &2<
M !,              ( !Z]8! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $L 2P"$%   #=D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>322</ContextCount>
  <ElementCount>502</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail</Role>
      <ShortName>Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail</Role>
      <ShortName>Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Common Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail</Role>
      <ShortName>Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="grts-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="grts-20211231.htm">grts-20211231.htm</File>
    <File>grts-20211231.xsd</File>
    <File>grts-20211231_cal.xml</File>
    <File>grts-20211231_def.xml</File>
    <File>grts-20211231_lab.xml</File>
    <File>grts-20211231_pre.xml</File>
    <File>grts-ex10_10.htm</File>
    <File>grts-ex10_11.htm</File>
    <File>grts-ex10_3.htm</File>
    <File>grts-ex23_1.htm</File>
    <File>grts-ex31_1.htm</File>
    <File>grts-ex31_2.htm</File>
    <File>grts-ex32_1.htm</File>
    <File>grts-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img96160895_0.jpg</File>
    <File>img96160895_1.jpg</File>
    <File>img96160895_2.jpg</File>
    <File>img96160895_3.jpg</File>
    <File>img96160895_4.jpg</File>
    <File>img96160895_5.jpg</File>
    <File>img96160895_6.jpg</File>
    <File>img96160895_7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="852">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "grts-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 322,
   "dts": {
    "calculationLink": {
     "local": [
      "grts-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "grts-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "grts-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "grts-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "grts-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "grts-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 663,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://gritstonebio.com/20211231": 3,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 14
   },
   "keyCustom": 122,
   "keyStandard": 380,
   "memberCustom": 46,
   "memberStandard": 35,
   "nsprefix": "grts",
   "nsuri": "http://gritstonebio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Cash Equivalents and Marketable Securities",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Collaboration and License Agreements",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Balance Sheet Components",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stockholders' Equity",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stock-Based Compensation",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Income Taxes",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Common Share",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Defined Contribution Plan",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_64144ed4-7156-4df6-9ed4-71edcffd2730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Collaboration and License Agreements (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_64144ed4-7156-4df6-9ed4-71edcffd2730",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Income Taxes (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_1c539e79-df24-408f-baa2-48c4f8fe8cd7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Straight Line Method Over Estimated Useful Lives of Respective Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_1c539e79-df24-408f-baa2-48c4f8fe8cd7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Schedule of Amortized Cost, Unrealized Gains and Losses and Fair Value of Cash Equivalent and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "lang": null,
      "name": "grts:CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grts:CashAndCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "grts:CashAndCashEquivalentsAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_ef27cb81-c09f-4cb8-81bf-6b870908b71b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject To Fair Value Measurements on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_ef27cb81-c09f-4cb8-81bf-6b870908b71b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment and Related Accumulated Depreciation and Amortization (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_ffaa39a0-354a-45c2-b143-8dff6921739e",
      "decimals": "-5",
      "lang": null,
      "name": "grts:MaximumMilestonePaymentObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Minimum Annual Payments Under Operating Lease Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "lang": null,
      "name": "grts:DeferredContractAcquisitionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
     "shortName": "Collaboration and License Agreements - Schedule of Changes in Deferred Revenue Balance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d2ee84e1-e4c2-4cee-9cf0-52f74628f3db",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_b5b3f31b-7118-424c-be58-60dc31c876aa",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_b5b3f31b-7118-424c-be58-60dc31c876aa",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Deposits and Other Long-Term Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "lang": null,
      "name": "grts:PrepaidExpenseForResearchAndDevelopmentNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_7042b1ea-e9df-44d9-b8d5-859ef3010de3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ClassOfWarrantOrRightIssueDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
     "shortName": "Stockholders' Equity - Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "grts:ClassOfWarrantOrRightIssueDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_71278cac-f4bb-4914-9100-9aa2c97ad1c9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_71278cac-f4bb-4914-9100-9aa2c97ad1c9",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail",
     "shortName": "Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_5ab8f0df-9507-4ec5-b14f-b33c8795ac6f",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_7042b1ea-e9df-44d9-b8d5-859ef3010de3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-Based Compensation - Schedule of Stock Options Activity (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_7042b1ea-e9df-44d9-b8d5-859ef3010de3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_7042b1ea-e9df-44d9-b8d5-859ef3010de3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of the Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_6f2d73a7-30b6-410a-8148-9410d7383a67",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_6f2d73a7-30b6-410a-8148-9410d7383a67",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail",
     "shortName": "Income Taxes - Components of the Net Deferred Tax Assets/Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d7d371dd-a94d-4213-a570-7cce5450d104",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_d171005c-8d0e-451d-ba44-fff86b36b8da",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
     "shortName": "Income Taxes - Schedule of Net Operating Loss and Tax Credit Carryforwards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "grts:ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_b3dbdfb2-9a14-4b95-94f9-f7c4fd7b4d2d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_7042b1ea-e9df-44d9-b8d5-859ef3010de3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Activity Related Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_b5b3f31b-7118-424c-be58-60dc31c876aa",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Net Loss Per Common Share - Computation of Basic and Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "grts:ClassOfWarrantOrRightWarrantsExercised",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Net Loss Per Common Share - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
     "shortName": "Net Loss Per Common Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_fc5b8ba8-c6a4-48e5-882f-42a0934367be",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail",
     "shortName": "Net Loss Per Common Share - Computation of Potentially Anti-dilutive Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Defined Contribution Plan - Additional Information (Detail)",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
     "shortName": "Defined Contribution Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Organization",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "grts-20211231.htm",
      "contextRef": "C_f5581400-90ad-4249-923b-5cba9bd710c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "grts_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid for research and development activities due within one year or the normal operating cycle, if longer.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdditionalFunding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding.",
        "label": "Additional Funding",
        "terseLabel": "Additional funding"
       }
      }
     },
     "localname": "AdditionalFunding",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdjustmentToRightOfUseAssetsAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to Right-Of-Use Assets and Lease Liability .",
        "label": "Adjustment To Right Of Use Assets And Lease Liability",
        "terseLabel": "Adjustment to right-of-use assets and lease liability"
       }
      }
     },
     "localname": "AdjustmentToRightOfUseAssetsAndLeaseLiability",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital offering costs related to sale of common stock and pre funded warrants.",
        "label": "Adjustments To Additional Paid In Capital Offering Costs Related To Sale Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Offering costs related to the sale of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOfferingCostsRelatedToSaleOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate payment in specified development regulatory and commercial milestone.",
        "label": "Aggregate Payment In Specified Development Regulatory And Commercial Milestone",
        "verboseLabel": "Aggregate payment in specified development regulatory and commercial milestone"
       }
      }
     },
     "localname": "AggregatePaymentInSpecifiedDevelopmentRegulatoryAndCommercialMilestone",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AgreedUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed upfront payment.",
        "label": "Agreed Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AgreedUpfrontPayment",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AgreementTotalFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement total funding.",
        "label": "Agreement Total Funding",
        "terseLabel": "Agreement total funding"
       }
      }
     },
     "localname": "AgreementTotalFunding",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AmendedAndRestatedCertificateOfIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated Certificate Of Incorporation [Member]",
        "label": "Amended And Restated Certificate Of Incorporation [Member]",
        "terseLabel": "Amended and Restated Certificate of Incorporation [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedCertificateOfIncorporationMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AmountOfIrrevocableLettersOfCreditWithdrawn": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of irrevocable letters of credit withdrawn.",
        "label": "Amount Of Irrevocable Letters Of Credit Withdrawn",
        "terseLabel": "Withdrawal from irrevocable letters of credit"
       }
      }
     },
     "localname": "AmountOfIrrevocableLettersOfCreditWithdrawn",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AmountToExtendOptionTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to extend option term.",
        "label": "Amount To Extend Option Term",
        "terseLabel": "Amount to extend the option term"
       }
      }
     },
     "localname": "AmountToExtendOptionTerm",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_AnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc.",
        "label": "Arbutus Biopharma Corporation And Protiva Biotherapeutics Inc [Member]",
        "terseLabel": "Arbutus Biopharma Corporation and Protiva Biotherapeutics Inc [Member]"
       }
      }
     },
     "localname": "ArbutusBiopharmaCorporationAndProtivaBiotherapeuticsIncMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_AtTheMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program member.",
        "label": "At The Market Equity Offering Program [Member]",
        "terseLabel": "ATM Equity Offering Program [Member]",
        "verboseLabel": "ATM Equity Offering Program [Member]"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BlueBirdBioTo2SeventyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Bird Bio to 2seventy.",
        "label": "Blue Bird Bio to 2seventy [Member]",
        "verboseLabel": "Bluebird bio to 2seventy [Member]"
       }
      }
     },
     "localname": "BlueBirdBioTo2SeventyMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BluebirdBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bluebird Bio Inc.",
        "label": "Bluebird Bio Inc [Member]",
        "terseLabel": "Bluebird Bio Inc [Member]"
       }
      }
     },
     "localname": "BluebirdBioIncMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_BostonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston Lease [Member]",
        "label": "Boston Lease [Member]"
       }
      }
     },
     "localname": "BostonLeaseMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CEPIFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEPI funding agreement.",
        "label": "C E P I Funding Agreement [Member]",
        "terseLabel": "C E P I Funding Agreement [Member]"
       }
      }
     },
     "localname": "CEPIFundingAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge Massachusetts [Member]",
        "label": "Cambridge Massachusetts [Member]",
        "terseLabel": "Cambridge Massachusetts [Member]",
        "verboseLabel": "Cambridge Massachusetts [Member]"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CashAndCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and marketable securities.",
        "label": "Cash And Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashAndCashEquivalentsUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents, unrealized gains.",
        "label": "Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrealizedGains",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashAndCashEquivalentsUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents unrealized losses.",
        "label": "Cash And Cash Equivalents Unrealized Losses",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrealizedLosses",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashCashEquivalentsAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities accumulated gross unrealized gain before tax.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities accumulated gross unrealized loss before tax.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale debt securities amortized cost basis.",
        "label": "Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "grts_CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities debt securities.",
        "label": "Cash Equivalents And Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Line Items]",
        "terseLabel": "Cash equivalents and marketable securities [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesLineItems",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CashEquivalentsAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Table]",
        "terseLabel": "Cash Equivalents And Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesTable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CepInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Cep Innovations [Member]",
        "verboseLabel": "CEPI [Member]"
       }
      }
     },
     "localname": "CepInnovationsMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ClassOfWarrantOrRightIssueDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, issue date.",
        "label": "Class Of Warrant Or Right Issue Date",
        "terseLabel": "Issue Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssueDate",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "grts_ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right nominal exercise price of warrants or rights.",
        "label": "Class Of Warrant Or Right Nominal Exercise Price Of Warrants Or Rights",
        "terseLabel": "Warrant nominal exercise price",
        "verboseLabel": "Class of warrant nominal exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNominalExercisePriceOfWarrantsOrRights",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_ClassOfWarrantOrRightWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right warrants exercised",
        "label": "Class Of Warrant Or Right Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ClassOfWarrantOrRightsExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or rights expiration.",
        "label": "Class Of Warrant Or Rights Expiration",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExpiration",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CoalitionForEpidemicPreparednessInnovationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovation",
        "label": "Coalition for Epidemic Preparedness Innovation [Member]",
        "terseLabel": "Coalition For Epidemic Preparedness Innovation [Member]",
        "verboseLabel": "CEPI [Member]"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationAgreementEarlyTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement early termination notice period.",
        "label": "Collaboration Agreement Early Termination Notice Period",
        "terseLabel": "Collaboration agreement early termination notice period"
       }
      }
     },
     "localname": "CollaborationAgreementEarlyTerminationNoticePeriod",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement [Member]",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationAgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination term.",
        "label": "Collaboration Agreement Termination Term",
        "terseLabel": "Collaboration agreement termination term"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationTerm",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CollaborationOptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, option and license agreement.",
        "label": "Collaboration Option And License Agreement [Member]",
        "terseLabel": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CollaborationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration receivable.",
        "label": "Collaboration Receivable",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "CollaborationReceivable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_CollaborativeAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and license agreements.",
        "label": "Collaborative And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeAndLicenseAgreementsAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "grts_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments and Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_CommonStockAndOrPreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and/or pre-funded warrants.",
        "label": "Common Stock And Or Pre Funded Warrants [Member]",
        "terseLabel": "Common Stock and Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockAndOrPreFundedWarrantsMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock and warrants.",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common Stock and Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockAndWarrantsMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CommonStockFairValueClosingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock fair value closing price per share.",
        "label": "Common Stock Fair Value Closing Price Per Share",
        "terseLabel": "Common stock fair value closing price per share"
       }
      }
     },
     "localname": "CommonStockFairValueClosingPricePerShare",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_CommonStockPurchasePriceInExcessOfFairValue1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchase Price In Excess Of Fair Value1",
        "label": "Common Stock Purchase Price In Excess Of Fair Value1",
        "terseLabel": "Common stock purchase price in excess of fair value"
       }
      }
     },
     "localname": "CommonStockPurchasePriceInExcessOfFairValue1",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment And Software [Member]",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software [Member]",
        "verboseLabel": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ContractResearchOrganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Research Organization.",
        "label": "Contract Research Organization [Member]",
        "terseLabel": "Contract Research Organization [Member]"
       }
      }
     },
     "localname": "ContractResearchOrganizationMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ContractWithCustomerAssetAddition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset addition.",
        "label": "Contract With Customer Asset Addition",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAddition",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerAssetDeduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer asset deduction.",
        "label": "Contract With Customer Asset Deduction",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeduction",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityAddition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability addition.",
        "label": "Contract With Customer Liability Addition",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAddition",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability deductions.",
        "label": "Contract With Customer Liability Deductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability revenue recognized including new contracts in period.",
        "label": "Contract With Customer Liability Revenue Recognized Including New Contracts In Period",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingNewContractsInPeriod",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution.",
        "label": "Contribution [Member]",
        "terseLabel": "Contribution revenues [Member]"
       }
      }
     },
     "localname": "ContributionMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_CumulativeChangesInOwnershipInterestOfShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative changes in ownership interest of shareholders.",
        "label": "Cumulative Changes In Ownership Interest Of Shareholders",
        "terseLabel": "Cumulative changes in ownership interest of shareholders"
       }
      }
     },
     "localname": "CumulativeChangesInOwnershipInterestOfShareholders",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_DeferredContractAcquisitionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred contract acquisition costs.",
        "label": "Deferred Contract Acquisition Costs",
        "terseLabel": "Deferred contract acquisition costs"
       }
      }
     },
     "localname": "DeferredContractAcquisitionCosts",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredContractAcquisitionCostsAmortized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred contract acquisition costs amortized.",
        "label": "Deferred Contract Acquisition Costs Amortized",
        "terseLabel": "Deferred contract acquisition costs, amortized"
       }
      }
     },
     "localname": "DeferredContractAcquisitionCostsAmortized",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, amortization.",
        "label": "Deferred Tax Assets Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortization",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating lease right of uset assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Uset Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUsetAssets",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DeferredTaxLiabilitiesOtherDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, other depreciation.",
        "label": "Deferred Tax Liabilities Other Depreciation",
        "negatedLabel": "Other depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOtherDepreciation",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit assets and other assets noncurrent.",
        "label": "Deposit Assets And Other Assets Noncurrent Disclosure [Abstract]"
       }
      }
     },
     "localname": "DepositAssetsAndOtherAssetsNoncurrentDisclosureAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "grts_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Deposits And Other Assets.",
        "label": "Deposits And Other Assets Noncurrent",
        "terseLabel": "Deposits and other long-term assets",
        "totalLabel": "Total deposits and other long-term assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_DescriptionOfNewAccountingPronouncementsNotYetAdopted1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of New Accounting Pronouncements Not Yet Adopted 1",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted1",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_DisclosureOfNeedForAdditionalCapitalPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of need for additional capital.",
        "label": "Disclosure Of Need For Additional Capital Policy [Text Block]",
        "terseLabel": "Need for Additional Capital"
       }
      }
     },
     "localname": "DisclosureOfNeedForAdditionalCapitalPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_EarlyExercisedCommonStockSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercised common stock subject to future vesting.",
        "label": "Early Exercised Common Stock Subject To Future Vesting [Member]",
        "terseLabel": "Early Exercised Common Stock Subject To Future Vesting [Member]"
       }
      }
     },
     "localname": "EarlyExercisedCommonStockSubjectToFutureVestingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early termination reduction of future milestone and royalty payments.",
        "label": "Early Termination Reduction Of Future Milestone And Royalty Payments",
        "terseLabel": "Early termination reduction of future milestone and royalty payments, description"
       }
      }
     },
     "localname": "EarlyTerminationReductionOfFutureMilestoneAndRoyaltyPayments",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent income tax rate differential.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Income Tax Rate Differential",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRateDifferential",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_EmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emeryville California.",
        "label": "Emeryville California [Member]",
        "terseLabel": "Emeryville California [Member]"
       }
      }
     },
     "localname": "EmeryvilleCaliforniaMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EmployeeOrDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee or Director.",
        "label": "Employee Or Director [Member]",
        "terseLabel": "Employee or Director [Member]"
       }
      }
     },
     "localname": "EmployeeOrDirectorMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_EsppEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "ESPP Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EsppEmployeeStockPurchasePlanMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FirstTrancheOfFundingsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Tranche of Fundings Received",
        "label": "First Tranche of Fundings Received",
        "terseLabel": "First tranche of funding received"
       }
      }
     },
     "localname": "FirstTrancheOfFundingsReceived",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Public Offering [Member]"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Agreement.",
        "label": "Funding Agreement [Member]"
       }
      }
     },
     "localname": "FundingAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_FundingDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding development costs.",
        "label": "Funding Development Costs",
        "verboseLabel": "Funding development costs"
       }
      }
     },
     "localname": "FundingDevelopmentCosts",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FutureFundingExpected": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funding expected in future.",
        "label": "Future Funding Expected",
        "terseLabel": "Future Funding Expected"
       }
      }
     },
     "localname": "FutureFundingExpected",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_FutureMilestoneAndRoyaltyPaymentsReductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Milestone And Royalty Payments, Reduction Percentage",
        "label": "Future Milestone And Royalty Payments, Reduction Percentage",
        "terseLabel": "Future Milestone And Royalty Payments, Reduction Percentage"
       }
      }
     },
     "localname": "FutureMilestoneAndRoyaltyPaymentsReductionPercentage",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_GatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gates Foundation Member.",
        "label": "Gates Foundation [Member]"
       }
      }
     },
     "localname": "GatesFoundationMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GenevantSciencesGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genevant Sciences GmbH.",
        "label": "Genevant Sciences Gmb H [Member]",
        "terseLabel": "Genevant Sciences GmbH [Member]",
        "verboseLabel": "Genevant [Member]"
       }
      }
     },
     "localname": "GenevantSciencesGmbHMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GileadSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc.",
        "label": "Gilead Sciences Inc [Member]",
        "terseLabel": "Gilead [Member]"
       }
      }
     },
     "localname": "GileadSciencesIncMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_GrantAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Agreement.",
        "label": "Grant Agreement [Member]",
        "terseLabel": "Grant Agreement [Member]"
       }
      }
     },
     "localname": "GrantAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued and other liabilities non-current.",
        "label": "Increase Decrease In Accrued And Other Liabilities Non Current",
        "terseLabel": "Accrued and other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedAndOtherLiabilitiesNonCurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued research and development expenses.",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInDepositAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deposit and other assets noncurrent.",
        "label": "Increase Decrease In Deposit And Other Assets Noncurrent",
        "negatedLabel": "Deposits and other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositAndOtherAssetsNoncurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IncreaseInSharesAvailableForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in shares available for issuance percentage.",
        "label": "Increase In Shares Available For Issuance Percentage",
        "terseLabel": "Increase in shares available for issuance"
       }
      }
     },
     "localname": "IncreaseInSharesAvailableForIssuancePercentage",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_InitialFundingDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial funding development costs.",
        "label": "Initial funding development costs"
       }
      }
     },
     "localname": "InitialFundingDevelopmentCosts",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_InterestAndOtherReceivablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other receivables current.",
        "label": "Interest And Other Receivables Current",
        "terseLabel": "Interest and other receivables"
       }
      }
     },
     "localname": "InterestAndOtherReceivablesCurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_IssuanceOfCommonStockForWarrantExercisesShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for warrant exercises, Share",
        "label": "Issuance of common stock for warrant exercises, Share",
        "terseLabel": "Issuance of common stock for warrant exercises, Share"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForWarrantExercisesShare",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]",
        "verboseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lapse of repurchase rights related to common stock issued pursuant to early exercises.",
        "label": "Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises"
       }
      }
     },
     "localname": "LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercises",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares.",
        "label": "Lapse Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises Shares",
        "terseLabel": "Lapse of repurchase rights related to common stock issued pursuant to early exercises, shares"
       }
      }
     },
     "localname": "LapseOfRepurchaseRightsRelatedToCommonStockIssuedPursuantToEarlyExercisesShares",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_LeaseExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration term",
        "label": "Lease expiration term"
       }
      }
     },
     "localname": "LeaseExpirationTerm",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases additional number of renewal terms.",
        "label": "Lessee Leasing Arrangements Operating Leases Additional Number Of Renewal Terms",
        "terseLabel": "Operating leases number of renewal terms"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesAdditionalNumberOfRenewalTerms",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "grts_LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases term of contract month and year.",
        "label": "Lessee Leasing Arrangements Operating Leases Term Of Contract Month And Year",
        "terseLabel": "Operating lease termination date"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesTermOfContractMonthAndYear",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_LessorOperatingLeaseNoticePeriodToTerminate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating lease notice period to terminate for the additional temporary space.",
        "label": "Lessor Operating Lease Notice Period To Terminate",
        "terseLabel": "Temporary space lease termination notice period"
       }
      }
     },
     "localname": "LessorOperatingLeaseNoticePeriodToTerminate",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities [Member]"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_MarketableSecuritiesContractualMaturitiesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities contractual maturities period.",
        "label": "Marketable Securities Contractual Maturities Period",
        "terseLabel": "Marketable securities contractual maturities period"
       }
      }
     },
     "localname": "MarketableSecuritiesContractualMaturitiesPeriod",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_MarketableSecuritiesRealizedGainLossDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities realized gain loss, description.",
        "label": "Marketable Securities Realized Gain Loss Description",
        "terseLabel": "Realized gains or losses on marketable securities, description"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLossDescription",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_MaximumAggregateContingentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate contingent milestone payment.",
        "label": "Maximum Aggregate Contingent Milestone Payment",
        "terseLabel": "Maximum aggregate contingent milestone payment"
       }
      }
     },
     "localname": "MaximumAggregateContingentMilestonePayment",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumAggregateContingentMilestonePaymentToBeMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate contingent milestone payment to be made.",
        "label": "Maximum Aggregate Contingent Milestone Payment To Be Made",
        "terseLabel": "Maximum aggregate contingent milestone payments to be made by company"
       }
      }
     },
     "localname": "MaximumAggregateContingentMilestonePaymentToBeMade",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumMilestoneConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum consideration to be paid in the future based on milestones per the License Agreement.",
        "label": "Maximum Milestone Consideration Payable",
        "terseLabel": "Maximum milestone consideration payable"
       }
      }
     },
     "localname": "MaximumMilestoneConsiderationPayable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount to be paid upon achievement of certain milestones as defined under the research and development agreement.",
        "label": "Maximum Milestone Payment Obligation",
        "terseLabel": "Maximum milestone payments"
       }
      }
     },
     "localname": "MaximumMilestonePaymentObligation",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumOfferingExpensesAgreedToBeReimbursed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum offering expenses agreed to be reimbursed.",
        "label": "Maximum Offering Expenses Agreed To Be Reimbursed",
        "terseLabel": "Maximum offering expense agreed to be reimbursed"
       }
      }
     },
     "localname": "MaximumOfferingExpensesAgreedToBeReimbursed",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumPercentageOfCommonStockOwnershipToExerciseWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock ownership to exercise warrant.",
        "label": "Maximum Percentage Of Common Stock Ownership To Exercise Warrant",
        "terseLabel": "Maximum percentage of common stock ownership to exercise warrant"
       }
      }
     },
     "localname": "MaximumPercentageOfCommonStockOwnershipToExerciseWarrant",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_MaximumPotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable consideration relating to future milestones.",
        "label": "Maximum Potential Milestone Receivable",
        "terseLabel": "Maximum development, regulatory, and commercial milestones"
       }
      }
     },
     "localname": "MaximumPotentialMilestoneReceivable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MaximumSecuritiesCoveredUnderRegistrationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum securities covered under registration agreement.",
        "label": "Maximum Securities Covered Under Registration Agreement",
        "terseLabel": "Common stock, preferred stock, debt securities, warrants and units covered in Registration Statement"
       }
      }
     },
     "localname": "MaximumSecuritiesCoveredUnderRegistrationAgreement",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MilestonePaymentIncludedInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment included in research and development expense.",
        "label": "Milestone Payment Included In Research And Development Expense",
        "terseLabel": "Milestone payment included in research and development expense"
       }
      }
     },
     "localname": "MilestonePaymentIncludedInResearchAndDevelopmentExpense",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of taxable income where use of net operating losses is suspended.",
        "label": "Minimum Amount Of Taxable Income Where Use Of Net Operating Losses Suspended",
        "terseLabel": "Minimum amount of taxable income where use of net operating losses is suspended"
       }
      }
     },
     "localname": "MinimumAmountOfTaxableIncomeWhereUseOfNetOperatingLossesSuspended",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_MinimumPercentageFairMarketValueOfSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage fair market value of share price.",
        "label": "Minimum Percentage Fair Market Value Of Share Price",
        "terseLabel": "Minimum percentage fair market value of share price"
       }
      }
     },
     "localname": "MinimumPercentageFairMarketValueOfSharePrice",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_MinimumPercentageOfOutstandingSharesHeldByIndividual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of outstanding shares held by individual.",
        "label": "Minimum Percentage Of Outstanding Shares Held By Individual",
        "terseLabel": "Minimum percentage of outstanding shares held by individual"
       }
      }
     },
     "localname": "MinimumPercentageOfOutstandingSharesHeldByIndividual",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_NetContractAsset": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net contract asset.",
        "label": "Net Contract Asset",
        "terseLabel": "Net contract asset"
       }
      }
     },
     "localname": "NetContractAsset",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New right-of-use assets obtained in exchange for lease obligations [Abstract]",
        "label": "New Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "New right-of-use assets obtained in exchange for lease obligations (in thousands):"
       }
      }
     },
     "localname": "NewRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_NonExclusiveLicenseAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Exclusive license and development agreement.",
        "label": "Non Exclusive License And Development Agreement [Member]",
        "terseLabel": "Non-Exclusive License and Development Agreement [Member]"
       }
      }
     },
     "localname": "NonExclusiveLicenseAndDevelopmentAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_NonRefundableOptionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable option fee.",
        "label": "Non Refundable Option Fee",
        "terseLabel": "Non-refundable option fee"
       }
      }
     },
     "localname": "NonRefundableOptionFee",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_NonTaxableStockPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-taxable stock premium.",
        "label": "Non-Taxable Stock Premium",
        "terseLabel": "Non-taxable stock premium"
       }
      }
     },
     "localname": "NonTaxableStockPremium",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_OperatingLeaseCost1": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Cost 1.",
        "label": "Operating Lease Cost 1",
        "verboseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost1",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_OperatingLeasePaymentUnderTheBostonLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payment under the boston lease",
        "label": "Operating lease payment under the boston lease",
        "negatedLabel": "Less: Amounts representing lease payments under the Boston Lease"
       }
      }
     },
     "localname": "OperatingLeasePaymentUnderTheBostonLease",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_OperatingLeasePeriodForAdditionalTemporarySpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents operating lease term for the additional temporary space.",
        "label": "Operating Lease Period For Additional Temporary Space",
        "terseLabel": "Operating lease period or additional temporary space"
       }
      }
     },
     "localname": "OperatingLeasePeriodForAdditionalTemporarySpace",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating losses, Expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "grts_OperationsExpectedCommencedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations commenced date.",
        "label": "Operations expected commenced date",
        "terseLabel": "Operations expected commenced date"
       }
      }
     },
     "localname": "OperationsExpectedCommencedDate",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_OptionAndLicenseAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option and license and development agreement.",
        "label": "Option And License And Development Agreement [Member]",
        "terseLabel": "Option and License and Development Agreement [Member]"
       }
      }
     },
     "localname": "OptionAndLicenseAndDevelopmentAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding and ESPP shares issuable and outstanding.",
        "label": "Options Issued And Outstanding And E S P P Shares Issuable And Outstanding [Member]",
        "terseLabel": "Options Issued and Outstanding and ESPP Shares Issuable and Outstanding [Member]"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstandingAndESPPSharesIssuableAndOutstandingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_OtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other risks and uncertainties.",
        "label": "Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Other Risks and Uncertainties"
       }
      }
     },
     "localname": "OtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_OwnershipInterestChangeOverPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest change over period.",
        "label": "Ownership Interest Change Over Period",
        "terseLabel": "Changes in ownership over period"
       }
      }
     },
     "localname": "OwnershipInterestChangeOverPeriod",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_PaymentOfLeaseBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first twelve months of prepaid operating lease base rent.",
        "label": "Payment Of Lease Base Rent",
        "terseLabel": "Base rent paid for the year"
       }
      }
     },
     "localname": "PaymentOfLeaseBaseRent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for options to license for each indication.",
        "label": "Payments For Options To License Payments For Options To License For Each Indication",
        "terseLabel": "Payments for options to license for each indication"
       }
      }
     },
     "localname": "PaymentsForOptionsToLicensePaymentsForOptionsToLicenseForEachIndication",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PaymentsOfFinancingLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of financing lease",
        "label": "Payments of Financing Lease",
        "negatedLabel": "Payments of financing lease"
       }
      }
     },
     "localname": "PaymentsOfFinancingLease",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PercentageOfProceedsPayableAsCompensationToUnderwriter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of proceeds payable as compensation to underwriter.",
        "label": "Percentage Of Proceeds Payable As Compensation To Underwriter",
        "terseLabel": "Percentage of gross proceeds as underwriter compensation"
       }
      }
     },
     "localname": "PercentageOfProceedsPayableAsCompensationToUnderwriter",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_PercentageOfRealizationOfTaxBenefitUponUltimateSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of realization of tax benefit upon ultimate settlement.",
        "label": "Percentage Of Realization Of Tax Benefit Upon Ultimate Settlement",
        "terseLabel": "Percentage of realization of tax benefit upon ultimate settlement"
       }
      }
     },
     "localname": "PercentageOfRealizationOfTaxBenefitUponUltimateSettlement",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "grts_PipeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public equity financing.",
        "label": "PIPE Financing [Member]",
        "terseLabel": "PIPE Financing [Member]"
       }
      }
     },
     "localname": "PipeFinancingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PlacementAgentCommissionsAndLegalFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent commissions and legal fees.",
        "label": "Placement Agent Commissions And Legal Fees",
        "terseLabel": "Placement agent commissions and legal fees"
       }
      }
     },
     "localname": "PlacementAgentCommissionsAndLegalFees",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PleasantonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pleasanton [Member]",
        "label": "Pleasanton [Member]",
        "terseLabel": "Pleasanton [Member]"
       }
      }
     },
     "localname": "PleasantonMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PostDecember312017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post December 31, 2017.",
        "label": "Post December312017 [Member]",
        "terseLabel": "Post December312017"
       }
      }
     },
     "localname": "PostDecember312017Member",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PreJanuary12018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre January 1, 2018.",
        "label": "Pre January12018 [Member]",
        "terseLabel": "Pre January12018"
       }
      }
     },
     "localname": "PreJanuary12018Member",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_PrepaidExpenseForResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense For Research And Development",
        "terseLabel": "Prepaid research and development-related expenses"
       }
      }
     },
     "localname": "PrepaidExpenseForResearchAndDevelopment",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrepaidExpenseForResearchAndDevelopmentNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": 1.0,
       "parentTag": "grts_DepositsAndOtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development activities that provides economic benefits within a future period exceeding one year.",
        "label": "Prepaid Expense For Research And Development Non Current",
        "terseLabel": "Prepaid research and development-related expenses"
       }
      }
     },
     "localname": "PrepaidExpenseForResearchAndDevelopmentNonCurrent",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrepaymentsOnFinancingLease": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments on financing lease.",
        "label": "Prepayments on Financing Lease",
        "negatedLabel": "Prepayments on financing lease",
        "terseLabel": "Prepayments on financing lease"
       }
      }
     },
     "localname": "PrepaymentsOnFinancingLease",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PrivateInvestmentInPublicEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public equity.",
        "label": "Private Investment In Public Equity [Member]",
        "terseLabel": "Private Investment in Public Equity [Member]"
       }
      }
     },
     "localname": "PrivateInvestmentInPublicEquityMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants.",
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Proceed from issuance of stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNetOfIssuanceCosts",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturity of marketable securities.",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromNonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from non refundable upfront payment included in transaction price",
        "label": "Proceeds From Non Refundable Upfront Payment",
        "terseLabel": "Proceeds from non refundable upfront payment"
       }
      }
     },
     "localname": "ProceedsFromNonRefundableUpfrontPayment",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ReceivablesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables Gross",
        "label": "Receivables Gross",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesGross",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ReimbursementsExpenseMaterialsAndPersonnelCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements expense materials and personnel costs.",
        "label": "Reimbursements Expense Materials And Personnel Costs",
        "terseLabel": "Reimbursements expense materials and personnel costs"
       }
      }
     },
     "localname": "ReimbursementsExpenseMaterialsAndPersonnelCosts",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of operating lease right-of-use assets for lease modification",
        "label": "Remeasurement Of Operating Lease Right Of Use Assets For Lease Modification",
        "terseLabel": "Remeasurement of operating lease right-of-use asset for lease modification"
       }
      }
     },
     "localname": "RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModification",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration and License Agreement",
        "label": "Research Collaboration and License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement [Member]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_RestrictedCashDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash deposit",
        "label": "Restricted cash deposit",
        "terseLabel": "Restricted cash deposit"
       }
      }
     },
     "localname": "RestrictedCashDeposit",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RestrictedCashDepositUsedAsCollateralForLetterOfCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash deposit used as collateral for letter of credit.",
        "label": "Restricted Cash Deposit Used as Collateral for Letter of Credit",
        "terseLabel": "Restricted cash deposit used as collateral for letter of credit"
       }
      }
     },
     "localname": "RestrictedCashDepositUsedAsCollateralForLetterOfCredit",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_RestrictedStockSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Subject to Future Vesting.",
        "label": "Restricted Stock Subject to Future Vesting [Member]"
       }
      }
     },
     "localname": "RestrictedStockSubjectToFutureVestingMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_RevenueRecognitionContractEndMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract end year-month.",
        "label": "Revenue Recognition Contract End Month Year",
        "terseLabel": "Revenue recognition contract end month year"
       }
      }
     },
     "localname": "RevenueRecognitionContractEndMonthYear",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_RevenueRecognitionContractEndPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract end period.",
        "label": "Revenue Recognition Contract End Period",
        "terseLabel": "Revenue recognition contract end period"
       }
      }
     },
     "localname": "RevenueRecognitionContractEndPeriod",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_RevenueRecognitionContractStartMonthYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition contract start year-month.",
        "label": "Revenue Recognition Contract Start Month Year",
        "terseLabel": "Revenue recognition contract start month year"
       }
      }
     },
     "localname": "RevenueRecognitionContractStartMonthYear",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "grts_SaleOfStockPricePerSharePrepaidByPurchaser": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Price Per Share, Prepaid by Purchaser",
        "label": "Sale of Stock, Price Per Share, Prepaid by Purchaser",
        "terseLabel": "Offering price per share, prepaid by purchaser"
       }
      }
     },
     "localname": "SaleOfStockPricePerSharePrepaidByPurchaser",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "grts_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and restricted cash.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation calculated using straight Line method over estimated useful Lives of assets.",
        "label": "Schedule Of Depreciation Calculated Using Straight Line Method Over Estimated Useful Lives Of Assets Table [Text Block]",
        "terseLabel": "Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "ScheduleOfDepreciationCalculatedUsingStraightLineMethodOverEstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of net operating loss and tax credit carryforwards.",
        "label": "Schedule Of Net Operating Loss And Tax Credit Carryforwards Table [Text Block]",
        "terseLabel": "Schedule of Net Operating Loss and Tax Credit Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfNetOperatingLossAndTaxCreditCarryforwardsTableTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental information related to leases.",
        "label": "Schedule Of Supplemental Information Related To Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "grts_SeriesABAndCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A, B, and C convertible preferred stock.",
        "label": "Series A B And C Convertible Preferred Stock [Member]",
        "terseLabel": "Series A B And C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesABAndCConvertiblePreferredStockMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SeventyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2 Seventy [Member]",
        "label": "2 Seventy [Member]"
       }
      }
     },
     "localname": "SeventyMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grants exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants Exercised",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantsExercised",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for issuance cancelled",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceCancelled",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for issuance granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Issuance Granted",
        "negatedLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForIssuanceGranted",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award options cash received.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Cash Received",
        "terseLabel": "cash received upon exercise of stock options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCashReceived",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_ShortTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term marketable securities.",
        "label": "Short Term Marketable Securities [Member]",
        "terseLabel": "Short-Term Marketable Securities [Member]"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense and awards granted to non-employees",
        "label": "Stock-based compensation expense and awards granted to non-employees",
        "terseLabel": "Stock-based compensation expense and awards granted to non-employees"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAndAwardsGrantedToNonEmployees",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares common stock warrants exercised.",
        "label": "Stock Issued During Period Shares Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_StockIssuedDuringPeriodSharesPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares purchase agreement.",
        "label": "Stock Issued During Period Shares Purchase Agreement",
        "terseLabel": "Issuance of common stock under Sales Purchase Agreement, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value common stock warrants exercised.",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockIssuedDuringPeriodValuePurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value purchase agreement.",
        "label": "Stock Issued During Period Value Purchase Agreement",
        "terseLabel": "Issuance of common stock under Sales Purchase Agreement, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseAgreement",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_StockOptionsWarrantsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Warrants and Other [Member]",
        "label": "Stock Options, Warrants and Other [Member]",
        "terseLabel": "Stock Options, Warrants and Other [Member]"
       }
      }
     },
     "localname": "StockOptionsWarrantsAndOtherMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxable Year Two Zero Two One And Two Zero Two Zero [Member]",
        "label": "Taxable Year Two Zero Two One And Two Zero Two Zero [Member]",
        "terseLabel": "Taxable Year 2021 and 2020"
       }
      }
     },
     "localname": "TaxableYearTwoZeroTwoOneAndTwoZeroTwoZeroMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxable years two thousand and twenty two thousand and twenty one.",
        "label": "Taxable Years Two Thousand and Twenty Two Thousand and Twenty One [Member]",
        "terseLabel": "Taxable Years 2020 and 2021 [Member]"
       }
      }
     },
     "localname": "TaxableYearsTwoThousandAndTwentyTwoThousandAndTwentyOneMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TransactionPriceAllocatedToSharesOfCommonStockAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price allocated to shares of common stock at fair value.",
        "label": "Transaction Price Allocated To Shares Of Common Stock At Fair Value",
        "terseLabel": "Transaction price allocated to shares of common stock at fair value"
       }
      }
     },
     "localname": "TransactionPriceAllocatedToSharesOfCommonStockAtFairValue",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan [Member]",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Award Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one employment inducement incentive award plan.",
        "label": "Two Thousand Twenty One Employment Inducement Incentive Award Plan [Member]",
        "terseLabel": "2021 Employment Inducement Incentive Award Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEmploymentInducementIncentiveAwardPlanMember",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "grts_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment.",
        "label": "Up Front Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_UseOfBusinessIncentiveTaxCreditsPeriodCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Use of business incentive tax credits period cap.",
        "label": "Use Of Business Incentive Tax Credits Period Cap",
        "terseLabel": "Use of business incentive tax credits period cap"
       }
      }
     },
     "localname": "UseOfBusinessIncentiveTaxCreditsPeriodCap",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Use of net operating losses suspension period for medium and large business.",
        "label": "Use Of Net Operating Losses Suspension Period For Medium And Large Business",
        "terseLabel": "Use of net operating losses suspension period for medium and large business"
       }
      }
     },
     "localname": "UseOfNetOperatingLossesSuspensionPeriodForMediumAndLargeBusiness",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "grts_WarrantsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants cancelled.",
        "label": "Warrants Cancelled",
        "terseLabel": "Warrants cancelled"
       }
      }
     },
     "localname": "WarrantsCancelled",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_WarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Outstanding",
        "label": "Warrants Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsOutstanding",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "grts_WarrantsToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase shares of common stock.",
        "label": "Warrants To Purchase Shares Of Common Stock",
        "terseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseSharesOfCommonStock",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "grts_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "grts_WeightedAverageRemainingLeaseTermYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term (years).",
        "label": "Weighted Average Remaining Lease Term Years [Abstract]",
        "terseLabel": "Weighted average remaining lease term (years):"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermYearsAbstract",
     "nsuri": "http://gritstonebio.com/20211231",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r93",
      "r94",
      "r232",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r231",
      "r239",
      "r295",
      "r296",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r504",
      "r507",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r231",
      "r239",
      "r295",
      "r296",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r504",
      "r507",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r262",
      "r265",
      "r473",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r262",
      "r265",
      "r473",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r239",
      "r276",
      "r295",
      "r296",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r504",
      "r507",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r239",
      "r276",
      "r295",
      "r296",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r504",
      "r507",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r93",
      "r94",
      "r232",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r129",
      "r191",
      "r192",
      "r341",
      "r376",
      "r399",
      "r404",
      "r405",
      "r406",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r129",
      "r191",
      "r192",
      "r341",
      "r376",
      "r399",
      "r404",
      "r405",
      "r406",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "auth_ref": [
      "r3",
      "r101",
      "r102",
      "r109",
      "r116",
      "r191",
      "r192",
      "r341",
      "r376",
      "r399",
      "r406",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision Of Prior Period Accounting Standards Update Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r262",
      "r266",
      "r506",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r262",
      "r266",
      "r506",
      "r536",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r166",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "verboseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r105",
      "r168",
      "r169",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r218",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r375",
      "r376",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r428",
      "r429",
      "r453",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Net amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r205"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r55",
      "r56",
      "r57",
      "r495",
      "r515",
      "r519"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive gain",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r64",
      "r65",
      "r66",
      "r96",
      "r97",
      "r98",
      "r392",
      "r510",
      "r511",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain/(Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r341",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r337",
      "r338",
      "r339",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r105",
      "r116",
      "r168",
      "r169",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r218",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r373",
      "r374",
      "r375",
      "r376",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r428",
      "r429",
      "r453",
      "r474",
      "r475",
      "r476",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r298",
      "r300",
      "r344",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r230",
      "r252",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r300",
      "r330",
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock Based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Potentially dilutive securities that were not included in the diluted per share calculations"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area Of Land",
        "terseLabel": "Net rentable area"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r180",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset Backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r151",
      "r154",
      "r160",
      "r184",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r390",
      "r393",
      "r418",
      "r456",
      "r458",
      "r481",
      "r493"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r48",
      "r90",
      "r184",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r390",
      "r393",
      "r418",
      "r456",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r175",
      "r193"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r172",
      "r176",
      "r193",
      "r483"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r301",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r7",
      "r95",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganization1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment purchases accrued but not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Deferred incremental costs"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r30",
      "r79"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r80",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash Cash Equivalents And Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r430"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Operating Activities Lessee [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands):"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates Of Deposit [Member]",
        "terseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r90",
      "r119",
      "r120",
      "r121",
      "r123",
      "r125",
      "r136",
      "r137",
      "r138",
      "r184",
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r237",
      "r238",
      "r242",
      "r246",
      "r418",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "verboseLabel": "Common stock called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Number of Warrants Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfIssuedAndOutstandingWarrantsToPurchaseSharesOfTheCompanysCommonStockDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r386",
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r215",
      "r484",
      "r499"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 6 and 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2021 and 2020; 69,047,878 and 47,552,693 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r68",
      "r487",
      "r502"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r141",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r257",
      "r259",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020",
        "terseLabel": "Contract assets",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract Asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r257",
      "r258",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability [Abstract]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r263"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue, current portion",
        "verboseLabel": "Short term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r257",
      "r258",
      "r263"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Deferred revenue, non- current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "negatedTerseLabel": "Deductions",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r277",
      "r291",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "terseLabel": "Deferred financing costs included in accrued liabilities and accounts payable"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r177",
      "r193",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for credit losses",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of individual securities in an unrealized loss position for 12 months or greater"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r181",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position Number Of Positions",
        "terseLabel": "Number of individual securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "terseLabel": "Gross deferred tax assets",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Net deferred tax assets",
        "totalLabel": "Deferred tax assets, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r367",
      "r369",
      "r370"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Research and development tax credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan cost"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Employer's matching contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTaxStatusExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates tax status of defined contribution plan designed to provide retirement benefits.",
        "label": "Defined Contribution Plan Tax Status [Extensible List]",
        "terseLabel": "Defined Contribution Plan, Tax Status [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanTaxStatusExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r77",
      "r203"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total",
        "verboseLabel": "Net income (loss) per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share Basic [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "terseLabel": "Total provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r91",
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Change in state tax apportionment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r351",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total cost related to non-vested employee and consultant options expected to be recognized",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Total cost related to non-vested employee and consultant options unrecognized weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r64",
      "r65",
      "r66",
      "r96",
      "r97",
      "r98",
      "r102",
      "r112",
      "r115",
      "r135",
      "r188",
      "r252",
      "r254",
      "r337",
      "r338",
      "r339",
      "r375",
      "r376",
      "r404",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r510",
      "r511",
      "r512",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair Value, Assets, Level 1 to Level 2 Transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair Value, Assets, Level 2 to Level 1 Transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r407",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r408",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r407",
      "r408",
      "r410",
      "r411",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r233",
      "r277",
      "r279",
      "r284",
      "r291",
      "r408",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r277",
      "r279",
      "r284",
      "r291",
      "r408",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r408",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair Value, Liabilities, Level 1 to Level 2 Transfers"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair Value, Liabilities, Level 2 to Level 1 Transfers"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r233",
      "r235",
      "r236",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenues [Member]"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Impairment Of Investments",
        "terseLabel": "Marketable securities recognition of other-than-temporary impairment",
        "totalLabel": "Other than Temporary Impairment Losses, Investments, Total"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r77",
      "r202",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment losses",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r208",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r352",
      "r360",
      "r366",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r349",
      "r350",
      "r360",
      "r361",
      "r365",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r76",
      "r471"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase Decrease In Employee Related Liabilities",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease And Rental Expense",
        "terseLabel": "Operating leases rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r450",
      "r452"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Schedule of Components of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Minimum Annual Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail3": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: Amounts representing interest expense"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating leasing renewal option to extend lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating leasing term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters Of Credit Outstanding Amount",
        "terseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r90",
      "r155",
      "r184",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r391",
      "r393",
      "r394",
      "r418",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r90",
      "r184",
      "r418",
      "r458",
      "r482",
      "r497"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r90",
      "r184",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r391",
      "r393",
      "r394",
      "r418",
      "r456",
      "r457",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Collaboration and license revenues [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Total"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r38"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities",
        "totalLabel": "Marketable Securities, Noncurrent, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r58",
      "r60",
      "r66",
      "r67",
      "r78",
      "r90",
      "r101",
      "r106",
      "r107",
      "r109",
      "r110",
      "r114",
      "r115",
      "r122",
      "r151",
      "r153",
      "r156",
      "r159",
      "r161",
      "r184",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r406",
      "r418",
      "r486",
      "r501"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "negatedTerseLabel": "Net losses",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r99",
      "r100",
      "r103",
      "r104",
      "r116",
      "r117",
      "r118",
      "r170",
      "r171",
      "r189",
      "r190",
      "r272",
      "r273",
      "r274",
      "r275",
      "r340",
      "r377",
      "r378",
      "r379",
      "r402",
      "r425",
      "r426",
      "r427",
      "r454",
      "r477",
      "r478",
      "r479",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r151",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r444",
      "r452"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Non-cash operating lease expense",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liability",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less: Current portion of lease liability",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail4": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Noncurrent portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualPaymentsUnderOperatingLeaseAgreementsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r441",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Less: Amounts representing lease payments under Boston lease",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r449",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r448",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards Limitations On Use",
        "terseLabel": "Net operating losses, Expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperationsCommencedDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the operations of the entity commenced, in YYYY-MM-DD format.",
        "label": "Operations Commenced Date",
        "terseLabel": "Storage space commenced"
       }
      }
     },
     "localname": "OperationsCommencedDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]",
        "verboseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r182"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "verboseLabel": "Unrealized (loss) gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments Of Financing Costs",
        "negatedLabel": "Payments of deferred financing costs",
        "totalLabel": "Payments of Financing Costs, Total"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Payment for issuance cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r278",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r301",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r11",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r10",
      "r12",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds from issuance of stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from equity investment",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property, and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r204"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "verboseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r206",
      "r458",
      "r490",
      "r498"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r206",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r347",
      "r472",
      "r555"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r84",
      "r480",
      "r494"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r79",
      "r84",
      "r480",
      "r494"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r8",
      "r15",
      "r84"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r8",
      "r15",
      "r84",
      "r537",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r14",
      "r18",
      "r84",
      "r538"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit Awards under 2018 Equity Plan"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r254",
      "r341",
      "r458",
      "r496",
      "r514",
      "r519"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r96",
      "r97",
      "r98",
      "r102",
      "r112",
      "r115",
      "r188",
      "r337",
      "r338",
      "r339",
      "r375",
      "r376",
      "r404",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r261",
      "r262",
      "r473"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r447",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfSupplementalInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "terseLabel": "Sale of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Offering price per share",
        "verboseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfPotentiallyAntiDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Computation of Potentially Anti-Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Components of Net Deferred Tax Assets/Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r123",
      "r125",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule Of Earnings Per Share Basic By Common Class [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r300",
      "r329",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r300",
      "r329",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of noncurrent assets.",
        "label": "Schedule Of Other Assets Noncurrent [Text Block]",
        "terseLabel": "Schedule of Deposits and Other Long-Term Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentAndRelatedAccumulatedDepreciationAndAmortizationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfStraightLineMethodOverEstimatedUsefulLivesOfRespectiveAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Schedule Of Quarterly Financial Information Table [Text Block]",
        "terseLabel": "Summary of Company's Quarterly Financial Information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r301",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r309",
      "r318",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Purchase Rights Granted Under 2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r255",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Schedule of Issued and Outstanding Warrants to Purchase Shares of the Company's Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r359",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail": {
       "order": 0.0,
       "parentTag": "grts_DepositsAndOtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Operating lease cash security deposit",
        "verboseLabel": "Lease security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfDepositsAndOtherLongTermAssetsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]",
        "terseLabel": "Number of Shares Available for Issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "Share based compensation by shared based payment award, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Canceled/Forfeited | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled/Forfeited | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued | shares",
        "verboseLabel": "Issued | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, unvested ending balance | shares",
        "periodStartLabel": "Outstanding, unvested Beginning balance | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, unvested ending balance | $ / shares",
        "periodStartLabel": "Outstanding, unvested beginning balance | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested | shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Maximum contribution of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Maximum number of shares authorized",
        "verboseLabel": "Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Number of options ending balance",
        "periodStartLabel": "Number of options beginning balance",
        "terseLabel": "Number of shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of stock option awards exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "negatedLabel": "Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value granted employee stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r311",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Options Outstanding, Number of Shares, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Options Outstanding, Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Options Outstanding, Number of Shares, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r299",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r301",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Option granted expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r325",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfFairValueOfStockPurchaseRightsGrantedUnder2018EmployeeStockPurchasePlanDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageAssumptionsUsedInBlackScholesOptionPricingModelToEstimateFairValueOfEmployeeStockOptionsAtGrantDateDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options Outstanding, Weighted-Average Remaining Contractual Term, Vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Shares issued price per share",
        "verboseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r445",
      "r452"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r85",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r88",
      "r90",
      "r119",
      "r120",
      "r121",
      "r123",
      "r125",
      "r136",
      "r137",
      "r138",
      "r184",
      "r219",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r237",
      "r238",
      "r242",
      "r246",
      "r252",
      "r418",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r45",
      "r64",
      "r65",
      "r66",
      "r96",
      "r97",
      "r98",
      "r102",
      "r112",
      "r115",
      "r135",
      "r188",
      "r252",
      "r254",
      "r337",
      "r338",
      "r339",
      "r375",
      "r376",
      "r404",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r510",
      "r511",
      "r512",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r135",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r234",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (\"ESPP\"), shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Issuance of common stock for consulting services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs, shares",
        "verboseLabel": "Number of common shares sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r254",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionsActivityDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r45",
      "r252",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of Series A, B, and C convertible preferred stock into common stock upon initial public offering",
        "verboseLabel": "Reclassified common stock and additional paid in capital"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (\u201cESPP\u201d)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Services",
        "terseLabel": "Issuance of common stock for consulting services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r252",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r252",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r90",
      "r167",
      "r184",
      "r418",
      "r458"
     ],
     "calculation": {
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary Sale Of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Business incentive tax credits to offset against taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation related to use of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Limitations On Use",
        "terseLabel": "Tax credits, Expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossAndTaxCreditCarryforwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r101",
      "r102",
      "r103",
      "r105",
      "r116",
      "r168",
      "r169",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r192",
      "r218",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r373",
      "r374",
      "r375",
      "r376",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r428",
      "r429",
      "r453",
      "r474",
      "r475",
      "r476",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsScheduleOfChangesInDeferredRevenueBalanceDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r92",
      "r277",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government debt securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. Government Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r92",
      "r277",
      "r291",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfCashEquivalentAndMarketableSecuritiesDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r348",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year\u2014unrecognized tax benefits",
        "periodStartLabel": "Beginning of year\u2014unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "negatedLabel": "Decrease for tax positions taken during prior periods"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increases for tax positions taken during current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfActivityRelatedUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareAdditionalInformationDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and Rights outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic and diluted",
        "verboseLabel": "Weighted-average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail",
      "http://gritstonebio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://gritstonebio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerCommonShareComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r557": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r560": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r561": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r562": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r563": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r565": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r566": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r567": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0000950170-22-003366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003366-xbrl.zip
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MRYNG)H%7.4-ZZ5&5(Y/C7I>]/::SK<$+=%%#<;^T:4N'KDQ#69\P:R; .)5
M:8$UE\2"*2FZ7%A)Z%HE:=5+S\M>Q0^O>Z)>V&CGE-R?C$8A3A:IRD36WX:I
MTG+O=8?]3VXJHVN6QF_X.HS.,I?>W\$O56 /N_S+</)J(@YJ*M^U.&L[W2,A
M&,N#-^"51U#"!(B>9+>77"A%[$0<VQH/56'=.\BP.Z9%.GT6CO 21EWD69ZS
MT?/N=1@/_Z?GHCM)0Y+CPG@O(019!;H65>$RR$F;Z"/RM!61];L3E6K&*A9&
M"">8@V"P9H<72Z_(D,D,8PF.:U3-[>YEK>*]V:M#7'#%PF!]7@I6G/RBJ_#M
MZ$YN]8C>))XBI$Q"6C%>P)=",CMH3[14.:KF7(157+^L:GY!O/KV]_!V>#2_
MCD0K 1//CS] #Y?@X2U@B5]QC">T@0_2L$\N_/4H_G7M#I.E>7.%#A.;D?DL
M)1EZB1.4""1L2K3@63$\Y8HEFK/[=@Z3UG3QMCA,5NF[CM[ZH!@DEBTH63+$
MA!$*=]PI&]'Z9DUS4K;TJ+/3%R-Z>I*M517WDO67T_<[Z=QU3"R+W;LCZ.B#
M29F]"=UUYOGZ5,QVH@"RS3@W!/BK6"7#'S4$+SUX:U76.A:!K%6&^7QL[N@(
MNUKM_R+0>MR"7/NZ-.]F)$?441;)(UC.72TC21!1.S L)\F3LR:TE1FZRHPI
M)6KYE$&P2@E0F7/P*@;(OJ04(AK6;F9H XCUUIRK.^Q\/2][Y(Q,= _)J0+*
M)C+92<0#<I622%GPV!PO5RW[JG99>%Z>CO/P9)CGE^(ECX^.1Y-3Q.?=HV&'
M:3:Y3J!OIQ?>!UT<TQ**]*2,N29K'*MNSD[*K)Q"WZP7?K7IB#=2BZ09+E'O
M)II!EL!()R0(R;I:F^<A,N,A8!8Z>9L+;VXW+8./?I^,\71A?#V9C_-M)"UM
M B"M,.J)05ABK4BDE[J6AAOPVA5P489L-4$%'EOEA,]AA$NAL8\ PZH@PC6!
MEE^'(PSY7#>3+%DS;&9R15QA4A&B+X4H:$ I4K31U'82R%/(F*V2S7JJJJ']
M 1U>O9F\.IS,IX',[]H0#7&1H444J=<[P?J;;3%I0E!)U40^%U,?LB@0%-8^
M.=H4J;D)I=D=N[PSY+?%YIUTI^^.V1:1:D4NJ<3:3$G41D9,@TN%0^(Q";3.
M6-5<M'&9])['1]B=G@Q'(]P/HV&9=.-A: FP]IVX5N(]\DX9*0-XV:>9$V>0
MW9QK)RJ'49<@=+/NQJ8*L7=IYM^<JYYG;Y,G())939?!G,$G;8%C*CZC<)(W
MNW>6K*F\D.*]LLSR:T+Y3PC-3MX\/\MJ/X_CMR1\5^8M*+J88)0C,T0'4*%Z
M"VHG*!:LC,2KV;:7;]6D\-WU;KE%L8=H3)0^@0BF=@HT#&*T'(HK00;EK-6I
M5:Y=4NR])"TY'&-^' CXC5^ONZ9E,X%#,FV91E^ :66J8XQ 8"%A%#2BB$:1
M>FO6N%K:'7)W\H/7LYD=2Y)A\H#%$A.PR,$+K2 ($R)S%FUJUF'=$A/L=7$^
MFT^)!XX/0W<4SB'_PA?WHIO,2//0M[4Q13C&^6R8UN,D:R%^);Q/RE9<7*I@
M21:<8P5T<E)XJ4E'-"M8FH(UGT]$^W5R@MUX$09>M&/<F9=W"6?QH$VQ7@#Z
MVAP]U-[,B=2U-!Y5-)87IEO;1NWXUM;C[U11*8N):))=[:@K!01.VK/4)*Q8
MA"VBV62KG;IL%(<3VZ3H."1&NUO12W#$2[6]N66>.;*MMD%=?BMB619E8DH.
M1.TKH6K!A<\R0Y(R!$YRP"!O*LVNLK4!R5;Q\"5&;A.CI\W(*K33$(6L'1Z9
MRB$:B7PKS85OI#!D34' 9<80-+4C5OCPP05E@Y/@?$T?0$72VZD,IGCAO.0F
MQF:]86W$K';=4+]55<J3EAZMAUQJVWSF"L001-4KJKB"+N7FL@?:KW49CN]N
MK8LP)A?,8$U-KV61@3/*0/#91:D3#Z99AFF[A'E#$5"CN%*8%5BNS=G(EL5;
MS*F4+*S<V=/MQ" :$ &A2"=2YF"3UC5F'L$5SJ&8XI@)197V$I:NZU&"QT_'
MX\G)8@KGJO#$Y]BS)HR39%F6,;>34V2VV9?B0=-?4A:)."4QI+>)Q619-K99
M9;%'9\C#.N/XY +4?/PVC>89<QT MD 5BY3O<AZG?H'=P2'!"L*Q5Y[@HA<V
M=*/3QV]KA>44\X4\'])3?\<T>S5Y,I\1LOS/6O.Q[OR;C?4[LE:AL^"Y)OR9
M#1FNB D,P0R+%HT5S7HSUMLG=#L#C\H4QK5T8%6=?ZID!!\,T9.)K)537H:M
M1!//)N-^Z]=!!KLZT W4@6ZHOX\3+&F?ZTAH$D]6DWB*T0)+Q,L\*>_;"P N
M*Y[Z]PNOZ_2\<S#Q43^XXTY:.C[0.E>QQ$RL98BI@#>]PO&1K->2N+[3N9Z[
MQC1;WLE7HV&Q1 \NQ-HSEAMP3O,ZP2^J8D1B:NUQKZ]6KN'M?H=Y.-LG47-:
M)MV;T.6KE=DJ/'*?R8"8SHZ[A[_OM>^;=5I;G4C;2%$L*)$E!,$CI.AY*%P:
M9YL=E?(->F8N=U5A*QO3N<S,ZXU']AK :BR5'*R7D FS@?*&0W!207)&,T1?
M&T"TNEU67@MT8_Y=F<XRIFB9(Q2'K@[+S."CJ,UP8V2FIFNE9D'7G:OX7^IZ
MWU#C-A(8M5PP@TDU<Z D!DXFL@C(Y M]]71H-G-@_?Y)PF.S;IAFF+\UKV12
M2FC,%DS  *HZ)$/, ARG_[(6P;77UG=GG&W6.$.GDI,N0711$U#K ^/$,T*B
M-DK37]N<HJOR_44WR?,T>]X=8'="ZNLR;7ZM;J$[Z:DF].Q58AZ*E(SV.%>U
M%5&$P%2*S#.%[<+%S3;M;#I;;%=LO/)VR(4I'HV&K#F!)%U+$[DF$X&'HJ2+
MV>=FNS.UD5ZYZJ&MS; &DJ!,Q!80DB(9FG-:-/;#Y%ADA*TE-NNA:J8._8+=
M[5>8V,F$]YEGX#+53GM:0+"%(*SW4@4T7IDFDW3:F_I6.V'Z%15O)&9CM(P1
MRA"%9&F(X O7@")9@](JFTJ+5&ESO--F@&/R2047)# K!2C)+43)!$D^X6PP
MI!!U<S1LR<_80"0X!E8G7TI0)5=;31AP.BF0!JW23"<;F\M2N=Y6.W,^WLE-
MIZV),I< P; Z4\TG J&RUM3Q(*PMF6UGC4_KPVQV!3[;;KUQY%)% R)744?"
M#:+ VBHJ>(71"IN;@^C7(HXP&E9X\632/3ZF"QT-TXL.Z5#,8YQ.WV=RWT8B
M]_[C%T_7G\R]'N;(OIH#,H#TQ!?*U^E@2,S!K1-%>W0"UVXD?+G^V<3T>>T#
M 75&]FW$3)9NHI7*2H/P4=;^:TFV"_IV+>Q7N6>L5$9%1D:AS:(6P!D("6M*
MJ!$A>"N$;BYCO1'LN"&TCX6AMUF"UY;5>6X.@E(2$$N."8UTO#D5^$4UKN^(
M2$ %#R>C_/3HN)N<+!#+MNPK3!XMRZPV]2 J&8L0C9,@LX@20Q'2[^(QNX3@
M';B_F"'*F4C<&T!5"+]%^N.$*G0!@O61891Q:\L3;K/Y],:F1XML&='+8XQU
M5!6'6 A^&U5\T2[8*)I+&?@JQ;0_(2;O"'W0*9Z.^VIZLM.V99<)Q0UMI@08
M#6%_ETDS*<G :=IER;D2VPV ?GX\S:LW=+;3YV-<S(:KYWXZ)I2(BU=GXVKV
M:JK^+<RL86I%419;\SH<UGXF6/>5C+2O @(!08;6IIQTLU!BEW-ZQQNH<$DH
M5X< (G+"N<5[\+(&(!C)DSKRA8GF:N*_.BWX"Q#TU9,/%Q(KO*V0\6\8NND%
MZ;5W+L"N^HR$VIHS!YD!X5<AKB0S3)D:%/9<UGX:!F(B?N.<B)@5MXPUEVVZ
M?HYH;'A7 Y(C<([<14'<83CQ2<ZUJ7<$XX1(/I84VDL>^%:[:6PF2AHE+RF)
M A%Y(N## K@D/&3EF)16""--JQS2=G.NC;734,X(%\#H/HN+$6E]K2TTI#-\
M(JP@F]ORC69Q&6 "A%N%PM;<!>\B0@FJ#HT*!KQ-$22*XD.6T;8[MJ7AC-B=
MEW!-GG7)0O!2 LL&07EG(8C (<:$+DG-DV\.7S8Y#&2-*=T[_OU,WQ8,7-;.
M8(CL+'X7;6& 5B;+F<ZVO<JJNY#[=6OAH=V^6<N^T:9D5Y@&48<C*!9K"8!V
MD&Q&)[AEJ+82IMS2OMEAE.M]8*O#*-R(4"?W)E,(H\C:-S"Y.M(W*6Z834XU
M:[E^/L;R>/CZ<(8X7H18$'N[]L6<Y'"8XKJC*JNL79&^,.\U$<;6[E-6JCI>
M(E;O=52%1Q[;[>2Q5#/%VM6P(S-UG/?RT7 \G,YJI.4$'R_53O&&#H8-Y4:I
M3 M>@@2.H8 RK.;5*T.6K5=6,\Y<:M8V:-.4W14@KQK'!):XB'1&24J"-()'
M<$Q(DD,RE22E3K'9<&Y362Z;\6&6I*.+@7"G"0J40PW.U>I'$9B72AH;FZM$
M799\%\(,M75J]Z+#FD:-^;RAZK;@+Z5Y8-%8*)+,!.4-0A#>0X[>E! "DK70
M*I%VPO@6&267XI1*"9A"@N?""O!%6O ."VH;,/!F4PX_!QAZSODEI']@WBZK
MLADUK4O(QJ&$[+FMHZ02N&048!11!@*4S#8K0CZ5?G+^_2/Z=CH;ICXOJKNN
M>>C2EUU=4]QFN, &4]O\![""D8ZO&9.NQL8B=T(XC-KX9KE@R>KXO9S[\L.:
MT3_,3\?[X7@X"Z,[:1]RLNR=\PZ$MB3NM:AU;Z76/0DA5+)!M#O/H54?^+<"
M%8HLE4D4\.(<006.X%/MLA"==5D9XW2SO+.D*#B#^7?2;C-%*XV:@\TVDR2W
M 6+,"8K6D@=KM1?-N62_.I=X:<;8I25^/(W;D7%(*J+XON]VC.!,J9UT41ED
M-GK7G NQC<:7&THCC5*+?F2GLQ%441JB<Q9$T*Z(%$5J;]C]J@J8ET?F=ZT,
M8SMYU>1@&,<$@JP'@I^IEFXG#ZB%DUYKK5AS.J@E;\.N[\]6@>]5VN&6I7YN
M2,3:M=40CG-DK4$T,M96%=:*YC*'FTSZVVQM_\ZAO>Z-8HRQ',E*S9S78E'C
M("I2-JS$@KH$)]NU4AOO#K)"7X)4W)4:E4J\]O\C5 "!$:D8CYQ 0BPF-0E:
MKYM#MO_I.63+8]6[YT5FTG&F&=DH@B"?\L6!=]) BAB14!^7NMF2^V6]R"G-
MC^8C.G8Q<K,>U^%A/=L)+N(1=Q+2.V&U2C4-U0E3)P0KB$4Q0B<E.:^%DJ;9
M .*::]16S6*WUL9W4YX,S75*$B$[U?<XK\-74@9OG2_9!>9UDYZG9KII7T@4
MM2M,%&5)9Z,+9!L2J&(+^.@*8%!(_Q-6M9?+VU+1XJ6P7Y_ NUS8[X-<WQO-
M4I39!RT#)-I?1$(N(3(M0--^LTXJW7 SMK5&<5M1%=L94B+N,2KJ0**@1@0S
MLZ3[27YKAHZALB0WFNWBW6X.SPK-+,>MLB(6**YP4#(),K.R!)+GC&?C@Q"B
M50+M7/8W 66,KZJB("BO<JY#-)6O U_K9 Q4((34W,6<M6N6A98J$SF'9L1
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MK<YU2W8>US%!B'UC==+B3N8,MCAO&;.([=9]MA N78]EEZ)),CL/(B<!RIH
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M<+^W,QJ%O<-X&^:W#9JGWQ_T]U1_48V<DO'_)LW#ZA=P+Q)^VF^??SM[]4N
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MS NM"XQA848EQKAYJ"UN&^NFN081W"16W2;>.H81I#.,4R-W O+6T*<"-4U
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M8?Y\Z-Z!1_?^$'1O:Q)F]^!P]V!;_]]@/<[9G6+C(.?/083_-YBHI]I$]8;
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MF,@IFY$ .37^[MU#U>#ZCY)BHF)C/@>?7A^?G)W;747;R>U.$Y)!H\- ';X
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MAY+@+VMAN?T4]1:K$M=[? CORN"-?M)IKX[P[?<]S,HGH'T"VN<EFPGH/9^
M?N(;C>$/HE%^QK3*IYI-$ZSO5XYO])H\O."]+EX^%9_VXY1M[!-3Y(U/_ A^
M,#B8O3,*"9PT(BCZ#1+SN'6^>BV!3D_)A&E-0^\N24/OMJ6A#[>=-/1@X-/0
M]S+>.,AC<YEGDAM$TKM=S@EN'^YN#[9W/>G=_;)0T[J8YA(H,\E)">8ULH=(
M\=25'&(KP]M<0S:;J<;TXGGO^'!K6Y "Y[U/AUL[W2!<3 :X/?XD&*<[53GA
MZ5:^)6G:;>E^AFD>?0EC_GPSZ64"?A@9M.G>Y3Q2W9MRQG8QP(A<$78&72%N
MH]"V,V-8=\Z$<4341]KN=Y(O^P&U?Z= :T,/__ Q']PF>K6:*]IQ> BQ!STS
M">YNVQCD!I'Z:!DA0!0K0;(Y_ +=NY=%4E9YVGL_0_:4L[_J9#@DC$23K9'
M$;<GFN2+ALPVW7D^QNNH%[MMW(O?II2;%PF]I332M'16*J"1B0(2^]8A?7>2
MP9H'G=-71QN4PP GA?AILEQ#-AP $!B=RF)Q)LQ--YGDE,2 155$IE,AXSU:
MKLC9<U&0$"S!;NT9OL@1YNB$*%28UN$U%26JA'Y14BUF#4TUY%R;/FG=:4B
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M/U[_0"-16[XL;SMPWF;AI3B)#%PA2<]BYEW.Q(!X[TH7XL&T<WALF+WR_QN
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MYW77=UP8->9%@7/EC530^'#W7L<J)0#+V33YHE@JQ'$BC#C.0P0IHDU\[0>
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M-U:3L,(MI:CMA%8KS")J[%=8OMHR2F'GRZ3L!G652(64,<SP;&AD=BN'K+_
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MCIBDSW,*GI M4Q2&K89%IO58"C#2#\WTZV&)8O+C!_?(?IY]]6AE&![&V:"
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M[73R%$1_6_J^KLF!W$-D2 2J^9B9<=O/M!50DA*F9[8Y:3 '=TG>]:#[KH,
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M>1E#1^F$D;FQ4]Z_;L":P=\QYY;DQM*'VVLMKC?/MHRXX*:<9"8T.^WTQ0/
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MFVP1$PL<OJ5F#K/I66+3=_R,1PGUDI>MT[9VI.FA7**%H%^2I9$W&ENAI1(
M<^PTXDKQ&CP0J,[7%?<7"17O/#>9DI;9W#Q$#>=@W80KMC/'!P(6!V^!@DIP
MC"2C=G 3#KYM\!5?G4Z^UQX^"[XWH,A, -+]G@,-$IGMFNBS5O!>D[X<3_#'
MG^"G<I_1ITP#,D!AXHNJPL4X&.#Y\>D+:U_OS2YNK_ +VI@=#K_X*@(^+V.2
M\,.R7&/:\#,OZ%./+3B/@76CBAG PIY]&IGO;10)1H_Z^DRE0@ T<MFR2S#
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M3.!)OZ$;M8(%6#CF2@CX$1:V0;XE=, I9CE^]H%BJ\*?-!N<H6!3E!O!9#&
MEOZBD"HD<?IM<R+9[BMF"0))HR<\$G%+>;QG3[+:-;@<7:"+F'&TKB0/5P"G
MM67UMQ#)*N%/+ME>)<5$6KLM?:Y,[Q+?(BI:Z=TXJ:9W2!7Z!#U--OT790IE
MB[Z;LNZ_$'[ZT_F')\^__?+YL^=?S@2+^N5=L*B"XS1CQ_T$BZS*Z\L^%^YB
MR6#NAH6P,9Y3L&;-9L-$/6!P"VG)53XPHB88UADJP%_T)WJM*@_-%WW/":XB
ME![Y("A:)A\UW%W@1?SQ+V<B*"6S83,<)H0UJ2!4J5=304:=:;0L&X$UR'9\
M7W>R=@F/E(SAYR%,[8-3,YU.5ZT330NPT10Y%[IBKNSFM)G[R/L9.(Y,Q H9
MJ@GR!_.M@ZL+,24I;:R%-5@]."_E)$,E>WDIV$BEX-+:80!%1LRH II0(H+Z
MLE%(A/KC:FHC\RA\K)Z/(0OZQ$8/U2HAQ0E%TXLP&KW=NF268Z\*17Z<N,P&
M:>>DR)MWF7P[E#9T^F)DT^#Q6*R7C@!ZB[CT"S*O@:%!3:SJ!M/.<*R!P]ZU
MIXT'?:%TSG7H#T.M9?^FB^%=\Z)M:,SRZN?Y%JAICE2N6<N^^ZC8K+6S#C=C
MS!\36AI\18I 7I' 6ACLT&354;Y2S"]!UZ%%0'\TN$5<*_ID6;D+U3*;,ED0
M>\_1]6LLO?]U?!3^S[E'IL$%8/$#='P4RLO&T0I+2H/,U>@HF94DWTG]J%F#
M1-7K]-9;=]FJ*MFRKPLIGO'H]5NF;,]0;IIZ!O(R<, @,J":7F P.,)[+!RF
M,\6/LA+'\L/!C5$IYA@(J,T9<N3K28SIE((>\_;^0"/F#&R\=XV=N"B<[R2,
M1\5#&;[T/T;EZU_OH#B<7DQI^M\V36\ .6Q(F?%AHI[E4; E4][\<^7-S]]>
MG/WEU^;-T[*>ALEZ7^\0=P)[E2$=&91?!L>3SRL.F*Q\4M6ZZL&KZ=L9WY]=
MO#\Y;_YV(GB8\Y??_)_LPPFPL)G;E/1&X+*@95V3;9G@. KA<I7G5<&5G1'!
M1>XB0+R"2ML+\]=[./TQ@M>[+;SF5+^YBT!PAD0O1RZW][+_)%9!W?59R"E$
MP%=CD)64@J"2[.1GQV*I/ K^*N*: E=OWNEL;_S=$(ZDCB1G=/_N!+&[G\P^
MG+C^3*GJFS/5FC".<\3PSMUB(*HT6C7#9';,FQ>2*$K&P5EE%[K9[.$6NYJV
M1J$=9S;",'E1>I<G\,-JG'>:W@:AJ?9799M&*^,ZH+ZF$DZC'--LE&!2E*4P
M03B:DG8='B3<1-BBG>]U$^TVVU>TW)M,!!)X_S+_MF;@S]_^[?7+DZ??[M'8
M:?A%>PG?ED9-YH[.6M >HHG9J+^1/1?:7GJP\(Y32NDS)M#9EB7'\#>3UF7-
M-743BX]U<UVYQ:7ZBG-/HKF6=HXEF WD#-'HKV/\(C9KW=3!#G=.Z8@CV_K3
MZQ]#Q ?C"G/*%3UYR=9T$<XKT?<FHT418+73$XVWL)V@5TW5DP\ @:8'!<@[
M,K38OR .\9N$0_P,*RO9UT/VU?,UJX%]\^-%E#++&7LA?&[J6Z,;'QX\DWQ]
M.!L)<^YWDEDB]*#Q!,2?Z;V\W9PPF]E_7&Z_^^H)-Y@%A?,_GX8LG8#30RJU
M47'0X&6)+NO&2,EX0"<OWKY]_\$/2R]L&7/FCHCO)L*P\FSDY[=]*: ^>ARC
M/XZ\VK_^F7/&H4=FT3 =LV57#PS&SZ'=7H.?O[Y7* FFOKGF1J;4/G.GU1_A
M.^]M_1]T'EY(O&YI]FU8R6%%IM?_JU__^Z:G^.ILV=+["@[?^[,?WWW.%8"]
M"^FWVRP#'^O5&)!;?G?E.,:]@FIUP748EMYZ_;?!4H@?Y&@SHL<M3_*]2"/2
M6WL=94G.YA##?N\NN:\J;;5?O=7^SK569%;XZ-HHMJ83N(O2DK:.63.0H>ED
MR@.Y4\3-*CQP7*UW+;^K6B46U_E'[@R6RX/X377&H>CN7":;O/ANJAYW+',U
ME5OX">I]S\!"NUZK$%^L<G%6L& 2'OB=2FP?\Q/";<=[6'QGQQ@96.<53E&F
MIZ=8\ FX]-N21;B,6D]3SZ[JG- 3E$I/>U;7/8,8)9:OL^^AA/KTR<GM#LID
M%\>OZM5Z4S4[EY)8=RD#P<8IBN%DT997KAZP%W", )8_%VM,DB.AG"72,%3E
M\Z;5S[.8VY5K!<$-S3FYC!5-6K>LG%4-8'%7952,X:0PTTT#OW!IE):.7W5&
M1D=ZAD%53"Y0#Y".SS!S.>$CZU%J-$5N#: >K!'DE%-Y!>H?)CY0"1-]>H\^
MH="I(0/VOR[SDD3.5AHGPC\Z+U?3]:Q'=\H$#RM6'2WR#8QCUK /1!/JC8(]
MZ66#84-\.&BW YS$*?7:X8+,(FCCGRE&1<Z-FMZ>'X_5@%0HEEG^,(-70D+'
M'(M2-N7#!X_R<RF%+G^-!P$!^5VV[WU6RG_U]J55[ /%YT]-BI;I,1?9TV^?
M9\N^JDX8HA8MF\ &F=,JY/6ZS+Y\'JUT8>L\?7F**LZ[%7Y8T")TO",EC8#U
M=-VT'\G106/(-U^--@IML_Q2-KH!].(EN>:@X:MO\/?]PJP"#&6%/_]V?,%Y
MWZ$PVPTO)F>R8RE, ,ID2X*7O*<ATG,O/<7;;%!SW+IB50?V>^M/$<=0Y)1&
MHKU@GO\)J1TU(\-']U1$--KY+F,#F?6U@+I;KP\ZW['Y5.GK.:U&57S.,=-K
M08[]W7F=7KZ3R/+2;U;E)O!4A?LKX5+3+![$UDZ.S7C:SHVH.@[XDI6\2X3'
MD%*F*Q/S$90 OY0X[R5M*A8_,Y9PDY9XD^^"315.(RGLU: JY%; D.9]6UN_
MW^NZ.&58L?_;O&STUV^YI8-,<+GA^K=7.&=Y$C$@3$PH4A!??OOEM]F/%#2@
MX6-+=H$,W7N0(F;/GSR99:_6Y&Q=D=OC8J+'[-LOOGKR31![V[K*;588AZI\
MDROVZ,NG3QYGWWS]].2KIT^>R+BNW;S#I54/'1^[OKX^O;3'H*<X+1K%$0P[
M^P)H5C/.(M;+" -6W9O)B:%W*$70T-3D.$:2,%MDB>7/ ]KV^2YBW45P5=9L
M'DWK6$*O9N(Q3&TO%TN+U8M@+%P-)'(!)L-<?_%EV$UVN9#UJ-0P=]TH&H<K
MMYM^7K'L>I@5<9I;87#?>=X9II(/@L6Q2KIDT2^\4&+V_<L'8<:3[3ED>[C@
MSZR1;5,KS[@'VKU_=<ZK(9?L@&R ;I >8":GEM99M9OZ^_\([EWJ.'L?^.;D
MS\A0=4#J,\)&@65/GS_*63GRZ9>/%H\-MO7J9V5M.RNVO!O6.6!XGJ5;^]'\
MMMA.&@=RL\ 1CMAP1:^/\\0LJ^0))W64W(?;-=@G70!!H3L9^[000!3*QPQ/
M&LX@SRHK:?H]B$F="8R?3&!'X28>>6;S+#9+-REP_2UP_;PYH=A3[Z+.CVM]
M;8/WI"@N^C&DY-_)Y2Z\(;EHZ$2@3Y)%S;Y7>YW]]&J6_3TGAZV^9$+>EZ<T
MFF=/OOSBV[U!"3WP5-.T3TUZPK#)>\.GI!GR8$L9^-.3;YX\.:%_G#QY_OR)
MW!5_8K)^^G\8.'NM8L,;_;U_5Q2J_BSN<3RXD/S2PX;9W>-/M.2+MQQKL.A6
MJ_T8G]H6,D8SX/S(C%/SIP>67N>*T\OF:O\X*EDZ54X@Z==0Y5<_)_7PI*!/
M=PVG\R!?B\0O$G^+QLDYQ(+UY;;?NN&)=3BKQ_>G1243HB<;I%J5I6URC<D<
MXFO^:.HLV>!W'9II]H?*2L,L_2'@R;F[X;SKY,!+!\M#/EC@I4SXE__Q_SS]
M^HOOQ.P-_IQ!MBS>I5 59M]H"W2Q_,O*MS43+;S?<OTO?(73^6TIW<LWK__(
M@HR7<G0_7LVN9?GB\!M.N .&.J?@OKY4MD49@C0T803OF\I5.W6PZBM7ETI1
M,;P\_Y/]=1U+:_#B3^WA.%&"R8.-:[?(>413<E5V^#KY<YLJWS%EY$ZQO;RW
M4:?#E,I[@0F@G[Y\_AT4V2@\[*3#G(^R:*:PG<4!#EL::4^$!4QP6$,Z;N?1
MNUX<'36H=CNSF@72/ZCQ@K.6C(ZXERH?#;M(88_XY2T68Y=I5<O^)2=-_'EN
M9&P,]=ZY&V:;70C%E:@J$>[$WG5K$\8)E,&+]8V(T:4&+Q6V>K!D,#=PL%DX
M9I0=88^ ;MVTG61R\&V P>D7^ S=ON]P:@9CS0.Y'?OKT< "$QKROM&0WR8T
MY._"ROC-;_346;GX?_^-'G7]?Y_F_Q=]"O\7&6FR$D>:)GQ-0\V>GIUF%^7O
M5E3_->/\"&$5S./G<S=_S3".E63W5VRY;S_KCKL70W/D_O44U.6U-#DACI4T
M"&O?8.A-\1$M4!"_[:S128IE\"Y@2DZS_Z_ILV[%C68%^79PRW:AKB,N5_<1
M]:RN:,LYLIWD^E[O497MQ]>3;FSLN6*LDV@5 _BRSP2=LL:<?8,CO?$%L)#R
M>.G5I44^&V3B7<F^8H"JG3>UM.+Q9RY<UU?B3K[U *N9Q]K,F8^$(5$\X.N5
M:,2QRXM)GYIQB?F9\%M3N$MQX<1E96X(=A6C"N'>]&ISHG:H^4P2:!-:]-:I
M0)O<W6J.,U04[7D"8&P637)AC\]I$Q!PZ'3+8MFT92%,(.SV0_]/J"R$^:/]
MZ+;R&:LN#I::C'G!1)=*H[*CU<54%2PG"B+TUN<I=@U3HF,>A0W_331-@2A1
MEA\NUM<*"&4IK+S5>ZABWHQ""=IK[=Q2\@(15W0H0.,.C966Q[B&W\TU3;WC
M9=7,:89\ 9>Q&C1?#;[EZJNR;6JIN';LSF.F8_J,@P/E:H)476EKH0V+@>Q]
MY^L20[R[H^.S7/MWSE$;DO\@ RS;P1N/WO+]YDRF[-+!@TU-, Z8_WS&)UML
M]K\Y??ZIO,H?\+ [D@/^6'RS"+;YSE<D+WB#G76<9/3-OJ@.OM#]\,=><;\^
MHEF45U-3\<7IE\^^^??O-.'QG\O*_1P_] %\@[I()\BC8?KPM1,6COZ.'^T$
ML4KWGY -PW<G)V)-O[@N%]L5QO#\ZW]_0"Z8S599\\SPI/VB"]PP?_&T?/WE
MLZ=??_/5%]\^>_[U%U\_^_+?#07\[)E_O=%['0[K6">/\\-((>9(_$;H)J%O
MU$I++E+FJ)E[7#IYDMPC+NW(@:Y+6+J<+V<;L5F75VY0A!?]O"X"@9-3 GQ\
MQ_UIXHR@5R4&708BX&%",VZ9XVM/7=B0^' B.^<X3;GL@4]5W.E8=AAC./CD
M,RYZ=B@>+DH@,LC_8)HRQO:+,\T7SZY*Y:P+9H 6BO[O,9U !W;Z/51ZS&HF
M<YG,Y1%-7D0R'5,<1C$],./H^C5DN2A0&2>G6-,Z!"00Z",CJ9'3PJ$PQ+ H
M$:@2C?NKO"V=<&@*^ '698N$0 C[F.(U#N;C%N#IJ,NB^5&KKG0<2T>P!\$?
MLEQI9Z:=>123)^A-N *J SA0>H[XGC3W(H7BO%B5[DJ<#6ZW4%Q%MLS+2KF&
M%&@CI->^Z\+:-ZY7SC-1(8D5B=:Z=MUQ41&$4U5E4@R,@D>V@:[-&WXF/@:R
M1>1"<<D3WQ46 :7U9@K2V.1H\VTWBWPL(\\UF4*T][(S$[(2:1NG;7S<VQCI
M Y'XP-+--SN)*'+I"A/M:Y"_,?T\'8&YIJ<M=/$\OHAJ^IJ#D5I;:W><^Y-4
MH723((/*NS62<N$.-&8;HTO)/NUKC1GJ**LXX?[CO)9OT(PLRF(;>)^%=+CC
M3.O4AN8N.$]VA@NU@8C+J(]3 )$"B/O>HLF^W=F^^7)!Z]:,?$,ED$L-&\=[
MUS/82]_HLJ^&_6L3IF%$)&^^@ 8(H1%6A*T'!G9/P7MFO)R"^+(B7[-<GM!W
M3KJ5JY:A ?Y3UV*>4Y48!W&(7+1#+<<ZZ'BH/DI1-M69%*B6:I$%MSJ*5@X&
M)LDB)HN8+.*#L(C</L+Z0;UPVX:@:\K.&6O1GJ7I]D&KT?=C>7B!!)!)@*O%
ME7_%ER+C+95VN]NUUM K4868MJX30Y$V8$8'D&$WW3A\UOMX])AJ_5BBW-6]
MFPVKR=9[, DC2)8O6;[[WKS)\MU9,V(O-SL;-@2%7[M-*<E;-H!;Q@F+T8IU
M9.C9134)-M5 *T"\>V.4*UAIS](DTY),R]'LCF1:[NI4M<YDV,IVP2B_TOF^
M+15E8/LA498X,FY _5BJ)Z--.:SM\8LOJE7P4>!VFKVV+M_AM;0/*(2^P+_F
M+<!'TB!5:KT+-# HQ/5"TX*4/8L>< N]EMH^Z0I*'[!^E=F?4+4K1&XC7^ E
MBVC:KW%1/Q$:)SN;[.R]FXID9^]J9P-46,D\%9W]CZ:-E"^'S%6' T>66:K%
M99,B/=M;T?0KF20EMI8JDT,?ZIJU8^/7U()H/W0+(7 I:Q/2A.&+E"N[?FE<
MS:K;J)0,/B>H"3UA 59G58W\_MUFUBD*$)8-BI_A!,^PD^&7Y)O.,C6;7H<X
MJL+^,JN>2=^IS<SD$Z%$%*JUIE-:(<W*WV=<_;" *\F VSK5R;HGZW[?!BI9
M]SNS\N002XC I+!$;EM:2Q5Z<J)F%&"T<@K4HX)TH<69CDT0+J/\8(%U*S)T
MTDI47KEJI[<2WU-5;%%>9C(Q@:ZP)'(T..L)<K7S[(-OM.JL_4$\>&CM,1 W
M^C+=\))5N]K A(A2>@WW=]%X#*[5T<'<I;[PT%F742?S]^O,W[',3Z(/.$J3
M],631!^0FFV2/_$@_8FW@0M<P1Z=-0U'T1BT02V80#C(Q+^]B(:"ZWOG_0;\
M MAP(%('"#CE1LJOFI)IV!!T&BH\4/9P:JK[#I].AW6*59)M>?"V); & "U[
MU8#CJAKU_H]\=^!:H3"WREO73?((Y,R%E<\;%4^0Z^-RF[P,Y.&?Q73\!N(:
MQ]Q7+2W4%]J)0V\#;_$OVG+XUK<<_F@MAX>(,\ZU'>$B2H(=J8/] *BC?K?S
MZSB6H7QX2!:1VH)_O[;@8R40/+!H?]_-FEBGIN;OW40'B1;AAQN69I&>A39D
M:8Q3*(AL7,&T\5=.,)-;49V34K_O98T[Z,8T57>U#_V&3BX!=L.1*)C:**]Z
MZWD;(),\-5*P%+>U+3/[^#;;N:T'7!IW,J,N):%JI2M\2VX[-$EJ+6B6'9J1
M(.([99-&JA%,WF3MAZJW$XUGX=8@C+8AQ5'@(*<*'1CT":-2YTN*APB.EBB%
M2472U4S$&T1D\'H4L0&%*"XQ(E^-S^+%XQTM2U<M0.2-&B,6"ACE;UQ=#X(@
M^I@LR;T'KD<_0\=C:\WD0"@K=A^"43OLH62/N(4_M!]'A'RSK(L$/?]2DN=.
M']O%RI*LFOG4V+ _*2OY&/J:WF:C*AU06#I&?A+!D^,B,'Q"4\ V04T=VFR:
MNE8)"._S'!+G\LW((F.":YHPUE@-Z\IQ$R3(Q(>L44--5=.^T<O>IJ\['H]O
MN QU+*4.)/O[2%$& SU"MG4TY.ZQ%OFC #EG$ %CNC 'A2NOW!3L2QY_[FBQ
M^[8F\.4=/&3VSP;U4:,G/#!;?NDQ^9W*0NCA&^1I%$J'@T:9"^5PBY4;L^&9
MB5QA3N^J%S (/=$,,(F&A1DJ\F[+PRT/K?-'\<R[X/MNMU]OW #/;^U7C RE
MU\55KH2.T7SC@(R^-IIQB$0RP$] )>/PX!8AP53( 12C?M4>&DP=3D@Y!_>Q
M)^8EJ&(LQH&H@<&G8(,S#[0<82K%68**BSN\65GJ08GQ7Z$WFMXHGD>I$.AV
M2XH"U0^A6(IQ19NF#!ZF#XX.U(([!D8.+U36O*S%,0%0JFP6?IN7C<T\TQG,
MZ731A>[!F#HU]BEOD#WA9#S'LMCK _2<G-1:491,?_,4\C NFE@';3\6DE(\
MI.CL03SW4:=2$C')IXA)CG67W7^V,CGEDX2D4]G :Y]&!(DQ(NJ!XP&^ZZAK
MTU8C.ZW>FPXNXPURM-$A*KY"OV[:$^0H!-X%MV0(_P^=%.-.K>#FEL$;9"18
MA_U:LAJ8/NG)JH$HRA!+3#M>3ED^TM\=:.&8<A4BZW.;)SUHQ98]"MF&TG5;
MR>C.7<4V[&!&EAW!Q>!*8?8/NV!3X<F6^WG#J*V,-7*PQ.K<TLTR_Z98-8VH
M@XMKM4>U;L^TF!K"X7<U4$LR)5=ZO1 LTI6$(&YF;E>-C!,,,"_TX,7N!PW>
MPQ;WT_SD(8 [$#)XS3._1@9D$S3['Z?B'5"6NTW.@JFM1 KD2H8(@$GOI*JU
M=Q3,PD*X,;*,]^B0XGTXKZK7O./.[L[ITBKQGH-+SN+JTP&5.M2XU*$>J-$&
MFNGY*R'>?C X4XZ@L5ZU8-(':TA F_X#3D3YL%ZG4YQ2,QG$CK*,^CI$)0M]
M4J8K;\G4G&8O7)'WG=1PE7?0FM['#[WCX&M(#%AZGA*?;A2QV[P66B6ORPCY
M@[5&1IFV:>5K)")C3V4*-PKCL;>9#S*;W*8CX5.[/#D>R?'XA=G P<'&GL3/
MI0A^%'FWFO'_<D!)=L#K9T1<8YTC@QT=J?-!TPUM"YRGXF!7M+=<W)HMMG:;
M5;3;Z+-D0F@@CYX^>YRM:=@K.CM^;*YI<.TL3JG!K%50)0Y'#C32(OB9A0WA
M ):CCU5>(X4%;#NN0:CF4=3]U->1EL(0+:[' )\D<<C#?@.$75G:A%ZW/O#,
M'TF:VI)^G"O8%(W4F;9CO@UA4Q16Z"/,E,N#;L$5EDO.D459/VE"I4&V>=FY
M_9'9($3+CMVP<=XP;UM,D70=J2L2]6?Y) G[I=(_6];T!+1"N-S%34P"R-,L
M[X0C0G<E#Q$5:QZ(X[?&85R@NH,)7N97-"[-P_03^46,9/P2[,TOQ"D+U]!>
M B]1(GIZT4R*)HVN2Q=22;8_S!V/%K?,J_7'FGO6>)]LM%Y/L[/MUJTW6PV+
M>>>XZ:@9S[8H:>5OS3]011K)O+*4=KXCLW6RP)'HW5IC_..#<JJ?*ZK)Q<F[
MJ<:Z\7SKT7C9YWA]3DV&/FL8NEF!(*#,Z3(_:W9V8MKLQ<<!O6PX.%\<T*<C
M[8@>.K51'.4Q_L73U$;Q4'W$WPO0^>MQN$9YX9VJJ#59</\PY+$?%5&W_^>#
MFOC4MG/L2S+AZN^TGYF'M2#'=":9VH&PG[$Z,W!>O4-X= P1.\C $.LT_)K,
MDRNE>B*A&V*NII6L:!R:"%) 6GR.O+UG:OO<.T0J&:!D@.Y_\O[MOP)CJ.K#
M: ;<U%WV*CO#;,VD[&8R",D@)(/P0 V":DH(C]3,JS.+'Z+X?93+/E6BNH%*
M.=F'9!^2?7C ]J'NUW/72OBPRL&5Z5H4J8K.2KY1$GT:^^"3W729@A,8R2HD
MJY"LP@.V"NHU,!R*:TIF#.@[KMLV$%UIFUU>28'5&,AW6MZ4GC_-9BZ$./*C
M$UA4+J5K1M_OE?6&B0F@O:60F>7H*L35DVE)IB69E@=L6DS;;L1SV^^!8\>H
MV&NW!P/S2"\W5K2UNW1%SB"Y?N-9DD":.[[[@U$T2.8EF9=D7FYA7N9]6;$U
ML(Y!Z5IA(E:%OBHXU <U8^1HL@7)%B1;\ >P!?N8\!C5%QR'REWFW.6VWE0E
M.B%F 7(_B_@^%FA2+^<]7XJSJ<E4)%.13,4#-14C["Z4=KEAUM#Z4CGQ77;@
MPYD=1(K/AB!PR8P,P-]6A@FMA +4'<A*6KJC&P<V!S,SFD&Y58(&$&[5P-R[
M8S)ER90E4_9 35G4"TAVR(R:-P!5?MWUY19ZXIY(-*KK)C<F[?VT]Q_JWH=W
MX!NZE= #A98M*R#.LE79&MD5NS?=Q[*JZ#,;UW;HDJ\>XNY/J/*TJ__PNWJ:
MBF#N)+TY)'5[B)LX'>%ILZ?-/MCL$3I3V5,X$;$L*_XOB(Y=T4MVPA(6_(^%
M6X+01%,$#BRB1> %FM*( =O1LJG*YB'HNR3SD<Q',A^?1&[-A']VLQTE"I4\
M=9 Q])1!E@40AH!Z]WD%6QYX/'#<S;7'LP;/QMPH,?.KIZU@TLEKIX0O*[>>
M33"5[#-7>"I*YF/)%^Z?K ,@-S)RDW 7_A:36C+3<[7+R&J6@6ME/L HWJJ=
M^OGI\^?/C^&-I\#WV/=".LSN9$@^S2P[T08]VVMR]+GOVQ!7TH<=;BC$M37?
M;PTZ>.W0GN:RKTSUYSOZ_ ,\,Y/_G$Q.,CFW,CDQ'7#,O#O%W^GA0H&V<\#J
M&M !P0"Q[Z.NR8  <P!VEF#^D^3_K$(ASP"J&7J592#9CS@H8.1""D&H[R<&
MKXB'%!8<9UCP$ @Q66RD,-V4N#^(R0:'9(K[C(D!:0-"2=L_T:XQSFGAIH\H
M%$W*N,W^ 8$*"&5=UZ)8D8MBF!WQ W7D9I)ET?-4\X/P&*Y!"ZF"&H%MA=FM
M+?YIG>S=@<R+C\<]@2\V+>-V1*"+/J,M4"$^]_(:!T1'ZD8@/78G8PW4$4 %
MK#+%M+[>EA6*"./'!(NO^5(51*/!DSX[)*'F<95,7!PU:8CY<(O3[$.3X;J>
M?/TA*('=@_5*-(!':;R^>)9H !_FRCKZ<W'3EO0():3#&!'J%B.1,W\B,L,8
MG1@X,)3=.%!$\V$33/WH:!U1%L.?&X@T"0& IVA&I:CF;R_H DT@_A]A70^S
M+B^7KC6RY1'_,@7I-+22^WZKAEZ)DO+KB9NKM)-OT!D%XJ*B94^A%,ZB$!6A
M> \P-?,$!69%C\&=98YBGF9-#Q.HKSWEXEK%-(4 &(G&N=LURKV-6*EMJM/L
M=JG/D)0<*>V,LIN'V:;G$&GM>J:/&Z^"V9YRE3PR2()!YEU6O3^HN5P00X^'
M',E[',<B)2J.U'+O/B-28R:7\I30+(I!CD,IE<D]_FQ)[WK9#N@WP,5CJF;F
M'S>5!(Z,F.,:WHB.INM9)ZS%=;8K:'!@@QC7^G"0+P=K44H=]FYF<'JJ\B.>
MF?4RN :+S-&V+0L5)22?*F=<-JJR.U'PH$UP:5LBD(M3&%GE;?BZ;&5U52/>
MZ(&$+0>?4P%;Q/^G\Q2^%W6SB+R&;&WX?USV*:$'2?\H=C/9C'YM!%]\DY<+
M4S^T/YL SGB5F;JAB*4,VF%,4,4+E4#/>GL[]81T*/X!#\7/HXWV=J!18*R:
MV$C+"D*/6&F1A!.$4XRM'2+KD9KZ_E4&\NL;'$V%:8E@=X@62C,Y .;!YR.W
M:JY5:N>X=<J.0@TP)4@.$4+_L\];.I.KG4I1U8#JW&'ATUD2EC=B=DF-V"J_
M:5^81)+=A\\OW+@IH".E,A!Y=D7.JV.7[R:'J>FW4($(YP,[3?&I/K4-'P3;
M]>^]I1Y4N>3(=UVJF'Q.KBAMN!9GO4*%0;Q/^//L*8-KT@JQLUMH=TVKKZC:
M$&=' >Q@OY_^>^S8YP-[(=5?DT%)!F6"LM:#&)ME3$:+;1_3U/84\VM<JH'O
M7^L2;1+OMZ(WSYJ03/PD68?JZ+LDDJ5(EB)9BE_B>M!S;WO.6+F: HM*!-U,
M/VX("DN[/^W^^U[ :??_-DR2 \%D3P+7])+K$%%E!!"L2>PCBBO K*0LQ!\7
M-^*?(*N5:I8!)+BV,>268GEJU9T,@#"V206*=3=33\:0L-ET62:0P;">-ZZ#
MJS61C.@)9$1W\GCE ]#Q218N6;ADX6ZV<'>BX!XR//T1B;93UC69AG]1TP 0
M0IM?&IM+N9[W;2<2UINF@A:T F9;Q^!6HWGZ-&2\7'J$IS@C05-,#<>B[2\5
MQ@#&";=UJA_X@&BDDO>13$PR,3<N4":26I38\@'PCDBIK%'\1>%7I'YFL?S/
ML$ME7SA(R2\CB'TR%<E4W/=J3Z;BSJD87^L5M*9/O$YZ'&,_8Y2&&:!9,K@Z
MJ;B;+,51+/9D*3X#0R4>' Z$;/M)U6%.XI9;2ZXZ:;9E-/9,O) UC6T[ZI-(
M%B)9B/M>Y,E"?-:BKK22<MXR+ZM>&H F>#\$/C:B_CBL6JRQRD8:VP_TSC.$
ME;.JBC=3<(E^D=M!*OI*5^0;CVLEZT(OL-W%M/WT*KNFPI49TK9NM,G>+J3-
MS"CAU*C=/  :OF3*DBE+INS&!6I]E46!XHW:F9I^+K26VYAA8=@:BY!$G]4\
M[K&3;:1VDJ-=@!]P5O5KP"1Q5#EN..RB#EIIUM N)VGZP$JLZ+E'71_"%*$]
M&7GH26QNW;%RFIVA(53^)1);N1?^W.]O8<X^;NI<T.L[D9^$O2_NJEV[')0U
MRQXML[YKM%OQ$PGI!E((,M!-WFW]#=">6N.T)H<A[EO474LW7&+2:;/>JI'K
M7F@!T]X[XKU'"Q6-4;99)G>0[#PFQ0G;CU=ASCS/K$;EG'1>Q\V%TE4AGB8[
MQUY**J_S:M?)Z1+ZJ)?JSLH^XO9RW,8(8IJI+1CU-4[=?OI&] _Y"K>3-^2H
MTZ;K$M5+HGIY0%0OSQ/5R\-<64=_+&@-59@PI&UMY90CBW,.Y=(S>['E1-5U
M\M-*0O*+K+, 5S=M641MN.MU4PM%AAY'"TZN0&M]3K$:8S^JW6GVGD4"]9-R
M#?ND?$^Z@G&B>'9GT'S1 ;:5LX=.F[+I.W+(A#6&?@!HWRWB<\CE;<VT,9=]
MN8#[E0WG['AY)(["&[N'3?=[\:'^<AZ)?_NOB[+[V&470>P.+?8OE#;E2.?S
M7]0K>)",))Z!A[S]%5V[LB8"!MM*NCC0(<;]SK-!!Z/V-AYH@E9;/96F#MQA
MFGPNR4CV2O/X";C?+/OAXNRGUQ]>"=(/%^"TV]/BNV:Y/*'OG70K5RWEEXOO
M/GV]]W\YLZN=O[TX^XN248%9:Y%=NEH+=:'>=Y4710D@,V*- 5T$"(^&Z?P'
M9_GO/1E^]#-T/([9W]59J9L(JA93G8)V3U8VENIVU;K@0]DZ#8SPLH#?K?+.
M94_AULB/S_;6-+)BX&IE5M0E/52,?@F?;ND<&\!L]3ZZ;;?]F@/\1795MGEU
M M OKC':L?Q .6TPV8KLUGT(%LJ>QXQ:7,(:260K4:&O8G&74MCCCAT^\^H&
M/(,SH:,+=BMP\7TV8^G-&MNCV!Q%K6':+[%?&ERXEIG-N,W<S^ZGYC1&,=4.
MF"7VAYD4;_#TXLURSF=.AG'MAB?&P6'%&,P(<:DHS.^R57.-V\X.53Q1I5I8
M*O3 NN MT-3027&N5LY?O#_R^]=8]W6_GN/1EMFJIXUC='.7);Q^9HK+6W'K
M+YV@P:)W6'IF<V8'VM%G%0G&I(<S(Y^SP&'A*#01TO&%4E\NG:;2'*B"<M#9
M,<*=8Q2)>VX^!+<4NPL3"0@146%1+ J336_#XIJD-S[>(^C^P_UTKMQ\KFSC
M )ABZW6YQ;K.LQ=_.;/0_ON79YP%,.9(4?MC E?)S.X;09$&V.2ML(#3_J%Y
MB2DQ9B'YN^^P82O1=J/?:$&E<"UK [.U.6!)C&,VLM7[WIJ(#S!)Y-2X3[/O
M^Q:;<C8]M"ZB33]X$4DV2,IDQX?NC4,R5M5%\ZD+WP0=\2;<B%V5T]6@:B-,
MVFGV2@=Y[8;,Z,V<9WKR]LC[:YIGZK7%N7M[&_X48?9/8$EF6;^Q8Y5%(Y91
M_LA3I5"LV0*"PG3S]-1RC-%@+P^,CA<-+^I@'Y6(E6<XO@>C6K:EV-LY>$#]
M.8;7M46ED8L.7KNK&SA N70\TR9?&W6\3;UW->+/ZZ1T(W)]9L.?!!\?KT4_
MBG32,3WY41GU3977GEO[L%T>2;9,N67DFMS$6D1W@&"K1"%LVQDBT@KA]ZJ$
M\<$&+QK!H$V-Q;O[2%/8V5*:K^FO-^,V0;%*'11GL;NFKK?_5=Z8]-KX+*+[
M<*A"SJ*C]R5/ F3_Z Q3CG(%P^@N#9>D3^:M4'SO^WVGV=O1"-BC9K-$?RA9
M?L-NQDGQ2S02B$2N(O#X MN5,I*/CJ]A<"&F9! _( 5N,,4I N2IDT./VWWI
MP4S:K4:V3*G-H]=RR!RK%V S3X_71)/-SR]KC(+0?_0432Z4CSK9OP?SY,=C
M_QA89/MEO%&&N00C'A!HD)></>15AF1 AV 6<9@QRH9<A!3(JJJY3JRPB9\@
M05^/;?+^[;]&V4*5L4".,'0$^].OR#>HJ4PI8D2"OP^TMR?M]K3;_^B['<VY
MX%2# ^J&+O"M^G3BU/E\1&:?=73,<U:[%<8UB  !QY(SP"0(%@&H4I0;J3TL
M!M[$ ,@2<B(1Q%=2(X%&C<GIQ?%(=B?9G61WCG#R]KP,-4/N9U?TJM1K<?!4
M<"\LL:ALA4)0*&]IUE(;$?32TG[ G<AYQ<(;;$<\0]+!R'^0C(YJ8@_4N-P[
ML"$9H62$CF+R_NV_KE>.\XA:T?!1S7QG%;U!04]SN'$>[]+53-@F-22V'%&8
M-%%64W4Y=:A4B%!D[Y"6KE7UL=]LFC:J:!^T3LD*)2MTWQLI6:'/Z0II*(90
M*'O]T\O9E G*P11=F&BEJT%;S6*9;%9F^TK>@EG02W[JBEQ*/ICL318G69S[
MWC3)XMQI@6JJM@ZM1+3--TW'>,&%-P-,(<M83XK,ZL6&PK$M*\)VG=1]6_1F
M:*NK="=-7.5P8!6Y66RP;O"S B0JF9_/B"=/'3*I;U;[9K](?;,IF9K.\P=Y
MGN]%$'57=ENIK03!&C>1#TU)A>3B'^>J3B;A<YF$($QE-D*U:+AJRFASKSEQ
MO6K67)O5(BK#2ENW!GZ1_N^R:5BL3X2V5*5B/QO*L$JIE,RRJYS9$YVJA5,,
M@8L%U!G9HJN282/K@;86F27D+ZQ[*F^%O+$J@:_D6Q<_O'G736=H S@UV;)D
MR^Y[.R9;]CG=FZBUT!(/7;XM.Y@.!;#\\K1"U*,X\T!U0;X&7!LZ>4_FKG;+
M$AUAS1((_C]::28%3,FB_-$MBB0K@00ACP4J.+V26[#! 'K=A$,]/J0#BY.G
MX?2%7.EN*;L.C6MH!&E+7'*QIZLU(K V@EFC*1@VN-5)XSRY+?>^3Y*1^1QT
M^$BV<+ORAD5 :X>H!B45Z;/E-K30NHS6UU042=8B68M_,6N1%ZO275E3JN5)
MI.6U9ITM)_X"8!IS\!FYNI-,B>=[. "#S^3:PPS,S&=3BD@$U+[%-.!S6G91
M*9@_!"*90VW 87"F61I)%]_<0(@/)%<H&;=CW9_)N-W9%4)7#UFK6AN,-ZM=
M5Q8E\U )XPI3D"^S5=-Q3V'<;J18%,/UDW7IMZ4P,Y#A6#2;[12%8@';=H@O
M*UF59%7N>V,DJ_(Y\\(#P*NQ[.4#?@-.&E_NK"#6.@:TC,A>A@R$,Z$?_+0+
M\VA(N*B"8&2&?GS]MTRLCR.K51AOZN.;F&-H5'4N7035;D!ZQ.!<'SK.F-QD
MG\<$+#!#1A;1;O9T4>Q0<@HKKYK:"=4X?;RJ\GFCR3#Q"O&AAQI@IEQVLH)_
M="O(A?VKO*RBZGX!OB30>'(!:T%!FM!!E>MYWW8<KDFJB2Y!'X.KU$H#DM!2
M7^'C)>)+!_H6H5_B;VWR'?RT1VQ=\BY[ TT<?!EWDG^4B\=";FL<33XFU2\;
MI^%A9#!'M-I2;H;O@9J@Y+ E4Y5,53!5].17KN8BF1F P.M+AF'1=,I^1E^O
MTZ9/F_Z^UVW:])^KV6B^&Z1]U!T8I'84O*,@FVXVQ1]Y@^/PJ2AM$$K%O'32
MRG3%F>N\TO!+4^9!;-I;JH<:$"7#E Q3,DRR0(W<>N'6V.7&&A[5K&YG1I(I
M2*;@OE=S,@6?,Y/L.N!]RVZE9%-D&@K'6=D*?-Z]R 5M''(:0I[/.BO"Y7P
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M\Z&UY^-FKD<%OM:RA@\%<2I>..EEQ?73$/PMY013=DCFL[Z5SM?QO.*$&GT
MZS\E,N]D/ ;YF:F$1*3_ Q*HGTL,[G(W"]P'Y,-=E5>-0L>O2HJP,O+R\IC
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M,%'U*H02B0T#KK5A\AZ1H(K,"HM^7KD)G<]ITJ-)FE%S<F[50GM,JR4UT3Z
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MEF:F8S.*&^G[H#E#,"(<L\BL8&);/?GC8Y9[B+V &;[*0^XZ7_)""K9R@Q@
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MAS9#9CE<N3UGR8,O84"LB(#;@%X)PHQV#!D'NN\%[) Z<NF N+4>'E(9P&Y
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M.FQAM*05:!JA$#D*B8$1NGIMJ58,77/(*YRQ;8L^(@^V6?'SEM:O2),G/D,
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M&=_E:/ZHF;9BS^!Z&4?9>MJ$,#R[[(B,$V8)JT:[4N!6 W==YINZZ1B&&(V
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MA?6U:H/.1^0]+T8B\0AR3-IQ!GS-5N-<%OYL->[L(\0Q1]RV]@N@%&B+[TN
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M4G9V;P^-04ZH*M\[J>9OR+6OFFL9CF3Z*4X0@U;1BG2M[Q'AB#($%LM0$_>
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M"U4'OX.G#(&">L+N^OXO/YU&#_T=B-"N\: F/Y;;#P)IJ".K\4X!*^-S-X4
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M#D<5NPYL10/'TC1/K._:T<)K6.IB[%O)W\A6Y*R8]_[%\=;=*WX#E[W]KC9
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M=5+U"WZ+L93 #2H:F32U]B(MGTK*'CV"4&\S #N6KI_6N7B^V#;7CN<N+,+
MTZ]C9N+<*=/1Q$SYU2&>N1%O_P-KBIN;",ZM%92Y.82!N5Q%4A@J2N6Y%_LM
MU#)85^'[$L(CVK!&/S_I^/ ]Q#07T:F:"#.83BWSTGNUBFQ:$\?48E1*/6#E
M:4L()%\.E/<4=&V;II#(&<(X,F(7.1".0H]F1X^X=+5;ZPG$FS=]9NEF&+'E
MC'5<?./<+;FZ']@NG5M7SV%__S+O_56]^,XMVP%5)D^HC^:9@0Z6PN\_4.SS
M_F._A-VB9!^0Y[#W$JKT:KAW)2=O5%R7V [0ESU#@;AANCG(3UNM:.[Y2/[O
M5W^[7/R5.WZP,?486ZN;J]?-[)JF#Z6JL_#I^"JTB=G'T^W]$VN-/V9>:6;B
M8!6Q$EX5MB2WLO;>3P0CW%X>CJ]_>A?CVC3@"XC&,F\0VE[S/9-[^*=:N@.-
MQL; %!5B3^AGE<X-7B<4X7'D6QR0)<I=R0 0!+BN)W^_HWNP$[/:EHYET;SR
M#+2S:$&6ZE"8'-BP9Q>WCOD^_L]73YZ%T"(A([)1M<TAKTPCD>(,9=IE*J2C
M&.IR\=:1WT]VK3JP:_ABV$!Z[<GGC_\HVF/INCIQNHS.#OHHS:ZWH=]^\_VW
M9 .>/7V.7NI>Y-3( U-:X40'7D3OHY=%6]CUGKJ/M;'>O7S3J7Z3M'0]_AQ*
MCOJC?D$DB%E;S,85 !HKS)FL@[CCVI9TWH\WD(H@8<#D\1?3K\D"/ D!+Y\L
MEB$"C$A8;KE<1$2-)[^CA8/>;%HC??I^5;%L?=MGU/=B>XYG,FH>]Y,J5"9^
M,O&1LM-PQ1^ Y]S$?4X'RIPP>SA'[@LFLF/2(55\O,&?C@)I\X,[Y]Z/U-LB
M\YT:S<297BNS6L+:UDYGO<S4WQ ,"P<>9ZSJI+=TK;Q-+!)_=/$64^>5U:T5
MMV,"IEP;:/G1\'5^NM./=+EXEW [F;M2D&DOQA)WH\N8$]&=2%<PKT;<<+N*
M*+^8<=.]Y]-V+T1.TI9LMVC:)"-"H?=$]/ 0K-P]A!DS5<59VJTOG\Y4%0]S
M99W]D9@<4_""A2WT@Y?YO? ROS#J/DE.AU"S&L3C+?$-ST!HV>4T?MF""Z/>
MZ&4$5SWF(4P52''XF8I ',72Z67^<)I*1Q;7.^Z!7A7Y<GD\KFGO]I7E^"53
M=M,9]]W0PLF>S@WOVZ&0$I.*(XA/,<I2@>\AG(0U33T" .&%];$U1HL_'7]7
MN E/9^:\9G0TC^O\BBZAHQQF-M;9I?[M)O!=H"7V)=O3?K!F<^"]+K8NORK!
MSBP^H&UUSNH&D<6C:[)[]W*4"6Z3PF$-?AJ4'5D<W'+32B?#=2%1#<=&FKE5
M9K#6#-9ZD&"MQ"9(L3\.&I'3:EWO4W0X;"4R'IN;H!8;"(/94E& 61T6XP!V
MAF_/MN/>E_]L.WY%VV&^\WYHN\$=<:I_ IW<@C$MY)>C8,'7C(6O&\0G\/,_
MF@>D*V_:G(*#)9-'-?688$*08E"JWL*]LE1:&6,$UA2A=1&=/?TQ7_UC*+O2
MYQHML7;E0A5!<I7E":&W$]^B4.PJ+RLKO=.G@%?2/A@)8I IY,N!^)#)W@7%
M!%)>+XA#UUZ6M4P"6V/NQZ51!2.-"6.RW<Y&PIRV9=.RRSA;Y]DZW[>!F:WS
MKVR=10YGA,W-?-$8@+P$* F3@#I'?D3,(X85[*B,?$C_3%9L2;8<8>NQ<6?)
M.;([BP!OD*3-L8J.L8;F_ '4Q%$25J,[<6F!3(PHR&=#-ANR^]Z+LR'[%0V9
MH".Q857"C*F1V;5B_+<!-3C;G4C?9L$[4P +_!ZGD(Y*! !J_Q-?()8$TV;D
MF5]T-C!GMD=F W-'OJ+8Q,C&]ST5(V$/P7R6H"%8#C$@!'T.-4>GNZ:- D$+
MBQ&>EGW<_Q%ES!H?X+':R-ZU# 'LR-WI)-!#DA^ RECW6TIE(<\_FZ+9%-WW
M;II-T=WX4)TZ.!MH2D10[LC*C"MY6LM..D.'SF0!?<Z=C(:X-# SLZV8;<6]
M+_?95OP6Z7<3\?0-JAP4F78,YZ,K)-8'2>30A_N#F1=-O*,KX/1G)0SRVI^1
MRJ?T_%[3%=@D;4I@8UMX- #YRF4X,<Z9YSKA?;68#%;L9]=0S%9P=P1&X5L?
M?M&@6"1N#Y32(,VVODO.-Z/.UG"VAO>]H6=K>#>1&!KG@'(6#%C.1F?I^FLH
M&P\*B$K#/+$WH@ I;04J%B\8!Y]I%IIJZ?C+;M5\<%MI&L]VH'5(#O":3OI]
MO5U$ KY=EGT[4<^+9+/RGJV:]C#.E+JS93N;S3E;ME_)SV.<ID*HS4JA3]9:
M@>/?,=M&HH#'A30GZEEQQU6^1S\Z>T8"W5@+8/M6MHX;FO?[JEP)T\FLR#6;
MI-DD_7Y,DH6>S74M-N("_YJ.T3Q%6%J'4P/%^:ICZ+O6\=S.S%S$.]!%% %&
M J7]E$G>+"8Q&1DR)U>;'/!LJ&9#==][;394OW94R 8%3"O:Z )[03;+M=VV
MW%L?V;0!4QM"/A1[2LC0'R7D&=L^$QG/QN,,UO]L/'Y%7$#@C1%*&6G3]<R+
M4;>=8;5A-:*@31M+.<FSHXB)N0_9&D4!5)5?=^H1"8'$8D77K02O72*Z8WL$
M%DWZ^T,E2/ZW;UF?.2#.<D=_^<7, ?$P5]:#8QI]M19RN U(#<B,&SUHZ!WB
MDR(T&@&EJEYH%Z7ORAI].EJ0M5R=0N.Y'SQ;%&4U:'&TZYO5^RT]@$-K$%<W
MM.I)UQF0TEL*#7C7#3NG354;9.RL%EH:G;3U@LO7Y43CEN^9WG.F]_P7V6NE
M-G%7>36@_F]4Z,DNXL5Z8AL%1E]A]=1>.OY^JP1?RKN2!X)[_N)IF 3M3K?:
MUC0-&]XM8!W7UCN0DKR@^#%@#))FP1/[W?B!<W+TQKP+_@EFDH4YD)P#R0<9
M2-H97EA(2(;'?=B#95C,URKOMLFA/J>>YTU_W^MVWO1WEL%B-WOO>U9#T1T[
M=]F[@MOUI15VPA&?K<!L!>Y[(<]6X.YB>!UJ12MGV$"<\SV(D"DBG_?YO,_/
M8JG.^_QNM:*N*^E/ 0/L:S^G<@FJUZ"MY6M1#N0(H! R\?H0YR^*$HVC@^@:
MT-V:E<BL<0$)=]AH8 &R#+I#U]2UJV;+,EN6^]X<LV6YLP?!>/\N:B\(P/]0
ME@X= !Y*YSZ471\A[@(E&JQ/69>@H>8N+:A; M."#PNC6)2JW+EV@WIV0GTV
MFY;9M-SW[IA-RYT6:.O,8I!9>>\."Q"[-P?GN #I6(/4_N1="JD.0E^-)5;8
M'U&F^4@ST'>?XKN>F+!UXB%Q=68V(+,!N>\],!N0NQD0IH _M@?C^(0QMHP@
M0-63#80Z&>1CU!W <]"0B_57N7.(0;HJG)CW^F46U6!NU;%[<X*B2SLB@Z*<
MBB?/.-W9"IW%1IJMT)T6J+!"1,['QM7(OJ!O^\J!,YH#(I]=\>@-MB5_:"**
MOXB>"TZ,<R*&W# 4R@*E 2*8??[>#-4(XH%[,F1JO>Z<J$1&]C#^L%?Z<;6J
MKW?]0X7TWKM!FF%5MY[ 5T$QE_N&KYU?TRE"T6LVH83A!&B(KKI0NL@,2LA$
M+0%BN*R4OT @3/3[BB;-@2/O HI8*?Y!MR;RF'DM,K]T61>8.M'A%QJ98X4*
MPU7NFK:WOF2]=JQ@>)V(9)FN4]6L8":ZH>SY5\E.WN_IDD,=02(9E!DLC5*1
M[O9YV8[C'WK1U]P)L.0H*!=Q'[0;!>,3&QY^3FWMIBO2G;6[Z$CQ4A) %E(]
M.%VJ&:E\;DCEOSM5*TCI<D4/^WI+)R=+DK+>E*[0O$ ^TE5T@*[7HH>\/*@@
ME J%2U=<W;=-%30*ZIPV*[00RB[O>L8H[QM@'<#8O4)['G::N?RN;1OZW8YV
M;]Z&MAK:LO3EMMEORQ4?MJI $V\+DXLH-5ZP&T+:#@;A )WMJ"\G+]P_!M;X
MQI;L%?<L;@-9.T&=VD5F /0,@/Z7 : SP?4/:!&C#6/G4%M<2#1,B_.J7#EC
M\6]%R.UJJ. "ZS%7Y#MT(?!RGMB"(>Q>#J*W4I6[4I7C'=UE2WOC/;;FF@YI
M#K+75=,4O'NO:5,A3YAQ6_T \GV!9:]S\A9:IMT>R!M80:NNZK=^FYM-H'DO
MW*Y<R:.Y?2D_35D&^TIJ&>)/EC6T'%4^Q1N,IE[3 $2'1LJTK1J.R\4K:?CU
M!H*>A^>L69'3DHV/=2GKNM36Y+TI9>+7ZWRE\"UU$"#**1:D.C!8W(/#JX/B
MSV%X,O4D(OGXA[)?_K5G^CD]^?E8BM=\WK;[AM<G[;6"-FW;F\D8":++Q@A+
M-38"6E^,.*_U<Y"*;9TZS87ICK^EV?BNI?BU[%;-XL]TH+YH76Z"D?JA/6VN
MQ9:V+ESSEN+K%5P&&L4"*K1TT<C,B!YM615L;5C?MFB$0QOLU]%'6;($MR97
M_]O83OEO!R-P9/=T=\K]*[8 [;#7>#]T[F(PS"N2TZ1 UAT]'>+^0/\.GD)3
M)_8@\WQN(QS(ND287[+*?5V$%(!/=#ZXC3\'_0_'0."@.]H%=H(W0P\/(<B,
M,8LTGX&<,>/LNW!+TX_F&@_<3T7G&$,#DK <$6R$5TCL43-E?X37D!V5 @>^
MG>?K%L[^ %/D@@? X ;T&N^9TR/LK.[0(54L3+:Q#3-&1';\:V/RCZY!P^-3
M7J^0>7;&P,NO)B+T<4AZPP?N'J-%WV6F(K.Z2E:$P+[KD-[(F(5-6BN#LEWL
M5(CP4C<L.V0"6'4)3D3!D1&]W,O%=YQRP9]7CN\&3>[%=V[9#NAE0U8W6[P9
MZ(:T''>8:/R:K@O)@2H?ZM76%<E+\Q^2@LPBW^2XP>*O[UOZA[.^T [/Q"BU
MR*_2N5$68"'-W/!/=+/R/5E8D>N&DR/$*^&J0>)<;DS30G:\1DQI'MQ D>3H
MG +037O_:!#TJ8YF0KZ^// (_GKY]C);O,SKO,BEHOW7FOW:_Z'O%\U.?O?M
M $@>S1']42WRZ*[RNW:3UYIAZOS4-)PO9ATM:,>0"S[P#_+PFC>BOPR=7(GF
M1EY)MOBS(S]4N4F3&78Y^*WXYH< [PDMA2"OH6L[7T;S#X[.Q+H+-QZ]4#OS
M/GZ>85XV5;.D/U+ 7#<[Q2MZ1[LK^X&GXG*Q>-$9$Z"0-*\E4?:BK@%X?.-@
M"W#1[Z!I\?CSB__A=-RC\C-V)T0<@Y7 N"'3!+QH===-?>%_[GIZ[3R#=DK>
M\TET;N'_S#EQEN?NE\]FSHF'N;+.WJ5S)9]3_O"P$X5,IQTRC\K(S"+.@8WE
MS.YQXHB^1@Y> 4I'=N_T\F+;.SO0V6>A$T,Z6LAE^?[-BQ]?O?LV6[S]RPO\
MAR[S\O6;%W])RA8&/.41T9 THE.?;%DVJ;?F'< VO_;G%'T9K3-\P2QXD9H;
MZX*06SSZFR8'1]JC\BI,4'XM_VKEB*3+N?+*,;DD^T@INI9O?/!S9KKG\E <
M24MN2<K1U<)321V.W5/_C.9+UF[#T%SH/K'+1,-0%6+AOXR=+\;5P9DS1^#W
MD**>X\A[,3KO&(\^+J=@%4X57Z3,0NX>;RB@S*M\Y7FB44!"1DG3S5P*;E&,
MEHB!.:G)/#E?G['80N/3]41UAEDVXB0O9Y"42H=W;0BI0A$:^ME:8%9?U@;%
M(;/OW?O$)]<T6"9%-0H-<TBS7&^!$.$0IV\VCNV4EYND^7F/NTVEN;);._ /
MND8\FX.'8PZ^$[)XB!YFUH=6^1JR L/UI%QM&0M!NTDW*$[/I%)UG*6-COF"
M7D-&QF'=0(_#2:BN^6._ T)91W)%M=H*J^ODND5&H^(TSN]B<\UN^QD",!1>
MH6LK5J^*\$(^,\GG)#F66F(-'KIE/VTAM[MTK2[>"G"+/,P6628DU*S)H\A[
M=8EEOX6$GET/M4KR?9$)[9!F8BA8/%9S0Y44V9^*#'1*A0D%$)6X^O&5. T6
MBW9YJ2XK+,F0QD"4VQ1B^.(3M9C99YX/R=^.QPY4PD[#-=\<-=+.*\H-TSNR
M^"^'DV5'@2!V"I*X4BO@YH9TF7/!U/'!JE13M+%8%UTUTA=-_1&CHGGJN-IR
M"N\PKA5'86U\CTB;2N[A05K??O/]M[24GCU]#B>YQU?HP!;'OFGINGA8VM\X
M=$=P1\X<ZU1F8+O$T0]$#-I(H*\L*--\A^PY[WO$R66AF?-H?/%33#;H9XF@
MH+=E8RLE?7'IM>EI^-5YTR8*K5S'[AJ1XF$(+>*2FMR?I&,.TQ"/VC!LXEPQ
MLF4=<@!3S\81#[LQ#G"8JNQ0Z=EO#QU&DRT<GK5MZG)U5-F@"^UH_0"XPZF&
M?.TV0]X6ZFOQF-EWTF7#$9J8]IR/D.B4R"PW<<#Z"ZH;L-97='2QT^</M:Y9
M]TB_9'3-IK("!@T2ZM= VC>6JC+X,1>S;G%@6L>0$&?SJ9/9BNDZ>Y%83%P#
M7?M].#FE>=7A>.LE=55@,IFRS9;JB;&,*YE\AD=19P[FQZ6EVP*^R[)+.Q&G
MBUU4CRE6K.6)M?!:13/;T2J]G14PY',3-J.)/'DW1"#8B2A,)N!/UBY7! H=
MO?2@N8=KLI>10DX9<(K3_=KQNLDFP&QYWR-"YIICA&O#LAL0F%^5[= 98GN'
MC#I=XI&[W%R2/T#OO-GA-Y]E4TBX,;"LQTZ)86WBF/#VX8T=0&ZK [V\"QF<
M4'KQ+VCB:3C"]GOE!&;[BE^&(P/&']_*\@'6CFP 5K[8%-B:#LN=$2G1'A40
MF7Y&".3]4K 7>>*KLX\S^SB_85X0"'#+RB6!!HL0!X0 ?L)9(<#1)#?6;^EI
M-ML3^VGA]U,"6SV$[;^ES_->1I: )FZQP;ZK=QXF+A>VG0XV7^#2-$=?!<)M
M-L_8KF*7);F!J$=.XP[X\ZXWNX"'[FGG,3K$1JVGMAD "7SX9?&%KYO6;+F_
M*3M"H3E'3BWP'TOPQ#9XUU HQ%TA): <[%RH!3AU"O@;R"/9>^*7T!W'A'&(
M5;F\L$84BQ5/WL9G:R9=JDM !<9YUI>O__;JFXO'7WL@L&_6X9-VC71Q>"?\
M]OR(I>- RR*P=71HB*Y&4^N9APZ\I-\O>J>>D,UH#]#NP$<.O9KW@AK:-0+.
ME2G!L%:L7AVS.2:M0NR4\#!-L$-L^P>Z!SFH=I@I\.ERD230EDXXV[D; \,N
M_S&@%:/3J%JZB88Z'^A$;FEO%L'V"V()/AO9$#H7LY .V.8UGY..KB99=QS
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MS8POHQ(D=YO1HJ5M<XWN%* >*)4M;:$:@-6HV,B;T-X6VG(!"T!L'G_UZY5
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M :X2,5*3+T-3.! Y$DV>-&>@9#;6#4+A97RY-NX+/TIB*O#3'ZX>7%=[F,4
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M\FC<.(/WR] =@XWOD\/F;V0[%-<\#5U$MT=X43>.\ZA0L:>4#+7T4F7>4A_
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M W#-D@1/;Z P55ENG7%Z*49@,Z&4"5ITI- DDBHY!;#,Y$E#YW83EDB5P"5
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MA(;56?/E_&_HW1,PR9U^+DV-(MWZSY"$SA" JN3=OX .9'; GH\#IH1S=-;
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MJ29M=?#QK(<ZFY]L?AYL A,Y;!LM6UO4"2.435N()X6<G_VTW!-)%*7JF>[
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ML!O @OH%XY^I[%8$H.3U6?FM[V,1 OBQM\#%Z+#B=.:H*BKE9"FOZ_/$]N
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M%YF*2H3>)4+BX7K2WN7*KJ[H(S2 TT$>4WJTLJZ=XQ'@O>43.GO*OTX;]KG
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MK$+&OFTY)MBLT:0J6QP% [>+HL@,;[\;U;IIV'OZZ?^<O=\9',-X.:',4<]
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M 1!C=<R1L>@">)2SM&O,VO9N#G0-/J_6XSICX;##PB'F+R]D6WO#4MS#7>B
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MBJ[4\?D8V ,,?H3FNU!9,:.K(CL9=SWE;F-F7O >[^@8"-1T#$68W/$8+^R
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MQG\D*7C@M?5M<>HI10[XW^X;%*#=.O>UFXF&7:)0=YCW+ \^Q571\AE?IV_
M+,C8+INH;(SJT]RQ$(<9.P']N8_H^'[=V0U>(W/@$,%7>N6+_\I7^\J;T,8"
M5?#UPRD<\ L^Z?4,&?75<!\F;7EHD:O#Y8P."EQJ!38&&7EA.WNBSM-*LSGV
M.H5%4422G;T"UO:5;@].;."29W9:7*J<(UE\XQ$&O_YZ"EXF_ARFS\;"0BY(
ML) +$KPZW/?6 >*PD5-+^1^O3_[X+?AD6?XSNX%O@E[PA[%KG%>_.PBI\*RQ
MH%>(K;;(PJ^M&I\$H4_LD(VT\77"*'C/)@NN&FTT("K&X5;/T8EO(])WP^/C
M?GAT<'P5/:PYMW;J' XT"V])Z669O ML;Y?8F/6OAL/>L=N>)OC*N3XW.LET
M$/#)U5.DN2P1142YB/*'%.5>_,_$JUHB;RDA+8!CG>N(KN)!4,[J4M?HYN*5
M#<4;801B7%0)BT;8?KB_MQON[@^N-L*LF86CQY-(*V.7H0#:[>WNA2R;5V7
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MEPK?@I=C_"7\JZ[2#%:1!%%<%IK[G?M#F<_KWBJ1\01J8#.6V^+N]@N=O&Y
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M9VT=H0"5FH.EDU=MKM:"-\)/)<&W7J(A6@/!F(,^ET!:2J.3)L+*[.W^@?I
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M)U^;K9 ]FM42L>+Q+M=+WS*#,-(':K0K]$JOC=8CSV_;:STR+3T2Q:9M.?I
MC7:%M![1>N09;GNM1R:F1WS3LA\81-8'ZEAZ9'^.RQ]S/&N7Y0^[+%4O<]%7
MZ*7R7[["F@"\WHL#\Z"1MN=*%;10QR)4K=T?H]UM.S)]W]6'8(2+\T #\217
M99+0I(6J\7Y<D!+X9NP]90;*F-;F9(Z %JH6ZC2$JL'Z,=67?#/RGO+ZQIC6
MYNF/@,[UFXYIM.$X4UTO=+[?F%7((T1[_]1TO0@C6 2M]Q]5=3$RP^"!]YT.
MN;R;MP7&M*HG=MBT:$> 8WH11K (6ID\1IFX8$5:3Y^_H97)F Z;%NT(<$PO
MP@@602N31RB3T#/=V!_?ZFI=<O#LO]7ZM?B(![DUA[5@_5Y0(UN=\9RXWWF#
MG7I!OC4W7C(N_X;I@;)*L2SJ#G_!@NY7=(8%W77$8#0J[4%"784[Y\SQ$>Y8
MN<2:RM.B%.,Y2 ^\=G#H!=1TY#'9BX%E>N'Q"MQM6]GI49'QK*=.>-2::RSR
M'\^IT)KK]#27;3MFX#VPRH?67%/&2"U4K7BTXM&*YSAK"O#N/-"!J]7.D_IN
MX;_8%4MW.]QKM\,_57W(CUU]R/.-?-'A=(XXWGLU0?3/0M<]\C88?6_ 7Y:5
M: IXR8T;[+O#-_KN&-@HP92>]-M*B!K7M#9^\JVST(!WS?*R, T8='III&51
MYS6V!<3NLT;!&V-6UJ*=X$^A?V;WGZ<,!2;3EHNR(.*EZ27(F,N/._Y9U'Z\
M=_"+8;$EQPZOLCEL+4:YTC^6UJ+G(7YIEE/1]BY73[7/O/:A9P9V2]QX=S\%
MV1P1A(G?9!R6 OO#XG#X]P4O:M&E]Z?@S.UG53=E^HU@-WNL4CW'3\EOB'=;
M9\%  #"Z[N7]V&<BQC%\0=2+30ZY;XI[KVGC8O534;)K8RAJ:<[B3M3P6#F&
M]ADWIO&3M?H!FJ;5$OONPJMD6V(Q$]5B>/!R^*K;2QR_"E)<T)RU,ZP'SY#C
M%V\+AE\!T9=UWLZL+"X(T)WY<+KP#6]M?-@@'N9-;U!]F##+##Z-FZV-(]5*
MN&NORCA,@AD5O^(%B I&XZQ^I)T[-L"D52J#3\.>Q^W,S'9H6[\^W!UGA\2X
M$^]X>C]4L^Z-:E$\1*F[4<VV_"$ W UK=O_\_<&:UY_/1\ :/IG.2V"P_]Z&
M<\$]<2Y<P?G[PEQXYA\:YMR!1MD*<\[J!];10$!3^#@PB'\0#'<!E[4ZU$W$
M U6W=:@KRZ4&M?6#=X*[AJT#PY8=WQ^V_#/K1V K]GJ->0_4LOU#H);?;[Q#
MH98WY*BWHM8JC-\7M8)U/KD/U*(=;JDYN+WLX1&(-LM9T[;DWN L(!KT-X@=
M P(L>"HF>9TWE^(+3HT?;&Z,\XN*<X0I<_V5[N"5:E"X^0%<\..U,:=,] (7
MDY12H>W#%-:M/=$:/'&=TTF466=VN['/[E7%#X'PK7#WPX1,>QX>X'GX-"SS
M]F=;YNU#5^9-^R&T'V*K'V);)4"I^FP[&E+3+;KO)SN.!\0+?K)8 DZT> ("
M_<:%F]&H.?"<UG+U!S #'TOI G>#1!.6-TO &P&,ZEEX$QL@$7 5808S$1<*
M6R7J."L#0.8GP!3_U=_;%E@Z1+Z?(F?P3<$9RY1S5AM95<Z%%.>TP4'?[)R+
M'(&WRA@WGU/3&=_Y#$WVGLI&'5[HW[WK [_?T=LW?>BL&QL/W#C^N@?GAS;.
MZF8>[,%['4,Y G<O)U%OX:>R5^ZWA>V!AW<';MMN;]8\< ^O[C][\+P?V(!V
ML K?A]R!=_+*;?&]QVV_!_64>UB$;_S3'L^A6^U<@9*[["ZR+.@%E^%G0C.8
MQ6LZNZ8W]9L7QE]WRS@X"X+PJ:7\9,'C$5MJ3XCO!S+6WG<459MH$]H-3V&B
MW56!2FE[*]I4][WK:T7Q;ZKYO*Z7\&!!,]-R/B\+Z<V3KKN!\W/ 2CD\DQF?
M/GQZUP\+ Y*#2(;\]/_]/]^!O*1O:*,H!?( I T<Q2!_R]Z8PH,*[^O&DI:U
MB%<Z]H =P/*!B/ YO^9@S3'CBQCGIY89#)QN*['1;MS\.Z_27+K-U!P7Z)2"
M-UW3JJ+%T&NV):[0/:@C(_B@2XH410X.G79\OIB5-YRK5_3$94:+-<KNK3"F
MU@6X8K8*26A^?0P3\983YVXAV#M.W$^VX]]&M5L3;^7LX=9#&61+,=IN=PZ)
ML-IX\%7<=2M?1^<KG-)*A0-@9%>T$3LP%0?$:.!Q-4W5YO\IOLN!L1,D*CZC
M.%$8&([B]O-NM@=^2[CNWF_<QR'<\!MM'<(M<#$XQ=8@?J-/\?BLY-VG.%R)
MU-U^B,.U*,L/;%AQ&!?+!*A4?Q+0:7B'_7V ,W>'M^DISIR_ZJM]Z)F+]GGF
M[K9BHB>QW<9AM+SX^\<L(S_3F=@*7RXY"/T<]<^%#$(>T3:YMR5RIS'^'#'T
MG]RXI%>8"] 8PC\CXC\8%2_0R9>11*UY+=:<#M;<Q/ XXW"XX#ORQ']Y]]:H
MEK-!_.+1&^)AT[K7EM!'?*W ,?RV H6XI#/C(ZBF"Q&=E^;/6X#^O)G,6==\
M:?M9GZD,D2Q/N6G,:%)6M"DKZ3@'W5K1"SCJ^&)D QE-V\P9(!*8QU+!UIB5
MJ=H8\)&W,/>LK(J<BD?\@]9@0EPN02F#GA4I.IACTEDDZ\DK$GSX]T5>R=P@
M!BRF-A+>7'->H!'F(J5Q+-<],[9MO/M+UPU-^?^'$["8;HF1BFR)00K@(T4^
M7\[5M#M*TCLM!I( XH0A&&>86092DQ04K+%@R&X$[VH?A]_$M"%8#OQY 5M2
M$.+'2NS0^_$+T,+?2[!!@Y:V(K_&"EN"RBK6!M*L&_B!F*LVEQYU_'&G+"@&
MRD#@8'N(Q+K!'@1ZCFR_P5_+C7>M^ '6SY*?9\85&$/E$H]_PV<S+A5&%X(3
MEQ'5V=_RBE(J%FXLA>=B3K]Q(X4O4MB],' .(%0,]O; K@%<R0&"VBR.>L'3
M/,OA=R*_3M*1:Q@0_K<J;^A, )<Z%+/R&D157,S@J.07F HG$Q/1G*$SZ1+I
M)@AS8<L4)_&A,,Z7%["RRI+,RAD\J;4ZX70WN#\7@%W2@\)ITX[ORV_G?[PS
M48!=AN!/P_@JCO*.%+I=*86=G,0 /Z9-B?:N]%A=<YDN2#>E*3/B!T,8+C<M
ME%6EDB;EP@T'U2VB',BOO.!7\.4S8\T.KW<YL,63Y2B+<K!$UUP!V$J*PZXE
MZ5 CO#=JP+)5!F4LQ_G!;_(BPQ.TDGLX9J*J 6VK[&#O?^&+1FXR.)^AV/VK
M5@QN#D%J=Q^VM7U-80?F%5,X^?;S1YF.*YQ'W4/0=4%G-W4NV3$<@SPIV0UL
MW/EB)I,3LF4E$FUETG#_.L6$NJ^P:GEAI/ 4L8'K^Q\GZ:-6APK!24'-10$2
MQ#$9^1PV.:_P,- Y7EC E]\).EO8R9FAE >=U64'X0*5 5O$9U%0M^ XO'BY
MP,]C0&@0XBCN@O4S..P%5YP'T\&O%&\$[$[%-0F&4 J_WQ!0-^IE(=),X.V8
M&X,R$4.&OZ*@ 1MF^3<^RR_+4B;OBQ&U:]!-1F./QIXA]OP#=GYW\.Z%.DV;
MFO4#B-/C1%ZG)5A@-QTGJGEU!?IQ$S)V(P;JW;O._[5@)HJR; 6#>X?/#HE(
M]_;^KPU"66CR9L-*>MK1D7&8,ZR1<>S(>(04NAVP^+3Y7??0"$\V\_$HA'\J
M'2 U0(O_G?TI'PH_!Y-+G-ED">8HKVNI @ CY'E(06A8T09L23@MRO?ZC_5?
MULO%8G8#AEZQS-!A*Y 0/RH>!CC RDI^!6_NM=_J\*UNEJQ-MI6WP5I5HI(,
MI*TE'M#?J0-K<5&*R[72-7 !!F!%9S".5E?AY]'=!X>],UAA_JYE,'HCD*@H
M&^%Y%-H07LSA*Q*)4HPRS 0:]<*3%P-%->K94MVQ$_@D/D<3T(<ZR7<"TQ[/
M,;4M5R?Y/DF2[S.+G>']!039<UD:  'S$]"?M,79/R7LOU,TJ]8QZT>$6?):
MF$/+NNZNI+?NF#[=0ZC;0M)+\1EYD5O&HJ16PZ27@2?X7K2U57_"+9Y@E$K<
M+I3&GZ@,43$1,9>V7;\=%J"ETURXAWK5";]'%U:GV?XL<OS7ET;$P5[^>?;E
MS/CU_/S3*^E0EZ_JKM%OI=457H#!+!R0%KU0N7W*T]ZR?+DG_[5D%_([S25M
M#)IE/)4)0_":LL*!2"M-R&S'G7IA+,%BS,IZJ7(/48'#C(5S;<>7ZNX^/=H<
MZN];IZ.HPM8A=5?-66\,RL\)@8.A6;(SXV,AO-O%18D_A=7.81$'PN%7=+84
M0L&X0"<B4]$.^6!@/L-@Q)!7(9VZD81-WF\'XF8:&<TK Y_,=PNO(T)KG][(
M^]Q52^',^$<_CT1<K5J9 ^YJ."U-68F1HKRJG./N%-ROZ&(YD@;*/#&B+,U4
MG9J9\//C%)9SF7@E]\M A D8B6!_"L=G@H*B=2E-R]YF3O,J7<YA90OALSB7
M<:/V4,(QF>%&PA2U-A" ,N^F,@F;4"/V=N/H,L>$9H#7&L:+6TMLJ $V=JH2
MH^9H$V1+A$?&Z[3*DQX?P1J0NPP?M@.>>;L=Y385QZN+V^UZ:=HJ<'BVB*YC
M&F*M;BI^PX\/A]XCI[AQV!TW-<HUF-XU5O%E<4#P5+#6B%-X)#PP\,T.^/I'
MJ$,SB2-Q_.M@X^6-V^Y5?59U93Y+GR7NH6G>_-)(N-U-!"H8'9V[W<U29<*@
M5'Z62 52D7#3N,!;'Y(X= QD:S@3=.Q' 1]R/VUDL2NJ-GC+2CH2/%^\RL#[
M)BM1"U3>31_B );$%W*0UUP2\7]S43=)OGB0,RJ+Q$D7D?0TTP4FC@!U A8X
M@&8I@H[]GAEO94&TV8VI,''CV4A\%RA3> U8!K ]A!!;5Y+R18GL@A3H/T[^
M_,M;XX]R 40GL +3:$^>8!]O5[X)[Y=/!$[>?>.5\1*?(/Y65CNE9=3+Y%^"
M6$O-(L:4)TLA\8ME+JT%&%L_'( ^$EB^B2YU IN%?*K*+&^,=R =P9]E K_[
MQMB"%G)4ZA&O6G,%!#W+%4%K78^\?9S0D\!H>7ZU.K[=<E//OV="EL:"+5CP
MOJQVGK^5L\0I+F 7-,0((Y@3Z#N^Y-)]N\0/#,]"7ER5,UC,?X'-TVRO9*=P
M2-Z(P=ACMQ.0#X%4+^6G9<H8,*4%+7J']N!!@K-\1]^P,(V&/*G*ZV^U,B.N
M:<4P81QK.(B05J&.PWR.]SN$6SMM.9><4?<.M'XQUT),6P@A'TZ@N80%O;@L
MEY+MS?*LLRF'Z-,9^H/R>=)DK!>(B<-R>6"==T)II]P_ZLS8LGA#^7=R%&#+
M1&Q8VD;KATG*8/B@#A.D<4@EUHKP(; ^]" 88)/UVR3+@3\.<%4>^/8CV]\A
M<D9Q/[7#VG;.[QP:&FC=3 5MKWB&&8&X:T091!F+(!T@"Q,:@>4R7^!#S#X,
M8.X<0XOV HE7(;V'^G9H<FF&L[_/,BG=@RP;HR:#Q+CA (1FN&L J)M7]%HU
MP.8Y'-B2X>[MUDO6_I3XS+HK9E+7]8ZBY$; 07EQ\R.#JGNQ3,%6T,DFN_/*
MVS3Z+6=YD+ YH!TK*2G-S0*9XNRFC:4-DT)%&D$E#W#KBFL-YM>B,B><4)"#
M+'6[7!#8<DAU.*_?#+FG"7OR8CD3-PH40^W!?3/UX4V?!(&';C6:J4*<;6#R
MC50B7<XH3!OK ]R6*/H.M6:7'3'(*)8.)RQ)W'+J-:[=QT75&0.<Y=^1Y8J!
MMC^4)^\'QM1Q,=0+,U!F,IVCRU>^Z1ZMJIOB@G1NXTZC]31Y,)I[P@ B3U/V
M"3']9(!+B/N?\QR'?%&6H*S+8608QB*NB*OZIQCE[AZ?"Q>K2NE1;%(H@KJE
MO$()ROTJ?@_C0&]DVG0:2/%/X>H!:<O*KB*D+/3,QH@THDT7T3X4G?YK_?8K
MEN @-TSN[FZ+='E<M: ^RUF6 U,3U7\'5]:D_<@5 HA\VU5JW1KAJ\Y!T+N+
M^K7Q,G]EY+A\@L:V7CSE%=QU/O*6SLH3^ :> H]I9]D]I:7L=SQ-W-208Y2W
MKP>3Z\,2@X?=2$J78X:A,,J[T>!UH$YO# 8'HYMSBD&;5@^(U(J^"@1"#]*9
M81A$GF7X4"X9/,8/VJ2-_HCC\Z]>(8<N5^6W\?3.W;ICKAUE;WVLF/8XFZEX
M6J<87L+;AC1KL',$KKW$5+/Z%:X\!D[J[$9NCNVOU<@R760Y5]'!3IO -D$=
M4K8+W\<)^_K=[;;!( !FIXJSU.7 RFO.JU6_\RW1XI6KTGAYJ+5>9-1P^U[;
MH@CE0)$9# PB<:NON>9HU+^T'3B[((9+5*\Y*GO P&2%5.#5H2U-!(R!? 90
M.G 22F$)\2V:#4%T7C\5T+RG'*ZYFB0^6T3.*=9NZN+S&-/ 1>]>?;5.&FX7
M@WD?.<@A@P@$35N=B<QU5;TIA'-!NA*502C HON&RMINZ8^&BPG#Q6Y'MG2Q
MX:;;5,^=YA:%7'9M#*&:%)&X432VT]#RH2*XWSY5$>?6BTUWJ2?8P2O483 T
ML*)N1,HD>IH4A9$G=]?3C#PS<L''!\GYM].'_B9B.U.S?PJ^O);A3X[FIAJ$
M( G"1I&6E9K !F\R7O)<?"#A*5WB'<CNJ2E=B*=@]BP7=$V]1@A@\_/RU_B-
MVZ?SRL3OY]DM1,1@)9</;7-=A[-OU[T3G\"R2<#":%)$1Y:^^!PS8SV=&?LT
MUR.>HZ+]9T_HI"6XZL]LN1AZWI!/"F2EU4T?K%S@!Z2:7 \B;UB5JO+(AK&9
M2WW>NQ?6'%.#J@<]74VX#)3.MKFF6H>8-$AWFO/R4F#+%Y5S;_CJ>Q(*U.ZM
M S?+O_?9D&9OB7<_0:4(RO;,^.^M1KIDRV6!P06^><5B0WC"D!YHXSZPU;D$
M.&M=G'D]_#S,+I$7S42\935$B&5EZIYS#!9G.4=G,MH":\;:OX5M!*/'@8C+
M;I-0MAH:MCL#6^HX"(G)!-,VW+G+.\2_ YLV=^Q7C!=+!Q0>DT95[% 4OW.F
MKT3584<-2/.=/JG.NL<M*E+XZ P#'*L>*GG<^\\-?]D;EXS/<JRO).AJ/7!W
M(?Y=P/O_I<*J'.FG\.2W8J-7-!<WIX2IO>V3\L1VGQ/V#7)EA-H$7M7?_E1B
MV1RD+&/0C5&?M^F>MS9G*%_Q B%<"YU!I8>\]9/NM!N3FU7U1W<;I6OJ[[Q0
M3A?4QX.0TLH05@RL,L'\!^5^*F=RFU+ENVEUCKA/W+[3Q(=O)%_06FWO@9N]
M\Q2*;%P8OK@=O1$A,_#R/=Z,YCASZ3EO?8DP<< 1]!:4F.4B4O1G &9*B J6
MNFP&E5"_0Z[RP*_E$.3%8BF<5.6RP;^I/((5*"JH*#JF7K.^!MWBM&EHVGLU
M^9-\CL;85@?63I6(5S/0L25U(A<%)>1%&:R@(,_ 0MU^PA0GE2DE\[%$]+R<
M+=OMO"S:P@9M28+SXF;0E/,>BOF.^(_:VC7%8T=%O1U1C'!SSGH?3W<?#RXQ
MH84C(KWB$IO8'UW]Y\Y\09+47L$0-IFD+XB;NP+&9\9_=5^H^\=CKT/EH%57
MQK9M0W/XAAU1TK5/"#I(MO%!T=3B3I;9*K45BZ^$^5!1?[SKD3U,_4;EA/NF
MQD2<?)Y@K0'QBTI<3A&9;6!K846Y6=M.0Y2567:?4??_DY76P0U/+V6BN<SD
M;'-\VH1-<W@+9H=.K#=TX8Z)ZW,\W7/\_I8T>'5SH8^@KK#/P05.I8VZNUL[
M[TET+$YX $3]Q_]=8CU:<93[-L25L/M$01Q![0!&E*]#O&.0&::(8'=G$=..
M9).-/BI3E 5VP\;[8?*&<9\LKRIB#ZZLJ4SYG8G\9I_C*SB;ZC=3R8+<NW+O
M RMHF6Q97="B;<4M8Q.M'*6XN\#%'.MW2RLNR_LTB2$O_W5E@63<>M@P6^GJ
MM^\^?3#>JP7N&NP8+^NN!M"KB;1TGERCL,_#L_#+X"R\4[M]FE?%-)AN]YC+
MS(M[M%K'"[%M20-!D7O ^WSGEP?WII 3=-]%.W=9]]Z?K@#=^I-4BIU*<QT4
ML^RNMV_YM" 5I4AH%V%RB<FO157AJAB6*]HQ\&%B6MMFA+3)-MWD7K:62TUG
MM!*0F_ "(! U$M X>*PJ,U00T2=FUU7[]I&OWL#?[CG$@2RE3EFY?*"BZ&WI
M/S&V=K18$,I<J3+0%@\<(GYM]H;0:OKTRJ>,EUA"ZA4HFY0R/E<7^W'&"ZF.
M\@*>W2S[<O_(M)>SAHHL[3:W7.9[R_!].\'.WZ\H*@-6K>(XO8W720.W4E]T
MWEPI,-_E7(M-^$8-8V4_KC6YV75WZLQX*[XGXD1B358W7-X[?KJ\IGO4_INU
MZ2!=EIBT,51WVC:5JMV_!!VL=9DUU_(:D)A)C8X;S7"G"\KGM3BK@WS@]L::
MO/,OLO)WE260FVY@V+9>=W%<L'(([\Y*YX2L)(+V 8'N--U6LG)P/0^3[)8B
MO1 ]M@@W1%8:'7@&,5)0M9&-Y4)Y7?IW]D&Y80J4[*>E6.I]BIFW^<-=JN"@
M%L*P*D\+0G,0ZB5\&:,9L[*6H92:#Y.N)>RH!POU@Y'#%C15S[R54BT"9W?
MYMJM1@6#,M>H+;;ZJ;471)WU+F-2FBHR:Q*&L#4&G(BPB[ ,=J^<N)FG/.+2
MWAYF:JY)4QE+\"^)P\.$4Y5A-G1QKZ>85UP!5RES.)=SI P?VJA\W7;HZ.L<
MY4SE6K8#@6$N9?(:;S\Q5'^;:[Z:'BHMH%R4!C1N,"907)4P/F8.QJ!,N"Y
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MR"U0IAYU7$RT9R2R+6I31AG\_%!=XQ^K40_6E$[KTVFY'G2&P*'!0Y:"UZD
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MCJO*P*A.W-#E)'!=5&4AJ"46Q21.G-0+J&?S8"^1]R=09;X9A9Y69=.WRW4
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M,M-E9]5U0U\?88A,61XYZH.AERB%P:) BHB@DA 0O,F@B_%8/*)P?.  DZ<
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M(7T8C"E9)10$:S,H5[!KEA>K9^*YED4XH^Q]FN7UZ\/T$@WN;4(*L4E[;$+
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M8LE5[\,#=ZZZ*\H("+9XT%+XD&7*QO72@O%C =D/>BO]!&AY7^%98H_VV(.
M)6#'!2RY*^2NT&$@8 G840)+]$WT38>!@"5@1PDL19N&C#;)XB3+H@#Z:$%9
M;L'YD*$HR87B/-65[:,'(T6;CI8])M.$\=B3 ?^^JL@NZZOS;+G>;F>51.K'
M^1?N0ESB;(NI'NS= K>4:MN(*A.D;4!*'BH5HAWU 2!("=+V(26:)IH^Z@-
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MOE(=C1=S)ONZ.B/B:(\X"%@"=ES 4JR6ZO3I,!"P!.PH@25/9=#"+-3(O+'
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M#<4.#Y8H1:'E <O8;T:39^LRJ[_^;'%QMMV'FO-BF^H;[49=K6;UH_X+KP8
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M'@&OFM&R/C]T144>"DH5R0J,>2B2D.0RC G-PCAD/LU2=I#$J.]Y6?^3SU<
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M?DBR((,?&8Q:IBI/V58R]9<6#S_)1',>18J'L-]RB07@8<I9XH-HD,0T3_-
MPF0/74K\R!.]Q,+BEME7MB?&P*KAKRU TKQT46UR]*[E@J[Y,72&:$RM:E,
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M/HIV,M2P'V^]4UL-J_6P)3Q\K;7*VAE:B^]P)JU?2<]1$DT84&$M+]!Z+!Y
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M/>I( 8PPV):+K+W,FL'T$YN.E^E8##YO!B[9$3M7\U+=6V%@Y#VX\GYH.__
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M:M:R6O01;#>F( %:IXS,N(\'P:V_JU9CI8TJ*$]1+24H@H2I(B.LB$'_\*.
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M4I7S7*%O3VXZ_;*B"!/&(L)YE!.:QR')PL0G4L1)SG(5"#_==/I=W_-RCHZ
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MGI P5910F2B3%:*4\&DB?49S=0Q8/7+CSR1R;;,GPCY<X\]+DW-^NWI_Y;5
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MBFJ^ LUC+E#O"4AK4/.",.!*CEU2Z944C''1.Q_X(E8^K.91C9 Z5LV;S)J
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MA?$%L/H=[_[^H5FB<-O58I*&?>C@=./  \F^U(48R$*,, UV4@6042O*"8]
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M\J:-\[!Y88'>1 F23Z?SSVWS^\D,'8SYJL4WMG]X^]6@VQ&@_24YK^?LE\>
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M3F1<A)%F@LET*VOF;H?H:WPCT4EX;(>H=8V4LSMQ<*!NY^@^ "B_]UR3!X0
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M;# ',,<W_=A<58F]YBS1M7H5G%>?8:OJ=6#F\UVG8&^ 2&U6+X'[W;Y<5^D
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MQV&; V6/WD"'HRPR=/7V74D?.AJFNL^M-T8M>RD?-JK3J9W]D4Q$(W;@%LZ
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M1YKG 5$*DXF$JI30!!,=(Q$18?((YX'F1BAN>+R5Z&B2!"SI,"1%R &B4%8
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MB3/!P#@S&D,;-:X$SJ"T/_=B#A)NC:&6D^"GT@8:T'>':=ZK5>B-(L=^85"
M$7UY/L$*RO\@I= Y@OVTM&]QX8S)CMS7W;<TZYKR'!"PGIUA8*5G6]ITFA''
M'<&RAR,:=N"XZ-:V36>"V1RRG3E?V[[P#1P'UW@+=,/M@IEBC9X:PB_F4Z A
M1@0__'H:?.]N)5\U_ )^=[^I5R^"2RYE:8.-9_!6((L^GG[X2%Y7_R+4O?9E
M62\;E^8N^1+[W+U^]Z^W/Y*HZ">X?14%GDW-1TK#,$QE0=)(2<(8A7U)I29,
M)JJ((@9*>:N&-V.I@@\,,84JL+**D[P0!3&PV*)0,DRUO&^OS1%CQ$WO8.\T
M;:@.4*(:Q$V)*M1V2L(^>;U =LNMS]5#7RBE> :VC<D2 YB3@F7$\!]N8A'2
M+"KR+>:EFK%48B&%$C%81JD!:PHLHURS-.6&ZE@GNTK\.D?]:PN6SF#G-@LG
M/E4_Z%] <!R&P=/T>/&HJWOP9-J5NS)'V.4 VR283WL5JXO2ICEW/O>)RQ[9
M2$/I.S?W>O5M_5![WP;D/0=XUF!7"-!D>HGWV4AEZ3VU.X1M<S-X5+F8.F<;
MQP5@5A4_LT>-6[O$ZZ"-6B4\LHT[LX 8O0IM>L7J-RJF'M!L5P/4=2X2M\A?
MK-?7EX3TZ.U]@>[UGH=,2'64%C1)"64\Q;9H@N2I2HE,$LKS,,]%EG^[3-@X
M^8<I3#]B _1K"P(]8[X_!RLNB#;J_BQW@V2P?D18YYFKFOKU[2F NF8Y1S\X
M?/;VQ]<?7I\$/U2^JNKI\S85G$=YE!.59.@O88+ [X;H(DRIH30R<LL3R%(3
M1DF<DXPE .M8#%P."(^D(54)W**(>3B"M1O!VO-PXD6AD%*%("V% 6N@""41
MQBBXC4A!IIH\$=MM^836H8DR0B6P(LL*G(J9"Q(9E0$^HR9E;!2>U_'8#GQD
MDU:_IE[[M@TF#Y9H.\@ZC,?W1@UGT</-$'Y=P0]=^XV?YJ72%Z4,WN.T N X
M ./8>FY67;I8WU%Y $?'YR-+U7==VXJ(M57R>^MH[0<_O7\;O($W1_&Y44.+
MGTV\J>9:7=NK>ZFY=74)[!L8__UG%)9F-%>L,!E)62@(4R8DG'-%0A5&/ KS
MC%*ZW5])R% 6.:'&1(0EF!E9" 4_L0(Q+2OR]83<M\Z"\-O3RX@\7#LP&IZD
MQXH<UC.CK&="7=HF2#L3IEZ_^W#Z3^39LYI?M,W;;:6.I2LR, \:C>87.=,S
MW\:J\Z:WGOB)+S!?9:)OV&_8@Z9:8BJ6J>'/?2_\[BZB$W>NK*L%CQ(Z,9;3
M14EX?=$9B<UBJ>#\7O+ITE>2XQK[2UJMU,40VA?&%YIQ^%2;5Y?P^AA[Q!1.
MJ5N7Z]_?_NO_:LU4G\3I'F=?R3\3WOYS%:C2&&UGYVP\!$?T+&K, G5^()L'
ML !Q"G:Q:(W49E[^CH-YJH4N9[UY/*N8AO^*<TAQK%W2#4A>)V]4C0Y@>[>Z
M$BCE?K#7?0JDAA>UA?4(')MYA5XFMY)6.-FUV#0=;T3C@"#2[1TNV+J^["$B
M2Q>XP9.#D=/-)D08$';!7>#)I8%SXP H9L7B G#* 'K,2I<IV]BI61VMO.]O
M#&H>P;*'(_?VB)'=&GR";D]D2'N^%N?P8;,.!9"]^_K<C]HJ+_!LM*WDSJ:5
M@,.A_[LL'0MCI[FF:47O.D/OREK=^7+N8';RM#2^$E*KB8WZ@%$G?=61T#X:
M><G+*?>A("?Z_G7Z_P9ON+03"BV6AEM@(D+G%O>3/5:M(]>_PLN+Q@5JIR7.
MZ]BUR$WA[[JDPHU!WBUG(.]M]OS"_F6*\J'9\,]/? .RLCEWQ4Q8*%5B4L/)
M+BW[6#T_!G\,1^DS@ E0C:SFVD><;,Z44XS7"B*; 22T:XQNRU.P+MKJ2FR-
M>5;AC[T#LY)K[=$#+&7;B'0U@LW2G<_*[ -ZZX<6V_XHV_>A?1"\QRH"M>>]
M7<N>2RMP.BE:*^+RI?8_PTYQZWS]&*%RK_GOJIX"U-)\"O#E77W&9^4?CG[?
M__OO[UYX$&AK)?LEX@ DJQK%U3F_Q!?\#P"-1I7.%K%SAO@F /5#C&ZS2*5=
M<I;VJ(VO+;)-*EO1#QLA8>_\!:(;6[!PABO%>&:%>5JE35KF>_H<'F9CD V:
M\VH)U!3:)<R5;LP,YL?@'"A7<>ID+1"R=G39R'%!^"A]PUJ$R&=5!=_D#MM?
M=2EX-:@%W=CPH7V?6;7PIJ_4[;B]K1U R(=U'M<L^'M\F9;\W3GZ?*X=JZV>
M@#,!*V^1VYO:1PQ)>0RQY\78,&IX*B2*P[%AU#UZF\>&46/#J('3=FP8-3:,
M.H F:;!4H/,-;-178#,3,"/@Z&()>R-KC>CJA4T5:VOK/-I&.(M?M>6YMIGG
MK,2&)[6%MNMU"WO0J,W/VUFU47K$N(FQOR]?^&GBZ-_L"BM<Y<9ZR7Z#381@
M*TH97,!*7&*0+>X F(YPLVP:+%SI>BL#:/R/JU]1F"OW.[S-!G5N@M<3>#_W
M@@>X60^G=\14]@G^$>V-A);5A<T+;'T\N'/GUI6*F]F?Q7J;%5RNWQY@_=2*
M] L<&=^E$?I2F*"QN5OUXKSKT+[GQD#Y[S=NC;F7^(:FYDOES#?3J8JR=KN)
M!MPDL+83 GCKOG/.;6,K#:Y][.@F/H)E#T<V@I3KM.QV +CS^FYV5%X-KKO6
M=7NK>'"O@KF-OCR7N' 2"JH*E9,H8X:P-->$9VE!J$FSF/,B3]56VYQ"9YSS
M2!*=Y#%A^$].0TS%+20+C: RW&C4U-'7[\]!0L')T>:03;S'Q\XG>TY9")QG
M-$UU"@8SIFZGFL-/14(XS0U3:105AGT[M[5G_Q.2]Y <1Y.C33Z8[,@^:/$9
M]T'[MSO<@KVO_*\F>'=1RAIV<]L]N)E$<%3*<,0 C\RE3B^[9)C&M26QFKAQ
MYDKKT]Y \]8;WBRZ_*\N247Y*B1?YV,=\/)<JR4V N--J_=OPK$N':.LL: >
M7DF>VQ!S+WGLZ0MLR16 HT@1):(81^PI4F!&F#&I%/ GE65;*>8JE*'.:$Y4
MCIWX; V#R K"61BF:0@J(%IO$_8&2?S)4?B=\?O0?'#%6(<9]QY%)_&12NYV
M&)@EQN; L%YF]Q B*X,7>:.D?^Q.!VW-1)^C5VF0&-*UM11=&U^S7/AF'?9X
MXV7>$^&:J=E"4"VKLYD-J?)6?=18';'4&*%T0GYO309*@TN7^L973]+J)'B-
MO=SG6V]\<\37+J$!$&73@GB;?U36P=)./L9F+;84!.PB6%WC).C%W*W::Z56
MT?"U^Y8S5^EAW8-=_<BVX=RCR3I!GH7>XJE@(LD8D5EL=9 D A072?*\B#,-
MU"K23;T5J3R"+R5@6>22L)P:(G*NB4PTHS@V$T#OFM["VG)\[+\!?+R&@U==
MZ/J?)1<V7>N#(_>';AO>MM/MX>W;;S9O9^]M%YIG7[AWPY$Z"4[W#=5KSC$W
MUO8WZH3"L^+UA$4A93$#;M4%88HF1' AB$X-<#/0)));+AP3Z2AF(B54*6#X
M),1>7CHB)N<%TR*CF5*;<^^O9?>#,'!QM+.^UR>V^M14V8_'"CZURJLYUQH'
MW6^R:MNXH">W;;:4#6Q8&8%ZP;DQ]VB'E1[KZ<_%=38,*I1^]BH&30+00E+W
MZ@VLOIDMIE<!3FB^X*M,UWZ]-[8S\_Z"5B/1:T[MTS^6)DQ9'(F0<%5@.WN*
M!Y3E)#8%!6424ZFW5)#*5)Q%2A$XA=C$'&PNCL7CF90Z@5.JHI!M'LL/'=!
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MM5-FL[N.GZ5C<'%M/H2E37S4U^ELRYOZ[=JJ?*Z:N.A;=!O\;,,XKA9KA64
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M:!BI)E1-*EY.%^V>6U2%+Q?-R^5JRLC&F]+)2G-]^O 0A'-6"0DB&CA G6!
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MTZUTQ;?Q"7Y"?SI]XY06622- (I0!6C:WU.8,$"X"(11K:.1;FT'"JJ)E0Q
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MWI7^XEOX LTT@%=Z\DU?UZ]_*/Y\CE)^^&"U'_[ZMUDYK^=I!*<IJU&:JWV
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M<OU>GMZ@'%(9Y89G?+F-T? J)?,8H6/78F;QGH9X\Y&%(Q]90($B9P70%GE
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M#8K_:,@L$-@YCX036NF#I0\SW62Z.1OKS+-B^\-0_3&A/"NV=WY%%N\@Q3M
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ME/-^:_S5'DO07ISNZ%4YCS=KXVU^:ORV5H6+-TFPMVI HKM^R 8! B.//'8
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MZ0AQ/J(TCR,Z!Y3)XCUK\?8'A/\]D^P9DJRTGA,L/%#*Z-2/$+7M?6Q0QOJ
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MVPC_W==>S^Q%LTGL_%<_J:Y2(53AV_*+.I<>Y;+5\S6/7+9ZCF6K6BH4*$1
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MC@*EI'2!*TS@U@P+H@)4*H;'2A@.J" 42*;BKP2;&#$;9*PZ(OFBD>0XD^\
MT2B?"1C>ED+3'"]OOO64O?/(B7Y9RW&*,/+,BL'X8TXCK03EP"/BHF^%;/2R
MH >.8>HL)='1VJK7>$R;V9?TQ^"(L4,Z9'GJQ"GQS  19^ 2S\R>F7T0=G92
MS(X9#8HJ!#P)'%".!5#!.8 HL5(@@['>VN9 ' 5LT@Z'-#2^1T.@@S7 6,V0
M@YX&*X_([&*$4!XGE8D]$WL_))Z)/1/[(.SLI(A=$BN$DP$@RU+(CM/&B".
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M$#DD% X9+-8A(8M"C(IP=P5TUNI4<E!E3F2@"$&I2<T8T7E.'4NHR^.#;5I
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M53#S^?H>M^P^Z1^;LJF@Z?<>LMMJ8U;CFXHDN]-U_&[WXU,I[W(AG:8TWN$
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MFDR$?/*2EF_+/!ID6/(7=OP$-78H9(T:&S7V;=T.M>*2&DTL4YP($RN2)TJ
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M/<1*#GLM# 7D<!8#H\\H?\;D,5L3*/Y'*_[@G Q@G@[@JSQ(%X3GK#S8+CH
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M#Q3B@  =&^^BR*+(#@%/-!4P33[\X 5<Q'[0/\+$QB(X*L*$^9 CHCO95I_
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MI0$&NT(.)P:$Z"B2#(@GXADRGLBH*+'#PA-SBBBR \,3118A'A7$:"I@I<%
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MWI'1],M \U/>ZC"D<XC^)(ET.J2W:.B9N<5D3*,DZC\3E6:P_7IM_Y>?SJ*
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MRIS[-#5[@I); 714M-#T/<4@!.SI>.5,2*_\FKT4^924YP%8&L#8H+W]ZZH
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M2@#52/(-&NZ74)*Q/VJ8&]JJ6&/_'::'9%"_HB2L#?!KNRQ]P\;6B*>#(6P
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M?LGHVTB-9 U8,L.\82EMBBY<2M?@['C.TW,(!0]XUAOVG%?$ZD=GO5'/687
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M2>RT1$V$]!V-P#1.MD X$Y -H^P327:ZD_<[_/F>!$PG@CI-UVGVQRL"-C4
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MUE*O'&?I[6'B!""E)(Q%*=3\MMBV.2QR-K2;$*^VV"6VN+ +&FWW)$ZHGWW
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M17O()!6C^&T'DAX3]YOGZ.74(WY&]1_?L3^^S?^8D0I_!9/A&=Q3V$.2+8=
M7HM)R,J_QZW&T_@9KU9%D,+F0[T+/[H-74FY"EZ[22L9W='(2]UL73X0^@);
M7LS%2MY6W_W-?(^6E_*OM=&![H(6> D*6G&;'0M:B=?7SV",.]X#6*HA"*%T
MB8F:?G6%S;I;3.4UG^R!S<7R(8G<WR5[C[B]O@<S*I1(WUKB--18<(N"!W9Y
M!V,22HF7$275<+(>TZH19G8(A'O_V_0D<=$[_'52LLJH@HBP^N_:9!'T9;0F
MNY7]@7V*V<9B+2#K81H;4I4@[S,?5O17,95&D:2*3Z4G7I43&KF$>/$-C=;@
MP]Z391IZS#__O%G2*$R*P"#/"%'MBNJ 7.2.Q6/T_@&P"9.MW \1-1_'&U]L
M!%$V1>^\K3\BU4Z01?UN(GJ]\3VR]EW8:,%&(UY(8K HP^BEM9)JQS&FW8K\
M4+X5U7[7^!A=U;IY6 %X\6T<IT14Z$O2 ;%HSX$8UA21@E!W&P"O_ Q]2I,T
MAO6^ 5S63ODF>$X+J*O$?W'@UV1%J+,A:>*[<C=KV( :A6JOF)EL.. D9IFA
M+^Q9<%#0=2$22EJW4="F$?:2ZU<W2&/_A?25P,YCX'GQ)"0O3IB4SOG/ZZ>_
M2QQY<6M]KIK#XOS9I-[1_.9'IF=$?IJH.1ZD[!G[FXA9%_(MB=\0;]>\OKN]
M2?.,/X6=7=S:.,VP7D=A'UVP[X<&<JM9-Y(A]S-UE#0+MYW&<!: G^__5REE
M%Z"S:UJY7?")?,E^$L>VE#IC5QF[BQ) SG>"7?;!/7$)[*2"MWQ4NHU\NG;M
MT&!;WGR#'ZI7XM3/W*2CX+TR<_"5>^+E3VDMEC<I>[)PAQ_+OXRV3I!L"U>-
M6Q1[T'AH7+5^:D<6X.FRK-)GKC#U&@>Q4"/HKI0);O2<)X&4]W4>$H?FEW9$
M=9>5^TY [77H]:2UUE-?"+V@AB6F7Z8@"6M"=S>!ZL3_2^B*=1S$3&;[\&8H
M*Y<I."/"8L=*7<UDC*75].>MTAM1,Y0[;UP\!<S3 0=MS+)Z:>ZWL"<IA:M
MH2.BX;$SIF\<G_[B!"FY#*(X*VHC]L*Z]<7TT??QWCS<<T.XM E:8AN5Y\]@
M93V#_[?+^$P.DULEMJ5*[Y%-S(J%)2H!K-81C<Y*$ELF1>=!UIMXCU'N(M0\
MP/-D)WH\VOL/IE$G[^A1",R*6H^A(.Z*U)0,R5L6Z2+LH'^'V>&K!=W[3V-#
MBATHE6Z(R'8QY&Y#-TA95 <\Y+)G?!O*G$&\X8TR4+*;])^$C_1(N^ACQ-GX
MB1,PJ$L"+Z,XX9DQ2EW0I/#SYJ;EP/6@A9E'VWT.M;'#!$78M;Q-*8X#'#8<
MK: ^>]+<]XIKGC"!+;$N>3\\*@]LG%SW,!W498H'#86XT?CKIY3&>49^F2W!
M+HGZ3L"R>T&#QE$8DH"M78''TFT(O(-+9LMY[1D7W':(5!1&\&X*'V!9^$N?
M5"?NGCRG 1MSFUVO6H-2=ZM!63[=*"-C/^W#JH?F'DG\&!6GA)*?6)Z#XZYN
M066XPD<QL(9&?GKI,;K.+I?E'Q8Y&,*V&KRUQ^@"UIXGTY)=1AE-9W(U2;,1
MVO=OF3GL!,7.55D^0K76T@-Q[U4F:71:KHK4A-)>.W?_2/VX<"0$1+7VF8PZ
M6(<TX42>.W;&FUF?QMF=-G=%V*E/-GEQ'N 3F%?R'CI-UTJ5!'G$F-\63S'O
M+MX6\' U<J,1KM&1Z\A$3@.WH2%3R,*P+T[ =&R7V>1T,X2AUF"_L+E%3U2-
M>=&[5@)]A/O1UCW(,/#><^6U"MG%8T-A47KX1WH9N5XIL2.$-J(BN??,L&C>
M/S:42?&*$%VAWI<#YUYUMHY/I;O0M;)L]9O'AC+<^BJ1[(9R^4J"!!=#V1[K
M%2+AO6-#<3@^2J7TBLCX-6(XS[P=;J%F8J=F%;1>%:_RS[N4;2CS[9:B^(9Y
M_7TAR95N0WEOU1V-R]X[A5&]<FTH=RT[1//2>,G<P<5M0]E36K4*E[NK0MQR
M\]AX)&1O=V)",8,G.Y4NF2L7 C1\K2@H^9%B+_DQF.JU<NL>YU/R'86WU*UC
M=Y3@4>L]>3-A,L3DYL9GS$1LQ)=SNQ8PL!,@B<E6+W!@'7M3'0'(*BQ8]R8F
MEC;N6.'!.IQ:-^F!I2+,!,20_4DA?F(F?D9HJXZE.ZQ[O19+A76O$F(=5*U:
M3%9KQ$QN#5%1XD,B,V$S0#.)J\)8]U!R^[KB%YRQCE$TYUU2^,9,4 S2,Y43
M!3.Q,D"Y*-0ELNZQ\58M,VIH< (&L;0+O_*2F7 8I%?X60YFPF: BE&ME(4+
M(-;[I(;(G=+)HID(ZCX14RI^A@O=!,_!3@)=GYILN$A.\)#L)$@.JPV'B^D$
MK]!.@FF_RG3(YS5SR1M0+Y"'#. ,3KPZU>Q#AF]&(?BNM0&1D9Q1R+"E\" R
M<#,*AZB5.43&;T:^GG(U160(Y^*K-,L[(@,U \^D2W%)9/3FXHVHE[Q$!G N
MKH>H"B=R>L5<G(LNI4*1(9R+>Z%8NQ09O1EX%T,KJB(C.BLO0U"F%1FR&?@7
M/>K((H,X R=#O:PM,G9S\2Y0R^TB8SPCQT1>L1<9MQFX)&H%@I%QFXLG<EB\
M&#F-<@8>B&+Q9&3@YN)W".HZ(Z,U%S]#K?HT,G@S<"F&%<5&QG,N_D;GPMS(
M.,[%Y> 7"4<&:RX^!E8M<V1X9^!>X!901\9W!FY(2]%V9,#FXG_TJ2N/?!MC
M!CZ*J, ],E)S<4K:2O$CPS87[V0JO.;BD+2_98 ,W%P\CP[/+" C.!>?H^WA
M!V389N!]M#PT@0S87/P)SEL8R$C-QC/@O]J!C-8,W +UYT*0KTS.P ]H?YFD
M#;._GAY !M_Y/?N!\^\U+$GF\NY?%:J!]0S?S'R3)S_ZQHW6I^6S-J>)\QJ%
MT7I[FF%W#__Y[<J/V0RDE-2SEIIE!^/*K<D50RF^#4OCH3B0OG "EMEY11+'
M#][H>BH&6'(*%]=GE[8*XAJ3>/!D3&LW;6_?""A[Y+R/J=1E(",Q<;]YCEY.
M/>)G//SQ'?OCV_R/&>&2QS$*.GDM)B'KFE-LH$)3[6>T5Z3X+V74/BYN9^1K
MQN=/<?:;0/R4NAK)6 ^&S&)DER348XJ:?<UDK0]+:*S$-*FP 7\[9*%7T=:"
ME6Y]T124\'63IHX2-9T47MGC)14DN<VTB73/$C '0MYU%,2WH_.#_38[42PZ
M'4?0-E'2E\X.IH/?%M5R$-9)YQL0HN9H-'4O*]TDM/,8B-0+=O(RO,(GMZW3
MJ/3M]^6.-#8[(M+9I58]C]P._?$V.G[10LXVQVTXS2Q?E;4PN"\PJW;%HU52
MV)!#GKCU^&MXQWZG1;SOA?W,MP)>8V/%+QS'$7A>.PM?RU6-_E1#>/( BZ&/
MUQR?)_TJGB?M$XW1=<-%,QS"T(>V>BL3 M)'[RF":!TFQZ=>:U!\%4^]3E"#
MMVL$Q%"@CJ^]#ZD=JW(8-_F;O\<G_<S:0N;R\AKZJIC'LWQ];7+5 *2U@& 9
MH4T0K86DLZ/2)0IL+2J#'UO1^%+J!%<,S'A\9]*[%.BKI!I%MQ87>QXETBPL
M_;?=RIF!F8B@&V%3/8QBT4.)=CW<9>Q[0V9E-&?EVU91 -C'>979_16*VW 9
MT76V4#2G*S^D3['O^0[=5EX/;%C,!VDG+9VTI<[LZ5K0'/*/)%E%WFWX0N*$
MD JU%]MFX[*9++49]1/Z@"J?!<JINHS6&Y!OMEC%N4;R/MI8.:"&F]<H;ZLQ
MRW17YE&:=-=L9\ *JPBZ3&B$[?6QL">$F1Z+964_DDJ/0D>TO(GS=;8?L9=J
M0%^P^K.7['7I):O* 5]FCWOM7D,79U7T&$6_2FH^12Y71XWV^M9SA1*I)'$:
MZL.=4)_$E_5'RZ7J2-9CVC3W_;.M-4+KOTU/$A>]PU\G):NL-B<BK/Z["1MB
M7B?Z/ 7;BN;W_]NVQD8//&6</*[(1X?^3@K;9[$$R<^>0(B>J<.'M4M/;8#7
MU[ BYBV=IA5L\.BD@EW['3$%=%\"/O1^S9S;A']SHKT]&E5WU'^!33'W,?*2
M:G?I4^"[I:,B(D^MHR%2>N?0!<UV?R^K@+Y_@D1!6H6=#6&N7AY?>?D5'8QB
M8I$F8',6Q0^4.:GV,F<?DDZ(J+4YY+=/A;2+"8S\$K%B<??^\RH1>02BUOI,
MZXHT'+R6Q#>LA>TU>F5J3W(+7#2ESAJU%N==L.KS+D*]U=8/;4LO#/,'X@*
M"7.[HA<"&O,S^/7TGCS[[+PI"_R7P7+>_MYC%#RC9/>B[F)9 E?4MSZ/62B.
MA''^+%&4D?,%*!18*?U&0C2O6J:=%4K.*Z"3G8W'-[?Z#(0M4Z4K4I1[CO/B
MQ:SVYJX<].&.U[F[OMO.WC_3W)2-'Z/]N<N=XWNW8?%\1(&L=&_O/HX1<<V4
M&>SPE\J&<AM6PI4*$<[6(72'V0K8%S3;YJ]?66'HXIVDW8]Q\6M\)H_$=1S+
MA#E6,BA$S=%TB>@+6;JI[UULR_>KN!J]0V\TBLO9?(S*P3GONO&(5>N(M]L$
MCIMG;#]GF;_KM1^SY MVGI[EL-Z0AN'5H2/V;E+=G"MX++Z$A,8K?\,*9>>K
MJL!1LK5T'PN-&^YV?!/1XD/E=V/>JNLQ +I47[)O!P%_YVXVP@N(\?1H^;V2
M:2Y1BCW1D1+[Q,)FVM1^20P[R,NVH':'7MK%PHO5:GDJU<QNW&00R^\-C9$9
M4P-;GE!B)GIJ=]&4<F6J6 @R4@S%H#V93YIA(WCFU>SK=HH3WY;K4EL "EDE
MAH+1+@'J*3.5YU&Z)[ 8BD\W+2%*7ZDM%$ZBB*',*^3#"[->:NM#EF9B*.^M
M5]L;"2B[^^S5-!!#N6NY?=I,9"F9.T@FL8Z]_B:E-#_%VMMP?;2[8D:,O9AT
MEHVV5!HSH3#'@1 ;6V8B-T!_UG.6K&-/V2]02)4R\\[;.$I3,3W+7D@&ZDQQ
M8I>9D)BC.\6^A[57*G$VX/)LUTP8M O0@0]C[753'&&I!=617QPR&0MAMB,N
M!A.^'(> P8C",.&+<(. J*=<XF(PX5MO/4Z.Q'F;N"A,^(9;#Q044S^1_1>C
M T *&:/(<!@9\^B=FHH,CI'.S:"L5V2 C#38AR33(N-CI(W:/4D7&16CK=4>
MF;W(\!AMR';+ D9&QFS+ME_:,#)$9AN^PO1B9!2,-'P[)S0CAR6-M'R[Y$PC
MXV&NZ:N8FXV,A[G6;O\<<&2(S+5W.R:6(^-BKIW+25Q'YMU(:[93TCPR($;:
MK^+<?&3NC;91Y8G^%M:_O !;P:O&.XRL@<ET;I/2?<72B^V^R9VSS7;^+P[U
M&G/)N] _;&!]5PW=%?'23&S;N(A%;$@+::*-K[>^0R_"<^J!0!;E"IQ0^"+W
MJ)_2!AQ+"0?G*BF.7S^#5HKO'SY+J\[)^^B[:+Z#5URJL-[F**[]/O4;[%].
M&O2Y[(E5+Z2@1S+5M2;:"97.D2G*H >Q T1!<"OT\4OTN(K2&$RM:V9X$9)[
M:+<A\VC]%\(($!=0Z]+]6"+S6")3@ZU:/PTX?P&#FUE/-Q']F7,=?_3/?0U5
M(CE:X7J]":(MR9VC,IC:6;>TC6)"P;;B*"Z??_9V)7TA'DS_39J <UB&PP1B
MUWV<,2;M\0M[1' 1DASO/&7;2_/0[TZU9^*N/(7]QL2K;Q&ZE("PW(;-A5EB
MN0_C\GCI.(+UBK*M&B[^=_!*L^1JK1J6K\23\N_^G03>Q19$T'_QO=0)>%/>
M:YSQN+AQ?)K?/<NN"10(9J=U2M3+^MLGKME_?@'G>)>A)ZIUA?H)O4 ]M7/Q
M=,C%]>O&SQ/2<AYD**&,;Y\L79'8I?Y&5B$.8VC[@"F,_YW=E3[MN+EW$FD]
MUS$^9Q^ ^2.9<6;[Q[?%"OF59/:L=_Y"*.CE[,<KX(\IZ$PU8^/:DPJ\:GG<
M(Y$BM^\\S!5M3AY+\OL4[2Q];J6W(<-9*T*[D_)R_AZCA!TF)=0/8]\=4VZ4
M/HTG+'TWHH+:2R=>W1.7@#O!+;R&.KZ^Y[]*'0E^(1AP_"D&R<]NP!4K(INV
MZN^749Q\BI)_D 08BIY#B;D_WO?F!V&^2, O+/Z)M1,9IQ,389_Y6JRZ7S+^
M2P6TVZ.D-O\8G[.QA"#:,7\M9Q;OG-S>2CHCGBQ6L6XY-S84/Z7Z8=QSY,:E
M1'2,C8>L..@S![/=V:.AV*D7%<!.\*E=E*P=E9N)E-K"Y!WZ\SB=Q8KJQJSI
M2T%AYQ+O.=W3 @P%X5C%<-Y5#,>Q:D=+,S"SW)G>77/4.CS'@G?Z-HO6= ]K
ML1A'[?3('[&]-MR85OB!@V0F5*@+KV?*CK7(X"[#7BE"9M;6L]YR&JUT\)1W
M0?&ELU].D[W5_"9 4)I/96\-0+-6-S=-R]ZZ@N.!BY/:96^U0K/$MI819F_Q
M0[- ;<TFL[BDHEE(]TT[L[B(([[!,"AKS>**CT:*LEKZF\5E)$>07]1$.HLK
M4(XBT",FX%E<UM(NJ 6)>A;7S33+/VG-W9M#99]])'O'65E(L3CXR$L:%89"
M5O;X_;NS[X5G),>J0,*!CU6!S*T*=*P24B/V>#=^Z++?J=/S.$[7I1NP(2P/
M]HJ%N$'!CW$+3?F[]B73RUA[)'2-GD[?_L%YR.6]'_]^0PD!AY10,'>FDDON
M=^<!:2DFOT0!#!. E3CU8C_X\O'JQ]=R]<.,+)9C+KEAO,X@4^[K/1)1MR:/
MN8DXT1\%8_.8?S:></--TF/6VOCJY-!BG5>4\^ 8N<+_YYA%>2\"Q_T=FL.H
M<1X 9BE5?OC\,?)(\!A=QXF_KAX[+Y:U3; (&I\GNP/J8T#T&!#5'Q!5JKCY
MZ">,YGT.IJ &+;^=7E)_]9/5/0DR>(MG:\($U!8W3MIGA'FSAU^<N52+"WKE
M4]A9(BJ." O;SBL8=(S['N.^)LGE,>Y[C/L>X[['N"]&W%=B/YH)5WN)!:DY
M+.2YS5(S'@U>J9&QX+"X&,D ,WT74A?;R-;!86&DZQ@X/P;.C8'Z&#BW%7%+
M ^<',?/&4G](UVN';A=+3OW&<S<!W0G;6A;;CH_![6-PVZILW][3>_U'"F)_
M&\**2#,&%\F*T,>5$Q8'/[N+'/=1$-Q$E'7"EK%^1,P9[+P*ASZ<B^_/&>+6
M^[=&"'PG*K_JZ3)XC@R>&+,?VSV^#7U\&QIGL=9K+TRN*PX^/WN S=/6X[^V
M9/P4U2_^3CX#!Y^?/<#FK8&N],UPBL!47A)?YS)H4C!?F%-*8O.602?BCND&
M7TNZP9C!^T%A-I1 ?_?8T]<W2^,<L?2<^Z\/_G%C=Q//Y>3E_4R:X>-#:Z(T
M+&E0YFM]:,V,"]ZC/E-@0_J,!4;*81CO.$DV;I*Z"^%:,,VZ3=%NPO/UY;]9
MH"L/P[W'2;)15W:.*7]]F9$6K$5.V/DX3S8NQVZ!;<,S9CN6FI!6X-=<%4*I
M*/5YD)$ ?V))P/6RTZP@==RPN@[.)+"_8D!*+0Y+:NFUF-_2!MUM""L*U@JL
M=*8A/A3$2I)K9#U,8T.:XB7OHS-7B\#^M3H/O2OR0H)HPZ@K]%);QE9K3WUY
M6_E"(!Y_G114BA*ZU#IK8^YG$L*N&;!W6[PU;'*PX3KL34R565/K:^'![4B;
M&/\4%U7QSR:N/,)V6(5?NGF8":+:>8;"KJB @]G'% J^D=*N>G#$U;YW60O'
M! I-=9>T-H3<6:04MU:[?-,<A4?GE<3GGN?GA-Z&RXBN<SAZNI^"6E^5SXE\
M0G$[M(ICE=%Y#A:_C6:/ B@I'HU.MJT^4:.Q0<0K>$*<YMH8@.^S9WW=RR@-
M$[J5&M#\MMI(!Q@O*8%%?>E0NEWF83V)[(C;F\5"ZY6IME[S8F= 14;D0(%2
M3 !Y52A5R=SM\C^3Z)DZFY7O"FN6BMM.2W+N!%>)$);P%+<=2'),W&^>HY?3
M.-G0G&3VIXS<G%#XVV^7YX<D%?\Z*5[W[ A",*7[WZ8GB;LF#G^=E*R/8%^N
MT[60L/KOVI0*.^K9^3%?G- E5V1)*"A"9A[$,4DN5PS"V_!\S?9;@=KI/(R^
MLP.F>,"[8)Y(\#\I]6//=QGE4K7:UFL*#?"1JP$^3JP!BG?7Q7)=^UW;-"\V
MA/F-X?.'*(ZK.[K(+)-T,)")#_[:3_*R=HOPLS".WF$ -+=/_$UPX7V:??,?
M8*/PW$'EOF;9EE+5*.MA%AN*0J76%T^>OH2$LN*-90FU?"=9O!#*O0.IV F-
MOLMTG099B"K_1GP;-KY>9'ROHL"#'W@$]QA%F_!\#NDNT G"<$%"LO23^''E
M)+]&:>#=KC>.FUPOEX35)6-Q!DG1Y9Z#F<;\+J1R1T(G2'P2@[503MRYZ]*4
MB"[K#AG1HF/"ULCDK@QK,W!HYA%"ZP&=- S:/%!J!A_-Y+O+F9HHH"KG?B8G
M:>* ;)5]0>S34-Z5YKXU)EKEOS5<9SP2O!+=8T!A<7GNCK%9WB&SS0M#*3Q:
M%FV7!"4-Y5U>EKTUR)HQ7@8Y#66Q=7H;H=%R.FL!2D.YDT\@)\1:,G<0YK2.
M/26KM'^PU/*\#34#IC6D:B8*>.:[9(\WDW4TA?T176%/Q*),I=4CW-:QUTFE
MR>+DUEVY1.*\&0<U$XGA"JS%++7NDI]ZC$G]E,),$'#FOF*SXK+YG2%SK71L
M@\OZGVQ@?6P5]V=#0% ]0<+E_B\F<=_G? H7CN\-@6/H^14N*C_8@8K:P9:U
MZ?C[NU.?2%(S"H!-KNJ,-=\5E]FM\OO?*CT-S'61W<YNZV501O[Q.L'Q.H%:
M9DYNE,BO$%3:Z">U+:^^ULHN<@>D_0ORA>ZB.+DB;B9FWYZ]?W?V%ZYXRML:
MJ*8[:^AC#K!(0BCY'R=,';IE4_Z]1#RX#<U**K0O-]+LK%L[$T#-3DWK85JK
M19+M3E_K:)H?$]J."6TS3FAK6N4'4=:Z<6D\MRU):YW8G4=B&L\[V(51Q6:[
MM2RC;W<6'I8?\UU0]OL#A6$F !A:@.^:6<MO3Q4PX7'J!&DCH^G#L4]9)RR;
MC"DHW6$QZ_CH$TD8"J H+J/U.@JSLU/4NDY8984=&L*4,4K+^F*^VYBOPRK!
M\DXF%/WE47BQS2?C,G!BU8*^BN-H8SFOY\T*PH&,AHDT;LUOJXWT7QU6KCR1
M!E3K;?1&@[.ZA74(8\D)C+R//E;2I]CW?#!/'IQ=S7,9&\+V^EC8$\*N!2V6
MCR CL>,VJP8>\M+>$>_.=Z[W,[1";T'!++Q)V393B'0LCMFK=M4V 9GB6RP+
M<A;TGKT3D+^J"? 2%_P=E@5RZ00!\2ZV)=E%0Y&D#1T5;^JXA$1K'W;NZU=P
MD/R8W%'?);LV(M8&#X=7:3&.4W8;9;&L2-=-1(LOEG3$V2['XZ+; ./.10E3
M^5%N?0?%GFB4ED-?,I28B/*(:C8R:Q$O4K!VG= #FZ?+*JUVL_!01\T(%E09
M5[4TK8T!2DW,*B@'!IVA#"L%\Y4,OBKO I#,Q*!/V?AN#E5MK8@M3C/A4121
M-D.ZAH&"R6HH& KO92G;X_N,<U7KV%I0NN\I@ZUJ,T/,$RL;N>(V$R)4<1KN
MPE@;G>\(4D>?R-K /(;L<%PNZZX#]L2#X]A9=QT0>5>JN8DS.)EAVT2:%$^T
MW$7PU<2';79[#O][Y0<IN^.UWX$U']DPHKP&4=>O;I "5C<PWS5V#J>\,=N'
M#ZMA#6_ ,=! 7M3.B% ^HN\1OF'47VSY TA.%,;\HF$PMKXHT=IM;@SA7Y8I
MWBUFQASQF#.YWYO@;]</=W>9V&0-V%*K-Q&?PJ",:]CT*2\RZ94,G+'1! #&
M#[8[N[1BRC^D3_\D;O(8W:3L/6OVT+QTQOL-A,;'/0P++AE[Z:T/]5VZ6QBC
MQ[9Z^-%\'(/!S*!5CT ,IOU4>]-P3*/#3/35@LH36&/M\S";PKJ&H3F#*Q"J
M5F&EB!:&=38SO'!V+203S]J0>&=9[&DH6AL.[PQ0)PO4KK#?%?L<F_00.'Q*
MV7?O B<T,25;0.J>E[8(7H<!])5?X=,HB[A)NQR?.#3SB4,[GH(3B%;QNCO]
MZ"3N"E1?[7?81L#!72RS'[N);(=QCP]28LX6^C09!\)E%"?WNR)]W?@]Z&L:
M:X_.*\ON2,'$39CW!VK_@Q]WG%/1(!9&Q+K;";4*#-(-V$R'2SF"I6)=C%[@
M^/BNB,5%^">,$8RRCKN8+M9% '0^.#-A@$.78%@<\A@%LD.;RMI$P)$L!H%9
MIBE U+ [,W0(\=:G>PJOPW1-\B<<&+&QMF#/(WQAL3SW<FBD=Z&Y3?4E&+@N
MBQ^#!GE@P7I6YN'SQG,2\O[=V9_?O9=RHM;7[%U;-G&U*+T:3CT72_'/[#]/
M3DS^]O\!4$L#!!0    ( ,>!:E3MCFJ#'>@  .Y*"@ 5    9W)T<RTR,#(Q
M,3(S,5]L86(N>&UL[+U[<^0VDB_Z__D4N-Z-NW;<DMUJ[YF'9V=/E%X]VJ-6
M::72^'@=-QP4B9(X9I&U?$BJB?WP)Q,/$F01)*L(D*SV_C%CM40D,D$0R.<O
M_^5_O:\#\DKCQ(_"/W]U^NV'KP@-W<CSP^<_?_7X<#)_.+^^_NI__>O_^)?_
MY^2$7%Q=WY);^D;F;NJ_T@L_<8,HR6)*OG[X_ WY/V?W-^3&#W]]<A)*+B(W
M6],P)2?D)4TW/WSWW=O;V[?>R@^3*,A2F##YUHW6WY&3$T'^/*8._IY<."DE
M/WS\\/'CR8?O3TX_+$]_]\/IZ0^G__SM[_YP^L?_[\.''SY\4(9%FVWL/[^D
MY&OW&X*C8.XPI$&P)5=^Z(2N[P3D04XZ(]>A^RV9!P&YQU$)N:<)C5^I]RVG
M&8 $/P12C/?$_R%Q7^C:N8E<QMZ?OU+D>7^*@V^C^/F[CQ\^?/]=/DK[!/[K
M1#YV@K\Z.?UX\OWIM^^)]Q6!MQ$F;.X.D\C'WW>>?_N>/7WZQS_^\3OVU_S1
MQ*][$,B>?O=_/M\\,#E/X VEL&KTJW_]'X3PY8BC@-[3%<'_/MY?:[G[XW?X
MQ'<A?897Z-TX3S2 N1F)EYBNZL<%<5P:ALOR1UR6T]_ALOQ#';5TNZ%__BKQ
MUYN ?O5=7T:7\ 50L]SNDM2Q'.!#^-F(YY!XP^MG<XN7RNGZ*0[(R93GH^\I
M#3WJL9>93QFYI8<"W-I1O"M\ BRPZ5=.\L1XR)*39\?9 "\?3[^C09K(WYS@
M;TX^G(K-_ _BU[]<KS>.'^-)L%C=1.'S#9P<WCQ):)K\A0;>510_LKU<K,6?
MO]IO['=CB79#X3.\?-_X,3L8\-@ZU4A2^^AHC#^\.#$] XZ\\VB]H6'"F)K'
ML1,^4USNLVWQR)VSQ5_-WYS88__W5YJD<$'<T=B//)W 1J<8;:&N8/O]U0DR
M>N,[3W[@ISY-;N@K#4Z7$?OOQR4(E*S@8Y^OHRQ,-:NQ/YW11#ZG<>JO?)B
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M0N@;]P:NJ.N4KK7?4O,@<]4]N?]?U S7%OCL/#3:8C8F$Q>9>BV&W;Y4S'4
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MX&/'#8*@4<NWZ#]H',%_%LS6+OZ-_]&;?ON2&/_<SQ/!L/0RO\H:J_2ZC9V
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MNHD2/\WA-YG!P/]56" %-X:RWL6L4OG&31TQ2T7\(LRGMM=5<1"YY>4GY%6
M6;EE)GY13%EZ\P.$S.]+K20.-SK+1_!-%#Z?L-J^N-PT8OJ"Y*92N1O*$"X
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M/-#*W"CR4<I:@WG$MC&#LN)%W;G(+('1'49DY0XS#@FNWN*BSQ3N9E6A' J
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MT 'W*L<N_*N0T7;*UE-[H.])DV.$_3*H!WM6%G$M(_R5@"W!5:I@J-Y33)4
M6TFJN)D3X(U_*'Q.P5U[J/6I(<.+"\*.!RD*-H/ 7Q-%FEV VEP@HDC$U"O;
M\#U'^=I:<\GDQ"?M"SR3;PUO/*J\I*_!\D9;QB9:_])YYPZ'/LG\SKO$);*M
M9_5BMY2_G_-L&1%!EN+WA?MDM&3&[R!]XXRP7W)B"N99'GGR@R5%9/D6+5^B
M+(&OZ9)]@S2\7&^":$LI"[S>P< 7.%#N@+J16!A,2%(Q(Z%B2D+%G *(:B-F
M)1N8UG8LR?X2R"\?1)<S$3D5D7.)0+><C=Q]$:*7._6<_F$L<0N8@WOZ[./7
M&::WSMH$5D-!D"#%Z?(>#,MV#J_? <'T#@T24&;2-/:?,A9N749WCH&KH#N<
M*Q%,$)4+U <Y'X/<(B.M54E!TX# BE9(MBXB5MWNB:(P,^5[G"3)RH5FMMP=
M)@20Z@MGO%)^.&&^!ZWK*[R(<(&\1($'DW/'WVV4LGX=L%&SN'_?(86^=)+B
M#*288J@&0[8D+3DEE$G^2<AK\RZ[#F%VEI% +YS4,5 5)RXVA3!!RO8*_TP+
M$XPDAY+;J8_(F[A;+F12Y[VM/ RKHDC_<EN2Q:#(VN?PXR)>1F^]:I&JN&-(
ME40Q0;J3%B*HXY^SO[#%/D]!Q"V<;GM9A!^)H&(]7[(/LQ6U:C"FSR*,O#*7
MN!'&.3WA8Y\Z[V*'#,DS#[=?9<PI*YW$?0X5D58@*.8^]BFS'QPMYUH@BI40
M(L?& UN.9S=8,(5V>^J!T7CNQ/%V%<4,5_[&7_N<R601/B8]0?^P2AO-^-(4
M1)F#+$+,:CY&2:OX4$I/=]9+>4:*WEZ6TKAR"R3;; (69'*",R= Q)*'%TK3
MP@9)>IM;RA1$S$'8)(K!E0QE<5F45WVM93GMYZVHB='WU*7^:]^JX'*N=9S3
MG+8$01WS]T?"_$[V<OT;L'BZ'QR*1JQZ!A(R3Y)L+=N=B'#TB!D!#,N?@_@K
MG"E9 1,-[1M?SY)-**6WT^P1C<!E[*!N\K!=/T5!KP@U)T0XI0DR&PS#)SMG
MF.>()ND\Y.WCBJ/F8*C[<OL@1IUE8/"6<<6A8^OF,B]24)$&LX!X[$.A;1DT
MS+Q4E;NA^5W)?@46;PI-U=MU^ I<E:K>>CKE&LL9\^F4<L9!XGGVQ2]_F5+,
M(0H:&W&J'L'FY(W3J7?Y[F+;/&:0VH+F4N<C?$+"9SS6!:@M[L0I?Q"")? I
M;Q !D(/O^/)3%YA_%K45D;XJ.@WM0,;< Q>QCYH#BRD]AGZ:,&U%[/:MP4Q:
M@4D4K4@QJT@MP7GE]VXADC61U5 5X).*:EOHC[/ZY9GEZR,@FXA5ZYK'F\,P
M0Z,ZH?<&0OR,&-8Q8)V;Q>!^+Z;%.Q+,(A5R;S&@WXO7$O12976M@3GT!)X2
M<%-*!<4UF$/H6/F$^4U[^%)K#UU!Y,N7WAZBF80Q*Q7A2#;);VV!=^!A< 'Y
MV>VJ"ZT" SUM1:<]_IS(KN&]6DG(%UIVXTLJI6"^7.AGSJ^]BJ_U4^Q[S_2S
MDR2.^Y(E-$T-];*0I$F)MO6N' 8EDC['XY>DY/\]?G$JO6H&%PA]2S>1ZP1W
M+U%(#^M!J[X21HLP8M9Z$)O@.1B.W;Q*(P<K?<#B(XS2/6ZP0]C'#Z>_^_"Q
M'[1; 82:$R<J]2'PW&S(5_X^&L0D.,O)((+VQ4EO+X:;2$/QKC6*4V\V;FO!
M6VL+;W/=B.MQN@+"(=-WS64D3YGK:GMX$>R>/LMJ*_<C8'H7V#]1:/Z___"'
MCZ>__Q-#B["Q7WB7KBA<.N\,AI'5C<5T[6?K7@DO47B2<I*R*) 3G;0$0<&\
MH";KW(Z ^6JK--T;L)U88*;]2:6875PT] X;U=]'02"RM$:_X-4V,SM  Y)K
MPM@F/R/CZ#M!"A/6KNR_!O6HV$$/**_:$*[_?\_@QJ!QL+WR0[@N?">X#D&R
M-5LW,PY^B1FR6)%\-I)/1Y3Y!H5'&60--"$?W)Q.N/VGI&U%[(G_&!:8D' $
MGXDV;(<V\5.HL9)426_R E1U/<10A#>$6:E, ?GXITR5#>Z5O&7=D<A64@KI
MLQ\R>)+192R'GTT XS7$F ,6=9?H=R0+0<$DHD2!_6WJ<@;24"SG$=B#.#3+
M?MD34TC!\)Y70?26D%4<K=5,<9S.HEPUM>JL"]"6_W_?6Z^V;I^3EO\9YIJS
M)6<YE5H5%LL)K*6=N3'NB^M0']JZ Q4*;8'GONG)(HCLBSFQ^J0Y2+7)9[85
MI[(KO]BZ<A+,/VL.?Q93':6\Y0RTCF_9WI=:[DK#!48A#RAE4_PJE7XT,_E*
M.>4987Z78Q JJ)6G+,XQR%%IARN$2?C+$5O//QIIRA=[19ZAQ.$09GE)05'K
MU ^%3:FM*$@>@12E3"@NR@I%^;_MO>N.Y+J5)OK_/(6 &4SO#63!KO(YTWVZ
M#P:(O)5SG%61$QFY-]S^82@E1J9LA136)3/#Z(<_7(L741*I4(1$45$V#'A7
M55 D%T61Z_I];W9(;H%F= 7^E0'8@OB\-5C!03.L0XU0W2 O(HC[?J/7!7TY
M=J!B*IR!QZT?QY=E'B74NAD!* '[\T2'LYUY/.FD4=GXYG\ J;!$;;]2:>^I
MX3-"Q1L? M@,JJZ](J7FMH>\Z%3[*%Z)P'!G&5.TA01SST')Q";WG!@&49!L
MPD/96!;^=L5R5/#]M<X]WOL9":9^<$*Z"HF__MIWMJ3KNN45!_=03YE)LZP%
ML6]8?,!Z,-**K*KGK)>TE7OMW 3NUJZ5CL]&HCYZ=CJ%7 ([:NU_,&V,_N&*
M_CTJ:J +0XP\"4\%KG<VR 7^F8U3!YFP;O-9$C@VRFH4]>QDK-,@Y<3/@E?,
M]PG)&XG3'89AP3\?X%@V_;[9BY]$?_<YP5.>QE'(@JE)^, <ZSXGNQ&!*\F.
M,K0D4AW;JPV.Z63J\$@")"-GU0RF 3UUL4:-I-\68V!+,;1>28F1@7P<OSFO
MEV1=3NLI'U&8>E3*;B!#.@P4@[3R(OP^HNHF/43VURD0$YR**E5Y0M115 ^)
M',C[$QO*XINR*G(-!TPG'WQDWQ>_6'0$A7\I\P*%6J>+,$0&/#]^H ;B77+E
M[R)Z>^N!-U:0*Y='!7DDV5N$OG&JQBI4?2C+( :>A[LKKOMV%6U*=SJXSI'Y
M1IF$=05D;@LHW(K5M" 3NIJ8!S.#< N?FPKW4LO1DM/S^/P$(8=*!_F+'3??
M7!>W!07\J5V0-D4644LCI$J **J/2#YZ+I5.#U[@_2_'=)1/974E^M%1 :B&
M9H%^HTS#WDK<;7?TWH O9)E=1_DNS?UXN;E/DY?[Z(V$;"KCJ$O54  :*P:#
M[0'#>3B>V!R3*E-3K$&]="QY^:2*:T\T89<-JKF2QIW]BJ-A\S5:I->516K)
M0?LKEA'#-2/(5KA3:$,_]FV:X&D_T",OQ@ GO"3O$=ZA#5PB="#F-;+E8+<B
M)M]F4CQ@ Q'B":<>'IH@'HYP3M+5DJC[OT&K659"EE]2R%];06;WR3R@RFOQ
M6'\>ZW#V$C32PN32>V],C,RR& \9I! 6>V!E G0R*$S",^HI)YLROH\VIVKO
MHF<D?&*H:[)SC_7N0?=G)5O=2<ZZOV %AJ+S"P^@N;8 *^*53,S8BIA5Y'BX
MX<[ZF=\<8W5Z$WA*J X<)6"%)8QS"2*;M"_.999]\XO@5?!DBM]9/MUR@S^>
M[J2'<3VU8\:4)H;VQ-B--FQTN)RPP0^T-+7]R4?YE]S;BG4(U'7864RMK"QY
MK?$^-"[<]&M$TJ\Q73AX5-'4,'"7<!-&?T>2K^;9ZY#,NK]N%&EBO2"57VWV
M$M0R]RHQ(#7H$WT?@2TQ)+4[U2H:#.]0BN3'4!?TE5Y5@_3!JBL/^SHG.81F
M#O4JH/KA'Y3NO7,6K@59E3,3'ZMS2#7,A5=64@*U8F[+)J:Z:$!(F-]FZ58D
M^M<L1A9A!>81$@H+<*#R"P.R*B19T0&X9&B]P&KL,O)I@P-Z[WS$<Y8^K@F>
M>S!85=K1< Z(N+O'QO1^_0$6H+'KY4*TMH#J0C#M!-L5/]=$5,+4"_+02E]N
MJ 7(W)Z#8;=YW.ZGD _X,R@"C;(\9L5_2C>?J$'(>;[/=0&$(UT(+L8!M:%9
M;8ECP:?QE!-K;F:[4FMQ0I>'7Z\E.950D1*:,<E:C++'95P(\JAB)5JFW>5P
M  "0GN5M/LE"5,9Y%1A3PX5=^[VPN^'MRC^?72_=K3$=8;GA=]<R8[(-SM_%
M;N&-\8XA*LC?XA2IKF-+5<-5DG!HTN-O52;<EFLZ4 Z<!&F"D"R+.$X#'T'@
M-&&,12&3D 92PHA!J:H!61Z^&!:"'/K8AN<75JN\IEV.N+T2#$A(C@@1+7T@
MRUL42F+:N:]$X_(:86_8)4UA$ .  3 "+PK'34"BQ(E83X;/OW%HP2639O\^
M2:K%AA&IG(:DHO@"&9U0\>HGWIIL=VD&N$5*KLD]IW%4AK/N)!Q)3*'O*XDS
M&U6.V0M0+S'+_DH*!G1'@C)C:ERF) /2DP#9DS[!R_Q4R)<9R<DX!&/+#Z"Q
M(4I]?I>P1,$N0#:+8'AY/S0\-E>P&GE*Y@%(O'_(95?WKEWN!&%/",K[1<!R
M3[%2(R^ TR@KP(\Y1 1I2 5\%,^OAJ'_F,.QZ(N1SDW2IK4H!O"4$3"W&PFK
MSE-&DVO _$*K]VD33=1'6B;0W;[[6_I'1>T;E'@ '2.M":J%T#?\354J[><D
MC"]<+2?89_G EG+:A! ,\'B@BLLZL:K9XN=SD^]V/.. X^SR/#E(>!B>%GKS
M^/ @\CHD;+#(Q,.D#\N<&A;D:QP,4CJ.)RRDV]$!;+D$+4@5NW]A55;R&TE*
M A$><:K_&A6O5R5=86HS#?RR>.\LJ"4O+AC $R-,8E!V,BT*,,7KDBPV](/Z
M(_&SV^CM5&7V(-6D&,^[!K9H&-&#(3T8\\R7H.8^H^8.\:$WBZF8]$&XO 9=
MQOBEX1UL_](=-N%:I%S,VE;L-]H17BZ=O R_G![N'FX\V9_MFVB$R;?"TM$;
M,-1$TF,  =E=^1Q' :=&\#9B1&OI&,/%BEV\CH;MNB*P^<4A!#3S<-Z<[.AK
MEI((@]_G!G\FAN,!)F"C]WX"U.7\9VO%)%8EYB^QY=J0P_ [!P;"N\6NVW8"
MB75P_;U>L 6'+TL TRA+\CJ])F&)=M3 T&C5SYE(T:R?T2I\E29TKO(U$_6$
MG.\@9R#DC*6<H1S)HK."14R@V+<L7M,,S.+3@2!YQ =+=D5WUG AQY6@ 2?<
M$L/6W<Q4Z.4&#[R1Z*E7 CP_9WB$49877O%.XC?B;>FN>\48(VV#J(7-Q!GK
MK-;CR"Q4$N[/AZ)IG+YMGNMQ9J]NMTNQX Q%$D WX+7!331Y 0TX9%>23&*@
M>QV+B.J%,6!^@"?VS 2+ZS*U"J,NT)4^K1D.VA'D*21#E$&#VP%50,S,8+V?
MDV1U:D;U;(/_@I9GT5#G'A&)&08E:/FP<+YT_*0;Q?:Z8O$IVP#P(\D3-T19
MMD29L0Q:)5M]*Z$(/$E3GD6;[,D$R4@L,!S'Z3NDNC=A6ZY>(6!\ES!"G1/?
MEQS&D^-H@%D\-A9$S]EHYRNWB53B32Z$+P:V&)W:; C5^P7A"Y5L13<>7%YT
M;U'S .:!2(2 S ,LUK(=.1FI6PSI*;HOC.K5AV48C0RI"/FSJ^8V,7FF7)$F
M8CR!3/,++R&83+XA@  ="X8M2SKFBN14OP"Z8JCFNB:[-(\ )R!<Y @96< <
M;M/LGA3TC_2J1#S1@> P?$16-Q:R,2%Y/O3\G)YG8EC43V,<&#,5<>BS7H>X
MM0180\>'@_1Y7(*K^A+<RR6X.O\E:!F0@W:#S=P*"'<RLI/K,J,W+4MSPN3<
M[^0=?SGU$&2A5-:YQWH7Z6 ,19(.P'ZV>-19$;!VK37+(^79)JOF+"DO'+=?
M)#T^RIS'E5+^"LFIUR0/L@C3V8:=:6JQJP<;%3-?D9-!EWMY03>Z'/D\Y>=;
M64DMK8;Q5FJ-,\O+OCYW@5L<'?J<6F4GX"ZHO6J+Y]6-GT&((:=?L<C:C(+[
M*"%W!=F>K*WQ3N%TJI);H\#[$_3L8=<6':[CRE3+17(C&.[3"K$!"I,'ECLI
M\ ^;TF:)T^!9QZT)W\Y[PDV>Q]9*6_R:.[FF*\JO@0':0SS;U4#VX[. S GN
M.-TI/CR] W$_,>ZJO[ L)QB,+UQ<R<5\J#^(7(V/KGIO6CW*PA>8%[OLSU>+
M4T/*B_N[V^7J^]UB-C.K02U2[81^WDGD6S,B,:%2 >L6SG5$Q_H&,4%(M!AL
M-K*\3;6$2>;BYS 2!K4^80S25G31EJS22\!D5#';920?1_!P"$R@.3,1Z\;3
MP7>)K]%2F)*=8Y+3@U[K:@E4/5R4U^-%*/XB"4?8T#PZ)F)'OEI7UB0[9_E#
M6+O+5XFM#T#.P!K9VN_3+U(]=,A'KA?=->*)>2N@R#\2<"1;_%"F7QMS\)$E
MF%&%#C^ET"]LI>!>E=LR]L%;SF(A^5VR?$_HO%ZCW5U")T'R8KE!Z^HUC4/Z
MP]!$)CF@%[ 1$75(C$G_P@9%CY,RK*TOPOX""+6B$IR/A+A#4G Q&-9L*<.=
MK=PUI>7$M^[&=<K^^3;-.'N)-1\Q_XF.)%A>SE5BD].XADT![G\@1BUC/.AR
M^R)KZZ.'Y%<<I$/ZGB88!;GY@/&(]:2+<42,%>DT1?)SG[Y;8J 'EAO)WSC5
M!1!3@^%67959-B!?D6==\JY1 V* '9SHA7=_5K(UV%I10,+ZSU$!1A0++V"]
M6X?GLB&A<F#@YR_39QW*R7&*(;(A=%?(;/J:I</(YF6*3P0I,*CIQ;8SFL:4
M1:AG59>5W0&=7GC8[11L6OK#$ \TCM>Q@,26J-B/3C%FA$=A.HR /A'C.Z(;
MFVJ!3,QC^L5P0 .RID\/*TCMHCB!WJ<H5!U?.@-/V)K.,((-B\>Z1;SN!E@W
M%4KG5A_F_LU?+UIPW7B?:-WK9R=L7,G9AEZ'?:J-DIR=F!H@]F->J\6X93V)
M[$05J$Y=W4@1NQ!*S\R%Z,AYG/G,X]:DV0:S9B]T(?N"FGL-569!=))UUQ/4
M^8(KU*$RU,08SD,EC1LJ=0NU&0541S@3^?2HS*W7Y38IG!E^%>>Q[?1X;LE7
M YZW^+5H!O1EL^":U],-SRJI5>=E+(YI/>=BN BZ\G#>H;5(R>!)QYHEM[S2
MYNCW31(R![BUP#<!_A <XGR$B^MR:1,7;H @YLSD.B;YI'IO]M).HNUS2;<1
M'K3<]?@-BB0B/P8+@PJ9ITE"XI,**%O"JJ,)'R2P$;+Q&-&-&)'Y[LY4<KE]
M:Q(+][D<AW$<28DMU91.(7#],#K^/5L%6 >;XR%+WZ*0A)=[J$.Z2V19+?>>
MG>XA -1X=!"((0"]&>NO[A*E8+@:YQQE54,)(#!Z"'9"X&<%$,SS)Q#T(."T
M"6_ZF_\1;<NM!+DLGV5!!6BB%D&]NS&]^;P4B$QE9JBU__B+68>99^M1 ^)(
M-Q[A8_T+/5?BB#E3IXFN K=&Q"P28$.D\Z*;G= M3_+1DNB5,1CEHSK*5"GT
M"B8)1\"FY[,2EN*!RGJ$LIK;T&B0 OX-V-=J/$Q$:5OA9W5E)@D%3;TVID!0
M(S#/KE:V--S%9HU#2_H)Z[QPR^?"![B9N^3F@Z58W::9 8KU5*VJQ8GGB5'A
MRA7C8CJ3$9KVAUB0NG>[D;HYQ^N7P8_?)?3P*EE.*^S5-5T6'LS\A>0%K)66
M" +Y&Z[IS3(*YQ4;ROLO[[][O^$L1O]<L4X-AV<S&36<9Z[A-//20(X+CT//
M*Z)X"ND/E^;"XZ\E$JPF%VU:$Y3* [&LLFY)INTAS(>VC]_3)M?.#+*=]B,W
MX%VR*XO\GKR1^,L@]UWUZCW6I\<ZG0!)?D1AU!.IDNB"BW3!9/)L"L4K7(6_
M?9TVF5X!GV;0-=6J?A5C 7\<CO9IN?E4,=RB%M.$DK?E";(JN3@$*HG7J8[3
MEX$3V=90[,M;+R=77[.&ZA1?,ZLRB>VK98:T<T:=J*9N";JI4WW6'=GVG#VR
MGKXEQSMGV7OEW9<[^D<B.,DDTWTJKG[K2IB]9= &EB=XLT]))O%!U_[')4/X
MRF5X]8$D?@R^./IIBW*:11!DY0FO6-$9U&$QKBP&OE"#S7)P_-)E81$?WWI)
MPH1K$Q]8%OVJ+#2K\D,L1^T:8%U4I57,^R_6(".Q8)(MU=6#I!J.5V>3(+-%
M>B^<F2LV+R7K9,CW(F$9?Q(C_0P6CO3V\M'4)!O[[*8698\;8HLQT#_3(?1Y
M2JO;[M,XI1'K$52L^X'H3+*CB>"8AD^\!7DYX>R5O4(/2]0<>*$H<W*<6IRN
MI-C!W:!VS-TGYR-3V\6@Y$CB)9 K8_R/__9O7S[_ZW]P>B$'N?X#(S>==0Q3
M1&OD)[#<0 CX-D[?AW+N5%\58"! P!=[G42<"B'KP8^H.L)C+(,<1@KJ%G0*
M=Q'O=@*7T:@"&5#;H.=/DTC%2"4@^,1ARJL< W0@#(0IKSH&V,LJM0"=!3.6
MQE19>L:RQ%HQJK26^_,0HT5QU_56++@:0Q+]F1?I[#]_>5Y'13R,<1(Z !?*
MYR\_/?\L"I L7)QC3%S<)U4W'O9C-5ECEY%7JH#+7//OA%Z-U,P=HL?4ND5(
MUK,0(=;-GGLD()D+^+C]#XNE:X?+UK!.=H3:-6=5:[9E%>^P=R6B]R<<QUKI
M@#U1FV6FKN4]IGA%,'G<)#Z4N_$VMBMX*BX3/JYL^2.L1FT_,$DC""EPF@O/
MW^W2#(;;VBLI_!8ED(_("%KP$(;-QD3_%=B?GW*RW, !+3-[$+;]L<QW) F'
MN5#YX)Z/H\.M7[#Q >L"]L4[S "(#N W!,:O4H$8>GR4>[F8RH^R1'%]==C
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M#BV3A_*9*IG+S88 /^2P4G3LTEM2O0H[]42OMM_"F++4*M&QWT_IE ))^IR
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M"@D(5L4>2 L+" K_K8QV=0JMH5JU& ()&PL60!>C3*]GVQ2XCHG)I?95>2\
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MCD!58<Q#^4QMK-LX]0=%4'AY#.O-P^YF.NMXP@ES/@*R\Z.0T](A<F%._"P
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M/-9<]@';UK"#.W= U<SEY<%"[<K5EH1*2IB\Z SWR%%/.SR560'JS99D+W#
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MC+Z3SG3$/L\Y]5N5VRW=XO3[C:@9!-FK] "K-!MPM4=$[P8XY7F7HM[[NYR
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M<SU L''@$>=0< TP<OH'!BET/">*_E'7=WWVXB><&@,V%+WF0E'-25]-#K<
M3_04>I=,D.QTN8[2\2R\L*C;Y#V4AX[FC@61E\DW.CEZD^ BRW_\?40/D2QX
MW;=KJ$[JP/5E&_ZE9-2>^3JMJGH>D,_PRM]%!2_Q:46I5H0:VWE4$%XKQC+Z
ME"1O8QVA[3%G8\^U3C6L^I8("<=8=$=UY9KW8;NCFQW>[S*C"MDNS?UXN;E/
MJ>5##860S;_'$7%*/S-!<3L,V.8^8T0@/J]3D>;)%8J-PN/54JQZ/>7>J!4S
M^24%BYM!6AML6%U3YZJA@7?K*2>;,KZ/-@8BVH./.;<\VM=F\S?W6BPU>9#
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M(7IMZLC'78,K^A^,FA WU88I'N8LX8[F,[0\.KA:.IK/Q?6J>%#S%4PRT\:
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MJ?#Q>H1/V40GG=]+F74\@I'[XO2^)\=IME]3<3!@GB5P?P,0>\?7:-GI$;&
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M2@#3*HJ> AR")^$*E[.33/GOSA4L9R>A\E^W*UC.3DYEO*%7>)R=D,I[L*]
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MEU$R%B/N9^YF/WHL<"_Q=C-C$R[*41P1O$]BGPL^IX.Q132+O@J7P&QN\DZ
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M<#H.EHH_1M=RYR@X7#ME-ZJW:QUT%!<YHR@?(,?/E9(HS+//GHN[K(0R);0
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M-V?:D?"B:3T=!!;'S&?2Y^"OJ&IY&-98$8%H;)T+2[C)5FYTH 8:?QV@7/B
M+&&#L8$2M@K>V$;!$EOG+]OX"[*O(J\INA(B5N)6Q@VI(L.S%,1ABY"NT"DZ
MH=B)<H+Y'JJ@XR9CNJ+'<AMDN#/LZ*4K95).9ZC8DM*:(JY7B(M! I8X53#5
M)"PS)&X?PX;XO:3><Y[ZJ92YG3OZ&9X EE? Y4!^E"31[8@1"1?,85+HW+1V
M694'_:#%Y^L4-$M<?-NZ,-D-JN_"S+!^D8 MY9*3R7#S*_2[NU MWCVY5NPJ
M;;@Q3-OA1/'@)<,N.H7&YM?- DJ2-%66FAUQ<D)QP.3!!,,EX'H&$X]E/4UA
M>]&XEXS%E/MD+^QIE7B'&NCWJ0 :Z2^X>^MBG9<6P=&$H SSA![<EW A-=:_
M& 9MP ]LXOO.I]D6ZL#'@C%.UGVTC%IVG[1LOTK6[ZM+40$AKRNW,47AC**_
M42OS^VR#)MQW.PX[0S-3BPE)4?%"2\28S1>RM>:.[8_;%W"C@W)IUJ6W9XE7
M?ZG3#L"SS8/,B0'#-WRU7'_W;3#+'!J:32I;UN[J #,-HV7,3T%]8 LEK%:<
M=JB5O;7PJUN.N(J![WR'JW@Z7%S%*Q!$%'IR8H9T?H\GY^#WS_[C*]Y*=A%W
MUGD<(_M1=#D#:> 3@.(S=.(%VX[[P0X'D$$F@OJMC(0#^$O7O2 [3 J5ZH7"
M+*^TLU=X78N\][";BDL8)AD# ";YHQ/$,*-U &/O;,O<%61"2BLB\5(@$7 ?
M^0N>KEIXK;@Y;P,_<GA&D3U*.B-28N<Z=3!'2L68Q3'?<:P84ZHXJ$@P;2Q3
MEB@@CL(Q[>37NL7,W 0J/)I($(XP*2+&LQH#>-0/@UD-03:.P'#;?AK>?<4W
MWX6,\3.(&!G9TB@/ZUH/'C*3-3H <\>%$G>4,4LEF"H,@?7)2.WX )[HC2.R
MDX"83*#DG!APX(H&W]O$D;TQTUE1(-2"E<?6U^!@(P^L#&DH-R1L.PK0;R5[
MN_>H?.,Y7$N''F]$5&7(9?3T8,; Y(/XD,MH+.ZB@01"VSDNS"P 4SBP#!P1
M?J84.<>:RN['! OA*QB[-UM+;>W442-MYGX9''N:0'T/LE[0MG>F!]D8716V
MEW55<O[FE>L@_PH3&'D:O27T8N]MC]?SB<6T=?6@P!.N,.S;=%<9YY]<@^B
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M\U_)A6TD!WQNM).X]&M2*XPAN#T*P>UI$YP+-NT'@:UYO55"L)4N,Z6TE22
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MI6RSP8DMSB[.61(7+>1RPWY=OT0:QL\WP:* GYS9XNKB=.\"->8>(OZ!)Y>
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MWP1_ GAR?K2KB],)0XU2JXQ$A:,<)^DOIG*<Y)M@6\!4SIUV=7%.]$A;6X"
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M8U"ZZ5QA;9V%,'APWI=!EA/A 3H%&.@]=15J[1JEHGL/!?A,T ^)-M8;&01
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MOYXJX O;_^&#^;IST'%[TZL<!$C5:;&/P#8"8[TP:"&A?1 WI$X?F"&DK>L
M]Z%.P"2\$ EO>$+"00"#(-WE*@-"D"9TW!TS0].?VU=M,5 QB%KD7@P"-4:
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M6YP4*U-&/(IKH0NGU@>FU_JA2H,BC ?4JM])8BOG9J1&/0S#*7[V$FG"Z26
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M>"''^%9Q3TC;(]U!BE1&=#B08]178)&2X"M^,-G(;@U,O$EM.:SZ4*;B0E.
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M(-HY7O.[9=G+MFDKN9+V2RS8,=4H="X6[CF]++_\W?D*6-:6CQA+8F6-1#-
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M$^I$<286^19C6U\2#BP9'\-ZCC#OV?' C+=1"F9]N[WN]CKPIKX8.GC20J)
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MEOBDX*%HN#G.)#J*KL:2.E&'ED^Q$58H_@O8)TQ&3.2+$;DGL8:G51Z@5SE
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M<4!(FJ5Z/H >AC%DP WR=N_RMC(6X8U53$+WRBATV#'8CS\O(.AO<>(*T86
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M/D8PR<F%X$XKPF7Z#&[R(;/7 9L>.Y40TN0;ILD//$Z3XS52QS& O2R<\1/
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M$:&<XTR#E&J%RCKX0\S^]OS(;7'JZVUKZ]YDW<C.U9UY(Q>PG<SP.HW^!WU
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MZ(@%<<Y$.2%I;ITA;$A-&H3MI<YPC!GSFE%8#)<FJP^?V^DF,#&M18-^A?6
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M+[1*4SZVE^0&PLNWOL/GCBY;Z#L,?8>A[S#T'8:^PRV,R=%+LUSB/MOR2-6
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MPVW0H =N[[_74YT]0OK$*ZJ,BQDBKTO[$.@Y;-T,>FY+ZR&T'OYH;)WAH>K
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M6<W2PO5&CAJI**Y6MF@.=I$I B^E8I8:LD6J<5F*P:K;.,UCM=N3/)NU8$#
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MC%!N8"Q0>2:R*D#M!T&X5Z<AK.;FE+V6#B=>AWL[46%S B'2PV<-#PX<7;9
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M^XAWK",4"R;\[B;\Q=Z3E3GC;DL=J(%/A%L-3"WWD/ZQ2+<4;A1/)X=;%/:
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M$\"'9MFEI/G-(#V#JV6-ZDKF=8&OQ+2VEO81%K/6H)==#>"R=Z#?=!;M*+4
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MO9_N:#=J.$YF%HC&[\&M/K8\UW4:TE+^VDN]ET;"4<.Y00OAN"'^CIL''3_
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MCDUU)E2CV"Y/(2^=?/YDC+I@+/M9WSELXBTV,4S#$S>Q>(R3C>+W]#=,06*
M\-2M%?BH:P6XMN#1$1Y1P'ALA_& B3C8?[+:1 '5"*DGESEP1U"QAWZ?4-J"
M)4;;I%JN6$6M^&U?^-:)WH8\W-;FPENLUFHJ9/H4'E X (VB=.HU_9]KKPLM
M__:+AMJD.+6I%*%:X7]=YGDR%DT0G7Y<L7TXUV1_0-'ZNNTF#%Q_U=$1*&S/
M&]8^1K?->YMHG%_?3X@$:R%U,NE1 #F[I^@?W90-ENRVENQAGR7;;@>&8:AU
MINV@>=Z/JT4V 3OP7Z=^[[.N=?OS(/9=($/O)4-/1D_$LH(Q%>5UKM(+(BA(
M%BV\,D635#47XBD1@9,O$I(]+9Y*R,K:U3;,Y?_)YKE9C: RVRMC\[I,&^26
M<VSH_K5!- '?=B)I("&/Z&NS.:_ =9HTC(ZAV+PJF(W,[1F*XTNE: ,9R.6^
M\,^/DD.0AIM[7T86NR9M7P2[=L/[.:C9O=/  WXO9O[>:9C)K6>26@+L+4<.
M..U"QU]%K!W@3F)C#YKAQ_06B?9P>]#"+$<C[F6;+9K%36UIP9LF)&C'P\:0
M/_L7>T+"WV*6&0)><XOPMM]"8^"=A+Q_;#,J6%%WMJ+&HR?G#BTG;6_+!"L'
M*VYIBP W#8DLE^<]G;M=<J>OW#*[T#)K,*Z4CI<ZQ%AW6W=+UKM2:KAB0HU:
MU8>=HVFC24_5K/9:QQKK2F^P)[8N6,QZ%BI,ZY8;CILL:0%^R[[2Z[+J=Y/B
MML#'5"V3+SOE"[3C7,V.;:#"2FVW4B/: 9MUE2S?!T+/]Z]?[X+A/S%^6)M>
MHQDOW#7B8TR=K,TZ38D2\2J#\3%KI8Y_3*>8U+E2T1LLJ<(TH_Z:"S"-XJ0>
M8=R*;+-GOE.5X3_MO_1;RLAMHU47CE%)6IHBNEU:C8/G^\]]7Q!!"E_=9M_;
MC22HU*=G*B=^AYL40-#8#RJ (\]ECAH="MFQ:4;-?3Z).[RMRF]Y/H0#8!@'
M0-NE&2<88$- \"KUN4'"+DQ0[<;SPY:F/GIZVM="B#L5SM#O%U52U%BP\G,S
MGZL*HZ</%Y6T,8;3OX^K7UY_>/_V],W)^_/3XW>GY_\> *0YRM+_^5M:3K[@
MEY6:'KXX\!7F?(@0U_=HIU/U#QS^?FN5=H<IC7\GEGW=0@D/EB$$W\^(R,Q0
M7OH][[;[,P,)3>-NKB<KIESJEN3(SF\*W7HZPP]F>=[PCAC<^K2M>Q>.2S'1
MGR//,_)[B>]&K6'?8'8H$OV)&+-KMP+SSV"548Z$,Z"RI&W&%*Y9U$YS\XY>
MB(B#&Q9SS6-U;QGFGU$+9)+)VGM0TQ]\SI"<!/YSE>2-8@8=MP6*'5GBEFFE
MBK(N<",9;*<IS<II=PBGG==+N#?V7<904'1%[@V2)85M;F+B3LUA\,NNTHO!
MKR=R&/3#K(W0F_W]_BSNH9%=_.3IM 6RBT!V$<@N ME%(+NXUZ##D;>P'O4%
MFR<B1^H<N>E(+%;\EJ%&:-WPE==&YJO'J$7[6DM],@1+O;G12)]*<8T4RVJS
M&LQT^,-N @<AYF3:#!@H-DF4A!%IRL3"N'TUW(F>*;T/6XDXP;BK+]@7G7_>
MP=!)U5S-Q:$.OSI[%28VOQ]%YRW258)'39QWSW! V-?%^@S<"A$^:DQ=WJ"W
MN<G]'GI?<JJQ<,@$U.34<7+"ZZ$(9J&/Y!7810.+F0\@?>NY$ENJI*J=G@C"
M\#M;P[TJM#@K]*O]#CI^V@T9T8*G<(^J7-XJ0MN]K360, W'V2!%C.B@$K+%
MNM$XA_CF"-%SWR-$W=AIK-F9PV;8<F93<+ C\K;E.)IG4E.!DD94Q4FKZM2L
M0>B%_:TR]3Z/KV]>+\MK=:5Z*7=]&39.:RLOB66!E4)/^><;PN?/?%>.X)?[
M/<"O/^_@6#.&<9]%S%E/Z[>"17N%9A*9QRVM5;DJ;7TR[A4',A"KM'<P,J@H
MY"[B=.G:5T "HVIR2=E7P>#IU@+:NT#/H%XD8)_7E]K@P&I0*A4EC TZ!U4?
M\=RQ1>R\2ZYUQ"4;D?>"*]S,HYE*LP2'C%4/,^R:(&X)W GFH:+*B(K',<;$
M%\P9-XI/4@8$K_ V?59JWO(@N"B720@E+@2S-T5V2D/TE]E*Z RF?3;/RZ5"
M:GK,:C3Y AEN8KV&^+EE!L&_6GU@DO0JJ\N*;^@\!Q:N9VRA8N >-FE9='U&
MXR,Z;J/ R3$[F=0+:;>T$"\EJ;5LMVY#YVYM:\$Z67!.CE7J(JD>@PCL6[B@
MGK/R/#I$[U89P\"$V0\1.]Q_PG[J "AL U/0%DQ!N-0'P^UK^ILJ5)7DGDOH
M@P.POMN0)W$Z@SV[[&6"=EJ+WBE$UJU\T_BM=3?Z^3:J*=  K"-3N@9;#WF4
M$/ 4M_I':>\#B;?9GH<UZP^,2A8&EK3M3E"Q@KIB2!WQBFB %#:<K5+R%J3\
MQ+%-UX1!;X4M""N]CO !K'5PU&J,@A<+-UFOM]QM5Q4]C(3\"==!P$H41!B
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MGMW/]=D=TS%]/,6^-$0"CJA>^.23R:4HW284CW:AM5DYQ-N8S$18<B)X8D&
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M;HOJAL--U0W=ZH7QLJ> 0:LMSX4DBKYGC+WG<92 X_[&O='N >$\"&2JKTM
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M%G""RAZF[GOFM^Y[L1*VY,55:2=RV=*)M5&*M4Z=Z^7G(\XM.:$P$NP05\Y
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M9U2EZ+!OLJJ=L<DN5; D[D2;0&L27)=(_IC,:6 @U!ZAHOH&(O/3<,Z1/S
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M8KT6*6+W?IU94/IXAG^?IW\ >QZ\'PW?#(]I0[V",R\YDG4GW-:=<(0=<89
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MO4&E9^#V^(1)+;AC9%04+J[N59<M1'H76K"UPK:RWI7<JK2AS+V6%7.PW/F
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M $,T\0O:C!*J_Z$W[<% S\.,LYE67A@AF<N:&F7Q65EM%O>>%P3HCZRZK!^
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M=>(AVD)H- ?\>J526U=)P+!(E$PAY7##!EX5U*[;*\W"A7E05*&9Y@UJ5F3
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M+T0@D7>2;6VFA809%]H*#+XF TC,88D?J^/MEWM(9O)Z :LIRBQAIG*C5U?
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M+70_X8%CGQ78B^L$8UQP/M%,3O'\DOL='>"%[XLL6Q11T_F4+\EJ5NH_/3#
MG7\D!+0F [4T0*N.07S%Q/31L;U*OL"<#+9&@]6>7'MR6Z)$W62_/%HE\+"6
M$N]WW32=8?=C\AX*A:0 93C]XGBY$28U\!/D:DPN18H<NRG0:00U@"%',)K
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MD$OP_Q*]]:B.WJ*'P@Y$/3W#.._\:A, ^XJV9290<7?9!)F'$9H -8T9)E3
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M;HPSVM,U3#:!:?[+U(A 3K#+E4#V+YS;4]_A.W+0(PF0: ([ 'S.*<0=!1K
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MA;@4CO6Z6ZJ \^1>L57['+MTLRF2? 2ZCM%K6K;"D$)G2@RRS3*I"=,E-2
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MQ*#E43LG-'.=>$%$Q[M!#_TG:O_,[-]'+.1_B=E_)?;?>"T"6,A(?XV'C >
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M>%<""9$81'&UF]S_-?);=$SVO*#![CQ<9;R@>JGXH\4";FJX$"TUIXB?[TR
M?N?]]5@7)<N[L'[/?)2-[?!1R5I+!!!1/W4;'GA]^%UUM&,;+K5! &4,,9VL
M(#1O#4/A;-H;3M+ LO 4PT4 .EK/L_)@]5L;8?D;)]J*3O7]Q$G6?9O\E^JT
M+^0<7VQ1;,5HYT_(RP=W+'F_,93=4*P,KQ/4PH3E?HIG)1]*<2,44I/A= Z(
M+,-%@VGW&E&<AT>R(8":#X<"MI&V(=YQWI9L&?,DV)EV<]:%HQV7H!?^C!/?
MNF<1P'F"3>"GHMY4U9L4\N=*Q-OV5%QWD]:K6-.0MU"NBEJ[9_YB+L0IKR^G
M[TSB91SZL9#..BL5LR^$-^,\T7Y8J_*70]L-I\VI]V]>1F#BG-5IHUV AUK%
MJ^!B&Z74V/H&TM:7'VYY>"\519[[D-Q_!1Y9S+YGS*,2J*K]/0A5_E&@T4-1
MMQW(9B=(WBPOEXA0!9ED@BFHNVKL&>*5&I\&SLLP/+SZ%YWR225A]^!,14^R
MT02G\H-J70,+%M<*X5*<S]KTQ.%P]7Q=\:Q"90N'>010CFR>54F]93AMA::0
MU*HM6_/40F7$\'W&R3HW0$"_DG[Q<73S;6Z:LSS>$&5E[1[:9%XE1]LX7#Y_
MJ=N!\GA2P7WO5BOH"\G3I<N3V\?6J;SQ2?2<F4J&N3R:"+8EU\HJ! #Z\M&Y
M1.MV9LVTGYK/0]C3+@",NI)9*&WN;:P38/<^;M?RF8<Y1>-!HQ<\HCQU)]V
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MUM-.3=EBQGQ9*Q\GL!7A2EF.#KWAP%8NKAZ0^3\MU;;@BE!:V?.*\L>, (<
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M-+_W6%S3%.8T,;=75]DX;5&5IBBSBP$0XE>/.=:Y&C[U)Y?H)&PQZ59'6O]
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MN:P=:GE6RP^Q7I80W3_S^=6;S3ZA<78=P//A;S)8ZT&N .(1$9\0[F\A&17
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M8E+STZ+57\<Z",$)Z%5SV7%569J##]@:'.(7-U]<7%BR@ D.[BTP;/A_%ME
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M9@A7:/8ZW7,('?KNAJ6?#\I7<LGR?- OZI+GR@O?T*-O%\L\7BY=?@2YB//
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M)I0?A3D<UZ!)-0)H$Y9>N52=5#Q9%@Z!%ZR"Z'I4V?1H4R#?G'NX>1UVJ7[
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M\&N^=G@Q5QAZQC)&M%E5XT\_Q+NXV&,9(A*$N7>[B1#H]1K42-: PJ85>=_
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M>:?^#U?S_N-O=?FOT?\"4$L#!!0    ( ,>!:E0880W7%SX! ,2@ 0 1
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ME%ZB/'# YW@5F8%*_;BLC4!Y^)"&T]#1'PV=\!X1,0DM'3T#(Q,7-P\O'[_
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MSJ^_?\^SJ&O$MS1J:UU2E*"^/6-._$8LCB,[HM./ZK=$#@.X8V>%"XN82]&
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MZ0N<S$9H(T<V/*]O6.3PN-M!U_-RML7+*""MX:O7%3K0GUDD\]+C3KENGX6
MV+=99LG'U9XO5I&39VRN)/##31RIWP<&A\D'T:>K@)UF\6'EWVC3%[L];JG1
MB06M#0GLMUE&D:^B^'J(5[G5A06NM(Q#! 6#HCB#)(*#5481C4* 8@G-ZSN+
MLR(]YUJ042@@Y%W1DNM[H)\\?(XQ5.T3L1M]6PAQOS0#/;M=:.)/1S]5C6[C
MKARX\UE9@NEV+5+VXT$W-SF ?W$="07J00FY*HO[4I MB*D?L02^(G+IU*ZU
M#:M)BTZP29T"MU'@9U]M8S\9IFEZ<KZN5>D958ZFSQ.3PVQI.(IL].JZ%8YX
M *Y.B3U[IP]CYW'[5>\$\WE=B)?)<9RTDC$VA0S@W^?/.9F8<,;*X:6UBXFG
M/7T9RO*0"%=DB2=EZ1V6^!#BBZLO\*!V=N=<@TH];9VWFYJ<U-7$[^%K9_*H
M_.]@+R?E)/7H)&G1ZKS=6U<UO1WE;]^_= B[,LUK/D*JFGO ]495M0$L/;:T
MPA5&A0@%O,*@@+:WR/W*"-66.O:A\I4KTA@XR<=9<50GD\A^3%"@G?OAG=L,
MHX_]-GW[WFCNER+["OI9U $#Q@J(<9.X;0R?(_DEB;^*MQ6;3+!.]+QD9%LN
M\"GE(YH.,RHU.$G,*AA"FC_K&&.E,TV501> JY(S=D3KV4Q3\ 3R8,9#R;CA
MA )JL*J[B1(R($&)"07&+44/I*! A9(8^1Z^DAC2=W!JYH6E2N6=[9:KNR4A
M=8ND4*"[P.7,X!95$>7=1%>0K?+$QKE4%(VHX7OZ!'_B:MA&SW]ZH'FJB%S<
M7.;"VM'((8.ION'LIIDA';-T9I-N1G%60#NGX;9 \\IV16L_6^1I*96:LP9-
M"<2/H)._K<-Q3!%%?U)]\QFD[YXBN=3N@X>5'NGT5P,0C831_:-),B-NJX%K
MY!3CB@6IC7"Z=66)&)RH1:9",T1PLJ>#KD_*[4" M,T<W(-=%V,-=8I S;L6
M-6[1B\]H:WWZ/^"(*7[X(  @ Q3ML*2"KU5<DL 5+4[=Q6YV3\.+< QY4/F1
MN*$[_YK#2&YC4PTRDEQM2+BMS%LM<5+'1_.>+IL[NC[X<",+^D^X6X*?Z&8E
MV YG]/L=P,W&GA%U/1]S=[W8)<0=,J+]8&GH,L=&HSJ/Q:_&(K9V=A"RD9]^
M9Q%//+?#"6/+L8/E.67_2W:WQ=I-_CU82?V.,UK1HD*"(K!8\OA!8^1G'#E
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M)7&.,A\>V&M ,@7>H?5<H5=?!3;H?8N2V9#)BEKAD5C 3BQ\M.SC:S!2)\N
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M*<JSF 0*? "6#=D!+1ML&YR<V%S6?%."(4,!99B'DNP&6MK]^)F8BZ% (*@
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MV_37CRO>\;*$WY_KHL&>/^T^$".WZ7R5I3?'W3$8_9)KWW%$QCJL:UMZ0%/
M)=2 ]:BBAC?D$1NFW 9<F)$KYY?$-9%Q)XK"POFN?#V/&MZ^ES:8#E+4Y9T-
M[ZFH '$.[W[75U'BPJ[>#T%>GMQ<#18I-B6-[P=:P^3:&5\L&'3;:YY"G.%
MURA2UP8S4*#<VG=TPZ/9;3K:]V;3==>,?Y/;^0G1^WYJ<6:&Q]>2*^E1R#[\
MH@DEDN0*JH^F+(.4%N]LY*Q)6:SG?D(0A!ODM05L!QU>=6];8N_I.<]8.-)V
M?!ZU+-DO:R.C^@1<MNE]0^K=(S8"^VX)BPF&,(?'77P.-EDCJ,7+Z?%I*&Z>
M9LU'8,$WY6A[CQ5 A?5Z[)&5=DD>"^&,3\=9/[L.RZB>CKAM5(4@GX1)3" 1
MNE.EH]1+,?(.@B[N\R86/-+"MKPJ<#)] XX4:5G, 37BON(CO]06=Z.)\D75
M<9%QNOSR[HL="S,+@EK5*;ID9-_:K>.T1OZE9$64S&%=(TN1!^5V%=TU3/&.
M3^SLG+P_W@N1I/>81?L$9%'S;09$JE=Z6:5]DW>187NHO6?#FED3OJ:&Q;L^
M19Z.>2B(Q7Z6CI5;V 8KM>\9G'T!?<509VJD/#IR@=4C*!"_2KB(E;0SPKK.
M1<ZTD\N)L3LDVEGP\$@[2I8\C/E:E9CVG@6GW+'(X?D"J&RVL3:3$(_C?M$<
MZSH3Q*0JL-L 27B.5URFR9C+G>%7:X^G6;?G@\Y*7%=,*.@:+#+G+>,_]9E(
M3R<: 8K9\9CWTO8A? .N[\0)*IDQ&7"YOR))3A#:.=IJ3R#8:U@D]9$>A1FY
MZ<<F9R>-&FEVY)1L,G%9@&.M;.QRBFR="XK7V\+@&%4!,@JGBOPARU0KC(:F
MISV$\2QH7%[&>)?/_#RLT\-P>Y>27QC?E7?^J/W)FNAQDIO+6F)B]#$CVR89
M5\.T3;^9C(O'WE(@>:+HJ6DX6.:3\Z;];'*:+'CU25/B9PGDY!=QXAY-K\)\
M+I_D"R7O(Y!C-[E6*F,0>Q*43MO0&A'T*W!U2NJDL?#8HTA#%/D@+@42^)@E
M+<=WXR%U]">6# :7J'*P+!5]684/9P#1WP<M4EZACVZE'5\X0;[!*FSUM%_>
MN?[]E,6RS!O6&SZX@0)J$)<<RA6I<;)O+1>>J1''0BLA#*7YHGSH4:BT];72
M5(^/NUT_@#>RBB,P9-]]B^M9HV);J1/)D:8L(""@646A_3+QFD"V['5*M 5)
MP5)M[ A&N.4,<S7E-KR_3UD<(D0MS6(Y>&,R>Z2$[F[W6P//DL-/X!1A*^EO
MWCTK&)OCA)=&9AQ/6"NMK\OG' G*.LRWKIP][<"82@-<'7O/PDYX-FC2=+TT
M4H_P9*XO7)N[:C]RY3$LQ#-M5%RD[&VT]'9J?Q.8<#R:L9JHF -D.].=(G39
MJ8^+6 5E$V&-H;SHK6Y@2!VU(/ODI891+@\8"E@T#7.-S 0V@URXPH@"YCU>
M>$4<#G$U4A.J*$VPF8&1O3NCI>T_#/30OQ.(/9#7*" :J*DJ=BYU6PN.0WZ]
MK:PHIU-C.E-^XN/I021P_O:*=LX^P?OKFOP.W7SZ%3CO)K'";3G!YA3517/S
M1&U<;Q4MW ]<-\1=4V)QI.O^G!II5V/$8C/!J.T2FP@6,4;'A18%$B]SS.WG
M;7CB%8ER[WR!+_0'Q:^87PU(H=9N[Q]LVH"H($/I'\94U$-#K'2FJ^-NK0>U
M;H3+)V63]K2NO4/>'T.!\36PY\GD3(X!EG9)J<=+I\)/MJSM>U$2"+Z2[DA!
MLE]=DL1?0@'4LP]E)B%[:C+;DLLA&T(Z4(!:XF!<]!2I,$O=12^F1@%6@5(+
MJ9. 2=B>W[/HX':;8&UN.N,J%:*T,,*QJ)K"J;[WU!G=8"L^)ZEM0KV_T*%T
MMGTWP[\[)(\R=-0;UL!3DH!N89V5]L)$26-2;3P$IV7OX5S!26/3U-I-B_,M
MB*1K9F(]8&/AMMXSQ4"][5HVTGE$J49+^):;3UB]%P-C%*EIS<VBDI)'R$@D
M&4_U ^2CUAD_C8W0% I07*?7(,G>A5"";9FA'RM86Y@FJB>A&A52WI*V4[H
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M#'TO#USPG(F15;1D,]* ]M-D_K9,0XO"L="A^Q,]F'R4-V%I-VH/;QZ0'-S
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M.'YHQD"$C>X!Z-R>K96&9B!UQBN@>9=,UOBV:F5HKOM#<;>*H8V?G#Z/0ZV
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MB)2W8]L5 B381AR?OWM)W9H(/Z#XF8-I)5I&"*/ZX\\ZM;^F,*#Z-9/9W]S
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MP;0'%DESC==EA',LO+\SBY;W*^]/9:WP=S[\'!^&]O_JIY^-:)L"#\Q1]C3
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M26<5@9Q<=$+"MLPM9*C(75#2M42/PH_RPLCZB'6DNW6U2MO5'YU0I8XA?VK
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MJ>P&<\]O[VPD<BC$]R)]9$YXM8G*TI#DP"PQM.P=([4$I_C\-1U/OS:(TVV
MWFBVEJV=8YT[-SUV6K)FF%FI@%ZW3-AH[,6A8!:!UFK0@HAY>UX(:/'9:#EN
M".V]I"<IS!>F796ZIM/\Y&RS'>ETENP,1M;F$D65GV:@^?VU9A V&<8^%ZPA
M*%B@&DZEO4F_E:*46*56S>[0$"DB'1+XY#TU]3HQYL^D54%P'?,A#(3GW\B/
M<P(*8"NFS&ZV]<55J6,&\3#]GFFB9/!EQ8XMTC7T#KZB>P%WZ(=_%<P?5)V_
MBFGI^#J]_:JJ/=F^OJY!B;P'[[I3ZANUY'*O?5U8;S>][O""(4F_;A!7EMV
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M@0WX.D4!31VGZC+M4%GC2;GPSCQ(#BF_WPG>JX^UOWU$RJNSI-QS"F_W<#&
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M7:&Y 9\UIK*R.T]=[&GP-CXAV(.5]QPI:5'D%#D8 O#%$5[?D]I//_EXBDA
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M2-G7V;\G=5!CT=GI?R?Y^';G[.MOV]]?M?<+B:/I;R;2+^B.OQGR7X@<?\\
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MFL5#6G7$DCXMN,7HSV"I7G\7.?[O,@D!_P4H5K6A.SV;-?:YQVTAT:=X:'\
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M*GWK%'RQ4,T_H)K>0HW"-,,PQ+:V],GC3-\N") \Y^J+\(\L)?V N >*CB)
M$#Y*YE25,K-'7^^<=_SAY9NFT7M5Y4\0%I"[)49:%)EA55?],7W2Y<6;ZD$2
M)>ZKEG@08G3E==: (5Q+MV*EEM5.KGNZ1B17$IVF.%G5;'$&L-P]Z?C$'].
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M+;1RL__QO$KI>VNQU;%T9(:JP/_3WG='1;DL^PZ2!$1 @N2<D^2,!,E(SDE
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MB@T^/\&-E'YC-)7?<!&9^\8+"Z0!4]%X E1^8N]2*<O3/]%,.RB4I99GZ2:
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MI.RZ7P; 1;>X\9N.K*;/,N+52'HFO$) X5\=@>V##<*E_(WU0Q6#1\[+V]<
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M&<ZK26(X\[><$N>(_HQ3FX%? &AG=X0A#\PM7*Z&7NW Y3Z1DU$)7+L]7B?
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MZ?'$.Q/T?K?#F+2EW6?AZB=$C^9WO#2GG(.VI'OB-7$N!#&I!A9I<#X;#=Y
M"?U#-VZ1N6RR$P&,!)P@//13SV1M@#FZ^>^_)#>IZ7TD?ZH>PXSJMQ^5O?H4
MA4R+%6B<6.8)DI_+#163'7Q[@6-N]99<XE9/GB[GK\&5EGSN!!,^<-,<[8"/
M7XO6NS34NV3Y[H0PH+)9%0"]LWJ6S:<TZV"IK%^.IU3KDJ2BZ6A/WA7%-%#/
M#!R0C"ODV]WSU1#F]6Z ;,%)!N\#V^Y+KI @UR*KR)[^ZO6U0;NJ6&ST^)*'
M]*6Y_AZ.0O0'=EUW!A^5V1>5E849:NI3;2+>#F#2I8>N;:7?CQ?&D=2VTJA,
ML&&7I]I@YR-'_MPP?-5?\H3LY0[-XVW*"G> ?N&-Q9\?%/&KLHKK=;/5\I)Q
M%@0X<QFW&MX4K/GCV,U=F!@#BR^'8_F29:78A>TQ)!WZ"KEKIG%07@ &=>.A
M21M0L;=*8JH???@(,L9V^GCP+):NR4XC1JJJ,KO>G)UHVX .#T%AFV7(2(G^
MFP-RF\:M_NO'3)I5L.J6R@@ED(W>FT@*+;*O)UPQF4GT>TTNATZ';+9AZC'T
M&*J)<6&P AUAQ"&W0T^&B6?ZVKB^/K8/J%%)-&_F@^G'U^(-JO<AX+D>90K%
MEOK@!VYLAA$;6TTO96;_G\=[\L1PB3#></KI/!_2!3[^9<\R!8)TA,0Q2H0I
M8@T39$]O/\;%3XDJGT%V2I*B?<OXHAD5&=V7>1D(G9Y%2F='VH1 X8\5VVWM
MMK#D ?D8$M^@DCX4.35A\J44N:E:C@AJ*J/WHRR\#;6-,9:![F$8"(:!<ZBM
MKN-W<E*PJ>S*2.5H<$Z#0;ZD@;A=>AB3$-,AI)4_Q<JI!'Z@T4%^,6-DEL+T
MCM2L87^$W51(-?PWQ<<I\*XSQ&^T"$FGC )QB"E.-4=P1*UMX@K,M)$5TEY]
M?'Q<D,P2R_^.Z-U[^C^Z@7=1M_UU'G.S))",'_4ZL^=+!HK-QD(HTAC]4Z+X
MZ\MT%Q3#;$(:!Y1_7'AC?G-SRBJ(6D2I%5BB(F1[^BLYO+K+TDL88N9#8,PF
M<#>L!I":>N.H[FIO0C@P8]$\<U431OVX13!W$+,ONOM4-] >0>/9XZ[-1NR[
MRJ$3&J-; ];?N;I3'AYW1;<FC>Y\%-K&IV0:JQ5<MS[*!(9W8$:W[(J:>A2-
M%5.K%L-7BH*NFIN_;Q)X1NH:E&YG_+8=6.#J.Q+"#*B#610N[QN+3KU-QL:5
M!8)W%,!E3. Y?.31XV;)/_*CH D.UU)L.66P\,4D<]G"!U(CYP8J\9^_R"6^
MN8JA;)^X/B#'K,^9)2WGF[8O(X?3_O7,5XA#H5DDD=E2Q<M B'U-3J\S4ZQ>
MU<]N=_3$T"\7_:+XD.ME]PW/1YX20SW[AP]P^;,UEV8SNIJ4#G%2I1= /7OB
MZ]0=KV8!@60:H>4:$9<['85%H@*&CG,_'>FS#5_2ZNGU"-SZ:FFZ92ROZD^_
M!8*65<\M?7QTS')$G1[5STFMM2PL;+N9D **F/;U"7Q%SM)KE%CVS@F9675\
MOB%=*!8+?CYYOU.Q]H1HU!BQJSZ5 ,PUBEA/53 YR<BW]"&W5PC<KNE'R5NC
MJ-7&1AZ+U+67GM%7R7["=OU*-^EJ)&$T<25&WQVWO'R<?,#"]$/&KI5H8"VX
ML6&CF>$L,X0JH"I6)9Q-9J 9G]DT5\V9U.5XJD!$_ZPO=H,DI(Z%BS7.9BC>
M*'Y*S'%(JI=R#Y>]5H&-X2[$;ES7 +\0-6%1U=Q,;G[A\*\9C:CY!21G3#U;
ME)KA_9D3JTF@WUKW6_?2*BG5(\@[_7&!JNK8. 2\-H:ST.]"59]"I.3B< /L
MXL'E%O<4O? 2O;XM/O+%7H>*J$7<3RE&"&WLT#=&]/EI*72(WXW\?;#0.55O
M;VM8S//H-HFR/ISY)Y>A[%!.M9S4?):T3E^\1^%=;+<'ILWZ,6ED(*7UT/KM
M\D>YWS\7+YU&57>-8YIPDHO47@ ?PD-S%\N[M[\5D6Y1"VM1L72*4T\X)%_T
M*\N?X!%'+RP\5GJ'+*FL=L6XF0H0Z&[9:,;KQ:T'"+WW>V().:]/ Y5Z+G;Q
M>TR@0S-.R#;MH[\A(1YP"^O(Y=FR%-A!1F[V;NUT7AD5HV&\"N!)'!1-A%<8
M MUUO$,*'L]0FVJ6M^05ANQ)'>SEH(KNIEY?Z\Q !78KPM65@6Q0AG&D$21I
M.X?NJ./]="THW>BPUGEA&A J370FM?[@41GDB$%"3\#YN5,,=;+YH0(7J -[
M#7M- F* U;\ K!K,?XL.-/[Q/I^^VFF,)?;\>N!32KIQ=IQ<D[?80:]DP9$H
MBB6(;,F41(](=JQ9X ?8*(>6L8ERG#.N*L%9)P^0H]X,&.O0^B#&W^DHE=WY
M*YT]EZPUUI8*'EL+[",.DW;+1X4Y6CSJW4)I,.[>OIFH\^1K%9]]5Z?77?<-
MRUV:/ #? \OR/$'&+06B'/VPT#K3-##K' X=9/CBR(F+^F=\N_BU;6[$[_]O
MCB<5V?R:/WBMDSP+>Z50MH6_Q(C&546&&+^_I(4N:I(M4\!?>/_#_/>G<71^
MV BMX/L\,HLKE(93BN6E.Z6>SP?)ZC7^X 4*6L*ZR7.*KQ]CNXH/X:*99"UG
MEG3/(I@B@I;?5X;1D@5/2!$; ]?LA3K%WD^K44?G>T8JS)DF@X7/W^JJO-7
MX+5Y*C!%^\6?*7(V<Y-;SW^?[\!3)3\ZBW8DPA)?FY533F0P4K)ZEZM$Y7AP
M'VE[C)2@#V=U3/#26BJ3%N<6#X/7046EUX5$Z=</\9%T+NV#!%WOG';Z.3M8
M=8+XTQ.4Q3518*&^+J!R._)I[C$BIX7??815/[PP4(PBL1#3S_LG:WE7*3U=
MM-N56-B4J;UXMDOI:1.IW),! NO&/L6#-]$4&SBI#K2@RV**X"]%M[%H[W0#
MIZ.LZT35R_8@*]'KAU2O/-DY(#?+QW3!R&M:$ERT?N.HJ()Y20ASL&A?X::N
M?1JXO /<PF'KF[ET3'^,>.M[7"J0ASY*(-5Q_B"A7SGI\K(4 EGELE_SK$<@
M=$UX-;+H8GS(S4-C'FD-(78'*,["R[RV!0I9!K3!N-EYDE8''DL8&A,0/>3/
MOP:7&_,59A0SP#":'ZO+0E(>AANPNY>T3;ZU:'.(2A2-E"UGM[0U0U8HY:*W
MC0(HL7!>MUH=0))3*SRGND#92U)N?+4)RJS)6_C$;;_-ON\G!D;LN!Y^+_/E
M67OZL-WCGGR_W0FQN+5 S@<DSEMGO:^DAC%6F.$4NNZS$]OWH&SU!F>Q4I*,
M<LU6Y=V%K2O8!!'-OF'T10)'PYBRV:(0CT 9S_.5L^*,RX-%2_U.1/I$\;7Q
MZ27@/[34=P/[>M$.K[Z.%@^38RV6Y:_YO0!X?5=-O(ETU(3W'D&(CQ^RNJ%T
MK,SV_%ELM[Q_A#2< EY%[1:U&M2?KX:67Q-5A6E&%\8_-@S*HAWOE<M.?@UM
MO&ZIK;M+=:/:"O KE0ZGBQ4$QNR\_3Q3!6^T=1.L;7VM\OQ[YJ@.^LXPMSMW
MM:/=+@3F:M1R8KC+&*/9<?UDO&&@3/*\0X!4N3A(1\ 3BB&_T1B+]2@U<8TM
MHA3TH!GVH+'!0. ;HC8DQ]),X7(,V6N1]-^ S."J7@GY7R$:Z[%7Y*P\DE=-
ME%F&*FMH1KP#_ZTR]=D%7ADXJ"_MCD]&-"%.\641[T&0)CI+3%@_#S0GOY7U
M6#P,00H\U<@BL.V6?H8+1[??V//<1*]R%(JY9"Z#XJ8XCEPYOF?2"E_W\,^]
MYEQL+;M%>M]B]].TS'.]*6([,&R0?"S!?YV,FDF YF!TC,-ZE8=F:559"N'
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M!,T4I!HVL6Z+C!US$#)^6.OC83H0P1E+W>*_=8=QR*F>V :"^U<]BH#V<G8
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M]C)M&'6]$(*%D.G$4N_0ZQ43[V72-3;=9O+ .UYIUT? YYM2'.:'BMY#KD<
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M)A'*7QK?JR*1:OZ=8<P"_;I,0Y+WZP'>]P-Q^Y1\;Y1:KSB\&A\!75S)38^
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MN@TY-$AT3KL01F5"Y7"]?5X8TO"3.#^E3-UBVF5J2C&)LB*Q-V.3C.$6?KG
M8K3\93K* ^GGD\F\B<'GS?G4S8W.#9PE[P;[ J+@PYB6^)(;.;1VSX50M"QY
M)TIR%K2'$KE&!OITU!XTJW\@E8E[K,^!VG^2-+@4:<P,6F,/MDE03:0KT[KW
M+'U3*8:BR;![!)P,K.M,V+#/7-"!!C<'\@6"WGNI'@G-W?,I[MV65$"Q+V!U
MGL U!NEE9MG*",6235_.YY$YB @;,(&=2WT/)Z5))VD!W,\I\BV)?37?3>;Q
M]^RXB=TXMB\Y732/.QJJ)YC+,[6D^;02:@*^!&\=*HJ0) V37#!WA/9>$.M)
MG$S&Q^ZA&N-"G"MJ%:%O5R7Y ;+>;Z43M>"6=NO#RT %(MXFS"G6O,?AT+#(
M/,URGFLC#WL#I^)K0]CDP59-W,*\UJ?5D _;?%^XN2D=81?N')_CT[X].8KP
MOYI60HR)&Y-'Q$E9&V13&G<BW!FHD"B0I'1A8#TTIF5U'=09=0KU=/E4,P&*
M45^ITQDM[0<'#6NKQ;M.#3T"9*'.63E *&3V7O7M\\!/"X*40D%#7N#$M0:S
M:JA@$=")%GS'+R^1R_8B-!L >!]T34.1.M48['.,X!,6Q::LI%$1JQ4K(0G1
M$T-._]0J1!_K$SN>(75:_HHSG5_F]Z:I$CUV(]EONUVO]C1E6GB$N3$:IJ*M
ML\#0PX6:GXMB10OF)4PIE]E=JK4L42[.R]\<TMF.I:,PC!%>"U-0@/!)LAOE
MVL6'[XS:EF=DO)S:W\(67KMEN) *)35$- EUU>OYSU%EA=QIQ9M8/@)J%EK+
M3CEQ!!:?G>>NZO.6O[YNESS)JB)(Z<D_^A!$H3/3Q=H]@AJRB/ >X97(!J:N
M4+FF13,'U+GFUBO)UM/$S&;.V'3-]IW$V\TTUPV_!P;PM5-)?[&K%+)-.\H^
M(J?+RT47&@",@A2$SJD&7YH=0@^@+6Z7K^'J&A Z_C;$TCW.89HB8T,Y/M/;
M",6.CPRR<M3RH5]8IF#'@&Q8-ZD)5FNY!O0==[@D$Y&KUE4%&R==P@Y='/&'
M]2RV8=0:?>P,.E]&)1M&RQ0/62;RA>UO]&'8K4N_"J57=BYV<XQ#M29AX]YI
M=ZKH'RWNO*S3'"(55+.3:X<=>[H<.N4GP25HKSMT]88WVW2,%.$,![H! (9N
MY<4"GS+8L /['.YEHY==M<:';NM' ",.ZS++Y[64\GE7B_4V2)6YO 5C_KR%
M/(N;] \L+HQ-^"&6:<$)6@ND.F-4XPAW^4_$G[#7YL;-PTOW:+0L6PZ@!9V/
M &1HY, LQ.S$Z/HLLNDXN0(QTK[<U:^-DX02]]UA3L\TK4Y4!:KS$47S>[G:
MG"@,K:9&/[F*]-/-2Q$$:PI(MD^LQA(AE"EC#<1P)RH#Y,_<XM3 M63 4+@.
MV?*B'G9@BC98#6<5N'(OS7Z?\I,_=[/2 ]U/2'/@)'1/D!#Z,)12!!P!GEBR
MO "M0!('PHW#]+_9+YA%YE&1.J^XAV,I_&.9WK\L'QLLNR:C"75J.@<*-(8X
M(2]FU?;,UKEG':=Z\RZ4,:^IIC@(^EF7 *'LR0'17Q+MBNG>M1*Q?N/A(>U+
MM5K\03"53@=N@)*4Y)9:!>>3LU_)MHKCU\U?=%HQ+E;->^8QD9NS9+!S,T1J
MGY?C-X]PN F2BA1)6S+(%>XMSQ'$D>,X8\8X!\BBT*X<7A4B1CLOX=4G+XU=
MKHOS=K M:%)%^QC[BRP91=KS.81%\*J<,JVX3U6LI3%\''T$@&GJ-*Q#@T9:
M?UU5< ,<(D] +SA0:!5I$HX6<?0N3/( 0N/IEMW@)CZ9B:_X)0OFZ;A-U6#I
M:RH9Z/LS"0GSM3T_(B)T!\6]FCF+_407]X+ XW+V4! K[;EQQ.@/$?]?,GX/
M6F;$]A+D\-,%S=5@[MKZ (KPF1CA1L=A]OG]'?9#WK7;U59?Y&0UVTOA03?.
MV%6ME.-7UXK#'36OM4MYV=/-DZ3I?SI4:-0;/^,>MM@3I&9\@$6;K XR(0&=
M)#MD5PG[(Z@VCLCL>#&&$NF;OLV>!(:6WAOE27H L:+P\EAZ47-ME+Z)K%<@
MUA.<86!H[#?C70=#%,$U=TQ5 $7'G85VHNAO6*F1<='=Z[H94I(TF<__6 [0
MF$.Z#[TDO?CE'6\^]2?Q()?Y6SV0\2P3Z#QD")O[W!38X]TZ"?4USM4/D^C<
M),<W%?*+DJP)S#\"2AEBRQV>HVLR#"MMG$DU7B<TF#^!K5.ZJYK,2IKH07V5
M9H,A7WSK(\#5$08>&,^)7HNG# ^I?]777H&-#2R.LO>4,5=QM!#/WO&0P8[/
MW%>PY$0A>VLF$FQT+M@BJ@D^JPK]GFI2=QFW)YZKO'9N((:EG/ W%#5^34=6
M!K>=-R'O=4#"W.*&L+L-?!B,HT1^<:[= \@!&C#\1"U*%.3.&NU+*^RV%+[J
M:;HM/<9Q?:_S-3F^.Y%_S649ON2+$>8)DO;+6/7K(I(DD)X(\7=6]=VS=[BL
M B.229%*1*XWWXX'U?U68XJJJ^N@B%D.V;,#5'ZR=EDB2/0H$9](X@VO5B<<
M]KD2:Y*;.N-PQ]]=R4N\9C$E=J[#_WS5"72%%!+E-Y5:H!A!GWWB0(E_I:WI
MF9:@R _69X.,<]1Y0\G7NCLB<\0*YKEF!SXM6S2^ZA5<>6'>CI:+>L514/A5
MT!>&\:K#Z841P4!4STP8*4U_%^!BB![-8W7X\F( YESWY5W!;//BJN1+ZT-"
M"(O?#MV2@/ 17 _25$*.+Q8$$H%\5LF!7,>S@OHRIO(ODK78O1'-(7M9.*KT
MF*HQJ(*E]8ORMQ>'R77*3BFAH3JO86NC7 N=MA0=M4/J=!0767!;]0SW<B/G
M/]AWV*5?&/@X=YE$NSP_7^UTEPUGRN&,M*8&(=CI56Z9K_.H\!SV'D9<K-2H
M)3NPZ2Q<)ZR6V3H6)6^I&6KR7/EB2NC:P_#*+4[$-C<? ;[G)267IG4Q1%5<
MJOAD;RX I%W@Y#T*KYST)<(?86JONM^9Q<30&MP0Q(3T&+/-:>E\>%L+"3 /
M_!@-S[QAP1=DY36,G=?Q'H_X._!-U\M87V'X F&+2=.]EOWSX=M[TEOX<6$-
M3\$^:4>(!Y^S+UM<>+9BL6? >[IA(R!5F[9 *1JO9R_!>PVOP,*BG5P$2P0&
M/MD*LOA6-#*%NF\[+S*U6IG06@.$^,O&J4=K(S]?_*[ $;LT%QR]C*06$K)9
M9C-?_/VK]%\TVENR9W(BPIBA06%;K]8'X+F++%-Q$70]<QX:8=BCS_">\9)8
M;*,K\3ILU58KB(ED_FM"\*W\)\IG$I\CXJKE$:A=-8\/NI-4$&HI,H?8% \1
M_'RB1Z;L'@'1:4]Z?]#[G$U3&? -( DPOA"LKNU\FO9ACCF_]1+"RFOWE_3I
M)5RSY_V!2$@VHQ?\2E)';;&55ALRZVB?ES":MH[OV6#8"^+[E!9[7TKAD.8:
M;^N7,;1O;EWBY 9?S%\[ES5^%)B8%@U$$7+KO. H;.UBZ<12PU\2Y3^9TTJB
MO#%"8(:?^":DI'B@D\(9WOQCK0J\?(/0\N 4^@@09P3*/\-6"OMF/QX15[OU
MY)/=/#G/_HFLRY_;H2,S'N74LR&W>^V)OC%VP7L$$*17L7LW%3X"IM<? 50@
MWC]E3J)_D.,8?4.4S'R>75$MAZFU_T5; DN.\.,7^%<NS""K2=G7?ILQ$T-I
MZBJ1_,0C?\ZI:'+\20\K[IB;CXHI3AYU1D0[?7'/-2/5];O(INO-#4Z-,]RX
M)3$"+7I"M!I2B8JB_&_1D4Y+;WD$W$?UI/$*<Q-%5[=I>'@$L\2PE"A_7U2%
MF8=]P0*HLS2?![=V1R*+N--YSC;"VD1%Y@.GK^Q1SA?2/0:?[(J2P *U-0E9
M4GPUC!,!/D<!9V*SSZFF?'=?A/8SL7F7YEH6Z[X_4&*ONR*!\>#SOO#7"U"Z
M,_!EJ#,W7OJ\,\LINB5P)3OG6,N,'@VZ!^[;\S[,;I)*<# S'C*WCIIYKEX_
M EH%TD.@DQ/,2D=+LH(Q!/%.( 5W"URAJY.)QGH=2LVAU2G4BSF&WNZ@"__=
M0IGKU(G^-1#0>_,\HY@.%L_,5+2(4U4L8/@(P#@3D HYHX)&5+><0@D]#;'I
MK^?5B3^C740^ LH53V^;Q4K7,68?ED_D/F4W0K^Z%&$TV5HL^V'L*S%'EB,M
M57Q[( I)] '-@%,,,M2NB ^QVPLZD& "/-XKK(^ B^(9:#.CZNYYW4?4K?=K
MPB(&0[S*_,0FXZ?L$28!"6/WI#?$UMB]Y9&E<LO5=:0R!;?3*H3!%&K$>,_8
M-)1S>+T)*IJ(9.BG+VTNB<6P5$U752Y0@AG9]TM^Y+R6Q)(CS^)>$*9$O2S!
MEE.NCE08.SJ_H3KM'&#&U'<#^+()DU!00] FT-:0KBWAYS<:M'UA&MLQPH1R
M E!=_U5FXL'2/?M=WHA0ZB3^!)@G9# N1L@&R;8]9"M1\CK4.IL4[<.MT>X=
MZK/] >T;LS"G8=&'A:E'0.!7_"+@$DU%8UU]A!8::ZN6EC4/*PLI3[=!S'*>
M-9,6\G%A=DB'@49]^>T#&ZP%"?;M(N]/7\Y'?B<WR?Z:,RLIE-S4X!EF/(WL
M JG*5E!K<@?:_IC\I?M1V3F4C<'A<\I@]4NY@4#@K7,I;T.^S.:BE0 EWKV'
MZ@7VFH-B?*Z-@AAVG_._7!8%ERRT8>9]>Z;W@#H5;QIY@[\,:YQ^!(ARY,G\
M7EOY]A?UC](Q;@T.>.5U=R0D\@17H+F-1E&NI**#8<Q,O8XS+?GP+8/@^*(6
M-FHP.V%&U9[4]U430HQIR,U5:;V*J3AJ 6H!V=VT8\Y ,O^,=(*41):"_)PL
M$X@\S9W7[WIB<A-LC6' 5Y+#I?,(B))^0@/UEG/#IXO9;SE]X7V[CPL+TQPK
M&#'XG<OZKZ%FLYF23^+D2L/15!P3E345\PS$7G: I"3V];!HK_Y[,ZI?.RDP
M3@=8)2?0CLAS&N_R=KCY[$;-TA/Z^A$@R7EK\IW3RJIZA_K'(CZ*[,"W YF<
M,@PEU=V?=7MQ:BF+UU<ZM0T-.N1M':*(B22Y70>U)HJL2O!%![R.1=49)!;C
M%NZVEWG^N9P$:6&0*#?T04J+T-JC822*\:F":)\=9;746=<S;1:@9N=EBG$R
M3HDCXRIF3Y<KY#5V2L40G[*]ZWCGM+L-N&@.6&]0-4Z5_([%@3*?\P .=D@4
MAB&57<?XIO/TVJ^C;:B-5DLV4BYBRRU"^@7EIKSS[O2NCC5UZ6_R_^D/F$4=
M)#VV$+IX HI>2]F_!5BK9W\T$=/P(J^_(_%QH>4V3,'=<X6!B[0#(VTN-33G
MX <BM"/UA3JF9EP=)D-X[,$"Z21?3N^';-NNEO6G0;,1KT4WA=;'+SK=TUPS
M*5^)_"+RTVW(T4.3_E13/SRP&_A$(NV\-0\'@'L%I_P#"34QN0_> TW_%8G5
MM15=9+>,@RXNQ^>U6V"P2<:>ZWJG,Y24<T/!RQEER"(W^F',:VY"8_5V\ENE
MC6#^^['RJG8A 72;$-IRQYM_9*4 [J2=:@#ZZ_51C/C+G(GD\]U[(91KLSLZ
MEKC/.=XU/,-KWFEN[E44B.(F!B-%O[!GM8??7SM8TR:+O+5/7'+Q/%NJA=K'
MVE75%!0DRJ8:*25S7>DMSJSK$' 9.]'O.5>F=ZA5SGMWEPH=,9^6$YB^Z_R1
M8/A%DH>Z*6$>)O 4A>R]XPU^')(F3<9\5;KQRJW^G1)MQOYU?07#'!2\75:;
M,FV0S@*RXT [TV),/I%%%2!M'S\P-):VO/J5+Y.UV RR)N[,9>&/*,V,>I8:
M?\X]S+YVT'JRP]A,*)F+DF3+P7W\M7+99$%N< C7)3'"TW-_YA[Q1'(EG.XP
M*P;OLX3AI_D?:-W-B-[T9^%L&O$';ZT95K\[S/@$F3@RJ9L5&:9.EYISO5G<
M<8[5GO'T-95+GL8[_6D?X0<&*AG\UA?&[TL7U1Z\DAX!>GZ/ &'WL;_]:HY&
M_T?#T]_F *ET@\1PZ=L)O5RJC>V%Q,@=@1Q4P-@3VV67(E)X)8BZR#Q8<:K;
M/..B9,E848X&R9ZFNV]L@E=IXGE(1355>JG,C.I?;X6WA= 6T?[?%"?\]15@
MJ$^BDH+OR?.3'P$[IM4E[-X]0T]1::OE%A]$_]=Y )!%E+'C4KRY<OCL'=Y;
MUJ^<TC/.1,K-]UZP(&2-H1R-F)#;/F;RX].1][@C$MO5^#(39M+EC_2RGE#P
M$<"[5$8C57='G8?U?55R9EE4!VRW1@%<KMM=+1A$<69S^C.-4F4.=D)AT.'N
MM'>S10V#5N;&%,<@A,; "3"H+FTMG6)R5$/E,"F1@MOI[L6,1G:H2A^D54-E
MY_)08][WR-O[[%ELG%$U8K '(OM1UUJ6)#;4Q;CQ5NSN\+V<"A=T<:D8#BHY
MF$S8E@:N$5H&J_)@9IFNX/#@WTYUNFTZ)I.4;SVOKK5-M2=,AW4O59=\Z(.R
M905]^5K%M?,$G'S_J72D"KQ(LMQ!0#45[WA*B4N//4<.#Q?EVB,8GR,&^,)%
MBEYM&=HDM9E;I^&$PE$55\+<ETG;!VTG]F.'/)&*ZKNZ,5?F"T(ZF4I-V:DJ
M!+:N3 !A1"VQ. ,HNR3)Y^DAM.$7>!;?VC..<"6@Z*_TH,^TMI)%IRUM)$O;
M/M^M&=\9"V8BO:.?/#10HQ?-81IOB9 58-%(IY\ 2[?@ '5QQHY3Y.Z4F1WL
M'4/PVYCAU 1>D)U]6-IK1AAS8FAYM9<Q5X-9B4(]'QI@NF[IO+\L$"Y@7?M&
MXRO/F)7M8;Y6R8TU(Q7;W(RTX,[;K]OTM</$E1;G!*S71L(3.6.'U!,;Z4 F
MM.J8XB2"#URTA@#X?>VAJO79\J]OUYY# JP9U,=7(V32+23]3?%,3'H$ \<2
M2'&U@9I'+0Z%<OR7G+PZN?O/5NZ/$#_=Q@[R21XAEK=[OQQ<]<;H@43EJD$<
M\$W"M5P2FK#9EN%OIDVTE_V_JL*HSB# &,UB^OH^&LD<.P\;I78/@EUZ*H^]
M?Q[5=:W7I<N%]%C\XGW?9P1O/'GHN:\P0NPWWNE("USJ,\6Z6IH'X[#VW72&
MD?Y5MSIG_J];>47BQ,L;JF7+K6JS$5N_(A<%+3",?L'B.U03_+P?TD#SLK)O
MG+L? 8[0I_.52V#*S2G:\VMCVQKILNY.;[D/_L=ZDTK.GT#^ZQ.%. A'U"_6
MB #@4S<ZPW:6]KAP:6":/>J>;-V[NBEK6BT5UUY'PG8#S9H/6B&GQ1>L.^9;
M7V%.JJ?A0C^>N,TNR3^T1J=FX/ (H!R;?WBZOAPT^XL9[:<18J]Y!'SUWFG7
MG@E?A5$ZK]24P'!OB3P]."#W[NVPM4< /33YTM+V^B+PH1.F,IAD39JT_!_P
M+#'R7'F2+&9;LM$7*WPS >FCAN NU2? G4K]V7 P"=]$(YT *#W#$F?_QY5G
MOKY4 7<K2=,C((\[?S$*GY/ K*,% _C"*CD@%CNMMBUIT2YTM[9<#N1.$W!4
M9OM5P,S>S<'6P6Y'>M#*@9 HHU[,-3>!2Y<"RNF#6+6F/)DU86S+RB?II>X<
MMHX'>),A,M8T_7G<VC&<$TVPCXVX&@6,5<%-JJ3VGO$OC8O^I**?"-.?)37P
M#_+VVX8G-^9M*B+*EC-++1J*)9M/REQ%0O)TE">S[2==8I_8:.E A0E7M'.8
M^YOJ!S1'CG[5R?!;:8)NBN=1]L-050XC3X4F_'EQO>P0!OC<_Q/\,H1?9]@[
M6:\DI0^M:;G-N2H8A_=%)\(7EO55W,MDT@0[FH[GUGHXL>:F3(H(,<"'D>9Q
M-[SG-]*!FI8[K7J2]Z'<_2AWO-[D]<O-96$@"W?!G!:$@1<MO=]T19?H:HJ9
MH$[=.G?6N3%]_\+#/9P0>&S4I-EX;6#@1-VX[T$I4U+/TJ%_P^VY@:$=K;2G
MAZ%XK-;07#5Y]$[U/*LA@ELA-/ZH5%P^_1K$C$@>D0<EN%W:5[M##R4>3/_Q
ML__=H7T52T]F&!/OV:U*"FG0&Y2[(' X[4P;^WI1V^[[Z&3,V6]$7&"MNA-*
M7)0U;-RQ['VZU^]G,.)>Z1M-<Q=E_,*)M;#7T=;FKV"*?T@XB0?PNEA=LC>-
M)LV915R\L'6L*#;W[>M7ZZE(,D-W""NTCV!EN9ER:ND(M[#%D%Q#/#FPS/NX
M2B+BE" D./76?L04?-X2N-8':[,<M#B"+<L@'7".%?M_C_XF252#]'GD]K6K
MUNIB5S@Q:*DRK%)BLQUO:<F ?UT T7WTR*<@[SIJ;XEFHGK>'+OTP# ,//+U
M*+KK@T^D[$V9;QUSH"!12GOZFP#"#@9/NRZ/;[*?:+[EW@&$-/<MJ"QWX'[S
M[+\62[!)W(<=/P)T+1\!6<ECI7\;5(O^VNT<3Y<ZQ;KTO5]_\_HY*:Q^RU*K
M0\FM/KW5-?P9C":YMUP\S!K!33W80?F)Q:L&O-5I3G2Z;.*EPUB"M_04L\=N
M6BW)C)6VZ XD3-SC?01D6'1C$K8]1*2RWYC9;-EVM" *A;*;$PR^N?LPI[ 9
MVZ40A/KBP1O#?<_1FGY>=!3$WB_6P0G]3N0DT'M%0P,MF910G,@>7Z&,,J78
MD+VY$)SL*&<0(_F>FUTV$(FI=QRET>6ELO79_1+;3^IHC(\O9J";,GTKI@E/
M3)R3/SG6(9'M)1S9!A'F4@A]$*\ LYXB#N%4N^/K2R$]*.CD5QQKE,B.F-NA
M!GB"J73XB(J^99$_LJ]NSV!\BD;GG5)$S,118=D7C#<_ 7)6&/6D.Q9[KA&_
M @>WLJ[D3LI<Q"VS)DK&/64L&-CNO.4> >F@)Z0B$(*<']\<>!_[*1ULSY1;
MHN^,9U=Y0ZJ/;YZ&/B)9H6RW&Z8K!!V7J,HPN%-W$0_'SGBH*_ >;GT$-,M=
M*SQ GC[W/0*6:>YI-Q+U+Z..PE_2!UY.I3T"A*1O2$]R[BQEGP8U[S[R6O'?
M_@\]5R$]3..#><5>Y,&FQX?OF[IO1GN9?AV^7>B&<OGG3QX?.%ESR?-Z@8QJ
MQ802FS0(BRNOL".9VTO"I24FR:<XZFS Q!\^;9Q-LA!1">ZHGX4Y"X)GT+3D
MA$ZO<+>E'TJ>>*^0O?>RBJ2,([JK"W?>M9,3M5_I[+"G82+!=^!K0BWL$.[X
M3P)(E*GN4SXG*CW-DV6&DQ^9/8V>%[.VXG49X5$&])#=&C4Y+L\ED)Y=83R<
MTZDI5NI++7ZT8_4RZ"1Y!!B<==?UN4JW5EY[:-=.EC&!/E>VDIU:@>Y_1)(E
M4- P=CJ#U>ZD^F%>JT^#U*FABIH5YXO<0]'TN;R! 'C R$C%^*GMGPBMB,Y-
M+I>,+T_U[=I82R[X,;9UI76N(IEJ@#67F6?O4H(N%6"4:O"Z0\]P\KRV!\RP
M>4I.+T4D+&C+UOOX2BXGP,N!D=2Q'APU!5@>T6M6.(Y[!7M"/XHS7I)-#OO[
MP\H][%GJA'9.^EQ#J%;T/5)A> 77Z(\ JVD<5%?[K<PK(M)=G;;B;'_Y9Q$
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M2E='=<5I9EE!L>SG<C?R/4$5;>YN=X54;J*2B9,KQI*$7CL'ZQ[G4P!BM+]
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M9HQG! GS%'HI$/H3]K/\P9F#//K\$8!!U9F-P;&,?N<0(7>M$HPEZ9:[R&_
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MN,FP2I5^Q'[0/#%:+2%UOBOD>CZW&Q^YG1+MT;0T$6$YA92IA[/DV +9(1!
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M3=*_Y8?EO^_?%A'0F[\!4$L#!!0    ( ,>!:E0RD,<B6F   .]S   1
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MX7@)4C-O9M RE^&P\TV1^#1UIZ0"PPVGZ!DS 6,3[-VSED>3IUS<!\^/JLG
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M6[19!#G[ R(\''_@UZ,3=6D\\O^?BPYM1*S)P&ON#"$G^8<Q=U:][V]UN>%
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M#=H5+C+%=:W]@?J/PKN1',7!5OOW(JV^\#NSN9K.DWZR#863A%=%F$BWC)V
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M)JB7LB'3Q=/'T!I;VG.4_#43JMF^-5D+JU*?D17#4OPV43B_T_'TWR& G&I
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MN%7-.F=*)7PX6V@DQYKZ^R3XYP*V\,W_N&\M_)=]ZX?#GQUH.M,S%R6W&U4
MV7K:M%_6Y6-ICX-0G48&0MF*B$=*]6HPN*<'F3=9-U8U+K?#0&@9IGYN_=[@
M.%<Y],,]ZD=\@7*!G@R''-<\V^ZD?MN#XNDDSS"4[#GD@&2-PZ;245>!D19:
MS$HY='!E^0+#;K:D#LH5SH:^H@&I*31P/E/*DUEV^:.18>GGX?ZP*NKGN-3F
MY1+JBD*@^;3XIZF#$WV.WUG/$,?WPJ)#A<O=I7/-R\GQDG7F(C,3?%K7^=B9
M7U:9Z8U-M66U? O/F3[>(01Y[RC5FGN-Q4 ;W9^=Z$@A'XJR7N,R8:@7^(_&
M0>XS-)#^'G(^ /E@_<L&#7!<A4O6AOQNV!W(=U-$8?B8"H84RMQ$ P?Q?_00
M'HU*;=T'71\MK2B4%R)+]TF*,3QN$W8U6BYW[YZ_@JRR/L,_?)_R/R-:;KZ,
MO4;CJ;UJ[Y5QCL.7\QFH24>@S>I5A]GPMJ.>2D4"Q0'@QPV^@"4:FLL1?!!&
MR1VJZ\'>CZ=78:"+TYB3/::19&>)PJ+R\NIQ3M.*B@^F-1_<>VE/L,M/[1PT
MPO2,6!7&,QH:[A!^-?!"9C_CU,+R5V+.OS1;+-X2;4IL+MJ 3?^:=J^LKNZ2
M.<]SQ+H U]T/N&;#T?G?[_2*K_[9\PT6_YR]CVU\7ES>DNJ,RL3DX>R1'9\_
MI^AN!"M*BAL-_"9OHGL<+2%M47?ID&_,_NSZS7>[I8X>&_IJ_F84FV[!3*MB
M9: .O]8U##=YY?[A3P!YY'T:YH X#;GN1FF/!R^DNIM5^9E7;RP^0 .?KI>N
M.B]NG20>.Y!"^OP.KE>0'XQ95^3U(7!01@(FY&EV\=Q2,<YE] ZU S%8V_V+
M5U\DCD7U1/J8'%I<NXG1;B(M,?1F8ND@][@D$//(:#"/LEKH:ANY.X4!!EK)
MO L?R%6QJL(%HP7FFF-IJ:'*<@Q;.+.9:$ C;1_JR_OX]!%J*W?Z.]])=QD&
MK(C^HPV-?]CP2(:[)CZ8!7<7&@RZ\4?*%;F75\[;XS#WUFY0KS*3&C&8[7K3
M-V1/);@GAC?XGGZ#DV]!5VU7G2MJ<1FRCM*)[]^CK><=MO0HD7GM+NX24CU1
MK%W?WF[";Y::GNH];;<2,IJD0)#1PU0=\;W)0M^(>;G,<4EP7]Y%.=,J9MO%
M:&%AAVQIR>@SV=!6GF")>T'!(3 /$9V^A<4,$-(G$W_SI_RS@S:IP@1SWE&%
M(F6<&^(FJWLBK,VX$X@T/^MZL73&^*\<GWL-OK-X8^+I(3]Q2FCW]$JYJKZI
M6B30^C71Z'%TH.]%.D%IR>,5J&!%F7*NV7'A\/H>TM'%L!F5 2.%13Q)D [(
MIJP%:UY)WY[O7K)D:!7=^]OU"MTKW6ZI$XXY-("/[)IN7401+Q5K3K+"=7),
M'^8BF=Q'#[CB46/X 'TIG1@J;GI4J;#P28\*%[^7 Y*IA;T7&5#<0'(!8;A$
M R0V)@@%'\VT"QRP&Y.4 T,#J'&Q61XZL'-RQ2!E5#Q_M(10:-(.1P.OYRR!
MU;W=I;RKYGS("CU<21C56].C.#S7JVK2:)PE!]+-G9%L!-?_D,M'%'"XRJR\
M<]9A1@-?$J_WW_L.=28F8%1F?".U0E,[UX2YG#5)8R3)_.DJQ:@ZF#XW:<?
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M+2U$.#LC\)P=)3?E+%/%?Z_'""1-_ =02P,$%     @ QX%J5-WZR0.+:0$
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MO4\!(3RO)7,%OL\]2$C]F9N_A,^H(XZUW(SBA.A0V=V'M8G*SBV7@(.9@!#
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M*/V06VV!;1]4H(;VM",S,?:CGZN"7D.(P.-T,;F2-_N=0JYJ,J$\*#'RKBG
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M)JGQW2"GI*1'QZ'-@D;X2\G&7]NZG6,F^KXP3BN..-1AOZC0BE)<L)H5*D"
MB>P(NK=2,;<63\H>#?XRG$; 1:&DS^-C+'G63O3V;""QHI] >BX8;I1K]R/
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M_"K70P^$7?2FC@)..I'RB$7$V.UN"NP/HD.2%\Z8\"*\%9$ZD:R*IU/X"YT
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MY7.O!P9M%,:.JB"T4TB8HZ,M[D&J7O2OBRHCCI;-")=5%"R)'HH@28E<7JF
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MAIK2QMJCTH$*[*U>O'F145]!8QG966-W1[.U,%7"QKHO/,Q._;QKP_!EG?&
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MHMA_L_-.FY#<D]9G\:QDHGU73U9"G)S+_6H0.9<R-X<;^-O?+QH^@Y\UO@B
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M046TGV8B",S9T8>84YJ_HA4BL4R)@.T0(:$$]MR=-_$%#CY1[APUWNG9]&,
M,,KIIG?YG%K),%!2-RP6!:.R<0>@%(=103FA^]J0_0$4X0PC.Q4 +R]6%4^+
M'HS<!&\?[[',GIEA:)>"\4JK[QBB'S3U>8H >X9]BY':VT2(_K;1(I@3IP_R
MB0HF&+:(SZ?:\1,A\3*ZRF8;G[=ZD( ZBM?.HQ-_YT#;9;:ST6]I C@MC)^5
MVZM<TFH"#&&.1NSIRB)"+T/ Z'QBNJ7V3&'?,*$\ @(#@LLP 65<+P]63103
M $4B,2RJL]%[:"6F*#J9V!:!(T*KR8;!,TM*0,35T'*%%;*[ZRZ#C//I<?3S
M'2A)XDNV12E9L6?Y*YIDE.B,M=F$HL:X1RVZ(?X>S^@!S$Q?YQ\\?D=<.U L
M+5I4=F(^\QB!?/G'23,@BXC;N3GK]X26C^K8E-@%X,.I0[UQEW81Y91BC 04
M@^"?'-^+UA_KE\Z2-E<A!,&/"N"Y"C1(JVR?M9B@]!'DND2,]JFA%/R&_>D8
M &O5Z+CKU_&C1K5GE!\6@PT+EHS"B@HDN)L"[#Z%CF7D^5>M%H9\!&T-YS"7
M_7(I$8#G K["L.>,5MH)D. ]M1\>.:]7"T[W]/.#7[^H^?4>;9S,!9V:? 5O
MJ __PV5/NPH27%2477S7V2 *)CML1F.V[KAAZ%_[&#QHT7" V9*<W;FPQW><
MB:'[CW_O#7V%N A*7+QE[A1EWC&V*<K3X[B=-185L9UT)\XMJZQM#&C ?=62
M]KK]ZS:GC4]3_^J;Q-B>3%20+ 7ZZI4[-SO%"H'#";+Q% FYKN>"W2KX /I8
M9JGXLT%._8:K3]38(X,.1$*:1?.Q,JM<EW-59D\CN2_;X 2,5!7$\ID^1\9P
MKRE]C],O?:X33<S*S+'U4J;(G,KB"FUPDNM!I$]>2+/-+\U9BD?H@1$'>_J*
MA*QT7JV3TQL;=MG.D6!-[#Y/%J=03SC@_@-@2>3S*"!,GW[Y&*-;+EU2G($Z
M[6MVM>W7N[DQECVS8#4FA)CP1^@:?K;D'1BF5[&\^&KZ$B])?]:V'4 )R^3,
M[%L9SZBI8F?+MJ+SY12<H\=#.4CLYR(\#Z#$Z<2?5EO*++JF*2FEFUR&.P=[
MNU?0\Y%+I:FE=J@X,)NZ; 99S0I#\!57]4^.@<5;*W#: VDH_9+\.'PBP+8?
M%C;+WWF@-*;U_!=/>:R?JUO<3.E/WGM -W^YR6?^,*ZSO\499;O1%4H6B2YM
M;3Q[MI[,32O.MIKAJF%'&V-=[=!_S"V?>LL4FKO,;.OR(BY(6J42]&Y%9G:J
M<Y(?X[0$W3Q#V6?/W0A;9UOS\72"L=Y^M2#1RDU3*J_7/A(@%:O(_":$<"X*
MH91FK*](*(UUG/FC@DLZU$2I8HQVA"UN>9R&DQ+>/V S4%6J?Q&TYL#VG9FA
M58,$%>BW8.L(/":30:A<'MR7C#?0+]?KA/22+-8L:56:EUTC'B,$'='V4M\#
M>*;ZAG-&?,FNC"[\X&^9CU 9S.)D3O$X8"&:+XU%NG1'?IU]X&%>U:0HC.D@
M6VZB$](S#@5AU&JB4YN$4@.6%*FG(E_ /[G#=D,V/ZG&/GT4:!K!U1@5C!M7
MG$KTO9%*H)@(VM>2I>8:)&26OZ1VD=[+S&HC\UDH"3C4B1%G'2TB><XZ0X\+
M:BA0M*:%/;T'S-1*>.TTYMIY76<C[!</51Q&#JKJ_(?6I!UQ?;6ZT1YWMX.%
MT5U[MK1'.AYR>='[R\DZ"PN"&&<%_O*4C%P-35_&\['8>/2'5]+Y=6(A/AG?
M>= 6I_#TG/#C #\OW5^F7]\4D9#+G4>_(3^BJ;GUZ[E)A FQ*B'7C:R&^-2I
MW@/1J-$]H01!,8A.)>L\WM]PX_7?=F#87A-_CT_@3UG%->HJ!KQJWI]6CYT6
M_+1D+XK)]%S_AE!GGTG>&^\\J^V^HQ1E(=TMO (9A^'$%+EUE164Q.%9=2@X
MJ3P]$]G&[7%XDSXF-KF/NMHZ"8Z/8D!HGO5].<3E'?CN>ZFZ+&*LI"NQON0Z
M52IG<$2X73]A[$U,&\HBGPD4PRY1I&<]<BZ:8&]+44U:@/Y7T3C[C(&,67TM
M>^)U:0WU829JB0<O:$!:56_:L,'6,KI*^^L]0-=.]4OFA$=/^=?M?)'_N&8I
M>B0!"TDUB&Q,]^C[N6+L4GT54WM$QCH#0L6>I2.;2%$<=,")B8[@X$(ME*F=
ML""R3]A$1XLZ>R4%\$]CUMOF/7J&R'_GOCT=6N68;<WJ[L2_&2Y8)E+4/=2:
M3$X2BERO3&K TY^>V'JW%5-#5@DR- HC^J2@2[ 4R=5*S3.X2<;U5B/9WM%4
MVX$XQ'VSL[&=])JHRIBT=&^<Y3)4$BU:?Q!22]FW)[ 3Q:PI(D D*MM#:DNR
M1B2:"R/L*K8N^?(8FQ!SUQ3&]--_H!13])4PT9'C4\I[X$WXZLE<\)76E]E^
MFG*N;YT^RXU%'2[>*;<])\9(@$H@3K>F,;$PEJYT1!%G+9/XJCJ*FC3!RI=]
M&_<$ I#HNFCF(*($IRH,<25..I<:NQ44):8[/WPJ9$"A\&OZ4S"3MQU=)R#R
MX]5 8MM3&=*H(W'(A2*@]G#6&M-\59U.8);X@JD<Z\/5J+ Y@+*>P5Q'2SA9
M>()XDOGHFW>_<+?<KH.3J)&-MG 9!1<R@T_(CCP;G*.Q<7<72Q>(J-X+=^)0
M8JXZRL]:#/>!>B33]$J)2--ELS8"V>!AF% ITD7,;0F:4-* @43\::EO:0)W
MXLQ7'9R8UQ?WP FED<8@1*!$1V2\,")<!CLB]M3FV/&=(D_H)WN[+C)?\V@3
MPQZW%U8#R 8P54.>PQ3[J^9/#E@<K;)7\5 R"X(HV,MLVQ<SH>07SO/9+.RX
MQECJ<CAPJ#*)L0H"IG^E<_CK&'EP2 (A 0PJ^F'0>QU&,K"&1SCYA03!"[=5
M(G9A(EQ3[(%O'42@Y]Q ECS=+HDEGL>,6CK!35#;TH"'F%A2KM66+KIN\:<<
MW3>,5&DS1N$_&RK2OWN$2D66S7GC@M#3=9!B9<[R8LFT/'OYVR!Q0H=Z5])O
MS<?=;#_!:R2QWPJ9F8+,PEOUK(DD'S7TL>N74G.#LDHGK:OYV",%U_*E([B>
M3%YIFL6&J*9#J&K<X9CZF\QH2M09/D$SWFB[MI0Y;%QEV.D7F6C-),G%IWVN
MW;-.TL6.7B,=-4_C(GF'):*T.&NWN2:UGAD?/,VUI^9CIA"@K[91?BI)M3/Q
MN&ZV/*V[/0L7%%.CWL7P0>'Z.&TFRG9$F+ZTIU"7P('8;<BU]I2JL39\UY]4
MKT^T0@ J1Z-CIP(IMC[.@W^*$AQ-FE"]32VLEOTZBEXBK>!1\%-'^5,NX"K*
M$$?SZ[:5FC)4C.@84<T)!&08,H^\-D(CQ;3#!,''&UO9J0'7G10@=BC;.!(V
MM9,Z,L3774"3]42X;)>IO#XG7*8;DE^LU_C6O+>_4\H[$VVZ,]D,,>S*8+.V
M^A5BXF+P?'FJ2?7*EA+G8UR^7T' KJO,@AM.-RZ((3FD)@YAJ4[LF5@:%%D;
M?'0\.GQ @]3U_(?5%I'X6$2K@MD13&"J@285<QG&J/A8ZB)*E:%+A4,ABLYC
M<4]U-'TLRS*/9?J][NR R20QV[M&YYY]=G:L-359,^I-:Q^"2]_>0B9+F/,#
M&;-\ZQSKV<O0+<M;Z,E?D!1^$12!4L2\-*>P1S?QI?MV^:33>R-*[&-AC0>^
MYN.P?9.CJ5"?X+U1%<CP%5TV9E6>[C8[3I(*,5G3CFECP-+3QNXC:[4R)B45
M'ZUO*I /-TIC+14.="_$FI,UM$BA772-@?[6_,0?STLFEF?W[_@2J198G.D@
M8^(EY$PJ.&WP#2CJVOO7K05@4B9;;T@2MYIQDFI5V"J.0A!=_2>+-<35M2@(
M'K[)PCB,1J6L^_/+V<+6^HTO!6SKX7IUYD'/V.C$6,PWK(J>5N@./&5>-<8E
MK:!7W95VUC"7E/HN$Y5S2CX.HZ)F(B9QZ\9S51XM<5M+-G8N=Y^BX@QZ5#1/
M,I0[05M?$?Y2$^< VE6$)=>?/K3K,#^_3:>#O?3!@QOT:.<8F],G<#@XT2FW
M8F#0"H @GD#R?1KKV;+94JX^:);[Q6+R15D!PY7OW/U4[>SS(Q[+S,^B!VHX
M?+6HJ//U?IDH11WUENQ$3VE0KEPZ;B=.I+;3*U_6UZW;S%L_:P,RL0/%X5;"
M%E#)GCW6FT<=-9S1NF:WF.',^*DE.AN8,5[YFA]R0^.!WG(\ CGB!FWC^_3G
M)=F>O>]I++NA;B WT=:<%_I6EY9M%,.Q$H#7[I5W9[OGORG37TZ([ERP"\%[
MM\"?B>55TX#,?OB-:;*8ILFU6\6/P]!W$6W*T<[!?M54L1DU?DK1L]Y5>OWU
M?/(ZC) _8159@Y\^9:/1*K9K:2>7?[6$T\?5(&1&RMAN,8X?K\UK/H#Y.4=P
M!J^D/E\--VB#HYF$=U BQGN#AZ6<^'UB"A1Y)1T9LJ1PJ6 2"$1E1K7(E9O+
MOXD07'9?H7!JO[%"J*^+,J%1?*M&J.W!?6F>N*Q3DN-AK5/#19;/P\V+_P2.
MBTRGMHLGSP;AOI7[[D>LFMAI:22 26RR.(B$URGHJD1H1Y8S3':QH]YFS3+4
M1R-_U-&0&C^H@B#7C4.-8Q_KVC2ZX9DK3:+(\@:S=MMF/.4;;RY*O5_UXD%\
M1!R$!LLUPI_'4;LI:"TGI>-NWRD/NHF3,!$,0UE<).^$<<4T56[1.+[#79-+
M3]@APBQ&KLJ7NFY7@'G#HD(;-]3'R&R[PVKQT6R^O&-IX7A-$@_GIQ<F&A[F
MD;<EQS,RJ'Q_YNDQ%1%"T9M=<TT;O00E"Z8MFY<(G)@H]D@G0'*3"=RI:TES
M/C1B&91DX9#:7B2!39)[YHON76K99\6X_6 ^]ZP63<[$8/K',6+9GV9;T7II
M:TDMP ?F?LYS?/ :J[.I9?FKW1EK<.L;R[LKGJ69LDTKD!(*/43T T,;XDAR
M1 2GCX^ZD]\]( BHQZ"_(<UOXF:D%VEB&LM9>BJSX6+*(&-TUJ#Q_#03S9:U
M?FL/^TWRY.WQY$M4**%#^IQU>$X$^DC'B_2Z*R(@1IC^<UI[&?>.9VV<>]2,
MY\<N5&P7Q1>X4;,:14(]NVS9=36O'G=.J4<,(ACI&>K,$1QDQ])VROCG%9$9
M!5YJ%&NI-XR5ZFZ?/:?),>/OA.0QQ9"SXX("E((('0@M:-6M17Q'6<XZ%B79
M_&9R7Y"CM5%#Q'0%C-DY9?=&!Q&6A5?6P2(^@YM%<1&$ ;H5MVGLZ,,);Y &
M2+\I+VGP1MP>=*M U!>;Y#2:_$0M+*N3E;2&ZVE^:7ZL$;-1V)M+"TW[M:F=
M)@@-*W9O0==QL6V)5JJ1.61.I$]]!JA ,KP^W^YRMZTZ875S3#>NI:6==\O"
MBWT]WS4R8Y;F*.)]_?@!HY=XO-'05_Z]P#1QF(Z!$KL5 NEL# 9W8'!$L%H=
MRZ-'8B!58YB+F!R@3-L]+0 7U@P)#0[P=A09=?9?!R72'%]J^D(BV'8CVZG2
MD^*[$F174=N1-,(@#T6?MT1IMV?G-[^HL<.,G-(K_]:$!-7_. #_6R%BV66D
MPXL^WSP]::<&LS=QF1@-+9U5V5(:K_J>H$M1X5+".3&$-._Z&H]->M0CTD/K
M(Y]W#HHF]IBCZM?U7$I!!,32G!2#;H#,=&0?C?>VWFR>88/-\TI#T^5\+_J?
M9A7UL!RVL;:SH8?@"_F)Q19^FS:8JRBNY)11]62'*D&:K*U2"B=1LKPFD\TC
M2JBEUUR[^D<$M@7P:!._U!MFNXQ0-Z]+M;4)J*>ZCHPX7;ZU 7JN2;NK\*4(
MA8-F7H3XZU]9!!(S"3P&>KG"Y[WMV=RD]03$?+"IJ6/8P?OPG7"W9JH')<^V
M4XL\V>[8*T-!EE8!)1FDC5+6/<_X=]W?:*0Q2C7J\%0RC!H0!X,C.Z+28<M-
M^4M8HBABI^?T1[K /IL2ZTRJV\9A*<E%RY?;S]O#0P0$@Y9DISLI7],UD[FB
M6O\7<V\5%-<3?HMN&&" X $RN#L$#PZ#6W!W=W<-#$G0X 0)02;!/1#<W2UX
ML. $".XV7'[G?^\YK_>^W8==M6M_W;N^5=7?ZK5Z2X=RFX)/T>32M>/& PR!
MS3"2+0*6? !\7D(L%0G#*(0I;,#(<?KH"10?678"8H."YZDO468L8@3I<7#<
M W7*_OX*_J+-6EO2E*0J-8DJ*_4/^:QWD\CR;-)@N#J@]$B;>&D<MT!O)5FP
MB["I<XA$_ )8"X^04Q4JT'&VH^S-M$^3O2^7%?LT-+0K?H%44M!'*KW[II ]
M7VY<+\UBSU#+Z<YEV<^IV$C9@XW:*$#:BLJP$ %)X\0*=5'T0D=9D\[-F,-%
MY;)'NB$9YQ*QS4*Q\K!<C@<N\S5:  31MU W*S=6UM9<'K3AM=A)-/\!02'P
M?*QN:MNR85SF7D.-2]<H3^XZ?\ZO'IBFIOR]-.$0QXJ.\5J9-ZL]<D P?RG]
M5\WEP?R3H4'^>7^[[M"%P\>*,IYO4:XR3$5MZB<A;0RI#[[I.(88JK]2KE5<
M_4>4Y^NT2']_=E(-E_;*#01F3Q MQ+6OK:'@E->_$,=6)I2]'BDQ6Z)LZ[N3
MWK>Q9V@YP=8X'X@8\S;0^9Z E2\8'@NDP&(SZY2+Y'1%@$"4>F&#)\2KN9GX
MM#QJP!EZWN\D8-S0V!*!;?%9SE70IPNR=BCT!-B#$IXE68L_^;G6@(WOW+%P
MYR%RCC$GR=U<VI?OG_X2>PD,OPV;=V,E9)F@Q]VX_,OFN]3+([]>(2^;A,+I
M"''C.AD0[!I:VSU8A0D!^[36()1$Q0G"SDX\":79:5$)C\#JP3XI!9X.P:&#
MI1.)5-<X\:6>&NZF&H-\['!?]TY*Z*-V0C=,L%]WGW!WJCY8L)!#3K%(%I/:
M'2N^6, JX4L8<KG#G36";BY?SD;65!^^ANMXR/' 7\A*]D8O]1?44QNFRIL$
MI0P-F7Q=;QMM8?_QVP]T&S'>G-4.PPXOCNK:5DV7MZ'V'*Z@U]!5M97^D..0
MR+"YNLM03",CH[;MJ#^8 SOFN9]CKR0J/.;]6+S5/_EO,'/Y^L&Q'W4..>O(
MU'B=H'0I?I_78@$E3S0T_\WBOXY4-?;X(]G++VLYLP>O$3H3^>=2?^AC2P-C
M9UREA83&@R;1/F,@W\2ON*A:G&^R>N7DD]LM%;Q3-&-U<)2KLM5I-Q,7#UV3
M:B^#8\[3\4KQPG"<NA"LQE\>[)A14A5F98-<OWDGK8BJP%95+R8J5?SE$[Y[
ME,M[KM";JK4!GE8,32"*,U8O/VKUQ T^JA4*1UK!K?,]C:Q)E,HS!<+![9L!
MQDS"AK>D3@(5U.-<S,@6A%4DM$SF;0HD1/@6B=Q+2<>Z')=D9?JKS(4V\A ;
MBGT@"VWP8'D2.1:^EI1TD>_J:1#_[B_K.,;!AS%JK810)< [Q*%7XQ5#/'+)
M?DBJ[<;JO:J7F\?+I63IU'X,L3A2F^R5G2(WBI@4+G.=9D ^< ^:WFM*FS.A
MU117!++D.>$144=#":P;E5P8-!;L >_R*_O[OEY;RS7\6>9P7.#(8ZC0%:-C
M[0HU1Y\(F0&(C=WS,2=5I%Y\M:[MD!K,P]P\YE!WYZY3[#S4L :E3,$$_K62
M4.9++SIRU[[K%S<73YV>X"B"/0C0+N+-IV2Q4>8_ ;!*)ND9F^E+!9O8[/(N
M@W>2&VU,^B<KA?E79\9Y8*U&K)-WQ<AS*5X<.ZEV09RX[!9QCK6=16,P<.!(
M<W/\^*PO-7YOBXZ\A7'<1%1ACB:(B+(?)FR&/X2]FL2'/FQ&KI=B),TQMF@(
M1Y9WC\$EH=^HKSK:3AKB$1"]+/<<_QG0->AV;(<&>Q-7T!'Y(._\&FB$"=?\
MQ"D-_30=+[]N0EQB4WB3HL\H3VQA+D^&F73.I9$R75+)SA[M0M;27%IOJ;Z"
M6UQ"H*(WDJ*NVX2_ZZ0\_BQ7<-+,D.11G-CVDVH:5M2%F*AQ0LK!FP:DE=%7
M1D1)HC51<DK5*Q-55&KC-5-G9X)7%;W#WVK0SKL&)29#=+XSI/]+PABM(1%I
M22QZL$?B>R0^LO]XKY!0O90<\J'-V?@F\%XF?#M\\S,7-FVM^2:8>FUN(/*U
MJ3+-3@ &N8R+K5#7A.@[5A7'<[4(DJPC!W7(IFVZKR1@?8<0+X0)*E= E8XL
M=.62W@SOWMRBY(YJAR[Z.3A<62>B)YCGT65MBGGD.+:DL@>!--6N*&)H>-/H
MLA?Z@+<^94] 1L 3$*#4,"R$ H2F2OH%>01*J["\:^KJI%!5.]")0!<4[!,,
MQ\1PR[B"X^2N;U50Q983J8(&D1X._N[?CJPO!STX6/Y92:2::X^#X^8@6!-N
M&E^]DYCM?;ZMNQX)U: D*R[<HL^W@RB=4K1%8C6&\Q%%CU"_&KCZ*\8,:"(3
MD_/DL.BT6^K['*B #G)F6CY;(?V,]X(BL2(MRO.UT2XU9.UF_K3PP2[HGF#(
M]R/SE%)078P(, U877]?DI@2-OF.&=E$&/&.%2$R$LP^B#,5Z*4Q)CK?\%)-
MM*7 *]FH3?JZL5]M+G73FLZ]BYH\4!W$HRA4&8-+M*_QETY!D5:_V=4'@:O4
M'4UGN_A/+O335'TYWPJQ"REB_T"3=H?_<52I<0A1B_0-[A1(E%UWO<B>SRL:
M9+6(1"%"N3S/5W^^,KQJS/XOQ!(L2(0N\1KH,YKV$8GCV9T(B]@H@.!WH:BC
MZDF260S7"X?S<\0-_>R(V$,++L)A;:)/=D=3]5_3&!QG!LGW$KMX^=Z%__B#
MM1L*^B8F:TE/,$0M(V<G"J Z&IHMZS<?BFQ*!+[95JB"3KGR_>:K.B0+XN<I
MZ0%X)"_@F CB:DK"R=V.F1\UQC7%":)A.>"Y%O1-E#13-<-S;-M=G5/=4IJZ
M\(<HA>XJV<,4TW3R7,MHZ4:7ZM(FJV4<%4"-5GRJ-\LJ9<_X50+D,?.7$,A#
MPI2ML/54+J<IX1 $JA2JE.Z;GUN,*VA-J^H8]B0).H>2AWEZ=&Y\YAX2B3^:
MN?PH8E[S/2E'36FO5H6SY]J0:'OV\4:Y=OA[2JRYQT#P))I8V_96_>&+9:%H
MPO87WIV'ZO0CM*K315_9BM&W:SKO<KOA(]QK05A^)2[EKL<%W(:=4PK"I5=P
M]$B?10'\V$S??G4Y-;H&:;TZ,8)[Q45.RV>W#AWD5_Q TR76? U'"V=7W V;
MP0PJ%[&Z%QX<U^-,RGE75G[B7;!VS^Y9[->DYS^B@ %M$GS1XY$#P3_4=B&Y
MP,4WA1Z22^8MU"A,R9YEE^..G"-#P9072!-]E*<TMDMA64F93F^./);0FI4I
MY,;_J+7#5B(,2"T%TI;74S &Y$2:C_9F XK+Z2=54^W3\6F:.E]R_TE\FY R
M0,XX<9X)'+>_4L'Y]GU%FNN<H9;.,?=HOMB07=GU.]%B9*(8VZ HJ'R/.(0>
MSY!5SE5:OO\)^(J*N2NA]]">^D^]GU:E;)I^$N7S_W[5O><&@>^!57TX].;V
M4248T<G"*B\=.S_53C=MTY(X'&6@RY$?PO3@M/O.<K:"WR@JJI]\$I5>1LR(
M_+)(B8B\](*J@EKJ(=;N0!+*V]1)[<X,:#N([R?W5*+25P_F@^,2*>7D#:O=
M0OG+;6A8"YKKA?JDSD0KFN79Y=]F N809TI6E0*/1-^<S38^3WDB3\7?%W\K
M2#G:C=*PY(TG4=0\#P$8:WG 4.?6S)V1/L.#IIDK5\D(+8Y:@8:8NP,.L*:.
MNB+'K'NE"]MA=!D$%W!\UNUJO?]%W4 "4<V?_:1"3Z81%,H<LT3%/#'Z1RFH
MUK @I<^YW4C*,WHE#49ZU4P3SJB\%W%4?1M ^SW@T.7[DNU8<NB<0BN"*(,H
M=9 .A?*29M L XMK#* 3$?WZ>X3\<<-!)WM0ED(50/Y:&XX2CZNT_T#R_5WS
M=N5V[*T'5?KR)-AG307=H5D].[5U3X@^/G6NGV2<>XPX,2 PV*D!)78VG$SG
MBXC/!HPMI3I"'D#XC-WDR;]*'$;Q0%SQ5@]?2!CNK_C)D R81A(97H$8<^F2
M$%4HZN#QT2JL*GP1 U5</M<T6?SU#) )9]Q%;UVK<J-5M^)UQVJEODB\']$%
M'*Q(V+@0LG%=./(JG=R51/7A!%>M O6J<$H1G**U:,A>:I.^%2:<:V:AIYI5
MJIS&Z./8_SD@7[Q[=#1X#PD?]R&P?+^ZUD.69UEF4 Y9[O?294'R\2$Q>R+C
MU!&=Y!^BY%,^G@P(WK"[?)N39KYE6[98<_L3<"("T2Q@&5F<^_/]7\=$"W8G
M"V3KNL2B-6>%A,:+<G/(%#%+8AR?%S_3B:NFM"L\E)=JV:BH?U;14F28HM5H
M5"'E]!'RYSUX76,,LZ!5DXX82]QBF33.;&<(#49&)IS2 )/#%NQ%WFI$"<46
MMY&EIG'.-92_C>>>M&*$0=#0@9WVL!L=)X:J]Y;G:*)#.9(7@E13K<H]=V^;
MQW^B9EG19+@*_F7;JQ"?$R%#Y_@&R!.@ NJH[[PWY1J?!<43\%>J57K@Y&%R
M)-:7__#N^B',E1LQ@?C(-OC@XK;K(-(Y) VEM >8_GNG1X/X9*FIDPA"OI&/
M/Z@',:;2@N*?)Q=]N\S?1Z>_PZQSN[)GH-U["_?6%D/4_CZB2Y/G-LIW[/GO
M.: ."8B?^;8Z48@(,NZAY_PO\TPD N?54&P'4U4=0$\<)\$NHY"7YA53B6Z<
M [=+4FQ,'7*^)TT#Z^>OGH(A_=.3DT@T7RQEDO(7Y'3TLW"[RS*79WU09@_I
M&OV_Q]O+I]<)D@7IREB0Z@0@G87=OK]31V:A7ILZI@]>/GQDTQ3T_KHN^EV1
MXZ,_:V2R+(]1T M[4G]&I_?^BSUD]B ABZ3ACW+O5KB8;?R7K+;PEZ;R!1I0
MWM<XOYAD[B2<MW;[ZJI_/1$([#U@Y"\Z&J:TS4&Z0;1V)9=5NA^4[):UT+,_
MD:Z'4/K[_/ZJGI6*Q54JQC8M0$E(CK0(X^&LC=YH"*"E?8OS:9RMQ\W4@+/H
M_),;CN38._RV7S78[N+<)\&O]-3>.:^^K13 _UT,&GVCL,\5^VY_Q%' $ZQ8
MP$-7K!DW""$W]WU@!349AUNBB]=.=Z2)ALW!.!:75XW@Q$?E8=%GOT&@1*1!
M,7G068G5S[DZIVC+^%=IBE]'T[?[%2;H$8P_T1YX8\/'>5C'ZO/\+#>4G:(U
M3M]+JZ-\OT*,RT;;+$QF =!-DB=@X^MY2:6/T:'C@7.L#0]^1N?!>[5SVX>#
M-P;;V0U*?A),'@=CIC\54E32%+Z,[;D3:=5,*S98,\[H_/[C[TIBKDB ?MB#
M:C(VSIOSA6+@1D^>%O^+0H AHX,E%+H+>?$WI+"U2'Z^Z-=KXX]8&+>3.85U
M1\%! =1+;LC4#WO\+A#&S&;A"3RSI=\.+^D;L?;JK/82>NH"7B:.*Z[9U1FV
MMN><6=%7*EIEM^]6$9GZN"P#:$)PZYH^^[3UC4:[Q$NI-M;*2;G ("UY[ ]C
MRH0AUCF&B4A',TAN;V/C-+L^58T)>SP!R$27LL$E!97\G\0EGP %M4=TO5EO
MI*&;[!A'#^$L?+R):<9&"5*'#I<IK$&) *1E\>R#]E.>775H( 3ZJ&+.)Q7D
M&QTAAYDU"8[.A?<A59,!,7[>5C,ZAV9J+B+:.2MA 'EE4$S1625PV^8/1R,<
M/B+9B"OZXWZHV>=Y,EQQEB@12=C=5_ Z@!%&9\Z;-$U44K#P>^S^4&EWJ,%T
M9&;.X&!/=76@:E1D$JWRI_C7G0'*1'+)6E=;"$,9)Q67'0F%PK$","$FAAOX
M1W:Z]I'J\!7>%\[=^Z24L^]WDVA\ KQ=M*T\/VS&T3<KV%_6U1YXD%GZN'0]
M[K=O'.FOV4VE>JJ!Q/XB7Y444^B>VF4<>L*YKTO/ES*XNF52R;Y):\#CH@FL
M/;HH:ZM9,93>+D'!.^23* $T3?F#0T<L_SZ49G='F.2[!QQ"B;V_DAQ?&OF[
MS*3LL-B"PH%=QK:-I;=!4729^RHE"8DX1:L_6L'K-X=\,@$;+^CS1E,GC'T-
M_[WX6:^TAA].^1XFU.8F:>4:7,A!_H7D@G_WE2FD?;IUJ%*)E5/M:XKIU!)#
M])K'F03)Q(IXW4Z.4$U0$-WK'9X>1K+&17M06(Y\4O4,#JJ*G>L(JUA_%QDE
M41.'>M+.6228_(-"E'YD8D+**HQ@?[WRM4$60+BN[8U<+EOV1][VRG(]O"PK
M [;)CQZ.M53T&=7J030SPH-TN N#&9=<'67.#]]H)3]YJ?Q7R;)ZEO5,P\]E
MTPF&0:QJN[ '5C%48L,@8RE;KVVX! OBDN/P;# "%3O<K34HS 2O@,IV5\!U
MU8Y#Z>RJ-)L_!*$03]:D(_KCN#KA[66Q36H#WJC:S)0T*_T>7:6&FO1J=H#P
MJJH-'KW,)<;DO-",5,!QC%2+N\+!-'^09@/Q@:,VEJAD=*&!*C3(+XY>'@6Y
MYRC7$:C\]F)MB^4@)CH"$CYAJ)D'%_L[U(_##&J_T3*_-J4]AVVP<XMG\!_S
M=SUP33X!-:+<%#/1T<<0H0GUMK)6."[:3<,+SEA#8_=?3.(='.ZF1JQE643@
MI,S+B9@Y*H>D(QT,_S=;"5*H ;3%0T)T(,$!0X#!.EE*"@7\_4Y+;235AOST
M6-K.8["KQ$9A_F/BSS7?3CCZ9^Y;O0[D2LE\QY?TA2)"^O(CB8)$\F#RK7=L
M%77-PKCAZ!'K.=?JNR/8B IANP,H^<R;5WJ:"HDRX[]H_##%_U(X<K^'IR3[
ME] D*WRJ4=H?Y=(GP+@D8B<U.1PE6)8%\3%CV%WT 0SI"Y.#KGD!%)]O%8K<
MZ.;*5Q<=)O>NO"1];9M2E54@$/P[S''CU\N-79>'*G][\9\9>^&7J(A719<?
M0TLQ%Z-[P-!%>82N'/.P=#R$RG#E9+S#Y[O8L&$_I1&,"$D4F8U)HZ6IHRF@
M$D*BN LB1#(J18AJ;<0.;_NQ)@H.'1RJ:)OL5][+EQRJY3"%=]?SQKX78T;2
M0"=3-+L*#PS]V"HFGEY %LVD*\!@+"?,W!?@S37D)2R-Z9JT ("]3,_A#F>+
M#KH'WLJ#48 9_ !*LN="4;B)I0Q)26-M4PDX_L0?%%WGX&R56*YQVM6ORO9[
M?$C"]R^$<F'/5&LS]X7QXG[AW3A3VJHSKPL)VR),L(^:A?Y\3PW "ZP,)/>0
MI)&;A@B*KGEI5+,&0'9@=%WTQ*:\XRQYF%[+]]I?V[W"LK+.C83E?MH5#9L>
M*+Y?J\'#6$L(!$8^RC6X?TW6Y=@,$1.9*ZSF([6M.8 O-_?4!N\'T%^-V1BW
M<C+>9"5*,NA[%DT&:<VMZB=C'-&X,4KY^JZ"#8&:PZ# ]N!SDB^1(DM%FWH<
MP6]<.0J3E6<B]#?.=1E,M@?>6GN+[LXG!-;XL#E]TO8J6#)"EP-5>CT!\_RI
M;RKHD_[!:M@\>^;!,7^UOY=XC?V^,!F7-]4L+YG64_9;&HPW]][UKRA::?-M
M8?+84S=9739%;[W"WF;L.PPO[B8V^=UY=U&(AW%HO*O_5Y_^:TP$J+HPZ^<V
ME#)GUG)?G^F+;%MCN!00XKQUS8^<Q]W_#[0\B98;L6W_(&U[*])P&M]45<!7
MEA=0-, "$?UPXV$F[*\T:N(?0=R%@;<:<%'U353B":".>@+^^T*6]/_8!C*%
M;U]X7J NRS?<$FU2$8L*7"DW7@99][X,KFJX,6P3T6R[)VYY:?V/"[:YY*5]
MMYKN5F6O];L1F[SD+%=Z81(\DD<1F*0BP46>T%^UWVQ\I_J-(W]?FLZ<0#BF
M(.5!&PC'A"FL7?#3X]=6U 4X4PI/&Q\OJO*@L8Y][%X\8T$7M;::IR-$0O&L
M?4VA%$&XVYBL:^='WU#!W873 Q(2DQ572$6&+7UU5<55 CQ;I2:/-*WM#OZR
M_,AHG_SN'"4YQ"JBI8,2KJ. M>RE,/PM!OD%I]8!E)C3;?5*-41_TN+E#R)D
MD=[UI'JN(VRAMTXO>'=#92E*2F@S8EWSX[]%:D")11=<(UR-K':1)?\<Z)@@
MO\$ 3WY03*G%<F>12AGG/LX$@KE:S_/Q'\9W ;TZ^T#['Y.':P#:BW-ROTIP
ME["4BN_\>?#>JQ7*R[\GPZ=E7*!G=[@ ^66I9TG,(#GAV-4V.YI,U""5A-O#
M;VI4E#:FG2/BI=VU66D/,AS06\IP#>-N< \Y=!+ZF3P%?4T8(<6=XY0B>%6D
MR(N>[M@@U@?8'!@ZDQ;4UM>8-^B(7V[I^4[]7E5V8TT<["4_[0M21O%HH<>?
MF0=MCHF%SP1^U$B.?=-T38@T8)X,D+6QSH[UC!/@A1')HQ?%E))$"CT4Z[+B
MK!8UEFI]UHK9ERGIU]1TTJFFSB@WTEY/K4'GX^CY%,9K\55(I&5&,L0<HS]P
M>A=:\P-,)ZJ=QE[$\Y,))#10@%W;&:[(D=*H1?A0!**>?D]L' \<0+%W(;N$
M6R9;Q?<#A0XM_D-]0G+(/\28 9JN13GT[WQVGUE+[*Q@J"(,7TF6]2\.3.;#
M1?DL7KSS_3"Z'Q,:N0H3$"7Y_@18==8T4CFEDUQ2SNY?A?75'$OP>\S1DC$C
MEKS>R]\5/ZIX9V+WINOB\E6D.1B=[/4!AC.IAGVS[7NLN(\7;/&G=I$4M24Y
M-$UODCM]*W\:NF2^'<LRKT)\9*[.YKPX;00E5?<!P0WTIB8]W]9*^N0&_,!9
M'GV^9G@//'>4M5/]^4LJYRQ]'MDG@>K(2'_H-3=S-51#]-@FR=\Y*MO'7N/W
M37OAO"M&JF;EA?W#H\R?J>%C$5)@>->X'=7O*/(1;WD((H39Z_5VH-(#^H)Z
M51GV[B:?+('"47\7__<(.OF@Y,H_EBNE3ZS+HP+2)$/@FX0"P,A$S,6%>.,R
MQHU$OR6W0A+YT^TBD0:)Q1G2@<I,5?Y,%>F&5NQ)J3#S16FUB-0!J[OV>W0X
M2C(+=?9&HHN-(/6I$DFJPE](B(]M4%XH34#U3D[<@<Z*M3I1%Y(J $=;BW?*
M.RG\Z&,T\<9:PC;VDNZ]$^;BHE'31GVXGT@]&MOOVA5A,5[%]W-\75 !*JUG
MRRM?N%A1^97T^R&]-XA<)ZXTZW*@PAXBM320IB,C>4XY&^U3+E,^Y$*LU](0
M"-0<[ 0O#/ ;'N&+I;"0]_-F^98XUZ&[3J0PZV])>#0C.VZOM!1F>W*?!P2,
M ?X2L=[?BO9SO/WQU08!;_Z)")<XT@O7QF/3]$UL_JH+DT%>=B9WRMD=$).@
M(!P<81V=2(YVD*GU(HI8#K(R27E)*;AY4B*C.4XXJ-#9?7^/";*DU_R'+\FN
M"A#5$;3%-:P$<(\D99?H**CP4/1@>VZ^#_VHK7L7-]O*VTW/*#0P7C'N5*V\
MOQ0<FOY -7B^C5OI]L!_TW'V,%R^M-!0,E3B\CZ@^!JI]7TGMR'L=$#-T>0)
M:-'>_9"Y*88=1W;+;M7H]N_2U_BAX$ L^YIB1<UX)FV'1M3HO)9K3*V<WF/?
M"_WKUK@L( V)&J"V<1.Y41#5UO>A:;F+\6E2Z15WUY[64-#Z<$F(Y/76?+$M
M!PTWE^K9F.YGWG[JOG.^*XIR_M8@I9"J?P]X.NTM MNM;R6F\\23<'<<*^/(
M/?<IC1[GS>8J;M(1$IM4%X.AO/I7?F@O/IJ'6 L1(F6?"G2-,.8^5EA&CL)"
M+N5]+JMHXJX:[QM%R>=GT!0J#].DS[M8#WW$A*IR19W6YT^.HVP;U/_8)1Z'
M5\^J %ZN<.XC%AZ//<G[!9('1T5B/ED96P>)J MD&)W&.&Z@%(F1 Z1@<6%P
M@"*@Z#,C-Z.GHD0XP$X6O&:4*-3W<H)AIE!>2+"3\GVB1'H</"C7,#:[""8O
M7@M8K]G!]\:,JGT4&3R1'I>0<K5TY'@ST]1XS<F@%#^8D1FQ/I9A%ZVF,$UF
MAIQ9+G8*?!M0<DPD=P6[!0)!1"A$@X,DE)>+_E1R*IX'8YD4W4R8<0NYH04>
M:C#5Z:2%^=8;(QE$WTGXIW[<10.9A.-VF#"^&Z%&N4<L[8G8X]Z_QOY9\)YZ
MNC\=CW)<VV,9CXOA^E>\^IDK.+;M!\^7\4Z<>E/K,^5?&$QZ7\\#/I0=X<HN
M9<I,0[21(;\WJB19DLT+*>+EZ7.XH50BCG,<!8X_%]^X1VZ+Y]5IV)(!6[B[
MIA6G(,F&S%4#RP1>F;#9 4TQMB'HRL(D\M& J]A^7SZVAZ Z/.PZP9SEAQ%)
MH?YY[,5.A<D$.==CSA_JE^<\UQ5[6G%M^0BBFUORV?UAQ'!Z[Q. NH+XV/RQ
MTB4R_6RIS'E03*UHJF;6J'B7CUA$8<2%27!,;%FA^B%,*=8]<$:[>%_IWU0<
M9"J!]0F(?#>8X2E9%+4@0[]TMDNEI [O_8?+*@_Y9G;M0LF#,6$X.N.US+=J
MV"#RRKZ/]CAZ3EV8DE=%QQ9+(^38&-.+&[-1%']X$NEUI[XY]@!U_.RW]3::
MRVS'U1FLPC7C37CYEA8+>NGHJ#^@5^9/)^O"([AD=_<VWVY&'5QFU$=._$L*
MAB*+"??M4]/7(XW@K&#/H]Z0/8<$[A:X3H)?;=AK[JHWAG>R#B)1Z51AS_XC
M>SMC4T>]KC;\3C:HL"UUGMYB!2J^C+D6[)17MUW<&HV11C,.UH'C"KETU:QX
MK2;%*PCN'JB^:(P0PSA4^O6/.@LFIYTT!\/7_\?2\F%\>GG*31 UXT20,?45
MNV"_&DE1'Z_46+BF1[R<+& \7=MR:"B+)YM[]34V)D*1H?[+^LN&D<\N<7T*
M_$:G^+*--F^M'$^XM;F[A.AR<FJ!-831>\#9U_7BZY>%)NH&CQC/(19I/!U6
MU<U.\'D1]-> 9X0L)\3<P&LF4!WTBCY-]=/XNLH0%IDO;F!PU8ZQ2"F0GTP4
MA-,=11NOG!IO=[;)A'J:70OPTL^_7;NU'TL47M-\_<)3\1^/\/,L$W+ID2Q^
M$#BOMT9!Y*.B4EGYTJ>M05",I!CDU)F#[Q& /;M_F"SY65-\_Y+IP#1G$"N7
M>1&VAG\HE^HJ)7HO_! =MM14M#Q"D1F1&F:[1Q7:#Z-+$L#?3O:8(<TKEK*=
MEMXJKVZ@H^I6,:[.?OTVII$G*>E&NQ#_2CD"!!YVE< $;J\-JU-4YUQI;NO3
M7Y?[L[-^'<DPI!40P3,8W K2<]I<LK7G<'W_!)2YQ'H=3#6:'%%%T#U7/YL@
M7H U2X_K1$@J641W-0IH<(S%F$:(PD-SU+4H[C4#]G98M2*$/% =U:L?)_!^
M+KQ9V8^ +%J_"[V3_H+R/;P&ICI.9A\G9_!S4OLZ'7\,Q4/RL\X$168S2S=W
M0FU)@^P?!-*0;GX1IY5R2%7# ^6? .SM7U_1/SBS=5>83//Y==2F[1ZZ2Y+3
M(].+-CR7",S=&-9T./>9)O$G2_>N>.KG79:13+F+O?XL;:MJ6[_W?/9T'-1,
M.RF0B:G2?T.8A%MWVA5.HK[5*WSZ,5)2#25$>)]+L/)93#,VX)/J+;Q-4#?I
M&:UTVYW=^#JR+PR)@[_MK))55+!X3-2P\+[Q2 Q^DS>>!#NMO1 =\/+M?.BE
M?63[?8%[BS* . \5[CS)_4@WS5?F?R0_^HJ1^^#81"5%SL*- 0K]!U#VP]BG
M2 VEH2_^VRR 9<.;22-N7@@O]OS(4057\VS^7[(@YI_]A9S(J03\T$%)B8-$
MA&TUB53U&NR=B#J:6IRH.+\5HY[+(GE9X+U>\H0;1_DAUJ_#)%Q6I]7>O5""
M+D^I94[\X="H0-+M8/EU?Q\9Y^*80_&#NWMU\&=NK("BN F>0Q"0T%UNZG!-
M^JY'T@M?CD*P]!]RV(=G,4(7VX+GSQ1OG[#MTOMR0EJQ0>(Q4#I^-U<),&M6
M1IIPM-_-LMN#6BH"+^6.,T!03#TF(= 2WY9O[#:475Z73^:[(C(!H8"N6,F_
MY8"WK:"S)"BV]KNO5]E-_4$@+:,EL95N2323C#4/#3GR!'8"/\HOE??=S4P+
MZ_?:)??75,QBX8"+ S'W7AK7(IPZWGBSI+)'JC;B2'X51.L#;O-ZSWMS74%&
M-N1,-1IWM64>#Y\$ZXE'V_&LT20\3AO/512U?V6B'XQ,E"=J*+J))XO 5Q4M
MP47J^#B7WRZ3$>^C"TY*Z@,\WN")K2S;GU9');6 ZORXE[H(4!1FF"$@PJ1\
MO'4-'<G=, /A^.8D-H9&]A6!)R <L/5/)O-__;F72/F],4[JJ,EBSSOGJW-F
M^V6K/4,WM@DV43A!4/50L8D>&)/+'C1T.8%K_/?\94^GVO#!Q+H!JTC:6!!'
MWV>!R5K-8FM1/'FE#1\UE G".(:4B+>/<YN$2(/-:R4#&HM96R(_ 87KDIV?
M.8M:Y'E8V-)ATR5P])DS)*8]-76PDH<FVA'O7U1QD0!Z"7K5K7M2()9Y%U(D
MBY5.@+ZI^<S+NBL)X<=N]+KN=%J'4RW99#UIBX$?"$VMVY9C@(&3XX_)"PRS
M.Z2JI1EK>N9P:I2$(B+>?HL$KT1P4^EOGN !^"$4U]+&@PYKL]"IZF3Q<*KZ
M"5#!O:@4]?0RB8R4V"(.> +2(N_449I/5KXOXUZ'7M#H"U/".2I;FW (5''%
M<"N\A>=)99Z $ZI'=#WB!7GL9VLHOW&(+('W-WDI47120&[U\CSGFY7X5_^K
MZ1)4-8^Y]H1?==Q\9C:I'?YY6TPWX1ZFO">CAGD*@RVOP72T,%%GK'5/@#$+
M7KY?['4.H!]KF2RJ6+E/+LMI?)YYNT[&TH6X!#A^8?NQ3*"V,6<_["&@1-#N
M&$4ET?#(53$/C6\]=DPQ0+ GZ[#H1*,P3'@F74#.;:4\B&8_1D0;1YJ\B@1N
M'6M5U 8H<VG+@!T\>0<<G64%_J6+< 502!8FI4Q0&0K;=6Q",>K4J,^$;5-_
M__XY)#Y3D;KV4#09\_>!<WW/1Z2@.87%B62(Z:889-=%RE(?5R?2.'Z]P4#7
M4.'WXXA.<'Q3_;=A>?+K-62D<..-YC(.1@9D/5/A<$*DW'*3%D-9Y&UMI);5
M:N#6RR1[]2OVLO5KHA9\XXJC7"_[$/NL2O<WYYE Z0"D:V_<R1';4+JHE6#[
MK%'W.*;,Y=NJL<)[_8?&I>2@C884J3J%*YL$"B\HN?4OBS]^8V0^D"K:4YS<
MQZ_E$^A4-"(I?YU6?"@$%X]&=J=76X_[#<G^&'%LD8^\PFH;A..*F\!WZ3?K
M'-R,F-,<T(,BJ6AW:5!M@T>ZUB,-N<\]59R4BGZV*)OFR!$5WVM__],RZW?&
M^87.2$U<^]QD",3T[;+T&IDQ*X"$N=/GGT/W@3<:FKHZ5E5U:>_U4LQ0R_Y8
MLJ(!;IH0@10$T,U[D1([4\6F4-*Z%18CCXF')]XZR3TUL#WPL@P-BW? 2FO_
MQ1>Z1"P,/-+REE8X<-PGKD@RR[,,[P/X99P_<INO%"MD-&J310L"?O 2S](O
M'/'R%8%%/;G(*3R.F<E;G-R]\OOVH+P;CW6:;P[O[_:YKT;"P3G%[:FKVIJ#
MB87ZL%;,-)B0&\%['\BCZ+>',4L^&]@B5T^!-R5]=/B,%D[X&T31@].KJ@+
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MFXG9_H#E&5#Y!%@[;JVAN;9?]OK'X/YTE/^7A]Y#C],/PW[SJF6&-O[U@)<
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M)Z/!@5)O_@E'7=R"8938\G)!9Q\XYGX?A0F&KE:B?(53MFOHS_4Y'A)W5:Z
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MA_0'5O#-)U*?F9<21U4W>E&OK+)^4O7#\C>S[B;!=46]GY.N/IV(C3HAB(K
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M*)_E".^E6^5\XPUAH3F. )*?]3>08RYY1L9(&0JFK,_7">:>O=/8:8).,U,
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MGG3T2YWO:8X#FP%.]4^5Y40AOH5P'P5H/4?-J:F-/W"/YGE&O+""7UC@$1L
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MMM]')^5.<ML:GY3*31K*+O%U!!T4DU@#65'7=9G*#9,A.%1K/>)Q"5(U0>Y
MB.5P(^*Y=3!0P@M ^0KUUC6*4X>P\M$8\[F?7JF4J92:E?A,38#>WS^W+Z,:
M0O&1&6TI<+K0I4*TVG$P>_L;>;N+NW]:2_7['V5"A%&\^@MH(M?Y@59 \T6(
M6Z3&UD8C(QL3AO9/&K,2Q:+N$6^R*;*1F^:W;Y&ZV\A8G97SIT+V0KH]EH]W
M;V2J+&'UV[X9Q#PL!U3RU9]]],@ZM+L4:I7DAD,76E]N&#C'83/)!('CND!H
MNN-6O_.'"7:0[2CK4A<6CW4QKJSGZRVMX)AWEPFC[4%H/.JS.TIT$^-X]B[U
MZ\IYFROKQKF-L"7I,K]JUQG,._32!!G4AO-+3^Q3_ K@PWW22]P+'AC"W6Y=
MKYZQ4C<@27:8;'*\%DP35V*@&FPT8<:X];UT$\#,2&-1-@L_+W4,17'MT?S\
M1_'^MZF5K"8NEVYS11WV+SL(J9+9L5M)4 C1$N1 +0)B9 D&;]'L8AH'6TEN
M8_XPDGS]0_K :4(%E!5TP8!X&Z:$3+:B@=(Z(O9/#/<IPYR %8(?)?O758+&
MT7U/<OM.(EZ!M_J5=O[V,LE9AJ;:LF$-V4FFV A?RQH'0@A'D ZZE>HVC:X"
M&D7(AQR@N.4NRHIQ\@$.#]5)W*8>T9KL'06F1L*_O%(TCO9;D]LW)R4BWO35
MKAK]^74UU]'E[$VN&N8$VY^@_Z0*(>-"5_3!UIKS[5H_+I<L0UTBO?ULR%?Y
MFJE%8'D$A+TF_;J\#^Y6[1];R#\HM-#[1]1,,L4NP4!%8'9^UA\/P^AM3>JK
MP$NWN*_* J&7,:9W!:CX!%<Q2D=EB2_=#?])N#B)5)P+K/Q=JO4LWU4S6A*V
M-F^E)8&J[:5N+H>YZY:7;5A9L]@AOQJU:CF-N06--P$2*+0468DP)6DQMMIT
M(8D&X0YW=(V7X09TD&UENTSJ'RK><C_';T/31] Y@Y6</3)#I_+BS.U)XDA"
MM=COCOR>RU<NK:"KC?2/<*27C]!-_G3\953B^K+S XEK.<9W"[IN& ]BG+_D
M*VZLLYU^&MN_A9(>C8LS ;/N/D-5/2R(K3EUDMN$"D:4X&(YUVL'INOE9YQ>
MYZ0VVQ>"A;4J$^BN<<DX#6$77;92]'=,1G2W[^M$HJ9[0)<8KI4I\9^6B(:4
MF<_Y45ZNS;S@L&4>,\\66:$JX:V%24&W\N*%UB)1KQ/J$,K=56=@U'7M.H"-
M;->-Z:G+'$)HZ0/ON&N+!)YU+M+Y>T0M+S5Q"ZF]Q"F"F\/8:[)P/:94I8GV
M(7"4;?8E5Y%C"(HT1^ ;36XN2;7>:\W&F%SV(QLT(CG/\E/2K4S>T>"DE;]?
MS=B^'-&BE&O62Y(T.C\WW;MQGOA<N(;SS+'OW@8-<9-:[>XP(HT>]'U3L179
M BV;C8'R((5NS/)N/X!3]>E7',I_'T((8GEC7=EU!5=(OP3EV6U]RXO2NIO_
MA//1H?\<M=";TX)W!5--Z@F:B.+Q9#&C?<X*%;I_6]#TZ)^0M.\>!Q-&;=RO
M^"L ];F[TW/@.8,9I5$Y,+YQ*70Z5/SESMQ8;G0#49OPBN(=KG^NU[^]#:$P
MY[ZZ3Z4\*)N\A^DJH)'+.7W]\BPGWSVW'G:W %W.B&6>:[^]X3NF];U%LO=_
M&A+[+;RHHSW\SXM'K.*?12KBWQ3*K*"L'\&QN,E]_?=Q#O\/L1^!:?2'=W7@
M-!2,RJ8_A@<_'@&&8N6;M:P>%8RB_]W^O]+X'GOZH ES^!Y=R_U\0<\CZ^5
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ME]O3Z<C#/$VYG\XL:9D-F3?5B:A@Z2< -FF^\$?R+;$'=5ULJ";3BH*I >(
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MX5,<BO3>UWIXVIRJU!?1 DXM.+APR $GV>I^+5,_[H@>>3?4)\8^@E,  0]
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M3NN)-9<NG3UEDXY/'VND'BVXO5K6ZUSEUYPF2J0 C0']%S@ZMJ*6(8@+J*V
MTQN?8U#)VQP)5)%]35R8[<1A@D.%M4  ((+(=]$7' <_&5*,EA)/P,V+7%/#
M%#1,U5_T)H#:7L=A8%S"8)P&01MGX]\*^*#UDT*9?S5'#P=2HOIK(\F8,J4\
M7YP-79;'>:XJ7FTEHT*<-0MO<,*K]H:YQT$)W;*U!E$.NIOT,?PG<7.(+ 7S
MF9\!"P.[8?_U&;O:Q2*7K=HC$PR))L&N3]"JBD5*X >V],#12R&[_UUZ&RLW
M#A].>DQD)M&]0PLW%6[^+H6)*5.A/"O_+B7">JQHV&#N+H6V*;.GZ7ZK&36
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MR+H[5^7RP_W/1$F)8LUM>%7:BBMG:A2ZK!OIZZK*@IMR#*%/6)6-Z+,K_GS
M5;(F4]4A,Z&,$5='H/.-"L2V%XEJPD$CAH1E7E4;&.7@NOK*OH"6%N!D >>:
MBG>ZW\7 K_JMS2T1R_@ZBQ'ITV3^FM23MZ=JM^-24L\U&A/JH=F.AN\<T#7!
M.2_+-SU0%\?P-H _Z;S$6S]=.X51$Y.N+__(5U;V]!T^TR6_PT+AT:>(7WBE
MTMQD1VBM_A46<)8+OR3!\8"J6>_^<(E&DC#C,)4G&%AQ.U3M978 ;06@L85%
MT2^(\UM\V2@:6-\@B5>H+(RR3&X\'&[)L93+J_3IM1[OZ:K^8%6O/5Z6'K5V
M3.<>72%?D"T2Y'9I''T6/3,N!;^=<@'#/I*S(K1=3*:*J6#L9BS/'0%%DK+%
M?F+YBI#!2QF3EY_?.B1I* W+6,A#FB" "JF]P?3Y38AGX\ZY(_1F3#8B_>J7
M^EO98<%@YS_O1B%594*C/-3($8Z/ZWK?UBTT)EPO#FCA#/E[ MG//@CO63>.
M5S[^LD[[H_0,T*]B07=OU#WSGH$>OOFG^@]GL%?8_]UK,KS'<-4_7R3Z5 [U
MD/\S&E],:L3"(*,:OS)MFL#^52F;] 8YWPXF$V!WV-WG&</"*_J$#4JE70%%
M+7X[L,J94-A3.[9U2S,P#!GV=SQ6CZ1,*F'T<&I-712&87PX10K9'C5CHSFV
M1;G5O__35<Y61RE@U)Q]ZXY5Q0XS-?R,YV#]Y10W:&DF.97776PR"XGJA6"'
M$SLG*09-YT@B+O:HH_&3:LE^X0(A+05@.B'O+L4BC>_*,U0*!'4K2O? P00E
MARS@M*/4EJ;8/XO$WB9]IK*D0N89E FVC(MQLSV^R(]UW)1[#8A+WZW/C(\S
M]WWO9VW%AX4LAYE,PVY(VQ)Q8THV1E;\T;V]DX"Y$XRO)I5GOV*OPWQZ"?&[
M^% O+(J92DW.T]_0QW!=T=07-^8%B55PU103;':]\G<KL"282')!1))G=8Z2
M44!,RUL=I?QU\#LRPG@'8WRLWKR.=A,UWL!MK:%'0!AAE&6!_!L$U+;^#)0H
MA\-U])G8Q'@Y0U^/V%#6U)[_+-+AN?W&.R=(3RRC6/M[PEB$'3OHNA6CP9NT
M1*)PV=_4/VLV'[U]RWB((<5HK+?^;*";JAIP]4J(1,RSJX0J#S"TNSGN6'?Z
M:*_LA[.M:?_PF.\;TB.?%.RN]II*=G0VRK+ 0'*EN57K*# OFC^,8>K.0#IF
M GQ:HAP<1UPZR:DB4AX99GS$3JJ9-SRKIE2=AT#=6PS#U1A(UE[:;(/&Y/K'
M]#&TX'2$KU0K)#=Y*!L12.%4KNA^-D1FN=X,7U;:R;H+"<2J4TY^]][0P9"%
M!8A(C63A'V:'&+3ZV_FZ<LADK/&U!:^F73-]Z.)PDK7K-&++8KXR6H"_GUR'
M'#>)^?V>[_*I\#/O!M3_W#BW7^F1EF-"L?NRT"^ITXW-<V:_':QI:ZN0LF-]
MG@POM&;3 UN;H&I?F!]= (?NJMQCA-K&]W$0=G^/<5L.ND]")L5DWYPT[]:G
M8&.4U2$GG+VWE(3U1Q+2R8H3RPK)5C&_@\[R+CF 1/5H*I&Q#BP,_@U!$\BJ
M+E?D,T"6['\M?\[9(46K$[9Q43K]T7:.L[R++>\V">#\YYKT/]3:"6_89MJ\
ML,-\W"P,\Y4Q/L\V1=V6>'AH151[/@<0I2L8UMFZ3(@FA;_SMT) ?K5(UVI\
ML-8&:\#)..X9,)G*"O!&_<R;-MM/C<J]I#PR@A2VK+&P>\UD[Q1LHF_WYT7)
MI.2; ^9E.5Y'E9F:UC4M/'/K1[_O^_5L"V_\[B42V3)BR#RBQ85AJ!"K>+D9
MS6C'L(C<9'@_D\9L&J.P<J'X-S'LM4'[<FCJ"\:Q^]!WI9>\=G'B<)UOPNC)
MNDDN92.PT1QXL]^[.XZ$JHNVP3N!6F'P:-[FQ+L:7* >LC,Z[!1,6?PNE"YD
M&)S$\. PYZB'_$?K^W)/A_2=4:*P9P"_< [IJ]GDUAM)-+>"ZV12[QGUG-FY
M=GL"T3<'@8B %C 3,J5L3Z"=Q5'*A_[W%U/J8M(SD/VQCS# :[+YK5HHX2U"
M.WQX'/W;>9RI(*+1$*72O#P'"W  &K!]EJ%Q&V2U61GPPEKOTH(]F=:E+$+S
M%Z%6HZ,<9K^9&#<XPECXUP)8;<CK0BVS4M&<V#;=T<QW=8:_NV04[%YS-7EF
M;44*_E3W7F.8MS@4^-U6*HP "!24:KF_Q?FECN9W<@W#P*0?Y<\J4%?^C&$5
MC4] C2#N>);N=?B@NAKM1O#4Z\BR]1%\K(Z,^95^VY)8^! *ZM8?BE?I#19C
M7%J8^,'^RI*<4(05_@1#VD99@.VK'O(N%/QWAV6OSSN$F%[PIUU6CI99?<),
MX^:Z\G5R>2YCAFT2A$[F;7]:UBX4*YMY1U?8@&\M&LZP]O.+5L5L,J=W>^(H
M))&8*QS8SD4 * YI9Y$$RY<:EE_=6)92R>QG4W#RALL[[RM[N/^%N.T]"DY]
M."V= >%A=<$,#$ CJ$#4[_"/CNN"/'GB7T!IJ8^[%#_LJ<*24DY?@%'&\?L+
MWOCX\QTS?*L(WJP/5W@C"N>QJ]L,.#_1/ .)^C>D%Z7>5)@22-6N#<.S&YAM
MD/XMNWF::\E.9]QW8UK]%6(D'>@88P'<5<VBA^7()@;,QO?9SP!FJ7+W$C+!
M8N->@X\W)W+WL1'IV8A_^">?GA0I0AS7#:RY!EUV#>U+Y(WW<R?"*X* SR2C
M/+Z)*7V?0^OEX,>W+2]:J,FC>_6P]AO6,:.J[27 UO_ YNO[N-_%*4A_+M'@
M;5U'0/>B*W']<P#S!D\[YY1(+0N!T[")4O>:+5[!\Z7X]S-YR/67E$F ,*&G
MC?0)7U+8Z0@F1HE (P)9;(C ^:<VRCQLH'Z(-4I,9P+B=:HC[O1>N!%\\Q4Q
M(^I[+RM,#1P=\><28 9T5LPY0&0]WP-XAG625#2I3<*Q4F<.58EBK"6D1EU?
M>WD<%F>8VP5_6_&UGA'XL*++_Y<E7$(Q2F?9>)/G5N&.]O(:AN3Q]J_,JB_6
MT7%HSF%?$#GD;-#[PU2#A>8&+KNG*65401A+FW&$''U)YWH_13_]$>7/M2><
M:WME)6&BVG,)]L2%KS'H  SMT3=;.]_0X*,(BXH;3;-I#,S)NKZA_/,5!KT)
M&FO;D5#\USP/U\P_;@U1,F]\.\'X=R/P<Q^27+*VCF:H;OU2]W;(F7^9$*HN
M.T%4[?A4"TH2+)HJ U(#UG[;F=95_NPP,@:M&Q*1YF7 T/G7]+_\6N&+SS8-
M-4EQ(XG?Z--4B?%G'?OSJZHQPJ.S>H@J BJ20.P_*W2Y)<1[8\V(09V3V67R
MY6$,RE=6]R)RMYPDM3C4-@(LCYW0L#H);C]BI!3<;V4Z]'1JX!AXPAN$6@*E
M\MM)0+4I6ZO9(D'O'[9&[13O25.E VPZXQE0DL;+7-<(5)I?D#5UW/H[8X.)
MS@Y%HS_%JG=,&Z![<F%.UL(LF8T;:V[781!8Z:7=Z<K<8QV?&0%[]()"+ W#
MLZ,HZ,R-7Q!"C>.1ZUBY0=N:P3U)C0>$Z,]WI8_D(U SXJ:WIVW'^;9/G%<%
MABP 6@&9$UAI)9F9X4OV="&X\3UE)B1D3I$)=..U/F$I[?%E>]GX1%W+":D0
M(SB5GLFSRS <14<.6("F6->.X+R.];?U G6(2X6F,1Y=]+=U-P%G]S/QAHE3
MV71J4U7C'<>V8N\B]:J4CO7HD;M(K>;2])MD:<'$6]10_/7Z,&W=-"04\KVO
M#[1P<;@?C)UB"R!TNX>ZJ@?OM*["1C\)]%L'MW6K"E4/Z6H,VG3JHHCV&/90
M9(^5S<O&=9(M6I-O>'F/($5Z%+5S^Q%,:BTY#(*)VIEY3)\!@G:\U_=-&^IC
M7EW1>?M>CA7-8M[N^*&*DQCE91BG$E\^/+"Z?2S:TF)]7-@?N2<5A1(MA-=_
MAWA<9KB5+2E)5#,C>JSXN8RQ+9< @J4H\DSB$T=(_B7R3LX(M;)M7%$8<E;(
MX\Y(9,AMQY*=OWZNU@O2@EZMH(%:<R-\Z6THF/^R=#CY,LA(G'25E=8L\HUN
M?EKI:T>%O(7BTX<=E1<F1$=@HV??JS=[D+9+K:8"51M,!RM2#@/^DQ$95HE!
M?B1S-WZ*_@52Q)UW:&'^15\?9%V3U^KJA*D%2F95(!W^3<LC"@C][A':SGP?
M'=QQX%VO2^GRK'\1F/,R.SGK/@TY$49*KPM(F#7X_AVT[^N3,GG:O8(A[L8T
M><7!,<NPP'N%[I8*5#7:?WCT3XPGJ19MGW/RC;?;> ;T;N>?6E^B-YDVQ&['
MTB&9DIW:!L/@O8G/?,R3]\Z?=@;>*R$YL+3?34>7CG<=PIQ[RW(V:[XJEB?1
MU2VW!_6(7]X1G)#BW+CYH^^_$68T[W72HCX0 \Q15!FUJ(!?A%LVSH$S2E(V
M3(?K;#4$PLW ]F;A\E_6,/2G"_2 <KQ#Z-MD=U\A&9BZ59U2_?:^JH/\6(YZ
M'\_B>!2"5DV%%%/3+C/EIW(0>R\,50:MF*5P<!E0PIF9L?G,%Z3$XI'=NA#&
M?YV=8!Y]+3F?WDB2&P#>]&Q429#741UDD$M4:I:D0(H])W+!T1H;T][/_@S/
M1$D$('C[!SU@D"2:5>KDO_G=V[,50#MK.;H[YR7^HQK;RY5C9]R3V7LJI)+1
M2<\W#>/2PK%33;&:%@0%#-2=_Z]H*!69FW<S36; W//U#793"RLQ!=,?*A-$
M"2+2PEG]=\O)!F?E,_#6\_1I^.DS?9QR+WRF9#*\]^7=U%1>SM+"'EL_MD'7
MO(,[* U!^>GO!&0[]!E8-GZP  4S';>Q?OF\WF3R4')Q4:@L<LH:H=%'*JI%
M.J,5^ PDB#[=XY@Q$*OB]B? IWTXZEEYDJ@&G,/M).B=6K0,HJ-6GP$VAK)(
MD=J?9I)4@2T-5&@,;,] .[?8,S#ZN>=/=H#$-I1(KVS5^K4V&^V9^=.="T11
MYZ6+OKCR$\7I"T%4]O4:_A!-9H&Q*/U;NV\F@MKO8M$X&R)O"$:0/DO!CQ)7
M?-R1,*+[$B.A@WK]O8G&G:<C(;IV,J$H+Q"/2S:,\@F>%MP1@T]UJ\1E?,"N
MS>?^Q35<*MZH.@J\$'J53(HB:O.*,^G= 0BGD.Q/()>VEAAI'44 CS_Z VO5
M./X'3D^?7O5HS!T&6/.40).6!FT(YSH]_<05P<1\(+#A[^/ZL)?IX?8, %70
M6N7SR%,8VK5R2H^4\T3:Q204T@!!G>+#>7+>I(,<1Y[F/@.&5I#S#O]_<04S
M3=0N\@@6J4O]B3'E8N-=#NM86J\&BTRP#C \ [ZAOJ7A!<*^V%WOR75(=!SX
M1Q $=<HG\QCE$('AL4+BG\/Z)?96#9R+@_?]\ 99!AN_B2;%1SCA(!-ECU>T
M<,7<(62@=K(#>O7)][B_=:#):-95GU\85EYN8'[$[_Q_6^S<K] SG@$!]:=[
M;% 1QK=B;3@C([=UGIZ'?2F:$%,2G=.Z[GS.OM[50[&^IT,HZ6'D:1[-UTN<
MEX0;D%YWWXP@25Y%\]MQ31U?"B<95'Z7\VNS$0J%_"U'#"_(;T5#TGL/OAM[
M!HSWS"O]V%["@AYD$NB00:'C5KR?*MXU&0FQ2,]%(E,%9UM],0BA7!)^XB2]
M>O?OAA+_W9#:V=/:X]<7:OK!A(BV<!9OG6>'IX0RPPJ/)]!7Z"8_7612'@7N
MI?AT$0!S_F*#V-Y"/VNTAX6D*?O7>\=3.)3C Z3KGUY*R%SM&4A[]0SXOPM@
M^\$Z?%DF/ +90+)^VGTRJY>_$>?4OUW+>D)L6=>-B+=_GYL(_R:,CQEYR'L$
MWFOYX?,+#PMX!G9$ZB?3&+*Q=%_&S$'[+<%.=;79& URV(';JHI)^D^W4D5;
MNT@9S6< +_)& 5S*9%9+Z="7IMK6E]Y54+=-YL07-E72,G_X1_6SFN@D 9OP
M([W;V--<KHQ%]F?AZ\QH2=) &+I-B":*<MC]B!;O2"<; [A-#1^QZOVXW7HL
MJ=G/E2L12T*Y.L-G@*32?[D22F26MY*LG<"F61NS?>-X-LWNO,JD-)ML(R*\
ME]NL?\]WZG?8='-!:W&/<^PM]0P<SW* UIPL$T=2.!O-=Z&_FYP[J[(O[N,/
M7^?IILG&%0NN\3ZI'!_L!T[U*?AF0E:A)!"DKYS:0<%5+M=^#+!Q =2V!)E;
M;H-GH$@N/=6+=(89VEJ=_G1C)6KN$D!:L4!J2*B @&=K5!5L_!$U*R S5_ZG
M2RMQH<?!!WW&J?.@-(B;E6'>HCGUG/W]R@B"*)[I!IKJ#_[[5#;945Y6]\CR
MO,>( Y?JY*?']).<>^)9TM-#9LC^+]CKFTM*=^2Z:C<RA].T @6KAI2$D<<T
M;HB%:__O)]"NYIP*MYM6L?R59U/>K?X&3]ME=G-U4\R5^9F937D;LF,H,(0J
MM:!3Z;XR1N2/V66U/,M<\PQT%S\#UP?__ 0J&DQY:_YS41BJ 65X'EG25O4R
M4KO/IQ$0=G<=$<%^Q"_'1HHEQ\@[,TNQG!D;0LW39T!G$/ 8W/Y:S4 M9((0
M.XDH9OYS5A\MK.X2YYA&+D%X,'LYS/R!'O>D@YO>?2:]BQXX&>OX7,^S'^JA
M'OU'Q<SX4*_'!]<VC1'C\9Z340A'VSF^@O)I-A9*HIWGH:TP(6DF3PTYYG2[
M@X0P5OVF>@:TN:][2A/OA32^OJLL)P;"UF Q4S<IK_@#+\+^>?P)4P40%Z7<
M*V>&A6PX3^5%RC;JL-:D"Z5I%B1T[6#<7*6G7[T&/O*LXQ6]NQI;E"J'K'R\
MP+%[36%(^LLAHNAQ4J<\.V6QPI-E3@:;\K=HPMT(>.!TOLIM:@ /EW"#M/,9
MF"JMJ/MI:_?E]*TM+>CK0Z50B_1A/CC]E+>U^@5 GH&#ZEB$JXXS.TQ9I&NI
M3=_N''OK&F[N=/-[ <,KN\4$,'X7WR,#Y3WJPV4 Q@T>#-C][L0],U"!<<3;
MCEHD],OS[1$+'\NVT\O#T-<U4&?F4;!@Y#MJJ165:#]4B%?DW<NQWXX@\+_V
MZ<ID.)/C>1,XOJ]^*8C[Z90X,=$=S9F<E/%'6&1&EO*8NF+M$CG6 GI*A&\1
M_;CDE$VR:ST]?X&#, P=0^]&RMNV09?>44#WHWT[ZJJ]CV#A#*],,GY4Q#T*
MSD5U2F(QU^(\/?=U=!O228%)=:C/]XSP[@)LT%G1W_UV\94[+)$VALV/<DL!
M=&5Y5"=+L0Q'UK2]=\J05<)Q8][02>Q[6AA&2HD+DY8G;D_YKTCCJD!=KNB3
MJ[TU1>HLLN_.L01.RX]65U)5%0'?;/&';1H"'_:Y?!DTHPS)PG%'>& H'-9,
M[.UN4D1&/-]WD*CNDYH]$!84I2C".[8$G@'DE^E,<..LXLG."+V__5Q]4'S)
M_W%FA+%0:,<3- ]]?991$314S[B1'B,4'*X6J]5@2L%6_L$@*T?*/7O//=:S
M@O8"E0B :)6ZO!8EW>M^F0R@4>OI\L\Y"9\NJ!1\Q#QZSS[B="\9?[+'L(+W
M+\)_4:2J\\2(ABV'](CB2&0CB*)[T^,R=0/M+4API=K[;*64C88<$M/'&#F<
M3;S>38?"@2/'1&/^?_E]TR_I_5>, CC@P0SO*[]G&*>V;&>4X#;(<Y+?2TL(
M\:A!/'P92.:E)VTA$[3R6:$ALG!/FCZ]%&C;J?-=_JD O_8)=>0:V9C.G&_:
MSC/0;R&'\L _#2[T(9U8H=J]5M2![92=U=ZH9X@:ELXWO$SRMID>Y$=K)7Q7
M5[R$.9IK= 3 @W.X_1G F@^K2:?T;QQ4UT?<'W!PF3WSGRW+>J,=(^0M@E$9
MI$QGQ!M6<-T)^-Q:GFQWN&/4'HB!GFAX<"9W(4B?V0:+]9G;>B.P(B>F2S =
MK,+;=2,OWR7/5PH$@5^ (DDO.F='+9ECW^)P';P5_Y5F3UXKRW^--N,U<6BB
M\Y01))YI*K58K\9<H;WB*X#QM[#VZR6:X<NT/%% %&7]%1;#SE[>:[:O;FN;
M4]^=D$Y_IEFG>#/5E;RZI8;A$6!P$A"47B)3J+&\*+79COK#=0<,2@*&:KVM
MM?,3!.19'5ZM;^IY>TT;ZJ3^"?8E[I ;I7UAJ$."UL4P=(B>Z]-,O-3VJ^Y5
MS>S ??4'86-/KDK&J#E9"LPZ4R4)Z<P$@J2+\CK*)78H;O&EY:$*.8D-9,%O
M67I"DF/0\-5'@8+&P+:'QBEZC66LET'C''EO9OEW7$$*%#&V*GF$&0JD?J :
M+=4;VD5+V-@F"9I0Z^J7%6F+^M)4Z?@YC#VTJ^ZK<@,R=75\'SI>]R#;W+1B
M9>) ;6TJAN/OE1$D]M('NM"5YJ$@IZ*)QS2]I=9I<+Z'C.ZXSH]4/@/07E&=
M7_S%^]2.1/A7/^@R$N]7T5_K,G 39:'?OG3AZN]&XVK;G!<QB,^99;J::G>E
MRG6GVO]VV5+Q;GK,&G6;FK9[1+D756CW 0'PE \1PN%P^E'B&PAE8QJ-U+\*
M=Q^%[A+,69XPY60ZGH57"R[E"'B^N_/M*)F)(U,CGDA:/#^T]EP7?J#] H82
MN+?386.^K8V1N(XLR/WX/0]6]R<J$>**I"P7NG=H2'C1B]9J[" :VEM?.6&7
MR]8//] ]B8$-,MK6JX]O<?M(MX,HJRK/K]PT3[Z8%I+UU/]G^%W,HUM2=<[,
MLK85%F]MO HW54$7+5S3-/MN915]I^2NUIQ?1:+4E74%3G*P7Q=LNNK^UW&"
M1LELFW!,00K!(('M#>GI[H?'$PNPC^15(J$ID<OP=7>S:.E.C=91\A7_Y.+;
M9Z PF91#5BQV\0!S:?;3#H\ZLA.]:WT];AA!E[/5'@@!79AX!_RW26:E6;W=
MF37A7=(TY/U?M%+!1X94HL AZSV-0X7.WW06R<=4L/1MG:.BD^7VAJS$>[J:
MN/,&<.1X#N!S1\2L7KXOBU0CB7. "T$\7#RW+^2+E/A&NJE0UI:5GJY"JAH1
M() KM;B0X-0:$9^1=>.O.%VJ1DA+W"90PT.JK-=H>)+W\3?]M9#O.KI;&NBA
MJ+RJ0L;:$:>Y0NLOTJ)P+PS=_:\0RN^3-0;)=]Y3^.9=(H\,,KI3"0A<"=ML
MM6@2)Z&<KWY<J7WN&S(1;8LU["U6';,7#9L;C/%\_QI0^XST,ES-G:>)IHKY
MW&,RO=<HOCF]A; 33&ND?RI7J:FQI#&,$8D=;C8:MBW0@?QB:CKZ3]9>;Z[K
M2J4V4A+11P2HZ_^_M)3PP0<5\P/GV(.0QE<(IN.'\1-%R'$X@L*=@,9_[6CA
M0M<N%[7NYK7J0@CS),?ML/T;,"Z+5TOW4K;.Y <4D#)']5P?ZPM)$BO\7(B]
ME0^]+D [5>JIN=6%C09ZDG[QEIS$"L[O'X+F O@+&;[Q->]%WMS'_)P[7'N!
MOO$1)%<QA_3YV@Y'Q_=JB9W*4'_O?/AGP#, AO$QLZE!GE3\2U A*^5]5FCA
M"]YE(:6*"T-):L4\!?PQUQ,)7:5 UVLUM@]R%?,"_<6(8ALIH<#Q3AE-XEK*
MNP&1!1DN=+^=W-HNC\3<E,%+&P6D$D4]5=O3A,7-><XOH1BR36/RIURSV]WS
M.6'@OB^[4)(2,4_.XXY&C14VX?R!XQ3DUGV-X5.K!^Z>BO7%?/!"?AF*_P^"
MW+&W?I(K"87F:WG?Y*5.H:3"BGI@W$Y95_EC*D;!<,NY!\4$G5<_?OR4SV]'
M!:X:& :*FS3?/[VNJ6R9)R/MJQ(O*C2FN!S.M0 W9=;I'X9+^5UV?-V%3AU+
MD2U*0["@Q),X[34Y?NT,OBP0G4GS24[7#3WI5B\L*$F0F&>_M5?F-G>E7YR_
MG=7/M2OYH0!!@M"5JD-SQ43EZ@B9>GP"534EK[!I;R@"3M!:T?>2 S(+LQAJ
MMI4XH^P37X;8I_$)WF= KJ'[T<W^%(8AG=DT?:^L\,_A[3]V:Q)7I1GCA],O
M'RDM>>( [:JHO\@2RSV:R%I=_^6I9X @B;]$\?;>=H3DG/M%%64JZE#H+G9?
M'Y?BW0\LKTO/E?2])/6@Y?KB&0@'W%74@;GF61[MHJ!GP/:U,'.]YSN9I0;0
MXV[DRW>S%/7DN</7:R%-D]E"_90$+W3U38F"H[O+\@D7#,,PL\G1CT:[TF!!
ME_;2'+*N5?/G@_:E?J65W8 7F(YT*D"0+W3-L.&/F\-U[*8#2P7I:1&!;$<M
MMQ+C=6P,[$"9G=882NR*DTJ4&%K'LCZ^O?@PR)GW9PE4^]Y[)1I*X*).7*B[
M,+>,E]7XTU04YUQJQI=O\N,DL]1M&3/2P^O\?ZEQS%^\Q%6.?M%=KVDG[+X_
M Y$%+PIC%8:^%+HZ^#CM7?]RM/L2$F%O%R^]A6?@/_$!CBQ*B187C9\@=OXH
MV@]6=#0M MWY.O^[>FQ1QN-]J,1^KO<2SZV7,Q:3KH#_^M7VTU/M2TRR1_4\
M.'_4D').]@QGAS]Q!"DT&<=/E/J%_//5 RZD&8;_+/M'V&\_ RUY#Q;<T\OG
MSX#C?UP8+< C%J5PK^[;G#&M[S^_"@MB('D&M(YW@,PZ>\SE)=%2'0F<A5/8
M?+ F,GB3N%(S2V6"_1D@G>9YR?3@OTR[J">EJCWXSL^7=9F]7 PQ+S\VT-<Y
M=G[P?\KDBC]5JM[[/I[DK,8_5?XQRYD4\6JUY;"(=!]*O(C3_W%<V,R^6E!.
M1L: /?'G9XEMG:V\4W/Q\9^=>9W.?NV1K-GD\FL6X'':,KB)/XS6UZ5B=3(:
M]\B]P]L:%1[7'6<NDT<J_I64_N& [P<QGQ=N@Q+Y/27&]5#BI,[PT8*$]90/
M[1FPVX,G^57W[X;R\LM2;/PH;T+G+>J:DS:1=/K:6@2F=?-\I,M3,W%Q$W\3
MU_FSSH0](08(?@X]1_8CLQQ=S@Y2LZ1 BK<D1#HOC<!X:S&MSZ&U@G\P#"4V
MQ1GZT>@IR;H?'3W_YAFXW$O+*2)=;+?W.N.+;9"<";Q8+P%<)]3A[%VI$ 8G
M-J&+3]4-?J[P:51G+=-[ME@7[%B/%N!1BS)N>6SQ=8:B&,A^?5[D&P8BZL*.
M.\_MAW]KI?#6N%3FA\K1>^\AZ]*<WX=);=*?GEA@Z%>AJR$Y3NT_>B/'E)\X
MIAH;_1)KI7US7QX2_2CTO+M^8CJ^I?Y%#^LF/UB!"_88IJYV?$W_V[KJBI"S
M1^?_F#A:\.5FI-\\_8\5YG]:U]_*BO1_;3HM7CH?Z:'E?\H.N&A@&(14NZ*1
M_J\CZ%4T97^V5E/$T"'>^Y\;24"CF(-72&6^6,&B>*(3/=4  ._ 9E5[M520
MXENC_W]0W\5U4;[ZX.LRY0,=I-;UI9P^5"C\:VLWSF:5TZM>9^7. JNRS],Q
M@0\[X.;,NHS"I?SN>2J:J5)QU]X VK%\@8<-9@MP06:=]J#;7I]$A*^P0D8;
M-13!>/@4<0EM6U-<Z'O"DPIH3T4]LK93QF7X3G4B_0A&.O3EILS&[V(Z:-D"
M,O6?_#+(D\XO'9Y=LI6V?XD*YBQ.ZGR 8=<Y%3O@14.)FW&Z2IYRF!;4=MU$
M)1U0.//1"GWJJU]5M'_N"Q0#[!4UT ^$MO(<_B2W&MZIODH^%)^#1KHLA!71
MK0;_2_H[5^UGX/;&O]0C^VGBSPLP2L>2P$:0K,4<D10F,&1V)1Z05204)KL?
M_O1># +N<>J@QX+B#P_-DG[9!-96<ZV0T\L7T22<V;2S[P7CX8X)59VN9GT)
ME1.15])_.KJKQ4]<:)H6HB@O:W6S_<@[Y&7R,L0L2M'VDJ(W]/H/V!7];:T,
M/9MB(5K !0'#L++^!'M(8URDOO01QZZ6+=^2!%6E. I-"S;(ZO]G^Z<3N;+^
M!,=  R:VUGXY0?\J]NGXZ3.#$(-;;(J!]PB\9N_?ZX+U:D915GI!>H<BN(="
M_.$26HG$7W*X%2-P1?3AY:5^<8\1C[AG^"6Z_)(8*'4IWVSCWL9V25S@]'K4
MK@D&?['-LW LCL&(W^H&[T+?E966V%!:,F]CD3V=;CPR1$P(N!4.)/GFM^Y2
MI3X#J!L?/I26;;+K?AIC%1R6SQ'NQANNA[UF*,.TJLW^SKQ ]X3-@Y-V<"05
MG1IY+YXE*(]CI)$V W.#KPC!X\7C *&>08%S.1LW(O3<O.KOU-'#(OG=2+NJ
M\_S 8AU&7P"HJ@S^Z.)0CKD7MV^#3B!L7,5NG6AD3SW2"^#^0!449N!KQ;4_
M+-I)M[*=HCK(+5,W6:JV-$6AD:9?$:D,Q=),/$_2#?Y"JY'BF#:)U9'.0U6_
M&8BS-T5"6%4^EM1*%M67+7FS&>XY5)VELU,;B1;PA7=F*3. '6EIQ8G..617
MZ>-G%1LBZ:8 [U#-.>KH3]+J@76D^E: W4!WRS)B%L=#G0AKP,):'&@SX1_!
M8B$Z[:0C"TK9< %GY*#R7N;^!E*N8 C/@!H8'/(,F)PQ.,N<FN7E8N8J"U#>
MO-\^XPSNO>2XF?QU99SBOA8@:"UZRI5>7"%>^<T,XL6+SGIQ69JY+57_7?1G
M4/>TD[.^4-!F19P1D7/TS+3IZO%WK:F0 OCB#TQ?272:H5<<H!T,9)H-HY)=
MJ8:/J].4DU:Z-%U+N*=T6'U^[6[+[33]L0=>:O%;T8(-M]$L28SF#!,8.@J(
MO)+;2CPT\R5*+E@UZ.ZJVPP![0G'H2&N:.P3EX@!KVG"]0;6>5,A%^1ZB7JV
M.8[%FI%W-ND#ZMDC2/SK&+=(PB\PUI)1ROV'H?PT\B&HY+;[^.605PH-W4L!
M_%#K_#=6^7TR-V.KMU%Q$1"P 7A>9:,-L331';V4JF?H@J'XUL6^M,!N?5=G
MP?I71C@Z,QKPQ%3XXM2O51F,VKWS#\F1BQV\5'>@A1%XM22T"N#L]3?O\HTI
M]6\"HC /+YI 8O-Z >*F]=UC'8SO?ZBL&@Y*B!N3943_9I)(7G-VU5OBIXDS
M>FVDC"!)%=S,*S09)60=C+K-]Y-VU=_:,3,3_<IS,W[<R@=,-XB,4GB5]Z<"
M7A<ZH+0=2Y>S1V&;N'*,2.Z/Y89WN)W3VO"O& 50T(-X-L!AH^?BPB+J@L@<
M:SVVDRI8Y#[E!Q)6+OL5>%&1/^'DMZ'O8%.<_*I"JA=[>&Y^F2D-1X5A^)RO
MPNY9"Y=-HVUCU.&1AA;&&.6*FIA7^+<#H80*-^,=+S._:")WO5:K!:G#_BT:
MS;Q[I0.*UN:7,?'D^"NB,]:IFB9!V' ^^U)?L.V:DC(EX7P-+=BPR5> Z6N5
ME(ER$/5QD_>$.P3S:"OXBYLB57!E0SU<<2R'739;;+2\Q=^,.!8#"? ?WQVP
MFCZ^M1/1][\?=.C#5*)OUC7$VB7#C]1^BQP;(++W[LN2'2SXQ8'&)=9+/G$?
MP_%<"*A5IT<<;I+;&7@T:\J).11A&2!OQ]XIX$)8NRDIL4'[5UHIN!8D4YLZ
M7F\'+:@.'RR'\W'66 8YT*A"U,3WXSG'=O6X_U0Q$,^<KQWY?U- RO,L_[WQ
M&</J^Z&QGW*D54&NU916D_!AJD9:H0=%U69%#*.YB]\O(@5$[_E>_-WH0X65
M"-B&UU3D,251^/I<6"<WO,_2RW#F3W'="EMQD-6*&2FC==Y[K496UM<_G %#
M89*_4Z$I.\:]G<Y73]3V[UX@O1SU3_4*!QQ(WL]QWJ?KQSX#PCBQ4]4/XCD/
MHDX U4/Z'7)AN58A+9O3!$B/%BTE-IAX4(Z MB[<O39_*\=!!P% V$T")%76
MP?4TU0 '50Q:S[W$M9CQWA-=Y<GIJIIU1I]HROK"%/>W!S,R)NM<S#$72PGA
MBS*()XDEB29QZLSF#Z*M ([J%DPK/_(&]CU<61H(H\$JIA=(TP"=;RTJ,H[
M@S^CC9+>&8K:\Y?3+VM7&$HU]Z)\+1M_8AB/I17N4[ 2Q;"F78 (_DP:1C29
M1??:!05VRCKCA6Y]! ?(T6%W,,U*Q](9B'J_=)V?/A4H99LZT<YPB0\<),OO
M[E,/7BH3@V>P$KC_(GN8FA4#7,%0R7R:*Y.BH.Y1#H+SH;\'K6#%H+;]^M:M
M(L0E#2Z-6OD2@/*VYJ#O/>7C%$_1<;[>7+&BJ#.CGXXQ/6']5HT/_RI=::Y,
MXP6=71[]UZ(7@E68_N-BEM'5O1[XF<M+Y""8#^:255>*PO'>#ZHSB&29I%8S
MTIPIOZ3A-.(2$>EI;&F8[1*J1@&Y@T(!"]FB;B2. !:!MYV2 VB_9KCNE.54
MQ244H>]LJV5%!@-K&^-]:QUU7T=&V!F!/MB..3YNKA8EH&'T(<$;Q:_/DX?Y
M'KR )T3^E#G2/Q@7$07CI+?3!;D8F\/IZ 7:HO6(C!G(]596IJ9^K'D_DO_]
MRBZ<9NR<WO>"MRX!3O77V1\('5;\5/[@35WHOX621]A7+I6=L'8=YU@L[2IK
M.5,@1L),86@)U1+WX4'3.*_F>C# $.D:@[8!DZ!C6;8J_WW,1V$8*H*FWUFT
MU,U4$DZ<$^ANTOH;W$,/SQ$M7/X#P^B%'(>V_-T6PY"$UX4O[A-T*OWRA6XA
MO<C?'JV3?[]('8\_KJL, V';4Z56W[35F@W8X(^7'[-4%65^J^Y#7Z_OSJB<
MSE<%408>T7<H,(HZ _+-TJ)LASO-.W! +PIMZ("$\KXZ$V-V4ZQU16%@?84#
MME>L:G8,OPOCO (H1MY0SW'-_]UP/CYC\7N7JB<N)!+[%R41P._KO(;X8_7O
M5(. 3/[R!T0C?[>O^\LG#_N!$TW^:[*R/WOS!:3]-U,HC9Y2K9-4;HEK08'C
M+5H2*YL:T3,C\#'XS"@Q9I8H N]XJ<:-Q&Q*-^5%/ K>+PA\9TW=C6_;D4#,
M0-:F(DE)LP"MD1E;^G_A6L#0UU*VOH_DJ AN;46B&F,^3);[Y-E+4N5WP+?!
M-1#>FN:XC TD@]^P\! C>8V-NRZJR[J\JXWYHAQ-R$KO#U:)C^$=B#KY-@M=
M2'&[&\56&B:3'$FT"U! $GGBFT:;;]J)B_@I/5US4U;6%5K!R+8>5G%92I47
MM^FGUJV#ZE+ :%N];E!R[K)_#"6)M3_U'<9MT/F$]'"^#4F5?Y$G4^G%'=/<
MZ+8#5*^+ZUH%0QCZC32I3#[3=I0^T"HF#.?8[:7AUXTU\6.??1[_Y<RC]XVU
M%88^VZ2:(0&*TP]1<L 19DK/47D&OAQ+?*A.LDL5<=333W,+O/%6BO"8GPZP
M $\F=B7A*RQ;[<]DX#B18EFZ\V N0>6O90R>JM</"<D-6A'U8*-4C%^('#RU
M@*O-)A'V" S'GDYIFO" V\1TY=#3'\3ZBN,]UMH%.!(GL?$/X2YS_A$A*PWQ
M^=O%T?[!@-<K\0CT#33!PJ8$JX4,B A]:7+^[ERF?47]ZP-TY >&C]_5L^RZ
M5RS @FLF$+85;V6/W31OM>_)J15T=VL_IW8_,)S=*2 PII X'DJCHWL.:T4?
M+O)V^7:*(.G1PD&[+=?3M2YT*9^@5^F7O?[QGOEV_(\,8U7^M^#99V#Z_0NO
M=_LO7>5IMJ/BV^Q/D^]_!F"A,*IMK#.KKN;F)C&G4'G^%UWA@UH6%PYE"CR&
M I&I@S'6XE/\VM92G(+28J%#)$[+'6*FLJY$CAQAJY2*"6[KH>?ZN!X5OGXF
M-=_[=D].B7RY296A!"3L-\&>:W1:8YU)R[)((*379)>051T)G;L[I3?>REG^
M3!6 4%8Y#%XYXG;86-[B%R5Z,;X\4IH_O=E"^J>K;%ZB\[$ ..AE ;C@"QVC
MKCS)SUP';P5$=.?('$#S\XH$12F@W+9^GB=L^GYP;?YCX\\T##E!OWA=[-]&
MXDZ.6F/M[T,28C(H9,+"+OA]\^'^:D%?(;O=8I(O4OKW2UQ=%8LD)T_$[LJI
MFY&#6?%6I4J(45OW^";>U=,PU7^%P5[;8]S0VQH4CV_Q.X^X6UVDLK<G\-G^
M#D7^BV80Q0O1&J^JEM%V"<8%08E0DULNL$'I7'%A0N(;+L7$QN*A1X@AJ^QI
M($'ATI;:/_3-$PQ4$IL;:"-(0=9\ G.RO6K#"?)]?RLU:[%B8_?UVHMW1O:X
M8H1IE(34+C@W:J=B=J<KM.7P!,PC9J]A<$-+,KUA6 8]XBHD6PD*)_F!(?AR
MVD)_XHF4)"N+,ZY^\\*[9OQH9.<WK>SE *;#H^C(5D.$+PLH:A9)4^EF21Q0
M]OSBRQ$.&%9WUF(6J6-XY1GYP)KJ[M1;T.%J83SD)@08<@YMY=MW4*2P\<PX
MSQ*JX.]M;<->UNT4?Z81G-A0=L38+8&W*6X<0*@3],A*,R[KP$"8V(H%!)Y>
M2OEI/O EP/L2AN#P$X%-7L_7.O_D..+2%B&!.C6WZFD])?Y.G9/Q-2&.NOJ%
M*2<)GK%#]XM^_,.DM*P2_(&IYB#*9'UZ5UK1A)*4[K*,X62KF3K<+7_;M3**
MV%=P?][%EV]>83QFIYZ!9M%P+H"MF&*^:#:V[2W9W1G#2%&D#)U-]0^+;'P2
MJWA[Q6C=8,#Y#\LS$.5">CE_1[#NI6ZZCLZQ ]DON^#L$T4\3AWNG=Z'OFEK
ML&^^QJTMT5P5E^K\2 UU@PW_+@[WUP\2JUW8$-A^U(%>7\->I\K_/VQ]Y5_4
M3]CN=VF0D)+.!6FD<X$%)15!NB6EN[LD1+I!6);.I;NDNZ2EN[ND/?Z>%\\Y
M+\Y_,#.?F2ONF;FOGF1J@BF_.2%M5TS)"UHJV:8*DEG7TB=O9>]1J2_Q,A#L
ML]P)W*[<G].<KN_[FUOCTN:?WTZH?S'$&U+:A&+ !21I"2>S1%*[Z$AI3;-T
MY#8O]8*ZA3;Y(2$ZL\(8HO_,)Q900<I9ELIP34RZ!N/6."[06D+_)L=T"LLI
MK?5(2Q'N/!"=0!HDE.EVBB4UDS]A*3SU]I[>V5\8D:1=>KE->OW9/E]*6/@(
M%:!3^D%)DXV0RXE^X;'KT7-1#OT0B>?$DBRB.'K$(\+@V-=:&R\PD5,,\39S
MI P<@@GL9GD!VMNPC;?L7^/] ?3* FFB&@4"1G,W".LU0I%&NFG.3@-#+>"G
M[[B107'VK<BPG+J9_A3^<(,.L%5+@\)ZW#P3K5O2)>+'OT":"P6K8<$=X,:U
M"SWXG?MJ.W6F#+N7<#S><[<0QJ3UUA"\Y,<,-_[ATLKEFMQK*NO?]@CIY99N
MYJ4R[E%/F9J"X;P#'!(ZYT0^4%:DZP!?4;##XT!!#8E3S];]S'#1!XV))9:!
M1G2(2R^@=GJ1X5[(BD_(#3$AZF7*\'(C-DM2F>2W"3-I#-Q?"*#_9F+SC;(0
MI1@9,DG\-%F%'@\=Y>/\*&(>J#I,BHLO:?3R+IP23P=XKUM\9$:X*'<N BNQ
MGH6 SZG'+E"F7-=*;A<2N#;/*Q@U5+$S+J>Q545,J)0JK(![D5-Y-&YGXPT+
MW5BBW8OK,DLZS;6@,@ED Z/U58J#9XI4=N>[V;7'B:8!\$*;M=PY[K=-49M.
MVOIV9$8*8/<^ AA'THJ1X'EP+<2G'(PN%+N?^5[$6)O:*P1$AU51UZDO<#-1
M"A;!,<#A_;X$,)CQYF6%8H5HU/LE*7FR2Q+TN?0K!6"3OQ=9I]&.Q^TOL$=?
MNK@P[,XYD,N^"B]=R&]9\@C5FG@<T<R2K%6[KZ\JN'TO(TB"T_].\D^!_1D<
M;4EGOYDJV."@ 1F+-_),"4YUV _YM$GF:OW-J(I:ND90:*WROSKP;:'RN?1Y
M\OY0%RXX1 F+#5^MBDXWP^4:#H*"D_O++;%MB#),<3>R* /0-3\EZZ%=\4FR
M+3:9]6%THICB0S&&?Y@9H@F21R*MI"'0ZR]=*FIU8^(8>P*R6N+ZU[5WR?HL
M %I#TZW=?'DR<2L[)CO) IHTQW[J&<9VE/.[" 6[!>?)  KPW93H%4H\"Q8
M(A.FSCST?G_6>_QT%5?MJ1%;;Z"Q)UNG/GM,,'N=++RQ(*ZNM2A$?05*:; )
MH&ZO \N\DA+,[O>9]F?V,:V\IM0(C<J7+[/"M'T%9=IAJH1C<+#;O3'3LMW@
MW-K<WK^=R][SPPG^*,D_>=> WJ!<-[.W@ J+LZGJQ@KMYXB61RBQ2+1 2=D%
MBE!<CB/R2RR3[Q$)DMQDQT?6^<DS-">1-+O:DXNVQH4Q","CK[!@.'^EK16^
MYCMUP)JMG$MWF65U]6])]P:+M.I)>&4OZ9Z3MD^BRS\%HG[$@*/;V$8,#QA+
MBB=19#146+49,1CH]];^[OEVT?!'2YTCXYH(V'L)Z3!92=^NEB<=+$5:\4",
M3JB 36K%-,WHSJ>OX2B<(XV[1-BVN^56,M)R))1-PN"%;P+BXRQ8YV.>@W"4
M"'FC)+-OOZD\L0O1VEYT9Q%7'"'I')P_5<\[?+[M>*[KT,L0^F 8 @IK>U>:
M9+(/I7FG]3[W-GY^:6_.NC6R]MT%7N.QVF[(6EP.C >QYT5^UB9^?ZG8K/N#
M;(5,>=>)TL_U@)RDAV^.3A='75G/'R63QP+9I@NT%%7U\ZWBPY &%/V"3X@3
M*45\>A:'9JC?@0_T:2:I'C:SE_[F,1 A<9A:CJ3.%.LDD>2%%O47H+7^X#_.
M#:5\58)^T[;[^?HTIGSSO4VVC)**T'B^A'+D8-D*Z"\@MIIUBU]Z0^[8?+K=
ME>4G<_1/N>^W%)>(1)>BI=E]:4XRDIR"5-UCK<[RM[%UB5@TQJEKA]*%7S(4
MWN-YG459:S7.\6.^X?Q,D7H<4QUC!?R::U5W+"7$%LVN0S_93;Z?@RBA@.8N
MB]?K+T^P)6<A9X+UPL<?H[E1:B2=25)>=R$+HNH$L'UUD:1O/-!$1G!%\RJ0
ML+L33A47OM\.8P,YDVW9(TOD X([&#^%:!,NHG-B"9H  CQ*U5B:=73Q_GRL
M_'PL+5RO!E+X"QX=TMJ!<M/U_+@@NL/ U<N2 Q)+CGBY-:RI]FF<YSC#R+=*
M5CKTJRNJ T4NBZ3VY:W%IQNUD?Z4$4H7<"PSG_H%M8HV*X[E[?S N@8+=28R
M2_I.8S', ]:"G.3*93ZWAI_6G_K3MI.>7;&XHV;E_N *+Y_.!J#AEH VKQ%4
M-%+MLV87B%_)M'Z6%"<Q?<T5F!X\HO/_>(R0NW+$\3Y&U2 *)[.5&V,CZA,Z
M-!=01N?/]? :EHYDEV-H-+K\T)W5/:'Q]6;?*5ZW^50&Y:5WQ)RUQ[PYY7U$
MOJ.%B3! S)0.G(^_W(O?<]]&.FEP3EVZNJ?Q@B<<QTW2I6Y1TE'A>)T4YW<6
M_:XE+#8UZCS!0WCB9IMQ_O#GR%LVL3&GDC6!X@N8Q2:A-&TEW$T2=ETV7FVY
M%)3+[PI1[1^3X>(WCBLN&2HCHZUY#(CGP-R.T>V@FPC2SL[3?85N"\AY!H"N
M"GU!E*"C5U;Y0>73 +/U1*OP)F.[>MU/(ZIQ:;N(O\"3UV5LK_A^)]QQ8I-*
MO!9TA3S_L7Y0M$=!)#ANH%?%(GR'A^C>E;C+X_.&3.[Z]GO17L%Z_V6WNUAO
MFGV#S((5"QAKPX-,@DNQA$9@H]$US;0CE$Q*BL+F>_!\]%7\(CIJ"G#33^QT
M,+.6E-,88WD,^PN\72DEXH:1'A_63J YJF"J=A+OW4L\!OZ#W<-_ V)=XR0B
MP6U%6YOSS]U](!\7\\G_)]6]_J]4C_*]L4ZA\#MG2?@+@(@SZ<'-[5S GK6]
MRI1IZYQ=FNR0P%;6'VFG%>%&$=Q(@0P]/9PB,70$X/#,>4[X>:DNI-1X@3>4
M]NGRF7B(,+"ALA#HB1>Y+H!Y=L)1.^@3F<CV1,DM;%PVRAA'@@CQ%P:\D$24
MD>DO9J5Y3MA6[76J?)%Z>6HYFLG0/E7=DP=S9Z"AVXG@UE45+.H:Z,I;XG3S
M-L?'-6]:X[V%DL4NOF5PXDMA(V0>"LH[*=F,QN.WVNFZ6+0:MSGP.Z7=*!GP
M<QZS0'I*JEA8UF!YR07)BXH9JFM5WK/CH V/JNPB(>UUAB:IR/A&V6OKZEC-
M5HO-7.@NYQAI?'B<_P/'MJ?7UF/'3Z.*!JBLIQ[)UJ?RI%((.>U>]^T<Y4YH
MDJP+8U._;EB-><->V C1;-:RK%SJJ^F5.''L0(9, #(OR<.?K%XW?C-G-M?0
M&)3"^Z025!C;$;P/!?(/5P*/%V>#H:1_XI*2PJPV6W6S<72&QQLD;QIY_%>H
M>MTUY1MW%ZH+OZ6P,R/WJ#J%JC3:7.!9.6(7)MQJ2F[\($6XIF%[JM+B=E-J
MO* ;DP8L=-EE!A-Y[24$)B40YB.E#5B_!X4WFI4PYF6+WKOO@GE8#6VORTI;
MWC4TM4*_AOAP*BD <9RZFB\7]$:2][%%37S;' ^UG:@0M0H,+SK ^:(.N!C[
MZ3%8A1$ E$=LCU7VTT?T= <"<6#8= T+^%ZN*,ZG;8JEQP)Q8ADGBFLG?PW@
M>A04H*2!2>%H"4U]>%1L4\]D'@.Z8WR*4DI+HST?5[M\V4:Q(V\!O"*BDE/L
M0U93(IL@9N0#2XZOXR^-$BA*<[V1)\OG7JPKX>L92)HR^ Z^1E/22S\I0D;O
M5=#IHL3>T'L.;5(;3FAR[D-UHZ9K\"[BV/BP-;RX9\U_=6O#\279!F-#:NSN
M9A]*Z=90V@F?KQT-YCW[?F ]5/'&CO]%<F.CTTD_!!94?ANCZ6NB$:_WO(\[
M/S>A81S"^M[!&]L5CM: #16FGN99K_2:=,R2/%9AXUPNC)O_0P2$0=SXC8DN
M.<Q0(NEP93Q+E;L+^3C[SF,W=Z*F,AY4*#!MPV$0);ME'7&//U1%R/PUX&<(
MUH=XQRFJ@YFM%_;":DMJD<5@!-)=5&#M!=UB1MCBI9\+2*O8AEGX5 D_%A[M
MH,A.X*G*@BTYCE9_M<S(Z?+BH<[)-)BA0 092@HT+"_U0VR)\G7 @YW/IU[J
M WK%K-Z:NNL26'I6JE$R)^S00E;$H_G</I3J9Q"?HU&N++B (='>CJT$@JWV
MRDJ%*L_EJGC@D1E4.P?=)-W)7"2J!27P>6.B-;UYM4]_^=$R3L*3AO9^SM8C
M31FZ-6O-*OZI@W7).  B#*4(1KXNQ70PF%AL,5([_6>D-<*^\5456//T1H)]
MAF]GY0''V8#7#2[:FSS8M$8M2^K'OG0-TZM'8^2OE=6\L#4,A'81"J;F#_U"
MO<"[1GW$3/&[\I(U4> OX(V.(.!<>4RW0+93TIM #H?RE,D7F+C?3@TEH8,3
M)@OK&K74_\A@& 5Y1P"(2T%CV>)BV_(OM8W:QUL6VV]CAQQ5VN)8VLE0OD7"
M'&2GU1V":>UH5*'4^>NKI%1.2]JK7 \*>$DQYQH[O62H_O@&;-BGU@X)4K<N
MM$%L\SX4Q;(;TE':02.YN,Q(5U@J&YP'>B:+Z5>L.Q5\_C6#1&=.+7WG^Z,N
MM: AJY1BDS+]D0Y#UJTLQ9Q6P5X#VJ;S5Y67[^FX92_>-:U+>YGWM&P:I_0J
MC3.K?7[8THQD%L,!F%$]B0@3XF93,@QWB::RN@(8HOP7%I2L-+\ETS5A"$L(
M0<C#=V&\ITK:5$HGPZ!5,69D69DX[>WJV*@4^5KS&MRD'PSV1*.$Q;AA*.J-
M]O1!MH<VY1U;W C[8]LW*A^L-$+)' /Y/L\&",] SH-\#S6[T]72^ZJ(X]"'
MF%SR7 #5G8D-ETN^P[UR-/'U]9^L1[4X]7X4Z>MT:M.0ZDC1+ 6@[]RN]9)D
MZFJ'Q0PTO^T?_N3+%AO$<V%^ZQ]^C[7_/T;X_;Q6 I=^+^_T+'9U\\DW97J6
M3B5_+Z!\$1F?U!9^+78XU4ZYCT.$Y\UCE"_!#*YS:L<_^S7'C\=CP&%$VR[Q
M?:'-:E;HF(R "RD:V(>2HU,GKO#VBK4;8.[D,B1 04)%G+FKU.N1,0I95W_R
M')/LO)71&"(H$)Z%D;4)1L6^^23XBN-445X^WR\I-63#^=9+]FHD.Y-DML6O
M0%L,&<]M+&/N3<9<2D83*LTB+6!.LH]X=2)"F7^!WS0K8JB 0=T,M1BG-TEG
MU#S/[JWB)[#Q8][6F24Y+T62,:98YR@S:B#IHP42@;P0$1S_,'WJ>2328M^;
MJ,OR0X@. QG;B34D+DAN.&&U#N#;97CV+$Q615M.];F0//ZT]0<>-_A8!#IO
M@JY18_2Q!"09'O0(":.HM61;$+W4D)R^X2>51C^-) >N*M!O ZR25TV;[*]2
MPU#^ J3E;8C7^'>17_N\-_,]0K/<7V?Z$H\HAD8%BF^T)TV^05QSO%HXH:K
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MR,T?@SG^ DO$78N?%5RRJ2\^3>,GI)^XY&:RSO\%IKBAE'9%\(,4CI@[B[_
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MF$L=%SH8_45<E=%4+<?\R8%0^7AV6:QRB6]I3O(E8SM0^7T8]V2&\D5/N?,
M.D)X_*1]7UG\E,H"><*/S$KSE;)>^.(6 =*0%[[!E"T7;$$8VN&*3KS1CO+]
M2P+##[_'PJQ\[]=I_V4,VM_O_!P*X/C?A!4T4%7$I?[TN[S';(R_0+OLK6:L
MC^($B<Q<_ [HAW?O$D7]^K1F^; +AX\BBQV!8E'_04[E,[U%H=I9R&"4^[CQ
MLY/CV,KFQ;,::-V!2!LTCPG 6ET*3N+7ZVMS*\X%@ +L3;%SQ3]@\&0 !P7?
M]R?7'N@]RY*_0A)#9?CI;X83=*Q'3M^#;S97I#N1CM!7NZWQ>W*447"<\%;6
M)]:2>(P5H<,($=R<!&'*>M\B0&@)"C%ODZ>4^; N^]"SAF6HEP&ZG0JJ 0LR
M< !RL[SY)4O':*^-2R3)-A<O'Z.TGD>:ZN,'5[@V#BVCN/P,'9\P]N5<V<*J
M'MA&3E^"-'C_$.&NN8EY_N$[/;;>>QY[I1_Z$ML.CD9*2GF]QWT%1\U2:'R>
M:(Y8P624,V7NXQ^;&J?TQ>&^.AQ //ZVW8JFER&7!HLGYFJV$(R^^?$PF#7B
MI.:T='F?7FN_<C#8/N786(,Z3X2G=$8$RE +02' N*I0/CMIG>/&X/@Q<C&!
ME$<M1-V=L5M@G3%AZ^)>]:7]'9.GRL@NK2&,^^HTXN21>'U8UUN[ O^<,E6T
M^7R/%TJR4=?4_H:USPTYH#?@=%%\AFHFXT;79[[1Z$]-5C?"GHO'5JYO/N6D
M*,^,X-WLI5/4ZD-! .^:NZF*,FH_Z5_@>GK)!%:G/3P_8IR(),JU9VG6','\
M/9D4CAWSJKD?KI=R\M6XU7+:="L+X=8N<$Z@+WLC1TD\IK6+<%0Q^^I#-=*T
MV0:\T\7FXHW1L8X?_WG;GE@F /-ZF'*@H$(%V(RZCI<3IG$]2_<(%<-YU\NU
M''XN$]'W%TKO-"Z+XB7Y-XM9BVWQ"+L;C_0SS*G4H?Y_0LGCMI=W".27)(==
M"U@V*S=_>EF J9AM<&>&EJ_-K>39Z+JG*%6(^VT>5'8?-Z*=//BPT?T5KI10
M+/W-I](OI'L28&*QFB2Y^^,E5MPZ@1<)R>!*XB/\^:?D0:X0$W4L^+TRTGZP
M7YW-+CS)\6XN>PZ4#WK*M8ST1WS>U7\"E&?*=)Z7351 .#"_I+6LEU>_758)
M?Z8V\L -O:EGKD0;-=3%=&DUDQX-IIYG\N8/LOT\&+B:J,,*+YXLD <F&=WT
M)QV<8]'YSITI3;;J(S=;G#\QD0D=]XH(?U ,49,XQ8X 8+8?3US4L8N*N%"L
M(Z+9=']\<\NS&UN!_P5$?!JJ[9[FY?ISF(FFBO0].?#3!NPPQJV 7Z&>?(OR
MM+QY%5$K*A>E)TJ(+VU+%TC:_4SYW!283&3L %%' 0^NY'X''[ .=B*74?9:
MF](.A")=B-Y/<I/9F")YJ6TLIQ,R>+NY#]X5(37+30R4MTF.HDF=C,DR;/UJ
MF"/FJ)6R_AH9\-8Q8Y,(&(GO,*_PVG\4*\W9Z%:)^M( 0=I,>K1.CV>*^*)!
MRNJQ&Y$LS'6@RR1F@3Q-V-%.T_Z)*Z32\TXW8JKN;"<K_]VPF25Y**E)M.ZA
M@7N^1_U?0"YA&&^G"U>@P<@@(?=PMAD1/T9*MZ<V@?ZBPL*/.L+<NT*@3\4Y
MA$SUJHAO65?R[(AS%O>/(%['%^)5*XWDA3);E%B&7P0\&&4>$,8<[3&&5UAD
MGA2I<5GY@)7%Y+*!3C_C &@Q'EC3.%C<AO(EXQ<U:+""Q$)T;W8"A/V),-FO
MOG_+@6XK/Q:NM%I2ENN5\\YKMA^^.G0L_! UIA9QEJST6I-LKS]2&;4%M3&6
MO=E)WQ>!JY0P@-2LNNFKS<YYQ!"8+J=JK7 8Y-RY45GKZ_8@ZYG>/XS#NEX=
M'./55K8O2+ ?:RWN]K3&'H''<#^!_F:']S5IYN^!@L ,W+RI-(%Z7.<]2^X
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M36DGC-M+\4I7<,S:F;_ MY"J/O3T #_7%4VR_,7:AHD!71M+^GAOPKA _4S
MS-JYKM9MBGE0OB;F4[!:JV1^0<MZF\R$T==?=W$T/J9^.87G++T93 T_GG#4
M?M5ALVGSVK+C)2I5Y ,^6^>U'\Z%NHM9.VX*<%.)YV\/WPHT7*SV-,HF$'"*
M'WK-D7^T ,!,^2QD!:8W?*WGL"N@%8NGZ4\>UD?9"@5(/1;:)*[7!'+B)IQ2
M^3WA)8V3M"!R8$RYE6IJ6BQ^D/#BQ 2R0K$9UGODXPCDU.&0$XSB8YL3SJ7O
M'L,V*L=[0,ENPE0"%&])@;5J3(CL6$=$L49?KTR"DZKJTNU>PPDOBZR/]?Z
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M-M5#VD8&3^Y *95><M4>^-47TOJ1V":IBI/K.\!J!$\&$+!&#X^0 >G\5O<
M&VF0(Y0@88"+ZA4ID8];0]'S(Z[>S7Z[@N"L-(V[ARJVT4?<Z>XJRG2^3QM:
MXP#IP2WY6L:^+9"4LEI/'(]2(GL%D8$#E]OMSQP7!ZTJ-WR5Z(C?.YKKENIN
MI#^J(F6& =V@719AOCO\_;NLU6I'J3H2O9*WRQ1L)7TQ;A]7\4%Z";P_ZH%(
M'QSW[%'F+-S8MKQ8FS[YG-+^K&JNP5H!(Y&EZ::ZNKI:3O%GWE K@I[LN)D.
M,!&#T_#%DO,Y,7ZB 7NA%T7U)S<!!P^<70<5FM6:V)7!P=L18E)#TY\MU+4Z
MMRL)1N/WI.89B[6%/,9%O\;L>[!0@&X+-W6,L8GR%*&]9J,X2_:E]PQV+/:3
M>))=#YR1EA?V4F0CD9FC9$WJKY9MA@O@>> AF5YQTOQ.'N[P7J[H^_'V4OTG
M[DF*=JO@J?,,_'@M3D?<Z-K'H.^]1KJ<QZ\7Y+Q,EP3C[N:5M_$M9_<Q9BP%
M&],A^J5_#]-E$=ZT%GA>MK0_#YV46+U;!(A ZTRTF7?C^C![6-R#UNO?![ZP
MF2S=; JI3TDK X]99'./6AFQR,<P)"*9Q&C#)V.X_3=@"9/.@B]C2'0W38*
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ME.;P91GG9XFK<4?91:]]<HV?1M>!&6KT&E(6/TT.4@VLF0H@UR<&;>HR\VL
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MB]5_:EQ"/).^$?GX=X,>$L.6M4%M; SU<I8H;=4&)QC^7F&"/\W69$$&09I
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MEN :0#Q$.][J5-D:ISX#R,XCD$U:6) KK)5L$!XU@!)4A:XW0 ,8[%XWA6U
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MQQGF"VG>EMPHP.?%K65-EB__9-8N?^\\P=VMWG'!2/#/A+XZD-=CM* U6C!
M?.J$&^M>I!4!D^=6K_DF8PMFB5R3V$*6=H0!",GHGP,'=.<-S@)TC:?7DW1'
M]QEW^H;"?*6BJ<[5BEB$ORA:=>/7O2A\>E+O_'Q2[G[$'N[=\RZ@(3(?0Q+O
M6/U_4/3VY:5:?L%NT(_FT"NQ/7^=B0)$6B^OT1!0S;D'W]ZDW^SX]#0Q,X*C
M[KNGL.1L;]U\>K)BI:;=V1+^,4VGA C4SA>,=(8LQ*( ZQ>W%L&=266W5^G_
M;("NGP3@A@)N:9/J;J]]$'OW/#X= D7']Z$H(!H-P!AC!CXM;(R7\3.9IG'M
M0BAS%<6N'0C=84L0@8+70C&<.6*X$WTR2TV,U7;V='V/<P+PPSK'@RS23>I0
M0-I3GY4'OOR+'OW61QDL7>X]=WB:6F1>[]E,UYCL3]^_ZKO%^ZQG%GSOVHL"
M/,-4@^@%-,:H%-&0"Q4Q6>5W]:F+++WTRY(Z"-AE&:?D\?D5MJ*49#O_!ZV8
M$P6LT/A"CFCS;][O?'"=@8I'%Q'8ZT:<N_ILA?M<]&7O'_F,H@G!WV@HI3)[
M1+["O*7TZ>X+HM _)3RU$M4^$>YU\QG_T1-5)88"($8HX!<:BM^UZ4:? (T7
MD>T2NGR!SXPM-\H^L#FOF 7\MY4BPUBWQU'W5^@.W6RHWM0HC<#]NR0')G;I
MK5:;X'OTE+YA>E6=_^JS8P#7X((?"*E[_2_34,!_VT8NF2"T^.EI3W<XMV>X
M2,W;RI5C+A.LC=!W@&7%DW?XXM($-UEQF:&1<#J&*71O+XH5CCC.H;6[C]NF
M^A<VD='_&-0FQ7I^VLN*%Z3P"SFML1=_(;<!JQ7@[&,(@+?^:S^L2BSEBG/K
MKAU*^C(XD$=8XYF]T;-GMS+M=RQ)S9=R61_R]R?D'CMOT;2 5%4,5 @R<C,(
MF%% H "V%0HP)_=I4K/V?KISS,_W D9S#=)-E&0$ITPV,V69']_&]V'?,^2T
M'A.I%7P<?U^^JF_'DF4^?G_"XB5ID6Z*-D#JGRM$@--^&_8W]*=FALO^J80B
M^W&[KMWN!/^S&]_%L'<("2ZQ,_#?LC ]N*JC:H@JA2F?$<F[BYN2F7!V+EW8
MECA;$]E>9"LCB=+_A0'X4S)WE\4N&J[NH73U)""=&?)/ZR<+;'ZV%CGT4M"D
M]4O$YY :4Z6;0)*D"&KU%0L^76@29 3C/WJC]=@M/U1*?E'RDU8+X?(AVSB3
M__N#VVY+=+!%5+]<3A#"ME[0J!H GZ2[CZ5_T%%X<&!U)"W%>%FRRP@>XH4%
M'>MR<RU4"MPS'G%K3X]V>*EPOMWXX8S[T".7"+1*^\<V1*;]"PA9],V386H$
MLOF9,NRA!SI;K<>WXB+J[$[@PT($?Q'$S4G$MTHAF94G8TXX /$R>F[OU'R]
M!=F;$N.K61O7M>K#@[_9U9SB@5^1\W-J!T2@G@CF&]M;#YFS/!1@O.)/HB43
M/791.A$&; SN%3X*-8CVVW;M^ZDW_^+@5+@Y,+3_=1.<$1Q^/_"+@LV8*LYR
M<7&8OC$YV4V\\."BR"$,V"R5+*$?&,8K>KWRA^*^!FXIM-C2H2/<;M."7=H8
M!IS*M0*=[ALYDW:PSVM5.9?J9 [1LK_FR[2S?"'Q5%]V4OHWO;BU%FP[==BG
M.V4 ?N1FTP#C@]S<B%_IMAN+'<30[>Q8S<; GD([7+7:2O'4)03#SHX6.@GB
M7+.AV5;EP)""C/">;&?GR+AMXV]2K$/\O,8P1G!"O3\*L/"?Z5X+GH7434US
MYJ(IZFC1K 4Z]Q+D[E(;PZ6]@EB*)PFESQ:=XG#XH:0P([5M=*1,%=OJ*3>9
M5->;6*3XT] ]K3]5#4HM<*E,\4,!'^ MK]$K\LM?\8NJ6#I#.]X'IH\]=UIV
ME?5X*$ [^99E'%V'GK+9DF'MNX"%Q<(G[OSW[KULN+=I(+.?T3,_&+FX]\JG
M.@)WB^XO^&)8-U(CR<B2#M"IDFY^F=+S:WK[RV]SRX@[\=ZES-+E,&#59)*]
MHKNFD\H\@NXYGVRF?&Y?^ZZA[5'I?1BP]C!UE>0&LG)QT-J1[2'4]O@Q:55:
M)CXZGS<R@@.?J[N2UJ4?AT;H3M#4UTX1RE@?/N"@3F<\OE;7E  <7L:53"5]
M'R5N+@ZLMV4]54D;V2-]J[QU]R,)C3Y:VH7>!S&". Z)VI&U*@U!5V&MJ Y:
MG6$B4-=<:;XY+(YX O>,N<M;H_M3:6YA05<MWIL)+I;,+%^.AR.G-\,T]O>[
M28GLF:I;L!:&L2X%%M,PH"U9L>5QY4R'].Q4CPQ5KO$P?J;08?SC8)%MGXY_
M'"SHAF)^=>$#5K59DD1=J]_0N)8VZY?/&@M-/QG!OAR?,,CG%88\?B3?,K^N
MF>*,JM#V\HPO$T?[T-+.Q3H*Z$WM\=F+]0ET2?K8:*'V<U>U2Q:;%H-<=8 1
M^%_78/_?^'?$H&,$-?]?4$L#!!0    ( ,>!:E10C@_#R5L  (YK   1
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MZ?R?#7>A\4XU:]=A=^"#_.J$')>PB7K,":+P<$U3#9),,!><O?;(/^4@#]@
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M172U%KP:BHD<$GE.>I*"+0FM]MQCX9Y3BA9J<WS:V<E+=4"96?PT?EFK;+B
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MF0%1Z3UD+ALG8@$/2&KK^2WRN6)4OKW?K7[S*:)IX:,R3?UIQ3"^Y]N=NQ+
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M5(88,VHJ]9S.>!S2Z-06:AIMA'(B6E5"EJYE),3I)Z?RVO,]M')0C,GK1N'
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M?!E2S13"PMI<76SZ8&P]"@&N6TF$_[)_"NS"XB'X<-RFH\ L#!\J6G-/#5(
MFJ,:OARS-VO_ZIQA+A:8+Q?]7/I@OT5<;.C!;K=%72T0*DZ;Z#MR"O)VL%/0
MP9>L[NI*EI/Z:BKR4@AA0@[G_[F',,-(2;&W2<E&DO>.QV-_/\O"I$?L6B\'
ML8I(\2G>O%+E/@Y_6N6CR/_Y0\=)"OK'BL6/ @?+)OS+=1+@J$'V5^)@H?$#
MF/(N'#"%'M^$"+,(P)SW21KI,XLVHFM@,31! XO5XF0*M3C:A"YSW8X;-DL'
ML+G$Z&W]=2D&<8U!*TXRR9WB1_?YQ)%7P]S!QJJ5\68;E[G@MLD]Q&"Q_2(>
M+KI>]OV[)!0E/RZKH80HIW8[$(QCJ8ILW;ZL^39'I)9VVQ"%&:5N'G"S5L&9
M/WV%]PE_4*#J!](,+]X3H3;UE5" .L(#3=$\;L.^T($,3X8S']=]C??*=?SE
M1'F%VA+1$Q21+4@_%[YW;-F7+CIR<^S8,X5-Q=;[1[>I/GCWQ;"SBY=U[%WJ
M]F7"=O1,7'EG][KT D4QVK&L1ZZ2UH^S!\&VB2*_+QO^$[5'D(00ZC_X2:/I
M,S7_. 'X?CD7Q=)#^QI#*WUK.2B[(53)[97;W77F<( *W''M=Y.OP?HF*C9N
M M+LF'HU YE/A7'^=<FU>J(J-[K D)0*!]#G?+<1A/RC[\7@[_\9CQD4'UT@
M$!*%/:K''EN&W6(?IO]U6<3Q>J P>Q@K.U?7/7R@:[6C@H<#.I0,!^YU)FA(
M,\B\1"^<8J.K^G&'V;GS]"SG3,G7P8'B(''C(Y3B? ,2]-NES?.62FMSU3-'
M_O@FU%1YHAB6IT\^$!SFHS5M(GR9506J3_L(G6FSS73-?9?!G5S4R>&_MZC)
MG-^B*)F1R1!"MO+HV:I>"TL9UFB<4HY(OO]ZSK_KA#=7=7=^K^5*S;CP:=&(
MEMCIK4W7[JOG/OSJ,AXR;GJP#0,5-VY_@0,#WF IG$!-T=<GQ+^6<_/_P.5.
M]NCTPLG-\ S;.*)82RLF3&?3V>E!LRO^3O^-IC ?4>10L/RH7<E'/T9%9Y[0
ME396HHX<O5DY:ZT"&ZEXFN&,(=&L]A4MS1>8K&\_]. EHKR76+]PWGQ!!JZL
MU[//(>%-###(DU!%9V"9PYCMW$>P>*[TG]"O(NR7\06?Q5(PJ\JDN;4$D@<-
M*17?W7*]965X]S. 3<&([ KM0OG"7QH*HG=G?Z>"3DCZ,,/K0M&R>]'2 HL#
MAH.Y?[F+O2U^\_1\_GB*8BP=-C$"6M_3_1&R&R0*^[AZL]T!FTR_*3X@N$H4
M;USJ BUB-R!<V0"L'-),X0X'A%)OS4#_N'7CKV?C0=UP ( #;W+.;]2?_U-X
MR(7H?N-Z.:A0_+8D!](_TYA(,4WL>W/;<SEX6R9^J;M L65/#@<"J.' 9^%K
MF*OH%6)&WG,_OSGS_9EZJ^3"OKR..4Z_UI='Q"C5$'Y0I0D<8+A!OI5-GS\T
M2#[PG8?TJT$T_M2Q@N*L'3'!038P.\A[,XKC<Y9U\;,^BE6(!R1WQ!7&& %[
M>/W?F+_QA_78I_PAD+;P/VTV^5/#$<B?)OQI$R<D"H8$RU;8OR@K&BHD[Y#Q
MF7J)F?(D;+A0*T_C=:E<9A-U@?H$:<E^GW:QQM>1A:R:D$EZ4(VNL5S5O^QH
MBGJ+I^S8X,E#VW;$OT@(!Z2LSH(:\Q%4H1(.8(28HXX2[*Q/5( 58^0#V]VR
M!*XM_4IN<DI&].N9_0M*.\Y'O$*^C^2-S$1:Y5.4)K-P!53\MO9=P4'YCTPB
M\N=#JY9:=_6D:VDZ*Q=G.T%JWROB(W=1F?JA(IGZT_)0*0'6A5MLERO9O'G3
M,9?$:L^S*;IE4/-V_$YZ8"1G=,[Q(9$;?8.)27\";;'V" QO$XK2D&S/E$ZQ
M8#7W!-98:*L*PN2:\#NB*4]TU>M.[@S9UCYL&XK1)%<ZX%H\L]KX<**JCC!H
MN76R8V+YZC)?I1!&8'Z,LU91@#EO]SEY0+GF)&9*S!Q3_3;:FHNK,+/OM'EZ
M2H1ZF.<5N*M8<?CCH\E6T2W5(2V7CH<3C<FZJ]H-">FF4X+"RMX9\BPVZ1&G
M0C*V(QTO07>SM1E+,RJ2OBS6T1V,,B4)['Y@# ^)8_*ES[Y-G]_4"?[YF2>R
M!YH9;3%WIKJ28]C.8"H&VZHGPKV5<?WMGODEV-/26#MSUUQB(7;74^FQ!Y_*
MT(#DE];:F:+VIE;N[\_.Y<4YF5D'.ZO1#E*PN0X?0'T*[.0>:6ZPA_%,+G&T
M8$9[BRUZ"ACE;D2'3SNUM_-\JQC<TRMQUGN\T\M26G<_:;F(82CUX"S(2H_I
MLX9AGH8TK!3GX10<4)C+3I#^5A4^)5FP&+8K^];HQ6OQVV0IX)@)8[JY>#$1
M]&:T2)TKCOF8L:3[X^#ZWG45&F^QVJYZ_N(NF?VCG ?L(SJ/(G@B>8S'A2LR
M7Q"Y['W27R)!-G<EM^Z6:'3&SN%:)J<ZL,Q>G"1:">PW3HY>8OM.L8LUNF\7
MF+>E',F>E!+HI8W'QIZ9M;'2NK"HJYJ^Y]8!=K4L.UA^-4J4^4FCW?;'QL=-
MX>WAHR+VZT6C"DO)\OBY30';DI %IUOS(1_FR)J)PZVW#"V&$%'OM!IT-^PE
M-5D*J5@$?Q*%4,F$-'VD"EVTBSN&C:$=<T$K?(^IDB>48:KGA)RJQH8'+:T$
MU,[;J'GGQ]1=-][V4^+-L_1]T3(O35D,*)K.'QUM0?B[G?(4MFW-G(B/-ZW>
M1%TX745"%:=:+*@KK;HBTMKG-4X#!.[MC/10W8T@K5Z@/<OG/AO0>/EMNC7L
M53K&EZH[99S3,F]V'67R?H2WK!G-$J20+Q\5\U<^'6U\Y<K[GMJDT-[PAJ04
M'=6BXX5+(QS0*!@$VR1^^J_[?OZS U_5X8(#86G+MZTPY:V*3[D7TG*C5DE'
MBUFXK,#N>RP&#0[YJ(FX54[53#C0C)SQ<TLE[#H=]I#L^?4YQ?FLW>V[.R5K
MD?^FED+-0VVM/%%7SH*<"20?K>G,E'V<DL0YWY^*U_!T_'T%F4JSIO[3X!DD
MZL!/TE\]9=&&:N0N7M@E[R/<H!WD3X$Y9Y'[UI.Q9U,-'C"&QM&BV0D.Y/?W
MU9NF[BX)E;SF'XOZP,4D?'2TIFG>K@X>C_%1):N\^L!@]9<:!QZ;H)\[2ALV
M7:4^ZAE9$P]OHBX$2/@UB\6&F_*R0XL$5+1==&^>\,N=[X'V:T"+2$.0G]M1
MW<?\ZW"_%3AGXF]"_I2Q@4!=-$G8;<?MN?C8D\>"0[5ROKJ'MPA(UA*'?6;0
M_;-9TXTYTK*!U6AIE= X G.K]X=?1Y0*B< 9G$$N_^*T.9!;QQVE#B8+>"@,
M8Q_N SW=L^EH%[:S0=P4#UZ/Y0O\>#*"A_T$#,M#1?@3/1=\H>/QHZ)H?V"5
M$WV?R9XCFRDC[#N2:>J3G4K+=FX8M67/B*WVZY]+CK)_[.]"4DQ'Z!UB"ID!
M=6?D[(&6IW3/L8]R8YH[R ;7(Q7 ;D_//LF^,J564HC6]Z"KH*G;M^"7(>=)
M[0[GZ..=VKI&GYLB,\K.R!E\S?8=>9J^"H+P_"[?3@6N&6K5J"JA1[/"Q_I$
M",> :U;GDKFBJJC%6!W^>F^&'<L]+VXE0GOBJ]*S1H="=XH>_6 ?8GD857V%
MKE#?-,=[&&F#VD)KIT==4-=SH7HZHL*,@[JL>]SL4JEQU8RN\=W^>R86:Y\(
M[ZT16@>7,\WD&IVEA-!-\!&N@S2B_$+H5:Z9++;UZ@2+9F%#KE?$5V8:KZ Q
M*AN&K-,^"NSK:_L=F=I*I0&M'WPJ[THNBP'N(]2D7U5(7>I7'"GM#;!7OW1.
ML*K.*!DKUEB\T"6X^\&)^@,(8XRW1B%045.XW:9%*3)C>M:1L@;0D4636;\<
MX5QW"!=SN.ZU,:U8EYRM= 2K4R,X/67P_"LX$"K4.  '^ <*;A_!7IS! =&;
M[9<-TP]N[KFP=%[>%S_,W((#['\LH(:G_\I'JJP]_9D#H0F4)GJI+K*EM#"(
MQ_;]$]6+/ $,=[QJY3V!6C7Z.D2D[D[?]BM3R8;S1PRE/%)QSZZ0>PFVP.<S
M>S_XH<&"BSQJ'CVF9F?1SI/ZERI$:>I*C82*[!R7P[T'@49J[:H?>K#$BX<\
MJ-/2)1>CXO2C>1C./;_Q7@V2M>*&4L7S/.?%6#C9?H&KH);T]% E8?&3Z6W*
M$"2CJX3[_O)(LE[\>+237J D=8Z_R^.W2(@X,5+%**9HTJS&I#&HES5.Y^GZ
MPXS2K^2G'Z6_/.U/X#3]%%']?7D,T5H<]>#+3ZO1G&^^,WY'EOL_/KW!.(=^
MF]",RWIN]&+A3?@6$8ZVK@\1T=W4D?V" J;[XSOY6 M\6BNW]&I%A49@-IE'
M#(#273)Z/C-;W>Q41U^FPESVFI+FTHB-!TRL;23W\= .LB[!D-'.GAUGO'V:
M 957Y4HZ^ME7K<O7/9TW>>"W+?0B:%59\>],4TW2_-_]VZ_/_J[\IQ5]H BM
M=:=%.^&^>'<]=H7CZ'>G9)CH,*2FL3M"4.O\=M(%%M@Y,S]G]2.H[W;M9I,V
MPRUJHC;ANN]RL+JQ;CZ1!@]UDEI2<+^4)ESL1"M"M&!0&,&2X<#L>R]MK& C
M.:Q9(9]%^W7:L%##4:&\L4+J:-Q-:&ERA0 #I?,AJMYP1'#V]NN3QP_XI=(C
M-FX*9FMG5NL2D@6ZCE:/(=5>R=VA;1]R?G31*@NHA;Y 0.NF?D-,VWF).GM;
M-4%?C*44LX#K2"'OJ-7I [ITDS$3D2^=M=+L<(#@\B1E_%I(H,C8M;Q\%D'T
M=#D"#.)PM#_[AYRKK:-MOOYE4>6-''O Q'M*/O\?3RE&2[I@RKX2"\6HLNF>
MCM 3.(#CR'.><)QN"W%NY)>B9:LE^'6U*4C<:[4G\DX\8@8.E#/$%T4T-1X]
MK(8#1:!KUBS'U9#;(O+&U,G1WY),6>Y--#_#YE\+8MEO_D@: KDB1(2<"B]P
MW..Q+Y<I;H]HKSDICMM!URM*Y4I'XB5:1WO@,Q/0>B#DO#-]9P#2CT"G_3#%
M07%J5S3!VK"_>4JAB[RIGWE%U\@+YM3Q<S>Y<!_:S6$([!*?"<]&_)MM3S7!
M9 H"?MD0O)<RI$P$#@CJ(WP!6!I,&K9#^K]L;HD^CU890)I0' 0KT/P//]C"
M#UKJ<2ZZ>9ZG.=TZU$=32T]Y/YIW@\'('UA\VU@_<O-DZLZ&1F)%_YGU9VE!
M/?VYDF6B?AO> H**T5,J)&UB&(Y52H^)6VO[IM."[6Z;2[M<(9%P.=(J@3!)
M[?#2&ST+FM"(EIV81X\JW/:J]"=#"D%-GO.P1T$".S7F$SE#7\+4/\TMO&U$
M.16Z'L_IP97#;*-'"VI242%"(4\9?<#S8LC.F5R&OYG$T=K'@#1L\P6I3OWB
MK6V;\/,1'=Y4SQ^85J4OQ[](N,^490EX#8R9JV^-LYFP;[N0K>X\EN\S9JHI
MDHN]B_O:.%2,[XQK&\_@:@#-+^2!.5VFZ;MUF1KN3BBM1:NPN=C./-UTV/1%
MO@,+QLS,%MNS3$.A7OD-<@W!](SI'P1>YQY<FY?"Y?)H$5T99IBF:3WY&^,U
M07FF00!45H/HZ(.:\3#I69MCP\.RAF\'F=Y%&7)385@+'31B3HKNWA9K_G]N
MJZ1-*[&?QS<5)I<[Z0GL#RS .5H_V+T8#M1*#'_V)A!_92<H#QOY^:<M)_SE
M*6@;D\IF'.=&>EE F?OZS?5'_"[M[?C"XYB:$6;JYT4&O$6=;XU@S_7[<^.&
M@L-4A;UJ982O0&6S7.7=L@X<N>N;\0F&#4U$.*C(2$Z;.JB+W$:'#K'J?K<7
M6^8SKTUDI>ANZ)1;7+FC>E*#SG(;-!\W= !$K]BNVZ76C](-6R$V(K0GH6]A
M[_(^3TF*&3ZOXJ*?Z4YV0R>8]E+CMSGEU]=AL3&H5K$(OF\#L;]&Q%&V8!\F
MHHG96^P1Q;L^6^QUK'L9-O2"7>8CY:&P]\E+#,_Q3HRZM178):MV]2INA3Y&
M7NG3O_;P"G56>7/E_\JVM@?2P$^QCY%0D4X_/HJK ,9_]8^E-:]-Q-\JX<A(
MX%^S?_]:_MS,#OS]6L"'.:JRF@3-J"5HU$#>8I0D_LR8]OX7NUWAU<(]:ONP
M%]0H?5P$3+B"-]U1].5*YG)1NK;>L!_UB(A<$O'N>8F?V>_?7,DA7F3BG<9%
MYB'0>GGR^5[(A71YR.7N\]OK_#-\4%02P<@'BI.'C<A!_Q=/ID\HP50H%+Y#
M!E[>8,G./5 9DCD[U'X%R\E0$.0O'/&47*J)ZA#[((D_!FG6SH#TFX+V$?PS
MQI3B>$KN^ES\6^YDU.EK A:6,;M3W35;C*LEJ:/4>G4*DEC+'OVQ^!9U\ZAJ
MPSJ.G.9.D1FTL9KDO]J%X>Y2P5P1.G[<.,,78&\H])K>!OG# 8Z0\![Y:+%P
M:7,?!SXC6LEG";>)KG! . *!5'=K6?ZM .%,#\CQPX83Z\;)\<;C3=#M@<EO
MW: =<T,S)7YS%@&[_9F/<PB# T((-MYHYXJ1W-UV2HIVB\+R?1E25@Q9'X)<
M+XR++C)H?F$I(C:A#GJMAAI#Q(>?_OMC]HYR8^\KQ.TJPN)"#4NKEB(R>?/+
M[=\>Q/*J!N:.*;J7L_R.^3G"@7^SKO#;+G'DSU9?<*;;EFCW]AB7:DOBPH>>
M=;(#U2O&26:P3TNNLV^TH25)M"I\G#G[ZJ&D^^^0R%QL%;(]_<H/\6RY"B+,
M;,I#)0976C&6DV$5*K[-.D^&[1FD=UGDA\<DRC=V,AXU]V(-AXL+CV;7H,Z3
M.&6=MQQ.B69.TXSNK'YM__[UE1?CC"HX:UXT=],!>L#*IO6JE.[*?V7Z^[G+
MC]*KF"_[K>&8UBC2;S6>U"6V'L_S%D(P-@B([P8P1UG;1$PS%I^YIWB60 ^2
MK15WW_*0*TDDR7S/NR,[G!35NMGP]-"R!(6_S2=!GSF*<UH?.O=J][%U(_6R
MT*'VLXC%69Y7E4ES[<\EUOE".:+["?=/BRR'F\F??(,&2%:,Z_N*^5BQ"X6%
M\;Y>-]J+357#6O/GO___[IO@_UH41XN398<-:X*1!;*XV_E+GN,_2[8YCW<C
MP&T>$ RH3K?,EZ:X>C6'B)U4XG!"=%7@ $;_F.7GDBZ#P._L46'_3S77'=5T
MTZ6#*%A0$$$Z4>FA]TXHTIMTI#>I@A*DA1(4 8E(DUZE=Q#I"$2:%.DE"$HO
MH8-4 R%L4,_;]GMWO^UG_YB3\SN9N6?FSLR]S\P\]\;,['ZF'B)!^>;WE<AK
M2/0L^-I]([K?D.0"7QV.B#..ZM1\<'A8QAYWGR4V)TDA6D'4UCI:_:%78&L\
M->/BQP>5UCNJ*^M^:Z2-A0(9&D*ANU[P?5#W[O$S.&M)N)M="VQ'R"%]_ZM!
M?5K5K!3Y?+N1W8FGT:$ULM;5G%22@^)#"YRU5*=2%L%CH5*[W)I?Q&/R2,HD
M@=2C0^%(#ZJ %[)*G*/V)MN$>:[K,XT"'_?1,\C:R;3KQIJ.V"4RBYEPO1#'
M!PU-CK&PID:_DY6WV#GSBO1:?_NFU+%MK+G*4@R4OYJO*3].>*HAC&<V)"-O
M1/.X[GQJ1/?TP$C5=3\JS7H^]_):X[*DHC@P0[F>OQBIF)ZJ:N5NY8$#%8DW
M7"TB"GU(7N+CZG3Q;IWL;!^YK$O7D:X"2O-)F 2MLQ5\T!K@/M=P5#E6#=%1
M7LGKA9GSUZ=,O]-R=79"\P57/!DC[;A:)/Y<A\T^>!-*-%]U.WSJ8*?%/)D"
M+RQ =.'ID?X(NTM^&2FCY0@]0%M>MN:F*I\""</6 _/7E")=>1R2B_W:JOH(
M@FJTP^[%L4IO2PK<F9[^%# F1WU> 5$[977;Y2(-"B1]0#Z45J47W3GY(HFR
MIZ?)UN.:8JGCP.U@F?/00.-9^V.N!T_V>=OT#N(\WN*\PHC;;_SJOQ;U1Z.%
MU#AT?>\?$9X,4KQJL I4B$GS1;,(,]>Y:32E[2G '1;K/H,(W9&"A8(G*;['
M+_2(L68VRLV>K>.KSN(R<4>#I0NUP<C/0H.,'301;PJ(@[:"<SD.Y0.!R2@7
MM!!TJ<RA+'<52D;MOCA39<_,Y89Q])-<<W>G8;^TGJ':&4;0FQ$^$^EOH3A%
M%T+>)5:AGH,&RH1\L'34"<O>&S;>]\FMAZ8D>=D>F&H]S/#*N2"'[AR7SJO+
MMQED#D=B9SJ#'BY<K]UL2W$UCC=*???]M:;79F1 /M=BQ*+BG1=5"1P;@EVW
MXRB25",'&5XU?X3.KVA.Z XOHB.W$\2[S.VX$)/U-?U;4-J-@T3.5R4I.V)O
MZV57"2TD86(YIL2A[I15-.IL2*4)O:"&48US:2+M;J.-0E\?<?;S4VFDBO4)
MI([&+^"V0I&H;'W_N5- Q^+T"0385R>V)G'E% ",A^UWPL1:;V"8H8G<Q_O@
MM2SQ/]U#S*=G19^YYE\8VUWHY]5]+-F.*B6]+KT+%'/LJCTH32XUZ(US+V T
M)2P(:(\[HZ8#,6'@EI(%:$1?6(06>N""9J49K#\"JP"<59S@!J-P<)J!>+O(
MFSYK-XMAQ/\)GLX&1?KN_"D@*N2[UL'+?O2W4T!G*P8TI9B/6>[<!Z8"=(_E
M49COIX %2RR97^8NUA>VPX,S)#51JV Q/DE%U/]&'V2(*MY'<=;$U:XA//<*
MEC,#.'X\GX)$?MA0P-\'<OU=R7<Q1%L)B'A?&_"3U%S4T<4_C._QN9N P4$-
MHR2\&AW.U$00X):SS);)IC)CM+)$M \RN$SH./8%/8G-":Z2,1KI!Z6TA[2<
M]#-0Z23E<=]5E+ANTK+= _]6V\I.](R]UU=UUN%)O%/RO:'[-_9YCX&/H'NK
M"GI/6%>IE)H),TKSN]KF4LBB9D<,S.=@%ZL2?29%KQCO>X4P27940<CK'4JN
MW9=O'T_"WL1I)4\==R9;,]N$)FW#B&"=@[DX.^!>YBVI[CK7Q BEY X*E2<S
M8)LXTP#S/$TH&:11,7\3--J"CB0,>_4I1&Y+K]!'X61<;I28]D 2G(]A!Q45
M#,H:[407<6P' ]W'<A@YU"R$I\QCL&2?'D5^(CX$,BSC9I0:BJFY)LYS]?L>
M>*@N)ZL.6:7/O^_DD!<W.@=7OBG$]$Q$9QA9U.7@!NIX-Z7WA:PHE)$(HDB+
M7"3OEV"T8V&>:DKE7%QX1*2614Y6O8^M3TF=J]2PCI5376PCVUJ2P(L*/P4$
MF22U+'07'^3:W!_O=L$'&9 W6"M8M).]759:T"FZ$/]Q*\D<B8-5!N$>^N9C
MRVZ(\9HIV7QMFO5UA-=C51ON18,])X>2K/A>!>DV<EE%6NBUV#QY9TW"RVXZ
MZLMV.A2B[>TY^3C+AX0$_><L'WO)=S.4SLA"?;C]J"$ WT["0$_>5"PZ=^M&
M/$5@SLN0BL+*K[/@6<(SK)8 8U#$W#I$[.X2+SB]SZP^FC1#I6++9F"Q)^M_
M4R>B9'03N(HE1)M/]=W DOA,H]$A.P*P%F(<: 3S8!7>U[/BI,S^7PD1K)J=
M/.='[[V0I.MZYP*>?]7 H(Z$NG*IOG-(U]L$*+Q$8+.AY8\$3PMH=LS99OS!
M[$S]0?-D/9<C[]9>/+TIO%/@R)[^?2\96U>S\R81P[$+E'IX"BB!'2\/HGIQ
MV-0<>R1(=<9)F19X'^V]"^LW.".[TOM.[X[B4'"6UFBJF,CB2$E6\HFQ4D;%
M2M+E"('L++^/%'47:2N;B16Z.E!*MBD M6B -Q5+TAKWEJ!'TPC'7&6XJM(P
M'AU S\2=L-':<:+'*#:U@7?B19BI<5@-?>N80%_WR&UUL-^DI[IIGIVS6K_0
MO,,C/M.L)@W673N0H3+7X,C"W'OCVR^OT,B_4L^NAD@@N/6/D#*U<!B!6KEQ
ML2I9=W:X:HJ[ (4$$(0 *V 7TM?JGC&GAM]4OK1'9$_Z]>8$O?940,J8<G9"
MAKKLW,<II27X !GIU;8:#_R=$@[34X#SVZIPUH9.AN@E2$I>/M#H<MY3"#Q>
M:BMS?V_=];?Q*Z8+8_9QRAKM=?$J=7\9:AG602,,"+,+KSTL/E),U]Y.AGN6
ML_RJ]+M&Z<BN]W*A,KW\7MI[M(>R$+[>+Q'KV3[$!)3 )L$]R%2MP\^:,W*#
M_O)_ J3+OUVY_4B94*Z'.IY?D;[^KT^/NK4C)26VT6P)&4H-0QVY_&%^;NKL
M3UW@/=CQ"VT.UAY;BZ'W]13T--5V5;GJ'EQ-+1GFIRPU!%E ))4/*)?2V?%5
MX!F>1?(.$.>V&[UW\A+FF/I&]\$GCN]I7W(HWZ$M"O@P7\7.0W?/&&+KLJ3-
MO\ZK,W(3]FTU;Z0:QJ\HS<.5TKC0TW:C(4#QS8J6]CFEKE4'IS'X.R4T^GW7
MVTPX6S2= K'*+$9SEFBK:9@!M:4,V-I$S)JVDXTD02]K:>O;17DY1=Q8&9\)
M'4./-=+GUJHBKDH?3986.;_(";^WD[\\/[9FZCUBQ>&O>,(N=IBL3CWK?'XD
MT06><9+IALV+,!UIS5=/(P<<$I0?0,1,[3T%\HMS&VIM.U_;[UT&":?9B?+5
MXJ!2.:;@F%FU[(9M=K5(W8/Y"WQ^7A(P?I-C[.Z))3?V6Z_Q4).IK"#M.1JT
M[DB.O3!D>:SQ;O'#B#C,D0 LD>!-O4_["&?#"[T,45+>=7Z=+AR > NK/P4,
MY96)98N.EEF//:\SW7B<"0>]^*]?H_Y;?O.L%/T(/JGZ0>65)OU'((6\DQEI
M0:"L@-7C%%+8F??\Z/',5<YC1-V-G=[Z@!V'$#J*3P&'&XB6B'+<ZN\_^UA!
MM-1/?U<)P:!/ 3@D<.((GF4_!>2!,3"<A3"#'<11X/X@Q"HF8O.0FZ< XEU1
M[C^VC2B?#,0!Y(I?#^%KL#^T5L0PP?90IX"('XSKH1:<49S! 0SPR-'D]"S6
M]GQ-_<+!M%WD9*5A,_W]!7\]Q74#V.X:^.3HT79I#984<>2&Z_ /!GD+SB!I
MP'!8Z"R$9T.">Q=+C'F9?LG*=HM-^!"6V*_H6MQNXTQBRD'(8!&V!PZ2+LC/
M*3(J%CY':-&3IM4LU<A^%BU4ADTY!> @#K8*N!U["AA.QX)_4+ UKV!. ;A1
MW/)E"?7I/5BIF7);<R]AZO[*6D]:Z&W9D'7H)Z8SCQC+C%8FF22(6>R/\0;'
MNIP"_M2K[RJG@)5^W/KX05G/"\+"FG$(0C6HW,DQ8LM\"7+(NRKL5KG;_'A'
MB.\C0_^*EA]\"^MG=PI J&/)D?^4L.39RQN375C@$L3<ZCW.D=S'&:=A'/3[
MXX<[XH]#^Y,2'2QAZ=NP!>Y]J1K/[[#$K#<,BIG&[$7L  BE1;B32M&XR<F[
M/O%7R<)A&WVN^NSU?-KPZ/&T&#8Q7MWT\>'-/R$_K=_(43_LD_[/5QK6<Z"_
M+OCVD4K-#4ZUKZ(@TNF'&C2QKSUD.J 3Q3Z-&D[F)%^,><W?2<!$&2+;9C7\
M:X&O=+G] *5'@GTY$A7FV"7]FNO!SW1: \=6U$U)-_>UN"]_4;R*B'R)U_GP
M9'XX+ !L%*^"7*ROB^6B6(SVBW2F;+%(\Z_-,?5+\K1\N#1NL2O"X"H.QYKH
MIQT-R'L_F50PM+HQT2I00/+J@3)<C$2IBR&?@1!H-%VE;%T9Q +CTY.F.U&W
MPDV%['"E[!0QVG&PVY/@(X6'#"UUW+3YJ[E7/?P2,G&B7#SGBFHTP-=UF)BK
M\1W?5,Z)4KSK;#W"S5N>=7')^K>. P>K^[%)+!">+QK$0Z7R.Z8]J0F$^'N"
MG()95'V=F:(VTA!R.%8A6;^*$E.$%@$(T5J?1<@D%9EET\TESHQ&<$S\B3K_
M&X7^(#*C+'0S7PEKCLQ'-KT$=@GDT49FC85K[I*'WYY(%N,I;]0U!0L>16PJ
M:"ZYZHR08 YO='TF"=Q>TQE+ZK?'R9#^IY*L_L_F;0*)1WP_B#]IQ12JA,]C
M)7'GZ\>G %"B+X?K)+TW#E"W &W)OELYH)1>;XE? .JH%7 N.?DD+)DWTA
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MS>_)JGYE/WCL&2Y^[[SN?]L8?ZLDS\'&=:G3_;@X[[RN#RKDQ I=<+)'BV7
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M_)$MP5 J."< \I/6_+>OC/^/"_!T_%\ 4$L#!!0    ( ,>!:E1]YRG][ZH
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M)78DCTI]CT3R'I@(@%@?-,8AVCUHM%,-W9 2E[!=.(B=0?H++F2-3<BN"\R
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M5,W1AN>&-00S+;X]<L>W $X#69"Z^D:G0UN1@/[3X'F*T10\(XSK^\ "^ZC
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M!Q(RVM:W^89TV*TXFME.J!27E#9K3POKH_I,B(?\GMRECW\88GRN-QMQX5B
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MBUZNIYQW9_SC*=/I=Z?8CL$,"UX7R;@L^?P=/K.1+G/*?,("<(NCPY*&D)T
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M0>"9BR4X!SINOC1;'.-'A^U1S*26L!Z\E,30$]EO5KF."-#[,E:LG':<F'/
M]'T=S7Y'8")-%M_F490TE3P5P:? 5"PZ;\+W9\#IEZ6!%BBA"W>+JH6;6KT@
MD5LDO8A1;WE^3 >.)%O1IJ3I !8ON]7H*24*B+B"46TCD+\,S4+$C@+\W6$J
M)Q62%]?I+Y3H80->UY''.2C@+>,5;BK62O<6RT%2[C=+SHVB !C3#V35*HY@
M/9^"(C$CD"SUNL' =RC"M!$3!;AKH("FJ-\1'O[) G3? H(@D40D'%FP8?1
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M?N+520+8N7K;IK"S'"S?\/<);"TX^N-5SW8N$(*IEY1#\K8;;D2/*$;LDG#
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ML2R#"^^JL(J%&P86CZY@U-9SGQ5_J$%]:_[TN>-MX2.B$_(,]*)V9YHUF9(
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M?23U2"CPKO%IXSB\]?MQ8847 *($[V'Y%= )PW6\P\<O (SAPI@RJPSNYC(
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M2?."+\P$G4B.EW$F*BE9CD5J3A6-H3OT<X%]@K3UQWTJSE>Z_U'B_Q\ \KM
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MCC]$)3%MOR++]W%ACM#'92);"Y3Q'7H7W[3YXJ/YV@0*R+Q=D\[/.CP0,LV
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M.]T$D^X:0([0:A7Y/;D>QI;_CH>Y1SK^!3V< SATCT4<*A X_R\5R/'3Y+E
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M#@?NGY>=*_>&ZS3MRBES,I)/2)F(1F#2':,8?35]DI<W]A<=NS*#SE0S.MG
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M9L'[X:FXUINMQ]8?B'X2TC@)M83% \^7SDXA.#GKS2@<DRW,?W1GD6?2[5H
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M%0"OAM<*6F_ ?^T*Y,DC #."!*#5:"LL_6U\#_OMA.KHR@(<?7\A4OX$TDH
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M6%;C47UVT,WM. .7FO[-QNZK=W!>D[KPC?*U=?M'$B^$7.Z'S<7Q&ID&V;$
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M@Z:)G4_783O5+(F)O]3.)'WFO6[K;(Q7U^'RJ@5SLY-LK'W;>$/DLO*%%.!
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M1DD&H"L_;IJ"_TVS*FO*,WD&XLBER_^L UX(<_!^X7SHI?&+E!/D'":Q103
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M72WNO7OWN<W?]LA5N41'X(4V9_>314ZIC-TM^-OZCO@/X?LCQ#\-5>85S0A
MF/%LP[_OB/R 8_Z['9'M4=)YDS2R>$;K8 +PMUW>'O#F(K3UO^WK9!582G&]
MN8TU##Q/ +)NX+6U__5$*[()OD=. +K>-V"K-QQR4BT;%QKF#+$B^*"9(\D;
M?QRHO=IPE@#TLQ& R_E$*M=+L^,<O4CC?F/ZC>DWIM^8?F/ZC>F_$5.*1,WS
MCC^EC_ASPBA;585_0MS_C%S^,V+Z7;[_%4QY/<*S;C-_3C_GSPE[C@[ _@F1
M_\^S*9?2CJ="$X#P>P,B96G@+Q92Q62/\1Z(G;FXZ]_5#2%)OA+,ST]0_)@'
MFP,2MJM%C7 ,JNC8L\E&^EW%8!6'6;U1%)+^H:BJ!G-1*#:, '"+G", HT_
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M5Y[N.$+GWNWU'>V[G"R.('$",!H"\/:77T[?TK L0?(*[A!P X)9FSGL*D'
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MN/6F8+BA7 WC@E>1TS@-SB'@?:MBUXK2QP<J;J_.@!+Z![_\Z)JLDFW0VV=
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MI.NL$]$OH8:ETVSZB;W,*5*9&G; HL*U]^MU>.%1WF'F<@*3]WB"DEPQS.3
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M,O?7W^J1^8ML_/",K('J!JSP7(')U5B?R'6RKQU.39MERUZOCIIH&%)AX>1
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M8I'-)CT#VF^M9.UVMFPG:. D.,//  53_)$D&4Y\/.4,4 [:D<A"#S3HXLX
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M@C_%[9P9 #>GWH=SDR#=;=/(A%8#;S+1#'-WUK>%AKUC%_I6I H+]*:JYNQ
M%VK+O\_ *%B9'>8R1*$?]NO/ G9@>"O)W AOZ?Q5@]>?\-Q("BY5F'GJDLV8
M4C9O;YG4EB!$=@;>WHI^_5YWJ+B522@8&:%)**_IKR4(AF1.UYTDR4PI;K8)
MQ<JRG)_;"F8(BG2VYG/FO]7]^F%-#$\[,[IP.E!A21MM",NVC@'KHGB .0*&
M SV1",F1FTPT8J@TNBOF^**B97&%;Q[9VE-=J3JRHH7$ =Y'LRFAGO"7++;<
MK33PZ_GOE>9$(Y"J6M[J*-%,AJMQ"WRVN_=2PQ$#;HDT"3 LP"I&L\.J$WY9
MO:1_;P,,^C0J1\$\<(,,<$]HP>'N5=?M%<^#A,LJTC'9;UZ4]X\4K$RSVIH-
MG)O^]K$NPO73S&E;;6V_Q>W(M-?[!!8,G>^:&3AW0EA_*IN K+Q:] ._:# (
M"@';(U=$0\+CCVW.AMH)+]2.I5645I2JQO<I4AZS^UVW 7:W_MK,$_8W;E&Y
MZWZKL]]C'-*_1SN\$H'^(T4F"5^[5S=.74*UE7=8YXXW%AE\!4^(IW40>(X@
M(C'TH^CVV^6?]'6F%H<=23.9\"/WYU(HP/C(;O'6J@^5#S^5ZCYXJS$66\V"
MSF, M6[1H+5C1HY(BY=(!;2VVLNM\ MQD'U]WP5:<,<QUT:CPYXDD"='X93A
M<!QJ5;"14>'OVLJPH;U'O3A%AQZ?W?"8*W_38?O, ?0&,#J##B#CKD981#1G
MD.;COY('9/[ 1$-<]7X+FF4\H>" NKU9KW$1'K^$7IFC^ARML\J?%LQ:1;T/
M3:^B<J#7>_AB0D=N.SOH6XRS(:4Z[ JLR4\&C-*-V(^B4V%<_93_!K,YW,:[
MPOI<7-@(3>_V?MTA8R5T%Q*5:)*2;3)&PLC#WP@^4J(%>^GFG[+>53\W;JM1
M";QW0_I)'?^16]M\'9>!D0GZZ@ZC7J*^,@'[ONC(@'!^^/=0.6#;_J*W'(HP
MX/26?6;%"_ML*Q5?E"$P/X(X%6#VPKSTP@(GR[J%/O'3&/=V+. =*M-ECP7
MYEB@S@J_ S;KL#:]QS&-!:9O1Z&-) _/B ZQP&$?W."$O_X4%84YRE@OQS'[
M-L@)CO3>86C):[' ;5$L<+9W#?*K>VOM__RS^?M_&:J/, :'$&81]<N*]=]C
M%%BW/[ML'5-L88&M-).* T/8T1SKV0[/GT>BPIM/^=4O%'_S_F>_\_[R@ ?W
MKW[TW;<JR 0+I+%@ <PQ]9KIXPHLD"STW4?W[[Z2X"_W0W\>I. O@PS\UW#
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MH#K_*H9+CRF-.9*<=[XKBO547N4ME<U8(#[3(_>U/3@\F.!A^ MM3.,3V,(
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M54N))XP*0[&Z ZFUX8\LC)!^@C^D@P>U1H'<T[% .T*7 3H9]D1^?*$:D#B
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MW6P_V>N_IV7JND0S*KI_[--!7%I)E=J[#@>D9C!$3>KAR300;S\@<WZHF !
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M^EQJ;^JYLK702"4PM[4Q^5A/IP^R%BH@R1DB[T4V7E9OY106UH6U7"W2>T0
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M (,?)[\1@'_G[-A?/IISH:K\S=SEN>A#_B!91B)V)^G%CL]^1>:\=GL["D%
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MX,8 *;/FJIDF$.V*L\VB8LK6W=F:JT+ZYFUFM)+8)_OX(^8V3_!7#U/(J%6
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MC!5V+9>A"'' %9]7)R+$5W^T!5T%;\&MX"S]D/E9*;E=]?^_02JSHF$MOF?
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M#D,WU.9!KVQG+O@E?"<FL(]S9!-,OC&ZVC!@IU5G0.4R$PKL_&&SXR\V4I\
MQ/M(>Y)@Q-XAHR*KCGNS;K2<9B)Y%SE,LKFCETH &N?1L&.R= )0ETT @CMF
M"<#A27D"X*=!F:9I"B, I^*^$H =QC#\80;^+&\0<3Y</'N\*\L9*.]% '!7
MU2F)9%CEVM%*%-8X!?1#X&>V/P)XDS,O$@!TI128 -SFJ]_\#$$Z>T+PSS1A
M,]HD2TS_XZZKCWTW-P&G\O2=,53@O/^&EV,EJA'./HT=;+6!7Z :.&3?+S@U
MM]E\#82-:KHT=+]&V9+',4MZU7S/NSQ)FG%.[U6"6.^H-$B$9/U7)^A_GZT]
M@Y0+U6*FG,-729DM CMC5B/Y[V=#$V:>]L/S SIB*36DV]- ,;X7D5WPEW57
MW:HJ'O+X]ES3(H&[JP>:<JA)C1\4"9MSVMRNJ@'+C[J!7^"OPZ;B3U[BT355
M@C\Q&P<WS3SN,ISRR^(XX5N9!KJ V0PR0BZ&KJ/**KP>D5LH@\A<!NO2T&*Y
MEXJ1Y\XMLQ1+;*F7^A;/S3";^M[%N-6DG[EB8*XTX/.D+@\=^=K5C&;L6TP0
MF^MA/\6O-Q7\$1VJ9X'-OX&"=[MA$HLX!TPHY*1GBA]7HW%S6NQ9:6@ )K'U
M#4X-">TY_]!2_%3X>@M@]).8L[!_7WF@[[V]]V.L]2J'3WZOD#,XS,/\/L8_
MU8OGAI1FR=,)"F\]3>(<3VUJH#$RW2$ *:XD2SMZR;#&)?0^[LB4R/ZK($A7
M3Q^\'QRV.05X2S,O@M%54M($0 91O[\1A37AY"0 J="9HWU9SBAYKS;<U2@0
MK*]T\_B(N%P40^H7Q_?QQ_V4&0.F3L3K9#3-;*_[$ #_'UF. \C-@[U: E#_
MO]?\AZZIAI(VM3O=5#P]4;!,SPYJK-E$@IOM]%H.>];S=VQS&"FTZ'R&I&PP
MJ@JC->+2[TM+Q^*_MC[@R'U[G"I@/X?8/?F]/)[;NH&F4U:JGW)@^ _6%?R^
M/4T!.",V%^./DAV^'Y5^X,"G8?%Z;X]Y/>NC+Y0SI8IX:0/!J_>73'&Y05,>
MKFFTY\#ATP)?DN\-O=5.7H].9C"3PTEBINHC=C1ODEQ%@>O"79F[<7>Q=LCV
M&M"MPJ&Y\A1 3*56MH!_SSD^?737\_:!H2CEM@C)CMUOL!D,Q@WEND43=>XJ
MP7325"U>%JF U#6!_/,5U5WL*?+>+4289-622K+L3UU9'G4_08^1T[=W4J\<
MQUJFZD J]R6NYL6MW1:OME\H=/?[5:_]V=#E( !!-=(YT])3&W%0Z:;C9<[K
MROF=?*1)Q)GOAX0< F.PF0^*./[-'Z76*;KPQ]3+UFET4#SS_H_"[*3FQ$42
M#$;#:WB)+__<M:,=_H_I ;?@6+UIXFVET48='S+!&NO0J<? T_K-_H*$_\/>
M=\<UF64-/X@(4D7I+2@H*"#2!"D)BC01 94B+2HB302D!0@$Z;T**$A10#H1
MI1-ZE2)5D%Z"%&D)-4 (7YR=V7%VISF[[\[L^WY_G-\OA"?WE'ON*?>>Y]P@
M8*9Z$@K3('B>AV[-$6T7Y6X=8IWD#7%Y72K7_]UH37^"%O2/:..^0HOX>;3$
MR.%?QON[V&WVE.6G5?*]!UF*R*L0 O=>\[QH9L-!3QO(-J$=_[^KC>^]WI,H
M.O$01GHU$3G/C'YHP-*G<F(^<) WD(N<:J,1<!D/Q$M,C =>]W_=MZ1[G2]6
MYQW?O*'67L(&J'"),.C=*K?)$32%(G$#^>#=*1>.LMMQI*B&*;IK64]5,BV?
MC&*?&V2YQ]%%?GS"QD??S.>AXG1NG.[MVV I?$Z/E;C5T!UNJM+MK1QL2[02
MUWGJC!>_O7?R!:22C^#/8F8#'0,EY"X-N#=X'GJ )J:I4\)UX=0X1,U06(:)
MU9L9AM;SRS'+CC^MY'F',&O3&X9&382/G7E-CD&F"_S[3T<2LLS9'N;6(JUC
MK\M900A';(A1:J<7P;%;2YYC!<\]1@R-D\GP1$?EPTY,^-8FJA,=;FJ2R^P#
M%))$@SQ;BY"&3!XBYGUXG/"L$2,#R7NBYM,0#?,V!OH^''<1!2'Z*ZKM 45%
MP+X:XPU#$.#,:ZG_'\TWH7$CP(^MY;G1G.^]6G+D5EV!D@R)SMS_MC?UR-/A
M6N??GO+%'EC3\C&=1#F1SC55#2 AY3C(9$);6?Z]@.VH,J<)1W$2M.MXL]R-
M6SVO"F",.EI>EX*F473HG&HRZ,BH ;>)%,ECQG4S_&D$%:*3"4^TINEXH7U
MUF"5@63&UJ-+O[!$1,EZP.H<^2?&=:9@^%!LL(5K/8WXG9;\LQ!O8^:PFY%W
MK5L?23&.W1IJ-C5C+%2@;ZC0G9<_]ILN4WLE'_SNCIU]R+;66_2<F#&]\!(]
MK[TT%47+=25;\P/)/]=R=JVZ02. !OUL,C)%#_6VAG2H<G>B:'P(10-B6?TH
M//\EL/OS]\?_+YPI)>>G1<VQ^=C.MELY4X65U>;T2#>RJ\Q2IO(.^,/JT>TZ
MTCZQTE>I9WB\SUYD3:%CBZL%\T:91:D)^#UJ%FQ5E3@#TVVTRSS,.?7X(Q/C
M?+SDTJ$%V\!LO>W(@GI13Q'CA53+6+;E!)J-9Z'H2(7;MV,VQ4E6.<!L6-O2
MX!/K\/K$#J@N[!15,.+PH**#7GO.VL,%@S%#Q BT]3G ^?N\\-<[G(89X1XB
M:I,0)HVTDSDM)[1E_&0&DG%OT5?'3F$^C$7TYWM-VNI%RK/M U]?8 ,=W%RS
M">+J!;FPOL7I]M[\L^LQ_RSX'[\NY/<"Q:SO6:%IKXM/(J^\WCAX%[5-H(+)
M39M)N]Y[GE0T5ZA)WEK-*LN9!KN^/"I>>O#*; 0X9@ET: GM7=/U@&7<#V*H
MF^#1#<'N V8;A)CY<0K$M&+1#MTG><ZE/[O4YL^&_T2IS^-&N$Z?60^>Q-W>
M^GB8_*5E+K\J2YSS1"QV)2"M*,K)3^*0+MQ,=J!K'V"'3#\=WP>J8M#5!V65
M7\$0NF5QFG%MNB&>Y@ N&1,O3'%+ 7''=JUI.I A__Q4A<U@KV:L$?/UHIBV
M,U<J1%VI;W@(X&8O]J/.;O9'QSWQ#IH!D^-RU#"+NFV9K9HM$\A/\J"K6H:W
M<:F3L;8O%Z>?TPKDO*GTURQ42W :95^E ?1^AX4A?=)/X((AH'WCFM4%80;^
M -.=#EO$T2H.F+TBAC8=86K"X$Q_2MMSWKC34+@)M'V*K7G/'O3>4S9A$UX2
MLA#U7GZ,T1/BZ\[W[S]L^6^$__&+!;X!M-UVO2TR#$<>ES8>D^(J944F?=I[
ML<$RX\"F4A=UP16 #O$1((L_N9 \9Q;$A2.@FX\U"FZ^I!/$D'2XDV.N+X["
MV&3S98NI-J8\Y4[\!:3\I\)_KM,FVH-_KD1_'WC\<'U70DCL3030>66['7X<
M*S5/1?<R?F<G"-BFP)_ 7ER@2L8=3@-1P*])7ZJ?>U55]=(3K.@_R1?$!'L7
MB&$YZA2_XUS;?\PBB:6PL+0S@6UBIL3\]S'[=2-+.R@]6/@S%P/6MRG:QI)+
M*N;:U,?WBBY;@00Q2_!)S,;[:(E,E5D6H0JI%-K@KU].@;_;A1B]P64M.>'S
MV,\C*'<>_NDGGO\[3UJ_!=Z]5)V$&9IR7GF]*=$(J;,Y7!%G=>K=!8CD/J!?
M0?0+GZI#/9AZ4)(N#\KOG3HW&W'-3;< S_'X.$:<_9#D[>1\@0Z$>3*.&&ON
M[ -7UE=\(*LGAO;(5U-H-__L!?IGPW_.0'QK&<IL$91LKKQQS=A87YFW_=RM
M)\<,00W[ .F<*[1^]/IJ_WNIF5#17(8# @-6/VG:WT4>3>B,>-&?_N0Q2H":
MP+@>\V^\#?Z_&?XZRUE+NXC=K[#W;/XQ]I>^S\WZ#EC-!.X#YB"&M-4S)U]]
MN$N^[ M8$GXF;X"*X=J:RS-"TX/452Y3(YS;#'6[DP_F)\W6M() %;:I7$]3
MZ%1?_@<VG/_*\)_:#/]6%?RZ[MZQ%JZ*RT'BS)KBI(U"LV7I7T8T<#T2Z$0I
M8ZT:P,>[\L4KVFZJ\+'<![#RG+I?7Z^V';[I41X)U^FO]5 *?9I<5_7\SS>B
M?Q+\Z?&[YNAHK<F#+69103ON-I$O'<.,C1#8SOKS)?=93AY+D3I+*V(4[B=K
ME@I[\['ME5%:;K4[N98\YY<4EB9*//9\F")U".6;)!^V6?;)+9];P9+^BZJR
MT9\&OE2J-F,'+O8XJ+5I]PIR%U)[W#F*EM7-AW,%2:&H; H.+ //G:60XG]R
M7>=?%=:@@=6K8C"UO=WDO4/2Z]D__3MS^5!^-%ZBW\"]UC#I^P_7R>+_ODQ_
MNI?@[/@/]3.9<)4?3Z]_$Q)X QD>+-=J*ZG*Y7CV$X1Q5BIE;@X582Y')KU*
M%.2YO!4?<;'C(B=7CK9R%U>&&$8F"\@.0+_;Y6 9\O<M3+RVE)^?=UU5[W8!
M8QW\)N95> 9>^L-#ZR7ZDY=;7Q^HO/Z3[O4NRHM;1SGOWQ)9 ^J)>3[/_\_S
M_P)V@G&JNA 4:-;K$*S.Q63*G/*644KJ4&5VE?5>*J_SP'JC37G!:VB[YD$0
M#>'(+5A%W3'+K2B5D]&/AGW@0'U_&>*@Y1:8 A>]><])8-/;<B&)UH 5Z8$[
M]<*#58^DEYBY26]W&FV#!0P9%O;2Z- H3?+!]9M,#WMNU2V#[WI+S$!8X!8Y
MN.L"Q])?F A$-)CU#GG*Z01M:Q"8(2&066\$>GQ2&7\6P8+H/+0/-%?7>4H+
M#_'2NW\7>%13/.8B^R[P$(&5- Z5!.4?-5*_=66='-)?+"N#E6PH/_14,#=R
MC+YKK1%P]U6$9WRI56H"K1%7"G8%D_HW',%?<,B#=+2@I_>!NEFL/QYC@W?#
M\^\#OIUHNNVI<=P63I/\PQ/=5@2F[,OQJRS[/L"U#U!")NUQ]028)$&.P$"R
M8<JXFOPW0IF^(S0<9T@@>M0DH7T@'.$+N-_Z"GWU5]CW@7]$C_T:_<0_HS?X
M=?2'?H*>YC?0_Q/S6,2O,_]3["7_$G;OG\=^&H2&!+?2?Y+>Q8]X/"'9L&9<
M90 QXPU+R'S[HA"O]?K#?Z(1X-R753>^%I?6]ZAJOZ!*H<OA1S[9![ZB%_&5
MF$D_MPI\@GQ/KO!WY(*^YQ3Z-TZ!G3=_U\?@?];'K[%/_09VR6_ ;O SV+_3
M%>6OM>R7F6_\5?28?T9/\RW,,_\&\S^#_8OH&:_MHIF#TYM,H\;G5%+H\OF1
MT=8>HK#*XX!-PEYJ](U?E W=MQ#W,Z+YUV9&Z"?80=\^,[\EFU^?&:%O4HP_
M.#6_5S'8OT*O6B6&0[W@NA&.2 CO>3N%JY[Z5":T6<:Q#]C;I= AS7_$ /D&
M^?X,@][?,KO?&?>?,EC][T/_6\O^9\3[-7;$'YC=7\?^6ZO^6TS>U]A/K:!!
MP<^SSF)NSV:Q(MUQ1E,&X\=PIL(V!3,1TAQ=Y/9_WFG\[RH,36Y*9JSVAY_>
MA#U-*ZE-U>%4A/G70_WIL =F9@R"GYWP.M40%79-I=-UN=I\-US$X:D;3\&>
M '33/H3/;^/\<F_6'C]ID\0>V];D;$@/6?QEF*%TJ91@&3(7SXX4#I05-LO*
M%SF##K?<7MGTDY=UH0K;;!7HKZ+0F(%+O@G>]:U.!%P56;F*.G!K-ZNZ49P(
M1,;9A<PG#"P=\!7B9"&:!R$5Q*3H$'$N6S:^/ILW9O_NW^-KG<2HD*T=2]Z
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MT1_O47)4OXZ'K(QTWK@>LU(?KS[PV*$L_:U2Y NR0$ZK5H@YW3:= F%K'?D
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MA]_1Q&\@'X]Q1]_ N.H;BLEVO84W;.9"AVB4-P75QP7P"S*;L,1W%3Y[7<]
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M'QJ /^JHMB%D]\B_Y7A!X4[\F@Q[%HH*2Q9RU7GPO8G4"E0#?E(SF68]G?,
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M7>1:NQ<_%KJB)$TI=.O\FHT%BG''LH='8+?R?(*X1H":^#D"#XR/< Q*I?B
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MS]'P\Z48\OI.>E4[&%^\V]V*:&ZZ=, 2?P+S*O2%5?2HGI6ZVW$?OTNE@.M
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M4M]6<['Z4+4O=%4IN'@-'L4U8LVW,0G?YV;WU 6N@=7,CY_F'.(Q$:BUD;9
MXRDM\>=S!\I'6:!<:8(<VS3PA_(-X=S):+>?9$H.W^' C3EGW&3QY?%R4-36
MI6P5W3_"66UAAJTH9J*P'DA6(FD>1^0(+;')QJEQ#[WGB$+LQ.XU\%_.+\/P
MI75L$"VT>^-<![MKT5G.2B(X6XOD6"J,C^P=,XO-%*U9#3OZ^&0L&U]_\QV'
MBDU_B=KJQXZU=</HZ26#*NA+]$F4#8)OENJG0<8>)</MFX"; O,H!URP/& 4
M28DG5?O5'1GP\-*@T!03U>/%8?/X[49[QD #]5%&,"JU@V:!-7)A^V6L4?KC
M Y;&R+/,3K&#C06I>COJ>.[-!%5F T^'K28")%E((<:3[Q!26$2W -(*E&,5
MQ&P_@Q%!)O<6!NF^Q9JV*N?YK$<+>H HH>1!#GZC5>;&O9&2$EL.?<T<V\5(
M9T;SH;<O4M9,%0+[J/<F&8;B.O;#:HJ+VWX*<NA/&["M:!($87BZ],$TXPR^
MNT*[WY7$;.C*#APU;E1M#'QW+6-&@&W]],OLOMZ0L!)*MK/X[%NHWA@/KN?T
M1Q*L1P=4&45=&^3T*G8&,\^?>]C#F@SXT5LM[9/T(8A*V53V^=,>MP;WX$:>
M::A5!3G3S\ZH?*YU6.0ON) JCSR5#4B=2C6GF&3+4$[D/;A;?M$B)&_.FO\\
M'K)'9"WQK*4/'.P'^"5G0VQ44 =UHSNC<RJ 8].V>:'=>5=LOM&[=:/G@ GS
M]RL BKA0@/7:@\[7JM?-F= &4>X.5C01'M):Y+V*0SY"NS<^(GNA[';:E#)*
M2.U'(VI;IBM7N_E)_7H3 #DIABT[4X6$7NP:F 7MP@TQ?*CA:T"Y";LXD6W+
M-:/%YC(RV90F0/LB)%C9ZD["G(#%C8.V*A1[#1S(:F"WKH$'VUC*2_Y?QW%D
MHMAJ^UH!"5)R'L;;+C?O6<N*?^;5!%9OKX5(5ZAC_N%Y)R]N%&8D^X\M*UG*
M<#L[$]@'FGT3)/ZYN'I;>6.\NQM ,P389R$WUF'@<CONQB^8=) ]WK'%'6Q4
MLY]J?M)8JQ/,A1GRHR?HL"!37J)6>!5J]8[+9L^$V6']2@'[W'KQ^-#""'1&
MJ7SE ]NIPD''?GZ5VGR_]@?GJ:L98>_)?.2Y<H\L::-D/E2B&<)_UW1&OE[2
M-]@<%Z$)ZF1\$7?F=].6XJW%"-D##5'X^:GL< #X/89E%<QCN/25;E$V60U=
M:9"JC1XO]R[HC0'T1H!Q5KR6E0+#.,,Y_X^9]%6;[HLL@V4M?%FO?)E^$9@L
MF<!#:\RI0P7>"*RT)*BD?SIP&/!PB#(!T8RX?>NG^/-V'D<#<:.7]5"@("@E
M4HA8P<,74K[P8,V=S<6(HJ!CUO&M&D]ZC;)@ZP"-VQ#@QX@HWM\%@0R'7QJV
M-\0U\QE7BA";^*HS_!$PK.+&>:HDT67WZ__Q#YZ9_]>U4>.P&R..DPN;-F>]
MNO4\Z?E6M88U@<$_61WN_I/?03<PY_\4RO_S$?=?IV/UF%O_Q]+/_$\L)"3K
M3/_\S6R0"'5#G93"-\4>;>H_GJ\7IC'L5H&;9 =(UR[YAWRW-:=.(=7N-U%]
M,=C&12<!U_[7V>M6YMLW?:AL_+]^>\[_'ZQO %<?%D2"<3%ANFCNXZODKJP@
MI X;&893],B,"J<3*H1R' EJ%+K*]/G=U)>0G@96(G7 C'7L(BV(+>S*'6DI
MNO7O.0469V4'@&W&8#:+%(J%;=QS)_[/'[Z]<R9Z%%+](^IEY$3 @P3"WG,2
MO4A>W$ZH+TKXPO(*?D1$09\KZ9'PHR7$9?(:N"7]VDTHR<.;-CX,CUZ5-<1/
M5A%P807YLQA!>#0>4%LWN*5\/( ]B4+2=JB!&&8^/UI=9.N7D.@[+3N(!,X@
MEX3H]*H@.F=VPJM1;8)ELZD ?Z(87-TXK4ESJ8CX]UFK;MOF(XJ -ZPK+JR^
M-L:QU&ITI5:#N^)9&"Y=<>:=1E 1AD^C+E@[A=;N4>V 9)</-Q4.4I;"G\0"
M$F>NKO#4 :+W\?.STN@:GRDUA 6.O<-2&&H_TCIH3;K\:9B+Z=%:T[V;9A3K
M8VXCB=7^</\NRZ$Y.W-C)Y-]4.J(XNMF^%#H[&SU,/C0^5-2W+NIL7%- H$E
M&-XT1DC91$K36$DJ?391PV?+]I_QL0R_#*_$L@XW"B%. U.[*]4=F?*E/FCW
M_VFE@V<U/[)C"*U<VBP]VC82O"?1SM8G/46.DFJ?60LK51<KR!]Q8%1JI<?G
MQ4V5Q8&^=O%8U?# ?9#9/)KX:#?MY!H(RP25-)+F/U8^G!_$^=PW IZ8T9)C
M\4)3(ASCHG,N7K I%O*VU\HI-WE3M>!<6CEA7XB___1IR?%C(&9J7$23(!)"
MO&1I.[59Z##*-44NMC$IUK^^T"35Q4(UUJCWK3G5EW6O)0!^6V73I$J38' F
MK%6#TLA<53#9ZVZP['V*^.G+^S6P6])&A:;/SI-WW@+^C@>)TR=#?N**@%L&
M%<HO[,,19X%1$<[4Z8=3B2Y(7&0S[K9&Z9!'KBI13?(I,'1XZZ7#)@,O[H _
M.8;8#&6U!2HQS<U&Z'(4IW23^B3?:-V$2WV,32ED2BMR63UM7DOW%O<[&^H&
M5$.;3VJP>VCUN'7$7-S96]<G4[!_GSB#P#I'/OA< U&-6H(%!2/V/RH":)3:
MX"]0@L$>B!:B/W:IL7'2A-21[D/N'S4)"- Z;3-QT9<2_")_.%2?12XV2=!1
M!Z(J$?G52WVB^./YM2XN1,_(ORY-E?Z68Y4Q@Y*C118>)>F91,FRYQ_BFWSU
ML6P:-%2[!@A/IUV;G1-6UVM<(D=OQH[[;S ^)E,#K=Z<)]J5F<3<\\FS695^
MR#<LZNA+C%>[3^QG^_[*N6=:Q.[X-1M9( *,!\JM$TR%SBLK]1/-,>DLH5,Z
MXQ'=R !CO LP,YT12@-5K WQ3&ZSHC?/EU5(MA5&;ZRV.KOPE-,ML$);XK1L
MI'41UT1YXO6X:!]G7:)P^G=7(KA3=@!#>'EV-D"M!# 7_=]9@_C?6?['5A![
MGW;.%KY[@^I:'=BIK9UD3S%HD]+SYL%-:A7=$#5>HTJ3J>"H/^X@B;3[,T=F
M@:4I"+H&-H2O@<1*&)H*UCZ.LKC"AQWH.V,Y2BSL]'>_FG1= ] [W:F*X9G'
MY-? (D=F/7[<I8#&[9LVV5P#W&^O >0_>^ 6+;6<DUP#*R6+EXIO8):*UX T
M)?:,ZO\X\LVROP;^]?IQ&.,,XFL@:P3[?.@:Z-0W..&R.&R3W4]0_H^#>GSX
M7]1?U%_47]1?U%_47]1?U%_47]1?U%_47]1?U%_4_X8HOEBT5Z2[!24FLX-3
MN?%"X\\"3/STY1>O!\O[.)GU/C[ZZ_]%6+LM)]>)WE(/_,WEJ=V[V[OW5;H\
M]!?=]05BBEZXF/PHH](-%/V7%0$$EYJTF?\Y5;WF"$,?O8%FOT_08U*1G3V"
M^]< L4X;[(C^&N@S:L%$RB+L(4+88-DS/O%K@-Q J*K!<U@ >0TTW[94S^XT
MQ")E+Y9T3N5:_JMB1A;3"; 1O!LI19X3IO^XX=K_1M]:7P.ON_Y+Y_['D6^6
M ^R_UK<:_T'XB_J+^HOZB_J+^HOZB_J+^HOZB_J+^HOZB_J+^HOZ[T997<JA
M"\(N5?,W]7U>?COY\F$<D9S4E_ PZ^&PD=Q6>[V9@ I'L6*.4@EA" YS>^1L
M>26O,I58C=R[I[*>O$56+]BR<XG=)^D+M.2H<P/$[0/^W-\UIOI$A9-YPGV4
MLZ.V:4Q']4H3'S:=.AI7+I1G^THK4([^&K"T> [N;$[^%JAT&["YBO#CO: X
MUP^]3?=7[J_<7[F_<O\BI_4VZZ@8<W/R-F2)>*9 *]+S7Y;DQD>/_I:C7OGP
MC^(IVC5 *_'B2MU<3'G:8+3*Y=\J?'\K?RM_*_][5*2->'=UN.O,)QRH+ /H
M:&]%^OVORVOPM_PM_]\I.A/O5L=%BHLEG-(F59<?1?QZDR1-(<F$#)#<IX-<
M \]1>0W=UB;IS^(2)QBY6 UDVV6-*Y?4%;0F&CEM"K<JB9R<U)J?WK[3$*X)
MX/ZX<AB&>B_-T[:SW&5]J^I4S3<;$K=+F3X2:[C+3, &,O>9*K.=Y'SQ:X<?
MP-TYV23O*=0D!5S-Q='5>\E%QAB87(U)^MMM/"=ZP[;-'CC>82ONO1_'S&I(
MBP^[2J5%(U:%?]CQ;7,4!U]EK#S(['S;@$;XW8>^@#YE<]Z]IQZJ\3!>:;X)
MA!L8R_<5DXDT,9/JJ-PD?#83F]7\XCT//]6QI:S\%HP!V!8QTR=U4ZH:WZW@
M^!DM0? ]8^F*3!EAL(W;]N39.6VP^_R3]8CEZ*K@BY)!T[@.3]D[BUD@-DS,
M,ORN'<O]E [%I@.VZEJE3]Y:+8,]\$$B+!?UUHS'R*Q(@UJVV_K31)NMK&O
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M@RO]\2;SDQ"[?$\3M]3%?IE4S^Y_"GN[X*KAZC)^E$7ZI*C(7C]-*5WTZFB
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MOPA4T<*=7LU,J'$=NR1O@\HY?JT?BF[1%!"VV.E+A])*H\G^VS_]3F^)4M0
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MFU %'9N7JDCBV>*!@;$U>;RQ1[A><XH$(2/\+K/_?/I3]%9*_P;9[J8I+K:
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MEQ[Y/=C6JG_UPZ3;[.?V!L%/"=QM<P^4]N U8+U5G\-+ZN;*R:I(CW4^U[:
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MX>>A:\[*\F1,0I:@3P7!J'2IKXN\4;D6[%BH[7 L'_NF,_O,\PY@?$NCV15
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MCS4I,-9:OB3-7[CCWR]1/O=>CF<@/L(6^U$@XCSDU"%P,&58TCG11;^+<"H
M-U@%[Y$;T,RPV'H-QFI#D2%/TDO[JX.JREHGA7",VAR,:P(,P9)?X=_,5!3O
MDA797;RP_Z?RL,5%='!;&ED@K,@2YVT==;[LYXPZ:)U?=&;F11^NT_X+#7"@
M#J#9]1C$S'8^PI3+>L,;[>5?CVV2A#$<_6"&S'[Q?4?X_K J5[;R_3MU46:
MO(:W<W<Q>3.:I*>-/4ISGI[>XI-P RU>@)0BC-%OA1"]6454.=.BBS/9)!5(
M>=@6L6%\RS%K;0LO<M<D-K998#-8SDG45C/ 3H@@?1_)NXYY9I.KP#][R!OU
MW+)]3/3P^B.Q3Z#^"$SP^G1HLX487MS"!X\\W2M^DK0^=*PZEJ3_?\1S$P&
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MJ >,;I?1HVG92"E7$;ZI?;#9;)U$L.0BQ7PAOJ"$IS>#[GS([_HRAX+:I80
M  H#0&$)IV"F_FR!K<@S>Y)%54XF;7R<E(Q8-",:,_O'1C]K00$T6>'E)+JH
M\EAZE%,)7/8>[1G%'=DBX)__?/QW=<FEX^/'+PA(10,UG5^;$=MZ^7"'_19;
MW'F2A%A^*/J\IY@I7DB5L$#V'9ZI9*:1,YZ]R(N?B/$^%7-E8FS4[XJP=R^
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MPCK;A_</Y'T1WKDP2)Z-YZW)Q)G)K4G=TD/?%CQY*2@4]U/K/6D6\C:E IF
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M%<[="/9Y^J#+$XP^K. %?EN*+5DQP8J4UB<V<QJ ^:UNBC^\N@+Z2LS?$WE
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M"DN7;VK:Z!OU^'*YJ8X8D.4&$,-I-]:,EW-? :6R<+\.-+7WDJ+HP?E(+_=
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M,<Q1$@U8SPP-PLSJ(XZ(YC#M&NI&==#\J/H7,F[O,EN\""<:?6%AE&\^Q7Q
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M=QO.'/@4-%/?\@'>AQ:, *E$G^RK[H?]>-6^H?.E8>"0,& :]G)B\N78?LW
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M0_3!Z4]YL9^LHV_CZCEKGCYRL/ <CT6NEFE"G&DV\F8FR[<+E.-FIU4[02D
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M!.#=_/\&4$L! A0#%     @ QX%J5(![@HW2C@4 B@)* !$
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M+65X,3!?,3 N:'1M4$L! A0#%     @ QX%J5$!NDS7O#   0:0  !
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M-5\P+FIP9U!+ 0(4 Q0    ( ,>!:E0880W7%SX! ,2@ 0 1
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M-5\U+FIP9U!+ 0(4 Q0    ( ,>!:E1]YRG][ZH  *_<   1
M  "  =](#@!I;6<Y-C$V,#@Y-5\V+FIP9U!+ 0(4 Q0    ( ,>!:E0.((G'
M>PX" "4G P 1              "  ?WS#@!I;6<Y-C$V,#@Y-5\W+FIP9U!+
4!08     %@ 6 &L%  "G A$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
